



**Standard Commercial  
Prior Authorization Guidelines**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**1. Formulary Agents**

Drug products that are listed in the Formulary as Prior Authorization (PA) require evaluation, per MedImpact Pharmacy and Therapeutics Committee guidelines, when the member presents a prescription to a network pharmacy. Each request will be reviewed on individual patient need. If the request does not meet the criteria established by the P & T Committee, the request will not be approved and alternative therapy will be recommended.

**2. Non-Formulary Agents**

Any product not found in the Formulary listing, or any Formulary updates published by MedImpact, shall be considered a Non-Formulary drug. Coverage for non-formulary agents may be applied for in advance. When a member gives a prescription order for a non-formulary drug to a pharmacist, the pharmacist will evaluate the patient's drug history and contact the physician to determine if there is a legitimate medical need for a non-formulary drug. Each request will be reviewed on individual patient need. The following basic criteria are used:

- a. The use of Formulary Drug Products is contraindicated in the patient.
- b. The patient has failed an appropriate trial of Formulary or related agents.
- c. The choices available in the Drug Formulary are not suited for the present patient care need, and the drug selected is required for patient safety.
- d. The use of a Formulary drug may provoke an underlying condition, which would be detrimental to patient care.

If the request does not meet the criteria established by the P & T Committee, the request will not be approved and alternative therapy will be recommended.

**3. Obtaining Coverage**

Coverage may be obtained by:

- a. Faxing a completed **Medication Request Form** to MedImpact at (858) 790-7100.
- b. Contacting MedImpact at (800) 788-2949 and providing all necessary information requested.

MedImpact will provide an authorization number, specific for the medical need, for all approved requests. Non-approved requests may be appealed. The prescriber must provide information to support the appeal on the basis of medical necessity.



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ABALOPARATIDE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ABALOPARATIDE	TYMLOS	44231		GPI-10 (3004400500)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of postmenopausal osteoporosis AND meet **ONE** of the following criteria?
  - The patient has a high risk for fractures defined as ONE of the following:
    - History of osteoporotic (i.e., fragility, low trauma) fracture(s)
    - 2 or more risk factors for fracture (e.g., history of multiple recent low trauma fractures, BMD T-score less than or equal to -2.5, corticosteroid use, or use of GnRH analogs such as nafarelin, etc.)
    - No prior treatment for osteoporosis AND FRAX score  $\geq$  20% for any major fracture OR  $\geq$  3% for hip fracture
  - The patient is unable to use oral therapy (i.e., upper gastrointestinal [GI] problems - unable to tolerate oral medication, lower GI problems - unable to absorb oral medications, trouble remembering to take oral medications or coordinating an oral bisphosphonate with other oral medications or their daily routine)
  - The patient had a trial of, intolerance to, or a contraindication to bisphosphonates (e.g., Fosamax, Actonel, Boniva)

If yes, continue to #3.

If no, continue to #2.

2. Is the request to increase bone density in a male patient with osteoporosis who meets **ONE** of the following criteria?
  - The patient is at high risk for fracture defined as ONE of the following:
    - History of osteoporotic fracture (e.g., fragility, low trauma, etc.)
    - Multiple risk factors for fracture (e.g., history of multiple recent low trauma fractures, BMD T-score less than or equal to -2.5, corticosteroid use, GnRH analogs use such as nafarelin, etc.)
  - The patient has failed or is intolerant to other available osteoporosis therapy (e.g., Forteo, Prolia, Fosamax, Actonel)

If yes, continue to #3.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ABALOPARATIDE

GUIDELINES FOR USE (CONTINUED)

3. Has the patient received a total of 24 months cumulative treatment with any parathyroid hormone therapy (e.g., Tymlos, Forteo)?

If yes, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

If no, **approve up to 24 months cumulative lifetime treatment duration by HICL or GPI-10 with a quantity limit of #1.56mL per 30 days.**

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ABALOPARATIDE (Tymlos)** requires the following rule(s) be met for approval:

A. The request is for ONE of the following:

1. Postmenopausal osteoporosis (a type of bone condition)
2. Increase bone density in a male patient with osteoporosis (a type of bone condition)

B. **If the request is for postmenopausal osteoporosis, approval also requires:**

1. You have NOT received a total of 24 months or more of treatment with any parathyroid hormone therapy (such as Tymlos, Forteo)
2. You meet ONE of the following (a, b, or c):
  - a. You have high risk for fractures defined as ONE of the following:
    - i. History of osteoporotic fracture(s) (broken bones) due to trauma (injury) or fragility (weakness)
    - ii. 2 or more risk factors for fracture such as history of multiple recent low trauma fractures, bone mineral density T-score (a type of lab test) less than or equal to -2.5, corticosteroid use, or use of GnRH (Gonadotropin-releasing hormone) analogs such as nafarelin
    - iii. No prior treatment for osteoporosis AND FRAX (Fracture Risk Assessment Tool) score greater than or equal to 20 percent for any major fracture OR greater than or equal to 3 percent for hip fracture
  - b. You are unable to use oral therapy due to upper gastrointestinal (stomach and intestine) problems, you cannot tolerate oral medication, you have lower gastrointestinal problems (unable to absorb oral medications), you have trouble remembering to take oral medications or cannot plan to use an oral bisphosphonate (such as alendronate, risedronate, ibandronate) with other oral medications in your daily routine
  - c. You had a trial of, intolerance (side effect) to, or a contraindication (harmful for) to bisphosphonates such as Fosamax, Actonel, Boniva

***(Denial text continued on next page)***

CONTINUED ON NEXT PAGE





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ABALOPARATIDE

GUIDELINES FOR USE (CONTINUED)

C. If the request is to increase bone density in a male patient with osteoporosis, approval also requires:

1. You have NOT received a total of 24 months or more of treatment with any parathyroid hormone therapy (such as Tymlos, Forteo)
2. You meet ONE of the following (a or b):
  - a. You have high risk for fractures defined as ONE of the following:
    - i. History of osteoporotic fracture (such as fragility [weakness] fracture, low trauma [injury] fracture)
    - ii. Multiple risk factors for fracture (such as history of multiple recent low trauma fractures, bone mineral density T-score (a type of lab test) less than or equal to -2.5, corticosteroid use, GnRH [Gonadotropin-releasing hormone] analogs use such as nafarelin)
  - b. You have failed or are intolerant (side effect) to other available osteoporosis therapy (such as Forteo, Prolia, Fosamax, Actonel)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Tymlos.

**REFERENCES**

- Tymlos [Prescribing Information]. Boston, MA: Radius Health, Inc.; December 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/23/23

Created: 04/17

Client Approval: 01/23

P&T Approval: 01/23



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**ABATACEPT - SQ**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ABATACEPT - SQ	ORENCIA - SQ ORENCIA CLICKJECT - SQ		30289 41656 43389 43397	GPI-14 (6640001000D520) (6640001000E510) (6640001000E515) (6640001000E520)	

**NOTE: For requests for the IV dosage form of Orencia, please see the Orencia IV PA Guideline.**

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a rheumatologist
  - The patient had a trial of or contraindication to at least 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
  - The patient meets ONE of the following:
    - The patient had a trial of or contraindication to any TWO of the following preferred immunomodulators: Enbrel, Humira, Rinvoq, Xeljanz (IR/XR)
    - The patient has tried any TNF inhibitor (e.g., Humira, Enbrel) AND the physician has indicated the patient cannot use a JAK inhibitor (e.g., Rinvoq, Xeljanz) due to the black box warning for increased risk of mortality, malignancies, and serious cardiovascular events  
**[NOTE: pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]**

If yes, **approve for 6 months by GPID or GPI-14 with the following quantity limits:**

- **Orencia 125mg/mL SQ syringes: 4mL (#4 - 125mg/mL syringes) per 28 days.**
- **Orencia 125mg/mL ClickJect - SQ: 4mL (#4 - 125mg/mL auto-injectors) per 28 days.**

If no, continue to #2.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ABATACEPT - SQ

INITIAL CRITERIA (CONTINUED)

2. Does the patient have a diagnosis of moderate to severe polyarticular juvenile idiopathic arthritis (PJIA) and meet **ALL** of the following criteria?

- The patient is 2 years of age or older
- Therapy is prescribed by or in consultation with a rheumatologist
- The patient had a trial of or contraindication to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
- The patient had a trial of or contraindication to any TWO of the following preferred immunomodulators: Enbrel, Humira, Actemra, Xeljanz IR [**NOTE:** pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

If yes, **approve for 6 months by GPID or GPI-14 with the following quantity limits:**

- **Orencia 125mg/mL SQ syringes: 4mL (#4 - 125mg/mL syringes) per 28 days.**
- **Orencia 87.5mg/0.7mL SQ syringes: 2.8mL (#4 - 87.5mg/0.7mL syringes) per 28 days.**
- **Orencia 50mg/0.4mL SQ syringes: 1.6mL (#4 - 50mg/0.4mL syringes) per 28 days.**

If no, continue to #3.

3. Does the patient have a diagnosis of psoriatic arthritis (PsA) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- Therapy is prescribed by or in consultation with a rheumatologist or dermatologist
- The patient had a trial of or contraindication to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
- The patient had a trial of or contraindication to any TWO of the following preferred immunomodulators: Cosentyx, Enbrel, Humira, Stelara, Xeljanz (IR/XR), Otezla, Tremfya, Rinvoq, Skyrizi [**NOTE:** pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

If yes, **approve for 6 months by GPID or GPI-14 with the following quantity limits:**

- **Orencia 125mg/mL SQ syringes: 4mL (#4 - 125mg/mL syringes) per 28 days.**
- **Orencia 125mg/mL ClickJect - SQ: 4mL (#4 - 125mg/mL auto-injectors) per 28 days.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ABATACEPT - SQ

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ABATACEPT - SQ (Orencia - SQ)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:

1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
2. Moderate to severe polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)
3. Psoriatic arthritis (PsA: a type of skin and joint condition)

B. **If you have moderate to severe rheumatoid arthritis, approval also requires:**

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
3. You had a trial of or contraindication (harmful) to at least 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
4. You meet ONE of the following:
  - a. You had a trial of or contraindication (harmful) to any TWO of the following preferred immunomodulators (class of drugs): Enbrel, Humira, Rinvoq, Xeljanz (immediate release/extended release)
  - b. You have tried any tumor necrosis factor (TNF) inhibitor (such as Humira, Enbrel) AND your physician has indicated you cannot use a JAK inhibitor (such as Rinvoq, Xeljanz) due to the black box warning for increased risk of mortality (death), malignancies (cancerous), and serious cardiovascular (heart-related) events

C. **If you have moderate to severe polyarticular juvenile idiopathic arthritis, approval also requires:**

1. You are 2 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
3. You had a trial of or contraindication (harmful) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
4. You had a trial of or contraindication (harmful) to any TWO of the following preferred immunomodulators (class of drugs): Enbrel, Humira, Actemra, Xeljanz immediate release

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ABATACEPT - SQ

INITIAL CRITERIA (CONTINUED)

D. If you have psoriatic arthritis, approval also requires:

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
3. You had a trial of or contraindication (harmful) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
4. You had a trial of or contraindication (harmful) to any TWO of the following preferred immunomodulators (class of drugs): Cosentyx, Enbrel, Humira, Stelara, Xeljanz (immediate/extended release), Otezla, Tremfya, Rinvoq, Skyrizi

**NOTE:** The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) or psoriatic arthritis (PsA) **AND** meet the following criterion?
  - The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

If yes, **approve for 12 months by GPID or GPI-14 with the following quantity limits:**

- **Orencia 125mg/mL SQ syringes: 4mL (#4 - 125mg/mL syringes) per 28 days.**
- **Orencia 125mg/mL ClickJect - SQ: 4mL (#4 - 125mg/mL auto-injectors) per 28 days.**

If no, continue to #2.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ABATACEPT - SQ

RENEWAL CRITERIA (CONTINUED)

2. Does the patient have a diagnosis of moderate to severe polyarticular juvenile idiopathic arthritis (PJIA) **AND** meet the following criterion?

- The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

If yes, approve for 12 months by GPID or GPI-14 with the following quantity limits:

- Orenzia 125mg/mL SQ syringes: 4mL (#4 - 125mg/mL syringes) per 28 days.
- Orenzia 87.5mg/0.7mL SQ syringes: 2.8mL (#4 - 87.5mg/0.7mL syringes) per 28 days.
- Orenzia 50mg/0.4mL SQ syringes: 1.6mL (#4 - 50mg/0.4mL syringes) per 28 days.

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ABATACEPT - SQ (Orenzia - SQ)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following diagnoses:
  1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
  2. Moderate to severe polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)
  3. Psoriatic arthritis (PsA: a type of skin and joint condition)
- B. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Orenzia SQ.

**REFERENCES**

- Orenzia [Prescribing Information]. Princeton, NJ: Bristol-Myers Squibb Company; December 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 03/14/22

Created: 11/11

Client Approval: 02/22

P&T Approval: 01/22

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ABEMACICLIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ABEMACICLIB	VERZENIO	44537		GPI-10 (2153101000)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of early breast cancer and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient's cancer is hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive
  - Verzenio will be used in combination with endocrine therapy (tamoxifen or an aromatase inhibitor such as anastrozole, letrozole, exemestane) for adjuvant treatment
  - The patient is at high risk of recurrence and has a Ki-67 score greater than or equal to 20%, as determined by an FDA-approved test

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.**

If no, continue to #2.

2. Does the patient have advanced or metastatic breast cancer **AND** meet the following criterion?
  - The patient's cancer is hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative

If yes, continue to #3.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

3. Will Verzenio be used in combination with an aromatase inhibitor (e.g., anastrozole, letrozole, exemestane) and the patient meets **ALL** of the following criteria?
  - The patient is a postmenopausal female or is a male
  - Verzenio will be used as initial endocrine-based therapy

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.**

If no, continue to #4.

4. Is the patient 18 years of age or older and meet **ONE** of the following criteria?
  - Verzenio will be used in combination with fulvestrant **AND** the patient has had disease progression following endocrine therapy (e.g., anastrozole, letrozole, exemestane)
  - Verzenio will be used as monotherapy **AND** the patient has had disease progression following endocrine therapy and prior chemotherapy

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ABEMACICLIB

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ABEMACICLIB (Verzenio)** requires the following rules be met for approval:

- A. You have ONE of the following diagnoses:
1. Early breast cancer (initial stage of breast cancer)
  2. Advanced or metastatic breast cancer (cancer that has progressed or has spread to other parts of the body)
- B. **If you have early breast cancer, approval also requires:**
1. You are 18 years of age or older
  2. Your cancer is hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive (a type of protein)
  3. Verzenio will be used in combination with endocrine therapy (tamoxifen or an aromatase inhibitor such as letrozole, anastrozole, exemestane) for adjuvant (add-on) treatment
  4. You are at high risk of recurrence (disease returning) and has a Ki-67 score of greater than or equal to 20 percent, as determined by a Food and Drug Administration (FDA)-approved test
- C. **If you have advanced or metastatic breast cancer, approval also requires:**
1. Your cancer is hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (a type of protein)
  2. You meet ONE of the following:
    - a. You are a postmenopausal female or male AND Verzenio will be used in combination with an aromatase inhibitor (such as letrozole, anastrozole, or exemestane) as initial endocrine-based therapy
    - b. You are 18 years of age or older AND Verzenio will be used in combination with fulvestrant, and you have had disease progression following endocrine therapy
    - c. You are 18 years of age or older AND Verzenio will be used as monotherapy (one drug) and you have had disease progression following endocrine therapy and prior chemotherapy (drugs used to treat cancer)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE





**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**ABEMACICLIB**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Verzenio.

**REFERENCES**

- Verzenio [Prescribing Information]. Indianapolis, IN. Eli Lilly and Company; October 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/01/22

Created: 10/17

Client Approval: 10/22

P&T Approval: 01/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ABIRATERONE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ABIRATERONE ACETATE	ZYTIGA, ABIRATERONE ACETATE	37571		GPI-10 (2140601020)	
ABIRATERONE ACET, SUBMICRONIZED	YONSA	44946			

**\*\* Please use the criteria for the specific drug requested \*\***

**GUIDELINES FOR USE**

**ZYTIGA**

1. Does the patient have **ONE** of the following diagnoses?

- Metastatic castration-resistant prostate cancer (mCRPC)
- Metastatic high-risk castration-sensitive prostate cancer (mCSPC)

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Is the requested medication being used in combination with prednisone?

If yes, continue to #3.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

3. Does the patient meet **ONE** of the following criteria?

- The patient previously had a bilateral orchiectomy
- The patient has a castrate level of testosterone (i.e., < 50 ng/dL)
- The requested medication will be used concurrently with a gonadotropin-releasing hormone (GnRH) analog (e.g., leuprolide, goserelin, histrelin, degarelix)

If yes, continue to #4.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ABIRATERONE

GUIDELINES FOR USE - ZYTIGA (CONTINUED)

4. Is the patient concomitantly using a strong CYP3A4 inducer (e.g., phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital)?

If yes, approve for 12 months by GPID or GPI-14 with a quantity limit as follows:

- Zytiga 250mg: #8 per day.
- Zytiga 500mg: #4 per day.

If no, approve for 12 months by GPID or GPI-14 with a quantity limit as follows:

- Zytiga 250mg: #4 per day.
- Zytiga 500mg: #2 per day.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ABIRATERONE (Zytiga)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:

1. Metastatic castration-resistant prostate cancer (mCRPC: prostate cancer that has spread to other parts of the body and no longer responds to testosterone lowering treatment)
2. Metastatic high-risk castration-sensitive prostate cancer (mCSPC: prostate cancer that has spread to other parts of the body and may respond to testosterone lowering treatment)

B. The requested medication will be used in combination with prednisone

C. You meet ONE of the following:

1. You previously had a bilateral orchiectomy (both testicles have been surgically removed)
2. You have a castrate level of testosterone (your blood testosterone levels are less than 50 ng/dL)
3. The requested medication will be used together with a gonadotropin-releasing hormone (GnRH) analog (such as leuprolide, goserelin, histrelin, degarelix)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**YONSA**

1. Does the patient have a diagnosis of metastatic castration-resistant prostate cancer (mCRPC) and meet **ALL** of the following criteria?

- The requested medication is being used in combination with methylprednisolone
- The patient had a trial of or contraindication to Zytiga (abiraterone acetate)

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ABIRATERONE

GUIDELINES FOR USE - YONSA (CONTINUED)

2. Does the patient meet **ONE** of the following criteria?

- The patient previously had a bilateral orchiectomy
- The patient has a castrate level of testosterone (i.e., < 50 ng/dL)
- The requested medication will be used concurrently with a gonadotropin-releasing hormone (GnRH) analog (e.g., leuprolide, goserelin, histrelin, degarelix)

If yes, continue to #3.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

3. Is the patient concomitantly using a strong CYP3A4 inducer (e.g., phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital)?

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #8 per day.**

If no, **approve for 12 months by GPID or GPI-14 with a quantity limit of #4 per day.**

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ABIRATERONE (Yonsa)** requires the following rule(s) be met for approval:

- A. You have metastatic castration-resistant prostate cancer (mCRPC: prostate cancer that has spread to other parts of the body and no longer responds to testosterone lowering treatment)
- B. The requested medication will be used in combination with methylprednisolone
- C. You have previously tried or have a contraindication to (medical reason why you cannot use) Zytiga (abiraterone acetate)
- D. You meet ONE of the following:
  1. You previously had a bilateral orchiectomy (both testicles have been surgically removed)
  2. You have a castrate level of testosterone (your blood testosterone levels are less than 50 ng/dL)
  3. The requested medication will be used together with a gonadotropin-releasing hormone (GnRH) analog (such as leuprolide, goserelin, histrelin, degarelix)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**ABIRATERONE**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Yonsa and Zytiga.

**REFERENCES**

- Yonsa [Prescribing Information]. Cranbury, NJ: Sun Pharmaceuticals Industries, Inc.; June 2018.
- Zytiga [Prescribing Information]. Horsham, PA: Janssen Biotech; October 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/21

Created: 06/11

Client Approval: 02/21

P&T Approval: 07/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ABROCITINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ABROCITINIB	CIBINQO	47767		GPI-10 (9027200500)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of refractory, moderate to severe atopic dermatitis and meet **ALL** of the following criteria?
  - The patient is 12 years of age or older
  - Therapy is prescribed by or in consultation with a dermatologist, allergist, or immunologist
  - The patient has atopic dermatitis involving at least 10% of body surface area (BSA) OR atopic dermatitis affecting the face, head, neck, hands, feet, groin, or intertriginous areas
  - The patient has TWO of the following: intractable pruritus, cracking and oozing/bleeding of affected skin, impaired activities of daily living
  - The patient had a trial of or contraindication to ONE preferred immunomodulator: Dupixent (dupilumab) or Rinvoq (upadacitinib)
  - Cibinqo will NOT be used concurrently with other systemic biologics (e.g., Adbry, Dupixent) or any JAK inhibitors (e.g., Rinvoq, topical Opzelura) for the treatment of atopic dermatitis

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Does the patient have a trial of or contraindication to **TWO** of the following?
  - High or super-high potency topical corticosteroid (e.g., triamcinolone acetonide, fluocinonide, clobetasol propionate)
  - Topical calcineurin inhibitor (e.g., tacrolimus, pimecrolimus)
  - Topical PDE-4 inhibitor (e.g., crisaborole)
  - Topical JAK inhibitor (e.g., ruxolitinib)
  - Phototherapy

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #1 per day.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ABROCITINIB

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ABROCITINIB (Cibinqo)** requires the following rule(s) be met for approval:

- A. You have refractory, moderate to severe atopic dermatitis (a type of skin condition)
- B. You are 12 years of age or older
- C. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor), allergist (a type of allergy doctor), or immunologist (a type of immune system doctor)
- D. You have atopic dermatitis involving at least 10% of body surface area (BSA) OR atopic dermatitis affecting the face, head, neck, hands, feet, groin, or intertriginous areas (between skin folds, the hands, feet, etc.)
- E. You have TWO of the following: intractable pruritus (severe itching), cracking and oozing/bleeding of affected skin, impaired activities of daily living
- F. You had a trial of or contraindication (harmful for) to TWO of the following:
  - 1. High or super-high potency topical corticosteroid (such as triamcinolone acetonide, fluocinonide, clobetasol propionate)
  - 2. Topical calcineurin inhibitor (e.g., tacrolimus, pimecrolimus)
  - 3. Topical PDE-4 inhibitor (e.g., crisaborole)
  - 4. Topical JAK inhibitor (e.g., ruxolitinib)
  - 5. Phototherapy (light therapy)
- G. You had a trial of or contraindication (harmful for) to ONE preferred immunomodulator: Dupixent (dupilumab) or Rinvoq (upadacitinib)
- H. You will NOT use Cibinqo concurrently (at the same time) with other systemic biologics (such as Adbry, Dupixent) or any JAK inhibitors (such as Rinvoq, topical Opzelura) for the treatment of atopic dermatitis

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ABROCITINIB

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

- Does the patient have a diagnosis of refractory, moderate to severe atopic dermatitis and meet **ALL** of the following criteria?
  - The patient has shown improvement while on therapy
  - Cibinqo will NOT be used concurrently with other systemic biologics (e.g., Adbry, Dupixent) or any JAK inhibitors (e.g., Rinvoq, topical Opzelura) for the treatment of atopic dermatitis

If yes, **approve for 12 months by HICL with a quantity limit of #1 per day.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ABROCITINIB (Cibinqo)** requires the following rule(s) be met for renewal:

- You have refractory, moderate to severe atopic dermatitis (a type of skin condition)
- You have shown improvement while on therapy
- You will NOT use Cibinqo concurrently (at the same time) with other systemic biologics (such as Adbry, Dupixent) or any JAK inhibitors (such as Rinvoq, topical Opzelura) for the treatment of atopic dermatitis

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Cibinqo.

**REFERENCES**

- Cibinqo [Prescribing Information]. New York, NY: Pfizer Labs; February 2023.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 03/06/23

Created: 02/22

Client Approval: 02/23

P&T Approval: 04/23





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ACALABRUTINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ACALABRUTINIB	CALQUENCE	44607		GPI-10 (2153210300)	
ACALABRUTINIB MALEATE	CALQUENCE	48182		GPI-10 (2153210350)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of mantle cell lymphoma (MCL) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient has received at least one prior therapy for mantle cell lymphoma (MCL)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.**  
If no, continue to #2.

2. Does the patient have a diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) **AND** meet the following criterion?

- The patient is 18 years of age or older

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ACALABRUTINIB (Calquence)** requires the following rules be met for approval:

A. You have ONE of the following diagnoses:

1. Mantle cell lymphoma (MCL: a type of blood cancer)
2. Chronic lymphocytic leukemia (CLL: a type of blood cancer)
3. Small lymphocytic lymphoma (SLL: a type of blood cancer)

B. **If you have mantle cell lymphoma (MCL), approval also requires:**

1. You are 18 years of age or older
2. You have received at least one prior therapy for mantle cell lymphoma

C. **If you have chronic lymphocytic leukemia or small lymphocytic lymphoma, approval also requires:**

1. You are 18 years of age or older

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**ACALABRUTINIB**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Calquence.

**REFERENCES**

- Calquence [Prescribing Information]. Wilmington, DE: AstraZeneca Pharmaceuticals; August 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 08/29/22

Created: 02/18

Client Approval: 08/22

P&T Approval: 01/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ACETAMINOPHEN DAILY LIMIT OVERRIDE

Generic	Brand	HICL	GCN	Medi-Span	Exception/other
N/A	N/A	N/A	N/A	N/A	N/A

GUIDELINES FOR USE

1. Is the patient taking a dose of the requested drug in an amount exceeding 4000mg of acetaminophen per day?

If yes, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

If no, continue to #2.

2. Is the requested medication being taken together with other acetaminophen containing product(s) and the combination will exceed 4000mg of acetaminophen per day?

If yes, continue to #3.

If no, **approve for ONE FILL count by GPID or GPI-14 for the requested medication and set override type MAXINGREDIENTDOSE to a value of "Y".**

3. Will the patient discontinue the concurrent acetaminophen containing drug(s) that place the patient over 4000mg of acetaminophen per day?

If yes, **approve for ONE FILL count by GPID or GPI-14 for the requested medication and set override type MAXINGREDIENTDOSE to a value of "Y".**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ACETAMINOPHEN DAILY LIMIT OVERRIDE** will cause a denied claim for acetaminophen when the total daily dose acetaminophen exceeds 4000mg. The claim will also deny if the requested drug is being used at the same time with other acetaminophen containing product(s) and the combination exceeds 4000mg of acetaminophen per day limit.

**Approval requires the following rule be met:**

- A. You will discontinue the other acetaminophen containing drug(s) that cause the daily acetaminophen dose to exceed 4000mg.

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ACETAMINOPHEN DAILY LIMIT OVERRIDE

**RATIONALE**

To ensure appropriate use of acetaminophen products and address overuse from a medication safety perspective while preserving patient access to medically necessary drug regimens. The maximum daily dose for an adult is 4000 mg. However, in some people, taking the maximum daily dose or more for an extended period of time can lead to serious liver damage.

A claim may reject at POS due to exceeding the acetaminophen daily limit as a result of concurrent use with other acetaminophen products. An approval is granted if the the concurrent acetaminophen containing product will be discontinued. In some cases, the member’s history claim may have an incorrect day supply due to a pharmacy error. This will cause the new claim to reject at POS for exceeding the acetaminophen daily limit. This is addressed in question #2.

**REFERENCES**

- “FDA Drug Safety Communication: Prescription Acetaminophen Products to be Limited to 325 mg Per Dosage Unit; Boxed Warning Will Highlight Potential for Severe Liver Failure”. January 13, 2011. Available at <https://www.fda.gov/Drugs/DrugSafety/ucm239821.htm> [Accessed 12/3/18].
- “Medicare Part D Overutilization Monitoring System – Updates”. October 25, 2013. Available at <https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/MemoMedicare-Part-D-OMS-Updates-10-25-13.pdf> [Accessed 12/3/18].

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 05/01/20

Created: 12/18

Client Approval: 04/20

P&T Approval: 01/19



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ACNE AGE RESTRICTION OVERRIDE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ADAPALENE	DIFFERIN, PLIXDA	11233		GPI-10 (9005000300)	
ADAPALENE/BENZOYL PEROXIDE	EPIDUO, EPIDUO FORTE	36015		GPI-10 (9005990203)	
TRETINOIN	ATRALIN, AVITA, RETIN-A, TRETIN-X, ALTRENO	02468		GPI-10 (9005003000)	FDB: ROUTE ≠ ORAL OR MISCELL. MEDISPAN: ROUTE ≠ ORAL OR DOES NOT APPLY
TRETINOIN MICROSPHERES	RETIN-A MICRO, RETIN-A MICRO PUMP	32888		GPI-10 (9005003020)	
TRIFAROTENE	AKLIEF	46048		GPI-10 (9005003500)	
TAZAROTENE	FABIOR, ARAZLO		32178 47488	GPI-10 (9005002700)	

**GUIDELINES FOR USE**

1. Is the patient older than the age limit, as noted in the POS reject message?

If yes, continue to #2.

If no, guideline does not apply. (**NOTE:** If the request also rejects for step therapy required, please review as such and evaluate if the patient has met the step therapy requirements.)

2. Is the request for a cosmetic indication such as melasma, photoaging, or wrinkles?

If yes, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

If no, continue to #3.

3. Does the requested medication also require step therapy?

(**NOTE:** Analyze the claim for the requested drug to determine if also rejects for step therapy)

If yes, continue to #4.

If no, **approve for 12 months by HICL or GPI-10.**

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ACNE AGE RESTRICTION OVERRIDE

GUIDELINES FOR USE (CONTINUED)

4. Has the patient met the step therapy requirement? (**NOTE:** Analyze the claim for the requested drug to determine the step therapy agents)

If yes, **approve for 12 months by HICL or GPI-10.**

**(NOTE: Please override both PA and step therapy restrictions by entering 'Y' for OVR\_RES).**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ACNE AGE RESTRICTION OVERRIDE** requires the following rule(s) be met for approval:

- You are above **[enter age on POS message]** years of age
- The request is for a non-cosmetic (not for appearance) diagnosis.
- Approval may also require that you have tried preferred agent(s), unless there is a medical reason why you cannot (contraindication): **[NOTE TO REVIEWER: Please provide the list of the preferred medication(s)]**

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for agents in this guideline

**REFERENCES**

- Differin [Prescribing Information]. Fort Worth, TX: Galderma laboratories, L.P; February 2018.
- Epiduo [Prescribing Information]. Fort Worth, TX: Galderma laboratories, L.P; February 2018.
- Atralin [Prescribing Information]. Bridgewater, NJ: Valeant Pharmaceuticals International, Inc.; July 2016.
- Retin-A [Prescribing Information]. Bridgewater, NJ: Valeant Pharmaceuticals International, Inc.; June 2018.
- Aklief [Prescribing Information]. Fort Worth, TX: Galderma laboratories, L.P; October 2019.
- Fabior [Prescribing Information]. Greenville, NC: Mayne Pharma; April 2018.
- Arazlo [Prescribing Information]. Bridgewater, NJ: Bausch Health US LLC; December 2019.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**ACNE AGE RESTRICTION OVERRIDE**

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/01/22

Created: 08/11

Client Approval: 09/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ADAGRASIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ADAGRASIB	KRAZATI	48522		GPI-10 (2153241000)	

**GUIDELINES FOR USE**

- Does the patient have a diagnosis of locally advanced or metastatic non-small cell lung cancer (NSCLC) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient's cancer has a KRAS G12C mutation as determined by an FDA-approved test
  - The patient has received at least one prior systemic therapy

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #6 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ADAGRASIB (Krazati)** requires the following rule(s) be met for approval:

- You have locally advanced or metastatic non-small cell lung cancer (NSCLC: a type of lung cancer that has spread from where it started to nearby tissue or lymph nodes or to other parts of the body)
- You are 18 years of age or older
- Your cancer has a KRAS G12C mutation (a type of abnormal gene) as determined by a Food and Drug Administration (FDA)-approved test
- You have received at least one prior systemic therapy

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Krazati.

**REFERENCES**

- Krazati [Prescribing Information]. San Diego, CA: Mirati Therapeutics, Inc.; December 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/23

Created: 01/23

Client Approval: 02/23

P&T Approval: 01/23





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ADALIMUMAB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ADALIMUMAB	HUMIRA	24800		GPI-10 (6627001500)	

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- Therapy is prescribed by or in consultation with a rheumatologist
- The patient had a trial of or contraindication to at least 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine

If yes, **approve for 6 months by GPID or GPI-14 for Humira 40mg/0.4mL OR 40mg/0.8mL with a quantity limit of #2 per 28 days.**

If no, continue to #2.

2. Does the patient have a diagnosis of moderate to severe polyarticular juvenile idiopathic arthritis (PJIA) and meet **ALL** of the following criteria?

- The patient is 2 years of age or older
- Therapy is prescribed by or in consultation with a rheumatologist
- The patient had a trial of or contraindication to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
- Documentation of the patient's current weight

If yes, **approve for 6 months by GPID or GPI-14 with a quantity limit of #2 per 28 days based on patient weight as follows:**

- **If 10kg to <15kg in weight: Approve Humira 10mg/0.2mL OR 10mg/0.1mL.**
- **If 15kg to <30kg in weight: Approve Humira 20mg/0.4mL OR 20mg/0.2mL.**
- **If 30kg or heavier: Approve Humira 40mg/0.8mL OR 40mg/0.4mL.**

If no, continue to #3.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ADALIMUMAB

INITIAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of psoriatic arthritis (PsA) and meet **ALL** of the following criteria?
- The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a rheumatologist or dermatologist
  - The patient had a trial of or contraindication to ONE DMARD (disease-modifying antirheumatic drug) such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

If yes, **approve for 6 months by GPID or GPI-14 for Humira 40mg/0.8mL OR 40mg/0.4mL with a quantity limit of #2 per 28 days.**

If no, continue to #4.

4. Does the patient have a diagnosis of ankylosing spondylitis (AS) and meet **ALL** of the following criteria?
- The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a rheumatologist
  - The patient had a trial of or contraindication to an NSAID

If yes, **approve for 6 months by GPID or GPI-14 for Humira 40mg/0.8mL OR 40mg/0.4mL with a quantity limit of #2 per 28 days.**

If no, continue to #5.

5. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) and meet **ALL** of the following criteria?
- The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a dermatologist
  - The patient has psoriasis covering 3% or more of body surface area (BSA) OR psoriatic lesions affecting the hands, feet, genital area, or face
  - The patient had a trial of or contraindication to ONE or more forms of conventional therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids, calcipotriene, acitretin, methotrexate, or cyclosporine

If yes, **approve for a total of 6 months by GPID or GPI-14. Please enter two authorizations as follows:**

- **Approve for 1 fill for Humira 40mg/0.8mL Psoriasis Starter Package with a quantity of #4 pens OR for Humira Psoriasis Starter Package (contains one 80 mg/0.8 mL pen and two 40 mg/0.4 mL pens) with a quantity limit of #3 pens.**
- **Approve for 5 months for Humira 40mg/0.8mL OR 40mg/0.4mL with a quantity limit of #2 per 28 days.**

If no, continue to #6.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ADALIMUMAB

INITIAL CRITERIA (CONTINUED)

6. Does the patient have a diagnosis of moderate to severe Crohn's disease (CD) and meet **ALL** of the following criteria?
- The patient is 6 years of age or older
  - Therapy is prescribed by or in consultation with a gastroenterologist
  - The patient had a trial of or contraindication to ONE conventional agent, such as corticosteroids (e.g., budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine

If yes, **approve for a total of 6 months by GPID or GPI-14. Please enter two authorizations as follows:**

- **Approve for 1 fill for Humira 40mg/0.8mL Crohn's Disease Starter Package with a quantity limit of #6 pens, OR for Humira 40mg/0.8mL Pediatric Crohn's Starter Package with quantity limit of either #3 syringes or #6 syringes, OR for Humira 80mg/0.8mL Pediatric Crohn's Disease Starter Package with a quantity limit of #3 syringes, OR for Humira Pediatric Crohn's Disease Starter Package (contains one 40mg/0.4mL syringe and one 80mg/0.8mL syringe) with a quantity limit of #2 syringes, OR for Humira 80 mg/0.8 mL Crohn's Disease Starter Package with a quantity limit of #3 pens.**
- **Approve for 5 months for Humira 40mg/0.8mL, OR 40mg/0.4mL, OR 20mg/0.4mL, OR 20mg/0.2mL with a quantity limit of #2 per 28 days.**

If no, continue to #7.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ADALIMUMAB

INITIAL CRITERIA (CONTINUED)

7. Does the patient have a diagnosis of moderate to severe ulcerative colitis (UC) and meet **ALL** of the following criteria?

- The patient is 5 years of age or older
- Therapy is prescribed by or in consultation with a gastroenterologist
- The patient had a trial of or contraindication to ONE conventional agent, such as corticosteroids (e.g., budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine

If yes, **approve for a total of 6 months by GPID or GPI-14. Please enter two authorizations as follows:**

- **Approve for 1 fill for ONE of the following as requested:**
  - Humira 40mg/0.8mL Pen Ulcerative Colitis Starter Package: #6 pens.
  - Humira 80 mg/0.8 mL Ulcerative Colitis Starter Package: #3 pens.
  - Humira 80mg/0.8mL Pen Pediatric UC Starter Package: #4 pens.
  - Humira 40mg/0.8mL OR 40mg/0.4mL: #4 pens/syringes.
- **Approve for 5 months for ONE of the following as requested:**
  - Humira 40mg/0.8mL OR 40mg/0.4mL: #4 per 28 days.
  - Humira 80mg/0.8mL: #2 per 28 days.
  - Humira 20mg/0.4mL OR 20mg/0.2mL: #4 per 28 days.

If no, continue to #8.

8. Does the patient have a diagnosis of moderate to severe hidradenitis suppurativa (HS) and is 12 years of age or older?

If yes, **approve for a total of 6 months by GPID or GPI-14. Please enter two authorizations as follows:**

- **Approve for 1 fill for Humira 40mg/0.8mL Pen Starter Package for Hidradenitis Suppurativa (HS) with a quantity limit of #6 pens OR for Humira 80 mg/0.8 mL Hidradenitis Suppurativa Starter Package with a quantity limit of #3 pens.**
- **Approve for 5 months for the requested agent as follows:**
  - Humira 40mg/0.8mL OR 40mg/0.4mL: #4 per 28 days.
  - Humira 80mg/0.8mL: #2 per 28 days.

If no, continue to #9.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ADALIMUMAB

INITIAL CRITERIA (CONTINUED)

9. Does the patient have a diagnosis of non-infectious intermediate, posterior and panuveitis and meet **ALL** of the following criteria?

- The patient is 2 years of age or older
- Therapy is prescribed by or in consultation with an ophthalmologist
- The patient does NOT have isolated anterior uveitis
- Documentation of the patient's current weight if between 2 to 17 years of age

If yes, approve for a total of 6 months by GPID or GPI-14 as follows:

- For age 2 to 17 years, approve with a quantity limit of #2 per 28 days based on patient weight as follows:
  - If 10kg to <15kg in weight: Approve Humira 10mg/0.2mL OR 10mg/0.1mL.
  - If 15kg to <30kg in weight: Approve Humira 20mg/0.4mL OR 20mg/0.2mL.
  - If 30kg or heavier: Approve Humira 40mg/0.8mL OR 40mg/0.4mL.
- For age 18 years and above, please enter two authorizations as follows:
  - Approve for 1 fill for Humira 40mg/0.8mL Uveitis Starter Package with a quantity limit of #4 pens OR for Humira Uveitis Starter Package (contains one 80 mg/0.8 mL pen and two 40 mg/0.4 mL pens) with a quantity limit of #3 pens.
  - Approve for 5 months for Humira 40mg/0.8mL OR 40mg/0.4mL with a quantity limit of #2 per 28 days.

If no, do not approve.

**INITIAL DENIAL TEXT:** *\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **ADALIMUMAB (Humira)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
  2. Psoriatic arthritis (PsA: a type of skin and joint condition)
  3. Moderate to severe polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)
  4. Ankylosing spondylitis (AS: a type of joint condition)
  5. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
  6. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
  7. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
  8. Moderate to severe hidradenitis suppurativa (a type of skin condition)
  9. Non-infectious intermediate posterior and panuveitis (a type of eye condition)

*(Initial denial text continued on next page)*

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ADALIMUMAB

INITIAL CRITERIA (CONTINUED)

- B. If you have moderate to severe rheumatoid arthritis, approval also requires:**
1. You are 18 years of age or older
  2. The medication is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
  3. You had a trial of or contraindication (harmful for) to at least 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
- C. If you have moderate to severe polyarticular juvenile idiopathic arthritis, approval also requires:**
1. You are 2 years of age or older
  2. The medication is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
  3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
  4. There is documentation of your most current weight
- D. If you have psoriatic arthritis, approval also requires:**
1. You are 18 years of age or older
  2. The medication is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
  3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
- E. If you have ankylosing spondylitis, approval also requires:**
1. You are 18 years of age or older
  2. The medication is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
  3. You had a trial of or contraindication (harmful for) to an NSAID (non-steroidal anti-inflammatory drug)
- F. If you have moderate to severe plaque psoriasis, approval also requires:**
1. You are 18 years of age or older
  2. The medication is prescribed by or in consultation with a dermatologist (a type of skin doctor)
  3. You have psoriasis covering 3 percent or more of body surface area (BSA) OR psoriatic lesions (rashes) affecting the face, hands, feet, or genital area
  4. You had a trial of or contraindication (harmful for) to ONE or more forms of standard therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids, calcipotriene, acitretin, methotrexate, or cyclosporine

*(Initial denial text continued on next page)*

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**ADALIMUMAB**

**INITIAL CRITERIA (CONTINUED)**

- G. If you have moderate to severe Crohn's disease, approval also requires:**
1. You are 6 years of age or older
  2. The medication is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
  3. You had a trial of or contraindication (harmful for) to ONE standard therapy, such as corticosteroids (such as budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine
- H. If you have moderate to severe ulcerative colitis, approval also requires:**
1. You are 5 years of age or older
  2. The medication is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
  3. You had a trial of or contraindication (harmful for) to ONE standard therapy, such as corticosteroids (such as budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine
- I. If you have moderate to severe hidradenitis suppurativa, approval also requires:**
1. You are 12 years of age or older
- J. If you have non-infectious intermediate, posterior and panuveitis, approval also requires:**
1. You are 2 years of age or older
  2. The medication is prescribed by or in consultation with an ophthalmologist (a type of eye doctor)
  3. You do not have isolated anterior uveitis (a different type of eye inflammation)
  4. If you are 2 to 17 years of age, we require documentation of your current weight

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RENEWAL CRITERIA**

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA)?

If yes, continue to #2.

If no, continue to #4.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ADALIMUMAB

RENEWAL CRITERIA (CONTINUED)

2. Is the request for Humira 40mg dosed **every other week** and has the following criterion been met?
- The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

If yes, **approve for 12 months by GPID or GPI-14 for Humira 40mg/0.8mL OR 40mg/0.4mL with a quantity limit of #2 per 28 days.**

If no, continue to #3.

3. Is the request for Humira 40mg dosed **every week OR Humira 80mg dosed every other week** and have **ALL** of the following criteria been met?
- The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
  - The patient had a trial of at least a 3-month regimen of Humira 40mg dosed every other week

If yes, **approve for 12 months by GPID or GPI-14 for the requested agent with the following quantity limits:**

- **Humira 40mg/0.8mL OR 40mg/0.4mL: #4 per 28 days.**
- **Humira 80mg/0.8mL: #2 per 28 days.**

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

**PAC NOTE:** Please enter a proactive prior authorization for 12 months by GPID or GPI-14 for Humira 40mg/0.8mL syringe/pen OR 40mg/0.4mL syringe/pen with a quantity limit of #2 syringes/pens per month.

4. Does the patient have a diagnosis of moderate to severe polyarticular juvenile idiopathic arthritis (PJIA) **AND** meet the following criterion?
- The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

If yes, **approve for 12 months by GPID or GPI-14 for Humira 10mg/0.1mL, OR 10mg/0.2mL, OR 20mg/0.2mL, OR 20mg/0.4mL, OR 40mg/0.4mL, OR 40mg/0.8mL with a quantity limit of #2 per 28 days.**

If no, continue to #5.

CONTINUED ON NEXT PAGE





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ADALIMUMAB

RENEWAL CRITERIA (CONTINUED)

5. Does the patient have a diagnosis of psoriatic arthritis (PsA) **AND** meet the following criterion?
- The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

If yes, **approve for 12 months by GPID or GPI-14 for Humira 40mg/0.8mL OR 40mg/0.4mL with a quantity limit of #2 per 28 days.**

If no, continue to #6.

6. Does the patient have a diagnosis of ankylosing spondylitis (AS) **AND** meet the following criterion?
- The patient has experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) while on therapy

If yes, **approve for 12 months by GPID or GPI-14 for Humira 40mg/0.8mL OR 40mg/0.4mL with a quantity limit of #2 per 28 days.**

If no, continue to #7.

7. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) **AND** meet the following criterion?
- The patient has achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more while on therapy

If yes, **approve for 12 months by GPID or GPI-14 for Humira 40mg/0.8mL OR 40mg/0.4mL with a quantity limit of #2 per 28 days.**

If no, continue to #8.

8. Does the patient have a diagnosis of moderate to severe Crohn's disease (CD)?

If yes, **approve for 12 months by GPID or GPI-14 for Humira 40mg/0.8mL, OR 40mg/0.4 mL, OR 20mg/0.4mL, OR 20mg/0.2mL with a quantity limit of #2 per 28 days.**

If no, continue to #9.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ADALIMUMAB

RENEWAL CRITERIA (CONTINUED)

9. Does the patient have a diagnosis of moderate to severe ulcerative colitis (UC)?

If yes, approve for 12 months by GPID or GPI-14 for the requested agent as follows:

- Humira 40mg/0.8mL OR Humira 40mg/0.4mL: #4 per 28 days.
- Humira 80mg/0.8mL: #2 per 28 days.
- Humira 20mg/0.4mL OR Humira 20mg/0.2mL: #4 per 28 days.

If no, continue to #10.

10. Does the patient have a diagnosis of moderate to severe hidradenitis suppurativa (HS)?

If yes, approve for 12 months by GPID or GPI-14 for the requested agent as follows:

- Humira 40mg/0.8mL OR 40mg/0.4mL: #4 per 28 days.
- Humira 80mg/0.8 mL: #2 per 28 days.

If no, continue to #11.

11. Does the patient have a diagnosis of non-infectious intermediate, posterior and panuveitis **AND** meet the following criteria?

- The patient has not experienced treatment failure, defined as **ONE** of the following criteria:
  - Development of new inflammatory chorioretinal or retinal vascular lesions
  - A 2-step increase from baseline in anterior chamber cell grade or vitreous haze grade
  - A worsening of best-corrected visual acuity (BCVA) by at least 15 letters relative to best state achieved

If yes, approve for 12 months by GPID or GPI-14 for Humira 10mg/0.1mL, OR 10mg/0.2mL, OR 20mg/0.2mL, OR 20mg/0.4mL, OR 40mg/0.8mL, OR 40mg/0.4mL with a quantity limit of #2 per 28 days.

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ADALIMUMAB

RENEWAL CRITERIA (CONTINUED)

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ADALIMUMAB (Humira)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following diagnoses:
    - 1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
    - 2. Psoriatic arthritis (PsA: a type of skin and joint condition)
    - 3. Moderate to severe polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)
    - 4. Ankylosing spondylitis (AS: a type of joint condition)
    - 5. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
    - 6. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
    - 7. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
    - 8. Moderate to severe hidradenitis suppurativa (a type of skin condition)
    - 9. Non-infectious intermediate posterior and panuveitis (a type of eye condition)
  - B. **If you have moderate to severe rheumatoid arthritis, renewal also requires:**
    - 1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
    - 2. If you are requesting Humira 40mg weekly dosing OR Humira 80mg every other week dosing, we require you have tried at least a 3-month of Humira 40mg every other week
  - C. **If you have moderate to severe polyarticular juvenile idiopathic arthritis, renewal also requires:**
    - 1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
  - D. **If you have psoriatic arthritis, renewal also requires:**
    - 1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
  - E. **If you have ankylosing spondylitis, renewal also requires:**
    - 1. You have experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) while on therapy
  - F. **If you have moderate to severe plaque psoriasis, renewal also requires:**
    - 1. You have achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more while on therapy
- (Renewal denial text continued on next page)***

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ADALIMUMAB

RENEWAL CRITERIA (CONTINUED)

G. If you have non-infectious intermediate, posterior and panuveitis, renewal also requires:

1. You have not experienced treatment failure, defined as ONE of the following:
  - a. You have development of new inflammatory chorioretinal or retinal vascular lesions (eye tumors)
  - b. A 2-step increase from baseline in anterior chamber cell grade or vitreous haze grade (types of classifications on how bad eye inflammation is)
  - c. A worsening of best-corrected visual acuity (BCVA) by at least 15 letters relative to best visual acuity achieved

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Humira.

REFERENCES

- Humira [Prescribing Information]. North Chicago, IL: AbbVie Inc.; February 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/22

Created: 05/03

Client Approval: 05/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

AFATINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
AFATINIB DIMALEATE	GILOTRIF	40478		GPI-10 (2136000610)	

GUIDELINES FOR USE

1. Does the patient have a diagnosis of metastatic squamous non-small cell lung cancer (NSCLC) **AND** meet the following criterion?

- The patient has disease progression after platinum-based chemotherapy (i.e., cisplatin, carboplatin, oxaliplatin)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**  
If no, continue to #2.

2. Does the patient have a diagnosis of metastatic non-small cell lung cancer (NSCLC) and meet **ALL** of the following criteria?

- The patient's tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test
- Gilotrif will NOT be used concurrently with an epidermal growth factor receptor (EGFR) tyrosine kinase-inhibitor (e.g., Tarceva [erlotinib], Tagrisso [Osimertinib], Iressa [gefitinib])

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **AFATINIB (Gilotrif)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:

1. Metastatic squamous non-small cell lung cancer (type of lung cancer that has spread to other parts of the body)
2. Metastatic non-small cell lung cancer (a different type of lung cancer that has spread to other parts of the body)

B. **If you have metastatic squamous non-small cell lung cancer, approval also requires:**

1. Your disease has worsened after using platinum-based chemotherapy (such as cisplatin, carboplatin, oxaliplatin)

C. **If you have metastatic non-small cell lung cancer, approval also requires:**

1. Your tumors have non-resistant epidermal growth factor receptor (EGFR: type of protein) mutations as shown by an FDA (Food and Drug Administration)-approved test
2. You will NOT be using Gilotrif concurrently (at the same time) with an epidermal growth factor receptor (EGFR) tyrosine kinase-inhibitor (such as Tarceva [erlotinib], Tagrisso [Osimertinib], Iressa [gefitinib])

***(Denial text continued on next page)***

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

AFATINIB

GUIDELINES FOR USE (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Gilotrif.

REFERENCES

- Gilotrif (afatinib) [prescribing information]. Boehringer Ingelheim Pharmaceuticals, Inc.; Ridgefield, CT. April 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/22

Created: 10/13

Client Approval: 05/22

P&T Approval: 04/22



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**ALECTINIB**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ALECTINIB HCL	ALECENSA	42895		GPI-10 (2153050710)	

**GUIDELINES FOR USE**

- Does the patient have a diagnosis of metastatic non-small cell lung cancer (NSCLC) **AND** meet the following criterion?
  - Patient is positive for anaplastic lymphoma kinase (ALK) fusion oncogene as detected by an FDA-approved test

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #240 per 30 days.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ALECTINIB (Alecensa)** requires the following rules be met for approval:

- You have a diagnosis of metastatic non-small cell lung cancer (NSCLC; type of cancer that has spread)
- You are positive for anaplastic lymphoma kinase (ALK; gene mutation) fusion oncogene as detected by an FDA (Food and Drug Administration) -approved test

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Alecensa.

**REFERENCES**

- Alecensa [Prescribing Information]. South San Francisco, CA: Genentech, Inc. May 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/10/21

Created: 12/15

Client Approval: 03/21

P&T Approval: 01/18



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ALLERGEN EXTRACT-HOUSE DUST MITE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
HOUSE DUST MITE	ODACTRA		42527	GPI-14 (20109902220740)	ROUTE = SUBLINGUAL

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of house dust mite (HDM)-induced allergic rhinitis with or without conjunctivitis and meet **ALL** of the following criteria?
  - Diagnosis is confirmed by in vitro testing for IgE antibodies to *Dermatophagoides farinae* or *Dermatophagoides pteronyssinus* house dust mites, or skin testing to licensed house dust mite allergen extracts
  - Patient is between 18 and 65 years old
  - The medication is prescribed by or given in consultation with an allergist, immunologist, or other physician experienced in the diagnosis and treatment of allergic diseases
  - The patient has persistent symptoms of allergic rhinitis (persistent symptoms are defined as symptoms presenting at least 4 days a week or for at least 4 weeks)
  - The patient has moderate to severe symptoms of allergic rhinitis (moderate-to-severe symptoms include one or more of the following: troublesome symptoms, sleep disturbance, impairment of daily activities, or impairment of school or work)
  - The patient has a current claim or prescription for auto-injectable epinephrine within the past 365 days

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #1 per day.**

**APPROVAL TEXT:** Renewal requires that the patient has experienced an improvement in signs and symptoms of allergic rhinitis from baseline.

If no, do not approve.

**INITIAL DENIAL TEXT:** **\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ALLERGEN EXTRACT-HOUSE DUST MITE (Oductra)** requires the following rule(s) be met for approval:

- A. You have allergic rhinitis (itchy, watery eyes, sneezing) caused by house dust mites, with or without conjunctivitis (type of inflammation of eye and eyelid)
  - B. Your diagnosis is confirmed by in vitro testing (testing outside of your body in a tube) for IgE (Immunoglobulin E) antibodies to *Dermatophagoides farinae* or *Dermatophagoides pteronyssinus* house dust mites, or skin testing to licensed house dust mite allergen extracts
  - C. You are between 18 and 65 years old
- (Initial denial text continued on next page)**

CONTINUED ON NEXT PAGE





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ALLERGEN EXTRACT-HOUSE DUST MITE

INITIAL CRITERIA (CONTINUED)

- D. The medication is prescribed by or given in consultation with an allergist (allergy doctor), immunologist (immune system doctor), or other physician experienced in the diagnosis and treatment of allergic diseases
- E. You have persistent symptoms of allergic rhinitis (persistent symptoms are defined as symptoms presenting at least 4 days a week or for at least 4 weeks)
- F. You have moderate to severe symptoms of allergic rhinitis (moderate-to-severe symptoms include troublesome symptoms, sleep disturbance, impairment of daily activities, or impairment of school or work)
- G. You have a current claim or prescription for auto-injectable epinephrine within the past 365 days

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Has the patient experienced an improvement in signs and symptoms of allergic rhinitis from baseline?

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #1 per day.**  
If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ALLERGEN EXTRACT-HOUSE DUST MITE (Odactra)** requires the following rule is met for renewal:

- A. You have experienced an improvement in signs and symptoms of allergic rhinitis (itchy, watery eyes, sneezing) from baseline

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**ALLERGEN EXTRACT-HOUSE DUST MITE**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Odactra.

**REFERENCES**

- Odactra [Prescribing Information]. Merck, Sharp & Dohme Corp. Whitehouse Station, NJ. March 2017.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 05/01/20

Created: 02/18

Client Approval: 04/20

P&T Approval: 01/18



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ALLERGEN EXTRACT-MIXED GRASS POLLEN

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
GR POL-ORC/SW VER/RYE/KENT/TIM	ORALAIR	39918		GPI-10 (2010990520)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of grass pollen-induced allergic rhinitis that is confirmed by a positive skin prick test and/or a positive titer to specific IgE antibodies for any of the five grass (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens) species included in Oralair?

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Was Oralair prescribed by or given in consultation with an allergist, immunologist, or other physician experienced in the diagnosis and treatment of allergic diseases?

If yes, continue to #3.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

3. Does the patient have persistent and moderate-to-severe symptoms of allergic rhinitis (persistent symptoms are defined as symptoms presenting at least 4 days a week or for at least 4 weeks, and moderate-to-severe symptoms include one or more of the following items: troublesome symptoms, sleep disturbance, impairment of daily activities, or impairment of school or work)?

If yes, continue to #4.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

4. Does patient have a current claim or prescription for auto-injectable epinephrine?

If yes, continue to #5.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ALLERGEN EXTRACT-MIXED GRASS POLLEN

INITIAL CRITERIA (CONTINUED)

5. Is the patient between the ages of 5 and 17 years of age?

If yes, **approve for 12 months by GPID or GPI-14 for a quantity limit of #3 tablets of 100 IR for the first 2 days of therapy initiation and #1 tablet of 300 IR per day thereafter.**

**APPROVAL TEXT:** Renewal requires that the patient has experienced an improvement in signs and symptoms of allergic rhinitis from baseline.

If no, continue to #6.

6. Is the patient between 18 and 65 years of age?

If yes, **approve for 12 months by GPID or GPI-10 for a quantity limit of #1 tablet (300 IR) per day.**

**APPROVAL TEXT:** Renewal requires that the patient has experienced an improvement in signs and symptoms of allergic rhinitis from baseline.

If no, do not approve.

**INITIAL DENIAL TEXT:** *\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **ALLERGEN EXTRACT-MIXED GRASS POLLEN (Oralair)** requires the following rule(s) be met for approval:

- A. You have a diagnosis of allergic rhinitis (itchy, watery eyes, sneezing) caused by grass pollen
- B. Your diagnosis is confirmed by a positive skin prick test and/or a positive titer (the amount of antibodies in the blood) to specific IgE (Immunoglobulin E) antibodies for any of the five grass types included in Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens)
- C. Therapy is prescribed by or given in consultation with an allergist (allergy doctor), immunologist (immune system doctor), or other physician experienced in the diagnosis and treatment of allergic diseases
- D. You have persistent and moderate-to-severe symptoms of allergic rhinitis (persistent symptoms are defined as symptoms presenting at least 4 days a week or for at least 4 weeks, and moderate-to-severe symptoms include: troublesome symptoms, sleep disturbance, impairment of daily activities, or impairment of school or work)
- E. You have a current claim or prescription for auto-injectable epinephrine
- F. You are between 5 and 65 years of age

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ALLERGEN EXTRACT-MIXED GRASS POLLEN

INITIAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

- 1. Has the patient experienced an improvement in signs and symptoms of allergic rhinitis from baseline?

If yes, **approve for 12 months by HICL or GPI-14 for a quantity limit of #1 tablet per day.**  
If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ALLERGEN EXTRACT-MIXED GRASS POLLEN (Oralair)** requires the following rules be met for renewal:

- A. You have experienced an improvement in signs and symptoms of allergic rhinitis (itchy, watery eyes, sneezing) from baseline

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Oralair.

REFERENCES

- Oralair [Prescribing Information]. Lenoir, NC: GREER Laboratories, Inc., December 2018.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 05/01/20

Created: 05/14

Client Approval: 04/20

P&T Approval: 01/19



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ALLERGEN EXTRACT-SHORT RAGWEED POLLEN

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
WEED POLLEN- SHORT RAGWEED	RAGWITEK		36402	GPI-14 (20100060200720)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of short ragweed pollen-induced allergic rhinitis and meet **ALL** of the following criteria?
  - The patient is between 5 and 65 years of age
  - Diagnosis is confirmed by a positive skin test or in vitro testing for pollen-specific IgE antibodies for short ragweed pollen
  - Therapy was prescribed by or given in consultation with an allergist, immunologist, or other physician experienced in the diagnosis and treatment of allergic diseases
  - The patient has persistent and moderate-to-severe symptoms of allergic rhinitis (persistent symptoms are defined as symptoms presenting at least 4 days a week or for at least 4 weeks, and moderate-to-severe symptoms include one or more of the following items: troublesome symptoms, sleep disturbance, impairment of daily activities, or impairment of school or work)
  - The patient has a current claim or prescription for auto-injectable epinephrine

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #1 per day.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ALLERGEN EXTRACT-SHORT RAGWEED POLLEN

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **ALLERGEN EXTRACT-SHORT RAGWEED POLLEN (Ragwitek)** requires the following rule(s) be met for approval:

- A. You have allergic rhinitis (itchy, watery eyes, sneezing) caused by short ragweed pollen
- B. You are between 5 and 65 years of age
- C. Your diagnosis is confirmed by a positive skin test or in vitro testing (testing outside of your body in a tube) for pollen-specific IgE (Immunoglobulin E) antibodies for short ragweed pollen
- D. Therapy is prescribed by or given in consultation with an allergist (allergy doctor), immunologist (immune system doctor), or other physician experienced in the diagnosis and treatment of allergic diseases
- E. You have persistent and moderate-to-severe symptoms of allergic rhinitis (persistent symptoms are defined as symptoms presenting at least 4 days a week or for at least 4 weeks, and moderate-to-severe symptoms include: troublesome symptoms, sleep disturbance, impairment of daily activities, or impairment of school or work)
- F. You have a current claim or prescription for auto-injectable epinephrine

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Has the patient experienced an improvement in signs and symptoms of allergic rhinitis from baseline?

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #1 per day.**  
If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ALLERGEN EXTRACT-SHORT RAGWEED POLLEN

RENEWAL CRITERIA (CONTINUED)

**RENEWAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **ALLERGEN EXTRACT-SHORT RAGWEED POLLEN (Ragwitek)** requires the following rule(s) be met for renewal:

A. You have experienced an improvement in signs and symptoms of allergic rhinitis from baseline

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Ragwitek.

**REFERENCES**

- Ragwitek [Prescribing Information]. Swindon, UK: Catalent Pharma Solutions Limited; April 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 06/01/21

Created: 05/14

Client Approval: 05/21

P&T Approval: 07/21





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ALLERGEN EXTRACT-TIMOTHY GRASS POLLEN

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
GRASS POLLEN-TIMOTHY, STD	GRASTEK	22138		GPI-10 (2010004800)	ROUTE = SUBLINGUAL

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of grass pollen-induced allergic rhinitis and meet **ALL** of the following criteria?
  - The patient is between 5 and 65 years of age
  - Diagnosis is confirmed by a positive skin prick test and/or a positive titre to specific IgE antibodies for Timothy grass or cross-reactive grass pollens
  - Therapy is prescribed by or in consultation with an allergist, immunologist, or other physician experienced in the diagnosis and treatment of allergic diseases
  - The patient has persistent and moderate-to-severe symptoms of allergic rhinitis (persistent symptoms are defined as symptoms presenting at least 4 days a week or for at least 4 weeks, and moderate-to-severe symptoms include one or more of the following: troublesome symptoms, sleep disturbance, impairment of daily activities, or impairment of school or work)
  - The patient has a current claim or prescription for auto-injectable epinephrine

If yes, **approve for 12 months by GPID or GPI-14 for a quantity limit of #1 per day.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ALLERGEN EXTRACT-TIMOTHY GRASS POLLEN (Grastek)** requires the following rule(s) be met for approval:

- A. You have allergic rhinitis (itchy, watery eyes, sneezing) caused by grass pollen
- B. You are between 5 and 65 years of age
- C. Your diagnosis is confirmed a positive skin prick test and/or a positive titre (the amount of antibodies in the blood) to specific IgE (Immunoglobulin E) antibodies for Timothy grass or cross-reactive grass pollens
- D. Therapy is prescribed by or in consultation with an allergist (allergy doctor), immunologist (immune system doctor), or other physician experienced in the diagnosis and treatment of allergic diseases

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ALLERGEN EXTRACT-TIMOTHY GRASS POLLEN

INITIAL CRITERIA (CONTINUED)

- E. You have persistent and moderate-to-severe symptoms of allergic rhinitis (persistent symptoms are defined as symptoms presenting at least 4 days a week or for at least 4 weeks, and moderate-to-severe symptoms include: troublesome symptoms, sleep disturbance, impairment of daily activities, or impairment of school or work)
- F. You have a current claim or prescription for auto-injectable epinephrine

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Has the patient experienced an improvement in signs and symptoms of allergic rhinitis from baseline?

If yes, **approve for 12 months by GPID or GPI-14 for a quantity limit of #1 per day.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ALLERGEN EXTRACT-TIMOTHY GRASS POLLEN (Grastek)** requires the following rule be met for renewal:

- A. You have experienced an improvement in signs and symptoms of allergic rhinitis (itchy, watery eyes, sneezing) from baseline

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Grastek.

**REFERENCES**

- Grastek [Prescribing Information]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp; August 2020.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**ALLERGEN EXTRACT-TIMOTHY GRASS POLLEN**

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/22

Created: 05/14

Client Approval: 12/21

P&T Approval: 01/18



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ALPELISIB-PIQRAY

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ALPELISIB	PIQRAY	45761		GPI-10 (2153801000)	BRAND ≠ VIJOICE

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of advanced or metastatic breast cancer and meet **ALL** of the following criteria?
  - The patient is a postmenopausal female or a male
  - Piqray will be used in combination with Faslodex (fulvestrant)
  - The patient's breast cancer is hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative with PIK3CA-mutation as detected by an FDA-approved test
  - The patient has disease progression on or after an endocrine-based regimen

If yes, approve for 12 months by GPID or GPI -14 for all strengths as follows:

- Piqray 300mg daily dose: #56 per 28 days.
- Piqray 250mg daily dose: #56 per 28 days.
- Piqray 200mg daily dose: #28 per 28 days.

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ALPELISIB-PIQRAY** requires the following rule(s) be met for approval:

- A. You have advanced or metastatic breast cancer (breast cancer that has spread to other parts of the body)
- B. You are a postmenopausal (after menopause) female or a male
- C. Piqray will be used in combination with Faslodex (fulvestrant)
- D. Your breast cancer is hormone receptor (HR: type of protein)-positive, human epidermal growth factor receptor 2 (HER2: type of protein)-negative with PIK3CA (type of gene)-mutation as detected by a Food and Drug Administration (FDA)-approved test
- E. You have disease progression on or after an endocrine-based regimen (your disease has worsened after using a type of hormone therapy)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**ALPELISIB-PIQRAY**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Piqray.

**REFERENCES**

- Piqray [Prescribing Information]. East Hanover, NJ. Novartis Pharmaceuticals Corp., July 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 05/09/22

Created: 08/19

Client Approval: 04/22

P&T Approval: 07/19



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ALPELISIB - VIJOICE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ALPELISIB	VIJOICE	45761		GPI-10 (9948601000)	BRAND ≠ PIQRAY

**GUIDELINES FOR USE**

- Does the patient have a diagnosis of PIK3CA-related overgrowth spectrum (PROS) and meet **ALL** of the following criteria?
  - The patient is 2 years of age or older
  - The patient has severe manifestations of PROS that require systemic therapy

If yes, **approve for 12 months by GPID or GPI-14 for the requested strength as follows:**

- 50 mg daily dose: #28 per 28 days.**
- 125 mg daily dose: #28 per 28 days.**
- 250 mg daily dose: #56 per 28 days.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ALPELISIB - VIJOICE** requires the following rule(s) be met for approval:

- You have PIK3CA-related overgrowth spectrum (PROS: group of disorders that cause overgrowth of parts of the body due to mutations in a type of gene)
- You are 2 years of age or older
- You have severe manifestations of PROS that require systemic therapy (treatment that targets the entire body)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Vioice.

**REFERENCES**

- Vioice [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals, Corp.; April 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/01/22

Created: 08/22

Client Approval: 09/22

P&T Approval: 07/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

AMANTADINE EXTENDED RELEASE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
AMANTADINE EXTENDED RELEASE	GOCOVRI		43787 43788	GPI-14 (73200010107020) (73200010107040)	
AMANTADINE HCL	OSMOLEX ER		44471 44472 44473 48017	GPI-14 (73200010107520) (73200010107530) (73200010107540) (7320001010C320)	

**\*\* Please use the criteria for the specific drug requested \*\***

**GUIDELINES FOR USE**

**GOCOVRI**

- Does the patient have a diagnosis of Parkinson's disease and meet **ALL** of the following criteria?
  - The patient has dyskinesia
  - The patient is receiving levodopa-based therapy
  - The patient had a trial of generic amantadine capsules, tablets, or solution

If yes, **approve for 12 months by GPID or GPI-14 for all the following strengths with the following quantity limits:**

- Gocovri 68.5mg: #1 per day.**
- Gocovri 137mg: #2 per day.**

If no, continue to #2.

- Does the patient have a diagnosis of Parkinson's disease and meet **ALL** of the following criteria?
  - The patient is experiencing 'off' episodes
  - Therapy is given as an adjunctive treatment to levodopa/carbidopa therapy
  - The patient had a trial of generic amantadine capsules, tablets, or solution

If yes, **approve for 12 months by GPID or GPI-14 for all the following strengths with the following quantity limits:**

- Gocovri 68.5mg: #1 per day.**
- Gocovri 137mg: #2 per day.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

AMANTADINE EXTENDED RELEASE

GUIDELINES FOR USE - GOCOVRI (CONTINUED)

**GOCOVRI DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **AMANTADINE EXTENDED RELEASE (Gocovri)** requires the following rule(s) be met for approval:

- A. You have Parkinson's disease (nervous system disorder that affects movement)
  - B. **If you have dyskinesia (abnormal involuntary movements), approval also requires:**
    1. You are receiving levodopa-based therapy
    2. You have previously tried generic amantadine capsules, tablets, or solution
  - C. **If you are experiencing 'off' episodes (when the medication stops working), approval also requires:**
    1. You are also receiving levodopa-carbidopa therapy
    2. You have previously tried generic amantadine capsules, tablets, or solution

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**OSMOLEX ER**

1. Does the patient have a diagnosis of Parkinson's disease?

If yes, continue to #3.  
If no, continue to #2.

2. Is the request for the treatment of drug-induced extrapyramidal symptoms (EPS) **AND** the patient meets the following criterion?

- The patient is 18 years of age or older

If yes, continue to #3.  
If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

AMANTADINE EXTENDED RELEASE

GUIDELINES FOR USE - OSMOLEX ER (CONTINUED)

3. Does the patient meet **ALL** of the following criteria?

- Therapy is prescribed by or given in consultation with a psychiatrist, neurologist, or geriatrician
- The patient has had a trial of generic amantadine IR capsules, tablets, or solution

If yes, **approve for 12 months by GPID or GPI-14 for all strengths with a quantity limit of #1 per day.**

If no, do not approve.

**OSMOLEX ER DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **AMANTADINE EXTENDED RELEASE (Osmolex ER)** requires the following rule(s) be met for approval:

- A. You have Parkinson's disease (nervous system disorder that affects movement) OR you are being treated for drug-induced extrapyramidal symptoms (group of movement disorders)
- B. Therapy is prescribed by or given in consultation with a psychiatrist (mental disorder doctor), neurologist (nerve doctor), or geriatrician (doctor who treats elderly people)
- C. You have previously tried generic amantadine immediate-release capsules, tablets or solution
- D. **If you are being treated for drug-induced extrapyramidal symptoms, approval also requires:**
  1. You are 18 years of age or older

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Gocovri and Osmolex ER.

**REFERENCES**

- Gocovri [Prescribing Information]. Emeryville, CA: Adamas Pharma, LLC.; January 2021.
- Osmolex ER [Prescribing Information]. Bridgewater, NJ: Vertical Pharmaceuticals, LLC. October 2019.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**AMANTADINE EXTENDED RELEASE**

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/21

Created: 09/17

Client Approval: 05/21

P&T Approval: 04/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

AMBRISENTAN

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
AMBRISENTAN	LETAIRIS, AMBRISENTAN	34849		GPI-10 (4016000700)	

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of pulmonary arterial hypertension (WHO Group 1) and meet **ALL** of the following criteria?

- Therapy is prescribed by or in consultation with a cardiologist or pulmonologist
- The patient has NYHA-WHO Functional Class II to IV symptoms
- The patient does not have idiopathic pulmonary fibrosis (IPF)

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Does that patient have a documented confirmatory PAH diagnosis based on right heart catheterization with the following parameters?

- Mean pulmonary artery pressure (PAP) of > 20 mmHg
- Pulmonary capillary wedge pressure (PCWP) of ≤ 15 mmHg
- Pulmonary vascular resistance (PVR) of ≥ 3 Wood units

If yes, **approve for 12 months by HICL or GPI-10 for #1 per day.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **AMBRISENTAN (Letairis)** requires the following rule(s) be met for approval:

- A. You have pulmonary arterial hypertension (a type of heart and lung condition) (World Health Organization Group 1)
- B. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung doctor)
- C. You have New York Heart Association-World Health Organization (NYHA-WHO) Functional Class II to IV symptoms (a classification system of heart failure symptoms)
- D. You do not have idiopathic pulmonary fibrosis (scarring of the lungs for an unknown reason) **(Initial denial text continued on next page)**

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

AMBRISENTAN

INITIAL CRITERIA (CONTINUED)

- E. You have documentation confirming your diagnosis of pulmonary arterial hypertension based on right heart catheterization (a test using a thin tube that is placed into the right side of your heart) with the following values:
1. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
  2. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
  3. Pulmonary vascular resistance (PVR) greater than or equal to 3 Wood units

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group 1)?

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

2. Does the patient meet **ONE** of the following criteria?

- The patient has shown improvement from baseline in the 6-minute walk distance test
- The patient has remained stable from baseline in the 6-minute walk distance test AND World Health Organization (WHO) functional class has remained stable or improved

If yes, **approve for 12 months by HICL or GPI-10 for #1 per day.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **AMBRISENTAN (Letairis)** requires the following rule(s) be met for renewal:

- A. You have pulmonary arterial hypertension (a type of heart and lung condition) (World Health Organization Group 1)
- B. You meet ONE of the following:
  1. You have shown improvement from baseline in the 6-minute walk distance test
  2. You have remained from baseline in the 6-minute walk distance test AND World Health Organization (WHO) functional class has remained stable or improved

***(Renewal denial text continued on next page)***

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

AMBRISENTAN

RENEWAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Letairis.

REFERENCES

- Letairis [Prescribing Information]. Foster City, CA: Gilead Sciences, Inc.; August 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/01/22

Created: 10/22

Client Approval: 10/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

AMIFAMPRIDINE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
AMIFAMPRIDINE	FIRDAPSE	36930		GPI-10 (7600001210)	
AMIFAMPRIDINE	RUZURGI	34158		GPI-10 (6270104010)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of Lambert-Eaton myasthenic syndrome (LEMS) and meet **ALL** of the following criteria?

- Therapy is prescribed by or in consultation with a neurologist or hematologist-oncologist
- Diagnosis is confirmed by ALL of the following:  
Electrodiagnostic studies (e.g., reduced compound muscle action potential (CMAP)) and/or voltage-gated calcium channel (VGCC) antibody testing  
Clinical triad of muscle weakness, autonomic dysfunction, and decreased tendon reflexes

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Is the request for **Firdapse** and the patient meets the following criterion?

- The patient is 6 years of age or older

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #8 per day.**

If no, continue to #3.

3. Is the request for **Ruzurgi**?

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #10 per day.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

AMIFAMPRIDINE

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **AMIFAMPRIDINE (Firdapse, Ruzurgi)** requires the following rule(s) be met for approval:

- A. You have Lambert-Eaton myasthenic syndrome (a type of muscle disorder)
- B. Therapy is prescribed by or in consultation with a neurologist (type of brain doctor) or hematologist-oncologist (a type of blood-cancer doctor)
- C. Diagnosis is confirmed by ALL of the following:
  1. Electrodiagnostic studies and/or voltage-gated calcium channel (types of lab tests) antibody testing
  2. Three clinical symptoms of muscle weakness, autonomic dysfunction (nerve dysfunction), and decreased tendon reflexes
- D. **If you are requesting Firdapse, approval also requires:**
  1. You are 6 years of age or older

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of Lambert-Eaton myasthenic syndrome (LEMS) **AND** meet the following criterion?
  - The patient has experienced improvement or stabilization in muscle weakness compared to baseline

If yes, **approve for 12 months for the requested drug as follows:**

- **Firdapse: Approve by HICL or GPI-10 with a quantity limit of #8 per day.**
- **Ruzurgi: Approve by HICL or GPI-10 with a quantity limit of #10 per day.**

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

AMIFAMPRIDINE

RENEWAL CRITERIA (CONTINUED)

**RENEWAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **AMIFAMPRIDINE (Firdapse, Ruzurgi)** requires the following rule(s) be met for renewal:

- A. You have Lambert-Eaton myasthenic syndrome (a type of muscle disorder)
- B. You have experienced improvement or stabilization in muscle weakness compared to baseline

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Firdapse and Ruzurgi.

**REFERENCES**

- Firdapse [Prescribing Information]. Coral Gables, FL: Catalyst Pharmaceuticals, Inc; September 2022.
- Ruzurgi [Prescribing Information]. Princeton, NJ: Jacobus Pharmaceutical Company, Inc., May 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/01/22

Created: 02/19

Client Approval: 10/22

P&T Approval: 10/22





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

AMIKACIN LIPOSOMAL INHALATION

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
AMIKACIN LIPOSOMAL/NEB. ACCESSR	ARIKAYCE	45298		GPI-10 (0700001012)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA, SEE BELOW)**

1. Does the patient have a diagnosis of *Mycobacterium avium complex* (MAC) lung disease with limited or no alternative treatment options and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient has **NOT** achieved negative sputum cultures after a minimum of 6 consecutive months of multidrug background regimen therapy
  - Arikayce will be used as part of a combination antibacterial drug regimen
  - Arikayce is being prescribed by or given in consultation with a pulmonologist or infectious disease specialist physician

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #8.4mL (1 vial) per day.**

**APPROVAL TEXT:** Renewal requires that the patient has not had a positive MAC sputum culture after consecutive negative cultures and also has had improvement in symptoms. Additionally, for first renewal requests, approval requires documentation of at least one negative sputum culture for MAC by six months of Arikayce treatment. For second and subsequent renewal requests, approval requires documentation of at least three negative sputum cultures for MAC by 12 months of Arikayce treatment.

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **AMIKACIN LIPOSOMAL INHALATION (Arikayce)** requires the following rule(s) be met for approval:

- A. You have *Mycobacterium avium complex* (MAC – group of bacteria that cause serious infections) lung disease with limited or no alternative treatment options
- B. You are 18 years of age or older
- C. You have NOT achieved negative sputum cultures (mucus tests) after using multidrug background regimen therapy for at least 6 months in a row
- D. Arikayce will be used as part of a combination antibacterial drug regimen
- E. Arikayce is being prescribed by or given in consultation with a pulmonologist (lung doctor) or infectious disease specialist physician

**(Initial denial text continued on next page)**

**CONTINUE ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

AMIKACIN LIPOSOMAL INHALATION

INITIAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Is the request for the first renewal of Arikayce for the treatment of patients with a diagnosis of *Mycobacterium avium complex* (MAC) lung disease and the patient meets **ALL** of the following criteria?
  - There is documentation of at least **ONE** negative sputum culture for MAC by 6 months of Arikayce treatment
  - The patient has **NOT** had a positive MAC sputum culture after consecutive negative cultures
  - The patient has had an improvement in symptoms

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #8.4mL (1 vial) per day.**

If no, continue to #2.

2. Is the request for the second or subsequent renewal of Arikayce for treatment of patients with a diagnosis of *Mycobacterium avium complex* (MAC) lung disease and the patient meets **ALL** of the following criteria?
  - There is documentation of at least **THREE** negative sputum cultures for MAC by 12 months of Arikayce treatment
  - The patient has **NOT** had a positive MAC sputum culture after consecutive negative cultures
  - The patient has had an improvement in symptoms

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #8.4mL (1 vial) per day.**

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

CONTINUE ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

AMIKACIN LIPOSOMAL INHALATION

INITIAL CRITERIA (CONTINUED)

**RENEWAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **AMIKACIN LIPOSOMAL INHALATION (Arikayce)** requires the following rule(s) be met for renewal:

- A. You have *Mycobacterium avium complex* (MAC- group of bacteria that cause serious infections) lung disease
- B. You have not had a positive *Mycobacterium avium complex* sputum culture (mucus test) after repeated negative cultures
- C. You have experienced an improvement in symptoms
- D. You meet ONE of the following:
  1. For first renewal requests, approval also requires documentation of at least ONE negative sputum culture (mucus test) for *Mycobacterium avium complex* by 6 months of Arikayce treatment
  2. For second or later renewal requests, approval also requires documentation of at least THREE negative sputum cultures (mucus test) for *Mycobacterium avium complex* by 12 months of Arikayce treatment

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Arikayce.

**REFERENCES**

- Arikayce [Prescribing information]. Bridgewater, NJ: Insmmed Incorporated; September 2018.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 05/01/20

Created: 11/18

Client Approval: 04/20

P&T Approval: 10/18



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

AMLODIPINE SUSPENSION

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
AMLODIPINE BENZOATE	KATERZIA	45864		GPI-10 (3400000308)	

GUIDELINES FOR USE

1. Is the patient unable to swallow oral amlodipine tablets at prescribed dose?

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of 10mL per day.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **AMLODIPINE SUSPENSION (Katerzia)** requires the following rule(s) be met for approval:

A. You are unable to swallow oral amlodipine tablets at prescribed dose

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Katerzia.

REFERENCES

- Katerzia [Prescribing Information]. Greenwood Village, CO: Silvergate Pharmaceuticals, Inc., July 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/20

Created: 02/20

Client Approval: 02/20

P&T Approval: 01/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

AMLODIPINE/CELECOXIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
AMLODIPINE BESYLATE/CELECOXIB	CONSENSI	44972		GPI-10 (3499870210)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of both hypertension and osteoarthritis and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient had a trial of amlodipine AND celecoxib
  - The patient has an adherence or other challenge which requires the use of the combination product over separate agents
  - Consensi will NOT be used together with any other calcium channel blocker agents (e.g. diltiazem, felodipine, verapamil)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **AMLODIPINE/CELECOXIB (Consensi)** requires the following rule(s) be met for approval:

- A. You have both hypertension (abnormal high blood pressure) and osteoarthritis (a type of arthritis that occurs when tissue at the ends of your bones wears down)
- B. You are 18 years of age or older
- C. You have previously tried amlodipine AND celecoxib
- D. You have an adherence or other challenge requiring the use of the combination product over separate agents
- E. You will NOT use Consensi together with any other calcium channel blocker agents (such as diltiazem, felodipine, verapamil)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**AMLODIPINE/CELECOXIB**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Consensi.

**REFERENCES**

- Consensi [Prescribing Information]. Hot Springs, AR: Burke Therapeutics, LLC; February 2017.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/20

Created: 02/20

Client Approval: 02/20

P&T Approval: 01/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

AMPHETAMINE SULFATE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
AMPHETAMINE SULFATE	EVEKEO		19821 19822	GPI-14 (61100010100320, 61100010100310)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of narcolepsy **AND** meet the following criterion?

- The patient is 6 years of age or older

If yes, **approve the requested strength for 12 months by GPID or GPI-14 with a quantity limit of #6 per day.**

If no, continue to #2.

2. Does the patient have a diagnosis of attention deficit disorder with hyperactivity and meet **ALL** of the following criteria?

- The patient is 3 years of age or older
- The patient had a previous trial of at least **ONE** of the following stimulant medications: mixed amphetamine salts (Adderall IR), methylphenidate (Ritalin IR), or dextroamphetamine (Dexedrine)

If yes, **approve the requested strength for 12 months by GPID or GPI-14 with a quantity limit of #4 per day.**

If no, continue to #3.

3. Is the requested medication being used for weight loss or exogenous obesity?

If yes, continue to #4.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

4. Are weight loss products (anti-obesity medications) a covered benefit?

If yes, continue to #5.

If no, guideline does not apply for plans that exclude treatment of obesity.

5. Is this an initial request (per MRF and claims history)?

If yes, continue to #6.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

AMPHETAMINE SULFATE

GUIDELINES FOR USE (CONTINUED)

6. Does the patient meet **ALL** of the following criteria?

- The patient is 12 years of age or older
- The patient had a previous trial of other weight loss medications (e.g., Contrave, Belviq, Qsymia, Xenical, phentermine, phendimetrazine, benzphetamine, diethylpropion)

If yes, **approve the requested strength for 12 weeks by GPID or GPI-14 with a quantity limit of #3 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it**

Our guideline named **AMPHETAMINE SULFATE (Evekeo)** requires the following rule(s) be met for approval:

A. You have **ONE** of the following diagnoses:

1. Narcolepsy (condition where you suddenly fall asleep)
2. Attention deficit disorder with hyperactivity (difficulty paying attention)
3. Use for weight loss or exogenous obesity (overweight due to overeating)

B. **If you have narcolepsy, approval also requires:**

1. You are 6 years of age or older

C. **If you have attention deficit disorder with hyperactivity, approval also requires:**

1. You are 3 years of age or older
2. You had a previous trial of at least **ONE** of the following stimulant medications: mixed amphetamine salts (Adderall immediate release), methylphenidate (Ritalin immediate release), dextroamphetamine (Dexedrine)

D. **If the request is for weight loss or exogenous obesity, approval also requires:**

1. You are 12 years of age or older
2. You had a previous trial of other weight loss medications such as Contrave, Belviq, Qsymia, Xenical, phentermine, phendimetrazine, benzphetamine, diethylpropion

**Note:** The approval of Evekeo for use as a short-term adjunct (add-on) in a regimen of weight reduction is for a maximum duration of 12 weeks

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE





**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**AMPHETAMINE SULFATE**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Evekeo.

**REFERENCES**

- Evekeo [Prescribing Information]. Atlanta, GA: Arbor Pharmaceuticals LLC; August 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 05/01/20

Created: 05/15

Client Approval: 04/20

P&T Approval: 07/19



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

AMPHETAMINE SULFATE ODT

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
AMPHETAMINE SULFATE	EVEKEO ODT		45976 45977 45978 45979	GPI-14 (61100010107210, 61100010107220, 61100010107230, 61100010107240)	

GUIDELINES FOR USE

1. Does the patient have a diagnosis of attention deficit disorder with hyperactivity (ADHD) and meet **ALL** of the following criteria?

- The patient is 6 to 17 years of age
- The patient is unable to swallow amphetamine sulfate tablets
- The patient had a trial of **TWO** of the following immediate-release stimulant medications: methylphenidate, dexamethylphenidate, amphetamine, dextroamphetamine, dextroamphetamine-amphetamine

If yes, **approve the requested strength for 12 months by GPID or GPI-14 with the following quantity limits:**

- **5 mg: #8 per day.**
- **10 mg: #4 per day.**
- **15 mg and 20 mg: #2 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **AMPHETAMINE SULFATE ODT (Evekeo ODT)** requires the following rule(s) be met for approval:

- A. You have attention deficit disorder with hyperactivity (ADHD: difficulty paying attention)
- B. You are 6 to 17 years of age
- C. You are unable to swallow amphetamine sulfate tablets
- D. You had a trial of TWO of the following immediate-release stimulant medications: methylphenidate, dexamethylphenidate, amphetamine, dextroamphetamine, dextroamphetamine-amphetamine

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**AMPHETAMINE SULFATE ODT**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Evekeo ODT.

**REFERENCES**

- Evekeo ODT [Prescribing Information]. Atlanta, GA: Arbor Pharmaceuticals LLC; September 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/23

Created: 11/22

Client Approval: 02/23

P&T Approval: 10/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**ANABOLIC STEROIDS**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
OXYMETHOLONE	ANADROL-50	01409		GPI-10 (2320005000)	
OXANDROLONE	OXANDRIN	01412		GPI-10 (2320004000)	FDB: ROUTE ≠ MISCELL.

**\*\*Please use the criteria for the specific drug requested\*\***

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

**ANADROL-50**

1. Does the patient have a diagnosis of anemia and meet **ALL** of the following criteria?
  - The anemia is caused by one of the following conditions: acquired aplastic anemia, congenital aplastic anemia, myelofibrosis and the hypoplastic anemias, or Fanconi's anemia
  - The patient does **not** have any of the following contraindications to anabolic steroid therapy:
    - Known or suspected carcinoma of the prostate or breast in male patients
    - Known or suspected carcinoma of the breast in females with hypercalcemia
    - Known or suspected nephrosis (the nephrotic phase of nephritis)
    - Known or suspected hypercalcemia
    - Severe hepatic dysfunction
  - The patient will be monitored for peliosis hepatis, liver cell tumors and blood lipid changes

If yes, **approve for 6 months by HICL or GPI-10.**

If no, continue to #2.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ANABOLIC STEROIDS

INITIAL CRITERIA - ANADROL-50 (CONTINUED)

2. Does the patient have a diagnosis of cachexia associated with AIDS and meet the following criteria?
- The patient is on anti-retroviral therapy
  - The patient has a documented viral load (with date) of less than 200 copies per mL within the past 3 months
  - Therapy is prescribed by or given in consultation with a gastroenterologist, nutritional Support Specialist (SBS) or Infectious Disease specialist
  - The patient meets **ONE** of the following criteria:
    - The patient has 10% unintentional weight loss over 12 months
    - The patient has 7.5% unintentional weight loss over 6 months
    - The patient has 5% body cell mass (BCM) loss within 6 months
    - The patient has a body cell mass (BCM) of less than 35% (men) and a body mass index (BMI) of less than 27 kg per meter squared
    - The patient has a body cell mass (BCM) of less than 23% (women) of total body weight and a body mass index (BMI) of less than 27 kg per meter squared
    - The patient has a BMI of less than 18.5 kg per meter squared
  - The patient does **not** have any of the following contraindications to anabolic steroid therapy:
    - Known or suspected carcinoma of the prostate or breast in male patients
    - Known or suspected carcinoma of the breast in females with hypercalcemia
    - Known or suspected nephrosis (the nephrotic phase of nephritis)
    - Known or suspected hypercalcemia
    - Severe hepatic dysfunction
  - The patient will be monitored for peliosis hepatis, liver cell tumors and blood lipid changes

If yes, **approve for 12 weeks by HICL or GPI-10.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ANABOLIC STEROIDS (Anadrol-50)** requires the following rule(s) be met for approval:

- A. You have anemia (lack of healthy red blood cells) or cachexia (condition with extreme weight loss and muscle loss) associated with AIDS (acquired immune deficiency syndrome)
- B. You will be monitored for peliosis hepatis (blood-filled spaces in the liver), liver cell tumors and blood lipid (fats) changes

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ANABOLIC STEROIDS

INITIAL CRITERIA - ANADROL-50 (CONTINUED)

C. You do not have ANY of the following reasons why you cannot use anabolic steroid therapy:

1. Known or suspected prostate or breast cancer in male patients
2. Known or suspected breast cancer in females with hypercalcemia (high calcium levels)
3. Known or suspected nephrosis (the nephrotic phase of nephritis-kidney inflammation)
4. Known or suspected hypercalcemia (high calcium levels)
5. Severe hepatic (liver) dysfunction

D. **If you have anemia, approval also requires:**

1. The anemia is caused by one of the following conditions: acquired aplastic anemia, congenital aplastic anemia, myelofibrosis and the hypoplastic anemias, or Fanconi's

E. **If you have cachexia associated with AIDS, approval also requires:**

1. You are on anti-retroviral therapy (therapy that treats a type of immune system virus)
2. You have a documented viral load (amount of virus in your blood) of less than 200 copies per mL dated within the past 3 months
3. Therapy is prescribed by or given in recommendation with a gastroenterologist (doctor of the stomach, intestine and related organs), nutritional support specialist (SBS), or infectious disease specialist
4. You meet ONE of the following:
  - a. You have 10% unintentional weight loss over 12 months
  - b. You have 7.5% unintentional weight loss over 6 months
  - c. You have 5% body cell mass (BCM) loss within 6 months
  - d. You have a BCM of less than 35% (men) and a body mass index (BMI) of less than 27 kg per meter squared
  - e. You have a BCM of less than 23% (women) of total body weight and a body mass index (BMI) of less than 27 kg per meter squared
  - f. You have a BMI of less than 18.5 kg per meter squared

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ANABOLIC STEROIDS

INITIAL CRITERIA (CONTINUED)

OXANDRIN

1. Is the request for adjunctive therapy to promote weight gain and the patient meet **ALL** of the following criteria?
  - The patient's weight loss is due to one of the following conditions: extensive surgery, chronic infections, or severe trauma
  - The patient does not have any of the following contraindications to anabolic steroid therapy:
    - Known or suspected carcinoma of the prostate or breast in male patients
    - Known or suspected carcinoma of the breast in females with hypercalcemia
    - Known or suspected nephrosis (the nephrotic phase of nephritis)
    - Known or suspected hypercalcemia
    - Severe hepatic dysfunction
  - The patient will be monitored for peliosis hepatis, liver cell tumors and blood lipid changes

If yes, **approve for 12 weeks by HICL or GPI-10.**

If no, continue to #2.

2. Is the request for adjunctive therapy to offset the protein catabolism associated with prolonged administration of corticosteroids and the patient meet **ALL** of the following criteria?
  - The patient does not have any of the following contraindications to anabolic steroid therapy:
    - Known or suspected carcinoma of the prostate or breast in male patients
    - Known or suspected carcinoma of the breast in females with hypercalcemia
    - Known or suspected nephrosis (the nephrotic phase of nephritis)
    - Known or suspected hypercalcemia
    - Severe hepatic dysfunction
  - The patient will be monitored for peliosis hepatis, liver cell tumors and blood lipid changes

If yes, **approve for 6 months by HICL or GPI-10.**

If no, continue to #3.

3. Is the request for the relief of the bone pain accompanying osteoporosis and the patient meet **ALL** of the following criteria?
  - The patient does not have any of the following contraindications to anabolic steroid therapy:
    - Known or suspected carcinoma of the prostate or breast in male patients
    - Known or suspected carcinoma of the breast in females with hypercalcemia
    - Known or suspected nephrosis (the nephrotic phase of nephritis)
    - Known or suspected hypercalcemia
    - Severe hepatic dysfunction
  - The patient will be monitored for peliosis hepatis, liver cell tumors and blood lipid changes

If yes, **approve for 6 months by HICL or GPI-10.**

If no, continue to #4.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ANABOLIC STEROIDS

INITIAL CRITERIA - OXANDRIN (CONTINUED)

4. Does the patient have a diagnosis of cachexia associated with AIDS and meet **ALL** of the following criteria?
- The patient is on anti-retroviral therapy
  - The patient has a documented viral load (with date) of less than 200 copies per mL within the past 3 months
  - Therapy is prescribed by or given in consultation with a gastroenterologist, nutritional support specialist (SBS) or Infectious disease specialist
  - The patient meets ONE of the following criteria:
    - The patient has 10% unintentional weight loss over 12 months,
    - The patient has 7.5% unintentional weight loss over 6 months
    - The patient has 5% body cell mass (BCM) loss within 6 months
    - The patient has a body cell mass (BCM) of less than 35% (men) and a body mass index (BMI) less than 27 kg per meter squared
    - The patient has a body cell mass (BCM) of less than 23% (women) of total body weight and a body mass index (BMI) less than 27 kg per meter squared
    - The patient has a BMI of less than 18.5 kg per meter squared
  - The patient does not have any of the following contraindications to anabolic steroid therapy:
    - Known or suspected carcinoma of the prostate or breast in male patients
    - Known or suspected carcinoma of the breast in females with hypercalcemia
    - Known or suspected nephrosis (the nephrotic phase of nephritis)
    - Known or suspected hypercalcemia
    - Severe hepatic dysfunction
  - The patient will be monitored for peliosis hepatis, liver cell tumors and blood lipid changes

If yes, **approve for 12 weeks by HICL or GPI-10.**

If no, continue to #5.

5. Does the patient have a diagnosis of Turner's Syndrome and meet **ALL** of the following criteria?
- The patient does not have any of the following contraindications to anabolic steroid therapy:
    - Known or suspected carcinoma of the prostate or breast in male patients
    - Known or suspected carcinoma of the breast in females with hypercalcemia
    - Known or suspected nephrosis (the nephrotic phase of nephritis)
    - Known or suspected hypercalcemia
    - Severe hepatic dysfunction
  - The patient will be monitored for peliosis hepatis, liver cell tumors and blood lipid changes

If yes, **approve for 6 months by HICL or GPI-10.**

If no, do not approve.

**DENIAL TEXT: See Oxandrin initial denial text on the next page.**

CONTINUED ON NEXT PAGE





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ANABOLIC STEROIDS

INITIAL CRITERIA - OXANDRIN (CONTINUED)

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ANABOLIC STEROIDS (Oxandrin)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:

1. Weight loss
2. Protein catabolism (breakdown) caused by long-term use of corticosteroids
3. Bone pain accompanying osteoporosis (weak and brittle bones)
4. Cachexia (condition with extreme weight loss and muscle loss) associated with AIDS (acquired immune deficiency syndrome)
5. Turner's Syndrome (disorder where female has one X chromosome)

B. You will be monitored for peliosis hepatis (blood-filled spaces in the liver), liver cell tumors and blood lipid (fats) changes

C. You do not have ANY of the following reasons why you cannot use anabolic steroid therapy:

1. Known or suspected prostate or breast cancer in male patients
2. Known or suspected breast cancer in females with hypercalcemia (high calcium levels)
3. Known or suspected nephrosis (the nephrotic phase of nephritis-kidney inflammation)
4. Known or suspected hypercalcemia (high calcium levels)
5. Severe hepatic (liver) dysfunction

D. **If you have weight loss, approval also requires:**

1. Your weight loss is caused by extensive surgery, chronic infections, or severe trauma
2. Medication is being used as add-on therapy to help weight gain

E. **If you have cachexia associated with AIDS, approval also requires:**

1. You are on anti-retroviral therapy (therapy that treats a type of immune system virus)
2. You have a documented viral load (amount of virus in your blood) of less than 200 copies per mL dated within the past 3 months
3. Therapy is prescribed by or given in consultation with a gastroenterologist (doctor of the stomach, intestine and related organs), nutritional support specialist (SBS) or infectious disease specialist
4. You meet ONE of the following:
  - a. You have 10% unintentional weight loss over 12 months
  - b. You have 7.5% unintentional weight loss over 6 months
  - c. You have 5% body cell mass (BCM) loss within 6 months
  - d. You have a BCM of less than 35% (men) and a body mass index (BMI) of less than 27 kg per meter squared
  - e. You have a BCM of less than 23% (women) of total body weight and a body mass index (BMI) of less than 27 kg per meter squared
  - f. You have a BMI of less than 18.5 kg per meter squared

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ANABOLIC STEROIDS

INITIAL CRITERIA - OXANDRIN (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

(NOTE: For the diagnosis of anemia, weight loss, protein catabolism associated with prolonged administration of corticosteroids, bone pain accompanying osteoporosis, or Turner's Syndrome, please refer to the Initial Criteria section)

OXANDRIN and ANADROL-50

1. Is the request for cachexia associated with AIDS and the patient meet **ALL** of the following criteria?
  - The patient is on anti-retroviral therapy
  - The patient's viral load is less than 200 copies per mL within the past 3 months
  - The patient has responded to therapy as measured by at least a 10% increase in weight from baseline (current weight must have been measured within the last 4 weeks, document date of measurement)
  - The patient has not received more than 24 weeks of therapy in a calendar year

If yes, **approve for 12 weeks by HICL or GPI-10.** (Note: therapy is limited to 24 weeks per calendar year.)

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ANABOLIC STEROIDS (Oxandrin and Anadrol-50)** requires the following rule(s) be met for renewal:

- A. You have cachexia (condition with extreme weight loss and muscle loss) associated with AIDS (acquired immune deficiency syndrome)
- B. You are on anti-retroviral therapy (therapy that treats a type of immune system virus)
- C. Your viral load (amount of virus in your blood) is less than 200 copies per mL within the past 3 months
- D. You have a 10% increase in weight from baseline (current weight must have been measured within the last 4 weeks, document date of measurement)
- E. You have not received more than 24 weeks of therapy in a calendar year  
**(Renewal denial text continued on next page)**

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ANABOLIC STEROIDS

RENEWAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Anadrol-50 and Oxandrin.

**REFERENCES**

- Anadrol-50 [Prescribing Information]. Marietta, GA: Alaven Pharmaceutical LLC; October 2012
- Oxandrin [Prescribing Information]. East Brunswick, NJ: Savient Pharmaceuticals; April 2007.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 05/15

Client Approval: 04/20

P&T Approval: 05/15



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ANAKINRA

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ANAKINRA	KINERET	22953		GPI-10 (6626001000)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Is the request for the treatment of coronavirus disease 2019 (COVID-19) in a hospitalized adult?

If yes, **do not approve**. [NOTE: This indication is for hospital use only.]

**DENIAL TEXT:** See initial denial text at the end of the guideline.

If no, continue to #2.

2. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- Therapy is prescribed by or in consultation with a rheumatologist
- The patient had a trial of or contraindication to at least 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drugs), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
- The patient meets ONE of the following:
  - The patient had a trial of or contraindication to TWO of the following preferred agents: Enbrel, Humira, Rinvoq, Xeljanz (IR/XR)
  - The patient has tried a TNF inhibitor (e.g., Humira, Enbrel) AND the physician has indicated the patient cannot use a JAK inhibitor (e.g., Rinvoq, Xeljanz) due to the black box warning for increased risk of mortality, malignancies, and serious cardiovascular events  
[NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #28 syringes per 28 days.**

If no, continue to #3.

3. Does the patient have a diagnosis of Neonatal-Onset Multisystem Inflammatory Disease (NOMID) Cryopyrin-Associated Periodic Syndromes (CAPS)?

If yes, **approve for 12 months by HICL or GPI-10.**

If no, continue to #4.

4. Does the patient have a diagnosis of Deficiency of Interleukin-1 Receptor Antagonist (DIRA)?

If yes, **approve for 12 months by HICL or GPI-10.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ANAKINRA

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ANAKINRA (Kineret)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
1. Moderate to severe rheumatoid arthritis (a type of joint condition)
  2. Neonatal-Onset Multisystem Inflammatory Disease (NOMID) Cryopyrin-Associated Periodic Syndromes (CAPS) (a type of immune disorder)
  3. Deficiency of Interleukin-1 Receptor Antagonist (a type of immune system disorder)
- B. **If you have moderate to severe rheumatoid arthritis, approval also requires:**
1. You are 18 years of age or older
  2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
  3. You had a trial of or contraindication (harmful for) to at least 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drugs), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
  4. You meet ONE of the following:
    - a. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Enbrel, Humira, Rinvoq, Xeljanz (immediate release/extended release)
    - b. You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira, Enbrel) AND your physician has indicated you cannot use a JAK inhibitor (such as Rinvoq, Xeljanz) due to the black box warning for increased risk of mortality (death), malignancies (cancerous), and serious cardiovascular (heart-related) events

NOTE: Kineret will not be approved for the treatment of coronavirus disease 2019 (COVID-19) in hospitalized adults

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ANAKINRA

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

**NOTE:** For the diagnoses of Neonatal-Onset Multisystem Inflammatory Disease (NOMID) Cryopyrin-Associated Periodic Syndromes (CAPS) or Deficiency of Interleukin-1 Receptor Antagonist (DIRA), please refer to the Initial Criteria section.

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) **AND** meet the following criterion?
  - The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #28 syringes per 28 days.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ANAKINRA (Kineret)** requires the following rule(s) be met for renewal:

- A. You have moderate to severe rheumatoid arthritis (RA: a type of joint condition)
- B. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Kineret.

**REFERENCES**

- Kineret [Prescribing Information]. SE-112 76 Stockholm, Sweden: Swedish Orphan Biovitrum AB (publ); December 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/23

Created: 02/03

Client Approval: 11/22

P&T Approval: 01/23



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ANTI-OBESITY AGENTS

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
NALTREXONE HCL/ BUPROPION HCL	CONTRAVE ER	41389		GPI-10 (6125990250)	
PHENTERMINE/ TOPIRAMATE	QSYMIA	39347		GPI-10 (6120990230)	
LIRAGLUTIDE	SAXENDA		37637	GPI-10 (6125205000)	
ORLISTAT	XENICAL, ORLISTAT		95213	GPI-14 (61253560000120)	
SEMAGLUTIDE	WEGOVY	44675		GPI-10 (6125207000)	BRAND ≠ OZEMPIC, RYBELSUS

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Are weight loss products (anti-obesity medications) a covered benefit?

If yes, continue to #2.

If no, guideline does not apply.

2. Is the request for **Contrave** for weight loss or weight management and the patient meets **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient meets ONE of the following criteria:
  - Body mass index (BMI) of 30 kg/m<sup>2</sup> or greater
  - BMI of 27 kg/m<sup>2</sup> or greater AND at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes mellitus, or hyperlipidemia)
- Evidence of active enrollment in an exercise and caloric reduction program or a weight loss/behavioral modification program

If yes, **approve for a total of 4 months by HICL or GPI-10 as follows:**

- **FIRST APPROVAL: #78 for 30 days.**
- **SECOND APPROVAL: #4 per day for 3 months with a start date of one day after the end date of the first approval.**

If no, continue to #3.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ANTI-OBESITY AGENTS

INITIAL CRITERIA (CONTINUED)

3. Is the request for **Xenical** for weight loss or weight management and the patient meets **ALL** of the following criteria?

- The patient meets **ONE** of the following criteria:
  - Body mass index (BMI) of 30 kg/m<sup>2</sup> or greater
  - BMI of 27 kg/m<sup>2</sup> or greater **AND** at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes mellitus, or hyperlipidemia)
- Evidence of active enrollment in an exercise and caloric reduction program or a weight loss/behavioral modification program

If yes, **approve for a total of 3 months by GPID or GPI-14 with a quantity limit of #3 per day.**

If no, continue to #4.

4. Is the request for **Qsymia** for weight loss or weight management and the patient meets **ALL** of the following criteria?

- Evidence of active enrollment in an exercise and caloric reduction program or a weight loss/behavioral modification program
- The patient had a trial of or contraindication to the preferred agents: Saxenda **AND** Wegovy

If yes, continue to #5.

If no, continue to #7.

5. Is the patient 18 years of age or older and meets **ONE** of the following criteria?

- Body mass index (BMI) of 30 kg/m<sup>2</sup> or greater
- BMI of 27 kg/m<sup>2</sup> or greater **AND** at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes mellitus, or hyperlipidemia)

If yes, **approve for all of the following strengths by GPID or GPI-14 as follows:**

- **3.75/23mg: #1 per day for 2 weeks.**
- **7.5/46mg: #1 per day for 3 months with a start date of one day after the end date of the first authorization.**

If no, continue to #6.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ANTI-OBESITY AGENTS

INITIAL CRITERIA (CONTINUED)

6. Is the patient 12 to 17 years of age **AND** meets the following criterion?

- The patient's initial body mass index (BMI) is in the 95th percentile or greater for age and sex (See table below)

95th Percentile BMI Value for Age and Sex

Age (in years)	Male	Female
	95th Percentile BMI Value	95th Percentile BMI Value
12	24.2	25.3
12.5	24.7	25.8
13	25.2	26.3
13.5	25.6	26.8
14	26.0	27.3
14.5	26.5	27.7
15	26.8	28.1
15.5	27.2	28.5
16	27.6	28.9
16.5	27.9	29.3
17	28.3	29.6
17.5	28.6	30.0

If yes, approve for all of the following strengths by GPID or GPI-14 as follows:

- 3.75/23mg: #1 per day for 2 weeks.
- 7.5/46mg: #1 per day for 3 months with a start date of one day after the end date of the first authorization.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

7. Is the request for **Saxenda** for weight loss or weight management and the patient meets **ALL** of the following criteria?

- The patient is NOT currently taking a GLP-1 receptor agonist (e.g., Victoza, Byetta, Bydureon, Tanzeum)
- Evidence of active enrollment in an exercise and caloric reduction program or a weight loss/behavioral modification program

If yes, continue to #8.

If no, continue to #10.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**ANTI-OBESITY AGENTS**

**INITIAL CRITERIA (CONTINUED)**

8. Is the patient 18 years of age or older and meet **ONE** of the following criteria?

- Body mass index (BMI) of 30 kg/m<sup>2</sup> or greater
- BMI of 27 kg/m<sup>2</sup> or greater AND at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes mellitus, or hyperlipidemia)

If yes, **approve for 4 months by GPID or GPI-10 with a quantity limit of #15mL per 30 days.**  
If no, continue to #9.

9. Is the patient 12 to 17 years of age and meets **ALL** of the following criteria?

- The patient's body weight is greater than 60 kg
- The patient's initial BMI corresponds to 30 kg/m<sup>2</sup> or greater to that for adults (See table below)

**BMI Cut-offs for Obesity in Patients 12 to 17 years that corresponds to 30 kg/m<sup>2</sup> in Adults**

Age	Body Mass Index	
	Males	Females
12	26.02	26.67
12.5	26.43	27.24
13	26.84	27.76
13.5	27.25	28.20
14	27.63	28.57
14.5	27.98	28.87
15	28.30	29.11
15.5	28.60	29.29
16	28.88	29.43
16.5	29.14	29.56
17	29.41	29.69
17.5	29.70	29.84

If yes, **approve for 3 months by GPID or GPI-10 with a quantity limit of #15mL per 30 days.**  
If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

10. Is the request for **Wegovy** for weight loss or weight management and the patient meets **ALL** of the following criteria?

- Evidence of active enrollment in an exercise and caloric reduction program or a weight loss/behavioral modification program
- The patient is NOT currently taking another GLP-1 receptor agonist (e.g., Victoza, Byetta, Bydureon, Tanzeum)

If yes, continue to #11.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ANTI-OBESITY AGENTS

INITIAL CRITERIA (CONTINUED)

11. Is the patient 18 years of age or older and meets **ONE** of the following criteria?

- Body mass index (BMI) of 30 kg/m<sup>2</sup> or greater
- BMI of 27 kg/m<sup>2</sup> or greater AND at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes mellitus, or hyperlipidemia)

If yes, approve all of the following strengths for 5 months by GPID or GPI-14 with the following quantity limits:

- 0.25mg/0.5mL, 0.5mg/0.5mL, 1mg/0.5mL: #2mL per 28 days.
- 1.7mg/0.75mL, 2.4mg/0.75mL: #3mL per 28 days.

If no, continue to #12.

12. Is the patient 12 to 17 years of age **AND** meets the following criterion?

- The patient has an initial BMI at the 95th percentile or greater standardized for age and sex (See table below)

**BMI Cut-offs for Obesity by Age and Sex**

Age (in years)	Male	Female
	95th Percentile BMI Value	95th Percentile BMI Value
12	24.2	25.2
12.5	24.7	25.7
13	25.1	26.3
13.5	25.6	26.8
14	26.0	27.2
14.5	26.4	27.7
15	26.8	28.1
15.5	27.2	28.5
16	27.5	28.9
16.5	27.9	29.3
17	28.2	29.6
17.5	28.6	30.0

If yes, approve all of the following strengths for 5 months by GPID or GPI-14 with the following quantity limits:

- 0.25mg/0.5mL, 0.5mg/0.5mL, 1mg/0.5mL: #2mL per 28 days.
- 1.7mg/0.75mL, 2.4mg/0.75mL: #3mL per 28 days.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ANTI-OBESITY AGENTS

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ANTI-OBESITY AGENTS (Contrave, Qsymia, Saxenda, Wegovy, Xenical)** requires the following rule(s) be met for approval:

- A. The request is for weight loss OR weight loss management
- B. You have evidence of active enrollment in an exercise and caloric reduction program or a weight loss/behavioral modification program
- C. **If you are requesting Contrave, approval also requires:**
  - 1. You are 18 years of age or older
  - 2. You meet ONE of the following:
    - a. Body mass index (BMI: a tool for evaluating body fat) of 30 kg/m(2) or greater
    - b. BMI of 27 kg/m(2) or greater AND at least one weight-related comorbidity (disease) such as hypertension (high blood pressure), type 2 diabetes mellitus, or hyperlipidemia (high cholesterol)
- D. **If you are requesting Xenical, approval also requires you meet ONE of the following:**
  - 1. Body mass index (BMI: a tool for evaluating body fat) of 30 kg/m(2) or greater
  - 2. BMI of 27 kg/m(2) or greater AND at least one weight-related comorbidity (disease) such as hypertension (high blood pressure), type 2 diabetes mellitus, or hyperlipidemia (high cholesterol)
- E. **If you are requesting Qsymia, approval also requires:**
  - 1. You had a trial of or contraindication (harmful for) to the preferred medications: Saxenda AND Wegovy
  - 2. You are 18 years of age or older and meet ONE of the following:
    - a. Body mass index (BMI: a tool for evaluating body fat) of 30 kg/m(2) or greater
    - b. BMI of 27 kg/m(2) or greater AND at least one weight-related comorbidity (disease) such as hypertension (high blood pressure), type 2 diabetes mellitus, or hyperlipidemia (high cholesterol)
  - 3. You are 12 to 17 years of age and meet the following:
    - a. Your initial body mass index (BMI: a tool for evaluating body fat) is in the 95th percentile or greater for age and sex

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**ANTI-OBESITY AGENTS**

**INITIAL CRITERIA (CONTINUED)**

**F. If you are requesting Saxenda, approval also requires:**

1. You are NOT currently taking a GLP-1 receptor agonist (type of drug for type 2 diabetes such as Victoza, Byetta, Bydureon, Tanzeum)
2. You are 18 years of age or older and meet ONE of the following:
  - a. Body mass index (BMI: a tool for evaluating body fat) of 30 kg/m<sup>2</sup> or greater
  - b. BMI of 27 kg/m<sup>2</sup> or greater AND at least one weight-related comorbidity (disease) such as hypertension (high blood pressure), type 2 diabetes mellitus, or hyperlipidemia (high cholesterol)
3. You are 12 to 17 years of age and meet the following:
  - a. Body weight greater than 60 kg AND an initial BMI corresponding to 30 kg/m<sup>2</sup> for adults

**G. If you are requesting Wegovy, approval also requires:**

1. You are 18 years of age or older and meet ONE of the following:
  - a. Body mass index (BMI: a tool for evaluating body fat) of 30 kg/m<sup>2</sup> or greater
  - b. BMI of 27 kg/m<sup>2</sup> or greater AND at least one weight-related comorbidity (disease) such as hypertension (high blood pressure), type 2 diabetes mellitus, or hyperlipidemia (high cholesterol)
2. You are 12 to 17 years of age and meet the following:
  - a. You have an initial body mass index (BMI: a tool for evaluating body fat) in the 95th percentile or greater standardized for age and sex
3. You are NOT currently taking another GLP-1 receptor agonist (type of drug for type 2 diabetes such as Victoza, Byetta, Bydureon, Tanzeum)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RENEWAL CRITERIA**

1. Is the request for weight loss or weight management?

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ANTI-OBESITY AGENTS

RENEWAL CRITERIA (CONTINUED)

2. Is the request for **Saxenda** AND does the patient meet **ONE** of the following criteria?
- The patient is 18 years of age or older AND has achieved or maintained at least 4% weight loss of baseline body weight after 4 months of treatment
  - The patient is 12 to 17 years of age AND has achieved or maintained at least 1% weight loss of baseline body weight after 3 months of treatment

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #15mL per 30 days.**

If no, continue to #3.

3. Is the request for **Xenical** AND does the patient meet the following criterion?
- The patient has achieved or maintained at least 5% weight loss of baseline body weight after 3 months of treatment

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #3 per day.**

If no, continue to #4.

4. Is the request for **Contrave** AND does the patient meet the following criterion?
- The patient has achieved or maintained at least 5% weight loss of baseline body weight after 3 months of treatment at the maintenance dose (two 8/90mg tablets twice daily)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**

If no, continue to #5.

5. Is the request for **Wegovy** and the patient meets **ONE** of the following criteria?
- The patient is 18 years of age or older AND has achieved or maintained at least 5% weight loss from baseline
  - The patient is 12 to 17 years of age AND has achieved or maintained at least 5% reduction from baseline body mass index (BMI)

If yes, **approve all of the following strengths for 12 months by GPID or GPI-14 with the following quantity limits:**

- **0.25mg/0.5mL, 0.5mg/0.5mL, 1mg/0.5mL: #2mL per 28 days.**
- **1.7mg/0.75mL, 2.4mg/0.75mL: #3mL per 28 days.**

If no, continue to #6.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ANTI-OBESITY AGENTS

RENEWAL CRITERIA (CONTINUED)

6. Is the request for **Qsymia 7.5/46mg AND** does the patient meet **ONE** of the following criteria?
- The patient is 18 years of age or older AND has achieved or maintained at least 3% weight loss of baseline body weight after at least 3 months of treatment
  - The patient is 12 to 17 years of age AND has achieved or maintained at least 3% of baseline BMI after at least 3 months of treatment

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #1 per day.**  
If no, continue to #7.

7. Is the request for dose escalation to **Qsymia 11.25/69mg** for 2 weeks, followed by Qsymia 15/92mg?

If yes, **approve and enter two authorizations by GPID or GPI-14 as follows:**

- **11.25/69mg: #1 per day for 2 weeks.**
- **15/92mg: #1 per day for 3 months with a start date of one day after the end date of the first authorization.**

If no, continue to #8.

8. Is the request for continuation of therapy after at least 12 weeks on **Qsymia 15/92mg AND** does the patient meet **ONE** of the following criteria?
- The patient is 18 years of age or older AND has achieved or maintained at least 5% weight loss of baseline body weight after 3 months of treatment
  - The patient is 12 to 17 years of age AND has achieved or maintained at least 5% of baseline BMI after 3 months of treatment

If yes, **approve Qsymia 15/92mg for 12 months by GPID or GPI-14 for #1 per day.**

If no, do not approve. If the request is for **Qsymia 15/92mg**, please also enter a partial approval for ONE fill of Qsymia by HICL up to #4 total to taper dose in order to discontinue therapy.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ANTI-OBESITY AGENTS (Contrave, Qsymia, Saxenda, Wegovy, Xenical)** requires the following rule(s) be met for renewal:

- A. The request is for weight loss OR weight loss management  
*(Renewal denial text continued on next page)*

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ANTI-OBESITY AGENTS

RENEWAL CRITERIA (CONTINUED)

- B. If you are requesting Saxenda, renewal also requires ONE of the following:**
1. You are 18 years of age or older AND have achieved or maintained at least 4% weight loss of baseline body weight after 4 months of treatment
  2. You are 12 to 17 years of age AND have achieved or maintained at least 1% weight loss of baseline body weight after 3 months of treatment
- C. If you are requesting Xenical, renewal also requires:**
1. You have achieved or maintained at least 5% weight loss of baseline body weight after 3 months of treatment
- D. If you are requesting Contrave, renewal also requires:**
1. You have achieved or maintained at least 5% weight loss of baseline body weight after 3 months of treatment at the maintenance dose (two 8/90mg tablets twice daily)
- E. If you are requesting Wegovy, renewal also requires ONE of the following:**
1. You are 18 years of age or older AND have achieved or maintained at least 5% weight loss from baseline
  2. You are 12 to 17 years of age AND have achieved or maintained at least 5% reduction from baseline body mass index (BMI: a tool for evaluating body fat)
- F. If you are requesting Qsymia 7.5/46mg, renewal also requires ONE of the following:**
1. You are 18 years of age or older AND have achieved or maintained at least 3% weight loss of baseline body weight after 3 months of treatment
  2. You are 12 to 17 years of age AND have achieved or maintained at least 3% of baseline body mass index (BMI: a tool for evaluating body fat) after at least 3 months of treatment
- G. If you are requesting Qsymia 15/92mg, renewal also requires ONE of the following:**
1. You are 18 years of age or older AND have achieved or maintained at least 5% weight loss of baseline body weight after 3 months of treatment
  2. You are 12 to 17 years of age AND have achieved or maintained at least 5% of baseline body mass index (BMI: a tool for evaluating body fat) after 3 months of treatment

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE





**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**ANTI-OBESITY AGENTS**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for the requested Anti-Obesity agent.

**REFERENCES**

- Contrave [Prescribing Information]. San Diego, CA: Nalpropion Pharmaceuticals, Inc.; March 2021.
- Qsymia [Prescribing Information]. Mountain View, CA: Vivus, Inc.; June 2022.
- Saxenda [Prescribing Information]. Plainsboro, NJ: Novo Nordisk, Inc.; December 2020.
- Wegovy [Prescribing Information]. Plainsboro, NJ: Novo Nordisk, Inc.; December 2022.
- Xenical [Prescribing Information]. Greifswald, Germany: CHEPLAPHARM Arzneimittel GmbH; November 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/23

Created: 10/14

Client Approval: 02/23

P&T Approval: 01/23



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

APALUTAMIDE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
APALUTAMIDE	ERLEADA	44773		GPI-10 (2140241000)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of metastatic castration-sensitive prostate cancer (mCSPC)?

If yes, continue to #3.

If no, continue to #2.

2. Does the patient have a diagnosis of non-metastatic castration-resistant prostate cancer (nmCRPC) **AND** meet the following criterion?

- The patient has high risk prostate cancer (i.e., rapidly increasing prostate specific antigen [PSA] levels)

If yes, continue to #3.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

3. Does the patient meet **ONE** of the following criteria?

- The patient previously received a bilateral orchiectomy
- The patient has a castrate level of testosterone (i.e., < 50 ng/dL)
- The requested medication will be used concurrently with a gonadotropin releasing hormone (GnRH) analog (e.g., leuprolide, goserelin, histrelin, degarelix)

If yes, **approve for 12 months by GPID or GPI-14 with the following quantity limits:**

- **60mg: #4 per day.**
- **240mg: #1 per day.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

APALUTAMIDE

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **APALUTAMIDE (Erleada)** requires the following rule(s) be met for approval:

- A. You have **ONE** of the following diagnoses:
1. Non-metastatic castration-resistant prostate cancer (nmCRPC: prostate cancer that does not respond to hormone reduction therapy and has not spread to other parts of the body)
  2. Metastatic castration-sensitive prostate cancer (mCSPC: prostate cancer that has spread to other parts of the body and responds to hormone therapy)
- B. You meet **ONE** of the following:
1. You previously received a bilateral orchiectomy (both testicles have been surgically removed)
  2. You have a castrate level of testosterone (your blood testosterone levels are less than 50 ng/DI)
  3. The requested medication will be used together with a gonadotropin releasing hormone analog (such as leuprolide, goserelin, histrelin, degarelix)
- C. **If you have a non-metastatic castration-resistant prostate cancer, approval also requires:**
1. You have high risk prostate cancer (rapidly increasing prostate specific antigen [PSA] levels)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have **ONE** of the following diagnoses?
  - Metastatic castration-sensitive prostate cancer (mCSPC)
  - Non-metastatic castration-resistant prostate cancer (nmCRPC)

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

APALUTAMIDE

RENEWAL CRITERIA (CONTINUED)

2. Does the patient meet **ONE** of the following criteria?

- The patient previously received a bilateral orchiectomy
- The patient has a castrate level of testosterone (i.e., < 50 ng/dL)
- The requested medication will be used concurrently with a gonadotropin releasing hormone (GnRH) analog (e.g., leuprolide, goserelin, histrelin, degarelix)

If yes, **approve for 12 months by GPID or GPI-14 with the following quantity limits:**

- **60mg: #4 per day.**
- **240mg: #1 per day.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **APALUTAMIDE (Erleada)** requires the following rule(s) be met for renewal:

A. You have **ONE** of the following diagnoses:

1. Non-metastatic castration-resistant prostate cancer (nmCRPC: prostate cancer that does not respond to hormone reduction therapy but has not spread)
2. Metastatic castration-sensitive prostate cancer (mCSPC: prostate cancer that has spread and responds to hormone therapy)

B. You meet **ONE** of the following:

1. You previously received a bilateral orchiectomy (both testicles have been surgically removed)
2. You have a castrate level of testosterone (your blood testosterone levels are less than 50 ng/dL)
3. The requested medication will be used together with a gonadotropin releasing hormone analog (such as leuprolide, goserelin, histrelin, degarelix)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**APALUTAMIDE**

---

**RATIONALE**

For further information, please refer to the prescribing information and/or drug monograph for Erleada.

**REFERENCES**

- Erleada [Prescribing Information]. Horsham, PA: Janssen; February 2023.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 03/13/23

Created: 05/18

Client Approval: 03/23

P&T Approval: 10/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

APOMORPHINE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
APOMORPHINE HCL	APOKYN, APOMORPHINE HCL		42078	GPI-14 (7320301010E220)	

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

- Does the patient have a diagnosis of advanced Parkinson's disease and meet **ALL** of the following criteria?
  - Therapy is prescribed by or in consultation with a neurologist
  - Apokyn will be used for the acute, intermittent treatment of hypomobility, OFF episodes associated with advanced Parkinson's disease
  - The physician has optimized drug therapy as evidenced by BOTH of the following:
    - Change in levodopa/carbidopa dosing strategy or formulation
    - Trial of or contraindication to TWO Parkinson disease agents from two different classes: dopamine agonist (i.e., ropinirole, pramipexole, rotigotine), monoamine oxidase-inhibitors (MAO-I) (i.e., selegiline, rasagiline), catechol-O-methyl transferase (COMT) inhibitors (i.e., entacapone, tolcapone)

If yes, **approve for 6 months by GPID or GPI-14 with a quantity limit of #60mL per month.**  
If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **APOMORPHINE (Apokyn)** requires the following rule(s) be met for approval:

- You have a diagnosis of advanced Parkinson's disease (a type of movement disorder)
- Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor)
- The requested medication will be used for acute, intermittent treatment of hypomobility (short and sudden episodes where you have decreased ability to move), OFF episodes associated with advanced Parkinson's disease
- Your doctor has optimized your drug therapy as evidenced by BOTH of the following:
  - Change in levodopa/carbidopa dosing strategy or formulation
  - You have had a trial of or contraindication (harmful for) to TWO Parkinson disease agents from two different classes: dopamine agonist (ropinirole, pramipexole, rotigotine), monoamine oxidase-inhibitors (MAO-I) (selegiline, rasagiline), catechol-O-methyl transferase (COMT) inhibitors (entacapone, tolcapone)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

APOMORPHINE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of advanced Parkinson's disease **AND** meet the following criterion?
  - Patient has experienced improvement with motor fluctuations during OFF episodes with the use of Apokyn (e.g., improvement in speech, facial expression, tremor at rest, action or postural tremor of hands, rigidity, finger taps, hand movements, rapid alternating movements of hands, posture, leg agility, arising from chair)

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #60mL per month.**  
If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **APOMORPHINE (Apokyn)** requires the following rule(s) be met for renewal:

- A. You have a diagnosis of advanced Parkinson's disease (a type of movement disorder)
- B. You have had improvement with motor fluctuations during OFF episodes with the use of Apokyn (such as improvement in speech, facial expression, tremor [shaking] at rest, action or postural tremor of hands, rigidity, finger taps, hand movements, rapid alternating movements of hands, posture, leg agility, arising from chair)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Apokyn.

**REFERENCES**

- Apokyn [Prescribing Information]. Louisville, KY: US WorldMeds, LLC, April 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/22

Created: 11/04

Client Approval: 03/22

P&T Approval: 04/19



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

APOMORPHINE - SL

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
APOMORPHINE	KYNMOBI	01934		GPI-10 (7320301010)	BRAND = KYNMOBI

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of Parkinson's disease and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or given in consultation with a neurologist
  - The physician has optimized drug therapy as evidenced by **BOTH** of the following:
    - Change in levodopa/carbidopa dosing strategy or formulation
    - Trial of or contraindication to at least **TWO** Parkinson's agents from two different classes: dopamine agonist (i.e., ropinirole, pramipexole, rotigotine), monoamine oxidase-inhibitor (MAO-I) (i.e., selegiline, rasagiline), or catechol-O-methyl transferase (COMT) inhibitors (i.e., entacapone, tolcapone)
  - Kynmobi is being used for the acute, intermittent treatment of 'OFF' episodes

If yes, **approve for 6 months for all strengths by GPID or GPI-14 as follows:**

- **Kynmobi Titration Kit: no quantity limit.**
- **Kynmobi 10mg, 15mg, 20mg, 25mg and 30mg: #5 per day.**

**APPROVAL TEXT:** Renewal requires the patient had improvement with motor fluctuations during OFF episodes with the use of Kynmobi (e.g., improvement in speech, facial expression, tremor at rest, action or postural tremor of hands, rigidity, finger taps, hand movements, rapid alternating movements of hands, posture, leg agility, arising from chair).

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **APOMORPHINE (Kynmobi)** requires the following rule(s) be met for approval:

- A. You have Parkinson's disease (central nervous system disorder that affects movement, often including tremors)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or given in consultation with a neurologist  
*(Initial denial text continued on next page)*

CONTINUED ON NEXT PAGE





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

APOMORPHINE - SL

INITIAL CRITERIA (CONTINUED)

- D. The physician has optimized drug therapy as evidenced by **BOTH** of the following:
1. Change in levodopa/carbidopa dosing strategy or formulation
  2. Trial of or contraindication to at least two Parkinson's agents from two different classes: dopamine agonist (i.e., ropinirole, pramipexole, rotigotine), monoamine oxidase-inhibitor (MAO-I) (i.e., selegiline, rasagiline), or catechol-o-methyl transferase (COMT) inhibitors (i.e., entacapone, tolcapone)
- E. The requested medication is being used for acute, intermittent treatment (sudden and periodic treatment) of 'OFF' episodes (when symptoms return due to your medication for Parkinson's disease wearing off)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of Parkinson's disease **AND** meet the following criterion?
  - The patient had improvement with motor fluctuations during 'OFF' episodes with the use of Kynmobi (e.g., improvement in speech, facial expression, tremor at rest, action or postural tremor of hands, rigidity, finger taps, hand movements, rapid alternating movements of hands, posture, leg agility, arising from chair)

If yes, **approve for 12 months by GPID or GPI-14 for all of the following:**

- Kynmobi 10mg, 15mg, 20mg, 25mg and 30mg: #5 per day.

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **APOMORPHINE (Kynmobi)** requires the following rule(s) be met for renewal:

- A. You have Parkinson's disease (central nervous system disorder that affects movement, often including tremors)
- B. You had improvement with motor fluctuations during 'OFF' episodes (when symptoms return due to your medications for Parkinson's disease wearing off) with the use of Kynmobi (such as improvement in speech, facial expression, tremor at rest, action or postural tremor of hands, rigidity, finger taps, hand movements, rapid alternating movements of hands, posture, leg agility, arising from chair)

***(Renewal denial text continued on next page)***

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

APOMORPHINE - SL

RENEWAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Kynmobi.

**REFERENCES**

- Kynmobi [Prescribing Information]. Marlborough, MA: Sunovion Pharmaceuticals Inc., May 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/01/20

Created: 08/20

Client Approval: 08/20

P&T Approval: 07/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

APREMILAST

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
APREMILAST	OTEZLA	40967		GPI-10 (6670001500)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of psoriatic arthritis (PsA) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a rheumatologist or dermatologist
  - The patient had a trial of or contraindication to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

If yes, enter approval(s) by GPID or GPI-14 as follows:

- If the starter pack is requested for dosage titration, approve for 1 fill for either #1 Otezla Two Week Starter Pack (#27 tablets) OR for #1 Otezla 28-day Starter Pack (#55 tablets) AND
- Approve for 6 months for #2 per day.

If no, continue to #2.

2. Does the patient have a diagnosis of mild plaque psoriasis (PsO) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a dermatologist
  - The patient meets ONE of the following:
    - The patient has psoriasis covering 2% of body surface area (BSA)
    - The patient has a static Physician Global Assessment (sPGA) score of 2
    - The patient has a Psoriasis Area and Severity Index (PASI) score of 2 to 9
  - The patient had a trial of or contraindication to one conventional systemic agent (e.g., methotrexate, acitretin, cyclosporine) OR one conventional topical agent (e.g., PUVA, UVB, topical corticosteroids)

If yes, enter approval(s) by GPID or GPI-14 as follows:

- If the starter pack is requested for dosage titration, approve for 1 fill for either #1 Otezla Two Week Starter Pack (#27 tablets) OR for #1 Otezla 28-day Starter Pack (#55 tablets) AND
- Approve for 6 months for #2 per day.

If no, continue to #3.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

APREMILAST

INITIAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) and meet **ALL** of the following criteria?
- The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a dermatologist
  - The patient has psoriasis covering 3% or more of body surface area (BSA) OR psoriatic lesions affecting the hands, feet, face, or genital area
  - The patient had a trial of or contraindication to ONE or more forms of conventional therapies, such as PUVA, UVB, topical corticosteroids, calcipotriene, acitretin, methotrexate, or cyclosporine

If yes, enter approval(s) by GPID or GPI-14 as follows:

- **If the starter pack is requested for dosage titration, approve for 1 fill for either #1 Otezla Two Week Starter Pack (#27 tablets) OR for #1 Otezla 28-day Starter Pack (#55 tablets) AND**
- **Approve for 6 months for #2 per day.**

If no, continue to #4.

4. Does the patient have a diagnosis of Behcet's disease with oral ulcers or history of recurrent oral ulcers based on clinical symptoms and meet **ALL** of the following criteria?
- The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a rheumatologist
  - The patient had a trial of or contraindication to ONE or more conservative treatments (e.g., colchicine, topical corticosteroid, oral corticosteroid)

If yes, enter approval(s) by GPID or GPI-14 as follows:

- **If the starter pack is requested for dosage titration, approve for 1 fill for either #1 Otezla Two Week Starter Pack (#27 tablets) OR for #1 Otezla 28-day Starter Pack (#55 tablets) AND**
- **Approve for 6 months for #2 per day.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

APREMILAST

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **APREMILAST (Otezla)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
  - 1. Psoriatic arthritis (a type of skin and joint condition)
  - 2. Plaque psoriasis (a type of skin condition)
  - 3. Behcet's disease (a type of inflammation disorder) with oral ulcers or history of recurrent oral ulcers based on clinical symptoms
- B. You are 18 years of age or older
- C. **If you have psoriatic arthritis, approval also requires:**
  - 1. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
  - 2. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
- D. **If you have mild plaque psoriasis, approval also requires:**
  - 1. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
  - 2. You have psoriasis covering 2 percent of body surface area (BSA), OR a static Physician Global Assessment (Spga: a measure used to evaluate severity of your disease) score of 2, OR a Psoriasis Area and Severity Index (PASI: a measure used to evaluate severity of your disease) score of 2 to 9
  - 3. You had a trial of or contraindication to (harmful for) one conventional (standard) systemic (treatment that targets the entire body) agent (such as methotrexate, acitretin, cyclosporine) OR one conventional topical agent (such as Phototherapy Ultraviolet Light A [PUVA], Ultraviolet Light B [UVB], topical corticosteroids)
- E. **If you have moderate to severe plaque psoriasis, approval also requires:**
  - 1. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
  - 2. You have psoriasis covering 3 percent or more of body surface area (BSA) OR psoriatic lesions (rashes) affecting your hands, feet, face, or genital area
  - 3. You had a trial of or contraindication (harmful for) to ONE or more forms of conventional (standard) therapies, such as Phototherapy Ultraviolet Light A (PUVA), Ultraviolet Light B (UVB), topical corticosteroids, calcipotriene, acitretin, methotrexate, cyclosporine
- F. **If you have Behcet's disease with oral ulcers or history of recurrent oral ulcers based on clinical symptoms, approval also requires:**
  - 1. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
  - 2. You had a trial of or contraindication (harmful for) to ONE or more conservative treatments such as colchicine, topical corticosteroid, oral corticosteroid

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

APREMILAST

INITIAL CRITERIA (CONTINUED)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have psoriatic arthritis (PsA) **AND** meet the following criterion?
  - The patient has experienced or maintained a 20% or greater improvement in tender or swollen joint count while on therapy

If yes, **approve for 12 months by HICL or GPI-10 for #2 per day.**  
If no, continue to #2.
  
2. Does the patient have mild plaque psoriasis (PsO) **AND** meet the following criterion?
  - The patient has achieved or maintained clear or minimal disease OR a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more OR a decrease in sPGA (static Physician Global Assessment) by at least a 2-point reduction from baseline

If yes, **approve for 12 months by HICL or GPI-10 for #2 per day.**  
If no, continue to #3.
  
3. Does the patient have moderate to severe plaque psoriasis (PsO) **AND** meet the following criterion?
  - The patient has achieved or maintained clear or minimal disease OR a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more

If yes, **approve for 12 months by HICL or GPI-10 for #2 per day.**  
If no, continue to #4.
  
4. Does the patient have Behcet's disease with oral ulcers or history of recurrent oral ulcers based on clinical symptoms **AND** meet the following criterion?
  - The patient has achieved or maintained clinical benefit compared to baseline (e.g., pain scores, number of ulcers)

If yes, **approve for 12 months by HICL or GPI-10 for #2 per day.**  
If no, do not approve.  
**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

APREMILAST

RENEWAL CRITERIA (CONTINUED)

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **APREMILAST (Otezla)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following diagnoses:
  - 1. Psoriatic arthritis (a type of skin and joint condition)
  - 2. Plaque psoriasis (a type of skin condition)
  - 3. Behcet's disease (a type of inflammation disorder) with oral ulcers or history of recurrent oral ulcers based on clinical symptoms
- A. **If you have psoriatic arthritis, renewal also requires:**
  - 1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
- B. **If you have mild plaque psoriasis, renewal also requires:**
  - 1. You have achieved or maintained clear or minimal disease OR a decrease in Psoriasis Area and Severity Index (PASI: a measure used to evaluate severity of your disease) of at least 50 percent or more OR a decrease in static Physician Global Assessment (Spga: a measure used to evaluate severity of your disease) by at least a 2-point reduction from baseline
- C. **If you have moderate to severe plaque psoriasis, renewal also requires:**
  - 1. You achieved or maintained clear or minimal disease OR a decrease in Psoriasis Area and Severity Index (PASI: a measure used to evaluate severity of your disease) of at least 50 percent or more
- E. **If you have Behcet's disease with oral ulcers or history of recurrent oral ulcers based on clinical symptoms, renewal also requires:**
  - 1. You have achieved or maintained clinical benefit compared to baseline such as an improvement in pain scores, number of ulcers

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**APREMILAST**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Otezla.

**REFERENCES**

- Otezla [Prescribing Information]. Summit, NJ: Celgene Corporation; December 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/23

Created: 04/14

Client Approval: 02/23

P&T Approval: 01/23





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ARIPIPRAZOLE SENSOR TABS

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ARIPIPRAZOLE TABLETS WITH SENSOR	ABILIFY MYCITE	24551		GPI-10 (5925001502, 5925001503)	BRAND = ABILIFY MYCITE

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of schizophrenia and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- Therapy is prescribed by or in consultation with a psychiatrist
- The patient has a medical necessity for tracking medication ingestion

If yes, **approve all strengths for 12 months by GPID or GPI-14 with a quantity limit of #1 kit per 30 days.**

If no, continue to #2.

2. Does the patient have a diagnosis of major depressive disorder and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- Therapy is prescribed by or in consultation with a psychiatrist
- Abilify MyCite will be used as an adjunctive treatment
- The patient has a medical necessity for tracking medication ingestion

If yes, **approve all strengths for 12 months by GPID or GPI-14 with a quantity limit of #1 kit per 30 days.**

If no, continue to #3.

3. Does the patient have a diagnosis of bipolar I disorder and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- Therapy is prescribed by or in consultation with a psychiatrist
- The patient has a medical necessity for tracking medication ingestion

If yes, continue to #4.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ARIPIPRAZOLE SENSOR TABS

GUIDELINES FOR USE (CONTINUED)

4. Does the patient meet **ONE** of the following criteria?

- The request is for acute treatment of manic and mixed episodes as monotherapy, OR as an adjunct to lithium or valproate
- The request is for maintenance treatment as monotherapy, OR as an adjunct to lithium or valproate

If yes, **approve all strengths for 12 months by GPID or GPI-14 with a quantity limit of #1 kit per 30 days.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ARIPIPRAZOLE SENSOR TABS (Abilify MyCite)** requires the following rule(s) be met for approval:

A. You have **ONE** of the following diagnoses:

1. Schizophrenia (a type of mental health disorder)
2. Bipolar I disorder (a type of mood disorder)
3. Major depressive disorder (MDD: a type of mental health disorder)

B. **If you have schizophrenia, approval also requires:**

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a psychiatrist (a type of mental health doctor)
3. You have a medical necessity for medication ingestion tracking

C. **If you have major depressive disorder, approval also requires:**

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a psychiatrist (a type of mental health doctor)
3. Abilify MyCite will be used as an adjunctive (add-on) treatment
4. You have a medical necessity for medication ingestion tracking

D. **If you have bipolar I disorder, approval also requires:**

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a psychiatrist (a type of mental health doctor)
3. You have a medical necessity for medication ingestion tracking
4. You meet **ONE** of the following:
  - i. The request is for acute (short-term) treatment of manic and mixed episodes as monotherapy (used alone), OR as an adjunct (add-on) to lithium or valproate
  - ii. The request is for maintenance treatment as monotherapy, OR as an adjunct to lithium or valproate

***(Denial text continued on the next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ARIPIRAZOLE SENSOR TABS

GUIDELINES FOR USE (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Abilify MyCite.

**REFERENCES**

- Abilify MyCite [Prescribing Information]. Redwood City, CA: Proteus Digital Health, Inc.: February 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/24/22

Created: 02/19

Client Approval: 10/22

P&T Approval: 01/19



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ASCIMINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ASCIMINIB HYDROCHLORIDE	SCSEMBLIX	47647		GPI-10 (2153180610)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient had a mutational analysis prior to initiation AND Scemblix is appropriate per the NCCN guideline table for treatment recommendations based on BCR-ABL1 mutation profile (*Please see header CML-5 of the current NCCN guidelines*)

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Is the patient's cancer positive for the T315I mutation?

If yes, **approve Scemblix 40mg for 12 months by GPID or GPI-14 with a quantity limit of #10 per day.**

If no, continue to #3.

3. Has the patient been previously treated with at least TWO tyrosine kinase inhibitors (TKIs) (e.g., bosutinib, dasatinib, imatinib, nilotinib)?

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ASCIMINIB (Scemblix)** requires the following rule(s) be met for approval:

- D. You have Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML: type of blood cancer) in chronic phase (CP)
- E. You are 18 years of age or older
- F. You had a mutational analysis prior to initiation of therapy AND Scemblix is appropriate per the National Comprehensive Cancer Network (NCCN) guideline table for treatment recommendations based on BCR-ABL1 mutation (breakpoint cluster region-Abelson murine leukemia 1; a type of abnormal gene) profile
- G. You meet ONE of the following:
  1. Your cancer has the T315I mutation (a type of abnormal gene)
  2. You have been previously treated with at least TWO tyrosine kinase inhibitors (TKIs), such as bosutinib, dasatinib, imatinib, nilotinib

**(Denial text continued on next page)**

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ASCIMINIB

GUIDELINES FOR USE (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Scemblix.

**REFERENCES**

- Scemblix [Prescribing Information]. East Hanover, New Jersey: Novartis Pharmaceuticals Co.; October 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective:04/01/22

Created: 02/22

Client Approval: 02/22

P&T Approval: 01/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ASPARAGINASE ERWINIA-RYWN

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ASPARAGINASE ERWINIA-RYWN	RYLAZE	47474		GPI-10 (2125001060)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) and meet **ALL** of the following criteria?
  - The patient is 1 month of age or older
  - The patient has developed hypersensitivity to E. coli-derived asparaginase
  - Rylaze will be used as a component of a multi-agent chemotherapeutic regimen

If yes, **approve for 12 months by HICL or GPI-10.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ASPARAGINASE ERWINIA-RYWN (Rylaze)** requires the following rule(s) be met for approval:

- A. You have acute lymphoblastic leukemia (ALL: type of blood cancer) or lymphoblastic lymphoma (LBL: type of cancer affecting the immune system)
- B. You are 1 month of age or older
- C. You have developed hypersensitivity to E.coli-derived asparaginase (you are allergic to an enzyme/protein that is from a type of bacteria)
- D. Rylaze will be used as a component of a multi-agent chemotherapeutic regimen

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Rylaze.

**REFERENCES**

- Rylaze [Prescribing Information]. Palo Alto, CA: Jazz Pharmaceuticals, Inc.; June 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/22

Created: 10/21

Client Approval: 11/21

P&T Approval: 10/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ASFOTASE ALFA

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ASFOTASE ALFA	STRENSIQ	42649		GPI-10 (3090561000)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Is this a request for treatment of perinatal/infantile-onset hypophosphatasia (HPP)?

If yes, continue to #2.

If no, continue to #3.

2. Does the patient have a documented diagnosis of perinatal/infantile-onset hypophosphatasia (HPP) and meet **ALL** of the following criteria?

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient was 6 months of age or younger at hypophosphatasia (HPP) onset
- The patient is NOT currently receiving treatment with a bisphosphonate [e.g., Boniva (ibandronate), Fosamax (alendronate), Actonel (risedronate)].
- The patient is positive for a tissue non-specific alkaline phosphatase (TNSALP) (ALPL) gene mutation as confirmed by genetic testing OR meets at least TWO of the following criteria:
  - Serum alkaline phosphatase (ALP) level below that of normal range for patient age
  - Serum pyridoxal-5'-phosphate (PLP) levels elevated AND patient has not received vitamin B<sub>6</sub> supplementation in the previous week
  - Urine phosphoethanolamine (PEA) level above that of normal range for patient age
  - Radiographic evidence of hypophosphatasia (HPP) (e.g., flared and frayed metaphyses, osteopenia, widened growth plates, areas of radiolucency or sclerosis)
  - Presence of two or more of the following:
    - Rachitic chest deformity
    - Craniosynostosis (premature closure of skull bones)
    - Delay in skeletal growth resulting in delay of motor development
    - History of vitamin B<sub>6</sub> dependent seizures
    - Nephrocalcinosis or history of elevated serum calcium
    - History or presence of non-traumatic postnatal fracture and delayed fracture healing

If yes, continue to #5.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

3. Is this a request for treatment of juvenile-onset hypophosphatasia (HPP)?

If yes, continue to #4.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ASFOTASE ALFA

INITIAL CRITERIA (CONTINUED)

4. Does the patient have a documented diagnosis of juvenile-onset hypophosphatasia (HPP) and meet **ALL** of the following criteria?

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient was 18 years of age or younger at hypophosphatasia (HPP) onset
- The patient is NOT currently receiving treatment with a bisphosphonate [e.g., Boniva (ibandronate), Fosamax (alendronate), Actonel (risedronate)].
- The patient is positive for a tissue non-specific alkaline phosphatase (TNSALP) (ALPL) gene mutation as confirmed by genetic testing OR meets at least TWO of the following criteria:
  - Serum alkaline phosphatase (ALP) level below that of normal range for patient age
  - Serum pyridoxal-5'-phosphate (PLP) levels elevated AND patient has not received vitamin B<sub>6</sub> supplementation in the previous week
  - Urine phosphoethanolamine (PEA) level above that of normal range for patient age
  - Radiographic evidence of hypophosphatasia (HPP) (e.g., flared and frayed metaphyses, osteopenia, osteomalacia, widened growth plates, areas of radiolucency or sclerosis)
  - Presence of two or more of the following:
    - Rachitic deformities (rachitic chest, bowed legs, knock-knees)
    - Premature loss of primary teeth prior to 5 years of age
    - Delay in skeletal growth resulting in delay of motor development
    - History or presence of non-traumatic fractures or delayed fracture healing

If yes, continue to #5.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

5. Does the patient meet **ANY** of the following criteria?

- The patient's serum calcium or phosphate level is below the normal range
- The patient has a treatable form of rickets

If yes, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline

If no, **approve for 6 months by HICL or GPI-10.**

CONTINUED ON NEXT PAGE





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ASFOTASE ALFA

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ASFOTASE ALFA (Strensiq)** requires the following rules be met for approval:

- A. You have a documented diagnosis of perinatal/infantile-onset hypophosphatasia (HPP: a type of genetic condition) or juvenile-onset hypophosphatasia (HPP).
- B. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
- C. You are NOT currently receiving treatment with a bisphosphonate [such as Boniva (ibandronate), Fosamax (alendronate), Actonel (risedronate)]
- D. **If you have perinatal/infantile-onset hypophosphatasia, approval also requires:**
  1. You were 6 months of age or younger at hypophosphatasia onset
  2. You are positive for a tissue non-specific alkaline phosphatase (a type of enzyme) (ALPL) gene mutation as confirmed by genetic testing OR you meet at least TWO of the following criteria:
    - a. Serum alkaline phosphatase (type of enzyme) level below that of normal range for your age
    - b. Serum pyridoxal-5'-phosphate (PLP) levels elevated AND you have not received vitamin B6 supplementation in the previous week
    - c. Urine phosphoethanolamine (PEA) level above that of normal range for your age
    - d. Radiographic evidence of hypophosphatasia [such as flared and frayed metaphyses (narrow part of long bone), osteopenia (bone loss), widened growth plates, areas of radiolucency (ability to see through with x-rays/ radiation) or sclerosis (hardening of an area)]
    - e. Presence of two or more of the following:
      - i. Rachitic chest deformity (chest bones are not normal)
      - ii. Craniosynostosis (premature closure of skull bones)
      - iii. Delay in skeletal growth resulting in delay of motor development
      - iv. History of vitamin B6 dependent seizures
      - v. Nephrocalcinosis (high calcium levels in kidney) or history of elevated serum calcium
      - vi. History or presence of fracture after birth not due to injury or delayed fracture healing

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ASFOTASE ALFA

INITIAL CRITERIA (CONTINUED)

**E. If you have juvenile-onset hypophosphatasia, approval also requires:**

1. You were 18 years of age or younger at hypophosphatasia onset
2. You are positive for a tissue non-specific alkaline phosphatase (TNSALP) (ALPL) gene mutation as confirmed by genetic testing OR meet at least TWO of the following criteria:
  - a. Serum alkaline phosphatase (type of enzyme) level below that of normal range for your age
  - b. Serum pyridoxal-5'-phosphate (PLP) levels elevated AND you have not received vitamin B6 supplementation in the previous week
  - c. Urine phosphoethanolamine (PEA) level above that of normal range for your age
  - d. Radiographic evidence of hypophosphatasia [such as flared and frayed metaphyses (narrow part of long bone), osteopenia (bone loss), osteomalacia (bone softening), widened growth plates, areas of radiolucency or sclerosis (hardening of an area)]
  - e. Presence of two or more of the following:
    - i. Rachitic deformities (rachitic chest, bowed legs, knock-knees)
    - ii. Premature loss of primary teeth prior to 5 years of age
    - iii. Delay in skeletal growth leading to motor development delay
    - iv. History or presence of fracture after birth not due to injury or delayed fracture healing

**Strensiq will not be approved if you meet any of the following:**

1. Your serum calcium or phosphate level is below the normal range
2. You have a treatable form of rickets (softening and weakening of bones in children, usually due to low vitamin D)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ASFOTASE ALFA

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. During the last 6 months of treatment, has the patient experienced improvement in the skeletal characteristics of hypophosphatasia (HPP) (e.g., improvement of the irregularity of the provisional zone of calcification, physeal widening, metaphyseal flaring, radiolucencies, patchy osteosclerosis, ratio of mid-diaphyseal cortex to bone thickness, gracile bones, bone formation and fractures)?

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

2. Is the patient currently receiving treatment with a bisphosphonate [e.g., Boniva (ibandronate), Fosamax (alendronate), Actonel (risedronate)]?

If yes, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

If no, **approve for 12 months by HICL or by GPI-10.**

**RENEWAL DENIAL TEXT:** **\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ASFOTASE ALFA (Strensiq)** requires that the following rule(s) be met for renewal:

- A. You have experienced improvement in the skeletal characteristics of hypophosphatasia (HPP: genetic disorder causing abnormal development of bones and teeth). Characteristics may include irregularity of the provisional zone of calcification (area on long bone for calcium build-up), physeal widening (area of bone that helps length growth), metaphyseal flaring (a narrow part of long bone grows), radiolucencies (ability to see with x-rays/ radiation), patchy osteosclerosis (parts of abnormal hardening of bone), ratio of mid-diaphyseal cortex to bone thickness, gracile (slender) bones, bone formation and fractures.
- B. You are NOT currently receiving treatment with a bisphosphonate [such as Boniva (ibandronate), Fosamax (alendronate), Actonel (risedronate)].

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**ASFOTASE ALFA**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Strensiq.

**REFERENCES**

- Strensiq [Prescribing Information]. Cheshire, CT: Alexion Pharmaceuticals, Inc.; June 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/22

Created: 11/15

Client Approval: 05/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ASPIRIN ER

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ASPIRIN ER	DURLAZA		17988	GPI-10 (8515001000)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of chronic coronary artery disease, (e.g., a history of MI or unstable angina), or a history of an ischemic stroke or transient ischemic attack (TIA)?

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of guideline.

2. Does the patient meet the following criteria?

- Patient has previously tried aspirin over-the-counter (OTC)
- Durlaza is NOT being used for acute treatment of myocardial infarction or before percutaneous coronary intervention

If yes, **approve for 12 months by GPID or GPI-10 for a quantity limit of #30 per 30 days.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ASPIRIN ER (Durlaza)** requires the following rules be met for approval:

1. You have ONE of the following:
  - a. Diagnosis of chronic coronary artery disease [damage or disease in the heart's major blood vessels; may include a history of myocardial infarction (heart attack) or unstable angina (chest pain when your heart doesn't get enough oxygen)] OR
  - b. History of an ischemic stroke or transient ischemic attack (arteries to your brain become narrowed or blocked, causing blood flow loss).
2. You have previously tried aspirin over-the-counter (OTC)
3. Durlaza is NOT being used for acute treatment (short term treatment) of myocardial infarction (heart attack) or before percutaneous coronary intervention (non-surgical procedure used to treat narrowing of the coronary arteries of the heart)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**ASPIRIN ER**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Durlaza.

**REFERENCES**

- Durlaza [Prescribing Information] North Haven, CT. New haven Pharmaceuticals, Inc., September 2015.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 11/15

Client Approval: 04/20

P&T Approval: 11/15



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ASPIRIN-OMEPRAZOLE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ASPIRIN-OMEPRAZOLE	YOSPRALA, ASPIRIN-OMEPRAZOLE	43771		GPI-10 (8515990204)	

**GUIDELINES FOR USE**

1. Does the patient require aspirin for secondary prevention of cardiovascular or cerebrovascular events and have **ONE** of the following diagnoses?

- Ischemic stroke
- Transient ischemia of the brain due to fibrin platelet emboli
- Previous myocardial infarction
- Unstable angina pectoris
- Chronic stable angina pectoris
- Previously undergone revascularization procedures (i.e., coronary artery bypass graft, percutaneous transluminal coronary angioplasty)

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient have a risk of developing aspirin associated gastrointestinal (GI) ulcers and meet **ALL** of the following criteria?

- The patient is 55 years of age or older
- Documented history of gastrointestinal (GI) ulcers

If yes, continue to #3.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

3. Has the patient tried **ALL** of the following medications?

- Aspirin over-the-counter (OTC)
- Generic proton pump inhibitors (e.g., omeprazole, lansoprazole, pantoprazole, or rabeprazole)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ASPIRIN-OMEPRAZOLE

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ASPIRIN-OMEPRAZOLE (Yosprala)** requires the following rule(s) be met for approval:

- A. The request is for secondary prevention of cardiovascular (related to heart and blood vessels) or cerebrovascular (related brain and blood vessels) events
- B. You have ONE of the following:
  - 1. Ischemic stroke (arteries to your brain become narrowed or blocked, causing less blood flow)
  - 2. Transient ischemia of the brain due to fibrin platelet emboli (blood flow to your brain gets cut off for a short time due to temporary blockage)
  - 3. Previous myocardial infarction (heart attack)
  - 4. Unstable angina pectoris (chest pain when your heart doesn't get enough oxygen)
  - 5. Chronic stable angina pectoris (chest pain when your heart doesn't get enough oxygen)
  - 6. History of undergoing revascularization procedures (procedures that restore blood flow to heart such as coronary artery bypass graft, percutaneous transluminal coronary angioplasty)
- C. You have a risk of developing aspirin associated gastrointestinal (GI) ulcers due to age (55 years or older) **AND** have a documented history of gastrointestinal (GI) ulcers
- D. You have tried both aspirin over-the-counter (OTC) **AND** generic proton pump inhibitors (such as omeprazole, lansoprazole, pantoprazole, rabeprazole)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Yosprala.

**REFERENCES**

- Yosprala [Prescribing Information]. Princeton, NJ: Aralez Pharmaceuticals US Inc. June 2018.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 05/19

Client Approval: 04/20

P&T Approval: 11/16





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ASPIRIN ZERO COST SHARE OVERRIDE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ASPIRIN	ASPIRIN, ASPIRIN EC, VARIOUS		161 16701 16713 16720	GPI-14 (64100010000315, 64100010000510, 64100010000601, 64100010000605)	

**GUIDELINES FOR USE**

1. Is the patient requesting a cost share exception for the requested aspirin agent **AND** does the plan cover these agents at zero cost share (i.e., the plan follows Affordable Care Act [ACA] recommendations and is linked to MedImpact's Essential Health Benefit Tables)?

If yes, continue to #2.

If no, guideline does not apply.

2. Does the patient's plan have specific procedures, instructions, and/or policies for cost share exception processes or for multi-source brand agent overrides (DAW1 override)?

If yes, guideline does not apply.

If no, continue to #3.

3. Is the request for a generic agent?

If yes, **approve the requested agent for 12 months by GPID or GPI-14 at zero copay.**

If no, continue to #4.

4. Is the request for **ONE** of the following?

- A single-source brand (SSB) agent that has no preferred generic agents or therapeutically equivalent products available
- A multi-source brand (MSB) agent

If yes, continue to #5.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ASPIRIN ZERO COST SHARE OVERRIDE

GUIDELINES FOR USE (CONTINUED)

5. Does the patient meet **ONE** of the following criteria?

- Two preferred medications are medically inappropriate for the patient (one if only one agent is available)
- The patient has tried or has a documented medical contraindication to TWO preferred medications (one if only one agent is available)
- The prescriber provided documentation confirming that the requested drug is considered medically necessary (considerations may include severity of side effects and ability to adhere to the appropriate use of the item or service)

If yes, **approve the requested agent for 12 months by GPID or GPI-14 at zero copay.**

**APPROVAL TEXT (applies to multi-source brand agents only):** Although your cost share has been reduced to zero-dollar, you may incur a dispense-as-written (DAW) penalty fee if you choose to fill a brand prescription instead of its generic equivalent.

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ASPIRIN ZERO COST SHARE OVERRIDE** requires the following rule(s) be met for approval:

A. The request is for ONE of the following:

1. A generic aspirin agent
2. A single-source brand (SSB) aspirin agent that has no preferred generic agents or therapeutically equivalent products available
3. A multi-source brand (MSB) aspirin agent

B. **If the request is for a single-source brand or multi-source brand agent, approval also requires ONE of the following:**

1. Two preferred medications are medically inappropriate for you (one if only one agent is available)
2. You have tried or have a documented medical contraindication (harmful for) to TWO preferred medications (one if only one agent is available)
3. Your doctor has provided documentation confirming that your requested drug is considered medically necessary for you (considerations may include severity of side effects and ability to adhere to the appropriate use of the item or service)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ASPIRIN ZERO COST SHARE OVERRIDE

**RATIONALE**

This guideline applies to plans where the pharmacy benefit allows for coverage of aspirin for preventative use at zero copay. The override criteria allow patient access to all FDA-approved aspirin medications at zero copay by waiving the applicable cost-sharing for branded or non-preferred branded aspirin medications.

**REFERENCES**

- U.S. Department of Labor. Affordable Care Act Implementation Frequently Asked Questions. Available at: <https://www.dol.gov/agencies/ebsa/laws-and-regulations/laws/affordable-care-act/for-employers-and-advisers/aca-implementation-faqs>. Accessed May 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/22

Created: 05/22

Client Approval: 05/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ATOGE PANT

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ATOGE PANT	QULIPTA	47599		GPI-10 (6770101000)	

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Is the request for the preventative treatment of episodic migraine and the patient meets **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Qulipta will NOT be used concurrently with other CGRP inhibitors (e.g., Ajovy, Aimovig, Emgality, Vyepti, Nurtec ODT) for migraine prevention
  - The patient had a trial of or contraindication to ONE of the following preventative migraine treatments: divalproex sodium/sodium valproate, topiramate, propranolol, timolol, metoprolol, atenolol, nadolol, amitriptyline, venlafaxine

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #1 per day.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ATOGE PANT (Qulipta)** requires the following rule(s) be met for approval:

- A. The request is for the preventative treatment of episodic migraine
- B. You are 18 years of age or older
- C. You will NOT use Qulipta concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Ajovy, Aimovig, Emgality, Vyepti, Nurtec ODT) for migraine prevention
- D. You had a trial of or contraindication (harmful for) to ONE of the following preventative migraine treatments: divalproex sodium/sodium valproate, topiramate, propranolol, timolol, metoprolol, atenolol, nadolol, amitriptyline, venlafaxine

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ATOGEPAANT

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Is the request for the preventative treatment of episodic migraine **AND** does the patient meet the following criterion?

- Qulipta will NOT be used concurrently with other CGRP inhibitors (e.g., Ajovy, Aimovig, Emgality, Vyepti, Nurtec ODT) for migraine prevention

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

2. Does the patient meet **ONE** of the following criteria?

- The patient has experienced a reduction in migraine or headache frequency of at least 2 days per month
- The patient has experienced a reduction in migraine severity
- The patient has experienced a reduction in migraine duration

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ATOGEPAANT (Qulipta)** requires the following rule(s) be met for renewal:

- A. The request is for the preventative treatment of episodic migraine
- B. You will NOT use Qulipta concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Ajovy, Aimovig, Emgality, Vyepti, Nurtec ODT) for migraine prevention
- C. You meet ONE of the following criteria:
  1. You have experienced a reduction in migraine or headache frequency of at least 2 days per month
  2. You have experienced a reduction in migraine severity
  3. You have experienced a reduction in migraine duration

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**ATOGEPANT**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Qulipta.

**REFERENCES**

- Qulipta [Prescribing Information]. North Chicago, IL: AbbVie, Inc., October 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/22

Created: 10/21

Client Approval: 02/22

P&T Approval: 01/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

AVACOPAN

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
AVACOPAN	TAVNEOS	47626		GPI-10 (8580551000)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] or microscopic polyangiitis [MPA]) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a rheumatologist or nephrologist
  - The patient is ANCA seropositive (anti-PR3 or anti-MPO)
  - Tavneos will be used as adjunctive therapy in combination with standard therapy including glucocorticoids (e.g., methylprednisolone, prednisone)

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #6 per day.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **AVACOPAN (Tavneos)** requires the following rule(s) be met for approval:

- A. You have severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (inflammation of blood vessels) (granulomatosis with polyangiitis [GPA: condition that affects the blood vessels] or microscopic polyangiitis [MPA: condition that affects the blood vessels])
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or nephrologist (a type of kidney doctor)
- D. You are ANCA seropositive for anti-PR3 or anti-MPO (a type of lab test)
- E. Tavneos will be used as adjunctive (add-on) therapy in combination with standard therapy including glucocorticoids (such as methylprednisolone, prednisone)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

AVACOPAN

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] or microscopic polyangiitis [MPA]) AND meet the following criterion?
  - The patient continues to benefit from therapy (e.g., improvement of clinical manifestations, if renal vasculitis - improvement in eGFR and proteinuria values, reduction of corticosteroid dose without disease flares)

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #6 per day.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **AVACOPAN (Tavneos)** requires the following rule(s) be met for renewal:

- A. You have severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (inflammation of blood vessels) (granulomatosis with polyangiitis [GPA: condition that affects the blood vessels] or microscopic polyangiitis [MPA: condition that affects the blood vessels])
- B. You continue to benefit from the medication

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Tavneos.

**REFERENCES**

- Tavneos [Prescribing Information]. Cincinnati, OH: ChemoCentryx Inc.; October 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/24/22

Created: 02/22

Client Approval: 10/22

P&T Approval: 01/22





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

AVAPRITINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
AVAPRITINIB	AYVAKIT	46291		GPI-10 (2149000900)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of unresectable or metastatic gastrointestinal stromal tumor (GIST) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient has a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**  
If no, continue to #2.

2. Does the patient have a diagnosis of advanced systemic mastocytosis (AdvSM) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient's AdvSM includes aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **AVAPRITINIB (Ayvakit)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
    1. Unresectable (cannot be removed completely through surgery) or metastatic (cancer that has spread to other parts of the body) gastrointestinal stromal tumor (GIST: type of growth in the digestive system tract, most commonly in the stomach or small intestine)
    2. Advanced systemic mastocytosis (AdvSM: group of rare diseases in which uncontrolled growth and accumulation of mast cells [type of white blood cell] occurs in one or more organs)
  - B. You are 18 years of age or older
  - C. **If you have unresectable or metastatic gastrointestinal stromal tumor (GIST), approval also requires:**
    1. You have a platelet-derived growth factor receptor alpha (PDGFRA: a type of gene/protein) exon 18 mutation, including PDGFRA D842V mutations (a change in your DNA that make up your gene)
- (Denial text continued on next page)**

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

AVAPRITINIB

GUIDELINES FOR USE (CONTINUED)

D. If you have advanced systemic mastocytosis (AdvSM), approval also requires:

1. Your AdvSM includes aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (abnormal mass of blood and blood-forming tissue that forms when cells grow and divide) (SM-AHN), and mast cell leukemia (MCL: an aggressive subtype of acute myeloid leukemia)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Ayvakit.

**REFERENCES**

- Ayvakit [Prescribing Information]. Cambridge, MA: Blueprint Medicines Corporation, June 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/26/21

Created: 05/20

Client Approval: 07/21

P&T Approval: 07/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

AVATROMBOPAG

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
AVATROMBOPAG MALEATE	DOPTELET	44942		GPI-10 (8240501020)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of thrombocytopenia and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a hematologist, gastroenterologist, hepatologist, immunologist, surgeon, or endocrinologist
  - The patient has chronic liver disease
  - The patient is scheduled to undergo a procedure 10 to 13 days following the initiation of Doptelet therapy
  - The patient has a platelet count of  $<50 \times 10^9/L$  measured within the last 30 days
  - The patient is NOT receiving other thrombopoietin receptor agonist therapy (e.g., Promacta)

If yes, **approve by HICL or GPI-10 for 1 fill with a quantity limit of #15.**

If no, continue to #2.

2. Does the patient have a diagnosis of chronic immune thrombocytopenia (cITP) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a hematologist or immunologist
  - The patient had a trial of or contraindication to corticosteroids or immunoglobulins OR had an insufficient response to splenectomy

If yes, **approve for 2 months by HICL or GPI-10 with a quantity limit of #2 per day.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

AVATROMBOPAG

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it**

Our guideline named **AVATROMBOPAG (Doptelet)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
  - a. Thrombocytopenia (**a type of blood disorder**)
  - b. Chronic immune thrombocytopenia (**immune system attacks your blood platelets**)
- B. **If you have thrombocytopenia, approval also requires:**
  - 1. You are 18 years of age or older
  - 2. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor), gastroenterologist (doctor who treats digestive conditions), hepatologist (a type of liver doctor), immunologist (a type of immune system doctor), surgeon, or endocrinologist (a type of hormone doctor)
  - 3. You have chronic (long-term) liver disease
  - 4. You are scheduled to undergo a procedure 10 to 13 days after starting Doptelet therapy
  - 5. You have a platelet (type of blood cell that prevents bleeding) count of less than 50 x 10(9)/L measured within the last 30 days
  - 6. You are NOT receiving other thrombopoietin receptor agonist therapy such as Promacta
- C. **If you have chronic immune thrombocytopenia (cITP), approval also requires:**
  - 1. You are 18 years of age or older
  - 2. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or immunologist (a type of immune system doctor)
  - 3. You had a trial of or contraindication (harmful for) to corticosteroids or immunoglobulins OR you had an insufficient response to splenectomy (surgical removal of spleen did not work)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

AVATROMBOPAG

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

**NOTE:** For the diagnosis of thrombocytopenia in chronic liver disease, please refer to the Initial Criteria section.

1. Does the patient have a diagnosis of chronic immune thrombocytopenia (cITP) **AND** meet the following criterion?
  - Patient had a clinical response to therapy as defined by an increase in platelet count to at least  $50 \times 10^9/L$  (at least 50,000 per microliter), compared to baseline.

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.**  
If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **AVATROMBOPAG (Doptelet)** requires the following rule(s) be met for renewal:

- A. You have a diagnosis of chronic immune thrombocytopenia (**immune system attacks your blood platelets**)
- B. You had a clinical response to therapy as defined by an increase in platelet count to at least  $50 \times 10^9/L$  (at least 50,000 per microliter), compared to baseline.

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Doptelet.

**REFERENCES**

- Doptelet [prescribing information]. Durham, NC. Dova Pharmaceuticals, Inc. July 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/22

Created: 08/18

Client Approval: 02/22

P&T Approval: 01/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

AXITINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
AXITINIB	INLYTA	38446		GPI-10 (2133501300)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of advanced renal cell carcinoma (RCC) and meet **ONE** of the following criteria?

- The patient has tried at least **ONE** systemic therapy for the treatment of RCC [e.g., Nexavar (sorafenib), Torisel (temsirolimus), Sutent (sunitinib), Votrient (pazopanib), or Avastin (bevacizumab) in combination with interferon]
- Inlyta will be used in combination with avelumab (Bavencio) as a first-line treatment
- Inlyta will be used in combination with pembrolizumab (Keytruda) as a first-line treatment

If yes, approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:

- Inlyta 1mg: #6 per day.
- Inlyta 5mg: #4 per day.

If no, do not approve.

**DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **AXITINIB (Inlyta)** requires the following rule(s) be met for approval:

- A. You have advanced renal cell carcinoma (RCC; type of kidney cancer)
- B. You also meet ONE of the following:
  1. You have tried at least ONE systemic therapy (treatment that spreads throughout the body) for the treatment of renal cell carcinoma such as Nexavar (sorafenib), Torisel (temsirolimus), Sutent (sunitinib), Votrient (pazopanib), or Avastin (bevacizumab) in combination with interferon
  2. Inlyta will be used in combination with avelumab (Bavencio) as a first-line treatment
  3. Inlyta will be used in combination with pembrolizumab (Keytruda) as a first-line treatment

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**AXITINIB**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Inlyta.

**REFERENCES**

- Inlyta [Prescribing Information]. New York, NY: Pfizer; June 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/10/21

Created: 02/12

Client Approval: 03/21

P&T Approval: 07/20



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**AZACITIDINE**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
AZACITIDINE	ONUREG		48545 48540	GPI-14 (21300003000330) (21300003000320)	

**GUIDELINES FOR USE**

- Does the patient have a diagnosis of acute myeloid leukemia and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy
  - The patient is not able to complete intensive curative therapy

If yes, **approve for 12 months for all strengths by GPID or GPI-14 with a quantity limit of #14 per 28 days.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **AZACITIDINE (Onureg)** requires the following rule(s) be met for approval:

- You have acute myeloid leukemia (AML: type of blood and bone marrow cancer with too many white blood cells)
- You are 18 years of age or older
- You have achieved first complete remission (CR: signs or symptoms of cancer have disappeared) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy (medications for cancer)
- You are not able to complete intensive curative therapy (treatment to cure the disease)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Onureg.

**REFERENCES**

- Onureg [Prescribing Information]. Summit, NJ: Celgene Corporation; September 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/21

Created: 10/20

Client Approval: 11/20

P&T Approval: 10/20

Copyright © 2023 MediImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MediImpact. MediImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**AZTREONAM INHALED**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
AZTREONAM LYSINE	CAYSTON		28039	GPI-10 (1614001040)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of cystic fibrosis and meet **ALL** of the following criteria?
  - The patient is 7 years of age or older
  - The patient has a lung infection with a Gram negative species (such as *Pseudomonas aeruginosa*; not *Staphylococcus aureus* because it is not a Gram negative species)

If yes, **approve for 12 months by GPI-10 for 6 fills of #84 vials per 56 days.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **AZTREONAM INHALED** requires the following rule(s) be met for approval:

- A. You have a diagnosis of cystic fibrosis (inherited life-threatening disorder that damages the lungs and digestive system)
- B. You are 7 years of age or older
- C. You have a lung infection with a Gram negative species such as *Pseudomonas aeruginosa*

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Cayston.

**REFERENCES**

- Cayston [Prescribing Information]. Foster City, CA. Gilead Sciences, Inc.; November 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 05/12

Client Approval: 04/20

P&T Approval: 05/12



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**BACLOFEN**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
BACLOFEN	OZOBAX, BACLOFEN		64209	GPI-14 (75100010002070)	
BACLOFEN	FLEQSUVY		51885	GPI-14 (75100010001825)	
BACLOFEN	LYVISPAH		51638 51639 51652	GPI-14 (75100010003010), (75100010003020), (75100010003030)	

**GUIDELINES FOR USE**

1. Is the request for Ozobax and the patient meets **ALL** of the following criteria?

- The patient had a trial of or contraindication to generic baclofen tablets
- The patient is unable to swallow generic baclofen tablets

If yes, **approve for 6 months by GPID or GPI-14 with a quantity limit of #80mL per day.**  
If no, continue to #2.

2. Is the request for Fleqsuvy and the patient meets **ALL** of the following criteria?

- The patient had a trial of or contraindication to generic baclofen tablets
- The patient is unable to swallow generic baclofen tablets

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #16mL per day.**  
If no, continue to #3.

3. Is the request for Lyvispah and the patient meets **ALL** of the following criteria?

- The patient had a trial of or contraindication to generic baclofen tablets
- The patient is unable to swallow generic baclofen tablets

If yes, **approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:**

- **5mg: #9 per day.**
- **10mg: #3 per day.**
- **20mg: #4 per day.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

BACLOFEN

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **BACLOFEN (Ozobax, Fleqsuvy, Lyvispah)** requires the following rule(s) be met for approval:

- A. You have tried or have a contraindication (harmful for) to generic baclofen tablets
- B. You are unable to swallow generic baclofen tablets

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Ozobax Fleqsuvy, and Lyvispah.

**REFERENCES**

- Ozobax [Prescribing Information]. Athens, GA: Metacel Pharmaceuticals, LLC; May 2020.
- Fleqsuvy [Prescribing Information]. Wilmington, MA: Azurity Pharmaceuticals, Inc.; February 2022.
- Lyvispah [Prescribing Information]. Roswell, GA: Saol Therapeutics, Inc.; November 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/01/22

Created: 11/19

Client Approval: 09/22

P&T Approval: 07/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**BARICITINIB**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
BARICITINIB	OLUMIANT	44296		GPI-10 (6660301000)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a rheumatologist
  - The patient had a trial of or contraindication to at least 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
  - The patient had a trial of or contraindication to any TWO of the following preferred agents: Enbrel, Humira, Rinvoq, Xeljanz (IR/XR) [**Note:** pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #1 per day.**  
If no, continue to #2.

2. Is the request for the treatment of coronavirus disease 2019 (COVID-19) in a hospitalized adult?

If yes, **do not approve.** [NOTE: This indication is for hospital use only.]  
**DENIAL TEXT:** See initial denial text at the end of the guideline.  
If no, continue to #3.

3. Does the patient have a diagnosis of severe alopecia areata and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a dermatologist
  - The patient has had at least 50% scalp hair loss as measured by the Severity of Alopecia Tool (SALT) for more than 6 months

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #1 per day.**  
If no, do not approve.  
**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

BARICITINIB

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **BARICITINIB (Olumiant)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
  - 1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
  - 2. Severe alopecia areata (a type of hair loss)
- B. **If you have moderate to severe rheumatoid arthritis, approval also requires:**
  - 1. You are 18 years of age or older
  - 2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
  - 3. You had a trial of or contraindication (harmful for) to at least 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
  - 4. You have tried or have a contraindication (harmful for) to any TWO of the following preferred medications: Enbrel, Humira, Rinvoq, Xeljanz (immediate release/extended release)
- C. **If you have severe alopecia areata, approval also requires:**
  - 1. You are 18 years of age or older
  - 2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
  - 3. You have had at least 50% scalp hair loss as measured by the Severity of Alopecia Tool (SALT: a type of disease evaluation tool) for more than 6 months
- D. NOTE: Olumiant will not be approved for the treatment of coronavirus disease 2019 (COVID-19) in hospitalized adults.

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

BARICITINIB

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) **AND** meet the following criterion?
  - The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**  
If no, continue to #2.

2. Does the patient have a diagnosis of severe alopecia areata **AND** meet the following criterion?
  - The patient has had improvement while on therapy (e.g., scalp hair coverage)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**  
If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **BARICITINIB (Olumiant)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following diagnoses:
  1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
  2. Severe alopecia areata (a type of hair loss)
- B. **If you have moderate to severe rheumatoid arthritis, renewal also requires:**
  1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
- C. **If you have severe alopecia areata, renewal also requires:**
  1. You have had improvement while on therapy (such as scalp hair coverage)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**BARICITINIB**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Olumiant.

**REFERENCES**

- Olumiant [Prescribing Information]. Indianapolis, IN: Eli Lilly and Company; June 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/23

Created: 06/18

Client Approval: 02/23

P&T Approval: 01/23



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

BEDAQUILINE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
BEDAQUILINE FUMARATE	SIRTURO	39895		GPI-10 (0900001510)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of pulmonary multi-drug resistant tuberculosis (MDR-TB) (i.e., an isolate of *M. tuberculosis* that is resistant to at least isoniazid and rifampin) and meet **ALL** of the following criteria?

- The patient meets ONE of the following:
  - The patient is 5 to less than 18 years of age **AND** weighs at least 15kg
  - The patient is 18 years of age or older
- Sirturo will be used in combination with at least 3 other antibiotics

If yes, approve for a total of 24 weeks by GPID or GPI-14 as follows:

- **FIRST APPROVAL:** Approve for 4 weeks for the requested strength as follows:
  - Sirturo 20mg: #340 per 28 days.
  - Sirturo 100mg: #68 per 28 days.
- **SECOND APPROVAL:** Approve for 20 weeks (total fill count 5) for the requested strength as follows:
  - Sirturo 20mg: #120 per 28 days.
  - Sirturo 100mg: #24 per 28 days.

Please enter a start date of 3 WEEKS AFTER the START date of the first approval.

If no, continue to #2.

2. Does the patient have a diagnosis of pulmonary multi-drug resistant tuberculosis (MDR-TB) (i.e., an isolate of *M. tuberculosis* that is resistant to at least isoniazid and rifampin) **OR** pulmonary extensively drug resistant tuberculosis (XDR-TB) (i.e., an isolate of *M. tuberculosis* that is resistant to at least isoniazid, rifampin, a fluoroquinolone, and an aminoglycoside) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- Sirturo will be used in combination with pretomanid and linezolid

If yes, approve for a total of 26 weeks for Sirturo 100mg by GPID or GPI-14 as follows:

- **FIRST APPROVAL:** Approve for 4 weeks with a quantity limit of #68 per 28 days.
- **SECOND APPROVAL:** Approve for 22 weeks (total fill count 6) with a quantity limit of #24 per 28 days. Please enter a start date of 3 WEEKS AFTER the START date of the first approval.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

BEDAQUILINE

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **BEDAQUILINE (Sirturo)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
  - 1. Pulmonary multi-drug resistant tuberculosis (MDR-TB: tuberculosis bacteria in lungs does not respond to multiple drugs, including at least isoniazid and rifampin)
  - 2. Pulmonary extensively drug resistant tuberculosis (XDR-TB: tuberculosis bacteria is resistant to at least isoniazid, rifampin, a fluoroquinolone [type of antibiotic], and an aminoglycoside [a type of antibiotic])
- B. **If you have pulmonary multi-drug resistant tuberculosis, approval also requires ONE of the following:**
  - 1. You are 5 years to less than 18 years of age AND weigh at least 15 kg (33 lbs), AND will be using Sirturo in combination with at least 3 other antibiotics
  - 2. You are 18 years of age, AND will be using Sirturo in combination with at least 3 other antibiotics
  - 3. You are 18 years of age, AND will be using Sirturo in combination with pretomanid and linezolid
- C. **If you have pulmonary extensively drug resistant tuberculosis, approval also requires:**
  - 1. You are 18 years of age or older
  - 2. You will be using Sirturo in combination with pretomanid and linezolid

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Sirturo.

**REFERENCES**

- Sirturo [Prescribing Information]. Titusville, NJ: Janssen Therapeutics; May 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 12/01/21

Created: 05/13

Client Approval: 11/21

P&T Approval: 07/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**BELIMUMAB - SQ**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
BELIMUMAB	BENLYSTA		43658 43661	GPI-14 (9942201500D520, 9942201500E520)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of autoantibody-positive systemic lupus erythematosus (SLE) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a rheumatologist
  - The patient is currently using corticosteroids, antimalarials, NSAIDs, or immunosuppressives

If yes, **approve for 6 months by GPID or GPI-14 for the requested product with a quantity limit of #4mL per 28 days.**

If no, continue to #2.

2. Does the patient have a diagnosis of active lupus nephritis and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a rheumatologist or nephrologist
  - The patient is receiving standard therapy (e.g., steroids, antimalarials, NSAIDs, immunosuppressives)

If yes, **approve for a total of 6 months by GPID or GPI-14 for the requested product as follows:**

**FIRST APPROVAL:**

- **200mg/mL: Approve for 1 month with a quantity limit of #8mL per 28 days.**

**SECOND APPROVAL:**

- **200mg/mL: Approve for 5 months with a quantity limit of #4mL per 28 days (Please enter a start date 3 weeks after the start date of the first approval).**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

BELIMUMAB - SQ

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **BELIMUMAB - SQ (Benlysta)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
1. Autoantibody-positive systemic lupus erythematosus (SLE: a type of immune condition)
  2. Active lupus nephritis (LN: A type of immune condition that affects the kidneys)
- B. **If you have autoantibody-positive systemic lupus erythematosus (SLE), approval also requires:**
1. You are 18 years of age or older
  2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
  3. You are currently using corticosteroids, antimalarials (drugs that treat parasites), non-steroidal anti-inflammatory drugs (NSAIDs), or immunosuppressives (drugs that weaken your immune system)
- C. **If you have active lupus nephritis, approval also requires:**
1. You are 18 years of age or older
  2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or nephrologist (a type of kidney doctor)
  3. You are receiving standard treatment (such as steroids, antimalarials, nonsteroidal anti-inflammatory drugs (NSAIDs), or immunosuppressives (drugs that weaken your immune system))

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of autoantibody-positive systemic lupus erythematosus (SLE) **AND** meet the following criterion?
  - The patient has had clinical improvement while on Benlysta

If yes, **approve for 12 months by GPID or GPI-14 for the requested product with a quantity limit of #4mL per 28 days.**

If no, continue to #2.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

BELIMUMAB - SQ

RENEWAL CRITERIA (CONTINUED)

2. Does the patient have a diagnosis of active lupus nephritis **AND** meet the following criterion?
- The patient has had clinical improvement in renal response as compared to baseline (i.e., eGFR or proteinuria) and/or clinical parameters (e.g., fluid retention, use of rescue drugs, glucocorticoid dose)

If yes, **approve for 12 months by GPID or GPI-14 for the requested product with a quantity limit of #4mL per 28 days.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **BELIMUMAB - SQ (Benlysta)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following diagnoses:
- Autoantibody-positive systemic lupus erythematosus (SLE: a type of immune condition)
  - Active lupus nephritis (LN: a type of immune condition that affects the kidneys)
- B. **If you have autoantibody-positive systemic lupus erythematosus (SLE), renewal also requires:**
- You have had clinical improvement while on Benlysta
- C. **If you have active lupus nephritis, renewal also requires:**
- You have had clinical improvement in renal response as compared to baseline laboratory values (eGFR [measurement of kidney function] or proteinuria [level of protein in urine]), and/or clinical parameters (such as fluid retention, use of rescue drugs, glucocorticoid dose)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Benlysta.

**REFERENCES**

- Benlysta [Prescribing Information]. Rockville, Maryland: Human Genome Sciences, Inc.; July 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Created: 08/17

Commercial Effective: 08/29/22

Client Approval: 08/22

P&T Approval: 01/21

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**BELUMOSUDIL**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
BELUMOSUDIL MESYLATE	REZUROCK	47503		GPI-10 (9939851050)	

**GUIDELINES FOR USE**

- Does the patient have a diagnosis of chronic graft-versus-host-disease (cGVHD) and meet ALL of the following criteria?
  - The patient is 12 years of age or older
  - The patient had failure of at least two prior lines of systemic therapies

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **BELUMOSUDIL (Rezurock)** requires the following rule(s) be met for approval:

- You have chronic graft-versus-host-disease (cGVHD: a long-term type of immune disorder)
- You are 12 years of age or older
- You had failure of at least two prior lines of systemic therapies (treatment that spreads throughout the body)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Rezurock.

**REFERENCES**

- Rezurock [Prescribing Information]. Warrendale, PA: Kadmon Pharmaceuticals, LLC, July 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/16/22

Created: 08/21

Client Approval: 03/22

P&T Approval: 07/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**BELZUTIFAN**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
BELZUTIFAN	WELIREG	47546		GPI-10 (2142102000)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of von Hippel-Lindau (VHL) disease and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient requires therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET)
  - The patient does NOT require immediate surgery

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #3 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **BELZUTIFAN (Welireg)** requires the following rule(s) be met for approval:

- A. You have von Hippel-Lindau (VHL) disease (genetic disorder that causes tumors to grow in the body)
- B. You are 18 years of age or older
- C. You require therapy for associated renal cell carcinoma (RCC: a type of kidney cancer), central nervous system (CNS) hemangioblastomas (tumor in the brain or spinal cord), or pancreatic neuroendocrine tumors (pNET: tumor in the pancreas)
- D. You do NOT require immediate surgery

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Welireg.

**REFERENCES**

- Welireg [Prescribing Information]. Whitehouse Station, NJ: Merck & Co, Inc.; August 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/22

Created: 10/21

Client Approval: 11/21

P&T Approval: 10/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**BENRALIZUMAB**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
BENRALIZUMAB	FASENRA	44635		GPI-10 (4460402000)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

- 1 Does the patient have a diagnosis of severe asthma with an eosinophilic phenotype and meet **ALL** of the following criteria?
  - The patient is 12 years of age or older
  - Therapy is prescribed by or in consultation with a physician specializing in pulmonary medicine or allergy medicine
  - The patient has a documented blood eosinophil level of at least 150 cells/mcL within the past 12 months
  - The patient is concurrently treated with a medium, high-dose, or maximally tolerated dose of an inhaled corticosteroid AND at least one other maintenance medication (e.g., a long-acting inhaled beta2-agonist such as formoterol, salmeterol, long-acting muscarinic antagonist such as tiotropium, a leukotriene receptor antagonist such as montelukast, theophylline, or oral corticosteroid)
  - Fasenra will NOT be used concurrently with Xolair, Dupixent, or another anti-IL5 biologic (e.g., Nucala, Cinqair) when used for the treatment of asthma

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**BENRALIZUMAB**

**INITIAL CRITERIA (CONTINUED)**

2 Does the patient meet **ONE** of the following criteria?

- The patient experienced at least **ONE** asthma exacerbation requiring systemic corticosteroid burst lasting at least 3 days within the past 12 months OR at least **ONE** serious exacerbation requiring hospitalization or emergency room visit within the past 12 months
- The patient has poor symptom control despite current therapy as evidenced by at least **THREE** of the following within the past 4 weeks:
  - Daytime asthma symptoms more than twice a week
  - Any night waking due to asthma
  - Use of a short-acting inhaled beta2-agonist reliever (SABA; such as albuterol) for symptoms more than twice a week
  - Any activity limitation due to asthma

If yes, **approve for a total of 4 months as follows:**

- **If the plan covers non-self-administered (NSA) agents: Enter TWO approvals by HICL or GPI-10 as below:**
  - **FIRST APPROVAL:** approve for 2 months (total fill count of 2) with a quantity limit of #1mL (one 30mg/mL pre-filled syringe/autoinjector pen) per 28 days.
  - **SECOND APPROVAL:** approve for 2 months (total fill count of 2) with a quantity limit of #1mL (one 30mg/mL pre-filled syringe/autoinjector pen) per 56 days. (Start date is 1 week before the end of the first approval.)
- **If the plan does NOT cover NSA agents: Approve Fasentra autoinjector pen by GPID or GPI-14 and enter TWO approvals as below:**
  - **FIRST APPROVAL:** approve for 2 months (total fill count of 2) with a quantity limit of #1mL (one 30mg/mL autoinjector pen) per 28 days.
  - **SECOND APPROVAL:** approve for 2 months (total fill count of 2) with a quantity limit of #1mL (one 30mg/mL autoinjector pen) per 56 days. (Start date is 1 week before the end of the first approval.)

If no, do not approve.

**INITIAL DENIAL TEXT:** **\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **BENRALIZUMAB (Fasentra)** requires the following rule(s) be met for approval:

- A. You have severe asthma with an eosinophilic phenotype (type of inflammatory asthma)
  - B. You are 12 years of age or older
  - C. Therapy is prescribed by or in consultation with a physician specializing in pulmonary (lung/breathing) medicine or allergy medicine
- (Initial denial text continued on next page)**

**CONTINUED ON NEXT PAGE**





**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**BENRALIZUMAB**

**INITIAL CRITERIA (CONTINUED)**

- D. You have a documented blood eosinophil level (type of white blood cell) of at least 150 cells/mcL within the past 12 months
- E. You are being treated with medium, high-dose, or a maximally tolerated dose of an inhaled corticosteroid AND at least one other maintenance medication which includes a long-acting inhaled beta2-agonist (such as formoterol, salmeterol), long-acting muscarinic antagonist (such as tiotropium), leukotriene receptor antagonist (such as montelukast), theophylline, or oral corticosteroid
- F. You have ONE of the following:
  - 1. Experienced at least ONE asthma exacerbation (worsening of symptoms) requiring systemic corticosteroid burst lasting at least 3 days within the past 12 months OR at least ONE serious exacerbation requiring hospitalization or emergency room visit within the past 12 months
  - 2. Poor symptom control despite current therapy as evidenced by at least THREE of the following within the past 4 weeks:
    - a. Daytime asthma symptoms more than twice per week
    - b. Any night waking due to asthma
    - c. Use of a short-acting inhaled beta2-agonist reliever (such as albuterol) for symptoms more than twice per week
    - d. Any activity limitation due to asthma
- G. You will NOT use Fasenra concurrently (at the same time) with Xolair, Dupixent, or another anti-IL5 biologic (such as Nucala, Cinqair) when used for the treatment asthma

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**BENRALIZUMAB**

**GUIDELINES FOR USE (CONTINUED)**

**RENEWAL CRITERIA**

1. Does the patient meet **ALL** of the following criteria?

- The patient will continue to use an inhaled corticosteroid (ICS) AND at least one other maintenance medication (e.g., a long-acting inhaled beta2-agonist such as formoterol or salmeterol, a long-acting muscarinic antagonist such as tiotropium, a leukotriene receptor antagonist such as montelukast, theophylline, or oral corticosteroid)
- Fasenra will NOT be used concurrently with Xolair, Dupixent, or another anti-IL5 biologic (e.g., Nucala, Cinqair) when used for the treatment of asthma
- The patient has shown a clinical response as evidenced by ONE of the following:
  - Reduction in asthma exacerbation from baseline
  - Decreased utilization of rescue medications
  - Increase in percent predicted FEV1 from pretreatment baseline
  - Reduction in severity or frequency of asthma-related symptoms (e.g., wheezing, shortness of breath, coughing, etc.)

If yes, **approve for 12 months as follows:**

- **If the plan covers non-self-administered (NSA) agents: Approve by HICL or GPI-10 with a quantity limit of #1mL (one 30mg/mL pre-filled syringe/autoinjector pen) per 56 days.**
- **If the plan does NOT cover NSA agents: Approve by GPID or GPI-14 with a quantity limit of #1mL (one 30mg/mL autoinjector pen) per 56 days.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **BENRALIZUMAB (Fasenra)** requires the following rule(s) be met for renewal:

- A. You will continue to use an inhaled corticosteroid (ICS) AND at least one other maintenance medication such as a long-acting inhaled beta2-agonist (such as formoterol, salmeterol), a long-acting muscarinic antagonist (such as tiotropium), a leukotriene receptor antagonist (such as montelukast), theophylline, or oral corticosteroid
- B. You will NOT use Fasenra concurrently (at the same time) with Xolair, Dupixent, or another anti-IL5 biologic (such as Nucala, Cinqair) when used for the treatment asthma  
*(Renewal denial text continued on next page)*

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

BENRALIZUMAB

RENEWAL CRITERIA (CONTINUED)

- C. You have shown a clinical response as evidenced by ONE of the following:
  1. Reduction in asthma exacerbation (worsening of symptoms) from baseline
  2. Decreased use of rescue medications
  3. Increase in percent predicted FEV1 (amount of air exhaled in one second) from pretreatment baseline
  4. Reduction in severity or frequency of asthma-related symptoms (such as wheezing, shortness of breath, coughing, etc.)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Fasenra.

REFERENCES

- Fasenra [Prescribing Information]. Wilmington, DE: AstraZeneca Pharmaceutical LP.; February 2021.

Library	Commercial	NSA
Yes	Yes	Yes

Part D Effective: N/A

Commercial Effective: 07/01/22

Created: 02/18

Client Approval: 05/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**BEROTRALSTAT**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
BEROTRALSTAT HYDROCHLORIDE	ORLADEYO	47016		GPI-10 (8584001020)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of hereditary angioedema (HAE) and meet **ALL** of the following criteria?
  - The patient is 12 years of age or older
  - The diagnosis of HAE is confirmed via documentation of complement testing
  - Orladeyo is being used for prophylaxis against HAE attacks
  - Therapy is prescribed by or in consultation with an allergist, immunologist or hematologist
  - The patient is NOT on concurrent treatment with an alternative prophylactic agent for HAE (e.g., Takhzyro, Haegarda, Cinryze, danazol)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **BEROTRALSTAT (Orladeyo)** requires the following rule(s) be met for approval:

- A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
- B. Your diagnosis is confirmed by documented complement testing (a type of blood test)
- C. You are 12 years of age or older
- D. Orladeyo is being used for prevention of hereditary angioedema attacks
- E. Therapy is prescribed by or in consultation with an allergist, immunologist (allergy or immune system doctor) or hematologist (blood doctor)
- F. You will NOT use Orladeyo concurrently (at the same time) with an alternative preventive agent for HAE (such as Takhzyro, Haegarda, Cinryze, danazol)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

BEROTRALSTAT

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of hereditary angioedema (HAE) and meet **ALL** of the following criteria?
  - The patient has experienced improvement (i.e., reductions in attack frequency or attack severity) compared to baseline in HAE attacks
  - The patient is NOT on concurrent treatment with an alternative prophylactic agent for HAE (e.g., Takhzyro, Haegarda, Cinryze, danazol)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **BEROTRALSTAT (Orladeyo)** requires the following rule(s) be met for renewal:

- A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
- B. You have experienced improvement (reductions in attack frequency or attack severity) compared to baseline in HAE attacks
- C. You will NOT use Orladeyo concurrently (at the same time) with an alternative preventive agent for HAE (such as Takhzyro, Haegarda, Cinryze, danazol)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Orladeyo.

**REFERENCES**

- Orladeyo [Prescribing Information]. Durham, NC: BioCryst Pharmaceuticals, Inc.; December 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/22

Created: 12/20

Client Approval: 05/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

BETAINE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
BETAINE	CYSTADANE, BETAINE ANHYDROUS	12233		GPI-10 (3090452000)	

**GUIDELINES FOR USE**

- Does the patient have a diagnosis of homocystinuria (including cystathionine beta-synthase (CBS) deficiency, 5,10-methylenetetrahydrofolate reductase (MTHFR) deficiency, and cobalamin cofactor metabolism (cbl) defect)?

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #20 grams per day.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **BETAINE (Cystadane)** requires the following rule(s) be met for approval:

- You have homocystinuria (a type of genetic metabolic disorder), including cystathionine beta-synthase (CBS: a type of enzyme) deficiency, 5,10-methylenetetrahydrofolate reductase (MTHFR: a type of enzyme) deficiency, and cobalamin cofactor metabolism (cbl: vitamin B12 that is required for enzyme activity) defect

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Cystadane.

**REFERENCES**

- Cystadane [Prescribing Information]. Lebanon, NJ: Recordati Rare Diseases, Inc.; October 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/23

Created: 05/22

Client Approval: 02/23

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**BEXAROTENE**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
BEXAROTENE SOFTGEL	TARGRETIN, BEXAROTENE	20832		GPI-10 (2170822000)	
BEXAROTENE 1% TOPICAL GEL	TARGRETIN, BEXAROTENE		GPI-10 (9037622000)		

**GUIDELINES FOR USE**

**TARGRETIN (BEXAROTENE) CAPSULE**

1. Does the patient have a diagnosis of cutaneous T-cell lymphoma (CTCL) **AND** meet the following criterion?

The patient is refractory to at least one prior systemic therapy (e.g., gemcitabine, methotrexate, liposomal doxorubicin, bortezomib)

If yes, **approve for 12 months by GPID or GPI-10.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **BEXAROTENE (Targretin capsule)** requires the following rule(s) be met for approval:

- A. You have cutaneous T-cell lymphoma (CTCL: a type of blood cancer)
- B. You are refractory (resistant) to at least one prior systemic therapy (therapy that spreads through the blood) such as gemcitabine, methotrexate, liposomal doxorubicin, or bortezomib

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**TARGRETIN (BEXAROTENE) GEL**

1. Does the patient have a diagnosis of cutaneous T-cell lymphoma (CTCL) (stage IA or IB) and meet **ONE** of the following criteria?

- The patient has refractory or persistent disease after other therapies
- The patient has not tolerated other therapies

If yes, **approve for 12 months by GPID or GPI-10.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

BEXAROTENE

GUIDELINES FOR USE - TARGRETIN (BEXAROTENE) GEL (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **BEXAROTENE (Targretin gel)** requires the following rule(s) to be met for approval:

- A. You have cutaneous T-cell lymphoma (CTCL: a type of blood cancer) (stage IA or IB)
- B. You meet ONE of the following:
  - 1. You have refractory (resistant) or persistent disease after other therapies
  - 2. You have not tolerated other therapies

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Targretin.

**REFERENCES**

- Targretin Capsule [Prescribing Information]. Bridgewater, NJ: Bausch Health US, LLC; April 2020.
- Targretin Gel [Prescribing Information]. Bridgewater, NJ: Bausch Health US, LLC; February 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 06/15/22

Created: 05/12

Client Approval: 05/22

P&T Approval: 04/20





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**BINIMETINIB**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
BINIMETINIB	MEKTOVI	45040		GPI-10 (2153352000)	

**GUIDELINES FOR USE**

- Does the patient have a diagnosis of unresectable or metastatic melanoma and meet **ALL** of the following criteria?
  - The patient has BRAF V600E or V600K mutation as detected by an FDA-approved test
  - The medication will be used in combination with Braftovi (encorafenib)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #6 per day.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **BINIMETINIB (Mektovi)** requires the following rule(s) be met for approval:

- You have a diagnosis of unresectable (cannot completely remove by surgery) or metastatic (disease that has spread) melanoma (skin cancer)
- You have a BRAF V600E or V600K mutation (types of gene mutations) as detected by a Food and Drug Administration-approved test
- The medication will be used in combination with Braftovi (encorafenib)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Mektovi.

**REFERENCES**

- Mektovi [Prescribing Information]. Boulder, CO: Array BioPharma Inc. February 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 08/18

Client Approval: 04/20

P&T Approval: 07/18



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**BOSENTAN**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
BOSENTAN	TRACLEER, BOSENTAN	22990		GPI-10 (4016001500)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of pulmonary arterial hypertension (WHO Group 1) and meet **ALL** of the following criteria?

- The patient is 3 years of age or older
- Therapy is prescribed by or in consultation with a cardiologist or pulmonologist
- The patient has NYHA-WHO Functional Class II to IV symptoms
- The patient does not have idiopathic pulmonary fibrosis (IPF)
- The patient is NOT concurrently taking cyclosporine A or glyburide

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Does that patient have a documented confirmatory PAH diagnosis based on right heart catheterization with the following parameters?

- Mean pulmonary artery pressure (PAP) of > 20 mmHg
- Pulmonary capillary wedge pressure (PCWP) of ≤ 15 mmHg
- Pulmonary vascular resistance (PVR) of ≥ 3 Wood units

If yes, **approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:**

- **62.5mg tablet: #2 per day.**
- **125mg tablet: #2 per day.**
- **32mg tablet for suspension: #4 per day.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

BOSENTAN

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **BOSENTAN (Tracleer)** requires the following rule(s) be met for approval:

- A. You have pulmonary arterial hypertension (a type of heart and lung condition) (World Health Organization Group 1)
- B. You are 3 years of age and older
- C. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung doctor)
- D. You have New York Heart Association-World Health Organization (NYHA-WHO) Functional Class II to IV symptoms (a classification system of heart failure symptoms)
- E. You do not have idiopathic pulmonary fibrosis (scarring of the lungs for an unknown reason)
- F. You are NOT concurrently (at the same time) taking cyclosporine A or glyburide
- G. You have documentation confirming your diagnosis of pulmonary arterial hypertension based on right heart catheterization (a test using a thin tube that is placed into the right side of your heart) with the following values:
  - 1. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
  - 2. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
  - 3. Pulmonary vascular resistance (PVR) greater than or equal to 3 Wood units

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of pulmonary arterial hypertension (WHO Group 1)?

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

2. Is the patient concurrently taking cyclosporine A or glyburide?

If yes, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

If no, continue to #3.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

BOSENTAN

RENEWAL CRITERIA (CONTINUED)

3. Is the patient between the ages of 3 and 17 years old and meets **ONE** of the following criteria?
- The patient has demonstrated an improvement in pulmonary vascular resistance (PVR)
  - The patient has remained stable or shown improvement in exercise ability (e.g., 6-minute walk test, World Health Organization [WHO] functional class symptoms)

If yes, **approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:**

- **62.5mg tablet: #2 per day.**
- **125mg tablet: #2 per day.**
- **32mg tablet for suspension: #4 per day.**

If no, continue to #4.

4. Is the patient 18 years of age or older and meets **ONE** of the following criteria?
- The patient has shown improvement from baseline in the 6-minute walk distance test
  - The patient has remained stable from baseline in the 6-minute walk distance test AND World Health Organization (WHO) functional class has remained stable or improved

If yes, **approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:**

- **62.5mg tablet: #2 per day.**
- **125mg tablet: #2 per day.**
- **32mg tablet for suspension: #4 per day.**

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

BOSENTAN

RENEWAL CRITERIA (CONTINUED)

**RENEWAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **BOSENTAN (Tracleer)** requires the following rule(s) be met for renewal:

- A. You have pulmonary arterial hypertension (a type of heart and lung condition) (World Health Organization Group 1)
- B. You are NOT concurrently (at the same time) taking cyclosporine A or glyburide
- C. **If you are 3 to 17 years of age, renewal also requires ONE of the following:**  
 You have demonstrated an improvement in pulmonary vascular resistance (a type of measurement for pulmonary arterial hypertension)  
 You have remained stable or shown improvement in exercise ability (such as the 6-minute walk test, World Health Organization [WHO] functional class symptoms) [way to classify how limited you are during physical activity]
- D. **If you are 18 years of age or older, renewal requires ONE of the following:**
  - 1. You have shown improvement from baseline in the 6-minute walk distance test
  - 2. You have remained stable from baseline in the 6-minute walk distance test AND World Health Organization (WHO) functional class has remained stable or improved

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Tracleer.

**REFERENCES**

- Tracleer [Prescribing Information]. South San Francisco, CA: Actelion Pharmaceuticals US, Inc.; January 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/01/22

Created: 10/22

Client Approval: 10/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**BOSUTINIB**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
BOSUTINIB	BOSULIF	39590		GPI-10 (2153181200)	

**GUIDELINES FOR USE**

1. Does the patient have a newly diagnosed, chronic phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) **AND** meet the following criterion?

- The patient is 18 years of age or older

If yes, **approve for 12 months by GPID or GPI-14 with the following quantity limits:**

- **Bosulif 500mg: #1 per day.**
- **Bosulif 400mg: #1 per day.**
- **Bosulif 100mg: #3 per day.**

If no, continue to #2.

2. Does the patient have a diagnosis of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient previously tried or has a contraindication to other tyrosine kinase inhibitors [e.g., Gleevec (imatinib), Sprycel (dasatinib), Tassigna (nilotinib)]
- The patient had a mutational analysis prior to initiation **AND** Bosulif is appropriate per the NCCN guideline table for treatment recommendations based on BCR-ABL1 mutation profile  
(Please see header CML-5 of the current NCCN guidelines)

If yes, **approve for 12 months by GPID or GPI-14 with the following quantity limits:**

- **Bosulif 500mg: #1 per day.**
- **Bosulif 400mg: #1 per day.**
- **Bosulif 100mg: #3 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **BOSUTINIB (Bosulif)** requires the following rule(s) be met for approval:

A. You have **ONE** of the following diagnoses:

1. Newly diagnosed, chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML; a type of blood cancer)
2. Chronic, accelerated, or blast phase Philadelphia chromosome-positive chronic myelogenous leukemia

B. You are 18 years of age or older

**(Denial text continued on next page)**

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

BOSUTINIB

GUIDELINES FOR USE (CONTINUED)

- C. If you have chronic, accelerated, or blast phase Philadelphia chromosome-positive, approval also requires:
1. You have previously tried or have a contraindication to (a medical reason why you cannot use) other tyrosine kinase inhibitors such as Gleevec (imatinib), Sprycel (dasatinib), Tassigna (nilotinib)
  2. You had a mutational analysis prior to initiation of therapy AND Bosulif is appropriate per the National Comprehensive Cancer Network (NCCN) guideline table for treatment recommendations based on BCR-ABL1 mutation (breakpoint cluster region-Abelson murine leukemia 1; a type of abnormal gene) profile

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Bosulif.

REFERENCES

- Bosulif [Prescribing Information]. New York, NY: Pfizer; November 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/22

Created: 09/12

Client Approval: 02/22

P&T Approval: 01/22



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**BOWEL PREP FOR CRC SCREENING ZERO COST SHARE OVERRIDE**

Generic	Brand	HICL	GCN	Medi-Span	Exception/ Other
SOD PICOSULF/MAG OX/CITRIC AC	PREPOPIK, CLENPIQ	24291		GPI-10 (4699200345)	
BISACODYL/PEG/ ELECTROLYTES	PEG-PREP	33281		GPI-10 (4699200520)	
PEG3350/SOD SULF,BICARB,CL/KCL	GAVILYTE-C, GAVILYTE-G, GOLYTELY COLYTE WITH FLAVOR PACKS, PEG 3350- ELECTROLYTES	34667 01344		GPI-10 (4699200530)	
SODIUM CHLORIDE/NAHCO3/ KCL/PE	NULYTELY, GAVILYTE-N, PEG 3350-ELECTROLYTE	07981 33276		GPI-10 (4699200430)	
PEG3350-SOD SUL- NACL-KCL-ASB-C	MOVIPREP, PLENVU, PEG3350-SOD SUL- NACL-KCL-ASB-C	34026		GPI-10 (4699200630)	
SODIUM, POTASSIUM,MAG SULFATES	SUPREP	37152		GPI-10 (4699200360)	
SOD SULF/POT CHLORIDE/MAG SULF	SUTAB	46967		GPI-10 (4699200358)	
SOD PHOSPHATE MBAS/SOD PHOS,DI	OSMOPREP	21886		GPI-10 (4610990212)	

**GUIDELINES FOR USE**

1. Is the patient requesting a cost share exception for the requested bowel preparation agent **AND** does the plan cover these agents at zero cost share (i.e., the plan follows Affordable Care Act [ACA] recommendations and is linked to MediImpact's Essential Health Benefit Tables)?

If yes, continue to #2.  
If no, guideline does not apply.

2. Does the patient's plan have specific procedures, instructions, and/or policies for cost share exception processes or for multi-source brand agent overrides (DAW1 override)?

If yes, guideline does not apply.  
If no, continue to #3.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**BOWEL PREP FOR CRC SCREENING ZERO COST SHARE OVERRIDE**

**GUIDELINES FOR USE (CONTINUED)**

3. Does the patient meet **ALL** of the following criteria?

- The patient is between 45 to 75 years of age
- The request is for colorectal cancer screening

If yes, continue to #4.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

4. Is the request for a generic agent?

If yes, **approve for 12 months for the requested agent by HICL or GPI-10 at zero copay as follows:**

**If no fills in the past 365 days: Approve for 2 fills.**

**If 2 or more fills in the past 365 days: Approve for 1 fill.**

If no, continue to #5.

5. Is the request for **ONE** of the following?

- A single-source brand (SSB) agent that has no preferred generic agents or therapeutically equivalent products available
- A multi-source brand (MSB) agent

If yes, continue to #6.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**BOWEL PREP FOR CRC SCREENING ZERO COST SHARE OVERRIDE**

**GUIDELINES FOR USE (CONTINUED)**

6. Does the patient meet **ONE** of the following criteria?

- Two preferred medications are medically inappropriate for the patient (one if only one agent is available)
- The patient has tried or has a documented medical contraindication to TWO preferred medications (one if only one agent is available)
- The prescriber provided documentation confirming that the requested drug is considered medically necessary (considerations may include additional follow-up colonoscopy required after a positive/abnormal screening test)

If yes, **approve for 12 months for the requested agent by HICL or GPI-10 at zero copay as follows:**

- **If no fills in the past 365 days: Approve for 2 fills.**
- **If 2 or more fills in the past 365 days: Approve for 1 fill.**

**APPROVAL TEXT (applicable to multi-source brand agents only):** Although your cost share has been reduced to zero-dollar, you may incur a dispense-as-written (DAW) penalty fee if you choose to fill a brand prescription instead of its generic equivalent.

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **BOWEL PREP FOR CRC SCREENING ZERO COST SHARE OVERRIDE** requires the following rule(s) be met for approval:

A. Your request is for ONE of the following:

1. A generic agent
2. A single-source brand (SSB) agent that has no preferred generic agents or therapeutically equivalent products available
3. A multi-source brand (MSB) agent

B. You are 45 to 75 years of age

C. The request is for colorectal cancer screening

D. **If the request is for a single-source brand or multi-source brand agent, approval also requires you meet ONE of the following:**

1. Two preferred medications are medically inappropriate for you (one if only one agent is available)
2. You have tried or have a documented medical contraindication (harmful for) to TWO preferred medications (one if only one agent is available)
3. Your doctor has provided documentation confirming that your requested drug is considered medically necessary for you (considerations may include additional follow-up colonoscopy required after a positive/abnormal screening test)

***(Denial text continued on the next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**BOWEL PREP FOR CRC SCREENING ZERO COST SHARE OVERRIDE**

**GUIDELINES FOR USE (CONTINUED)**

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for bowel preparation for colonoscopy agents listed.

This guideline applies to plans where the pharmacy benefit allows for coverage of bowel preparation for colonoscopy medications (used for colorectal cancer screening) at zero copay. The override criteria allow patient access to all FDA-approved bowel preparation for colonoscopy medications (if used for colorectal cancer screening) at zero copay by waiving the applicable cost-sharing for branded or non-preferred branded medications.

**REFERENCES**

- U.S. Department of Labor. Affordable Care Act Implementation Frequently Asked Questions. Available at: <https://www.dol.gov/agencies/ebsa/laws-and-regulations/laws/affordable-care-act/for-employers-and-advisers/aca-implementation-faqs>. Accessed May 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/22

Created: 05/22

Client Approval: 05/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**BREAST CANCER PREVENTION ZERO COST SHARE OVERRIDE**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ANASTROZOLE	ARIMIDEX, ANASTROZOLE	10249		GPI-10 (2140281000)	
EXEMESTANE	AROMASIN, EXEMESTANE	20803		GPI-10 (2140283500)	
RALOXIFENE HCL	EVISTA, RALOXIFENE HCL	16917		GPI-10 (3005306010)	
TAMOXIFEN CITRATE	TAMOXIFEN CITRATE		38720 38721	GPI-14 (214026801003)	

**GUIDELINES FOR USE**

1. Is the patient requesting a cost share exception for the requested **AND** does the plan cover these agents at zero cost share (i.e., the plan follows Affordable Care Act [ACA] recommendations and is linked to MedImpact's Essential Health Benefit Tables)?

If yes, continue to #2.

If no, guideline does not apply.

2. Does the patient's plan have specific procedures, instructions, and/or policies for cost share exception processes or for multi-source brand agent overrides (DAW1 override)?

If yes, guideline does not apply.

If no, continue to #3.

3. Is the patient using the requested medication for prevention (risk reduction) of breast cancer **AND** meets the following criterion?

- The patient is 35 years of age or older

If yes, continue to #4.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

4. Is the request for a generic agent?

If yes, **approve the requested agent for 12 months at zero copay as follows:**

- **Anastrozole:** Approve by HICL or GPI-10 with a quantity limit of #1 per day.
- **Exemestane:** Approve by HICL or GPI-10 with a quantity limit of #1 per day.
- **Raloxifene:** Approve by HICL or GPI-10 with no quantity limit.
- **Tamoxifen 10mg and 20mg:** Approve both by GPID or GPI-14 (no quantity limit).

If no, continue to #5.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

BREAST CANCER PREVENTION ZERO COST SHARE OVERRIDE

GUIDELINES FOR USE (CONTINUED)

5. Is the request for **ONE** of the following?

- A single-source brand (SSB) agent that has no preferred generic agents or therapeutically equivalent products available
- A multi-source brand (MSB) agent

If yes, continue to #6.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

6. Does the patient meet **ONE** of the following criteria?

- Two preferred medications are medically inappropriate for the patient (one if only one agent is available)
- The patient has tried or has a documented medical contraindication to TWO preferred medications (one if only one agent is available)
- The prescriber provided documentation confirming that the requested drug is considered medically necessary (considerations may severity of side effects and ability to adhere to the appropriate use of the item or service)

If yes, **approve the requested agent for 12 months at zero copay as follows:**

- **Arimidex (anastrozole): Approve by HICL with a quantity limit of #1 per day.**
- **Aromasin (exemestane): Approve by HICL with a quantity limit of #1 per day.**
- **Evista (raloxifene): Approve by HICL with no quantity limit.**
- **Tamoxifen 10mg and 20mg: Approve by GPID or GPI-14 (no quantity limit).**

**APPROVAL TEXT (applies to multi-source brand agents only):** Although your cost share has been reduced to zero-dollar, you may incur a dispense-as-written (DAW) penalty fee if you choose to fill a brand prescription instead of its generic equivalent.

If no, do not approve.

**DENIAL TEXT:** **\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **BREAST CANCER PREVENTION ZERO COST SHARE OVERRIDE** requires the following rule(s) be met for approval:

A. The request is for ONE of the following:

1. A generic agent
2. A single-source brand (SSB) agent that has no preferred generic agents or therapeutically equivalent products available
3. A multi-source brand (MSB) agent

**(Denial text continued on next page)**

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

BREAST CANCER PREVENTION ZERO COST SHARE OVERRIDE

GUIDELINES FOR USE (CONTINUED)

- B. The requested medication is being used for prevention (risk reduction) of breast cancer
- C. You are 35 years of age or older
- D. **If the request is for a single-source brand or multi-source brand agent, approval also requires ONE of the following:**
  1. Two preferred medications are medically inappropriate for you (one if only one agent is available)
  2. You have tried or have a documented medical contraindication (harmful for) to TWO preferred medications (one if only one agent is available)
  3. Your doctor has provided documentation confirming that your requested drug is considered medically necessary for you (considerations may include severity of side effects and ability to adhere to the appropriate use of the item or service)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

This guideline applies to plans where the pharmacy benefit allows for coverage of medications for breast cancer prevention at zero copay. The override criteria allow patient access to all FDA-approved medications at zero copay by waiving the applicable cost-sharing for branded or non-preferred branded medications.

**REFERENCES**

- U.S. Department of Labor. Affordable Care Act Implementation Frequently Asked Questions. Available at: <https://www.dol.gov/agencies/ebsa/laws-and-regulations/laws/affordable-care-act/for-employers-and-advisers/aca-implementation-faqs>. Accessed May 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/22

Created: 05/22

Client Approval: 05/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**BREMELANOTIDE**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
BREMELANOTIDE	VYLEESI	45878		GPI-10 (6217351510)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Is Vyleesi (bremelanotide) a covered benefit?

If yes, continue to #2.

If no, guideline does not apply.

2. Does the patient have a diagnosis of acquired, generalized hypoactive sexual desire disorder (HSDD) (also referred to as female sexual interest/arousal disorder [FSIAD] per DSM-5), as defined by **ALL** of the following criteria?

- Persistently or recurrently deficient (or absent) sexual fantasies and desire for sexual activity that has persisted for at least 6 months
- HSDD is **NOT** a result of a co-existing medical or psychiatric condition, a problem within the relationship or the effects of a medication or drug substance
- HSDD symptom causes marked distress or interpersonal difficulty

If yes, continue to #3.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

3. Does the patient meet **ALL** of the following criteria?

- The patient is a premenopausal female
- The patient is 18 years of age or older
- The patient had a previous trial of or contraindication to bupropion
- The patient is **NOT** currently using Addyi (flibanserin)

If yes, **approve for 8 weeks by HICL or GPI-10 with a quantity limit of #2.4mL per month.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

BREMELANOTIDE

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **BREMELANOTIDE (Vyleesi)** requires the following rule(s) be met for approval:

- A. You have a diagnosis of acquired, generalized hypoactive sexual desire disorder (HSDD; also referred to as female sexual interest/arousal disorder where you do not desire sexual activity), as defined by **ALL** of the following:
  1. Persistently or recurrently deficient (or absent) sexual fantasies and desire for sexual activity that has persisted for at least 6 months
  2. HSDD is **NOT** a result of a co-existing medical or psychiatric (mental) condition, a problem within the relationship or the effects of a medication or drug substance
  3. HSDD symptom causes marked distress or interpersonal difficulty
- B. You are a premenopausal female
- C. You are 18 years of age or older
- D. You had a previous trial of bupropion, unless there is a medical reason why you cannot (contraindication)
- E. You are **NOT** currently using Addyi (flibanserin)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of acquired, generalized hypoactive sexual desire disorder (HSDD) (also referred to as female sexual interest/arousal disorder [FSIAD] per DSM-5), as defined by **ALL** of the following criteria?
  - Persistently or recurrently deficient (or absent) sexual fantasies and desire for sexual activity that has persisted for at least 6 months
  - HSDD is **NOT** a result of a co-existing medical or psychiatric condition, a problem within the relationship or the effects of a medication or drug substance
  - HSDD symptom causes marked distress or interpersonal difficulty

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

BREMELANOTIDE

RENEWAL CRITERIA (CONTINUED)

2. Does the patient meet **ALL** of the following criteria?

- The patient is a premenopausal female
- The patient is **NOT** currently using Addyi (flibanserin)
- The patient has demonstrated continued improvement in symptoms of HSDD/FSIAD (e.g., increased sexual desire, lessened distress)

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #2.4mL per month.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **BREMELANOTIDE (Vyleesi)** requires the following rule(s) be met for approval:

- A. You have a diagnosis of acquired, generalized hypoactive sexual desire disorder (HSDD; also referred to as female sexual interest/arousal disorder [FSIAD] where you do not desire sexual activity), as defined by **ALL** of the following:
1. Persistently or recurrently deficient (or absent) sexual fantasies and desire for sexual activity that has persisted for at least 6 months
  2. HSDD is **NOT** a result of a co-existing medical or psychiatric (mental) condition, a problem within the relationship or the effects of a medication or drug substance
  3. HSDD symptom causes marked distress or interpersonal difficulty
- B. You are a premenopausal female
- C. You are **NOT** currently using Addyi (flibanserin)
- D. You have experienced continued improvement in symptoms of HSDD/FSIAD such as increased sexual desire, lessened distress)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**BREMELANOTIDE**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Vyleesi.

**REFERENCES**

- Vyleesi [Prescribing Information]. Waltham, MA: AMAG Pharmaceuticals, Inc.; June 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 08/19

Client Approval: 04/20

P&T Approval: 07/19



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**BRIGATINIB**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
BRIGATINIB	ALUNBRIG	44226		GPI-10 (2153051000)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of metastatic non-small cell lung cancer (NSCLC) and meet ALL of the following criteria?
  - The patient is 18 years of age or older
  - The patient is positive for anaplastic lymphoma kinase (ALK) fusion oncogene as detected by an FDA-approved test

If yes, **approve for 12 months by GPID or GPI-14 with the following quantity limits:**

- **Alunbrig 30mg: #120 per 30 days.**
- **Alunbrig 90mg: #30 per 30 days.**
- **Alunbrig 180mg: #30 per 30 days.**
- **Alunbrig 90mg-180mg initiation pack: #30 per 30 days.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **BRIGATINIB (Alunbrig)** requires the following rule(s) be met for approval:

- A. You have metastatic non-small cell lung cancer (NSCLC: type of lung cancer that has spread to other parts of the body)
- B. You are 18 years of age or older
- C. You are positive for anaplastic lymphoma kinase (ALK) fusion oncogene (a type of gene mutation that causes a change in your DNA) as detected by a Food and Drug Administration (FDA)-approved test

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Alunbrig.

**REFERENCES**

- Alunbrig [Prescribing Information]. Cambridge, MA: Ariad Pharmaceuticals; May 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/10/21

Created: 07/17

Client Approval: 03/21

P&T Approval: 07/20

Copyright © 2023 MediImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MediImpact. MediImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**BRODALUMAB**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
BRODALUMAB	SILIQ	44102		GPI-10 (9025052000)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- Therapy is prescribed by or in consultation with a dermatologist
- The patient has psoriasis covering 3% or more of body surface area (BSA) OR psoriatic lesions affecting the hands, feet, genital area, or face
- The patient had a trial of or contraindication to ONE or more forms of conventional therapies such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids, calcipotriene, acitretin, methotrexate, or cyclosporine
- The patient has been counseled on and expresses understanding of the risk of suicidal ideation and behavior
- The patient had a trial of or contraindication to any TWO of the following preferred immunomodulators: Cosentyx, Humira, Stelara, Tremfya, Skyrizi, Enbrel, Otezla [**NOTE:** Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

If yes, **approve for 6 months by entering TWO approvals by HICL or GPI-10 as follows:**

- **FIRST APPROVAL:** approve for 1 month with a quantity limit of #6mL.
- **SECOND APPROVAL:** approve for 5 months with a quantity limit of #3mL per 28 days (Enter a start date that is 5 weeks AFTER the START date of the first approval).

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**BRODALUMAB**

**INITIAL CRITERIA (CONTINUED)**

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **BRODALUMAB (Siliq)** requires the following rule(s) be met for approval:

- A. You have moderate to severe plaque psoriasis (PsO: a type of skin condition)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
- D. You have psoriasis covering 3% or more of body surface area (BSA) OR psoriatic lesions (rashes) affecting the hands, feet, genital area, or face
- E. You had a trial of or contraindication (harmful for) to ONE or more forms of conventional therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids, calcipotriene, acitretin, methotrexate, or cyclosporine
- F. You have been counseled on and express an understanding of the risk of suicidal thoughts and behavior
- G. You had a trial of or contraindication (harmful for) to any TWO of the following preferred immunomodulators: Cosentyx, Humira, Stelara, Tremfya, Skyrizi, Enbrel, Otezla

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

BRODALUMAB

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

- Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) **AND** meet the following criteria?
  - The patient has achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more
  - The patient has NOT developed or reported worsening depressive symptoms or suicidal ideation and behaviors

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #3mL per 28 days.**  
If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

- Our guideline named **BRODALUMAB (Siliq)** requires the following rule(s) be met for renewal:
- You have moderate to severe plaque psoriasis (PsO: a type of skin condition)
  - You have achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more
  - You have NOT developed or reported worsening depressive symptoms or suicidal thoughts and behaviors while on treatment with Siliq

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Siliq.

**REFERENCES**

Siliq [Prescribing Information]. Bridgewater, NJ: Valeant Pharmaceuticals; April 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 03/14/22

Created: 01/17

Client Approval: 02/22

P&T Approval: 01/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**BUDESONIDE - ORTIKOS**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
BUDESONIDE	ORTIKOS		46496 46497	GPI-14 (22100012007025) (22100012007030)	

**GUIDELINES FOR USE**

- Does the patient have a diagnosis of mild to moderate active Crohn's Disease and meet **ALL** of the following criteria?
  - The patient is 8 years of age or older
  - The patient had a trial of generic budesonide 3mg capsules **OR** the patient cannot tolerate the pill burden associated with the generic product

If yes, **approve for 6 months for all strengths by GPID or GPI-14 with a quantity limit of #1 per day.**  
If no, continue to #2.

- Does the patient have a diagnosis of mild to moderate Crohn's Disease and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The requested medication is being used for the maintenance of clinical remission
  - The patient had a trial of generic budesonide 3mg capsules **OR** the patient cannot tolerate the pill burden associated with the generic product

If yes, **approve for 6 months for all strengths by GPID or GPI-14 with a quantity limit of #1 per day.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **BUDESONIDE - ORTIKOS** requires the following rule(s) be met for approval:

- You have mild to moderate Crohn's Disease (a type of bowel disorder)
- If you have mild to moderate active Crohn's Disease, approval also requires:**
  - You are 8 years of age or older
  - You have tried generic budesonide 3mg capsules OR you cannot tolerate the pill burden associated with the generic product

***(Denial text continued on the next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

BUDESONIDE - ORTIKOS

GUIDELINES FOR USE (CONTINUED)

C. If you have mild to moderate Crohn's Disease, approval also requires:

1. You are 18 years of age or older
2. The requested medication is being used for the maintenance of clinical remission (signs and symptoms of disease have either improved or disappeared)
3. You have tried generic budesonide 3mg capsules OR you cannot tolerate the pill burden associated with the generic product

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Ortikos.

REFERENCES

- Ortikos [Prescribing Information]. Cranbury, NJ: Sun Pharmaceuticals Industries, Inc. June 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/17/22

Created: 11/20

Client Approval: 01/22

P&T Approval: 10/20





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**BUDESONIDE - TARPEYO**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
BUDESONIDE	TARPEYO		51745	GPI-14 (22100012006520)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of primary immunoglobulin A nephropathy (IgAN) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a nephrologist
  - The patient's diagnosis is confirmed by a renal biopsy
  - The patient is currently on an ACE inhibitor (e.g., benazepril, lisinopril) or an ARB (e.g., losartan, valsartan) at maximum tolerated dose for at least three months OR has a contraindication to both
  - The patient has a progressively declining glomerular filtration rate (GFR) and/or worsening proteinuria (e.g., >1 gram protein/24-hour urine collection or UPCR [urine protein to creatinine ratio]  $\geq 1$  g/g)
  - The patient had a trial of or contraindication to one generic systemic corticosteroid therapy (e.g., oral prednisone, oral prednisolone)

If yes, **approve for 9 months by GPID or GPI-14 with a quantity limit of #4 per day.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **BUDESONIDE - TARPEYO** requires the following rule(s) be met for approval:

- A. You have primary immunoglobulin A nephropathy (IgAN: a type of kidney disease)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a nephrologist (a type of kidney doctor)
- D. Your diagnosis is confirmed by a renal biopsy (removal of cells or tissue from the kidney for examination)
- E. You are currently on an angiotensin converting enzyme inhibitor (ACE-I: a type of drug used to protect kidneys such as benazepril, lisinopril, etc.) or an angiotensin receptor blocker (ARB: a type of drug used to protect kidneys such as losartan, valsartan, etc.) at maximum tolerated dose for at least three months OR have a contraindication (harmful for) to both  
***(Initial denial text continued on the next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

BUDESONIDE - TARPEYO

INITIAL CRITERIA (CONTINUED)

- F. You have a progressively declining glomerular filtration rate (GFR: a tool for evaluating kidney function) and/or worsening proteinuria (such as greater than 1 gram protein in a 24-hour urine collection or greater than or equal to 1g/g urine protein to creatinine ratio [UPCR: test that measures the amount of protein in urine])
- G. You had a trial of or contraindication to one generic systemic corticosteroid therapy (such as oral prednisone, oral prednisolone)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of primary immunoglobulin A nephropathy (IgAN) and meet **ONE** of the following criteria?
  - The patient has improved, or stable kidney function compared to baseline
  - The patient has had a reduction in proteinuria

If yes, **approve for 9 months by GPID or GPI-14 with a quantity limit of #4 per day.**  
If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **BUDESONIDE - TARPEYO** requires the following rule(s) be met for renewal:

- A. You have primary immunoglobulin A nephropathy (IgAN: a type of kidney disease)
- B. You have improved, or stable kidney function compared to baseline OR a reduction in proteinuria

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**BUDESONIDE - TARPEYO**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Tarpeyo.

**REFERENCES**

- Tarpeyo [Prescribing Information]. Stockholm, Sweden: Calliditas Therapeutics, Inc.; December 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/17/22

Created: 01/22

Client Approval: 01/22

P&T Approval: 07/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

C1 ESTERASE INHIBITOR - BERINERT

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
C1 ESTERASE INHIBITOR	BERINERT	18568		GPI-10 (8580202200)	FDB & MEDI-SPAN: BRAND = BERINERT

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of hereditary angioedema (HAE) and meet **ALL** of the following criteria?
  - Therapy is prescribed by or in consultation with an allergist, immunologist or hematologist
  - The patient's diagnosis of HAE is confirmed via complement testing
  - Berinert is being used for acute attacks of hereditary angioedema
  - Berinert will NOT be used concurrently with alternative acute treatment for HAE attacks (e.g., Ruconest, Firazyr, Kalbitor)

If yes, **approve for 12 months by NDC.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **C1 ESTERASE INHIBITOR - BERINERT** requires the following rule(s) be met for approval:

- A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
- B. Therapy is prescribed by or in consultation with an allergist (a type of allergy doctor), immunologist (a type of immune system doctor) or hematologist (a type of blood doctor)
- C. Your diagnosis is confirmed by complement testing (a type of lab test)
- D. Berinert is being used for acute (short term) attacks of hereditary angioedema
- E. You will NOT be using Berinert concurrently (at the same time) with alternative acute treatment for HAE attacks (such as Ruconest, Firazyr, Kalbitor)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

C1 ESTERASE INHIBITOR - BERINERT

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

- Does the patient have a diagnosis of hereditary angioedema (HAE) **AND** meet the following criterion?
  - Berinert will NOT be used concurrently with alternative acute treatment for HAE attacks (e.g., Ruconest, Firazyr, Kalbitor)

If yes, **approve for 12 months by NDC.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **C1 ESTERASE INHIBITOR - BERINERT** requires the following rule(s) be met for renewal:

- You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
- You will NOT be using Berinert concurrently (at the same time) with alternative acute treatment for HAE attacks (such as Ruconest, Firazyr, Kalbitor)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Berinert.

**REFERENCES**

- Berinert [Prescribing Information]. Kankakee, IL: CSL Behring LLC. May 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/01/22

Created: 04/09

Client Approval: 10/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

C1 ESTERASE INHIBITOR - CINRYZE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
C1 ESTERASE INHIBITOR	CINRYZE	18568		GPI-10 (8580202200)	FDB & MEDI-SPAN: BRAND = CINRYZE

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of hereditary angioedema (HAE) and meet **ALL** of the following criteria?
  - The patient is 6 years of age or older
  - Therapy is prescribed by or in consultation with an allergist, immunologist or hematologist
  - The patient's diagnosis of HAE is confirmed via documentation of complement testing
  - Cinryze is being used for prophylaxis against HAE attacks
  - Cinryze is NOT being used concurrently with alternative prophylactic agent for HAE (e.g., Takhzyro, Haegarda, danazol)

If yes, **approve for 12 months for all NDCs with a quantity limit of #40 vials per 28 days.**  
If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **C1 ESTERASE INHIBITOR - CINRYZE** requires the following rule(s) be met for approval:

- A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
- B. You are 6 years of age or older
- C. Therapy is prescribed by or in consultation with an allergist (a type of allergy doctor), immunologist (a type of immune system doctor) or hematologist (a type of blood doctor)
- D. Your diagnosis is confirmed by documented complement testing (a type of lab test)
- E. Cinryze is being used for prevention of hereditary angioedema attacks
- F. You will not be using Cinryze concurrently (at the same time) with an alternative preventive agent for HAE (such as Takhzyro, Haegarda, danazol)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

C1 ESTERASE INHIBITOR - CINRYZE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

- Does the patient have a diagnosis of hereditary angioedema (HAE) and meet **ALL** of the following criteria?
  - The patient has experienced improvement (i.e., reductions in attack frequency or attack severity) compared to baseline in HAE attacks
  - Cinryze will NOT be used concurrently with alternative prophylactic agent for HAE (e.g., Takhzyro, Haegarda, danazol)

If yes, **approve for 12 months by NDC with a quantity limit of #40 vials per 28 days.**  
If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **C1 ESTERASE INHIBITOR - CINRYZE** requires the following rule(s) be met for renewal:

- You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
- You have experienced improvement (reductions in attack frequency or attack severity) compared to baseline in HAE attacks
- You will NOT be using Cinryze concurrently (at the same time) with alternative prophylactic (preventive) agent for HAE (such as Takhzyro, Haegarda, danazol)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Cinryze.

**REFERENCES**

- Cinryze [Prescribing Information]. Lexington, MA: Shire Viropharma Inc. December 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/01/22

Created: 10/22

Client Approval: 10/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**C1 ESTERASE INHIBITOR - HAEGARDA**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
C1 ESTERASE INHIBITOR	HAEGARDA	18568		GPI-10 (8580202200)	FDB & MEDI-SPAN: BRAND = HAEGARDA

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of hereditary angioedema (HAE) and meet **ALL** of the following criteria?
  - The patient is 6 years of age or older
  - Therapy is prescribed by or in consultation with an allergist, immunologist or hematologist
  - The patient's diagnosis of HAE is confirmed via documentation of complement testing
  - Haegarda is being used for prophylaxis against HAE attacks
  - Haegarda will NOT be used concurrently with alternative prophylactic agent for HAE (e.g., Takhzyro, Cinryze, danazol)

If yes, **approve for 12 months by GPID or GPI-14 for all strengths.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **C1 ESTERASE INHIBITOR - HAEGARDA** requires the following rule(s) be met for approval:

- A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
- B. You are 6 years of age or older
- C. Therapy is prescribed by or in consultation with an allergist (a type of allergy doctor), immunologist (a type of immune system doctor) or hematologist (a type of blood doctor)
- D. Your diagnosis of HAE is confirmed by documented complement testing (a type of lab test)
- E. Haegarda is being used for prevention of hereditary angioedema attacks
- F. You will not be using Haegarda concurrently (at the same time) with an alternative preventive agent for HAE (such as Takhzyro, Cinryze, danazol)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

C1 ESTERASE INHIBITOR - HAEGARDA

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

- Does the patient have a diagnosis of hereditary angioedema (HAE) and meet **ALL** of the following criteria?
  - The patient has experienced improvement (i.e., reductions in attack frequency or attack severity) compared to baseline in HAE attacks
  - Haegarda will NOT be used concurrently with alternative prophylactic agent for HAE (e.g., Takhzyro, Cinryze, danazol)

If yes, **approve for 12 months by GPID or GPI-14 for all strengths.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **C1 ESTERASE INHIBITOR - HAEGARDA** requires the following rule(s) be met for renewal:

- You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
- You have experienced improvement (reductions in attack frequency or attack severity) compared to baseline in HAE attacks
- You will NOT be using Haegarda concurrently (at the same time) with alternative prophylactic (preventive) agent for HAE (such as Takhzyro, Cinryze, danazol)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Haegarda.

**REFERENCES**

- Haegarda [Prescribing Information]. Marburg, German: CSL Behring LLC. September 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/01/22

Created: 10/22

Client Approval: 10/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

C1 ESTERASE INHIBITOR - RUCONEST

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
C1 ESTERASE INHIBITOR, RECOMBINANT	RUCONEST	37766		GPI-10 (8580202210)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

- Does the patient have a diagnosis of hereditary angioedema (HAE) and meet **ALL** of the following criteria?
  - Therapy is prescribed by or in consultation with an allergist, immunologist or hematologist
  - The patient's diagnosis of HAE is confirmed via complement testing
  - Ruconest is being used for acute attacks of hereditary angioedema
  - Ruconest will NOT be used concurrently with alternative acute treatment for HAE attacks (e.g., Berinert, Firazyr, Kalbitor)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #8 vials per fill.**  
If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **C1 ESTERASE INHIBITOR - RUCONEST** requires the following rule(s) be met for approval:

- You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
- Therapy is prescribed by or in consultation with an allergist (a type of allergy doctor), immunologist (a type of immune system doctor) or hematologist (a type of blood doctor)
- Your diagnosis is confirmed by complement testing (a type of lab test)
- Ruconest is being used for acute (short term) attacks of hereditary angioedema
- You will NOT be using Ruconest concurrently (at the same time) with alternative acute treatment for HAE attacks (such as Berinert, Firazyr, Kalbitor)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

C1 ESTERASE INHIBITOR - RUCONEST

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

- Does the patient have a diagnosis of hereditary angioedema (HAE) **AND** meet the following criterion?
  - Ruconest will NOT be used concurrently with alternative acute treatment for HAE attacks (e.g., Berinert, Firazyr, Kalbitor)

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #8 vials per fill.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **C1 ESTERASE INHIBITOR - RUCONEST** requires the following rule(s) be met for renewal:

- You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
- You will NOT be using Ruconest concurrently (at the same time) with alternative acute treatment for HAE attacks (such as Berinert, Firazyr, Kalbitor)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Ruconest.

**REFERENCES**

- Ruconest [Prescribing Information]. Raleigh, NC: Salix Pharmaceuticals; December 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/01/22

Created: 10/22

Client Approval: 10/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CABOZANTINIB S-MALATE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
CABOZANTINIB S-MALATE	COMETRIQ, CABOMETYX	39815		GPI-10 (2153301010)	

**\*\* Please use the criteria for the specific drug requested \*\***

**GUIDELINES FOR USE**

**COMETRIQ**

1. Does the patient have a diagnosis of progressive, metastatic medullary thyroid cancer (MTC)?

If yes, approve for 12 months by GPID or GPI-14 with a quantity limit of #112 per 28 days for the requested daily dose pack. (NOTE: Cometriq is available in three dosage packs each containing 7 days supply)

- Cometriq 140mg daily dose pack.
- Cometriq 100mg daily dose pack.
- Cometriq 60mg daily dose pack.

If no, do not approve.

**DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **CABOZANTINIB S-MALATE (Cometriq)** requires the following rule be met for approval:

A. You have progressive, metastatic medullary thyroid cancer (type of thyroid cancer that has spread)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CABOZANTINIB S-MALATE

GUIDELINES FOR USE (CONTINUED)

CABOMETYX

1. Does the patient have a diagnosis of advanced renal cell carcinoma (RCC) and meet **ONE** of the following criteria?
  - Cabometyx will be used as a single agent
  - Cabometyx will be used in combination with Opdivo (nivolumab) as first-line treatment (no prior treatment for advanced RCC)

If yes, **approve for 12 months by GPID or GPI-14 for the requested strength with the following quantity limits:**

- Cabometyx 60mg: #1 per day.
- Cabometyx 40mg: #2 per day.
- Cabometyx 20mg: #1 per day.

If no, continue to #2.

2. Does the patient have a diagnosis of hepatocellular carcinoma (HCC) **AND** meet the following criterion?
  - The patient has previously been treated with Nexavar (sorafenib)

If yes, **approve for 12 months by GPID or GPI-14 for the requested strength with the following quantity limits:**

- Cabometyx 60mg: #1 per day.
- Cabometyx 40mg: #2 per day.
- Cabometyx 20mg: #1 per day.

If no, continue to #3.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CABOZANTINIB S-MALATE

GUIDELINES FOR USE - CABOMETYX (CONTINUED)

3. Does the patient have a diagnosis of locally advanced or metastatic differentiated thyroid cancer (DTC) and meet **ALL** of the following criteria?
- The patient is 12 years of age or older
  - The patient has disease progression following prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy
  - The patient is radioactive iodine-refractory or ineligible

If yes, **approve for 12 months by GPID or GPI-14 for the requested strength with the following quantity limits:**

- Cabometyx 60mg: #1 per day.
- Cabometyx 40mg: #2 per day.
- Cabometyx 20mg: #1 per day.

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **CABOZANTINIB S-MALATE (Cabometyx)** requires the following rule(s) be met for approval:

- A. You have **ONE** of the following diagnoses:
1. Advanced renal cell carcinoma (RCC: type of kidney cancer)
  2. Hepatocellular carcinoma (HCC: type of liver cancer)
  3. Locally advanced or metastatic differentiated thyroid cancer (DTC: type of thyroid cancer)
- B. **If you have advanced renal cell carcinoma, approval also requires ONE of the following:**
1. Cabometyx will be used as a single agent (used alone)
  2. Cabometyx will be used in combination with Opdivo (nivolumab) as first-line treatment (You have not received prior treatment for advanced renal cell carcinoma)
- C. **If you have hepatocellular carcinoma, approval also requires:**
1. You have previously been treated with Nexavar (sorafenib)
- D. **If you have locally advanced or metastatic differentiated thyroid cancer, approval also requires:**
1. You are 12 years of age or older
  2. You have disease progression (disease has gotten worse) following prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy (a type of cancer therapy)
  3. You are radioactive iodine-refractory (resistant to) or ineligible

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**CABOZANTINIB S-MALATE**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Cometriq or Cabometyx.

**REFERENCES**

- Cometriq [Prescribing Information]. South San Francisco, CA: Exelixis, Inc.; February 2020.
- Cabometyx [Prescribing Information]. South San Francisco, CA: Exelixis, Inc.; September 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/04/21

Created: 01/13

Client Approval: 09/21

P&T Approval: 10/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CAPECITABINE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
CAPECITABINE	XELODA, CAPECITABINE	18385		GPI-10 (2130000500)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of Stage III colon cancer **AND** meet the following criterion?
- The requested medication will be used as adjuvant treatment

If yes, **approve for 12 months by HICL or GPI-10 for 8 fills.**

If no, continue to #2.

2. Does the patient have a diagnosis of locally advanced rectal cancer and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The requested medication will be used as perioperative treatment
- The requested medication will be used as part of chemoradiotherapy

If yes, **approve for 12 months by HICL or GPI-10.**

If no, continue to #3.

3. Does the patient have a diagnosis of unresectable or metastatic colorectal cancer?

If yes, **approve for 12 months by HICL or GPI-10.**

If no, continue to #4.

4. Does the patient have a diagnosis of advanced or metastatic breast cancer and meet **ONE** of the following criteria?

- The requested medication will be used as a single agent, if an anthracycline- or taxane-containing chemotherapy is not indicated
- The requested medication will be used in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy

If yes, **approve for 12 months by HICL or GPI-10.**

If no, continue to #5.

5. Does the patient have a diagnosis of unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The requested medication will be used as part of a combination chemotherapy regimen

If yes, **approve for 12 months by HICL or GPI-10.**

If no, continue to #6.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CAPECITABINE

GUIDELINES FOR USE (CONTINUED)

6. Does the patient have a diagnosis of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma and meet **ALL** of the following criteria?
- The patient is 18 years of age or older
  - The patient has not received prior treatment for metastatic disease
  - The requested medication will be used as part of a combination regimen

If yes, **approve for 12 months by HICL or GPI-10.**

If no, continue to #7.

7. Does the patient have a diagnosis of pancreatic adenocarcinoma and meet **ALL** of the following criteria?
- The patient is 18 years of age or older
  - The requested medication will be used as adjuvant treatment
  - The requested medication will be used as part of a combination chemotherapy regimen

If yes, **approve for 12 months by HICL or GPI-10.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **CAPECITABINE (Xeloda)** requires the following rule(s) to be met for approval:

A. You have **ONE** of the following diagnoses:

1. Stage III colon cancer (colon cancer that has spread to lymph nodes)
2. Locally advanced rectal cancer (cancer that has spread from where it started to nearby tissue or lymph nodes)
3. Unresectable (unable to remove by surgery) or metastatic colorectal cancer (a type of digestive cancer that has spread to other parts of the body)
4. Metastatic breast cancer (breast cancer that has spread to other parts of the body)
5. Unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer (a type of digestive system cancer that has spread to other parts of the body)
6. HER2 (a type of protein)-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma (a type of digestive system cancer that has spread to other parts of the body)
7. Pancreatic adenocarcinoma (a type of cancer of the pancreas)

B. **If you have Stage III colon cancer, approval also requires:**

1. The requested medication will be used as adjuvant (add-on) treatment

***(Denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CAPECITABINE

GUIDELINES FOR USE (CONTINUED)

- C. If you have locally advanced rectal cancer, approval also requires:**
1. You are 18 years of age or older
  2. The requested medication will be used as perioperative (the time period before and after surgery) treatment
  3. The requested medication will be used as part of chemoradiotherapy (a type of cancer treatment)
- D. If you have advanced or metastatic breast cancer, approval also requires ONE of the following:**
1. The requested medication will be used as a single agent (used alone), if an anthracycline (such as doxorubicin, daunorubicin)- or taxane (such as paclitaxel, docetaxel)-containing chemotherapy is not indicated
  2. The requested medication will be used in combination with docetaxel after disease progression (worsens) on prior anthracycline (such as doxorubicin, daunorubicin)-containing chemotherapy
- E. If you have unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer, approval also requires:**
1. You are 18 years of age or older
  2. The requested medication will be used as part of a combination chemotherapy (drugs used to treat cancer) regimen
- F. If you have HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, approval also requires:**
1. You are 18 years of age or older
  2. You have not received prior treatment for metastatic disease
  3. The requested medication will be used as part of a combination regimen (such as with cisplatin, trastuzumab)
- G. If you have pancreatic adenocarcinoma, approval also requires:**
1. You are 18 years of age or older
  2. The requested medication will be used as adjuvant (add-on) treatment
  3. The requested medication will be used as part of a combination chemotherapy regimen (such as with gemcitabine)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**CAPECITABINE**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Xeloda.

**REFERENCES**

- Xeloda [Prescribing Information]. South San Francisco, CA: Genentech Inc., December 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/23/23

Created: 02/13

Client Approval: 01/23

P&T Approval: 01/23



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CAPLACIZUMAB-YHDP

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
CAPLACIZUMAB-YHDP	CABLIVI	45591		GPI-10 (8515102080)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of acquired thrombotic thrombocytopenia purpura (aTTP) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- Therapy is prescribed by or in consultation with a hematologist

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Has the patient experienced more than two recurrences of aTTP, while on Cablivi therapy (i.e., new drop in platelet count requiring repeat plasma exchange during 30 days post-plasma exchange therapy [PEX] and up to 28 days of extended therapy)?

If yes, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

If no, continue to #3.

3. Is the request for continuation of Cablivi therapy from inpatient (hospital) setting **AND** the patient meets the following criterion?

- Cablivi was previously initiated as part of the FDA approved treatment regimen in combination with plasma exchange and immunosuppressive therapy within the inpatient setting

If yes, **approve for 1 month by HICL or GPI-10 for a maximum quantity of #30 vials.**

If no, continue to #4.

4. Is the request for continuation of Cablivi therapy from the initial 30 days treatment course (e.g., no break in therapy) and the patient meets **ALL** of the following criteria?

- The patient is receiving immunosuppressive therapy
- The patient is experiencing signs of persistent underlying disease (e.g., suppressed ADAMTS13 [a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13] activity level remain present)

If yes, **approve for 1 month by HICL or GPI-10 for a maximum quantity of #28 vials.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CAPLACIZUMAB-YHDP

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it**

Our guideline named **CAPLACIZUMAB-YHDP (Cablivi)** requires the following rule(s) be met for approval:

- A. You have a diagnosis of acquired thrombotic thrombocytopenia purpura (aTTP- a type of blood disorder)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or given in consultation with a hematologist (blood specialist)
- D. You have NOT experienced more than two recurrences of acquired thrombotic thrombocytopenia purpura, while on Cablivi therapy. For example there's a new drop in platelet count requiring repeat plasma exchange during 30 days post-plasma exchange therapy (process of replacing a liquid part of the blood) and up to 28 days of extended therapy
- E. You also meet ONE of the following:
  - 1. Your request is for continuation of Cablivi therapy from inpatient (hospital) setting and you previously received plasma exchange and immunosuppressive therapy (treatment that weakens your immune system) within the inpatient setting
  - 2. Your request is for continuation of Cablivi therapy from the initial 30 days treatment course (no break in therapy) AND:
    - a. You are receiving immunosuppressive therapy, and
    - b. You are experiencing signs of persistent underlying disease (such as suppressed ADAMTS13 [a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13: type of blood clot disorder] activity level remain present)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Cablivi.

**REFERENCES**

- Cablivi [Prescribing Information]. Cambridge, MA: Genzyme Corporation; February 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/21/22

Created: 05/19

Client Approval: 11/22

P&T Approval: 04/19

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CAPMATINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
CAPMATINIB HYDROCHLORIDE	TABRECTA	46519		GPI-10 (2153371620)	

**GUIDELINES FOR USE**

- Does the patient have a diagnosis of metastatic non-small cell lung cancer (NSCLC) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient's tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **CAPMATINIB (Tabrecta)** requires the following rule(s) be met for approval:

- You have metastatic non-small cell lung cancer (NSCLC: type of lung cancer that has spread to other parts of the body)
- You are 18 years of age or older
- Your tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping (an abnormal change in a gene that makes MET protein) as detected by an FDA-approved test

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Tabrecta.

**REFERENCES**

- Tabrecta [Prescribing Information]. East Hanover, NJ: Novartis; May 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/10/21

Created: 08/20

Client Approval: 03/21

P&T Approval: 07/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CAPSAICIN

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
CAPSAICIN 8% PATCH	QUTENZA	36916		GPI-10 (9085002530)	

**GUIDELINES FOR USE**

1. Does the patient have neuropathic pain associated with **ONE** of the following conditions?

- Postherpetic neuralgia (PHN)
- Diabetic peripheral neuropathy (DPN) of the feet

If yes, **approve for 12 months by HICL or GPI-10 for 4 fills with a quantity limit of up to #4 patches per fill (maximum dose is 4 patches every 3 months).**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **CAPSAICIN (Qutenza)** requires the following rule be met for approval:

A. You have a diagnosis of neuropathic pain associated with ONE of the following conditions:

- Postherpetic neuralgia (PHN) (painful condition that affects the nerve fibers and skin after having shingles)
- Diabetic peripheral neuropathy (DPN) of the feet (numbness of the feet that is caused by diabetes)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Qutenza.

**REFERENCES**

- Qutenza [Prescribing Information]. Ardsley, NY. Acorda Therapeutics, Inc. July 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 08/24/20

Created: 05/10

Client Approval: 07/20

P&T Approval: 10/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**CARBIDOPA-LEVODOPA**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
CARBIDOPA/ LEVODOPA	DUOPA		37829	GPI-14 (73209902101820)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of advanced Parkinson's disease?

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #100mL per day.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **CARBIDOPA-LEVODOPA (Duopa)** requires the following rule be met for approval:

- A. You have a diagnosis of advanced Parkinson's disease (nerve system disorder that affects movement)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Duopa.

**REFERENCES**

- Duopa [Prescribing Information]. North Chicago, IL: Abbvie, Inc. February 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A  
Commercial Effective: 07/01/20

Created: 05/15  
Client Approval: 04/20

P&T Approval: 05/15





**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**CARBOXYMETHYLCELLULOSE-CELLULOSE-CITRIC ACID**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
CARBOXYMETHYLCELLULOSE -CELLULOSE-CITRIC ACID	PLENITY	47522		GPI-10 (6120990306)	

**GUIDELINES FOR USE**

1. Is the request for weight management and the patient meets **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient has a body mass index (BMI) of 25 to 40 kg/m(2)
- The requested medication will be used in conjunction with diet and exercise

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #168 per 28 days.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **CARBOXYMETHYLCELLULOSE-CELLULOSE-CITRIC ACID (Plenity)** requires the following rule(s) be met for approval:

- A. The request is for weight management
- B. You are 18 years of age or older
- C. You have a body mass index (BMI) of 25 to 40 kg/m(2)
- D. The requested medication will be used in conjunction (together) with diet and exercise

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Plenity.

**REFERENCES**

- Plenity [Prescribing Information]. Boston, MA: Gelesis, Inc., 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/01/21

Created: 08/21

Client Approval: 08/21

P&T Approval: 07/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**CARGLUMIC ACID**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
CARGLUMIC ACID	CARBAGLU CARGLUMIC ACID	25643		GPI-10 (3090823000)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of acute or chronic hyperammonemia (HA) due to N-acetylglutamate synthase (NAGS) deficiency **AND** meet the following criterion?
  - NAGS gene mutation is confirmed by biochemical or genetic testing

If yes, continue to #2.

If no, continue to #4.

2. Is the request for generic carglumic acid?

If yes, **approve carglumic acid (generic only) by HICL or GPI-10 as follows:**

**Acute HA due to NAGS deficiency: approve for 7 days.**

**Chronic HA due to NAGS deficiency: approve for 6 months.**

If no, continue to #3.

3. Is the request for brand Carbaglu **AND** the patient meets the following criterion?

- The patient had a trial of generic carglumic acid

If yes, **approve by HICL or GPI-10 as follows:**

**Acute HA due to NAGS deficiency: approve for 7 days.**

**Chronic HA due to NAGS deficiency: approve for 6 months.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

4. Does the patient have a diagnosis of acute hyperammonemia (HA) due to propionic acidemia (PA) **AND** meet following criterion?

- The diagnosis is confirmed by the presence of elevated methylcitric acid and normal methylmalonic acid OR genetic testing confirming mutation in the PCCA or PCCB gene

If yes, **approve for 7 days by HICL or GPI-10.**

If no, continue to #5.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CARGLUMIC ACID

INITIAL CRITERIA (CONTINUED)

5. Does the patient have a diagnosis of acute hyperammonemia (HA) due to methylmalonic acidemia (MMA) **AND** meet following criterion?
- The diagnosis is confirmed by the presence of elevated methylmalonic acid, methylcitric acid OR genetic testing confirming mutation in the MMUT, MMA, MMAB or MMADHC genes

If yes, **approve for 7 days by HICL or GPI-10.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **CARGLUMIC ACID (Carbaglu)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
1. Acute or chronic hyperammonemia (HA) due to N-acetylglutamate synthase (NAGS) deficiency (short-term or long-term high ammonia blood levels due to a genetic disorder)
  2. Acute hyperammonemia (HA) due to propionic acidemia (PA) or methylmalonic acidemia (MMA) (short-term high ammonia blood levels due to a genetic disorder)
- B. **If you have acute or chronic hyperammonemia due to N-acetylglutamate synthase deficiency, approval also requires:**
1. Your N-acetylglutamate synthase gene mutation is confirmed by biochemical or genetic testing (types of lab test)
  2. Requests for brand Carbaglu requires a trial of generic carglumic acid
- C. **If you have acute hyperammonemia due to propionic acidemia, approval also requires:**
1. Your diagnosis is confirmed by the presence of elevated methylcitric acid and normal methylmalonic acid (substances that indicate presence of a disease) OR genetic testing confirming mutation in the PCCA or PCCB gene (types of abnormal genes)
- D. **If you have acute hyperammonemia due to methylmalonic acidemia, approval also requires:**
1. Your diagnosis is confirmed by the presence of elevated methylmalonic acid, methylcitric acid OR genetic testing confirming mutation in the MMUT, MMA, MMAB or MMADHC genes (types of abnormal genes)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CARGLUMIC ACID

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

**NOTE:** For the diagnoses of acute hyperammonemia (HA) due to N-acetylglutamate synthase (NAGS) deficiency or acute hyperammonemia (HA) due to propionic acidemia (PA) or methylmalonic acidemia (MMA), please refer to the Initial Criteria section.

- Does the patient have a diagnosis of chronic hyperammonemia (HA) due to N- acetylglutamate synthase (NAGS) deficiency **AND** meet the following criterion?
  - The patient has clinical improvement or improved plasma (blood) ammonia levels

If yes, **approve for 12 months by HICL or GPI-10.**

If no, do not approve.

**RENEWAL DENIAL TEXT:** *\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **CARGLUMIC ACID (Carbaglu)** requires the following rule(s) be met for renewal:

- You have chronic hyperammonemia (HA) due to N-acetylglutamate synthase (NAGS) (long-term high ammonia blood levels due to a genetic disorder)
- You have clinical improvement or improved plasma (blood) ammonia levels

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Carbaglu.

**REFERENCES**

- Carbaglu [Prescribing Information]. Lebanon, NJ: Recordati Rare Diseases, Inc.; August 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/22

Created: 05/22

Client Approval: 05/22

P&T Approval: 01/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CELECOXIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
CELECOXIB	ELYXYB		48006	GPI-10 (6760403000)	

**GUIDELINES FOR USE**

1. Is the request for the acute treatment of migraine and the patient meets **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient had a trial of generic celecoxib AND OTC or generic aspirin, diclofenac, ibuprofen, or naproxen
- The patient is unable to swallow pills (e.g., tablets or capsules)

If yes, **approve for 6 months by GPID or GPI-14 with a quantity limit of #38.4 mL per 30 days.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **CELECOXIB (Elyxyb)** requires the following rule(s) be met for approval:

- A. The request is for the acute (quick onset) treatment of migraines
- B. You are 18 years of age or older
- C. You had a trial of generic celecoxib AND over-the-counter (OTC) or generic aspirin, diclofenac, ibuprofen, or naproxen
- D. You are unable to swallow pills (such as tablets or capsules)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Elyxyb.

**REFERENCES**

- Elyxyb [Prescribing Information]. Raleigh, NC: BioDelivery Sciences International, Inc.; September 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/22

Created: 02/22

Client Approval: 02/22

P&T Approval: 01/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CENEGERMIN-BKBJ

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
CENEGERMIN-BKBJ	OXERVATE	45258		GPI-10 (8677002020)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of neurotrophic keratitis (NK) and meet **ALL** of the following criteria?
  - Therapy is prescribed by or given in consultation with an ophthalmologist
  - The patient has a medical history supportive of causative etiology for trigeminal nerve damage (e.g., herpes zoster infection, multiple sclerosis, diabetes, ocular surgical damage)
  - The patient has loss of corneal sensitivity, corneal epithelium changes, and/or loss of tear production
  - The patient is refractory to conservative management (i.e., artificial tears, ocular lubricants, topical antibiotics, therapeutic contact lenses)

If yes, **approve for 8 weeks per lifetime by HICL or GPI-10 as follows:**

- **If treatment is for 1 eye: #28 vials per 28 days for 2 fills.**
- **If treatment is for 2 eyes: #56 vials per 28 days for 2 fills.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **CENEGERMIN-BKBJ (Oxervate)** requires the following rule(s) be met for approval:

- A. You have a diagnosis of neurotrophic keratitis (an eye disease due to a damaged eye nerve)
- B. Therapy is prescribed by or given in consultation with an ophthalmologist (eye doctor)
- C. You have a medical history that supports a cause for trigeminal nerve damage (damage to a nerve in the head) such as herpes zoster infection (shingles virus), multiple sclerosis (disorder where immune system attacks nerves), diabetes, ocular surgical (eye surgery) damage
- D. You have loss of corneal sensitivity, corneal epithelium changes, and/or loss of tear production
- E. You are refractory (not fully responsive) to conservative management that includes artificial tears, ocular lubricants, topical antibiotics, therapeutic contact lenses

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use.



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**CENEGERMIN-BKBJ**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Oxervate.

**REFERENCES**

- Oxervate [Prescribing Information]. Boston, MA: Dompe U.S., Inc., December 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 09/04/20

Created: 02/19

Client Approval: 09/20

P&T Approval: 01/19



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CEQUR SIMPLICITY INSULIN DEVICE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
BOLUS INSULIN PUMP, 200 UNIT	CEQUR SIMPLICITY	44109		GPI-10 (9705105012)	Medi-Span: BRAND = CEQUR SIMPLICITY
DIABETIC SUPPLIES, MISCELL	CEQUR SIMPLICITY INSERTER	04476		GPI-10 (9705105012)	FDB/Medi-Span: BRAND = CEQUR SIMPLICITY INSERTER

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of diabetes mellitus (type 1 or type 2) and meet **ALL** of the following criteria?

The patient is 21 years of age or older

Therapy is prescribed by or in consultation with an endocrinologist

The patient follows a maintenance program of at least 3 injections of insulin per day

The patient has worked with the physician to adjust the dose of insulin for the past 6 months and has not met glucose goals

The patient requires bolus insulin dosing in increments of 2 units per bolus

The patient had a trial of ONE of the following preferred devices: Omnipod, Omnipod Dash, V-Go

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Is the patient on a multiple daily insulin injection regimen and meets **ONE** of the following criteria?

- The patient's glycosylated hemoglobin level (HbA1c) is greater than 7%
- The patient has a history of recurring hypoglycemia
- The patient has wide fluctuations in blood glucose before mealtime
- The patient experiences the dawn phenomenon with fasting blood glucose levels frequently exceeding 200 mg/dL
- The patient has a history of severe glycemic excursions (i.e., sudden spikes in blood sugar levels)

If yes, continue to #3.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CEQUR SIMPLICITY INSULIN DEVICE

INITIAL CRITERIA (CONTINUED)

3. Is the request for more than 10 patches per month?

If yes, continue to #4.

If no, **approve for 12 months for both agents as follows:**

- **CeQur Simplicity Inserter: Approve for 1 fill by NDC [FDB] or GPI-14.**
- **CeQur Simplicity Patches: Approve by HICL or NDC [Medi-Span] with a quantity limit of #10 per 30 days.**

4. Is the patient using more than more than 180 units of insulin per 72 hours?

If yes, **approve for 12 months for both agents as follows:**

- **CeQur Simplicity Inserter: Approve for 1 fill by NDC [FDB] or GPI-14.**
- **CeQur Simplicity Patches: Approve by HICL or NDC [Medi-Span] for the requested quantity per 30 days.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**[PAC NOTE: Enter proactive PAs for 12 months for both agents as follows:**

- **CeQur Simplicity Inserter: Approve for 1 fill by NDC [FDB] or GPI-14.**
- **CeQur Simplicity Patches: Approve by HICL or NDC [Medi-Span] with a quantity limit of #10 per 30 days.]**

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **CEQUR SIMPLICITY INSULIN DEVICE** requires the following rule(s) be met for approval:

- A. You have diabetes mellitus (type 1 or type 2) (a disorder with high blood sugar)
- B. You are 21 years of age or older
- C. Therapy is prescribed by or in consultation with an endocrinologist (a type of hormone doctor)
- D. You follow a maintenance program of at least 3 injections of insulin per day
- E. You have worked with the physician to adjust the dose of insulin for the past 6 months and have not met glucose (blood sugar) goals
- F. You require bolus insulin dosing in increments of 2 units per bolus
- G. You had a trial of ONE of the following preferred devices: Omnipod, Omnipod Dash, V-Go
- H. If requesting more than 10 patches per month, then you must be using more than 180 units of insulin per 72 hours

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CEQR SIMPLICITY INSULIN DEVICE

INITIAL CRITERIA (CONTINUED)

- I. You are on a multiple daily insulin injection regimen and meet ONE of the following criteria:
1. You have a glycosylated hemoglobin level (HbA1c: a type of lab test) greater than 7 percent
  2. You have a history of recurring hypoglycemia (low blood sugar)
  3. You have wide fluctuations (variations) in blood glucose before mealtime
  4. You experience the dawn phenomenon (abnormal early morning increase in blood sugar, usually between 2 a.m. and 8 a.m.) with fasting blood glucose levels frequently exceeding 200 mg/dL
  5. You have a history of severe glycemic excursions (sudden spikes in blood sugar levels)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of diabetes mellitus (type 1 or type 2) and meet **ALL** of the following criteria?
- The patient has shown a positive response to therapy
  - The patient is adherent to physician follow-up visits

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

2. Is the request for more than 10 patches per month?

If yes, continue to #3.

If no, **approve 12 months for both as follows:**

- **CeQur Simplicity Inserter: Approve for 1 fill by NDC [FDB] or GPI-14.**
- **CeQur Simplicity Patches: Approve by HICL or NDC [Medi-Span] with a quantity limit of #10 per 30 days.**

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CEQUR SIMPLICITY INSULIN DEVICE

RENEWAL CRITERIA (CONTINUED)

3. Is the patient using more than more than 180 units of insulin per 72 hours?

If yes, approve 12 months for both as follows:

- CeQur Simplicity Inserter: Approve for 1 fill by NDC [FDB] or GPI-14.
- CeQur Simplicity Patches: Approve by HICL or NDC [Medi-Span] for the requested quantity per 30 days.

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

**[PAC NOTE: Enter proactive PAs for 12 months for both as follows:**

- CeQur Simplicity Inserter: Approve for 1 fill by NDC [FDB] or GPI-14.
- CeQur Simplicity Patches: Approve HICL or NDC [Medi-Span] with a quantity limit of #10 per 30 days.]

**RENEWAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **CEQUR SIMPLICITY INSULIN DEVICE** requires the following rule(s) be met for renewal:

- A. You have diabetes mellitus (type 1 or type 2) (a disorder with high blood sugar)
- B. You have shown a positive response to therapy
- C. You are adherent to your doctor follow-up visits
- D. If requesting more than 10 patches per month, you are using more than 180 units of insulin per 72 hours

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CEQUR SIMPLICITY INSULIN DEVICE

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for CeQur Simplicity.

**REFERENCES**

- CeQur Simplicity. CeQur Corp. Available at: <https://myceqursimplicity.com/healthcare-professionals/>. [Accessed July 27, 2004].

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/23

Created: 08/22

Client Approval: 02/23

P&T Approval: 07/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CERITINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
CERITINIB	ZYKADIA	41111		GPI-10 (2153051400)	

GUIDELINES FOR USE

- Does the patient have a diagnosis of metastatic non-small cell lung cancer (NSCLC) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient's tumors are anaplastic lymphoma kinase (ALK)-positive, as detected by an FDA-approved test

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #3 per day.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **CERITINIB (Zykadia)** requires the following rule(s) be met for approval:  
A. You have metastatic non-small cell lung cancer (type of lung cancer that has spread)  
B. You are 18 years of age or older  
C. Your tumors are anaplastic lymphoma kinase (ALK: a type of enzyme) positive as confirmed by a Food and Drug Administration-approved test

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Zykadia.

REFERENCE

- Zykadia [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; August 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/25/21

Created: 05/14

Client Approval: 10/21

P&T Approval: 10/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CERTOLIZUMAB PEGOL

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
CERTOLIZUMAB PEGOL	CIMZIA	35554		GPI-10 (5250502010)	

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a rheumatologist
  - The patient had a trial of or contraindication to at least 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
  - The patient meets ONE of the following:
    - The patient is pregnant, breastfeeding, or trying to become pregnant
    - The patient had a trial of or contraindication to any TWO of the following preferred immunomodulators: Enbrel, Humira, Rinvoq, Xeljanz (IR/XR)
    - The patient has tried any TNF inhibitor (e.g., Humira, Enbrel) AND the physician has indicated the patient cannot use a JAK inhibitor (e.g., Rinvoq, Xeljanz) due to the black box warning for increased risk of mortality, malignancies, and serious cardiovascular events [NOTE: pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

If yes, approve for a total of 6 months. Please enter two authorizations as follows:

- **FIRST APPROVAL:** Approve for 1 month by HICL or GPI-10 for 1 fill with a quantity limit of #3 (1200 mg) per 28 days (equals one starter kit of 6 syringes or three kits of 2 syringes/vials per kit).
- **SECOND APPROVAL:** Approve for 5 months by HICL or GPI-10 with a quantity limit of #1 kit (each kit contains 2 syringes/vials) per 28 days. (Start date is 2 days before the end date of the first approval).

If no, continue to #2.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CERTOLIZUMAB PEGOL

INITIAL CRITERIA (CONTINUED)

2. Does the patient have a diagnosis of psoriatic arthritis (PsA) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- Therapy is prescribed by or in consultation with a rheumatologist or dermatologist
- The patient had a trial of or contraindication to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
- The patient meets ONE of the following:
  - The patient is pregnant, breastfeeding, or trying to become pregnant
  - The patient had a trial of or contraindication to any TWO of the following preferred immunomodulators: Cosentyx, Enbrel, Humira, Stelara, Xeljanz (IR/XR), Otezla, Tremfya, Rinvoq, Skyrizi [**NOTE:** pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

If yes, approve for a total of 6 months. Please enter two authorizations as follows:

- **FIRST APPROVAL:** Approve for 1 month by HICL or GPI-10 for 1 fill with a quantity limit of #3 (1200 mg) per 28 days (equals one starter kit of 6 syringes or three kits of 2 syringes/vials per kit).
- **SECOND APPROVAL:** Approve for 5 months by HICL or GPI-10 with a quantity limit of #1 kit (each kit contains 2 syringes/vials) per 28 days. (Start date is 2 days before the end date of the first approval).

If no, continue to #3.

3. Does the patient have a diagnosis of ankylosing spondylitis (AS) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- Therapy is prescribed by or in consultation with a rheumatologist
- The patient had a trial of or contraindication to an NSAID (e.g., ibuprofen, naproxen, meloxicam, diclofenac, etc.)
- The patient meets ONE of the following:
  - The patient is pregnant, breastfeeding, or trying to become pregnant
  - The patient had a trial of or contraindication to any TWO of the following preferred immunomodulators: Cosentyx, Enbrel, Humira, Xeljanz (IR/XR), Rinvoq [**NOTE:** pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

If yes, approve for a total of 6 months. Please enter two authorizations as follows:

- **FIRST APPROVAL:** Approve for 1 month by HICL or GPI-10 for 1 fill with a quantity limit of #3 (1200 mg) per 28 days (equals one starter kit of 6 syringes or three kits of 2 syringes/vials per kit).
- **SECOND APPROVAL:** Approve for 5 months by HICL or GPI-10 with a quantity limit of #1 kit (each kit contains 2 syringes/vials) per 28 days. (Start date is 2 days before the end date of the first approval).



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

If no, continue to #4.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CERTOLIZUMAB PEGOL

INITIAL CRITERIA (CONTINUED)

4. Does the patient have a diagnosis of moderate to severe Crohn's disease (CD) and meet **ALL** of the following criteria?
- The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a gastroenterologist
  - The patient had a trial of or contraindication to ONE conventional therapy (e.g., corticosteroids [e.g., budesonide, methylprednisolone], azathioprine, mercaptopurine, methotrexate, mesalamine)
  - The patient meets ONE of the following:
    - The patient is pregnant, breastfeeding, or trying to become pregnant
    - The patient had a trial of or contraindication to the following preferred immunomodulator: Humira [**NOTE:** pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

If yes, approve for a total of 6 months. Please enter two authorizations as follows:

- **FIRST APPROVAL:** Approve for 1 month by HICL or GPI-10 for 1 fill with a quantity limit of #3 (1200 mg) per 28 days (equals one starter kit of 6 syringes or three kits of 2 syringes/vials per kit).
- **SECOND APPROVAL:** Approve for 5 months by HICL or GPI-10 with a quantity limit of #1 kit (each kit contains 2 syringes/vials) per 28 days. (Start date is 2 days before the end date of the first approval).

If no, continue to #5.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CERTOLIZUMAB PEGOL

INITIAL CRITERIA (CONTINUED)

5. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) and meet **ALL** of the following criteria?
- The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a dermatologist
  - The patient has psoriasis covering 3% or more of body surface area (BSA) OR psoriatic lesions affecting the hands, feet, genital area, or face
  - The patient had a trial of or contraindication to ONE or more forms of conventional therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids, calcipotriene, acitretin, methotrexate, or cyclosporine
  - The patient meets ONE of the following:
    - The patient is pregnant, breastfeeding, or trying to become pregnant
    - The patient had a trial of or contraindication to any TWO of the following preferred immunomodulators: Cosentyx, Humira, Stelara, Tremfya, Skyrizi, Enbrel, Otezla [**NOTE:** pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #2 kits (each kit contains 2 syringes/vials) per 28 days.**

If no, continue to #6.

6. Does the patient have a diagnosis of non-radiographic axial spondyloarthritis (nr-axSpA) and meet **ALL** of the following criteria?
- The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a rheumatologist
  - The patient had a trial of or contraindication to an NSAID (e.g., ibuprofen, naproxen, meloxicam, diclofenac, etc.)
  - The patient meets ONE of the following objective signs of inflammation:
    - C-reactive protein (CRP) levels above the upper limit of normal
    - Sacroiliitis on magnetic resonance imaging (MRI)

If yes, **approve for a total of 6 months. Please enter two authorizations as follows:**

- **FIRST APPROVAL:** Approve for 1 month by HICL or GPI-10 for 1 fill with a quantity limit of #3 (1200 mg) per 28 days (equals one starter kit of 6 syringes or three kits of 2 syringes/vials per kit).
- **SECOND APPROVAL:** Approve for 5 months by HICL or GPI-10 with a quantity limit of #1 kit (each kit contains 2 syringes/vials) per 28 days. (Start date is 2 days before the end date of the first approval).

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CERTOLIZUMAB PEGOL

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **CERTOLIZUMAB PEGOL (Cimzia)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
  - 1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
  - 2. Psoriatic arthritis (PsA: a type of skin and joint condition)
  - 3. Ankylosing spondylitis (AS: a type of joint condition)
  - 4. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
  - 5. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
  - 6. Non-radiographic axial spondyloarthritis (nr-axSpA: a type of joint condition)
- B. **If you have moderate to severe rheumatoid arthritis, approval also requires:**
  - 1. You are 18 years of age or older
  - 2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
  - 3. You had a trial of or contraindication (harmful for) to at least 3 months of ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
  - 4. You meet ONE of the following:
    - a. You are pregnant, breastfeeding, or trying to become pregnant
    - b. You had a trial of or contraindication (harmful for) to any TWO of the following preferred immunomodulators (class of drugs): Enbrel, Humira, Rinvoq, Xeljanz (immediate release/extended release)
    - c. You have tried any tumor necrosis factor (TNF) inhibitor (such as Humira, Enbrel) AND your physician has indicated you cannot use a JAK inhibitor (such as Rinvoq, Xeljanz IR/XR) due to the black box warning for increased risk of mortality (death), malignancies (cancerous), and serious cardiovascular (heart-related) events

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CERTOLIZUMAB PEGOL

INITIAL CRITERIA (CONTINUED)

**C. If you have psoriatic arthritis, approval also requires:**

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
4. You meet ONE of the following:
  - a. You are pregnant, breastfeeding, or trying to become pregnant
  - b. You had a trial of or contraindication (harmful for) to any TWO of the following preferred immunomodulators (class of drugs): Cosentyx, Enbrel, Humira, Stelara, Xeljanz (immediate release/extended release), Otezla, Tremfya, Rinvoq, Skyrizi

**D. If you have ankylosing spondylitis, approval also requires:**

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
3. You had a trial of or contraindication (harmful for) to an NSAID (non-steroidal anti-inflammatory drug)
4. You meet ONE of the following:
  - a. You are pregnant, breastfeeding, or trying to become pregnant
  - b. You had a trial of or contraindication (harmful for) to any TWO of the following preferred immunomodulators (class of drugs): Cosentyx, Enbrel, Humira, Xeljanz (immediate release/extended release), Rinvoq

**E. If you have moderate to severe Crohn's disease, approval also requires:**

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
3. You had a trial of or contraindication (harmful for) to ONE standard therapy, such as corticosteroids (such as budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine
4. You meet ONE of the following:
  - a. You are pregnant, breastfeeding, or trying to become pregnant
  - b. You had a trial of or contraindication (harmful for) to the following preferred immunomodulator (class of drug): Humira

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**CERTOLIZUMAB PEGOL**

**INITIAL CRITERIA (CONTINUED)**

**F. If you have moderate to severe plaque psoriasis, approval also requires:**

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
3. You have psoriasis covering 3% or more of body surface area (BSA) OR psoriatic lesions (rashes) affecting the hands, feet, genital area, or face
4. You had a trial of or contraindication (harmful for) to ONE or more forms of standard therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids, calcipotriene, acitretin, methotrexate, or cyclosporine
5. You meet ONE of the following:
  - a. You are pregnant, breastfeeding, or trying to become pregnant
  - b. You had a trial of or contraindication (harmful for) to any TWO of the following preferred immunomodulators (class of drugs): Cosentyx, Humira, Stelara, Tremfya, Skyrizi, Enbrel, Otezla

**G. If you have non-radiographic axial spondyloarthritis, approval also requires:**

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
3. You had a trial of or contraindication (harmful for) to an NSAID (non-steroidal anti-inflammatory drug)
4. You have ONE of the following signs of inflammation:
  - a. C-reactive protein (CRP; a measure of how much inflammation you have) levels above the upper limit of normal
  - b. Sacroiliitis (type of inflammation where lower spine and pelvis connect) on magnetic resonance imaging (MRI)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CERTOLIZUMAB PEGOL

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) **AND** meet the following criterion?

- The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 kit (each kit contains 2 syringes/vials) per 28 days.**

If no, continue to #2.

2. Does the patient have a diagnosis of psoriatic arthritis (PsA) **AND** meet the following criterion?

- The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 kit each kit contains 2 syringes/vials) per 28 days.**

If no, continue to #3.

3. Does the patient have a diagnosis of ankylosing spondylitis (AS) or non-radiographic axial spondyloarthritis (nr-axSpA) **AND** meet the following criterion?

- The patient has experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) while on therapy

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 kit (each kit contains 2 syringes/vials) per 28 days.**

If no, continue to #4.

4. Does the patient have a diagnosis of moderate to severe Crohn's disease (CD)?

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 kit (each kit contains 2 syringes/vials) per 28 days.**

If no, continue to #5.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CERTOLIZUMAB PEGOL

RENEWAL CRITERIA (CONTINUED)

5. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) **AND** meet the following criterion?

- The patient has achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more while on therapy

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 kits (each kit contains 2 syringes/vials) per 28 days.**

If no, do not approve.

**RENEWAL DENIAL TEXT: Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **CERTOLIZUMAB PEGOL (Cimzia)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following diagnoses:
1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
  2. Psoriatic arthritis (PsA: a type of skin and joint condition)
  3. Ankylosing spondylitis (AS: a type of joint condition)
  4. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
  5. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
  6. Non-radiographic axial spondyloarthritis (nr-axSpA: a type of joint condition)
- B. **If you have moderate to severe rheumatoid arthritis, renewal also requires:**
1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
- C. **If you have psoriatic arthritis, renewal also requires:**
1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
- D. **If you have ankylosing spondylitis OR non-radiographic axial spondyloarthritis, renewal also requires:**
1. You have experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI: diagnostic test which allows a physician to determine the effectiveness of a current medication) while on therapy
- E. **If you have moderate to severe plaque psoriasis, renewal also requires:**
1. You have achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index: used to measure the severity and extent of psoriasis) of at least 50% or more while on therapy

***(Renewal denial text continued on next page)***

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CERTOLIZUMAB PEGOL

RENEWAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Cimzia.

**REFERENCES**

- Cimzia [Prescribing Information]. Smyrna, GA: UCB, Inc.; September 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 06/15/22

Created: 05/08

Client Approval: 05/22

P&T Approval: 04/22





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CHENODIOL

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
CHENODIOL	CHENODAL	01364		GPI-10 (5210001000)	

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Is the requested medication being prescribed for the treatment of cerebrotendinous xanthomatosis (CTX)?

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #3 daily.**  
If no, continue to #2.

2. Is the requested medication being prescribed for the treatment of radiolucent gallstones?

If yes, continue to #3.  
If no, do not approve.  
**DENIAL TEXT:** See the initial denial text at the end of the guideline.

3. Has the patient received previous chenodiol therapy with a total duration exceeding 24 months?

If yes, do not approve.  
**DENIAL TEXT:** See the initial denial text at the end of the guideline.  
If no, continue to #4.

4. Has the patient had a previous trial of or contraindication to ursodiol?

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #7 daily.**  
If no, do not approve.  
**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **CHENODIOL (Chenodal)** requires the following rule(s) be met for approval:

- A. You have radiolucent gallstones (hard deposits in your gall bladder that can barely be seen with x-rays) OR cerebrotendinous xanthomatosis (condition of missing an enzyme that changes cholesterol into a bile acid)
- B. **If you have radiolucent gallstones, approval also requires:**
  1. You have tried ursodiol, unless there is a medical reason why you cannot (contraindication)
  2. You have not received previous chenodiol therapy for more than a total of 24 months  
**(Initial denial text continued on next page)**

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CHENODIOL

INITIAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Is the requested medication being used for radiolucent gallstones?

If yes, continue to #2.  
If no, continue to #5.

2. Has the patient previously received a total duration of chenodiol therapy exceeding 24 months?

If yes, do not approve.  
**DENIAL TEXT:** See the renewal denial text at the end of the guideline.  
If no, continue to #3.

3. Does the patient have complete or no gallstone dissolution seen on imaging after 12 months of therapy?

If yes, do not approve.  
**DENIAL TEXT:** See the renewal denial text at the end of the guideline.  
If no, continue to #4.

4. Does the patient have partial gallstone dissolution seen on imaging after 12 months of therapy?

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #7 daily.**  
If no, do not approve.  
**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

5. Does the patient have a diagnosis of cerebrotendinous xanthomatosis (CTX) **AND** meet the following criterion?

- The patient has experienced improvement in **ONE** of the following:
  - Normalization of elevated serum or urine bile alcohols
  - Normalization of elevated serum cholestanol levels
  - Improvement in neurologic and psychiatric symptoms (dementia, pyramidal tract and cerebellar signs)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #3 daily.**  
If no, do not approve.  
**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CHENODIOL

RENEWAL CRITERIA (CONTINUED)

**RENEWAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **CHENODIOL (Chenodal)** requires the following rule(s) be met for renewal:

- A. You have radiolucent gallstones (hard deposits in your gall bladder that can barely be seen with x-rays) OR cerebrotendinous xanthomatosis (condition of missing an enzyme that changes cholesterol into a bile acid)
- B. **If you have radiolucent gallstones, renewal also requires:**
  - 1. You have **NOT** had chenodiol therapy for more than a total of 24 months
  - 2. You do **NOT** have complete or no gallstone dissolution (disappearance) seen on imaging (such as oral cholecystograms or ultrasonograms) after 12 months of therapy
  - 3. You have partial gallstone dissolution seen on imaging (such as oral cholecystograms or ultrasonograms) after 12 months of therapy
- C. **If you have cerebrotendinous xanthomatosis, renewal also requires you have experienced an improvement in ONE** of the following:
  - 1. Normalization of elevated serum or urine bile alcohols
  - 2. Normalization of elevated serum cholestanol levels
  - 3. Improvement in neurologic and psychiatric symptoms (dementia, pyramidal tract and cerebellar signs)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Chenodal.

**REFERENCES**

- Chenodal [Prescribing Information]. Manchester Pharmaceuticals, Inc. Fort Collins, CO. July 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 11/09

Client Approval: 04/20

P&T Approval: 07/18



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CHOLIC ACID

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
CHOLIC ACID	CHOLBAM	39124		GPI-10 (5270002500)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient exhibit manifestations of liver disease, steatorrhea, or complications from decreased fat-soluble vitamin absorption secondary to **ONE** of the following conditions?
  - Bile acid synthesis disorders
  - Peroxisomal disorders (i.e., Zellweger spectrum disorders)

If yes, **approve for 3 months by HICL or GPI-10.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **CHOLIC ACID (Cholbam)** requires the following rule(s) be met for approval:

- A. You show signs of liver disease, steatorrhea (excess fat in feces), or complications from your body not being able to absorb fat-soluble vitamins that occur from **ONE** of the following conditions:
  1. Bile acid synthesis disorders (your body has a problem making bile acid)
  2. Peroxisomal disorders (Zellweger spectrum disorders) (problems with a part of a cell that contains enzymes)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RENEWAL CRITERIA**

1. Did the patient experience improvement in liver function (as defined by at least **ONE** of the following criteria)?
  - ALT or AST values reduced to less than 50 U/L or baseline levels reduced by 80%
  - Total bilirubin values reduced to less than 1 mg/dL
  - No evidence of cholestasis on liver biopsy

If yes, **approve for 12 months by HICL or GPI-10.**

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CHOLIC ACID

RENEWAL CRITERIA (CONTINUED)

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **CHOLIC ACID (Cholbam)** requires the following rule(s) be met for renewal:

- A. You have experienced an improvement in your liver function as defined by at least ONE of the following criteria:
1. ALT (alanine aminotransferase) or AST (aspartate transaminase) (types of liver enzymes) values have been lowered to less than 50 U/L or baseline levels reduced by 80%
  2. Total bilirubin values reduced to less than 1 mg/dL
  3. No evidence of cholestasis (condition where bile cannot flow from liver) on liver biopsy

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Cholbam.

**REFERENCES**

- Cholbam [Prescribing Information]. Baltimore, MD: Asklepiion Pharmaceuticals, LLC; March 2015.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 04/15

Client Approval: 04/20

P&T Approval: 05/15



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CLADRIBINE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
CLADRIBINE	MAVENCLAD		44338	GPI-10 (6240101500)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

- Does the patient have a diagnosis of a relapsing form of multiple sclerosis (MS) (e.g., relapsing-remitting MS [RRMS], active secondary progressive MS [SPMS], etc.) **AND** meet the following criterion?
  - The patient is 18 years of age or older

If yes, **approve for 48 weeks by GPID or GPI-10.**

**APPROVAL TEXT:** Renewal requires 1) physician attestation that the patient has demonstrated a clinical benefit compared to pre-treatment baseline, 2) the patient does not have lymphopenia, and 3) the patient has not received a total of two years of Mavenclad treatment (i.e., two treatment cycles divided into 2 yearly treatment courses).

If no, do not approve.

**INITIAL DENIAL TEXT:** *\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **CLADRIBINE (Mavenclad)** requires the following rule(s) be met for approval:

- You have a relapsing form of multiple sclerosis (MS: disease where body attacks its own nerves and returns after having no symptoms). This includes relapsing-remitting MS [RRMS], active secondary progressive MS [SPMS], etc.
- You are 18 years of age or older

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RENEWAL CRITERIA**

- Does the patient have a diagnosis of a relapsing form of multiple sclerosis (MS) (e.g. relapsing-remitting MS [RRMS], active secondary progressive MS [SPMS], etc.)?

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CLADRIBINE

RENEWAL CRITERIA (CONTINUED)

2. Has the patient received a total of two years of Mavenclad treatment (i.e., two treatment cycles divided into 2 yearly treatment courses)?

If yes, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

If no, continue to #3.

3. Does the patient meet **ALL** of the following criteria?

- The patient has demonstrated a clinical benefit compared to pre-treatment baseline
- The patient does not have lymphopenia

If yes, **approve for 48 weeks by GPID or GPI-10.**

If no, do not approve.

**RENEWAL DENIAL TEXT:** *\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **CLADRIBINE (Mavenclad)** requires the following rule(s) be met for renewal:

- A. You have a relapsing form of multiple sclerosis (MS: disease where body attacks its own nerves and returns after having no symptoms). This includes relapsing- remitting MS [RRMS], active secondary progressive MS [SPMS], etc.
- B. You have demonstrated a clinical benefit compared to pre-treatment baseline (before you started therapy)
- C. You do not have lymphopenia (low amount of a type of white blood cell called lymphocyte)
- D. You have not received a total of two years of treatment with Mavenclad

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Mavenclad.

**REFERENCES**

- Mavenclad [Prescribing Information]. Rockland, MA: EMD Serono, Inc., March 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Created: 04/19

Commercial Effective: 07/01/20

Client Approval: 04/20

P&T Approval: 10/19

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CLASCOTERONE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
CLASCOTERONE	WINLEVI	46803		GPI-10 (9005001100)	

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of acne vulgaris and meet **ALL** of the following criteria?

- The patient is 12 years of age or older
- Therapy is prescribed by or given in consultation with a dermatologist
- The patient had a trial of or contraindication to **BOTH** of the following:
  - ONE oral acne agent (e.g. oral antibiotics or oral isotretinoin)
  - TWO topical acne agents (e.g. topical retinoids, topical antibiotics, benzoyl peroxide)

If yes, **approve for 3 months by HICL or GPI-10 with a quantity limit of #60 grams (1 tube) per 30 days.**

**APPROVAL TEXT:** Renewal requires the patient had improvement of acne lesions.

If no, do not approve.

**INITIAL DENIAL TEXT:** **\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **CLASCOTERONE (Winlevi)** requires the following rule(s) be met for approval:

- A. You have acne vulgaris (skin condition in which hair follicles become plugged with oil and dead skin cells)
- B. You are 12 years of age or older
- C. Therapy is prescribed by or given in consultation with a dermatologist (skin doctor)
- D. You have previously tried BOTH of the following unless there is a medical reason why you cannot (contraindication):
  1. ONE oral acne agent (such as oral antibiotics or oral isotretinoin)
  2. TWO topical acne agents (such as topical retinoids, topical antibiotics, benzoyl peroxide)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CLASCOTERONE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

- Does the patient have a diagnosis of acne vulgaris **AND** meet the following criterion?
  - The patient had improvement of acne lesions

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #60 grams (1 tube) per 30 days.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **CLASCOTERONE (Winlevi)** requires the following rule(s) be met for approval:

- You have acne vulgaris (skin condition in which hair follicles become plugged with oil and dead skin cells)
- You had improvement of acne lesions

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Winlevi.

**REFERENCES**

- Winlevi [Prescribing Information]. Milan, Italy: Cosmo S.p.A.; August 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/21

Created: 12/20

Client Approval: 12/20

P&T Approval: 10/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**CLOBAZAM-SYMPAZAN**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
CLOBAZAM	SYMPAZAN	06536		GPI-10 (7210000700)	DOSAGE FORM = FILM

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of Lennox-Gastaut syndrome and meet **ALL** of the following criteria?

- The patient is 2 years of age or older
- Therapy is prescribed by or in consultation with a neurologist
- Sympazan will be used for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome
- The patient is unable to take tablets or suspension
- The patient had a trial of or contraindication to generic/branded clobazam products (Onfi)

If yes, **approve for 12 months by GPID or GPI-14 for all of the following strengths with a quantity limit of #2 per day:**

- **5mg film**
- **10mg film**
- **20mg film**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **CLOBAZAM-SYMPAZAN** requires the following rule(s) be met for approval:

- A. You have Lennox-Gastaut Syndrome (a type of seizure disorder in young children)
- B. You are 2 years of age or older
- C. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor)
- D. Sympazan will be used for adjunctive (add-on) treatment of seizures associated with Lennox-Gastaut syndrome
- E. You are unable to take tablets or suspension
- F. You had a trial of or contraindication (harmful for) to generic/branded clobazam products (Onfi)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**CLOBAZAM-SYMPAZAN**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Sympazan.

**REFERENCES**

- Sympazan [Prescribing Information]. Warren, NJ. Aquestive Therapeutics; March 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/22

Created: 02/19

Client Approval: 05/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

COBIMETINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
COBIMETINIB FUMARATE	COTELLIC	42796		GPI-10 (2153353020)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of unresectable or metastatic melanoma and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient's tumor has a BRAF V600E OR V600K mutation
- Cobimetinib will be used in combination with vemurafenib (Zelboraf)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #63 per 28 days.**  
If no, continue to #2.

2. Does the patient have a diagnosis of histiocytic neoplasms and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- Cobimetinib will be used as a single agent

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #63 per 28 days.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **COBIMETINIB (Cotellic)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:

1. Unresectable or metastatic melanoma (skin cancer that has spread or cannot be completely removed with surgery)
2. Hystiocytic neoplasms (a type of white blood cell disorder)

B. **If you have unresectable or metastatic melanoma, approval also requires:**

1. You are 18 years of age or older
2. Your tumor has a BRAF V600E OR V600K mutation (a type of gene mutation)
3. Cobimetinib will be used in combination with vemurafenib (Zelboraf)

C. **If you have histiocytic neoplasms, approval also requires:**

1. You are 18 years of age or older
2. Cobimetinib will be used as a single agent

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**COBIMETINIB**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Cotellic.

**REFERENCES**

- Cotellic [Prescribing Information]; San Francisco, CA: Genentech USA, Inc.; October 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/21/22

Created: 11/15

Client Approval: 11/22

P&T Approval: 01/23



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

COLLAGENASE TOPICAL

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
COLLAGENASE CLOSTRIDIUM HIST.	SANTYL		21190	GPI-14 (90700010004205)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of chronic dermal ulcer(s) or severe burn(s) that require(s) debridement?

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Is the requested quantity for one tube (30 grams) or less?

If yes, **approve by GPID or GPI-14 for one fill with a quantity limit of #30 grams.**

If no, continue to #3.

3. Are **BOTH** of the following provided?

- The patient's wound size (width/length)
- The anticipated duration of therapy

If yes, **approve by GPID or GPI-14 for one fill with a quantity limit based on the Santyl dosing calculator (<https://santyl.com/hcp/dosing>).**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **COLLAGENASE TOPICAL (Santyl)** requires the following rule(s) be met for approval:

- A. You have chronic dermal (skin) ulcer(s) or severe burn(s) that require(s) debridement (removal of damaged tissue from a wound)
- B. **If the requested quantity is more than one tube (30 grams), approval also requires:**
  1. The higher quantity is based on the size of your wound (width/length) and the anticipated duration of therapy, using the Santyl dosing calculator (<https://santyl.com/hcp/dosing>)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**COLLAGENASE TOPICAL**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Santyl.

**REFERENCES**

- Santyl [Prescribing Information]. Fort Worth, TX: Smith & Nephew, Inc., May 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/22

Created: 11/21

Client Approval: 02/22

P&T Approval: 10/21



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**CONTINUOUS GLUCOSE MONITORS - STAND-ALONE**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
CONTINUOUS BLOOD-GLUCOSE METER/RECEIVER	DEXCOM G4, DEXCOM G5, DEXCOM G6	36756			Medi-Span: BRAND = DEXCOM G4%, DEXCOM G5%, DEXCOM G6%
FLASH GLUCOSE SCANNING READER, CONTINUOUS BLOOD-GLUCOSE RECEIVER	FREESTYLE LIBRE 14/10, FREESTYLE LIBRE 2	44578		GPI-10 (9720201202)	Medi-Span: BRAND = FREESTYLE LIBRE%
BLOOD-GLUCOSE TRANSMITTER	DEXCOM G4, DEXCOM G5, DEXCOM G6, EVERSENSE SMART TRANSMITTER, GUARDIAN CONNECT TRANSMITTER	36760		GPI-10 (9720201206)	FDB & Medi-Span: BRAND = DEXCOM G4%, DEXCOM G5%, DEXCOM G6%, EVERSENSE SMART TRANSMITTER, GUARDIAN CONNECT TRANSMITTER
BLOOD-GLUCOSE SENSOR	DEXCOM G6, DEXCOM G5-G4 SENSOR, DEXCOM G4 SENSOR, GUARDIAN SENSOR 3	36696			FDB & Medi-Span: BRAND = DEXCOM G5-G4%, DEXCOM G6%, DEXCOM G4 SENSOR, GUARDIAN SENSOR 3
FLASH GLUCOSE SENSOR, CONTINUOUS BLOOD GLUCOSE SENSOR	FREESTYLE LIBRE SENSOR, FREESTYLE LIBRE 2 SENSOR, FREESTYLE LIBRE 3 SENSOR	44576			Medi-Span: BRAND = FREESTYLE LIBRE%

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of type 1, type 2, or gestational diabetes?

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CONTINUOUS GLUCOSE MONITORS - STAND-ALONE

GUIDELINES FOR USE (CONTINUED)

2. Is the patient receiving treatment with insulin and meets **ONE** of the following criteria?

- The patient is using a continuous subcutaneous insulin infusion pump
- The patient utilizes 3 or more daily administrations of insulin
- The patient's insulin treatment plan requires frequent adjustment of insulin dosing

If yes, continue to #4.

If no, continue to #3.

3. Does the patient meet **ALL** of the following criteria?

- The patient has a clinical need that cannot be managed with self-monitoring of blood glucose (SMBG) (e.g., frequent hypoglycemia, hypoglycemic unawareness, unable to achieve control of diabetes)
- The patient has either tried (without sufficient results or continuous need is identified by provider) or does not have access to a professional CGM from the provider's office

If yes, continue to #4.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

4. Is the request for Dexcom G6 (i.e., meter, sensor, transmitter) **AND** the patient meets the following criterion?

- The patient is 2 years of age or older

If yes, **approve all of the following for 12 months by NDC [FDB or Medi-Span] with a quantity limit as follows:**

- **Dexcom G6 meter: #1 per 12 months.**
- **Dexcom G6 Transmitter: #1 per 90 days.**
- **Dexcom G6 Sensor: #3 per 30 days.**

If no, continue to #5.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CONTINUOUS GLUCOSE MONITORS - STAND-ALONE

GUIDELINES FOR USE (CONTINUED)

5. Is the request for Dexcom G4 or Dexcom G5 (i.e., meter, sensor, transmitter) and the patient meets **ALL** of the following criteria?

- The patient is 2 years of age or older
- The patient had a trial of Dexcom G6

If yes, **approve all of the following for 12 months by NDC [FDB or Medi-Span] with a quantity limit as follows:**

- **Dexcom G4 or G5 meter: #1 per 12 months.**
- **Dexcom Transmitters: Approve the requested transmitter**
  - **G4 Transmitter: #1 per 180 days**
  - **G5 Transmitter: #1 per 90 days.**
- **Dexcom Sensors**
  - **G4-5 Sensor: #4 per 28 days.**

If no, continue to #6.

6. Is the request for FreeStyle Libre 14 or 10 system (i.e., reader, sensor) and the patient meets **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient had a trial of Dexcom G6

If yes, **approve all of the following for 12 months by NDC [FDB or Medi-Span] with a quantity limit as follows:**

- **Freestyle Libre 14 or 10 Reader: #1 per 12 months.**
- **Freestyle Libre 14 Day Sensor: #2 per 28 days.**
- **Freestyle Libre 10 Day Sensor: #3 per 30 days.**

If no, continue to #7.

7. Is the request for FreeStyle Libre 2 system (i.e., reader, sensor) and the patient meets **ALL** of the following criteria?

- The patient is 4 years of age or older
- The patient had a trial of Dexcom G6

If yes, **approve all of the following for 12 months by NDC [FDB or Medi-Span] with a quantity limit as follows:**

- **Freestyle Libre 2 Reader: #1 per 12 months.**
- **Freestyle Libre 2 Sensor: #2 per 28 days.**

If no, continue to #8.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CONTINUOUS GLUCOSE MONITORS - STAND-ALONE

GUIDELINES FOR USE (CONTINUED)

8. Is the request for FreeStyle Libre 3 system (i.e., sensor) and that patient meets **ALL** of the following criteria?

- The patient is 4 years of age or older
- The patient had a trial of Dexcom G6

If yes, **approve for 12 months by NDC [FDB or Medi-Span] with a quantity limit of #2 per 28 days.**

If no, continue to #9.

9. Is the request for Medtronic Guardian Connect (i.e., sensor, transmitter) and the patient meets **ALL** of the following criteria?

- The patient is 14 to 75 years of age
- The patient had a trial of Dexcom G6

If yes, **approve all of the following for 12 months by NDC [FDB or Medi-Span] with a quantity limit as follows:**

- **Guardian Connect Transmitter: #1 per 12 months.**
- **Guardian Sensor 3: #5 per 35 days.**

If no, continue to #10.

10. Is the request for Eversense Smart Transmitter and the patient meets **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient had a trial of Dexcom G6

If yes, **approve for 12 months by NDC [FDB or Medi-Span] with a quantity limit of #1 per 12 months.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**[Please enter a proactive PA for Dexcom G6] Approve all of the following for 12 months by NDC [FDB or Medi-Span] with a quantity limit as follows:**

- **Dexcom G6 meter: #1 per 12 months.**
- **Dexcom G6 Transmitter: #1 per 90 days.**
- **Dexcom G6 Sensors: #3 per 30 days.**

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CONTINUOUS GLUCOSE MONITORS - STAND-ALONE

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **CONTINUOUS GLUCOSE MONITORS - STAND-ALONE** requires the following rule(s) be met for approval:

- A. You have type 1, type 2, or gestational (during pregnancy) diabetes (too much sugar in your blood)
  - B. You meet ONE of the following:
    1. You are being treated with insulin and meet ONE of the following:
      - a. You are using a continuous subcutaneous (injection under the skin) insulin infusion pump
      - b. You use 3 or more administrations of insulin daily
      - c. You are on an insulin treatment plan that requires frequent adjustment of insulin dosing
    2. You meet ALL of the following:
      - a. You have a clinical need that cannot be managed with self-monitoring of blood glucose (such as frequent hypoglycemia [low blood sugar], hypoglycemic unawareness, unable to achieve control of diabetes)
      - b. You have either tried (without adequate results or continuous need is identified by your doctor) or do not have access to a professional continuous glucose monitor from your doctor's office
  - C. **If you are requesting Dexcom G6 system (meter, sensor, transmitter), approval also requires:**
    1. You are 2 years of age or older
  - D. **If you are requesting Dexcom G4 or Dexcom G5 system (meter, sensor, transmitter), approval also requires:**
    1. You are 2 years of age or older
    2. You had a trial of Dexcom G6
  - E. **If you are requesting FreeStyle Libre system (reader, sensor), approval also requires:**
    1. You are 18 years of age or older
    2. You had a trial of Dexcom G6
  - F. **If you are requesting FreeStyle Libre 2 (reader, sensor) or FreeStyle Libre 3 system (sensor), approval also requires:**
    1. You are 4 years of age or older
    2. You had a trial of Dexcom G6
- (Denial text continued on next page)***

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CONTINUOUS GLUCOSE MONITORS - STAND-ALONE

GUIDELINES FOR USE (CONTINUED)

G. If you are requesting Medtronic Guardian Connect (sensor, transmitter), approval also requires:

1. You are between 14 to 75 years of age
2. You had a trial of Dexcom G6

H. If you are requesting Eversense Smart Transmitter, approval also requires:

1. You are 18 years of age or older
2. You had a trial of Dexcom G6

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different product or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for the related continuous glucose monitor.

REFERENCES

- FreeStyle Libre Flash Glucose Monitoring System, Freestyle Libre 2 System, Freestyle Libre 3 System. Abbott Laboratories. Indications and Safety Information. Available at: <https://www.freestylelibre.us/safety-information>
- Dexcom Continuous Glucose Monitoring Products. Dexcom, Inc. Available at: <https://www.dexcom.com/>
- Medtronic Guardian Connect. Medtronic MiniMed, Inc. Available at: <https://www.medtronicdiabetes.com/products/guardian-connect-continuous-glucose-monitoring-system>
- Eversense Continuous Glucose Monitoring System. Senseonics, Inc. Available at: <https://www.eversenseddiabetes.com/>

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/01/22

Created: 02/18

Client Approval: 09/22

P&T Approval: 07/22



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**CONTRACEPTIVE ZERO COST SHARE OVERRIDE**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
CONTRACEPTIVES, ORAL				GPI-2 (25)	STC = 0248
CONTRACEPTIVES, TRANSDERMAL					STC = 9495
CONTRACEPTIVES, INTRAVAGINAL, SYSTEMIC					STC = 9654
INTRA-UTERINE DEVICES (IUD'S)					STC = 4730
CONTRACEPTIVES, INJECTABLE					STC = 4139
CONTRACEPTIVES, IMPLANTABLE					STC = 3669
CONTRACEPTIVE, INTRAVAGINAL				GPI-10 (5530001000)	STC = 0249
DIAPHRAGMS/CERVICAL CAP				GPI-10 (9740208000) (9740181000) (9740201000)	STC = 3322

**GUIDELINES FOR USE**

1. Is the patient requesting a cost share exception for the requested contraceptive agent **AND** does the plan cover contraceptives at zero cost share (i.e., the plan follows Affordable Care Act [ACA] recommendations and is linked to MediImpact's Essential Health Benefit Tables)?

If yes, continue to #2.  
If no, guideline does not apply.

2. Does **ANY** of the following criteria apply?
  - The patient's plan has specific procedures, instructions, and/or policies for cost share exception processes or for multi-source brand agent overrides (DAW1 override)
  - The request is for an agent with an excluded route of administration, such that the agent will be covered on the medical benefit

If yes, guideline does not apply.  
If no, continue to #3.

3. Is the request for a generic contraceptive agent?

If yes, continue to #6.  
If no, continue to #4.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CONTRACEPTIVE ZERO COST SHARE OVERRIDE

GUIDELINE FOR USE (CONTINUED)

4. Is the request for ONE of the following?

- A single-source brand (SSB) contraceptive agent that has no preferred generic agents or therapeutically equivalent products available
- A multi-source brand (MSB) contraceptive agent

If yes, continue to #5.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

5. Does the patient meet ONE of the following criteria?

- Two preferred medications are medically inappropriate for the patient (alternatively, one if only one agent is available)
- The patient has tried or has a documented medical contraindication to two preferred medications (alternatively, a trial of one if only one agent is available)
- The prescriber provided documentation confirming that requested drug is considered as medically necessary (considerations may include severity of side effects, differences in permanence and reversibility of contraceptives, and ability to adhere to the appropriate use of the item or service)

If yes, continue to #6.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

6. Does the requested medication also require step therapy? (**NOTE:** Analyze the claim to determine if it also rejects for step therapy)

If yes, continue to #7.

If no, **approve the requested agent for 12 months by GPID or GPI-14 at zero copay. (Note: If the claim also rejects for exceeds quantity limit, please review for a quantity limit exception)**

**APPROVAL TEXT (applicable to multi-source brand agents only):** Although your cost share has been reduced to zero-dollar, you may incur a dispense-as-written (DAW) penalty fee if you choose to fill a brand prescription instead of its generic equivalent.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CONTRACEPTIVE ZERO COST SHARE OVERRIDE

GUIDELINE FOR USE (CONTINUED)

7. Has the patient met the step therapy requirement? (**NOTE:** Analyze the claim to determine step therapy agents)

If yes, **approve the requested agent for 12 months by GPID or GPI-14 at zero copay and also override the step restriction. (Note: If the claim also rejects for exceeds quantity limit, please review for a quantity limit exception)**

**APPROVAL TEXT (applicable to multi-source brand agents only):** Although your cost share has been reduced to zero-dollar, you may incur a dispense-as-written (DAW) penalty fee if you choose to fill a brand prescription instead of its generic equivalent.

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **CONTRACEPTIVE ZERO COST SHARE OVERRIDE** requires that the following rules be met for approval:

- A. The request is for ONE of the following:
1. A generic contraceptive agent
  2. A single-source brand (SSB) contraceptive agent that has no preferred generic agents or therapeutically equivalent products available
  3. A multi-source brand (MSB) contraceptive agent
- B. Approval may also require that you have tried preferred agent(s), unless you have a contraindication (harmful for). (**NOTE TO REVIEWER:** Provide the list of the preferred medication(s))
- C. **If the request is for a single-source brand or multi-source brand contraceptive medication, approval also requires ONE of the following:**
1. Two preferred medications are medically inappropriate for you (or one if only one agent is available)
  2. You have tried or have a documented medical contraindication (harmful for) to two preferred medications (or one if only one agent is available)
  3. Your doctor has provided documentation confirming that the requested drug is considered medically necessary for you (considerations may include severity of side effects, differences in durability and reversibility of contraceptive and ability to adhere to the appropriate use)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CONTRACEPTIVE ZERO COST SHARE OVERRIDE

**RATIONALE**

This guideline applies to plans where the pharmacy benefit allows for coverage of contraceptives at zero copay. The override criteria allow patient access to all FDA-approved contraceptive methods at zero copay by waiving the applicable cost-sharing for branded or non-preferred branded contraceptives.

The MedImpact standard Zero Copay list currently offers coverage of all methods at zero cost share. The zero cost share list offers a variety of contraceptives. Covered methods (zero cost share) include 1) specified barrier contraceptives (condoms, diaphragms, cervical caps, and nonoxynol-9) 2) generic oral hormonal contraceptives under STC 0248, including generic emergency contraceptives and Ella 3) generic transdermal patch contraceptive (currently marketed by Mylan as Xulane) 4) Nuvaring vaginal ring 5) Intrauterine devices – levonorgestrel IUDs and copper IUDs 6) Depo-Provera injections and 7) Nexplanon implant devices. The majority of the contraceptives on the EHB Zero cost share list are generic agents, which promotes a cost-effective formulary.

The healthcare.gov website (<https://www.healthcare.gov/coverage/birth-control-benefits/>) currently recommends: All approved contraceptive methods prescribed by a woman’s doctor are covered, including:

- Barrier methods (used during intercourse), like diaphragms and sponges
- Hormonal methods, like birth control pills and vaginal rings
- Implanted devices, like intrauterine devices (IUDs)
- Emergency contraception, like Plan B® and Ella®
- Sterilization procedures
- Patient education and counseling

**REFERENCES**

- Birth control benefits; <https://www.healthcare.gov/coverage/birth-control-benefits/>
- FAQs about Affordable Care Act Implementation Part XII; <http://www.dol.gov/ebsa/faqs/faq-aca12.html>
- FAQ about Affordable Care Act Implementation (Part XXVI); <http://www.dol.gov/ebsa/faqs/faq-aca26.html>

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/22

Created: 04/15

Client Approval: 05/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CORTICOTROPIN

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
CORTICOTROPIN	ACTHAR , CORTROPHIN	02830		GPI-10 (3030001000)	FDB: ROUTE = INJECTION

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of infantile spasms and meet the following criterion?
  - The patient is less than 2 years of age

If yes, **approve for 28 days by HICL or GPI-10 with a maximum of #8 vials (each 5mL vial contains 400 units).**

If no, continue to #2.

2. Is the request for any other indications other than infantile spasms?

If yes, do not approve. See note and use denial text below.

**Note: Off-label guideline should not be used for Acthar because it hasn't demonstrated proven benefits in the other indications and has no proven advantage over synthetic steroids. Therefore, there isn't a pathway to approval for any other listed indications.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **CORTICOTROPIN (Acthar, Cortrophin)** requires the following rule(s) be met for approval:

- A. You have infantile spasms (type of seizure disorder in young children)
- B. You are less than 2 years of age

Acthar will not be approved for any other indications other than infantile spasms. Acthar has not demonstrated proven benefits or advantage over synthetic steroids in the treatment of other indications.

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**CORTICOTROPIN**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Acthar.

**REFERENCES**

- Acthar Gel [Prescribing Information]. Bedminster, NJ: Mallinckrodt ARD LLC; April 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/23

Created: 11/07

Client Approval: 11/22

P&T Approval: 04/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CRIZOTINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
CRIZOTINIB	XALKORI	37916		GPI-10 (2153051700)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of metastatic non-small cell lung cancer (NSCLC) and meet **ONE** of the following criteria?
  - The patient's tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test
  - The patient's tumors are ROS1-positive as detected by an FDA-approved test

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.**  
If no, continue to #2.

2. Does the patient have a diagnosis of relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) and meet **ALL** of the following criteria?
  - The patient is 1 year of age or older
  - The patient's tumors are anaplastic lymphoma kinase (ALK)-positive

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**  
If no, continue to #3.

3. Does the patient have a diagnosis of unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) and meet **ALL** of the following criteria?
  - The patient is 1 year of age or older
  - The patient's tumors are anaplastic lymphoma kinase (ALK)-positive

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **CRIZOTINIB (Xalkori)** requires the following rule(s) be met for approval:

A. You have **ONE** of the following diagnoses:

1. Metastatic non-small cell lung cancer (NSCLC: type of lung cancer that has spread to other parts of the body)
2. Relapsed (disease that has returned) or refractory (disease does not respond to treatment), systemic anaplastic large cell lymphoma (ALCL: type of blood cell cancer)
3. Unresectable (unable to remove by surgery), recurrent, or refractory (disease does not respond to treatment) inflammatory myofibroblastic tumor (IMT: a rare type of tumor)

***(Denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CRIZOTINIB

GUIDELINES FOR USE (CONTINUED)

- B. **If you have metastatic non-small cell lung cancer, approval also requires:**
  - 1. Your tumors are anaplastic lymphoma kinase (ALK: a type of enzyme)-positive or ROS1 (a type of gene)-positive as detected by a Food and Drug Administration (FDA)-approved test
- C. **If you have relapsed or refractory systemic anaplastic large cell lymphoma, approval also requires:**
  - 1. You are 1 year of age or older
  - 2. Your tumors are anaplastic lymphoma kinase (ALK: a type of enzyme)-positive
- D. **If you have unresectable, recurrent, or refractory inflammatory myofibroblastic tumor, approval also requires:**
  - 1. You are 1 year of age or older
  - 2. Your tumors are anaplastic lymphoma kinase (ALK: a type of enzyme)-positive

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Xalkori.

**REFERENCE**

- Xalkori [Prescribing Information]. New York, New York: Pfizer; July 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 08/29/22

Created: 09/11

Client Approval: 07/22

P&T Approval: 10/22



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**CYCLOSPORINE**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
CYCLOSPORINE	VERKAZIA		46848	GPI-14 (86720020001630)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of vernal keratoconjunctivitis **AND** meet the following criterion?

- The patient had a trial of or contraindication to TWO ophthalmic dual-acting mast cell stabilizer/antihistamines (e.g., ketotifen) or mast cell stabilizers (e.g., cromolyn)

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #4 vials per day.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **CYCLOSPORINE (Verkazia)** requires the following rule(s) be met for approval:

- A. You have vernal keratoconjunctivitis (allergic eye disease)
- B. You had a trial of or contraindication (harmful for) to TWO ophthalmic dual-acting mast cell stabilizer/antihistamines (such as ketotifen) or mast cell stabilizers (such as cromolyn)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Verkazia.

**REFERENCES**

- Verkazia [Prescribing Information]. Emeryville, CA: Santen Inc.; June 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/01/22

Created: 08/22

Client Approval: 09/22

P&T Approval: 07/22



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**CYSTEAMINE BITARTRATE**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
CYSTEAMINE BITARTRATE	PROCYSBI		34656 34657 47723 47724	GPI-14 (56400030106520) (56400030106530) (56400030103020) (56400030103040)	

**GUIDELINES FOR USE**

- Does the patient have a diagnosis of nephropathic cystinosis and meet **ALL** of the following criteria?
  - The patient is 1 year of age or older
  - The patient has previously tried an immediate-release formulation of cysteamine bitartrate such as Cystagon

If yes, **approve for 12 months by GPID or GPI-14 for all strengths.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **CYSTEAMINE BITARTRATE (Procysbi)** requires the following rule(s) be met for approval:

- You have nephropathic cystinosis (rare genetic, metabolic disease which results in an abnormal accumulation of a protein known as cysteine)
- You are 1 year of age or older
- You have previously tried an immediate-release formulation of cysteamine bitartrate such as Cystagon

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Procysbi.

**REFERENCES**

- Procysbi [Prescribing Information]. Novato, CA: Raptor Pharmaceuticals Inc.; February 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 08/13

Client Approval: 04/20

P&T Approval: 11/15

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CYSTEAMINE HYDROCHLORIDE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
CYSTEAMINE HCL	CYSTARAN, CYSTADROPS		33485 40466	GPI-10 (8680552510)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of cystinosis?

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient require treatment for corneal cystine crystal accumulation or deposits?

If yes, **approve the requested drug for 12 months by GPID or GPI-14 with a quantity limit as follows:**

- **Cystaran: #60mL(4 bottles) per 28 days.**
- **Cystadrops: #20mL (4 bottles) per 28 days.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **CYSTEAMINE HYDROCHLORIDE (Cystaran/Cystadrops)** requires the following rule(s) be met for approval:

- A. You have cystinosis (a type of genetic disorder where a substance called cysteine builds up in body organs)
- B. You require treatment for corneal cystine crystal accumulation or deposits (build up of cysteine in the eye)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**





**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**CYSTEAMINE HYDROCHLORIDE**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Cystaran/Cystadrops.

**REFERENCES**

- Cystaran [Prescribing Information]. Gaithersburg, MD: Leadiant Biosciences, Inc.; May 2018.
- Cystadrops [Prescribing Information]. Lebanon, NJ: Recordati Rare Diseases Inc.; August 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/01/20

Created: 05/13

Client Approval: 09/20

P&T Approval: 05/13



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DABRAFENIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
DABRAFENIB MESYLATE	TAFINLAR	40360		GPI-10 (2153202510)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of unresectable or metastatic melanoma and meet **ONE** of the following criteria?

- The patient has BRAF V600E mutation as detected by an FDA-approved test AND the requested medication will be used as a single agent
- The patient has BRAF V600E or V600K mutations as detected by an FDA-approved test AND the requested medication will be used in combination with Mekinist (trametinib)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**  
If no, continue to #2.

2. Does the patient have a diagnosis of melanoma and meet **ALL** of the following criteria?

- The patient has BRAF V600E or V600K mutations as detected by an FDA-approved test
- The requested medication has not previously been used for more than one year
- The requested medication will be used in combination with Mekinist (trametinib) for adjuvant treatment
- There is involvement of lymph node(s) following complete resection

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**  
If no, continue to #3.

3. Does the patient have a diagnosis of metastatic non-small cell lung cancer (NSCLC) and meet **ALL** of the following criteria?

- The patient has BRAF V600E mutation as detected by an FDA-approved test
- The requested medication will be used in combination with Mekinist (trametinib)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**  
If no, continue to #4.

4. Does the patient have a diagnosis of locally advanced or metastatic anaplastic thyroid cancer (ATC) and meet **ALL** of the following criteria?

- The patient has BRAF V600E mutation
- The requested medication will be used in combination with Mekinist (trametinib)
- The patient has no satisfactory locoregional treatment options available

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**  
If no, continue to #5.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DABRAFENIB

GUIDELINES FOR USE (CONTINUED)

5. Does the patient have a diagnosis of unresectable or metastatic solid tumors and meet **ALL** of the following criteria?

- The patient is 6 years of age or older
- The patient has BRAF V600E mutation
- The requested medication will be used in combination with Mekinist (trametinib)
- The patient has progressed following prior treatment and have no satisfactory alternative treatment options

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DABRAFENIB (Tafinlar)** requires the following rule(s) be met for approval:

A. You have **ONE** of the following diagnoses:

1. Unresectable or metastatic melanoma (skin cancer that cannot be completely removed by surgery or has spread to other parts of the body)
2. Metastatic non-small cell lung cancer (NSCLC: type of lung cancer that has spread to other parts of the body)
3. Melanoma (a type of skin cancer)
4. Locally advanced or metastatic anaplastic thyroid cancer (ATC: a type of thyroid cancer that has spread from where it started to nearby tissue or lymph nodes, or it has spread to other parts of the body)
5. Unresectable or metastatic solid tumors (tumors that cannot be completely removed by surgery or has spread to other parts of the body)

B. **If you have unresectable or metastatic melanoma, approval also requires ONE of the following:**

1. You have BRAF V600E mutation (type of gene mutation) as detected by an FDA (Food and Drug Administration)-approved test **AND** the requested medication will be used as a single agent (by itself)
2. You have BRAF V600E or V600K mutations (types of gene mutation) as detected by an FDA (Food and Drug Administration)-approved test **AND** the requested medication will be used in combination with Mekinist (trametinib)

***(Denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DABRAFENIB

GUIDELINES FOR USE (CONTINUED)

- C. **If you have melanoma, approval also requires:**
  1. You have BRAF V600E or V600K mutations (types of gene mutation) as detected by an FDA (Food and Drug Administration)-approved test
  2. The requested medication has not previously been used for more than one year
  3. The requested medication will be used in combination with Mekinist (trametinib) for adjuvant (add-on) treatment
  4. There is involvement of lymph node(s) following complete resection (removal by surgery)
- D. **If you have metastatic non-small cell lung cancer, approval also requires:**
  1. You have BRAF V600E mutation (types of gene mutation) as detected by an FDA (Food and Drug Administration)-approved test
  2. The requested medication will be used in combination with Mekinist (trametinib)
- E. **If you have locally advanced or metastatic anaplastic thyroid cancer, approval also requires:**
  1. You have BRAF V600E mutation (types of gene mutation)
  2. The requested medication will be used in combination with Mekinist (trametinib)
  3. You have no satisfactory locoregional (restricted to a localized region of the body) treatment options available
- F. **If you have unresectable or metastatic solid tumors, approval also requires:**
  1. You are 6 years of age or older
  2. You have a BRAF V600E mutation (type of gene mutation)
  3. The requested medication will be used in combination with Mekinist (trametinib)
  4. You have progressed following prior treatment and have no satisfactory alternative treatment options

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Tafinlar.

**REFERENCES**

- Tafinlar [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; June 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/25/22

Created: 06/13

Client Approval: 07/22

P&T Approval: 07/18

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DACLATASVIR

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
DACLATASVIR DIHYDROCHLORIDE	DAKLINZA	41377		GPI-10 (1235302510)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of hepatitis C, genotype 1 or genotype 3 infection and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- There is evidence of current HCV infection and chronic HCV infection documented by at least ONE detectable HCV RNA level within the past 6 months
- The patient is 1) without cirrhosis or 2) has decompensated cirrhosis or 3) post-liver transplant patient (with or without cirrhosis)
- The request is for Daklinza in combination with Sovaldi

**CLINICAL PHARMACIST:** Patient must also meet all criteria in Sovaldi guideline to be approvable for both agents. Review hepatitis C MRF and Sovaldi request to ensure patient meets criteria for both agents.

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient meet **ONE** of the following criteria?

- The patient has a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions (e.g., physician attestation)
- The patient is concurrently taking the following medications:
  - For Daklinza: amiodarone, carbamazepine, phenytoin, or rifampin **OR**
  - For Sovaldi: phenobarbital, oxcarbazepine, rifabutin, rifapentine, or tipranavir/ritonavir

If yes, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

If no, continue to #3.

3. Does the patient meet **ONE** of the following?

- The patient is decompensated cirrhosis (moderate or severe hepatitis impairment (Child-Pugh B or C))
- The patient is post-liver transplant (with or without cirrhosis)

If yes, continue to #4.

If no, continue to #6.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DACLATASVIR

GUIDELINES FOR USE (CONTINUED)

4. Is the request for triple therapy using Daklinza/Sovaldi **WITH** ribavirin?

If yes, continue to #5.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

5. Does the patient meet **ONE** of the following criteria for the patient type? [**NOTE:** An individual who has completed a full course of therapy with Mavyret, Harvoni or Epclusa that did not achieve SVR will not be approved]

- Genotype 1, decompensated cirrhosis: short trial of Harvoni or Epclusa OR contraindication to Harvoni and Epclusa
- Genotype 1, post-liver transplant: short trial of Harvoni or Mavyret OR contraindication to Harvoni and Mavyret
- Genotype 3, decompensated cirrhosis short trial of or contraindication to Epclusa
- Genotype 3, post-liver transplant WITHOUT cirrhosis: short trial of or contraindication to Mavyret
- Genotype 3, post-liver transplant with compensated cirrhosis: short trial of Epclusa or Mavyret OR contraindication to Epclusa and Mavyret

If yes, continue to #7.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

6. Does the patient meet **ONE** of the following criteria? [**NOTE:** An individual who has completed a full course of therapy with Mavyret, Harvoni or Epclusa that did not achieve SVR will not be approved]

- Genotype 1, without cirrhosis: treatment naïve or treatment experienced with a peginterferon and ribavirin regimen AND a short trial of Epclusa, Harvoni or Mavyret OR a contraindication Epclusa, Harvoni and Mavyret
- Genotype 3, without cirrhosis: treatment naïve or treatment experienced with a peginterferon and ribavirin regimen AND a short trial of Epclusa or Mavyret OR a contraindication to Epclusa and Mavyret

If yes, continue to #7.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DACLATASVIR

GUIDELINES FOR USE (CONTINUED)

7. Is the patient using any of the following moderate CYP3A inducers while taking Daklinza in combination with Sovaldi: rifapentine, bosentan, dexamethasone, efavirenz, etravirine, modafinil, nafcillin, or nevirapine?

**CLINICAL PHARMACIST:** Patient is on combination therapy with Sovaldi; please also review Sovaldi prior authorization guideline, member history, and hepatitis C MRF, if available to ensure appropriate length of approval and that the patient also meets approval for Sovaldi.

If yes, **approve Daklinza 90mg strength for 12 weeks by GPID or GPI-14 with a quantity limit of #1 tablet per day. (NOTE: 90mg tablet used for drug interactions listed above)**

If no, continue to #8.

8. Is the patient concurrently using any of the following with Daklinza?
- HIV protease inhibitors (atazanavir with ritonavir, indinavir, nelfinavir, saquinavir)
  - A cobicistat-containing regimen (exception: darunavir/cobicistat does not require Daklinza 30mg dose), such as atazanavir/cobicistat, elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate, or other cobicistat-containing regimen
  - Strong CYP3A inhibitors, such as clarithromycin, itraconazole, ketoconazole, nefazodone, posaconazole, telithromycin, or voriconazole

If yes, **approve Daklinza 30mg strength for 12 weeks by GPID or GPI-14 with a quantity limit of #1 tablet per day. (NOTE: 30mg tablet used for drug interactions listed above)**

If no, **approve Daklinza 60mg strength for 12 weeks by GPID or GPI-14 with a quantity limit of #1 tablet per day.**

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DACLATASVIR (Daklinza)** requires the following rule(s) be met for approval:

- A. You have hepatitis C, with genotype 1 or genotype 3 infection
- B. You are 18 years of age or older
- C. You have documentation showing at least ONE detectable HCV (hepatitis C virus) RNA level (amount of virus in your blood) within the past 6 months as evidence of a current and chronic HCV infection.
- D. You must be taking Daklinza in combination with Sovaldi, and must meet all required criteria for Sovaldi

***(Denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DACLATASVIR

GUIDELINES FOR USE (CONTINUED)

**E. For Genotype 1 infection approval also requires:**

1. Patients without cirrhosis (liver scarring):
  - a. You are treatment naïve (never previously treated) or treatment experienced with a peginterferon and ribavirin regimen
  - b. You have previously tried Epclusa, Harvoni or Mavyret required and you had adverse effects, intolerance early in therapy or contraindication to (medical reason why you cannot use) Epclusa, Harvoni and Mavyret; [an individual who has completed a full course of therapy that did not achieve SVR (sustained virological response) will not be approved]
2. Patients with decompensated cirrhosis (you have symptoms related to liver scarring):
  - a. You have previously tried Epclusa or Harvoni and you had adverse effects, intolerance early in therapy, or contraindication to (medical reason why you cannot use) Epclusa and Harvoni; [an individual who has completed a full course of therapy that did not achieve SVR (sustained virological response) will not be approved]
  - b. Concurrent (used at the same time with) ribavirin use required
3. Patients status post liver transplant:
  - a. You have previously tried Harvoni or Mavyret and you had adverse effects, intolerance early in therapy, or contraindication to (medical reason why you cannot use) Harvoni and Mavyret; [an individual who has completed a full course of therapy that did not achieve SVR (sustained virological response) will not be approved]
  - b. Concurrent (used at the same time with) ribavirin use required

**F. For Genotype 3 infection approval also requires:**

1. Patients without cirrhosis:
  - a. You are treatment naïve (never previously treated) or treatment experienced with a peginterferon and ribavirin regimen
  - b. You have previously tried Epclusa or Mavyret and you had adverse effect, intolerance early in therapy, or contraindication to (medical reason why you cannot use) Epclusa and Mavyret; [an individual who has completed a full course of therapy that did not achieve SVR (sustained virological response) will not be approved]
2. Patients with decompensated cirrhosis (Child-Pugh B or C; you have symptoms related to liver scarring):
  - a. You have previously tried Epclusa and you had adverse effect, intolerance early in therapy, or contraindication to (medical reason why you cannot use) therapy; [an individual who has completed a full course of therapy that did not achieve SVR (sustained virologic response) will not be approved]
  - b. Concurrent (used at the same time with) ribavirin use required

**(Denial text continued on next page)**

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DACLATASVIR

GUIDELINES FOR USE (CONTINUED)

- 3. Post-liver transplant, without cirrhosis:
  - a. Previous trial of Mavyret required and you had adverse effects, intolerance early in therapy, or contraindication to (medical reason why you cannot use) therapy; [an individual who has completed a full course of therapy that did not achieve SVR (sustained virologic response) will not be approved]
  - b. Concurrent (used at the same time with) ribavirin use required
- 4. Post-liver transplant, with compensated cirrhosis
  - a. Previous trial of Epclusa or Mavyret required and you had adverse effects, intolerance early in therapy or contraindication to (medical reason why you cannot use) Epclusa and Mavyret; [an individual who has completed a full course of therapy that did not achieve SVR (sustained virologic response) will not be approved]
  - b. Concurrent (used at the same time with) ribavirin use required

**Daklinza will not be approved if you meet ANY of the following:**

- You are using any of the following medications at the same time while on Daklinza: amiodarone, carbamazepine, phenytoin, or rifampin
- You are using any of the following medications at the same time while on Sovaldi: phenobarbital, oxcarbazepine, rifabutin, rifapentine, or tipranavir/ritonavir
- You have a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions (having two or more diseases at the same time)
- You have compensated cirrhosis (Child-Pugh A; you have no symptoms related to liver damage) and are not status post liver transplant (you have not had a liver transplant)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Daklinza.

**REFERENCES**

- Daklinza [Prescribing Information]. Princeton, NJ: Bristol Myers Squibb; February 2017.
- Guidance from the American Association for the Study of Liver Diseases (AASLD) and the Infectious Disease Society of America (IDSA) Recommendations for Testing, Managing, and Treating hepatitis C. Available online at <http://www.hcvguidelines.org/full-report-view> Accessed July 26, 2016.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Created: 08/15

Commercial Effective: 01/01/23

Client Approval: 11/22

P&T Approval: 10/17

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DACOMITINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
DACOMITINIB	VIZIMPRO	45283		GPI-10 (2136001900)	

GUIDELINES FOR USE

1. Does the patient have a diagnosis of metastatic non-small cell lung cancer (NSCLC) and meet **ALL** of the following criteria?
  - The patient has epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test
  - Vizimpro will be used as first-line treatment
  - Vizimpro will NOT be used concurrently with an epidermal growth factor receptor (EGFR) tyrosine kinase-inhibitor (e.g., Tarceva [erlotinib], Tagrisso [osimertinib], Iressa [gefitinib])

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DACOMITINIB (Vizimpro)** requires the following rule(s) be met for approval:

- A. You have metastatic non-small cell lung cancer (type of cancer that has spread) to other parts of the body)
- B. You have epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations (types of gene mutations) as detected by an FDA (Food and Drug Administration)-approved test
- C. Vizimpro will be used as first-line treatment
- D. You will NOT be using Vizimpro concurrently (at the same time) with an epidermal growth factor receptor (EGFR) tyrosine kinase-inhibitor (such as Tarceva [erlotinib], Tagrisso [osimertinib], Iressa [gefitinib])

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**DACOMITINIB**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Vizimpro.

**REFERENCES**

- Vizimpro [Prescribing Information]. New York, NY: Pfizer Labs; December 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/22

Created: 11/18

Client Approval: 05/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DALFAMPRIDINE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
DALFAMPRIDINE	AMPYRA, DALFAMPRIDINE ER	13907		GPI-10 (6240603000)	FDB: ROUTE ≠ MISCELL.

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

- Does the patient have a diagnosis of multiple sclerosis (MS) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a neurologist
  - The patient has symptoms of a walking disability such as mild to moderate bilateral lower extremity weakness or unilateral weakness plus lower extremity or truncal ataxia

If yes, **approve for 3 months by HICL or GPI-10 for #2 tablets per day.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DALFAMPRIDINE (Ampyra)** requires the following rule(s) be met for approval:

- You have multiple sclerosis (MS: a type of nerve disorder)
- You are 18 years of age or older
- Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor)
- You have symptoms of a walking disability such as mild to moderate bilateral (both sides) lower extremity weakness or unilateral (one side) weakness plus lower extremity or truncal ataxia (impaired balance or coordination)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DALFAMPRIDINE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

- Does the patient have a diagnosis of multiple sclerosis (MS) **AND** meet the following criterion?
  - The patient has experienced or maintained at least a 15% improvement in walking ability

If yes, **approve for 12 months by HICL or GPI-10 for #2 tablets per day.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DALFAMPRIDINE (Ampyra)** requires the following rule(s) be met for renewal:

- You have multiple sclerosis (MS: a type of nerve disorder)
- You have experienced or maintained at least a 15% improvement in walking ability

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Ampyra.

**REFERENCES**

- Ampyra [Prescribing Information]. Ardsley, NY: Acorda Therapeutics; November 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 08/29/22

Created: 02/10

Client Approval: 07/22

P&T Approval: 07/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DARBEPOETIN ALFA

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
DARBEPOETIN ALFA IN POLYSORBAT	ARANESP	22890		GPI-10 (8240101510)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of anemia associated with chronic kidney disease (CKD) and meet **ALL** of the following criteria?
  - The patient had a trial of the preferred agent: Retacrit
  - The patient has a hemoglobin level of less than 10g/dL

If yes, approve for 12 months by GPID or GPI-14 for the requested strength as follows:

- 25mcg/mL vial: #4mL per 28 days.
- 40mcg/mL vial: #4mL per 28 days.
- 60mcg/mL vial: #4mL per 28 days.
- 100mcg/mL vial: #4mL per 28 days.
- 200mcg/mL vial: #4mL per 28 days.
- 300mcg/mL vial: #4mL per 28 days.
- 10mcg/0.4mL syringe: #1.6mL per 28 days.
- 25mcg/0.42mL syringe: #1.68mL per 28 days.
- 40mcg/0.4mL syringe: #1.6mL per 28 days.
- 60mcg/0.3mL syringe: #1.2mL per 28 days.
- 100mcg/0.5mL syringe: #2mL per 28 days.
- 150mcg/0.3mL syringe: #1.2mL per 28 days.
- 200mcg/0.4mL syringe: #1.6mL per 28 days.
- 300mcg/0.6mL syringe: #2.4mL per 28 days.
- 500mcg/mL syringe: #4mL per 28 days.

If no, continue to #2.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DARBEPOETIN ALFA

INITIAL CRITERIA (CONTINUED)

2. Does the patient have a diagnosis of anemia due to the effect of concomitantly administered cancer chemotherapy and meet **ALL** of the following criteria?
- The patient had a trial of the preferred agent: Retacrit
  - The patient has a hemoglobin level of less than 11g/dL OR the patient's hemoglobin level has decreased at least 2g/dL below baseline level

If yes, approve for 12 months by GPID or GPI-14 for the requested strength as follows:

- 25mcg/mL vial: #4mL per 28 days.
- 40mcg/mL vial: #4mL per 28 days.
- 60mcg/mL vial: #4mL per 28 days.
- 100mcg/mL vial: #4mL per 28 days.
- 200mcg/mL vial: #4mL per 28 days.
- 300mcg/mL vial: #4mL per 28 days.
- 10mcg/0.4mL syringe: #1.6mL per 28 days.
- 25mcg/0.42mL syringe: #1.68mL per 28 days.
- 40mcg/0.4mL syringe: #1.6mL per 28 days.
- 60mcg/0.3mL syringe: #1.2mL per 28 days.
- 100mcg/0.5mL syringe: #2mL per 28 days.
- 150mcg/0.3mL syringe: #1.2mL per 28 days.
- 200mcg/0.4mL syringe: #1.6mL per 28 days.
- 300mcg/0.6mL syringe: #2.4mL per 28 days.
- 500mcg/mL syringe: #4mL per 28 days.

If no, continue to #3.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DARBEPOETIN ALFA

INITIAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of anemia due to concurrent hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa and meet **ALL** of the following criteria?
- The patient had a trial of the preferred agent: Retacrit
  - The patient has a hemoglobin level of less than 10g/dL
  - The patient had a trial of or contraindication to ribavirin dose reduction

If yes, **approve for 6 months by GPID or GPI-14 for the requested strength as follows:**

- **25mcg/mL vial: #4mL per 28 days.**
- **40mcg/mL vial: #4mL per 28 days.**
- **60mcg/mL vial: #4mL per 28 days.**
- **100mcg/mL vial: #4mL per 28 days.**
- **200mcg/mL vial: #4mL per 28 days.**
- **300mcg/mL vial: #4mL per 28 days.**
- **10mcg/0.4mL syringe: #1.6mL per 28 days.**
- **25mcg/0.42mL syringe: #1.68mL per 28 days.**
- **40mcg/0.4mL syringe: #1.6mL per 28 days.**
- **60mcg/0.3mL syringe: #1.2mL per 28 days.**
- **100mcg/0.5mL syringe: #2mL per 28 days.**
- **150mcg/0.3mL syringe: #1.2mL per 28 days.**
- **200mcg/0.4mL syringe: #1.6mL per 28 days.**
- **300mcg/0.6mL syringe: #2.4mL per 28 days.**
- **500mcg/mL syringe: #4mL per 28 days.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DARBEPOETIN ALFA

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DARBEPOETIN ALFA (Aranesp)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
  - 1. Anemia (low amount of healthy red blood cells) associated with chronic kidney disease
  - 2. Anemia due to the effects of concomitantly administered (given at the same time) cancer chemotherapy
  - 3. Anemia due to hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa
- B. **If you have anemia associated with chronic kidney disease, approval also requires:**
  - 1. You have tried the preferred medication: Retacrit
  - 2. You have a hemoglobin level (type of blood test) of less than 10g/dL
- C. **If you have anemia due to the effect of concomitantly administered cancer chemotherapy, approval also requires:**
  - 1. You have tried the preferred medication: Retacrit
  - 2. You have a hemoglobin level of less than 11g/dL OR your hemoglobin level has decreased at least 2g/dL below your baseline level
- D. **If you have anemia due to concurrent hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa, approval also requires:**
  - 1. You have tried the preferred medication: Retacrit
  - 2. You have tried or have a contraindication (harmful for) to a lower ribavirin dose
  - 3. You have a hemoglobin level of less than 10g/dL

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DARBEPOETIN ALFA

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of anemia associated with chronic kidney disease (CKD) and meet **ONE** of the following criteria?

- The patient has a hemoglobin level of less than 10g/dL if not on dialysis
- The patient has a hemoglobin level of less than 11g/dL if on dialysis
- The patient has a hemoglobin level that has reached 10g/dL (if not on dialysis) and dose reduction/interruption is required to reduce the need for blood transfusions
- The patient has a hemoglobin level that has reached 11g/dL (if on dialysis) and dose reduction/interruption is required to reduce the need for blood transfusions

If yes, approve for 12 months by GPID or GPI-14 for the requested strength as follows:

- 25mcg/mL vial: #4mL per 28 days.
- 40mcg/mL vial: #4mL per 28 days.
- 60mcg/mL vial: #4mL per 28 days.
- 100mcg/mL vial: #4mL per 28 days.
- 200mcg/mL vial: #4mL per 28 days.
- 300mcg/mL vial: #4mL per 28 days.
- 10mcg/0.4mL syringe: #1.6mL per 28 days.
- 25mcg/0.42mL syringe: #1.68mL per 28 days.
- 40mcg/0.4mL syringe: #1.6mL per 28 days.
- 60mcg/0.3mL syringe: #1.2mL per 28 days.
- 100mcg/0.5mL syringe: #2mL per 28 days.
- 150mcg/0.3mL syringe: #1.2mL per 28 days.
- 200mcg/0.4mL syringe: #1.6mL per 28 days.
- 300mcg/0.6mL syringe: #2.4mL per 28 days.
- 500mcg/mL syringe: #4mL per 28 days.

If no, continue to #2.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DARBEPOETIN ALFA

RENEWAL CRITERIA (CONTINUED)

2. Does the patient have a diagnosis of anemia due to the effects of concomitantly administered cancer chemotherapy **AND** meet the following criterion?

- The patient has a hemoglobin level between 10g/dL and 12g/dL

If yes, **approve for 12 months by GPID or GPI-14 for the requested strength as follows:**

- 25mcg/mL vial: #4mL per 28 days.
- 40mcg/mL vial: #4mL per 28 days.
- 60mcg/mL vial: #4mL per 28 days.
- 100mcg/mL vial: #4mL per 28 days.
- 200mcg/mL vial: #4mL per 28 days.
- 300mcg/mL vial: #4mL per 28 days.
- 10mcg/0.4mL syringe: #1.6mL per 28 days.
- 25mcg/0.42mL syringe: #1.68mL per 28 days.
- 40mcg/0.4mL syringe: #1.6mL per 28 days.
- 60mcg/0.3mL syringe: #1.2mL per 28 days.
- 100mcg/0.5mL syringe: #2mL per 28 days.
- 150mcg/0.3mL syringe: #1.2mL per 28 days.
- 200mcg/0.4mL syringe: #1.6mL per 28 days.
- 300mcg/0.6mL syringe: #2.4mL per 28 days.
- 500mcg/mL syringe: #4mL per 28 days.

If no, continue to #3.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DARBEPOETIN ALFA

RENEWAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of anemia due to concurrent hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa **AND** meet the following criterion?
- The patient has a hemoglobin level between 10g/dL and 12g/dL

If yes, **approve for 6 months by GPID or GPI-14 for the requested strength as follows:**

- 25mcg/mL vial: #4mL per 28 days.
- 40mcg/mL vial: #4mL per 28 days.
- 60mcg/mL vial: #4mL per 28 days.
- 100mcg/mL vial: #4mL per 28 days.
- 200mcg/mL vial: #4mL per 28 days.
- 300mcg/mL vial: #4mL per 28 days.
- 10mcg/0.4mL syringe: #1.6mL per 28 days.
- 25mcg/0.42mL syringe: #1.68mL per 28 days.
- 40mcg/0.4mL syringe: #1.6mL per 28 days.
- 60mcg/0.3mL syringe: #1.2mL per 28 days.
- 100mcg/0.5mL syringe: #2mL per 28 days.
- 150mcg/0.3mL syringe: #1.2mL per 28 days.
- 200mcg/0.4mL syringe: #1.6mL per 28 days.
- 300mcg/0.6mL syringe: #2.4mL per 28 days.
- 500mcg/mL syringe: #4mL per 28 days.

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DARBEPOETIN ALFA (Aranesp)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following diagnoses:
1. Anemia (low amount of healthy red blood cells) associated with chronic kidney disease
  2. Anemia due to the effects of concomitantly administered (given at the same time) cancer chemotherapy
  3. Anemia due to hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa

***(Renewal denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DARBEPOETIN ALFA

RENEWAL CRITERIA (CONTINUED)

**B. If you have anemia associated with chronic kidney disease, renewal also requires ONE of the following:**

1. You have a hemoglobin level (type of blood test) of less than 10g/dL if you are not on dialysis (process of removing excess water, toxins from the blood)
2. You have a hemoglobin level of less than 11g/dL if you are on dialysis
3. Your hemoglobin has reached 10g/dL (if you are not on dialysis) and dose reduction/interruption is required to reduce the need for blood transfusions
4. Your hemoglobin has reached 11g/dL (if you are on dialysis) and dose reduction/interruption is required to reduce the need for blood transfusions.

**C. If you have anemia due to the effects of concomitantly administered cancer chemotherapy, renewal also requires:**

1. You have a hemoglobin level between 10g/dL and 12g/dL

**D. If you have anemia due to concurrent hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa, renewal also requires:**

1. You have a hemoglobin level between 10g/dL and 12g/dL

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Aranesp.

**REFERENCES**

- Aranesp [Prescribing Information]. Thousand Oaks, CA: Amgen, January 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 02/06/23

Created: 02/11

Client Approval: 01/23

P&T Approval: 01/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DARIDOREXANT

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
DARIDOREXANT HCL	QUVIVIQ	47751		GPI-10 (6050002010)	

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

- Does the patient have a diagnosis of insomnia and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient has premature awakening and/or abnormal sleep onset delay lasting 30 minutes or longer, occurring 3 or more times weekly for the last month for acute insomnia or for at least 3 months for chronic insomnia
  - The patient has daytime impairment despite adequate time attempting to sleep and treatment of any treatable causes
  - The patient is NOT concurrently using Z hypnotics (e.g., eszopiclone, zaleplon, zolpidem) or benzodiazepines (e.g., estazolam, temazepam, triazolam) for sleep
  - The patient does NOT have narcolepsy
  - The patient had a trial of or contraindication to TWO generic insomnia medications (e.g., eszopiclone, zaleplon, zolpidem) AND Belsomra

If yes, **approve for 3 months by HICL or GPI-10 with a quantity limit of #1 per day.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DARIDOREXANT (Quviviq)** requires the following rule(s) be met for approval:

- You have insomnia (a type of sleep condition)
- You are 18 years of age or older
- You have premature awakening (waking up too early) and/or abnormal sleep onset delay (cannot fall asleep) lasting 30 minutes or longer, occurring 3 or more times weekly for the last month for acute (short-term) insomnia or for at least 3 months for chronic (long-term) insomnia
- You have daytime impairment despite adequate time attempting to sleep and treatment of any treatable causes
- You are NOT using Quviviq at the same time with Z hypnotics (such as eszopiclone, zaleplon, zolpidem) or benzodiazepines (such as estazolam, temazepam, triazolam) for sleep
- You do NOT have narcolepsy (a type of sleep condition)
- You had a trial of or contraindication (harmful for) to TWO generic insomnia medications (such as eszopiclone, zaleplon, zolpidem) AND Belsomra  
**(Initial denial text continued on next page)**

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DARIDOREXANT

INITIAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of insomnia and meet **ALL** of the following criteria?
  - The patient has demonstrated improvement of insomnia symptoms but is not currently a candidate for discontinuation
  - The patient is NOT concurrently using Z hypnotics (e.g., eszopiclone, zaleplon, zolpidem) or benzodiazepines (e.g., estazolam, temazepam, triazolam) for sleep

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #1 per day.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DARIDOREXANT (Quviviq)** requires the following rule(s) be met for renewal:

- A. You have insomnia (a type of sleep condition)
- B. You have demonstrated improvement of insomnia symptoms but are not currently a candidate for discontinuation
- C. You are NOT using Quviviq at the same time with Z hypnotics (such as eszopiclone, zaleplon, zolpidem) or benzodiazepines (such as estazolam, temazepam, triazolam) for sleep

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**DARIDOREXANT**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Quiviviq.

**REFERENCES**

- Quiviviq [Prescribing Information]. Radnor, PA: Idorsia Pharmaceuticals US, Inc.; January 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 05/09/22

Created: 04/22

Client Approval: 04/22

P&T Approval: 10/21





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DAROLUTAMIDE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
DAROLUTAMIDE	NUBEQA	45909		GPI-10 (2140242500)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of non-metastatic castration resistant prostate cancer (nmCRPC) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient has high risk prostate cancer (i.e., rapidly increasing prostate specific antigen [PSA] levels)

If yes, continue to #3.

If no, continue to #2.

2. Does the patient have a diagnosis of metastatic hormone-sensitive prostate cancer (mHSPC) **AND** meet the following criterion?

- The requested medication will be used in combination with docetaxel

If yes, continue to #3.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

3. Does the patient meet **ONE** of the following criteria?

- The patient previously received a bilateral orchiectomy
- The patient has a castrate level of testosterone (i.e., < 50 ng/dL)
- The requested medication will be used concurrently with a gonadotropin releasing hormone (GnRH) analog (e.g., leuprolide, goserelin, histrelin, degarelix)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DAROLUTAMIDE

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DAROLUTAMIDE (Nubeqa)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
  - 1. Non-metastatic castration resistant prostate cancer (nmCRPC: prostate cancer that has not spread to other parts of the body and does not respond to hormone therapy)
  - 2. Metastatic hormone-sensitive prostate cancer (mHSPC: prostate cancer that has spread to other parts of the body and responds to hormone therapy)
- B. You meet ONE of the following:
  - 1. You previously received a bilateral orchiectomy (both testicles have been surgically removed)
  - 2. You have a castrate level of testosterone (your blood testosterone levels are less than 50 ng/dL)
  - 3. The requested medication will be used together with a gonadotropin releasing hormone analog (such as leuprolide, goserelin, histrelin, degarelix)
- C. **If you have non-metastatic castration resistant prostate cancer, approval also requires:**
  - 1. You are 18 years of age or older
  - 2. You have high risk prostate cancer (rapidly increasing prostate specific antigen [PSA: lab result that may indicate prostate cancer] levels)
- D. **If you have metastatic hormone-sensitive prostate cancer, approval also requires:**
  - 1. The requested medication will be used in combination with docetaxel

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

- 1. Does the patient have a diagnosis of non-metastatic castration resistant prostate cancer (nmCRPC)?

If yes, continue to #3.

If no, continue to #2.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DAROLUTAMIDE

RENEWAL CRITERIA (CONTINUED)

2. Does the patient have a diagnosis of metastatic hormone-sensitive prostate cancer (mHSPC) **AND** meet the following criterion?

- The requested medication will be used in combination with docetaxel

If yes, continue to #3.

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

3. Does the patient meet **ONE** of the following criteria?

- The patient previously received a bilateral orchiectomy
- The patient has a castrate level of testosterone (i.e., < 50 ng/dL)
- The requested medication will be used concurrently with a gonadotropin releasing hormone (GnRH) analog (e.g., leuprolide, goserelin, histrelin, degarelix)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**

If no, do not approve.

**RENEWAL DENIAL TEXT:** **\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DAROLUTAMIDE (Nubeqa)** requires the following rule(s) be met for renewal:

A. You have **ONE** of the following diagnoses:

1. Non-metastatic castration resistant prostate cancer (nmCRPC: prostate cancer that has not spread to other parts of the body and does not respond to hormone therapy)
2. Metastatic hormone-sensitive prostate cancer (mHSPC: prostate cancer that has spread to other parts of the body and responds to hormone therapy)

B. You meet **ONE** of the following:

1. You previously received a bilateral orchiectomy (both testicles have been surgically removed)
2. You have a castrate level of testosterone (your blood testosterone levels are less than 50 ng/dL)
3. The requested medication will be used together with a gonadotropin releasing hormone analog (such as leuprolide, goserelin, histrelin, degarelix)

C. **If you have metastatic hormone-sensitive prostate cancer, approval also requires:**

1. The requested medication will be used in combination with docetaxel

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**DAROLUTAMIDE**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Nubeqa.

**REFERENCES**

- Nubeqa [Prescribing Information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; August 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/23

Created: 11/19

Client Approval: 11/22

P&T Approval: 10/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DASATINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
DASATINIB	SPRYCEL	33855		GPI-10 (2153182000)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase and meet **ONE** of the following criteria?

- The patient is 18 years of age or older **AND** is newly diagnosed
- The patient is between 1 and 17 years of age

If yes, approve for all strengths for 12 months by GPID or GPI-14 as follows:

- **SPRYCEL 20MG with a quantity limit of #3 per day.**
- **SPRYCEL 50MG with a quantity limit of #1 per day.**
- **SPRYCEL 70MG with a quantity limit of #1 per day.**
- **SPRYCEL 80MG with a quantity limit of #1 per day.**
- **SPRYCEL 100MG with a quantity limit of #1 per day.**
- **SPRYCEL 140MG with a quantity limit #1 per day.**

If no, continue to #2.

2. Does the patient have a diagnosis of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient is in chronic, accelerated, or myeloid or lymphoid blast phase
- The patient has a resistance or intolerance to prior therapy including imatinib (Gleevec)
- The patient had a mutational analysis prior to initiation AND Sprycel is appropriate per the NCCN guideline table for treatment recommendations based on BCR-ABL1 mutation profile *(Please see header CML-5 of the current NCCN guidelines)*

If yes, approve for all strengths for 12 months by GPID or GPI-14 as follows:

- **SPRYCEL 20MG with a quantity limit of #3 per day.**
- **SPRYCEL 50MG with a quantity limit of #1 per day.**
- **SPRYCEL 70MG with a quantity limit of #1 per day.**
- **SPRYCEL 80MG with a quantity limit of #1 per day.**
- **SPRYCEL 100MG with a quantity limit of #1 per day.**
- **SPRYCEL 140MG with a quantity limit #1 per day.**

If no, continue to #3.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DASATINIB

GUIDELINES FOR USE (CONTINUED)

3. Does the patient have a diagnosis of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) and meet **ALL** of the following criteria?
- The patient is 18 years of age or older
  - The patient has a resistance or intolerance to prior therapy (e.g., imatinib (Gleevec), or nilotinib (Tasigna))

If yes, approve for all strengths for 12 months by GPID or GPI-14 as follows:

- **SPRYCEL 20MG** with a quantity limit of #3 per day.
- **SPRYCEL 50MG** with a quantity limit of #1 per day.
- **SPRYCEL 70MG** with a quantity limit of #1 per day.
- **SPRYCEL 80MG** with a quantity limit of #1 per day.
- **SPRYCEL 100MG** with a quantity limit of #1 per day.
- **SPRYCEL 140MG** with a quantity limit #1 per day.

If no, continue to #4.

4. Does the patient have a diagnosis of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) and meet **ALL** of the following criteria?
- The patient is between 1 and 17 years of age
  - The patient is newly diagnosed
  - The patient is using Sprycel in combination with chemotherapy

If yes, approve for all strengths for 12 months by GPID or GPI-14 as follows:

- **SPRYCEL 20MG** with a quantity limit of #3 per day.
- **SPRYCEL 50MG** with a quantity limit of #1 per day.
- **SPRYCEL 70MG** with a quantity limit of #1 per day.
- **SPRYCEL 80MG** with a quantity limit of #1 per day.
- **SPRYCEL 100MG** with a quantity limit of #1 per day.
- **SPRYCEL 140MG** with a quantity limit #1 per day.

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DASATINIB (Sprycel)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:

1. Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML: a type of blood cancer) in chronic, accelerated, or myeloid or lymphoid blast phase
2. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL: a type of blood cancer)

***(Denial text continued on the next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DASATINIB

GUIDELINES FOR USE (CONTINUED)

- B. **If you have Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, approval also requires ONE of the following:**
  1. You are 18 years of age or older AND are newly diagnosed
  2. You are between 1 and 17 years of age
- C. **If you have Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, accelerated phase, or myeloid or lymphoid blast phase, approval also requires:**
  1. You are 18 years of age or older
  2. You have resistance or intolerance (side effect) to prior therapy including imatinib (Gleevec)
  3. You had a mutational analysis prior to initiation of therapy AND Sprycel is appropriate per the National Comprehensive Cancer Network (NCCN) guideline table for treatment recommendations based on BCR-ABL1 mutation (breakpoint cluster region-Abelson murine leukemia 1; a type of abnormal gene) profile
- D. **If you have Philadelphia chromosome-positive acute lymphoblastic leukemia, approval also requires ONE of the following:**
  1. You are 18 years of age or older AND you have a resistance or intolerance (side effect) to prior therapy such as imatinib (Gleevec) or nilotinib (Tasigna)
  2. You are newly diagnosed, between 1 and 17 years of age, AND using Sprycel in combination with chemotherapy

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Sprycel.

**REFERENCES**

- Sprycel [Prescribing information]. Princeton, NJ: Bristol-Myers Squibb; December 2018.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/22

Created: 05/12

Client Approval: 02/22

P&T Approval: 01/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DECITABINE/CEDAZURIDINE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
DECITABINE/ CEDAZURIDINE	INQOVI	46686		GPI-10 (2199000225)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of myelodysplastic syndromes (MDS) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient has **ONE** of the following International Prognostic Scoring System groups: intermediate-1, intermediate-2, or high-risk

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #5 per 28 days.**  
If no, continue to #2.

2. Does the patient have a diagnosis of chronic myelomonocytic leukemia (CMML) **AND** meet the following criterion?

- The patient is 18 years of age or older

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #5 per 28 days.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DECITABINE/CEDAZURIDINE (Inqovi)** requires the following rule(s) be met for approval:

A. You have **ONE** of the following diagnoses:

1. Myelodysplastic syndromes (MDS: type of blood cancer)
2. Chronic myelomonocytic leukemia (CMML: rare form of blood cancer)

B. You are 18 years of age or older

C. **If you have myelodysplastic syndromes (MDS), approval also requires:**

1. You meet **ONE** of the following International Prognostic Scoring System groups (scoring system used to predict the course of a patient's disease):
  - a. Intermediate-1
  - b. Intermediate-2
  - c. High-risk

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**





**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**DECITABINE/CEDAZURIDINE**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Inqovi.

**REFERENCES**

- Inqovi [Prescribing Information]. Pleasanton, CA: Astex Pharmaceuticals, Inc.; July 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/21

Created: 10/20

Client Approval: 11/20

P&T Approval: 10/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DEFERASIROX

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
DEFERASIROX	EXJADE, JADENU, JADENU SPRINKLE, DEFERASIROX	33337		GPI-10 (9310002500)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Is the request prescribed by or given in consultation with a hematologist or hematologist-oncologist?

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Does the patient have a diagnosis of chronic iron overload due to blood transfusions?

If yes, continue to #3.

If no, continue to #4.

3. Does the patient meet **ALL** of the following criteria?

- The patient is 2 years of age or older
- The patient's serum ferritin levels are consistently greater than 1000mcg/L (at least 2 lab values in the previous 3 months)

If yes, continue to #6.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

4. Does the patient have a diagnosis of chronic iron overload resulting from non-transfusion dependent thalassemia (NTDT)?

If yes, continue to #5.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DEFERASIROX

INITIAL CRITERIA (CONTINUED)

5. Does the patient meet **ALL** of the following criteria?

- The patient is 10 years of age or older
- The patient's serum ferritin levels are consistently greater than 300mcg/L (at least 2 lab values in the previous 3 months)
- The patient's liver iron concentration (LIC) is at least 5mg Fe/g dry weight

If yes, continue to #6.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

6. Is the request for Exjade or Jadenu tablets?

If yes, **approve Exjade or Jadenu tablets for all strengths of the requested drug for 6 months by GPID or GPI-14.**

If no, continue to #7.

7. Is the request for Jadenu sprinkle packets **AND** the patient has tried a generic equivalent of Exjade or Jadenu tablets?

If yes, **approve Jadenu Sprinkle for all strengths for 6 months by GPID or GPI-14.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DEFERASIROX (EXJADE, JADENU, JADENU SPRINKLE, DEFERASIROX)** requires the following rule(s) be met for approval:

- A. You have chronic iron overload due to blood transfusions (you have too much iron from blood transfers) or non-transfusion dependent thalassemia (a blood disorder involving less than normal amounts of an oxygen-carrying protein)
- B. The medication is prescribed by or given in consultation with a hematologist (blood specialty doctor) or hematologist/oncologist (tumor/cancer doctor)
- C. **If you have chronic iron overload due to blood transfusions, approval also requires:**
  1. You are 2 years of age or older
  2. Your serum ferritin levels (amount of iron-containing blood cell proteins) are regularly greater than 1000mcg/L (we need at least 2 lab values taken within the previous 3 months)

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DEFERASIROX

INITIAL CRITERIA (CONTINUED)

- D. If you have chronic iron overload resulting from non-transfusion dependent thalassemia (NTDT), approval also requires:
1. You are 10 years of age or older
  2. Your serum ferritin levels (amount of iron-containing blood cell proteins) are regularly greater than 300mcg/L (we need at least 2 lab values taken within the previous 3 months)
  3. Your liver iron concentration (LIC) is at least 5mg Fe/g dry weight or greater
- E. Requests for Jadenu sprinkle packets require a trial of equivalent generic Exjade or Jadenu tablets

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of chronic iron overload due to blood transfusions **AND** meet the following criterion?
  - The patient's serum ferritin levels are consistently greater than 500mcg/L (at least 2 lab values in the previous 3 months)

If yes, **approve for 12 months by HICL or GPI-10.**

If no, continue to #2.

2. Does the patient have a diagnosis of chronic iron overload resulting from non-transfusion dependent thalassemia (NTDT) and meet **ONE** of the following criteria?
  - The patient's serum ferritin levels are consistently greater than 300mcg/L (at least 2 lab values in the previous 3 months)
  - The patient's liver iron concentration (LIC) is at least 3mg Fe/g dry weight (*Liver iron concentration supersedes serum ferritin level when both measurements are available*)

If yes, **approve for 12 months by HICL or GPI-10.**

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DEFERASIROX

RENEWAL CRITERIA (CONTINUED)

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DEFERASIROX (EXJADE, JADENU, JADENU SPRINKLE, DEFERASIROX)** requires the following rule(s) be met for renewal:

- A. You have chronic iron overload due to blood transfusions (you have too much iron from blood transfers) or non-transfusion dependent thalassemia (a blood disorder involving less than normal amounts of an oxygen-carrying protein)
- B. **If you have chronic iron overload due to blood transfusions, renewal also requires:**
  - 1. Your serum ferritin levels (amount of iron-containing blood cell proteins) are regularly greater than 500 mcg/L (we need at least 2 lab values taken within the previous 3 months)
- C. **If you have chronic iron overload resulting from non-transfusion dependent thalassemia (NTDT), renewal also requires ONE of the following:**
  - 1. Your serum ferritin levels (amount of iron-containing blood cell proteins) are regularly greater than 300mcg/L (we need at least 2 lab values taken within the previous 3 months)
  - 2. Your liver iron concentration (LIC) is at least 3mg Fe/g dry weight or greater

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Exjade and Jadenu.

**REFERENCES**

- Jadenu [Package Insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; July 2017.
- Exjade [Package Insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; August 2016.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 09/07/20

Created: 08/17

Client Approval: 08/20

P&T Approval: 01/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DEFERIPRONE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
DEFERIPRONE	FERRIPROX, DEFERIPRONE	18544		GPI-10 (9310002800)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have **ONE** of the following diagnoses?

- Transfusional iron overload due to thalassemia syndrome
- Transfusional iron overload due to sickle cell disease or other anemias

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Does the patient meet **ALL** of the following criteria?

- Therapy is prescribed by or given in consultation with a hematologist or hematologist/oncologist
- The patient had a trial of or contraindication to at least ONE of the following: Exjade (deferasirox), Jadenu (deferasirox), or Desferal (deferroxamine)

If yes, continue to #3.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

3. Is the patient experiencing intolerable toxicities, clinically significant adverse effects, has a contraindication to current chelators: Exjade (deferasirox), Jadenu (deferasirox), or Desferal (deferroxamine), **OR** current chelation therapy is inadequate?

If yes, continue to #4.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

4. Does the patient meet **ONE** of the following criteria?

- The request is for Ferriprox (deferiprone) tablets **AND** the patient is 8 years of age or older
- The request is for Ferriprox oral solution **AND** the patient is 3 years of age or older

If yes, **approve for 6 months for all strengths of the requested formulation by GPID or GPI-14.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DEFERIPRONE

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DEFERIPRONE (Ferriprox)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
1. Transfusional iron overload due to a thalassemia syndrome (you have too much iron in your body due to a type of blood disorder)
  2. Transfusional iron overload due to a sickle cell disease or other anemias (you have too much iron in your body due to a type of blood disorder)
- B. Therapy is prescribed by or given in consultation with a hematologist (a type of blood doctor) or hematologist/oncologist (a type of cancer doctor)
- C. You have tried or have a contraindication (harmful for) to at least ONE of the following: Exjade (deferasirox), Jadenu (deferasirox), or Desferal (deferoxamine)
- D. You meet ONE of the following:
1. You are experiencing intolerable toxicities or clinically significant adverse effects or have a contraindication (harmful for) to current chelators (drugs that bind to iron): Exjade (deferasirox), Jadenu (deferasirox), or Desferal (deferoxamine)
  2. Current chelation therapy (therapy that lowers iron levels) with Exjade [deferasirox], Jadenu [deferasirox], or Desferal [deferoxamine] is not working well enough
- E. **If the request is for Ferriprox (deferiprone) tablets, approval also requires:**
1. You are 8 years of age or older
- F. **If the request is for Ferriprox oral solution, approval also requires:**
1. You are 3 years of age or older

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have **ONE** of the following diagnoses?
  - Transfusional iron overload due to thalassemia syndrome
  - Transfusional iron overload due to a sickle cell disease or other anemias

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DEFERIPRONE

RENEWAL CRITERIA (CONTINUED)

2. Does the patient meet the following criterion?

- The patient has serum ferritin levels consistently greater than 500mcg/L (at least 2 lab values in the previous 3 months)

If yes, continue to #3.

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

3. Does the patient meet **ONE** of the following criteria?

- The request is for Ferriprox (deferiprone) tablets **AND** the patient is 8 years of age or older
- The request is for Ferriprox oral solution **AND** the patient is 3 years of age or older

If yes, **approve for 12 months for all strengths of the requested formulation by GPID or GPI-14.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DEFERIPRONE (Ferriprox)** requires the following rule(s) be met for renewal:

A. You have **ONE** of the following diagnoses:

1. Transfusional iron overload due to thalassemia syndrome (you have too much iron in your body due to a type of blood disorder)
2. Transfusional iron overload due to a sickle cell disease or other anemias (you have too much iron in your body due to a type of blood disorder)

B. Your serum ferritin levels (amount of iron-containing blood cell proteins) stay above 500mcg/L (at least 2 lab values in the previous 3 months)

C. **If the request is for Ferriprox (deferiprone) tablets, approval also requires:**

1. You are 8 years of age or older

D. **If the request is for Ferriprox oral solution, approval also requires:**

1. You are 3 years of age or older

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**





**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**DEFERIPRONE**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Ferriprox.

**REFERENCES**

- Ferriprox [Prescribing Information]. Weston, FL: ApoPharma USA, Inc.; April 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/22

Created: 08/17

Client Approval: 02/22

P&T Approval: 01/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DEFEROXAMINE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
DEFEROXAMINE MESYLATE	DESFERAL, DEFEROXAMINE MESYLATE	01104		GPI-10 (9300002010)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of chronic iron overload due to transfusion-dependent anemias and meet **ALL** of the following criteria?
  - The medication is prescribed by or given in consultation with a hematologist or hematologist-oncologist
  - The patient is 3 years of age or older
  - Serum ferritin levels consistently greater than 1000mcg/L (at least 2 lab values in the previous 3 months)

If yes, **approve for 6 months by HICL or GPI-10.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DEFEROXAMINE (Desferal)** requires the following rule(s) be met for approval:

- A. You have chronic iron overload due to transfusion-dependent anemias (blood doesn't have enough healthy red blood cells)
- B. Therapy is prescribed by or given in consultation with a hematologist (blood specialty doctor) or hematologist-oncologist (tumor/cancer doctor)
- C. You are 3 years of age or older
- D. Your serum ferritin levels (amount of iron-containing blood cell proteins) stay greater than 1000mcg/L (shown by at least 2 lab values in the previous 3 months)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DEFEROXAMINE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

- Does the patient have a diagnosis of chronic iron overload due to transfusion-dependent anemias and meet the following criterion?
  - Serum ferritin levels consistently greater than 500mcg/L (at least 2 lab values in the previous 3 months)

If yes, **approve for 12 months by HICL or GPI-10.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DEFEROXAMINE (Desferal)** requires the following rules be met for renewal:

- You have chronic iron overload due to transfusion-dependent anemias (blood doesn't have enough healthy red blood cells)
- Your serum ferritin levels (amount of iron-containing blood cell proteins) stay greater than 500mcg/L (at least 2 lab values in the previous 3 months)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Desferal.

**REFERENCES**

- Desferal [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 08/17

Client Approval: 04/20

P&T Approval: 07/17



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DEFLAZACORT

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
DEFLAZACORT	EMFLAZA	11668		GPI-10 (2210001700)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of Duchenne muscular dystrophy (DMD) and meet **ALL** of the following criteria?
  - The patient is 2 years of age or older
  - Documented genetic testing confirming Duchenne muscular dystrophy (DMD) diagnosis
  - Therapy is prescribed by or given in consultation with a neurologist specializing in treatment of Duchenne muscular dystrophy (DMD) at a DMD treatment center

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Has the patient tried prednisone or prednisolone for at least 6 months?

If yes, continue to #3.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

3. Is the request for Emflaza due to lack of efficacy with prednisone or prednisolone and **ALL** of the following criteria are met?

- Patient is not in Stage 1: pre-symptomatic phase
- Steroid myopathy has been ruled out
- Documented deterioration in ambulation, functional status, or pulmonary function while on prednisone or prednisolone, using standard measures over time, consistent with advancing disease (stage 2 or higher); Acceptable standard measures: [such as 6-minute walk distance (6MWD), time to ascend/descend 4 stairs, rise from floor time (Gower's maneuver), 10-meter run/walk time, or North Star Ambulatory Assessment (NSAA), Physician global assessments (PGA), pulmonary function (FVC, PFTs), upper limb strength (propelling a wheelchair 30 feet)]

If yes, **approve for 6 months by GPID or GPI-14 for all the following strengths with the following quantity limits:**

- **6mg tablet: #60 per 30 days**
- **18mg tablet: #30 per 30 days**
- **30mg tablet: #60 per 30 days**
- **36mg tablet: #60 per 30 days**
- **22.75mg/mL oral suspension: #39mL (3 bottles) per 30 days**

If no, continue to #4.

**CONTINUED ON NEXT PAGE**

Copyright © 2023 MediImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MediImpact. MediImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DEFLAZACORT

INITIAL CRITERIA (CONTINUED)

4. Is the patient experiencing an adverse consequence of prednisone or prednisolone and is the adverse consequence named or listed in the prescribing information adverse event profile of Emflaza?

If yes, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

If no, continue to #5.

5. Has documentation of literature-based evidence been provided supporting the mitigating effect of Emflaza for the named adverse consequence?

If yes, **approve for 6 months by GPID or GPI-14 for all the following strengths with the following quantity limits:**

- **6mg tablet: #60 per 30 days**
- **18mg tablet: #30 per 30 days**
- **30mg tablet: #60 per 30 days**
- **36mg tablet: #60 per 30 days**
- **22.75mg/mL oral suspension: #39mL (3 bottles) per 30 days**

If no, do not approve.

**INITIAL DENIAL TEXT:** **\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DEFLAZACORT (Emflaza)** requires the following rules be met for approval:

- A. You have Duchenne muscular dystrophy (inherited muscular weakness that gets worse)
- B. You are 2 years of age or older
- C. Your doctor confirms your diagnosis with genetic testing
- D. The drug is prescribed by or recommended by a neurologist (nerve system doctor) specializing in treatment of Duchenne muscular dystrophy (DMD) at a DMD treatment center  
**(Initial denial text continued on next page)**

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DEFLAZACORT

INITIAL CRITERIA (CONTINUED)

- E. You have tried prednisone or prednisolone for at least 6 months and meet one of the following:
1. Prednisone or prednisolone did not work and you meet ALL of the following criteria:
    - a. You are not in Stage 1: pre-symptomatic phase
    - b. There is no steroid myopathy (muscle disease due to steroid)
    - c. You have documentation that your disease is advanced– you cannot walk, cannot function, cannot breathe using standard measures over time, consistent with advancing disease (stage 2 or higher). Acceptable standard measures include: 6-minute walk distance (6MWD), time to ascend/descend 4 stairs, rise from floor time (Gower's maneuver), 10-meter run/walk time, or North Star Ambulatory Assessment (NSAA), Physician global assessments (PGA), pulmonary function (forced vital capacity, lung function tests), upper limb strength (propelling a wheelchair 30 feet)
  2. You had adverse side effects while on prednisone or prednisolone and there is documentation of literature-based evidence provided supporting Emflaza's decreased effect for that side effect  
Note: Requests due to side effects while on prednisone or prednisolone that are named or listed in the prescribing information of Emflaza will not be approved

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of Duchenne muscular dystrophy (DMD) and is currently ambulatory?

If yes, continue to #2.

If no, continue to #3.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DEFLAZACORT

RENEWAL CRITERIA (CONTINUED)

2. Has the patient shown function, stabilization or improvement in a standard set of ambulatory or functional status measures since being on Emflaza that are being monitored, tracked, and documented consistently; Acceptable standard measures: [such as 6-minute walk distance (6MWD), time to ascend/descend 4 stairs, rise from floor time (Gower's maneuver), 10-meter run/walk time, or North Star Ambulatory Assessment (NSAA), Physician global assessments (PGA)]?

If yes, approve for 12 months by GPID or GPI-14 for all the following strengths with the following quantity limits:

- 6mg tablet: #60 per 30 days
- 18mg tablet: #30 per 30 days
- 30mg tablet: #60 per 30 days
- 36mg tablet: #60 per 30 days
- 22.75mg/mL oral suspension: #39mL (3 bottles) per 30 days

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

3. Is the patient non-ambulatory and has the patient maintained or demonstrated a less than expected decline in pulmonary function and/or upper limb strength assessed by standard measures since being on Emflaza, that are being monitored, tracked and documented consistently; Acceptable standard measures: pulmonary function (FVC, PFTs), upper limb strength measures (propelling a wheelchair 30 feet), Physician Global assessments (PGA)?

If yes, approve for 12 months by GPID or GPI-14 for all the following strengths with the following quantity limits:

- 6mg tablet: #60 per 30 days
- 18mg tablet: #30 per 30 days
- 30mg tablet: #60 per 30 days
- 36mg tablet: #60 per 30 days
- 22.75mg/mL oral suspension: #39mL (3 bottles) per 30 days

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DEFLAZACORT

RENEWAL CRITERIA (CONTINUED)

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DEFLAZACORT (Emflaza)** requires the following rules be met for renewal:

- A. You have Duchenne muscular dystrophy (inherited muscular weakness that worsens)
- B. You meet ONE of the following criteria:
  - i. **If you are currently ambulatory (can walk), renewal also requires:**
    - a. You have shown function, stabilization or improvement in a standard set of ambulatory or functional status measures since being on Emflaza. These measures must be monitored, tracked, and documented consistently. Acceptable standard measures include: 6-minute walk distance, time to ascend/descend 4 stairs, rise from floor time (Gower's maneuver), 10-meter run/walk time, North Star Ambulatory Assessment, Physician Global Assessments
  - ii. **If you are currently non-ambulatory (cannot walk), renewal also requires:**
    - a. You have maintained or have a less than expected decrease in pulmonary (breathing) function and/or upper limb strength assessed by standard measures since being on Emflaza. These measures must be monitored, tracked, and documented consistently. Acceptable standard measures include: pulmonary function (force vital capacity, pulmonary function tests), upper limb strength measures (propelling a wheelchair 30 feet), Physician Global Assessments

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Emflaza.

**REFERENCES**

- Emflaza [Prescribing Information]. Northbrook, IL: Marathon Pharmaceuticals. June 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 02/17

Client Approval: 04/20

P&T Approval: 07/19





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DELAFLORACIN

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
DELAFLORACIN	BAXDELA		43532	GPI-14 (05000025100320)	

**GUIDELINES FOR USE**

1. Is therapy prescribed by or given in consultation with an Infectious Disease (ID) specialist?

If yes, approve as follows:

- **Acute bacterial skin or skin structure infection (ABSSSI):** approve 450mg tablets for one fill by GPID or GPI-14 with a quantity limit of #28 tablets per 14 days.
- **Community-acquired bacterial pneumonia (CABP):** approve 450mg tablets for one fill by GPID or GPI-14 with a quantity limit of #20 tablets per 10 days.
- **Other indications:** approve 450mg tablets for one fill by GPID or GPI-14 with a quantity limit of #28 tablets per 14 days.

If no, continue to #2.

2. Does the patient have a diagnosis of acute bacterial skin or skin structure infection (ABSSSI) and meet **ALL** of the following?

- The patient is 18 years of age or older
- Infection is suspected to be caused by **ONE** of the following organisms: *Staphylococcus aureus* (including methicillin-resistant [MRSA] and methicillin susceptible [MSSA] isolates), *Staphylococcus haemolyticus*, *Staphylococcus lugdunensis*, *Streptococcus agalactiae*, *Streptococcus anginosus Group* (including *Streptococcus anginosus*, *Streptococcus intermedius*, and *Streptococcus constellatus*), *Streptococcus pyogenes*, *Enterococcus faecalis*, *Escherichia coli*, *Enterobacter cloacae*, *Klebsiella pneumoniae*, or *Pseudomonas aeruginosa*

If yes, continue to #3.

If no, continue to #6.

3. Does the patient have a diagnosis of animal or human bite, necrotizing fasciitis, diabetic foot infection, decubitus ulcer formation, myonecrosis or ecthyma gangrenosum?

If yes, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

If no, continue to #4.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DELAFLORACIN

GUIDELINES FOR USE (CONTINUED)

4. Have antimicrobial susceptibility tests been performed that meet **ALL** of the following criteria?
- The results from the infection site culture indicate pathogenic organism(s) with resistance to **ONE** standard of care agent for acute bacterial skin or skin structure infection (ABSSSI) (e.g., sulfamethoxazole/trimethoprim, levofloxacin, clindamycin, cephalexin, or vancomycin)
  - The results from the infection site culture indicate pathogenic organism(s) with susceptibility to delafloxacin

If yes, **approve 450mg tablets for one fill by GPID or GPI-14 with a quantity limit of #28 tablets per 14 days.**

If no, continue to #5.

5. Does the patient meet **ALL** of the following criteria?
- Antimicrobial susceptibility results are unavailable
  - The patient has had a trial of or contraindication to **ONE** of the following agents:
    - Gram positive targeting antibiotic (e.g., linezolid, clindamycin, doxycycline, Bactrim, vancomycin)
    - Penicillin antibiotic (e.g., amoxicillin)
    - Fluoroquinolone antibiotic (e.g., levofloxacin, ciprofloxacin, moxifloxacin)
    - Cephalosporin antibiotic (e.g., ceftriaxone, cephalexin, cefazolin)

If yes, **approve 450mg tablets for one fill by GPID or GPI-14 with a quantity limit of #28 tablets per 14 days.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

6. Does the patient have a diagnosis of community-acquired bacterial pneumonia (CABP) and meet **ALL** of the following criteria?
- The patient is 18 years of age or older
  - Infection is caused by any of the following susceptible microorganisms: *Streptococcus pneumoniae*, *Staphylococcus aureus* (methicillin-susceptible [MSSA] isolates only), *Klebsiella pneumoniae*, *Escherichia coli*, *Pseudomonas aeruginosa*, *Haemophilus influenzae*, *Haemophilus parainfluenzae*, *Chlamydia pneumoniae*, *Legionella pneumophila* or *Mycoplasma pneumoniae*

If yes, continue to #7.

If no, do not approve

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DELAFLORACIN

GUIDELINES FOR USE (CONTINUED)

7. Have antimicrobial susceptibility tests been performed that meet **ALL** of the following criteria?
- The results from the infection site culture indicate pathogenic organism(s) with resistance to at least **TWO** standard of care agents for community-acquired bacterial pneumonia (CABP) (e.g., macrolide, doxycycline, alternative fluoroquinolone, beta-lactam, linezolid)
  - The results from the infection site culture indicate pathogenic organism(s) with susceptibility to delafloxacin

If yes, **approve 450mg tablets for one fill by GPID or GPI-14 with a quantity limit of #20 tablets per 10 days.**

If no, continue to #8.

8. Does the patient meet **ALL** of the following criteria?
- Antimicrobial susceptibility results are unavailable
  - The patient has had a trial of or contraindication to at least **TWO** standard of care agents for community-acquired bacterial pneumonia (CABP) (e.g., macrolide, doxycycline, alternative fluoroquinolone, beta-lactam, linezolid)

If yes, **approve 450mg tablets for one fill by GPID or GPI-14 with a quantity limit of #20 tablets per 10 days.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DELAFLORACIN (Baxdela)** requires the following rule(s) be met for approval:

A. You meet **ONE** of the following:

1. The requested medication is prescribed by or given in consultation with an infectious disease (ID) specialist or
2. You have an acute (serious and short-term) bacterial skin or skin structure infection (ABSSSI); **OR** community-acquired bacterial pneumonia (CABP: type of lung infection)

B. **If you have an acute bacterial skin or skin structure infection, approval also requires:**

1. You are at least 18 years of age
2. The infection is caused by any of the following bacteria: *Staphylococcus aureus* (including methicillin-resistant [MRSA] and methicillin susceptible [MSSA] isolates), *Staphylococcus haemolyticus*, *Staphylococcus lugdunensis*, *Streptococcus agalactiae*, *Streptococcus anginosus* Group (including *Streptococcus anginosus*, *Streptococcus intermedius*, and *Streptococcus constellatus*), *Streptococcus pyogenes*, and *Enterococcus faecalis*, *Escherichia coli*, *Enterobacter cloacae*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa*

**(Denial text continued on next page)**

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DELAFLORACIN

GUIDELINES FOR USE (CONTINUED)

3. You do not have a diagnosis of animal or human bite, necrotizing fasciitis (flesh eating disease), diabetic foot infection, decubitus ulcer formation (pressure/bed ulcer), myonecrosis (dead muscle tissue) or ecthyma gangrenosum
  4. You meet **ONE** of the following criteria:
    - i. If antimicrobial susceptibility test is available (you have a test showing what drugs work on which bacteria of the infection site), we require the results of the test from the infection site show the bacteria is both a) resistant to **ONE** standard of care agent for acute bacterial skin or skin structure infection (such as sulfamethoxazole/trimethoprim, levofloxacin, clindamycin, cephalexin, or vancomycin), **AND** b) delafloxacin will work against the bacteria
    - ii. If antimicrobial susceptibility test is not available (you do not have a test showing what drugs work on which bacteria of the infection site), we require you had a trial or contraindication to (a medical reason why you cannot use) **ONE** of the following agents: a penicillin (such as amoxicillin), a fluoroquinolone (such as levofloxacin, ciprofloxacin, moxifloxacin), a cephalosporin (such as ceftriaxone, cephalexin, cefazolin), or a gram positive targeting antibiotic (such as linezolid, clindamycin, doxycycline, sulfamethoxazole/trimethoprim, vancomycin)
- C. **If you have community-acquired bacterial pneumonia (CABP: type of lung infection), approval also requires:**
1. You are 18 years of age or older
  2. The infection is caused by any of the following bacteria: *Streptococcus pneumoniae*, *Staphylococcus aureus* (methicillin-susceptible [MSSA] isolates only), *Klebsiella pneumoniae*, *Escherichia coli*, *Pseudomonas aeruginosa*, *Haemophilus influenzae*, *Haemophilus parainfluenzae*, *Chlamydia pneumoniae*, *Legionella pneumophila* or *Mycoplasma pneumoniae*
  3. You meet **ONE** of the following criteria:
    - a. If antimicrobial susceptibility test is available (you have a test showing what drugs work on which bacteria of the infection site), we require the results of the test from the infection site show the bacteria is both a) resistant to **TWO** standard of care agents for community-acquired bacterial pneumonia (such as azithromycin, doxycycline, levofloxacin, moxifloxacin, amoxicillin, ceftriaxone, linezolid) **AND** b) delafloxacin will work against the bacteria
    - b. If antimicrobial susceptibility test is not available (you do not have a test showing what drugs work on which bacteria of the infection site), we require you had a trial or contraindication to (a medical reason why you cannot use) **TWO** standard of care agents for community-acquired bacterial pneumonia (such as azithromycin, doxycycline, levofloxacin, moxifloxacin, amoxicillin, ceftriaxone, linezolid)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**DELAFLOXACIN**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Baxdela.

**REFERENCES**

- Baxdela [Prescribing Information]. Lincolnshire, Illinois USA: Melinta Therapeutics, Inc.; November 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/20

Created: 10/17

Client Approval: 02/20

P&T Approval: 01/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DESIRUDIN

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
DESIRUDIN	IPRIVASK	19072		GPI-10 (8333403000)	

GUIDELINES FOR USE

1. Is the request for Iprivask for the prevention (prophylaxis) of deep vein thrombosis (DVT) for a patient undergoing elective hip replacement surgery?

If yes, approve for a total of 35 days of treatment. Enter two authorizations as follows:

- Approve for 12 days by HICL or GPI-10 for #24 vials.
- Also enter one fill for 23 days by HICL or GPI-10 for #46 vials with a start date of 7 days following the initial approval.

If no, do not approve.

**DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **DESIRUDIN (Iprivask)** requires that you are receiving Iprivask for the prevention of deep vein thrombosis (DVT; blood clot in a deep vein, usually in the legs) and you are undergoing elective hip replacement surgery.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Iprivask.

REFERENCES

- Iprivask [Prescribing Information]. Northbrook, IL: Marathon Pharmaceuticals; November 2014.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 08/10

Client Approval: 04/20

P&T Approval: 11/13



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DEUCRAVACITINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
DEUCRAVACITINIB	SOTYKTU	48292		GPI-10 (9025052400)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a dermatologist
  - The patient has psoriasis covering 3% or more of body surface area (BSA) OR psoriatic lesions affecting the hands, feet, face, or genital area
  - The patient had a trial of or contraindication to ONE conventional therapy (e.g., PUVA [Phototherapy Ultraviolet Light A], UVB [Ultraviolet Light B], topical corticosteroids, calcipotriene, acitretin, methotrexate, cyclosporine)
  - The patient had a trial of or contraindication to TWO of the following preferred agents: Cosentyx, Humira, Stelara, Skyrizi, Enbrel, Tremfya, Otezla

If yes, **approve for 4 months by HICL or GPI-10 with a quantity limit of #1 per day.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DEUCRAVACITINIB (Sotyktu)** requires the following rule(s) be met for approval:

- A. You have moderate to severe plaque psoriasis (a type of skin condition)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
- D. You have psoriasis covering 3% or more of body surface area (BSA) OR psoriatic lesions (rashes) affecting the hands, feet, face, or genital area
- E. You had a trial of or contraindication (harmful for) to ONE standard therapy (such as PUVA [Phototherapy Ultraviolet Light A], UVB [Ultraviolet Light B], topical corticosteroids, calcipotriene, acitretin, methotrexate, cyclosporine)
- F. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Cosentyx, Humira, Stelara, Skyrizi, Enbrel, Tremfya, Otezla

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DEUCRAVACITINIB

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) **AND** meet the following criterion?

- The patient has achieved or maintained clear or minimal disease OR a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more while on therapy

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**  
If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DEUCRAVACITINIB (Sotyktu)** requires the following rule(s) be met for renewal:

- A. You have moderate to severe plaque psoriasis (a type of skin condition)
- B. You have achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index: a tool for evaluating severity of psoriasis) of at least 50% or more while on therapy

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Sotyktu.

**REFERENCES**

- Sotyktu [Prescribing Information]. Princeton, NJ: Bristol-Myers Squibb Company, September 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/23

Created: 09/22

Client Approval: 02/23

P&T Approval: 01/23





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DEUTETRABENAZINE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
DEUTETRABENAZINE	AUSTEDO	44192		GPI-10 (6238003000)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of chorea (involuntary movements) associated with Huntington's disease and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a neurologist or movement disorder specialist

If yes, **approve for 12 months by GPID or GPI-14 for all the dosage strengths with the following quantity limits:**

- **6mg tablet: #2 per day**
- **9mg tablet: #4 per day**
- **12mg tablet: #4 per day**

If no, continue to #2.

2. Does the patient have a diagnosis of moderate to severe tardive dyskinesia and meet ALL of the following criteria?
  - Moderate to severe tardive dyskinesia has been present for at least 3 months
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a neurologist, movement disorder specialist, or psychiatrist
  - Patient has a prior history of using antipsychotic medications or metoclopramide for at least 3 months (or at least 1 month if patient is 60 years of age or older) as documented in the prescription claims history

If yes, **approve for 12 months by GPID or GPI-14 for all the dosage strengths with the following quantity limits:**

- **6mg tablet: #2 per day**
- **9mg tablet: #4 per day**
- **12mg tablet: #4 per day**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DEUTETRABENAZINE

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DEUTETRABENAZINE (Austedo)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
  1. Chorea (involuntary muscle movements) associated with Huntington's disease
  2. Moderate to severe tardive dyskinesia (uncontrolled body movements)
- B. You are 18 years of age or older
- C. **If you have chorea associated with Huntington's disease, approval also requires:**
  1. Therapy is prescribed by or in consultation with a neurologist (type of brain doctor) or movement disorder specialist
- D. **If you have moderate to severe tardive dyskinesia, approval also requires:**
  1. Moderate to severe tardive dyskinesia (uncontrolled body movements) has been present for at least 3 months
  2. Therapy is prescribed by or in consultation with a neurologist (type of brain doctor), movement disorder specialist, or psychiatrist (type of mental health doctor)
  3. You have a prior history of using antipsychotic medications or metoclopramide for at least 3 months (or at least 1 month if you are 60 years of age or older) as documented in the prescription claims history

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Austedo.

**REFERENCES**

- Austedo [Prescribing Information]. North Wales, PA. Teva Pharmaceuticals, Inc.; June 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/22

Created: 04/17

Client Approval: 12/21

P&T Approval: 01/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DEXTROMETHORPHAN-BUPROPION

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
DEXTROMETHORPHAN HBR/BUPROPION	AUVELITY	48220		GPI-10 (5899990230)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of major depressive disorder (MDD) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient had a trial of or contraindication to Trintellix
  - The patient had a trial of or contraindication to any generic antidepressant indicated for the treatment of MDD (e.g., sertraline, duloxetine)

If yes, **approve for 2 months by HICL or GPI-10 with a quantity limit of #2 per day.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DEXTROMETHORPHAN-BUPROPION (Auvelity)** requires the following rule(s) be met for approval:

- A. You have major depressive disorder (MDD: a type of mental illness)
- B. You are 18 years of age or older
- C. You had a trial of or contraindication (harmful for) to Trintellix
- D. You had a trial of or contraindication (harmful for) to any generic antidepressant indicated for the treatment of major depressive disorder (such as sertraline, duloxetine)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DEXTROMETHORPHAN-BUPROPION

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

- Does the patient have a diagnosis of major depressive disorder (MDD) **AND** meet the following criterion?
  - The patient has responded to therapy

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DEXTROMETHORPHAN-BUPROPION (Auvelity)** requires the following rule(s) be met for renewal:

- You have major depressive disorder (MDD: a type of mental illness)
- You have responded to therapy

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Auvelity.

**REFERENCES**

- Auvelity [Prescribing Information]. New York, NY: Axsome Therapeutics, Inc., August 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective:10/17/22

Created: 10/22

Client Approval: 10/22

P&T Approval:07/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**DEXTROMETHORPHAN with QUINIDINE**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
DEXTROMETHORPHAN/ QUINIDINE	NUEDEXTA	37278		GPI-10 (6260990230)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of pseudobulbar affect (PBA)?

If yes, **approve for 12 months by HICL or GPI-10 for #2 per day per month.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DEXTROMETHORPHAN with QUINIDINE (Nuedexta)** requires you have a pseudobulbar affect (sudden, uncontrollable laughter) for approval.

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Nuedexta.

**REFERENCES**

- Nuedexta [Prescribing Information]. Aliso Viejo, CA: Avanir Pharmaceuticals, Inc.; June 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A  
Commercial Effective: 07/01/20

Created: 02/11  
Client Approval: 04/20

P&T Approval: 01/15



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DIABETIC TEST STRIPS

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
BLOOD SUGAR DIAGNOSTIC, BLOOD SUGAR DIAGNOSTIC, DISC, BLOOD SUGAR DIAGNOSTIC, DRUM	DIABETIC TEST STRIPS VARIOUS		25200	GPI-14 (94100030006100)	

**CSR NOTE: Requests for blood glucose (diabetic) test strips manufactured by Abbott (FreeStyle and Precision) will adjudicate at the point of service with no restrictions. Non-formulary test strips will require prior authorization.**

**GUIDELINES FOR USE**

- Has the patient tried one of the following preferred blood glucose (diabetic) meters and test strips by Abbott: FreeStyle or Precision?

If yes, **approve open-ended by GPID or GPI-14.**  
 If no, continue to #2.

- Does the patient require the use of a non-preferred blood glucose test strip due to significant visual and/or cognitive impairment?

If yes, **approve open-ended by GPID or GPI-14.**  
 If no, continue to #3.

- Is the prescriber requesting a non-preferred test strip due to a need for data management software? **[Note: The preferred test strips include FreeStyle and Precision by Abbott]**

If yes, do not approve, and recommend the prescriber contact Abbott for data management software and a connection cable for the meter.  
**DENIAL TEXT:** See the denial text at the end of the guideline.

If no, continue to #4.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DIABETIC TEST STRIPS

GUIDELINES FOR USE (CONTINUED)

- 4. Does the patient require the use of a non-preferred blood glucose test strip based on his/her use of another manufacturer's companion insulin pump?

If yes, **approve open-ended by GPID or GPI-14.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DIABETIC TEST STRIPS** requires ONE of following rules be met for approval:

- A. You have tried ONE preferred blood glucose (diabetic) meter and test strips. The preferred meters and test strips are FreeStyle and Precision by Abbott
- B. You require a non-preferred blood glucose test strip due to significant visual and/or cognitive impairment (problems with sight and/or memory and thinking)
- C. You require a non-preferred blood glucose test strip because you use another manufacturer's companion insulin pump

Request for non-preferred test strips will not be approved if due to a need for data management software. Please note that data management software is available for the formulary test strip products. Please contact Abbott for data management software and a connection cable for the meter.

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different product or get us more information if it will allow us to approve this request.

**RATIONALE**

The intent of this prior authorization is to encourage the use of cost-effective formulary preferred glucose testing strips before considering coverage of non-preferred alternatives.

**REFERENCES**

- Drug Facts and Comparisons (online version), Blood Glucose Meters. Available at <http://online.factsandcomparisons.com>.
- American Diabetes Association. Standards of Medical Care in Diabetes- 2017. Diabetes Care 2017; 40 (suppl 1): S11-S135.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 02/08/21

Created: 01/12

Client Approval: 01/21

P&T Approval: 08/14

Copyright © 2023 MediImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MediImpact. MediImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DICHLORPHENAMIDE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
DICHLORPHENAMIDE	KEVEYIS, DICHLORPHENAMIDE	03642		GPI-10 (3710002000)	

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of primary hypokalemic periodic paralysis and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient has tried acetazolamide AND a potassium-sparing diuretic (i.e., spironolactone, triamterene)
  - Therapy is prescribed by or in consultation with a neurologist
  - The patient does not have hepatic insufficiency, pulmonary obstruction, or a health condition that warrants concurrent use of high-dose aspirin

If yes, **approve for two months by HICL or GPI-10 with a quantity limit of #4 per day.**  
If no, continue to #2.

2. Does the patient have a diagnosis of primary hyperkalemic periodic paralysis or related variants and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient has tried acetazolamide AND a thiazide diuretic (i.e., hydrochlorothiazide)
  - Therapy is prescribed by or in consultation with a neurologist
  - The patient does not have hepatic insufficiency, pulmonary obstruction, or a health condition that warrants concurrent use of high-dose aspirin

If yes, **approve for two months by HICL or GPI-10 with a quantity limit of #4 per day.**  
If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DICHLORPHENAMIDE (Keveyis)** requires the following rule(s) be met for approval:

- A. You have a primary hypokalemic periodic paralysis (extreme muscle weakness with low potassium levels in your blood), primary hyperkalemic periodic paralysis (extreme muscle weakness with high potassium levels in your blood), or related variants
- B. You are 18 years of age or older
- C. The medication is prescribed by or in consultation with a neurologist (a type of brain doctor)  
***(Initial denial text continued on next page)***

CONTINUED ON NEXT PAGE





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DICHLORPHENAMIDE

INITIAL CRITERIA (CONTINUED)

- D. You do not have hepatic insufficiency (liver failure), pulmonary obstruction (difficulty breathing due to blockage of airflow), or a health condition that requires you to use high-dose aspirin at the same time
- E. **If you have primary hypokalemic periodic paralysis, approval also requires:**
  - 1. You have tried acetazolamide AND a potassium-sparing diuretic (spironolactone, triamterene)
- F. **If you have primary hyperkalemic periodic paralysis or related variants, approval also requires:**
  - 1. You have tried acetazolamide AND a thiazide diuretic (hydrochlorothiazide)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

- 1. Does the patient have a diagnosis of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, or related variants **AND** meet the following criterion?
  - The patient has experienced at least two fewer attacks per week from their baseline

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**

If no, do not approve.

**RENEWAL DENIAL TEXT: Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DICHLORPHENAMIDE (Keveyis)** requires the following rules be met for renewal:

- A. You have primary hyperkalemic periodic paralysis (extreme muscle weakness with high potassium levels in your blood), primary hypokalemic periodic paralysis (extreme muscle weakness with low potassium levels in your blood), or related variants
- B. You have experienced at least two fewer attacks per week from baseline (measurement before you started treatment)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**DICHLORPHENAMIDE**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Keveyis.

**REFERENCES**

- Keveyis [Prescribing Information]. Chicago, IL: Xeris Pharmaceuticals, Inc.; December 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 02/06/23

Created: 09/15

Client Approval: 01/23

P&T Approval: 11/15



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DICLOFENAC TOPICAL GEL

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
DICLOFENAC SODIUM	SOLARAZE, DICLOFENAC SODIUM		86831	GPI-10 (9037403530)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of actinic keratosis and meet **ALL** of the following criteria?
  - Therapy is prescribed by or in consultation with a dermatologist or oncologist
  - The patient had a trial of or contraindication to topical fluorouracil (e.g., Efudex, Fluoroplex, Carac)

If yes, **approve for 3 months by GPID or GPI-10 with a quantity limit of #100 grams per 30 days.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DICLOFENAC TOPICAL GEL (Solaraze)** requires the following rule(s) be met for approval:

- A. You have actinic keratosis (a type of skin condition)
- B. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor) or oncologist (a type of cancer doctor)
- C. You had a trial of or contraindication (harmful for) to topical fluorouracil (such as Efudex, Fluoroplex, Carac)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Solaraze.

**REFERENCES**

- Solaraze [Prescribing Information]. PharmaDerm: Melville, NY; May 2016.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/01/22

Created: 10/22

Client Approval: 10/22

P&T Approval: 01/22



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**DICLOFENAC TOPICAL SOLUTION**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
DICLOFENAC SODIUM	PENNSAID, DICLOFENAC SODIUM		35936 43213	GPI-14 (90210030302030)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of osteoarthritis of the knee(s) **AND** meet the following criterion?

- The patient had a trial of diclofenac 1% gel AND diclofenac 1.5% drops

If yes, **approve for 6 months by GPID or GPI-14 with a quantity limit of #224 grams per 28 days.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DICLOFENAC TOPICAL SOLUTION (Pennsaid)** requires the following rule(s) be met for approval:

- A. You have osteoarthritis (a type of joint condition) of the knee(s)
- B. You had a trial of diclofenac 1% gel AND diclofenac 1.5% drops

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Pennsaid.

**REFERENCES**

- Pennsaid [Prescribing Information]. Lake Forest, IL: Horizon Pharma USA Inc.; January 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/01/22

Created: 10/22

Client Approval: 10/22

P&T Approval: 01/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DIGOXIN

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
DIGOXIN	DIGOXIN		00130	GPI-14 (31200010000303)	GENERIC ONLY

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of heart failure?

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #1 per day.**  
If no, continue to #2.

2. Does the patient have a diagnosis of chronic atrial fibrillation **AND** meet the following criterion?

- The patient is 18 years of age or older

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #1 per day.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DIGOXIN** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
1. Heart failure (a type of heart condition)
  2. Chronic atrial fibrillation (a type of heart condition)
- B. **If you have chronic atrial fibrillation, approval also requires:**
1. You are 18 years of age or older

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Lanoxin.

**REFERENCES**

- Lanoxin [Prescribing Information]. 17 Northwood [House, Dublin 9, Ireland: Concordia Pharmaceuticals, Inc.; February 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/22

Created: 05/22

Client Approval: 05/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**DIMETHYL FUMARATE**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
DIMETHYL FUMARATE	TECFIDERA, DIMETHYL FUMARATE	40168		GPI-10 (6240552500)	FDB ROUTE ≠ MISCELL

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of a relapsing form of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, **AND** meet the following criterion?

- The patient is 18 years of age or older

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Is the request for generic dimethyl fumarate?

If yes, **approve generic dimethyl fumarate for 12 months by HICL or GPI-10 with a quantity limit of #2 per day and override 'Generic Only' field.**

If no, continue to #3.

3. Is the request for brand Tecfidera **AND** the patient meets the following criterion?

- The patient had a previous trial of generic dimethyl fumarate

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.**

If no, do not approve.

**DENIAL TEXT: \*\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DIMETHYL FUMARATE (Tecfidera)** requires the following rules be met for approval:

- A. You have a relapsing form of multiple sclerosis (MS: an illness where the immune system eats away at the protective covering of the nerves), which includes clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms go away and return), and active secondary progressive disease (advanced disease)
- B. You are 18 years of age or older
- C. If you are requesting brand Tecfidera, you must have previously tried generic dimethyl fumarate

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**DIMETHYL FUMARATE**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Review for Tecfidera.

**REFERENCES**

- Tecfidera [Prescribing Information]. Cambridge, MA: Biogen Inc.; February 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/19/20

Created: 05/13

Client Approval: 10/20

P&T Approval: 01/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DIROXIMEL FUMARATE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
DIROXIMEL FUMARATE	VUMERITY	46164		GPI-10 (6240553000)	

GUIDELINES FOR USE

- Does the patient have a diagnosis of a relapsing form of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease **AND** meet the following criterion?
  - The patient is 18 years of age or older

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 capsules per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DIROXIMEL FUMARATE (Vumerity)** requires the following rule(s) be met for approval:

- You have a relapsing form of multiple sclerosis (immune system eats away at protective covering of nerves and you have new or increasing symptoms), to include clinically isolated syndrome, relapsing-remitting disease (symptoms return and go away) and active secondary progressive disease (advanced disease)
- You are 18 years of age or older

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Vumerity.

REFERENCES

- Vumerity [Prescribing Information]. Waltham, MA: Alkermes, Inc.; October 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/20

Created: 11/19

Client Approval: 02/20

P&T Approval: 01/20





**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**DONEPEZIL**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
DONEPEZIL HCL	ADLARITY		52053 52054	GPI-14 (62051025108820) (62051025108830)	

**GUIDELINES FOR USE**

- Does the patient have a diagnosis of dementia associated with Alzheimer's disease and meet **ALL** of the following criteria?
  - The patient had a trial of or contraindication to TWO generic oral acetylcholinesterase inhibitors (e.g., donepezil, galantamine)
  - The patient had a trial of or contraindication to one generic acetylcholinesterase inhibitor patch (e.g., rivastigmine)

If yes, **approve all strengths for 12 months by GPID or GPI-14 with a quantity limit of #4 per 28 days.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DONEPEZIL (Adlarity)** requires the following rule(s) be met for approval:

- You have dementia (a type of memory disorder) associated with Alzheimer's disease (a progressive brain disorder that slowly destroys memory and thinking skills)
- You had a trial of or contraindication (harmful for) to TWO generic oral acetylcholinesterase inhibitors (such as donepezil, galantamine)
- You had a trial of or contraindication (harmful for) to one generic acetylcholine inhibitor patch (such as rivastigmine)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Adlarity.

**REFERENCES**

- Adlarity [Prescribing Information]. Grand Rapids, MI: Astellas Corium, Inc.; March 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/18/22

Created: 06/22

Client Approval: 06/22

P&T Approval: 01/22

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DORNASE ALFA

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
DORNASE ALFA	PULMOZYME	08832		GPI-10 (4530402000)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of cystic fibrosis?

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Is the request for once daily dosing (30 ampules per month)?

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #30 ampules per month.**

If no, continue to #3.

3. Has the patient tried once daily dosing (30 ampules per month per MRF or claims history)?

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #60 ampules per month.**

If no, do not approve. **Enter a proactive authorization for 12 months by HICL or GPI-10 with a quantity limit of #30 ampules per month.**

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DORNASE ALFA (Pulmozyme)** requires the following rule(s) be met for approval:

- A. You have cystic fibrosis (CF: an inherited disorder that damages lung and digestive system with fluid build up)
- B. If you are requesting twice daily dosing, we require that you have tried and failed once daily dosing

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**DORNASE ALFA**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Pulmozyme.

**REFERENCE**

- Pulmozyme [Prescribing Information]. South San Francisco, CA: Genentech, Inc.; December 2018.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 05/12

Client Approval: 04/20

P&T Approval: 05/12



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DROXIDOPA

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
DROXIDOPA	NORTHERA, DROXIDOPA	40936		GPI-10 (3870003000)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a documented diagnosis of neurogenic orthostatic hypotension (NOH) caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, or non-diabetic autonomic neuropathy and meets **ALL** of the following criteria?

- Patient is 18 years of age or older
- Therapy is prescribed by or given in consultation with a neurologist or cardiologist
- The patient had a previously had a trial of or contraindication to midodrine **OR** fludrocortisone

If yes, continue to #2.

If no, do not approve

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Has the prescriber performed baseline blood pressure readings while the patient is sitting and also within minutes of standing from a supine (lying face up) position?

If yes, continue to #3.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

3. Does the patient have a documented decrease of at least 20mmHg in systolic blood pressure or 10mmHg diastolic blood pressure within 3 minutes after standing from a sitting position?

If yes, continue to #4.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DROXIDOPA

INITIAL CRITERIA (CONTINUED)

4. Does the patient have persistent symptoms of neurogenic orthostatic hypotension, which include dizziness, lightheadedness, and the feeling of 'blacking out'?

If yes, **approve for 1 month by HICL or GPI-10 for #180 per 30 days.**

**APPROVAL TEXT:** Renewal requires a diagnosis of Neurogenic Orthostatic Hypotension (NOH) and that the patient meets **ALL** of the following criteria while on therapy with Northera:

- Patient has demonstrated improvement in severity from baseline symptoms of dizziness, lightheadedness, feeling faint, or feeling like the patient may black out
- Patient had an increase in systolic blood pressure from baseline of at least 10mmHg upon standing from a supine (laying face up) position

If no, do not approve.

**INITIAL DENIAL TEXT:** **\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DROXIDOPA (Northera)** requires the following rules be met for approval:

- A. You have neurogenic orthostatic hypotension (a type of low blood pressure)
- B. You are 18 years of age or older
- C. You have a documented diagnosis of neurogenic orthostatic hypotension caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency (you are missing a type of enzyme), or non-diabetic autonomic neuropathy (nerve pain/damage)
- D. You have previously tried midodrine OR fludrocortisone, unless there is a medical reason why you cannot (contraindication)
- E. Theray is prescribed or given in consultation with a neurologist (nerve doctor) or cardiologist (heart doctor)
- F. Your doctor performed baseline blood pressure readings while you are sitting and also within 3 minutes of standing from a supine (lying face up) position
- G. You have a documented decrease of at least 20 mmHg in systolic blood pressure or 10 mmHg diastolic blood pressure within 3 minutes after standing from a sitting position
- H. You have persistent symptoms of neurogenic orthostatic hypotension which includes dizziness, lightheadedness, and the feeling of 'blacking out'

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DROXIDOPA

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of neurogenic orthostatic hypotension (NOH) and meets **ALL** of the following criteria?
  - The patient has demonstrated improvement in severity from baseline symptoms of dizziness, lightheadedness, feeling faint, or feeling like the patient may black out
  - The patient had an increase in systolic blood pressure from baseline of at least 10mmHg upon standing from a supine (lying face up) position

If yes, **approve for 3 months by HICL or GPI-10 for #180 per 30 days.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DROXIDOPA (Northera)** requires the following rule(s) be met for renewal:

- A. You have neurogenic orthostatic hypotension (NOH)
- B. You have demonstrated improvement in severity from baseline symptoms of dizziness, lightheadedness, feeling faint, or feeling like you may black out
- C. You had an increase in systolic blood pressure from baseline of at least 10mmHg upon standing from a supine (lying face up) position

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Northera.

**REFERENCES**

- Northera [Prescribing Information]. Deerfield, IL: Lundbeck Pharmaceuticals LLC; July 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 03/15/21

Created: 9/14

Client Approval: 03/21

P&T Approval: 11/14



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DULOXETINE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
DULOXETINE HCL	DRIZALMA SPRINKLE		46703 46713 46714 46715	GPI-14 (5818002510H120) (5818002510H130) (5818002510H140) (5818002510H160)	

**GUIDELINES FOR USE**

1. Does the patient have **ONE** of the following diagnoses?

- Major depressive disorder
- Diabetic peripheral neuropathy
- Fibromyalgia
- Chronic musculoskeletal pain

If yes, continue to #2.

If no, continue to #3.

2. Does the patient meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient had a trial of generic duloxetine
- The patient cannot swallow duloxetine capsules

If yes, **approve the requested strength for 12 months by GPID or GPI-14 with the following quantity limits:**

- **20 mg, 30 mg, 40 mg: #1 per day.**
- **60 mg: #2 per day.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

3. Does the patient have a diagnosis of generalized anxiety disorder and meet **ALL** of the following criteria?

- The patient is 7 years of age or older
- The patient had a trial of generic duloxetine
- The patient cannot swallow duloxetine capsules

If yes, **approve the requested strength for 12 months by GPID or GPI-14 with the following quantity limits:**

- **20 mg, 30 mg, 40 mg: #1 per day.**
- **60 mg: #2 per day.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DULOXETINE

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DULOXETINE (Drizalma Sprinkle)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
  1. Major depressive disorder (a type of mental illness)
  2. Generalized anxiety disorder (a type of mental illness)
  3. Diabetic peripheral neuropathy (a type of nerve damage caused by high blood sugar)
  4. Fibromyalgia (a type of pain disorder)
  5. Chronic musculoskeletal pain (severe pain relating to muscles and bones)
- B. **If you have major depressive disorder, diabetic peripheral neuropathy, fibromyalgia, or chronic musculoskeletal pain, approval also requires:**
  1. You are 18 years of age or older
  2. You had a trial of generic duloxetine
  3. You cannot swallow duloxetine capsules
- C. **If you have generalized anxiety disorder, approval also requires:**
  1. You are 7 years of age or older
  2. You had a trial of generic duloxetine
  3. You cannot swallow duloxetine capsules

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Drizalma Sprinkle.

**REFERENCES**

- Drizalma Sprinkle [Prescribing Information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; July 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/23

Created:11/22

Client Approval: 02/23

P&T Approval: 10/22





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DUPILUMAB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
DUPILUMAB	DUPIXENT	44180		GPI-10 (9027302000)	

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of moderate to severe atopic dermatitis and meet **ALL** of the following criteria?
  - The patient is 6 months of age or older
  - Therapy is prescribed by or in consultation with a dermatologist, allergist, or immunologist
  - The patient has atopic dermatitis involving at least 10% of body surface area (BSA) OR atopic dermatitis affecting the face, head, neck, hands, feet, groin, or intertriginous areas
  - The patient has TWO of the following: intractable pruritus, cracking and oozing/bleeding of affected skin, impaired activities of daily living
  - Dupixent will NOT be used concurrently with other systemic biologics (e.g., Adbry) or any JAK inhibitors (e.g., Rinvoq, topical Opzelura, Cibinqo) for the treatment of atopic dermatitis

If yes, continue to #2.

If no, continue to #3.

2. Does the patient have a trial of or contraindication to **ONE** of the following?
  - Topical corticosteroid (e.g., hydrocortisone, clobetasol, halobetasol propionate)
  - Topical calcineurin inhibitor [e.g., Elidel (pimecrolimus), Protopic (tacrolimus)]
  - Topical PDE-4 inhibitor [e.g., Eucrisa (crisaborole)]
  - Topical JAK inhibitor [e.g., Opzelura (ruxolitinib)]
  - Phototherapy

If yes, enter **TWO** approvals by GPID or GPI-14 for the requested strength for a total of 6 months as follows:

- **FIRST APPROVAL: Approve with an end date of 1 month as follows:**
  - 200mg/1.14mL: #4.56mL.
  - 300mg/2mL: #8mL.
- **SECOND APPROVAL: Approve for 5 months as follows (enter a start date of 1 week after the end of the first approval):**
  - 200mg/1.14mL: #2.28mL per 28 days.
  - 300mg/2mL: #4mL per 28 days.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DUPILUMAB

INITIAL CRITERIA (CONTINUED)

Does the patient have a diagnosis of moderate to severe asthma with an eosinophilic phenotype **AND** meet the following criterion?

- The patient has a documented blood eosinophil level of 150 to 1500 cells/mcL within the past 12 months

If yes, continue to #5.

If no, continue to #4.

Does the patient have a diagnosis of moderate to severe oral corticosteroid-dependent asthma?

If yes, continue to #5.

If no, continue to #8.

Does the patient meet **ALL** of the following criteria?

- The patient is 6 years of age or older
- Therapy is prescribed by or in consultation with a physician specializing in pulmonary or allergy medicine
- The patient is on concurrent treatment with medium, high-dose, or maximally tolerated inhaled corticosteroid (ICS) [e.g., triamcinolone acetonide, beclomethasone, mometasone, budesonide, etc.] **AND** at least one other maintenance medication (e.g., long-acting inhaled beta2-agonist [e.g., salmeterol, formoterol, etc.], long-acting muscarinic antagonist [e.g., aclidinium bromide, ipratropium, tiotropium, umeclidinium, etc.], a leukotriene receptor antagonist [e.g., montelukast, zafirlukast, zileuton, etc.], theophylline)
- Dupixent will **NOT** be used concurrently with Xolair or an anti-IL5 biologic (e.g., Nucala, Cinqair, Fasenra) when these are used for the treatment of asthma

If yes, continue to #6.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DUPILUMAB

INITIAL CRITERIA (CONTINUED)

Does the patient meet **ONE** of the following criteria?

- The patient experienced at least **ONE** asthma exacerbation requiring systemic corticosteroid burst lasting at least 3 days within the past 12 months OR at least **ONE** serious exacerbation requiring hospitalization or emergency room visit within the past 12 months
- The patient has poor symptom control despite current therapy as evidenced by at least **THREE** of the following within the past 4 weeks:
  - Daytime asthma symptoms more than twice per week
  - Any night waking due to asthma
  - Short-acting inhaled beta2-agonist (SABA; e.g., albuterol) reliever for symptoms more than twice per week
  - Any activity limitation due to asthma

If yes, continue to #7.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

Is the request for the 100 mg/0.67mL strength?

If yes, approve 100 mg/0.67mL by GPID or GPI-14 for 4 months with a quantity limit of #1.34mL per 28 days.

If no, enter **TWO** approvals by GPID or GPI-14 for the requested strength for a total of 4 months as follows:

- **FIRST APPROVAL:** Approve with an end date of 1 month as follows:
  - 200mg/1.14mL: #4.56mL.
  - 300mg/2mL: #8mL.
- **SECOND APPROVAL:** Approve for 3 months as follows (enter a start date of 1 week after the end of the first approval):
  - 200mg/1.14mL: #2.28mL per 28 days.
  - 300mg/2mL: #4mL per 28 days.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DUPILUMAB

INITIAL CRITERIA (CONTINUED)

Does the patient have a diagnosis of chronic rhinosinusitis with nasal polyposis (CRSwNP) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- Therapy is prescribed by or in consultation with an otolaryngologist, allergist, or immunologist
- There is documentation of evidence of nasal polyps by direct examination, endoscopy, or sinus CT scan
- The patient has inadequately controlled disease as determined by ONE of the following:
  - Use of systemic steroids in the past 2 years
  - Endoscopic sinus surgery
- Dupixent will be used as add-on maintenance treatment (i.e., in conjunction with maintenance intranasal steroids)
- The patient had a previous 90-day trial of ONE intranasal corticosteroid

If yes, **approve 300mg/2mL for 6 months by GPID or GPI-14 with a quantity limit of #4mL per 28 days.**

If no, continue to #9.

Does the patient have a diagnosis of eosinophilic esophagitis (EoE) and meet **ONE** of the following criteria?

- The patient is 18 years of age or older
- The patient is 12 to 17 years of age AND weighs at least 40kg

If yes, continue to #10.

If no, continue to #11.

Does the patient meet **ALL** of the following criteria?

- Therapy is prescribed by or in consultation with a gastroenterologist, allergist, or immunologist
- The patient's diagnosis is confirmed by an esophagogastroduodenoscopy (EGD) with biopsy
- The patient had a trial of or contraindication to dietary therapy
- The patient had a trial of or contraindication to a proton pump inhibitor (e.g., omeprazole, lansoprazole, pantoprazole)

If yes, **approve 300mg/2mL for 6 months by GPID or GPI-14 with a quantity limit of #8mL per 28 days.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DUPILUMAB

INITIAL CRITERIA (CONTINUED)

Does the patient have a diagnosis of prurigo nodularis (PN) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- Therapy is prescribed by or in consultation with a dermatologist, immunologist or allergist
- The patient has chronic pruritis (i.e., itch lasting longer than 6 weeks), presence of multiple pruriginous lesions (localized or general), and a history or sign of a prolonged scratching behavior
- The patient had a trial of or contraindication to ONE of the following: topical capsaicin, topical ketamine/amitriptyline/lidocaine, gabapentinoids (e.g., gabapentin, pregabalin), antidepressants (SNRI, SSRI, TCA), k-/mu-opioid receptor antagonists (e.g., naltrexone, butorphanol), thalidomide, topical corticosteroids, topical calcineurin inhibitors, topical calcipotriol, intralesional corticosteroids, phototherapy, methotrexate, cyclosporine, azathioprine

If yes, enter **TWO** approvals by GPID or GPI-14 for the requested strength for a total of **6 months** as follows:

- **FIRST APPROVAL:** Approve with an end date of 1 month as follows:
  - 300mg/2mL: #8mL
- **SECOND APPROVAL:** Approve for 5 months as follows (enter a start date of 1 week after the end of the first approval):
  - 300mg/2mL: #4mL per 28 days.

If no, do not approve.

**INITIAL DENIAL TEXT:** *\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **DUPILUMAB (Dupixent)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
1. Moderate to severe atopic dermatitis (a type of skin condition)
  2. Moderate to severe asthma
  3. Chronic rhinosinusitis with nasal polyposis (a type of long-term nasal condition)
  4. Eosinophilic esophagitis (a type of immune system disorder)
  5. Prurigo nodularis (a type of skin condition)

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**DUPILUMAB**

**INITIAL CRITERIA (CONTINUED)**

**B. If you have moderate to severe atopic dermatitis, approval also requires:**

1. You are 6 months of age or older
2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor), allergist (a type of allergy doctor), or immunologist (a type of immune system doctor)
3. You have atopic dermatitis involving at least 10 percent of body surface area (BSA) OR atopic dermatitis affecting the face, head, neck, hands, feet, groin, or intertriginous areas (between skin folds)
4. You have TWO of the following: intractable pruritus (severe itching), cracking and oozing/bleeding of affected skin, impaired activities of daily living
5. You had a trial of or contraindication (harmful for) to ONE of the following: topical corticosteroid (such as hydrocortisone, clobetasol, halobetasol propionate), topical calcineurin inhibitor [Elidel (pimecrolimus), Protopic (tacrolimus)], topical PDE-4 inhibitor [Eucrisa (crisaborole)], topical JAK inhibitor [Opzelura (ruxolitinib)], phototherapy (light therapy)
6. You will NOT use Dupixent concurrently (at the same time) with other systemic biologics (such as Adbry) or any JAK inhibitors (such as Rinvoq, topical Opzelura, Cibinqo) for the treatment of atopic dermatitis

**C. If you have moderate to severe asthma, approval also requires:**

1. You are 6 years of age or older
2. Therapy is prescribed by or in consultation with a doctor specializing in pulmonary (lung/breathing) or allergy medicine
3. You have an eosinophilic phenotype asthma (type of adult inflammatory asthma) with a documented blood eosinophil level of 150 to 1500 cells/mcL within the past 12 months OR you have oral corticosteroid-dependent asthma
4. You are being treated at the same time with medium, high-dose, or maximally tolerated inhaled corticosteroid [such as triamcinolone acetonide, beclomethasone, mometasone, budesonide] AND at least one other maintenance medication such as long-acting inhaled beta2-agonist (such as salmeterol, formoterol), long-acting muscarinic antagonist (such as aclidinium bromide, ipratropium, umeclidinium, tiotropium), a leukotriene receptor antagonist (such as montelukast, zafirlukast, zileuton), or theophylline

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DUPILUMAB

INITIAL CRITERIA (CONTINUED)

5. You meet ONE of the following:
    - a. You have experienced at least ONE asthma exacerbation (worsening of symptoms) requiring systemic corticosteroid burst lasting at least 3 days within the past 12 months OR at least ONE serious exacerbation requiring hospitalization or emergency room (ER) visit within the past 12 months
    - b. You have poor symptom control despite current therapy as evidenced by at least THREE of the following within the past 4 weeks:
      - i. Daytime asthma symptoms more than twice per week
      - ii. Any night waking due to asthma
      - iii. Use of short-acting inhaled beta2-agonist reliever (such as albuterol) for symptoms more than twice per week
      - iv. Any activity limitation due to asthma
  6. You will NOT use Dupixent concurrently (at the same time) with Xolair or an anti-IL5 biologic (such as Nucala, Cinqair, Fasenra) when these are used for the treatment of asthma
- D. If you have chronic rhinosinusitis with nasal polyposis, approval also requires:**
1. You are 18 years of age or older
  2. Therapy is prescribed by or in consultation with an otolaryngologist (ear, nose, throat doctor), allergist (a type of allergy doctor), or immunologist (a type of immune system doctor)
  3. There is documentation of evidence of nasal polyps (non-cancerous growths) by direct examination, endoscopy (using a small camera) or sinus CT scan
  4. You have inadequately controlled disease as determined by ONE of the following:
    - Use of systemic steroids in the past 2 years
    - Endoscopic sinus surgery (using a small camera to help in surgery)
  5. Dupixent will be used as add-on maintenance treatment (in conjunction with maintenance intranasal steroids)
  6. You had a previous 90-day trial of ONE intranasal corticosteroid
- E. If you have eosinophilic esophagitis, approval also requires:**
1. You meet ONE of the following:
    - a. You are 18 years of age or older
    - b. You are 12 to 17 years of age AND weigh at least 40 kilograms
  2. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions), allergist (a type of allergy doctor), or immunologist (a type of immune system doctor)
  3. Your diagnosis is confirmed by an esophagogastroduodenoscopy (EGD) with biopsy (a test that looks at the lining of your food pipe, stomach, and small intestine)
  4. You had a trial of or contraindication (harmful for) to dietary therapy
  5. You had a trial of or contraindication (harmful for) to a proton pump inhibitor (such as omeprazole, lansoprazole, pantoprazole)

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DUPILUMAB

INITIAL CRITERIA (CONTINUED)

F. If you have prurigo nodularis, approval also requires:

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a dermatologist (skin doctor), immunologist (type of immune system doctor), or allergist
3. You have chronic pruritis (itch lasting longer than 6 weeks), presence of multiple pruriginous lesions (wounds), and a history or sign of a prolonged scratching behavior
4. You had a trial of or contraindication (harmful for) to ONE of the following: topical capsaicin, topical ketamine/amitriptyline/lidocaine, gabapentinoids (e.g., gabapentin, pregabalin), antidepressants (serotonin-norepinephrine reuptake inhibitor [SNRI], selective serotonin reuptake inhibitor [SSRI], tricyclic antidepressant [TCA]), k-/mu-opioid receptor antagonists (e.g., naltrexone, butorphanol), thalidomide, topical corticosteroids, topical calcineurin inhibitors, topical calcipotriol, intralesional corticosteroids, phototherapy, methotrexate, cyclosporine, azathioprine

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of moderate to severe atopic dermatitis and meet **ALL** of the following criteria?
  - The patient has shown improvement while on therapy
  - Dupixent will NOT be used concurrently with other systemic biologics (e.g., Adbry) or any JAK inhibitors (e.g., Rinvoq, topical Opzelura, Cibinqo) for the treatment of atopic dermatitis

If yes, **approve for 12 months by GPID or GPI-14 for the requested strength as follows:**

- **200mg/1.14mL: #2.28mL per 28 days.**
- **300mg/2mL: #4mL per 28 days.**

If no, continue to #2.

CONTINUED ON NEXT PAGE





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DUPILUMAB

RENEWAL CRITERIA (CONTINUED)

2. Does the patient have a diagnosis of moderate to severe asthma and meet **ALL** of the following criteria?

- The patient continues to use an inhaled corticosteroid (ICS) AND at least one other maintenance medication (e.g., long-acting inhaled beta2-agonist [such as salmeterol, formoterol, etc.], long-acting muscarinic antagonist [such as acclidinium bromide, ipratropium, tiotropium, umeclidinium, etc.], a leukotriene receptor antagonist [such as montelukast, zafirlukast, zileuton, etc.], theophylline)
- The patient has shown a clinical response as evidenced by ONE of the following:
  - Reduction in asthma exacerbation from baseline
  - Decreased utilization of rescue medications
  - Increase in percent predicted FEV1 from pretreatment baseline
  - Reduction in severity or frequency of asthma-related symptoms (e.g., wheezing, shortness of breath, coughing, etc.)
- Dupixent will NOT be used concurrently with Xolair or an anti-IL5 biologic (e.g., Nucala, Cinqair, Fasenra) when these are used for the treatment of asthma

If yes, **approve for 12 months by GPID or GPI-14 for the requested strength as follows:**

- **100mg/0.67mL: #1.34mL per 28 days.**
- **200mg/1.14mL: #2.28mL per 28 days.**
- **300mg/2mL: #4mL per 28 days.**

If no, continue to #3.

3. Does the patient have a diagnosis of chronic rhinosinusitis with nasal polyposis (CRSwNP) **AND** meet the following criterion?

- The patient has shown clinical benefit compared to baseline (e.g., improvements in nasal congestion, sense of smell or size of polyps)

If yes, **approve 300mg/2mL for 12 months by GPID or GPI-14 with a quantity limit of #4mL per 28 days.**

If no, continue to #4.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DUPILUMAB

RENEWAL CRITERIA (CONTINUED)

4. Does the patient have a diagnosis of eosinophilic esophagitis (EoE) **AND** meet the following criterion?
- The patient has shown improvement while on therapy (e.g., symptom improvement or achieving histological remission defined as peak esophageal intraepithelial eosinophil count of less than or equal to 6 eos/hpf)

If yes, **approve 300mg/2mL for 12 months by GPID or GPI-14 with a quantity limit of #8mL per 28 days.**

If no, continue to #5.

5. Does the patient have a diagnosis of prurigo nodularis **AND** meet the following criterion?
- The patient has had prurigo nodularis improvement (reduction) of pruritis or pruriginous lesions

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #4mL per 28 days.**  
If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DUPILUMAB (Dupixent)** requires the following rule(s) be met for renewal:

- A. You have **ONE** of the following diagnoses:
1. Moderate to severe atopic dermatitis (a type of skin condition)
  2. Moderate to severe asthma
  3. Chronic rhinosinusitis with nasal polyposis (inflammation of nasal and sinus ways with small growths in the nose)
  4. Eosinophilic esophagitis (a type of immune system disorder)
  5. Prurigo nodularis (a type of skin condition)
- B. **If you have moderate to severe atopic dermatitis, renewal also requires:**
1. You have shown improvement while on therapy
  2. You will **NOT** use Dupixent concurrently (at the same time) with other systemic biologics (such as Adbry) or any JAK inhibitors (such as Rinvoq, topical Opzelura, Cibinqo) for the treatment of atopic dermatitis

***(Renewal denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

DUPILUMAB

RENEWAL CRITERIA (CONTINUED)

**C. If you have moderate to severe asthma, renewal also requires:**

1. You will continue to use an inhaled corticosteroid (ICS) AND at least one other maintenance medication (e.g., long-acting inhaled beta2-agonist [such as salmeterol, formoterol, etc.], long-acting muscarinic antagonist [such as aclidinium bromide, ipratropium, tiotropium, umeclidinium, etc.], a leukotriene receptor antagonist [such as montelukast, zafirlukast, zileuton, etc.], theophylline)
2. You have shown a clinical response as evidenced by ONE of the following:
  - a. Reduction in asthma exacerbation (worsening of symptoms) from baseline
  - b. Decreased use of rescue medications
  - c. Increase in percent predicted FEV1 (amount of air you can forcefully exhale) from pretreatment baseline
  - d. Reduction in severity or frequency of asthma-related symptoms such as less wheezing, shortness of breath, coughing, etc.
3. You will NOT use Dupixent concurrently (at the same time) with Xolair or an anti-IL5 biologic (such as Nucala, Cinqair, Fasenra) when these are used for the treatment of asthma

**D. If you have chronic rhinosinusitis with nasal polyposis, renewal also requires:**

1. You have shown a clinical benefit compared to baseline (such as improvements in nasal congestion, sense of smell or size of polyps)

**E. If you have eosinophilic esophagitis, renewal also requires:**

1. You have shown improvement while on therapy (such as symptom improvement or achieving histological remission defined as peak esophageal intraepithelial eosinophil count of less than or equal to 6 eos/hpf [a type of test that evaluates disease status])

**F. If you have prurigo nodularis, renewal also requires:**

1. You have had prurigo nodularis improvement or reduction of pruritis (itching) or pruriginous lesions (wounds)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**DUPILUMAB**

---

**RATIONALE**

For further information, refer to the Prescribing Information and/or Drug Monograph for Dupixent.

**REFERENCES**

- Dupixent [Prescribing Information]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc.; September 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/23

Created: 01/17

Client Approval: 11/22

P&T Approval: 10/22



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**DUVELISIB**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
DUVELISIB	COPIKTRA	45269		GPI-10 (2153803000)	

**GUIDELINES FOR USE**

- Does the patient have a diagnosis of relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient has received at least two prior therapies for CLL or SLL

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **DUVELISIB (Copiktra)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:

- Relapsed or refractory chronic lymphocytic leukemia (CLL: a type of blood cancer that has returned after treatment or does not fully respond to treatment)
- Small lymphocytic lymphoma (SLL: a type of blood cancer)

B. You are 18 years of age or older

C. You have received at least two prior therapies for chronic lymphocytic leukemia or small lymphocytic lymphoma

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Copiktra.

**REFERENCES**

- Copiktra [Prescribing Information]. Needham, MA: Verastem, Inc.; December 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/22

Created: 11/18

Client Approval: 03/22

P&T Approval: 10/18



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

EDARAVONE ORAL

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
EDARAVONE	RADICAVA ORS		52318	GPI-14 (74509030001820)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of amyotrophic lateral sclerosis (ALS) and meet **ALL** the following?
  - Therapy is prescribed by or in consultation with a neurologist or ALS specialist at an ALS Specialty Center or Care Clinic
  - The duration of patient's disease (from onset of symptoms) is 3 years or less
  - The patient has a forced vital capacity (FVC) greater than 70%
  - The patient has mild to moderate ALS with a score of 2 or higher in all of the following 12 items of the Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R): speech, salivation, swallowing, handwriting, cutting food, dressing and hygiene, turning in bed, walking, climbing stairs, dyspnea, orthopnea, respiratory insufficiency
  - The patient has tried riluzole OR is currently taking riluzole

If yes, enter two approvals by GPID or GPI-14 for a total of 6 months as follows:

- **FIRST APPROVAL:** Approve for 30 days with a quantity limit of #70mL per 28 days.
- **SECOND APPROVAL:** Approve for 5 months with a quantity limit of #50mL per 28 days (Enter a start date of 2 days before the end of the first approval).

If no, do not approve.

**INITIAL DENIAL TEXT:** *\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **EDARAVONE ORAL (Radicava ORS)** requires the following rule(s) be met for approval:

- A. You have amyotrophic lateral sclerosis (ALS: a type of brain and nerve condition)
- B. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor) or ALS specialist at an ALS Specialty Center or Care Clinic
- C. You have had ALS (from onset of symptoms) for 3 years or less
- D. You have a forced vital capacity (FVC: amount of air exhaled from lungs) of greater than 70 percent
- E. You have tried riluzole OR are currently taking riluzole  
*(Initial denial text continued on next page)*

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

EDARAVONE ORAL

INITIAL CRITERIA (CONTINUED)

- F. You have mild to moderate ALS with a score of 2 or higher in all of the following 12 items of the Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFERS-R: a tool for evaluating functional status): speech, salivation, swallowing, handwriting, cutting food, dressing and hygiene, turning in bed, walking, climbing stairs, dyspnea (difficulty breathing), orthopnea (shortness of breath while lying down), respiratory insufficiency (a type of breathing condition)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of amyotrophic lateral sclerosis (ALS) and meet **ALL** of the following criteria?
  - The patient does not require invasive ventilation
  - The patient has improved baseline functional ability OR the patient has maintained a score of 2 or greater in all 12 items of the ALSFRS-R

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #50mL per 28 days.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **EDARAVONE ORAL (Radicava ORS)** requires the following rule(s) be met for renewal:

- A. You have amyotrophic lateral sclerosis (ALS: a type of brain and nerve condition)
- B. You do not require invasive ventilation (inserting a breathing tube into your throat)
- C. You have improved baseline functional ability OR you have maintained a score of 2 or greater in all 12 items of the Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFERS-R)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**EDARAVONE ORAL**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Radicava ORS.

**REFERENCES**

- Radicava ORS [Prescribing Information]. ]. Jersey City, NJ: Mitsubishi Tanabe Pharma America, Inc.; May 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 06/15/22

Created: 05/22

Client Approval: 05/22

P&T Approval: 04/22





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

EFINACONAZOLE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
EFINACONAZOLE	JUBLIA	41184		GPI-10 (9015403700)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of onychomycosis (fungal infection) of the toenail(s) and meets the following criteria?

- The patient previously tried or has a contraindication to oral terbinafine OR oral itraconazole AND ciclopirox topical solution
- The patient has at least **ONE** of the following conditions:
  - The patient has diabetes, peripheral vascular disease (PVD), or immunosuppression
  - The patient has pain surrounding the nail or soft tissue involvement

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Are five or less toenails affected?

If yes, **approve for 48 weeks by HICL or GPI-10 with a quantity limit of #4mL (1 bottle) per 30 days.**

If no, **approve for 48 weeks by HICL or GPI-10 with a quantity limit of #8mL (2 bottles) per 30 days.**

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **EFINACONAZOLE (Jublia)** requires the following rule(s) be met for approval:

You have onychomycosis of the toenail(s) (toenail fungus)

A. You have previously tried the following unless contraindicated (a medical reason why you cannot use): ciclopirox topical solution AND either oral terbinafine OR oral itraconazole

B. You have at least ONE of the following conditions:

1. Diabetes, peripheral vascular disease (narrowed blood vessels reduce blood flow to the limbs), or immunosuppression (weakened immune system)
2. Pain surrounding the nail or soft tissue involvement

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**EFINACONAZOLE**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Jublia.

**REFERENCES**

- Jublia [Prescribing Information]. Bridgewater, NJ: Valeant Pharmaceuticals; September 2016.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 06/14

Client Approval: 04/20

P&T Approval: 01/17



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ELAPEGADEMASE-LVLR

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ELAPEGADEMASE-LVLR	REVCOVI	45340		GPI-10 (3090203020)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of adenosine deaminase severe combined immune deficiency (ADA-SCID) as manifested by **ONE** of the following?
  - Confirmatory genetic test
  - Suggestive laboratory findings (e.g. elevated deoxyadenosine nucleotide [dAXP] levels, lymphopenia) **AND** hallmark signs/symptoms (e.g. recurrent infections, failure to thrive, persistent diarrhea)

If yes, continue to #2.

If no, do not approve

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Is therapy prescribed by or given in consultation with an immunologist, hematologist/oncologist, or physician specializing in inherited metabolic disorders?

If yes, continue to #3.

If no, do not approve

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

3. Does the patient meet **ONE** of the following criteria?
  - The patient has failed or is not a candidate for hematopoietic cell transplantation (HCT)
  - The requested medication will be used as a bridging therapy prior to planned hematopoietic cell transplant or gene therapy

If yes, **approve for 6 months by HICL or GPI-10.**

**APPROVAL TEXT:** Renewal requires 1) documentation of trough plasma ADA activity greater than or equal to 30 mmol/hr/L and trough dAXP levels less than 0.02 mmol/L, **AND** 2) improvement in/maintenance of immune function from baseline, and patient has not received successful hematopoietic cell transplant (HCT) or gene therapy.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ELAPEGADEMASE-LVLR

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ELAPEGADEMASE-LVLR (Revcovi)** requires the following rule(s) be met for approval:

- A. You have adenosine deaminase severe combined immune deficiency (type of inherited disorder that damages immune system) as shown by ONE of the following:
  - 1. Confirmatory generic test
  - 2. Suggestive laboratory findings such as elevated deoxyadenosine nucleotide levels or lymphopenia (not enough of a type of white blood cell) AND you have hallmark signs/symptoms such as recurrent infections, failure to thrive, persistent diarrhea
- B. The requested medication is prescribed by or given in consultation with an immunologist (immune system doctor), hematologist/oncologist (blood/cancer doctor), or physician specializing in inherited metabolic disorders
- C. You have failed or are not a candidate for hematopoietic cell transplant (blood cell transplant from bone marrow), OR the requested medication will be used as a bridging therapy prior to planned hematopoietic cell transplant or gene therapy

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

- 1. Does the patient have a diagnosis of adenosine deaminase severe combined immune deficiency (ADA-SCID) and meet **ALL** of the following criteria?
  - Documentation of trough plasma ADA activity  $\geq 30$  mmol/hr/L **AND** trough dAXP levels  $< 0.02$  mmol/L
  - The patient has improvement in/maintenance of immune function from baseline (e.g. decrease in number and severity of infections), **AND** has not received successful hematopoietic cell transplant (HCT) or gene therapy

If yes, **approve for 12 months by HICL or GPI-10.**

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ELAPEGADEMASE-LVLR

RENEWAL CRITERIA (CONTINUED)

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ELAPEGADEMASE-LVLR (Revcovi)** requires the following rule(s) be met for renewal:

- A. You have adenosine deaminase severe combined immune deficiency (type of inherited disorder that damages immune system)
- B. You have documentation of trough plasma adenosine deaminase activity greater than or equal to 30 mmol/hr/L AND trough deoxyadenosine nucleotide levels less than 0.02 mmol/L
- C. You have improvement in/maintenance of immune function from baseline (such as decrease in number and severity of infections), AND you have not received successful hematopoietic cell transplantation (HCT) or gene therapy

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Revcovi.

**REFERENCES**

- Revcovi [Prescribing Information]. Gaithersburg, MD: Leadiant Biosciences Inc., October 2018.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 02/19

Client Approval: 04/20

P&T Approval: 01/19



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ELAGOLIX

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ELAGOLIX SODIUM	ORILISSA	45108		GPI-10 (3009003010)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of moderate to severe pain associated with endometriosis and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with an obstetrician/gynecologist
  - The diagnosis is confirmed via surgical or direct visualization (e.g., pelvic ultrasound) or histopathological confirmation (e.g., laparoscopy or laparotomy) in the last 10 years
  - The patient had a trial of or contraindication to a nonsteroidal anti-inflammatory drug (NSAID) AND a progestin-containing preparation (e.g., combination hormonal contraceptive preparation, progestin-only therapy)
  - Orilissa will NOT be used concurrently with another GnRH-modulating agent (e.g., Lupron Depot, Synarel, Zoladex)

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Does the patient have normal liver function or mild hepatic impairment (Child-Pugh Class A)?

If yes, **approve for 6 months by GPID or GPI-14 for the requested strength with the following quantity limits:**

- **Orilissa 150mg: #1 per day.**
- **Orilissa 200mg: #2 per day.**

If no, continue to #3.

3. Does the patient have moderate hepatic impairment (Child-Pugh Class B)?

If yes, **approve Orilissa 150mg for 6 months by GPID or GPI-14 with a quantity limit of #1 per day.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ELAGOLIX

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ELAGOLIX (Orilissa)** requires the following rule(s) be met for approval:

- A. You have moderate to severe pain associated with endometriosis (condition affecting the uterus)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with an obstetrician/gynecologist (a type of women's health doctor)
- D. Your diagnosis of endometriosis is confirmed by surgical or direct visualization (such as pelvic ultrasound [type of imaging]) or histopathological (tissue) confirmation (such as laparoscopy [type of surgery] or laparotomy [type of surgery]) in the last 10 years
- E. You had a trial of or contraindication (harmful for) to a nonsteroidal anti-inflammatory drug (NSAID such as ibuprofen, meloxicam, naproxen) AND a progestin-containing preparation (such as combination hormonal contraceptive preparation, progestin-only therapy)
- F. Orilissa will NOT be used at the same time with another GnRH-modulating agent (such as Lupron Depot, Synarel, Zoladex)
- G. Requests for Orilissa 200mg twice daily will only be approved if you have normal liver function or mild hepatic (liver) impairment (Child-Pugh Class A)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Has the patient received **ONE** of the following regimens?
  - A 6-month course of Orilissa 200mg twice daily
  - A 6-month course of Orilissa 150mg once daily and the patient has moderate hepatic impairment (Child-Pugh Class B)
  - A 24-month course of Orilissa 150mg once daily and the patient has normal liver function or mild hepatic impairment (Child-Pugh Class A)

If yes, do not approve.

**RENEWAL DENIAL TEXT:** See the renewal denial text at the end of the guideline.

If no, continue to #2.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ELAGOLIX

RENEWAL CRITERIA (CONTINUED)

2. Does the patient have a diagnosis of moderate to severe pain associated with endometriosis and meet **ALL** of the following criteria?

- The patient has had improvement of pain related to endometriosis while on therapy
- The patient has normal liver function or mild hepatic impairment (Child-Pugh Class A)
- Orilissa will NOT be used concurrently with another GnRH-modulating agent (e.g., Lupron Depot, Synarel, Zoladex)

If yes, **approve Orilissa 150mg for 18 months by GPID or GPI-14 with a quantity limit of #1 per day.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ELAGOLIX (Orilissa)** requires the following rule(s) be met for renewal:

- A. You have moderate to severe pain associated with endometriosis (condition affecting the uterus)
- B. You have improvement of pain related to endometriosis while on therapy
- C. You have normal liver function or mild hepatic (liver) impairment (Child-Pugh Class A)
- D. Orilissa will NOT be used at the same time with another GnRH-modulating agent (such as Lupron Depot, Synarel, Zoladex)

Requests will not be approved if you meet ONE of the following:

- A. You have received a 6-month course of Orilissa 200mg twice daily
- B. You have received a 6-month course of Orilissa 150mg once daily and you have moderate hepatic (liver) impairment (Child-Pugh Class B)
- C. You have received a 24-month course of Orilissa 150mg once daily and you have normal liver function or mild (liver) hepatic impairment (Child-Pugh Class A)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**





**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**ELAGOLIX**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Orilissa.

**REFERENCES**

- Orilissa [Prescribing Information]. North Chicago, IL: AbbVie Inc.; February 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 08/29/22

Created: 08/18

Client Approval: 07/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ELBASVIR/GRAZOPREVIR

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ELBASVIR/ GRAZOPREVIR	ZEPATIER	43030		GPI-10 (1235990230)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of chronic hepatitis C, with genotype 1 or genotype 4 and meet **ALL** the following criteria?

- The patient has an HCV RNA level within the past 6 months
- The patient is 12 years of age or older OR weighs at least 30kg

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient meet at least **ONE** of the following criteria?

- The patient has a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions
- The patient has moderate or severe hepatitis impairment (Child-Pugh B or C)
- The patient is currently taking any of the following medications: phenytoin, carbamazepine, rifampin, efavirenz (e.g., Atripla, Sustiva), atazanavir (e.g., Evotaz, Reyataz), darunavir (e.g., Prezcofix, Prezista), lopinavir, saquinavir, tipranavir, cyclosporine, nafcillin, ketoconazole, modafinil, bosentan, etravirine, elvitegravir/cobicistat/emtricitabine/tenofovir (e.g., Stribild, Genvoya), atorvastatin at doses higher than 20mg daily, rosuvastatin at doses greater than 10mg daily, sofosbuvir (Sovaldi) (as a single agent), velpatasvir/sofosbuvir (Epclusa), ledipasvir/sofosbuvir (Harvoni), pibrentasvir/glecaprevir (Mavyret), or velpatasvir/sofosbuvir/voxilaprevir (Vosevi)

If yes, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

If no, continue to #3.

3. Does the patient meet **ONE** of the following criteria?

- The patient has a contraindication to Epclusa AND Harvoni
- The patient has previously failed a short trial with Epclusa or Harvoni (e.g., inability to tolerate, adverse effect early in therapy); [**NOTE:** An individual who has completed a full course of therapy with Harvoni or Epclusa that did not achieve SVR will not be approved.]

If yes, continue to #4.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ELBASVIR/GRAZOPREVIR

**GUIDELINES FOR USE (CONTINUED)**

4. Is the patient **ONE** of the following?

- Genotype 1a infection, treatment naïve, and NO baseline NS5A polymorphisms
- Genotype 1a infection, previously treated with peginterferon/ribavirin, and NO baseline NS5A polymorphisms
- Genotype 1b infection, treatment naïve
- Genotype 1b infection, previously treated with peginterferon/ribavirin
- Genotype 4 infection, treatment naïve

If yes, **approve for 12 weeks by HICL or GPI-10 for #1 per day.**

If no, continue to #5.

5. Is the requested medication being used with ribavirin and the patient meets **ONE** of the following criteria?

- Genotype 1a infection, previously treated with HCV protease inhibitor triple therapy (HCV protease inhibitor (e.g., Victrelis, Incivek, Olysio) plus peginterferon/ribavirin)
- Genotype 1b infection, previously treated with HCV protease inhibitor triple therapy (HCV protease inhibitor (e.g., Victrelis, Incivek, Olysio) plus peginterferon/ribavirin)

If yes, **approve for 12 weeks by HICL or GPI-10 for #1 per day.**

If no, continue to #6.

6. Is the requested medication being used with ribavirin and the patient meets **ONE** of the following criteria?

- Genotype 1a infection, treatment naïve, and has baseline NS5A polymorphisms
- Genotype 1a infection, previously treated with peginterferon/ribavirin, and has baseline NS5A polymorphisms
- Genotype 4 infection, previously treated with peginterferon/ribavirin

If yes, **approve for 16 weeks by HICL or GPI-10 for #1 per day.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ELBASVIR/GRAZOPREVIR

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline for **ELBASVIR/GRAZOPREVIR (Zepatier)** requires the following rule(s) be met for approval:

- A. You have chronic hepatitis C (type of liver infection)
- B. You have genotype 1 or genotype 4 hepatitis C
- C. You are 12 years of age or older OR weigh at least 30kg
- D. You have an HCV RNA level (amount of virus in your blood) within the past 6 months
- E. You have previously tried Epclusa or Harvoni unless you have a contraindication (harmful for) to both. Patients with previous failure of a full treatment of Epclusa or Harvoni will not be approved
- F. If you have genotype 1a infection, we require testing for baseline NS5A (nonstructural protein 5A) polymorphisms (variations of a type of protein)
- G. Ribavirin use is required if you meet ANY of the following:
  - 1. You have genotype 1a or 1b infection and were previously treated with HCV protease inhibitor triple therapy (HCV protease inhibitor (such as Victrelis, Incivek, Olysio) plus peginterferon/ribavirin
  - 2. You have genotype 1a infection, are treatment naïve, and have baseline NS5A (nonstructural protein 5A) polymorphisms (variations of a type of protein)
  - 3. You have genotype 1a infection, were previously treated, and have baseline NS5A (nonstructural protein 5A) polymorphisms (variations of a type of protein)
  - 4. You have genotype 4 infection and were previously treated
- H. Treatment experienced patients will be approved per product labeling (previous failure of peginterferon/ribavirin for genotype 1a, 1b or 4; previous failure of HCV protease inhibitor triple therapy regimen for genotype 1a or 1b infection)

***(Denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ELBASVIR/GRAZOPREVR

GUIDELINES FOR USE (CONTINUED)

**Zepatier will not be approved if you meet any of the following:**

- A. You are using any of the following interacting medications at the same time while on elbasvir/grazoprevir (Zepatier): phenytoin, carbamazepine, rifampin, efavirenz (such as Atripla, Sustiva), atazanavir (such as Evotaz, Reyataz), darunavir (such as Prezcofix, Prezista), lopinavir, saquinavir, tipranavir, cyclosporine, nafcillin, ketoconazole, modafinil, bosentan, etravirine, elvitegravir/cobicistat/emtricitabine/tenofovir (such as Stribild, Genvoya), atorvastatin at doses higher than 20mg daily, rosuvastatin at doses greater than 10mg daily, sofosbuvir (Sovaldi), velpatasvir/sofosbuvir (Epclusa), ledipasvir/sofosbuvir (Harvoni), pibrentasvir/glecaprevir (Mavyret), or velpatasvir/sofosbuvir/voxilaprevir (Vosevi)
- B. You have moderate or severe liver impairment (Child-Pugh B or C: type of liver condition)
- C. You have a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions (having two or more diseases at the same time)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Zepatier.

**REFERENCES**

- Zepatier [Prescribing Information]. Kenilworth, NJ: Merck; December 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/23

Created: 02/16

Client Approval: 11/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ELAGOLIX/ESTRADIOL/NORETHINDRONE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ELAGOLIX AND ESTRADIOL AND NORETHINDRONE	ORIAHNN	46577		GPI-10 (2499350340)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Has the patient received a total of 24 months cumulative treatment with Oriahnn?

If yes, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

If no, continue to #2.

2. Is the request for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) and the patient meets **ALL** of following criteria?
  - The patient is 18 years of age or older
  - The patient is a premenopausal woman
  - Therapy is prescribed by or given in consultation with an OB/GYN

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #2 per day.**

**APPROVAL TEXT:** Renewal for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) requires the patient had improvement of heavy menstrual bleeding.

If no, do not approve.

**INITIAL DENIAL TEXT:** **\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ELAGOLIX/ESTRADIOL/NORETHINDRONE (Oriahnn)** requires the following rule(s) be met for approval:

- A. The request is for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids: non-cancerous growths in the uterus)
- B. You are 18 years of age or older
- C. You are a premenopausal woman
- D. Therapy is prescribed by or given in consultation with an obstetrician or gynecologist (OB/GYN: doctor who specializes in women's reproductive system)
- E. You have not received a total of 24 months cumulative treatment with Oriahnn  
**(Initial denial text continued on next page)**

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ELAGOLIX/ESTRADIOL/NORETHINDRONE

**INITIAL CRITERIA (CONTINUED)**

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RENEWAL CRITERIA**

1. Has the patient received a total of 24 months cumulative treatment with Oriahnn?

If yes, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

If no, continue to #2.

2. Is the request for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) **AND** the patient meets the following criterion?

- The patient has had improvement of heavy menstrual bleeding

If yes, **approve for 18 months (or up to 24 months cumulative lifetime treatment duration) by HICL or GPI-10 with a quantity limit of #2 per day.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ELAGOLIX/ESTRADIOL/NORETHISTERONE (Oriahnn)** requires the following rule(s) be met for renewal:

- A. The request is for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids: non-cancerous growths in the uterus)
- B. You had improvement of heavy menstrual bleeding on therapy
- C. You have not received a total of 24 months cumulative treatment with Oriahnn

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**ELAGOLIX/ESTRADIOL/NORETHINDRONE**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Oriahnn.

**REFERENCES**

- Oriahnn [Prescribing Information]. North Chicago, IL: AbbVie Inc., May 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/21

Created: 08/20

Client Approval: 11/20

P&T Approval: 07/20





**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**ELEXACAFTOR/TEZACAFTOR/IVACAFTOR**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ELEXACAFTOR/ TEZACAFTOR/ IVACAFTOR	TRIKAFTA	46112		GPI-10 (4530990340)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

- Does the patient have a diagnosis of cystic fibrosis (CF) and meet **ALL** of the following criteria?
  - The patient is 6 years of age or older
  - Therapy is prescribed by or given in consultation with a pulmonologist or cystic fibrosis expert

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

- Does the patient meet **ONE** of the following criteria?
  - Documentation that the patient has at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
  - Documentation that the patient has at least one of the following mutations in the CFTR gene:

<i>3141delI9</i>	<i>E822K</i>	<i>G1069R</i>	<i>L967S</i>	<i>R117L</i>	<i>S912L</i>
<i>546insCTA</i>	<i>F191V</i>	<i>G1244E</i>	<i>L997F</i>	<i>R117P</i>	<i>S945L</i>
<i>A46D</i>	<i>F311del</i>	<i>G1249R</i>	<i>L1077P</i>	<i>R170H</i>	<i>S977F</i>
<i>A120T</i>	<i>F311L</i>	<i>G1349D</i>	<i>L1324P</i>	<i>R258G</i>	<i>S1159F</i>
<i>A234D</i>	<i>F508C</i>	<i>H139R</i>	<i>L1335P</i>	<i>R334L</i>	<i>S1159P</i>
<i>A349V</i>	<i>F508C; S1251N</i>	<i>H199Y</i>	<i>L1480P</i>	<i>R334Q</i>	<i>S1251N</i>
<i>A455E</i>	<i>F508del</i>	<i>H939R</i>	<i>M152V</i>	<i>R347H</i>	<i>S1255P</i>
<i>A554E</i>	<i>F575Y</i>	<i>H1054D</i>	<i>M265R</i>	<i>R347L</i>	<i>T338I</i>
<i>A1006E</i>	<i>F1016S</i>	<i>H1085P</i>	<i>M952I</i>	<i>R347P</i>	<i>T1036N</i>
<i>A1067T</i>	<i>F1052V</i>	<i>H1085R</i>	<i>M952T</i>	<i>R352Q</i>	<i>T1053I</i>
<i>D110E</i>	<i>F1074L</i>	<i>H1375P</i>	<i>M1101K</i>	<i>R352W</i>	<i>V201M</i>
<i>D110H</i>	<i>F1099L</i>	<i>I148T</i>	<i>P5L</i>	<i>R553Q</i>	<i>V232D</i>
<i>D192G</i>	<i>G27R</i>	<i>I175V</i>	<i>P67L</i>	<i>R668C</i>	<i>V456A</i>
<i>D443Y</i>	<i>G85E</i>	<i>I336K</i>	<i>P205S</i>	<i>R751L</i>	<i>V456F</i>
<i>D443Y; G576A; R668C</i>	<i>G126D</i>	<i>I502T</i>	<i>P574H</i>	<i>R792G</i>	<i>V562I</i>
<i>D579G</i>	<i>G178E</i>	<i>I601F</i>	<i>Q98R</i>	<i>R933G</i>	<i>V754M</i>
<i>D614G</i>	<i>G178R</i>	<i>I618T</i>	<i>Q237E</i>	<i>R1066H</i>	<i>V1153E</i>
<i>D836Y</i>	<i>G194R</i>	<i>I807M</i>	<i>Q237H</i>	<i>R1070Q</i>	<i>V1240G</i>
<i>D924N</i>	<i>G194V</i>	<i>I980K</i>	<i>Q359R</i>	<i>R1070W</i>	<i>V1293G</i>
<i>D979V</i>	<i>G314E</i>	<i>I1027T</i>	<i>Q1291R</i>	<i>R1162L</i>	<i>W361R</i>
<i>D1152H</i>	<i>G463V</i>	<i>I1139V</i>	<i>R31L</i>	<i>R1283M</i>	<i>W1098C</i>
<i>D1270N</i>	<i>G480C</i>	<i>I1269N</i>	<i>R74Q</i>	<i>R1283S</i>	<i>W1282R</i>

Copyright © 2023 MediImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MediImpact. MediImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

E56K	G551D	I1366N	R74W	S13F	Y109N
E60K	G551S	K1060T	R74W; D1270N	S341P	Y161D
E92K	G576A	L15P	R74W; V201M	S364P	Y161S
E116K	G576A; R668C	L165S	R74W; V201M; D1270N	S492F	Y563N
E193K	G622D	L206W	R75Q	S549N	Y1014C
E403D	G628R	L320V	R117C	S549R	Y1032C
E474K	G970D	L346P	R117G	S589N	
E588V	G1061R	L453S	R117H	S737F	

If yes, **approve for 24 weeks by HICL or GPI-10 with a quantity limit of #3 per day.**

**APPROVAL TEXT:** Renewal requires the patient has shown improvement in clinical status compared to baseline as shown by ONE of the following: i) patient has improved, maintained, or demonstrated less than expected decline in FEV1, ii) patient has improved, maintained, or demonstrated less than expected decline in BMI, or iii) patient has experienced a reduction in rate of pulmonary exacerbations.

If no, do not approve.

**INITIAL DENIAL TEXT:** *\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **ELEXACAFTOR/TEZACAFTOR/IVACAFTOR (Trikafta)** requires the following rule(s) be met for approval:

- A. You have cystic fibrosis (life-threatening disorder that damages lungs and digestive system)
- B. You are 6 years of age or older
- C. Therapy is prescribed by or given in consultation with a pulmonologist (doctor who specializes in lungs) or cystic fibrosis expert
- D. You meet ONE of the following:
  - 1. Documentation that you have at least one *F508del* mutation (a permanent change in your DNA that make up your gene) in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
  - 2. Documentation that you have at least one of the following mutations in the CFTR gene:

3141del9	E822K	G1069R	L967S	R117L	S912L
546insCTA	F191V	G1244E	L997F	R117P	S945L
A46D	F311del	G1249R	L1077P	R170H	S977F
A120T	F311L	G1349D	L1324P	R258G	S1159F
A234D	F508C	H139R	L1335P	R334L	S1159P
A349V	F508C; S1251N	H199Y	L1480P	R334Q	S1251N
A455E	F508del	H939R	M152V	R347H	S1255P
A554E	F575Y	H1054D	M265R	R347L	T338I
A1006E	F1016S	H1085P	M952I	R347P	T1036N
A1067T	F1052V	H1085R	M952T	R352Q	T1053I



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

D110E	F1074L	H1375P	M1101K	R352W	V201M
D110H	F1099L	I148T	P5L	R553Q	V232D
D192G	G27R	I175V	P67L	R668C	V456A
D443Y	G85E	I336K	P205S	R751L	V456F
D443Y; G576A; R668C	G126D	I502T	P574H	R792G	V562I
D579G	G178E	I601F	Q98R	R933G	V754M
D614G	G178R	I618T	Q237E	R1066H	V1153E
D836Y	G194R	I807M	Q237H	R1070Q	V1240G
D924N	G194V	I980K	Q359R	R1070W	V1293G
D979V	G314E	I1027T	Q1291R	R1162L	W361R
D1152H	G463V	I1139V	R31L	R1283M	W1098C
D1270N	G480C	I1269N	R74Q	R1283S	W1282R
E56K	G551D	I1366N	R74W	S13F	Y109N
E60K	G551S	K1060T	R74W; D1270N	S341P	Y161D
E92K	G576A	L15P	R74W; V201M	S364P	Y161S
E116K	G576A; R668C	L165S	R74W; V201M; D1270N	S492F	Y563N
E193K	G622D	L206W	R75Q	S549N	Y1014C
E403D	G628R	L320V	R117C	S549R	Y1032C
E474K	G970D	L346P	R117G	S589N	
E588V	G1061R	L453S	R117H	S737F	

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ELEXACAFTOR/TEZACAFTOR/IVACAFTOR

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of cystic fibrosis (CF) and improvement in clinical status compared to baseline as shown by **ONE** of the following?
  - The patient has improved, maintained, or demonstrated less than expected decline in FEV1 (forced expiratory volume)
  - The patient has improved, maintained, or demonstrated less than expected decline in BMI (body mass index)
  - The patient has experienced a reduction in rate of pulmonary exacerbations

If yes, **approve for lifetime by HICL or GPI-10 with a quantity limit of #3 per day.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ELEXACAFTOR/TEZACAFTOR/IVACAFTOR (Trikafta)** requires the following rule(s) be met for renewal:

- A. You have cystic fibrosis (life-threatening disorder that damages lungs and digestive system)
- B. You have shown improvement in clinical (medical) status compared to baseline as shown by **ONE** of the following:
  1. You have improved, maintained, or demonstrated less than expected decline in FEV1 (forced expiratory volume: amount of air you can exhale in 1 second)
  2. You have improved, maintained, or demonstrated less than expected decline in BMI (body mass index)
  3. You have experienced a reduction in rate of pulmonary exacerbations (you have less attacks of breathing problems)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**ELEXACAFTOR/TEZACAFTOR/IVACAFTOR**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Trikafta.

**REFERENCES**

- Trikafta [Prescribing Information]. Boston, MA: Vertex Pharmaceuticals Inc.; June 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/21

Created: 02/20

Client Approval: 06/21

P&T Approval: 07/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ELTROMBOPAG

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ELTROMBOPAG OLAMINE	PROMACTA	35989		GPI-10 (8240503010)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of chronic immune (idiopathic) thrombocytopenia (ciTP) and meet **ALL** of the following criteria?
  - The patient is 1 year of age or older
  - Therapy is prescribed by or given in consultation with a hematologist or immunologist
  - The patient had a trial of or contraindication to corticosteroids or immunoglobulins, or had an insufficient response to splenectomy

If yes, continue to #2.

If no, continue to #5.

2. Is the request for Promacta tablets?

If yes, **approve for 2 months by GPID or GPI-14 for all strengths as follows:**

- **Promacta 12.5mg tablet: #1 per day.**
- **Promacta 25mg tablet: #1 per day.**
- **Promacta 50mg tablet: #1 per day.**
- **Promacta 75mg tablet: #1 per day.**

**APPROVAL TEXT:** Renewal requires a clinical response, as defined by an increase in platelet count to at least 50X10<sup>9</sup>/L (at least 50,000 per microliter).

If no, continue to #3.

3. Is the request for Promacta packets **AND** the patient is 12 years of age or less?

If yes, **approve for 2 months by GPID or GPI-14 for all strengths as follows:**

- **Promacta 12.5mg packets: #1 per day.**
- **Promacta 25mg packets: #3 per day.**

**APPROVAL TEXT:** Renewal requires a clinical response as defined by an increase in platelet count to at least 50X10<sup>9</sup>/L (at least 50,000 per microliter).

If no, continue to #4.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ELTROMBOPAG

INITIAL CRITERIA (CONTINUED)

4. Is the request for Promacta packets and the patient meets **ALL** of the following criteria?
- The patient is greater than 12 years of age
  - The patient had a trial of Promacta tablets
  - The patient has a medical need for powder packets

If yes, **approve for 2 months by GPID or GPI-14 for all strengths as follows:**

- **Promacta 12.5mg packets: #1 per day.**
- **Promacta 25mg packets: #3 per day.**

**APPROVAL TEXT:** Renewal requires a clinical response as defined by an increase in platelet count to at least  $50 \times 10^9/L$  (at least 50,000 per microliter).

If no, do not approve for Promacta packets. **Please enter proactive approvals for all strengths of Promacta tablets for 2 months by GPID or GPI-14 as follows:**

- **Promacta 12.5mg tablet: #1 per day.**
- **Promacta 25mg tablet: #1 per day.**
- **Promacta 50mg tablet: #1 per day.**
- **Promacta 75mg tablet: #1 per day.**

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

5. Does the patient have a diagnosis of thrombocytopenia due to chronic hepatitis C **AND** meet the following criterion?
- The patient's thrombocytopenia prevents the initiation of interferon-based therapy or limits the ability to maintain interferon-based therapy

If yes, continue to #6.

If no, continue to #9.

6. Is the request for Promacta tablets?

If yes, **approve for 12 months by GPID or GPI-14 for all strengths as follows:**

- **Promacta 12.5mg tablet: #1 per day.**
- **Promacta 25mg tablet: #1 per day.**
- **Promacta 50mg tablet: #2 per day.**
- **Promacta 75mg tablet: #1 per day.**

If no, continue to #7.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ELTROMBOPAG

INITIAL CRITERIA (CONTINUED)

7. Is the request for Promacta packets **AND** the patient is 12 years of age or less?

If yes, **approve for 12 months by GPID or GPI-14 for all strengths as follows:**

- **Promacta 12.5mg packets: #1 per day.**
- **Promacta 25mg packets: #4 per day.**

If no, continue to #8.

8. Is the request for Promacta packets and the patient meets **ALL** of the following criteria?

- The patient is greater than 12 years of age
- The patient had a trial of Promacta tablets
- The patient has a medical need for powder packets

If yes, **approve for 12 months by GPID or GPI-14 for all strengths as follows:**

- **Promacta 12.5mg packets: #1 per day.**
- **Promacta 25mg packets: #4 per day.**

If no, do not approve for Promacta packets. **Please enter proactive approvals for all strengths of Promacta tablets for 12 months by GPID or GPI-14 as follows:**

- **Promacta 12.5mg tablet: #1 per day.**
- **Promacta 25mg tablet: #1 per day.**
- **Promacta 50mg tablet: #2 per day.**
- **Promacta 75mg tablet: #1 per day.**

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

9. Does the patient have a diagnosis of severe aplastic anemia and meet **ALL** of the following criteria?

- The patient is 2 years of age or older
- Promacta will be used in combination with standard immunosuppressive therapy as first-line treatment

If yes, continue to #10.

If no, continue to #13.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ELTROMBOPAG

INITIAL CRITERIA (CONTINUED)

10. Is the request for Promacta tablets?

If yes, approve for 12 months by GPID or GPI-14 for all strengths as follows:

- Promacta 12.5mg tablet: #3 per day.
- Promacta 25mg tablet: #1 per day.
- Promacta 50mg tablet: #2 per day.
- Promacta 75mg tablet: #2 per day.

If no, continue to #11.

11. Is the request for Promacta packets **AND** the patient is 12 years of age or less?

If yes, approve for 12 months by GPID or GPI-14 for all strengths as follows:

- Promacta 12.5mg packets: #3 per day.
- Promacta 25mg packets: #6 per day.

If no, continue to #12.

12. Is the request for Promacta packets and the patient meets **ALL** of the following criteria?

- The patient is greater than 12 years of age
- The patient had a trial of Promacta tablets
- The patient has a medical need for powder packets

If yes, approve for 12 months by GPID or GPI-14 for all strengths as follows:

- Promacta 12.5mg packets: #3 per day.
- Promacta 25mg packets: #6 per day.

If no, do not approve for Promacta packets. **Please enter proactive approvals for all strengths of Promacta tablets for 12 months by GPID or GPI-14 as follows:**

- Promacta 12.5mg tablet: #3 per day.
- Promacta 25mg tablet: #1 per day.
- Promacta 50mg tablet: #2 per day.
- Promacta 75mg tablet: #2 per day.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

13. Does the patient have a diagnosis of severe aplastic anemia **AND** meet the following criterion?

- The patient had an insufficient response to immunosuppressive therapy

If yes, continue to #14.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ELTROMBOPAG

INITIAL CRITERIA (CONTINUED)

14. Is the request for Promacta tablets?

If yes, **approve for 12 months by GPID or GPI-14 for all strengths as follows:**

- **Promacta 12.5mg tablet: #1 per day.**
- **Promacta 25mg tablet: #1 per day.**
- **Promacta 50mg tablet: #2 per day.**
- **Promacta 75mg tablet: #2 per day.**

If no, continue to #15.

15. Is the request for Promacta packets **AND** the patient is 12 years of age or less?

If yes, **approve for 12 months by GPID or GPI-14 for all strengths as follows:**

- **Promacta 12.5mg packets: #1 per day.**
- **Promacta 25mg packets: #6 per day.**

If no, continue to #16.

16. Is the request for Promacta packets and the patient meets **ALL** of the following criteria?

- The patient is greater than 12 years of age
- The patient had a trial of Promacta tablets
- The patient has a medical need for powder packets

If yes, **approve for 12 months by GPID or GPI-14 for all strengths as follows:**

- **Promacta 12.5mg packets: #1 per day.**
- **Promacta 25mg packets: #6 per day.**

If no, do not approve for Promacta packets. **Please enter proactive approvals for all strengths of Promacta tablets for 12 months by GPID or GPI-14 as follows:**

- **Promacta 12.5mg tablet: #1 per day.**
- **Promacta 25mg tablet: #1 per day.**
- **Promacta 50mg tablet: #2 per day.**
- **Promacta 75mg tablet: #2 per day.**

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ELTROMBOPAG

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ELTROMBOPAG (Promacta)** requires the following rule(s) be met for approval:

- A. You have one of the following diagnoses:
  - 1. Chronic immune (idiopathic) thrombocytopenia (low levels of the blood cells that prevent bleeding)
  - 2. Thrombocytopenia (low blood platelet count) due to chronic hepatitis C
  - 3. Severe aplastic anemia (type of blood disorder)
- B. **If you are greater than 12 years of age and the request is for Promacta packets, approval also requires:**
  - 1. You previously had a trial of Promacta tablets
  - 2. You have a medical need for powder packets
- C. **If you have chronic immune (idiopathic) thrombocytopenia, approval also requires:**
  - 1. You are 1 year of age or older
  - 2. You have tried corticosteroids or immunoglobulins, or did not have a good enough response to a splenectomy (removal of spleen) - unless there is a medical reason why you cannot (contraindication)
  - 3. The medication is prescribed by or given in consultation with a hematologist (blood specialist) or immunologist (allergy/immune system doctor)
- D. **If you have thrombocytopenia due to chronic hepatitis C, approval also requires:**
  - 1. Your thrombocytopenia does not allow you to start interferon-based therapy (type of drug for hepatitis) or limits your ability to maintain interferon-based therapy
- E. **If you have severe aplastic anemia, approval also requires ONE of the following:**
  - 1. You are 2 years of age or older and Promacta will be used in combination with standard immunosuppressive therapy (treatment that prevents activity from your immune system) as first-line treatment
  - 2. You did not have a good enough response to immunosuppressive therapy

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ELTROMBOPAG

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

**NOTE:** For the diagnoses of thrombocytopenia due to chronic hepatitis C or severe aplastic anemia, please refer to the Initial Criteria section.

1. Does the patient have a diagnosis of chronic immune (idiopathic) thrombocytopenia (cITP), **AND** meet the following criterion?
  - The patient has a clinical response, as defined by an increase in platelet count to at least  $50 \times 10^9/L$  (at least 50,000 per microliter)

If yes, **approve for 12 months by GPID or GPI-14 for all strengths and formulations as follows:**

- Promacta 12.5mg tablet: #1 per day.
- Promacta 25mg tablet: #1 per day.
- Promacta 50mg tablet: #1 per day.
- Promacta 75mg tablet: #1 per day.
- Promacta 12.5mg packets: #1 per day.
- Promacta 25mg packets: #3 per day.

If no, do not approve.

**RENEWAL DENIAL TEXT:** **\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ELTROMBOPAG (Promacta)** requires the following rules be met for renewal:

- A. You have chronic immune (idiopathic) thrombocytopenia (low levels of the blood cells that prevent bleeding)
- B. You have a clinical response, as defined by an increase in platelet count to at least  $50 \times 10^9/L$  (at least 50,000 per microliter)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**ELTROMBOPAG**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Promacta.

**REFERENCES**

- Promacta [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; October 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/20/20

Created: 01/09

Client Approval: 04/20

P&T Approval: 07/19



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ELUXADOLINE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ELUXADOLINE	VIBERZI	42445		GPI-10 (5255802000)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of irritable bowel syndrome with diarrhea (IBS-D) and meets **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or given in consultation with a gastroenterologist
  - The patient had a trial of or contraindication to Xifaxan (rifaximin) **AND** either tricyclic anti-depressants (e.g., amitriptyline, desipramine) **OR** dicyclomine

If yes, continue to #2.

If no, do not approve.

**INITIAL DENIAL TEXT:** **\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ELUXADOLINE (Viberzi)** requires the following rule(s) be met for approval:

- A. You have irritable bowel syndrome with diarrhea (an intestinal problem causing pain in the belly, gas, diarrhea, and constipation)
- B. You are 18 years of age or older
- C. The medication is prescribed by or given in consultation with a gastroenterologist (a doctor who specializes in conditions of the stomach, intestine and related organs)
- D. You had a trial of Xifaxan (rifaximin) **AND** either tricyclic anti-depressants (such as amitriptyline, desipramine) **OR** dicyclomine, unless there is a medical reason why you cannot (contraindication)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ELUXADOLINE

INITIAL CRITERIA (CONTINUED)

2. Does the patient meet **ANY** of the following criteria?

- Patient does not have a gallbladder
- Patient is receiving concomitant OATP1B1 inhibitors (e.g., atazanavir, cyclosporine, eltrombopag, gemfibrozil, lopinavir, rifampin, ritonavir, saquinavir, tipranavir)
- Patient has mild or moderate hepatic impairment
- Patient is intolerant to Viberzi 100mg

If yes, **approve ELUXADOLINE 75MG for 12 weeks by GPID or GPI-14 with a quantity limit of #2 per day.**

**APPROVAL TEXT:** Renewal requires that the patient has experienced at least 30% decrease in abdominal pain (on a 0-10 point pain scale) and the patient has experienced at least 50% reduction in the number of days per week with a stool consistency of mushy stool (Bristol Stool scale type 6) or entirely liquid stool (Bristol Stool scale type 7).

If no, **approve ELUXADOLINE 100MG for 12 weeks by GPID or GPI-14 with a quantity limit of #2 per day.**

**APPROVAL TEXT:** Renewal requires that the patient has experienced at least 30% decrease in abdominal pain (on a 0-10 point pain scale) and the patient has experienced at least 50% reduction in the number of days per week with a stool consistency of mushy stool (Bristol Stool scale type 6) or entirely liquid stool (Bristol Stool scale type 7).

RENEWAL CRITERIA

1. Is the patient being treated for irritable bowel syndrome with diarrhea (IBS-D) and meets **ALL** of the following criteria?

- Patient has experienced at least 30% decrease in abdominal pain (on a 0-10 point pain scale)
- Patient has experienced at least 50% reduction in the number of days per week with a stool consistency of mushy stool (Bristol Stool scale type 6) or entirely liquid stool (Bristol Stool scale type 7)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.**

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text on the next page.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ELUXADOLINE

RENEWAL CRITERIA (CONTINUED)

**RENEWAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **ELUXADOLINE (Viberzi)** requires the following rule(s) be met for renewal:

1. You have irritable bowel syndrome with diarrhea (an intestinal problem causing pain in the belly, gas, diarrhea, and constipation)
2. You had at least 30% decrease in abdominal pain (stomach pain) on a 0-10 point pain scale
3. You had at least 50% reduction in the number of days per week with a stool consistency of mushy stool (Bristol Stool scale type 6) or entirely liquid stool (Bristol Stool scale type 7).

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Viberzi.

**REFERENCES**

- Viberzi [Prescribing Information]. Madison, NJ: Allergan USA, Inc; June 2018.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 02/16

Client Approval: 04/20

P&T Approval: 02/16





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

EMICIZUMAB-KXWH

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
EMICIZUMAB-KXWH	HEMLIBRA	44640		GPI-10 (8510503020)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of hemophilia A (congenital factor VIII deficiency) and meet **ALL** of the following criteria?
  - Therapy is prescribed by or in consultation with a hematologist
  - The requested medication will be used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Is the request for a patient **WITH** factor VIII inhibitors **AND** the patient meets the following criterion?
  - The patient has a history of a high titer of factor VIII inhibitor defined as at least 5 or more Bethesda units per milliliter

If yes, **approve for 12 months by HICL or GPI-10.**

If no, continue to #3.

3. Is the request for a patient **WITHOUT** factor VIII inhibitors?

If yes, continue to #4.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

4. Does the patient have moderate to severe hemophilia A, defined as less than 5% factor VIII activity compared to normal?

If yes, **approve for 12 months by HICL or GPI-10.**

If no, continue to #5.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

EMICIZUMAB-KXWH

INITIAL CRITERIA (CONTINUED)

5. Does the patient have mild hemophilia A, defined as 5%-40% factor VIII activity compared to normal, and meet **ONE** of the following criteria?
- The patient has experienced severe, traumatic, or spontaneous bleeding episode(s) (may occur in joint or muscle)
  - The patient has experienced a life-threatening bleed (e.g., intracranial hemorrhage [ICH])
  - The patient has venous access difficulties impeding regular clotting factor infusions

If yes, **approve for 12 months by HICL or GPI-10.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **EMICIZUMAB-KXWH (Hemlibra)** requires the following rule(s) be met for approval:

- A. You have hemophilia A (congenital factor VIII deficiency: a type of bleeding disorder)
- B. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor)
- C. The requested medication will be used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes
- D. **If you have hemophilia A with factor VIII inhibitors (a type of protein), approval also requires:**
  - 1. You have a history of a high titer (concentration) of factor VIII inhibitor defined as at least 5 or more Bethesda units per milliliter
- E. **If you have hemophilia A without factor VIII inhibitors (a type of protein), approval also requires ONE of the following criteria:**
  - 1. You have moderate to severe hemophilia A, defined as less than 5% factor VIII activity compared to normal
  - 2. You have mild hemophilia A, defined as 5%-40% factor VIII activity compared to normal, and meet ONE of the following:
    - a. You have experienced severe, traumatic, or spontaneous (sudden) bleeding episode(s) (may occur in joint or muscle)
    - b. You have experienced a life-threatening bleed (for example intracranial hemorrhage [ICH: a type of bleeding in your head])
    - c. It is difficult to access your veins which prevents or delays you in receiving regular clotting factor infusions

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

EMICIZUMAB-KXWH

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

- Does the patient have a diagnosis of hemophilia A (congenital factor VIII deficiency) **AND** meet the following criterion?
  - The patient has had clinical benefit compared to baseline

If yes, **approve for 12 months by HICL or GPI-10.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **EMICIZUMAB-KXWH (Hemlibra)** requires the following rule(s) be met for renewal:

- You have hemophilia A (congenital factor VIII deficiency: a type of bleeding disorder)
- You had a clinical benefit after using the medication compared to baseline

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Hemlibra.

**REFERENCES**

- Hemlibra [Prescribing Information]. Genentech, Inc.: South San Francisco, CA; June 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/23

Created: 02/18

Client Approval: 02/23

P&T Approval: 01/23



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ENASIDENIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ENASIDENIB	IDHIFA	44450		GPI-10 (2153503020)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of relapsed or refractory acute myeloid leukemia (AML) **AND** meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient is isocitrate dehydrogenase-2 (IDH2) mutation positive as detected by an FDA-approved diagnostic test

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ENASIDENIB (Idhifa)** requires the following rule(s) be met for approval:

- A. You have relapsed or refractory acute myeloid leukemia (a type of blood and bone marrow cancer that has returned after or is resistant to treatment)
- B. You are 18 years of age or older
- C. You are isocitrate dehydrogenase-2 (a type of enzyme) mutation positive as detected by an FDA (Food and Drug Administration)-approved diagnostic test

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Idhifa.

**REFERENCES**

- Idhifa [Prescribing Information]. Summit, NJ: Celgene Corporation; September 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A  
Commercial Effective: 07/01/20

Created: 08/17  
Client Approval: 04/20

P&T Approval: 10/17



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ENCORAFENIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ENCORAFENIB	BRAFTOVI	45039		GPI-10 (2153204000)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of unresectable or metastatic melanoma and meet **ALL** of the following criteria?
  - The patient has a BRAF V600E or V600K mutation as detected by an FDA-approved test
  - Braftovi will be used in combination with Mektovi (binimetinib)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #6 per day.**  
If no, continue to #2.

2. Does the patient have a diagnosis of metastatic colorectal cancer (mCRC) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient has a BRAF V600E mutation as detected by an FDA-approved test
  - Braftovi will be used in combination with Erbitux (cetuximab)
  - The patient has previously received prior therapy

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ENCORAFENIB (Braftovi)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
  1. Unresectable or metastatic melanoma (a type of skin cancer that cannot be completely removed with surgery or has spread to other parts of the body)
  2. Metastatic colorectal cancer (a type of digestive cancer that has spread to other parts of the body)
- B. **If you have unresectable or metastatic melanoma, approval also requires:**
  1. You have a BRAF V600E or V600K mutation (types of gene mutations) as detected by an FDA (Food and Drug Administration)-approved test
  2. Braftovi will be used in combination with Mektovi (binimetinib)
- C. **If you have metastatic colorectal cancer, approval also requires:**
  1. You are 18 years of age or older
  2. You have a BRAF V600E mutation (types of gene mutation) as detected by an FDA (Food and Drug Administration)-approved test
  3. Braftovi will be used in combination with Erbitux (cetuximab)
  4. You have previously received treatment

***(Denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ENCORAFENIB

**GUIDELINES FOR USE (CONTINUED)**

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Braftovi.

**REFERENCES**

- Braftovi [Prescribing Information]. Boulder, CO: Array BioPharma Inc.; February 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/22

Created: 08/18

Client Approval: 03/22

P&T Approval: 04/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ENTRECTINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ENTRECTINIB	ROZLYTREK	45952		GPI-10 (2153382000)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of metastatic non-small cell lung cancer (NSCLC) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient has *ROS1*-positive tumors

If yes, **approve for 12 months by GPID or GPI-14 for all strengths as follows:**

- **Rozlytrek 100mg: #5 per day.**
- **Rozlytrek 200mg: #3 per day.**

If no, continue to #2.

2. Does the patient have a diagnosis of solid tumor and meet **ALL** of the following criteria?
  - The patient is 12 years of age or older
  - The tumor has a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation
  - The tumor is metastatic or surgical resection is likely to result in severe morbidity
  - There are no satisfactory alternative treatments, or the patient has progressed following treatment

If yes, **approve for 12 months by GPID or GPI-14 for all strengths as follows:**

- **Rozlytrek 100mg: #5 per day.**
- **Rozlytrek 200mg: #3 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ENTRECTINIB (Rozlytrek)** requires the following rule(s) be met for approval:

- A. You have metastatic non-small cell lung cancer (type of lung cancer that has spread to other parts of body) OR a solid tumor
- B. **If you have metastatic non-small cell lung cancer (NSCLC), approval also requires:**
  1. You are 18 years of age or older
  2. You have *ROS1*-positive tumors (you have a type of gene mutation)

***(Denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ENTRECTINIB

GUIDELINES FOR USE (CONTINUED)

C. If you have a solid tumor, approval also requires:

1. You are 12 years of age or older
2. The tumor has a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation (you have a type of gene mutation that doesn't have any known resistance)
3. The tumor is metastatic (has spread to other parts of body) or surgical resection (removal) is likely to result in severe morbidity (disease)
4. There are no satisfactory alternative treatments, or you have progressed (gotten worse) after treatment

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Rozlytrek.

**REFERENCES**

- Rozlytrek [Prescribing Information]. South San Francisco, CA: Genentech USA, Inc.; August 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 11/19

Client Approval: 04/20

P&T Approval: 10/19





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ENZALUTAMIDE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ENZALUTAMIDE	XTANDI	39580		GPI-10 (2140243000)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have **ONE** of the following diagnoses?

- Metastatic castration-sensitive prostate cancer (mCSPC)
- Metastatic castration-resistant prostate cancer (mCRPC)

If yes, continue to #3.

If no, continue to #2.

2. Does the patient have a diagnosis of non-metastatic castration-resistant prostate cancer (nmCRPC) **AND** meet the following criterion?

- The patient has high risk prostate cancer (i.e., rapidly increasing prostate specific antigen levels)

If yes, continue to #3.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

3. Does the patient meet **ONE** of the following criteria?

- The patient previously received a bilateral orchiectomy
- The patient has a castrate level of testosterone (i.e., < 50 ng/dL)
- The requested medication will be used concurrently with a gonadotropin releasing hormone (GnRH) analog (e.g., leuprolide, goserelin, histrelin, degarelix)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ENZALUTAMIDE

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **ENZALUTAMIDE (Xtandi)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
1. Metastatic castration-resistant prostate cancer (mCRPC: prostate cancer that has spread to other parts of the body and does not respond to hormone therapy)
  2. Metastatic castration-sensitive prostate cancer (mCSPC: prostate cancer that has spread to other parts of the body and responds to hormone therapy)
  3. Non-metastatic castration-resistant prostate cancer (nmCRPC: prostate cancer that has not spread to other parts of the body and does not respond to hormone therapy)
- B. You meet ONE of the following:
1. You previously received a bilateral orchiectomy (both testicles have been surgically removed)
  2. You have a castrate level of testosterone (your blood testosterone levels are less than 50 ng/dL)
  3. The requested medication will be used together with a gonadotropin releasing hormone analog (such as leuprolide, goserelin, histrelin, degarelix)
- C. **If you have non-metastatic castration-resistant prostate cancer, approval also requires:**
1. You have a high-risk prostate cancer (rapidly increasing prostate specific antigen levels)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have ONE of the following diagnoses?
  - Metastatic or non-metastatic castration-resistant prostate cancer (CRPC)
  - Metastatic castration-sensitive prostate cancer (mCSPC)

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ENZALUTAMIDE

RENEWAL CRITERIA (CONTINUED)

2. Does the patient meet **ONE** of the following criteria?

- The patient previously received a bilateral orchiectomy
- The patient has a castrate level of testosterone (i.e., < 50 ng/dL)
- The requested medication will be used concurrently with a gonadotropin releasing hormone (GnRH) analog (e.g., leuprolide, goserelin, histrelin, degarelix)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ENZALUTAMIDE (Xtandi)** requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:

1. Metastatic castration-resistant prostate cancer (mCRPC: prostate cancer that has spread to other parts of the body and does not respond to hormone therapy)
2. Metastatic castration-sensitive prostate cancer (mCSPC: prostate cancer that has spread to other parts of the body and responds to hormone therapy)
3. Non-metastatic castration-resistant prostate cancer (nmCRPC: prostate cancer that has not spread to other parts of the body and does not respond to hormone therapy)

B. You meet ONE of the following:

1. You previously received a bilateral orchiectomy (both testicles have been surgically removed)
2. You have a castrate level of testosterone (your blood testosterone levels are less than 50 ng/dL)
3. The requested medication will be used together with a gonadotropin releasing hormone analog (such as leuprolide, goserelin, histrelin, degarelix)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**ENZALUTAMIDE**

**RATIONALE**

For further information, please refer to the prescribing information and/or drug monograph for Xtandi.

**REFERENCES**

- Xtandi [Prescribing Information]. Northbrook, IL: Astellas Pharma US, Inc.; September 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/23

Created: 09/12

Client Approval: 11/22

P&T Approval: 10/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

EPOETIN ALFA

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
EPOETIN ALFA	EPOGEN, PROCRIT	04553		GPI-10 (8240102000)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of anemia associated with chronic kidney disease (CKD) and meet **ALL** of the following criteria?
  - The patient had a trial of the preferred agent: Retacrit
  - The patient has a hemoglobin level of less than 10g/dL

If yes, approve for 12 months by GPID or GPI-14 for the requested agent as follows:

- Procrit 2,000U/mL: #12mL per 28 days.
- Procrit 3,000U/mL: #12mL per 28 days.
- Procrit 4,000U/mL: #12mL per 28 days.
- Procrit 10,000U/mL: #12mL per 28 days.
- Procrit 20,000U/mL: #12mL per 28 days.
- Procrit 40,000U/mL: #4mL per 28 days.
- Procrit 20,000U/2mL: #12mL per 28 days.
- Epogen 2,000U/mL: #12mL per 28 days.
- Epogen 3,000U/mL: #12mL per 28 days.
- Epogen 4,000U/mL: #12mL per 28 days.
- Epogen 10,000U/mL: #12mL per 28 days.
- Epogen 20,000U/mL: #12mL per 28 days.
- Epogen 20,000U/2mL: #12mL per 28 days.

If no, continue to #2.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

EPOETIN ALFA

INITIAL CRITERIA (CONTINUED)

2. Does the patient have a diagnosis of anemia due to the effects of concomitantly administered cancer chemotherapy and meet **ALL** of the following criteria?
- The patient had a trial of the preferred agent: Retacrit
  - The patient has a hemoglobin level of less than 11g/dL OR the patient's hemoglobin level has decreased at least 2g/dL below baseline level

If yes, approve for 12 months by GPID or GPI-14 for the requested agent as follows:

- Procrit 2,000U/mL: #12mL per 28 days.
- Procrit 3,000U/mL: #12mL per 28 days.
- Procrit 4,000U/mL: #12mL per 28 days.
- Procrit 10,000U/mL: #12mL per 28 days.
- Procrit 20,000U/mL: #12mL per 28 days.
- Procrit 40,000U/mL: #4mL per 28 days.
- Procrit 20,000U/2mL: #12mL per 28 days.
- Epogen 2,000U/mL: #12mL per 28 days.
- Epogen 3,000U/mL: #12mL per 28 days.
- Epogen 4,000U/mL: #12mL per 28 days.
- Epogen 10,000U/mL: #12mL per 28 days.
- Epogen 20,000U/mL: #12mL per 28 days.
- Epogen 20,000U/2mL: #12mL per 28 days.

If no, continue to #3.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

EPOETIN ALFA

INITIAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of anemia related to zidovudine therapy and meet **ALL** of the following criteria?

- The patient had a trial of the preferred agent: Retacrit
- The patient has a hemoglobin level of less than 10g/dL

If yes, approve for 12 months by GPID or GPI-14 for the requested agent as follows:

- Procrit 2,000U/mL: #12mL per 28 days.
- Procrit 3,000U/mL: #12mL per 28 days.
- Procrit 4,000U/mL: #12mL per 28 days.
- Procrit 10,000U/mL: #12mL per 28 days.
- Procrit 20,000U/mL: #12mL per 28 days.
- Procrit 40,000U/mL: #4mL per 28 days.
- Procrit 20,000U/2mL: #12mL per 28 days.
- Epogen 2,000U/mL: #12mL per 28 days.
- Epogen 3,000U/mL: #12mL per 28 days.
- Epogen 4,000U/mL: #12mL per 28 days.
- Epogen 10,000U/mL: #12mL per 28 days.
- Epogen 20,000U/mL: #12mL per 28 days.
- Epogen 20,000U/2mL: #12mL per 28 days.

If no, continue to #4.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

EPOETIN ALFA

INITIAL CRITERIA (CONTINUED)

4. Does the patient have a diagnosis of anemia due to concurrent hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa and meet **ALL** of the following criteria?
- The patient had a trial of the preferred agent: Retacrit
  - The patient has a hemoglobin level of less than 10g/dL
  - The patient had a trial of or contraindication to ribavirin dose reduction

If yes, **approve for 6 months by GPID or GPI-14 for the requested agent as follows:**

- Procrit 2,000U/mL: #12mL per 28 days.
- Procrit 3,000U/mL: #12mL per 28 days.
- Procrit 4,000U/mL: #12mL per 28 days.
- Procrit 10,000U/mL: #12mL per 28 days.
- Procrit 20,000U/mL: #12mL per 28 days.
- Procrit 40,000U/mL: #4mL per 28 days.
- Procrit 20,000U/2mL: #12mL per 28 days.
- Epogen 2,000U/mL: #12mL per 28 days.
- Epogen 3,000U/mL: #12mL per 28 days.
- Epogen 4,000U/mL: #12mL per 28 days.
- Epogen 10,000U/mL: #12mL per 28 days.
- Epogen 20,000U/mL: #12mL per 28 days.
- Epogen 20,000U/2mL: #12mL per 28 days.

If no, continue to #5.

CONTINUED ON NEXT PAGE





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

EPOETIN ALFA

INITIAL CRITERIA (CONTINUED)

5. Is the patient undergoing elective, noncardiac, nonvascular surgery and meet **ALL** of the following criteria?

- The patient had a trial of the preferred agent: Retacrit
- The patient has a hemoglobin level of less than 13g/dL

If yes, approve for 1 month by GPID or GPI-14 for the requested agent as follows:

- Procrit 2,000U/mL: #12mL per 28 days.
- Procrit 3,000U/mL: #12mL per 28 days.
- Procrit 4,000U/mL: #12mL per 28 days.
- Procrit 10,000U/mL: #12mL per 28 days.
- Procrit 20,000U/mL: #12mL per 28 days.
- Procrit 40,000U/mL: #4mL per 28 days.
- Procrit 20,000U/2mL: #12mL per 28 days.
- Epogen 2,000U/mL: #12mL per 28 days.
- Epogen 3,000U/mL: #12mL per 28 days.
- Epogen 4,000U/mL: #12mL per 28 days.
- Epogen 10,000U/mL: #12mL per 28 days.
- Epogen 20,000U/mL: #12mL per 28 days.
- Epogen 20,000U/2mL: #12mL per 28 days.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

EPOETIN ALFA

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **EPOETIN ALFA (Procrit, Epogen)** requires the following rules be met for approval:

- A. You have ONE of the following diagnoses:
  - 1. Anemia (low amount of healthy red blood cells) due to chronic kidney disease
  - 2. Anemia due to the effect of concomitantly administered (given at the same time) cancer chemotherapy
  - 3. Anemia related to zidovudine therapy (type of drug to treat human immunodeficiency virus)
  - 4. Anemia due to hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa
  - 5. You are undergoing elective, noncardiac (not heart related), nonvascular surgery
- B. **If you have anemia associated with chronic kidney disease, approval also requires:**
  - 1. You had a trial of the preferred medication: Retacrit
  - 2. You have a hemoglobin level (type of blood test) of less than 10g/dL
- C. **If you have anemia due to the effects of concomitantly administered cancer chemotherapy, approval also requires:**
  - 1. You had a trial of the preferred medication: Retacrit
  - 2. You have a hemoglobin level of less than 11g/dL OR your hemoglobin level has decreased at least 2g/dL below your baseline level
- D. **If you have anemia related to zidovudine therapy, approval also requires:**
  - 1. You had a trial of the preferred medication: Retacrit
  - 2. You have a hemoglobin level of less than 10g/dL
- E. **If you have anemia due to concurrent hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa, approval also requires:**
  - 1. You had a trial of the preferred medication: Retacrit
  - 2. You have tried or have a contraindication (harmful for) to a lower ribavirin dose
  - 3. You have a hemoglobin level of less than 10g/dL
- F. **If you are undergoing elective, noncardiac, nonvascular surgery, approval also requires:**
  - 1. You had a trial of the preferred medication: Retacrit
  - 2. You have a hemoglobin level of less than 13g/dL

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

EPOETIN ALFA

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

**NOTE:** Requests for patients undergoing elective, noncardiac, nonvascular surgery, please refer to the Initial Criteria section.

1. Does the patient have a diagnosis of anemia associated with chronic kidney disease (CKD) and meet **ONE** of the following criteria?
  - The patient has a hemoglobin level of less than 10g/dL if not on dialysis
  - The patient has a hemoglobin level of less than 11g/dL if on dialysis
  - The patient has a hemoglobin level that has reached 10g/dL (if not on dialysis) and dose reduction/interruption is required to reduce the need for blood transfusions
  - The patient has a hemoglobin level that has reached 11g/dL (if on dialysis) and dose reduction/interruption is required to reduce the need for blood transfusions

If yes, **approve for 12 months by GPID or GPI-14 for the requested agent as follows:**

- Procrit 2,000U/mL: #12mL per 28 days.
- Procrit 3,000U/mL: #12mL per 28 days.
- Procrit 4,000U/mL: #12mL per 28 days.
- Procrit 10,000U/mL: #12mL per 28 days.
- Procrit 20,000U/mL: #12mL per 28 days.
- Procrit 40,000U/mL: #4mL per 28 days.
- Procrit 20,000U/2mL: #12mL per 28 days.
- Epogen 2,000U/mL: #12mL per 28 days.
- Epogen 3,000U/mL: #12mL per 28 days.
- Epogen 4,000U/mL: #12mL per 28 days.
- Epogen 10,000U/mL: #12mL per 28 days.
- Epogen 20,000U/mL: #12mL per 28 days.
- Epogen 20,000U/2mL: #12mL per 28 days.

If no, continue to #2.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

EPOETIN ALFA

RENEWAL CRITERIA (CONTINUED)

2. Does the patient have a diagnosis of anemia due to the effects of concomitantly administered cancer chemotherapy **AND** meet the following criterion?
- The patient has a hemoglobin level between 10g/dL and 12g/dL

If yes, **approve for 12 months by GPID or GPI-14 for the requested agent as follows:**

- Procrit 2,000U/mL: #12mL per 28 days.
- Procrit 3,000U/mL: #12mL per 28 days.
- Procrit 4,000U/mL: #12mL per 28 days.
- Procrit 10,000U/mL: #12mL per 28 days.
- Procrit 20,000U/mL: #12mL per 28 days.
- Procrit 40,000U/mL: #4mL per 28 days.
- Procrit 20,000U/2mL: #12mL per 28 days.
- Epogen 2,000U/mL: #12mL per 28 days.
- Epogen 3,000U/mL: #12mL per 28 days.
- Epogen 4,000U/mL: #12mL per 28 days.
- Epogen 10,000U/mL: #12mL per 28 days.
- Epogen 20,000U/mL: #12mL per 28 days.
- Epogen 20,000U/2mL: #12mL per 28 days.

If no, continue to #3.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

EPOETIN ALFA

RENEWAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of anemia related to zidovudine therapy **AND** meet the following criterion?

- The patient has a hemoglobin level between 10g/dL and 12g/dL

If yes, **approve for 12 months by GPID or GPI-14 for the requested agent as follows:**

- Procrit 2,000U/mL: #12mL per 28 days.
- Procrit 3,000U/mL: #12mL per 28 days.
- Procrit 4,000U/mL: #12mL per 28 days.
- Procrit 10,000U/mL: #12mL per 28 days.
- Procrit 20,000U/mL: #12mL per 28 days.
- Procrit 40,000U/mL: #4mL per 28 days.
- Procrit 20,000U/2mL: #12mL per 28 days.
- Epogen 2,000U/mL: #12mL per 28 days.
- Epogen 3,000U/mL: #12mL per 28 days.
- Epogen 4,000U/mL: #12mL per 28 days.
- Epogen 10,000U/mL: #12mL per 28 days.
- Epogen 20,000U/mL: #12mL per 28 days.
- Epogen 20,000U/2mL: #12mL per 28 days.

If no, continue to #4.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

EPOETIN ALFA

RENEWAL CRITERIA (CONTINUED)

4. Does the patient have a diagnosis of anemia due to concurrent hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa **AND** meet the following criterion?
- The patient has a hemoglobin level between 10g/dL and 12g/dL

If yes, **approve for 6 months by GPID or GPI-14 for the requested agent as follows:**

- Procrit 2,000U/mL: #12mL per 28 days.
- Procrit 3,000U/mL: #12mL per 28 days.
- Procrit 4,000U/mL: #12mL per 28 days.
- Procrit 10,000U/mL: #12mL per 28 days.
- Procrit 20,000U/mL: #12mL per 28 days.
- Procrit 40,000U/mL: #4mL per 28 days.
- Procrit 20,000U/2mL: #12mL per 28 days.
- Epogen 2,000U/mL: #12mL per 28 days.
- Epogen 3,000U/mL: #12mL per 28 days.
- Epogen 4,000U/mL: #12mL per 28 days.
- Epogen 10,000U/mL: #12mL per 28 days.
- Epogen 20,000U/mL: #12mL per 28 days.
- Epogen 20,000U/2mL: #12mL per 28 days.

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

EPOETIN ALFA

RENEWAL CRITERIA (CONTINUED)

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **EPOETIN ALFA (Procrit, Epogen)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following diagnoses:
  - 1. Anemia (low amount of healthy red blood cells) due to chronic kidney disease
  - 2. Anemia due to the effects of concomitantly administered (given at the same time) cancer chemotherapy
  - 3. Anemia related to zidovudine therapy (type of drug to treat human immunodeficiency virus)
  - 4. Anemia due to hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa
- B. **If you have anemia associated with chronic kidney disease, renewal also requires ONE of the following:**
  - 1. You have a hemoglobin level (type of blood test) of less than 10g/dL if you are not on dialysis (process of removing excess water, toxins from the blood)
  - 2. You have a hemoglobin level of less than 11g/dL if you are on dialysis
  - 3. Your hemoglobin level has reached 10g/dL (if you are not on dialysis) and dose reduction/interruption is required to reduce the need for blood transfusions
  - 4. Your hemoglobin level has reached 11g/dL (if you are on dialysis) and dose reduction/interruption is required to reduce the need for blood transfusions
- C. **If you have anemia due to the effects of concomitantly administered cancer chemotherapy, renewal also requires:**
  - 1. You have a hemoglobin level between 10g/dL and 12g/dL
- D. **If you have anemia related to zidovudine therapy, renewal also requires:**
  - 1. You have a hemoglobin level between 10g/dL and 12g/dL
- E. **If you have anemia due to concurrent hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa, renewal also requires:**
  - 1. You have a hemoglobin level between 10g/dL and 12g/dL

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**EPOETIN ALFA**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Procrit, Epogen.

**REFERENCES**

- Procrit [Prescribing Information]. Thousand Oaks, CA: Amgen, July 2018.
- Epogen [Prescribing Information]. Thousand Oaks, CA: Amgen, July 2018.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 02/06/23

Created: 02/11

Client Approval: 01/23

P&T Approval: 01/21





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

EPOETIN ALFA-EPBX

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
EPOETIN ALFA-EPBX	RETACRIT	44931		GPI-10 (8240102004)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of anemia associated with chronic kidney disease (CKD) **AND** meet the following criterion?

- The patient has a hemoglobin level of less than 10g/dL

If yes, **approve for 12 months by GPID or GPI-14 for the requested strength as follows:**

- **2,000U/mL: #12mL in 28 days.**
- **3,000U/mL: #12mL in 28 days.**
- **4,000U/mL: #12mL in 28 days.**
- **10,000U/mL: #12mL in 28 days.**
- **20,000U/mL: #12mL in 28 days.**
- **40,000U/mL: #4mL in 28 days.**
- **20,000U/2mL: #12mL in 28 days.**

If no, continue to #2.

2. Does the patient have a diagnosis of anemia due to the effects of concomitantly administered cancer chemotherapy and meet **ONE** of the following criteria?

- The patient has a hemoglobin level of less than 11g/dL
- The patient's hemoglobin level has decreased at least 2g/dL below baseline level

If yes, **approve for 12 months by GPID or GPI-14 for the requested strength as follows:**

- **2,000U/mL: #12mL in 28 days.**
- **3,000U/mL: #12mL in 28 days.**
- **4,000U/mL: #12mL in 28 days.**
- **10,000U/mL: #12mL in 28 days.**
- **20,000U/mL: #12mL in 28 days.**
- **40,000U/mL: #4mL in 28 days.**
- **20,000U/2mL: #12mL in 28 days.**

If no, continue to #3.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

EPOETIN ALFA-EPBX

INITIAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of anemia related to zidovudine therapy **AND** meet the following criterion?

- The patient has a hemoglobin level of less than 10g/dL

If yes, **approve for 12 months by GPID or GPI-14 for the requested strength as follows:**

- **2,000U/mL: #12mL in 28 days.**
- **3,000U/mL: #12mL in 28 days.**
- **4,000U/mL: #12mL in 28 days.**
- **10,000U/mL: #12mL in 28 days.**
- **20,000U/mL: #12mL in 28 days.**
- **40,000U/mL: #4mL in 28 days.**
- **20,000U/2mL: #12mL in 28 days.**

If no, continue to #4.

4. Does the patient have a diagnosis of anemia due to concurrent hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa and meet **ALL** of the following criteria?

- The patient has a hemoglobin level of less than 10g/dL
- The patient has had a trial or contraindication to ribavirin dose reduction

If yes, **approve for 6 months by GPID or GPI-14 for the requested strength as follows:**

- **2,000U/mL: #12mL in 28 days.**
- **3,000U/mL: #12mL in 28 days.**
- **4,000U/mL: #12mL in 28 days.**
- **10,000U/mL: #12mL in 28 days.**
- **20,000U/mL: #12mL in 28 days.**
- **40,000U/mL: #4mL in 28 days.**
- **20,000U/2mL: #12mL in 28 days.**

If no, continue to #5.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

EPOETIN ALFA-EPBX

INITIAL CRITERIA (CONTINUED)

5. Is the patient undergoing elective, noncardiac, nonvascular surgery **AND** meet the following criterion?

- The patient has a hemoglobin level of less than 13g/dL

If yes, **approve for 1 month by GPID or GPI-14 for the requested strength as follows:**

- 2,000U/mL: #12mL in 28 days.
- 3,000U/mL: #12mL in 28 days.
- 4,000U/mL: #12mL in 28 days.
- 10,000U/mL: #12mL in 28 days.
- 20,000U/mL: #12mL in 28 days.
- 40,000U/mL: #4mL in 28 days.
- 20,000U/2mL: #12mL in 28 days.

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **EPOETIN ALFA-EPBX (Retacrit)** requires the following rule(s) be met for approval:

A. You have **ONE** of the following diagnoses:

1. Anemia (low amount of healthy red blood cells) due to chronic kidney disease
2. Anemia due to the effect of concomitantly administered (given at the same time) cancer chemotherapy
3. Anemia related to zidovudine therapy (type of drug to treat human immunodeficiency virus)
4. Anemia due to hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa
5. You are undergoing elective, noncardiac (not heart related), nonvascular surgery

B. **If you have anemia associated with chronic kidney disease, approval also requires:**

1. You have a hemoglobin level (type of blood test) of less than 10g/dL

C. **If you have anemia due to the effect of concomitantly administered cancer chemotherapy, approval also requires ONE of the following:**

1. You have a hemoglobin level of less than 11g/dL
2. Your hemoglobin level has decreased at least 2g/dL below your baseline level

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

EPOETIN ALFA-EPBX

INITIAL CRITERIA (CONTINUED)

- D. **If you have anemia related to zidovudine therapy, approval also requires:**
1. You have a hemoglobin level of less than 10g/dL
- E. **If you have anemia due to concurrent hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa, approval also requires:**
1. You have tried or have a contraindication (harmful for) to a lower ribavirin dose
  2. You have a hemoglobin level of less than 10g/dL
- F. **If you are undergoing elective, noncardiac, nonvascular surgery, approval also requires:**
1. You have a hemoglobin level of less than 13g/dL

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

**NOTE:** Requests for patients undergoing elective, noncardiac, nonvascular surgery, please refer to the Initial Criteria section.

1. Does the patient have a diagnosis of anemia associated with chronic kidney disease (CKD) and meet **ONE** of the following criteria?
  - The patient has a hemoglobin level of less than 10g/dL if not on dialysis
  - The patient has a hemoglobin level of less than 11g/dL if on dialysis
  - The patient has a hemoglobin level that has reached 10g/dL (if not on dialysis) and dose reduction/interruption is required to reduce the need for blood transfusions
  - The patient has a hemoglobin level that has reached 11g/dL (if on dialysis) and dose reduction/interruption is required to reduce the need for blood transfusions

If yes, **approve for 12 months by GPID or GPI-14 for the requested strength as follows:**

- **2,000U/mL: #12mL in 28 days.**
- **3,000U/mL: #12mL in 28 days.**
- **4,000U/mL: #12mL in 28 days.**
- **10,000U/mL: #12mL in 28 days.**
- **20,000U/mL: #12mL in 28 days.**
- **40,000U/mL: #4mL in 28 days.**
- **20,000U/2mL: #12mL in 28 days.**

If no, continue to #2.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

EPOETIN ALFA-EPBX

**RENEWAL CRITERIA (CONTINUED)**

2. Does the patient have a diagnosis of anemia due to the effects of concomitantly administered cancer chemotherapy **AND** meet the following criterion?

- The patient has a hemoglobin level between 10g/dL and 12g/dL

If yes, **approve for 12 months by GPID or GPI-14 for the requested strength as follows:**

- **2,000U/mL: #12mL in 28 days.**
- **3,000U/mL: #12mL in 28 days.**
- **4,000U/mL: #12mL in 28 days.**
- **10,000U/mL: #12mL in 28 days.**
- **20,000U/mL: #12mL in 28 days.**
- **40,000U/mL: #4mL in 28 days.**
- **20,000U/2mL: #12mL in 28 days.**

If no, continue to #3.

3. Does the patient have a diagnosis of anemia related to zidovudine therapy **AND** meet the following criterion?

- The patient has a hemoglobin level between 10g/dL and 12g/dL

If yes, **approve for 12 months by GPID or GPI-14 for the requested strength as follows:**

- **2,000U/mL: #12mL in 28 days.**
- **3,000U/mL: #12mL in 28 days.**
- **4,000U/mL: #12mL in 28 days.**
- **10,000U/mL: #12mL in 28 days.**
- **20,000U/mL: #12mL in 28 days.**
- **40,000U/mL: #4mL in 28 days.**
- **20,000U/2mL: #12mL in 28 days.**

If no, continue to #4.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

EPOETIN ALFA-EPBX

RENEWAL CRITERIA (CONTINUED)

4. Does the patient have a diagnosis of anemia due to concurrent hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa **AND** meet the following criterion?
- The patient has a hemoglobin level between 10g/dL and 12g/dL

If yes, **approve for 6 months by GPID or GPI-14 for the requested strength as follows:**

- 2,000U/mL: #12mL in 28 days.
- 3,000U/mL: #12mL in 28 days.
- 4,000U/mL: #12mL in 28 days.
- 10,000U/mL: #12mL in 28 days.
- 20,000U/mL: #12mL in 28 days.
- 40,000U/mL: #4mL in 28 days.
- 20,000U/2mL: #12mL in 28 days.

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **EPOETIN ALFA-EPBX (Retacrit)** requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:

1. Anemia (low amount of healthy red blood cells) due to chronic kidney disease
2. Anemia due to the effect of concomitantly administered (given at the same time) cancer chemotherapy
3. Anemia related to zidovudine therapy (type of drug to treat human immunodeficiency virus)
4. Anemia due to hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa

B. **If you have anemia associated with chronic kidney disease, renewal also requires ONE of the following:**

1. You have a hemoglobin level (type of blood test) of less than 10g/dL if you are not on dialysis (process of removing excess water, toxins from the blood)
2. You have a hemoglobin level of less than 11g/dL if you are on dialysis
3. Your hemoglobin level has reached 10g/dL (if you are not on dialysis) and dose reduction/interruption is required to reduce the need for blood transfusions
4. Your hemoglobin level has reached 11g/dL (if you are on dialysis) and dose reduction/interruption is required to reduce the need for blood transfusions

***(Renewal denial text continued on next page)***

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

EPOETIN ALFA-EPBX

RENEWAL CRITERIA (CONTINUED)

- C. **If you have anemia due to the effects of concomitantly administered cancer chemotherapy, renewal also requires:**
  - 1. You have a hemoglobin level between 10g/dL and 12g/dL
- D. **If you have anemia related to zidovudine therapy, renewal also requires:**
  - 1. You have a hemoglobin level between 10g/dL and 12g/dL
- E. **If you have anemia due to concurrent hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa, renewal also requires:**
  - 1. You have a hemoglobin level between 10g/dL and 12g/dL

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Retacrit.

REFERENCES

- Retacrit [Prescribing Information]. Lake Forest, IL: Pfizer Inc. August 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 02/06/23

Created: 02/11

Client Approval: 01/23

P&T Approval: 01/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ERDAFITINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ERDAFITINIB	BALVERSA	45687		GPI-10 (2153222500)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of locally advanced or metastatic urothelial carcinoma (i.e., bladder cancer) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient has susceptible fibroblast growth factor receptor (FGFR3) or (FGFR2) genetic alterations as detected by a Food and Drug Administration (FDA)-approved companion diagnostic test

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient have **ONE** of the following criteria?

- The patient has progressed during or following at least one line of prior platinum-containing chemotherapy (e.g., cisplatin, carboplatin, oxaliplatin)
- The patient has progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy (e.g., cisplatin, carboplatin, oxaliplatin)

If yes, **approve for 12 months by GPID or GPI-14 for all strengths as follows:**

- **Balversa 3mg tablet: #3 per day.**
- **Balversa 4mg tablet: #2 per day.**
- **Balversa 5mg tablet: #1 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ERDAFITINIB (Balversa)** requires the following rule(s) be met for approval:

- A. You have locally advanced or metastatic urothelial carcinoma (type of bladder cancer that has spread)
- B. You are 18 years of age or older
- C. You have susceptible fibroblast growth factor receptor (FGFR3 or FGFR2) genetic alterations (abnormalities) as detected by a Food and Drug Administration (FDA)-approved companion diagnostic test

**(Denial text continued on next page)**

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ERDAFITINIB

**GUIDELINES FOR USE (CONTINUED)**

D. You meet ONE of the following:

1. You have progressed (worsened disease) during or following at least one line of prior platinum-containing chemotherapy (such as cisplatin, carboplatin, oxaliplatin)
2. You have progressed within 12 months of neoadjuvant (treatment given before main therapy) or adjuvant (add-on) platinum-containing chemotherapy (such as cisplatin, carboplatin, oxaliplatin)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Balversa.

**REFERENCES**

- Balversa [Prescribing Information]. Horsham, PA: Janssen Products, LP; April 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 04/19

Client Approval: 04/20

P&T Approval: 04/19



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ERENUMAB-AOOE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ERENUMAB-AOOE	AIMOVIG	44923		GPI-10 (6770202010)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of episodic migraines and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Aimovig is prescribed for the preventive treatment of migraines
  - Aimovig will NOT be used concurrently with other CGRP inhibitors (e.g., Ajovy, Emgality, Vyepti, Nurtec ODT, Qulipta) for migraine prevention
  - The patient had a trial of ONE of the following preventative migraine treatments: valproic acid/divalproex sodium, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol

If yes, **approve for 6 months by NDC or GPI-14 for the requested strength as follows:**

- **Aimovig 70mg/mL: #1mL per 30 days.**
- **Aimovig 140mg/mL: #1mL per 30 days.**
- **Aimovig 140mg-Dose 2-autoinjectors: #2mL (1 pack containing #2 70mg/mL) per 30 days.**

If no, continue to #2.

2. Does the patient have a diagnosis of chronic migraines and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Aimovig is prescribed for the preventive treatment of migraines
  - Aimovig will NOT be used concurrently with other CGRP inhibitors (e.g., Ajovy, Emgality, Vyepti, Nurtec ODT, Qulipta) for migraine prevention
  - The patient had a trial of ONE of the following preventative migraine treatments: valproic acid/divalproex sodium, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol, or Botox [**Note: For Botox, previous trial of only NDCs # 00023-1145-01 or 00023-3921-02 are allowable**]

If yes, **approve for 6 months by NDC or GPI-14 for the requested strength as follows:**

- **Aimovig 70mg/mL: #1mL per 30 days.**
- **Aimovig 140mg/mL: #1mL per 30 days.**
- **Aimovig 140mg-Dose 2-autoinjectors: #2mL (1 pack containing #2 70mg/mL) per 30 days.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ERENUMAB-AOOE

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ERENUMAB-AOOE (Aimovig)** requires the following rule(s) be met for approval:

- A. You have migraines
- B. **If you have episodic migraines (0-14 headache days per month), approval also requires:**
  - 1. You are 18 years of age or older
  - 2. Aimovig is prescribed for the preventive treatment of migraines
  - 3. You will NOT use Aimovig concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Ajovy, Emgality, Vyepti, Nurtec ODT, Qulipta) for migraine prevention
  - 4. You have tried ONE of the following preventative migraine treatments: valproic acid/divalproex sodium, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol
- C. **If you have chronic migraines (15 or more headache days per month), approval also requires:**
  - 1. You are 18 years of age or older
  - 2. Aimovig is prescribed for the preventive treatment of migraines
  - 3. You will NOT use Aimovig concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Ajovy, Emgality, Vyepti, Nurtec ODT, Qulipta) for migraine prevention
  - 4. You have tried ONE of the following preventative migraine treatments: valproic acid/divalproex sodium, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol, or Botox [Note: For Botox, previous trial of only NDCs # 00023-1145-01 or 00023-3921-02 are allowable]

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ERENUMAB-AOOE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Is Aimovig being prescribed for the preventive treatment of migraines **AND** does the patient meet the following criterion?
  - Aimovig will NOT be used concurrently with other CGRP inhibitors (e.g., Ajovy, Emgality, Vyepti, Nurtec ODT, Qulipta) for migraine prevention

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

2. Does the patient meet **ONE** of the following criteria?
  - The patient has experienced a reduction in migraine or headache frequency of at least 2 days per month with Aimovig therapy
  - The patient has experienced a reduction in migraine severity with Aimovig therapy
  - The patient has experienced a reduction in migraine duration with Aimovig therapy

If yes, **approve for 12 months by NDC or GPI-14 for the requested strength as follows:**

- **Aimovig 70mg/mL: #1mL per 30 days.**
- **Aimovig 140mg/mL: #1mL per 30 days.**
- **Aimovig 140mg-Dose 2-autoinjectors: #2mL (1 pack containing #2 70mg/mL) per 30 days.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ERENUMAB-AOOE (Aimovig)** requires the following rule(s) be met for renewal:

- A. Aimovig is being prescribed for preventive treatment of migraines.
  - B. You will NOT use Aimovig concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Ajovy, Emgality, Vyepti, Nurtec ODT, Qulipta) for migraine prevention
  - C. You meet ONE of the following criteria:
    1. You have experienced less migraines or headache attacks by at least 2 days per month with Aimovig therapy
    2. You have experienced a lessening in migraine severity with Aimovig therapy
    3. You have experienced a lessening in migraine duration with Aimovig therapy
- (Renewal denial text continued on next page)**

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ERENUMAB-AOOE

RENEWAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Aimovig.

REFERENCE

- Aimovig [Prescribing Information]. Thousand Oaks, CA: Amgen/Novartis; May 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/22

Created: 05/18

Client Approval: 02/22

P&T Approval: 01/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ERGOTAMINE-CAFFEINE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ERGOTAMINE TARTRATE/CAFFEINE	MIGERGOT	01868		GPI-10 (6799100210)	ROUTE ≠ ORAL

**GUIDELINES FOR USE**

1. Is Migergot being used to abort or prevent vascular headaches (e.g., migraine, migraine variants, so-called 'histaminic cephalgia') and the patient meets **ALL** of the following criteria?
  - The patient cannot swallow ergotamine/caffeine tablets
  - The patient had a trial of or contraindication to generic ergotamine/caffeine tablets AND two triptans (e.g., sumatriptan, rizatriptan)

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #24 per 30 days.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ERGOTAMINE-CAFFEINE (Migergot)** requires the following rule(s) be met for approval:

- A. Migergot is being used to abort (stop) or prevent vascular headaches (such as migraines, migraine variants, so-called 'histaminic cephalgia' [types of headaches])
- B. You cannot swallow ergotamine/caffeine tablets
- C. You had a trial of or contraindication (harmful for) to generic ergotamine/caffeine tablets AND two triptans (such as sumatriptan, rizatriptan)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Migergot.

**REFERENCES**

- Migergot [Prescribing Information]. South Plainfield, NJ: Cosette Pharmaceuticals, Inc., August 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/23

Created: 11/22

Client Approval: 02/23

P&T Approval: 10/22

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ERLOTINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ERLOTINIB HCL	TARCEVA, ERLOTINIB HCL	26745		GPI-10 (2136002510)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of metastatic non-small cell lung cancer (NSCLC) and meet **ALL** of the following criteria?

- The patient's tumor has epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test
- Tarceva (erlotinib) will NOT be used concurrently with an epidermal growth factor receptor (EGFR) tyrosine kinase-inhibitor (e.g., Gilotrif, Tagrisso, Iressa, Vizimpro)

If yes, **approve for 12 months by GPID or GPI-14 as requested with the following quantity limits:**

**25mg: #2 per day.**

**100mg: #2 per day.**

**150mg: #3 per day.**

If no, continue to #2.

2. Does the patient have a diagnosis of locally advanced, unresectable, or metastatic pancreatic cancer and meet **ALL** of the following criteria?

- The requested medication will be used in combination with gemcitabine
- The medication will be used as a first line treatment

If yes, **approve for 12 months by GPID or GPI-14 as requested with the following quantity limits:**

**25mg: #2 per day.**

**100mg: #2 per day.**

**150mg: #3 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ERLOTINIB (Tarceva)** requires the following rule(s) be met for approval:

A. You have **ONE** of the following diagnoses:

1. Metastatic non-small cell lung cancer (type of lung cancer that has spread to other parts of the body)
2. Locally advanced, unresectable, or metastatic pancreatic cancer (pancreas cancer that has spread or cannot be completely removed by surgery)

**(Denial text continued on next page)**

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ERLOTINIB

GUIDELINES FOR USE (CONTINUED)

- B. If you have metastatic non-small cell lung cancer, approval also requires:**
1. Your tumor has epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations (types of gene mutations or permanent change in the DNA that makes up a gene) as detected by an FDA (Food and Drug Administration)-approved test
  2. You will NOT be using Tarceva (erlotinib) concurrently (at the same time) with an epidermal growth factor receptor (EGFR) tyrosine kinase-inhibitor (e.g., Gilotrif, Tagrisso, Iressa, Vizimpro)
- C. If you have locally advanced, unresectable, or metastatic pancreatic cancer, approval also requires:**
1. The requested medication will be used in combination with gemcitabine
  2. The medication will be used as a first line treatment

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Tarceva.

**REFERENCES**

- Tarceva [Prescribing Information]. Northbrook, IL: Astellas Pharma US, Inc.; October 2016.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/22

Created: 11/10

Client Approval: 05/22

P&T Approval: 04/22





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ETANERCEPT

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ETANERCEPT	ENBREL	18830		GPI-10 (6629003000)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- Therapy is prescribed by or in consultation with a rheumatologist
- The patient had a trial of or contraindication to at least 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine

If yes, **approve for 6 months by GPID or GPI-14 for the requested strength as follows:**

- **25mg syringes: #4mL per 28 days.**
- **25mg vials: #8 vials OR #4mL per 28 days.**
- **50mg syringes/cartridges: #4mL per 28 days.**

If no, continue to #2.

2. Does the patient have moderate to severe polyarticular juvenile idiopathic arthritis (PJIA) and meet **ALL** of the following criteria?

- The patient is 2 years of age or older
- Therapy is prescribed by or in consultation with a rheumatologist
- The patient had a trial of or contraindication to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

If yes, **approve for 6 months by GPID or GPI-14 for the requested strength as follows:**

- **25mg syringes: #4mL per 28 days.**
- **25mg vials: #8 vials OR #4mL per 28 days.**
- **50mg syringes/cartridges: #4mL per 28 days.**

If no, continue to #3.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ETANERCEPT

INITIAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of psoriatic arthritis (PsA) and meet **ALL** of the following criteria?
- The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a rheumatologist or dermatologist
  - The patient had a trial of or contraindication to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

If yes, **approve for 6 months by GPID or GPI-14 for the requested strength as follows:**

- **25mg syringes: #4mL per 28 days.**
- **25mg vials: #8 vials OR #4mL per 28 days.**
- **50mg syringes/cartridges: #4mL per 28 days.**

If no, continue to #4.

4. Does the patient have a diagnosis of ankylosing spondylitis (AS) and meet **ALL** of the following criteria?
- The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a rheumatologist
  - The patient had a trial of or contraindication to an NSAID (e.g., naproxen, ibuprofen, diclofenac)

If yes, **approve for 6 months by GPID or GPI-14 for the requested strength as follows:**

- **25mg syringes: #4mL per 28 days.**
- **25mg vials: #8 vials OR #4mL per 28 days.**
- **50mg syringes/cartridges: #4mL per 28 days.**

If no, continue to #5.

5. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) and meet **ALL** of the following criteria?
- Therapy is prescribed by or in consultation with a dermatologist
  - The patient has psoriasis covering 3% or more of body surface area (BSA) OR psoriatic lesions affecting the hands, feet, genital area, or face
  - The patient had a trial of or contraindication to ONE or more forms of conventional therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids, calcipotriene, acitretin, methotrexate, or cyclosporine

If yes, continue to #6.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ETANERCEPT

INITIAL CRITERIA (CONTINUED)

6. Is the patient 18 years of age or older?

If yes, approve for a total of 6 months by GPID or GPI-14 and enter two approvals as follows:

- **FIRST APPROVAL:** approve for 3 months for the requested strength:
  - 25mg syringes: #8mL per 28 days.
  - 25mg vials: #16 vials OR #8mL per 28 days.
  - 50mg syringes/cartridges: #8mL per 28 days.
- **SECOND APPROVAL:** approve for the requested strength for the next 3 months:
  - 25mg syringes: #4mL per 28 days.
  - 25mg vials: #8 vials OR #4mL per 28 days.
  - 50mg syringes/cartridges: #4mL per 28 days.

If no, continue to #7.

7. Is the patient aged 4 to 17 years old?

If yes, approve for 6 months by GPID or GPI-14 for the requested strength as follows:

- 25mg syringes: #4mL per 28 days.
- 25mg vials: #8 vials OR #4mL per 28 days.
- 50mg syringes/cartridges: #4mL per 28 days.

If no, do not approve.

**INITIAL DENIAL TEXT:** *\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **ETANERCEPT (Enbrel)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:

1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
2. Psoriatic arthritis (PsA: a type of skin and joint condition)
3. Moderate to severe polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)
4. Ankylosing spondylitis (AS: a type of joint condition)
5. Moderate to severe plaque psoriasis (PsO: a type of skin condition)

*(Initial denial text continued on next page)*

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ETANERCEPT

INITIAL CRITERIA (CONTINUED)

- B. If you have moderate to severe rheumatoid arthritis, approval also requires:**
1. You are 18 years of age or older
  2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
  3. You had a trial of or contraindication (harmful for) to at least 3 months of ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
- C. If you have moderate to severe polyarticular juvenile idiopathic arthritis, approval also requires:**
1. You are 2 years of age or older
  2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
  3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
- D. If you have psoriatic arthritis, approval also requires:**
1. You are 18 years of age or older
  2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
  3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
- E. If you have ankylosing spondylitis, approval also requires:**
1. You are 18 years of age or older
  2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
  3. You had a trial of or contraindication (harmful for) to an NSAID (non-steroidal anti-inflammatory drug)
- F. If you have moderate to severe plaque psoriasis, approval also requires:**
1. You are 4 years of age or older
  2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
  3. You have psoriasis covering 3% or more of body surface area (BSA) OR psoriatic lesions (rashes) affecting the hands, feet, genital area, or face
  4. You had a trial of or contraindication (harmful for) to ONE or more forms of standard therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids, calcipotriene, acitretin, methotrexate, or cyclosporine

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ETANERCEPT

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) **AND** meet the following criterion?

- The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

If yes, **approve for 12 months by GPID or GPI-14 for the requested strength as follows:**

- **25mg syringes: #4mL per 28 days.**
- **25mg vials: #8 vials OR #4mL per 28 days.**
- **50mg syringes/cartridges: #4mL per 28 days.**

If no, continue to #2.

2. Does the patient have a diagnosis of moderate to severe polyarticular juvenile idiopathic arthritis (PJIA) **AND** meet the following criterion?

- The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

If yes, **approve for 12 months by GPID or GPI-14 for the requested strength as follows:**

- **25mg syringes: #4mL per 28 days.**
- **25mg vials: #8 vials OR #4mL per 28 days.**
- **50mg syringes/cartridges: #4mL per 28 days.**

If no, continue to #3.

3. Does the patient have a diagnosis of psoriatic arthritis (PsA) **AND** meet the following criterion?

- The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

If yes, **approve for 12 months by GPID or GPI-14 for the requested strength as follows:**

- **25mg syringes: #4mL per 28 days.**
- **25mg vials: #8 vials OR #4mL per 28 days.**
- **50mg syringes/cartridges: #4mL per 28 days.**

If no, continue to #4.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ETANERCEPT

RENEWAL CRITERIA (CONTINUED)

4. Does the patient have a diagnosis of ankylosing spondylitis (AS) **AND** meet the following criterion?
- The patient has experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) while on therapy

If yes, **approve for 12 months by GPID or GPI-14 for the requested strength as follows:**

- **25mg syringes: #4mL per 28 days.**
- **25mg vials: #8 vials OR #4mL per 28 days.**
- **50mg syringes/cartridges: #4mL per 28 days.**

If no, continue to #5.

5. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) **AND** meet the following criterion?
- The patient has achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more while on therapy

If yes, **approve for 12 months by GPID or GPI-14 for the requested strength as follows:**

- **25mg syringes: #4mL per 28 days.**
- **25mg vials: #8 vials OR #4mL per 28 days.**
- **50mg syringes/cartridges: #4mL per 28 days.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ETANERCEPT (Enbrel)** requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:

1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
2. Psoriatic arthritis (PsA: a type of skin and joint condition)
3. Moderate to severe polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)
4. Ankylosing spondylitis (AS: a type of joint condition)
5. Moderate to severe plaque psoriasis (PsO: a type of skin condition)

B. **If you have moderate to severe rheumatoid arthritis, renewal also requires:**

1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy.

**(Renewal denial text continued on next page)**

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ETANERCEPT

RENEWAL CRITERIA (CONTINUED)

- C. **If you have psoriatic arthritis, renewal also requires:**
  - 1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy.
- D. **If you have moderate to severe polyarticular juvenile idiopathic arthritis, renewal also requires:**
  - 1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy.
- E. **If you have ankylosing spondylitis, renewal also requires:**
  - 1. You have experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) while on therapy.
- F. **If you have moderate to severe plaque psoriasis, renewal also requires:**
  - 1. You have achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more while on therapy.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Enbrel.

**REFERENCES**

Enbrel [Prescribing Information]. Thousand Oaks, CA: Immunex Corporation; March 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 03/14/22

Created: 02/03

Client Approval: 02/22

P&T Approval: 01/22





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ETHACRYNIC ACID

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ETHACRYNIC ACID	EDECIN, ETHACRYNIC ACID	03659		GPI-10 (3720002000)	

**GUIDELINES FOR USE**

1. Does the patient have **ONE** of the following diagnoses?
  - Edema associated with congestive heart failure, cirrhosis of the liver, or renal disease (including nephrotic syndrome)
  - Ascites due to malignancy, idiopathic edema, or lymphedema

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient have a trial of or contraindication to **TWO** generic loop diuretics (e.g., furosemide, bumetanide, torsemide)?

If yes, **approve for 12 months by HICL or GPI-10.**

If no, do not approve.

**DENIAL TEXT:** **\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ETHACRYNIC ACID (Edecrin)** requires the following rule(s) be met for approval:

A. You have **ONE** of the following diagnoses:

1. Edema (swelling caused by fluid build-up in the body) associated with congestive heart failure (a type of heart condition), cirrhosis (liver damage), or renal disease (including nephrotic syndrome [a type of kidney disorder])
2. Ascites (accumulation of fluid in the abdominal cavity) due to malignancy (cancer), idiopathic (unknown cause) edema, or lymphedema (swelling in an arm or leg due to build-up of lymph fluid)

B. You had a trial of or contraindication (harmful for) to **TWO** generic loop diuretics (such as furosemide, bumetanide, torsemide)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**ETHACRYNIC ACID**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Edecrin.

**REFERENCES**

- Edecrin [Prescribing Information]. Greenville, NC: Bausch Health Companies, Inc., August 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/22

Created: 05/22

Client Approval: 05/22

P&T Approval: 04/22



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**EVEROLIMUS**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
EVEROLIMUS	AFINITOR, EVEROLIMUS		20784 20844 28783 31396	GPI-10 (2153253000)	
EVEROLIMUS	AFINITOR DISPERZ, EVEROLIMUS		34589 34590 34592		

**\*\*Please use the criteria for the specific drug requested\*\***

**GUIDELINES FOR USE**

**AFINITOR DISPERZ**

- Does the patient have a diagnosis of subependymal giant cell astrocytoma (SEGA) in tuberous sclerosis complex (TSC) and meet **ALL** of the following criteria?
  - The patient is 1 year of age or older
  - The patient's diagnosis requires therapeutic intervention but cannot be curatively resected

If yes, **approve for 12 months by GPID or GPI-14.**

If no, continue to #2.

- Does the patient have a diagnosis of tuberous sclerosis complex (TSC)-associated partial-onset seizures and meet **ALL** of the following criteria?
  - The patient is 2 years of age or older
  - Afinitor Disperz will be used as adjunctive treatment

If yes, **approve for 12 months by GPID or GPI-14.**

If no, do not approve.

**AFINITOR DISPERZ DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **EVEROLIMUS (Afinitor Disperz)** requires the following rule(s) be met for approval:

- You have ONE of the following diagnoses:
  - Subependymal giant cell astrocytoma (SEGA: a type of brain tumor) in tuberous sclerosis complex (TSC: a rare type of tumor disorder)
  - Tuberous sclerosis complex (TSC: a rare type of tumor disorder)-associated partial-onset seizures

***(Afinitor Disperz denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

EVEROLIMUS

GUIDELINES FOR USE - AFINITOR DISPERZ (CONTINUED)

- B. **If you have subependymal giant cell astrocytoma (SEGA) in tuberous sclerosis complex (TSC), approval also requires:**
1. You are 1 year of age or older
  2. Your diagnosis requires therapeutic intervention but cannot be curatively resected (completely remove with surgery)
- C. **If you have tuberous sclerosis complex (TSC)-associated partial-onset seizures, approval also requires:**
1. You are 2 years of age or older
  2. Afinitor Disperz will be used as adjunctive (add-on) treatment

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

AFINITOR

1. Does the patient have a diagnosis of advanced hormone receptor (HR)-positive, HER2-negative breast cancer and meet **ALL** of the following criteria?
  - The patient is a postmenopausal woman
  - Afinitor will be used in combination with Aromasin (exemestane)
  - The patient has failed or has a contraindication to treatment with Femara (letrozole) or Arimidex (anastrozole)

If yes, **approve for 12 months for the requested strength by GPID or GPI-14 with the following quantity limits:**

- **Afinitor 2.5mg: #1 per day.**
- **Afinitor 5mg: #1 per day.**
- **Afinitor 7.5mg: #2 per day.**
- **Afinitor 10mg: #2 per day.**

If no, continue to #2.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

EVEROLIMUS

**GUIDELINES FOR USE - AFINITOR (CONTINUED)**

2. Does the patient have a diagnosis of progressive, neuroendocrine tumors (NET) with unresectable, locally advanced or metastatic disease and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient meets ONE of the following:
  - The patient has a neuroendocrine tumors of pancreatic origin (PNET)
  - The patient has well-differentiated, non-functional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin

If yes, **approve for 12 months for the requested strength by GPID or GPI-14 with the following quantity limits:**

- **Afinitor 2.5mg: #1 per day.**
- **Afinitor 5mg: #1 per day.**
- **Afinitor 7.5mg: #2 per day.**
- **Afinitor 10mg: #2 per day.**

If no, continue to #3.

3. Does the patient have a diagnosis of advanced renal cell carcinoma (RCC) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient has failed or has a contraindication to treatment with Sutent (sunitinib) OR Nexavar (sorafenib)

If yes, **approve for 12 months for the requested strength by GPID or GPI-14 with the following quantity limits:**

- **Afinitor 2.5mg: #1 per day.**
- **Afinitor 5mg: #1 per day.**
- **Afinitor 7.5mg: #2 per day.**
- **Afinitor 10mg: #2 per day.**

If no, continue to #4.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

EVEROLIMUS

GUIDELINES FOR USE - AFINITOR (CONTINUED)

4. Does the patient have a diagnosis of renal angiomyolipoma and tuberous sclerosis complex (TSC) and meet **ALL** of the following criteria?
- The patient is 18 years of age or older
  - The patient does not require immediate surgery

If yes, **approve for 12 months for the requested strength by GPID or GPI-14 with the following quantity limits:**

- **Afinitor 2.5mg: #1 per day.**
- **Afinitor 5mg: #1 per day.**
- **Afinitor 7.5mg: #2 per day.**
- **Afinitor 10mg: #2 per day.**

If no, continue to #5.

5. Does the patient have a diagnosis of subependymal giant cell astrocytoma (SEGA) in tuberous sclerosis complex (TSC) and meet **ALL** of the following criteria?
- The patient is 1 year of age or older
  - The patient's diagnosis requires therapeutic intervention but cannot be curatively resected

If yes, **approve for 12 months by GPID or GPI-14.**

If no, do not approve.

**AFINITOR DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **EVEROLIMUS (Afinitor)** requires the following rule(s) be met for approval:

A. You have **ONE** of the following diagnoses:

1. Advanced hormone receptor-positive (HR: a type of protein), human epidermal growth factor receptor 2 (HER2: a type of protein)-negative breast cancer
2. Progressive, neuroendocrine tumors (NET: a rare type of tumor) with unresectable (unable to remove by surgery), locally advanced (cancer that has spread from where it started to nearby tissue or lymph nodes) or metastatic disease (cancer that has spread to other parts of the body)
3. Advanced renal cell carcinoma (RCC: type of kidney cancer)
4. Renal angiomyolipoma (type of kidney tumor) and tuberous sclerosis complex (TSC: a rare type of tumor disorder)
5. Subependymal giant cell astrocytoma (SEGA: a type of brain tumor) in tuberous sclerosis complex (TSC: a rare type of tumor disorder)

**(Afinitor denial text continued on next page)**

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

EVEROLIMUS

GUIDELINES FOR USE - AFINITOR (CONTINUED)

- B. **If you have advanced hormone receptor-positive, HER2-negative breast cancer, approval also requires:**
  - 1. You are a postmenopausal woman
  - 2. Afinitor will be used in combination with Aromasin (exemestane)
  - 3. You have failed or have a contraindication (harmful for) to treatment with Femara (letrozole) or Arimidex (anastrozole)
- C. **If you have progressive, neuroendocrine tumors (NET) with unresectable, locally advanced or metastatic disease, approval also requires:**
  - 1. You are 18 years of age or older
  - 2. You meet ONE of the following:
    - a. You have neuroendocrine tumors of pancreatic origin (PNET: tumor in the pancreas)
    - b. You have well-differentiated, non-functional neuroendocrine tumors (NET) of gastrointestinal (GI: relates to the digestive system) or lung origin
- D. **If you have advanced renal cell carcinoma, approval also requires:**
  - 1. You are 18 years of age or older
  - 2. You have failed or have a contraindication (harmful for) to treatment with sunitinib OR sorafenib
- E. **If you have a renal angiomyolipoma and tuberous sclerosis complex (TSC), approval also requires:**
  - 1. You are 18 years of age or older
  - 2. You do not require immediate surgery
- F. **If you have subependymal giant cell astrocytoma (SEGA) in tuberous sclerosis complex (TSC), approval also requires:**
  - 1. You are 1 year of age or older
  - 2. Your diagnosis requires therapeutic intervention but cannot be curatively resected (completely remove with surgery)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**EVEROLIMUS**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Afinitor/Afinitor Disperz.

**REFERENCES**

- Afinitor/Afinitor Disperz [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation. April 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/25/21

Created: 05/11

Client Approval: 10/21

P&T Approval: 04/18





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

EXCLUDED FORMULARY DRUG EXCEPTION CRITERIA

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
EXCLUDED DRUGS					

**\*\*\*\*\*Customer Service/PAC Alert\*\*\*\*\***  
**(For Internal Use Only)**

**DO NOT OVERRIDE OR APPROVE WITHOUT SUBMITTING FOR PHARMACIST OR PHYSICIAN REVIEW.**

**GUIDELINES FOR USE**

1. Is the request for an excluded drug and the claim is rejecting with the error code **REJ-922**?

If yes, continue to #2.  
If no, guideline does not apply.

2. Is the request for a glucose test strip or meter?

If yes, please refer to the corresponding guideline for further clinical review.  
If no, continue to #3.

3. Is the requested drug being used for the treatment of an FDA-approved indication?

If yes, continue to #5.  
If no, continue to #4.

4. If the drug is requested for a non-FDA approved indication, does the patient have a diagnosis for which the drug is considered safe and effective based on sound medical evidence found in peer-reviewed medical literature, accepted standards of medical practice, or in one of the following compendia?

- American Hospital Formulary Service-Drug Information (AHFS-DI): Contains narrative text supporting use
- Clinical Pharmacology: Contains narrative text supporting use
- National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium: Category 1 or 2A
- Non-Formulary & Excluded Drug Exceptions Process
- Truven Health Analytics Micromedex DrugDex: Class I, Class IIa, or Class IIb
- Wolters Kluwer Lexi-Drugs: Use: Off-label rated as 'Evidence Level A' with a 'Strong' recommendation

If yes, continue to #5.  
If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

EXCLUDED FORMULARY DRUG EXCEPTION CRITERIA

GUIDELINES FOR USE (CONTINUED)

5. Is the requested drug under **ANY** of the following categories?

- Protected class drugs (such as Anticonvulsants, Antidepressants, Antineoplastic, Antipsychotics, Antiretroviral, or Immunosuppressants) and the member is already stabilized, and discontinuation of therapy could lead to harm
- The request is for a member who is stabilized on an Attention Deficit Hyperactivity Disorder or an Anti-mania (Bipolar Affective Disorder) drug prescribed by or given in consultation with a psychiatrist and discontinuation of therapy could lead to harm
- The member is in the middle of completing an antibiotic or Hepatitis C treatment regimen

If yes, **approve the requested drug for 12 months by GPID or GPI-14. For requests for antibiotic or Hepatitis C drugs, please approve based on the duration of remaining therapy per AASLD (Hepatitis C) or the FDA approved duration.**

If no, continue to #6.

6. Does the requested drug have a corresponding clinical PA guideline on the standard commercial formulary?

If yes, please refer to the corresponding guideline for further clinical review.

If no, continue to #7.

7. Is the request for a combination product (e.g., Vimovo, Duexis) for which the individual components with the same route of administration are commercially available and covered by the plan?

If yes, continue to #8.

If no, continue to #9.

8. Have **ALL** of the following criteria been met?

- The patient has tried and failed the individual components together, **AND**
- The prescriber provided a medical rationale that the requested combination product would be safer and/or more efficacious than using the individual components together. Document the rationale in PA approval.

If yes, continue to #11.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

EXCLUDED FORMULARY DRUG EXCEPTION CRITERIA

GUIDELINES FOR USE (CONTINUED)

9. Does the requested medication have clinically appropriate covered alternatives with the same active ingredient and same route of administration?

Examples of possible alternatives:

- Conzip: generic tramadol extended-release capsules or tablets
- Zipsor: generic diclofenac DR tablets
- Metformin ER gastric: trial of generic Glucophage XR
- Onzetra Xsail: trial of sumatriptan nasal spray

If yes, continue to #10.

If no, continue to #11.

10. Has the patient had a previous trial of at least three covered alternatives with the same active ingredients and same route of administration (if available), OR does the patient have a documented intolerance or contraindication to those agents? Provide reason for therapeutic failure, intolerance or contraindication.

If yes, continue to #11.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

11. Has the patient tried and failed at least three clinically appropriate covered agents with different active ingredients but the same route of administration for the specified indication (if available), one of which must be in the same class as the requested medication? Provide reasons for therapeutic failure.

If yes, **approve the requested drug for 12 months by GPID or GPI-14.**

If no, continue to #12.

12. Does the patient have a documented intolerance or contraindication to the agents identified in question #11? Provide reason for therapeutic failure, intolerance or contraindication.

If yes, **approve the requested drug for 12 months by GPID or GPI-14.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

EXCLUDED FORMULARY DRUG EXCEPTION CRITERIA

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT:** Our guideline named **EXCLUDED FORMULARY DRUG EXCEPTION CRITERIA** (reviewed for **<insert drug name>**) requires that ALL of the following rule(s) be met for approval:

- A. The requested medication is being used for the treatment of ONE of the following:
  1. A Food and Drug Administration (FDA)-approved indication
  2. A medically accepted indication and it is considered safe and effective by approved compendia (medical references), peer-reviewed medical literature, or accepted standards of medical practice.
- B. You meet one of the following criteria (1, 2, or 3):
  1. If the request is for a combination product and the individual components with the same route of administration are commercially available and are covered by your plan, you must meet the following (a, b, and c):
    - a. You have previously tried **<insert individual components>** together
    - b. Your doctor provided a medical rationale that the requested combination product would be safer and/or more efficacious than using the individual components together
    - c. You have previously tried at least three clinically appropriate covered agents with different active ingredients but the same route of administration for the specified indication (if available), one of which must be in the same class as the requested drug for the specific indication (if available) OR your physician has provided documentation that you have experienced a therapeutic failure, contraindication to (medical reason why you cannot use), or intolerance to those agents
  2. If the request is for a medication that has clinically appropriate covered alternative(s) with the same active ingredient and same route of administration, you must meet the following (a and b):
    - a. You have previously tried at least three clinically appropriate covered alternatives with the same active ingredients and same route of administration (if available), including but not limited to **<insert formulary agents>**, OR there is a medical rationale why the covered alternatives cannot be tried.
    - b. You have previously tried at least three clinically appropriate covered agents with different active ingredients but the same route of administration for the specified indication (if available), one of which must be in the same class as the requested drug for the specific indication (if available) OR your physician has provided documentation that you have experienced a therapeutic failure, contraindication to (medical reason why you cannot use), or intolerance to those agents
  3. If the requested medication does NOT have clinically appropriate covered alternatives with the same active ingredient and same route of administration, you must have previously tried at least three clinically appropriate covered agents with different active ingredients but the same route of administration for the specified indication (if available), one of which must be in the same class as the requested drug for the specific indication (if available) OR your physician has provided documentation that you have experienced a therapeutic failure, contraindication to (medical reason why you cannot use), or intolerance to those agents.

***(Denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**EXCLUDED FORMULARY DRUG EXCEPTION CRITERIA**

**GUIDELINES FOR USE (CONTINUED)**

A previous trial of <insert applicable drugs/therapies to this case> is noted but we do not have information showing that you have tried the above alternatives. Therefore, your request was not approved. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request. Note: The preferred alternatives may also require a prior authorization.

---

**RATIONALE**

To allow an exception for coverage of an excluded drug based on the following considerations:

- The drug is being requested for treatment of an FDA or medically supported indication.
- The patient cannot use covered products due to therapeutic failure, contraindication or intolerance as documented by their physician.
- Any applicable prior authorization clinical criteria for the excluded drug have been met.

**FDA APPROVED INDICATIONS**

See package insert for requested drug.

Part D Effective: N/A  
Effective: 12/17/20

Created: 01/18  
Client Approval: 12/20

P&T Approval: 10/19



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FECAL MICROBIOTA

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
FECAL MICROBIOTA, LIVE-JSLM	REBYOTA	48488		GPI-10 (5252201030)	

GUIDELINES FOR USE

1. Is the request for the prevention of recurrent *Clostridioides difficile* infection (CDI) **AND** the patient meets the following criterion?

- The patient is 18 years of age or older

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Has the patient previously received Rebyota?

If yes, continue to #4.

If no, continue to #3.

3. Has the patient completed antibiotic treatment for recurrent CDI (at least 3 CDI episodes) at least 24 hours prior?

If yes, **approve for 30 days by HICL or GPI-10 for 1 fill with a quantity limit of #150 mL.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

4. Does the patient meet **ALL** of the following criteria?

- The patient had treatment failure, defined as the presence of CDI diarrhea within 8 weeks of first dose of Rebyota **AND** a positive stool test for *C.difficile*
- The patient has not previously received more than 1 dose **AND** that dose was at least 7 days and not more than 8 weeks prior

If yes, **approve for 30 days by HICL or GPI-10 for 1 fill with a quantity limit of #150 mL.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **FECAL MICROBIOTA (Rebyota)** requires the following rule(s) be met for approval:

A. You are using the requested medication for the prevention of recurrent *Clostridioides difficile* infection (CDI: a bacterial infection)

B. You are 18 years of age or older

**(Denial text continued on next page)**

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FECAL MICROBIOTA

GUIDELINES FOR USE (CONTINUED)

C. If you have NOT previously received Rebyota, approval also requires:

- 1. You have completed antibiotic treatment for recurrent CDI (at least 3 CDI episodes) at least 24 hours prior

D. If you have been previously treated with Rebyota, approval also requires:

- 1. You had treatment failure, defined as the presence of CDI diarrhea within 8 weeks of first dose of Rebyota AND a positive stool test for *C.difficile*
- 2. You have not previously received more than 1 dose AND that dose was at least 7 days and not more than 8 weeks prior

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Rebyota.

REFERENCES

- Rebyota [Prescribing Information]. Parsippany, NJ: Ferring Pharmaceuticals, Inc.; November 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective:04/01/23

Created: 02/23

Client Approval: 02/23

P&T Approval: 01/23



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FEDRATINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
FEDRATINIB DIHYDROCHLORID E	INREBIC	45953		GPI-10 (2153752020)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

- Does the patient have a diagnosis of intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient had a trial of or contraindication to Jakafi (ruxolitinib)

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #4 per day.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **FEDRATINIB (Inrebic)** requires the following rule(s) be met for approval:

- You have intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (type of bone marrow cancer)
- You are 18 years of age or older
- You previously had a trial of or contraindication (medical reason why you cannot use) to Jakafi (ruxolitinib)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FEDRATINIB

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF)?

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

2. Has the patient shown symptom improvement by meeting **ONE** of the following criteria?
  - The patient has a spleen volume reduction of 35% or greater from baseline
  - The patient has a 50% or greater reduction in total symptom score (e.g., Myeloproliferative Neoplasm Symptom Assessment Form [MPN-SAF TSS], modified Myelofibrosis Symptom Assessment Form [MFSAF] v2.0)
  - The patient has a 50% or greater reduction in palpable spleen length

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**

If no, do not approve.

**RENEWAL DENIAL TEXT:** **\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **FEDRATINIB (Inrebic)** requires the following rule(s) be met for renewal:

- A. You have intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (type of bone marrow cancer)
- B. You have shown symptom improvement by meeting ONE of the following:
  1. You have a spleen volume reduction of 35% or greater from baseline
  2. You have a 50% or greater reduction in total symptom score (such as Myeloproliferative Neoplasm Symptom Assessment Form [MPN-SAF TSS], modified Myelofibrosis Symptom Assessment Form [MFSAF] v2.0)
  3. You have a 50% or greater reduction in palpable (can be felt by external examination) spleen length

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**FEDRATINIB**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Inrebic.

**REFERENCES**

- Inrebic [Prescribing Information]. Summit, NJ: Celgene Corporation; September 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/22

Created: 11/19

Client Approval: 11/21

P&T Approval: 10/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FENFLURAMINE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
FENFLURAMINE HCL	FINTEPLA	02116		GPI-10 (7260002810)	

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of seizures associated with Dravet syndrome and meet **ALL** of the following criteria?
  - The patient is 2 years of age or older
  - Therapy is prescribed by or in consultation with a neurologist
  - The patient had a trial of or contraindication to TWO of the following: valproic acid derivative, clobazam, topiramate

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #11.8mL per day.**  
If no, continue to #2.

2. Does the patient have a diagnosis of seizures associated with Lennox-Gastaut syndrome (LGS) and meet **ALL** of the following criteria?
  - The patient is 2 years of age or older
  - Therapy is prescribed by or in consultation with a neurologist
  - The patient had a trial of or contraindication to valproic acid or derivatives
  - The patient had a trial of or contraindication to TWO of the following: Epidiolex, rufinamide, felbamate, clobazam, topiramate, lamotrigine, clonazepam

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #11.8mL per day.**  
If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **FENFLURAMINE (Fintepla)** requires the following rule(s) be met for approval:

- A. You have seizures associated with ONE of the following:
  1. Dravet syndrome (a rare type of seizure)
  2. Lennox-Gastaut syndrome (LGS: a type of seizure disorder in young children)
- B. **If you have Dravet syndrome, approval also requires:**
  1. You are 2 years of age or older
  2. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor)
  3. You had a trial of or contraindication (harmful for) to TWO of the following: valproic acid derivative, clobazam, topiramate

***(Initial denial text continued on next page)***

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FENFLURAMINE

INITIAL CRITERIA (CONTINUED)

C. If you have Lennox-Gastaut syndrome, approval also requires:

1. You are 2 years of age or older
2. Therapy is prescribed by or given in consultation with a neurologist (a type of brain doctor)
3. You had a trial of or contraindication (harmful for) to valproic acid or derivatives
4. You had a trial of or contraindication (harmful for) to TWO of the following: Epidiolex, rufinamide, felbamate, clobazam, topiramate, lamotrigine, clonazepam

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

**NOTE:** For the diagnosis of Lennox-Gastaut syndrome (LGS), please refer to the Initial Criteria section.

1. Does the patient have a diagnosis of seizures associated with Dravet syndrome **AND** meet the following criterion?
  - The patient has shown continued clinical benefit (e.g., reduction of seizures, reduced length of seizures, seizure control maintained)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #11.8mL per day.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **FENFLURAMINE (Fintepla)** requires the following rule(s) be met for approval:

- A. You have seizures associated with Dravet syndrome (a rare type of seizure)
- B. You have shown continued clinical benefit (such as reduction of seizures, reduced length of seizures, seizure control maintained) while on therapy

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**FENFLURAMINE**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Fintepla.

**REFERENCES**

- Fintepla [Prescribing Information]. Emeryville, CA: Zogenix, Inc., March 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/22

Created: 07/20

Client Approval: 05/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FENTANYL NASAL SPRAY

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
FENTANYL CITRATE	LAZANDA		27648 29146 41539	GPI-14 (65100025102050) (65100025102060) (65100025102057)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of cancer?

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Is the patient on a maintenance dose of controlled release pain medication (MS Contin, Oxycontin, Oramorph SR, Duramorph, Roxanol SR, Duragesic, Avinza or the generic forms of any of these drugs)?

If yes, continue to #3.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

3. Has the patient tried, or does the patient have a contraindication to at least 1 immediate-release oral pain agent (morphine sulfate immediate-release [MSIR], Percodan, Percocet, Vicodin, Tylenol with Codeine, Dilaudid, Demerol or the generic forms of any of these)?

If yes, continue to #5.

If no, continue to #4.

4. Does the patient have difficulty swallowing tablets or capsules?

If yes, continue to #5.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

5. Has the patient tried, or does the patient have a contraindication to generic fentanyl citrate lozenge?

If yes, continue to #6.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FENTANYL NASAL SPRAY

GUIDELINES FOR USE (CONTINUED)

6. Has the patient tried, or does the patient have a contraindication to Abstral, or Fentora?

If yes, **approve for 6 months by GPID or GPI-14 with a quantity limit of #15 per month.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **FENTANYL NASAL SPRAY (Lazanda)** requires the following rule(s) to be met for approval:

- A. You have a diagnosis of cancer-related pain
- B. You are currently taking a maintenance dose of a controlled-release pain medication (such as MS Contin, Oxycontin, Oramorph SR, Duramorph, Roxanol SR, Duragesic, Kadian, Avinza or the generic forms of any of these drugs)
- C. You had a trial of an oral immediate-release pain medication (such as morphine sulfate immediate-release [MSIR], Percodan, Percocet, Vicodin, Tylenol with Codeine, Dilaudid, Demerol or the generic forms of any of these), unless you have difficulty swallowing tablets or capsules OR there is a medical reason why you cannot (contraindication)
- D. You had a trial of generic fentanyl citrate lozenge (which also requires a prior authorization), unless there is a medical reason why you cannot (contraindication)
- E. You had a trial of Abstral or Fentora (which also requires a prior authorization), unless there is a medical reason why you cannot (contraindication)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Lazanda.

**REFERENCES**

- Lazanda [Prescribing Information]. Northbrook, IL: West Therapeutic Development, LLC; October 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 08/11

Client Approval: 04/20

P&T Approval: 11/14



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FENTANYL SUBLINGUAL SPRAY

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
FENTANYL SUBLINGUAL SPRAY	SUBSYS		31187 31188 31189 31192 31193 31596 31597	GPI-12 (651000250009)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of cancer?

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Is the patient on a maintenance dose of controlled release pain medication (MS Contin, Oxycontin, Oramorph SR, Duramorph, Roxanol SR, Duragesic, Avinza or the generic forms of any of these drugs)?

If yes, continue to #3.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

3. Has the patient tried or does the patient have a contraindication to at least one immediate-release oral pain agent (morphine sulfate immediate-release [MSIR], Percodan, Percocet, Vicodin, Tylenol with Codeine, Dilaudid, Demerol or the generic forms of any of these)?

If yes, continue to #5.

If no, continue to #4.

4. Does the patient have difficulty swallowing tablets or capsules?

If yes, continue to #5.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

5. Has the patient tried or does the patient have a contraindication to generic fentanyl citrate lozenge?

If yes, continue to #6.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FENTANYL SUBLINGUAL SPRAY

GUIDELINES FOR USE (CONTINUED)

6. Has the patient tried or does the patient have a contraindication to Abstral or Fentora?

If yes, **approve for 6 months by GPID or GPI-12 with a quantity limit of #120 per month.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **FENTANYL SUBLINGUAL SPRAY (Subsys)** requires the following rule(s) be met for approval:

- A. You have cancer-related pain
- B. You are currently using the requested medication with a controlled-release pain medication (MS Contin, Oxycontin, Oramorph SR, Duramorph, Roxanol SR, Duragesic, Kadian, Avinza or the generic forms of any of these drugs)
- C. You had a trial of an oral immediate-release pain medication (morphine sulfate immediate-release [MSIR], Percodan, Percocet, Vicodin, Tylenol with Codeine, Dilaudid, Demerol or the generic forms of any of these), unless you have difficulty swallowing tablets or capsules OR there is a medical reason why you cannot (contraindication)
- D. You had a trial of generic fentanyl citrate lozenge (which also requires a prior authorization), unless there is a medical reason why you cannot (contraindication)
- E. You had a trial of Abstral or Fentora, all of which may also require a prior authorization, unless there is a medical reason why you cannot (contraindication)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Subsys.

**REFERENCES**

- Subsys [Prescribing Information]. Chandler, AZ: Insys Therapeutics; November 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 04/12

Client Approval: 04/20

P&T Approval: 11/14



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FENTANYL TRANSDERMAL PATCH

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
FENTANYL	DURAGESIC, FENTANYL		24635 19200 37952 19201 37947 19202 37948 19203	GPI-12 (651000250086)	

**GUIDELINES FOR USE**

1. Does the patient meet the definition of opioid tolerance (defined as those who are taking, for one week or longer, at least 60mg oral morphine per day, 25mcg transdermal fentanyl/hour, 30mg oral oxycodone/day, 25mg oral oxymorphone/day, 8mg oral hydromorphone/day, or an equianalgesic dose of another opioid)?

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the request form indicate that this medication will be used on an "as needed" or "PRN" basis?

If yes, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

If no, continue to #3.

3. Is the request for more than one strength of transdermal fentanyl patch OR does the patient have an active prior authorization(s) for a different strength of fentanyl patch?

If yes, send to Clinical Pharmacist for review.

If no, continue to #4.

4. Is the request for every 72 hours dosing?

If yes, **approve for 12 months by GPID or GPI-14 for the requested strength(s) with the following quantity limits:**

- **FOR EVERY 72 HOUR DOSING (12, 25, 37.5, 50, 62.5, 75, 87.5mcg/hr): #10 patches per 30 days.**

- **FOR 100mcg/hr: up to #20 patches per 30 days.**

**(NOTE: Please override both PA and step therapy [if applicable] restrictions by entering 'Y' for OVR\_RES).**

If no, continue to #5.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FENTANYL TRANSDERMAL PATCH

GUIDELINES FOR USE (CONTINUED)

5. Is the request for dosing every 48 hours?

If yes, continue to #6.

If no, send to Clinical Pharmacist for review.

6. Has the patient tried every 72 hours dosing?

If yes, approve for 12 months by GPID or GPI-14 for the requested strength(s) with the following quantity limits:

- FOR EVERY 48 HOUR DOSING (12, 25, 37.5, 50, 62.5, 75, 87.5mcg/hr): #15 patches per 30 days.
- FOR 100mcg/hr: up to #30 patches per 30 days.

(NOTE: Please override both PA and step therapy [if applicable] restrictions by entering 'Y' for OVR\_RES).

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **FENTANYL TRANSDERMAL PATCH (Duragesic)** requires the following rule(s) be met for approval:

- A. You meet the definition of opioid tolerance. This is defined as those who are taking, for one week or longer, at least 60mg oral morphine per day, 25mcg transdermal fentanyl/hour, 30mg oral oxycodone/day, 25mg oral oxymorphone/day, 8mg oral hydromorphone/day, or an equianalgesic dose (equal pain-relieving dose) of another opioid
- B. The requested medication is not prescribed on an 'as needed' basis
- C. Requests for dosing every 48 hours requires a trial of transdermal (absorbed through the skin) fentanyl patch dosed every 72 hours

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**FENTANYL TRANSDERMAL PATCH**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Duragesic.

**REFERENCES**

- Fentanyl Patch [Prescribing Information]. Morgantown, WV: Mylan Pharmaceuticals, Inc.; March 2015.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 02/03

Client Approval: 04/20

P&T Approval: 07/19



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FENTANYL TRANSMUCOSAL AGENTS

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
FENTANYL CITRATE	ACTIQ, ABSTRAL, FENTORA	01747		GPI-10 (6510002510)	FDB & Medi-Span: ROUTE = BUCCAL, SUBLINGUAL

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of cancer?

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Is the patient on a maintenance dose of controlled release pain medication (MS Contin, Oxycontin, Oramorph SR, Duramorph, Roxanol SR, Duragesic, Avinza or the generic forms of any of these drugs)?

If yes, continue to #3.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

3. Has the patient tried or does the patient have a contraindication to at least one immediate-release oral pain agent (morphine sulfate immediate-release [MSIR], Percodan, Percocet, Vicodin, Tylenol with Codeine, Dilaudid, Demerol or the generic forms of any of these)?

If yes, continue to #5.

If no, continue to #4.

4. Does the patient have difficulty swallowing tablets or capsules?

If yes, continue to #5.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

5. Is the request for generic fentanyl citrate lozenge?

If yes, **approve for 6 months by GPID or GPI-14 for the requested strength with a quantity limit of #120 per month.**

If no, continue to #6.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FENTANYL TRANSMUCOSAL AGENTS

GUIDELINES FOR USE (CONTINUED)

6. Has the patient tried or does the patient have a contraindication to generic fentanyl citrate lozenge?

If yes, **approve for 6 months by GPID or GPI-14 for the requested strength with a quantity limit of #120 per month.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **FENTANYL TRANSMUCOSAL AGENTS (Actiq, Fentora, Abstral)** requires the following rule(s) be met for approval:

- A. You have cancer-related pain
- B. You are currently using the requested medication with a controlled-release pain medication (MS Contin, Oxycontin, Oramorph SR, Duramorph, Roxanol SR, Duragesic, Avinza or the generic forms of any of these drugs)
- C. You had a trial of an oral immediate-release pain medication (such as morphine sulfate immediate-release [MSIR], Percodan, Percocet, Vicodin, Tylenol with Codeine, Dilaudid, Demerol or the generic forms of any of these), unless you have difficulty swallowing tablets or capsules OR there is a medical reason why you cannot (contraindication)
- D. You had a trial of generic fentanyl citrate lozenge (which also requires a prior authorization) unless there is a medical reason why you cannot (contraindication)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Actiq, Fentora, and Abstral.

**REFERENCES**

- Actiq [Prescribing Information]. North Wales, PA: Cephalon, Inc.; October 2019.
- Fentora [Prescribing Information]. North Wales, PA: Cephalon, Inc.; October 2019.
- Abstral [Prescribing Information]. Solana Beach, CA: Sentynt Therapeutics, Inc.; October 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 02/03

Client Approval: 04/20

P&T Approval: 11/14



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FERRIC MALTOL

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
FERRIC MALTOL	ACCRUFER	44098		GPI-10 (8230006300)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of iron deficiency and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient had a trial of or contraindication to an OTC oral iron preparation (e.g., ferrous sulfate, ferrous gluconate, ferrous fumarate)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **FERRIC MALTOL (Accrufer)** requires the following rule(s) be met for approval:

- A. You have iron deficiency (low iron levels)
- B. You are 18 years of age or older
- C. You had a trial of an over-the-counter (OTC) oral iron preparation (e.g., ferrous sulfate, ferrous gluconate, ferrous fumarate), unless there is a medical reason why you cannot (contraindication)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Accrufer.

**REFERENCES**

- Accrufer [Prescribing Information]. Bourgoin-Jallieu, France: Patheon., October 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/01/21

Created:07/21

Client Approval: 08/21

P&T Approval: 07/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FILGRASTIM

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
FILGRASTIM	NEUPOGEN	06070		GPI-10 (8240152000)	

**GUIDELINES FOR USE**

1. Is the request to increase survival in a patient acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome) **AND** the patient meets the following criterion?

- Therapy is prescribed by or in consultation with a hematologist or oncologist

If yes, **approve for 12 months by HICL or GPI-10.**

If no, continue to #2.

2. Does the patient meet **ONE** of the following criteria?

- The patient has a non-myeloid malignancy and is receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever
- The patient has a diagnosis of acute myeloid leukemia (AML) and is undergoing induction or consolidation chemotherapy treatment
- The patient has a non-myeloid malignancy, is undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT), and is experiencing neutropenia and/or neutropenia-related clinical sequelae (e.g., febrile neutropenia)
- The patient is using the requested medication for mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis
- The patient has a diagnosis of congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia

If yes, continue to #3.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

3. Does the patient meet **ALL** of the following criteria?

- Therapy is prescribed by or in consultation with a hematologist or oncologist
- The patient had a trial of or contraindication to the preferred agent: Nivestym

If yes, **approve for 12 months by HICL or GPI-10.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FILGRASTIM

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **FILGRASTIM (Neupogen)** requires the following rule(s) be met for approval:

A. You meet ONE of the following:

1. You have a non-myeloid malignancy (cancer not affecting bone marrow) and are receiving myelosuppressive anti-cancer drugs (drugs that decrease bone marrow activity) associated with a significant incidence of severe neutropenia (a type of blood condition) with fever AND you had a trial of or contraindication (harmful for) to the preferred medication: Nivestym
2. You have acute myeloid leukemia (a type of blood cancer) undergoing induction or consolidation chemotherapy treatment (you are starting therapy so there is no sign of cancer cells or you have therapy to kill any remaining cancer cells in the body) AND you had a trial of or contraindication (harmful for) to the preferred medication: Nivestym
3. You have a non-myeloid malignancy (cancer not affecting bone marrow), are undergoing myeloablative chemotherapy (high-dose drugs used to treat cancer) followed by bone marrow transplantation, and neutropenia (a type of blood condition) and/or neutropenia-related clinical symptoms (such as febrile neutropenia [a type of blood condition with fever]) are expected, AND you had a trial of or contraindication (harmful for) to the preferred medication: Nivestym
4. You are using the requested drug for mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis (a type of blood cell is stimulated to be collected by a process where it is separated from the blood), AND you had a trial of or contraindication (harmful for) to the preferred medication: Nivestym
5. You have congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia (low levels of a type of white blood cell at birth, in cycles, or due to unknown cause) AND you had a trial of or contraindication (harmful for) to the preferred medication: Nivestym
6. You are using Neupogen to increase survival if you have been acutely exposed to myelosuppressive doses of radiation (doses that decrease bone marrow activity)

B. Therapy is prescribed by or in consultation with a hematologist (blood doctor) or oncologist (cancer/tumor doctor)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**FILGRASTIM**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Neupogen.

**REFERENCES**

- Neupogen [Prescribing Information]. Thousand Oaks, CA: Amgen Inc.; February 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/01/22

Created: 08/21

Client Approval: 10/22

P&T Approval: 07/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FILGRASTIM-AAFI

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
FILGRASTIM-AAFI	NIVESTYM	45154		GPI-10 (8240152010)	

**GUIDELINES FOR USE**

1. Does the patient meet **ONE** of the following criteria?

- The patient has a non-myeloid malignancy and is receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever
- The patient has a diagnosis of acute myeloid leukemia (AML) and is undergoing induction or consolidation chemotherapy treatment
- The patient has a non-myeloid malignancy, is undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT), and is experiencing neutropenia and/or neutropenia-related clinical sequelae (e.g., febrile neutropenia)
- The patient is using the requested medication for mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis
- The patient has a diagnosis of congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Is therapy prescribed by or in consultation with a hematologist or oncologist?

If yes, **approve for 12 months by HICL or GPI-10.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FILGRASTIM-AAFI

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **FILGRASTIM-AAFI (Nivestym)** requires the following rule(s) be met for approval:

- A. You meet ONE of the following:
  1. You have a non-myeloid malignancy (cancer not affecting bone marrow) and are receiving myelosuppressive anti-cancer drugs (drugs that decrease bone marrow activity) associated with a significant incidence of severe neutropenia (a type of blood condition) with fever
  2. You have acute myeloid leukemia (a type of blood cancer) and are undergoing induction or consolidation chemotherapy treatment (you are starting therapy so there is no sign of cancer cells or you have therapy to kill any remaining cancer cells in the body)
  3. You have a non-myeloid malignancy (cancer not affecting bone marrow), are undergoing myeloablative chemotherapy (high-dose drugs used to treat cancer) followed by bone marrow transplantation and neutropenia (a type of blood condition) and/or neutropenia-related clinical symptoms (such as febrile neutropenia [a type of blood condition with fever]) are expected
  4. You are using the requested drug for mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis (a type of blood cell is stimulated to be collected by a process where it is separated from the blood)
  5. You have congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia (low amount of a type of white blood cell at birth, in cycles or due to unknown cause)
- B. Therapy is prescribed by or in consultation with a hematologist (blood doctor) or oncologist (cancer/tumor doctor)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Nivestym.

**REFERENCES**

- Nivestym [Prescribing Information]. Lake Forest, IL: Pfizer; April 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/01/22

Created: 10/22

Client Approval: 10/22

P&T Approval: 07/21

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FILGRASTIM-AYOW

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
FILGRASTIM-AYOW	RELEUKO	47848		GPI-10 (8240152015)	

**GUIDELINES FOR USE**

1. Does the patient meet **ONE** of the following criteria?

- The patient has a nonmyeloid malignancy and is receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever
- The patient has acute myeloid leukemia (AML) and is undergoing induction or consolidation chemotherapy treatment
- The patient has a nonmyeloid malignancy, is undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT), and is experiencing neutropenia and/or neutropenia-related clinical sequelae (e.g., febrile neutropenia)
- The patients have congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient meet **ALL** of the following criteria?

- Therapy is prescribed by or in consultation with a hematologist or oncologist
- The patient had a trial of or contraindication to the preferred agent: Nivestym

If yes, **approve for 12 months by HICL or GPI-10.**

If no, do not approve.

**DENIAL TEXT:** **\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **FILGRASTIM-AYOW (Releuko)** requires the following rule(s) be met for approval:

A. The request is for ONE of the following:

1. You have a nonmyeloid malignancy (a type of cancer) and are receiving myelosuppressive anti-cancer drugs (drugs that decrease bone marrow activity) associated with a significant incidence of severe neutropenia (a type of blood condition) with fever
2. You have acute myeloid leukemia (AML: a type of blood cancer) and are undergoing induction or consolidation chemotherapy treatment (drug used to treat cancer)

***(Denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FILGRASTIM-AYOW

GUIDELINES FOR USE (CONTINUED)

- 3. You have a nonmyeloid malignancy (a type of cancer), are undergoing myeloablative chemotherapy (drugs used to treat cancer) followed by bone marrow transplantation, and are experiencing neutropenia (a type of blood condition) and/or neutropenia-related clinical sequelae (such as febrile neutropenia [a type of blood condition with fever])
- 4. You have congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia (low amount of a type of white blood cell at birth, in cycles, or due to unknown cause)
- B. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
- C. You had a trial of or contraindication (harmful for) to the preferred medication: Nivestym

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Releuko.

REFERENCES

- Releuko [Prescribing Information]. Piscataway, NJ: Kashiv BioSciences, LLC; February 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/22

Created: 05/22

Client Approval: 05/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FILGRASTIM-SNDZ

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
FILGRASTIM-SNDZ	ZARXIO	41814		GPI-10 (8240152060)	

**GUIDELINES FOR USE**

1. Does the patient meet **ONE** of the following criteria?

- The patient has a non-myeloid malignancy and is receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever
- The patient has a diagnosis of acute myeloid leukemia (AML) and is undergoing induction or consolidation chemotherapy treatment
- The patient has a non-myeloid malignancy, is undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT), and is experiencing neutropenia and/or neutropenia-related clinical sequelae (e.g., febrile neutropenia)
- The patient is using the requested medication for mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis
- The patient has a diagnosis of congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient meet **ALL** of the following criteria?

- Therapy is prescribed by or in consultation with a hematologist or oncologist
- The patient had a trial of or contraindication to the preferred agent: Nivestym

If yes, **approve for 12 months by HICL or GPI-10.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FILGRASTIM-SNDZ

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **FILGRASTIM-SNDZ (Zarxio)** requires the following rule(s) be met for approval:

A. You meet ONE of the following:

1. You have a non-myeloid malignancy (cancer not affecting bone marrow) and are receiving myelosuppressive anti-cancer drugs (drugs that decrease bone marrow activity) associated with a significant incidence of severe neutropenia (a type of blood condition) with fever AND you had a trial of or contraindication (harmful for) to the preferred medication: Nivestym
2. You have acute myeloid leukemia (a type of blood cancer) undergoing induction or consolidation chemotherapy treatment (you are starting therapy so there is no sign of cancer cells or you have therapy to kill any remaining cancer cells in the body) AND you had a trial of or contraindication (harmful for) to the preferred medication: Nivestym
3. You have a non-myeloid malignancy (cancer not affecting bone marrow), are undergoing myeloablative chemotherapy (high-dose drugs used to treat cancer) followed by bone marrow transplantation, and neutropenia (a type of blood condition) and/or neutropenia-related clinical symptoms (such as febrile neutropenia [a type of blood condition with fever]) are expected, AND you had a trial of or contraindication (harmful for) to the preferred medication: Nivestym
4. You are using the requested drug for mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis (a type of blood cell is stimulated to be collected by a process where it is separated from the blood), AND you had a trial of or contraindication (harmful for) to the preferred medication: Nivestym
5. You have congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia (low levels of a type of white blood cell at birth, in cycles, or due to unknown cause) AND you had a trial of or contraindication (harmful for) to the preferred medication: Nivestym

B. Therapy is prescribed by or in consultation with a hematologist (blood doctor) or oncologist (cancer/tumor doctor)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**





**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**FILGRASTIM-SNDZ**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Zarxio.

**REFERENCES**

- Zarxio [Prescribing Information]. Princeton, NJ: Sandoz Inc.; March 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/01/22

Created: 10/22

Client Approval: 10/22

P&T Approval: 07/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FINASTERIDE-TADALAFIL

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
FINASTERIDE/TADALAFIL	ENTADFI	47719		GPI-10 (5685990230)	

**GUIDELINES FOR USE**

1. Has the patient received a 26-week course of Entadfi?

If yes, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

If no, continue to #2.

2. Is the request for a male patient with a diagnosis of benign prostatic hyperplasia (BPH) who meets **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient had a trial of or contraindication to TWO alpha blockers (e.g., terazosin, doxazosin, tamsulosin)
- The patient had a trial of or contraindication to ONE 5-alpha-reductase inhibitor (e.g., finasteride, dutasteride)
- The patient had a trial of or contraindication to tadalafil 2.5 mg or tadalafil 5 mg

If yes, **approve for 26 weeks by HICL or GPI-10 with a quantity limit of #1 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **FINASTERIDE-TADALAFIL (Entadfi)** requires the following rule(s) be met for approval:

- A. You are male and have benign prostatic hyperplasia (BPH: a type of prostate condition)
- B. You are 18 years of age or older
- C. You had a trial of or contraindication (harmful for) to TWO alpha blockers (such as terazosin, doxazosin, tamsulosin)
- D. You had a trial of or contraindication (harmful for) to ONE 5-alpha-reductase inhibitor (such as finasteride, dutasteride)
- E. You had a trial of or contraindication (harmful for) to tadalafil 2.5 mg or tadalafil 5 mg

Requests will not be approved if you have received a 26-week course of Entadfi.

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**FINASTERIDE-TADALAFIL**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Entadfi.

**REFERENCES**

- Entadfi [Prescribing Information]. Miami, FL: Veru, Inc.; December 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 08/29/22

Created: 08/22

Client Approval: 08/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**FINERENONE**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
FINERENONE	KERENDIA	47487		GPI-10 (3035403000)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of chronic kidney disease (CKD) associated with type 2 diabetes (T2D) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient had a trial of or contraindication to **BOTH** of the following:
    - A sodium-glucose cotransport-2 (SGLT2) inhibitor (e.g., Farxiga, Invokana, Jardiance, Steglatro)
    - Spironolactone OR eplerenone

If yes, **approve for 12 months by HICL or GPI-10 with a quantity of #1 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **FINERENONE (KERENDIA)** requires the following rule(s) be met for approval:

- A. You have chronic kidney disease (CKD) associated with type 2 diabetes (T2D)
- B. You are 18 years of age or older
- C. You had a trial of or contraindication to (medical reason why you cannot use) **BOTH** of the following:
  1. A sodium-glucose cotransport-2 (SGLT2) inhibitor (such as Farxiga, Invokana, Jardiance, Steglatro)
  2. Spironolactone OR eplerenone

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**FINERENONE**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Kerendia.

**REFERENCES**

- Kerendia [Prescribing Information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc., July 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 08/01/21

Created: 07/21

Client Approval: 07/21

P&T Approval: 04/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FINGOLIMOD

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
FINGOLIMOD	GILENYA	37180		GPI-10 (6240702510)	

**GUIDELINES FOR USE**

1. Does the patient have the diagnosis of a relapsing form of multiple sclerosis to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease **AND** meet the following criterion?

- The patient is 10 years of age or older

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient have **ANY** of the following contraindications to Gilenya?

- A recent (within past 6 months) occurrence of myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or Class III/IV heart failure
- A history or presence of Mobitz Type II 2nd degree or 3rd degree AV block or sick sinus syndrome, unless patient has a functioning pacemaker
- A baseline QTC interval 500 msec or above
- Current treatment with Class Ia (quinidine, procainamide, or disopyramide) or Class III anti-arrhythmic drugs (amiodarone, dofetilide, dronedarone, ibutilide, or sotalol)

If yes, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

If no, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **FINGOLIMOD (Gilenya)** requires the following rule(s) be met for approval:

- A. You have a relapsing form of multiple sclerosis (immune system eats away at protective covering of nerves and you have new or increasing symptoms), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease
- B. You are 10 years of age or older.
- C. You do not have any of the following contraindications (medical reason why you cannot use) to Gilenya:
  1. A recent (within past 6 months) occurrence of myocardial infarction (heart attack), unstable angina (chest pain), stroke, transient ischemic attack (short stroke-like attack), decompensated heart failure requiring hospitalization, or Class III/IV heart failure

**(Denial text continued on next page)**

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FINGOLIMOD

GUIDELINES FOR USE (CONTINUED)

2. A history or presence of Mobitz Type II 2nd degree or 3rd degree AV block or sick sinus syndrome (types of irregular heartbeats), unless you have a functioning pacemaker
3. A baseline QTC interval 500 msec or above (a measure of the speed of electrical conduction in the heart)
4. Current treatment with Class Ia (quinidine, procainamide, or disopyramide) or Class III anti-arrhythmic drugs (amiodarone, dofetilide, dronedarone, ibutilide, or sotalol)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Gilenya.

REFERENCES

- Gilenya [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceutical Corporation; December 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 11/10

Client Approval: 04/20

P&T Approval: 07/18



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FINGOLIMOD LAURYL SULFATE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
FINGOLIMOD LAURYL SULFATE	TASCENSO ODT	48165		GPI-10 (6240702520)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of a relapsing form of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease, and meet **ALL** of the following criteria?

- The patient is 10 years of age or older
- The patient had a trial of fingolimod capsules
- The patient is unable to swallow fingolimod capsules
- The patient had a trial of or contraindication to ONE agent indicated for the treatment of MS

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient have **ANY** of the following contraindications to Tascenso ODT?

- A recent (within past 6 months) occurrence of myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or Class III/IV heart failure
- A history or presence of Mobitz Type II 2nd degree or 3rd degree AV block or sick sinus syndrome, unless patient has a functioning pacemaker
- A baseline QTc interval of 500 msec or greater
- Current treatment with Class Ia (quinidine, procainamide, or disopyramide) or Class III anti-arrhythmic drugs (amiodarone, dofetilide, dronedarone, ibutilide, or sotalol)

If yes, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

If no, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FINGOLIMOD LAURYL SULFATE

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **FINGOLIMOD LAURYL SULFATE (Tascenso ODT)** requires the following rule(s) be met for approval:

- A. You have a relapsing form of multiple sclerosis (a type of nerve disorder), to include clinically isolated syndrome (a type of nerve disorder that occurs once), relapsing-remitting disease (symptoms or disease returns and goes away) and active secondary progressive disease (advanced disease)
- B. You are 10 years of age or older
- C. You had a trial of fingolimod capsules
- D. You are unable to swallow fingolimod capsules
- E. You had a trial of or contraindication (harmful for) to one other agent indicated for the treatment of multiple sclerosis
- F. You do not have any of the following contraindications (harmful for) to Tascenso ODT:
  - 1. A recent (within past 6 months) occurrence of myocardial infarction (heart attack), unstable angina (chest pain), stroke, transient ischemic attack (short stroke-like attack), decompensated heart failure requiring hospitalization, or Class III/IV heart failure
  - 2. A history or presence of Mobitz Type II 2<sup>nd</sup> degree or 3<sup>rd</sup> degree AV block or sick sinus syndrome (types of irregular heartbeats), unless you have a functioning pacemaker
  - 3. A baseline QTc interval of 500 msec or greater (a measure of the speed of electrical conduction in the heart)
  - 4. Current treatment with Class Ia (quinidine, procainamide, or disopyramide) or Class III anti-arrhythmic drugs (amiodarone, dofetilide, dronedarone, ibutilide, or sotalol)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**FINGOLIMOD LAURYL SULFATE**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Tascenso ODT.

**REFERENCES**

- Tascenso ODT [Prescribing Information]. San Jose, CA: Handa Neuroscience, LLC; December 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/16/23

Created: 11/22

Client Approval: 12/22

P&T Approval: 10/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FLIBANSERIN

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
FLIBANSERIN	ADDYI	42447		GPI-10 (6217503000)	FDB: ROUTE ≠ MISCELL.

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA, SEE BELOW)**

1. Is Addyi (flibanserin) a covered benefit?

If yes, continue to #2.

If no, guideline does not apply.

2. Does the patient have a diagnosis of acquired, generalized hypoactive sexual desire disorder (HSDD) (also referred to as female sexual interest/arousal disorder [FSIAD] per DSM-5), as defined by **ALL** of the following criteria?

- Persistently or recurrently deficient (or absent) sexual fantasies and desire for sexual activity that has persisted for at least 6 months
- HSDD is not a result of a co-existing medical or psychiatric condition, a problem within the relationship or the effects of a medication or drug substance
- HSDD symptom cause marked distress or interpersonal difficulty

If yes, continue to #3.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

3. Have **ALL** of the following criteria been met?

- The patient is a premenopausal female
- The patient is 18 years of age or older
- The patient had a previous trial of or contraindication to bupropion
- The patient is not currently using Vyleesi (bremelanotide)

If yes, **approve for 8 weeks by HICL or GPI-10 with a quantity limit of #1 tablet per day.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FLIBANSERIN

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **FLIBANSERIN (Addyi)** requires the following rule(s) be met for approval:

- A. You have acquired, generalized hypoactive sexual desire disorder (HSDD; lack or absence of sexual desire). This is also referred to as female sexual interest/arousal disorder per DSM-5 (a diagnostic tool for mental disorders), as defined by **ALL** of the following criteria:
  1. Persistently or recurrently deficient (or absent) sexual fantasies and desire for sexual activity that has persisted for at least 6 months
  2. Hypoactive sexual desire disorder is not a result of a co-existing medical or psychiatric condition, a problem within the relationship or the effects of a medication or drug substance
  3. Hypoactive sexual desire disorder symptom causes marked distress or interpersonal difficulty
- B. You are a premenopausal female
- C. You are 18 years of age or older
- D. You previously had a trial of bupropion, unless there is a medical reason why you cannot (contraindication)
- E. You are not currently using Vyleesi (bremelanotide)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of acquired, generalized hypoactive sexual desire disorder (HSDD) (also referred to as female sexual interest/arousal disorder [FSIAD] per DSM-5), as defined by **ALL** of the following criteria?
  - Persistently or recurrently deficient (or absent) sexual fantasies and desire for sexual activity that has persisted for at least 6 months
  - HSDD is not a result of a co-existing medical or psychiatric condition, a problem within the relationship or the effects of a medication or drug substance
  - HSDD symptom cause marked distress or interpersonal difficulty

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FLIBANSERIN

RENEWAL CRITERIA (CONTINUED)

2. Does the patient meet **ALL** of the following criteria?

- The patient is a premenopausal female
- The patient is not currently using Vyleesi
- The patient has demonstrated continued improvement in symptoms of HSDD/FSIAD (e.g., increased sexual desire, lessened distress)?

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #1 tablet per day.**  
If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline for **FLIBANSERIN (Addyi)** requires the following rule(s) be met for renewal:

- A. You have acquired, generalized hypoactive sexual desire disorder (HSDD; lack or absence of sexual desire). This is also referred to as female sexual interest/arousal disorder per DSM-5 (a diagnostic tool for mental disorders), as defined by **ALL** of the following criteria:
1. Persistently or recurrently deficient (or absent) sexual fantasies and desire for sexual activity that has persisted for at least 6 months
  2. Hypoactive sexual desire disorder is not a result of a co-existing medical or psychiatric condition, a problem within the relationship or the effects of a medication or drug substance
  3. Hypoactive sexual desire disorder symptom causes marked distress or interpersonal difficulty
- B. You are a premenopausal female
- C. You are 18 years of age or older
- D. You are not currently using Vyleesi (bremelanotide)
- E. You have demonstrated continued improvement in symptoms of hypoactive sexual desire disorder/female sexual interest and arousal disorder (such as increased sexual desire, lessened distress)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FLIBANSERIN

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Addyi.

**REFERENCES**

- Addyi [Prescribing Information]. Raleigh, NC: Sprout Pharmaceuticals, Inc.; October 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 09/15

Client Approval: 04/20

P&T Approval: 07/19



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FLUORIDE ZERO COST SHARE OVERRIDE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
FLUORIDE (SODIUM)	SODIUM FLUORIDE, LUDENT FLUORIDE		7472 7473 7476 7510 7511 7512	GPI-14 (79300020000505, 79300020000510, 79300020000515, 79300020002050)	

**GUIDELINES FOR USE**

1. Is the patient requesting a cost share exception for the requested agent **AND** does the plan cover these agents at zero cost share (i.e., the plan follows Affordable Care Act [ACA] recommendations and is linked to MedImpact's Essential Health Benefit Tables)?

If yes, continue to #2.  
If no, guideline does not apply.

2. Does the patient's plan have specific procedures, instructions, and/or policies for cost share exception processes or for multi-source brand agent overrides (DAW1 override)?

If yes, guideline does not apply.  
If no, continue to #3.

3. Is the patient 6 months to 6 years of age?

If yes, continue to #4.  
If no, do not approve.  
**DENIAL TEXT:** See the denial text at the end of the guideline.

4. Is the request for a generic agent?

If yes, **approve the requested agent for 12 months by GPID or GPI-14 at zero copay.**  
If no, continue to #5.

5. Is the request for **ONE** of the following?

- A single-source brand (SSB) agent that has no preferred generic agents or therapeutically equivalent products available
- A multi-source brand (MSB) agent

If yes, continue to #6.  
If no, do not approve.  
**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FLUORIDE ZERO COST SHARE OVERRIDE

GUIDELINES FOR USE (CONTINUED)

6. Does the patient meet **ONE** of the following criteria?

- Two preferred medications are medically inappropriate for the patient (one if only one agent is available)
- The patient has tried or has a documented medical contraindication to TWO preferred medications (one if only one agent is available)
- The prescriber provided documentation confirming that the requested drug is considered medically necessary (considerations may include severity of side effects and ability to adhere to the appropriate use of the item or service)

If yes, **approve the requested agent for 12 months by GPID or GPI-14 at zero copay.**

**APPROVAL TEXT (applies to multi-source brand agents only):** Although your cost share has been reduced to zero-dollar, you may incur a dispense-as-written (DAW) penalty fee if you choose to fill a brand prescription instead of its generic equivalent.

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **FLUORIDE ZERO COST SHARE OVERRIDE** requires the following rule(s) be met for approval:

- A. Your request is for ONE of the following:
1. A generic agent
  2. A single-source brand (SSB) agent that has no preferred generic agents or therapeutically equivalent products available
  3. A multi-source brand (MSB) agent
- B. You are 6 months to 6 years of age
- C. **If the request is for a single-source brand or multi-source brand agent, approval also requires ONE of the following:**
1. Two preferred medications are medically inappropriate for you (one if only one agent is available)
  2. You have tried or have a documented medical contraindication (harmful for) to TWO preferred medications (one if only one agent is available)
  3. Your doctor has provided documentation confirming that your requested drug is considered medically necessary for you (considerations may include severity of side effects and ability to adhere to the appropriate use of the item or service)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE





**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**FLUORIDE ZERO COST SHARE OVERRIDE**

---

**RATIONALE**

This guideline applies to plans where the pharmacy benefit allows for coverage of fluoride at zero copay. The override criteria allow patient access to all FDA-approved fluoride medications at zero copay by waiving the applicable cost-sharing for branded or non-preferred branded medications.

**REFERENCES**

- U.S. Department of Labor. Affordable Care Act Implementation Frequently Asked Questions. Available at: <https://www.dol.gov/agencies/ebsa/laws-and-regulations/laws/affordable-care-act/for-employers-and-advisers/aca-implementation-faqs>. Accessed May 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/22

Created: 05/22

Client Approval: 05/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FLUOROURACIL CREAM

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
FLUOROURACIL 0.5%	CARAC		12514	GPI-14 (90372030003705)	
FLUOROURACIL 1%	FLUROPLEX		30780	GPI-14 (90372030003710)	

**\*\* Please use the criteria for the specific drug requested \*\***

**GUIDELINE FOR USE**

**CARAC**

1. Does the patient have a diagnosis of actinic or solar keratosis of the face and anterior scalp **AND** meet the following criterion?
  - The patient had a trial of **TWO** generic topical agents indicated for AK (e.g., fluorouracil, imiquimod, diclofenac 3%)

If yes, **approve for 1 month by GPID or GPI-14.**

If no, do not approve.

**DENIAL TEXT:** **\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **FLUOROURACIL CREAM (Carac)** requires the following rule(s) be met for approval:

- A. You have actinic or solar keratosis (AK: rough, scaly patch on the skin caused by years of sun exposure) of the face and anterior (front) scalp
- B. You have previously tried TWO generic topical (applied to skin) agents for AK (such as fluorouracil, imiquimod, diclofenac 3%)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**FLUROPLEX**

1. Does the patient have a diagnosis of actinic or solar keratosis **AND** meet the following criterion?
  - The patient had a trial of **TWO** generic topical agents indicated for AK (e.g., fluorouracil, imiquimod, diclofenac 3%)

If yes, **approve for 1 month by GPID or GPI-14.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FLUOROURACIL CREAM

GUIDELINES FOR USE (CONTINUED) - FLUOROPLEX

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **FLUOROURACIL CREAM (Fluoroplex)** requires the following rule(s) be met for approval:

- A. You have actinic or solar keratosis (AK: rough, scaly patch on the skin caused by years of sun exposure)
- B. You have previously tried TWO generic topical (applied to skin) agents for AK (such as fluorouracil, imiquimod, diclofenac 3%)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Carac or Fluoroplex.

**REFERENCES**

- Carac [Prescribing Information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC.; May 2017.
- Fluoroplex [Prescribing Information]. Exton, PA: Almirall, LLC.; October 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/01/21

Created: 08/18

Client Approval: 08/21

P&T Approval: 04/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FOLIC ACID ZERO COST SHARE OVERRIDE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
FOLIC ACID	FOLIC ACID, VARIOUS		94783 94784	GPI-14 (82200010000305, 82200010000310)	

**GUIDELINES FOR USE**

1. Is the patient requesting a cost share exception for the requested folic acid agent **AND** does the plan cover these agents at zero cost share (i.e., the plan follows Affordable Care Act [ACA] recommendations and is linked to MedImpact's Essential Health Benefit Tables)?

If yes, continue to #2.  
If no, guideline does not apply.

2. Does the patient's plan have specific procedures, instructions, and/or policies for cost share exception processes or for multi-source brand agent overrides (DAW1 override)?

If yes, guideline does not apply.  
If no, continue to #3.

3. Is the request for a generic agent?

If yes, **approve the requested agent for 12 months by GPID or GPI-14 at zero copay.**  
If no, continue to #4.

4. Is the request for **ONE** of the following?
  - A single-source brand (SSB) agent that has no preferred generic agents or therapeutically equivalent products available
  - A multi-source brand (MSB) agent

If yes, continue to #5.  
If no, do not approve.  
**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FOLIC ACID ZERO COST SHARE OVERRIDE

GUIDELINES FOR USE (CONTINUED)

5. Does the patient meet **ONE** of the following criteria?

- Two preferred medications are medically inappropriate for the patient (one if only one agent is available)
- The patient has tried or has a documented medical contraindication to TWO preferred medications (one if only one agent is available)
- The prescriber provided documentation confirming that the requested drug is considered medically necessary (considerations may include severity of side effects and ability to adhere to the appropriate use of the item or service)

If yes, **approve the requested agent for 12 months by GPID or GPI-14 at zero copay.**

**APPROVAL TEXT (applies to multi-source brand agents only):** Although your cost share has been reduced to zero-dollar, you may incur a dispense-as-written (DAW) penalty fee if you choose to fill a brand prescription instead of its generic equivalent.

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **FOLIC ACID ZERO COST SHARE OVERRIDE** requires the following rule(s) be met for approval:

- A. Your request is for ONE of the following:
1. A generic agent
  2. A single-source brand (SSB) agent that has no preferred generic agents or therapeutically equivalent products available
  3. A multi-source brand (MSB) agent
- B. **If the request is for a single-source brand or multi-source brand agent, approval also requires ONE of the following:**
1. Two preferred medications are medically inappropriate for you (one if only one agent is available)
  2. You have tried or have a documented medical contraindication (harmful for) to TWO preferred medications (one if only one agent is available)
  3. Your doctor has provided documentation confirming that your requested drug is considered medically necessary for you (considerations may include severity of side effects and ability to adhere to the appropriate use of the item or service)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**FOLIC ACID ZERO COST SHARE OVERRIDE**

**RATIONALE**

This guideline applies to plans where the pharmacy benefit allows for coverage of folic acid 0.4 mg and 0.8 mg tablets at zero copay. The override criteria allow patient access to all FDA-approved folic acid medications at zero copay by waiving the applicable cost-sharing for branded or non-preferred branded medications.

**REFERENCES**

- U.S. Department of Labor. Affordable Care Act Implementation Frequently Asked Questions. Available at: <https://www.dol.gov/agencies/ebsa/laws-and-regulations/laws/affordable-care-act/for-employers-and-advisers/aca-implementation-faqs>. Accessed May 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/22

Created: 05/22

Client Approval: 05/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FOSDENOPTERIN

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
FOSDENOPTERIN HYDROBROMIDE	NULIBRY	47158		GPI-10 (3090643020)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of molybdenum cofactor deficiency (MoCD) Type A?

If yes, **approve for 12 months by HICL or GPI-10.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **FOSDENOPTERIN (Nulibry)** requires the following rule(s) be met for approval:

- A. You have molybdenum cofactor deficiency (MoCD) Type A (rare condition characterized by brain dysfunction)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Nulibry.

**REFERENCES**

- Nulibry [Prescribing Information]. Boston, MA: Origin Biosciences, Inc.; February 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/21

Created: 05/21

Client Approval: 05/21

P&T Approval: 04/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FOSTAMATINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
FOSTAMATINIB DISODIUM	TAVALISSE	44895		GPI-10 (8575604010)	

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of chronic immune thrombocytopenia (cITP) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or given in consultation with a hematologist or immunologist

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Has the patient received splenectomy?

If yes, **approve for 3 months by HICL or GPI-10 with a quantity limit of #2 per day.**

**APPROVAL TEXT:** Renewal requires clinically significant prevention of bleeds while on therapy, attainment of platelet levels of 50-450 x 10<sup>9</sup>/L, and proof of normal LFTs (liver function tests), total bilirubin, and ANC (absolute neutrophil count).

If no, continue to #3.

3. Has the patient had a previous trial of or contraindication to **TWO** of the following treatments?

- Corticosteroids
- IVIG (intravenous immunoglobulin)
- Rhogam
- Rituxan (rituximab)
- Thrombopoietin receptor agonist (i.e., Promacta (eltrombopag), Nplate (romiplostim))

If yes, **approve for 3 months by HICL or GPI-10 with a quantity limit of #2 per day.**

**APPROVAL TEXT:** Renewal requires clinically significant prevention of bleeds while on therapy, attainment of platelet levels of 50-450 x 10<sup>9</sup>/L, and proof of normal LFTs (liver function tests), total bilirubin, and ANC (absolute neutrophil count).

If no, do not approve.

**DENIAL TEXT:** See the initial denial text on the next page.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FOSTAMATINIB

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **FOSTAMATINIB (Tavalisse)** requires the following rule(s) be met for approval:

- A. You have chronic immune thrombocytopenia (cITP; Low levels of the blood cells that prevent bleeding)
- B. You are 18 years of age or older
- C. The requested medication is prescribed by or given in consultation with a hematologist (blood specialist) or immunologist (allergy/immune system doctor)
- D. You had a splenectomy (surgical removal of spleen) **OR** a previous trial of or contraindication to (medical reason why you cannot use) at least **TWO** of the following treatments:
  1. Corticosteroids
  2. IVIG (intravenous immunoglobulin)
  3. Rhogam
  4. Rituxan (rituximab)
  5. Thrombopoietin receptor agonist such as Promacta (eltrombopag), Nplate (romiplostim)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of chronic immune thrombocytopenia (cITP) and meet **ALL** of the following criteria?
  - The patient has had clinically significant prevention of bleeds while on therapy
  - The patient's AST and ALT levels have remained under 3 times the upper limits of normal per reference range
  - The patient's total bilirubin level has remained under 2 times the upper limits of normal per reference range
  - The patient's ANC has remained within normal limits per reference range
  - The patient's platelets have attained a level between 50 and 450 x 10<sup>9</sup>/L

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.**

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline on the next page.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FOSTAMATINIB

RENEWAL CRITERIA (CONTINUED)

**RENEWAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **FOSTAMATINIB (Tavalisse)** requires the following rule(s) be met for renewal:

- A. You have chronic immune thrombocytopenia (cITP; Low levels of the blood cells that prevent bleeding)
- B. You had clinically significant prevention of bleeds while on therapy
- C. Your AST (aspartate transaminase) and ALT (alanine transaminase) levels (types of liver enzymes) have remained under 3 times the upper limits of normal per reference range
- D. Your total bilirubin level has remained under 2 times the upper limits of normal per reference range
- E. Your absolute neutrophil count (ANC; a measure of the number of neutrophils which are a type of white blood cell) has remained within normal limits per reference range
- F. Your platelets have reached a level between 50 and 450 x 10(9)/L

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Tavalisse.

**REFERENCES**

- Tavalisse [Prescribing Information]. South San Francisco, CA. Rigel Pharmaceuticals, Inc. April 2018.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 08/18

Client Approval: 04/20

P&T Approval: 07/19



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FOSTEMSAVIR

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
FOSTEMSAVIR	RUKOBIA	46684		GPI-10 (1210233040)	

**GUIDELINES FOR USE**

- Does the patient have a diagnosis of human immunodeficiency virus type 1 (HIV-1) infection and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The requested medication will be used in combination with other antiretroviral(s)
  - The patient is treatment experienced
  - The patient has multidrug-resistant HIV-1 infection
  - The patient is failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **FOSTEMSAVIR (Rukobia)** requires the following rule(s) be met for approval:

- You have human immunodeficiency virus type 1 (HIV-1) infection (a virus that attacks the body's immune system and if untreated, can lead to AIDS [acquired immunodeficiency syndrome])
- You are 18 years of age or older
- The requested medication will be used in combination with other antiretroviral(s) (class of medication used to treat HIV)
- You are treatment experienced (previously treated)
- You have multidrug-resistant HIV-1 infection (your virus is resistant to more than one HIV medication)
- You are failing your current antiretroviral regimen due to resistance, intolerance, or safety considerations

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**FOSTEMSAVIR**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Rukobia.

**REFERENCES**

- Rukobia [Prescribing Information]. Research Triangle Park, NC: GlaxoSmithKline; July 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective:08/01/20

Created: 07/20

Client Approval: 07/20

P&T Approval:07/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FREMANEZUMAB-VFRM

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
FREMANEZUMAB-VFRM	AJOVY	45236		GPI-10 (6770203020)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of episodic migraines and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Ajoy is prescribed for the preventive treatment of migraines
  - Ajoy will NOT be used concurrently with other CGRP inhibitors (e.g., Aimovig, Emgality, Vyepti, Nurtec ODT, Qulipta) for migraine prevention
  - The patient had a trial of ONE of the following preventative migraine treatments: valproic acid/divalproex sodium, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol
  - The patient had a trial of TWO of the following preferred agents: Aimovig, Emgality, Nurtec ODT, Qulipta

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #1.5mL per 30 days.**

If no, continue to #2.

2. Does the patient have a diagnosis of chronic migraines and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Ajoy is prescribed for the preventive treatment of migraines
  - Ajoy will NOT be used concurrently with other CGRP inhibitors (e.g., Aimovig, Emgality, Vyepti, Nurtec ODT, Qulipta) for migraine prevention
  - The patient had a trial of ONE of the following preventative migraine treatments: valproic acid/divalproex sodium, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol, or Botox [**Note: For Botox, previous trial of only NDCs # 00023-1145-01 or 00023-3921-02 are allowable**]
  - The patient had a trial of TWO of the following preferred agents: Aimovig, Emgality, Nurtec ODT, Qulipta

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #1.5mL per 30 days.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FREMANEZUMAB-VFRM

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **FREMANEZUMAB-VFRM (Ajovy)** requires the following rule(s) be met for approval:

- A. You have migraines
- B. **If you have episodic migraines (0-14 headache days per month), approval also requires:**
  - 1. You are 18 years of age or older
  - 2. Ajovy is prescribed for the preventive treatment of migraines
  - 3. You will NOT use Ajovy concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Aimovig, Emgality, Vyepti, Nurtec ODT, Qulipta) for migraine prevention
  - 4. You have tried ONE of the following preventative migraine treatments: valproic acid/divalproex sodium, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol
  - 5. You have tried TWO of the following: Aimovig, Emgality, Nurtec ODT, Qulipta
- C. **If you have chronic migraines (15 or more headache days per month), approval also requires:**
  - 1. You are 18 years of age or older
  - 2. Ajovy is prescribed for the preventive treatment of migraines
  - 3. You will NOT use Ajovy concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Aimovig, Emgality, Vyepti, Nurtec ODT, Qulipta) for migraine prevention
  - 4. You have tried ONE of the following preventative migraine treatments: valproic acid/divalproex sodium, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol, or Botox [**Note:** For Botox, previous trial of only NDCs 00023-1145-01 or 00023-3921-02 are allowable]
  - 5. You have tried TWO of the following: Aimovig, Emgality, Nurtec ODT, Qulipta

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FREMANEZUMAB-VFRM

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Is Ajovy being prescribed for the preventive treatment of migraines **AND** does the patient meet the following criterion?

- Ajovy will NOT be used concurrently with other CGRP inhibitors (e.g., Aimovig, Emgality, Vyepti, Nurtec ODT, Qulipta) for migraine prevention

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

2. Does the patient meet **ONE** of the following criteria?

- The patient has experienced a reduction in migraine or headache frequency of at least 2 days per month with Ajovy therapy
- The patient has experienced a reduction in migraine severity with Ajovy therapy
- The patient has experienced a reduction in migraine duration with Ajovy therapy

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1.5mL per 30 days.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **FREMANEZUMAB-VFRM (Ajovy)** requires the following rule(s) be met for renewal:

- A. Ajovy is prescribed for the preventive treatment of migraines
- B. You will NOT use Ajovy concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Amovig, Emgality, Vyepti, Nurtec ODT, Qulipta) for migraine prevention
- C. You meet ONE of the following:
  1. You have experienced a reduction in migraine or headache frequency of at least 2 days per month with Ajovy therapy
  2. You have experienced a reduction in migraine severity with Ajovy therapy
  3. You have experienced a reduction in migraine duration with Ajovy therapy

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**FREMANEZUMAB-VFRM**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Ajovy.

**REFERENCES**

- Ajovy [Prescribing Information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; September 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/22

Created: 09/18

Client Approval: 02/22

P&T Approval: 01/22





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

FUTIBATINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
FUTIBATINIB	LYTGOBI	48369		GPI-10 (2153222800)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma (iCCA) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient has been previously treated for unresectable, locally advanced or metastatic iCCA
  - The patient has fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements
  - The patient will complete a comprehensive ophthalmological examination, including optical coherence tomography (OCT), prior to the initiation of Lytgobi and at the recommended scheduled intervals

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #5 per day.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **FUTIBATINIB (Lytgobi)** requires the following rule(s) be met for approval:

- A. You have unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma (iCCA) (a type of bile duct cancer inside the liver that is unable to be removed by surgery, has spread from where it started to nearby tissue/lymph nodes or to other parts of the body)
- B. You are 18 years of age or older
- C. You have been previously treated for unresectable, locally advanced or metastatic iCCA
- D. You have fibroblast growth factor receptor 2 (FGFR2: a type of protein) gene fusions or other rearrangements
- E. You will complete a comprehensive ophthalmological examination (eye exam), including optical coherence tomography (OCT: a type of eye imaging test), before starting Lytgobi and at the recommended scheduled times

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**FUTIBATINIB**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Lytgobi.

**REFERENCES**

- Lytgobi [Prescribing Information]. Princeton, NJ: Taiho Pharmaceutical Co., Ltd., September 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/14/22

Created: 11/22

Client Approval: 11/22

P&T Approval: 10/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**GALCANEZUMAB-GNLM**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
GALCANEZUMAB-GNLM	EMGALITY	45281		GPI-10 (6770203530)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of episodic migraines and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Emgality is prescribed for the preventive treatment of migraines
  - Emgality will NOT be used concurrently with other CGRP inhibitors (e.g., Ajovy, Aimovig, Vyepti, Nurtec ODT, Qulipta) for migraine prevention
  - The patient had a trial of ONE of the following preventative migraine treatments: valproic acid/divalproex sodium, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol

If yes, **approve for a total of 6 months by entering TWO approvals as follows:**

- **FIRST APPROVAL:** approve for 1 month by GPID or GPI-14 for the requested Emgality 120mg/mL formulation with a quantity limit of #2mL per 30 days.
- **SECOND APPROVAL:** approve for 5 months by GPID or GPI-14 for the requested Emgality 120mg/mL formulation with a quantity limit of #1mL per 30 days. (Please enter a start date of 23 days AFTER the start date of the first approval).

If no, continue to #2.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

GALCANEZUMAB-GNLM

INITIAL CRITERIA (CONTINUED)

2. Does the patient have a diagnosis of chronic migraines and meet **ALL** of the following criteria?
- The patient is 18 years of age or older
  - Emgality is prescribed for the preventive treatment of migraines
  - Emgality will NOT be used concurrently with other CGRP inhibitors (e.g., Ajovy, Aimovig, Vyepti, Nurtec ODT, Qulipta) for migraine prevention
  - The patient had a trial of ONE of the following preventive migraine treatments: valproic acid/divalproex sodium, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol, or Botox [**Note:** For Botox, previous trial of only NDCs 00023-1145-01 or 00023-3921-02 are allowable]

If yes, **approve for a total of 6 months by entering TWO approvals as follows:**

- **FIRST APPROVAL:** approve for 1 month by GPID or GPI-14 for the requested Emgality 120mg/mL formulation with a quantity limit of #2mL per 30 days.
- **SECOND APPROVAL:** approve for 5 months by GPID or GPI-14 for the requested Emgality 120mg/mL formulation with a quantity limit of #1mL per 30 days. (Please enter a start date of 23 days **AFTER** the start date of the first approval).

If no, continue to #3.

3. Is the request for the treatment of episodic cluster headache **AND** does the patient meet the following criterion?
- The patient is 18 years of age or older

If yes, **approve for 3 months by GPID or GPI-14 for Emgality 100mg/mL with a quantity limit of #3mL per 30 days.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **GALCANEZUMAB-GNLM (Emgality)** requires the following rule(s) be met for approval:

- A. You have migraines or episodic cluster headaches (very painful headaches that occur in patterns)

**(Initial denial text continued on next page)**

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

GALCANEZUMAB-GNLM

INITIAL CRITERIA (CONTINUED)

- B. If you have episodic migraines (0-14 headache days per month), approval also requires:**
1. You are 18 years of age or older
  2. Emgality is prescribed for the preventive treatment of migraines
  3. You will NOT use Emgality concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Ajovy, Aimovig, Vyepti, Nurtec ODT, Qulipta) for migraine prevention
  4. You have tried ONE of the following preventative migraine treatments: valproic acid/divalproex sodium, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol
- C. If you have chronic migraines (15 or more headache days per month), approval also requires:**
1. You are 18 years of age or older
  2. Emgality is prescribed for the preventive treatment of migraines
  3. You will NOT use Emgality concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Ajovy, Aimovig, Vyepti, Nurtec ODT, Qulipta) for migraine prevention
  4. You have tried ONE of the following preventative migraine treatments: valproic acid/divalproex sodium, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol, or Botox [**Note:** For Botox, previous trial of only NDCs 00023-1145-01 or 00023-3921-02 are allowable]
- D. If you have episodic cluster headaches, approval also requires:**
5. You are 18 years of age or older

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Is Emgality prescribed for the preventive treatment of migraines **AND** does the patient meet the following criterion?
  - Emgality will NOT be used concurrently with other CGRP inhibitors (e.g., Ajovy, Aimovig, Vyepti, Nurtec ODT, Qulipta) for migraine prevention

If yes, continue to #2.

If no, continue to #3.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

GALCANEZUMAB-GNLM

RENEWAL CRITERIA (CONTINUED)

2. Does the patient meet **ONE** of the following criteria?

- The patient has experienced a reduction in migraine or headache frequency of at least 2 days per month with Emgality therapy
- The patient has experienced a reduction in migraine severity with Emgality therapy
- The patient has experienced a reduction in migraine duration with Emgality therapy

If yes, **approve for 12 months by GPID or GPI-14 for the requested Emgality 120mg/mL formulation with a quantity limit of #1mL per 30 days.**

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

3. Is Emgality prescribed for the treatment of episodic cluster headache **AND** does the patient meet the following criterion?

- The patient had improvement in episodic cluster headache frequency as compared to baseline

If yes, **approve for 12 months by GPID or GPI-14 for Emgality 100mg/mL with a quantity limit of #3mL per 30 days.**

If no, do not approve.

**RENEWAL DENIAL TEXT:** **\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **GALCANEZUMAB-GNLM (Emgality)** requires the following rule(s) be met for renewal:

- A. Emgality is being prescribed for preventive treatment of migraines OR for the treatment of episodic cluster headache (very painful headaches that occur in patterns)
- B. **If you have migraines, renewal also requires:**
  1. You will NOT use Emgality concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Ajovy, Aimovig, Vyepti, Nurtec ODT, Qulipta) for migraine prevention
  2. You meet ONE of the following:
    - a. You have experienced a reduction in migraine or headache frequency of at least 2 days per month with Emgality therapy
    - b. You have experienced a reduction in migraine severity with Emgality therapy
    - c. You have experienced a reduction in migraine duration with Emgality therapy
- C. **If you have episodic cluster headaches, renewal also requires:**
  1. You had improvement in episodic cluster headache frequency as compared to baseline

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**GALCANEZUMAB-GNLM**

---

**RATIONALE**

For further information, please refer to the Prescribing information and/or Drug Monograph for Emgality.

**REFERENCES**

- Emgality [Prescribing Information]. Indianapolis, IN: Eli Lilly and Company; March 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/22

Created: 10/18

Client Approval: 02/22

P&T Approval: 01/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

GANAXOLONE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
GANAXOLONE	ZTALMY	47912		GPI-10 (7260003300)	

**GUIDELINES FOR USE**

- Does the patient have a diagnosis of seizures and meet **ALL** of the following criteria?
  - The patient is 2 years of age or older
  - The patient's seizures are associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #36 mL per day.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **GANAXOLONE (Ztalmy)** requires the following rule(s) be met for approval:

- You have seizures
- You are 2 years of age or older
- Your seizures are associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD: a type of genetic disorder)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Ztalmy.

**REFERENCES**

- Ztalmy [Prescribing Information]. Radnor, PA: Marinus Pharmaceuticals, Inc.; June 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A  
Commercial Effective: 10/01/22

Created: 08/22  
Client Approval: 09/22

P&T Approval: 07/22





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

GEFITINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
GEFITINIB	IRESSA	25178		GPI-10 (2136003000)	

**GUIDELINES FOR USE**

- Does the patient have a diagnosis of metastatic non-small cell lung cancer (NSCLC) and meets **ALL** of the following criteria?
  - The patient has tumors with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test
  - Iressa will NOT be used concurrently with an epidermal growth factor receptor (EGFR) tyrosine kinase-inhibitor (e.g., Tarceva, Tagrisso, Gilotrif, Vizimpro)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **GEFITINIB (Iressa)** requires the following rule(s) be met for approval:

- You have metastatic non-small cell lung cancer (NSCLC: type of lung cancer that has spread to other parts of the body)
- Your tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations (types of gene mutations) as detected by an FDA (Food and Drug Administration)-approved test
- You will NOT be using Iressa concurrently (at the same time) epidermal growth factor receptor (EGFR) tyrosine kinase-inhibitor (such as Tarceva, Tagrisso, Gilotrif, Vizimpro)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Iressa.

**REFERENCES**

- Iressa [Prescribing Information]. Wilmington, DE: AstraZeneca Pharmaceuticals; May 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/22

Created: 07/15

Client Approval: 05/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

GILTERITINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
GILTERITINIB FUMARATE	XOSPATA	45506		GPI-10 (2153302020)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of relapsed or refractory acute myeloid leukemia (AML) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient has FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #3 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **GILTERITINIB (Xospata)** requires the following rule(s) be met for approval:

- A. You have relapsed or refractory acute myeloid leukemia (AML: type of white blood cell cancer)
- B. You are 18 years of age or older
- C. You have FMS-like tyrosine kinase 3 (type of gene) mutation (change in the DNA gene) as detected by a Food and Drug Administration-approved test

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Xospata.

**REFERENCES**

- Xospata [Prescribing Information]. Northbrook, IL: Astellas Pharma US, Inc.; November 2018

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/10/21

Created: 03/19

Client Approval: 03/21

P&T Approval: 01/19



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

GLASDEGIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
GLASDEGIB MALEATE	DAURISMO	45502		GPI-10 (2137003030)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of newly-diagnosed acute myeloid leukemia (AML) **AND** meet the following criterion?

- The requested medication will be used in combination with low-dose cytarabine

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient meet **ONE** of the following criteria?

- The patient is 75 years of age or older
- The patient has comorbidities that prevent use of intensive induction chemotherapy

If yes, **approve for 12 months by GPID or GPI-14 for the requested strength with a quantity limit as follows:**

- **Daurismo 25mg: #2 per day.**
- **Daurismo 100mg: #1 per day.**

If no, do not approve.

**DENIAL TEXT:** **\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **GLASDEGIB (Daurismo)** requires the following rule(s) be met for approval:

- A. You have newly-diagnosed acute myeloid leukemia (AML: type of white blood cell cancer)
- B. The requested medication will be used in combination with low-dose cytarabine
- C. You are 75 years of age or older, **OR** you have comorbidities (having more than one disease) that prevents the use of intensive induction chemotherapy

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**GLASDEGIB**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Daurismo.

**REFERENCES**

- Daurismo [Prescribing Information]. New York, NY: Pfizer Inc.; November 2018.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 01/19

Client Approval: 04/20

P&T Approval: 01/19



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

GLATIRAMER ACETATE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
GLATIRAMER ACETATE	COPAXONE, GLATOPA, GLATIRAMER ACETATE	12810		GPI-10 (6240003010)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of a relapsing form of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease **AND** meet the following criterion?
  - The patient is 18 years of age or older

If yes, **approve for 12 months by GPID or GPI-14 for the requested strength with the following quantity limits:**

- **20mg/mL: #1mL per day.**
- **40mg/mL: #12mL per 28 days.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **GLATIRAMER ACETATE (Copaxone, Glatopa)** requires the following rule(s) be met for approval:

1. You have a relapsing form of multiple sclerosis (MS: an illness where the immune system eats away at the protective covering of the nerves), which includes clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms go away and return), and active secondary progressive disease (advanced disease)
2. You are 18 years of age or older

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**GLATIRAMER ACETATE**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Copaxone and Glatopa.

**REFERENCES**

1. Copaxone [Prescribing Information]. Overland Park, KS: Teva; January 2020.
2. Glatopa [Prescribing Information]. Princeton, NJ: Sandoz Inc.; January 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/21

Created: 02/14

Client Approval: 11/20

P&T Approval: 02/14



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

GLECAPREVIR/PIBRENTASVIR

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
GLECAPREVIR/ PIBRENTASVIR	MAVYRET	44453		GPI-10 (1235990235)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of chronic hepatitis C, genotype 1, 2, 3, 4, 5, or 6 and meet **ALL** the following criteria?

- The patient is 3 years of age or older
- The patient has an HCV RNA level within the past 6 months

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient meet at least **ONE** of the following criteria?

- The patient has moderate or severe liver impairment (Child-Pugh B or C)
- The patient is concurrently taking any of the following medications (alone or in combination): rifampin, atazanavir, carbamazepine, efavirenz, darunavir, lopinavir, ritonavir, atorvastatin, lovastatin, simvastatin, rosuvastatin (at doses greater than 10mg), cyclosporine (for patients requiring stable cyclosporine doses greater than 100mg/day), medications containing ethinyl estradiol, velpatasvir/sofosbuvir (Epclusa), ledipasvir/sofosbuvir (Harvoni), velpatasvir/sofosbuvir/voxilaprevir (Vosevi), or elbasvir/grazoprevir (Zepatier)
- The patient has prior failure of a direct-acting antiviral (DAA) regimen that contains a NS5A inhibitor AND a NS3/4A protease inhibitor (e.g., Viekira Pak, Viekira XR, Technivie, Vosevi, Zepatier), or previous concurrent treatments containing a NS5A inhibitor AND NS3/4A protease inhibitor
- The patient has a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions

If yes, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

If no, continue to #3.

3. Has the patient previously received a full treatment of a regimen that contains a NS5A inhibitor (e.g., Harvoni, Epclusa, or Daklinza/Sovaldi combination)?

If yes, continue to #10.

If no, continue to #4.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

GLECAPREVIR/PIBRENTASVIR

**GUIDELINES FOR USE (CONTINUED)**

4. Has the patient failed a short trial of the preferred formulary agent or has a contraindication to therapy with the preferred formulary agent(s) as specified below?
- For genotype 1, 4, 5, or 6 HCV infection: a short trial of Epclusa or Harvoni (e.g., adverse effect early in therapy to Harvoni or Epclusa) or contraindication to BOTH agents
  - For genotype 2 or 3 HCV infection: a short trial of Epclusa (e.g., adverse effect early in therapy to Epclusa) or contraindication to this agent

If yes, continue to #5.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

5. Is the patient post kidney transplant or post-liver transplant and meet **ONE** of the following criteria?
- Genotype 1 infection, treatment experienced (previous treatment with NS5A inhibitor) AND NS3/4A protease inhibitor naïve
  - Genotype 3 infection, treatment experienced (previous treatment with a regimen that contains interferon or peginterferon with ribavirin, and/or sofosbuvir)

If yes, **approve for 16 weeks for the requested strength by GPID or GPI-14 as follows:**

- **100mg-40mg tablet: #3 per day.**
- **50mg-20mg pellets: #5 per day.**

If no, continue to #6.

6. Is the patient post kidney transplant or post-liver transplant and meet **ALL** of the following criteria?
- Genotype 1, 2, 3, 4, 5 or 6 infection
  - Treatment experienced or treatment naïve
  - Without cirrhosis or with compensated cirrhosis

If yes, **approve for 12 weeks for the requested strength by GPID or GPI-14 as follows:**

- **100mg-40mg tablet: #3 per day.**
- **50mg-20mg pellets: #5 per day.**

If no, continue to #7.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

GLECAPREVIR/PIBRENTASVIR

**GUIDELINES FOR USE (CONTINUED)**

7. Is the patient **ONE** of the following?

- Genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis and treatment naïve
- Genotype 1, 2, 4, 5 or 6 infection without cirrhosis and treatment experienced (previous treatment failure with regimens containing interferon, peginterferon, ribavirin, and/or sofosbuvir)

If yes, **approve for 8 weeks for the requested strength by GPID or GPI-14 as follows:**

- **100mg-40mg tablet: #3 per day.**
- **50mg-20mg pellets: #5 per day.**

If no, continue to #8.

8. Is the patient **ONE** of the following?

- Genotype 1, 2, 4, 5 or 6 infection with compensated cirrhosis and treatment experienced (previous treatment failure with regimens containing interferon, peginterferon, ribavirin, and/or sofosbuvir)
- Genotype 1 infection and treatment experienced (previous treatment with NS3/4A inhibitor (e.g., boceprevir, telaprevir, simeprevir) AND is NS5A inhibitor naïve)

If yes, **approve for 12 weeks for the requested strength by GPID or GPI-14 as follows:**

- **100mg-40mg tablet: #3 per day.**
- **50mg-20mg pellets: #5 per day.**

If no, continue to #9.

9. Does the patient have genotype 1, 2, 3, 4, 5 or 6 infection with compensated cirrhosis and treatment naïve?

If yes, **approve for 8 weeks for the requested strength by GPID or GPI-14 as follows:**

- **100mg-40mg tablet: #3 per day.**
- **50mg-20mg pellets: #5 per day.**

If no, continue to #10.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

GLECAPREVIR/PIBRENTASVIR

GUIDELINES FOR USE (CONTINUED)

10. Is the patient **ONE** of the following?

- Genotype 1 infection and treatment experienced (previous treatment with NS5A inhibitor AND is NS3/4A protease inhibitor naïve)
- Genotype 3 infection and treatment experienced (previous treatment failure with regimens containing interferon, peginterferon, ribavirin, and/or sofosbuvir)

If yes, approve for 16 weeks for the requested strength by GPID or GPI-14 as follows:

- 100mg-40mg tablet: #3 per day.
- 50mg-20mg pellets: #5 per day.

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **GLECAPREVIR/PIBRENTASVIR (Mavyret)** requires the following rule(s) be met for approval:

- A. You have chronic hepatitis C (type of liver inflammation), genotype 1, 2, 3, 4, 5, or 6
- B. You are 3 years of age or older
- C. You have an HCV RNA level (amount of virus in your blood) within the past 6 months
- D. You have compensated cirrhosis (no symptoms related to liver damage) or no cirrhosis (no liver damage) and meet ONE of the following:
  1. You are treatment naïve (never been treated) (genotype 1-6)
  2. You are treatment experienced with regimens containing interferon, peginterferon, ribavirin, and/or sofosbuvir (genotype 1-6)
  3. You are treatment experienced with NS5A (nonstructural protein 5A) inhibitor or NS3/4A protease inhibitor (genotype 1)
  4. You had a kidney transplant or liver transplant and are treatment naïve or treatment experienced (genotype 1-6)
- E. You had a short trial of a preferred formulary agent (you stopped because of intolerance or adverse effect early in therapy) or have a contraindication (medical reason why you cannot use) to therapy with the preferred formulary agent(s) as specified below unless you had prior NS5A (nonstructural protein 5A) inhibitor treatment:
  1. If you have genotype 1, 4, 5, or 6 infection, you had a short trial of Epclusa or Harvoni, or you have a contraindication to BOTH agents
  2. If you have genotype 2 or 3 infection, you had a short trial of Epclusa or you have a contraindication to this agent

***(Denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

GLECAPREVIR/PIBRENTASVIR

GUIDELINES FOR USE (CONTINUED)

**Mavyret will not be approved if you meet any of the following:**

- A. You are concurrently taking (alone or in combination): rifampin, atazanavir, carbamazepine, efavirenz, darunavir, lopinavir, ritonavir, atorvastatin, lovastatin, simvastatin, rosuvastatin (at doses greater than 10mg), cyclosporine (for patients requiring stable cyclosporine doses greater than 100mg/day), medications containing ethinyl estradiol, velpatasvir/sofosbuvir (Epclusa), ledipasvir/sofosbuvir (Harvoni), velpatasvir/sofosbuvir/voxilaprevir (Vosevi), or elbasvir/grazoprevir (Zepatier)
- B. You have moderate or severe liver impairment (Child-Pugh B or C)
- C. You have prior failure of a direct-acting antiviral (DAA) regimen that contains NS5A inhibitor AND NS3/4A protease inhibitor (for example, Technivie, Viekira, Vosevi, Zepatier) or you had previous concurrent (used at the same time) treatments containing a NS5A inhibitor AND NS3/4A protease inhibitor
- D. You have a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions (having two or more diseases at the same time)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Mavyret.

**REFERENCES**

- Guidance from the American Association for the Study of Liver Diseases (AASLD) and the Infectious Disease Society of America (IDSA) Recommendations for Testing, Managing, and Treating hepatitis C. Available online at <http://www.hcvguidelines.org/full-report-view> Accessed July 7, 2017.
- Mavyret [Prescribing Information]. North Chicago, IL: Abbvie; September 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/23

Created: 09/17

Client Approval: 11/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

GLP-1 AGONIST

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
LIXISENATIDE	ADLYXIN	40782		GPI-10 (2717005600)	

**GUIDELINES FOR USE**

- Does the patient have a diagnosis of type 2 diabetes and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient had a trial of metformin (IR/ER), a sulfonylurea (e.g., glipizide, glimepiride), pioglitazone, or a preferred combination product containing any of the above agents (e.g., glipizide-metformin, pioglitazone-metformin)
  - The patient had a trial of a preferred GLP-1 agonist (e.g., Byetta, Bydureon, Victoza)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #6mL per 28 days.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **GLP-1 AGONIST (Adlyxin)** requires the following rule(s) be met for approval:

- You have type 2 diabetes (a disorder with high blood sugar)
- You are 18 years of age or older
- You had a trial of metformin (extended-release/immediate-release), a sulfonylurea (such as glipizide, glimepiride), pioglitazone, or a preferred combination product containing any of the above agents (such as glipizide-metformin, pioglitazone-metformin)
- You had a trial of a preferred GLP-1 agonist (such as Byetta, Bydureon, Victoza)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Adlyxin.

**REFERENCES**

- Adlyxin [Prescribing Information]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC, June 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 02/01/23

Created: 11/22

Client Approval: 01/23

P&T Approval: 10/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

GLP-1 STEP OVERRIDE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
EXENATIDE MICROSPHERES	BYDUREON, BYDUREON BCISE, BYDUREON PEN	38451		GPI-10 (2717002000)	
EXENATIDE	BYETTA	32893			
TIRZEPATIDE	MOUNJARO	48014		GPI-10 (2717308000)	
SEMAGLUTIDE	OZEMPIC, RYBELSUS	44675		GPI-10 (2717007000)	BRAND ≠ WEGOVY
DULAGLUTIDE	TRULICITY	41421		GPI-10 (2717001500)	
LIRAGLUTIDE	VICTOZA	36436		GPI-10 (2717005000)	BRAND ≠ SAXENDA

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of type 2 diabetes **AND** meet the following criterion?
  - The patient had a trial of:
    - metformin (IR/ER), OR
    - a sulfonylurea (e.g., glipizide, glimepiride), OR
    - pioglitazone, OR
    - any combination product containing any of the above agents (e.g., glipizide-metformin, pioglitazone-metformin)

If yes, **approve the requested agent for 12 months by HICL or GPI-10.**

**NOTE TO PAC: Override using the Step therapy edit only. Do not override any quantity limit without review. All other rejections will require clinical review.**

If no, continue to #2.

2. Is the patient currently stable on the medication while covered by their current or previous health coverage for the diagnosis of Type 2 Diabetes?

If yes, **approve the requested agent for 12 months by HICL or GPI-10.**

**NOTE TO PAC: Override using the Step therapy edit only. Do not override any quantity limit without review. All other rejections will require clinical review.**

If no, continue to #3.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

GLP-1 STEP OVERRIDE

GUIDELINES FOR USE (CONTINUED)

3. Is the patient currently stable on the medication while covered by their current or previous health coverage for the diagnosis of weight loss (Obesity)?

If yes, do not approve. See denial text below.

If no, do not approve. See denial text below.

**DENIAL TEXT (Use G09): \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **GLP-1 STEP OVERRIDE** requires ALL of the following rules be met for approval:

- A. You have type 2 diabetes (a disorder with high blood sugar) AND
- B. You meet ONE of the following rules:
  - 1. You had a trial of metformin (extended-release/immediate-release), a sulfonylurea (such as glipizide, glimepiride), pioglitazone, or any combination product containing any of the above agents (such as glipizide-metformin, pioglitazone-metformin)
  - 2. You are currently stable on the medication

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Bydureon, Byetta, Mounjaro, Ozempic, Rybelsus, Trulicity, Victoza.

**REFERENCES**

- Bydureon [Prescribing Information]. Wilmington, DE: AstraZeneca Pharmaceuticals, LP, July 2022.
- Byetta [Prescribing Information]. Wilmington, DE: AstraZeneca Pharmaceuticals, LP, June 2022.
- Mounjaro [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC, May 2022.
- Ozempic [Prescribing Information]. Plainsboro, NJ: Novo Nordisk Inc., October 2022.
- Rybelsus [Prescribing Information]. Plainsboro, NJ: Novo Nordisk Inc., LLC., June 2022.
- Trulicity [Prescribing Information]. Indianapolis, IN: Eli Lilly and Company, June 2022.
- Victoza [Prescribing Information]. Plainsboro, NJ: Novo Nordisk Inc., June 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Created: 11/22

Commercial Effective: 03/24/23

Client Approval: 03/23

Interim P&T Approval: 03/09/23

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

GLYCEROL PHENYLBUTYRATE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
GLYCEROL PHENYLBUTYRATE	RAVICTI	39990		GPI-10 (3090803000)	

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of a urea cycle disorder (UCD) and meet **ALL** of the following criteria?
  - Documentation of confirmation of UCD via enzymatic, biochemical or genetic testing
  - The patient is 2 months of age or older
  - Ravicti will be used as adjunctive therapy along with dietary protein restriction
  - The disorder cannot be managed by dietary protein restriction and/or amino acid supplementation alone
  - The patient does NOT have a deficiency of N-acetylglutamate synthetase deficiency (NAGS) or acute hyperammonemia
  - The patient has tried or has a contraindication to Buphenyl (sodium phenylbutyrate)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #17.5mL per day.**

**APPROVAL TEXT:** Renewal requires the patient has clinical benefit from baseline (e.g., normal fasting glutamine, low-normal fasting ammonia levels, or mental status clarity).

If no, do not approve.

**INITIAL DENIAL TEXT:** *\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **GLYCEROL PHENYLBUTYRATE (Ravicti)** requires the following rule(s) be met for approval:

- A. You have a urea cycle disorder (genetic disorder that causes buildup of ammonia in blood)
- B. Documentation of confirmation of urea cycle disorder via enzymatic, biochemical or genetic testing (types of lab tests)
- C. You are 2 months of age or older
- D. Ravicti will be used as adjunctive (add-on) therapy along with dietary protein restriction
- E. The disorder cannot be managed by dietary protein restriction and/or amino acid supplementation alone
- F. The patient does **NOT** have a deficiency of N-acetylglutamate synthetase (type of enzyme) or acute hyperammonemia (short and sudden high ammonia levels)
- G. You have previously tried Buphenyl (sodium phenylbutyrate), unless there is a medical reason why you cannot (contraindication)

***(Initial denial text continued on next page)***

CONTINUED ON NEXT PAGE





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

GLYCEROL PHENYLBUTYRATE

INITIAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

- Does the patient have a diagnosis of a urea cycle disorder (UCD) and meet the following criterion?
  - The patient had clinical benefit from baseline (e.g., normal fasting glutamine, low-normal fasting ammonia levels, or mental status clarity)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #17.5mL per day.**  
If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **GLYCEROL PHENYLBUTYRATE (Ravicti)** requires the following rule(s) be met for renewal:

- You have a urea cycle disorder (genetic disorder that causes buildup of ammonia in blood)
- You had clinical benefit from baseline (such as normal fasting glutamine, low-normal fasting ammonia levels, or mental status clarity).

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Ravicti.

REFERENCES

- Ravicti [Prescribing Information]. Lake Forest, IL: Horizon Pharma USA, Inc; November 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 02/13

Client Approval: 04/20

P&T Approval: 07/19





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

GLYCOPYRRONIUM TOPICAL

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
GLYCOPYRRONIUM TOSYLATE	QBREXZA	45086		GPI-10 (9097003020)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of primary axillary hyperhidrosis and meet **ALL** of the following criteria?

- The patient is 9 years of age or older
- The patient had a trial of prescription strength aluminum chloride product (e.g., Drysol)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 packet per day.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **GLYCOPYRRONIUM TOPICAL (Qbrexza)** requires the following rule(s) be met for approval:

- A. You have primary axillary hyperhidrosis (excessive underarm sweating)
- B. You are 9 years of age or older
- C. You had a trial of a prescription strength aluminum chloride product such as Drysol

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Qbrexza.

**REFERENCES**

6. Qbrexza [Prescribing Information]. Menlo Park, CA. Dermira, Inc. June 2018.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/01/20

Created: 11/18

Client Approval: 08/20

P&T Approval: 07/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**GOLIMUMAB - SQ**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
GOLIMUMAB - SQ	SIMPONI		22533 22536 34697 35001	GPI-14 (6627004000D540) (6627004000E540) (6627004000D520) (6627004000E520)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a rheumatologist
  - The patient had a trial of or contraindication to at least 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
  - The patient is currently using or has a contraindication to methotrexate
  - The patient meets ONE of the following:
    - The patient had a trial of or contraindication to any TWO of the following preferred immunomodulators: Enbrel, Humira, Rinvoq, Xeljanz (IR/XR)
    - The patient has tried any TNF inhibitor (e.g., Humira, Enbrel) AND the physician has indicated the patient cannot use a JAK inhibitor (e.g., Rinvoq, Xeljanz) due to the black box warning for increased risk of mortality, malignancies, and serious cardiovascular events  
**[NOTE: pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]**

If yes, **approve for 6 months by GPID or GPI-14 for 0.5mL of the 50mg prefilled SmartJect autoinjector or syringe per 28 days.**

If no, continue to #2.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

GOLIMUMAB - SQ

INITIAL CRITERIA (CONTINUED)

2. Does the patient have a diagnosis of psoriatic arthritis (PsA) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- Therapy is prescribed by or in consultation with a rheumatologist or dermatologist
- The patient had a trial of or contraindication to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
- The patient had a trial of or contraindication to any TWO of the following preferred immunomodulators: Cosentyx, Enbrel, Humira, Stelara, Xeljanz (IR/XR), Otezla, Tremfya, Rinvoq, Skyrizi [**NOTE:** pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

If yes, **approve for 6 months by GPID or GPI-14 for 0.5mL of the 50mg prefilled SmartJect autoinjector or syringe per 28 days.**

If no, continue to #3.

3. Does the patient have a diagnosis of moderate to severe ankylosing spondylitis (AS) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- Therapy is prescribed by or in consultation with a rheumatologist
- The patient had a trial of or contraindication to an NSAID
- The patient had a trial of or contraindication to any TWO of the following preferred immunomodulators: Cosentyx, Enbrel, Humira, Xeljanz (IR/XR), Rinvoq [**NOTE:** pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

If yes, **approve for 6 months by GPID or GPI-14 for 0.5mL of the 50mg prefilled SmartJect autoinjector or syringe per 28 days.**

If no, continue to #4.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

GOLIMUMAB - SQ

INITIAL CRITERIA (CONTINUED)

4. Does the patient have a diagnosis of moderate to severe ulcerative colitis (UC) and meet **ALL** of the following criteria?
- The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a gastroenterologist
  - The patient had a trial of or contraindication to ONE conventional therapy (e.g., corticosteroids [e.g., budesonide, methylprednisolone], azathioprine, mercaptopurine, methotrexate, or mesalamine)
  - The patient had a trial of or contraindication to the preferred immunomodulator: Humira [**NOTE:** pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

If yes, **approve for a total of 6 months by GPID or GPI-14 and enter two authorizations as follows:**

- **FIRST APPROVAL:** Approve 1 month of Simponi 100mg/mL prefilled syringe OR SmartJect autoinjector with a quantity limit of #3mL per 28 days.
- **SECOND APPROVAL:** Approve 5 months of Simponi 100mg/mL prefilled syringe OR SmartJect autoinjector with a quantity limit of #1mL per 28 days.

If no, do not approve.

**INITIAL DENIAL TEXT:** **\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **GOLIMUMAB-SQ (Simponi)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
  2. Psoriatic arthritis (PsA: a type of skin and joint condition)
  3. Moderate to severe ankylosing spondylitis (AS: a type of joint condition)
  4. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

GOLIMUMAB - SQ

INITIAL CRITERIA (CONTINUED)

**B. If you have moderate to severe rheumatoid arthritis, approval also requires:**

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
3. You had a trial of or contraindication (harmful for) to at least 3 months of ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
4. You are currently using methotrexate at the same time, unless there is a contraindication (harmful for)
5. You meet ONE of the following:
  - a. You had a trial of or contraindication (harmful for) to any TWO of the following preferred immunomodulators (class of drugs): Enbrel, Humira, Rinvoq, Xeljanz (immediate release/extended release)
  - b. You have tried any tumor necrosis factor (TNF) inhibitor (such as Humira, Enbrel) AND your physician has indicated you cannot use a JAK inhibitor (such as Rinvoq, Xeljanz IR/XR) due to the black box warning for increased risk of mortality (death), malignancies (cancerous), and serious cardiovascular (heart-related) events

**C. If you have psoriatic arthritis, approval also requires:**

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
4. You had a trial of or contraindication (harmful for) to any TWO of the following preferred immunomodulators (class of drugs): Cosentyx, Enbrel, Humira, Stelara, Xeljanz (immediate release/extended release), Otezla, Tremfya, Rinvoq, Skyrizi

**D. If you have moderate to severe ankylosing spondylitis, approval also requires:**

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
3. You had a trial of or contraindication (harmful for) to an NSAID (non-steroidal anti-inflammatory drug)
4. You had a trial of or contraindication (harmful for) to any TWO of the following preferred immunomodulators (class of drugs): Cosentyx, Enbrel, Humira, Xeljanz (immediate release/extended release), Rinvoq

*(Initial denial text continued on next page)*

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

GOLIMUMAB - SQ

INITIAL CRITERIA (CONTINUED)

- E. **If you have moderate to severe ulcerative colitis, approval also requires:**
1. You are 18 years of age or older
  2. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
  3. You had a trial of or contraindication (harmful for) to ONE standard therapy, such as corticosteroids (such as budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine
  4. You had a trial of or contraindication (harmful for) to the preferred immunomodulator (class of drug): Humira

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) and meet **ALL** of the following criteria?
  - The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
  - Concurrent use of methotrexate (unless contraindicated)

If yes, **approve for 12 months by GPID or GPI-14 for 0.5mL of the 50mg prefilled SmartJect autoinjector or syringe per 28 days.**

If no, continue to #2.

2. Does the patient have a diagnosis of psoriatic arthritis (PsA) **AND** meet f the following criterion?
  - The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

If yes, **approve for 12 months by GPID or GPI-14 for 0.5mL of the 50mg prefilled SmartJect autoinjector or syringe per 28 days.**

If no, continue to #3.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

GOLIMUMAB - SQ

RENEWAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of moderate to severe ankylosing spondylitis (AS) **AND** meet the following criterion?

- The patient has experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) while on therapy

If yes, **approve for 12 months by GPID or GPI-14 for 0.5mL of the 50mg prefilled SmartJect autoinjector or syringe per 28 days.**

If no, continue to #4.

4. Does the patient have a diagnosis of moderate to severe ulcerative colitis (UC)?

If yes, **approve for 12 months by GPID or GPI-14 for 1mL of the 100mg prefilled SmartJect autoinjector or syringe per 28 days.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **GOLIMUMAB-SQ (Simponi)** requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:

1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
2. Psoriatic arthritis (PsA: a type of skin and joint condition)
3. Moderate to severe ankylosing spondylitis (AS: a type of joint condition)
4. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)

B. **If you have moderate to severe rheumatoid arthritis, renewal also requires:**

1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
2. You are currently using methotrexate at the same time, unless there is a contraindication (harmful for)

C. **If you have psoriatic arthritis, renewal also requires:**

1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

***(Renewal denial text continued on next page)***

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

GOLIMUMAB - SQ

RENEWAL CRITERIA (CONTINUED)

D. If you have moderate to severe ankylosing spondylitis, renewal also requires:

1. You have experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (diagnostic test to determine the effectiveness of drug therapy) while on therapy

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Simponi.

REFERENCES

- Simponi [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. September 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 06/15/22

Created: 06/09

Client Approval: 05/22

P&T Approval: 05/22





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**GUSELKUMAB**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
GUSELKUMAB	TREMFYA	44418		GPI-10 (9025054200)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a dermatologist
  - The patient has psoriasis covering 3% or more of body surface area (BSA) OR psoriatic lesions affecting the hands, feet, genital area, or face
  - The patient had a trial of or contraindication to ONE or more forms of conventional therapies such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids, calcipotriene, acitretin, methotrexate, or cyclosporine

If yes, **approve for 6 months by entering TWO approvals by HICL or GPI-10 as follows:**

- **FIRST APPROVAL:** approve for 1 month with a quantity limit of #1mL per 28 days.
- **SECOND APPROVAL:** approve for 5 months with a quantity limit of #1mL per 56 days. (Please enter a start date of 3 WEEKS AFTER the START date of the first approval)

If no, continue to #2.

2. Does the patient have a diagnosis of psoriatic arthritis (PsA) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a rheumatologist or dermatologist
  - The patient had a trial of or contraindication to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

If yes, **approve for 6 months by entering TWO approvals by HICL or GPI-10 as follows:**

- **FIRST APPROVAL:** approve for 1 month with a quantity limit of #1mL per 28 days.
- **SECOND APPROVAL:** approve for 5 months with a quantity limit of #1mL per 56 days. (Please enter a start date of 3 WEEKS AFTER the START date of the first approval)

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

GUSELKUMAB

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **GUSELKUMAB (Tremfya)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
1. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
  2. Psoriatic arthritis (PsA: a type of skin and joint condition)
- B. **If you have moderate to severe plaque psoriasis, approval also requires:**
1. You are 18 years of age or older
  2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
  3. You have psoriasis covering 3% or more of body surface area (BSA) OR psoriatic lesions (rashes) affecting the hands, feet, genital area, or face
  4. You had a trial of or contraindication (harmful for) to ONE or more forms of standard therapies such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids, calcipotriene, acitretin, methotrexate, or cyclosporine
- C. **If you have psoriatic arthritis, approval also requires:**
1. You are 18 years of age or older
  2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
  3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug) such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) **AND** meet the following criterion?
  - The patient has achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1mL per 56 days.**  
If no, continue to #2.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

GUSELKUMAB

RENEWAL CRITERIA (CONTINUED)

- 2. Does the patient have a diagnosis of psoriatic arthritis (PsA) **AND** meet the following criterion?
  - The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1mL per 56 days.**  
If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **GUSELKUMAB (Tremfya)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following diagnoses:
  1. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
  2. Psoriatic arthritis (PsA: a type of skin and joint condition)
- B. **If you have moderate to severe plaque psoriasis, renewal also requires:**
  1. You have achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more
- C. **If you have psoriatic arthritis, renewal also requires:**
  1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Tremfya.

**REFERENCES**

Tremfya [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.; July 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 03/14/22

Created: 07/17

Client Approval: 02/22

P&T Approval: 01/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

HIGH CONCENTRATION OPIOID ORAL SOLUTIONS

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
MORPHINE SULFATE	MORPHINE SULFATE		16063	GPI-14 (65100055102090)	
OXYCODONE HCL	OXYCODONE HCL		16281	GPI-14 (65100075101320)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate?

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient meet **ONE** of the following?

- The patient is enrolled in hospice
- The patient is receiving palliative care or end-of-life care

If yes, **approve the requested drug for a lifetime approval by GPID or GPI-14.**

If no, continue to #3.

3. Does the patient meet **ALL** of the following criteria?

- The patient has previous use of at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid
- The patient has trouble swallowing opioid tablets, capsules, or large volumes of liquid

If yes, **approve the requested drug for 3 months by GPID or GPI-14.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **HIGH CONCENTRATION OPIOID ORAL SOLUTIONS (morphine sulfate, oxycodone hydrochloride)** requires the following rule(s) be met for approval:

- A. You have pain severe enough to require opioid analgesic and for which alternative treatments are inadequate

***(Denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

HIGH CONCENTRATION OPIOID ORAL SOLUTIONS

GUIDELINES FOR USE (CONTINUED)

- B. You meet ONE of the following:
  1. You are enrolled in hospice OR you are receiving palliative care or end-of-life care
  2. You meet ALL of the following:
    - a. You have previous use of at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid
    - b. You have trouble swallowing opioid tablets, capsules, or large volumes of liquid

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Morphine Sulfate or Oxycodone Hydrochloride oral solution.

**REFERENCES**

- Morphine Sulfate [Prescribing Information]. Baudette, MN: ANI Pharmaceuticals Inc., April 2021
- Oxycodone Hydrochloride [Prescribing Information]. East Windsor, NJ: Aurobindo Pharma USA, Inc., February 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/01/21

Created: 07/21

Client Approval: 08/21

P&T Approval: 04/21



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**HYDROCORTISONE**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
HYDROCORTISONE	ALKINDI SPRINKLE		46547 46548 46549 46551	GPI-14 (22100025006810) (22100025006815) (22100025006820) (22100025006830)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of adrenocortical insufficiency and meet **ALL** of the following criteria?

- The patient is less than 18 years of age
- The patient is unable to take the tablet formulation of hydrocortisone (e.g., need for lower strength, difficulty swallowing)

If yes, **approve for 6 months for all strengths by GPID or GPI-14.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **HYDROCORTISONE (Alkindi Sprinkle)** requires the following rule(s) be met for approval:

- You have adrenocortical insufficiency (your body does not produce enough of certain hormones)
- You are less than 18 years of age
- You are unable to take the tablet form of hydrocortisone (for example you need a lower strength, or you have difficulty swallowing)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Alkindi Sprinkle.

**REFERENCES**

- Alkindi Sprinkle [Prescribing Information]. Baden-Wuerttemberg, Germany: Eton Pharmaceuticals, Inc.; October 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Created: 02/21

Commercial Effective: 04/01/21

Client Approval: 02/21

P&T Approval: 01/21

Copyright © 2023 MediImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MediImpact. MediImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

HYDROMORPHONE ER

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
HYDROMORPHONE HCL	EXALGO, HYDROMORPHONE ER		22056 28427 22098 33088	GPI-12 (651000351075)	EXTENDED RELEASE ONLY

**GUIDELINES FOR USE**

1. Does the patient meet the definition of opioid tolerance (defined as those who are taking, for one week or longer, at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl/hour, 30 mg oral oxycodone/day, 25 mg oral oxymorphone/day, 8 mg oral hydromorphone/day, or an equianalgesic dose of another opioid)?

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the request form indicate that this medication will be used on an "as needed" or "PRN" basis?

If yes, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

If no, continue to #3.

3. Does the patient require a dosage of 16mg or less?

If yes, **approve for 12 months by GPID or GPI-14 for the requested agent (8mg, 12mg, 16mg) for #1 per day. (NOTE: Please override both PA and step therapy [if applicable] restrictions by entering 'Y' for OVR\_RES).**

If no, continue to #4.

4. Was this dosage recommended by a pain specialist?

If yes, **approve for 12 months by GPID or GPI-14 (32mg) for #2 per day. (NOTE: Please override both PA and step therapy [if applicable] restrictions by entering 'Y' for OVR\_RES).**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

HYDROMORPHONE ER

GUDIELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **HYDROMORPHONE ER (Exalgo)** requires the following rule(s) be met for approval:

- A. You meet the definition of opioid tolerance. This is defined as those who are taking, for one week or longer, at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl/hour, 30 mg oral oxycodone/day, 25 mg oral oxymorphone/day, 8 mg oral hydromorphone/day, or an equianalgesic dose (equal pain relieving dose) of another opioid
- B. The requested medication is not prescribed on an as-needed basis
- C. Dosages above 16mg require recommendation from a pain specialist

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Exalgo.

**REFERENCES**

- Exalgo [Prescribing Information]. Hazelwood, MO: Mallinckrodt; February 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 03/04/22

Created: 04/10

Client Approval: 02/22

P&T Approval: 07/19





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

IBREXAFUNGERP

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
IBREXAFUNGERP CITRATE	BREXAFEMME	47416		GPI-10 (1150704010)	

**GUIDELINES FOR USE**

1. Is the request for the treatment of vulvovaginal candidiasis (VVC) and the patient meets **ALL** of the following criteria?
  - The patient is a post-menarchal female
  - The patient had a trial of or contraindication to oral fluconazole AND an intravaginal azole (e.g., terconazole cream)

If yes, **approve for 30 days by HICL or GPI-10 for one fill with a quantity limit of #4.**  
If no, continue to #2.

2. Is the request for the reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC) and the patient meets **ALL** of the following criteria?
  - The patient is a post-menarchal female
  - The patient had a trial of or contraindication to oral fluconazole (the patient had a breakthrough episode of VVC while taking fluconazole 150 mg weekly)
  - The patient is NOT currently on oteseconazole for RVVC

If yes, continue to #3.  
If no, do not approve.  
**DENIAL TEXT:** See the denial text at the end of the guideline.

3. Has the patient previously received Brexafemme?

If yes, continue to #5.  
If no, continue to #4.

4. Has the patient had 3 or more episodes of VVC in the past 12 months?

If yes, **approve for 6 months by HICL or GPI-10 for 6 fills total with a quantity limit of #4 per 30 days.**

If no, do not approve.  
**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

IBREXAFUNGERP

GUIDELINES FOR USE (CONTINUED)

5. Does the patient meet **ALL** of the following criteria?

- The patient has successfully completed a course of Brexafemme for prevention of RVVC
- The patient is either being treated or has just completed treatment for a new recurrence of VVC

If yes, **approve for 6 months by HICL or GPI-10 for 6 fills total with a quantity limit of #4 per 30 days.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **IBREXAFUNGERP (Brexafemme)** requires the following rule(s) be met for approval:

- A. The request is for ONE of the following:
1. Treatment of vulvovaginal candidiasis (VVC: vaginal yeast infection)
  2. Reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC: repeated vaginal yeast infection)
- B. **If you are using Brexafemme for the treatment of vulvovaginal candidiasis, approval also requires:**
1. You are a post-menarchal (you have started having your period) female
  2. You have tried or have a contraindication to (harmful for) oral fluconazole AND an intravaginal azole (type of drug that is inserted into the vagina and used to treat yeast infections such as terconazole cream)
- C. **If you are using Brexafemme for the reduction in the incidence of recurrent vulvovaginal candidiasis, approval also requires:**
1. You are a post-menarchal (you have started having your period) female
  2. You have tried or have a contraindication to (harmful for) oral fluconazole (you had a breakthrough episode of VVC while taking fluconazole 150 mg weekly)
  3. You are NOT currently on oteseconazole for RVVC
  4. You meet ONE of the following:
    - a. You have not previously received Brexafemme AND you had 3 or more episodes of RVVC in the past 12 months
    - b. You have been previously treated with Brexafemme and meet ALL of the following:
      - i. You have successfully completed a course of Brexafemme for prevention of RVVC
      - ii. You are either being treated or have just completed treatment for a new recurrence of VVC

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

IBREXAFUNGERP

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Brexafemme.

**REFERENCES**

- Brexafemme [Prescribing Information]. Jersey City, NJ: Scynexis, Inc.; November 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/23

Created: 07/21

Client Approval: 02/23

P&T Approval: 07/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**IBRUTINIB**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
IBRUTINIB	IMBRUVICA	40745		GPI-10 (2153213300)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of mantle cell lymphoma (MCL) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient has received at least one prior therapy for mantle cell lymphoma (MCL)

If yes, continue to #5.

If no, continue to #2.

2. Does the patient have a diagnosis of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or Waldenström's macroglobulinemia (WM) **AND** meet the following criterion?

- The patient is 18 years of age or older

If yes, continue to #5.

If no, continue to #3.

3. Does the patient have a diagnosis of marginal zone lymphoma (MZL) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient requires systemic therapy
- The patient has received at least one prior anti-CD20-based therapy (e.g., Rituxan)

If yes, continue to #5.

If no, continue to #4.

4. Does the patient have a diagnosis of chronic graft versus host disease (cGVHD) and meet **ALL** of the following criteria?

- The patient is 1 year of age or older
- The patient has failed one or more lines of systemic therapy (e.g., corticosteroids)

If yes, continue to #5.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

IBRUTINIB

GUIDELINES FOR USE (CONTINUED)

5. Is the request for ibrutinib 140mg or 280mg tablets?

If yes, continue to #6.

If no, continue to #7.

6. Has the patient tried or have a contraindication to ibrutinib 140mg capsules?

If yes, **approve for 12 months by GPID or GPI-14 for 140mg and 280mg tablets with a quantity limit of #1 per day. Please also enter approvals for all of the following:**

- **70mg capsule with a quantity limit of #1 per day.**
- **140mg capsule with a quantity limit of #2 per day.**
- **420mg tablet with a quantity limit of #1 per day.**
- **560mg tablet with a quantity limit of #1 per day.**

If no, do not approve. **Please enter proactive approvals for 12 months by GPID or GPI-14 for all of the following:**

- **70mg capsule with a quantity limit of #1 per day.**
- **140mg capsule with a quantity limit of #2 per day.**
- **420mg tablet with a quantity limit of #1 per day.**
- **560mg tablet with a quantity limit of #1 per day.**

**DENIAL TEXT:** See the denial text at the end of the guideline.

7. Is the request for ibrutinib 70mg/mL oral suspension?

If yes, continue to #8.

If no, **approve for 12 months by GPID or GPI-14 for all of the following strengths:**

- **70mg capsule with a quantity limit of #1 per day.**
- **140mg capsule with a quantity limit of #2 per day.**
- **420mg tablet with a quantity limit of #1 per day.**
- **560mg tablet with a quantity limit of #1 per day.**

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

IBRUTINIB

GUIDELINES FOR USE (CONTINUED)

8. Is the patient unable to swallow the capsules or tablets?

If yes, approve for 12 months by GPID or GPI-14 for 70mg/mL oral suspension with a quantity limit of #8mL per day. Please also enter approvals for all of the following:

- 70mg capsule with a quantity limit of #1 per day.
- 140mg capsule with a quantity limit of #2 per day.
- 420mg tablet with a quantity limit of #1 per day.
- 560mg tablet with a quantity limit of #1 per day.

If no, do not approve. Please enter proactive approvals for 12 months by GPID or GPI-14 for all of the following:

- 70mg capsule with a quantity limit of #1 per day.
- 140mg capsule with a quantity limit of #2 per day.
- 420mg tablet with a quantity limit of #1 per day.
- 560mg tablet with a quantity limit of #1 per day.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **IBRUTINIB (Imbruvica)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:

1. Mantle cell lymphoma (a type of blood cancer)
2. Chronic lymphocytic leukemia (a type of blood cancer)
3. Small lymphocytic lymphoma (a type of blood cancer)
4. Waldenström's macroglobulinemia (a type of blood cancer)
5. Marginal zone lymphoma (a type of blood cancer)
6. Chronic graft versus host disease (a type of immune disorder)

B. Requests for ibrutinib 140mg or 280mg tablets requires you had a trial of or contraindication (harmful for) to ibrutinib 140mg capsules

C. Requests for ibrutinib 70mg/mL oral suspension requires you are unable to swallow the tablets or capsules

D. **If you have mantle cell lymphoma, approval also requires:**

1. You are 18 years of age or older
2. You have received at least one prior therapy for mantle cell lymphoma

***(Denial text continued on next page)***

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

IBRUTINIB

GUIDELINES FOR USE (CONTINUED)

- E. **If you have chronic lymphocytic leukemia, small lymphocytic lymphoma, or Waldenström's macroglobulinemia, approval also requires:**
  1. You are 18 years of age or older
- F. **If you have marginal zone lymphoma, approval also requires:**
  1. You are 18 years of age or older
  2. You need systemic (treatment spreads through the blood) therapy
  3. You have received at least one prior anti-CD20-based therapy (such as Rituxan)
- G. **If you have chronic graft versus host disease, approval also requires:**
  1. You are 1 year of age or older
  2. You have failed one or more lines of systemic therapy (treatment spread through the blood, such as corticosteroids)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Imbruvica.

**REFERENCES**

- Imbruvica [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.; August 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 09/17/22

Created: 01/14

Client Approval: 09/22

P&T Approval: 10/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ICATIBANT

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ICATIBANT ACETATE	FIRAZYR, SAJAZIR, ICATIBANT ACETATE	35962		GPI-10 (8582004010)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of hereditary angioedema (HAE) and meet ALL of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with an allergist, immunologist or hematologist
  - The patient's diagnosis is confirmed via complement testing
  - The requested medication is being used for treatment of acute attacks of hereditary angioedema
  - The requested medication will NOT be used concurrently with other acute treatments for HAE attacks (e.g., Berinert, Ruconest, Kalbitor)

If yes, **approve for 12 months by HICL or GPI-10, each fill of #18mL (6 syringes), up to 12 fills per year.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ICATIBANT (Firazyr, Sajazir)** requires the following rule(s) be met for approval:

- A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with an allergist, immunologist (allergy doctor or immune system doctor) or hematologist (blood doctor)
- D. Your diagnosis is confirmed by complement testing (a type of lab test)
- E. The requested medication is being used for treatment of acute (sudden and severe) attacks of hereditary angioedema
- F. The requested medication will NOT be used concurrently (at the same time) with other acute treatments for HAE attacks (such as Berinert, Ruconest, Kalbitor)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**





**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**ICATIBANT**

---

**RATIONALE**

For further information, please refer to the prescribing information and/or drug monograph for Firazyr and Sajazir.

**REFERENCE**

- Firazyr [Prescribing Information]. Lexington, MA: Shire Orphan Therapies; October 2021.
- Sajazir [Prescribing Information]. Cambridge, United Kingdom: Cycle Pharmaceuticals Ltd; June 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 08/01/22

Created: 09/11

Client Approval: 07/22

P&T Approval: 04/22



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**IDELALISIB**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
IDELALISIB	ZYDELIG	41297		GPI-10 (2153804000)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of relapsed chronic lymphocytic leukemia (CLL) **AND** meet the following criterion?

- Zydelig will be used in combination with rituximab

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **IDELALISIB (Zydelig)** requires the following rule(s) be met for approval:

- A. You have relapsed chronic lymphocytic leukemia (CLL: a type of blood cancer)
- B. Zydelig will be used in combination with rituximab

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the prescribing information and/or drug monograph for Zydelig.

**REFERENCES**

- Zydelig [Prescribing Information]. Foster City, CA: Gilead Sciences, Inc.; February 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/22

Created: 08/14

Client Approval: 02/22

P&T Approval: 11/14



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ILOPROST

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ILOPROST TROMETHAMI NE	VENTAVIS	26287		GPI-10 (4017006000)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group 1) and meet **ALL** of the following criteria?
  - Therapy is prescribed by or in consultation with a cardiologist or pulmonologist
  - Documented confirmatory pulmonary arterial hypertension (PAH) diagnosis based on right heart catheterization with the following parameters:
    - Mean pulmonary artery pressure (PAP) of > 20 mmHg
    - Pulmonary capillary wedge pressure (PCWP) of ≤ 15 mmHg
    - Pulmonary vascular resistance (PVR) of ≥ 3 Wood units
  - The patient has NYHA/WHO Functional Class III-IV symptoms

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See initial denial text at the end of the guideline.

2. Does the patient have WHO Functional Class III symptoms **AND** meet the following criterion?
  - The patient had a trial of or contraindication to TWO of the following agents from different drug classes:
    - Oral endothelin receptor antagonist (e.g., ambrisentan, bosentan, or macitentan)
    - Oral phosphodiesterase-5 inhibitor (e.g., sildenafil or tadalafil)
    - Oral cGMP stimulator (e.g., riociguat)

If yes, **approve for 12 months by HICL or GPI-10.**

If no, continue to #3.

3. Does the patient have WHO Functional Class III symptoms with evidence of rapid progression/poor prognosis, or WHO Functional Class IV symptoms **AND** meet the following criterion?
  - The patient had a trial of or contraindication to ONE IV/SQ prostacyclin (e.g., epoprostenol or treprostinil)

If yes, **approve up to 12 months by HICL or GPI-10.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ILOPROST

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ILOPROST (Ventavis)** requires the following rule(s) be met for approval:

- A. You have pulmonary arterial hypertension (PAH: a type of heart and lung condition; World Health Organization Group 1)
- B. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung doctor)
- C. You have documentation confirming your diagnosis of pulmonary arterial hypertension based on right heart catheterization (a test used to measure how well your heart is pumping) with the following values:
  1. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
  2. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
  3. Pulmonary vascular resistance (PVR) greater than or equal to 3 Wood units
- D. You have New York Heart Association-World Health Organization (NYHA-WHO) Functional Class III-IV symptoms (classification system for heart failure)
- E. **If you have WHO Functional Class III symptoms, approval also requires:**
  1. You had a trial of or contraindication (harmful for) to TWO of the following agents from different drug classes:
    - a. Oral endothelin receptor antagonist (such as Tracleer, Letairis, Opsumit)
    - b. Oral phosphodiesterase-5 inhibitor (such as Adcirca or Revatio)
    - c. Oral cGMP stimulator (such as Adempas)
- F. **If you have WHO Functional Class III symptoms with evidence of rapid progression/poor prognosis, or WHO Functional Class IV symptoms, approval also requires:**
  1. You had a trial of or contraindication (harmful for) to ONE intravenous or subcutaneous prostacyclin (such as Flolan/Veletri or Remodulin)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ILOPROST

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group 1) and meet **ONE** of the following criteria?
  - The patient shown improvement from baseline in the 6-minute walk distance test
  - The patient remained stable from baseline in the 6-minute walk distance test AND the patient's WHO functional class remained stable or has improved

If yes, **approve for 12 months by HICL or GPI-10.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ILOPROST (Ventavis)** requires the following rule(s) be met for renewal:

- A. You have pulmonary arterial hypertension (PAH: a type of heart and lung condition; World Health Organization Group 1)
- B. You meet ONE of the following:
  1. You have shown improvement from baseline in the 6-minute walk distance test
  2. You have remained stable in the 6-minute walk distance test AND your World Health Organization functional class has remained stable or improved (classification system for heart failure)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the prescribing information and/or drug monograph for Ventavis.

**REFERENCES**

- Ventavis [Prescribing Information]. South San Francisco, CA: Actelion; January 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/22

Created: 01/08

Client Approval: 02/22

P&T Approval: 01/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

IMATINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
IMATINIB MESYLATE	GLEEVEC, IMATINIB MESYLATE	22096		GPI-10 (2153183510)	

**GUIDELINES FOR USE**

1. Does the patient have **ONE** of the following diagnoses?

- Newly diagnosed Philadelphia positive chronic myeloid leukemia (Ph+ CML) in chronic phase
- Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis, accelerated phase, or chronic phase after failure of interferon-alpha therapy

If yes, continue to #2.

If no, continue to #3.

2. Has the patient received previous treatment with another tyrosine kinase inhibitor [e.g., Tasigna (nilotinib), Sprycel (dasatinib), Bosulif (bosutinib), Iclusig (ponatinib)]?

If yes, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

If no, **approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:**

- **Gleevec 400mg: #2 per day.**
- **Gleevec 100mg: #6 per day.**

3. Does the patient have a diagnosis of relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) **AND** meet the following criterion?

- The patient is 18 years of age or older

If yes, **approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:**

- **Gleevec 400mg: #1 per day.**
- **Gleevec 100mg: #6 per day.**

If no, continue to #4.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

IMATINIB

GUIDELINES FOR USE (CONTINUED)

4. Does the patient have newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) **AND** meet the following criterion?

- The requested medication will be used in combination with chemotherapy

If yes, **approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:**

- **Gleevec 400mg: #1 per day.**
- **Gleevec 100mg: #6 per day.**

If no, continue to #5.

5. Does the patient have a diagnosis of a myelodysplastic/myeloproliferative disease associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements **AND** meet the following criterion?

- The patient is 18 years of age or older

If yes, **approve Gleevec 400mg for 12 months by GPID or GPI-14 with a quantity limit of #1 tablet per day.**

If no, continue to #6.

6. Does the patient have a diagnosis of aggressive systemic mastocytosis without D816V c-Kit mutation or with c-Kit mutational status unknown **AND** meet the following criterion?

- The patient is 18 years of age or older

If yes, **approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:**

- **Gleevec 400mg: #1 per day.**
- **Gleevec 100mg: #3 per day.**

If no, continue to #7.

7. Does the patient have a diagnosis of hypereosinophilic syndrome and/or chronic eosinophilic leukemia **AND** meet the following criterion?

- The patient is 18 years of age or older

If yes, **approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:**

- **Gleevec 400mg: #1 per day.**
- **Gleevec 100mg: #3 per day.**

If no, continue to #8.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

IMATINIB

GUIDELINES FOR USE (CONTINUED)

8. Does the patient have a diagnosis of unresectable, recurrent, and/or metastatic dermatofibrosarcoma protuberans **AND** meet the following criterion?

- The patient is 18 years of age or older

If yes, **approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:**

- **Gleevec 400mg: #2 per day.**
- **Gleevec 100mg: #6 per day.**

If no, continue to #9.

9. Does the patient have a diagnosis of unresectable and/or metastatic malignant gastrointestinal stromal tumor (GIST) with a Kit (CD117) positive?

If yes, continue to #11.

If no, continue to #10.

10. Is the request for adjuvant treatment following complete gross resection of Kit (CD117) positive gastrointestinal stromal tumor (GIST) **AND** the patient meets the following criterion?

- The patient is 18 years of age or older

If yes, continue to #11.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

11. Is the request for Gleevec 400mg twice daily?

If yes, continue to #12.

If no, **approve as follows:**

- **For adjuvant GIST treatment: approve Gleevec 400mg for 36 months by GPID or GPI-14 with a quantity limit of #1 per day.**
- **For unresectable and/or metastatic malignant GIST: approve Gleevec 400mg for 12 months by GPID or GPI-14 with a quantity limit of #1 per day.**

CONTINUED ON NEXT PAGE





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

IMATINIB

GUIDELINES FOR USE (CONTINUED)

12. Has patient tried Gleevec 400mg once daily or does the patient have GIST tumor expressing a KIT exon 9 mutation?

If yes, **approve as follows:**

- **For adjuvant GIST treatment: approve Gleevec 400mg for 36 months by GPID or GPI-14 with a quantity limit of #2 per day.**
- **For unresectable and/or metastatic malignant GIST: approve Gleevec 400mg for 12 months by GPID or GPI-14 with a quantity limit of #2 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **IMATINIB (Gleevec)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:

1. Newly diagnosed Philadelphia positive chronic myeloid leukemia (type of blood cell cancer that begins in bone marrow with an abnormal gene) in chronic phase
2. Philadelphia chromosome positive chronic myeloid leukemia in blast crisis, accelerated phase, or chronic phase after failure of interferon-alpha therapy
3. Relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) (type of white blood cell cancer that has returned or did not respond to treatment)
4. Newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) (type of white blood cell cancer)
5. Myelodysplastic/myeloproliferative disease (a group of diseases where the bone marrow makes too many white blood cells) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements
6. Aggressive systemic mastocytosis (a type of cell accumulates in internal tissues and organs) without D816V c-Kit mutation or with c-Kit mutational status unknown
7. Hypereosinophilic syndrome and/or chronic eosinophilic leukemia (type of inflammatory cancer)
8. Unresectable, recurrent, and/or metastatic dermatofibrosarcoma protuberans (type of rare skin tumor that cannot be completely removed by surgery or returns/ spreads)
9. Unresectable and/or metastatic malignant gastrointestinal stromal tumor (tumor in stomach/intestines that spreads or cannot be removed by surgery) with a Kit (CD117) positive
10. Adjuvant (add-on) treatment after complete gross resection (surgical removal) of Kit (CD117) positive gastrointestinal stromal tumor

***(Denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

IMATINIB

GUIDELINES FOR USE (CONTINUED)

- B. **If you are newly diagnosed with Philadelphia positive chronic myeloid leukemia in chronic phase, approval also requires:**
  - 1. You have NOT received previous treatment with another tyrosine kinase inhibitor such as Tasigna (nilotinib), Sprycel (dasatinib), Bosulif (bosutinib), Iclusig (ponatinib)
- C. **If you have Philadelphia chromosome positive chronic myeloid leukemia in blast crisis, accelerated phase, or chronic phase after failure of interferon-alpha therapy, approval also requires:**
  - 1. You have NOT received previous treatment with another tyrosine kinase inhibitor such as Tasigna (nilotinib), Sprycel (dasatinib), Bosulif (bosutinib), Iclusig (ponatinib)
- D. **If you have relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), approval also requires:**
  - 1. You are 18 years of age or older
- E. **If you have newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), approval also requires:**
  - 1. The requested medication will be used in combination with chemotherapy
- F. **If you have myelodysplastic/myeloproliferative disease associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements, approval also requires:**
  - 1. You are 18 years of age or older
- G. **If you have aggressive systemic mastocytosis without D816V c-Kit mutation or with c-Kit mutational status unknown, approval also requires:**
  - 1. You are 18 years of age or older
- H. **If you have hypereosinophilic syndrome and/or chronic eosinophilic leukemia, approval also requires:**
  - 1. You are 18 years of age or older
- I. **If you have unresectable, recurrent, and/or metastatic dermatofibrosarcoma protuberans, approval also requires:**
  - 1. You are 18 years of age or older
- J. **If the request is for adjuvant treatment following complete gross resection of Kit (CD117) positive gastrointestinal stromal tumor (GIST), approval also requires:**
  - 1. You are 18 years of age or older
- K. **If you have gastrointestinal stromal tumor, approval also requires:**
  - 1. For request of Gleevec 400mg twice daily, approval requires a trial of Gleevec 400mg once daily OR a GIST tumor expressing a KIT exon 9 (type of gene) mutation (a permanent change in your DNA that make up your gene)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**IMATINIB**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Gleevec.

**REFERENCES**

- Gleevec [Prescribing Information] East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/10/21

Created: 11/11

Client Approval: 03/21

P&T Approval: 10/19



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

IMIQUIMOD

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
IMIQUIMOD 2.5% or 3.75%	ZYCLARA		28216 31436 32958	GPI-14 (90773040003715) (90773040003710)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of actinic keratosis of the full face or balding scalp and meet **ALL** of the following criteria?
- The patient is 18 years of age or older
  - The patient is immunocompetent
  - The patient had a trial of **TWO** generic topical agents indicated for AK (e.g., fluorouracil, imiquimod, diclofenac 3%)

If yes, **approve the requested strength for 4 months by GPID or GPI-14 with the following quantity limits:**

- **Zyclara 3.75% Packet: #28 packets per 28 days.**
- **Zyclara 2.5% or 3.75% Pump: #7.5g per 28 days.**

If no, continue to #2.

2. Does the patient have a diagnosis of external genital or perianal warts and meet **ALL** of the following criteria?
- The patient is 12 years of age or older
  - The patient had a trial of or contraindication to generic imiquimod 5% topical cream

If yes, **approve the requested strength for 2 months by GPID or GPI-14 with the following quantity limits:**

- **Zyclara 3.75% Packet: #28 packets per 28 days.**
- **Zyclara 2.5% or 3.75% Pump: #7.5g per 28 days.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **IMIQUIMOD (Zyclara)** requires the following rule(s) be met for approval:

A. You have **ONE** of the following diagnoses:

1. Actinic keratosis (AK: rough, scaly patch on the skin caused by years of sun exposure) of the full face or balding scalp
2. External genital or perianal (around the anus) warts

***(Denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

IMIQUIMOD

GUIDELINES FOR USE (CONTINUED)

- B. If you have actinic keratosis of the full face or balding scalp, approval also requires:**
1. You are 18 years of age or older
  2. You are immunocompromised (your immune system's defenses are low affecting its ability to fight off infections and diseases)
  3. You had a trial of TWO generic topical agents for AK (such as fluorouracil, imiquimod, or diclofenac 3%)
- C. If you have external genital or perianal warts, approval also requires:**
1. You are 12 years of age or older
  2. You have tried or have a contraindication to (medical reason why you cannot use) generic imiquimod 5% topical cream

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Zyclara.

**REFERENCES**

- Zyclara [Prescribing Information]. Bridgewater, N: Bausch Health Companies Inc.; June 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/01/21

Created: 08/97

Client Approval: 08/21

P&T Approval: 04/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

IMMUNE GLOBULIN

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
IMMUNE GLOBULIN	BIVIGAM, CARIMUNE NF NANOFILTERED, FLEBOGAMMA DIF GAMASTAN S-D, GAMMAGARD S-D, GAMMAPLEX, PRIVIGEN, GAMMAGARD LIQUID, HIZENTRA	04202 41798 41995		GPI-10 (1910002020) (1910002010) (1910002000) (1910002030)	
IMMUNE GLOB, GAM CAPRYLATE	GAMUNEX-C, GAMMAKED	25631		GPI-10 (1910002030)	
IMMUNE GLOBULIN / MALTOSE	OCTAGAM	33220		GPI-10 (1910002010)	
IGG/HYALURONIDA SE, RECOMBINANT	HYQVIA	41391		GPI-10 (1999000235)	
IMMUN GLOB G(IGG)/GLY/I GA OV50	CUVITRU	41796		GPI-10 (1910002020)	
IMMUN GLOB G(IGG)- IFAS/GLYCINE	PANZYGA	45354		GPI-10 (1910002060)	
IMMUN GLOB G(IGG)- HIP/MALTOSE	CUTAQUIG	45734		GPI-10 (1910002057)	
IMMUNE GLOBULIN (HUMAN)-KLHW	XEMBIFY	45891		GPI-10 (1910002064)	
IMMUNE GLOBULIN (HUMAN)-SLRA	ASCENIV	46208		GPI-10 (1910002080)	

This drug must be reviewed by a pharmacist.

**GUIDELINES FOR USE**

1. Is the request for use as a subcutaneous injection?

If yes, continue to #2.

If no, continue to #5.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

IMMUNE GLOBULIN

GUIDELINES FOR USE (CONTINUED)

2. Is the request for Hizentra and will be used for **ONE** of the following diagnoses?

- Primary immunodeficiency disease (PID)
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

If yes, **approve for 12 months by GPID or NDC (Medi-Span).**

If no, continue to #3.

3. Is the request for Gammagard Liquid, Cuvitru, Gamunex-C, Gammaked, Hyqvia, Cutaquig, or Xembify? (**NOTE:** Gammagard Liquid, Gamunex-C and Gammaked may be given via SC or IV route.)

If yes, continue to #4.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

4. Does the patient have a primary immunodeficiency disease (PID)?

If yes, **approve the requested agent for 12 months as follows:**

- **Gammagard Liquid, Gamunex-C or Gammaked: Approve by NDC (FDB or Medi-Span).**
- **Cuvitru: Approve by HICL or NDC (Medi-Span).**
- **Hyqvia, Cutaquig, or Xembify: Approve by HICL or GPI-10.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

5. Is the request for use as an intravenous (IV) injection or intramuscular (IM) injection? (**NOTE:** Bivigam, Carimune NF Nanofiltered, Flebogamma, Gamastand S-D, Gammagard S-D, Gammplex, Privigen, Octagam, Panzyga, and Asceniv are not self-administered (NSA) agents and may not be covered by some plans)

If yes, continue to #6.

If no, guideline does not apply.

6. Is the request for Cuvitru, Hizentra, Hyqvia or Xembify? (**NOTE:** Cuvitru, Hizentra, Hyqvia and Xembify are indicated only for SC route)

If yes, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

If no, continue to #7.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

IMMUNE GLOBULIN

GUIDELINES FOR USE (CONTINUED)

7. Is the request for Asceniv and meet **ALL** of the following criteria?

- The request is for primary immunodeficiency disease (PID)
- The patient is 12 years of age or older
- The patient has tried any other **TWO** immunoglobulin products (e.g., Panzyga, Bivigam, Flebogamma DIF, Gammaplex, Octagam, Privigen)

If yes, **approve for 12 months by HICL or GPI-10.**

If no, continue to #8.

8. Is the request for Gamastan S/D? (**NOTE:** Gamastan S/D is indicated for intramuscular use only)

If yes, continue to #9.

If no, continue to #10.

9. Is Gamastan S/D being used for hepatitis A, measles, varicella, or rubella prophylaxis, or passive immunization?

If yes, **approve for 12 months by GPID or GPI-10.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

IMMUNE GLOBULIN

GUIDELINES FOR USE (CONTINUED)

10. Does the patient have **ONE** of the following diagnoses?

- Primary Immunodeficiency Disease (PID)
- Idiopathic Thrombocytopenic Purpura (ITP)
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Multifocal Motor Neuropathy (MMN)
- Kawasaki Syndrome
- B-cell Chronic Lymphocytic Leukemia (CLL) with Hypogammaglobulinemia, Autoimmune Hemolytic Anemia (AIHA), Immune Thrombocytopenic Purpura (ITP), or pure Red Blood Cell Aplasia (PRCA)
- Guillain-Barre Syndrome (GBS)
- Myasthenia Gravis
- Autoimmune Graves' Ophthalmopathy
- Cytomegalovirus-induced Pneumonitis related to a solid organ transplant
- Prevention of bacterial infection in an HIV-infected child
- Reduction of secondary infections in pediatric HIV infections
- Dermatomyositis or polymyositis
- Autoimmune uveitis (Birdshot retinochoroidopathy)
- Lambert-Eaton myasthenic syndrome
- IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathy
- Stiff-man syndrome
- Neonatal sepsis
- Rotaviral enterocolitis
- Toxic shock syndrome
- Enteroviral meningoencephalitis
- Toxic Epidermal Necrolysis or Stevens-Johnson syndrome
- Autoimmune Mucocutaneous Blistering Disease (AMBD) (such as pemphigus vulgaris, bullous pemphigoid, mucous membrane pemphigoid, or epidermolysis bullosa acquisita)

If yes, **approve the requested agent for 12 months as follows:**

- **Gammagard Liquid, Gamunex-C, Gammaked, Bivigam, Flebogamma DIF, Gammaplex, or Privigen: Approve by NDC (FDB or Medi-Span).**
- **Carimune NF Nanofiltered: Approve by GPID or GPI-14.**
- **Gammagard S-D: Approve by NDC (FDB) or GPI-14.**
- **Octagam: Approve by HICL or NDC (Medi-Span).**
- **Panzyga: Approve by HICL or GPI-10.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

IMMUNE GLOBULIN

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **IMMUNE GLOBULIN** requires the following rule(s) be met for approval:

- A. **For Gammagard Liquid, Gamunex-C, Gammaked, Bivigam, Carimune NF Nanofiltered, Flebogamma DIF, Gammagard S-D, Gammaplex, Privigen, Octagam, or Panzyga for intravenous (IV) injection**, approval requires you to have ONE of the following diagnoses:
1. Primary Immunodeficiency Disease (genetic disease where your immune system is weak)
  2. Idiopathic Thrombocytopenic Purpura (Low levels of the blood cells that prevent bleeding)
  3. Chronic Inflammatory Demyelinating Polyneuropathy (a nerve disorder with increasing weakness and loss of sensory function in the legs and arms)
  4. Multifocal Motor Neuropathy (nerve disorder with increasing muscle weakness and wasting)
  5. Kawasaki Syndrome (inflammation in the walls of blood vessels in the body)
  6. B-cell Chronic Lymphocytic Leukemia (blood and bone marrow cancer of immune cells) with Autoimmune Hemolytic Anemia (body destroys red blood cells more rapidly than it produces them), Immune Thrombocytopenic Purpura (decreased number of blood cells that prevent bleeding with increased easy bruising) OR Pure Red Cell Blood Aplasia (bone marrow stops making red blood cells)
  7. Guillain-Barre Syndrome (immune system attacks the nerves)
  8. Myasthenia Gravis (weakness and rapid fatigue of muscles under voluntary control)
  9. Autoimmune Graves' Ophthalmopathy (type of eye disease from having little to no thyroid)
  10. Cytomegalovirus-induced Pneumonitis related to a solid organ transplant (lung tissue inflammation) related to a solid organ transplant
  11. Prevention of bacterial infection in an HIV-infected child (human immunodeficiency virus)-infected child
  12. Reduction of secondary infections in pediatric HIV infections
  13. Dermatomyositis (inflammatory disease with muscle weakness and skin rash) or polymyositis (type of inflammatory muscle disease)
  14. Autoimmune uveitis (Birdshot retinochoroidopathy; inflammation of the middle layer of the eye)
  15. Lambert-Eaton myasthenic syndrome (nerve disease in which the immune system attacks the body's own tissues)
  16. IgM (Immunoglobulin M) anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathy (type of nerve damage)
  17. Stiff-man syndrome (nerve disorder with increasing muscle stiffness (rigidity) and repeated episodes of painful muscle spasms)
  18. Neonatal sepsis (blood infection in infants)
  19. Rotaviral enterocolitis (severe diarrhea among infants and young children)
  20. Toxic shock syndrome (life-threatening complication of certain bacterial infections)
- (Denial text continued on next page)***

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

IMMUNE GLOBULIN

GUIDELINES FOR USE (CONTINUED)

21. Enteroviral meningoencephalitis (Inflammation of the brain and surrounding tissues caused by a virus)
  22. Toxic Epidermal Necrolysis or Stevens-Johnson syndrome (both are types of serious skin bacterial infections)
  23. Autoimmune Mucocutaneous Blistering Disease (group of serious skin conditions that start with blisters on the skin) such as pemphigus vulgaris, bullous pemphigoid, mucous membrane pemphigoid, or epidermolysis bullosa acquisita
- B. For Asceniv, approval requires:**
1. You have a diagnosis of primary immunodeficiency disease (genetic disease where your immune system is weak)
  2. You are 12 years of age or older
  3. You have tried any other TWO immunoglobulin products
- C. For Gamastan S-D, approval requires:**
1. You are using the requested drug for prophylaxis (prevention) or passive immunization (immune response where antibodies are obtained from outside the body) of hepatitis A, measles, varicella, or rubella
- D. For Hizentra, approval requires:**
1. The medication is only for subcutaneous (under the skin) use
  2. You have a diagnosis of primary immunodeficiency disease (genetic disease where your immune system is weak) OR chronic Inflammatory Demyelinating Polyneuropathy (a nerve disorder with increasing weakness and loss of sensory function in the legs and arms)
- E. For Cuvitru, Hyqvia, Cutaquig, or Xembify, approval requires:**
- The medication is only for subcutaneous (under the skin) use
  - You have a diagnosis of primary immunodeficiency disease (genetic disease where your immune system is weak)
- F. For Gammagard Liquid, Gamunex-C, or Gammaked for subcutaneous use, approval requires:**
1. You have a diagnosis of primary immunodeficiency disease (genetic disease where your immune system is weak)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

IMMUNE GLOBULIN

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monographs for the drugs listed in this guideline.

**REFERENCES**

- Bivigam [Prescribing Information]. Biotest Pharmaceuticals Co.: Boca Raton, FL. January 2017.
- Carimune NF [Prescribing Information]. CSL Behring LLC: Kankakee, IL. September 2013.
- Cuvitru [Prescribing Information]. Baxalta US Inc.: Westlake Village, CA. September 2016.
- Flebogamma 5% DIF [Prescribing Information]. Grifols: Barcelona, Spain. July 2017.
- Flebogamma 10% DIF [Prescribing Information]. Grifols: Barcelona, Spain. July 2017.
- Gamastan S/D [Prescribing Information]. Grifols: Research Triangle Park, NC. June 2017.
- Gammagard Liquid [Prescribing Information]. Baxalta US Inc.: Westlake Village, CA. March 2017.
- Gammagard S/D [Prescribing Information]. Baxalta US Inc.: Westlake Village, CA. March 2017.
- Gammaked [Prescribing Information]. Grifols: Research Triangle Park, NC. September 2016.
- Gammplex 5% [Prescribing Information]. BPL Inc.: Durham, NC. December 2016.
- Gammplex 10% [Prescribing Information]. BPL Inc.: Durham, NC. December 2016.
- Gamunex-C [Prescribing Information]. Grifols: Research Triangle Park, NC. March 2017.
- Hizentra [Prescribing Information]. CSL Behring LLC: Kankakee, IL. March 2018.
- Hyqvia [Prescribing Information]. Baxalta US Inc.: Westlake Village, CA. September 2016.
- Octagam 5% [Prescribing Information]. Octapharma USA Inc.: Hoboken, NJ. April 2015.
- Octagam 10% [Prescribing Information]. Octapharma USA Inc.: Hoboken, NJ. August 2015.
- Panzyga [Prescribing Information]. Octapharma USA Inc.: Hoboken, NJ. August 2018.
- Privigen [Prescribing Information]. CSL Behring LLC: Kankakee, IL. September 2017.
- Cutaquig [Prescribing Information]. Hoboken, NJ: Octapharma USA, Inc., May 2019.
- Asceniv [Prescribing Information]. Boca Raton, FL: ADMA Biologics; April 2019.
- Xembify [Prescribing Information]. Research Triangle Park, NC: Grifols Therapeutics LLC; October 2019.

Library	Commercial	NSA
Yes	Yes	Yes

Part D Effective: N/A

Commercial Effective: 04/01/20

Created: 08/12

Client Approval: 02/20

P&T Approval: 01/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

INDOMETHACIN RECTAL

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
INDOMETHACIN	INDOCIN		20240	GPI-14 (66100030005205)	

**GUIDELINES FOR USE**

1. Does the patient meet **ONE** of the following criteria?

- The patient has dysphagia, difficulty swallowing capsules, or has a feeding tube placed (e.g., G-tube, J-tube)
- The patient had a previous trial of at least **TWO** prescription strength oral NSAIDs (e.g., ibuprofen, meloxicam, diclofenac, sulindac, indomethacin, celecoxib)

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of 30 rectal suppositories per 30 days.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **INDOMETHACIN RECTAL (Indocin)** requires that you meet ONE of the following rule(s) for approval:

- A. You have dysphagia (difficulty swallowing), difficulty swallowing capsules, or have a feeding tube placed (such as a G-tube, J-tube)
- B. You had a previous trial of at least two prescription strength oral NSAIDs (non-steroidal anti-inflammatory drugs such as ibuprofen, meloxicam, diclofenac, sulindac, indomethacin, celecoxib)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the prescribing information and/or drug monograph for Indocin (indomethacin rectal suppositories).

**REFERENCES**

- Indocin [Prescribing Information]. Iroko Pharmaceuticals, LLC: Philadelphia, PA; May 2016.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 02/18

Client Approval: 04/20

P&T Approval: 01/18



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

INDOMETHACIN SUSPENSION

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
INDOMETHACIN	INDOCIN		36490	GPI-14 (66100030001805)	

**GUIDELINES FOR USE**

1. Does the patient have **ONE** of the following diagnoses?

- Moderate to severe rheumatoid arthritis (including acute flares of chronic disease)
- Moderate to severe ankylosing spondylitis
- Moderate to severe osteoarthritis
- Acute painful shoulder (bursitis, tendinitis)
- Acute gouty arthritis

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient meet **ALL** of the following criteria?

- The patient had a trial of generic indomethacin capsules
- The patient cannot swallow indomethacin capsules

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #40mL per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **INDOMETHACIN SUSPENSION (Indocin)** requires the following rule(s) be met for approval:

A. You have **ONE** of following diagnoses:

1. Moderate to severe rheumatoid arthritis (a type of joint condition)
2. Moderate to severe ankylosing spondylitis (a type of joint condition)
3. Moderate to severe osteoarthritis (a type of joint condition)
4. Acute painful shoulder (such as bursitis, tendinitis)
5. Acute gouty arthritis (a type of joint condition)

B. You had a trial of generic indomethacin capsules

C. You cannot swallow indomethacin capsules

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**INDOMETHACIN SUSPENSION**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Indocin.

**REFERENCES**

- Indocin [Prescribing Information]. Whitby, Ontario: Patheon Inc., April 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/23

Created: 11/22

Client Approval: 02/23

P&T Approval: 10/22





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

INFIGRATINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
INFIGRATINIB PHOSPHATE	TRUSELTIQ	47404		GPI-10 (2153223540)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of unresectable locally advanced or metastatic cholangiocarcinoma and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient has been previously treated for unresectable locally advanced or metastatic cholangiocarcinoma
  - The patient has a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement, as detected by an FDA-approved test
  - The patient will complete a comprehensive ophthalmological examination, including optical coherence tomography (OCT), prior to initiation of therapy and at the recommended scheduled intervals

If yes, **approve the requested dose pack for 12 months by GPID or GPI-14 with the following quantity limits:**

- **50mg: #42 per 28 days.**
- **75mg: #63 per 28 days.**
- **100mg: #21 per 28 days.**
- **125mg: #42 per 28 days.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **INFIGRATINIB (Truseltiq)** requires the following rule(s) be met for approval:

- A. You have unresectable locally advanced or metastatic cholangiocarcinoma (bile duct cancer that has grown outside the organ but has not yet spread to other parts of the body and cannot be removed by surgery, or bile duct cancer that has spread to other parts of the body)
- B. You are 18 years of age or older
- C. You have previously been treated for unresectable locally advanced or metastatic cholangiocarcinoma
- D. You have a fibroblast growth factor receptor 2 (FGFR2: type of protein) fusion or other rearrangement, as detected by a Food and Drug Administration (FDA)-approved test
- E. You will complete a comprehensive ophthalmological examination (eye exam), including optical coherence tomography (OCT: a type of eye imaging test), before starting the medication and at the recommended scheduled times

***(Denial text continued on next page)***

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

INFIGRATINIB

**GUIDELINES FOR USE (CONTINUED)**

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Truseltiq.

**REFERENCES**

- Truseltiq [Prescribing Information]. Brisbane, CA: QED Therapeutics, Inc.; May 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/23

Created: 07/21

Client Approval: 11/22

P&T Approval: 10/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

INGENOL

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
INGENOL MEBUTATE	PICATO	38449		GPI-10 (9037803520)	

**GUIDELINES FOR USE**

Do not approve requests for Picato gel.

**(NOTE:** Picato discontinued due to safety concerns and increased risk of cancer.)

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Picato.

Manufacturer provided FDA with notification of discontinuation in the manufacture of Picato. Discontinuation may be likely due to safety concerns; Picato is no longer authorized in the EU after concluding that Picato increases the risk of cancer.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/01/21

Created: 05/12

Client Approval: 08/21

P&T Approval: 04/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

INHALED INSULIN

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
INSULIN REGULAR, HUMAN	AFREZZA	00768		GPI-10 (2710401000)	FDB & Medi-Span: ROUTE = INHALATION

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient meet any **ONE** of the following criteria?
  - Chronic lung disease (i.e., asthma or chronic obstructive pulmonary disease)
  - Active lung cancer
  - Currently in diabetic ketoacidosis
  - Patient who smokes or who has quit smoking within the past 6 months

If yes, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

If no, continue to #2.

2. Has baseline spirometry to measure FEV1 been performed?

If yes, continue to #3.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

INHALED INSULIN

INITIAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis type 1 diabetes and meet **ALL** of the following criteria?
- The patient is 18 years of age or older
  - The patient is concurrently using a long-acting insulin
  - The patient had a trial of a preferred formulary rapid acting insulin: Humalog

If yes, **approve for 12 months by GPID or GPI-14 for the requested agent with the following quantity limits:**

- **Afrezza 90-4 Unit Cartridges: #180 cartridges (2 kits) per 28 days.**
- **Afrezza 90-8 Unit Cartridges: #180 cartridges (2 kits) per 28 days.**
- **Afrezza 90-12 Unit Cartridges: #180 cartridges (2 kits) per 28 days.**
- **Afrezza 90-4 Unit + 90-8 Unit Titration pack: #180 cartridges (1 kit) per 28 days.**
- **Afrezza 90-8 Unit + 90-12 Unit Cartridges: #180 cartridges (1 kit) per 28 days.**
- **Afrezza 30-4 Unit + 60-8 Unit Cartridges: #360 cartridges (4 kits) per 28 days.**
- **Afrezza 60-4 Unit + 30-8 Unit Cartridges: #360 cartridges (4 kits) per 28 days.**
- **Afrezza 60-8 Unit + 30-12 Unit Cartridges: #360 cartridges (4 kits) per 28 days.**
- **Afrezza 60-4 Unit + 60-8 Unit + 60-12 Unit Cartridges: #180 cartridges (1 kit) per 28 days.**

**APPROVAL TEXT:** Renewal requires a follow-up spirometry after 6 months of treatment and annually thereafter, and concurrent use of a long acting insulin. Renewal will not be provided for patients with a FEV1 that has declined 20% or more from baseline.

If no, continue to #4.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

INHALED INSULIN

INITIAL CRITERIA (CONTINUED)

4. Does the patient have a diagnosis of type 2 diabetes and meet **ALL** of the following criteria?
- The patient is 18 years of age or older
  - The patient had a trial of a preferred formulary rapid acting insulin: Humalog
  - The prescriber indicated that the patient is physically unable to or unwilling to administer injectable insulin

If yes, **approve for 12 months by GPID or GPI-14 for the requested agent with the following quantity limits:**

- **Afrezza 90-4 Unit Cartridges: #180 cartridges (2 kits) per 28 days.**
- **Afrezza 90-8 Unit Cartridges: #180 cartridges (2 kits) per 28 days.**
- **Afrezza 90-12 Unit Cartridges: #180 cartridges (2 kits) per 28 days.**
- **Afrezza 90-4 Unit + 90-8 Unit Titration pack: #180 cartridges (1 kit) per 28 days.**
- **Afrezza 90-8 Unit + 90-12 Unit Cartridges: #180 cartridges (1 kit) per 28 days.**
- **Afrezza 30-4 Unit + 60-8 Unit Cartridges: #360 cartridges (4 kits) per 28 days.**
- **Afrezza 60-4 Unit + 30-8 Unit Cartridges: #360 cartridges (4 kits) per 28 days.**
- **Afrezza 60-8 Unit + 30-12 Unit Cartridges: #360 cartridges (4 kits) per 28 days.**
- **Afrezza 60-4 Unit + 60-8 Unit + 60-12 Unit Cartridges: #180 cartridges (1 kit) per 28 days.**

**APPROVAL TEXT:** Renewal requires a follow-up spirometry after 6 months of treatment and annually thereafter. Renewal will not be provided for patients with a FEV1 that has declined 20% or more from baseline.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

INHALED INSULIN

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **INHALED INSULIN (Afrezza)** requires the following rule(s) be met for approval:

- A. You have type 1 or type 2 diabetes
- B. You are 18 years of age or older
- C. You have a baseline spirometry (test to measure how well your lungs work) to measure FEV1 (forced expiratory volume)
- D. **If you have type 1 diabetes, approval also requires:**
  - 1. You are using a long-acting insulin with the requested medication and that you have tried a formulary rapid acting insulin: Humalog
- E. **If you have type 2 diabetes, approval also requires:**
  - 1. You tried a formulary rapid acting insulin: Humalog
  - 2. Your prescriber has indicated that you are physically unable or unwilling to use injectable insulin

Note: Afrezza will not be approved if you have any of the following conditions: chronic lung disease, active lung cancer, currently in diabetic ketoacidosis (condition where body breaks down fat too fast), or if you are currently smoking or who have quit smoking within the past 6 months

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

- 1. Does the patient have a diagnosis of type 1 diabetes and currently on a long acting insulin?

If yes, continue to #3.  
If no, continue to #2.

- 2. Does the patient have a diagnosis of type 2 diabetes?

If yes, continue to #3.  
If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

INHALED INSULIN

RENEWAL CRITERIA (CONTINUED)

3. Was follow-up spirometry to measure FEV1 performed after 6 months of treatment and annually thereafter?

If yes, continue to #4.

If no, **approve for 1 month by GPID or GPI-14 (to allow for follow-up spirometry evaluation) with the following quantity limits:**

- **Afrezza 90-4 Unit Cartridges: #180 cartridges (2 kits) per 28 days.**
- **Afrezza 90-8 Unit Cartridges: #180 cartridges (2 kits) per 28 days.**
- **Afrezza 90-12 Unit Cartridges: #180 cartridges (2 kits) per 28 days.**
- **Afrezza 90-4 Unit + 90-8 Unit Titration pack: #180 cartridges (1 kit) per 28 days.**
- **Afrezza 90-8 Unit + 90-12 Unit Cartridges: #180 cartridges (1 kit) per 28 days.**
- **Afrezza 30-4 Unit + 60-8 Unit Cartridges: #360 cartridges (4 kits) per 28 days.**
- **Afrezza 60-4 Unit + 30-8 Unit Cartridges: #360 cartridges (4 kits) per 28 days.**
- **Afrezza 60-8 Unit + 30-12 Unit Cartridges: #360 cartridges (4 kits) per 28 days.**
- **Afrezza 60-4 Unit + 60-8 Unit + 60-12 Unit Cartridges: #180 cartridges (1 kit) per 28 days.**

4. Has FEV1 declined 20% or more from baseline?

If yes, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

If no, **approve for 12 months by GPID or GPI-14 for the requested agent with the following quantity limits:**

- **Afrezza 90-4 Unit Cartridges: #180 cartridges (2 kits) per 28 days.**
- **Afrezza 90-8 Unit Cartridges: #180 cartridges (2 kits) per 28 days.**
- **Afrezza 90-12 Unit Cartridges: #180 cartridges (2 kits) per 28 days.**
- **Afrezza 90-4 Unit + 90-8 Unit Titration pack: #180 cartridges (1 kit) per 28 days.**
- **Afrezza 90-8 Unit + 90-12 Unit Cartridges: #180 cartridges (1 kit) per 28 days.**
- **Afrezza 30-4 Unit + 60-8 Unit Cartridges: #360 cartridges (4 kits) per 28 days.**
- **Afrezza 60-4 Unit + 30-8 Unit Cartridges: #360 cartridges (4 kits) per 28 days.**
- **Afrezza 60-8 Unit + 30-12 Unit Cartridges: #360 cartridges (4 kits) per 28 days.**
- **Afrezza 60-4 Unit + 60-8 Unit + 60-12 Unit Cartridges: #180 cartridges (1 kit) per 28 days.**

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

INHALED INSULIN

RENEWAL CRITERIA (CONTINUED)

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **INHALED INSULIN (Afrezza)** requires the following rule(s) be met for renewal:

- A. You have type 1 or type 2 diabetes
- B. You have documentation of follow up spirometry (test to measure how well your lungs work) to measure FEV1 (forced expiratory volume in one second) after 6 months of treatment and annually thereafter
- C. Your FEV1 has NOT declined 20% or more from baseline
- D. **If you have type 1 diabetes**, approval requires that you are using a long acting insulin at the same time with the requested medication

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Afrezza.

**REFERENCES**

- Afrezza [Prescribing Information]. Danbury, CT: Mankind Corporation. October 2018.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 02/15

Client Approval: 04/20

P&T Approval: 07/17





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

INOTERSEN

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
INOTERSEN SODIUM	TEGSEDI	45353		GPI-10 (6270104010)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy and meet **ALL** the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a neurologist, cardiologist, hATTR specialist, or medical geneticist
  - The patient has documented diagnosis of hereditary TTR amyloidosis (hATTR) as confirmed by ONE of the following:
    - a. Biopsy of tissue/organ to confirm amyloid presence AND chemical typing to confirm presence of TTR protein
    - b. DNA genetic sequencing to confirm hATTR mutation
  - The patient has FAP stage 1 or 2 OR up to PND stage IIIb polyneuropathy
  - The patient had a trial of or contraindication to the preferred agent: Amvuttra

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #6mL per 28 days.**  
If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **INOTERSEN (Tegsedi)** requires the following rule(s) be met for approval:

- A. You have hereditary transthyretin-mediated amyloidosis (hATTR: a rare genetic disorder) with polyneuropathy (widespread nerve pain/damage)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor), cardiologist (a type of heart doctor), hATTR specialist, or medical geneticist (doctor who treats gene disorders)
- D. You have a documented diagnosis of hereditary TTR amyloidosis (hATTR) as confirmed by ONE of the following:
  1. Biopsy (surgical removal of a sample) of tissue/organ to confirm amyloid (abnormal protein that can build up in any tissue or organ) presence AND chemical typing to confirm presence of TTR (*transthyretin*) protein
  2. DNA genetic sequencing (lab test for genes) to confirm hATTR mutation
- E. You have familial amyloidotic polyneuropathy (FAP) stage 1 or 2 OR up to polyneuropathy disability (PND) stage IIIb polyneuropathy
- F. You had a trial of or contraindication (harmful for) to the preferred medication: Amvuttra  
**(Initial denial text continued on next page)**

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

INOTERSEN

INITIAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy **AND** meet the following criterion?
  - The patient has not progressed to FAP stage 3 OR PND stage IV polyneuropathy as evidenced by functional decline (e.g., wheelchair-bound, bedridden)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #6mL per 28 days.**  
If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **INOTERSEN (Tegsedi)** requires the following rule(s) be met for renewal:

- A. You have hereditary transthyretin-mediated amyloidosis (hATTR: a rare genetic disorder) with polyneuropathy (widespread nerve pain/damage)
- B. You have not progressed to familial amyloidotic polyneuropathy (FAP) stage 3 OR polyneuropathy disability (PND) stage IV polyneuropathy as shown by functional decline such as being wheelchair-bound or bedridden

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Tegsedi.

**REFERENCES**

- Tegsedi [Prescribing Information]. Carlsbad, CA: Ionis Pharmaceuticals, Inc.; June 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/01/22

Created: 10/18

Client Approval: 09/22

P&T Approval: 07/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

INTERFERON ALFA-2B

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
INTERFERON ALFA-2B, RECOMB.	INTRON A	04528		GPI-10 (2170006020)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have **ONE** of the following diagnoses?
  - Hairy cell leukemia
  - Condylomata acuminata
  - AIDS-related Kaposi's sarcoma
  - Chronic hepatitis B
  - Non-Hodgkin's lymphoma
  - Malignant melanoma
  - Chronic phase, Philadelphia chromosome (Ph) positive chronic myelogenous leukemia (CML) patients who are minimally treated (within 1 year of diagnosis)
  - Follicular lymphoma
  - Angioblastoma
  - Carcinoid tumor
  - Chronic myeloid leukemia
  - Laryngeal papillomatosis
  - Multiple myeloma
  - Neoplasm of conjunctiva-neoplasm of cornea
  - Ovarian cancer
  - Polycythemia vera
  - Renal cell carcinoma
  - Skin cancer
  - Thrombocytosis
  - Vulvar vestibulitis

If yes, **approve by HICL or GPI-10 for 24 weeks (6 months).**  
If no, continue to #2.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

INTERFERON ALFA-2B

INITIAL CRITERIA (CONTINUED)

2. Does the patient have a diagnosis of chronic hepatitis C, genotype 1, 2, 3, 4, 5, or 6 and meet **ALL** of the following criteria?
- Therapy is prescribed by or in consultation with a gastroenterologist, infectious disease specialist or a physician specializing in the treatment of hepatitis (e.g., hepatologist)
  - The patient has a detectable pretreatment HCV RNA level/viral load of 50 IU/mL or higher
  - The requested medication will be used with ribavirin or the patient has a contraindication to ribavirin
  - The patient had a trial of or contraindication to peginterferon alfa-2a or peginterferon alfa-2b

If yes, **approve by HICL or GPI-10 for 24 weeks (6 months).**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **INTERFERON ALFA-2B (Intron A)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
1. Chronic hepatitis C (type of liver inflammation)
  2. Hairy cell leukemia (bone marrow cancer that makes too many white blood cells)
  3. Condylomata acuminata (genital warts)
  4. AIDS (acquired immunodeficiency syndrome)-related Kaposi's sarcoma (cancer in those with weak immune system that causes tumors of lymph nodes/skin)
  5. Chronic hepatitis B (type of liver inflammation)
  6. Non-Hodgkin's lymphoma (cancer that starts in your lymphatic system- the disease-fighting network in the body)
  7. Malignant melanoma (serious type of skin cancer)
  8. Chronic phase, Philadelphia chromosome (type of abnormal gene) positive chronic myelogenous leukemia (type of blood cell cancer that starts in bone marrow) who are minimally treated (within 1 year of diagnosis)
  9. Follicular lymphoma (type of lymphatic system cancer)
  10. Angioblastoma (certain blood-vessel tumors of the brain)
  11. Carcinoid (cancer) tumor
  12. Chronic myeloid leukemia (type of cancer that starts in immature white blood cells)
  13. Laryngeal papillomatosis (tumors form along the pathways for breathing/digestion)

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

INTERFERON ALFA-2B

INITIAL CRITERIA (CONTINUED)

14. Multiple myeloma (plasma cell cancer)
  15. Neoplasm of conjunctiva-neoplasm of cornea (eye tumors)
  16. Ovarian cancer
  17. Polycythemia vera (cancer where bone marrow makes too many red blood cells)
  18. Renal cell carcinoma (type of kidney cancer)
  19. Skin cancer, thrombocytosis (your body makes too many platelets)
  20. Thrombocytosis (high level of platelets (cells that helps blood clot and stop bleeding) in your blood)
  21. Vulvar vestibulitis (type of pain around the female sex organ called the vulva)
- B. If you have chronic hepatitis C genotype 1, 2, 3, 4, 5, or 6, approval also requires:**
1. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions), infectious disease specialist (a doctor who specializes in the treatment of infections), or a physician specializing in the treatment of hepatitis (such as a hepatologist: a type of liver doctor)
  2. You have a detectable pretreatment HCV (hepatitis C virus) RNA level/viral load (amount of virus in your blood) of 50 IU/mL or higher
  3. The requested medication will be used with ribavirin or you have a contraindication (harmful for)
  4. You had a trial of or contraindication (harmful for) to peginterferon alfa-2a or peginterferon alfa-2b

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of chronic hepatitis C **AND** meet the following criterion?  
Therapy is prescribed by or in consultation with a gastroenterologist, infectious disease specialist or a physician specializing in the treatment of hepatitis (e.g., hepatologist)  
  
If yes, continue to #2.  
If no, **approve by HICL or GPI-10 for 24 weeks (6 months).**
2. Has the patient already received 24 weeks or more of interferon during this treatment?  
  
If yes, continue to #3.  
If no, **approve by HICL or GPI-10 for 24 weeks (6 months).**

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

INTERFERON ALFA-2B

RENEWAL CRITERIA (CONTINUED)

3. Is the patient's HCV RNA undetectable (less than 50 IU/mL) at 24 weeks?

If yes, **approve by HICL or GPI-10 for 24 weeks (6 months).**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **INTERFERON ALFA-2B (Intron A)** requires the following rule(s) be met for renewal:

- A. The request is for continuation of current therapy or renewal with Intron A therapy
- B. **If you have chronic hepatitis C (type of liver inflammation), renewal also requires:**
  - 1. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions), infectious disease specialist (a doctor who specializes in the treatment of infections), or a physician specializing in the treatment of hepatitis (such as a hepatologist: a type of liver doctor)
  - 2. If you already received 24 weeks or more of interferon treatment, your HCV (hepatitis C virus) RNA level (amount of virus in your blood) is undetectable (less than 50 IU/mL) at 24 weeks

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Intron A.

**REFERENCES**

- Intron A [Prescribing Information]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp.; November 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 06/15/22

Created: 02/14

Client Approval: 05/22

P&T Approval: 02/14



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**INTERFERON FOR MS - AVONEX**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
INTERFERON BETA-1A	AVONEX, AVONEX PEN	11253		GPI-10 (6240306045)	MEDI-SPAN: BRAND = AVONEX, AVONEX PEN, AVONEX PREFILLED

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of a relapsing form of multiple sclerosis, to include clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease **AND** meet the following criterion?

- The patient is 18 years of age or older

If yes, **approve for 12 months by GPID or GPI-14 as follows:**

- **Avonex: #1 kit per 28 days or 2mL (#4 syringes) per 28 days.**
- **Avonex Pen: #1 pen injector kit per 28 days or 2mL (#4 syringes) per 28 days.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **INTERFERON FOR MS - AVONEX** requires the following rule(s) be met for approval:

- You have a relapsing form of multiple sclerosis (MS: a type of nerve disorder), to include clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms go away and return), and active secondary progressive disease (advanced disease)
- You are 18 years of age or older

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Avonex.

**REFERENCES**

- Avonex [Prescribing Information]. Cambridge, MA: Biogen Inc.; July 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/01/22

Created: 10/22

Client Approval: 10/22

P&T Approval: 01/20

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

INTERFERON FOR MS - BETASERON

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
INTERFERON BETA-1B	BETASERON	08537		GPI-10 (6240306050)	BRAND = BETASERON

**GUIDELINES FOR USE**

- Does the patient have a diagnosis of a relapsing form of multiple sclerosis, to include clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease **AND** meet the following criterion?
  - The patient is 18 years of age or older

If yes, **approve for 12 months for all NDCs or GPI-14 of Betaseron for #14 vials or kits per 28 days.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **INTERFERON FOR MS - BETASERON** requires the following rule(s) be met for approval:

- You have a relapsing form of multiple sclerosis (MS: a type of nerve disorder), to include clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms go away and return), and active secondary progressive disease (advanced disease)
- You are 18 years of age or older

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Betaseron.

**REFERENCES**

- Betaseron [Prescribing Information]. Whippany, NJ: Bayer; August 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/01/22

Created: 10/22

Client Approval: 10/22

P&T Approval: 01/20





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

INTERFERON FOR MS - EXTAVIA

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
INTERFERON BETA-1B	EXTAVIA	08537		GPI-10 (6240306050)	BRAND = EXTAVIA

**GUIDELINES FOR USE**

- Does the patient have a diagnosis of a relapsing form of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient had a trial of or contraindication to any TWO of the following preferred agents for MS: Avonex, Copaxone/Glatiramer/Glatopa, Gilenya, Plegridy, Rebif, Betaseron, dimethyl fumarate, Mavenclad, Mayzent, Vumerity, Aubagio, Kesimpta  
(Please note: other multiple sclerosis agents may also require prior authorization)

If yes, **approve for 12 months for all NDCs or GPI-14 of Extavia for #14 vials or kits per 28 days.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **INTERFERON FOR MS - EXTAVIA** requires the following rule(s) be met for approval:

- You have a relapsing form of multiple sclerosis (MS: a type of nerve disorder), to include clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms go away and return), and active secondary progressive disease (advanced disease)
- You are 18 years of age or older
- You had a trial of or contraindication (harmful for) to any TWO of the following preferred medications: Avonex, Copaxone/Glatiramer/Glatopa, Gilenya, Plegridy, Rebif, Betaseron, dimethyl fumarate, Mavenclad, Mayzent, Vumerity, Aubagio, Kesimpta  
(Please note: other multiple sclerosis medications may also require prior authorization)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**INTERFERON FOR MS - EXTAVIA**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Extavia.

**REFERENCES**

- Extavia [Prescribing Information]. East Hanover, NJ: EMD Novartis; August 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/01/22

Created: 10/22

Client Approval: 10/22

P&T Approval: 01/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

INTERFERON FOR MS - PLEGRIDY

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
PEGINTERFERON BETA-1A	PLEGRIDY, PLEGRIDY PEN	41331		GPI-10 (6240307530)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of a relapsing form of multiple sclerosis, to include clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease **AND** meet the following criterion?
  - The patient is 18 years of age or older

If yes, approve for 12 months by GPID or GPI-14 as follows:

**INITIAL REQUESTS:**

- **FIRST APPROVAL:** Plegridy injection starter pack: approve for 1 month with a quantity limit of 1mL (#2 prefilled pens or syringes).
- **SECOND APPROVAL:** Plegridy Pen/Syringe: approve for 11 months (total approval duration of 12 months) with a quantity limit of 1mL (#2 125mcg prefilled pens or syringes) per 28 days. (Please enter start date of 3 weeks AFTER the START date of the first approval.)

**SUBSEQUENT REQUESTS:**

- **Plegridy Pen/Syringe:** approve for 12 months with a quantity limit of 1mL (#2 125mcg prefilled pens or syringes) per 28 days.

If no, do not approve.

**DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **INTERFERON FOR MS - PLEGRIDY** requires the following rule(s) be met for approval:

- A. You have a relapsing form of multiple sclerosis (MS: a type of nerve disorder), to include clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms go away and return), and active secondary progressive disease (advanced disease)
- B. You are 18 years of age or older

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**INTERFERON FOR MS - PLEGRIDY**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Plegridy.

**REFERENCES**

- Plegridy [Prescribing Information]. Cambridge, MA: Biogen Inc.; July 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/01/22

Created: 10/22

Client Approval: 10/22

P&T Approval: 01/20



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**INTERFERON FOR MS - REBIF**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
INTERFERON BETA-1A/ALBUMIN	REBIF, REBIF REBIDOSE	23353		GPI-10 (6240306045)	FDB: BRAND = REBIF, REBIF REBIDOSE  MED-SPAN: BRAND = REBIF REBIDOSE, REBIF REBIDOSE TITRATIONPACK, REBIF

**GUIDELINES FOR USE**

- Does the patient have a diagnosis of a relapsing form of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease **AND** meet the following criterion?
  - The patient is 18 years of age or older

If yes, **approve for 12 months by GPID or GPI-14 as follows:**

**INITIAL REQUESTS:**

- FIRST APPROVAL:** Rebif Titration Pack/Rebif Rebidoose Titration Pack: approve for 1 month with a quantity limit of 4.2mL (#12 syringes) per 28 days.
- SECOND APPROVAL:** Rebif/Rebif Rebidoose: approve for 11 months (total approval duration of 12 months) with a quantity limit of 6mL (#12 syringes) per 28 days. (Please enter start date of 3 weeks AFTER the START date of the first approval.).

**SUBSEQUENT REQUESTS:**

- Rebif/Rebif Rebidoose:** approve for 12 months with a quantity limit of 6mL (#12 syringes) per 28 days.

If no, do not approve.

**DENIAL TEXT:** *\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **INTERFERON FOR MS - REBIF** requires the following rule(s) be met for approval:

- You have a relapsing form of multiple sclerosis (MS: a type of nerve disorder), to include clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms go away and return), and active secondary progressive disease (advanced disease)
- You are 18 years of age or older

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**INTERFERON FOR MS - REBIF**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Rebif.

**REFERENCES**

- Rebif [Prescribing Information]. Rockland, MA: EMD Serono, Inc.; July 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/01/22

Created: 10/22

Client Approval: 10/22

P&T Approval: 01/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

INTERFERON GAMMA-1B, RECOMB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
INTERFERON GAMMA-1B, RECOMB.	ACTIMMUNE	06068		GPI-10 (2170006070)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of chronic granulomatous disease (CGD) **AND** meet the following criterion?
  - The medication is prescribed by or given in consultation with a hematologist, infectious disease specialist, or immunologist

If yes, **approve for 6 months by HICL or GPI-10.**

**APPROVAL TEXT:** Renewal requires the following: 1) patient has demonstrated clinical benefit compared to baseline (e.g. reduction in frequency and severity of serious infections), and 2) patient has not received hematopoietic cell transplantation.

If no, continue to #2.

2. Does the patient have a diagnosis of severe malignant osteopetrosis (SMO) **AND** meet the following criterion?
  - The medication is prescribed by or given in consultation with an endocrinologist

If yes, **approve for 6 months by HICL or GPI-10.**

**APPROVAL TEXT:** Renewal requires the following: 1) patient has demonstrated clinical benefit compared to baseline (e.g. reduction in frequency and severity of serious infections), and 2) patient has not received hematopoietic cell transplantation.

If no, do not approve.

**INITIAL DENIAL TEXT:** **\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **INTERFERON GAMMA-1B, RECOMB (Actimmune)** requires the following rules be met for approval:

A. You have **ONE** of the following diagnoses:

1. Chronic granulomatous disease (CGD: inherited immune system disorder that occurs when a type of white blood cells that usually helps your body fight infections does not work properly)
2. Severe malignant osteopetrosis (SMO: a bone disease that makes bone abnormally thick and prone to breakage/fracture)

**(Initial denial text continued on the next page)**

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

INTERFERON GAMMA-1B, RECOMB

INITIAL CRITERIA (CONTINUED)

**B. If you have chronic granulomatous disease, approval also requires:**

1. The medication is prescribed by or given in consultation with a hematologist (blood doctor), infectious disease specialist (doctor that specializes in treating infections), or immunologist (doctor that specializes in treating and managing allergies, asthma and immunologic disorders)

**C. If you have severe malignant osteopetrosis, approval also requires:**

1. The medication is prescribed by or given in consultation with an endocrinologist (doctor that specializes in all things relating to our hormones)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of chronic granulomatous disease (CGD) or severe malignant osteopetrosis (SMO) and meet **ALL** of the following criteria?
  - The patient has demonstrated clinical benefit compared to baseline (e.g., reduction in frequency and severity of serious infections)
  - The patient has not received hematopoietic cell transplantation

If yes, **approve for 12 months by HICL or GPI-10.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **INTERFERON GAMMA-1B, RECOMB (Actimmune)** requires the following rules be met for renewal:

**A. You have ONE of the following diagnoses:**

1. Chronic granulomatous disease (CGD: inherited immune system disorder that occurs when a type of white blood cells that usually helps your body fight infections does not work properly)
2. Severe malignant osteopetrosis (SMO: a bone disease that makes bone abnormally thick and prone to breakage/fracture)

**B. You have shown clinical (medical) benefit compared to baseline (such as reduction in frequency and severity of serious infections)**

**C. You have not received hematopoietic cell transplantation (transplant of stem cells from bone marrow, peripheral blood, or umbilical cord blood)**

**(Renewal denial text continued on the next page)**

CONTINUED ON NEXT PAGE





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

INTERFERON GAMMA-1B, RECOMB

RENEWAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Actimmune.

**REFERENCES**

- Actimmune [Prescribing Information] Lake Forest, IL: Horizon Therapeutics USA, Inc., January 2020.

Library	Commercial	NSA
No	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/20

Created: 09/05

Client Approval: 02/20

P&T Approval: 01/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ISAVUCONAZONIUM

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other?
ISAVUCONAZONIUM	CRESEMBA		38095	GPI-14 (11407030100120)	

**GUIDELINES FOR USE**

1. Is this request for continuation of therapy after the patient was started on Cresemba in the hospital?

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #60 per 30 days.**  
If no, continue to #2.

2. Does the patient have a diagnosis of invasive aspergillosis and meet **ALL** of the following?

- The patient is 18 years of age or older
- Therapy is prescribed by or given in consultation with an infectious disease specialist
- The patient had a trial and failure of or contraindication to voriconazole

If yes, **approve for 6 months by HICL or GPI-10 as follows:**

**INITIAL REQUESTS:**

**FIRST APPROVAL: approve for one fill with a quantity limit of #68 per 30 days.**

**SECOND APPROVAL: approve for 5 months with a quantity limit of #60 per 30 days.**

**SUBSEQUENT REQUESTS:**

**Approve for 6 months with a quantity limit of #60 per 30 days.**

If no, continue to #3.

3. Does the patient have a diagnosis of invasive mucormycosis and meet **ALL** of the following?

- The patient is 18 years of age or older
- Therapy is prescribed by or given in consultation with an infectious disease specialist

If yes, **approve for 6 months by HICL or GPI-10 as follows:**

**INITIAL REQUESTS:**

• **FIRST APPROVAL: approve for one fill with a quantity limit of #68 per 30 days.**

• **SECOND APPROVAL: approve for 5 months with a quantity limit of #60 per 30 days.**

**SUBSEQUENT REQUESTS:**

• **Approve for 6 months with a quantity limit of #60 per 30 days.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ISAVUCONAZONIUM

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ISAVUCONAZONIUM (Cresemba)** requires the following rule(s) be met for approval:

- A. You meet **ONE** of the following:
  - 1. This is a request for continuation of therapy after you were started on Cresemba in the hospital
  - 2. You have invasive aspergillosis OR invasive mucormycosis (types of fungal infections)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or given in consultation with an infectious disease specialist
- D. **If you have invasive aspergillosis, approval also requires:**
  - 1. You had a trial and failure of or contraindication to (medical reason why you cannot use) voriconazole

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Cresemba.

**REFERENCES**

- Cresemba [Prescribing Information]. Northbrook, IL: Astellas Pharma US, Inc., December 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/01/21

Created: 05/21

Client Approval: 08/21

P&T Approval: 04/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ISTRADefylline

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ISTRADefylline	Nourianz	45994		GPI-10 (7340102500)	

GUIDELINES FOR USE

1. Does the patient have a diagnosis of Parkinson's disease (PD) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient is experiencing 'OFF' episodes
- Nourianz will be used concurrently with levodopa/carbidopa
- The patient had a previous trial of, failure of, or contraindication to **TWO** Parkinson's agents from **TWO** different therapeutic classes: dopamine agonists (e.g., ropinirole, pramipexole, rotigotine), monoamine oxidase-inhibitors (e.g., selegiline, rasagiline), or catechol-O-methyl transferase inhibitors (e.g., entacapone, tolcapone)

If yes, **approve for lifetime by HICL or GPI-10 with a quantity limit of #1 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ISTRADefylline (Nourianz)** requires the following rule(s) be met for approval:

- A. You have Parkinson's disease (a nerve system disorder that affects movement)
- B. You are 18 years of age or older
- C. You are experiencing 'OFF' episodes (times when medication wears off and you have movement problems)
- D. Nourianz will be used along with levodopa/carbidopa
- E. You had a previous trial of or contraindication to (medical reason why you cannot use) **TWO** Parkinson's agents from **TWO** different drug classes:
  1. Dopamine agonists (such as ropinirole, pramipexole, rotigotine)
  2. Monoamine oxidase-inhibitors (such as selegiline, rasagiline)
  3. Catechol-O-methyl transferase inhibitors (such as entacapone, tolcapone)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**ISTRADefylline**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Nourianz.

**REFERENCES**

- Nourianz [Prescribing Information]. Bedminster, NJ: Kyowa Kirin, Inc.; September 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 11/19

Client Approval: 04/20

P&T Approval: 10/19



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ITRACONAZOLE - TOLSURA

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ITRACONAZOLE	TOLSURA		45848	GPI-14 (11407035000113)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of **ONE** of the following types of fungal infections?
  - Blastomycosis, pulmonary and extrapulmonary
  - Histoplasmosis, including chronic cavitory pulmonary disease and disseminated, nonmeningeal histoplasmosis
  - Aspergillosis, pulmonary and extrapulmonary, **AND** the patient is intolerant to or refractory to amphotericin B therapy

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or given in consultation with an infectious disease specialist
  - The patient had a previous trial of a generic itraconazole formulation
  - Tolsura is prescribed due to subclinical response to other formulations of itraconazole suspected to be due to poor bioavailability

If yes, **approve for a total of 12 months by GPID or GPI-14 as follows:**

**INITIAL REQUESTS**

- **FIRST APPROVAL:** approve for 1 fill with a quantity limit of #126 per 30 days.
- **SECOND APPROVAL:** approve for 11 months with a quantity limit of #120 per 30 days.

**SUBSEQUENT REQUESTS**

- **Approve for 12 months with a quantity limit of #120 per 30 days.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ITRACONAZOLE - TOLSURA

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ITRACONAZOLE (Tolsura)** requires the following rule(s) be met for approval:

- A. You have **ONE** of the following fungal infections:
  - 1. Blastomycosis, pulmonary and extrapulmonary (type of fungal infection affecting in and outside of the lungs)
  - 2. Histoplasmosis (type of fungal infection), including chronic cavitary pulmonary (affecting the lungs) disease and disseminated, nonmeningeal (not affecting spinal cord and brain membranes) histoplasmosis
  - 3. Aspergillosis, pulmonary and extrapulmonary (type of fungal infection in and outside of the lungs), **AND** you are intolerant to or refractory to (not responsive to) amphotericin B therapy
- B. You are 18 years of age or older
- C. Therapy is prescribed by or given in consultation with an infectious disease specialist
- D. You had a previous trial of a generic itraconazole formulation
- E. Tolsura is prescribed because you had a poor clinical response to other formulations of itraconazole due to poor bioavailability (amount of drug in the body that has an effect)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Tolsura.

**REFERENCES**

- Tolsura [Prescribing Information]. Greenville, NC: Mayne Pharma; September 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/21

Created: 03/19

Client Approval: 05/21

P&T Approval: 04/21



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**IVACAFTOR**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
IVACAFTOR	KALYDECO	38461		GPI-10 (4530203000)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

- Does the patient have a diagnosis of cystic fibrosis (CF) and meet **ALL** of the following criteria?
  - The patient is 4 months of age or older
  - Therapy is prescribed by or given in consultation with a pulmonologist or cystic fibrosis expert
  - The patient is **NOT** homozygous for the F508del mutation in the CFTR gene
  - Documentation of **ONE** of the following mutations in the CFTR gene:

<i>711+3A→G</i>	<i>F311del</i>	<i>I148T</i>	<i>R75Q</i>	<i>S589N</i>
<i>2789+5G→A</i>	<i>F311L</i>	<i>I175V</i>	<i>R117C</i>	<i>S737F</i>
<i>3272-26A→G</i>	<i>F508C</i>	<i>I807M</i>	<i>R117G</i>	<i>S945L</i>
<i>3849+10kbC→T</i>	<i>F508C; S1251N</i>	<i>I1027T</i>	<i>R117H</i>	<i>S977F</i>
<i>A120T</i>	<i>F1052V</i>	<i>I1139V</i>	<i>R117L</i>	<i>S1159F</i>
<i>A234D</i>	<i>F1074L</i>	<i>K1060T</i>	<i>R117P</i>	<i>S1159P</i>
<i>A349V</i>	<i>G178E</i>	<i>L206W</i>	<i>R170H</i>	<i>S1251N</i>
<i>A455E</i>	<i>G178R</i>	<i>L320V</i>	<i>R347H</i>	<i>S1255P</i>
<i>A1067T</i>	<i>G194R</i>	<i>L967S</i>	<i>R347L</i>	<i>T338I</i>
<i>D110E</i>	<i>G314E</i>	<i>L997F</i>	<i>R352Q</i>	<i>T1053I</i>
<i>D110H</i>	<i>G551D</i>	<i>L1480P</i>	<i>R553Q</i>	<i>V232D</i>
<i>D192G</i>	<i>G551S</i>	<i>M152V</i>	<i>R668C</i>	<i>V562I</i>
<i>D579G</i>	<i>G576A</i>	<i>M952I</i>	<i>R792G</i>	<i>V754M</i>
<i>D924N</i>	<i>G970D</i>	<i>M952T</i>	<i>R933G</i>	<i>V1293G</i>
<i>D1152H</i>	<i>G1069R</i>	<i>P67L</i>	<i>R1070Q</i>	<i>W1282R</i>
<i>D1270N</i>	<i>G1244E</i>	<i>Q237E</i>	<i>R1070W</i>	<i>Y1014C</i>
<i>E56K</i>	<i>G1249R</i>	<i>Q237H</i>	<i>R1162L</i>	<i>Y1032C</i>
<i>E193K</i>	<i>G1349D</i>	<i>Q359R</i>	<i>R1283M</i>	
<i>E822K</i>	<i>H939R</i>	<i>Q1291R</i>	<i>S549N</i>	
<i>E831X</i>	<i>H1375P</i>	<i>R74W</i>	<i>S549R</i>	

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

IVACAFTOR

INITIAL CRITERIA (CONTINUED)

2. Is the patient 6 years of age or older?

If yes, **approve Kalydeco 150mg tablets for 12 months by GPID or GPI-14 with a quantity limit of #2 per day.**

**APPROVAL TEXT:** Renewal requires the patient has shown improvement compared to baseline in clinical status as shown by ONE of the following: i) patient has improved, maintained, or demonstrated less than expected decline in FEV1, ii) patient has improved, maintained, or demonstrated less than expected decline in BMI, or iii) patient has experienced a reduction in rate of pulmonary exacerbations.

If no, continue to #3.

3. Does the patient weigh less than 14kg (documentation of weight required)?

If yes, **approve for 12 months by GPID or GPI-14 for all strengths below as follows:**

- **Kalydeco 25mg packets: #2 per day.**
- **Kalydeco 50mg packets: #2 per day.**

If no, **approve Kalydeco 75mg packets for 12 months by GPID or GPI-14 with a quantity limit of #2 per day.**

**APPROVAL TEXT:** Renewal requires the patient has shown improvement in clinical status compared to baseline as shown by ONE of the following: i) patient has improved, maintained, or demonstrated less than expected decline in FEV1, ii) patient has improved, maintained, or demonstrated less than expected decline in BMI, or iii) patient has experienced a reduction in rate of pulmonary exacerbations.

**INITIAL DENIAL TEXT:** *\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **IVACAFTOR (Kalydeco)** requires the following rule(s) be met for approval:

- A. You have cystic fibrosis (life-threatening disorder that damages lungs and digestive system)
- B. You are 4 months of age or older
- C. Therapy is prescribed by or given in consultation with a pulmonologist (lung doctor) or cystic fibrosis expert
- D. You are NOT homozygous (have 2 copies of the same gene) for the F508del mutation in the CFTR (cystic fibrosis transmembrane conductance regulator) gene
- E. If you are between 4 months and less than 6 years of age, **Ivacaftor packets** will be approved.  
Documentation of your weight is required

***(Initial denial text continued on next page.)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

IVACAFTOR

INITIAL CRITERIA (CONTINUED)

F. You have documentation of ONE of the following mutations in the CFTR (cystic fibrosis transmembrane conductance regulator) gene:

711+3A→G	F311del	I148T	R75Q	S589N
2789+5G→A	F311L	I175V	R117C	S737F
3272-26A→G	F508C	I807M	R117G	S945L
3849+10kbC→T	F508C; S1251N	I1027T	R117H	S977F
A120T	F1052V	I1139V	R117L	S1159F
A234D	F1074L	K1060T	R117P	S1159P
A349V	G178E	L206W	R170H	S1251N
A455E	G178R	L320V	R347H	S1255P
A1067T	G194R	L967S	R347L	T338I
D110E	G314E	L997F	R352Q	T1053I
D110H	G551D	L1480P	R553Q	V232D
D192G	G551S	M152V	R668C	V562I
D579G	G576A	M952I	R792G	V754M
D924N	G970D	M952T	R933G	V1293G
D1152H	G1069R	P67L	R1070Q	W1282R
D1270N	G1244E	Q237E	R1070W	Y1014C
E56K	G1249R	Q237H	R1162L	Y1032C
E193K	G1349D	Q359R	R1283M	
E822K	H939R	Q1291R	S549N	
E831X	H1375P	R74W	S549R	

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

IVACAFTOR

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of cystic fibrosis (CF) and improvement in clinical status compared to baseline as shown by **ONE** of the following?
  - The patient has improved, maintained, or demonstrated less than expected decline in FEV1 (forced expiratory volume)
  - The patient has improved, maintained, or demonstrated less than expected decline in BMI (body mass index)
  - The patient has experienced a reduction in rate of pulmonary exacerbations

If yes, **approve for lifetime by HICL or GPI-10 with a quantity limit of #2 (tablets/packets) per day.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **IVACAFTOR (Kalydeco)** requires the following rule(s) be met for renewal:

- A. You have cystic fibrosis (CF: life-threatening disorder that damages lungs and digestive system)
- B. You have shown improvement in clinical (medical) status compared to baseline as shown by ONE of the following:
  1. You have maintained, or demonstrated less than expected decline in FEV1 (forced expiratory volume: amount of air you can exhale in 1 second)
  2. You have improved, maintained, or demonstrated less than expected decline in BMI (body mass index)
  3. You have experienced a reduction in rate of pulmonary exacerbations (you have less attacks of breathing problems)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**IVACAFTOR**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Kalydeco.

**REFERENCES**

- Kalydeco [Prescribing Information]. Boston, MA: Vertex Pharmaceuticals Incorporated.; December 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 02/01/21

Created: 02/12

Client Approval: 01/21

P&T Approval: 01/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

IVOSIDENIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
IVOSIDENIB	TIBSOVO	45096		GPI-10 (2153494000)	

**GUIDELINES FOR USE**

1. Does the patient have a new diagnosis of acute myeloid leukemia (AML) and meet **ALL** of the following criteria?
  - The requested medication will be used in combination with azacitidine or as monotherapy
  - The patient's cancer has a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test

If yes, continue to #2.  
If no, continue to #3.
2. Does the patient meet **ONE** of the following criteria?
  - The patient is 75 years of age or older
  - The patient is 18 years of age or older AND has comorbidities that preclude the use of intensive induction chemotherapy

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.**  
If no, do not approve.  
**DENIAL TEXT:** See the denial text at the end of the guideline.
3. Does the patient have a diagnosis of relapsed or refractory acute myeloid leukemia (AML) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient's cancer has a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.**  
If no, continue to #4.
4. Does the patient have a diagnosis of locally advanced or metastatic cholangiocarcinoma and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient's cancer has an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test
  - The patient's cancer has been previously treated

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.**  
If no, do not approve.  
**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

IVOSIDENIB

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **IVOSIDENIB (Tibsovo)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
  - 1. Acute myeloid leukemia (AML: a type of blood cancer)
  - 2. Locally advanced or metastatic cholangiocarcinoma (bile duct cancer that has spread from where it started to nearby tissue/lymph nodes or to other parts of the body)
- B. **If you have a new diagnosis of acute myeloid leukemia, approval also requires:**
  - 1. The requested medication will be used in combination with azacitidine or as monotherapy (one drug)
  - 2. Your cancer has a susceptible (can be treated with the drug) isocitrate dehydrogenase-1 (IDH1: type of enzyme) mutation as detected by a Food and Drug Administration (FDA)-approved test
  - 3. You meet ONE of the following:
    - a. You are 75 years of age or older
    - b. You are 18 years of age or older AND have comorbidities (additional diseases) that prevent the use of intensive induction chemotherapy (start of a type of cancer treatment)
- C. **If you have relapsed or refractory acute myeloid leukemia, approval also requires:**
  - 1. You are 18 years of age or older
  - 2. Your cancer has a susceptible (can be treated with the drug) isocitrate dehydrogenase-1 (IDH1: type of enzyme) mutation as detected by a Food and Drug Administration (FDA)-approved test
- D. **If you have locally advanced or metastatic cholangiocarcinoma, approval also requires:**
  - 1. You are 18 years of age or older
  - 2. Your cancer has an isocitrate dehydrogenase-1 (IDH1: type of enzyme) mutation as detected by a Food and Drug Administration (FDA)-approved test
  - 3. Your cancer has been previously treated

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**IVOSIDENIB**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Tibsovo.

**REFERENCES**

- Tibsovo [Prescribing Information]. Cambridge, MA: Agios Pharmaceuticals; May 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/18/22

Created: 11/18

Client Approval: 06/22

P&T Approval: 07/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

IXAZOMIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
IXAZOMIB CITRATE	NINLARO	42826		GPI-10 (2153604510)	

**GUIDELINES FOR USE**

- Does the patient have a diagnosis of multiple myeloma and meet **ALL** of the following criteria?
  - Ninlaro (ixazomib) will be used in combination with lenalidomide and dexamethasone
  - The patient has received at least one prior therapy for the treatment of multiple myeloma such as bortezomib, carfilzomib, thalidomide, lenalidomide, melphalan or stem cell transplantation

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #3 per 28 days.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **IXAZOMIB (Ninlaro)** requires the following rule(s) be met for approval:

- You have multiple myeloma (plasma cell cancer)
- The requested medication will be used in combination with lenalidomide and dexamethasone
- You have received at least one prior therapy such as bortezomib, carfilzomib, thalidomide, lenalidomide, melphalan or stem cell transplantation

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Ninlaro.

**REFERENCES**

- Ninlaro [Prescribing Information]. Cambridge, MA: Takeda Pharmaceutical Company Limited; February 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 12/15

Client Approval: 04/20

P&T Approval: 02/16





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

IXEKIZUMAB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
IXEKIZUMAB	TALTZ	43193		GPI-10 (9025055400)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) and meet **ALL** of the following criteria?
  - The patient is 6 years of age or older
  - Therapy is prescribed by or in consultation with a dermatologist
  - The patient has psoriasis covering 3% or more of body surface area (BSA) OR psoriatic lesions affecting the hands, feet, genital area, or face
  - The patient had a trial of or contraindication to ONE or more forms of conventional therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids, calcipotriene, acitretin, methotrexate, or cyclosporine

If yes, continue to #2.

If no, continue to #3.

2. Does the patient meet **ONE** of the following criteria?
  - The patient is 6 to 17 years of age AND had a trial of or contraindication to THREE of the preferred agents: Enbrel, Cosentyx, Stelara
  - The patient is 18 years of age or older AND had a trial of or contraindication to any THREE of the following preferred agents: Cosentyx, Humira, Stelara, Tremfya, Skyrizi, Enbrel, Otezla  
[NOTE: pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

If yes, approve for a total of 6 months by HICL or GPI-10 as follows:

- For patients who are 6 years to 17 years of age, enter TWO approvals:
  - **FIRST APPROVAL:** Approve for 1 month with a quantity limit of 2mL per 28 days.
  - **SECOND APPROVAL:** Approve for 5 months with a quantity limit of 1mL per 28 days (Start date is 3 WEEKS AFTER the START date of the first approval).
- For patients who are 18 years of age or older, enter THREE approvals:
  - **FIRST APPROVAL:** Approve for 1 month with a quantity limit of 3mL per 28 days.
  - **SECOND APPROVAL:** Approve for 2 months with a quantity limit of 2mL per 28 days (Start date is 3 WEEKS AFTER the START date of the first approval).
  - **THIRD APPROVAL:** Approve for 3 months with a quantity limit of 1mL per 28 days (Start date is 1 WEEK BEFORE the END date of the second approval).

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

IXEKIZUMAB

INITIAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of psoriatic arthritis (PsA) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- Therapy is prescribed by or in consultation with a rheumatologist or dermatologist
- The patient had a trial of or contraindication to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
- The patient had a trial of or contraindication to any TWO of the following preferred agents: Cosentyx, Enbrel, Humira, Stelara, Xeljanz (IR/XR), Otezla, Tremfya, Rinvoq, Skyrizi [**NOTE:** pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

If yes, continue to #4.

If no, continue to #5.

4. Does the patient have coexistent moderate to severe plaque psoriasis (PsO)?

If yes, **approve for a total of 6 months by HICL or GPI-10 as follows:**

- **FIRST APPROVAL:** Approve for 1 month with a quantity limit of 3mL per 28 days.
- **SECOND APPROVAL:** Approve for 2 months with a quantity limit of 2mL per 28 days (Start date is 3 WEEKS AFTER the START date of the first approval).
- **THIRD APPROVAL:** Approve for 3 months with a quantity limit of 1mL per 28 days (Start date is 1 WEEK BEFORE the END date of the second approval).

If no, **approve for a total of 6 months by HICL or GPI-10 as follows:**

- **FIRST APPROVAL:** Approve for 1 month with a quantity limit of 2mL per 28 days.
- **SECOND APPROVAL:** Approve for 5 months with a quantity limit of 1mL per 28 days (Start date is 3 WEEKS AFTER the START date of the first approval).

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

IXEKIZUMAB

INITIAL CRITERIA (CONTINUED)

5. Does the patient have a diagnosis of ankylosing spondylitis (AS) and meet **ALL** of the following criteria?
- The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a rheumatologist
  - The patient had a trial of or contraindication to an NSAID (e.g., ibuprofen, naproxen, meloxicam, diclofenac, etc.)
  - The patient had a trial of or contraindication to any TWO of the following preferred agents: Enbrel, Humira, Cosentyx, Xeljanz (IR/XR), Rinvoq  
[NOTE: pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

If yes, **approve for a total of 6 months by entering TWO approvals by HICL or GPI-10 as follows:**

- **FIRST APPROVAL: Approve for 1 month with a quantity limit of 2mL per 28 days.**
- **SECOND APPROVAL: Approve for 5 months with a quantity limit of 1mL per 28 days (Start date is 3 WEEKS AFTER the START date of the first approval).**

If no, continue to #6.

6. Does the patient have a diagnosis of non-radiographic axial spondyloarthritis (nr-axSpA) and meet **ALL** of the following criteria?
- The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a rheumatologist
  - The patient had a trial of or contraindication to an NSAID (e.g., ibuprofen, naproxen, meloxicam)
  - The patient meets ONE of the following objective signs of inflammation:
    - C-reactive protein (CRP) levels above the upper limit of normal
    - Sacroiliitis on magnetic resonance imaging (MRI)
  - The patient had a trial of or contraindication to TWO of the following preferred agents: Cosentyx, Cimzia, Rinvoq [NOTE: pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of 1mL per 28 days.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

IXEKIZUMAB

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **IXEKIZUMAB (Taltz)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
1. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
  2. Psoriatic arthritis (PsA: a type of skin and joint condition)
  3. Ankylosing spondylitis (AS: a type of joint condition)
  4. Non-radiographic axial spondyloarthritis (nr-axSpA: a type of joint condition)
- B. **If you have moderate to severe plaque psoriasis, approval also requires:**
1. You are 6 years of age or older
  2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
  3. You have psoriasis covering 3% or more of body surface area (BSA) OR psoriatic lesions (rashes) affecting the hands, feet, genital area, or face
  4. You had a trial of or contraindication (harmful for) to ONE or more forms of standard therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids, calcipotriene, acitretin, methotrexate, or cyclosporine
  5. You meet ONE of the following:
    - a. You are 6 to 17 years of age AND had a trial of or contraindication (harmful for) to THREE of the preferred medications: Enbrel, Cosentyx, Stelara
    - b. You are 18 years of age or older AND had a trial of or contraindication (harmful for) to any THREE of the following preferred medications: Cosentyx, Humira, Stelara, Tremfya, Skyrizi, Enbrel, Otezla
- C. **If you have psoriatic arthritis, approval also requires:**
1. You are 18 years of age or older
  2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
  3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
  4. You had a trial of or contraindication (harmful for) to any TWO of the following preferred medications: Cosentyx, Enbrel, Humira, Stelara, Xeljanz (immediate release/extended release), Otezla, Tremfya, Rinvoq, Skyrizi

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

IXEKIZUMAB

INITIAL CRITERIA (CONTINUED)

**D. If you have ankylosing spondylitis, approval also requires:**

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
3. You had a trial of or contraindication (harmful for) to an NSAID (non-steroidal anti-inflammatory drug)
4. You had a trial of or contraindication (harmful for) to any TWO of the following preferred medications: Enbrel, Humira, Cosentyx, Xeljanz (immediate release/extended release), Rinvoq

**E. If you have non-radiographic axial spondyloarthritis, approval also requires:**

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
3. You had a trial of or contraindication (harmful for) to an NSAID (non-steroidal anti-inflammatory drug, such as ibuprofen, naproxen, meloxicam)
4. You have ONE of the following signs of inflammation:
  - a. C-reactive protein (CRP; a measure of how much inflammation you have) levels above the upper limit of normal
  - b. Sacroiliitis (type of inflammation where lower spine and pelvis connect) on magnetic resonance imaging (MRI)
5. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Cosentyx, Cimzia, Rinvoq

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) **AND** meet the following criterion?
  - The patient has achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of 1mL per 28 days.**  
If no, continue to #2.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

IXEKIZUMAB

RENEWAL CRITERIA (CONTINUED)

2. Does the patient have a diagnosis of psoriatic arthritis (PsA) **AND** meet the following criterion?
- The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of 1mL per 28 days.**  
If no, continue to #3.

3. Does the patient have a diagnosis of ankylosing spondylitis (AS) or non-radiographic axial spondyloarthritis (nr-axSpA) **AND** meet the following criterion?
- The patient has experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score while on therapy

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of 1mL per 28 days.**  
If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **IXEKIZUMAB (Taltz)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following diagnoses:
1. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
  2. Psoriatic arthritis (PsA: a type of skin and joint condition)
  3. Ankylosing spondylitis (AS: a type of joint condition)
  4. Non-radiographic axial spondyloarthritis (nr-axSpA: a type of joint condition)
- B. **If you have moderate to severe plaque psoriasis, renewal also requires:**
1. You achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index: used to measure the severity and extent of psoriasis) of at least 50% or more
- C. **If you have psoriatic arthritis, renewal also requires:**
1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
- D. **If you have ankylosing spondylitis OR non-radiographic axial spondyloarthritis, renewal also requires:**
1. You have experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI: diagnostic test which allows a physician to determine the effectiveness of a current medication) score while on therapy

***(Renewal denial text continued on next page)***

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

IXEKIZUMAB

RENEWAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Taltz.

**REFERENCES**

- Taltz [Prescribing Information]. Indianapolis, IN: Eli Lilly and Company; September 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 03/01/23

Created: 04/16

Client Approval: 02/23

P&T Approval: 05/22





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LACTIC ACID/CITRIC/POTASSIUM

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
LACTIC ACID/CITRIC/POTASSIUM	PHEXXI	46568		GPI-10 (5532990340)	

Please refer to **CONTRACEPTIVE ZERO COST SHARE OVERRIDE** section below if the request is also for zero copay override.

**GUIDELINES FOR USE**

- Is the request for prevention of pregnancy in a female patient with reproductive potential and the patient meets **ALL** of the following criteria?
  - The patient is NOT concurrently using vaginal ring products (e.g., Annovera, Nuvaring)
  - The patient had a previous trial of or contraindication to two contraceptive agents (e.g., intrauterine device [Mirena, Kyleena, Liletta, Skyla, ParaGard], hormonal implant/injection/patch/oral products [Nexplanon, Depo-Provera, Xulane, etc.]

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #60 grams per 30 days.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **LACTIC ACID/CITRIC/POTASSIUM (Phexxi)** requires the following rule(s) be met for approval:

- You are a female patient with reproductive potential using the requested medication for prevention of pregnancy
- You are not using vaginal ring products (such as Annovera or Nuvaring) together with Phexxi
- You had a previous trial of two contraceptive agents (such as an intrauterine device, hormonal implant, injection, patch, or oral products), unless there is a medical reason you cannot (contraindication)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LACTIC ACID/CITRIC/POTASSIUM

GUIDELINES FOR USE (CONTINUED)

CONTRACEPTIVE ZERO COST SHARE OVERRIDE CRITERIA

3. Is the patient requesting a cost share exception for the requested contraceptive agent **AND** does the plan cover contraceptives at zero cost share (i.e., the plan follows Affordable Care Act [ACA] recommendations and is linked to MedImpact's Essential Health Benefit Tables)?

If yes, continue to #2.

If no, guideline does not apply.

4. Do **ANY** of the following criteria apply?

- The patient's plan has specific procedures, instructions, and/or policies for cost share exception processes or for multi-source brand agent overrides (DAW1 override)
- The request is for an agent with an excluded route of administration, such that the agent will be covered on the medical benefit

If yes, guideline does not apply.

If no, continue to #3.

5. Is the request for a generic agent?

If yes, **approve for 12 months by HICL or GPI-10 at zero copay.**

If no, continue to #4.

6. Is the request for **ONE** of the following?

- A single-source brand (SSB) contraceptive agent that has no preferred generic agents or therapeutically equivalent products available
- A multi-source brand (MSB) contraceptive agent

If yes, continue to #5.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LACTIC ACID/CITRIC/POTASSIUM

**GUIDELINES FOR USE - CONTRACEPTIVE ZERO COST SHARE OVERRIDE CRITERIA  
(CONTINUED)**

7. Does the patient meet **ONE** of the following criteria?

- Two preferred medications are medically inappropriate for the patient (alternatively, one if only one agent is available)
- The patient has tried or has a documented medical contraindication to two preferred medications (alternatively, a trial of one if only one agent is available)
- The prescriber provided documentation confirming that the requested drug is considered medically necessary (considerations may include severity of side effects, differences in permanence and reversibility of contraceptives, and ability to adhere to the appropriate use of the item or service)

If yes, **approve for 12 months by HICL or GPI-10 at zero copay.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **CONTRACEPTIVE ZERO COST SHARE OVERRIDE** requires that the following rules be met for approval:

A. The request is for **ONE** of the following:

1. A generic contraceptive agent
2. A single-source brand (SSB) contraceptive agent that has no preferred generic agents or therapeutically equivalent products available
3. A multi-source brand (MSB) contraceptive agent

B. **If the request is for a single-source brand or multi-source brand contraceptive medication, approval also requires ONE of the following:**

1. Two preferred medications are medically inappropriate for you (or one if only one agent is available)
2. You have tried or have a documented medical contraindication (harmful for) to two preferred medications (or one if only one agent is available)
3. Your doctor has provided documentation confirming that the requested drug is considered medically necessary for you (considerations may include severity of side effects, differences in durability and reversibility of contraceptive and ability to adhere to the appropriate use)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LACTIC ACID/CITRIC/POTASSIUM

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Phexxi.

The Contraceptive Zero Cost Share Override criteria applies to plans where the pharmacy benefit allows for coverage of contraceptives at zero copay. The override criteria allow patient access to all FDA-approved contraceptive methods at zero copay by waiving the applicable cost-sharing for branded or non-preferred branded contraceptives.

The MedImpact standard Zero Copay list currently offers coverage of all methods at zero cost share. The zero cost share list offers a variety of contraceptives. Covered methods (zero cost share) include 1) specified barrier contraceptives (condoms, diaphragms, cervical caps, and nonoxynol-9) 2) generic oral hormonal contraceptives under STC 0248, including generic emergency contraceptives and Ella 3) generic transdermal patch contraceptive (currently marketed by Mylan as Xulane) 4) Nuvaring vaginal ring 5) Intrauterine devices – levonorgestrel IUDs and copper IUDs 6) Depo-Provera injections, 7) Nexplanon implant devices, and 8) Intravaginal contraceptives. The majority of the contraceptives on the EHB Zero cost share list are generic agents, which promotes a cost-effective formulary. The healthcare.gov website (<https://www.healthcare.gov/coverage/birth-control-benefits/>) currently recommends: All approved contraceptive methods prescribed by a woman’s doctor are covered, including:

- Barrier methods (used during intercourse), like diaphragms and sponges
- Hormonal methods, like birth control pills and vaginal rings
- Implanted devices, like intrauterine devices (IUDs)
- Emergency contraception, like Plan B® and Ella®
- Sterilization procedures
- Patient education and counseling

**REFERENCES**

- Phexxi [Prescribing Information]. San Diego, CA: Evofem, Inc., February 2022.
- Birth control benefits; <https://www.healthcare.gov/coverage/birth-control-benefits/>
- [FAQS About Affordable Care Act Implementation Part 51; https://www.dol.gov/sites/dolgov/files/EBSA/about-ebsa/our-activities/resource-center/faqs/aca-part-51.pdf](https://www.dol.gov/sites/dolgov/files/EBSA/about-ebsa/our-activities/resource-center/faqs/aca-part-51.pdf)

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 09/01/22

Created: 08/20

Client Approval: 08/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LANADELUMAB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
LANADELUMAB-FLYO	TAKHZYRO	45177		GPI-10 (8584204020)	

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of hereditary angioedema (HAE) and meet **ALL** of the following criteria?
  - The patient is 2 years of age or older
  - Therapy is prescribed by or in consultation with an allergist, immunologist or hematologist
  - The patient's diagnosis of HAE is confirmed via documentation (e.g., chart note, lab result, diagnostic test result, etc.) of complement testing
  - Takhzyro is being used for prophylaxis against HAE attacks
  - The patient is NOT on concurrent treatment with alternative prophylactic agent for HAE (e.g., Cinryze, Haegarda, danazol, berotralstat)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4mL per 28 days.**

**Approval Text:** Prescriber may consider a dosing interval of every 4 weeks if the patient is well-controlled for more than six months.

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **LANADELUMAB (Takhzyro)** requires the following rule(s) be met for approval:

- A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
- B. You are 2 years of age or older
- C. Therapy is prescribed by or in consultation with an allergist, immunologist (allergy or immune system doctor) or hematologist (blood doctor)
- D. Your diagnosis is confirmed via documentation (such as chart note, lab result, diagnostic test result) of complement testing (a type of blood test)
- E. Takhzyro is being used for prevention of hereditary angioedema attacks
- F. You will NOT be using Takhzyro concurrently (at the same time) with an alternative preventive agent for HAE (such as Cinryze, Haegarda, danazol, berotralstat)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LANADELUMAB

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of hereditary angioedema (HAE) and meet **ALL** of the following criteria?
  - The patient has experienced improvement (i.e., reductions in attack frequency or attack severity) compared to baseline in HAE attacks
  - The patient is NOT on concurrent treatment with alternative prophylactic agent for HAE (e.g., Cinryze, Haegarda, danazol, berotralstat)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4mL per 28 days.**  
**APPROVAL TEXT:** Prescriber may consider a dosing interval of every 4 weeks if the patient is well-controlled for more than six months.

If no, do not approve.

**RENEWAL DENIAL TEXT:** **\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **LANADELUMAB (Takhzyro)** requires the following rule(s) be met for renewal:

- A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
- B. You have experienced improvement (reductions in attack frequency or attack severity) compared to baseline in hereditary angioedema attacks
- C. You will NOT be using Takhzyro concurrently (at the same time) with an alternative preventive agent for HAE (such as Cinryze, Haegarda, danazol, berotralstat)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**LANADELUMAB**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Takhzyro.

**REFERENCES**

- Takhzyro [Prescribing Information]. Lexington, MA: Dyax Corp.; February 2023.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 03/01/23

Created: 09/18

Client Approval: 02/23

P&T Approval: 04/23



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LAPATINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
LAPATINIB DITOSYLATE	TYKERB, LAPATINIB	34541		GPI-10 (2153302610)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of advanced or metastatic breast cancer and meet **ALL** of the following criteria?

- The patient's breast cancer is human epidermal growth factor receptor 2 (HER2) positive
- The requested medication will be used in combination with Xeloda (capecitabine)
- The patient has received prior therapy with Herceptin (trastuzumab), an anthracycline (e.g., daunorubicin, doxorubicin, epirubicin, idarubicin), AND a taxane (e.g., paclitaxel, docetaxel)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #5 per day.**

If no, continue to #2.

2. Does the patient have a diagnosis of metastatic breast cancer and meet **ALL** of the following criteria?

- The patient's breast cancer is human epidermal growth factor receptor 2 (HER2) positive
- The patient's tumor is hormone receptor-positive
- The requested medication will be used in combination with Femara (letrozole)
- The patient is a postmenopausal woman

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #6 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **LAPATINIB (Tykerb)** requires the following rule(s) be met for approval:

A. You have advanced or metastatic breast cancer (breast cancer that has progressed or has spread to other parts of your body)

B. Your breast cancer is human epidermal growth factor receptor 2 (HER2: gene/protein in breast cancer) positive

C. **If you have advanced or metastatic breast cancer, approval also requires:**

1. The requested medication will be used in combination with Xeloda (capecitabine)
2. You have previously received treatment with Herceptin (trastuzumab), an anthracycline (such as daunorubicin, doxorubicin, epirubicin, idarubicin), AND a taxane (such as paclitaxel, docetaxel)

D. **If you have metastatic breast cancer, approval also requires:**

1. Your tumor is hormone receptor-positive
2. The requested medication will be used in combination with Femara (letrozole)
3. You are a postmenopausal woman

***(Denial text continued on the next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LAPATINIB

GUIDELINES FOR USE (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Tykerb.

REFERENCES

- Tykerb [Package Insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; December 2018.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/10/21

Created: 04/10

Client Approval: 03/21

P&T Approval: 08/13





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LAROTRECTINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
LAROTRECTINIB	VITRAKVI	45494		GPI-10 (2153383520)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of a solid tumor and meet **ALL** of the following criteria?
  - The tumor has a neurotrophic receptor tyrosine kinase (*NTRK*) gene fusion without a known acquired resistance mutation
  - The tumor is metastatic or surgical resection is likely to result in severe morbidity
  - There are no satisfactory alternative treatments, or the patient has progressed following treatment

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Is the request for Vitrakvi oral capsules?

If yes, **approve for 12 months by GPID or GPI-14 for all strengths as follows:**

- **Vitrakvi 25mg: #6 capsules per day.**
- **Vitrakvi 100mg: #2 capsules per day.**

If no, continue to #3.

3. Is the request for Vitrakvi oral solution and the patient meets **ONE** of the following criteria?
  - The request is for a pediatric patient
  - The patient is unable to take Vitrakvi capsules due to difficulty swallowing or dysphagia
  - The patient has other medical need for the oral solution

If yes, **approve for 12 months by GPID or GPI-14 as follows:**

- **Vitrakvi 20mg/mL oral solution: #10mL per day.**

If no, do not approve Vitrakvi oral suspension. **Please enter a proactive PA for Vitrakvi capsules and approve for 12 months by GPID or GPI-14 for all strengths as follows:**

- **Vitrakvi 25mg: #6 capsules per day.**
- **Vitrakvi 100mg: #2 capsules per day.**

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LAROTRECTINIB

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **LAROTRECTINIB (Vitrakvi)** requires the following rule(s) be met for approval:

- A. You have a solid tumor (abnormal mass of tissue that usually does not contain cysts or liquid)
- B. Your tumor has a neurotrophic receptor tyrosine kinase (*NTRK*) gene fusion without a known acquired resistance mutation (you have a type of enzyme that doesn't have a mutation)
- C. Your tumor is metastatic (spreads to other parts of body) or surgical resection (removal) is likely to result in severe morbidity (illness)
- D. There are no satisfactory alternative treatments, or your tumor has gotten worse after treatment
- E. **Requests for Vitrakvi oral solution also require ONE of the following:**
  - 1. You are a pediatric patient (less than 18 years of age)
  - 2. You are unable to take Vitrakvi capsules due to difficulty swallowing (or dysphagia)
  - 3. You have other medical need for the oral solution

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Vitrakvi.

**REFERENCES**

- Vitrakvi [Prescribing Information]. Stamford, CT: Loxo Oncology, Inc: December 2018.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 03/19

Client Approval: 04/20

P&T Approval: 01/19



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LASMIDITAN

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
LASMIDITAN SUCCINATE	REYVOW	46082		GPI-10 (6740654060)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Is the request for the acute treatment of migraine and the patient meets **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient had a trial of or contraindication to **ONE** triptan (e.g., sumatriptan, rizatriptan)

If yes, **approve for 6 months for the requested strength by GPID OR GPI-14 as follows:**

- **50mg: #8 per 30 days.**
- **100mg: #8 per 30 days.**

**APPROVAL TEXT:** Renewal requires that the request is for acute treatment of migraines and the patient has experienced an improvement from baseline in a validated acute treatment patient-reported outcome questionnaire (e.g., Migraine Assessment of Current Therapy [Migraine-ACT]) OR the patient has experienced clinical improvement as defined by ONE of the following: 1) ability to function normally within 2 hours of dose, 2) headache pain disappears within 2 hours of dose, or 3) therapy works consistently in majority of migraine attacks.

If no, do not approve.

**INITIAL DENIAL TEXT:** **\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **LASMIDITAN (Reyvow)** requires the following rule(s) be met for approval:

- A. You are being treated for acute (quick onset) migraine
- B. You are 18 years of age or older
- C. You have previously tried ONE triptan (such as sumatriptan, rizatriptan), unless there is a medical reason why you cannot (contraindication)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON THE NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LASMIDITAN

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Is the request for the acute treatment of migraine and the patient meets **ONE** of the following criteria?
  - The patient has experienced an improvement from baseline in a validated acute treatment patient-reported outcome questionnaire (e.g., Migraine Assessment of Current Therapy [Migraine-ACT])
  - The patient has experienced clinical improvement as defined by **ONE** of the following:
    - Ability to function normally within 2 hours of dose
    - Headache pain disappears within 2 hours of dose
    - Therapy works consistently in majority of migraine attacks

If yes, **approve for 12 months for the requested strength by GPID or GPI-14 as follows:**

- **50mg: #8 per 30 days.**
- **100mg: #8 per 30 days.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **LASMIDITAN (Reyvow)** requires the following rule(s) be met for renewal:

- A. You are being treated for acute (quick onset) migraine
- B. You meet ONE of the following:
  1. You have experienced an improvement from baseline in a validated acute treatment patient-reported outcome questionnaire (assessment tool used to help guide treatment such as Migraine Assessment of Current Therapy [MIGRAINE-ACT])
  2. You have experienced clinical improvement as defined by ONE of the following:
    - a. Ability to function normally within 2 hours of dose
    - b. Headache pain disappears within 2 hours of dose
    - c. Treatment works consistently in majority of migraine attacks

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON THE NEX PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**LASMIDITAN**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Reyvow.

**REFERENCES**

- Reyvow [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC, January 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 12/12/20

Created: 02/20

Client Approval: 12/20

P&T Approval: 01/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

L-GLUTAMINE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
GLUTAMINE (L-GLUTAMINE)	ENDARI		13365	GPI-10 (8280102000)	FDB: BRAND ≠ NUTRESTORE

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of sickle cell disease (SCD) and meet **ALL** of the following criteria?

- The medication is prescribed by or given in consultation with a hematologist
- The patient had a trial of or contraindication to hydroxyurea

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Is the patient between the ages of 5 to 17 years old?

If yes, **approve for 12 months by GPID or GPI-10 with a quantity limit of #180 packets per 30 days.**

**Approval Text:** Renewal requires that the patient has maintained or experienced a reduction in acute complications of sickle-cell disease (SCD) (e.g., number of sickle cell crises, hospitalizations, ACS).

If no, continue to #3.

3. Is the patient 18 years of age or older and meets **ONE** of the following criteria?

- The patient had at least 2 sickle cell crises in the past year (A sickle cell crises is defined as a visit to an emergency room/medical facility for sickle cell disease-related pain which was treated with a parenterally administered narcotic or parenterally administered ketorolac, the occurrence of chest syndrome, priapism, or splenic sequestration)
- The patients is having sickle-cell associated symptoms (e.g., pain or anemia) which are interfering with activities of daily living
- The patients has a history of or has recurrent acute chest syndrome (ACS)

If yes, **approve for 12 months by GPID or GPI-10 with a quantity limit of #180 packets per 30 days.**

**Approval Text:** Renewal requires that the patient has maintained or experienced a reduction in acute complications of sickle-cell disease (SCD) (e.g., number of sickle cell crises, hospitalizations, ACS).

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

L-GLUTAMINE

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **L-GLUTAMINE (ENDARI)** requires the following rule(s) be met for approval:

- A. You have sickle cell disease (type of red blood cell disorder)
- B. You are 5 years of age or older
- C. The medication is prescribed by or given in consultation with a hematologist (blood doctor specialist)
- D. The patient had a trial of or contraindication to hydroxyurea
- E. **If you are 18 years of age or older, approval also requires ONE of the following:**
  1. You had at least 2 sickle cell crises in the past year (A sickle cell crises is defined as a visit to an emergency room/medical facility for sickle cell disease-related pain which was treated with a parenterally administered given into the vein, narcotic or parenterally administered ketorolac, the occurrence of chest syndrome, priapism (prolonged erection of penis), or splenic sequestration [suppressing of spleen])
  2. You are having sickle-cell associated symptoms such as pain or anemia (your blood doesn't have enough healthy red blood cells and you're tired) which are interfering with activities of daily living
  3. You have a history of or have recurrent acute chest syndrome (ACS: chest pain, cough, fever, low oxygen level)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of sickle cell disease **AND** meet the following criterion?
  - The patient has maintained or experienced a reduction in acute complications of sickle-cell disease (SCD) (e.g., number of sickle cell crises, hospitalizations, ACS)

If yes, **approve for lifetime by GPID or GPI-10 with a quantity limit of #180 packets per 30 days.**

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

L-GLUTAMINE

RENEWAL CRITERIA (CONTINUED)

**RENEWAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **L-GLUTAMINE (Endari)** requires the following rule(s) be met for renewal:

- A. You have sickle cell disease (type of red blood cell disorder)
- B. You have maintained or experienced a reduction in acute complications of sickle-cell disease such as number of sickle cell crises, hospitalizations, acute chest syndrome (ACS: chest pain, cough, fever, low oxygen level)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Endari

**REFERENCES**

- Endari [Prescribing Information]. Torrance, CA: Emmaus Medical, Inc. October 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/20

Created: 09/17

Client Approval: 02/20

P&T Approval: 01/20





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LEDIPASVIR/SOFOSBUVIR

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
LEDIPASVIR/ SOFOSBUVIR	HARVONI, LEDIPASVIR/ SOFOSBUVIR	41457		GPI-10 (1235990240)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of chronic hepatitis C with genotype 1, genotype 4, genotype 5, or genotype 6 and meet **ALL** of the following criteria?
  - The patient is 3 years of age or older
  - The patient has an HCV RNA level within the past 6 months

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient meet at least **ONE** of the following criteria?
  - The patient is currently taking any of the following medications: amiodarone, carbamazepine, phenytoin, phenobarbital, oxcarbazepine, rifampin, rifabutin, rifapentine, rosuvastatin, simeprevir, sofosbuvir (Sovaldi), elvitegravir/cobicistat/emtricitabine/tenofovir (Stribild), tipranavir/ritonavir, pibrentasvir/glecaprevir (Mavyret), velpatasvir/sofosbuvir (Epclusa), elbasvir/grazoprevir (Zepatier), or velpatasvir/sofosbuvir/voxilaprevir (Vosevi)
  - The patient has a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions (e.g., physician attestation)

If yes, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

If no, continue to #3.

3. Does the patient have decompensated cirrhosis?

If yes, continue to #13.

If no, continue to #4.

4. Does the patient meet **ALL** of the following criteria?
  - Treatment of genotype 1, genotype 4, genotype 5 or genotype 6
  - A liver transplant recipient
  - Without cirrhosis **OR** with compensated cirrhosis (Child-Pugh A)

If yes, continue to #16.

If no, continue to #5.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LEDIPASVIR/SOFOSBUVIR

**GUIDELINES FOR USE (CONTINUED)**

5. Is this request for treatment of genotype 4, 5, or 6?

If yes, continue to #6.

If no, continue to #7.

6. Is the request for Harvoni 45mg/200mg pellets and the patient meets the following criterion?

- The patient is unable to swallow tablets

If yes, **approve Harvoni 45mg/200mg pellets for 12 weeks by GPID or GPI-14 with a quantity limit of #2 per day.**

If no, **approve for 12 weeks by GPID or GPI-14 for the requested strength as follows:**

- **90mg/400mg tablet: #1 per day.**
- **45mg/200mg tablet: #1 per day.**
- **33.75mg/150mg pellets: #1 per day.**

7. Is the patient treatment naive?

If yes, continue to #8.

If no, continue to #11.

8. Does the patient have cirrhosis **OR** is this request for treatment of a pediatric patient?

If yes, continue to #9.

If no, continue to #10.

9. Is the request for Harvoni 45mg/200mg pellets and the patient meets the following criterion?

- The patient is unable to swallow tablets

If yes, **approve Harvoni 45mg/200mg pellets for 12 weeks by GPID or GPI-14 with a quantity limit of #2 per day.**

If no, **approve for 12 weeks by GPID or GPI-14 for the requested strength as follows:**

- **90mg/400mg tablet: #1 per day.**
- **45mg/200mg tablet: #1 per day.**
- **33.75mg/150mg pellets: #1 per day.**

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LEDIPASVIR/SOFOSBUVIR

**GUIDELINES FOR USE (CONTINUED)**

10. Does the patient meet **ALL** of the following criteria?

- Genotype 1 HCV infection
- No cirrhosis
- No HIV co-infection
- Pre-treatment HCV RNA level < 6 million IU/mL

If yes, **approve for 8 weeks by GPID or GPI-14 for the requested strength as follows:**

- **90/400 tablet: #1 per day.**
- **45/200 tablet: #1 per day.**
- **33.75/150 pellets: #1 per day.**
- **45/200 pellets: #2 per day: Only approve if patient is unable to swallow tablets.**

If no, **approve for 12 weeks by GPID or GPI-14 for the requested strength as follows:**

- **90/400 tablet: #1 per day.**
- **45/200 tablet: #1 per day.**
- **33.75/150 pellets: #1 per day.**
- **45/200 pellets: #2 per day: Only approve if patient is unable to swallow tablets.**

11. Has the patient received prior treatment (e.g., treatment-experienced patient) for hepatitis C with 1) peginterferon and ribavirin, or 2) triple therapy with HCV protease inhibitor, peginterferon and ribavirin, or 3) is the patient without cirrhosis with a prior non-NS5A inhibitor, sofosbuvir-containing regimen?

If yes, continue to #12.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LEDIPASVIR/SOFOSBUVIR

GUIDELINES FOR USE (CONTINUED)

12. Does the patient have cirrhosis?

If yes, approve for 24 weeks by GPID or GPI-14 for the requested strength as follows:

- 90/400 tablet: #1 per day.
- 45/200 tablet: #1 per day.
- 33.75/150 pellets: #1 per day.
- 45/200 pellets: #2 per day: Only approve if patient is unable to swallow tablets.

If no, approve for 12 weeks by GPID or GPI-14 for the requested strength as follows:

- 90/400 tablet: #1 per day.
- 45/200 tablet: #1 per day.
- 33.75/150 pellets: #1 per day.
- 45/200 pellets: #2 per day: Only approve if patient is unable to swallow tablets.

13. Does the patient have genotype 1, 4, 5 or 6 hepatitis C infection?

If yes, continue to #14.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

14. Is the requested medication being used with ribavirin?

If yes, continue to #15.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

15. Has the patient previously failed a Sovaldi (sofosbuvir)-containing regimen?

If yes, approve for 24 weeks by GPID or GPI-14 for the requested strength as follows:

- 90/400 tablet: #1 per day.
- 45/200 tablet: #1 per day.
- 33.75/150 pellets: #1 per day.
- 45/200 pellets: #2 per day: Only approve if patient is unable to swallow tablets.

If no, approve for 12 weeks by GPID or GPI-14 for the requested strength as follows:

- 90/400 tablet: #1 per day.
- 45/200 tablet: #1 per day.
- 33.75/150 pellets: #1 per day.
- 45/200 pellets: #2 per day: Only approve if patient is unable to swallow tablets.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LEDIPASVIR/SOFOSBUVIR

GUIDELINES FOR USE (CONTINUED)

16. Is the requested medication being used with ribavirin?

If yes, continue to #17.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

17. Is the request for Harvoni 45mg/200mg pellets and the patient meets the following criterion?

- The patient is unable to swallow tablets

If yes, **approve Harvoni 45mg/200mg pellets for 12 weeks by GPID or GPI-14 with a quantity limit of #2 per day.**

If no, **approve for 12 weeks by GPID or GPI-14 for the requested strength as follows:**

- **90mg/400mg tablet: #1 per day.**
- **45mg/200mg tablet: #1 per day.**
- **33.75mg/150mg pellets: #1 per day.**

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **LEDIPASVIR/SOFOSBUVIR (Harvoni)** requires the following rule(s) be met for approval:

- A. You have chronic hepatitis C (type of liver inflammation)
- B. You have genotype 1, genotype 4, genotype 5, or genotype 6 hepatitis C
- C. You are 3 years of age or older
- D. You have an HCV RNA level (amount of virus in your blood) within the past 6 months
- E. If you are treatment-experienced (previously treated) with no cirrhosis (liver damage) and genotype 1, previous treatment should include one of the following: 1) peginterferon and ribavirin, 2) triple therapy with HCV protease inhibitor (type of drug to treat hepatitis C), peginterferon and ribavirin, or 3) a prior non-NS5A inhibitor (type of drug to treat hepatitis C), sofosbuvir-containing regimen
- F. If you are treatment-experienced (previously treated) with compensated cirrhosis (no symptoms related to liver damage) and genotype 1, previous treatment should include either 1) peginterferon and ribavirin, or 2) triple therapy with HCV protease inhibitor (type of drug to treat hepatitis C), peginterferon and ribavirin
- G. **If you have decompensated cirrhosis (symptoms related to liver damage) or are post-liver transplant (without cirrhosis or with compensated cirrhosis), approval also requires:**
  1. You will be using a ribavirin-containing regimen
- H. **If the request is for Harvoni 45mg/200 mg pellets, approval also requires:**
  1. You are unable to swallow tablets

**(Denial text continued on next page)**

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LEDIPASVIR/SOFOSBUVIR

GUIDELINES FOR USE (CONTINUED)

**Harvoni will not be approved if you meet ANY of the following:**

- You are using any of the following medications concurrently (at the same time) while on Harvoni: amiodarone, carbamazepine, phenytoin, phenobarbital, oxcarbazepine, rifampin, rifabutin, rifapentine, rosuvastatin, simeprevir, sofosbuvir (Sovaldi), elvitegravir/cobicistat/emtricitabine/tenofovir (Stribild), tipranavir/ritonavir, pibrentasvir/glecaprevir (Mavyret), velpatasvir/sofosbuvir (Epclusa), elbasvir/grazoprevir (Zepatier), or velpatasvir/sofosbuvir/voxilaprevir (Vosevi)
- You have a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Harvoni (sofosbuvir/ledipasvir).

**REFERENCES**

- Guidance from the American Association for the Study of Liver Diseases (AASLD) and the Infectious Disease Society of America (IDSA) Recommendations for Testing, Managing, and Treating hepatitis C. Available online at <http://www.hcvguidelines.org/full-report-view> Accessed November 2019.
- Harvoni [Prescribing Information]. Foster City, CA: Gilead Sciences; March 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/23

Created: 11/14

Client Approval: 11/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LEFAMULIN

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
LEFAMULIN	XENLETA		46826	GPI-14 (16240040100320)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of community-acquired bacterial pneumonia (CABP) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Infection is caused by any of the following susceptible microorganisms: *Streptococcus pneumoniae*, *Staphylococcus aureus* (methicillin-susceptible isolates), *Haemophilus influenzae*, *Legionella pneumophila*, *Mycoplasma pneumoniae*, or *Chlamydomphila pneumoniae*

If yes, continue to #2.  
If no, do not approve.  
**DENIAL TEXT:** See the denial text at the end of the guideline.
2. Is therapy prescribed by or given in consultation with an Infectious Disease (ID) specialist?

If yes, **approve Xenleta 600mg tablet for one fill by GPID or GPI-14 with a quantity limit of #10 per 5 days.**  
If no, continue to #3.
3. Have antimicrobial susceptibility tests been performed that meet **ALL** of the following criteria?
  - The results from the infection site culture indicate pathogenic organism(s) with **resistance** to at least **TWO** standard of care agents for CABP (e.g., azithromycin, doxycycline, levofloxacin, moxifloxacin, amoxicillin, ceftriaxone, linezolid)
  - The results from the infection site culture indicate pathogenic organism(s) with susceptibility to Xenleta

If yes, **approve Xenleta 600mg tablet for one fill by GPID or GPI-14 with a quantity limit of #10 per 5 days.**  
If no, continue to #4.
4. Does the patient meet **ALL** of the following criteria?
  - Antimicrobial susceptibility results are unavailable
  - The patient has had a trial of or contraindication to at least **TWO** standard of care agents for CABP (e.g., azithromycin, doxycycline, levofloxacin, moxifloxacin, amoxicillin, ceftriaxone, linezolid)

If yes, **approve Xenleta 600mg tablet for one fill by GPID or GPI-14 with a quantity limit of #10 per 5 days.**  
If no, do not approve.  
**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LEFAMULIN

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **LEFAMULIN (Xenleta)** requires the following rule(s) be met for approval:

- A. You have community-acquired bacterial pneumonia (type of lung infection)
- B. You are 18 years of age or older
- C. The infection is caused by any of the following susceptible microorganisms (bacteria that the drug can kill): *Streptococcus pneumoniae*, *Staphylococcus aureus* (methicillin-susceptible isolates), *Haemophilus influenzae*, *Legionella pneumophila*, *Mycoplasma pneumoniae*, or *Chlamydia pneumoniae*
- D. You meet **ONE** of the following criteria:
  - 1. The requested medication is prescribed by or given in consultation with an Infectious Disease (ID) specialist
  - 2. Antimicrobial susceptibility test (lab test that shows what drugs may kill the bacteria) is available, and the infection site culture results indicate pathogenic (disease-causing) organism(s) with a) resistance to at least **TWO** standard of care agents for community-acquired bacterial pneumonia (such as azithromycin, doxycycline, levofloxacin, moxifloxacin, amoxicillin, ceftriaxone), **AND** b) susceptibility to Xenleta
  - 3. Antimicrobial susceptibility test (lab test that shows what drugs may kill the bacteria) is unavailable, and you had a trial of at least **TWO** standard of care agents (such as azithromycin, doxycycline, levofloxacin, moxifloxacin, amoxicillin, ceftriaxone, linezolid) for community-acquired bacterial pneumonia, unless there is a medical reason why you cannot (contraindication)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Xenleta.

**REFERENCES**

- Xenleta [Prescribing Information]. Ireland DAC: Nabriva Therapeutics US, Inc.; August 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 08/19

Client Approval: 04/20

P&T Approval: 07/19





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LENACAPAVIR

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
LENACAPAVIR SODIUM	SUNLENCA	48555		GPI-10 (1210155520)	

**GUIDELINES FOR USE**

- Does the patient have a diagnosis of human immunodeficiency virus type 1 (HIV-1) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient is treatment-experienced
  - The patient's HIV-1 is multidrug resistant and have failed current antiretroviral regimen due to resistance, intolerance, or safety considerations

If yes, **approve for 12 months by GPID or GPI-14 for all dosage forms as follows:**

- 300mg tablet: #5 per 6 months.**
- 463.5mg/1.5mL vial: #3 mL per 6 months. (Note: This is a non-self-administered [NSA] agent and may not be covered by some plans.)**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **LENACAPAVIR (Sunlenca)** requires the following rule(s) be met for approval:

- You have human immunodeficiency virus type 1 (HIV-1: a type of immune disorder)
- You are 18 years of age or older
- You are treatment-experienced
- You have a multidrug resistant (not responding to treatment) HIV-1 infection and failed your current antiretroviral regimen (HIV treatment) due to resistance, intolerance (side effects), or safety considerations

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**LENACAPAVIR**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Sunlenca.

**REFERENCES**

- Sunlenca [Prescribing Information]. Foster City, CA: Gilead Sciences, Inc., December 2022.

Library	Commercial	NSA
Yes	Yes	Yes

Part D Effective: N/A

Commercial Effective: 01/16/23

Created: 01/23

Client Approval: 01/23

P&T Approval: 01/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LENALIDOMIDE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
LENALIDOMIDE	REVLIMID, LENALIDOMIDE	33412		GPI-10 (9939405000)	

**GUIDELINES FOR USE**

1. Is the patient 18 years of age or older?

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient have a diagnosis of multiple myeloma (MM)?

If yes, continue to #3.

If no, continue to #5.

3. Will Revlimid (lenalidomide) be used as induction treatment for multiple myeloma (MM)?

If yes, **approve for 12 months by HICL or GPI-10 for #21 every 28 days.**

If no, continue to #4.

4. Will Revlimid (lenalidomide) be used as maintenance treatment for multiple myeloma (MM)?

If yes, **approve for 12 months by HICL or GPI-10 for #1 per day.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

5. Does the patient have a diagnosis of anemia due to a myelodysplastic syndrome (MDS) **AND** meet the following criterion?

- The patient's myelodysplastic syndrome (MDS) is associated with a deletion 5q abnormality

If yes, **approve for 12 months by HICL or GPI-10 for #1 per day.**

If no, continue to #6.

6. Does the patient have a diagnosis of mantle cell lymphoma (MCL) **AND** meet the following criterion?

- The patient has relapsed or progressed after two prior therapies, one of which included Velcade (bortezomib)

If yes, **approve for 12 months by HICL or GPI-10 for #21 per 28 days.**

If no, continue to #7.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LENALIDOMIDE

GUIDELINES FOR USE (CONTINUED)

7. Does the patient have a diagnosis of follicular lymphoma (FL) and meet **ALL** of the following criteria?

- The patient has previously been treated for follicular lymphoma (FL)
- The requested medication is being taken in combination with a rituximab product

If yes, **approve for 12 months by HICL or GPI-10 for #21 per 28 days for 12 fills.**  
If no, continue to #8.

8. Does the patient have a diagnosis of marginal zone lymphoma (MZL) and meet **ALL** the following criterion?

- The patient has previously been treated for marginal zone lymphoma (MZL)
- The requested medication is being taken in combination with a rituximab product

If yes, **approve for 12 months by HICL or GPI-10 for #21 per 28 days for 12 fills.**  
If no, do not approve.

**DENIAL TEXT: Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **LENALIDOMIDE (Revlimid)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
1. Multiple myeloma (a type of blood cancer)
  2. Anemia due to a myelodysplastic syndrome (a type of blood cancer)
  3. Mantle cell lymphoma (a type of blood cell)
  4. Follicular lymphoma (a type of blood cancer)
  5. Marginal zone lymphoma (a type of blood cancer)
- B. You are 18 years of age or older
- C. **If you have anemia due to a myelodysplastic syndrome, approval also requires:**
1. You have a deletion 5q (type of gene) abnormality
- D. **If you have mantle cell lymphoma, approval also requires:**
1. You have relapsed or progressed (disease has returned or worsened) after two prior therapies, one of which included Velcade (bortezomib) (Note: Velcade may be covered under the medical benefit and/or require prior authorization).
- E. **If you have follicular lymphoma, approval also requires:**
1. You have previously been treated for follicular lymphoma
  2. The requested medication is being taken in combination with a rituximab product (type of cancer drug)

***(Denial text continued on next page)***

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LENALIDOMIDE

GUIDELINES FOR USE (CONTINUED)

F. If you have marginal zone lymphoma, approval also requires:

1. You have previously been treated for marginal zone lymphoma
2. The requested medication is being taken in combination with a rituximab product

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Revlimid.

REFERENCES

- Revlimid [Prescribing Information]. Summit, NJ: Celgene Corporation; August 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/22

Created: 08/12

Client Approval: 03/22

P&T Approval: 07/19



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LENVATINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
LENVATINIB MESYLATE	LENVIMA	41756		GPI-10 (2133505420)	

**GUIDELINES FOR USE**

- 1 Does the patient have a diagnosis of differentiated thyroid cancer (DTC) and meet **ALL** of the following criteria; (**NOTE:** Differentiated thyroid cancer (DTC) can be classified as papillary (PTC), follicular (FTC), or Hurthle cell)?
- The thyroid cancer is locally recurrent or metastatic
  - The thyroid cancer is progressive
  - The thyroid cancer is refractory to radioactive iodine therapy

If yes, **approve for 12 months by GPID or GPI-14 based on the following daily dose requirements:**

- For a daily dose of 10mg, approve for 30 blisters per 30 days.
- For a daily dose of 14mg, approve for 60 blisters per 30 days.
- For a daily dose of 20mg, approve for 60 blisters per 30 days.
- For a daily dose of 24mg, approve for 90 blisters per 30 days.

If no, continue to #2.

- 2 Does the patient have a diagnosis of advanced renal cell cancer (RCC) and meet **ALL** of the following criteria?
- The patient is 18 years of age or older
  - Lenvima will be used as a first-line treatment
  - Lenvima will be used in combination with pembrolizumab (Keytruda)

If yes, **approve for 12 months by GPID or GPI-14 based on the following daily dose requirements:**

- For a daily dose of 8mg, approve for 60 blisters per 30 days.
- For a daily dose of 10mg, approve for 30 blisters per 30 days.
- For a daily dose of 14mg, approve for 60 blisters per 30 days.
- For a daily dose of 20mg, approve for 60 blisters per 30 days.

If no, continue to #3.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LENVATINIB

**GUIDELINES FOR USE (CONTINUED)**

3 Does the patient have a diagnosis of advanced renal cell cancer (RCC) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- Lenvima will be used in combination with everolimus
- The patient has tried one anti-angiogenic therapy (e.g., Sutent [sunitinib], Votrient [pazopanib], Inlyta [axitinib], Nexavar [sorafenib])

If yes, **approve for 12 months by GPID or GPI-14 based on the following daily dose requirements:**

- **For a daily dose of 8mg, approve for 60 blisters per 30 days.**
- **For a daily dose of 10mg, approve for 30 blisters per 30 days.**
- **For a daily dose of 14mg, approve for 60 blisters per 30 days.**
- **For a daily dose of 18mg, approve for 90 blisters per 30 days.**

If no, continue to #4.

4 Does the patient have a diagnosis of unresectable hepatocellular carcinoma (HCC) **AND** meet the following criterion?

- Lenvima is being used as a first-line treatment

If yes, **approve for 12 months by GPID or GPI-14 based on the following daily dose requirements:**

- **For a dose of 4mg every other day, approve for 15 blisters per 30 days.**
- **For a daily dose of 4mg, approve for 30 blisters per 30 days.**
- **For a daily dose of 8mg, approve for 60 blisters per 30 days.**
- **For a daily dose of 12mg, approve for 90 blisters per 30 days.**

If no, continue to #5.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LENVATINIB

GUIDELINES FOR USE (CONTINUED)

5 Does the patient have a diagnosis of advanced endometrial carcinoma (EC) and meet **ALL** of the following criteria?

- Lenvima is used in combination with pembrolizumab (Keytruda)
- The patient does not have microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) biomarkers
- The patient has experienced disease progression following prior systemic therapy
- The patient is not a candidate for curative surgery or radiation

If yes, **approve for 12 months by GPID or GPI-14 based on the following daily dose requirements:**

- For a daily dose of 8mg, approve for 60 blisters per 30 days.
- For a daily dose of 10mg, approve for 30 blisters per 30 days.
- For a daily dose of 14mg, approve for 60 blisters per 30 days.
- For a daily dose of 20mg, approve for 60 blisters per 30 days.

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **LENVATINIB (Lenvima)** requires the following rule(s) be met for approval:

A. You have **ONE** of the following diagnoses:

1. Differentiated thyroid cancer (DTC: cancer cells look/act like normal thyroid cells)
2. Advanced renal cell cancer (RCC: kidney cancer)
3. Unresectable hepatocellular carcinoma (HCC: liver cancer that cannot be removed by surgery)
4. Advanced endometrial carcinoma (EC: type of cancer that starts in the uterus)

B. **If you have differentiated thyroid cancer (DTC), approval also requires:**

1. Your thyroid cancer is locally recurrent or metastatic (cancer that has spread to other parts of the body)
2. Your thyroid cancer is progressive (getting worse)
3. Your thyroid cancer is refractory (has not responded) to radioactive iodine therapy

***(Denial text continued on next page)***

CONTINUED ON NEXT PAGE





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LENVATINIB

GUIDELINES FOR USE (CONTINUED)

- C. **If you have advanced renal cell cancer (RCC), approval also requires:**
  - 1. You are 18 years of age or older
  - 2. You meet ONE of the following:
    - a. Lenvima will be used as first-line treatment in combination with pembrolizumab (Keytruda)
    - b. Lenvima is used in combination with everolimus AND you have tried one prior anti-angiogenic therapy (treatment that stop tumors from growing their own blood vessels, such as Sutent [sunitinib], Votrient [pazopanib], Inlyta [axitinib], Nexavar [sorafenib])
- D. **If you have unresectable hepatocellular carcinoma (HCC), approval also requires:**
  - 1. Lenvima is being used as a first-line treatment
- E. **If you have advanced endometrial carcinoma (EC), approval also requires:**
  - 1. Lenvima is used in combination with pembrolizumab (Keytruda)
  - 2. You do not have microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) biomarkers (characteristics that help determine what type of cancer you have and what treatment options there are for it)
  - 3. You have experienced disease progression following prior systemic therapy (disease has worsened after previous therapy)
  - 4. You are not a candidate for curative surgery or radiation

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Lenvima.

**REFERENCES**

- Lenvima [Prescribing Information]. Woodcliff Lake, NJ: Eisai, Inc. December 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/22

Created: 2/15

Client Approval: 03/22

P&T Approval: 10/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LETERMOVIR PO

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
LETERMOVIR	PREVYMIS		44049 44061	GPI-14 (12200045000320, 12200045000340)	

**GUIDELINES FOR USE**

1. Is the request for prophylaxis of cytomegalovirus (CMV) infection and disease and the patient meets **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient is a CMV-seropositive recipient [R+] of an allogeneic hematopoietic stem cell transplant (HSCT)
- Prevyomis will be initiated between Day 0 and Day 28 post-transplantation (before or after engraftment)
- Patient is not receiving the medication beyond 100 days post-transplantation

If yes, **approve for 98 days (14 weeks) by GPID or GPI-14 for all daily dosage strengths with the following quantity limits:**

- **240mg tablets: #1 per day.**
- **480mg tablets: #1 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **LETERMOVIR PO (Prevymis)** requires the following rule(s) be met for approval:

- A. Prevymis will be used for prophylaxis (prevention) of cytomegalovirus infection (a type of viral infection) and disease
- B. You are 18 years of age or older
- C. You are a CMV (*cytomegalovirus*)-seropositive recipient [R+] of an allogeneic hematopoietic stem cell transplant (you have cells transplanted from a matching donor)
- D. Prevymis will be started between Day 0 and Day 28 post-transplantation (before or after engraftment)
- E. You are not receiving the medication beyond 100 days post-transplantation

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**LETERMOVIR PO**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Prevymsis.

**REFERENCES**

- Prevymsis [Prescribing Information]. Merck & Co, Inc.; Whitehouse Station, NJ. March 2020

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 09/12/22

Created: 02/18

Client Approval: 08/22

P&T Approval: 01/18



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LEUPROLIDE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
LEUPROLIDE ACETATE	LEUPROLIDE ACETATE		84597	GPI-14 (21405010106407)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Is the requested medication being used for gender dysphoria?

If yes, **approve for 12 months by HICL or GPI-10 and override quantity limits.**  
If no, continue to #2.

2. Does the patient have a diagnosis of advanced prostate cancer?

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #2 kits per 28 days.**  
If no, continue to #3.

3. Is the request for a female patient who has a diagnosis of central precocious puberty (CPP) and meets **ALL** of the following criteria?

- The patient is 2 years of age or older
- Therapy is prescribed by or in consultation with a pediatric endocrinologist
- The patient has elevated levels of follicle-stimulating hormone (FSH) (level >4.0 mIU/mL) and luteinizing hormone (LH) (level > 0.2 to 0.3 mIU/mL) at diagnosis
- The patient is younger than 8 years of age at the onset of CPP
- There is documentation of pubertal staging using the Tanner scale for breast development (stage 2 or above) AND pubic hair growth (stage 2 or above)

If yes, **approve for 12 months by GPID or GPI-14.**  
If no, continue to #4.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LEUPROLIDE

INITIAL CRITERIA (CONTINUED)

4. Is the request for a male patient who has a diagnosis of central precocious puberty (CPP) and meets **ALL** of the following criteria?
- The patient is 2 years of age or older
  - Therapy is prescribed by or in consultation with a pediatric endocrinologist
  - The patient has elevated levels of follicle-stimulating hormone (FSH) (level >5.0 mIU/mL) and luteinizing hormone (LH) (level > 0.2 to 0.3 mIU/mL) at diagnosis
  - The patient is younger than 9 years of age at the onset of CPP
  - There is documentation of pubertal staging using the Tanner scale for genital development (stage 2 or above) AND pubic hair growth (stage 2 or above)

If yes, **approve for 12 months by GPID or GPI-14.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **LEUPROLIDE** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
1. Gender dysphoria (your gender identity conflicts with your sex assigned at birth)
  2. Advanced prostate cancer (prostate cancer that has spread to nearby tissue or organs)
  3. Central precocious puberty (CPP: early sexual development in girls and boys)
- B. **If you are female and have central precocious puberty, approval also requires:**
1. You are 2 years of age or older
  2. Therapy is prescribed by or in consultation with a pediatric endocrinologist (hormone doctor)
  3. You have high levels of follicle-stimulating hormone (FSH) (level greater than 4.0 mIU/mL) and luteinizing hormone (LH) (level greater than 0.2 to 0.3 mIU/mL) at diagnosis
  4. You are/were younger than 8 years of age when your condition started
  5. There is documentation of pubertal staging using the Tanner scale (scale of physical measurements of development based on external sex characteristics) for breast development (stage 2 or above) AND pubic hair growth (stage 2 or above)
- C. **If you are male and have central precocious puberty, approval also requires:**
1. You are 2 years of age or older
  2. Therapy is prescribed by or in consultation with a pediatric endocrinologist (hormone doctor)
  3. You have high levels of follicle-stimulating hormone (FSH) (level greater than 5.0 mIU/mL) and luteinizing hormone (LH) (level greater than 0.2 to 0.3 mIU/mL) at diagnosis
  4. You are/were younger than 9 years of age when your condition started  
**(Initial denial text continued on next page)**

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LEUPROLIDE

INITIAL CRITERIA (CONTINUED)

5. There is documentation of pubertal staging using the Tanner scale (scale of physical measurements of development based on external sex characteristics) for genital development (stage 2 or above) AND pubic hair growth (stage 2 or above)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

**NOTE:** For the diagnoses of gender dysphoria or advanced prostate cancer, please refer to the Initial Criteria section.

1. Does the patient have a diagnosis of central precocious puberty (CPP) and meet **ALL** of the following criteria?
  - The Tanner scale staging at initial diagnosis of CPP has stabilized or regressed during three separate medical visits in the previous year
  - The patient has not reached the actual age which corresponds to their current pubertal age

If yes, **approve for 12 months by GPID or GPI-14.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **LEUPROLIDE** requires the following rule(s) be met for renewal:

- A. You have central precocious puberty (CPP: early sexual development in girls and boys)
- B. Your Tanner scale staging (scale of physical measurements of development based on external sex characteristics) at initial diagnosis of CPP has stabilized or regressed (lowered) during three separate medical visits in the previous year
- C. You have not reached the actual age which corresponds to your current pubertal age

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**LEUPROLIDE**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Leuprolide.

**REFERENCES**

- Leuprolide acetate [Prescribing Information]. Princeton, NJ: Sandoz Inc.; Aug 2017.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/23/23

Created: 09/18

Client Approval: 01/23

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LEUPROLIDE-ELIGARD

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
LEUPROLIDE ACETATE	ELIGARD		17377 18155 19219 24301	GPI-14 (21405010106415, (21405010156432, (21405010206435, (21405010256445)	

**GUIDELINES FOR USE**

1. Is the requested medication being used for gender dysphoria?

If yes, **approve for 12 months by HICL or GPI-10 and override quantity limits.**  
If no, continue to #2.

2. Does the patient have a diagnosis of advanced prostate cancer?

If yes, **approve the requested strength for 12 months by GPID or GPI-14 with the following quantity limits:**

- **7.5mg: #1 per month.**
- **22.5mg: #1 per 3 months.**
- **30mg: #1 per 4 months.**
- **45mg: #1 per 6 months.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **LEUPROLIDE-ELIGARD** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:

1. Gender dysphoria (your gender identity conflicts with your sex assigned at birth)
2. Advanced prostate cancer (prostate cancer that has spread to nearby tissue or organs)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**





**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**LEUPROLIDE-ELIGARD**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Eligard.

**REFERENCES**

- Eligard [Prescribing Information]. Fort Collins, CO: Tolmar Pharmaceuticals, Inc.; April 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/23/23

Created: 09/18

Client Approval: 01/23

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LEVAMLODIPINE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
LEVAMLODIPINE MALEATE	CONJUPRI, LEVAMLODIPINE MALEATE	46284		GPI-10 (3400006728)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of hypertension and meet **ALL** of the following criteria?
  - The patient is 6 years of age or older
  - The patient had a trial of or contraindication to TWO generic dihydropyridine calcium channel blockers (e.g., amlodipine, felodipine, nicardipine)
  - The patient had a trial of or contraindication to TWO other antihypertensive agents in another class (e.g., hydrochlorothiazide, lisinopril, losartan)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **LEVAMLODIPINE (Conjupri)** requires the following rule(s) be met for approval:

- A. You have hypertension (high blood pressure)
- B. You are 6 years of age or older
- C. You have tried or have a contraindication (harmful for) to TWO generic dihydropyridine calcium channel blockers (such as amlodipine, felodipine, nicardipine)
- D. You have tried or have a contraindication (harmful for) to TWO other antihypertensive agents in another class (such as hydrochlorothiazide, lisinopril, losartan)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Conjupri.

**REFERENCES**

- Conjupri [Prescribing Information]. Hong Kong: CSPC Ouyi Pharmaceutical Co., Ltd.; December 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 06/01/22

Created: 10/20

Client Approval: 05/22

P&T Approval: 10/20

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LEVETIRACETAM

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
LEVETIRACETAM	SPRITAM		36266 31202 36046 36265	GPI-14 (7260004300G850 7260004300G820 7260004300G830 7260004300G840)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of partial-onset seizures and meet **ALL** of the following criteria?

- The patient is 4 years of age or older
- The patient is unable to swallow levetiracetam tablets
- The patient had a trial of levetiracetam oral solution

If yes, **approve for 12 months by GPID or GPI-14 for all strengths as follows:**

- **250mg: #4 per day.**
- **500mg: #4 per day.**
- **750mg: #4 per day.**
- **1000mg: #2 per day.**

If no, continue to #2.

2. Does the patient have a diagnosis of myoclonic seizures in juvenile myoclonic epilepsy and meet **ALL** of the following criteria?

- The patient is 12 years of age or older
- Spritam will be used as adjunctive therapy
- The patient is unable to swallow levetiracetam tablets
- The patient had a trial of levetiracetam oral solution

If yes, **approve for 12 months by GPID or GPI-14 for all strengths as follows:**

- **250mg: #4 per day**
- **500mg: #4 per day**
- **750mg: #4 per day**
- **1000mg: #2 per day**

If no, continue to #3.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LEVETIRACETAM

GUIDELINES FOR USE (CONTINUED)

3. Does the patient have a diagnosis of primary generalized tonic-clonic seizures and meet **ALL** of the following criteria?

- The patient is 6 years of age or older
- Spritam will be used as adjunctive therapy
- The patient is unable to swallow levetiracetam tablets
- The patient had a trial of levetiracetam oral solution

If yes, **approve for 12 months by GPID or GPI-14 for all strengths as follows:**

- **250mg: #4 per day.**
- **500mg: #4 per day.**
- **750mg: #4 per day.**
- **1000mg: #2 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **LEVETIRACETAM (Spritam)** requires the following rules be met for approval:

- A. You have **ONE** of the following diagnoses:
1. Partial-onset seizures (type of seizure)
  2. Myoclonic seizures in juvenile myoclonic epilepsy (type of seizure in childhood)
  3. Primary generalized tonic-clonic seizures (type of seizure)
- B. **If you have partial-onset seizures, approval also requires:**
1. You are 4 years of age or older
  2. You are unable to swallow levetiracetam tablets
  3. You had a trial of levetiracetam oral solution
- C. **If you have myoclonic seizures in juvenile myoclonic epilepsy, approval also requires:**
1. You are 12 years of age or older
  2. Spritam will be used as adjunctive (add-on) therapy
  3. You are unable to swallow levetiracetam tablets
  4. You had a trial of levetiracetam oral solution
- D. **If you have primary generalized tonic-clonic seizures, approval also requires:**
1. You are 6 years of age or older
  2. Spritam will be used as adjunctive (add-on) therapy
  3. You are unable to swallow levetiracetam tablets
  4. You had a trial of levetiracetam oral solution

***(Denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LEVETIRACETAM

**GUIDELINES FOR USE (CONTINUED)**

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Spritam.

**REFERENCES**

- Spritam [Prescribing Information]. Blue Ash, OH: Aprecia Pharmaceuticals LLC; January 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/23

Created: 11/22

Client Approval: 02/23

P&T Approval: 10/22



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**LEVODOPA**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
LEVODOPA	INBRIJA	01897		GPI-10 (73200040000)	ROUTE = INHALATION

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

- Does the patient have a diagnosis of Parkinson's disease and meet **ALL** of the following criteria?
  - Inbrija is being used for intermittent treatment of OFF episodes associated with Parkinson's disease
  - The patient is currently being treated with carbidopa/levodopa
  - Therapy is prescribed by or given in consultation with a neurologist
  - The patient is **NOT** currently taking more than 1600mg of levodopa per day
  - The physician has optimized drug therapy as evidenced by **BOTH** of the following:
    - Change in levodopa/carbidopa dosing strategy or formulation
    - Trial of or contraindication to at least **TWO** Parkinson's disease agents from **TWO** different classes of the following: dopamine agonist (e.g., ropinirole, pramipexole, rotigotine), monoamine oxidase-inhibitors (MAO-I) (e.g., selegiline, rasagiline), catechol-o-methyl transferase (COMT) inhibitors (e.g., entacapone, tolcapone), adenosine receptor antagonist A2A (e.g., istradefylline)

If yes, **approve for 6 months by GPID or GPI-14 with a quantity limit of #10 capsules per day.**

**APPROVAL TEXT:** Renewal requires that the patient has experienced improvement with motor fluctuations during OFF episodes with the use of Inbrija (e.g., improvement in speech, facial expression, tremor at rest, action or postural tremor of hands, rigidity, finger taps, hand movements, rapid alternating movements of hands, posture, leg agility, arising from chair)

If no, do not approve.

**INITIAL DENIAL TEXT: *\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.***

Our guideline named **LEVODOPA INHALATION (Inbrija)** requires the following rule(s) be met for approval:

- You have Parkinson's disease (a nerve system disorder that affects movement)
- Inbrija is being used for intermittent treatment of OFF episodes (times when you have symptoms return due to medication wearing off) associated with Parkinson's disease
- You are currently being treated with carbidopa/levodopa
- The requested medication is prescribed by or given in consultation with a neurologist (nerve doctor)

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LEVODOPA

INITIAL CRITERIA (CONTINUED)

- E. You are **NOT** currently taking more than 1600mg of levodopa per day
- F. Your doctor has optimized drug therapy as evidenced by **BOTH** of the following:
  - 1. Change in levodopa/carbidopa dosing strategy or formulation
  - 2. Trial of or contraindication to (medical reason why you cannot use) at least **TWO** Parkinson's agents from **TWO** different classes of the following: dopamine agonist (such as ropinirole, pramipexole, rotigotine), monoamine oxidase-inhibitors (MAO-I) (such as selegiline, rasagiline), catechol-O-methyl transferase (COMT) inhibitors (such as entacapone, tolcapone), adenosine receptor antagonist A<sub>2A</sub> (such as istradefylline)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

- 1. Does the patient have a diagnosis of Parkinson's disease **AND** meet the following criterion?
  - The patient had improvement with motor fluctuations during OFF episodes with the use of Inbrija (e.g., improvement in speech, facial expression, tremor at rest, action or postural tremor of hands, rigidity, finger taps, hand movements, rapid alternating movements of hands, posture, leg agility, arising from chair)

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #10 capsules per day.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **LEVODOPA INHALATION (Inbrija)** requires the following rule(s) be met for renewal approval:

- A. You have Parkinson's disease (a nerve system disorder that affects movement)
- B. You had improvement with motor fluctuations during OFF episodes (times when you have symptoms return due to medication wearing off) with the use of Inbrija. Improvements can be in speech, facial expression, tremor at rest, action or postural tremor of hands, rigidity, finger taps, hand movements, rapid alternating movements of hands, posture, leg agility, arising from chair.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**LEVODOPA**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Inbrija.

**REFERENCES**

- Inbrija [Prescribing Information]. Ardsley, NY: Acorda Therapeutics, Inc., September 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 05/19

Client Approval: 04/20

P&T Approval: 10/19





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LEVOKETOCONAZOLE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
LEVOKETOCONAZOLE	RECORLEV	47743		GPI-10 (3002204000)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of Cushing's syndrome and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with an endocrinologist
  - The patient is not a candidate for surgery or surgery has not been curative
  - The patient has tried or has a contraindication to oral ketoconazole

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #8 per day.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **LEVOKETOCONAZOLE (Recorlev)** requires the following rule(s) be met for approval:

- A. You have Cushing's syndrome (a type of hormone disorder)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with an endocrinologist (a type of hormone doctor)
- D. You are not a candidate for surgery or surgery has not been curative
- E. You have tried or have a contraindication (harmful for) to oral ketoconazole

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LEVOKETOCONAZOLE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

- Does the patient have a diagnosis of Cushing's syndrome and meet **ALL** of the following criteria?
  - The patient continues to have improvement of Cushing's syndrome (e.g., clinically meaningful reduction in 24-hour urinary free cortisol and/or improvements in signs and symptoms of disease)
  - The patient maintains tolerability to Recorlev

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #8 per day.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **LEVOKETOCONAZOLE (Recorlev)** requires the following rule(s) be met for renewal:

- You have Cushing's syndrome (a type of hormone disorder)
- You continue to have improvement of Cushing's syndrome (such as clinically meaningful reduction in 24-hour urinary free cortisol and/or improvements in signs and symptoms of your disease)
- You continue to tolerate treatment with Recorlev

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Recorlev.

**REFERENCES**

- Recorlev [Prescribing Information]. Chicago, IL: Xeris Pharmaceuticals, Inc.; January 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 02/01/22

Created: 01/22

Client Approval: 01/22

P&T Approval: 01/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LEVOTHYROXINE-ERMEZA

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
LEVOTHYROXINE SODIUM	ERMEZA		52325	GPI-14 (28100010102024)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of congenital or acquired hypothyroidism?

If yes, continue to #3.

If no, continue to #2.

2. Does the patient have a diagnosis of thyrotropin-dependent well-differentiated thyroid cancer **AND** meet the following criterion?

- The requested medication will be used as an adjunct to surgery and radioiodine therapy

If yes, continue to #3.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

3. Does the patient meet **ALL** of the following criteria?

- The patient had a trial and failure of Thyquidity
- The patient had a trial and failure of generic levothyroxine tablets
- The patient is unable to swallow levothyroxine tablets or capsules

If yes, **approve for 12 months by GPID or GPI-14.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **LEVOTHYROXINE-ERMEZA** requires the following rule(s) be met for approval:

A. You have **ONE** of the following diagnoses:

1. Congenital (present from birth) or acquired hypothyroidism (low thyroid function)
2. Thyrotropin (a type of thyroid hormone)-dependent well-differentiated thyroid cancer

B. You had a trial and failure (drug did not work) of Thyquidity

C. You had a trial and failure (drug did not work) of generic levothyroxine tablets

D. You are unable to swallow levothyroxine tablets or capsules

E. **If you have thyrotropin-dependent well-differentiated thyroid cancer, approval also requires:**

1. The requested medication will be used as an adjunct (add-on) to surgery and radioiodine therapy (a type of radiation therapy)

**(Denial text continued on next page)**

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LEVOTHYROXINE-ERMEZA

**GUIDELINES FOR USE (CONTINUED)**

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Ermeza.

**REFERENCES**

- Ermeza [Prescribing Information]. Morgantown, WV: Mylan Specialty L.P.; April 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/23

Created: 02/23

Client Approval: 02/23

P&T Approval: 01/23



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LEVOTHYROXINE-TIROSINT

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
LEVOTHYROXINE SODIUM	TIROSINT, LEVOTHYROXINE	02849		GPI-10 (2810001010)	FORM = CAPSULE

**GUIDELINES FOR USE**

1 Does the patient have a diagnosis of congenital or acquired hypothyroidism?

If yes, continue to #3.

If no, continue to #2.

2 Does the patient have a diagnosis of thyrotropin-dependent well-differentiated thyroid cancer **AND** meet the following criterion?

- The requested medication is being used as an adjunct to surgery and radioiodine therapy

If yes, continue to #3.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

3 Does the patient meet **ALL** of the following criteria?

- The patient is 6 years of age or older
- The patient had a trial and failure of generic levothyroxine tablets
- There is documentation of rationale for not using generic levothyroxine tablets

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #2 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **LEVOTHYROXINE-TIROSINT** requires the following rule(s) be met for approval:

A. You have **ONE** of the following diagnoses:

1. Congenital (present from birth) or acquired hypothyroidism (low thyroid function)
2. Thyrotropin (a type of thyroid hormone)-dependent well-differentiated thyroid cancer

B. You are 6 years of age or older

C. You had a trial and failure (drug did not work) of generic levothyroxine tablets

D. There is documentation of rationale (reason) for not using generic levothyroxine tablets

E. **If you have thyrotropin-dependent well-differentiated thyroid cancer, approval also requires:**

1. The requested medication will be used as an adjunct (add-on) to surgery and radioiodine therapy (a type of radiation therapy)

**(Denial text continued on next page)**

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LEVOTHYROXINE-TIROSINT

**GUIDELINES FOR USE (CONTINUED)**

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Tirosint.

**REFERENCES**

- Tirosint [Prescribing Information]. Pambio-Noranco, Switzerland: IBSA Institut Biochimique SA; June 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/23

Created: 07/21

Client Approval: 12/22

P&T Approval: 10/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LEVOTHYROXINE-TIROSINT-SOL

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
LEVOTHYROXINE SODIUM	TIROSINT-SOL	02849		GPI-10 (2810001010)	BRAND = TIROSINT-SOL

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of congenital or acquired hypothyroidism?

If yes, continue to #3.

If no, continue to #2.

4. Does the patient have a diagnosis of thyrotropin-dependent well-differentiated thyroid cancer **AND** meet the following criterion?

- The requested medication is being used as an adjunct to surgery and radioiodine therapy

If yes, continue to #3.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

5. Does the patient meet **ALL** of the following criteria?

- The patient had a trial and failure of Thyquidity
- The patient had a trial and failure of or contraindication to generic levothyroxine tablets
- There is documentation of rationale for not using Thyquidity and generic levothyroxine tablets

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #2mL per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **LEVOTHYROXINE-TIROSINT-SOL** requires the following rule(s) be met for approval:

A. You have **ONE** of the following diagnoses:

1. Congenital (present from birth) or acquired hypothyroidism (low thyroid function)
2. Thyrotropin (a type of thyroid hormone)-dependent well-differentiated thyroid cancer

B. You had a trial and failure (drug did not work) of Thyquidity

C. You had a trial and failure (drug did not work) of or contraindication (harmful for) to generic levothyroxine tablets

D. There is documentation of rationale (reason) for not using Thyquidity and generic levothyroxine tablets

***(Denial text continued on the next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LEVOTHYROXINE-TIROSINT-SOL

GUIDELINES FOR USE (CONTINUED)

E. If you have thyrotropin-dependent well-differentiated thyroid cancer, approval also requires:

1. The requested medication will be used as an adjunct (add-on) to surgery and radioiodine therapy (a type of radiation therapy)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Tirosint-Sol.

REFERENCES

- Tirosint-Sol [Prescribing Information]. Pambio-Noranco, Switzerland: IBSA Institut Biochimique SA; January 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/23

Created: 07/21

Client Approval: 12/22

P&T Approval:10/21





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LOFEXIDINE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
LOFEXIDINE	LUCEMYRA	07803		GPI-10 (6280504510)	

**GUIDELINES FOR USE**

1. Is the requested medication being used to mitigate opioid withdrawal symptoms to facilitate abrupt opioid discontinuation and the patient meets **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient is in a setting with close patient monitoring for a duration of Lucemyra (lofexidine) treatment not to exceed 18 days
  - Treatment with Lucemyra is being administered as part of an opioid discontinuation plan that includes other withdrawal symptom management medications (e.g., stool softeners, sleep aids) and psychosocial support is in place to help prevent relapse

If yes, **approve for 1 fill by HICL or GPI-10 with a quantity limit of #264 per 18 days.**

If no, do not approve.

**DENIAL TEXT: Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline name **LOFEXIDINE (Lucemyra)** requires the following rule(s) be met for approval:

- A. Lucemyra is being used to lessen opioid withdrawal symptoms to help abrupt opioid discontinuation
- B. You are 18 years of age or older
- C. You are in a setting with close patient monitoring of Lucemyra (lofexidine) treatment for a maximum of 18 days
- D. Treatment with Lucemyra is being administered as part of an opioid discontinuation plan that includes other withdrawal symptom management medications (such as stool softeners, sleep aids) and psychosocial support is in place to help prevent relapse

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**LOFEXIDINE**

---

**RATIONALE**

For further information, please refer to the prescribing information and/or drug monograph for Lucemyra.

**REFERENCES**

7. Lucemyra [Prescribing Information]. Louisville, KY. US Worldmeds, LLC. November 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 08/18

Client Approval: 04/20

P&T Approval: 07/18



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LOMITAPIDE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
LOMITAPIDE	JUXTAPID	39883		GPI-10 (3948005020)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of homozygous familial hypercholesterolemia (HoFH) as determined by meeting **ONE** of the following criteria?
  - Simon Broome diagnostic criteria (definite)
  - Dutch Lipid Network criteria with a score of at least 8
  - A clinical diagnosis based on a history of an untreated LDL-cholesterol level greater than 500 mg/dL, in combination with either:
    - (1) xanthoma before 10 years of age **OR**
    - (2) evidence of heterozygous familial hypercholesterolemia (HeFH) in both parents

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient meet **ALL** of the following criteria?
  - The requested medication is prescribed by or given in consultation with a cardiologist, endocrinologist, or lipidologist
  - The patient has a LDL-cholesterol level greater than or equal to 70 mg/dL

If yes, continue to #3.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

3. Does the patient meet **ONE** of the following criteria?
  - The patient has been taking a high-intensity statin (i.e., atorvastatin 40-80 mg daily, rosuvastatin 20-40 mg daily) for a duration of at least 8 weeks
  - The patient has been taking a maximally tolerated dose of any statin for a duration of at least 8 weeks given that the patient cannot tolerate a high-intensity statin (i.e., atorvastatin 40-80 mg daily, rosuvastatin 20-40 mg daily)

If yes, continue to #4.

If no, continue to #5.

4. Will the patient continue statin treatment as described above in combination with Juxtapid?

If yes, continue to #6.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LOMITAPIDE

GUIDELINES FOR USE (CONTINUED)

5. Does the patient meet **ONE** of the following criteria?

- The patient has an absolute contraindication to statin therapy (e.g., active decompensated liver disease, nursing female, pregnancy or plans to become pregnant, hypersensitivity reaction)
- The patient has complete statin intolerance as defined by severe and intolerable adverse effects (e.g., creatine kinase elevation greater than or equal to 10 times the upper limit of normal, liver function test elevation greater than or equal to 3 times the upper limit of normal, rhabdomyolysis, severe muscle weakness leading to temporary disability, fall, or inability to use a major muscle group) that have occurred with trials of at least two separate statins and have improved with the discontinuation of each statin

If yes, continue to #6.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

6. Does the patient meet **ONE** of the following criteria?

- The patient has had a previous trial of Repatha (evolocumab)
- The patient lacks functioning LDL receptors

If yes, **approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:**

- **Juxtapid 5mg: #45 per 30 days.**
- **Juxtapid 10mg: #30 per 30 days.**
- **Juxtapid 20mg: #90 per 30 days.**
- **Juxtapid 30mg: #30 per 30 days.**
- **Juxtapid 40mg: #30 per 30 days.**
- **Juxtapid 60mg: #30 per 30 days.**

If no, do not approve.

**DENIAL TEXT:** **\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **LOMITAPIDE (Juxtapid)** requires the following rule(s) be met for approval:

A. You have homozygous familial hypercholesterolemia (type of inherited high cholesterol)  
**(Denial text continued on next page)**

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LOMITAPIDE

GUIDELINES FOR USE (CONTINUED)

- B. Your diagnosis of homozygous familial hypercholesterolemia (type of inherited high cholesterol) was determined by meeting **ONE** of the following criteria:
  - 1. Simon Broome diagnostic criteria
  - 2. Dutch Lipid Network criteria with a score of at least 8
  - 3. A clinical diagnosis based on a history of an untreated LDL (low density lipoprotein) - cholesterol level greater than 500 mg/dL, in combination with either (1) xanthoma (condition where fatty growth develops under the skin) before 10 years of age **OR** (2) evidence of heterozygous familial hypercholesterolemia (type of inherited high cholesterol) in both parents
- C. The requested medication is prescribed by or given in consultation with a cardiologist (heart doctor), endocrinologist (hormone doctor), or lipidologist (cholesterol management doctor)
- D. You have an LDL (low density lipoprotein) - cholesterol level greater than or equal to 70 mg/dL while on maximally tolerated statin (drug used for cholesterol) treatment
- E. You previously had a trial of Repatha (evolocumab) unless you do not have functional LDL (low density lipoprotein) receptors
- F. **If you are statin tolerant, approval also requires:**
  - 1. You meet **ONE** of the following criteria:
    - a. You have been taking a high-intensity statin (atorvastatin 40-80 mg daily, rosuvastatin 20-40 mg daily) for a duration of at least 8 weeks
    - b. You have been taking a maximally tolerated dose of any statin for a duration of at least 8 weeks given you cannot tolerate a high-intensity statin (atorvastatin 40-80 mg daily, rosuvastatin 20-40 mg daily)
  - 2. You will continue statin (drug used for cholesterol) treatment in combination with Juxtapid
- G. **If you are statin intolerant, approval also requires ONE of the following:**
  - 1. You have an absolute contraindication to (medical reason why you cannot use) statin therapy (drug used for cholesterol) such as active decompensated liver disease (you have symptoms related to liver damage), nursing female, pregnancy or plans to become pregnant, or hypersensitivity (allergic) reaction
  - 2. You have complete statin intolerance as defined by severe and intolerable adverse effects such as creatine kinase elevation (a measurement of how much muscle damage you have) greater than or equal to 10 times the upper limit of normal, liver function test elevation greater than or equal to 3 times the upper limit of normal, rhabdomyolysis (muscle breakdown), severe muscle weakness leading to temporary disability, fall, or inability to use a major muscle group. These must have occurred with trials of at least two separate statins and have improved with the discontinuation of each statin.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**LOMITAPIDE**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Juxtapid.

**REFERENCES**

- Juxtapid [Prescribing Information]. Cambridge, MA: Aegerion Pharmaceuticals, Inc.; December 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 01/13

Client Approval: 04/20

P&T Approval: 04/18



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LOMUSTINE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
LOMUSTINE	GLEOSTINE	03900		GPI-10 (2110202000)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of Hodgkin's lymphoma?

If yes, **approve for 12 months by HICL or GPI-10.**

If no, continue to #2.

2. Does the patient have a diagnosis of primary and metastatic brain tumors **AND** meet the following criterion?

- The patient has previously received appropriate surgical and/or radiotherapeutic procedures

If yes, continue to #3.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

3. Will the patient be using this medication as a part of the PCV regimen (procarbazine, lomustine, and vincristine)?

If yes, **approve for 12 months by HICL or GPI-10.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **LOMUSTINE (Gleostine)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:

1. Hodgkin's lymphoma (type of immune system cancer)
2. Primary and metastatic brain tumors (tumor that has spread to other parts of body)

B. **If you have primary and metastatic brain tumors, approval also requires:**

1. You have previously received appropriate surgical and/or radiotherapeutic procedures
2. The requested medication will be used as a part of the PCV regimen (procarbazine, lomustine, and vincristine)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**LOMUSTINE**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Gleostine.

**REFERENCES**

- Gleostine [Prescribing Information]. NextSource Biotechnology, LLC: Miami, FL; December 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/23

Created: 02/18

Client Approval: 11/22

P&T Approval: 01/18





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LONAFARNIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
LONAFARNIB	ZOKINVY	46991		GPI-10 (9946304500)	

**GUIDELINES FOR USE**

1. Is the patient 1 year of age or older **AND** meets the following criterion?

- The patient has a body surface area (BSA) of 0.39m(2) or above

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient have a diagnosis of Hutchinson-Gilford progeria syndrome (HGPS)?

If yes, **approve for 12 months by HICL or GPI-10.**

If no, continue to #3.

3. Does the patient have a diagnosis of processing-deficient progeroid laminopathies with **ONE** of the following?

- Heterozygous LMNA mutation with progerin-like protein accumulation
- Homozygous or compound heterozygous ZMPSTE24 mutations

If yes, **approve for 12 months by HICL or GPI-10.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **LONAFARNIB (Zokinvy)** requires the following rule(s) be met for approval:

- A. You have Hutchinson-Gilford progeria syndrome (HGPS) OR processing-deficient progeroid laminopathies (rare genetic disorders that cause premature aging in children)
- B. You are 1 year of age or older
- C. You have a body surface area (BSA) of 0.39 meters squared or more
- D. **If you have processing-deficient progeroid laminopathies, approval also requires you have ONE of the following:**
  1. Heterozygous LMNA (type of gene) mutation with progerin-like protein accumulation
  2. Homozygous or compound heterozygous ZMPSTE24 (type of gene) mutations

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**LONAFARNIB**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Zokinvy.

**REFERENCES**

- Zokinvy [Prescribing Information]. Palo Alto, CA: Eiger BioPharmaceuticals, Inc.; November 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/21

Created: 02/21

Client Approval:02/21

P&T Approval: 01/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LONAPEG SOMATROPIN-TCGD

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
LONAPEG SOMATROPIN -TCGD	SKYTROFA	47565		GPI-10 (3010000380)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Is the requested medication being used for **ANY** of the following?

- Athletic enhancement
- Anti-aging purposes
- Idiopathic short stature (ISS)

If yes, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

If no, continue to #2.

2. Does the patient have a diagnosis of growth failure due to inadequate secretion of endogenous growth hormone and meet **ALL** of the following criteria?

- The patient is 1 year of age or older AND weighs at least 11.5kg
- Therapy is prescribed by or in consultation with an endocrinologist
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- The patient meets at least **ONE** of following criteria for short stature:
  - Patient's height greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender
  - Height velocity less than the 25th percentile for age
  - Documented low peak growth hormone (less than 10 ng/mL) on two GH stimulation tests or insulin-like growth factor 1 (IGF-1) greater than or equal to 2 SD below the mean for same age and gender

If yes, **approve for 12 months for all strengths by GPID or GPI-14 with the following quantity limits:**

- **Skytrofa 3mg, 3.6mg, 4.3mg, 5.2mg, 6.3mg, 13.3mg: #1 cartridge per week.**
- **Skytrofa 7.6mg, 9.1mg, 11mg: #2 cartridges per week.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LONAPEG SOMATROPIN-TCGD

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **LONAPEG SOMATROPIN-TCGD (Skytrofa)** requires the following rule(s) be met for approval:

- A. You have growth failure due to an inadequate secretion of endogenous (from your own body) growth hormone
- B. Skytrofa is not being used for the treatment of **ANY** of the following conditions:
  1. Athletic enhancement
  2. Anti-aging purposes
  3. Idiopathic short stature (ISS: a type of growth condition)
- C. You are 1 year of age or older and weigh at least 11.5 kg
- D. Therapy is prescribed by or in consultation with an endocrinologist (a type of hormone doctor)
- E. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
- F. You meet at least ONE of the following criteria for short stature:
  1. Your height is at least 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender
  2. Your height velocity is less than the 25th percentile for your age
  3. You have documented low peak growth hormone (less than 10ng/mL) on two GH (growth hormone) stimulation tests or insulin-like growth factor 1 (IGF-1) at least 2 standard deviations below the mean for your age and gender

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Is the requested medication being used for **ANY** of the following?
  - Athletic enhancement
  - Anti-aging purposes
  - Idiopathic short stature (ISS)

If yes, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

If no, continue to #2.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LONAPEG SOMATROPIN-TCGD

RENEWAL CRITERIA (CONTINUED)

2. Does the patient have a diagnosis of growth failure due to inadequate secretion of endogenous growth hormone and meet **ALL** of the following criteria?
- Therapy is prescribed by or in consultation with an endocrinologist
  - The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand OR the patient has not completed prepubertal growth)
  - The patient meets ONE of the following:
    - Annual growth velocity of 2 cm or more compared with what was observed from the previous year
    - Annual growth velocity of 1 cm or more compared with what was observed from the previous year for patients that are near terminal phase of puberty

If yes, **approve for 12 months for all strengths by GPID or GPI-14 with the following quantity limits:**

- Skytrofa 3mg, 3.6mg, 4.3mg, 5.2mg, 6.3mg, 13.3mg: #1 cartridge per week.
- Skytrofa 7.6mg, 9.1mg, 11mg: #2 cartridges per week.

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **LONAPEG SOMATROPIN-TCGD (Skytrofa)** requires the following rule(s) be met for renewal:

- A. You have growth failure due to an inadequate secretion of endogenous (from your own body) growth hormone
- B. Skytrofa is not being used for the treatment of **ANY** of the following conditions:
  1. Athletic enhancement
  2. Anti-aging purposes
  3. Idiopathic short stature (ISS: a type of growth condition)
- C. Therapy is prescribed by or given in consultation with an endocrinologist (a type of hormone doctor)
- D. Your epiphyses (end part of long bone) are NOT closed (confirmed by radiograph [type of imaging test] of the wrist and hand or you have not completed prepubertal growth)
- E. You meet ONE of the following:
  1. Your annual growth velocity is 2 cm or more compared with what was observed from the previous year
  2. Your annual growth velocity is 1 cm or more compared with what was observed from the previous year if you are near the terminal (end) phase of puberty

***(Renewal denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LONAPEG SOMATROPIN-TCGD

RENEWAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Skytrofa.

REFERENCES

- Skytrofa [Prescribing Information]. Palo Alto, CA: Ascendis Pharma US, Inc., August 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/01/21

Created: 10/21

Client Approval: 10/21

P&T Approval: 01/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LORCASERIN

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
LORCASERIN HCL	BELVIQ, BELVIQ XR	40373		GPI-10 (6125655010)	

**GUIDELINES FOR USE**

Do not approve requests for Belviq or Belviq XR.

(**NOTE:** Safety concerns [increased risk of cancer] have prompted market withdrawal of Belviq and Belviq XR.)

**RATIONALE**

For further information, please refer to the prescribing information and/or drug monograph for Belviq/Belviq XR.

FDA requested removal from the market as Belviq/Belviq XR displayed an increased risk of cancer in a safety trial. Manufacturer complied with FDA request and product has been discontinued.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/01/21

Created: 01/13

Client Approval: 08/21

P&T Approval: 04/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LORLATINIB

Generic	Brand	HICL		GCN	Medi-Span	Exception/Other
LORLATINIB	LORBRENA	45448			GPI-10 (2153055600)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of metastatic non-small cell lung cancer (NSCLC) and meet **ALL** of the following criteria?
- The patient is 18 years of age or older
  - The patient's tumors are anaplastic lymphoma kinase (ALK) - positive as detected by an FDA-approved test

If yes, **approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:**

- **Lorbrena 25mg: #3 per day.**
- **Lorbrena 100mg: #1 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **LORLATINIB (Lorbrena)** requires the following rule(s) be met for approval:

- A. You have metastatic non-small cell lung cancer (NSCLC: type of lung cancer that has spread to other parts of the body)
- B. You are 18 years of age or older
- C. Your tumors are anaplastic lymphoma kinase (ALK: type of enzyme) - positive which is shown by an FDA (Federal and Drug Administration) approved test

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**





**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**LORLATINIB**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Lorbrena.

**REFERENCES**

- Lorbrena [Prescribing Information]. New York, NY: Pfizer, Inc.; March 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/10/21

Created: 03/19

Client Approval: 03/21

P&T Approval: 04/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LOTEPREDNOL

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
LOTEPREDNOL ETABONATE	EYSUVIS		48834	GPI-14 (86300035101825)	

**GUIDELINES FOR USE**

- Does the patient have a diagnosis of dry eye disease **AND** meet the following criterion?
  - The patient had a trial of or contraindication to one generic loteprednol ophthalmic **AND** one non-loteprednol ophthalmic corticosteroid (e.g., fluorometholone, dexamethasone, prednisolone)

If yes, **approve for 2 weeks by GPID or GPI-14 with a quantity limit of #8.3mL (1 bottle) per 14 days.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **LOTEPREDNOL (Eysuvis)** requires the following rule(s) be met for approval:

- You have dry eye disease
- You previously tried one generic loteprednol ophthalmic product **AND** one non-loteprednol ophthalmic (eye) corticosteroid (such as fluorometholone, dexamethasone, prednisolone) unless there is a medical reason why you cannot (contraindication)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Eysuvis.

**REFERENCES**

- Eysuvis [Prescribing Information]. Watertown, MA: Kala Pharmaceuticals, Inc.; October 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/21

Created: 02/21

Client Approval: 02/21

P&T Approval: 01/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LUMACAFITOR-IVACAFITOR

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
LUMACAFITOR/IVACAFITOR	ORKAMBI	42235		GPI-10 (4530990230)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA, SEE BELOW)**

- Does the patient have a diagnosis of cystic fibrosis (CF) and meet **ALL** of the following criteria?
  - The patient is 1 year of age or older
  - Therapy is prescribed by or in consultation with a pulmonologist or CF expert
  - There is documentation that the patient is homozygous for the F508del-CFTR gene mutation

If yes, **approve by GPID or GPI-14 for 24 weeks for all of the formulations and strengths with the following quantity limits:**

- 75-94 mg granule packets: #2 per day.**
- 100-125 mg granule packets: #2 per day.**
- 150-188 mg granule packets: # 2 per day.**
- 100-125 mg tablets: #4 per day.**
- 200-125 mg tablets: #4 per day.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **LUMACAFITOR-IVACAFITOR (Orkambi)** requires the following rule(s) be met for approval:

- You have cystic fibrosis (a type of lung disorder)
- You are 1 year of age or older
- Therapy is prescribed by or in consultation with a pulmonologist (lung/breathing doctor) or cystic fibrosis expert
- There is documentation that you are homozygous (have 2 copies of the same gene) for the F508del-CFTR (type of gene: cystic fibrosis transmembrane conductance regulator) mutation

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LUMACAFTOR-IVACAFTOR

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of cystic fibrosis (CF) and improvement in clinical status as shown by **ONE** of the following?
  - The patient has improved, maintained, or demonstrated less than expected decline in FEV1 (forced expiratory volume)
  - The patient has improved, maintained, or demonstrated less than expected decline in BMI (body mass index)
  - The patient has experienced a reduction in rate of pulmonary exacerbations

If yes, **approve by GPID or GPI-14 for lifetime for all of the formulations and strengths with the following quantity limits:**

- 75-94 mg granule packets: #2 per day.
- 100-125 mg granule packets: #2 per day.
- 150-188 mg granule packets: #2 per day.
- 100-125 mg tablets: #4 per day.
- 200-125 mg tablets: #4 per day.

If no, do not approve.

**RENEWAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **LUMACAFTOR-IVACAFTOR (Orkambi)** requires the following rule(s) be met for renewal:

- A. You have cystic fibrosis (a type of lung disorder)
- B. You have shown improvement in clinical (medical) status compared to baseline as shown by ONE of the following:
  1. You have improved, maintained, or demonstrated less than expected decline in FEV1 (forced expiratory volume: amount of air you can exhale in 1 second)
  2. You have improved, maintained, or demonstrated less than expected decline in BMI (body mass index)
  3. You have experienced a reduction in rate of pulmonary exacerbations (worsening in lung condition)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**LUMACAFTOR-IVACAFTOR**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Orkambi.

**REFERENCES**

- Orkambi [Prescribing Information]. Boston, MA: Vertex Pharmaceuticals Incorporated, September 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/01/22

Created: 07/15

Client Approval: 09/22

P&T Approval: 10/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

LUSUTROMBOPAG

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
LUSUTROMBOPAG	MULPLETA	45127		GPI-10 (8240504500)	

GUIDELINES FOR USE

1. Does the patient have a diagnosis of thrombocytopenia and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a hematologist, gastroenterologist, hepatologist, immunologist, endocrinologist, or surgeon
  - The patient has chronic liver disease
  - The patient is scheduled to undergo a procedure 8 to 14 days following initiation of Mulpleta (lusutrombopag) therapy
  - The patient has a platelet count of less than  $50 \times 10^9$  cells/L measured within the last 30 days
  - The patient is not receiving other thrombopoietin receptor agonist therapy (e.g., avatrombopag, romiplostim, eltrombopag)

If yes, **approve for 1 fill by HICL or GPI-10 with a quantity limit of #7 tablets.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **LUSUTROMBOPAG (Mulpleta)** requires the following rule(s) be met for approval:

- A. You have thrombocytopenia (a type of blood disorder)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor), gastroenterologist (a doctor who treats digestive conditions), hepatologist (a type of liver doctor), immunologist (a type of immune system doctor), endocrinologist (a type of hormone doctor), or surgeon
- D. You have chronic liver disease
- E. You are scheduled to undergo a procedure 8 to 14 days after starting Mulpleta (lusutrombopag) therapy
- F. You have a platelet count of less than  $50 \times 10^9$  cells/L measured within the last 30 days
- G. You are not receiving other thrombopoietin receptor agonist therapy, such as avatrombopag, romiplostim, eltrombopag

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**LUSUTROMBOPAG**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Mulpleta.

**REFERENCES**

- Mulpleta [Prescribing Information]. Florham Park, NJ: Shionogi & Co, Ltd. May 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/22

Created: 11/18

Client Approval: 02/22

P&T Approval: 01/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MACITENTAN

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
MACITENTAN	OPSUMIT	40677		GPI-10 (4016005000)	

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of pulmonary arterial hypertension (WHO Group 1) and meet **ALL** of the following criteria?

- Therapy is prescribed by or in consultation with a cardiologist or pulmonologist
- The patient has NYHA-WHO Functional Class II to IV symptoms
- Documented confirmatory PAH diagnosis based on right heart catheterization with the following parameters:
  - Mean pulmonary artery pressure (PAP) of > 20 mmHg
  - Pulmonary capillary wedge pressure (PCWP) of ≤ 15 mmHg
  - Pulmonary vascular resistance (PVR) of ≥ 3 Wood units

If yes, **approve for 12 months by HICL or GPI-10 for #1 per day.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **MACITENTAN (Opsumit)** requires the following rule(s) be met for approval:

- A. You have pulmonary arterial hypertension (a type of heart and lung condition) (World Health Organization Group 1)
- B. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung doctor)
- C. You have New York Heart Association-World Health Organization (NYHA-WHO) Functional Class II to IV symptoms (a classification system of heart failure symptoms)
- D. You have documentation confirming your diagnosis of pulmonary arterial hypertension based on right heart catheterization (a test using a thin tube that is placed into the right side of your heart) with the following values:
  1. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
  2. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
  3. Pulmonary vascular resistance (PVR) greater than or equal to 3 Wood units

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MACITENTAN

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group 1)?

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

2. Does the patient meet **ONE** of the following criteria?

- The patient has shown improvement from baseline in the 6-minute walk distance test
- The patient has remained stable from baseline in the 6-minute walk distance test AND World Health Organization (WHO) functional class has remained stable or improved

If yes, **approve for 12 months by HICL or GPI-10 for #1 per day.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **MACITENTAN (Opsumit)** requires the following rule(s) be met for renewal:

- A. You have pulmonary arterial hypertension (a type of heart and lung condition) (World Health Organization Group 1)
- B. You meet ONE of the following:
1. You have shown improvement from baseline in the 6-minute walk distance test
  2. You have remained from baseline in the 6-minute walk distance test AND World Health Organization (WHO) functional class has remained stable or improved

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**MACITENTAN**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Opsumit.

**REFERENCES**

Opsumit [Prescribing Information]. South San Francisco, CA: Actelion Pharmaceuticals US, Inc.; October 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/01/22

Created: 10/22

Client Approval: 10/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MARALIXIBAT

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
MARALIXIBAT CHLORIDE	LIVMARLI	47604		GPI-10 (5235005010)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of cholestatic pruritus associated with Alagille syndrome (ALGS) **AND** meet the following criterion?

- The patient is 1 year of age or older

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #3mL per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **MARALIXIBAT (Livmarli)** requires the following rule(s) be met for approval:

- A. You have cholestatic pruritus (a type of skin condition) associated with Alagille syndrome (ALGS: a type of genetic disorder)
- B. You are 1 year of age or older

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Livmarli.

**REFERENCES**

- Livmarli [Prescribing Information]. Foster City, CA: Mirum Pharmaceuticals, Inc.; September 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/22

Created: 10/21

Client Approval: 11/21

P&T Approval: 10/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MARIBAVIR

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
MARIBAVIR	LIVTENCITY	47687		GPI-10 (1220005000)	

**GUIDELINES FOR USE**

- Does the patient have a diagnosis of post-transplant cytomegalovirus (CMV) infection and meet **ALL** of the following criteria?
  - The patient is 12 years of age or older
  - The patient is refractory to prior therapy with ganciclovir, valganciclovir, cidofovir or foscarnet

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **MARIBAVIR (Livtency)** requires the following rule(s) be met for approval:

- You have a post-transplant cytomegalovirus (CMV) infection (a type of viral infection)
- You are 12 years of age or older
- You are refractory to prior therapy with ganciclovir, valganciclovir, cidofovir or foscarnet

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Livtency.

**REFERENCES**

- Livtency [Prescribing Information]. Lexington, MA: Takeda Pharmaceuticals America, Inc.; November 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective:01/01/22

Created: 12/21

Client Approval: 12/21

P&T Approval: 10/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MAVACAMTEN

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
MAVACAMTEN	CAMZYOS	47972		GPI-10 (4019005000)	

**GUIDELINES FOR USE**

**NITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of symptomatic obstructive hypertrophic cardiomyopathy (HCM) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient has New York Heart Association (NYHA) class II-III symptoms
  - The patient has a left ventricular outflow track (LVOT) gradient of 50 mmHg or higher
  - Therapy is prescribed by or in consultation with a cardiologist
  - The patient had a trial of or contraindication to beta-blockers (e.g., metoprolol, carvedilol) AND non-dihydropyridine calcium channel blockers (e.g., verapamil, diltiazem)

If yes, **approve for 4 months by HICL or GPI-10 with a quantity limit of #1 per day.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **MAVACAMTEN (Camzyos)** requires the following rule(s) be met for approval:

- A. You have symptomatic obstructive hypertrophic cardiomyopathy (HCM: a type of heart condition)
- B. You are 18 years of age or older
- C. You have New York Heart Association (NYHA) class II-III (classification system for heart failure) symptoms
- D. You have a left ventricular outflow track gradient (a predictor of heart failure and cardiovascular death) of 50 mmHg or higher
- E. Therapy is prescribed by or in consultation with a cardiologist (a type of heart doctor)
- F. You had a trial of or contraindication (harmful for) to beta-blockers (such as metoprolol, carvedilol) AND non-dihydropyridine calcium channel blockers (such as verapamil, diltiazem)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MAVACAMTEN

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of symptomatic obstructive hypertrophic cardiomyopathy (HCM) **AND** meet the following criterion?

- The patient has experienced continued clinical benefit (e.g., reduction of symptoms, NYHA classification improvement)

If yes, **approve for 12 months by HICL or GPI-10 with quantity limit of #1 per day.**  
If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **MAVACAMTEN (Camzyos)** requires the following rule(s) be met for renewal:

- A. You have symptomatic obstructive hypertrophic cardiomyopathy (HCM: a type of heart condition)
- B. You have experienced continued clinical benefit (such as reduction of symptoms, NYHA classification improvement)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Camzyos.

**REFERENCES**

- Camzyos [Prescribing Information]. Brisbane, CA: MyoKardia, Inc.; April 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective:06/01/22

Created: 05/22

Client Approval: 05/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MEBENDAZOLE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
MEBENDAZOLE	EMVERM		43181	GPI-14 (15000010000505)	

**GUIDELINES FOR USE**

1. Is the patient being treated for *enterobius vermicularis* (pinworm) and meet **ALL** of the following criteria?

- The patient is 2 years of age or older
- The patient had a trial of or contraindication to pyrantel pamoate (OTC)

If yes, **approve for 1 month by GPID or GPI-14 with a quantity limit of #2 per 30 days.**  
If no, continue to #2.

2. Is the patient being treated for *trichuris trichiura* (whipworm) **OR** *ascaris lumbricoides* (common roundworm) and meet ALL of the following criteria?

- The patient is 2 years of age or older
- Documentation confirming a diagnosis of *trichuris trichiura* (whipworm) or *ascaris lumbricoides* (common roundworm)
- The patient had a trial of or contraindication to albendazole (Albenza)

If yes, **approve for 1 month by GPID or GPI-14 with a quantity limit of #6 per 30 days.**  
If no, continue to #3.

3. Is the patient being treated for *ancylostoma duodenale* (common hookworm) or *necator americanus* (American hookworm) and meet **ALL** of the following criteria?

- The patient is 2 years of age or older
- Documentation confirming a diagnosis of *ancylostoma duodenale* (common hookworm) or *necator americanus* (American hookworm)
- The patient had a trial of or contraindication to albendazole (Albenza) **OR** pyrantel pamoate (OTC)

If yes, **approve for 1 month by GPID or GPI-14 with a quantity limit of #6 per 30 days.**  
If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MEBENDAZOLE

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **MEBENDAZOLE (Emverm)** requires the following rule(s) be met for approval:

- A. Emverm is being used for the treatment of *Enterobius vermicularis* (pinworm), *trichuris trichiura* (whipworm), *ascaris lumbricoides* (common roundworm), *ancylostoma duodenale* (common hookworm), or *necator americanus* (American hookworm)
- B. You are 2 years of age or older
- C. **If you have *enterobius vermicularis* (pinworm), approval also requires:**
  - 1. You previously had a trial of over-the-counter (OTC) pyrantel pamoate, unless there is a medical reason why you cannot (contraindication)
- D. **If you have *trichuris trichiura* (whipworm) or *ascaris lumbricoides* (common roundworm), approval also requires:**
  - 1. You have documentation confirming your diagnosis of *trichuris trichiura* (whipworm) or *ascaris lumbricoides* (common roundworm)
  - 2. You previously had a trial of albendazole (Albenza), unless there is a medical reason why you cannot (contraindication)
- E. **If you have *ancylostoma duodenale* (common hookworm) or *necator americanus* (American hookworm), approval also requires:**
  - 1. You have documentation confirming your diagnosis of *ancylostoma duodenale* (common hookworm) or *necator americanus* (American hookworm)
  - 2. You previously had a trial of albendazole (Albenza), unless there is a medical reason why you cannot (contraindication) OR you had a trial of over-the-counter (OTC) pyrantel pamoate

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Emverm.

**REFERENCES**

- Emverm [Prescribing Information]. Horsham, PA: Amedra Pharmaceuticals LLC; January 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/01/20

Created: 03/16

Client Approval: 08/20

P&T Approval: 07/20

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MECAMYLAMINE HYDROCHLORIDE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
MECAMYLAMI NE HCL	VECAMYL		1471	GPI-10 (3660002010)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of moderately severe to severe essential (or primary) hypertension or uncomplicated malignant hypertension?

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Has the patient tried or does the patient have a contraindication to three of the following: angiotensin converting enzyme (ACE) inhibitor or ACE-I combination, angiotensin receptor blocker (ARB) or ARB combination, Beta Blocker, or Calcium Channel Blocker?

**PAC NOTE:** These drugs include: benazepril, benazepril-HCTZ, captopril, captopril-HCTZ, enalapril, enalapril-HCTZ, fosinopril, fosinopril-HCTZ, lisinopril, lisinopril-HCTZ, quinapril, ramipril, moexipril, moexipril-HCTZ, perindopril erbumine, quinapril, quinapril-HCTZ, trandolapril, trandolapril/verapamil, losartan, losartan-HCTZ, irbesartan, irbesartan-HCTZ, olmesartan, olmesartan-HCTZ, olmesartan-amlodipine-HCTZ, valsartan, valsartan-HCTZ, diltiazem HCL, diltiazem sustained release (generics only), verapamil, verapamil sustained release (generics only), atenolol, atenolol-chlorthalidone, bisoprolol, bisoprolol-HCTZ, carvedilol, metoprolol tartrate, nadolol, acebutolol, betaxolol, labetalol, metoprolol succinate, metoprolol-HCTZ, pindolol, propranolol, propranolol-HCTZ, sotalol, timolol maleate, or nebivolol.

If yes, **approve for 12 months by GPID or GPI-10.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MECAMYLAMINE HYDROCHLORIDE

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **MECAMYLAMINE HYDROCHLORIDE (Vecamyl)** requires the following rule(s) be met for approval:

- A. The requested medication will be used for the management of moderately severe to severe essential (or primary) hypertension or in uncomplicated cases of malignant hypertension
- B. You have had a trial of at least three of the following, unless there is a medical reason why you cannot (contraindication): angiotensin converting enzyme inhibitor (ACE-I) or ACE-I combination, angiotensin receptor blocker (ARB) or ARB combination, Beta Blocker, or Calcium Channel Blocker, such as benazepril, benazepril-HCTZ, captopril, captopril-HCTZ, enalapril, enalapril-HCTZ, fosinopril, fosinopril-HCTZ, lisinopril, lisinopril-HCTZ, quinapril, ramipril, moexipril, moexipril-HCTZ, perindopril erbumine, quinapril, quinapril-HCTZ, trandolapril, trandolapril/verapamil, losartan, losartan-HCTZ, irbesartan, irbesartan-HCTZ, olmesartan, olmesartan-HCTZ, olmesartan-amlodipine-HCTZ, valsartan, valsartan-HCTZ, diltiazem HCL, diltiazem sustained release (generics only), verapamil, verapamil sustained release (generics only), atenolol, atenolol-chlorthalidone, bisoprolol, bisoprolol-HCTZ, carvedilol, metoprolol tartrate, nadolol, acebutolol, betaxolol, labetalol, metoprolol succinate, metoprolol-HCTZ, pindolol, propranolol, propranolol-HCTZ, sotalol, timolol maleate, or nebivolol.

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Vecamyl.

**REFERENCES**

- 2. Vecamyl [Prescribing Information]. Fort Collins, CO: Manchester Pharmaceuticals; July 2015.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 05/13

Client Approval: 04/20

P&T Approval: 08/13



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MECASERMIN

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
MECASERMIN	INCRELEX	33207		GPI-10 (3016004500)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have **ONE** of the following diagnoses?
  - Severe primary IGF-1 deficiency
  - Growth hormone (GH) gene deletion (not growth hormone-deficient short stature) **AND** have neutralizing antibodies to GH

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Does the patient meet **ALL** of the following criteria?
  - The patient is 2 years to less than 18 years of age
  - The requested medication is prescribed by or given in consultation with a pediatric endocrinologist or a pediatric nephrologist
  - Height standard deviation score  $\leq -3.0$
  - Basal IGF-1 standard deviation score  $\leq -3.0$
  - Normal or elevated growth hormone (GH), [serum growth hormone level of  $\geq 10\text{ngm/mL}$  to at least two stimuli (insulin, levodopa, arginine, clonidine, or glucagon)]
  - The patient's epiphyses (bone growth plates) open (as confirmed by radiograph of the wrist and hand)

If yes, **approve by HICL or GPI-10 for 6 months up to a maximum dose of 9 vials per month.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **MECASERMIN (Increlex)** requires the following rule(s) be met for approval:

- A. You have **ONE** of the following diagnoses:
  1. Severe primary insulin growth-like factor 1 deficiency (IGF-1: hormone levels that promote normal bone and tissue growth and development are extremely low or undetectable in the blood)
  2. Growth hormone gene deletion (not growth hormone-deficient short stature) and developed neutralizing antibodies to growth hormone

***(Initial denial text continued on the next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MECASERMIN

INITIAL CRITERIA (CONTINUED)

- B. You are 2 years to less than 18 years of age
- C. The requested medication is prescribed by or given in consultation with a pediatric endocrinologist (hormone doctor) or pediatric nephrologist (kidney doctor)
- D. You have a height standard deviation score less than or equal to -3.0, basal IGF-1 (insulin growth-like factor 1) standard deviation score less than or equal to -3.0, and normal or elevated growth hormone [serum growth hormone level of greater than or equal to 10ngm/mL to at least 2 stimuli (insulin, levodopa, arginine, clonidine or glucagon)]
- E. Your bone growth plates (epiphyses) are open (as confirmed by radiograph of the wrist and hand)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Has the patient shown a response in the first 6 months of IGF-1 therapy (i.e., increase in height, increase in height velocity)?

If yes, **approve by HICL or GPI-10 for 12 months up to a maximum dose of 9 vials per month.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **MECASERMIN (Increlex)** requires the following rule(s) be met for renewal:

- A. You have shown a response in the first 6 months of insulin growth-like factor-1 (IGF-1) therapy (increase in height, increase in height velocity)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**MECASERMIN**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Increlex.

**REFERENCES**

- Increlex [Prescribing Information]. Cambridge, MA: Ipsen Biopharmaceuticals, Inc.; December 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/20

Created: 02/06

Client Approval: 03/20

P&T Approval: 04/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MECHLORETHAMINE GEL

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
MECHLORETHAMINE HCL	VALCHLOR		35387	GPI-10 (9037105020)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCLs)?

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Has the patient tried prior skin-directed therapy (such as corticosteroids, carmustine, topical retinoids [Targretin, Tazorac], imiquimod, or local radiation therapy)?

If yes, **approve for 12 months by GPID or GPI-10.**

If no, do not approve.

**DENIAL TEXT:** **\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **MECHLORETHAMINE GEL (Valchlor)** requires the following rule(s) be met for approval:

- A. You have stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (type of immune system cancer)
- B. You had prior skin-directed therapy such as corticosteroids, carmustine, topical retinoids (Targretin, Tazorac), imiquimod, or local radiation therapy

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Valchlor.

**REFERENCES**

- Valchlor [Prescribing Information]. South San Francisco, CA: Actelion Pharmaceuticals US, Inc.; January 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 11/13

Client Approval: 04/20

P&T Approval: 11/13

Copyright © 2023 MediImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MediImpact. MediImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MEPOLIZUMAB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
MEPOLIZUMAB	NUCALA	42775		GPI-10 (4460405500)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of severe asthma with an eosinophilic phenotype and meet **ALL** of the following criteria?
  - The patient is 6 years of age or older
  - Therapy is prescribed by or in consultation with a physician specializing in pulmonary medicine or allergy medicine
  - The patient has a documented blood eosinophil level of at least 150 cells/mcL within the past 12 months
  - The patient is concurrently treated with medium, high-dose, or maximally tolerated dose of an inhaled corticosteroid AND at least one other maintenance medication (e.g., a long-acting inhaled beta2-agonist such as formoterol or salmeterol, a long-acting muscarinic antagonist such as tiotropium, a leukotriene receptor antagonist such as montelukast, theophylline, or oral corticosteroid)
  - Nucala will NOT be used concurrently with Xolair, Dupixent, or another anti-IL-5 biologic (e.g., Cinqair, Fasenna) when these are used for the treatment of asthma

If yes, continue to #2.

If no, continue to #3.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MEPOLIZUMAB

INITIAL CRITERIA (CONTINUED)

2. Does the patient meet **ONE** of the following criteria?

- The patient experienced at least **ONE** asthma exacerbation requiring systemic corticosteroid burst lasting at least 3 days within the past 12 months OR at least **ONE** serious exacerbation requiring hospitalization or emergency room visit within the past 12 months
- The patient has poor symptom control despite current therapy as evidenced by at least **THREE** of the following within the past 4 weeks:
  - Daytime asthma symptoms more than twice per week
  - Any night waking due to asthma
  - Use of a short-acting inhaled beta2-agonist reliever (SABA; such as albuterol) for symptoms more than twice per week
  - Any activity limitation due to asthma

If yes, **approve for 4 months as follows:**

- **If the plan covers non-self-administered (NSA) agents: Approve by HICL or GPI-10 with a quantity limit of #1 vial/syringe per 28 days.**
- **If the plan does NOT cover NSA agents: Approve the requested strength by GPID or GPI-14 with the following quantity limits:**
  - **100mg/1mL: #1mL per 28 days.**
  - **40mg/0.4mL: #0.4mL per 28 days.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

3. Does the patient have a diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- Therapy is prescribed by or in consultation with an otolaryngologist or allergist/immunologist
- Nucala will be used as add-on maintenance treatment
- The patient had a 90-day trial of **ONE** intranasal corticosteroid (e.g., mometasone, fluticasone, beclomethasone)

If yes, **approve for 6 months as follows:**

- **If the plan covers non-self-administered (NSA) agents: Approve by HICL or GPI-10 with a quantity limit of #1 vial/syringe per 28 days.**
- **If the plan does NOT cover NSA agents: Approve Nucala autoinjector and 100mg/1mL syringe by GPID or GPI-14 with a quantity limit of #1mL per 28 days.**

If no, continue to #4.

CONTINUED ON NEXT PAGE





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MEPOLIZUMAB

INITIAL CRITERIA (CONTINUED)

4. Does the patient have a diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA), also known as Churg-Strauss syndrome, **AND** meet the following criterion?

- The patient is 18 years of age or older

If yes, **approve for 12 months as follows:**

- **If the plan covers non-self-administered (NSA) agents: Approve by HICL or GPI-10 with a quantity limit of #3 vials/syringes per 28 days.**
- **If the plan does NOT cover NSA agents: Approve Nucala autoinjector and 100mg/1mL syringe by GPID or GPI-14 with a quantity limit of #3mL per 28 days.**

If no, continue to #5.

5. Does the patient have a diagnosis of hypereosinophilic syndrome (HES) and meet **ALL** of the following criteria?

- The patient is 12 years of age or older
- The patient has had HES for 6 months or more without an identifiable non-hematologic secondary cause

If yes, **approve for 12 months as follows:**

- **If the plan covers non-self-administered (NSA) agents: Approve by HICL or GPI-10 with a quantity limit of #3 vials/syringes per 28 days.**
- **If the plan does NOT cover NSA agents: Approve Nucala autoinjector and 100mg/1mL syringe by GPID or GPI-14 with a quantity limit of #3mL per 28 days.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **MEPOLIZUMAB (Nucala)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:

1. Severe asthma with an eosinophilic phenotype (inflammatory type)
2. Chronic rhinosinusitis with nasal polyps (CRSwNP: inflammation of nasal and sinus passages with small growths in the nose)
3. Eosinophilic granulomatosis with polyangiitis (EGPA), also known as Churg-Strauss syndrome (inflammation of blood vessels with high levels of a type of white blood cell)
4. Hypereosinophilic syndrome (HES) (a rare blood disorder)

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MEPOLIZUMAB

INITIAL CRITERIA (CONTINUED)

**B. If you have severe asthma with an eosinophilic phenotype, approval also requires:**

1. You are 6 years of age or older
2. Therapy is prescribed by or in consultation with a doctor specializing in pulmonary (lung/ breathing) medicine or allergy medicine
3. You have a documented blood eosinophil level (type of white blood cell) of at least 150 cells/mcL within the past 12 months
4. You are being treated with medium, high-dose, or maximally tolerated dose of an inhaled corticosteroid AND at least one other maintenance medication such as a long-acting inhaled beta2-agonist (such as formoterol, salmeterol), a long-acting muscarinic antagonist (such as tiotropium), a leukotriene receptor antagonist (such as montelukast), theophylline, or oral corticosteroid
5. You have ONE of the following:
  - a. Experienced at least ONE asthma exacerbation (worsening of symptoms) requiring systemic corticosteroid burst lasting at least 3 days within the past 12 months OR at least ONE serious exacerbation requiring hospitalization or emergency room visit within the past 12 months
  - b. Poor symptom control despite current therapy as evidenced by at least THREE of the following within the past 4 weeks:
    - Daytime asthma symptoms more than twice per week
    - Any night waking due to asthma
    - Use of a short-acting inhaled beta2-agonist reliever (such as albuterol) for symptoms more than twice per week
    - Any activity limitation due to asthma
6. You will NOT use Nucala concurrently (at the same time) with Xolair, Dupixent, or another anti-IL-5 biologic (such as Cinqair, Fasentra) when these are used for the treatment of asthma

**C. If you have chronic rhinosinusitis with nasal polyps, approval also requires:**

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with an otolaryngologist (ear, nose, and throat doctor) or allergist/immunologist
3. Nucala will be used as add-on maintenance treatment
4. You had a 90-day trial of ONE intranasal corticosteroid (such as mometasone, fluticasone, beclomethasone)

**D. If you have eosinophilic granulomatosis with polyangiitis, approval also requires:**

1. You are 18 years of age or older

*(Initial denial text continued on next page)*

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MEPOLIZUMAB

INITIAL CRITERIA (CONTINUED)

E. If you have hypereosinophilic syndrome, approval also requires:

1. You are 12 years of age or older
2. You have had HES for 6 months or more without an identifiable non-hematologic (not present in the blood) secondary cause

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

**NOTE:** For the diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss syndrome) OR hypereosinophilic syndrome (HES), please refer to the Initial Criteria section.

1. Does the patient have a diagnosis of severe asthma with an eosinophilic phenotype and meet **ALL** of the following criteria?
  - The patient continues to use an inhaled corticosteroid (e.g., triamcinolone acetonide, beclomethasone, mometasone, budesonide) AND at least one other maintenance medication (e.g., a long-acting inhaled beta2-agonist such as formoterol or salmeterol, a long-acting muscarinic antagonist such as tiotropium, a leukotriene receptor antagonist such as montelukast, theophylline, or oral corticosteroid)
  - Nucala will NOT be used concurrently with Xolair, Dupixent, or another anti-IL-5 biologic (e.g., Cinqair, Fasentra) when these are used for the treatment of asthma

If yes, continue to #2.

If no, continue to #3.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MEPOLIZUMAB

RENEWAL CRITERIA (CONTINUED)

2. Has the patient shown a clinical response as evidenced by **ONE** of the following criteria?
- Reduction in asthma exacerbation from baseline
  - Decreased utilization of rescue medications
  - Increase in percent predicted FEV1 from pretreatment baseline
  - Reduction in severity or frequency of asthma-related symptoms (e.g., wheezing, shortness of breath, coughing, etc.)

If yes, **approve for 12 months as follows:**

- **If the plan covers non-self-administered (NSA) agents: Approve by HICL or GPI-10 with a quantity limit of #1 vial/syringe per 28 days.**
- **If the plan does NOT cover NSA agents: Approve the requested strength by GPID or GPI-14 with the following quantity limits:  
100mg/1mL: #1mL per 28 days.  
40mg/0.4mL: #0.4mL per 28 days.**

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

3. Does the patient have a diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP) **AND** meet the following criterion?
- The patient has had clinical benefit compared to baseline (e.g., improvements in nasal congestion, sense of smell or size of polyps)

If yes, **approve for 12 months as follows:**

- **If the plan covers non-self-administered (NSA) agents: Approve by HICL or GPI-10 with a quantity limit of #1 vial/syringe per 28 days.**
- **If the plan does NOT cover NSA agents: Approve Nucala autoinjector and 100mg/1mL syringe by GPID or GPI-14 with a quantity limit of #1mL per 28 days.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **MEPOLIZUMAB (Nucala)** requires the following rule(s) be met for renewal:

A. You have **ONE** of the following diagnoses:

1. Severe asthma with an eosinophilic phenotype (inflammatory type)
2. Chronic rhinosinusitis with nasal polyps (CRSwNP; inflammation of nasal and sinus ways with small growths in the nose)

***(Renewal denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MEPOLIZUMAB

RENEWAL CRITERIA (CONTINUED)

**B. If you have severe asthma with an eosinophilic phenotype, renewal also requires:**

1. You will continue to use an inhaled corticosteroid (such as triamcinolone acetonide, beclomethasone, mometasone, budesonide) AND at least one other maintenance medication such as a long-acting inhaled beta2-agonist (such as formoterol, salmeterol), a long-acting muscarinic antagonist (such as tiotropium), a leukotriene receptor antagonist (such as montelukast), theophylline, or oral corticosteroids
2. You will NOT use Nucala concurrently (at the same time) with Xolair, Dupixent, or another anti-IL-5 biologic (such as Cinqair, Fasenra) when these are used for the treatment of asthma
3. You have shown a clinical response as evidenced by ONE of the following:
  - a. You have experienced a reduction in asthma exacerbation (worsening of symptoms) from baseline
  - b. You have decreased use of rescue medications
  - c. You have an increase in percent predicted FEV1 (amount of air you can forcefully exhale in one second) from pretreatment baseline (before starting Nucala)
  - d. You have a reduction in severity or frequency of asthma-related symptoms (such as wheezing, shortness of breath, coughing, etc.)

**C. If you have chronic rhinosinusitis with nasal polyposis, renewal also requires:**

1. You have had a clinical benefit compared to baseline (before starting Nucala) (such as improvements in nasal congestion, sense of smell or size of polyps)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Nucala.

**REFERENCES**

- Nucala [Prescribing Information]. Philadelphia, PA: GlaxoSmithKline, LLC.; January 2022.

Library	Commercial	NSA
Yes	Yes	Yes

Part D Effective: N/A

Commercial Effective: 07/01/22

Created: 11/15

Client Approval: 05/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

METHOXY PEG-EPOETIN BETA

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
METHOXY PEG-EPOETIN BETA	MIRCERA	35005		GPI-10 (8240104010)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of anemia associated with chronic kidney disease (CKD)?

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Is the patient 18 years of age or older and meets **ALL** of the following criteria?

- The patient had a trial of the preferred agent: Retacrit
- The patient has a hemoglobin level of less than 10g/dL

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #0.6mL per 28 days.**

If no, continue to #3.

3. Is the patient between 5 and 17 years of age and meets **ALL** of the following criteria?

- The patient is on hemodialysis
- The patient is converting from another erythropoiesis-stimulating agent (ESA) (i.e., epoetin alfa, darbepoetin alfa) after the hemoglobin level has been stabilized with the ESA

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #0.6mL per 28 days.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

METHOXY PEG-EPOETIN BETA

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **METHOXY PEG-EPOETIN BETA (Mircera)** requires the following rule(s) be met for approval:

- A. You have anemia (low amount of healthy red blood cells) associated with chronic kidney disease
- B. **If you are 18 years of age or older, approval also requires:**
  1. You have tried the preferred medication: Retacrit
  2. You have a hemoglobin level (type of blood test) of less than 10g/dL
- C. **If you are between 5 and 17 years of age, approval also requires:**
  1. You are on hemodialysis (process of removing excess water, toxins from the blood)
  2. You are changing from another erythropoiesis-stimulating agent (ESA; epoetin alfa, darbepoetin alfa) after the hemoglobin level has been stabilized with the ESA

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of anemia associated with chronic kidney disease (CKD)?

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

2. Is the patient 18 years of age or older and meets **ONE** of the following criteria?
  - The patient has a hemoglobin level of less than 11g/dL if on dialysis
  - The patient has a hemoglobin level that has reached 11g/dL (if on dialysis) and dose reduction/interruption is required to reduce the need for blood transfusions
  - The patient has a hemoglobin level of less than 10g/dL if not on dialysis
  - The patient has a hemoglobin level that has reached 10g/dL (if not on dialysis) and dose reduction/interruption is required to reduce the need for blood transfusions

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #0.6mL per 28 days.**

If no, continue to #3.

CONTINUED ON NEXT PAGE





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

METHOXY PEG-EPOETIN BETA

RENEWAL CRITERIA (CONTINUED)

3. Is the patient between 5 and 17 years of age and meets **ALL** of the following criteria?
- The patient is currently receiving dialysis treatment
  - The patient has a hemoglobin level of less than 11g/dL OR the patient has a hemoglobin level that has reached 11g/dL and dose reduction/interruption is required to reduce the need for blood transfusions

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #0.6mL per 28 days.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **METHOXY PEG-EPOETIN BETA (Mircera)** requires the following rule(s) be met for renewal:

- A. You have anemia (low amount of healthy red blood cells) associated with chronic kidney disease
- B. **If you are 18 years of age or older, renewal also requires ONE of the following:**
1. You have a hemoglobin level (type of blood test) of less than 11g/dL if you are on dialysis (process of removing excess water, toxins from the blood)
  2. The patient has a hemoglobin level that has reached 11g/dL (if you are on dialysis) and dose reduction/interruption is required to reduce the need for blood transfusions
  3. You have a hemoglobin level (type of blood test) of less than 10g/dL if you are not on dialysis
  4. You have a hemoglobin level that has reached 10g/dL (if you are not on dialysis) and dose reduction/interruption is required to reduce the need for blood transfusions
- C. **If you are between 5 and 17 years of age, renewal also requires:**
1. You are currently receiving dialysis treatment (process of removing excess water, toxins from the blood)
  2. You have ONE of the following:
    - a. A hemoglobin level (type of blood test) of less than 11g/dL
    - b. A hemoglobin level that has reached 11g/dL and dose reduction/interruption is required to reduce the need for blood transfusions

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**





**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**METHOXY PEG-EPOETIN BETA**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Mircera.

**REFERENCES**

- Mircera [Prescribing Information]. St. Gallen, Switzerland: Vifor, August 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 02/06/23

Created: 02/11

Client Approval: 01/23

P&T Approval: 01/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

METHYLNALTREXONE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
METHYLNALTREXONE BROMIDE	RELISTOR	35611		GPI-10 (5258005010)	

**GUIDELINES FOR USE**

1. Is the request for methylnaltrexone (Relistor) tablets or injection for a patient with constipation due to an opioid (such as morphine or methadone) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient has chronic non-cancer pain (including chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation)
- The patient has been taking opioids for at least four weeks
- The patient has a previous trial of or contraindication to naloxegol (Movantik)

If yes, **approve for 12 months by GPID or GPI-14 for all of the following listed agents and quantity limits:**

- **Relistor 12mg vial: #1 vial per day.**
- **Relistor 12mg syringe: #1 syringe per day.**
- **Relistor 150mg tablets: #3 tablets per day.**

If no, continue to #2.

2. Is the request for methylnaltrexone (Relistor) injection for a patient with constipation due to an opioid (such as morphine or methadone) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient has advanced (terminal) illness or pain caused by active cancer who require opioid dosage escalation for palliative care

If yes, **approve Relistor injection for 6 months by GPID or GPI-14 with the following quantity limits:**

- **Relistor 12 mg vial: #1 vial per day.**
- **Relistor 12 mg syringe: #1 syringe per day.**
- **Relistor 8 mg syringe: #1 syringe per day.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

METHYLNALTREXONE

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **METHYLNALTREXONE (Relistor)** requires the following rule(s) be met for approval:

- A. You have opioid (type of pain medication)-induced constipation with chronic non-cancer pain, OR you have an advanced illness or pain caused by active cancer and you require opioid dosage increase for palliative care (treatment of symptoms)
- B. You are 18 years of age or older
- C. **If you have advanced (terminal) illness, or pain caused by active cancer** and you require opioid dosage increase for palliative care (treatment of symptoms), only Relistor injection may be approved
- D. **If you have chronic non-cancer pain, approval also requires:**
  - 1. You have been taking opioids for at least four weeks
  - 2. You had a previous trial of naloxegol (Movantik), unless there is a medical reason why you cannot (contraindication)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Relistor.

**REFERENCES**

- Relistor [Prescribing Information]. Bridgewater, NJ: Salix Pharmaceuticals. November 2018.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 11/08

Client Approval: 04/20

P&T Approval: 08/16



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

METHYLTESTOSTERONE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
METHYLTESTOSTERONE	TESTRED, ANDROID, METHITEST, METHYLTESTOS- TERONE		10380 10411	GPI-10 (2310002000)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Is the request for a male patient with a diagnosis of primary or secondary hypogonadism (hypotestosteronism or low testosterone) who meets **ONE** of the following criteria?
  - The patient has a previously approved prior authorization for testosterone or has been receiving any form of testosterone replacement therapy as indicated per physician attestation or claims history
  - The patient has AT LEAST ONE of the following laboratory values confirming low testosterone levels:
    - At least two total serum testosterone levels of less than 300 ng/dL (10.4 nmol/L) taken on separate occasions
    - Free serum testosterone level of less than 5 ng/dL (0.17 nmol/L)

If yes, continue to #2.

If no, continue to #5.

2. Is the patient 40 years of age or older?

If yes, continue to #3.

If no, continue to #4.

3. Has the patient's prostate specific antigen (PSA) been evaluated for prostate cancer screening?

If yes, continue to #4.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

4. Has the patient had a trial of or contraindication to **TWO** lower cost testosterone agents (e.g., testosterone cypionate, testosterone enanthate)?

If yes, **approve the requested agent for 12 months by GPID or GPI-14 with a quantity limit of #5 per day.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

METHYLTESTOSTERONE

INITIAL CRITERIA (CONTINUED)

5. Is the request for a male patient with a diagnosis of delayed puberty not secondary to a pathological disorder **AND** meets the following criterion?

- The patient had a trial of or contraindication to intramuscular testosterone enanthate

If yes, **approve the requested agent for lifetime by GPID or GPI-14 with a quantity limit of #5 per day.**

If no, continue to #6.

6. Is the requested agent for gender dysphoria as supported by the compendia (e.g., DrugDex strength of recommendation Class I, IIa, or IIb) **AND** the patient meets the following criterion?

- The patient is 16 years of age or older

If yes, **approve the requested agent for 12 months by GPID or GPI-14 and override quantity limits.**

If no, continue to #7.

7. Is the request for a female patient with a diagnosis of metastatic breast cancer **AND** meets the following criterion?

- The patient had a trial of or contraindication to intramuscular testosterone enanthate

If yes, **approve the requested agent for lifetime by GPID or GPI-14 with a quantity limit of #20 per day.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**INITIAL DENIAL TEXT:** **\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **METHYLTESTOSTERONE (Testred, Android, Methitest)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:

1. Primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
2. Delayed puberty not due to a pathological disorder (not due to disease) in a male
3. Gender dysphoria (you identify yourself as a member of the opposite sex)
4. Metastatic breast cancer (cancer spreading to other areas of body) in a female

***(Initial denial text continues on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

METHYLTESTOSTERONE

INITIAL CRITERIA (CONTINUED)

- B. If you are a male with primary or secondary hypogonadism, approval also requires:**
1. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening
  2. You meet ONE of the following:
    - a. You have a previously approved prior authorization for testosterone, or you have been receiving any form of testosterone replacement therapy as indicated per physician attestation or claims history
    - b. You have ONE of the following lab values showing you have low testosterone levels:
      - i. At least two total serum (blood) testosterone levels of less than 300 ng/DI (10.4 nmol/L) taken on separate occasions
      - ii. Free serum testosterone level of less than 5 ng/DI (0.17 nmol/L)
  3. You had a trial of or contraindication (harmful for) to TWO lower cost testosterone agents (such as intramuscular [injected into the muscle] testosterone cypionate, intramuscular testosterone enanthate)
- C. If you are a male with delayed puberty not secondary to a pathological disorder, approval also requires:**
1. You had a trial of or contraindication (harmful for) to intramuscular (injected into the muscle) testosterone enanthate.
- D. If you have gender dysphoria, approval also requires:**
1. Only agents supported by the compendia (accepted medical references such as DrugDex strength of recommendation Class I, IIa, or IIb) for treatment of gender dysphoria may be approved
  2. You are 16 years of age or older
- E. If you are a female with metastatic breast cancer, approval also requires:**
1. You had a trial of or contraindication (harmful for) intramuscular (injected into the muscle) testosterone enanthate.

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

METHYLTESTOSTERONE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Is the request for a male patient with a diagnosis of primary or secondary hypogonadism (hypotestosteronism or low testosterone) who meets **ALL** of the following criteria?
  - The patient has improved symptoms compared to baseline and tolerance to treatment
  - There is documentation (e.g., chart notes, lab results) of normalized serum testosterone levels and hematocrit concentrations compared to baseline
  - If the patient is 40 years of age or older, the patient's prostate specific antigen (PSA) has been evaluated for prostate cancer screening

If yes, **approve the requested agent for 12 months by GPID or GPI-14 with a quantity limit of #5 per day.**

If no, continue to #2.

2. Is the request for a male patient with a diagnosis of delayed puberty not secondary to a pathological disorder?

If yes, **approve the requested agent for lifetime by GPID or GPI-14 with a quantity limit of #5 per day.**

If no, continue to #3.

3. Is the request for a female patient with a diagnosis of metastatic breast cancer?

If yes, **approve the requested agent for lifetime by GPID or GPI-14 with a quantity limit of #20 per day.**

If no, continue to #4.

4. Is the requested agent for gender dysphoria as supported by the compendia (e.g., DrugDex strength of recommendation Class I, IIa, or IIb)?

If yes, **approve the requested agent for 12 months by GPID or GPI-14 and override quantity limits.**

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

METHYLTESTOSTERONE

RENEWAL CRITERIA (CONTINUED)

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **METHYLTESTOSTERONE (Testred, Android, Methitest)** requires the following rule(s) be met for renewal:

You have ONE of the following diagnoses:

1. Primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
2. Delayed puberty not due to a pathological disorder (not due to disease) in a male
3. Metastatic breast cancer (cancer spreading to other areas of body) in a female
4. Gender dysphoria (you identify yourself as a member of the opposite sex)

**B. If you have gender dysphoria, renewal also requires:**

1. Only agents supported by the compendia (accepted medical references such as DrugDex strength of recommendation Class I, IIa, or lib) for treatment of gender dysphoria may be approved

**C. If you are a male with primary or secondary hypogonadism, renewal also requires:**

1. You have shown improvement in your symptoms compared to baseline and tolerance to treatment
2. There is documentation (such as chart notes, lab results) of normalized serum testosterone levels and hematocrit concentrations (type of blood test) compared to baseline
3. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Testred, Android, and Methitest.

**REFERENCES**

Android [Prescribing Information]. Bridgewater, NJ: Valeant Pharmaceuticals.; April 2015.  
Methitest [Prescribing Information]. Hayward, CA: Impax Generics.; May 2019.  
Testred [Prescribing Information]. Bridgewater, NJ: Valeant Pharmaceuticals.; April 2015.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/23

Created: 02/23

Client Approval: 02/23

P&T Approval: 01/23

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.





**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**METOCLOPRAMIDE**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
METOCLOPRAMIDE	GIMOTI		48272	GPI-14 (52300020102080)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of acute and recurrent diabetic gastroparesis **AND** meet the following criterion?

- The patient is 18 years of age or older
- The patient had a trial of or contraindication to metoclopramide ODT

If yes, **approve for 3 months by GPID or GPI-14 with a quantity limit of #9.8 mL (1 bottle) per 28 days.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **METOCLOPRAMIDE (Gimoti)** requires the following rule(s) be met for approval:

- A. You have acute (short duration) and recurrent (occurring repeatedly) diabetic gastroparesis (disorder that causes delayed emptying of food from the stomach)
- B. You are 18 years of age or older
- C. You have previously tried or have a contraindication (medical reason why you cannot take) to metoclopramide ODT (orally disintegrating tablet)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Gimoti.

**REFERENCES**

- Gimoti [Prescribing Information]. Solana Beach, CA: Evoke Pharma, Inc.; June 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/21

Created: 11/20

Client Approval: 11/20

P&T Approval: 10/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MIDOSTAURIN

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
MIDOSTAURIN	RYDAPT	44227		GPI-10 (2153303000)	

**GUIDELINES FOR USE**

1. Does the patient have newly diagnosed acute myeloid leukemia (AML) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient is FLT3 mutation-positive as detected by an FDA-approved diagnostic test
  - The requested medication will be used in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation
  - The requested medication will not be used as a single-agent induction therapy for the treatment of patients with AML

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #56 per 28 days.**  
If no, continue to #2.

2. Does the patient have a diagnosis of aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL) **AND** meet the following criterion?
  - The patient is 18 years of age or older

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #224 per 28 days.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **MIDOSTAURIN (Rydapt)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
  1. Newly diagnosed acute myeloid leukemia (AML: a type of blood cancer)
  2. Aggressive systemic mastocytosis (ASM: a type of blood disorder)
  3. Systemic mastocytosis with associated hematological neoplasm (SM-AHN: type of blood cancer)
  4. Mast cell leukemia (MCL: type of blood cell cancer)

**(Denial text continued on next page)**

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MIDOSTAURIN

GUIDELINES FOR USE (CONTINUED)

**B. If you have newly diagnosed acute myeloid leukemia, approval also requires:**

1. You are 18 years of age or older
2. You are FLT3 (type of gene) mutation-positive as detected by a Food and Drug Administration (FDA)-approved diagnostic test
3. The requested medication will be used in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation (cancer drugs)
4. The requested medication will not be used by itself to start treatment (single-agent induction therapy)

**C. If you have aggressive systemic mastocytosis, systemic mastocytosis with associated hematological neoplasm, or mast cell leukemia, approval also requires:**

1. You are 18 years of age or older

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the prescribing information and/or drug monograph for Rydapt.

**REFERENCES**

- Rydapt [Prescribing Information]. East Hanover, New Jersey: Novartis Pharmaceuticals; November 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/22

Created: 08/17

Client Approval: 03/22

P&T Approval: 07/17



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MIFEPRISTONE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
MIFEPRISTONE	KORLYM		31485	GPI-10 (2730405000)	

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of endogenous Cushing's syndrome (CS) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or given in consultation with an endocrinologist
  - Diagnosis is confirmed by **ONE** of the following:
    - 24-hour urine free cortisol (2 or more tests to confirm)
    - Overnight 1mg dexamethasone test
    - Late night salivary cortisol (2 or more tests to confirm)
  - The patient's hypercortisolism is not a result of chronic glucocorticoids
  - The patient also has a diagnosis of type 2 diabetes mellitus **OR** glucose intolerance
  - Patient has failed surgical treatment for Cushing's syndrome **OR** is not a candidate for surgery

If yes, **approve for 12 months by GPID or GPI-10 with a quantity limit of #4 per day.**

**APPROVAL TEXT:** Renewal for endogenous Cushing's syndrome requires that the patient continues to have improvement of glucose tolerance and/or stable glucose tolerance (e.g., reduced A1C, improved fasting glucose, etc.), tolerability to Korlym, and continues to not be a candidate for surgical treatment or has failed surgery.

If no, do not approve.

**INITIAL DENIAL TEXT:** *\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **MIFEPRISTONE (Korlym)** requires the following rule(s) be met for approval:

- A. You have endogenous Cushing's syndrome (CS: condition that occurs after having high levels of cortisol hormone in the body for a long time)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or given in consultation with an endocrinologist (doctor who specializes in hormones)
- D. Your diagnosis has been confirmed by ONE of the following:
  1. 24-hour urine free cortisol test (at least 2 or more tests to confirm)
  2. Overnight 1mg dexamethasone test
  3. Late night salivary cortisol (at least 2 or more tests to confirm)

***(Initial denial text continued on the next page)***

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MIFEPRISTONE

INITIAL CRITERIA (CONTINUED)

- E. Your hypercortisolism (high levels of cortisol) is not a result of chronic glucocorticoids (class of drugs that consist of steroids)
- F. You have type 2 diabetes mellitus (too much sugar in your blood) OR glucose intolerance (term for a group of conditions that result in elevated blood sugar)
- G. You have failed surgical treatment for Cushing's syndrome OR you are not a candidate for surgery

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of endogenous Cushing's syndrome (CS) and meet **ALL** of the following criteria?
  - The patient continues to have improvement of glucose tolerance and/or stable glucose tolerance (e.g., reduced A1C, improved fasting glucose, etc.)
  - The patient continues to have tolerability to Korlym
  - The patient continues to not be a candidate for surgical treatment or has failed surgery

If yes, **approve for 12 months by GPID or GPI-10 with a quantity limit of #4 per day.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **MIFEPRISTONE (Korlym)** requires the following rule(s) be met for renewal:

- A. You have endogenous Cushing's syndrome (condition that occurs after having high levels of cortisol hormone in the body for a long time)
- B. You continue to have improvement of glucose tolerance and/or stable glucose tolerance (such as reduced hemoglobin A1C [average amount of sugar in your blood over the last 2 to 3 months], improved fasting glucose)
- C. You continue to tolerate Korlym
- D. You are not a candidate for surgery or have failed surgery for Cushing's syndrome  
**(Renewal denial text continued on the next page)**

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MIFEPRISTONE

RENEWAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the prescribing information and/or drug monograph for Korlym.

**REFERENCE**

- Korlym [Prescribing Information]. Menlo Park, CA: Corcept Therapeutics; November 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/01/20

Created: 04/12

Client Approval: 08/20

P&T Approval: 07/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MIGALASTAT

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
MIGALASTAT HCL	GALAFOLD	44433		GPI-10 (3090365010)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of Fabry disease and meet **ALL** of the following criteria?
  - The patient is 18 years or older
  - Therapy is prescribed by or in consultation with a nephrologist, cardiologist, or specialist physician in genetics or inherited metabolic disorders
  - The patient has an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data as interpreted by clinical genetics professional as pathogenic/likely pathogenic (i.e., patient does not have a benign amenable GLA variant)
  - The patient is NOT concurrently using enzyme replacement therapy (i.e., Fabrazyme)
  - The patient is symptomatic OR has evidence of injury from GL-3 to the kidney, heart, or central nervous system recognized by laboratory, histological, or imaging findings (e.g., decreased GFR for age, persistent albuminuria, cerebral white matter lesions on brain MRI, cardiac fibrosis on contrast cardiac MRI)

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Is the request for a female patient who meets the following criterion?  
Confirmation of Fabry disease via genetic test documenting galactosidase alpha gene (GLA) mutation

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #14 per 28 days.**

If no, continue to #3.

3. Is the request for a male patient who meets **ONE** of the following criteria?
  - Confirmation of Fabry disease via enzyme assay indicating deficiency of alpha galactosidase A (a-Gal -A)
  - Confirmation of Fabry disease via genetic test documenting galactosidase alpha gene (GLA) mutation

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #14 per 28 days.**

If no, do not approve.

**INITIAL DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MIGALASTAT

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **MIGALASTAT (Galafold)** requires the following rule(s) be met for approval:

- A. You have confirmed Fabry disease (rare genetic disease)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a nephrologist (kidney doctor), cardiologist (heart doctor), or specialist in genetics or inherited metabolic disorders
- D. You have an amenable (responsive) galactosidase alpha gene (GLA) variant based on in vitro assay data (data collected from lab test tubes or cultures) that is interpreted by clinical genetics professional as the cause of disease (pathogenic/likely pathogenic)
- E. You are NOT using Galafold together with an enzyme replacement therapy (Fabrazyme)
- F. You are symptomatic OR have evidence of injury from globotriaosylceramide (GL-3: a type of fat) to the kidney, heart, or central nervous system recognized by laboratory, histological, or imaging findings. Evidence of injury includes decreased GFR (measurement of how well your kidneys are working) for age, persistent albuminuria (buildup of a type of protein), cerebral white matter lesions on brain MRI (magnetic resonance imaging: a type of imaging lab), cardiac fibrosis (scarring of the heart) on contrast cardiac MRI
- G. You meet ONE of the following:
  - 1. Female patient: Confirmation of Fabry disease (rare genetic disease) via genetic test documenting galactosidase alpha gene (GLA) mutation
  - 2. Male patient: Confirmation of Fabry disease via enzyme assay (lab test) showing you have a low amount of alpha galactosidase A (a-Gal -A) OR genetic test documenting galactosidase alpha gene (GLA) mutation

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MIGALASTAT

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of Fabry disease and meet **ALL** of the following criteria?
  - The patient is NOT concurrently using enzyme replacement therapy (i.e., Fabrazyme)
  - The patient has demonstrated improvement or maintenance/stabilization while on therapy to at least ONE of the following:
    - Symptoms (e.g., pain, hypohidrosis/anhidrosis, exercise intolerance, GI symptoms, angiokeratomas, abnormal cornea, tinnitus/hearing loss)
    - Imaging (e.g., brain/cardiac MRI, DEXA, renal ultrasound)
    - Laboratory or histological testing (e.g., GL-3 in plasma/urine, renal biopsy)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #14 per 28 days.**  
If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **MIGALASTAT (Galafold)** requires the following rule(s) be met for renewal:

- A. You have Fabry disease (rare genetic disease)
- B. You are NOT using Galafold together with an enzyme replacement therapy (Fabrazyme)
- C. You have demonstrated improvement or maintenance/stabilization while on therapy to at least ONE of the following:
  1. Symptoms such as pain, hypohidrosis/anhidrosis (little to no sweat), exercise intolerance, gastrointestinal (GI) symptoms, angiokeratomas (dark red/purple raised spots), abnormal cornea, tinnitus (ringing in the ears), or hearing loss
  2. Imaging such as brain/cardiac MRI (magnetic resonance imaging: a type of imaging lab), DEXA (dual-energy X-ray absorptiometry: a type of bone scan), or renal (kidney) ultrasound
  3. Laboratory or histological (viewed by microscope) testing such as globotriaosylceramide (GL-3: a type of fat) in plasma/urine or renal biopsy

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**MIGALASTAT**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Galafold.

**REFERENCES**

- Galafold [Prescribing Information]. Cranbury, NJ: Amicus Therapeutics; December 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/22

Created: 11/18

Client Approval: 05/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MIGLUSTAT

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
MIGLUSTAT	ZAVESCA	25098		GPI-10 (8270007000)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of mild to moderate type 1 (non-neuronopathic) Gaucher disease and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The requested medication will be used as monotherapy
  - Enzyme replacement therapy is not a therapeutic option for this patient (e.g., due to allergy, hypersensitivity, or poor venous access)

If yes, **approve for up to 12 months by HICL or GPI-10 with a quantity limit of #90 per 30 days.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **MIGLUSTAT (Zavesca)** requires the following rule(s) be met for approval:

- A. You have mild to moderate type 1 Gaucher disease (rare genetic disorder that affects organs and tissues)
- B. You are 18 years of age or older
- C. The requested medication will be used as monotherapy (used alone)
- D. Enzyme replacement therapy is not a therapeutic option for this patient (due to allergy, hypersensitivity, or poor venous access)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Zavesca.

**REFERENCES**

- D. Zavesca [Package Insert]. South San Francisco, CA: Actelion Pharmaceuticals; November 2017.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 05/05

Client Approval: 04/20

P&T Approval: 08/12

Copyright © 2023 MediImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MediImpact. MediImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MILTEFOSINE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
MILTEFOSINE	IMPAVIDO	16200		GPI-10 (1600003600)	

GUIDELINES FOR USE

1. Does the patient have a diagnosis of Leishmaniasis and meet **ALL** of the following criteria?
  - The patient has **ONE** of the following types of infections:
    - Visceral leishmaniasis caused by *Leishmania donovani*
    - Cutaneous leishmaniasis caused by any of the following: *Leishmania braziliensis*, *Leishmania guyanensis*, or *Leishmania panamensis*
    - Mucosal leishmaniasis caused by *Leishmania braziliensis*
  - Leishmaniasis species is identified via **ONE** of the following CDC recommended tests:
    - Stained slides (using tissue from biopsy specimens, impression smears or dermal scrapings)
    - Culture medium
    - Polymerase chain reaction (PCR)
    - Serologic testing (e.g., rK39 Rapid Test)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #84 per 28 days.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline for **MILTEFOSINE (Impavido)** requires the following rule(s) be met for approval:

- A. You have Leishmaniasis (type of parasite disease) with ONE of the following types of infection:
  1. Visceral leishmaniasis (affects your organs) caused by *Leishmania donovani* (type of parasite)
  2. Cutaneous leishmaniasis (affects your skin layers) caused by any of the following types of parasites:
    - a. *Leishmania braziliensis*
    - b. *Leishmania guyanensis*
    - c. *Leishmania panamensis*
  3. Mucosal leishmaniasis (affects inside mouth, throat and nose) caused by *Leishmania braziliensis*
- B. Species identification must be confirmed via ONE of the following CDC (Center for Disease Control and Prevention) recommended tests:
  1. Stained slides (using tissue from biopsy specimens, impression smears or dermal scrapings)
  2. Culture medium
  3. Polymerase chain reaction (lab method to make copies of genes)
  4. Serologic testing (testing your blood and body fluids such as rK39 Rapid Test)

**(Denial text continued on next page)**

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MILTEFOSINE

GUIDELINES FOR USE (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Impavido.

**REFERENCES**

- Impavido [Prescribing Information]. Orlando, FL: Profounda, Inc.; May 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/01/21

Created: 04/16

Client Approval: 10/21

P&T Approval: 05/16



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MINOCYCLINE HCL MICROSPHERES (NSA)

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
MINOCYCLINE HCL MICROSPHERES	ARESTIN	25203		GPI-10 (8845205010)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: SEE RENEWAL CRITERIA BELOW)**

1. Is this medication excluded from coverage?

If yes, guideline does not apply.  
If no, continue to #2.

2. Does the patient have documentation of a confirmed diagnosis of periodontitis and meets **ALL** of the following criteria?

- The patient is 18 years of age or older
- Therapy is prescribed by or given in consultation with an oral health care professional
- The patient has no history of minocycline or tetracycline sensitivity or allergy
- The patient has no history of candidiasis or active oral candidiasis
- The requested medication will be administered by an oral health care professional
- The requested medication will be used as an adjunct to scaling and root planing procedures **OR** used as part of a periodontal maintenance program which includes good oral hygiene and scaling and root planing
- The requested medication is not being used for acutely abscessed periodontal pocket
- The requested medication will not be used in an immunocompromised individual, such as those immunocompromised by any of the following conditions:
  - Uncontrolled diabetes mellitus
  - Chemotherapy
  - Radiation therapy
  - HIV infection
- The requested medication is not being used in the regeneration of alveolar bone, either in preparation for or in conjunction with the placement of endosseous (dental) implants or in the treatment of failing implants

If yes, **approve for 3 months by HICL or GPI-10 for the quantity requested up to a maximum of 48 unit-dose cartridges.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MINOCYCLINE HCL MICROSPHERES (NSA)

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **MINOCYCLINE HCL MICROSPHERES (Arestin)** requires the following rule(s) be met for approval:

- A. You have documentation of confirmed periodontitis (inflammation and infection of the gums)
- B. You are age 18 years or older
- C. The medication is prescribed by or given in consultation with an oral health care professional
- D. You do not have a history of minocycline or tetracycline sensitivity or allergy
- E. You do not have a history of candidiasis (a type of fungal infection) or active oral candidiasis
- F. The requested medication will be administered by an oral health professional
- G. The requested medication will be used as an adjunct (add-on therapy) to scaling and root planing procedures OR used as part of a periodontal maintenance program which includes good oral hygiene and scaling and root planing
- H. The requested medication is not being used for acutely abscessed periodontal pocket (not used for short-term and sudden infection with pus-filled pocket)
- I. The medication is not being used in an immunocompromised individual (your immune system is weakened), such as those immunocompromised by any of the following conditions:
  - 1. Uncontrolled diabetes mellitus
  - 2. Chemotherapy
  - 3. Radiation therapy
  - 4. HIV (human immunodeficiency virus) infection
- J. The medication is not being used in the regeneration of alveolar bone (bone that has tooth sockets), either in preparation for or in conjunction with the placement of endosseous (dental) implants or in the treatment of failing implants

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

- 1. Is this medication excluded from coverage?

If yes, guideline does not apply.  
If no, continue to #2.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MINOCYCLINE HCL MICROSPHERES (NSA)

RENEWAL CRITERIA (CONTINUED)

2. Does the patient have documentation of a confirmed diagnosis of periodontitis and meets the following criteria?
- The requested medication will be used as an adjunct to scaling and root planing procedures **OR** used as part of a periodontal maintenance program which includes good oral hygiene and scaling and root planing

If yes, **approve for 6 months by HICL or GPI-10 for the quantity requested up to a maximum of 48 unit-dose cartridges per 3 months.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **MINOCYCLINE HCL MICROSPHERES (Arestin)** requires the following rule(s) be met for renewal:

- A. You have documentation of periodontitis (inflammation and infection of the gums)
- B. The medication will be used as an adjunct (add-on therapy) to scaling and root planing procedures **OR** used as part of a periodontal maintenance program which includes good oral hygiene and scaling and root planing

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the prescribing information and/or drug monograph for Arestin.

**REFERENCES**

- Arestin [Prescribing Information]. Bridgewater, NJ: OraPharma. December 2017.

Library	Commercial	NSA
Yes	Yes	Yes

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 08/16

Client Approval: 04/20

P&T Approval: 08/16





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MIPOMERSEN SODIUM

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
MIPOMERSEN SODIUM	KYNAMRO	40041		GPI-10 (3950004010)	

**GUIDELINES FOR USE**

1. Is the requested medication prescribed by or given in consultation with a cardiologist, endocrinologist, or lipidologist?

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient meet **ONE** of the following criteria?

- The patient has been taking a high-intensity statin (i.e., atorvastatin 40-80 mg daily, rosuvastatin 20-40 mg daily) for a duration of at least 8 weeks
- The patient has been taking a maximally tolerated dose of any statin for a duration of at least 8 weeks given that the patient cannot tolerate a high-intensity statin (i.e., atorvastatin 40-80 mg daily, rosuvastatin 20-40 mg daily)

If yes, continue to #3.

If no, continue to #4.

3. Will the patient continue statin treatment as described above in combination with Kynamro?

If yes, continue to #5.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

4. Does the patient meet **ONE** of the following criteria?

- The patient has an absolute contraindication to statin therapy (e.g., active decompensated liver disease, nursing female, pregnancy or plans to become pregnant, hypersensitivity reaction)
- The patient has complete statin intolerance as defined by severe and intolerable adverse effects (e.g., creatine kinase elevation greater than or equal to 10 times the upper limit of normal, liver function test elevation greater than or equal to 3 times the upper limit of normal, rhabdomyolysis, severe muscle weakness leading to temporary disability, fall, or inability to use a major muscle group) that have occurred with trials of at least two separate statins and have improved with the discontinuation of each statin

If yes, continue to #5.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MIPOMERSEN SODIUM

GUIDELINES FOR USE (CONTINUED)

5. Does the patient have a LDL-cholesterol level greater than or equal to 70 mg/dL while on maximally tolerated statin treatment?

If yes, continue to #6.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

6. Does the patient meet **ONE** of the following criteria?

- The patient has had a previous trial of Repatha (evolocumab)
- The patient lacks functioning LDL receptors

If yes, continue to #7.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

7. Does the patient have a diagnosis of homozygous familial hypercholesterolemia (HoFH) as determined by meeting **ONE** of the following criteria?

- Simon Broome diagnostic criteria (definite)
- Dutch Lipid Network criteria with a score of at least 8
- A clinical diagnosis based on a history of an untreated LDL-cholesterol level greater than 500 mg/dL, in combination with either (1) xanthoma before 10 years of age **OR** (2) evidence of heterozygous familial hypercholesterolemia (HeFH) in both parents

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4mL (4 syringes) per 28 days.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MIPOMERSEN SODIUM

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **MIPOMERSEN SODIUM (Kynamro)** requires the following rule(s) be met for approval:

- A. You have homozygous familial hypercholesterolemia (type of inherited high cholesterol) which was determined by meeting **ONE** of the following criteria:
  - 1. Simon Broome diagnostic criteria (definite)
  - 2. Dutch Lipid Network criteria with a score of at least 8
  - 3. A clinical diagnosis based on a history of an untreated LDL (low density lipoprotein)-cholesterol level greater than 500 mg/dL, in combination with either (1) xanthoma (fatty growths underneath the skin) before 10 years of age **OR** (2) evidence of heterozygous familial hypercholesterolemia (type of inherited high cholesterol) in both parents
- B. The medication is prescribed by or recommended by a cardiologist (heart doctor), endocrinologist (hormone doctor), or lipidologist (cholesterol management specialist)
- C. You have an LDL (low density lipoprotein)-cholesterol level greater than or equal to 70 mg/dL while on maximally tolerated drug treatment
- D. You previously had a trial of Repatha (evolocumab) unless you do not have functional LDL (low density lipoprotein) receptors
- E. **If you are statin tolerant, approval also requires:**
  - 1. You meet **ONE** of the following:
    - i. You have been taking a high-intensity statin (i.e., atorvastatin 40-80 mg daily, rosuvastatin 20-40 mg daily) for a duration of at least 8 weeks, **OR**
    - ii. You have been taking a maximally tolerated dose of any statin for a duration of at least 8 weeks and you cannot tolerate a high-intensity statin (i.e., atorvastatin 40-80 mg daily, rosuvastatin 20-40 mg daily)
  - 2. You will continue statin treatment in combination with Kynamro
- F. **If you are statin intolerant, approval also requires ONE of the following:**
  - 1. You have an absolute contraindication to (medical reason why you cannot use) statin therapy such as active decompensated liver disease (you have symptoms related to liver damage), nursing female, pregnancy or plans to become pregnant or hypersensitivity reaction
  - 2. You have complete statin intolerance as defined by severe and intolerable adverse effects such as creatine kinase elevation (a measure of how much muscle damage you have) greater than or equal to 10 times the upper limit of normal, liver function test elevation greater than or equal to 3 times the upper limit of normal, rhabdomyolysis (muscle breakdown), severe muscle weakness leading to temporary disability, fall, or inability to use a major muscle group. These must have occurred with trials of at least two separate statins and have improved with the discontinuation of each statin

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MIPOMERSEN SODIUM

GUIDELINES FOR USE (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Kynamro.

**REFERENCES**

- Kynamro [Prescribing Information]. Chicago, IL: Kastle Therapeutics; January 2017.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 03/13

Client Approval: 04/20

P&T Approval: 04/18



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MIRABEGRON SUSPENSION

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
MIRABEGRON	MYRBETRIQ		49454	GPI-14 (5420005000G220)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of neurogenic detrusor overactivity (NDO) and meet **ALL** of the following criteria?

- The patient is 3 years of age or older
- The patient had a trial of or contraindication to ONE anticholinergic (e.g., oxybutynin, solifenacin)
- The patient is unable to swallow Myrbetriq tablets

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #10mL per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **MIRABEGRON SUSPENSION (Myrbetriq)** requires the following rule(s) be met for approval:

- A. You have neurogenic detrusor overactivity (NDO: a type of bladder control condition)
- B. You are 3 years of age or older
- C. You had a trial of or contraindication (harmful for) to ONE anticholinergic (such as oxybutynin, solifenacin)
- D. You are unable to swallow Myrbetriq tablets

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Myrbetriq.

**REFERENCES**

- Myrbetriq [Prescribing Information]. Northbrook, IL: Astellas Pharma, Inc.; April 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/22

Created: 11/21

Client Approval: 11/21

P&T Approval: 10/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MITAPIVAT

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
MITAPIVAT SULFATE	PYRUKYND	47840		GPI-10 (8587005070)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of hemolytic anemia and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient has pyruvate kinase (PK) deficiency

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #2 per day.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **MITAPIVAT (Pyrukynd)** requires the following rule(s) be met for approval:

- A. You have hemolytic anemia (a type of blood condition)
- B. You are 18 years of age or older
- C. You have pyruvate kinase (PK: a type of enzyme) deficiency

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RENEWAL CRITERIA**

1. Does the patient have a diagnosis of hemolytic anemia with and meet **ALL** of the following criteria?
  - The patient has pyruvate kinase (PK) deficiency
  - The patient has had clinical benefit while on Pyrukynd

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.**

If no, do not approve.

**DENIAL TEXT:** See the renewal denial at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MITAPIVAT

GUIDELINES FOR USE (CONTINUED)

**RENEWAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **MITAPIVAT (Pyrukynd)** requires the following rule(s) be met for renewal:

- A. You have hemolytic anemia (a type of blood condition)
- B. You have pyruvate kinase (PK: a type of enzyme) deficiency
- C. You have had clinical benefit while on Pyrukynd

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Pyrukynd.

**REFERENCES**

- Pyrukynd [Prescribing Information]. Cambridge, MA: Agios Pharmaceuticals, Inc.; February 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/22

Created: 05/22

Client Approval: 05/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**MOBOCERTINIB**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
MOBOCERTINIB SUCCINATE	EXKIVITY	47578		GPI-10 (2136005060)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of locally advanced or metastatic non-small cell lung cancer (NSCLC) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient has epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test
  - The patient's disease progressed on or after platinum-based chemotherapy (e.g., cisplatin, carboplatin, oxaliplatin)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **MOBOCERTINIB (Exkivity)** requires the following rule(s) be met for approval:

- A. You have locally advanced or metastatic (cancer that has spread from where it started to nearby tissue or has spread to other parts of the body) non-small cell lung cancer (NSCLC: type of lung cancer)
- B. You are 18 years of age or older
- C. You have epidermal growth factor receptor (EGFR) exon 20 insertion mutations (type of gene mutation), as detected by a Food and Drug Administration (FDA)-approved test
- D. Your disease progressed (disease has gotten worse) on or after platinum-based chemotherapy such as cisplatin, carboplatin, oxaliplatin

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Exkivity.

**REFERENCES**

- Exkivity [Prescribing Information]. Lexington, MA: Takeda Pharmaceuticals America, Inc., September 2021.

**CONTINUED ON NEXT PAGE**





**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**MOBOCERTINIB**

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/22

Created: 11/21

Client Approval: 11/21

P&T Approval: 10/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MOMETASONE SINUS IMPLANT (NSA)

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
MOMETASONE FUROATE	SINUVA		44214	GPI-14 (42200045102350)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have non-self-administered (NSA) drug benefit coverage?

If yes, continue to #2.  
If no, guideline does not apply.

2. Has the patient previously had 4 implants (2 per nostril) per lifetime?

If yes, do not approve.  
**DENIAL TEXT:** See the renewal denial text at the end of the guideline.  
If no, continue to #3.

3. Does the patient have a diagnosis of nasal polyps and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- Therapy is prescribed by or given in consultation with an otolaryngologist
- The patient previously had ethmoid sinus surgery
- The patient is a candidate for repeat ethmoid sinus surgery due to refractory moderate to severe symptoms of nasal obstruction, nasal congestion or nasal polyps in both ethmoid sinuses
- The patient had a previous 90-day trial of **ONE** intranasal corticosteroid (e.g., fluticasone, beclomethasone, flunisolide, ciclesonide, mometasone)

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of 2 implants (1 per nostril).**

**APPROVAL TEXT:** Renewal requires the patient has nasal polyps and has NOT had 4 implants (2 per nostril) per lifetime. In addition, the patient has ethmoid sinus polyps grade  $\geq 1$  on any side and does not have extensive ethmoid sinus polyp grade (grade 4 on at least one side) or extensive adhesions/synechiae (grade 3 or 4).

If no, do not approve.  
**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MOMETASONE SINUS IMPLANT (NSA)

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **MOMETASONE IMPLANT (Sinuva)** requires the following rule(s) be met for approval:

- A. You have nasal polyps (small growths inside the nose)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or given in consultation with an otolaryngologist (ear, nose and throat doctor)
- D. You previously had ethmoid sinus surgery (process to remove blockage in your sinuses)
- E. You are a candidate for repeat ethmoid sinus surgery due to refractory moderate to severe symptoms (symptoms return and do not respond to surgery) of nasal obstruction, nasal congestion or nasal polyps in both ethmoid sinuses
- F. You previously had a 90-day trial of ONE intranasal corticosteroid (such as fluticasone, beclomethasone, flunisolide, ciclesonide, mometasone)
- G. You have not received 4 implants (2 per nostril) in your lifetime

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Has the patient previously had 4 implants (2 per nostril) per lifetime?

If yes, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

If no, continue to #2.

2. Does the patient have a diagnosis of nasal polyps and meet **ALL** of the following criteria?
  - The patient has ethmoid sinus polyps grade  $\geq 1$  on any side
  - The patient does **NOT** have extensive ethmoid sinus polyp grade (grade 4 on at least one side) or extensive adhesions/synechiae (grade 3 or 4)

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of 2 implants (1 per nostril). (Note: maximum #4 implants [2 per nostril] allowed per lifetime.)**

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MOMETASONE SINUS IMPLANT (NSA)

RENEWAL CRITERIA (CONTINUED)

**RENEWAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **MOMETASONE IMPLANT (Sinuva)** requires the following rule(s) be met for approval:

- A. You have nasal polyps (small growths inside the nose)
- B. You have ethmoid sinus polyps grade 1 or greater on any side
- C. You do not have extensive ethmoid sinus polyp grade (grade 4 on at least one side) or extensive adhesions/synechiae (scar tissue) (grade 3 or 4)
- D. You have not previously received 4 implants (2 per nostril) in your lifetime

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Sinuva.

**REFERENCES**

- Sinuva [Prescribing Information]. Menlo Park, CA: Intersect ENT.; April 2020.

Library	Commercial	NSA
Yes	Yes	Yes

Part D Effective: N/A

Commercial Effective: 10/01/20

Created: 05/18

Client Approval: 08/20

P&T Approval: 07/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MONOMETHYL FUMARATE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
MONOMETHYL FUMARATE	BAFIERTAM	46576		GPI-10 (6240555000)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of a relapsing form of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient had a trial of or contraindication to dimethyl fumarate AND **ONE** of the following agents: Avonex, Betaseron, Copaxone/Glatiramer/Glatopa, Plegridy, Rebif, Aubagio, Vumerity, Kesimpta (**Please note:** other MS agents may also require prior authorization)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **MONOMETHYL FUMARATE (Bafiertam)** requires the following rule(s) be met for approval:

- A. You have a relapsing form of multiple sclerosis (MS: immune system eats away at the protective covering of the nerves), to include clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms go away and return), and active secondary progressive disease (advanced disease)
- B. You are 18 years of age or older
- C. You have previously tried or have a contraindication to (medical reason why you cannot take) dimethyl fumarate AND ONE of the following: Avonex, Betaseron, Copaxone/Glatiramer/Glatopa, Plegridy, Rebif, Aubagio, Vumerity, Kesimpta  
(**Please note:** Other multiple sclerosis medications may also require prior authorization)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**MONOMETHYL FUMARATE**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Bafiertam.

**REFERENCES**

- Bafiertam [Prescribing Information]. High Point, NC: Banner Life Sciences LLC; May 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/21

Created: 11/20

Client Approval: 11/20

P&T Approval: 10/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

NAFARELIN

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
NAFARELIN ACETATE	SYNAREL	21103		GPI-10 (3008005510)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Is the requested medication being used for gender dysphoria?

If yes, **approve for 12 months by HICL or GPI-10 and override quantity limits.**  
If no, continue to #2.

2. Does the patient have a diagnosis of moderate to severe pain associated with endometriosis and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The diagnosis is confirmed via surgical or direct visualization (e.g., pelvic ultrasound) OR histopathological confirmation (e.g., laparoscopy or laparotomy) in the last 10 years
- Therapy is prescribed by or in consultation with an obstetrician/gynecologist
- The patient had a trial of or contraindication to a nonsteroidal anti-inflammatory drug (NSAID) AND a progestin-containing contraceptive preparation (e.g., combination hormonal contraceptive preparation, progestin-only contraceptive preparation)
- The requested medication will NOT be used concurrently with another GnRH-modulating agent (e.g., elagolix, relugolix, Lupron Depot)
- The patient has NOT received more than 6 months of treatment with Synarel per lifetime

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #96mL per 6 months.**  
If no, continue to #3.

3. Is the request for a female patient who has a diagnosis of central precocious puberty (CPP) and meets **ALL** of the following criteria?

- The patient is 2 years of age or older
- Therapy is prescribed by or in consultation with a pediatric endocrinologist
- The patient has elevated levels of follicle-stimulating hormone (FSH) (level >4.0 mIU/mL) and luteinizing hormone (LH) (level > 0.2 to 0.3 mIU/mL) at diagnosis
- The patient is younger than 8 years of age at the onset of CPP
- There is documentation of pubertal staging using the Tanner scale for breast development (stage 2 or above) AND pubic hair growth (stage 2 or above)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #32mL per month.**  
If no, continue to #4.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

NAFARELIN

INITIAL CRITERIA (CONTINUED)

4. Is the request for a male patient who has a diagnosis of central precocious puberty (CPP) and meets **ALL** of the following criteria?
- The patient is 2 years of age or older
  - Therapy is prescribed by or in consultation with a pediatric endocrinologist
  - The patient has elevated levels of follicle-stimulating hormone (FSH) (level >5.0 mIU/mL) and luteinizing hormone (LH) (level > 0.2 to 0.3 mIU/mL) at diagnosis
  - The patient is younger than 9 years of age at the onset of CPP
  - The patient has documentation of pubertal staging using the Tanner scale for genital development (stage 2 or above) AND pubic hair growth (stage 2 or above)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #32mL per month.**  
If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **NAFARELIN (Synarel)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
1. Gender dysphoria (your gender identity conflicts with your sex assigned at birth)
  2. Moderate to severe pain from endometriosis (condition affecting the uterus)
  3. Central precocious puberty (CPP: early sexual development in girls and boys)
- B. **If you have moderate to severe pain from endometriosis, approval also requires:**
1. You are 18 years of age or older
  2. Therapy is prescribed by or in consultation with an obstetrician/gynecologist (a type of women's health doctor)
  3. Your diagnosis is confirmed by surgical or direct visualization (such as pelvic ultrasound [type of imaging]) or histopathological (tissue) confirmation (such as laparoscopy [type of surgery] or laparotomy [type of surgery]) in the last 10 years
  4. You have tried or have a contraindication (harmful for) to a nonsteroidal anti-inflammatory drug (NSAID) AND a progestin-containing contraceptive preparation (such as combination hormonal contraceptive preparation, progestin-only contraceptive preparation)
  5. You are NOT using Synarel concurrently (at the same time) with another gonadotropin-releasing hormone (GnRH)-modulating agent (such as elagolix, relugolix, Lupron Depot)
  6. You have NOT received more than 6 months of treatment with Synarel per lifetime
- (Initial denial text continued on next page)***

CONTINUED ON NEXT PAGE





**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**NAFARELIN**

**INITIAL CRITERIA (CONTINUED)**

**C. If you are female and have central precocious puberty, approval also requires:**

1. You are 2 years of age or older
2. Therapy is prescribed by or in consultation with a pediatric endocrinologist (hormone doctor)
3. You have high levels of follicle-stimulating hormone (FSH) (level greater than 4.0 mIU/mL) and luteinizing hormone (LH) (level greater than 0.2 to 0.3 mIU/mL) at diagnosis
4. You are/were younger than 8 years of age when your condition started
5. There is documentation of pubertal staging using the Tanner scale (scale of physical measurements of development based on external sex characteristics) for breast development (stage 2 or above) AND pubic hair growth (stage 2 or above)

**D. If you are male and have central precocious puberty, approval also requires:**

1. You are 2 years of age or older
2. Therapy is prescribed by or in consultation with a pediatric endocrinologist (hormone doctor)
3. You have high levels of follicle-stimulating hormone (FSH) (level greater than 5.0 mIU/mL) and luteinizing hormone (LH) (level greater than 0.2 to 0.3 mIU/mL) at diagnosis
4. You are/were younger than 9 years of age when your condition started
5. There is documentation of pubertal staging using the Tanner scale (scale of physical measurements of development based on external sex characteristics) for genital development (stage 2 or above) AND pubic hair growth (stage 2 or above)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

NAFARELIN

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

**NOTE:** For the diagnoses of gender dysphoria or pain from endometriosis, please refer to the Initial Criteria section.

- Does the patient have a diagnosis of central precocious puberty (CPP) and meet **ALL** of the following criteria?
  - The Tanner scale staging at initial diagnosis of CPP has stabilized or regressed during three separate medical visits in the previous year
  - The patient has not reached the actual age which corresponds to their current pubertal age

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #32mL per month.**  
If no, do not approve.

**RENEWAL DENIAL TEXT:** *\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

- Our guideline named **NAFARELIN (Synarel)** requires the following rule(s) be met for renewal:
- You have central precocious puberty (CPP: early sexual development in girls and boys)
  - Your Tanner scale staging (scale of physical measurements of development based on external sex characteristics) at initial diagnosis of CPP has stabilized or regressed (lowered) during three separate medical visits in the previous year
  - You have not reached the actual age which corresponds to your current pubertal age

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Synarel.

**REFERENCES**

- Synarel [Prescribing Information]. New York, NY: Pfizer Inc.; May 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/23/23

Created: 09/18

Client Approval: 01/23

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

NERATINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
NERATINIB MALEATE	NERLYNX	44421		GPI-10 (2153303510)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of early stage (stage I-III) breast cancer and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient has a HER2-overexpressed/amplified (HER2-positive) tumor
- The requested medication will be used as a single agent for extended adjuvant therapy following Herceptin- (trastuzumab-) based therapy
- The medication is being requested within 2 years after completing last trastuzumab dose

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #180 per 30 days.**  
If no, continue to #2.

2. Does the patient have a diagnosis of advanced or metastatic breast cancer and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient has a HER2-overexpressed/amplified (HER2-positive) tumor
- The requested medication will be used in combination with capecitabine
- The patient has received two or more prior anti-HER2 based regimens in the metastatic setting

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #180 per 30 days.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **NERATINIB (Nerlynx)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:

1. Early stage (stage I-III) breast cancer
2. Advanced or metastatic breast cancer

B. **If you have early stage (stage I-III) breast cancer, approval also requires:**

1. You are 18 years of age or older
2. You have a HER2-overexpressed/amplified (HER2-positive) tumor
3. The requested medication will be used as a single agent for extended adjuvant therapy following Herceptin- (trastuzumab-) based therapy
4. The medication is being requested within 2 years of completing the last trastuzumab dose

***(Denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

NERATINIB

GUIDELINES FOR USE (CONTINUED)

C. If you have advanced or metastatic breast cancer, approval also requires:

1. You are 18 years of age or older
2. You have a HER2-overexpressed/amplified (HER2-positive) tumor
3. The requested medication will be used in combination with capecitabine
4. You have received two or more prior anti-HER2 based regimens in the metastatic setting

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Nerlynx.

**REFERENCES**

- Nerlynx [Prescribing Information]. Los Angeles, CA: Puma Biotechnology; July 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/10/21

Created: 07/17

Client Approval: 03/21

P&T Approval: 04/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

NILOTINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
NILOTINIB HCL	TASIGNA	35149		GPI-10 (2153186020)	

**GUIDELINES FOR USE**

1. Does the patient have a newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase **AND** meet the following criterion?

- The patient is 1 year of age or older

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**

If no, continue to #2.

2. Does the patient have a diagnosis of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase or accelerated phase and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient is resistant or intolerant to prior therapy that included imatinib (Gleevec)
- The patient had a mutational analysis prior to initiation AND Tasigna is appropriate per the NCCN guideline table for treatment recommendations based on BCR-ABL1 mutation profile *(Please see header CML-5 of the current NCCN guidelines)*

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**

If no, continue to #3.

3. Does the patient have a diagnosis of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase or accelerated phase and meet **ALL** of the following criteria?

- The patient is 1 to 17 years of age
- The patient is resistant or intolerant to prior therapy with other tyrosine kinase inhibitors (TKI) [e.g., Gleevec (imatinib), Sprycel (dasatinib), Bosulif (bosutinib)]
- The patient had a mutational analysis prior to initiation AND Tasigna is appropriate per the NCCN guideline table for treatment recommendations based on BCR-ABL1 mutation profile *(Please see header CML-5 of the current NCCN guidelines)*

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

NILOTINIB

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **NILOTINIB (Tasigna)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
  1. Newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML: a type of blood cell cancer) in chronic phase
  2. Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic or accelerated phase
- B. **If you have newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, approval also requires:**
  1. You are 1 year of age or older
- C. **If you have Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase or accelerated phase, approval also requires:**
  1. If you are 18 years of age or older, you are resistant or intolerant to prior therapy including Gleevec (imatinib)
  2. If you are 1 to 17 years of age, you are resistant or intolerant to prior therapy with other tyrosine kinase inhibitors (TKI) such as Gleevec (imatinib), Sprycel (dasatinib), Bosulif (bosutinib)
  3. You had a mutational analysis prior to initiation of therapy AND Tasigna is appropriate per the National Comprehensive Cancer Network (NCCN) guideline table for treatment recommendations based on BCR-ABL1 mutation (breakpoint cluster region-Abelson murine leukemia 1; a type of abnormal gene) profile

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Tasigna.

**REFERENCES**

- Tasigna [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/22

Created: 05/12

Client Approval: 02/22

P&T Approval: 01/22

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

NIMODIPINE SOLUTION

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
NIMODIPINE	NYMALIZE		34794 43848 47984 47985 48405	GPI-14 (34000022002050) (34000022002054)	

**GUIDELINES FOR USE**

1. Does the patient have a history of subarachnoid hemorrhage (SAH) from a ruptured intracranial berry aneurysm within the past 21 days and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient is unable to swallow nimodipine capsules

If yes, **approve once for the requested strength by GPID or GPI-14 up to a maximum 21 day supply with the following quantity limits:**

- Nymalize 30mg/10mL: #120mL per day.
- Nymalize 60mg/20mL: #120mL per day.
- Nymalize 30mg/5mL: #60mL per day.
- Nymalize 60mg/10mL: #60mL per day.

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **NIMODIPINE SOLUTION (Nymalize)** requires the following rule(s) be met for approval:

- A. You have a history of subarachnoid hemorrhage (SAH: bleeding in the space surrounding your brain) from a ruptured intracranial berry aneurysm (an area of an artery wall in your brain ballooned and burst) within the past 21 days
- B. You are 18 years of age or older
- C. You are unable to swallow nimodipine oral capsules

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**NIMODIPINE SOLUTION**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Nymalize.

**REFERENCES**

- Nymalize [Prescribing Information]. Atlanta, GA: Arbor Pharmaceuticals, Inc: April 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/26/21

Created: 08/13

Client Approval: 07/21

P&T Approval: 07/20





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

NINTEDANIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
NINTEDANIB	OFEV	41489		GPI-10 (4555405020)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of idiopathic pulmonary fibrosis (IPF) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a pulmonologist
  - The patient has a usual interstitial pneumonia (UIP) pattern as evidenced by high-resolution computed tomography (HRCT) alone or via a combination of surgical lung biopsy and HRCT
  - The patient does NOT have other known causes of interstitial lung disease (for example, connective tissue disease, drug toxicity, asbestos or beryllium exposure, hypersensitivity pneumonitis, systemic sclerosis, rheumatoid arthritis, radiation, sarcoidosis, bronchiolitis obliterans organizing pneumonia, human immunodeficiency virus infection, viral hepatitis, or cancer)
  - The patient has a predicted forced vital capacity (FVC) of at least 50% at baseline
  - The patient had a trial of or contraindication to the preferred agent: Esbriet (pirfenidone)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.**  
If no, continue to #2.

2. Does the patient have a diagnosis of systemic sclerosis-associated interstitial lung disease (SSc-ILD) and meet **ALL** of the following criteria?
  - The patient has a diagnosis of Systemic Sclerosis (SSc) according to American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR)
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a pulmonologist or rheumatologist
  - The patient has at least 10% fibrosis on a chest high resolution computed tomography (HRCT)
  - The patient has a baseline forced vital capacity (FVC) of at least 40% of predicted value
  - The patient does NOT have other etiologies of interstitial lung disease (ILD) [e.g., heart failure/fluid overload, drug-induced lung toxicity (cyclophosphamide, methotrexate, ACE-inhibitors), recurrent aspiration (such as from GERD), pulmonary vascular disease, pulmonary edema, pneumonia, chronic pulmonary thromboembolism, alveolar hemorrhage or ILD caused by another rheumatic disease, such as mixed connective tissue disease (MCTD)]
  - The patient had a trial of or contraindication to the preferred agent: subcutaneous Actemra

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #2 per day.**  
If no, continue to #3.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

NINTEDANIB

INITIAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (PF-ILD) and meet **ALL** of the following criteria?
- The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a pulmonologist or rheumatologist
  - The patient's lung function and respiratory symptoms OR chest imaging have worsened/progressed despite treatment with medications used in clinical practice for ILD (not attributable to comorbidities e.g. infection, heart failure)
  - The patient has  $\geq 10\%$  fibrosis on a chest high resolution computed tomography (HRCT) (e.g., defined as reticular abnormality with traction bronchiectasis with or without honeycombing)
  - The patient has a baseline forced vital capacity (FVC) at least 45% of predicted value

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **NINTEDANIB (Ofev)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
1. Idiopathic pulmonary fibrosis (IPF: scarring of the lungs with an unknown cause)
  2. Systemic sclerosis-associated interstitial lung disease (SSc-ILD: disorder that causes hardening of lung tissue)
  3. Chronic fibrosing interstitial lung disease (ILDs) with a progressive phenotype (PF-ILD: scarring of the lungs caused by different underlying diseases or conditions that worsens over time)
- B. **If you have idiopathic pulmonary fibrosis, approval also requires:**
1. You are 18 years of age or older
  2. Therapy is prescribed by or in consultation with a pulmonologist (lung/breathing doctor)
  3. You have a usual interstitial pneumonia pattern as evidenced by high-resolution computed tomography (HRCT: type of imaging test) alone or via a combination of surgical lung biopsy and HRCT
  4. You do NOT have other known causes of interstitial lung disease, such as connective tissue disease, drug toxicity, asbestos or beryllium exposure, hypersensitivity pneumonitis (lung inflammation from inhaled substances), systemic sclerosis (an immune system disorder), rheumatoid arthritis (joint pain and inflammation), radiation, sarcoidosis (growth of inflammatory cells in the body), bronchiolitis obliterans organizing pneumonia (type of lung infection), human immunodeficiency virus infection, viral hepatitis (type of liver inflammation), or cancer

***(Initial denial text continued on next page)***

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

NINTEDANIB

INITIAL CRITERIA (CONTINUED)

5. You have a predicted forced vital capacity (FVC: amount of air that can be forcefully exhaled) of at least 50 percent at baseline
  6. You had a trial of or contraindication to (harmful for) the preferred medication: Esbriet (pirfenidone)
- C. **If you have systemic sclerosis-associated interstitial lung disease, approval also requires:**
1. You have systemic sclerosis (SSc) according to the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR)
  2. You are 18 years of age or older
  3. Therapy is prescribed by or in consultation with a pulmonologist (lung/breathing doctor) or rheumatologist (a type of immune system doctor)
  4. You have at least 10 percent fibrosis (tissue scarring) on a chest high resolution computed tomography (HRCT: type of imaging testing)
  5. You have a baseline forced vital capacity (FVC: amount of air that can be forcefully exhaled) of at least 40 percent of predicted value
  6. Other causes of interstitial lung disease have been ruled out. Other causes may include heart failure/fluid overload, drug-induced lung toxicity [cyclophosphamide, methotrexate, ACE-inhibitors (class of blood pressure medications)], recurrent aspiration (inhaling) such as from GERD (acid reflux), pulmonary vascular disease (affecting blood vessels in lungs), pulmonary edema (excess fluid in the lungs), pneumonia (type of lung infection), chronic pulmonary thromboembolism (blood clot in lungs), alveolar hemorrhage (bleeding of a part of the lungs) or interstitial lung disease caused by another rheumatic (inflammatory) disease, such as mixed connective tissue disease (MCTD)
  7. You had a trial of or contraindication (harmful for) to the preferred medication: subcutaneous (under the skin) Actemra
- D. **If you have chronic fibrosing interstitial lung disease with progressive phenotype, approval also requires:**
1. You are 18 years of age or older
  2. Therapy is prescribed by or in consultation with a pulmonologist (lung/breathing doctor) or rheumatologist (a type of immune system doctor)
  3. Your lung function and respiratory (breathing) symptoms OR chest imaging have worsened/progressed despite treatment with medications used in clinical practice for interstitial lung disease (not caused by comorbidities such as infection, heart failure)
  4. You have at least 10 percent fibrosis (tissue scarring) on a chest high resolution computed tomography (HRCT: type of imaging testing)
  5. You have a baseline forced vital capacity (FVC: amount of air that can be forcefully exhaled) of at least 45 percent of predicted value

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

NINTEDANIB

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated interstitial lung disease (SSc-ILD), or chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (PF-ILD) **AND** meet the following criterion?
  - The patient has experienced a clinically meaningful improvement or maintenance in annual rate of decline

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **NINTEDANIB (Ofev)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following diagnoses:
  1. Idiopathic pulmonary fibrosis (IPF: scarring of the lungs with an unknown cause)
  2. Systemic sclerosis-associated interstitial lung disease (SSc-ILD: disorder that causes hardening of lung tissue)
  3. Chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (PF-ILD: scarring of the lungs caused by different underlying diseases or conditions that worsens over time)
- B. You have experienced a clinically meaningful improvement or maintenance in annual rate of decline

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Ofev.

**REFERENCES**

- Ofev [Prescribing Information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; October 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 05/23/22

Created: 02/15

Client Approval: 05/22

P&T Approval: 04/21

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

NIRAPARIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
NIRAPARIB TOSYLATE	ZEJULA	44177		GPI-10 (2153555020)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient is in complete or partial response to first-line platinum based-chemotherapy
  - The requested medication will be used for maintenance treatment

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #3 per day.**  
If no, continue to #2.

2. Does the patient have a diagnosis of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient is in complete or partial response to platinum-based chemotherapy
  - The requested medication will be used for maintenance treatment
  - The patient's cancer has deleterious or suspected deleterious germline *BRCA*-mutation (*gBRCAmut*)
  - The requested medication will be used as monotherapy
  - The requested medication will be started no later than 8 weeks after the patient's most recent platinum-containing regimen
  - The patient has completed at least 2 or more lines of platinum-based chemotherapy

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #3 per day.**  
If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

NIRAPARIB

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **NIRAPARIB (Zejula)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
1. Advanced epithelial ovarian (cancer that forms on the surface of the ovary), fallopian tube, or primary peritoneal cancer (type of abdominal cancer)
  2. Recurrent (returning) epithelial ovarian (cancer that forms on the surface of the ovary), fallopian tube, or primary peritoneal cancer (type of abdominal cancer)
- B. **If you have advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, approval also requires:**
1. You are 18 years of age or older
  2. You are in complete or partial response to first-line platinum based-chemotherapy (such as cisplatin, carboplatin)
  3. The requested medication will be used for maintenance treatment
- C. **If you have recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, approval also requires:**
1. You are 18 years of age or older
  2. You are in complete or partial response to platinum-based chemotherapy (such as cisplatin, carboplatin)
  3. The requested medication will be used for maintenance treatment (*treatment* to prevent cancer from coming back after it has disappeared after initial *therapy*)
  4. Your cancer has deleterious or suspected deleterious germline *BRCA*-mutation (*gBRCAmut*: a type of gene mutation)
  5. The requested medication will be used as monotherapy (used by itself for treatment)
  6. The requested medication is started no later than 8 weeks after your most recent platinum-containing regimen (such as cisplatin, carboplatin)
  7. You have completed at least 2 or more lines of platinum-based chemotherapy

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**NIRAPARIB**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Zejula.

**REFERENCES**

- Zejula [Prescribing Information]. Waltham, MA: Tesaro; December 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/16/23

Created: 08/17

Client Approval: 12/22

P&T Approval: 01/23





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

NITISINONE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
NITISINONE	ORFADIN, NITYR, NITISINONE	23253		GPI-10 (3090404500)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a documented diagnosis of hereditary tyrosinemia type 1 (HT-1) **AND** meet **ALL** of the following criteria?
  - The patient has elevated urinary or plasma succinylacetone (SA) levels **OR** a mutation in the fumarylacetoacetate hydrolase (FAH) gene
  - Therapy is prescribed by or given in consultation with a prescriber specializing in inherited metabolic diseases
  - The patient has been counseled on maintaining dietary restriction of tyrosine and phenylalanine

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Is the request for brand Orfadin 20mg capsules?

If yes, **approve for 6 months by GPID or GPI-14.**

**APPROVAL TEXT:** Renewal requires the patients urinary or plasma succinylacetone (SA) levels have decreased from baseline while on treatment with nitisinone.

If no, continue to #3.

3. Is the request for Nityr tablets; brand Orfadin 2mg, 5mg, 10 mg capsules; or Orfadin suspension **AND** the patient meets the following criterion?

- The patient had a trial of or contraindication to generic nitisinone capsule

If yes, **approve the requested drug for 6 months by GPID or GPI-14.**

**APPROVAL TEXT:** Renewal requires the patients urinary or plasma succinylacetone (SA) levels have decreased from baseline while on treatment with nitisinone.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

NITISINONE

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **NITISINONE (Orfadin, Nityr)** requires the following rule(s) be met for approval:

- A. You have hereditary tyrosinemia type 1 (HT-1: a type of genetic disorder where you cannot breakdown an important component in proteins)
- B. Your diagnosis is confirmed by elevated urinary or plasma succinylacetone levels (a chemical that is present in hereditary tyrosinemia) OR a mutation in the fumarylacetoacetate hydrolase gene
- C. Therapy is prescribed by or given in consultation with a prescriber specializing in inherited metabolic diseases
- D. You have been counseled on maintaining dietary restriction of tyrosine and phenylalanine
- E. **If you are requesting Nityr tablets; brand Orfadin 2mg, 5mg, 10 mg capsules; or Orfadin oral suspension, approval also requires:**
  1. You have previously tried generic nitisinone capsules unless there is a medical reason why you cannot (contraindication)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of hereditary tyrosinemia type 1 **AND** meet the following criterion?
  - The patients urinary or plasma succinylacetone (SA) levels have decreased from baseline while on treatment with nitisinone.

If yes, **approve for 12 months by GPID or GPI-14 for all strengths of the requested formulation.**

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

NITISINONE

RENEWAL CRITERIA (CONTINUED)

**RENEWAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **NITISINONE (Orfadin, Nityr)** requires the following rule(s) be met for renewal:

- A. You have hereditary tyrosinemia type 1 (HT-1: a type of genetic disorder where you cannot breakdown an important component in proteins)
- B. Your urinary or plasma succinylacetone levels (a chemical that is present in hereditary tyrosinemia) have decreased from baseline while on treatment with nitisinone

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Orfadin and Nityr.

**REFERENCES**

- Orfadin [Prescribing Information]. Waltham, MA: Sobi, Inc.; May 2019.
- Nityr [Prescribing Information]. Cambridge, UK: Cycle Pharmaceuticals Ltd.; September 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/21

Created: 08/16

Client Approval: 11/20

P&T Approval: 07/18



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OBETICHOLIC ACID

Generic	Brand	HICL	GCN	MEDISPAN	Exception/Other
OBETICHOLIC ACID	OCALIVA	43438		GPI-10 (5275006000)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of primary biliary cholangitis as confirmed by at least **TWO** of the following criteria?
  - An alkaline phosphatase level of at least 1.5 times the upper limit of normal
  - The presence of antimitochondrial antibodies at a titer of 1:40 or higher
  - Histologic evidence of non-suppurative destructive cholangitis and destruction of interlobular bile ducts

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of guideline.

2. Does the patient meet **ALL** of the following criteria?
  - The patient is at least 18 years of age and older
  - The patient does not have cirrhosis OR has compensated cirrhosis with no evidence of portal hypertension
  - The medication is prescribed by or in consultation with a gastroenterologist or hepatologist
  - The requested agent will be used in combination with ursodeoxycholic acid (e.g., Ursodiol, Urso 250, Urso Forte) in adults with an inadequate response to ursodeoxycholic acid at a dosage of 13-15mg/kg/day for at least 1 year, OR as monotherapy in adults unable to tolerate ursodeoxycholic acid
  - The patient does not have complete biliary obstruction

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OBETICHOLIC ACID

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **OBETICHOLIC ACID (Ocaliva)** requires the following rule(s) be met for approval:

- A. You have primary biliary cholangitis (type of liver disease), as confirmed by TWO of the following criteria:
  - 1. An alkaline phosphatase level (indicator of possible liver/gallbladder problems) of at least 1.5 times the upper limit of normal
  - 2. The presence of antimicrobial antibodies (indicator of body attacking its own cells) at a titer (concentration) of 1:40 or higher
  - 3. Histologic evidence of non-suppurative destructive cholangitis and destruction of interlobular bile ducts (you have lab data that shows you have certain symptoms of liver disease)
- B. You are 18 years of age and older
- C. You do not have cirrhosis (liver damage) OR have compensated cirrhosis (a type of liver condition) with no evidence of portal hypertension (high blood pressure in the major vein that leads to the liver)
- D. The medication is prescribed by or in consultation with a gastroenterologist (digestive system doctor) or hepatologist (liver doctor)
- E. You meet ONE of the following:
  - 1. You have had an inadequate response to ursodeoxycholic acid (such as Ursodiol, Urso 250, Urso Forte) at a dosage of 13-15 mg/kg/day for at least 1 year and the requested medication will be used in combination with ursodeoxycholic acid
  - 2. You are unable to tolerate ursodeoxycholic acid and the requested medication will be used as monotherapy (only drug used for treatment)
- F. You do not have complete biliary obstruction (blockage of bile ducts)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OBETICHOLIC ACID

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

- Does the patient have a diagnosis of primary biliary cholangitis and meets **ALL** of the following criteria?
  - The patient's alkaline phosphatase levels are less than 1.67-times the upper limit of normal OR have decreased by at least 15% from baseline while on treatment with obeticholic acid
  - The patient has not developed complete biliary obstruction

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**  
If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **OBETICHOLIC ACID (Ocaliva)** requires the following rule(s) be met for renewal:

- You have primary biliary cholangitis (type of liver disease)
- Your alkaline phosphatase levels (indicator of possible liver/gallbladder problems) are less than 1.67-times the upper limit of normal or have decreased by at least 15% from baseline while on treatment with obeticholic acid
- You have not developed complete biliary obstruction (blockage of bile ducts)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Ocaliva.

**REFERENCES**

- Ocaliva [Prescribing Information]. New York, NY: Intercept Pharmaceuticals, Inc. May 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/22

Created: 08/16

Client Approval: 11/21

P&T Approval: 10/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OCTREOTIDE - IM

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
OCTREOTIDE ACETATE,MI-SPHERES	SANDOSTATIN LAR DEPOT	19000		GPI-12 (301700701064)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of acromegaly and meet **ALL** of the following criteria?
  - Therapy is prescribed by or in consultation with an endocrinologist
  - The patient had a prior response to and tolerated subcutaneous octreotide injection for at least 2 weeks
  - The patient had an inadequate response to surgery or radiotherapy, OR surgery or radiotherapy is not an option for this patient

If yes, **approve the requested strength for 3 months by GPID or GPI-14 with the following quantity limit:**

- **10 mg: #6 mL per 28 days.**
- **20 mg: #12 mL per 28 days.**
- **30 mg: #6 mL per 28 days.**

If no, continue to #2.

2. Does the patient have a diagnosis of severe diarrhea and flushing episodes associated with metastatic carcinoid tumor and meet **ALL** of the following criterion?
  - The patient had a prior response to and tolerated subcutaneous octreotide injection for at least 2 weeks

If yes, **approve for 2 months by HICL or GPI-12 with a quantity limit of #6 mL per 28 days.**  
If no, continue to #3.

3. Does the patient have a diagnosis of profuse watery diarrhea associated with vasoactive intestinal peptide (VIP)-secreting tumor (VIPoma) and meet **ALL** of the following criterion?
  - The patient had a prior response to and tolerated subcutaneous octreotide injection for at least 2 weeks

If yes, **approve for 2 months by HICL or GPI-12 with a quantity limit of #6 mL per 28 days.**  
If no, do not approve.

**DENIAL TEXT:** See initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OCTREOTIDE - IM

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **OCTREOTIDE - IM (Sandostatin LAR Depot)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
1. Acromegaly (a type of hormone disorder)
  2. Severe diarrhea and flushing episodes associated with metastatic carcinoid tumor (a type of slow growing cancer that has spread to different parts of the body)
  3. Profuse watery diarrhea associated with vasoactive intestinal peptide (VIP)-secreting tumor (a type of cancer that starts from hormone producing cells)
- B. You had a prior response to and tolerated subcutaneous octreotide injection for at least 2 weeks
- C. **If you have acromegaly, approval also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (a type of hormone doctor)
  2. You had an inadequate response (drug did not work) to surgery or radiotherapy (radiation to treat cancer), OR surgery or radiotherapy is not an option for you

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of acromegaly and meet **ALL** of the following criteria?
  - The patient has a reduction, normalization or maintenance of IGF-1 levels based on age and gender
  - The patient has shown an improvement or sustained remission of clinical symptoms of acromegaly

If yes, **approve the requested strength for 12 months by GPID or GPI-14 with the following quantity limit:**

- **10 mg: #6 mL per 28 days.**
- **20 mg: #12 mL per 28 days.**
- **30 mg: #6 mL per 28 days.**

If no, continue to #2.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OCTREOTIDE - IM

RENEWAL CRITERIA (CONTINUED)

2. Does the patient have a diagnosis of severe diarrhea and flushing episodes associated with metastatic carcinoid tumor **AND** meet the following criterion?

- The patient has improvement or sustained remission of clinical symptoms

If yes, **approve for 12 months by HICL or GPI-12 with a quantity limit of #6 mL per 28 days.**

If no, continue to #3.

3. Does the patient have a diagnosis of profuse watery diarrhea associated with vasoactive intestinal peptide (VIP)-secreting tumor (VIPoma) **AND** meet the following criterion?

- The patient has improvement or sustained remission of clinical symptoms

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #6 mL per 28 days.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **OCTREOTIDE - IM (Sandostatin LAR Depot)** requires the following rule(s) be met for renewal:

- A. You have **ONE** of the following diagnoses:

1. Acromegaly (a type of hormone disorder)
2. Severe diarrhea and flushing episodes associated with metastatic carcinoid tumor (a type of slow growing cancer that has spread to different parts of the body)
3. Profuse watery diarrhea associated with vasoactive intestinal peptide (VIP)-secreting tumor (a type of cancer that starts from hormone producing cells)

- B. **If you have acromegaly, renewal also requires:**

1. You have a reduction, normalization or maintenance of insulin-like growth factor (IGF-1: a growth hormone) levels based on age and gender
2. You have shown an improvement or sustained remission (symptoms have gone away) of clinical symptoms of acromegaly

- C. **If you have severe diarrhea and flushing episodes associated with metastatic carcinoid tumor OR profuse watery diarrhea associated with vasoactive intestinal peptide-secreting tumor, renewal also requires:**

1. You have an improvement or sustained remission (symptoms have gone away) of clinical symptoms

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**OCTREOTIDE - IM**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Sandostatin LAR Depot.

**REFERENCES**

- Sandostatin LAR Depot [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation.; March 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/23

Created: 08/22

Client Approval: 02/23

P&T Approval: 07/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OCTREOTIDE - ORAL

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
OCTREOTIDE ACETATE	MYCAPSSA		48334	GPI-14 (30170070106520)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of acromegaly and meet **ALL** of the following criteria?
  - Therapy is prescribed by or in consultation with an endocrinologist
  - The patient has responded to and tolerated treatment with octreotide or lanreotide

If yes, **approve for 3 months by GPID or GPI-14 with a quantity limit of #4 per day.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **OCTREOTIDE - ORAL (Mycapssa)** requires the following rule(s) be met for approval:

- A. You have acromegaly (a type of hormone disorder)
- B. Therapy is prescribed by or in consultation with an endocrinologist (doctor who specializes in hormones)
- C. You have responded to and tolerated treatment with octreotide or lanreotide

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OCTREOTIDE - ORAL

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of acromegaly and meet **ALL** of the following criteria?
  - The patient has a reduction, normalization, or maintenance of IGF-1 levels based on age and gender
  - The patient has shown an improvement or sustained remission of clinical symptoms of acromegaly

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #4 per day.**  
If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **OCTREOTIDE - ORAL (Mycapssa)** requires the following rule(s) be met for renewal:

- A. You have acromegaly (a type of hormone disorder)
- B. You have had a reduction, normalization, or maintenance of insulin-like growth factor 1 (IGF-1: a type of hormone) levels based on your age and gender
- C. You have shown an improvement or sustained remission (symptoms have gone away) of clinical symptoms of acromegaly

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Mycapssa.

**REFERENCES**

- Mycapssa [Prescribing Information]. Scotland, UK: MW Encap Ltd., March 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/01/22

Created: 08/20

Client Approval: 09/22

P&T Approval: 07/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OCTREOTIDE - SQ

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
OCTREOTIDE ACETATE	BYNFEZIA		47454	GPI-14 (3017007010D220)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of acromegaly and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with an endocrinologist
  - The patient had a trial of or contraindication to ONE generic octreotide product (e.g., octreotide acetate)
  - The patient had an inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses

If yes, **approve for 6 months by GPID or GPI-14 with a quantity limit of #16.8mL per 28 days.**

If no, continue to #2.

2. Does the patient have a diagnosis of severe diarrhea and flushing episodes associated with metastatic carcinoid tumor and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient had a trial of or contraindication to ONE generic octreotide product (e.g., octreotide acetate)

If yes, **approve for 6 months by GPID or GPI-14 with a quantity limit of #16.8mL per 28 days.**

If no, continue to #3.

3. Does the patient have a diagnosis of profuse watery diarrhea associated with vasoactive intestinal peptide tumor (VIPoma) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient had a trial of or contraindication to ONE generic octreotide product (e.g., octreotide acetate)

If yes, **approve for 6 months by GPID or GPI-14 with a quantity limit of #16.8mL per 28 days.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OCTREOTIDE - SQ

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **OCTREOTIDE - SQ (Bynfezia)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
  - 1. Acromegaly (a type of hormone disorder)
  - 2. Severe diarrhea and flushing episodes associated with metastatic carcinoid tumor (a type of slow growing cancer that has spread to different parts of the body)
  - 3. Profuse watery diarrhea associated with vasoactive intestinal peptide tumor (VIPoma: a type of cancer that starts from hormone producing cells)
- B. **If you have acromegaly, approval also requires:**
  - 1. You are 18 years of age or older
  - 2. Therapy is prescribed by or in consultation with an endocrinologist (a type of hormone doctor)
  - 3. You had a trial of or contraindication (harmful for) to ONE generic octreotide product (such as octreotide acetate)
  - 4. You had an inadequate response to or cannot be treated with **ALL** of the following:
    - i. Surgical resection (removal by surgery)
    - ii. Pituitary irradiation (radiation therapy directed at the pituitary)
    - iii. Bromocriptine mesylate at maximally tolerated doses
- C. **If you have severe diarrhea and flushing episodes associated with metastatic carcinoid tumor, approval also requires:**
  - 1. You are 18 years of age or older
  - 2. You had a trial of or contraindication (harmful for) to ONE generic octreotide product (such as octreotide acetate)
- D. **If you have profuse watery diarrhea associated with vasoactive intestinal peptide tumor (VIPoma), approval also requires:**
  - 1. You are 18 years of age or older
  - 2. You had a trial of or contraindication (harmful for) to ONE generic octreotide product (such as octreotide acetate)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OCTREOTIDE - SQ

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

4. Does the patient have a diagnosis of acromegaly and meet **ALL** of the following criteria?
- The patient has a reduction, normalization or maintenance of IGF-1 levels based on age and gender
  - The patient has shown an improvement or sustained remission of clinical symptoms of acromegaly

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #16.8mL per 28 days.**

If no, continue to #2.

5. Does the patient have a diagnosis of severe diarrhea and flushing episodes associated with metastatic carcinoid tumor **AND** meet the following criterion?
- The patient has improvement or sustained remission of clinical symptoms

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #16.8mL per 28 days.**

If no, continue to #3.

6. Does the patient have a diagnosis of profuse watery diarrhea associated with vasoactive intestinal peptide tumor (VIPoma) **AND** meet the following criterion?
- The patient has improvement or sustained remission of clinical symptoms

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #16.8mL per 28 days.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **OCTREOTIDE - SQ (Bynfezia)** requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:

1. Acromegaly (a type of hormone disorder)
2. Severe diarrhea and flushing episodes associated with metastatic carcinoid tumor (a type of slow growing cancer that has spread to different parts of the body)
3. Profuse watery diarrhea associated with vasoactive intestinal peptide tumor (VIPoma: a type of cancer that starts from hormone producing cells)

***(Renewal denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OCTREOTIDE - SQ

RENEWAL CRITERIA (CONTINUED)

**B. If you have acromegaly, renewal also requires:**

1. You have a reduction, normalization or maintenance of insulin-like growth factor (IGF-1: a growth hormone) levels based on age and gender
2. You have shown an improvement or sustained remission (symptoms have gone away) of clinical symptoms of acromegaly

**C. If you have severe diarrhea and flushing episodes associated with metastatic carcinoid tumor OR profuse watery diarrhea associated with vasoactive intestinal peptide tumor, renewal also requires:**

1. You have an improvement or sustained remission (symptoms have gone away) of clinical symptoms

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Bynfezia.

**REFERENCES**

- Bynfezia [Prescribing Information]. Cranbury, NJ: Sun Pharmaceuticals Industries Inc., January 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/01/22

Created: 08/20

Client Approval: 09/22

P&T Approval: 07/22





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ODEVIXIBAT

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ODEVIXIBAT	BYLVAY	47501		GPI-10 (5235006000)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of pruritus associated with progressive familial intrahepatic cholestasis (PFIC) **AND** meet the following criterion?

- The patient is 3 months of age or older

If yes, **approve for all strengths for 12 months by GPID or GPI-14 with the following quantity limits:**

- **Bylvay 200mcg pellets: #30 per day.**
- **Bylvay 600mcg pellets: #10 per day.**
- **Bylvay 400mcg capsule: #15 per day.**
- **Bylvay 1200mcg capsule: #5 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ODEVIXIBAT (Bylvay)** requires the following rule(s) be met for approval:

- A. You have pruritus (itching) associated with progressive familial intrahepatic cholestasis (PFIC: an inherited liver condition)
- B. You are 3 months of age or older

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Bylvay.

**REFERENCES**

- Bylvay [Prescribing Information]. Boston, MA: Albireo Pharma, Inc.; July 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/22

Created: 10/21

Client Approval: 11/21

P&T Approval: 10/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OFATUMUMAB-SQ

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
OFATUMUMAB	KESIMPTA		48513	GPI-10 (6240506500)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of a relapsing form of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, **AND** meet the following criterion?

- The patient is 18 years of age or older

If yes, approve the requested drug for a total of 12 months by GPID or GPI-10 as follows:

**INITIAL REQUEST:**

- **FIRST APPROVAL:** Approve for 1 month with a quantity limit of #1.2mL per 28 days.
- **SECOND APPROVAL:** Approve for 11 months with a quantity limit of #0.4mL per 28 days (Enter a start date 3 weeks AFTER THE START DATE of the first approval).

**SUBSEQUENT/CONTINUATION REQUEST:**

- Approve for 12 months with a quantity limit of #0.4mL per 28 days.

If no, do not approve.

**DENIAL TEXT:** **\*\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **OFATUMUMAB-SQ (Kesimpta)** requires the following rules be met for approval:

- A. You have a relapsing form of multiple sclerosis (MS: an illness where the immune system eats away at the protective covering of the nerves), which includes clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms go away and return), and active secondary progressive disease (advanced disease)
- B. You are 18 years of age or older

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**OFATUMUMAB-SQ**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Kesimpta.

**REFERENCES**

- Kesimpta [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; August 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/21

Created: 09/20

Client Approval: 11/20

P&T Approval: 04/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OLANZAPINE/SAMIDORPHAN

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
OLANZAPINE/ SAMIDORPHAN MALATE	LYBALVI	47406		GPI-10 (6299480250)	

**GUIDELINES FOR USE**

1. Does the patient meet **ONE** of the following criteria?

- The patient has a diagnosis of schizophrenia
- The patient has a diagnosis of bipolar I disorder and meets ONE of the following:
  - Lybalvi is being used for acute treatment of manic or mixed episodes as monotherapy or as adjunct to lithium or valproate
  - Lybalvi is being used as maintenance monotherapy treatment

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- Therapy is prescribed by or in consultation with a psychiatrist
- The patient is at high risk for weight gain
- The patient had a trial and failure of or contraindication to BOTH of the following:
  - TWO generic antipsychotics (e.g., aripiprazole, quetiapine, risperidone, etc.)
  - ONE of the following preferred brand agents: Vraylar, Latuda or Rexulti

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **OLANZAPINE/SAMIDORPHAN (Lybalvi)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
  - 1. Schizophrenia (type of mental health disorder)
  - 2. Bipolar I disorder (type of mood disorder)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a psychiatrist (a type of mental health doctor)
- D. You are at high risk for weight gain
- E. You had a trial and failure of or contraindication (harmful for) to BOTH of the following:
  - 1. TWO generic antipsychotics (such as aripiprazole, quetiapine, risperidone)
  - 2. ONE of the following preferred brand agents: Vraylar, Latuda or Rexulti

***(Denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OLANZAPINE/SAMIDORPHAN

GUIDELINES FOR USE (CONTINUED)

F. If you have bipolar I disorder, approval also requires ONE of the following:

1. Lybalvi is being used for acute treatment of manic or mixed episodes as monotherapy or as adjunct to lithium or valproate
2. Lybalvi is being used as maintenance monotherapy treatment

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Lybalvi.

REFERENCES

- Lybalvi [Prescribing Information]. Waltham, MA: Alkermes, Inc., May 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/11/21

Created: 09/21

Client Approval: 09/21

P&T Approval: 10/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OLAPARIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
OLAPARIB	LYNPARZA	41642		GPI-10 (2153556000)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of advanced epithelial ovarian, fallopian tube or primary peritoneal cancer, and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The requested medication will be used for maintenance treatment
  - The patient is in complete or partial response to first-line platinum-based chemotherapy (e.g., paclitaxel, docetaxel, cisplatin, carboplatin)
  - The patient's diagnosis is confirmed by an FDA-approved companion diagnostic for Lynparza

If yes, continue to #2.

If no, continue to #3.

2. Does the patient meet **ONE** of the following criteria?
  - The patient's cancer has a deleterious or suspected deleterious germline or somatic BRCA mutation
  - The patient's cancer is associated with a homologous recombination deficiency (HRD)-positive status as defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability, AND Lynparza will be used in combination with bevacizumab

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

3. Does the patient have a diagnosis of recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient is in complete or partial response to their most recent platinum based-chemotherapy
  - The patient has completed at least 2 or more lines of platinum-based chemotherapy (e.g., paclitaxel, docetaxel, cisplatin, carboplatin)
  - The requested medication will be used as monotherapy for maintenance treatment

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**

If no, continue to #4.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OLAPARIB

GUIDELINES FOR USE (CONTINUED)

4. Does the patient have a diagnosis of HER2-negative high risk early breast cancer and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The requested medication will be used as adjuvant treatment
- The patient's cancer has a deleterious or suspected deleterious germline BRCA mutation (gBRCAm) as confirmed by an FDA-approved companion diagnostic for Lynparza
- The patient has been treated with neoadjuvant or adjuvant chemotherapy

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**  
If no, continue to #5.

5. Does the patient have a diagnosis of HER2-negative metastatic breast cancer and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient's cancer has a deleterious or suspected deleterious germline BRCA mutation (gBRCAm) as confirmed by an FDA-approved companion diagnostic for Lynparza
- The patient has been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting

If yes, continue to #6.  
If no, continue to #7.

6. Does the patient meet **ONE** of the following criteria?

- The patient does not have hormone receptor (HR)-positive breast cancer
- The patient has a hormone receptor (HR)-positive breast cancer and has been treated with a prior endocrine therapy or is considered inappropriate for endocrine therapy

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**  
If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OLAPARIB

**GUIDELINES FOR USE (CONTINUED)**

7. Does the patient have a diagnosis of metastatic pancreatic adenocarcinoma and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The requested medication will be used for maintenance treatment
- The patient's cancer has a deleterious or suspected deleterious germline BRCA mutation (gBRCAm) as confirmed by an FDA-approved companion diagnostic for Lynparza
- The patient's disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen (e.g., paclitaxel, docetaxel, cisplatin, carboplatin)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**

If no, continue to #8.

8. Does the patient have a diagnosis of metastatic castration-resistant prostate cancer (mCRPC) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient's cancer has a deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene mutation as confirmed by an FDA-approved companion diagnostic for Lynparza
- The patient's disease has progressed following prior treatment with enzalutamide or abiraterone

If yes, continue to #9.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

9. Does the patient meet **ONE** of the following criteria?

- The patient previously had a bilateral orchiectomy
- The patient has a castrate testosterone level (i.e., < 50 ng/dL)
- The requested medication will be used concurrently with a gonadotropin-releasing hormone (GnRH) analog (e.g., leuprolide, goserelin, histrelin, degarelix)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OLAPARIB

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **OLAPARIB (Lynparza)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
1. Recurrent (returning) or advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (types of reproductive system cancers)
  2. HER2 (a type of protein)-negative high risk early breast cancer (a type of breast cancer)
  3. HER2-negative metastatic breast cancer (a type of breast cancer that has spread to other parts of the body)
  4. Metastatic pancreatic adenocarcinoma (a type of pancreas cancer that has spread to other parts of the body)
  5. Metastatic castration-resistant prostate cancer (mCRPC: prostate cancer that has spread to other parts of the body and does not respond to hormone therapy)
- B. **If you have advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, approval also requires:**
1. You are 18 years of age or older
  2. The requested medication will be used for maintenance treatment
  3. You are in complete or partial response to first-line platinum-based chemotherapy (a type of therapy to treat cancer)
  4. Your diagnosis is confirmed by a Food and Drug Administration (FDA)-approved companion diagnostic for Lynparza
  5. You meet ONE of the following:
    - a. Your cancer has a deleterious or suspected deleterious germline or somatic BRCA mutation (a type of gene mutation)
    - b. Your cancer is associated with a homologous recombination deficiency (HRD: type of gene mutation) positive status as defined by either a deleterious or suspected deleterious BRCA mutation (type of gene mutation), and/or genomic instability (high rate of gene mutation), AND Lynparza will be used in combination with bevacizumab
- C. **If you have recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, approval also requires:**
1. You are 18 years of age or older
  2. You are in complete or partial response to your most recent platinum-based chemotherapy (a type of therapy to treat cancer)
  3. You have completed at least two or more lines of platinum-based chemotherapy
  4. The requested medication will be used alone for maintenance treatment

***(Denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OLAPARIB

GUIDELINES FOR USE (CONTINUED)

**D. If you have HER2-negative high risk early breast cancer, approval also requires:**

1. You are 18 years of age or older
2. The requested medication will be used as adjuvant (add-on) treatment
3. Your cancer has a deleterious or suspected deleterious germline BRCA mutation (gBRCAm: a type of gene mutation) as confirmed by a Food and Drug Administration (FDA)-approved companion diagnostic for Lynparza
4. You have been treated with neoadjuvant or adjuvant chemotherapy (cancer treatment given before main treatment or as add-on therapy)

**E. If you have HER2-negative metastatic breast cancer, approval also requires:**

1. You are 18 years of age or older
2. Your cancer has a deleterious or suspected deleterious germline BRCA mutation (gBRCAm: a type of gene mutation) as confirmed by a Food and Drug Administration (FDA)-approved companion diagnostic for Lynparza
3. You have been treated with chemotherapy in the neoadjuvant (given before main treatment), adjuvant (add-on to main treatment), or metastatic setting (to treat disease that has spread to other parts of the body)
4. You meet ONE of the following:
  - a. You do not have hormone receptor (HR)-positive breast cancer
  - b. You have hormone receptor (HR)-positive breast cancer and you have been treated with a prior endocrine (hormone) therapy or endocrine therapy is considered inappropriate for you

**F. If you have metastatic pancreatic adenocarcinoma, approval also requires:**

1. You are 18 years of age or older
2. The requested medication will be used for maintenance treatment
3. Your cancer has a deleterious or suspected deleterious germline BRCA mutation (gBRCAm: a type of gene mutation) as confirmed by a Food and Drug Administration (FDA)-approved companion diagnostic for Lynparza
4. Your disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen (a type of therapy to treat cancer)

***(Denial text continued on next page)***

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OLAPARIB

GUIDELINES FOR USE (CONTINUED)

G. If you have metastatic castration-resistant prostate cancer, approval also requires:

1. You are 18 years of age or older
2. Your cancer has a deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene mutation (type of mutation) as confirmed by a Food and Drug Administration (FDA)-approved companion diagnostic for Lynparza
3. Your disease has worsened following prior treatment with enzalutamide or abiraterone
4. You meet ONE of the following:
  - a. You previously had a bilateral orchiectomy (both testicles have been surgically removed)
  - b. You have a castrate level of testosterone (your blood testosterone levels are less than 50 ng/dL)
  - c. The requested medication will be used together with a gonadotropin-releasing hormone (GnRH) analog (such as leuprolide, goserelin, histrelin, degarelix)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Lynparza.

**REFERENCES**

- Lynparza Tablets [Prescribing Information]. Wilmington, DE: AstraZeneca Pharmaceuticals. August 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 09/12/22

Created: 12/14

Client Approval: 08/22

P&T Approval: 10/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**OLUTASIDENIB**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
OLUTASIDENIB	REZLIDHIA	48490		GPI-10 (2153496000)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of relapsed or refractory acute myeloid leukemia (AML) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient has a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **OLUTASIDENIB (Rezlidhia)** requires the following rule(s) be met for approval:

- A. You have relapsed or refractory acute myeloid leukemia (AML: a type of blood cancer that has returned or did not respond to treatment)
- B. You are 18 years of age or older
- C. You have a susceptible (can be treated with the drug) isocitrate dehydrogenase-1 (IDH1: a type of enzyme) mutation as detected by a Food and Drug Administration (FDA)-approved test

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Rezlidhia.

**REFERENCES**

- Rezlidhia [Prescribing Information]. Greenville, NC: Forma Therapeutics, Inc., December 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/23

Created: 01/23

Client Approval: 02/23

P&T Approval: 01/23



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OMACETAXINE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
OMACETAXINE MEPESUCCINATE	SYNRIBO	24243		GPI-10 (2170004010)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of chronic or accelerated phase chronic myeloid leukemia (CML) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient had a resistance or intolerance to TWO or more tyrosine kinase inhibitors (e.g., Gleevec, Sprycel, Tasigna, Bosulif, Iclusig)

If yes, **approve for 12 months by HICL.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **OMACETAXINE (Synribo)** requires the following rule(s) be met for approval:

- A. You have chronic or accelerated phase chronic myeloid leukemia (CML: type of blood cell cancer)
- B. You are 18 years of age or older
- C. You had a resistance or intolerance to TWO or more tyrosine kinase inhibitors (such as Gleevec, Sprycel, Tasigna, Bosulif, Iclusig)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Synribo.

**REFERENCES**

- Synribo [Prescribing Information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; November 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/11/22

Created: 12/12

Client Approval: 03/22

P&T Approval: 05/13



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OMADACYCLINE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
OMADACYCLINE	NUZYRA		45478	GPI-14 (04200050200320)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of community-acquired bacterial pneumonia (CABP) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Infection is caused by any of the following susceptible microorganisms: *Streptococcus pneumoniae*, *Staphylococcus aureus* (methicillin-susceptible isolates), *Haemophilus influenzae*, *Haemophilus parainfluenzae*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Mycoplasma pneumoniae*, or *Chlamydophila pneumoniae*

If yes, continue to #2.  
If no, continue to #5.
2. Is therapy prescribed by or given in consultation with an Infectious Disease (ID) specialist?

If yes, **approve Nuzyra 150mg tablet for one fill by GPID or GPI-14 with a quantity limit of #26 tablets per 13 days.**  
If no, continue to #3.
3. Have antimicrobial susceptibility tests been performed that meet **ALL** of the following criteria?
  - The results from the infection site culture indicate pathogenic organism(s) with **resistance** to at least **TWO** standard of care agents for CABP (e.g., azithromycin, doxycycline, levofloxacin, moxifloxacin, amoxicillin, ceftriaxone)
  - The results from the infection site culture indicate pathogenic organism(s) with susceptibility to Nuzyra

If yes, **approve Nuzyra 150mg tablet for one fill by GPID or GPI-14 with a quantity limit of #26 tablets per 13 days.**  
If no, continue to #4.
4. Does the patient meet **ALL** of the following criteria?
  - Antimicrobial susceptibility results are unavailable
  - The patient has had a trial of or contraindication to at least **TWO** standard of care agents for CABP (e.g., azithromycin, doxycycline, levofloxacin, moxifloxacin, amoxicillin, ceftriaxone)

If yes, **approve Nuzyra 150mg tablet for one fill by GPID or GPI-14 with a quantity limit of #26 tablets per 13 days.**  
If no, do not approve.  
**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OMADACYCLINE

GUIDELINES FOR USE (CONTINUED)

5. Does the patient have a diagnosis of an acute bacterial skin or skin structure infection (ABSSSI) and meet **ALL** of the following criteria?
- The patient is 18 years of age or older
  - Infection is caused by any of the following susceptible microorganisms: *Staphylococcus aureus* (methicillin-susceptible and -resistant isolates), *Staphylococcus lugdunensis*, *Streptococcus pyogenes*, *Streptococcus anginosus grp.* (includes *S. anginosus*, *S. intermedius*, and *S. constellatus*), *Enterococcus faecalis*, *Enterobacter cloacae*, or *Klebsiella pneumoniae*

If yes, continue to #6.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

6. Is therapy prescribed by or given in consultation with an Infectious Disease (ID) specialist?

If yes, **approve Nuzyra 150mg tablet for one fill by GPID or GPI-14 with a quantity limit of #30 tablets per 14 days.**

If no, continue to #7.

7. Have antimicrobial susceptibility tests been performed that meet **ALL** of the following criteria?
- The results from the infection site culture indicate pathogenic organism(s) with **resistance** to at least **TWO** standard of care agents for ABSSSI (e.g., linezolid, clindamycin, doxycycline, sulfamethoxazole/trimethoprim, vancomycin, amoxicillin, nafcillin, ceftriaxone, cephalixin, cefazolin)
  - The results from the infection site culture indicate pathogenic organism(s) with susceptibility to Nuzyra

If yes, **approve Nuzyra 150mg tablet for one fill by GPID or GPI-14 with a quantity limit of #30 tablets per 14 days.**

If no, continue to #8.

8. Does the patient meet **ALL** of the following criteria?
- Antimicrobial susceptibility results are unavailable
  - The patient has had a trial of or contraindication to at least **TWO** standard of care agents for ABSSSI (e.g., linezolid, clindamycin, doxycycline, sulfamethoxazole/trimethoprim, vancomycin, amoxicillin, nafcillin, ceftriaxone, cephalixin, cefazolin)

If yes, **approve Nuzyra 150mg tablet for one fill by GPID or GPI-14 with a quantity limit of #30 tablets per 14 days.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OMADACYCLINE

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **OMADACYCLINE (Nuzyra)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
1. Community-acquired bacterial pneumonia (CABP: type of lung infection)
  2. Acute (severe and sudden) bacterial skin or skin structure infection (ABSSSI)
- B. **If you have community-acquired bacterial pneumonia, approval also requires:**
1. You are 18 years of age or older
  2. The infection is caused by any of the following bacteria: *Streptococcus pneumoniae*, *Staphylococcus aureus* (methicillin-susceptible isolates), *Haemophilus influenzae*, *Haemophilus parainfluenzae*, *Klebsiella pneumoniae*, *Legionella pneumoniae*, *Mycoplasma pneumoniae*, or *Chlamydophila pneumoniae*
  3. You meet ONE of the following criteria:
    - a. The requested medication is prescribed by or given in consultation with an Infectious Disease (ID) specialist
    - b. Antimicrobial susceptibility test (lab test that shows what drugs may kill the bacteria) is available, and the infection site culture results indicate pathogenic (disease-causing) organism(s) with 1) resistance to at least TWO standard of care agents for community-acquired bacterial pneumonia (such as azithromycin, doxycycline, levofloxacin, moxifloxacin, amoxicillin, ceftriaxone), AND 2) Nuzyra will work against the bacteria
    - c. Antimicrobial susceptibility test (lab test that shows what drugs may kill the bacteria) is unavailable, and you have had a trial of or contraindication (medical reason why you cannot use) to at least TWO standard of care agents for community-acquired bacterial pneumonia (such as azithromycin, doxycycline, levofloxacin, moxifloxacin, amoxicillin, ceftriaxone)

**(Denial text continued on next page)**

CONTINUED ON NEXT PAGE





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OMADACYCLINE

GUIDELINES FOR USE (CONTINUED)

C. If you have acute bacterial skin or skin structure infection (ABSSSI), approval also requires:

1. You are 18 years of age or older
2. The infection is caused by any of the following bacteria: *Staphylococcus aureus* (methicillin-susceptible and -resistant isolates), *Staphylococcus lugdunensis*, *Streptococcus pyogenes*, *Streptococcus anginosus* grp. (Includes *S. anginosus*, *S. intermedius*, and *S. constellatus*), *Enterococcus faecalis*, *Enterobacter cloacae*, or *Klebsiella pneumoniae*
3. You meet ONE of the following criteria:
  - a. The requested medication is prescribed by or given in consultation with an Infectious Disease (ID) specialist
  - b. Antimicrobial susceptibility test (lab test that shows what drugs may kill the bacteria) is available, and the infection site culture results indicate pathogenic (disease-causing) organism(s) with 1) resistance to at least TWO standard of care agents for acute bacterial skin or skin structure infection (such as linezolid, clindamycin, doxycycline, sulfamethoxazole/trimethoprim, vancomycin, amoxicillin, nafcillin, ceftriaxone, cephalexin, ceftazolin), AND 2) Nuzyra will work against the bacteria
  - c. Antimicrobial susceptibility test (lab test that shows what drugs may kill the bacteria) is unavailable, and you had a trial of or contraindication to at least TWO standard of care agents for acute bacterial skin or skin structure infection (such as linezolid, clindamycin, doxycycline, sulfamethoxazole/trimethoprim, vancomycin, amoxicillin, nafcillin, ceftriaxone, cephalexin, ceftazolin)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Nuzyra.

**REFERENCES**

- Nuzyra [Prescribing Information]. Boston, MA: Paratek Pharmaceuticals, Inc.; February 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 03/19

Client Approval: 04/20

P&T Approval: 01/19



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OMALIZUMAB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
OMALIZUMAB	XOLAIR	25399		GPI-10 (4460306000)	

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have moderate to severe persistent asthma and meet **ALL** the following criteria?
  - The patient is 6 years of age or older
  - Therapy is prescribed by or in consultation with a physician specializing in allergy or pulmonary medicine
  - The patient has a positive skin prick or blood test (e.g., ELISA, FEIA) to a perennial aeroallergen
  - The patient has a documented baseline IgE serum level greater than or equal to 30 IU/mL
  - The patient is concurrently treated with a medium, high-dose, or maximally tolerated inhaled corticosteroid AND at least one other maintenance medication (e.g., long-acting inhaled beta2-agonist such as salmeterol or formoterol, long-acting muscarinic antagonist such as tiotropium, a leukotriene receptor antagonist such as montelukast, theophylline, or oral corticosteroid)
  - Xolair will NOT be used concurrently with Dupixent or an anti-IL5 biologic (e.g., Nucala, Cinqair, Fasenna) when these are used for the treatment of asthma

If yes, continue to #2.

If no, continue to #3.

2. Does the patient meet **ONE** of the following criteria?
  - The patient experienced at least ONE asthma exacerbation requiring systemic corticosteroid burst lasting at least 3 days within the past 12 months OR at least ONE serious exacerbation requiring hospitalization or emergency room visit within the past 12 months
  - The patient has poor symptom control despite current therapy as evidenced by at least THREE of the following within the past 4 weeks:
    - Daytime asthma symptoms more than twice per week
    - Any night waking due to asthma
    - Use of a short-acting inhaled beta2-agonist reliever (such as albuterol) for symptoms more than twice per week
    - Any activity limitation due to asthma

If yes, approve for 4 months by GPID or GPI-14 for the requested product as follows:

- Xolair 150mg vial: #6 vials per 28 days. (Note: This is a non-self-administered [NSA] agent and may not be covered by some plans.)
- Xolair 75mg/0.5mL syringe: #5mL per 28 days.
- Xolair 150mg/mL syringe: #5mL per 28 days.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OMALIZUMAB

INITIAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of nasal polyps and meet **ALL** of the following criteria?
- The patient is 18 of age or older
  - Therapy is prescribed by or in consultation with an otolaryngologist or allergist/immunologist
  - Xolair will be used as add-on maintenance treatment
  - The patient had a previous 90-day trial of ONE intranasal corticosteroid

If yes, **approve for 6 months by GPID or GPI-14 for the requested product as follows:**

- **Xolair 150mg vial: #8 vials per 28 days. (Note: This is a non-self-administered [NSA] agent and may not be covered by some plans.)**
- **Xolair 75mg/0.5mL syringe: #8mL per 28 days.**
- **Xolair 150mg/mL syringe: #8mL per 28 days.**

If no, continue to #4.

4. Does the patient have a diagnosis of chronic spontaneous urticaria (CSU; also called chronic idiopathic urticaria [CIU]) and meet **ALL** of the following criteria?
- The patient is 12 years of age or older
  - Therapy is prescribed by or in consultation with a physician specializing in allergy or pulmonary medicine
  - The patient still experiences hives on most days of the week for at least 6 weeks
  - The patient has tried a high dose H1 antihistamine (such as four-fold dosing of Clarinex or Xyzal) **AND** leukotriene antagonist (such as montelukast, zafirlukast) for at least 2 weeks

If yes, **approve for 6 months by GPID or GPI-14 for the requested product as follows:**

- **Xolair 150mg vial: #2 vials per 28 days. (Note: This is a non-self-administered [NSA] agent and may not be covered by some plans.)**
- **Xolair 75mg/0.5mL syringe: #2mL per 28 days.**
- **Xolair 150mg/mL syringe: #2mL per 28 days.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OMALIZUMAB

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **OMALIZUMAB (Xolair)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:

1. Moderate to severe persistent asthma
2. Nasal polyps (small growths in the nose)
3. Chronic spontaneous urticaria (also called chronic idiopathic urticaria) [severe itching with unknown cause]

B. **If you have moderate to severe persistent asthma, approval also requires:**

1. You are 6 years of age or older
2. Therapy is prescribed by or in consultation with a physician specializing in allergy or pulmonary (relating to lungs/breathing) medicine
3. You have a positive skin prick or blood test such as ELISA or FEIA (type of blood test to identify what you're allergic to) to a perennial aeroallergen (airborne particles that cause allergies year-round)
4. You have a documented baseline IgE (type of antibody that is produced by your immune system if you have an allergy) serum level greater than or equal to 30 IU/mL
5. You are being treated with medium, high-dose, or maximally tolerated inhaled corticosteroid AND at least one other maintenance medication such as long-acting inhaled beta2-agonist (such as salmeterol or formoterol), long-acting muscarinic antagonist (such as tiotropium), a leukotriene receptor antagonist (such as montelukast), theophylline, or oral corticosteroid
6. You have ONE of the following:
  - a. Experienced at least ONE asthma exacerbation (worsening of symptoms) requiring systemic corticosteroid burst lasting at least 3 days within the past 12 months OR at least ONE serious exacerbation requiring hospitalization or emergency room visit within the past 12 months
  - b. Poor symptom control despite current therapy as evidenced by at least THREE of the following within the past 4 weeks:
    - i. Daytime asthma symptoms more than twice per week
    - ii. Any night waking due to asthma
    - iii. Use of a short-acting inhaled beta2-agonist reliever (such as albuterol) for symptoms more than twice per week
    - iv. Any activity limitation due to asthma
7. You will NOT use Xolair concurrently (at the same time) with Dupixent or an anti-IL5 biologic (such as Nucala, Cinqair, Fasentra) when these are used for treatment of asthma

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OMALIZUMAB

INITIAL CRITERIA (CONTINUED)

**C. If you have nasal polyps, approval also requires:**

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with an otolaryngologist (ear, nose, and throat doctor) or an allergist/immunologist
3. Xolair will be used as add-on maintenance treatment
4. You had a previous 90-day trial of ONE intranasal corticosteroid

**D. If you have chronic spontaneous urticaria (chronic idiopathic urticaria), approval also requires:**

1. You are 12 years of age or older
2. Therapy is prescribed by or in consultation with a physician specializing in allergy or pulmonary (relating to lungs/breathing) medicine
3. You still experience hives on most days of the week for at least 6 weeks
4. You have tried a high dose H1 antihistamine (type of allergy medication such as four-fold dosing of Clarinex or Xyzal) AND leukotriene antagonist (type of allergy medication such as montelukast) for at least 2 weeks

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OMALIZUMAB

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of moderate to severe persistent asthma and meet **ALL** of the following criteria?
  - The patient will continue to use an inhaled corticosteroid (ICS) AND at least one other maintenance medication (e.g., a long-acting inhaled beta2-agonist such as formoterol or salmeterol, a long-acting muscarinic antagonist such as tiotropium, a leukotriene receptor antagonist such as montelukast, theophylline, or oral corticosteroid)
  - Xolair will NOT be used concurrently with Dupixent or an anti-IL5 biologic (e.g., Nucala, Cinqair, Fasentra) when these are used for the treatment of asthma
  - The patient has shown a clinical response as evidenced by ONE of the following:
    - Reduction in asthma exacerbation from baseline
    - Decreased utilization of rescue medications
    - Increase in percent predicted FEV1 from pretreatment baseline
    - Reduction in severity or frequency of asthma-related symptoms (e.g., wheezing, shortness of breath, coughing, etc.)

If yes, approve for 12 months by GPID or GPI-14 for the requested product as follows:

- Xolair 150mg vial: #6 vials per 28 days. (Note: This is a non-self-administered [NSA] agent and may not be covered by some plans.)
- Xolair 75mg/0.5mL syringe: #5mL per 28 days.
- Xolair 150mg/mL syringe: #5mL per 28 days.

If no, continue to #2.

2. Does the patient have a diagnosis of nasal polyps **AND** meet the following criterion?
  - The patient has had clinical benefit compared to baseline (e.g., improvements in nasal congestion, sense of smell, size of polyps)

If yes, approve for 12 months by GPID or GPI-14 for the requested product as follows:

- Xolair 150mg vial: #8 vials per 28 days. (Note: This is a non-self-administered [NSA] agent and may not be covered by some plans.)
- Xolair 75mg/0.5mL syringe: #8mL per 28 days.
- Xolair 150mg/mL syringe: #8mL per 28 days.

If no, continue to #3.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OMALIZUMAB

RENEWAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of chronic spontaneous urticaria (CSU; also called chronic idiopathic urticaria [CIU]) **AND** meet the following criterion?

- Therapy is prescribed by or in consultation with an allergist or immunologist

If yes, **approve for 6 months by GPID or GPI-14 for the requested product as follows:**

- **Xolair 150mg vial: #2 vials per 28 days. (Note: This is a non-self-administered [NSA] agent and may not be covered by some plans.)**
- **Xolair 75mg/0.5mL syringe: #2mL per 28 days.**
- **Xolair 150mg/mL syringe: #2mL per 28 days.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **OMALIZUMAB (Xolair)** requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:

1. Moderate to severe persistent asthma
2. Nasal polyps (small growths in the nose)
3. Chronic spontaneous urticaria (also called chronic idiopathic urticaria) [severe itching with unknown cause]

B. **If you have moderate to severe persistent asthma, renewal also requires:**

1. You will continue to use an inhaled corticosteroid (ICS) **AND** at least one other maintenance medication such as a long-acting inhaled beta2-agonist (such as formoterol, salmeterol), a long-acting muscarinic antagonist (such as tiotropium), a leukotriene receptor antagonist (such as montelukast), theophylline, or oral corticosteroid
2. You will **NOT** use Xolair concurrently (at the same time) with Dupixent or an anti-IL5 biologic (such as Nucala, Cinqair, Fasenra) when these are used for treatment of asthma
3. You have shown a clinical response as evidenced by ONE of the following:
  - a. Reduction in asthma exacerbation (worsening of symptoms) from baseline
  - b. Decreased use of rescue medications
  - c. Increase in percent predicted FEV1 (amount of air you can forcefully exhale) from baseline before treatment
  - d. Reduction in severity or frequency of asthma-related symptoms which may include wheezing, shortness of breath, or coughing

C. **If you have nasal polyps, renewal also requires:**

1. You have had a clinical benefit compared to baseline (before starting Xolair) (such as improvements in nasal congestion, sense of smell, size of polyps)

***(Renewal denial text continued on next page)***

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OMALIZUMAB

RENEWAL CRITERIA (CONTINUED)

D. If you have chronic spontaneous urticaria (chronic idiopathic urticaria), renewal also requires:

- 1. Therapy is prescribed by or in consultation with an allergist or immunologist (immune system doctor)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Xolair.

REFERENCES

- Xolair [Prescribing Information]. South San Francisco, CA: Genentech, Inc. July 2021.

Library	Commercial	NSA
Yes	Yes	Yes

Part D Effective: N/A

Commercial Effective: 07/01/22

Created: 08/03

Client Approval: 05/22

P&T Approval: 04/22





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OMBITASVIR/PARITAPREVIR/RITONAVIR

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
OMBITASVIR/ PARITAPREVIR/ RITONAVIR	TECHNIVIE	41734		GPI-10 (1235990360)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of hepatitis C, genotype 4 and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient is treatment naïve or treatment experienced (previous treatment with peginterferon/ribavirin)

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient have one or more of the following conditions?

- The patient is on hemodialysis
- Moderate or severe liver impairment (Child-Pugh B or Child-Pugh C), or decompensated liver disease
- A limited life expectancy (less than 12 months) due to non-liver related comorbid conditions (e.g., physician attestation)
- Concurrent use with any of these medications (contraindicated or not recommended by the manufacturer): alfuzosin, carbamazepine, phenytoin, phenobarbital, rifampin, ergotamine, dihydroergotamine, ergonovine, methylegonovine, ethinyl estradiol containing medications (such as combined oral contraceptives, NuvaRing, Ortho Evra or Xulane transdermal patch system), lovastatin, simvastatin, pimozide, efavirenz (Atripla, Sustiva), Revatio (sildenafil dose of 20mg and/or dosed TID for PAH), triazolam, oral midazolam, lopinavir/ritonavir, rilpivirine, salmeterol
- Prior use (failure of a full course of therapy) or concurrent use of any HCV protease inhibitors including Olysio (simeprevir), Victrelis (boceprevir), or Incivek (telaprevir)
- Prior use (failure of a full course of therapy) or concurrent use of any NS5B polymerase inhibitor including Sovaldi (sofosbuvir)
- Prior use (failure of a full course of therapy) or concurrent use of any NS5B polymerase inhibitor/NS5A inhibitor including Harvoni (ledipasvir/sofosbuvir)
- Prior use (short trial or failure of a full course of therapy) of Viekira Pak or Viekira XR

If yes, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

If no, continue to #3.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OMBITASVIR/PARITAPREVIR/RITONAVIR

**GUIDELINES FOR USE (CONTINUED)**

3. Does the patient have an HCV RNA level within the past 6 months?

If yes, continue to #4.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

4. Does the patient meet **ONE** of the following criteria?

- Patient has a contraindication to therapy with Epclusa, Harvoni, **AND** Mavyret
- Patient has previously failed a short trial with Epclusa, Harvoni or Mavyret (e.g., adverse effect early in therapy); [**NOTE:** An individual who has completed a full course of therapy with Epclusa, Harvoni or Mavyret that did not achieve SVR will not be approved.]

If yes, continue to #5.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

5. Is the requested medication being used with ribavirin?

If yes, **approve for 12 weeks by HICL or GPI-10 for #56 tablets (1 monthly carton) per 28 days.**

(**NOTE:** Approval allows patients to complete a total maximum of 12 weeks of therapy.)

If no, continue to #6.

6. Is the patient treatment naïve and without cirrhosis?

If yes, continue to #7.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

7. Does the patient have an intolerance or contraindication to ribavirin?

If yes, **approve for 12 weeks by HICL or GPI-10 for #56 tablets (1 monthly carton) per 28 days.**

(**NOTE:** Approval allows patients to complete a total maximum of 12 weeks of therapy.)

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OMBITASVIR/PARITAPREVIR/RITONAVIR

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **OMBITASVIR/PARITAPREVIR/RITONAVIR (Technivie)** requires the following rule(s) be met for approval:

- A. You have chronic hepatitis C, genotype 4 without cirrhosis (liver damage) or with compensated cirrhosis (you do not have symptoms related to liver damage; Child-Pugh A)
- B. You are treatment naïve (never previously treated) or treatment experienced (previous treatment with peginterferon/ribavirin)
- C. The requested medication will be used with ribavirin, unless you are treatment naïve without cirrhosis (you have never been previously treated and do not have liver damage) and you have an intolerance or contraindication to (medical reason why you cannot use) ribavirin
- D. You are 18 years of age or older
- E. You have previously failed a short trial of Harvoni or Epclusa or Mavyret. Reasons for failure may include adverse effect, intolerance to therapy, or contraindication to (medical reason why you cannot use) all 3 drugs (**NOTE:** If you completed a full course of therapy with Mavyret and you did not achieve sustained virologic response [no virus can be detected in blood], the request will not be approved)
- F. You have an HCV RNA level (amount of virus in your blood) within the past 6 months

**A total of 12 weeks of therapy will be approved.**

**The medication will NOT be approved for the following:**

- A. You are using any of the following medications at the same time while on Technivie: alfuzosin, carbamazepine, phenytoin, phenobarbital, rifampin, ergotamine dihydroergotamine, ergonovine, methylergonovine, ethinyl estradiol containing medications (such as combined oral contraceptives, NuvaRing, Ortho Evra or Xulane transdermal patch system), lovastatin, simvastatin, pimozide, efavirenz, Revatio, triazolam, oral midazolam, lopinavir/ritonavir, rilpivirine, or salmeterol
- B. You have moderate or severe liver impairment (Child Pugh B or Child Pugh C)
- C. You are on hemodialysis (process of purifying the blood of a person whose kidneys are not working normally)
- D. You have a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions

***(Denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**OMBITASVIR/PARITAPREVIR/RITONAVIR**

**GUIDELINES FOR USE (CONTINUED)**

- E. You have previously used (failed a full course of therapy) or are currently using any of the following regimens:
1. A nucleotide NS5B polymerase inhibitor (type of hepatitis C drug) including Sovaldi (sofosbuvir)
  2. A combination NS5B polymerase inhibitor/NS5A inhibitor (type of hepatitis C drug) including Harvoni (ledipasvir/sofosbuvir)
  3. Any HCV protease inhibitor including Olysio (simeprevir), Victrelis (boceprevir), and Incivek (telaprevir)
  4. Viekira Pak (dasabuvir/ombitasvir/paritaprevir/ritonavir) or Viekira XR

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Technivie.

**REFERENCES**

- Technivie [Prescribing Information]. North Chicago, IL: Abbvie Inc.; December 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/23

Created: 08/15

Client Approval: 11/22

P&T Approval: 04/17



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OMBITASVIR/PARITAPREVIR/RITONAVIR/DASABUVIR

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
OMBITASVIR/ PARITAPREVIR/ RITONAVIR/ DASABUVIR	VIEKIRA PAK, VIEKIRA XR	41644		GPI-10 (1235990460)	

**GUIDELINES FOR USE**

1. Does the patient meet **ONE** of the following criteria?

- The patient has a contraindication to therapy with Epclusa AND Harvoni
- The patient has previously failed a short trial with Epclusa or Harvoni (e.g., adverse effect early in therapy); [**NOTE:** An individual who has completed a full course of therapy with Epclusa or Harvoni that did not achieve SVR will not be approved]

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient have one or more of the following conditions?

- Decompensated liver disease
- Moderate liver impairment (Child-Pugh B) or severe liver impairment (Child-Pugh C)
- A limited life expectancy (less than 12 months) due to non-liver related comorbid conditions (e.g., physician attestation)
- Patient is on hemodialysis
- Concurrent use with any of these (contraindicated or not recommended by the manufacturer) medications: alfuzosin, carbamazepine, phenytoin, phenobarbital, gemfibrozil, rifampin, ergotamine dihydroergotamine, ergonovine, methylergonovine, ethinyl estradiol containing medications (such as combined oral contraceptives, Nuvaring, Ortho Evra or Xulane transdermal patch system), St. John's Wort, lovastatin, simvastatin, pimozone, efavirenz, Revatio (sildenafil dose of 20mg and/or dosed TID for PAH), triazolam, oral midazolam, darunavir/ritonavir, lopinavir/ritonavir, rilpivirine, salmeterol
- Prior use (failure of a full course of therapy) or concurrent use of any HCV protease inhibitors including Olysio (simeprevir), Victrelis (boceprevir), or Incivek (telaprevir)
- Prior use (failure of a full course of therapy) or concurrent use of any NS5B polymerase inhibitor including Sovaldi (sofosbuvir)
- Prior use (failure of a full course of therapy) or concurrent use of any NS5B polymerase inhibitor/NS5A inhibitor including Harvoni (ledipasvir/sofosbuvir)

If yes, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

If no, continue to #3.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OMBITASVIR/PARITAPREVIR/RITONAVIR/DASABUVIR

**GUIDELINES FOR USE (CONTINUED)**

3. Does the patient have an HCV RNA level within the past 6 months?

If yes, continue to #4.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

4. Does the patient have a diagnosis of hepatitis C, genotype 1 and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient is treatment naïve or treatment experienced (previous treatment with peginterferon/ribavirin)

If yes, continue to #5.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

5. Is the requested medication being used with ribavirin; (**NOTE:** Ribavirin combination therapy with Viekira is approved for genotype 1a without cirrhosis, genotype 1a with cirrhosis, and for use in liver transplant patients.)?

If yes, continue to #6.

If no, continue to #12.

6. Is the patient a liver transplant recipient?

If yes, **approve the requested strength for 24 weeks by GPID or GPI-14 with the following quantity limits (NOTE: Approval allows patients who are liver transplant recipients to complete a total of 24 weeks of therapy):**

- **Viekira XR: #84 tablets (1 pack) per 28 days OR**
- **Viekira Pak: #112 tablets (1 pack) per 28 days**

If no, continue to #7.

7. Does the patient have genotype 1a without cirrhosis?

If yes, **approve the requested strength for 12 weeks by GPID or GPI-14 with the following quantity limits (NOTE: Approval allows patients with genotype 1a without cirrhosis to complete a total maximum of 12 weeks of therapy):**

- **Viekira XR: #84 tablets (1 pack) per 28 days OR**
- **Viekira Pak: #112 tablets (1 pack) per 28 days**

If no, continue to #8.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OMBITASVIR/PARITAPREVIR/RITONAVIR/DASABUVIR

GUIDELINES FOR USE (CONTINUED)

8. Does the patient have genotype 1a with cirrhosis **AND** is treatment naïve?

If yes, **approve the requested strength for 12 weeks by GPID or GPI-14 with the following quantity limits (NOTE: Approval allows treatment naïve patients with genotype 1a with cirrhosis to complete a total maximum of 12 weeks of therapy):**

- **Viekira XR: #84 tablets (1 pack) per 28 days OR**
- **Viekira Pak: #112 tablets (1 pack) per 28 days**

If no, continue to #9.

9. Does the patient have genotype 1a with cirrhosis and has received prior treatment (e.g., treatment-experienced patient) for hepatitis C with peginterferon and ribavirin; (**NOTE: Approval not granted for patients with history of prior use of OR concurrent use of HCV protease inhibitors or HCV polymerase inhibitors: Olysio (simeprevir), Victrelis (boceprevir), Incivek (telaprevir), Sovaldi (sofosbuvir), or Harvoni (ledipasvir/sofosbuvir)?**)

If yes, continue to #10.

If no, continue to #12.

10. Is the patient a previous prior relapser or a prior partial responder?

If yes, **approve the requested strength for 12 weeks by GPID or GPI-14 with the following quantity limits (NOTE: Approval allows patients with genotype 1a that are previous prior relapsers or prior partial responders to complete a total of 12 weeks of therapy):**

- **Viekira XR: #84 tablets (1 pack) per 28 days OR**
- **Viekira Pak: #112 tablets (1 pack) per 28 days**

If no, continue to #11.

11. Is the patient a treatment-experienced patient and is a previous null responder?

If yes, **approve the requested strength for 24 weeks by GPID or GPI-14 with the following quantity limits (NOTE: Approval allows patients with genotype 1a that are previous null responders to complete a total of 24 weeks of therapy):**

- **Viekira XR: #84 tablets (1 pack) per 28 days OR**
- **Viekira Pak: #112 tablets (1 pack) per 28 days**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OMBITASVIR/PARITAPREVIR/RITONAVIR/DASABUVIR

GUIDELINES FOR USE (CONTINUED)

12. Does the patient have genotype 1b?

If yes, approve the requested strength for 12 weeks by GPID or GPI-14 with the following quantity limits (NOTE: Approval allows patients with genotype 1b to complete a total of 12 weeks of therapy):

- Viekira XR: #84 tablets (1 pack) per 28 days OR
- Viekira Pak: #112 tablets (1 pack) per 28 days

If no, do not approve.

**DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named OMBITASVIR/PARITAPREVIR/RITONAVIR/ DASABUVIR (Viekira Pak, Viekira XR) requires the following rule(s) be met for approval:

- A. You have chronic hepatitis C, genotype 1 (a type of liver infection)
- B. You are 18 years of age or older
- C. You are treatment naïve (never previously treated) or treatment experienced (previous treatment with peginterferon/ribavirin)
- D. You will be using ribavirin with the requested medication, unless you have genotype 1b
- E. You have previously failed a short trial with Epclusa or Harvoni unless you have a medical reason why you cannot use (contraindication) BOTH drugs. Reasons for failure include adverse effect early in therapy, intolerance to therapy (NOTE: If you completed a full course of therapy with Epclusa or Harvoni and you did not achieve sustained virologic response [no virus can be detected in blood], the request will not be approved)
- F. You have an HCV RNA level (amount of virus in the blood) within the past 6 months  
(Denial text continued on the next page)

CONTINUED ON NEXT PAGE





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OMBITASVIR/PARITAPREVIR/RITONAVIR/DASABUVIR

GUIDELINES FOR USE (CONTINUED)

**The medication will not be approved for the following patients:**

- A. You are using any of the following medications at the same time while on Viekira: alfuzosin, carbamazepine, phenytoin, phenobarbital, gemfibrozil, rifampin, ergotamine dihydroergotamine, ergonovine, methylegonovine, ethinyl estradiol containing medications (such as combined oral contraceptives, Nuvaring, Ortho Evra or Xulane transdermal patch system), St. John's Wort, lovastatin, simvastatin, pimozide, efavirenz, Revatio, triazolam, oral midazolam, darunavir/ritonavir, lopinavir/ritonavir, rilpivirine, or salmeterol
- B. You have decompensated cirrhosis (symptoms related to liver damage)
- C. You have moderate liver impairment (Child Pugh B) or severe liver impairment (Child Pugh C)
- D. You are on hemodialysis (process of purifying the blood of a person whose kidneys are not working normally)
- E. You have a limited life expectancy (less than 12 months) due to other conditions not related to the liver
- F. You have previously used/failed a full course of therapy, or currently using any of the following regimens:
  - 1. A nucleotide NS5B polymerase inhibitor (type of hepatitis C drug) including Sovaldi (sofosbuvir)
  - 2. A combination NS5B polymerase inhibitor/NS5A inhibitor including Harvoni (ledipasvir/sofosbuvir)
  - 3. A hepatitis C virus protease inhibitor (type of hepatitis drug) including Olysio (simeprevir), Victrelis (boceprevir), and Incivek (telaprevir)

A total of 12 weeks of therapy will be approved except 24 weeks of therapy for 1) genotype 1a with cirrhosis if patient is treatment experienced, previous null responder or 2) a liver transplant recipient.

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**OMBITASVIR/PARITAPREVIR/RITONAVIR/DASABUVIR**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Viekira Pak/XR.

**REFERENCES**

- Guidance from the American Association for the Study of Liver Diseases (AASLD) and the Infectious Disease Society of America (IDSA) Recommendations for Testing, Managing, and Treating hepatitis C. Available online at <http://www.hcvguidelines.org/full-report-view> Accessed November 3, 2022.
- Viekira Pak [Prescribing Information]. North Chicago, IL: Abbvie Inc.; December 2019.
- Viekira XR [Prescribing Information]. North Chicago, IL: Abbvie Inc.; December 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/23

Created: 01/15

Client Approval: 11/22

P&T Approval: 01/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OPICAPONE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
OPICAPONE	ONGENTYS	45536		GPI-10 (7315306000)	

GUIDELINES FOR USE

1. Does the patient have a diagnosis of Parkinson's disease and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient is experiencing "OFF" episodes
  - The patient is currently being treated with carbidopa/levodopa
  - The patient had a previous trial of, failure of, or contraindication to **TWO** Parkinson's disease agents from **TWO** different classes of the following:
    - Dopamine agonist (e.g., ropinirole, pramipexole, rotigotine)
    - Monoamine oxidase-inhibitors (MAO-I) (e.g., selegiline, rasagiline)
    - Adenosine receptor antagonist A2A (e.g., istradefylline)
    - Catechol-O-methyltransferase (COMT) inhibitors (e.g., entacapone, tolcapone)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **OPICAPONE (Ongentys)** requires the following rule(s) be met for approval:

- A. You have Parkinson's disease (PD: a nerve system disorder that affects movement)
- B. You are 18 years of age or older
- C. You are experiencing 'OFF' episodes (times when you have symptoms return due to medication wearing off)
- D. You are currently being treated with carbidopa/levodopa
- E. You have tried or failed or have a contraindication (medical reason why you cannot use) to TWO Parkinson's disease medications from TWO different classes of medications:
  1. Dopamine agonist (such as ropinirole, pramipexole, rotigotine)
  2. Monoamine oxidase-inhibitors (MAO-I) (such as selegiline, rasagiline)
  3. Adenosine receptor antagonist A2A (such as istradefylline)
  4. Catechol-O-methyltransferase (COMT) inhibitors (such as entacapone, tolcapone)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**OPICAPONE**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Ongentys.

**REFERENCES**

- Ongentys [Prescribing Information]. San Diego, CA: Neurocrine Biosciences, Inc.; April 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/21

Created: 09/20

Client Approval: 11/20

P&T Approval: 10/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OPIOID-ANTIPSYCHOTIC CONCURRENT USE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
N/A	N/A	N/A	N/A	N/A	N/A

**GUIDELINES FOR USE**

1. Is the claim rejecting with the following error code?
  - **REJ- 433-1205: OPIOID-ANTIPSYCHOTIC CONFLICT FOUND (H: DUR\_CONCURRENT\_USE)**

If yes, continue to #2.  
If no, guideline does not apply.

2. Does the patient meet at least **ONE** of the following criteria?
  - Patient has a diagnosis of active cancer
  - Patient is in hospice care
  - Patient is receiving palliative care or end-of-life care
  - Patient is a resident of a long-term care facility or intermediate care for intellectually disabled
  - Patient has a diagnosis of sickle cell disease

If yes, **approve for 12 months by HICL or GPI-10 and set DUR\_CONCURRENT\_OVR to 'OP\_PSY'**.  
If no, continue to #3.

3. Has the prescriber indicated that the concurrent use of an opioid and an antipsychotic medication is intended and clinically appropriate for the patient?  
**[NOTE:** Refer to the Medical Request Form (MRF) or chart notes if provided (e.g., patient is stable on the requested drug, patient needs to continue use, etc.). The member cannot provide this information.]

If yes, **approve for 12 months by HICL or GPI-10 and set DUR\_CONCURRENT\_OVR to 'OP\_PSY'**.  
If no, do not approve.  
**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON THE NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OPIOID-ANTIPSYCHOTIC CONCURRENT USE

GUIDELINES FOR USE (CONTINUED)

**OPTIONAL OPERATIONAL DENIAL TEXT FOR APPROVAL OF CLINICAL UM, BUT DENIAL OF THE OPIOID SAFETY EDIT:**

**[NOTE: Enter proactive PAs for other UM overrides not including the Opioid-Antipsychotic Concurrent Use, if applicable.]**

While your request for **[enter approved UM]** for **[enter requested drug]** has been granted, the drug has not been approved because of the use of an opioid drug and an antipsychotic drug together.

**[Proceed to enter Denial Text below]**

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **OPIOID-ANTIPSYCHOTIC CONCURRENT USE** allows an approval for use of an opioid with an antipsychotic medication (type of mental health drug) together when one of the following criteria is met:

- A. You have active cancer
- B. You are receiving palliative care or end-of-life care (care focused on treating symptoms of illness)
- C. You are enrolled in a hospice
- D. You are a resident of a long-term care facility or intermediate care for intellectually disabled
- E. You have sickle cell disease (type of red blood cell disorder)
- F. Your doctor confirms that the use of an opioid and an antipsychotic medication together is intended and clinically appropriate for you

Please consult your physician if you have any questions about this prescription pain medication and the requirements needed for you to obtain an approval for this agent.

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON THE NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OPIOID-ANTIPSYCHOTIC CONCURRENT USE

**RATIONALE**

To mitigate the risk of overdose from dangerous combinations of antipsychotics and opioids while preserving patient access to drug regimens if deemed medically necessary.

In addition, align with the opioid restrictions from the SUPPORT Act. The SUPPORT Act is an acronym for the Congress HR 6 - *Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act*. The rule identified six requirements that each State and Managed Care Entity must have in place by October 1, 2019. CMS defined the SUPPORT Act requirements as minimum Drug Utilization Review (DUR) standards for MMCPs and are listed below:

- Safety edits, as specified by the states, for subsequent opioid fills and maximum daily morphine milligram equivalent that exceed state-defined limitations
- Automated process that monitors when an individual is concurrently prescribed opioids and benzodiazepines or antipsychotics
- Monitoring antipsychotic prescribing for children
- Process that identifies potential fraud or abuse by enrolled individuals and pharmacies
- Report to the Secretary annually on state DUR activities
- Have in place managed care contracts that include these provisions

CMS noted that minimum standards may be expanded by the states or CMS in future rule making.

**REFERENCES**

- SUPPORT for Patients and Communities Act, H.R. 6, Section 1004, 115<sup>th</sup> Congress. (2018). Available at: <https://www.congress.gov/bill/115th-congress/house-bill/6> . [Accessed 7/30/19].
- CMS 2482 Final Rule - SUPPORT II: Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements. Available at: <https://www.cms.gov/files/document/122120-cms-2482-f-medicaid-dur-ofr-master-webposting-508.pdf> [Accessed 2/1/21].

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 03/01/21

Created: 08/19

Client Approval: 02/21

P&T Approval: 04/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OPIOID-BENZODIAZEPINE CONCURRENT USE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
N/A	N/A	N/A	N/A	N/A	N/A

**GUIDELINES FOR USE**

1. Is the claim rejecting with the following error code?
  - **REJ- 433-1201: CLAIM CONFLICTS IN THERAPY WITH MEMBER HISTORY (H: DUR\_CONCURRENT\_USE)**

If yes, continue to #2.  
If no, guideline does not apply.

2. Does the patient meet at least **ONE** of the following criteria?
  - Patient has a diagnosis of active cancer
  - Patient is in hospice care
  - Patient is receiving palliative care or end-of-life care
  - Patient is a resident of a long-term care facility or intermediate care for intellectually disabled
  - Patient has a diagnosis of sickle cell disease

If yes, **approve for 12 months by HICL or GPI-10 and set DUR\_CONCURRENT\_OVR to 'OP\_BZD'**.  
If no, continue to #3.

3. Has the prescriber provided attestation to proceed with the concurrent use of an opioid and a benzodiazepine for a clinically appropriate indication?

If yes, **approve for 12 months by HICL or GPI-10 and set DUR\_CONCURRENT\_OVR to 'OP\_BZD'**.  
If no, do not approve.  
**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON THE NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OPIOID-BENZODIAZEPINE CONCURRENT USE

GUIDELINES FOR USE (CONTINUED)

**OPTIONAL OPERATIONAL DENIAL TEXT FOR APPROVAL OF CLINICAL UM, BUT DENIAL OF THE OPIOID SAFETY EDIT:**

While your request for [enter approved UM] for [enter requested drug] has been granted, the drug has not been approved because of the use of an opioid drug and a benzodiazepine drug together.

**[Proceed to enter Denial Text below]**

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **OPIOID-BENZODIAZEPINE CONCURRENT USE** allows for an approval of use of an opioid with a benzodiazepine together when ONE of the following criteria is met:

- A. You have active cancer
- B. You are receiving palliative care (treatment for comfort from symptoms) or end-of-life care
- C. You are enrolled in a hospice
- D. You are a resident of a long-term care facility or intermediate care for intellectually disabled
- E. You have sickle cell disease (type of red blood cell disorder)
- F. Your doctor confirms (attests) to proceed with the concurrent use of an opioid and a benzodiazepine for a clinically appropriate indication

Please consult your physician if you have any questions about this prescription pain medication and the requirements needed for you to obtain an approval for this agent.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**PARTIALLY APPROVED OPIOID TEXT:**

Although we have entered a prior authorization for <DRUG+QL/UM (if any)> from <DATE RANGE>, your request has additional restrictions and criteria that you must meet as described above. You will be able to receive your medication once the additional criteria has been met and the restrictions have been removed.

**PREVIOUSLY APPROVED OPIOID CLAIMS WITH NO PA, BUT NOW REJECTS DUE TO SAFETY EDIT TEXT:**

Although you were previously approved for <DRUG> your new request now has additional safety restrictions that you must meet as described above. You will not be able to receive your medication until the newly added restrictions have been removed.

**CONTINUED ON THE NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OPIOID-BENZODIAZEPINE CONCURRENT USE

**RATIONALE**

To ensure appropriate use of opioids and addressing prescription opioid overuse from a medication safety perspective while preserving patient access to medically necessary drug regimens. In addition, align with the opioid restrictions from the CMS 2019 Call Letter:

“We expect that Part D sponsors implement a concurrent opioid and benzodiazepine soft POS safety edit (which can be overridden by the pharmacist) to prompt additional safety review at the time of dispensing beginning in 2019.” *CMS 2019 Call Letter, page 251*

The claim will deny when there is concurrent use of benzodiazepines and opioids with any overlap in day supply. This can be overridden at POS or by a Prior Authorization. If the pharmacy does not submit the specified PPS codes, the claim should reject unless a prior approval is in place.

This guideline allows an approval for patients with one of the following conditions:

- Diagnosis of active cancer
- Receiving palliative care or end-of-life care
- Enrolled in hospice
- Resident of a long-term care facility or intermediate care for intellectually disabled
- Diagnosis of sickle cell disease
- Physician attestation that the prescriber is aware that the patient is concurrently receiving a benzodiazepine with an opioid(s) and would like to proceed with an opioid and benzodiazepine

**REFERENCES**

- Announcement of Calendar Year (CY) 2019 Medicare Advantage Capitation Rates and Medicare Advantage and Part D Payment Policies and Final Call Letter. Available at: <https://www.cms.gov/Medicare/Health-Plans/MedicareAdvtgSpecRateStats/Downloads/Announcement2019.pdf> [Accessed 4/2/18].
- Frequently Asked Questions (FAQs) about Formulary-Level Opioid Point of Sale (POS) Safety Edits. Available at <https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/Frequently-Asked-Questions-about-Contract-Year-2019-Formulary-Level-Opioid-Point-of-Sale-Safety-Edits.pdf> [Accessed 5/13/19].
- CMS 2482 Final Rule - SUPPORT II: Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements. Available at: <https://www.cms.gov/files/document/122120-cms-2482-f-medicaid-dur-ofr-master-webposting-508.pdf> [Accessed 2/1/21].

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 03/01/21

Created: 10/17

Client Approval: 02/21

P&T Approval: 04/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OPIOID-BUPRENORPHINE CONCURRENT USE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
N/A	N/A	N/A	N/A	N/A	N/A

**GUIDELINES FOR USE**

1. Is the claim rejecting with **ONE** of the following error codes?
  - **REJ-433-1200 (DUR CONCURRENT USE): CLAIM CONFLICTS IN THERAPY WITH MEMBER HISTORY**
  - **REJ-1064 (DUR DD DENY): DRUG-DRUG INTERACTION FOUND**

If yes, continue to #2.  
If no, guideline does not apply.

2. Does the patient meet at least **ONE** of the following criteria?
  - Patient has a diagnosis of active cancer
  - Patient is in hospice care
  - Patient is receiving palliative care or end-of-life care
  - Patient is a resident of a long-term care facility or intermediate care for intellectually disabled

If yes, **approve for 12 months by HICL or GPI-10 with ONE of the following overrides:**

- **For DUR\_CONCURRENT\_USE Rejection: Set DUR\_CONCURRENT\_OVR to 'OP\_BUP'**
  - **For DUR\_DD\_DENY Rejection: Set DUR\_DD\_DENY to 'Y' for Yes**
- If the claim analysis continues to reject, follow the clinical coverage determination process.**

If no, continue to #3.

3. Has the prescriber provided attestation that the patient has discontinued or will be discontinuing opioid dependency treatment with buprenorphine or buprenorphine-containing agents and needs to resume chronic opioid treatment? (**NOTE:** Consultation with an addiction medicine specialist is recommended)

If yes, **approve for 4 months by HICL or GPI-10 with ONE of the following overrides:**

- **For DUR\_CONCURRENT\_USE Rejection: Set DUR\_CONCURRENT\_OVR to 'OP\_BUP'**
  - **For DUR\_DD\_DENY Rejection: Set DUR\_DD\_DENY to 'Y' for Yes**
- If the claim analysis continues to reject, follow the clinical coverage determination process.**

If no, continue to #4.

**CONTINUED ON THE NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OPIOID-BUPRENORPHINE CONCURRENT USE

GUIDELINES FOR USE

4. Is the prescriber aware that the patient is currently receiving buprenorphine or buprenorphine-containing agents for treatment of opioid dependency and has provided attestation to proceed with opioid treatment for an acute, clinically appropriate indication? (**NOTE:** Consultation with an addiction medicine specialist is recommended)

If yes, approve for 30 days by HICL or GPI-10 with ONE of the following overrides:

- For DUR\_CONCURRENT\_USE Rejection: Set DUR\_CONCURRENT\_OVR to 'OP\_BUP'
- For DUR\_DD\_DENY Rejection: Set DUR\_DD\_DENY to 'Y' for Yes

If the claim analysis continues to reject, follow the clinical coverage determination process.

If no, do not approve.

**OPTIONAL OPERATIONAL DENIAL TEXT FOR APPROVAL OF CLINICAL UM, BUT DENIAL OF THE OPIOID SAFETY EDIT:** While your request for [enter approved UM] for [enter requested drug] has been granted, the drug has not been approved because of the use of an opioid drug and a buprenorphine-containing drug together.

**[Proceed to enter Denial Text below]**

**DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **OPIOID-BUPRENORPHINE CONCURRENT USE** allows approval for use of an opioid with buprenorphine or a buprenorphine-containing agent together when ONE of the following rule(s) is met:

- A. You have active cancer
- B. You are receiving palliative care (treatment for comfort from symptoms) or end-of-life care
- C. You are enrolled in a hospice
- D. You are a resident of a long-term care facility or intermediate care for intellectually disabled
- E. Your doctor confirms (attests) that you have discontinued or will be discontinuing opioid dependency treatment with buprenorphine or buprenorphine-containing agents and you need to resume chronic opioid treatment. Consultation with an addiction medicine specialist is recommended.
- F. Your doctor is aware that you are currently receiving buprenorphine or a buprenorphine-containing agent for treatment of opioid dependency and has confirmed to proceed with opioid treatment for an acute, clinically appropriate indication. Consultation with an addiction medicine specialist is recommended

***(Denial text continued on next page)***

**CONTINUED ON THE NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OPIOID-BUPRENORPHINE CONCURRENT USE

GUIDELINES FOR USE

Please consult your physician if you have any questions about this prescription pain medication and the requirements needed for you to obtain an approval for this agent.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**PARTIALLY APPROVED OPIOID TEXT:**

Although we have entered a prior authorization for <DRUG+QL/UM (if any)> from <DATE RANGE>, your request has additional restrictions and criteria that you must meet as described above. You will be able to receive your medication once the additional criteria has been met and the restrictions have been removed.

**PREVIOUSLY APPROVED OPIOID CLAIMS WITH NO PA, BUT NOW REJECTS DUE TO SAFETY EDIT TEXT:**

Although you were previously approved for <DRUG> your new request now has additional safety restrictions that you must meet as described above. You will not be able to receive your medication until the newly added restrictions have been removed.

**RATIONALE**

To ensure appropriate use of opioids and addressing prescription opioid overuse from a medication safety perspective while preserving patient access to medically necessary drug regimens. In addition, align with the opioid restrictions from CMS guidance. For further information, please refer to the Drug Monograph for Opioid-Buprenorphine Concurrent Use.

**REFERENCES**

- Announcement of Calendar Year (CY) 2019 Medicare Advantage Capitation Rates and Medicare Advantage and Part D Payment Policies and Final Call Letter. Available at: <https://www.cms.gov/Medicare/Health-Plans/MedicareAdvtgSpecRateStats/Downloads/Announcement2019.pdf> [Accessed 4/2/18].
- CMS 2482 Final Rule - SUPPORT II: Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements. Available at: <https://www.cms.gov/files/document/122120-cms-2482-f-medicaid-dur-ofr-master-webposting-508.pdf> [Accessed 2/1/21].

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 03/01/21

Created: 12/18

Client Approval: 02/21

P&T Approval: 04/21

Copyright © 2023 MediImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MediImpact. MediImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OPIOID CUMULATIVE DOSING OVERRIDE

Generic	Brand	HICL	GCN	Medi-Span	Exception/other
N/A	N/A	N/A	N/A	N/A	N/A

**GUIDELINES FOR USE**

1. Is the request for an opioid product equal to or exceeding the soft-stop threshold or hard-stop threshold as noted in the POS reject messaging?

**NOTE:** Claims should stop for DUR\_MAX\_CUMUL\_DOSE 2 edit with Soft\_DENY\_LIMIT= X or HARD\_DENY\_LIMIT= X (i.e., Cumulative morphine milligram equivalent of [patient’s current MME] = / exceeds threshold of [**soft-stop threshold**-mg MME or **hard-stop threshold**-mg MME]).

If yes, continue to #2.  
If no, guideline does not apply.

2. Does the patient meet at least **ONE** of the following criteria?
  - Patient has a diagnosis of active cancer
  - Patient is in hospice care
  - Patient is receiving palliative care or end-of-life care
  - Patient is a resident of a long-term care facility or intermediate care for intellectually disabled
  - Patient has a diagnosis of sickle cell disease

If yes, **approve as follows:**

- **Approval duration should be for 12 months by HICL or GPI-10.**
- **NOTE: Please enter a class override to override the MME cumulative dosing for the duration of 12 months.**
- **If the claim rejects after analyzing, then follow the clinical coverage determination process.**

If no, continue to #3.

3. Is the prescriber aware of multiple prescribers for opioid prescriptions?

If yes, continue to #4.  
If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OPIOID CUMULATIVE DOSING OVERRIDE

GUIDELINES FOR USE (CONTINUED)

4. Have **TWO** of the following criteria been met?

- There is documentation that the patient's current level of opioid utilization is necessary and required for the level of pain management needed
- Patient has been evaluated by a pain specialist, and/or the request is based on the recommendation of a pain specialist
- Patient has a pain contract in place
- Patient does not have a history of substance abuse or addiction
- Provider has committed to monitoring the state's Prescription Monitoring Program to ensure controlled substance history is consistent with prescribing record

If yes, **approve as follows:**

- **Approval duration should be for 12 months by HICL or GPI-10.**
- **NOTE: Please enter a class override to override the MME cumulative dosing for the duration of 12 months.**
- **If the claim rejects after analyzing, then follow the clinical coverage determination process.**

If no, do not approve.

**OPTIONAL OPERATIONAL DENIAL TEXT FOR APPROVAL OF CLINICAL UM, BUT DENIAL OF THE OPIOID SAFETY EDIT:**

While your request for **[enter approved UM]** for **[enter requested drug]** has been granted, the drug has not been approved because of the amount of opiates prescribed and because your opiate amount exceeds or is equal to **[enter soft stop threshold]**-mg morphine milligram equivalent (MME) or **[enter hard stop threshold]**-mg morphine milligram equivalent (MME).  
**[Proceed to enter Denial Text below]**

CONTINUED ON NEXT PAGE





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OPIOID CUMULATIVE DOSING OVERRIDE

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

A claim for a pain medication will be denied when there are two or more providers prescribing opioid agents for a patient who is receiving a high quantity of these agents. Our guideline named **OPIOID CUMULATIVE DOSING OVERRIDE** will allow you to receive a higher quantity of an opioid medication if ONE of the following rules (A or B) is met:

- A. You have ONE of the following conditions:
1. You have active cancer
  2. You are receiving palliative care (treatment for comfort from symptoms) or end-of life care
  3. You are enrolled in a hospice
  4. You are a resident of a long-term care facility or intermediate care for intellectually disabled
  5. You have sickle cell disease (type of blood disorder)
- B. Your prescriber is aware that there is more than one provider prescribing opiates for you, and you meet **TWO** of the following:
1. You have documentation showing your current level of opioid use is necessary and required for your level of pain management needed
  2. You have been evaluated by a pain specialist, and/or the request is based on the recommendation of a pain specialist
  3. You have a pain contract in place
  4. You do not have a history of substance abuse or addiction
  5. Your provider has committed to monitoring the state's Prescription Monitoring Program to ensure controlled substance history is consistent with prescribing record.

This safety edit allows for an override for an opioid product equal to or exceeding the [enter soft stop threshold]-mg morphine milligram equivalent (MME) or [enter hard stop threshold]-mg morphine milligram equivalent (MME). Please consult your physician if you have any questions about this safety edit on prescription opioid medications and the requirements needed for you to obtain an approval for higher quantities of these agents.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**PARTIALLY APPROVED OPIOID TEXT:**

Although we have entered a prior authorization for <DRUG+QL/UM (if any)> from <DATE RANGE>, your request has additional restrictions and criteria that you must meet as described above. You will be able to receive your medication once the additional criteria has been met and the restrictions have been removed.

***(Denial text continued on next page)***

**CONTINUED ON NEXT PAGE**





**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**OPIOID CUMULATIVE DOSING OVERRIDE**

**GUIDELINES FOR USE (CONTINUED)**

**PREVIOUSLY APPROVED OPIOID CLAIMS WITH NO PA, BUT NOW REJECTS DUE TO**

**SAFETY EDIT TEXT:** Although you were previously approved for <DRUG> your new request now has additional safety restrictions that you must meet as described above. You will not be able to receive your medication until the newly added restrictions have been removed.

---

**RATIONALE**

To ensure appropriate use of opioids and addressing prescription opioid overuse from a medication safety perspective while preserving patient access to medically necessary drug regimens. In addition, align with the opioid restrictions from the CMS 2019 Call Letter.

Prior authorization will be required for opioid prescriptions in excess of hard opioid edit. Soft opioid edit thresholds may be overridden by a dispensing pharmacist or provider/patient may request a coverage determination. This requirement should not apply to patients with active cancer, hospice patients, those receiving palliative or end of life care, residents of a long term facility or patients approved by case management or retrospective DUR Programming. Following CMS guidance, patients with a diagnosis of sickle cell disease are also exempt from this restriction based on acute attacks and painful complications associated with the disease. Additional payment determination is required for patients identified as hospice. Soft-thresholds may also be overridden by the pharmacy via DUR PPS codes or as part of coverage determination process and by certain PPS codes. Hard-thresholds are overridable as part of the coverage determination process. The cumulative opioid edit minimizes false positives by accounting for known exceptions: 1) patients on hospice, have certain cancer diagnosis 2) overlapping dispensing dates for Rx refills and new Rx orders for continuing fills 3) high-dose opioid usage previously determined to be medically necessary (approved PAs, previous coverage determinations, case management) 4) no consecutive high-MME days' criterion as it would not prevent beneficiaries from reaching high opioid doses.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OPIOID CUMULATIVE DOSING OVERRIDE

REFERENCES

- Announcement of Calendar Year (CY) 2019 Medicare Advantage Capitation Rates and Medicare Advantage and Part D Payment Policies and Final Call Letter. Available at: <https://www.cms.gov/Medicare/Health-Plans/MedicareAdvtgSpecRateStats/Downloads/Announcement2019.pdf> [Accessed 4/2/18]
- Announcement of Calendar Year (CY) 2017 Medicare Advantage Capitation Rates and Medicare Advantage and Part D Payment Policies and Final Call Letter.
- Ballas SK. Pain Management of Sickle Cell Disease, 2005. Hematol Oncol Clin N Am 19 (2005) 785-802.
- Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016. MMWR Recomm Rep 2016;65(No. RR-1):1–49. DOI: <http://dx.doi.org/10.15585/mmwr.rr6501e1>. Available at <http://www.cdc.gov/drugoverdose/prescribing/guideline.html>. [Accessed 8/11/16].
- Washington State Interagency Guideline on Prescribing Opioids for Pain. June 2015. Available at <http://www.agencymeddirectors.wa.gov/Files/2015AMDGOpoidGuideline.pdf> [Accessed 8/11/16].
- CMS Medicare Benefit Policy Manual Chapter 9 – Coverage of Hospice Services Under Hospital Insurance. Available at <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/bp102c09.pdf> [Accessed 1/2/17].
- CMS Department of Health and Human Services Additional Guidance on CY 2017 Formulary-Level Cumulative Morphine Equivalent Dose (MED) Opioid Point-of-Sale (POS) Edit Memo. July 7, 2017.
- The Social Security Act: Title XVIII: Section 1861(t), Center for Medicare and Medicaid Service. March 23, 2012. Available at: [https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/DMEPOSFeeSched/DME\\_SSAAct.html](https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/DMEPOSFeeSched/DME_SSAAct.html) [Accessed 9/28/18].
- Additional Guidance on Contract Year 2019 Formulary-Level Opioid Point of Sale Safety Edits. Available at [https://mopa.memberclicks.net/assets/docs/Opioid\\_SafetyEdit\\_Memo\\_10232018%20%28002%29.pdf](https://mopa.memberclicks.net/assets/docs/Opioid_SafetyEdit_Memo_10232018%20%28002%29.pdf) [Accessed 11/20/18].
- CMS 2482 Final Rule - SUPPORT II: Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements. Available at: <https://www.cms.gov/files/document/122120-cms-2482-f-medicaid-dur-ofr-master-webposting-508.pdf> [Accessed 2/1/21].

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/01/22

Created: 09/16

Client Approval: 09/22

P&T Approval: 04/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OPIOID LONG-ACTING DUPLICATIVE THERAPY

Generic	Brand	HICL	GCN	Medi-Span	Exception/other
N/A	N/A	N/A	N/A	N/A	N/A

**GUIDELINES FOR USE**

1. Is the claim rejecting with the following error code?

- **REJ-1045: THERAPEUTIC DUPLICATION DENIAL (DRUG\_TD)**

(The incoming claim for a long-acting (LA) opioid will reject when the patient is concurrently taking a different long-acting opioid [different HICL] from a different prescriber.)

If yes, continue to #2.

If no, guideline does not apply.

2. Does the patient meet at least **ONE** of the following criteria?

- Patient has a diagnosis of active cancer
- Patient is in hospice care
- Patient is receiving palliative care or end-of-life care
- Patient is a resident of a long-term care facility or intermediate care for intellectually disabled
- Patient has a diagnosis of sickle cell disease

If yes, **approve for 12 months by HICL or GPI-10 and set DRUG\_TD\_OVR to 'Y' for Yes.**

If no, continue to #3.

3. Is the prescriber aware that the patient is concurrently receiving more than one long-acting opioid therapy?

If yes, **approve for 12 months by HICL or GPI-10 and set DRUG\_TD\_OVR to 'Y' for Yes.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUE ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OPIOID LONG-ACTING DUPLICATIVE THERAPY

GUIDELINES FOR USE (CONTINUED)

**OPTIONAL OPERATIONAL DENIAL TEXT FOR APPROVAL OF CLINICAL UM, BUT DENIAL OF THE OPIOID SAFETY EDIT:**

While your request for [enter approved UM] for [enter requested drug] has been granted, the drug has not been approved because of the use of two long-acting opioid drugs together that are from different prescribers. [Proceed to enter Denial Text below]

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **OPIOID LONG ACTING DUPLICATIVE THERAPY** allows approval of the requested drug taken together with other long-acting opioid drug(s) from different prescribers when ONE of the following conditions are met:

- A. You have active cancer
- B. You are receiving palliative care (treatment for comfort from symptoms) or end-of-life care
- C. You are enrolled in a hospice
- D. You are a resident of a long-term care facility or intermediate care for intellectually disabled
- E. You have sickle cell disease (type of red blood cell disorder)
- F. Your doctor confirms that they are aware that you are concurrently receiving more than one long-acting opioid medication

Please consult your physician if you have any questions about this prescription medication and the requirements needed for you to obtain an approval for this agent.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request

**PARTIALLY APPROVED OPIOID TEXT:**

Although we have entered a prior authorization for <DRUG+QL/UM (if any)> from <DATE RANGE>, your request has additional restrictions and criteria that you must meet as described above. You will be able to receive your medication once the additional criteria has been met and the restrictions have been removed.

**PREVIOUSLY APPROVED OPIOID CLAIMS WITH NO PA, BUT NOW REJECTS DUE TO SAFETY EDIT TEXT:**

Although you were previously approved for <DRUG> your new request now has additional safety restrictions that you must meet as described above. You will not be able to receive your medication until the newly added restrictions have been removed.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OPIOID LONG-ACTING DUPLICATIVE THERAPY

**RATIONALE**

To ensure appropriate use of opioids and addressing prescription opioid overuse from a medication safety perspective while preserving patient access to medically necessary drug regimens. In addition, align with the opioid restrictions from the CMS 2019 Call Letter:

“...we expect all Part D plan sponsors to implement a soft POS safety edit (which can be overridden by the pharmacist) for duplicative LA opioid therapy beginning in 2019, with or without a multiple prescriber criterion.” *CMS 2019 Call Letter, page 252*

Prior authorization will be required for Long Acting (LA) opioid prescriptions when an incoming claim for a long-acting opioid overlaps with another a long acting opioid (different HICL) claim(s) from a different prescriber(s). The edit can be overridden by professional pharmacy professional service (PPS) code at POS or by a PA. This requirement does not apply to patients with a diagnosis of active cancer, patients receiving palliative care or end-of-life care, those enrolled in hospice or resident of a long-term care facility. Following CMS guidance, patients with a diagnosis of sickle cell disease are also exempt from this restriction based on acute attacks and painful complications associated with the disease. This guideline also allows an override when there is physician attestation that the prescriber is aware that the patient is concurrently receiving long acting duplicative therapy and would like to proceed with treatment for a clinically appropriate indication.

**REFERENCES**

- Announcement of Calendar Year (CY) 2019 Medicare Advantage Capitation Rates and Medicare Advantage and Part D Payment Policies and Final Call Letter. Available at: <https://www.cms.gov/Medicare/Health-Plans/MedicareAdvtgSpecRateStats/Downloads/Announcement2019.pdf> [Accessed 4/2/18].
- Frequently Asked Questions (FAQs) about Formulary-Level Opioid Point of Sale (POS) Safety Edits. Available at <https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/Frequently-Asked-Questions-about-Contract-Year-2019-Formulary-Level-Opioid-Point-of-Sale-Safety-Edits.pdf> [Accessed 5/13/19].
- CMS 2482 Final Rule - SUPPORT II: Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements. Available at: <https://www.cms.gov/files/document/122120-cms-2482-f-medicaid-dur-ofr-master-webposting-508.pdf> [Accessed 2/1/21].

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 03/01/21

Created: 12/18

Client Approval: 02/21

P&T Approval: 04/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OPIOID-NAIVE CUMULATIVE DOSING (ONCD)

Generic	Brand	HICL	GCN	Medi-Span	Exception/other
N/A	N/A	N/A	N/A	N/A	N/A

**GUIDELINES FOR USE**

1. Does the patient meet **ALL** of the following criteria?

- The request is for an opioid product equal to or exceeding the soft-stop threshold or hard-stop threshold as noted in the POS reject messaging?

**NOTE:** The following reject code(s) may also be present:

- For Soft-Stop: **REJ-88-1080**
- For Hard-Stop: **REJ-88-1081**

If yes, continue to #2.

If no, guideline does not apply.

2. Is the patient opioid-naive meaning they have not used an opioid drug(s) in the past 60 days (starting the day prior to the fill date of the incoming claim)?

**[NOTE:** Please refer to the claims history in MedAccess, Medication Request Form (MRF) or chart notes (e.g., patient is stable on the requested drug, patient needs to continue use, etc.). The member cannot provide this information.]

If yes, continue to #3.

If no, **approve for one (1) month, for one (1) fill count by HICL or GPI-10 and set NAIVE\_OP\_HARD\_LIMIT\_OVR to 'Y' for Yes.**

3. Does the patient meet at least **ONE** of the following criteria?

- Patient has a diagnosis of active cancer
- Patient is enrolled in hospice
- Patient is receiving palliative care or end-of-life care
- Patient is a resident of a long-term care facility or intermediate care for intellectually disabled
- Patient has a diagnosis of sickle cell disease

If yes, **approve for 12 months by HICL or GPI-10 and set NAIVE\_OP\_HARD\_LIMIT\_OVR to 'Y' for Yes.**

If no, continue to #4.

**CONTINUE ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OPIOID-NAIVE CUMULATIVE DOSING

GUIDELINES FOR USE (CONTINUED)

4. Have **BOTH** of the following criteria been met?

- The provider has indicated that the patient's current level of opioid utilization is necessary and required for the level of pain management needed
- The provider has committed to monitoring the state's Prescription Monitoring Program to ensure controlled substance history is consistent with prescribing record

If yes, **approve for one (1) month, for one (1) fill count by HICL or GPI-10 and set NAIVE\_OP\_HARD\_LIMIT\_OVR to 'Y' for Yes.**

If no, do not approve.

**OPTIONAL OPERATIONAL DENIAL TEXT FOR APPROVAL OF CLINICAL UM, BUT DENIAL OF THE OPIOID SAFETY EDIT:**

**[NOTE: Enter proactive PAs for other UM overrides not including Opioid-Naive Cumulative Dosing, if applicable.]**

While your request for **[enter approved UM]** for **[enter requested drug]** has been granted, the drug has not been approved because you are considered opioid naive (those who have not used opioid drugs within the past 60 days) and the opiate amount exceeds or is equal to **[enter soft stop threshold]**-mg morphine milligram equivalent (MME) or **[enter hard stop threshold]**-mg morphine milligram equivalent (MME). **[Proceed to enter Denial Text below]**

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **OPIOID-NAIVE CUMULATIVE DOSING** allows approval of a higher quantity of an opioid medication if at least ONE of the following conditions is met:

- Diagnosis of active cancer
- Receiving palliative care or end-of-life care (care focused on treating symptoms of illness)
- Enrolled in hospice
- Resident of a long-term care facility or intermediate care for intellectually disabled
- Diagnosis of sickle cell disease (type of red blood cell disorder)
- You are not opioid naive

If none of these conditions apply, **BOTH** of the following criteria must be met:

- The provider has indicated that the patient's current level of opioid utilization is necessary and required for the level of pain management needed
- The provider has committed to monitoring the state's Prescription Monitoring Program to ensure controlled substance history is consistent with prescribing record

Please consult your physician and/or your pharmacist to discuss your options or if you have any questions about this prescription pain medication and the requirements needed for you to obtain an approval for this agent.

**CONTINUE ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OPIOID-NAIVE CUMULATIVE DOSING

**RATIONALE**

To ensure appropriate use of opioids and address the prescription opioid overuse from a medication safety perspective while preserving patient access to medically necessary drug regimens. The guideline is based on CDC dosage recommendations stated in the “Initial Opioid Prescribing at High Dosage” measures from the Pharmacy Quality Alliance (PQA) and Managed Medicaid program limits.

This requirement does not apply to patients with a diagnosis of active cancer, in palliative care, hospice patients, or patients living in a long-term care facility. Following CMS guidance, patients with a diagnosis of sickle cell disease are also exempt from this restriction based on acute attacks and painful complications associated with the disease.

In addition, approval is granted if BOTH of the following conditions are met:

- The provider has indicated that the patient’s current level of opioid utilization is necessary and required for the level of pain management needed
- The provider has committed to monitoring the state’s Prescription Monitoring Program to ensure controlled substance history is consistent with prescribing record

**REFERENCES**

- Announcement of Calendar Year (CY) 2019 Medicare Advantage Capitation Rates and Medicare Advantage and Part D Payment Policies and Final Call Letter. Available at: <https://www.cms.gov/Medicare/Health-Plans/MedicareAdvtgSpecRateStats/Downloads/Announcement2019.pdf> [Accessed 4/2/18]
- Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. MMWR Recomm Rep 2016;65(No. RR-1):1–49. DOI: <http://dx.doi.org/10.15585/mmwr.rr6501e1> [Accessed 6/28/18].
- Jones B, Cynthia. (2016). Implementation of CDC Guideline for Prescribing Opioids for Chronic Pain Coverage of Non-Opioid Pain Relievers and Uniform, Streamlines Prior Authorization for New Opioid Prescription Effective December 1, 2016. Department of Medical Assistance Services. Available at [https://www.msv.org/sites/default/files/PDFs/12.1.16\\_guideline\\_for\\_opioids\\_non\\_opioid\\_pain\\_relievers\\_revised\\_final.pdf](https://www.msv.org/sites/default/files/PDFs/12.1.16_guideline_for_opioids_non_opioid_pain_relievers_revised_final.pdf) [Accessed 6/28/18].
- CMS 2482 Final Rule - SUPPORT II: Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements. Available at: <https://www.cms.gov/files/document/122120-cms-2482-f-medicaid-dur-ofr-master-webposting-508.pdf> [Accessed 2/1/21].

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/01/22

Created: 12/19

Client Approval: 09/22

P&T Approval: 04/21





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OPIOID-NAIVE DAY SUPPLY LIMITATION

Generic	Brand	HICL	GCN	Medi-Span	Exception/other
N/A	N/A	N/A	N/A	N/A	N/A

**GUIDELINES FOR USE**

1. Is the claim rejecting with the following error code?

- **REJ-1044: INITIAL FILL DAYS SUPPLY EXCEEDS LIMITS (DS-NAIVE)**

If yes, continue to #2.

If no, guideline does not apply.

2. Does the patient meet at least **ONE** of the following criteria?

- Patient has a diagnosis of active cancer
- Patient is enrolled in hospice
- Patient is receiving palliative care or end-of-life care
- Patient is a resident of a long-term care facility or intermediate care for intellectually disabled
- Patient has a diagnosis of sickle cell disease
- Patient is NOT opioid naive  
(**NOTE:** For new patients with no claims history, please refer to the MRF or MedAccess).

If yes, **approve for one month, for one fill count by HICL or GPI-10 and set DS\_NAIVE\_OVR to 'Y' for Yes.**

If no, continue to #3.

3. Has the prescriber provided attestation that the opioid medication with the requested day supply is the intended and medically necessary amount for the beneficiary?

If yes, **approve for one month, for one fill count by HICL or GPI-10 and set DS\_NAIVE\_OVR to 'Y' for Yes.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUE ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OPIOID-NAIVE DAY SUPPLY LIMITATION

GUIDELINES FOR USE (CONTINUED)

**OPTIONAL OPERATIONAL DENIAL TEXT FOR APPROVAL OF CLINICAL UM, BUT DENIAL OF THE OPIOID SAFETY EDIT:** While your request for [enter approved UM] for [enter requested drug] has been granted, the drug has not been approved because of the day supply you are requesting for this opioid medication.

**[Proceed to enter Denial Text below]**

**DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **OPIOID-NAIVE DAY SUPPLY LIMITATION** allows approval of the requested drug for a longer day supply when you meet at least **ONE** of the following conditions:

- A. You have active cancer
- B. You are enrolled in hospice
- C. You are receiving palliative care (treatment for comfort from symptoms) or end-of-life care
- D. You are a resident of a long-term care facility or intermediate care for intellectually disabled
- E. You have sickle cell disease (type of blood disorder)
- F. You are NOT opioid naïve (you have been consistently using opioid pain medications)
- G. Your doctor confirms (attests) that the prescribed dose of opioids with the requested day supply is intended and medically necessary

Please consult your doctor if you have any questions about this prescription pain medication and the requirements needed for you to obtain an approval for this medication.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

To ensure appropriate use of opioids and addressing prescription opioid overuse from a medication safety perspective while preserving patient access to medically necessary drug regimens.

In addition, align with the opioid restrictions from the CMS 2019 Call Letter: "Beginning in 2019, we expect all Part D sponsors to implement a hard safety edit to limit initial opioid prescription fills for the treatment of acute pain to no more than a 7 days' supply...". *CMS 2019 Call Letter, page 237*

**CONTINUE ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OPIOID-NAIVE DAY SUPPLY LIMITATION

RATIONALE (CONTINUED)

Prior authorization will be required for opioid prescriptions with a longer day supply for opioid naive patients. This requirement does not apply to patients with a diagnosis of active cancer, patients receiving palliative care or end-of-life care, those enrolled in hospice or residents of a long-term care facility.

In addition, if the patient is determined to NOT be opioid naive during the coverage determination process, they are exempt from this safety edit. This exemption is based on the following guidance: "If during the coverage determination process, it becomes known that the patient is not opioid naive, he or she should be excluded from the opioid naive edit." *CMS Additional Guidance memo from October 23, 2018, page 8.*

Following CMS guidance, patients with a diagnosis of sickle cell disease are also exempt from this restriction based on acute attacks and painful complications associated with the disease. This guideline also allows an override when there is attestation from the prescriber that the prescribed dose of opioids with the requested day supply is intended and medically necessary.

REFERENCES

- Announcement of Calendar Year (CY) 2019 Medicare Advantage Capitation Rates and Medicare Advantage and Part D Payment Policies and Final Call Letter. Available at: <https://www.cms.gov/Medicare/Health-Plans/MedicareAdvtgSpecRateStats/Downloads/Announcement2019.pdf> [Accessed 4/2/18]
- The Social Security Act: Title XVIII: Section 1861(t), Center for Medicare and Medicaid Service. March 23, 2012. Available at: [https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/DMEPOSFeeSched/DME\\_SSAct.html](https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/DMEPOSFeeSched/DME_SSAct.html) [Accessed 9/28/18].
- Additional Guidance on Contract Year 2019 Formulary-Level Opioid Point of Sale Safety Edits. Available at [https://mopa.memberclicks.net/assets/docs/Opioid\\_SafetyEdit\\_Memo\\_10232018%20%28002%29.pdf](https://mopa.memberclicks.net/assets/docs/Opioid_SafetyEdit_Memo_10232018%20%28002%29.pdf) [Accessed 11/20/18].
- CMS 2482 Final Rule - SUPPORT II: Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements. Available at: <https://www.cms.gov/files/document/122120-cms-2482-f-medicaid-dur-ofr-master-webposting-508.pdf> [Accessed 2/1/21].

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/01/22

Created: 02/19

Client Approval: 10/22

P&T Approval: 04/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OPIOID NAIVE FILL LIMIT

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
N/A	N/A	N/A	N/A	N/A	N/A

GUIDELINES FOR USE

1. Is the claim rejecting with the following error code?  
**REJ-306-1066: THIS CLAIM EXCEEDS LIMIT OF 2 OPIOID FILLS IN 30 DAYS**

[NOTE: The incoming opioid analgesic claim will reject if an initially opioid-naive member exceeds two opioid fills regardless of day supply, for the same drug (HICL), within the past 30 days. In addition, the patient is considered opioid-naive if they have no history of an opioid analgesic drug(s) in the past 60 days (not counting same day claims).]

If yes, continue to #2.  
If no, guideline does not apply.

2. Does the patient meet at least **ONE** of the following criteria?
  - Patient has a diagnosis of active cancer
  - Patient is in hospice care
  - Patient is receiving palliative care or end-of-life care
  - Patient is a resident of a long-term care facility or intermediate care for intellectually disabled
  - Patient has a diagnosis of sickle cell disease

If yes, **approve for 12 months by HICL or GPI-10 and set FILL\_LIMIT\_OVR to 'Y' for Yes.**  
If no, continue to #3.

3. Has the prescriber indicated that the additional fill of the requested opioid analgesic medication is intended and clinically appropriate for the patient?

[NOTE: Refer to the Medical Request Form (MRF) or chart notes if provided (e.g., patient is stable on the requested drug, patient needs to continue use, etc.). The member cannot provide this information.]

If yes, **approve for 1 month, for one fill count by HICL or GPI-10 and set FILL\_LIMIT\_OVR to 'Y' for Yes.**  
If no, do not approve.  
**DENIAL TEXT:** See the denial text at the end of the guideline.

CONTINUED ON THE NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OPIOID NAIVE FILL LIMIT

GUIDELINES FOR USE (CONTINUED)

**OPTIONAL OPERATIONAL DENIAL TEXT FOR APPROVAL OF CLINICAL UM, BUT DENIAL OF THE OPIOID SAFETY EDIT:**

**[NOTE: Enter proactive PAs for other UM overrides not including the Opioid Naive Fill Limit, if applicable.]**

While your request for **[enter approved UM]** for **[enter requested drug]** has been granted, the drug has not been approved because you exceeded the fill limit of the requested opioid analgesic.

**[Proceed to enter Denial Text below]**

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **OPIOID NAIVE FILL LIMIT** allows an approval of the requested drug when it exceeds the fill limit for an initially opioid-naïve patient (those who have not used opioid drugs within the past 60 days) when ONE of the following conditions is met:

- A. You have active cancer
- B. You are receiving palliative care (treatment for comfort from symptoms) or end-of-life care
- C. You are enrolled in a hospice
- D. You are a resident of a long-term care facility or intermediate care for intellectually disabled
- E. You have sickle cell disease (type of red blood cell disorder)
- F. Your doctor confirms that the additional fill of the requested opioid analgesic (pain-relieving) medication is intended and clinically appropriate for you

Please consult your physician if you have any questions about this prescription pain medication and the requirements needed for you to obtain an approval for this agent.

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON THE NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OPIOID NAIVE FILL LIMIT

**RATIONALE**

To ensure appropriate use of opioids and to address prescription opioid overuse from a medication safety perspective while preserving patient access to medically necessary drug regimens.

In addition, the goal is to align with the opioid restrictions from the SUPPORT Act. The SUPPORT Act is an acronym for the Congress HR 6 - *Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act*. The rule identified six requirements that each State and Managed Care Entity must have in place by October 1, 2019. CMS defined the SUPPORT Act requirements as minimum Drug Utilization Review (DUR) standards for MMCPs and they are listed below:

- Safety edits, as specified by the states, for subsequent opioid fills and maximum daily morphine milligram equivalent that exceed state-defined limitations
- Automated process that monitors when an individual is concurrently prescribed opioids and benzodiazepines or antipsychotics
- Monitoring antipsychotic prescribing for children
- Process that identifies potential fraud or abuse by enrolled individuals and pharmacies
- Report to the Secretary annually on state DUR activities
- Have in place managed care contracts that include these provisions

CMS noted that minimum standards may be expanded by the states or CMS in future rule making.

**REFERENCES**

- SUPPORT for Patients and Communities Act, H.R. 6, Section 1004, 115<sup>th</sup> Congress. (2018). Available at: <https://www.congress.gov/bill/115th-congress/house-bill/6> . [Accessed 7/30/19]
- CMS 2482 Final Rule - SUPPORT II: Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements. Available at: <https://www.cms.gov/files/document/122120-cms-2482-f-medicaid-dur-ofr-master-webposting-508.pdf> [Accessed 2/1/21].

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 03/01/21

Created: 08/19

Client Approval: 02/21

P&T Approval: 04/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OPIOID SINGLE CLAIM DOSING AT POS (OSCDP)

Generic	Brand	HICL	GCN	Medi-Span	Exception/other
OPIOIDS	OPIOIDS	N/A	N/A	N/A	N/A

**GUIDELINES FOR USE**

1. Is the request for an opioid product equal to or exceeding the soft-stop threshold hard-stop threshold as noted in the POS reject messaging?

**NOTE:** Claims should stop for DUR\_MAX\_SINGLE\_DOSE edit with Soft\_DENY\_LIMIT = X or HARD\_DENY\_LIMIT = X (i.e., morphine milligram equivalent of [patient's current MME] = / exceeds threshold of [**soft-stop threshold**-mg MME or **hard-stop threshold**-mg MME]).

If yes, continue to #2.  
If no, guideline does not apply.

2. Is the request for an opioid product less than or equal to the hard-stop threshold-1 MME?

If yes, **approve 12 months by HICL or GPI-10 up to hard-stop threshold-1 MME. (NOTE: If the claim rejects after analyzing, follow the clinical prior authorization process).**  
If no, continue to #3.

3. Does the patient meet **ANY** of the following criteria?

- Diagnosis of active cancer
- Diagnosis of palliative care
- Diagnosis of sickle cell disease
- Patient is enrolled in hospice
- Prescriber is a pain management specialist

If yes, **approve 12 months by HICL or GPI-10. (NOTE: If the claim rejects after analyzing, follow the clinical prior authorization process).**  
If no, continue to #4.

4. Has the physician provided attestation that the requested high dose is considered medically necessary?

If yes, continue to #5.  
If no, do not approve.  
**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OPIOID SINGLE CLAIM DOSING AT POS (OSCDP)

GUIDELINES FOR USE (CONTINUED)

5. Is the request for an opioid with an MME equal to or exceeding the hard-stop threshold and the prescriber has not indicated an opioid MME threshold value?

If yes, **approve for 12 months by HICL or GPI-10 up to 25% greater than the previously approved MME via the patient's claim profile or physician attestation, up to 300 MME. (NOTE: If the claim rejects after analyzing, follow the clinical prior authorization process).**

If no, continue to #6.

6. Did the physician indicate a maximum opioid threshold for the requested drug that is less than 300 MME?

If yes, **approve for 12 months by HICL or GPI-10 as requested up to 300 MME. (NOTE: If the claim rejects after analyzing, follow the clinical prior authorization process).**

If no, continue to #7.

7. Is the request for an opioid with an MME equal to or exceeding the maximum threshold (300 MME) for a patient who is currently stable on this MME?

If yes, **approve for 3 months by HICL or GPI-10. (NOTE: If the claim rejects after analyzing, follow the clinical prior authorization process).**

**APPROVAL TEXT:** While your prior authorization for (enter requested drug) has been granted, your opiate amount is equal to or exceeds [300 morphine milligram equivalent (MME)] and is considered a high dose of opiate. Please consult with your pain management specialist regarding your treatment options.

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **OPIOID SINGLE CLAIM DOSING AT POS** allows for an override of an opioid product equal to or exceeding the soft-stop threshold of [**enter soft stop threshold**]-mg morphine milligram equivalent (MME) at the pharmacy or by a prior authorization. The hard-stop threshold of [**enter hard stop threshold**]-mg morphine milligram equivalent (MME) is not overridable and requires a prior authorization.

**(Denial text continued on next page)**

CONTINUED ON NEXT PAGE





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OPIOID SINGLE CLAIM DOSING AT POS (OSCDP)

GUIDELINES FOR USE (CONTINUED)

An override will be provided if ONE (A or B) of the following rule(s) are met:

- A. You meet ONE of the following conditions:
  - 1. You have active cancer
  - 2. You are receiving treatment for palliative care (treatment for comfort from symptoms)
  - 3. You have sickle cell disease (type of blood disorder)
  - 4. You are enrolled in a hospice
  - 5. Your doctor is a pain management specialist
- B. Your physician confirms that the requested high dose is considered medically necessary.
  - 1. If the requested dose is lower than 300 MME, your prescriber must provide a maximum opioid threshold. If your prescriber does not provide a maximum threshold and the request is for an opioid with an MME equal to or exceeding **[enter hard-stop threshold]**-mg morphine milligram equivalent (MME), the claim will be approved up to 25 percent greater than the previously approved MME.
  - 2. If the requested dose is equal to or greater than 300 MME, approval will be granted if you are stable on the dose.

Please consult your pain management specialist regarding your treatment options.

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

To align with opioid restrictions required by several states and to prevent overutilization of opioids and increase safety.

This advanced POS intervention blocks an incoming claim when a single claim's Morphine Milligram Equivalent (MME) is equal to or exceeds a specified hard-stop threshold (e.g. over 90 MME). The hard-stop is non-overridable except via prior authorization. The edit allows a soft stop on an incoming claim with an MME equal to or over a lower threshold (e.g. over 50 MME) that can be overridden by Pharmacy Professional Service (PPS) codes at the point-of-sale (POS) or by prior authorization. Overriding the hard threshold for OSCDP will also override the OSCDP soft threshold, but does not affect Opioid Cumulative Dosing Program (OCDP).

This requirement does not apply to patients with a diagnosis of active cancer, sickle cell disease, in palliative care, hospice patients, or patients with a prescription from a pain management specialist.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**OPIOID SINGLE CLAIM DOSING AT POS (OSCDP)**

**REFERENCES**

- Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. MMWR Recomm Rep 2016;65(No. RR-1):1–49. DOI: <http://dx.doi.org/10.15585/mmwr.rr6501e1> [Accessed June 28, 2018].
- Jones B, Cynthia. (2016). Implementation of CDC Guideline for Prescribing Opioids for Chronic Pain Coeverage of Non-Opioid Pain Relievers and Uniform, Streamlines Prior Authorization for New Opioid Prescription Effective December 1, 2016. Department of Medical Assitance Services. Available at [https://www.msv.org/sites/default/files/PDFs/12.1.16\\_guideline\\_for\\_opioids\\_non\\_opioid\\_pain\\_relievers\\_revised\\_final.pdf](https://www.msv.org/sites/default/files/PDFs/12.1.16_guideline_for_opioids_non_opioid_pain_relievers_revised_final.pdf) [Accessed June 28, 2018].

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/01/22

Created: 06/18

Client Approval: 09/22

P&T Approval: 07/18



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OPIOID-SOMA-BENZODIAZEPINE CONCURRENT USE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
N/A	N/A	N/A	N/A	N/A	N/A

GUIDELINES FOR USE

- Is the claim rejecting with the following error code?
  - REJ- 433-1204: SOMA-OPIOID-BENZODIAZEPINE CONFLICT FOUND (H: DUR\_CONCURRENT\_USE)**

If yes, continue to #2.  
If no, guideline does not apply.

- Does the patient meet at least **ONE** of the following criteria?
  - Patient has a diagnosis of active cancer
  - Patient is in hospice care
  - Patient is receiving palliative care or end-of-life care
  - Patient is a resident of a long-term care facility or intermediate care for intellectually disabled

If yes, **approve for 12 months by HICL or GPI-10 and set DUR\_CONCURRENT\_OVR to 'SOMA\_OP\_BZD'**.  
If no, continue to #3.

- Has the prescriber indicated that the concurrent use of an opioid with Soma (carisoprodol) and a benzodiazepine medication is intended and clinically appropriate for the patient?

**[NOTE:** Refer to the Medical Request Form (MRF) or chart notes if provided (e.g., patient is stable on the requested drug, patient needs to continue use, etc.). The member cannot provide this information.]

If yes, **approve for one (1) month by HICL or GPI-10 and set DUR\_CONCURRENT\_OVR to 'SOMA\_OP\_BZD'**.  
If no, do not approve.  
**DENIAL TEXT:** See the denial text at the end of the guideline.

CONTINUED ON THE NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OPIOID-SOMA-BENZODIAZEPINE CONCURRENT USE

GUIDELINES FOR USE (CONTINUED)

**OPTIONAL OPERATIONAL DENIAL TEXT FOR APPROVAL OF CLINICAL UM, BUT DENIAL OF THE OPIOID SAFETY EDIT:**

**[NOTE: Enter proactive PAs for other UM overrides not including Opioid-Soma-Benzodiazepine Concurrent Use, if applicable.]**

While your request for **[enter approved UM]** for **[enter requested drug]** has been granted, the drug has not been approved because of the use of an opioid with Soma (carisoprodol) and a benzodiazepine medication together.

**[Proceed to enter Denial Text below]**

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **OPIOID-SOMA-BENZODIAZEPINE CONCURRENT USE** allows an approval for use of an opioid with Soma (carisoprodol) and a benzodiazepine medication together when one of the following criteria is met:

- A. You have active cancer
- B. You are receiving palliative care (treatment for comfort from symptoms) or end-of-life care
- C. You are enrolled in a hospice
- D. You are a resident of a long-term care facility or intermediate care for intellectually disabled
- E. Your doctor confirms that the use of an opioid with Soma (carisoprodol) and a benzodiazepine medication together is intended and clinically appropriate for you

Please consult your physician if you have any questions about this prescription pain medication and the requirements needed for you to obtain an approval for this agent.

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON THE NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**OPIOID-SOMA-BENZODIAZEPINE CONCURRENT USE**

**RATIONALE**

To mitigate the risk of the overdose from dangerous combinations of CNS depressants while preserving patient access to drug regimens if deemed medically necessary.

The Opioid-Benzodiazepine-Soma Concurrent Use at POS edit will identify and deny concurrent use of opioids, benzodiazepines, and carisoprodol when there is an overlap in day supply (for at least one drug from each 'class'). This edit will reject the claim that creates the three-drug overlap.

The edit will have internal reject codes REJ- 433- 1204, and the following parameters:

1. Triple drug overlap = 1 day
2. Prescriber threshold = 1 prescriber
3. Exceptions =
  - a) Cancer diagnosis (edit will lookback for presence of claims related to these diseases in the past 180 days to automatically exclude from the edit)
  - b) Hospice or palliative care (edit will look for hospice attribute on claims to automatically exclude from the edit)
  - c) Long Term Care residence (edit will look for patient residence code to automatically exclude from the edit)

Please note that sickle cell disease will not be included in the exception criteria. Although opioids and benzodiazepines can be used in managing pain crises, treatment guidelines do not mention skeletal muscle relaxants such as carisoprodol as a typical treatment modality.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 03/01/21

Created: 07/19

Client Approval: 02/21

P&T Approval: 04/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OSILODROSTAT

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
OSILODROSTAT	ISTURISA	46396		GPI-10 (3002206060)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of Cushing's disease (CD) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or given in consultation with an endocrinologist
  - Pituitary surgery is not an option or has not been curative for the patient
  - The patient had a trial of or contraindication to oral ketoconazole

If yes, **approve for 6 months for all strengths by GPID or GPI-14 with the following quantity limits:**

- **Isturisa 1mg: #8 per day.**
- **Isturisa 5mg: #2 per day.**
- **Isturisa 10mg: #6 per day.**

**APPROVAL TEXT:** Renewal for Cushing's disease requires that the patient continues to have improvement of Cushing's disease (e.g., clinically meaningful reduction in 24-hour urinary free cortisol and/or improvements in signs and symptoms of disease) and maintains tolerability to Isturisa.

If no, do not approve.

**INITIAL DENIAL TEXT:** *\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **OSILODROSTAT (Isturisa)** requires the following rule(s) be met for approval:

- A. You have Cushing's disease (CD: a condition due to a tumor in the pituitary gland causing an excess release of the hormone cortisol in the blood)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or given in consultation with an endocrinologist (doctor who specializes in hormones)
- D. Pituitary (major hormone gland) surgery is not an option or has not cured your condition
- E. You previously had a trial of oral ketoconazole, unless there is a medical reason you are cannot (contraindication)

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OSILODROSTAT

INITIAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of Cushing's disease and meet **ALL** the following criteria?
  - The patient continues to have improvement of Cushing's disease (e.g., clinically meaningful reduction in 24-hour urinary free cortisol and/or improvements in signs and symptoms of disease)
  - The patient maintains tolerability to Isturisa

If yes, **approve for 12 months for all strengths by GPID or GPI-14 with the following quantity limits:**

- Isturisa 1mg: #8 per day.
- Isturisa 5mg: #2 per day.
- Isturisa 10mg: #6 per day.

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **OSILODROSTAT (Isturisa)** requires the following rule(s) be met for renewal:

- A. You have Cushing's disease (CD: a condition due to a tumor in the pituitary gland causing an excess release of the hormone cortisol in the blood)
- B. You continue to have improvement of Cushing's disease (such as clinically meaningful reduction in 24-hour urinary free cortisol and/or improvements in signs and symptoms of disease)
- C. You continue to tolerate treatment with Isturisa

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**OSILODROSTAT**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Isturisa.

**REFERENCES**

- Isturisa [Prescribing Information]. Lebanon, NJ: Recordati Rare Diseases, Inc.; March 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/01/20

Created: 08/20

Client Approval: 08/20

P&T Approval: 07/20





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OSIMERTINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
OSIMERTINIB MESYLATE	TAGRISSO	42803		GPI-10 (2136006820)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of non-small cell lung cancer (NSCLC) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The requested medication is being used as adjuvant therapy after tumor resection
- The patient is positive for an epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations and is confirmed by an FDA-approved test
- Tagrisso will NOT be used concurrently with an epidermal growth factor receptor (EGFR) tyrosine kinase-inhibitor (e.g., Tarceva, Iressa, Gilotrif, Vizimpro)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**

If no, continue to #2.

2. Does the patient have a diagnosis of metastatic non-small cell lung cancer (NSCLC) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- Tagrisso will NOT be used concurrently with an epidermal growth factor receptor (EGFR) tyrosine kinase-inhibitor (e.g., Tarceva, Iressa, Gilotrif, Vizimpro)

If yes, continue to #3.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

3. Does the patient's tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test **AND** Tagrisso will be used as first-line treatment?

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**

If no, continue to #4.

4. Does the patient's tumor have epidermal growth factor receptor (EGFR) T790M mutation, as detected by an FDA-approved test **AND** the patient meets the following criterion?

- The patient's disease has progressed while on or after epidermal growth factor receptor (EGFR) tyrosine kinase-inhibitor therapy (e.g., Tarceva, Iressa, or Gilotrif)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OSIMERTINIB

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **OSIMERTINIB (Tagrisso)** requires the following rule(s) be met for approval:

- A. You have non-small cell lung cancer (type of lung cancer)
- B. You are 18 years of age or older
- C. **If you have non-small cell lung cancer, approval also requires:**
  - 1. Tagrisso is being used as adjuvant therapy (add-on treatment) after tumor resection (surgical removal of a tumor)
  - 2. Your tumor is positive for an epidermal growth factor receptor (EGFR: type of protein) exon 19 deletions or exon 21 L858R (type of genes) mutations, as detected by an FDA-approved test
  - 3. You will NOT be using Tagrisso concurrently (at the same time) with an epidermal growth factor receptor (EGFR) tyrosine kinase-inhibitor (such as Tarceva, Iressa, Gilotrif, Vizimpro)
- D. **If you have metastatic non-small cell lung cancer (cancer that has spread throughout the body), approval also requires:**
  - 1. You will NOT receiving another epidermal growth factor receptor (EGFR) tyrosine kinase-inhibitor (such as Tarceva, Iressa, Gilotrif, Vizimpro) together with Tagrisso
  - 2. You meet ONE of the following:
    - a. Your tumor is positive for epidermal growth factor receptor (EGFR: type of protein) exon 19 deletions or exon 21 L858R (types of genes) mutations as confirmed by an FDA-approved test AND Tagrisso will be used as first-line treatment (initial treatment)
    - b. Your tumor is positive for an epidermal growth factor receptor (EGFR) T790M (type of gene) mutation, as detected by an FDA (Food and Drug Administration)-approved test AND your disease has progressed (worsening of disease) while on or after EGFR tyrosine kinase-inhibitor therapy such as (Tarceva, Iressa, Gilotrif)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**OSIMERTINIB**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Tagrisso.

**REFERENCES**

- Tagrisso [Prescribing Information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; January 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/22

Created: 11/15

Client Approval: 05/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OTESECONAZOLE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
OTESECONAZOLE	VIVJOA	47976		GPI-10 (1140805000)	

**GUIDELINES FOR USE**

1. Is the request for the reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC) and the patient meets **ALL** of the following criteria?

- The patient is female
- The patient is NOT of reproductive potential (defined as a biological female who is postmenopausal or has another reason for permanent infertility [e.g., tubal ligation, hysterectomy, salpingo-oophorectomy])
- The patient is NOT currently on ibrexafungerp for RVVC

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Has the patient previously received Vivjoa?

If yes, continue to #4.

If no, continue to #3.

3. Has the patient had 3 or more episodes of VVC in the past 12 months?

If yes, **approve for 3 months by HICL or GPI-10 with a quantity limit of #18 per 12 weeks.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

4. Does the patient meet **ALL** of the following criteria?

- The patient has successfully completed a course of Vivjoa for prevention of RVVC
- The patient is either being treated or has just completed treatment for a new recurrence of VVC

If yes, **approve for 3 months by HICL or GPI-10 with a quantity limit of #18 per 12 weeks.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OTESECONAZOLE

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **OTESECONAZOLE (Vivjoa)** requires the following rule(s) be met for approval:

- A. You have recurrent vulvovaginal candidiasis (RVVC: a repeating vaginal fungal infection)
- B. You are female
- C. You are not able to reproduce, which means you are a biological female and are postmenopausal (after menopause) or you have another reason for permanent infertility (such as tubal ligation [having tubes tied], hysterectomy [removal of the uterus], salpingo-oophorectomy [removal of an ovary and its fallopian tube])
- D. You are NOT currently on ibrexafungerp for RVVC
- E. **If you have not previously received Vivjoa, approval also requires:**
  - 1. You had 3 or more episodes of RVVC in the past 12 months
- F. **If you have previously received Vivjoa, approval also requires:**
  - 1. You have successfully completed a course of Vivjoa for prevention of RVVC
  - 2. You are either being treated or have just completed treatment for a new recurrence of VVC

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Vivjoa.

**REFERENCES**

- Vivjoa [Prescribing Information]. Durham, NC: Mycovia Pharmaceuticals, Inc.; April 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/23

Created: 07/22

Client Approval: 02/23

P&T Approval: 01/23



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OXYMETAZOLINE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
OXYMETAZOLINE HCL/PF	UPNEEQ	46701		GPI-10 (8680223610)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of blepharoptosis and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with an ophthalmologist or optometrist
  - The patient has been evaluated for surgical intervention
  - The patient had a trial of TWO ophthalmic alpha-adrenergic agonists (e.g., apraclonidine, tetrahydrozoline, naphazoline)

If yes, **approve for 3 months by HICL or GPI-10 with a quantity limit of #1 droperette per day.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **OXYMETAZOLINE (Upneeq)** requires the following rule(s) be met for approval:

- A. You have blepharoptosis (drooping of the upper eyelid)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with an ophthalmologist (a type of eye doctor) or optometrist (a type of eye doctor)
- D. You have been evaluated for surgical intervention
- E. You had a trial of TWO ophthalmic alpha-adrenergic agonists (such as apraclonidine, tetrahydrozoline, naphazoline)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OXYMETAZOLINE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

- Does the patient have a diagnosis of blepharoptosis **AND** meet the following criterion?
  - The patient continues to have benefit from Upneeq

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 droperette per day.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **OXYMETAZOLINE (Upneeq)** requires the following rule(s) be met for renewal:

- D. You have blepharoptosis (drooping of the upper eyelid)
- E. You continue to have benefit from Upneeq

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Upneeq.

**REFERENCES**

- Upneeq [Prescribing Information]. Bridgewater, NJ: RVL Pharmaceuticals, Inc.; June 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/22

Created: 11/21

Client Approval: 02/22

P&T Approval: 10/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OZANIMOD

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
OZANIMOD HYDROCHLORIDE	ZEPOSIA	46431		GPI-10 (6240705020)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient had a trial of ONE sphingosine-1-phosphate receptor modulator (e.g., Gilenya, Mayzent) AND any ONE agent indicated for the treatment of multiple sclerosis (MS)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**

If no, continue to #2.

2. Does the patient have a diagnosis of moderate to severe ulcerative colitis (UC) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- Therapy is prescribed by or in consultation with a gastroenterologist
- The patient had a trial of or contraindication to ONE conventional therapy (e.g., corticosteroids [e.g., budesonide, methylprednisolone], azathioprine, mercaptopurine, methotrexate, mesalamine)
- The patient had a trial of or contraindication to TWO of the following preferred immunomodulators: Humira, Stelara, Xeljanz (IR/XR), Rinvoq

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #1 per day.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **OZANIMOD (Zeposia)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:

1. A relapsing form of multiple sclerosis (MS: type of nerve disorder) to include clinically isolated syndrome (occurs once), relapsing-remitting disease (periods of symptoms and no symptoms), and active secondary progressive disease (advanced disease)
2. Moderate to severe ulcerative colitis (UC: a type of digestive condition)

B. You are 18 years of age or older

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OZANIMOD

INITIAL CRITERIA (CONTINUED)

- C. **If you have a relapsing form of multiple sclerosis, approval also requires:**
1. You had a trial of ONE sphingosine-1-phosphate receptor modulator (such as Gilenya or Mayzent) AND any ONE agent indicated for the treatment of multiple sclerosis
- D. **If you have moderate to severe ulcerative colitis, approval also requires:**
1. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
  2. You had a trial of or contraindication (harmful for) to ONE standard therapy, such as corticosteroids (such as budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, mesalamine
  3. You have tried or have a contraindication (harmful for) to TWO of the following preferred immunomodulators: Stelara, Humira, Xeljanz (immediate release/extended release), Rinvoq

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

**NOTE:** For the diagnosis of multiple sclerosis, please refer to the Initial Criteria section.

1. Does that patient have a diagnosis of moderate to severe ulcerative colitis (UC)?

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**  
If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **OZANIMOD (Zeposia)** requires the following rule(s) be met for renewal:  
A. You have moderate to severe ulcerative colitis (UC: a type of digestive condition)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**OZANIMOD**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Zeposia.

**REFERENCES**

- Zeposia [Prescribing Information]. Summit, NJ: Celgene Corporation, May 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 06/15/22

Created: 06/20

Client Approval: 05/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PACRITINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
PACRITINIB CITRATE	VONJO	47850		GPI-10 (2153755010)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

- Does the patient have a diagnosis of intermediate- or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocytopenia) myelofibrosis and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient has a platelet count below 50,000/uL

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #4 per day.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **PACRITINIB (Vonjo)** requires the following rule(s) be met for approval:

- You have intermediate- or high-risk primary or secondary (post-polycythemia vera [type of blood cell disorder] or post-essential thrombocytopenia [type of blood cell disorder] myelofibrosis (type of bone marrow cancer)
- You are 18 years of age or older
- You have a platelet count below 50,000/uL

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RENEWAL CRITERIA**

- Does the patient have a diagnosis of intermediate- or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocytopenia) myelofibrosis (MF)?

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PACRITINIB

RENEWAL CRITERIA (CONTINUED)

2. Has the patient shown symptom improvement by meeting **ONE** of the following criteria?
- The patient has a spleen volume reduction of 35% or greater from baseline
  - The patient has a 50% or greater reduction in total symptom score (e.g., Myeloproliferative Neoplasm Symptom Assessment Form [MPN-SAF TSS], modified Myelofibrosis Symptom Assessment Form [MFSAF] v2.0)
  - The patient has a 50% or greater reduction in palpable spleen length

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**  
If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **PACRITINIB (Vonjo)** requires the following rule(s) be met for renewal:

- A. You have intermediate- or high-risk primary or secondary (post-polycythemia vera [type of blood cell disorder] or post-essential thrombocythemia [type of blood cell disorder]) myelofibrosis (type of bone marrow cancer)
- B. You have shown symptom improvement by meeting ONE of the following:
  1. You have a spleen volume reduction of 35% or greater from baseline
  2. You have a 50% or greater reduction in total symptom score (such as Myeloproliferative Neoplasm Symptom Assessment Form [MPN-SAF TSS], modified Myelofibrosis Symptom Assessment Form [MFSAF] v2.0)
  3. You have a 50% or greater reduction in palpable (can be felt by external examination) spleen length

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Vonjo.

**REFERENCES**

- Vonjo [Prescribing Information]. Seattle, WA: CTI BioPharma Corp.; February 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/22

Created: 03/22

Client Approval: 03/22

P&T Approval: 10/21

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**PALBOCICLIB**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
PALBOCICLIB	IBRANCE	41725		GPI-10 (2153106000)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of advanced or metastatic breast cancer and meet **ALL** the following criteria?
  - The patient is 18 years of age or older
  - The patient's cancer is hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Will Ibrance be used in combination with an aromatase inhibitor (e.g., anastrozole, letrozole, exemestane) **AND** the patient meets the following criterion?
  - The patient has NOT received prior endocrine-based therapy (e.g., letrozole, anastrozole, tamoxifen)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #21 per 28 days.**

If no, continue to #3.

3. Will Ibrance be used in combination with Faslodex (fulvestrant) **AND** the patient meets the following criterion?
  - The patient has experienced disease progression following endocrine therapy (e.g., letrozole, anastrozole, tamoxifen)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #21 per 28 days.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PALBOCICLIB

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **PALBOCICLIB (Ibrance)** requires the following rule(s) be met for approval:

- A. You have advanced or metastatic breast cancer (cancer that has worsened or has spread to other parts of the body)
- B. You are 18 years of age or older
- C. Your cancer is hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (a type of protein)
- D. You meet ONE of the following:
  - 1. Ibrance will be used in combination with an aromatase inhibitor (such as anastrozole, letrozole, exemestane) AND you have not received prior endocrine (hormone)-based therapy (such as letrozole, anastrozole, tamoxifen)
  - 2. Ibrance will be used in combination with Faslodex (fulvestrant) AND your disease has worsened after endocrine (hormone) therapy (such as letrozole, anastrozole, tamoxifen)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Ibrance.

**REFERENCES**

- Ibrance [Prescribing Information]. New York, NY: Pfizer Laboratories. December 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/16/23

Created: 05/15

Client Approval: 12/22

P&T Approval: 01/23



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PANOBINOSTAT

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
PANOBINOSTAT	FARYDAK	41794		GPI-10 (2153155010)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of multiple myeloma and meets **ALL** of the following criteria?
  - The patient has been treated with at least 2 prior regimens, including Velcade (bortezomib) and an immunomodulatory agent, such as Thalomid, Revlimid, or Pomalyst
  - The requested medication will be used concurrently with Velcade (bortezomib) and dexamethasone

If yes, **approve for 12 months by HICL or GPI-10 for #6 per 21 days with a fill count of 8 (8 cycles).**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **PANOBINOSTAT (Farydak)** requires the following rule(s) be met for approval:

- A. You have multiple myeloma (cancer that forms in a type of white blood cell)
- B. You have been treated with at least 2 prior regimens including:
  1. Velcade (bortezomib)
  2. Immunomodulatory medication such as Thalomid, Revlimid, or Pomalyst. (These drugs adjust immune responses)
- C. The requested medication will be used in combination with Velcade (bortezomib) and dexamethasone

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PANOBINOSTAT

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

- 1. Has the patient tolerated the first 8 cycles of therapy without any severe or medically significant toxicity?

If yes, **approve for 12 months by HICL or GPI-10 for #6 per 21 days with fill count of 8 (8 cycles).**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **PANOBINOSTAT (Farydak)** requires the following rule(s) be met for renewal:

- A. You have tolerated the first 8 weeks of therapy without experiencing any severe or medically significant toxicity

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Farydak.

**REFERENCES**

- Farydak [Prescribing Information]. East Hanover, NJ: Novartis; September 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 03/15

Client Approval: 04/20

P&T Approval: 05/15





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PARATHYROID HORMONE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
PARATHYROID HORMONE	NATPARA	34000		GPI-10 (3004405510)	ROUTE = SUBCUTANE.

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of hypocalcemia secondary to hypoparathyroidism and meets the following criteria?
  - Previous trial of activated vitamin D (calcitriol) and calcium
  - Patient's hypoparathyroidism is **not** due to a calcium sensing receptor (CSR) mutation
  - Patient's hypoparathyroidism is **not** considered acute post-surgical hypoparathyroidism (surgery in past 30 days)
  - Therapy is prescribed by or given in consultation with an endocrinologist

If yes, **approve for 12 months by HICL or GPI-10 for quantity of #2 cartridges per 28 days.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline for **PARATHYROID HORMONE** requires the following rule(s) be met for approval:

- A. You have hypocalcemia secondary to hypoparathyroidism (low blood calcium due to low levels of a type of hormone)
- B. You have previously tried activated vitamin D (calcitriol) and calcium
- C. Your hypoparathyroidism (low levels of a type of hormone) is not due to a calcium sensing receptor (CSR) mutation (changes in your DNA that make up your gene)
- D. Your hypoparathyroidism is not considered acute post-surgical hypoparathyroidism (not sudden and severe due to surgery in past 30 days)
- E. Therapy is prescribed by or given in consultation with an endocrinologist (hormone specialist)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**PARATHYROID HORMONE**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Natpara.

**REFERENCES**

1. Natpara [Prescribing Information]. Bedminster, NJ: NPS Pharmaceuticals, Inc. December 2018.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 04/15

Client Approval: 04/20

P&T Approval: 05/15



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PASIREOTIDE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
PASIREOTIDE	SIGNIFOR	39866		GPI-10 (3017007520)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of Cushing's disease (CD) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or given in consultation with an endocrinologist
  - The patient has undergone pituitary surgery or pituitary surgery is not an option for this patient
  - The patient had a trial of or contraindication to oral ketoconazole

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #2 per day.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **PASIREOTIDE (Signifor)** requires the following rule(s) be met for approval:

- A. You have Cushing's disease (CD: a condition in which the pituitary gland releases too much of a hormone called adrenocorticotrophic hormone [ACTH])
- B. You are 18 years of age or older
- C. Therapy is prescribed by or given in consultation with an endocrinologist (doctor who specializes in hormones)
- D. You have undergone pituitary (a major hormone gland) surgery OR pituitary surgery is not an option
- E. You have previously tried oral ketoconazole, unless there is a medical reason you are cannot (contraindication)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PASIREOTIDE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of Cushing's disease (CD) and meet **ALL** of the following criteria?
  - The patient continues to have improvement of Cushing's disease (e.g., clinically meaningful reduction in 24-hour urinary free cortisol and/or improvements in signs and symptoms of disease)
  - The patient maintains tolerability to Signifor

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.**  
If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **PASIREOTIDE (Signifor)** requires the following rule(s) be met for renewal:

- A. You have Cushing's disease (CD: a condition in which the pituitary gland releases too much of a hormone called adrenocorticotrophic hormone [ACTH])
- B. You continue to have improvement of Cushing's disease (such as clinically meaningful reduction in 24-hour urinary free cortisol and/or improvements in signs and symptoms of your disease)
- C. You continue to tolerate treatment with Signifor

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Signifor.

**REFERENCES**

- Signifor [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; January 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/01/20

Created: 05/13

Client Approval: 08/20

P&T Approval: 07/20

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PATIROMER

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
PATIROMER CALCIUM SORBITEX	VELTASSA	42767		GPI-10 (9945006020)	

**GUIDELINES FOR USE**

1. Is the patient being treated for hyperkalemia **AND** meet the following criterion?

- Therapy is prescribed by or given in consultation with a nephrologist or cardiologist

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient meet **ONE** of the following criteria?

- The requested medication is being used as an emergency treatment for life-threatening hyperkalemia
- The patient is currently receiving dialysis

If yes, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

If no, continue to #3.

3. Has the patient attempted **ONE** of the following approaches in an effort to reduce the modifiable risks for hyperkalemia?

- Limit to taking no more than one of the following drugs at any given time:
  - Angiotensin converting enzyme inhibitor (ACE-I)
  - Angiotensin receptor blocker (ARB)
- Consideration of dose reduction of renin-angiotensin-aldosterone system (RAAS) inhibitors (e.g., ACE-I's, ARB's, aldosterone antagonists)

If yes, continue to #4.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

4. Does the patient have an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m<sup>2</sup> **AND** meet the following criterion?

- The patient has tried loop diuretics (e.g., bumetanide, ethacrynic acid, furosemide, torsemide) for the treatment of hyperkalemia

If yes, continue to #6.

If no, continue to #5.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PATIROMER

GUIDELINES FOR USE (CONTINUED)

5. Does the patient have an estimated glomerular filtration rate (eGFR) of 30 mL/min/1.73 m<sup>2</sup> or above and have tried **ONE** of the following for the treatment of hyperkalemia?

- The patient has tried loop diuretic (e.g., bumetanide, ethacrynic acid, furosemide, torsemide)
- The patient has tried thiazide diuretic (e.g., chlorthalidone, hydrochlorothiazide, metolazone)

If yes, continue to #6.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

6. Has the patient had a previous trial of Lokelma (sodium zirconium cyclosilicate)?

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #30 packets per 30 days.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **PATIROMER (Veltassa)** requires the following rule(s) be met for approval:

- A. You have hyperkalemia (high levels of potassium in blood)
- B. Therapy is prescribed by or given in consultation with a nephrologist (kidney doctor) or cardiologist (heart doctor)
- C. The requested medication is NOT being used as an emergency treatment for life-threatening hyperkalemia (high levels of potassium in blood)
- D. You are NOT currently receiving dialysis
- E. You have tried ONE of the following to lower the risks for hyperkalemia:
  1. Limit to taking no more than one of the following drugs at any given time:
    - i. Angiotensin converting enzyme inhibitor (ACE-I such as lisinopril, benazepril)
    - ii. Angiotensin receptor blocker (ARB such as valsartan, losartan)
  2. Lowering the dose of renin-angiotensin-aldosterone system (RAAS) inhibitors (such as ACE-I's, ARB's, aldosterone antagonists like spironolactone) has been considered
- F. **If your estimated glomerular filtration rate (eGFR) is below 30 mL/min/1.73 m<sup>2</sup>, approval also requires:**
  1. You have tried to treat hyperkalemia with loop diuretics such as bumetanide, ethacrynic acid, furosemide, torsemide

**(Denial text continued on next page)**

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PATIROMER

GUIDELINES FOR USE (CONTINUED)

G. If your estimated glomerular filtration rate (eGFR) is 30 mL/min/1.73 m(2) or above approval also requires:

1. You have tried to treat hyperkalemia with a loop diuretic such as bumetanide, ethacrynic acid, furosemide, torsemide, OR a thiazide diuretic such as chlorthalidone, hydrochlorothiazide, metolazone

H. You have previously tried Lokelma (sodium zirconium cyclosilicate)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Review for Veltassa.

REFERENCES

8. Veltassa [Prescribing Information]. Redwood City, CA: Relypsa, Inc.; October 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 2/16

Client Approval: 04/20

P&T Approval: 01/19



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PAZOPANIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
PAZOPANIB HCL	VOTRIENT	36709		GPI-10 (2153304210)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of advanced renal cell carcinoma (RCC) **AND** meet the following criterion?

- The patient is 18 years of age or older

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**  
If no, continue to #2.

2. Does the patient have a diagnosis of advanced soft tissue sarcoma (STS) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient has received prior chemotherapy (e.g., anthracycline treatment)
- The patient does NOT have a diagnosis of adipocytic soft tissue sarcoma (STS) or gastrointestinal stromal tumors (GIST)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **PAZOPANIB (Votrient)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:

1. Advanced renal cell carcinoma (RCC: a type of kidney cancer)
2. Advanced soft tissue sarcoma (STS: cancer that starts in soft tissues like muscle, tendons, fat, lymph vessels, blood vessels, and nerves)

B. **If you have advanced renal cell carcinoma, approval also requires:**

1. You are 18 years of age or older

C. **If you have advanced soft tissue sarcoma, approval also requires:**

1. You are 18 years of age or older
2. You have received prior chemotherapy (cancer treatment such as anthracycline treatment)
3. You do NOT have adipocytic soft tissue sarcoma (type of cancer in fat cells) or gastrointestinal stromal tumors (GIST: type of cancer that starts in a type of cell in the digestive system)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**





**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**PAZOPANIB**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Votrient.

**REFERENCES**

- Votrient [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; December 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/11/22

Created: 05/11

Client Approval: 03/22

P&T Approval: 08/16



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PEANUT ALLERGEN POWDER-DNFP

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
PEANUT (ARACHIS HYPOGAEA) ALLERGEN POWDER-DNFP	PALFORZIA	46332		GPI-10 (2010004020)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of peanut allergy?

If yes, continue to #2.

If no, do not approve

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Has the patient undergone a purposeful food challenge?

If yes, continue to #3.

If no, continue to #4.

3. Is there documentation of a positive skin prick test (wheal diameter  $\geq 3$  mm) **OR** peanut-specific immunoglobulin E ( $\geq 0.35$  kUA/L) within the past 24 months?

If yes, continue to #5.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

4. Is there documentation of a positive skin prick test (wheal diameter  $\geq 8$  mm) **OR** peanut-specific immunoglobulin E ( $\geq 14$  kUA/L) within the past 24 months?

If yes, continue to #5.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PEANUT ALLERGEN POWDER-DNFP

INITIAL CRITERIA (CONTINUED)

5. Does the patient meet **ALL** of the following criteria?
1. The patient is 4 to 17 years of age
  2. Therapy is prescribed by or given in consultation with an allergist/immunologist
  3. The patient has a clinical history of allergic reaction to peanuts
  4. The requested medication will be used in conjunction with a peanut-avoidance diet
  5. The patient is not on concurrent peanut-specific immunotherapy (e.g. Viaskin Peanut)

If yes, **approve for 12 months by GPID or GPI-14 for all of the following:**

6. **300 mg powder packet/sachet: #1 per day.**

7. **All other strengths: No quantity limit.**

**APPROVAL TEXT:** Renewal requires the patient has a peanut allergy and meets ALL of the following: 1) therapy is prescribed by given in consultation with an allergist/immunologist, 2) the requested medication is to be used in conjunction with a peanut-avoidance diet, 3) patient is not on concurrent peanut-specific immunotherapy. In addition, the patient must meet ONE of the following: 1) the patient has a *persistent* peanut allergy, or 2) if the patient has undergone a purposeful food challenge: documentation of persistent peanut allergy based on a positive skin prick test (wheal diameter greater than or equal to 3 mm) OR peanut-specific immunoglobulin E (greater than or equal to 0.35 kUA/L) within the past 24 months, or 3) if the patient has not undergone a purposeful food challenge: documentation of persistent peanut allergy based on a positive skin prick test (wheal diameter greater than or equal to 8 mm) OR peanut-specific immunoglobulin E (greater than or equal to 14 kUA/L) within the past 24 months.

If no, do not approve.

**INITIAL DENIAL TEXT:** **\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **PEANUT ALLERGEN POWDER-DNFP (Palforzia)** requires the following rule(s) be met for approval:

- A. You have a peanut allergy confirmed by ONE of the following:
1. If you have undergone a purposeful food challenge: you have documentation of a positive skin prick test (wheal diameter of 3 mm or greater) (skin test to check for peanut allergy) OR peanut-specific immunoglobulin E (IgE level at 0.35 kUA/L or greater) (blood test that indicates an allergy to peanuts) within the past 24 months
  2. If you have NOT undergone a purposeful food challenge: you have documentation of a positive skin prick test (wheal diameter of 8 mm or greater) (skin test to check for peanut allergy) OR peanut-specific immunoglobulin E (IgE level at 14 kUA/L or greater) (blood test that indicates an allergy to peanuts) within the past 24 months
- B. You are 4 to 17 years of age  
**(Initial denial text continued on next page)**

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PEANUT ALLERGEN POWDER-DNFP

INITIAL CRITERIA (CONTINUED)

- C. Therapy is prescribed by given in consultation with an allergist/immunologist (allergy/immune system doctor)
- D. You have a clinical history of allergic reaction to peanuts
- E. The medication is to be used in conjunction with a peanut-avoidance diet
- F. You are not currently on peanut-specific immunotherapy (such as Viaskin Peanut)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a peanut allergy and meet **ALL** of the following criteria?
  8. Therapy is prescribed by or given in consultation with an allergist/immunologist
  9. The requested medication is to be used in conjunction with a peanut-avoidance diet
  10. The patient is not on concurrent peanut-specific immunotherapy (e.g. Viaskin Peanut)

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

2. Does the patient meet **ONE** of the following criteria?
  11. The patient has a persistent peanut allergy
  12. The patient has undergone a purposeful food challenge AND there is documentation of persistent peanut allergy by a positive skin prick test (wheal diameter  $\geq 3$  mm) OR peanut-specific immunoglobulin E ( $\geq 0.35$  kUA/L) within the past 24 months
  13. The patient has **NOT** undergone a purposeful food challenge but there is documentation of persistent peanut allergy by a positive skin prick test (wheal diameter  $\geq 8$  mm) OR peanut-specific immunoglobulin E ( $\geq 14$  kUA/L) within the past 24 months

If yes, **approve for 12 months by GPID or GPI-14 for all of the following:**

14. **300 mg powder packet/sachet: #1 per day.**

15. **All other strengths: No quantity limit.**

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PEANUT ALLERGEN POWDER-DNFP

RENEWAL CRITERIA (CONTINUED)

**RENEWAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **PEANUT ALLERGEN POWDER-DNFP (Palforzia)** requires the following rule(s) be met for renewal:

- A. You have an allergy to peanuts
- B. Therapy is prescribed by or given in consultation with an allergist/immunologist (allergy/immune system doctor)
- C. Palforzia will be used together with a peanut-avoidance diet
- D. You are not currently on peanut-specific immunotherapy (such as Viaskin Peanut)
- E. You meet ONE of the following:
  - 1. You have a persistent peanut allergy (your peanut allergy has not gone away)
  - 2. If you have undergone a purposeful food challenge: you have documentation of a persistent peanut allergy based on a positive skin prick test (wheal diameter of 3 mm or greater) (skin test to check for peanut allergy) OR peanut-specific immunoglobulin E (IgE level at 0.35 kUA/L or greater) (blood test that indicates an allergy to peanuts) within the past 24 months
  - 3. If you have NOT undergone a purposeful food challenge: you have documentation of a persistent peanut allergy based on a positive skin prick test (wheal diameter of 8 mm or greater) (skin test to check for peanut allergy) OR peanut-specific immunoglobulin E (IgE level at 14 kUA/L or greater) (blood test that indicates an allergy to peanuts) within the past 24 months

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Palforzia.

**REFERENCES**

16. Palforzia [Prescribing Information]. Brisbane, CA: Aimmune Therapeutics, Inc.; January 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/01/20

Created: 02/20

Client Approval: 08/20

P&T Approval: 07/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PEGCETACOPLAN

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
PEGCETACOPLAN	EMPAVELI	47380		GPI-10 (8580406500)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or given in consultation with a hematologist
  - The patient has documented confirmation of PNH by flow cytometry demonstrating ALL of the following:
    - At least 2 different GPI-protein deficiencies (e.g., CD55, CD59) on at least 2 cell lineages (e.g., erythrocytes, granulocytes)
    - PNH granulocyte clone size of 10% or greater
  - The patient is NOT concurrently using C5 complement inhibitor therapy (e.g., Soliris, Ultomiris)
  - The patient has tried and failed Soliris or Ultomiris as evidenced by hemoglobin levels <10.5 g/dL directly following at least 3 months of stable dosing

If yes, **approve for 4 months by HICL or GPI-10 with a quantity limit of #200mL per 30 days.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **PEGCETACOPLAN (Empaveli)** requires the following rule(s) be met for approval:

- A. You have paroxysmal nocturnal hemoglobinuria (PNH: a rare disorder that causes red blood cells break)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or given in consultation with a hematologist (blood specialist)  
**(Initial denial text continued on next page)**

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PEGCETACOPLAN

INITIAL CRITERIA (CONTINUED)

- D. You have documented confirmation of PNH by flow cytometry (type of measurement of physical and chemical qualities of cells) demonstrating ALL of the following:
1. At least 2 different GPI-protein deficiencies (missing a certain type of protein such as CD55, CD59) on at least 2 cell lineages (types of cells such as erythrocytes, granulocytes)
  2. PNH granulocyte clone size of 10% or greater
- E. You have tried and failed Soliris or Ultomiris as evidenced by hemoglobin (type of protein in red blood cells) levels less than 10.5 g/dL, directly following at least 3 months of stable dosing
- F. You are not concurrently (at the same time) using C5 complement inhibitor therapy (such as Soliris, Ultomiris)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) and meet **ALL** of the following criteria?
- The patient had a clinical benefit while on Empaveli (e.g., reduction in number of blood transfusions, improvement/stabilization of lactate dehydrogenase (LDH) or hemoglobin levels) compared to baseline (baseline defined as patient condition post treatment with Soliris or Ultomiris)
  - The patient is NOT concurrently using a C5 complement inhibitor therapy (e.g., Soliris, Ultomiris)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #200mL per 30 days.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **PEGCETACOPLAN (Empaveli)** requires the following rule(s) be met for renewal:

- A. You have paroxysmal nocturnal hemoglobinuria (PNH: a rare disorder that causes red blood cells break)

***(Renewal denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PEGCETACOPLAN

RENEWAL CRITERIA (CONTINUED)

- B. You are not concurrently (at the same time) using a C5 complement inhibitor therapy (such as Soliris, Ultomiris)
- C. You had a clinical benefit while on Empaveli (such as reduction in number of blood transfusions [adding blood to your body], improvement/stabilization of lactate dehydrogenase [LDH: type of enzyme] or hemoglobin levels [type of protein in red blood cells]) compared to baseline (baseline defined as your condition post treatment with Soliris or Ultomiris)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Empaveli.

**REFERENCES**

- Empaveli [Prescribing Information]. Waltham, MA: Apellis Pharmaceuticals, Inc., May 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/24/22

Created: 05/21

Client Approval: 10/22

P&T Approval: 04/22





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PEGFILGRASTIM

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
PEGFILGRASTIM	NEULASTA, NEULASTA ONPRO	23255		GPI-10 (8240157000)	

**GUIDELINES FOR USE**

1. Is the request to increase survival in a patient acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome) **AND** does the patient meet the following criterion?
  - Therapy is prescribed by or in consultation with a hematologist or oncologist

If yes, **approve for 12 months by HICL or GPI-10.**  
If no, continue to #2.
2. Does the patient have a non-myeloid malignancy and meet **ALL** of the following criteria?
  - Therapy is prescribed by or in consultation with a hematologist or oncologist
  - The patient is receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever

If yes, continue to #3.  
If no, do not approve.  
**DENIAL TEXT:** See the denial text at the end of the guideline.
3. Is the request for Neulasta Onpro kit **AND** the patient meets the following criterion?
  - The patient has a barrier to access (e.g., travel barriers, or the patient is unable to return to the clinic for Neulasta injections)

If yes, **approve Neulasta Onpro for 12 months by GPID or GPI-14.**  
If no, continue to #4.
4. Has the patient had a trial of or contraindication to the preferred agent: Nyvepria?
  - If yes, **approve for 12 months by HICL or GPI-10.**  
If no, do not approve.  
**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PEGFILGRASTIM

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **PEGFILGRASTIM (Neulasta, Neulasta Onpro)** requires the following rule(s) be met for approval:

- A. The request is for ONE of the following:
  - 1. Increase survival if you have been acutely exposed to myelosuppressive doses of radiation (radiation that affects your blood and bone marrow)
  - 2. You have a non-myeloid malignancy (cancer not affecting bone marrow)
- B. **If you have a non-myeloid malignancy, approval also requires:**
  - 1. You are receiving myelosuppressive anti-cancer medications associated with a significant incidence of severe neutropenia (medications that affect the bone marrow and cause low levels of a type of white blood cell) with fever
  - 2. You had a trial of or contraindication (harmful for) to the preferred medication: Nyvepria OR your request is for Neulasta Onpro and you have a barrier to access (such as travel barriers, or you are unable to return to the clinic for Neulasta injections)
- C. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (cancer/tumor doctor)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Neulasta.

**REFERENCES**

- Neulasta [Prescribing Information]. Thousand Oaks, CA: Amgen Inc.; March 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/01/22

Created: 08/21

Client Approval: 10/22

P&T Approval: 07/21



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**PEGFILGRASTIM - APGF**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
PEGFILGRASTIM-APGF	NYVEPRIA	46612		GPI-10 (8240157002)	

**GUIDELINES FOR USE**

- Does the patient have a non-myeloid malignancy and meet **ALL** of the following criteria?
  - Therapy is prescribed by or in consultation with a hematologist or oncologist
  - The patient is receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever

If yes, **approve for 12 months by HICL or GPI-10.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **PEGFILGRASTIM - APGF (NYVEPRIA)** requires the following rule(s) be met for approval:

- You have a non-myeloid malignancy (cancer not affecting bone marrow)
- Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (cancer/tumor doctor)
- You are receiving myelosuppressive anti-cancer medications associated with a significant incidence of severe neutropenia (medications that affect the bone marrow and cause low levels of a type of white blood cell) with fever

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Nyvepria.

**REFERENCES**

- Nyvepria [Prescribing Information]. New York, NY: Pfizer; April 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/01/22

Created: 10/22

Client Approval: 10/22

P&T Approval: 07/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PEGFILGRASTIM - BMEZ

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
PEGFILGRASTIM-BMEZ	ZIEXTENZO	46183		GPI-10 (8240157005)	

**GUIDELINES FOR USE**

1. Does the patient have a non-myeloid malignancy and meet **ALL** of the following criteria?
- Therapy is prescribed by or in consultation with a hematologist or oncologist
  - The patient is receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever
  - The patient had a trial of or contraindication to the preferred agent: Nyvepria

If yes, **approve for 12 months by HICL or GPI-10.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **PEGFILGRASTIM - BMEZ (Ziextenzo)** requires the following rule(s) be met for approval:

- A. You have a non-myeloid malignancy (cancer not affecting bone marrow)
- B. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (cancer/tumor doctor)
- C. You are receiving myelosuppressive anti-cancer medications associated with a significant incidence of severe neutropenia (medications that affect the bone marrow and cause low levels of a type of white blood cell) with fever
- D. You had a trial of or contraindication (harmful for) to the preferred medication: Nyvepria

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Ziextenzo.

**REFERENCES**

- Ziextenzo [Prescribing Information]. Princeton, NJ: Sandoz Inc.; March 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/01/22

Created: 10/22

Client Approval: 10/22

P&T Approval: 07/21

Copyright © 2023 MediImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MediImpact. MediImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PEGFILGRASTIM - CBQV

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
PEGFILGRASTIM-CBQV	UDENYCA	45445		GPI-10 (8240157010)	

**GUIDELINES FOR USE**

1. Does the patient have a non-myeloid malignancy and meet **ALL** of the following criteria?
- Therapy is prescribed by or in consultation with a hematologist or oncologist
  - The patient is receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever
  - The patient had a trial of or contraindication to the preferred agent: Nyvepria

If yes, **approve for 12 months by HICL or GPI-10.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **PEGFILGRASTIM - CBQV (Udenyca)** requires the following rule(s) be met for approval:

- A. You have a non-myeloid malignancy (cancer not affecting bone marrow)
- B. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (cancer/tumor doctor)
- C. You are receiving myelosuppressive anti-cancer medications associated with a significant incidence of severe neutropenia (medications that affect the bone marrow and cause low levels of a type of white blood cell) with fever
- D. You had a trial of or contraindication (harmful for) to the preferred medication: Nyvepria

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Udenyca.

**REFERENCES**

- Udenyca [Prescribing Information]. Redwood City, CA: Coherus BioSciences Inc.; May 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/01/22

Created: 10/22

Client Approval: 10/22

P&T Approval: 07/21

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PEGFILGRASTIM-FPGK

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
PEGFILGRASTIM-FPGK	STIMUFEND	48269		GPI-10 (8240157015)	

**GUIDELINES FOR USE**

1. Does the patient have a non-myeloid malignancy and meet **ALL** of the following criteria?
  - Therapy is prescribed by or in consultation with a hematologist or oncologist
  - The patient is receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia
  - The patient had a trial of or contraindication to the preferred agent: Nyvepria

If yes, **approve for 12 months by HICL or GPI-10.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **PEGFILGRASTIM-FPGK (Stimufend)** requires the following rule(s) be met for approval:

- A. You have a non-myeloid malignancy (cancer not affecting bone marrow)
- B. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
- C. You are receiving myelosuppressive anti-cancer medications associated with a clinically significant incidence of neutropenia (medications that affect the bone marrow and cause low levels of a type of white blood cell) with fever
- D. You had a trial of or contraindication (harmful for) to the preferred medication: Nyvepria

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Stimufend.

**REFERENCES**

- Stimufend [Prescribing Information]. Lake Zurich, IL: Fresenius Kabi USA, LLC, September 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/16/23

Created: 12/22

Client Approval: 12/22

P&T Approval: 04/22

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**PEGFILGRASTIM-JMDB**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
PEGFILGRASTIM-JMDB	FULPHILA	45010		GPI-10 (8240157020)	

**GUIDELINES FOR USE**

- Does the patient have a non-myeloid malignancy and meet **ALL** of the following criteria?
  - Therapy is prescribed by or in consultation with a hematologist or oncologist
  - The patient is receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever
  - The patient had a trial of or contraindication to the preferred agent: Nyvepria

If yes, **approve for 12 months by HICL or GPI-10.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **PEGFILGRASTIM - JMDB (Fulphila)** requires the following rule(s) be met for approval:

- You have a non-myeloid malignancy (cancer not affecting bone marrow)
- Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (cancer/tumor doctor)
- You are receiving myelosuppressive anti-cancer medications associated with a significant incidence of severe neutropenia (medications that affect the bone marrow and cause low levels of a type of white blood cell) with fever
- You had a trial of or contraindication (harmful for) to the preferred medication: Nyvepria

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Fulphila.

**REFERENCES**

- Fulphila [Prescribing Information]. Zurich, Switzerland: Mylan GmbH; March 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/01/22

Created: 10/22

Client Approval: 10/22

P&T Approval: 07/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PEGFILGRASTIM-PBBK

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
PEGFILGRASTIM-PBBK	FYLNETRA	48035		GPI-10 (8240157060)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of non-myeloid malignancy and meet **ALL** of the following criteria?

- Therapy is prescribed by or in consultation with a hematologist or oncologist
- The patient is receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever
- The patient had a trial of or contraindication to the preferred agent: Nyvepria

If yes, **approve for 12 months by HICL or GPI-10.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **PEGFILGRASTIM-PBBK (Fylnetra)** requires the following rule(s) be met for approval:

- A. You have a non-myeloid malignancy (cancer not affecting bone marrow)
- B. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
- C. You are receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia (a type of blood condition) with fever
- D. You had a trial of or contraindication (harmful for) to the preferred agent: Nyvepria

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Fylnetra.

**REFERENCES**

- Fylnetra [Prescribing Information]. Bridgewater, NJ: Amneal Pharmaceuticals LLC, May 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/17/22

Created: 10/22

Client Approval: 10/22

P&T Approval: 04/22





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PEG-INTERFERON ALFA-2B

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
PEG-INTERFERON ALFA-2B	SYLATRON, SYLATRON 4-PACK		29809 29811 29812	GPI-10 (2170007520)	

**GUIDELINES FOR USE**

1. Is the patient currently taking the requested medication?

If yes, continue to #2.

If no, continue to #3.

2. Has the patient received 5 years of therapy with Sylatron?

If yes, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

If no, **approve for 12 months by HICL or GPI-10.**

3. Does the patient have a diagnosis of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection?

If yes, **approve for 12 months by HICL or GPI-10.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **PEG-INTERFERON ALFA-2B (Sylatron)** requires the following rule(s) be met for approval:

A. You meet ONE of the following:

1. You are currently taking Sylatron and have NOT received 5 years of treatment with Sylatron
2. You have melanoma (skin cancer) with the presence of cancer cells in your lymph nodes (microscopic or gross nodal involvement), within 84 days of surgical removal of the cancer

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**PEG-INTERFERON ALFA-2B**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Sylatron.

**REFERENCES**

17. Sylatron [Prescribing Information]. Whitehouse Station, NJ: Merck & Co.; August 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/01/20

Created: 05/11

Client Approval: 08/20

P&T Approval: 07/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**PEGINTERFERON ALFA 2A OR 2B (PEGASYS OR PEGINTRON)**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
PEGINTERFERON ALFA-2A	PEGASYS, PEGASYS PROCLICK	24035		GPI-10 (1235306005)	
PEGINTERFERON ALFA-2B	PEGINTRON	21367		GPI-10 (1235306010)	FDB: GCN ≠ 29809, 29811, 29812

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Is the request for Pegasys vial, kit, or syringes?

If yes, continue to #2.

If no, continue to #3.

2. Is the patient being treated for chronic hepatitis B and meet **ALL** of the following criteria?

- The patient is 3 years of age or older
- The medication is prescribed by or given in consultation with a gastroenterologist, infectious disease specialist, a physician specializing in the treatment of hepatitis (e.g., a hepatologist), or a specially trained group such as ECHO (Extension for Community Healthcare Outcomes) model
- The patient does NOT have cirrhosis
- The patient has serum HBeAg positive chronic hepatitis B
- The patient has evidence of viral replication with elevated serum ALT

If yes, **approve for 24 weeks (6 months) by HICL or GPI-10 with a quantity limit of #4 vials/syringes per 28 days.**

If no, continue to #4.

3. Is the request for PegIntron **AND** the patient is between 3 and 11 years old?

If yes, continue to #5.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

4. Is the patient between 3 and 11 years old?

If yes, continue to #5.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PEGINTERFERON ALFA 2A OR 2B (PEGASYS OR PEGINTRON)

INITIAL CRITERIA (CONTINUED)

5. Does the patient meet **ALL** of the following criteria?

- The patient is being treated for chronic hepatitis C and the medication is prescribed by or given in consultation with a gastroenterologist, infectious disease specialist, or a physician specializing in the treatment of hepatitis (e.g., a hepatologist)
- The patient has extrahepatic manifestations of hepatitis C such as cryoglobulinemia, rashes, and glomerulonephritis - as well as advanced fibrosis that requires urgent HCV treatment to minimize future morbidity and mortality
- Peginterferon is being used with ribavirin or patient has a contraindication to ribavirin
- The patient has a detectable pretreatment HCV RNA level/viral load (Varies by lab assay but is a level typically greater than or equal to 25 IU/mL)

If yes, continue to #6.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

6. Is the patient infected with genotype 2 or genotype 3 hepatitis C?

If yes, **approve by HICL or GPI-10 as follows:**

- **For two-drug regimen with ribavirin (peginterferon plus ribavirin only): approve for up to 24 weeks.**

If no, continue to #7.

7. Is the patient infected with genotype 1, 4, 5 or 6 hepatitis C?

If yes, **approve by HICL or GPI-10 as follows:**

- **For two-drug regimen with ribavirin (peginterferon plus ribavirin only): approve for 48 weeks (12 months).**

If no, do not approve.

**INITIAL DENIAL TEXT:** **\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **PEGINTERFERON ALFA-2A or 2B (Pegasys or PegIntron)** requires the following rule(s) be met for approval:

- A. You have chronic hepatitis C genotype 1, 2, 3, 4, 5, or 6 (type of liver inflammation caused by hepatitis C virus). Requests for Pegasys will also be approved for a diagnosis of chronic hepatitis B

**(Initial denial text continued on next page)**

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PEGINTERFERON ALFA 2A OR 2B (PEGASYS OR PEGINTRON)

INITIAL CRITERIA (CONTINUED)

**B. If you have chronic hepatitis B (type of liver inflammation caused by hepatitis B virus), approval also requires:**

1. You are 3 years of age or older
2. The medication is prescribed by or given in consultation with a gastroenterologist (digestive system doctor), infectious disease specialist (a doctor specializing in disorders caused by viruses, bacteria, fungi and parasites), a doctor specializing in the treatment of hepatitis such as a hepatologist (liver doctor), or a specially trained group such as ECHO (Extension for Community Healthcare Outcomes) model
3. You do not have cirrhosis (liver damage)
4. You have tested positive for HBeAg (hepatitis B e-antigen)
5. You have evidence of viral replication (the virus has multiplied in your body) with high serum ALT (high amount of a type of liver enzymes)

**C. If you have chronic hepatitis C (type of liver inflammation caused by hepatitis C virus), approval also requires:**

1. You are between 3 and 11 years old
2. The medication is prescribed by or given in a consultation with a gastroenterologist (digestive system doctor), infectious disease specialist (a doctor specializing in disorders caused by viruses, bacteria, fungi and parasites), or a doctor specializing in the treatment of hepatitis such as a hepatologist (liver doctor)
3. You have other symptoms of hepatitis C (extrahepatic manifestations) such as cryoglobulinemia (abnormal proteins in the blood), rashes, and glomerulonephritis (inflammation in your kidneys) AND you have advanced fibrosis (scar tissue in the liver) that requires urgent treatment to lower your risks of getting worse or dying
4. Peginterferon is being used with ribavirin, unless there is a medical reason why you cannot use ribavirin (contraindication)
5. You have a detectable pretreatment HCV RNA level/viral load (amount of virus in your blood). The level varies by lab assay (test) but is a level typically greater than or equal to 25 IU/mL

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PEGINTERFERON ALFA 2A OR 2B (PEGASYS OR PEGINTRON)

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Is the request for Pegasys and the patient is being treated for hepatitis B?

If yes, **approve for 24 weeks (6 months) by HICL or GPI-10 with a quantity limit of #4 vials/syringes per 28 days.**

If no, continue to #2.

2. Is the request for PegIntron and the patient is being treated for chronic hepatitis C?

If yes, continue to #3.

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

3. Does the patient meet **ONE** of the following criteria?

- The requested medication will be used in combination with ribavirin
- The patient has a contraindication to combination therapy with ribavirin

If yes, continue to #4.

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

4. Does the patient have genotype 1, 4, 5 or 6 hepatitis C?

If yes, **approve by HICL or GPI-10 for up to 32 weeks for a total of 48 weeks of treatment.**

If no, continue to #5.

5. Does the patient have genotype 2 or 3 hepatitis C?

If yes, **approve by HICL or GPI-10 for a maximum total of 24 weeks of treatment.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PEGINTERFERON ALFA 2A OR 2B (PEGASYS OR PEGINTRON)

RENEWAL CRITERIA (CONTINUED)

**RENEWAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **PEGINTERFERON ALFA-2A or 2B (Pegasys or PegIntron)** requires the following rule(s) be met for renewal:

- A. You meet ONE of the following:
  1. The request is for Pegasys and the patient is being treated for hepatitis B
  2. The request is for PegIntron and the patient is being treated for chronic hepatitis C
- B. **If you have chronic hepatitis C, approval also requires:**
  1. The requested medication will be used in combination with ribavirin or you have a medical reason why you cannot (contraindication)
  2. You have genotype 1, 2, 3, 4, 5, or 6 hepatitis C

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Pegasys/Pegintron.

**REFERENCES**

- Pegasys/Pegintron [Prescribing Information]. Princeton, NJ: Bristol-Myers Squibb Company; November 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 02/14

Client Approval: 04/20

P&T Approval: 01/17



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PEGVALIASE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
PEGVALIASE- PQPZ	PALYNZIQ	44944		GPI-10 (3090855040)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of phenylketonuria and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient has uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management, as confirmed by a measurement in the last 30 days
  - The patient has had a previous trial of Kuvan (sapropterin)
  - The patient is not concurrently receiving Kuvan (sapropterin)

If yes, **approve for 6 months by GPID or GPI-14 for all strengths with the following quantity limits:**

- **Palynziq 2.5mg/0.5mL: #1mL (2 syringes) per 7 days.**
- **Palynziq 10mg/0.5mL: #0.5mL (1 syringe) per day.**
- **Palynziq 20mg/mL: #3mL (3 syringes) per day.**

**APPROVAL TEXT:** Renewal requires that the patient has demonstrated a reduction in phenylalanine levels, compared to baseline, by at least 20% or to a level below 600 micromol/L.

If no, do not approve.

**INITIAL DENIAL TEXT:** **\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **PEGVALIASE (Palynziq)** requires the following rules be met for approval:

- A. You have phenylketonuria (PKU) (a type of birth defect that causes buildup of a chemical called phenylalanine)
- B. You are 18 years of age or older
- C. You have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management, as confirmed by a measurement in the last 30 days
- D. You have previously tried Kuvan (sapropterin)
- E. You are NOT receiving Kuvan (sapropterin) at the same time as Palynziq (pegvaliase)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PEGVALIASE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

- Does the patient have a diagnosis of phenylketonuria and meet the following criteria?
  - The patient has demonstrated a reduction in phenylalanine levels, compared to baseline, by at least 20% or to a level below 600 micromol/L

If yes, approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:

- Palynziq 2.5mg/0.5mL: #1mL (2 syringes) per 7 days.
- Palynziq 10mg/0.5mL: #0.5mL (1 syringe) per day.
- Palynziq 20mg/mL: #3mL (3 syringes) per day.

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **PEGVALIASE (Palynziq)** requires the following rules be met for renewal:

- You have a diagnosis of phenylketonuria (PKU: type of birth defect that causes buildup of a chemical called phenylalanine)
- Your phenylalanine levels have dropped by at least 20% from baseline or to a level under 600 micromol/L

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Palynziq.

**REFERENCES**

- Palynziq [Prescribing Information]. Novato, CA: BioMarin Pharmaceutical, Inc.; November 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 12/12/20

Created: 08/18

Client Approval: 12/20

P&T Approval: 07/18



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PEMIGATINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
PEMIGATINIB	PEMAZYRE	46462		GPI-10 (2153226000)	

GUIDELINES FOR USE

1. Does the patient have a diagnosis of unresectable locally advanced or metastatic cholangiocarcinoma and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient has been previously treated for unresectable locally advanced or metastatic cholangiocarcinoma
  - The patient has a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test
  - The patient will complete a comprehensive ophthalmological examination, including optical coherence tomography (OCT), prior to initiation of therapy and at the recommended scheduled intervals

If yes, **approve for 12 months by HICL or GPI-10 for #14 per 21 days.**

If no, continue to #2.

2. Does the patient have a diagnosis of relapsed or refractory myeloid/lymphoid neoplasms (MLNs) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient has a fibroblast growth factor receptor 1 (FGFR1) rearrangement
  - The patient will complete a comprehensive ophthalmological examination, including optical coherence tomography (OCT), prior to initiation of therapy and at the recommended scheduled intervals

If yes, **approve for 12 months by HICL or GPI-10 for #1 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **PEMIGATINIB (Pemazyre)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:

1. Unresectable locally advanced or metastatic cholangiocarcinoma (bile duct cancer that has spread to nearby tissue and lymph nodes and cannot be removed by surgery, or it has spread to other parts of the body)
2. Relapsed or refractory myeloid/lymphoid neoplasms (a type of blood cancer that has returned or did not respond to treatment)

***(Denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PEMIGATINIB

GUIDELINES FOR USE (CONTINUED)

- B. **If you have unresectable locally advanced or metastatic cholangiocarcinoma, approval also requires:**
  1. You are 18 years of age or older
  2. You have previously been treated for unresectable locally advanced or metastatic cholangiocarcinoma
  3. You have a fibroblast growth factor receptor 2 (FGFR2: a type of protein) fusion or other rearrangement as detected by a Food and Drug Administration (FDA)-approved test
  4. You will complete a comprehensive ophthalmological examination (eye exam), including optical coherence tomography (OCT: a type of eye imaging test), before starting the medication and at the recommended scheduled times
- C. **If you have relapsed or refractory myeloid/lymphoid neoplasms, approval also requires:**
  1. You are 18 years of age or older
  2. You have a fibroblast growth factor receptor 1 (FGFR1: a type of protein) rearrangement
  3. You will complete a comprehensive ophthalmological examination (eye exam), including optical coherence tomography (OCT: a type of eye imaging test), before starting the medication and at the recommended scheduled times

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Pemazyre.

**REFERENCES**

- Pemazyre [Prescribing Information]. Wilmington, DE: Incyte Corporation; August 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/23

Created: 07/20

Client Approval: 11/22

P&T Approval: 10/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PENICILLAMINE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
PENICILLAMINE	CUPRIMINE, PENICILLAMINE		7091	GPI-14 (99200030000110)	
PENICILLAMINE	DEPEN, PENICILLAMINE		7100	GPI-14 (99200030000305)	
PENICILLAMINE	D-PENAMINE		7101	GPI-14 (99200030000302)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Is the request for D-Penamamine and the patient has an active prior authorization approval for Depen?  
***[Note: D-Penamamine is temporarily available to address a critical drug shortage of Depen. Patients previously approved for Depen will be allowed access without additional criteria during this shortage.]***

If yes, approve D-Penamamine for 12 months by GPID or GPI-14 for the requested indication as follows:

- **Wilson's Disease: #16 per day.**
- **Active Rheumatoid Arthritis: #12 per day.**
- **Cystinuria: #32 per day.**

If no, continue to #2.

2. Does the patient have a diagnosis of Wilson's disease and meet **ALL** of the following criteria?

- Therapy is prescribed by or in consultation with a hepatologist
- The patient has a Leipzig score  $\geq 4$
- The patient is willing to follow a diet avoiding high copper foods (e.g., shellfish, nuts, chocolate, mushrooms, organ meat)

If yes, continue to #3.

If no, continue to #5..

3. Is the request for Depen or D-Penamamine?

If yes, approve for 12 months by GPID or GPI-14 for the requested drug as follows:

- **Depen: #8 per day.**
- **D-Penamamine: #16 per day.**

If no, continue to #4.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PENICILLAMINE

INITIAL CRITERIA (CONTINUED)

4. Is the request for Cuprimine and the patient had a trial of or contraindication to Depen (penicillamine) or D-Penamamine (penicillamine)?

If yes, **approve Cuprimine for 12 months by GPID or GPI-14 with a quantity limit of #8 per day.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

5. Does the patient have a diagnosis of cystinuria and meet **ALL** of the following criteria?

- Presence of nephrolithiasis and at least ONE of the following:
  - Stone analysis positive for cystine
  - Urinalysis positive for pathognomonic hexagonal cystine crystals
  - Family history of cystinuria with a positive cyanide-nitroprusside screen
- Daily cystine output greater than 300mg per 24 hours following urine cystine excretion testing
- The patient has failed to respond to an adequate trial of conventional therapy which includes ALL of the following (unless contraindicated): increased fluid intake, modest reductions in sodium and protein intake, and urinary alkalization
- Therapy is prescribed by or in consultation with a nephrologist

If yes, continue to #6.

If no, continue to #8.

6. Is the request for Depen or D-Penamamine?

If yes, **approve for 12 months by GPID or GPI-14 for the requested drug as follows:**

- **Depen: #16 per day.**
- **D-Penamamine: #32 per day.**

If no, continue to #7.

7. Is the request for Cuprimine and has the patient had a trial of or contraindication to Depen (penicillamine) or D-Penamamine (penicillamine) **AND** Thiola (tiopronin)?

If yes, **approve Cuprimine for 12 months by GPID or GPI-14 with a quantity of #16 per day.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PENICILLAMINE

INITIAL CRITERIA (CONTINUED)

8. Does the patient have a diagnosis of active rheumatoid arthritis and meet **ALL** of the following criteria?
- Therapy is prescribed by or in consultation with a rheumatologist
  - The patient does not have a history of or other evidence of renal insufficiency
  - The patient has failed to respond to an adequate trial of at least 3 months of conventional therapy including at least ONE of the following DMARD (disease-modifying antirheumatic drug) agents: methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine

If yes, continue to #9.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

9. Is the request for Depen or D-Penaminate?

If yes, **approve for 12 months by GPID or GPI-14 for the requested drug as follows:**

- **Depen: #6 per day.**
- **D-Penaminate: #12 per day.**

If no, continue to #10.

10. Is the request for Cuprimine and has the patient had a trial of or contraindication to Depen (penicillamine) or D-Penaminate (penicillamine)?

If yes, **approve Cuprimine for 12 months by GPID or GPI-14 with a quantity of #6 per day.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **PENICILLAMINE (Cuprimine, Depen, D-Penaminate)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:

1. Wilson's disease (a genetic disorder that leads to copper accumulation in the organs)
2. Cystinuria (a type of genetic metabolic disorder)
3. Active rheumatoid arthritis (a type of joint condition)

**(Initial denial text continued on next page)**

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PENICILLAMINE

INITIAL CRITERIA (CONTINUED)

- B. If you have Wilson's disease, approval also requires:**
1. Therapy is prescribed by or in consultation with a hepatologist (a type of liver doctor)
  2. You have a Leipzig score of 4 or greater (a type of diagnostic score)
  3. You are willing to follow a diet avoiding high copper foods (such as shellfish, nuts, chocolate, mushrooms, organ meat)
  4. If you are requesting Cuprimine, you had a trial or have a contraindication (harmful for) to Depen (penicillamine) or D-Penaminate (penicillamine)
- C. If you have cystinuria, approval also requires:**
1. You have nephrolithiasis (kidney stones) and one (1) or more of the following:
    - a. Kidney stone analysis shows that there is cystine (an amino acid);
    - b. Urine analysis shows there are hexagonal cystine crystals in your urine that are pathognomonic (signs relating to the disease)
    - c. You have a family history of cystinuria with positive tests results in the cyanide-nitroprusside screen (a test to determine the amount of cysteine in your body);
  2. You have a daily cystine output greater than 300mg per 24 hours after a urine cystine excretion testing
  3. You have failed to respond to an adequate trial of conventional therapy which includes ALL of the following, unless there is a medical reason why you cannot (contraindicated):
    - a. Increased fluid intake
    - b. Modest reductions in sodium and protein intake
    - c. Urinary alkalinization (a process that makes urine basic)
  4. Therapy is prescribed by or in consultation with a nephrologist (kidney doctor)
  5. For Cuprimine requests, you must have a trial of or contraindication (harmful for) to Depen (penicillamine) or D-Penaminate (penicillamine) AND Thiola (tiopronin)
- D. If you have active rheumatoid arthritis, approval requires:**
1. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
  2. You do not have a history of or other evidence of renal insufficiency (kidney problems)
  3. You have failed to respond to an adequate trial of at least 3 months of conventional therapy including at least ONE of the following DMARD (disease-modifying antirheumatic drug) agents: methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
  4. If you are requesting Cuprimine, you must have a trial of or contraindication (harmful for) to Depen (penicillamine) or D-Penaminate (penicillamine)
- E. If you have an active prior authorization approval for Depen, D-Penaminate will be approved without meeting additional criteria during the period of Depen shortage.**

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PENICILLAMINE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of Wilson's disease **AND** meet the following criterion?
  - The patient has achieved free serum copper of less than 10 mcg/dL

If yes, **approve for lifetime by GPID or GPI-14 for the requested drug as follows:**

- **Depen: #8 per day.**
- **Cuprimine: #8 per day.**
- **D-Penammine: #16 per day.**

If no, continue to #2.

2. Does the patient have a diagnosis of cystinuria **AND** meet the following criterion?
  - The patient has achieved cystine excretion of less than 200 mg/day

If yes, **approve for lifetime by GPID or GPI-14 for the requested drug as follows:**

- **Depen: #16 per day.**
- **D-Penammine: #32 per day.**
- **Cuprimine: #16 per day.**

If no, continue to #3.

3. Does the patient have a diagnosis of active rheumatoid arthritis and meet **ALL** of the following criteria?
  - The patient does not have a history of or other evidence of renal insufficiency
  - The patient has experienced or maintained improvement in tender joint count or swollen joint count while on therapy compared to baseline

If yes, **approve for lifetime by GPID or GPI-14 for the requested drug as follows:**

- **Depen: #6 per day.**
- **D-Penammine: #12 per day.**
- **Cuprimine: #6 per day.**

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PENICILLAMINE

RENEWAL CRITERIA (CONTINUED)

**RENEWAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **PENICILLAMINE (Cuprimine, Depen, D-Penamime)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following diagnoses:
  1. Wilson's disease (a genetic disorder that leads to copper accumulation in the organs)
  2. Cystinuria (a type of genetic metabolic disorder)
  3. Active rheumatoid arthritis (a type of joint condition)
- B. **If you have Wilson's disease, approval also requires:**
  1. You have achieved free serum copper of less than 10 mcg/dL
- C. **If you have cystinuria, approval also requires:**
  1. You have achieved cystine excretion of less than 200 mg/day
- D. **If you have active rheumatoid arthritis, approval also requires:**
  1. You do not have a history of or other evidence of renal insufficiency (kidney problems)
  2. You have experienced or maintained improvement in tender joint count or swollen joint count while on therapy compared to baseline

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for penicillamine

**REFERENCES**

- Cuprimine [Prescribing Information]. Bridgewater, NJ: Aton Pharma, a Division of Valeant Pharmaceuticals; September 2019.
- Thiola [Prescribing Information]. San Antonio, TX: Mission Pharmacal; June 2019.
- Depen [Prescribing Information]. Somerset, NJ: Meda Pharmaceuticals; January 2019.
- FDA Website: Penicillamine (Depen) Titratable Tablets Drug Shortage. Available at: [https://www.accessdata.fda.gov/scripts/drugshortages/dsp\\_ActiveIngredientDetails.cfm?AI=Penicillamine%20\(Depen\)%20Titratable%20Tablets&st=c](https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Penicillamine%20(Depen)%20Titratable%20Tablets&st=c). Accessed on January 21, 2019

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/23

Created: 05/16

Client Approval: 11/22

P&T Approval: 10/22

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PENTOSAN POLYSULFATE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
PENTOSAN POLYSULFATE SODIUM	ELMIRON	08734		GPI-10 (5650006010)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of interstitial cystitis/bladder pain syndrome ongoing for at least six weeks?

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #3 per day.**

**APPROVAL TEXT:** Renewal requires that the patient has experienced clinical improvement from baseline secondary to treatment.

If no, do not approve.

**INITIAL DENIAL TEXT:** *\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **PENTOSAN POLYSULFATE (Elmiron)** requires the following rule(s) be met for approval:

- A. You have a diagnosis of interstitial cystitis/bladder (painful bladder condition) pain syndrome ongoing for at least six weeks

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RENEWAL CRITERIA**

1. Has the patient experienced clinical improvement from baseline secondary to treatment?

If yes, **approve for lifetime by HICL or GPI-10 with a quantity limit of #3 per day.**

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PENTOSAN POLYSULFATE

RENEWAL CRITERIA (CONTINUED)

**RENEWAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **PENTOSAN POLYSULFATE (Elmiron)** requires the following rule(s) be met for renewal:

A. You have experienced clinical improvement from baseline secondary to treatment

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Elmiron.

**REFERENCES**

- Elmiron [Prescribing Information]. Titusville, New Jersey: Janssen Pharmaceuticals, Inc. September 2018

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/20

Created: 02/20

Client Approval: 02/20

P&T Approval: 01/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PEXIDARTINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
PEXIDARTINIB HYDROCHLORIDE	TURALIO	45912		GPI-10 (2153304501)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of symptomatic tenosynovial giant cell tumor (TGCT) and meet **ALL** of the following criteria?

- TGCT is associated with severe morbidity or functional limitations
- TGCT is NOT amenable to improvement with surgery
- The patient is 18 years of age or older

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **PEXIDARTINIB (Turalio)** requires the following rules be met for approval:

- A. You have symptomatic tenosynovial giant cell tumor (TGCT: type of non-cancerous growth in or around a joint causing tissue damage and reducing function)
- B. TGCT is associated with severe morbidity (disease) or functional limitations
- C. TGCT is NOT responsive to improvement with surgery
- D. You are 18 years of age or older

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Turalio.

**REFERENCES**

- Turalio [Prescribing Information]. Basking Ridge, NJ: Daiichi Sankyo, Inc.; August 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/10/21

Created: 08/19

Client Approval: 03/21

P&T Approval: 07/19



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PHENOXYBENZAMINE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
PHENOXYBENZAMINE HCL	DIBENZYLINE, PHENOXYBENZA -MINE HCL	02098		GPI-10 (3630001010)	FDB: ROUTE = ORAL

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of pheochromocytoma and meet **ALL** of the following criteria?
  - The requested medication is used for the treatment of pheochromocytoma prior to pheochromocytoma resection/removal
  - Therapy is prescribed by or in consultation with an endocrinologist, an endocrine surgeon, or a hematologist - oncologist
  - The patient has had a previous trial of or contraindication to an alpha-1 selective adrenergic receptor blocker (e.g., doxazosin, terazosin, or prazosin)

If yes, **approve for one fill by HICL or GPI-10 with a quantity limit of #10 capsules per day for 21 days.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **PHENOXYBENZAMINE (Dibenzylamine)** requires the following rules be met for approval:

- A. You have pheochromocytoma (tumor in your adrenal gland)
- B. The requested drug is used to treat pheochromocytoma before pheochromocytoma surgery to remove the tumor
- C. The requested drug is prescribed by an endocrinologist (hormone doctor), an endocrine surgeon (surgeon specializing in removal of glands such as adrenal glands), or a hematologist/oncologist (cancer doctor)
- D. You must have tried an alpha-1 selective adrenergic receptor blocker (such as doxazosin, terazosin, or prazosin), unless there is a medical reason why you cannot (contraindication)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**PHENOXYBENZAMINE**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Dibenzylamine.

**REFERENCES**

- Dibenzylamine [Prescribing Information]. Concordia Pharmaceuticals Inc.; February 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 08/18

Client Approval: 04/20

P&T Approval: 07/18



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PILOCARPINE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
PILOCARPINE HCL	VUITY		51425	GPI-14 (86501030102017)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

- Does the patient have a diagnosis of presbyopia and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with an ophthalmologist or optometrist
  - The patient is not using corrective lenses OR corrective lenses are insufficient to completely correct patient's vision
  - The patient had a trial of or contraindication to generic pilocarpine ophthalmic solution

If yes, **approve for 3 months by GPID or GPI-14 with a quantity limit of #5mL per 30 days.**  
If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **PILOCARPINE (Vuity)** requires the following rule(s) be met for approval:

- You have presbyopia (not able to focus on nearby objects)
- You are 18 years of age or older
- Therapy is prescribed by or in consultation with an ophthalmologist (a type of eye doctor) or optometrist (a type of eye doctor)
- You are not using corrective lenses OR corrective lenses are insufficient to completely correct your vision
- You had a trial of or contraindication (harmful for) to generic pilocarpine ophthalmic (eye) solution

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PILOCARPINE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

- 2. Does the patient have a diagnosis of presbyopia and meet **ALL** of the following criteria?
  - The patient is not using corrective lenses OR corrective lenses are insufficient to completely correct patient's vision
  - The patient continues to have benefit from Vuity

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #5mL per 30 days.**  
If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **PILOCARPINE (Vuity)** requires the following rule(s) be met for renewal:

- F. You have presbyopia (not able to focus on nearby objects)
- G. You are not using corrective lenses OR corrective lenses are insufficient to completely correct your vision
- H. You continue to have benefit from Vuity

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Vuity.

**REFERENCES**

- Vuity [Prescribing Information]. North Chicago, IL: AbbVie, Inc.; October 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 03/14/22

Created: 11/21

Client Approval: 02/22

P&T Approval: 10/21





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PIMAVANSERIN

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
PIMAVANSERIN	NUPLAZID	43373		GPI-10 (5940002820)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

- Does the patient have a diagnosis of Parkinson's disease psychosis and meets **ALL** of the following criteria?
  - Patient is 18 years of age or older
  - Medication is prescribed by or given in consultation with a physician specializing in one of the following areas: neurology, geriatric medicine, or behavioral health (such as psychiatrist)

If yes, **approve for 12 months by GPID or GPI-14 for the requested strength with the following quantity limits:**

- Nuplazid 34mg capsules: #30 capsules per 30 days.**
- Nuplazid 17mg tablets: #60 tablets per 30 days.**
- Nuplazid 10mg tablets: #30 tablets per 30 days.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named drug named **PIMAVANSERIN (Nuplazid)** requires you to meet the following rule(s) for approval:

- You have a diagnosis of psychosis associated with Parkinson's disease (a mental disorder that causes you to have false beliefs or to hear or see things that are not really there and is related to a movement disorder)
- You are at least 18 years old; and
- The drug is prescribed by a doctor specializing in one of the following areas: neurology (brain doctor), geriatric medicine (specialty that focuses on health care of elderly people), or behavioral health (such as a psychiatrist).

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PIMAVANSERIN

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

- 1. During the past 12 months of therapy, has the patient experienced an improvement in psychosis symptoms from baseline and demonstrates a continued need for treatment?

If yes, approve for 12 months by GPID or GPI-14 for the requested strength with the following quantity limits:

- Nuplazid 34mg capsules: #30 capsules per 30 days.
- Nuplazid 17mg tablets: #60 tablets per 30 days.
- Nuplazid 10mg tablets: #30 tablets per 30 days.

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **PIMAVANSERIN (Nuplazid)** requires that you have experienced an improvement in psychosis symptoms (mental issues such as false beliefs or hearing or seeing things that are not really there) from baseline during the past 12 months of therapy and you show a continued need for treatment.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Nuplazid.

REFERENCES

- 9. Nuplazid [Prescribing Information]. San Diego, CA. Arcadia Pharmaceuticals Inc.; May 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 04/16

Client Approval: 04/20

P&T Approval: 05/16



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PIRFENIDONE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
PIRFENIDONE	ESBRIET, PIRFENIDONE	40237		GPI-10 (4555006000)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of idiopathic pulmonary fibrosis (IPF) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a pulmonologist
  - The patient does NOT have other known causes of interstitial lung disease (e.g., connective tissue disease, drug toxicity, asbestos or beryllium exposure, hypersensitivity pneumonitis, systemic sclerosis, rheumatoid arthritis, radiation, sarcoidosis, bronchiolitis obliterans organizing pneumonia, human immunodeficiency virus (HIV) infection, viral hepatitis, or cancer)
  - The patient has a usual interstitial pneumonia (UIP) pattern as evidenced by high-resolution computed tomography (HRCT) alone or via a combination of surgical lung biopsy and HRCT
  - The patient has a predicted forced vital capacity (FVC) of at least 50% at baseline
  - The patient does NOT currently smoke cigarettes

If yes, enter two authorizations for a total of 12 months as follows:

**FIRST APPROVAL:** Approve for 1 month by GPID or GPI-14 for all dosage strengths with the following quantity limits:

- 267mg: #9 per day.
- 534mg: #3 per day.
- 801mg: #3 per day.

**SECOND APPROVAL:** Approve for 11 months by HICL or GPI-10 with a quantity limit of #3 per day (enter a start date of 2 days before the end of the first approval).

If no, do not approve.

**INITIAL DENIAL TEXT:** *\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **PIRFENIDONE (Esbriet)** requires the following rule(s) be met for approval:

- A. You have idiopathic pulmonary fibrosis (IPF: a type of lung condition)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a pulmonologist (lung/breathing doctor)  
*(Initial denial text continued on next page)*

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PIRFENIDONE

INITIAL CRITERIA (CONTINUED)

- D. You do NOT have other known causes of interstitial lung disease. Other causes may include connective tissue disease, drug toxicity, asbestos or beryllium exposure, hypersensitivity pneumonitis (type of lung infection), systemic sclerosis (chronic hardening and tightening of the skin and connective tissues), rheumatoid arthritis (a type of joint condition), radiation, sarcoidosis (a type of inflammatory disorder), bronchiolitis obliterans organizing pneumonia (infection affecting the small airways of the lung), human immunodeficiency virus infection (HIV: a type of immune disorder), viral hepatitis (a type of liver inflammation), or cancer
- E. You have a usual interstitial pneumonia (type of lung infection) pattern as evidenced by high-resolution computed tomography (HRCT: type of imaging test) alone or via a combination of surgical lung biopsy (removal of cells or tissue from the body for examination) and HRCT
- F. You have a predicted forced vital capacity (FVC: amount of air exhaled from lungs) of at least 50% at baseline
- G. You do NOT currently smoke cigarettes

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of idiopathic pulmonary fibrosis (IPF) **AND** meet the following criterion?
  - The patient has experienced a clinically meaningful improvement or maintenance in annual rate of decline

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #3 per day.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **PIRFENIDONE (Esbriet)** requires the following rule(s) be met for renewal:

- A. You have idiopathic pulmonary fibrosis (IPF: a type of lung condition)
- B. You have experienced a clinically meaningful improvement or maintenance in annual rate of decline.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**PIRFENIDONE**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Esbriet.

**REFERENCES**

- Esbriet [Prescribing Information]. South San Francisco, CA: Genentech USA, Inc.; February 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/23

Created: 02/15

Client Approval: 11/22

P&T Approval: 10/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PITOLISANT

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
PITOLISANT HCL	WAKIX	45575		GPI-10 (6145007010)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of excessive daytime sleepiness (EDS) with narcolepsy and narcolepsy is confirmed by **ONE** of the following criteria?
  - The patient has a Multiple Sleep Latency Test (MSLT) showing both a mean sleep latency of 8 minutes or less **AND** 2 or more early-onset rapid eye movement (REM) sleep test periods (SOREMPs)
  - The patient has a Multiple Sleep Latency Test (MSLT) showing both a mean sleep latency of 8 minutes or less **AND** one early-onset rapid eye movement (REM) sleep test period (SOREMP) **AND** additionally one SOREMP (within approximately 15 minutes) on a polysomnography the night preceding the MSLT, with the polysomnography ruling out non-narcolepsy causes of excessive daytime sleepiness (EDS)
  - The patient has low orexin/hypocretin levels on a cerebrospinal fluid (CSF) assay

If yes, continue to #2.

If no, continue to #3.

2. Does the patient meet **ALL** of the following criteria?
  - The patient has excessive daytime sleepiness (EDS) persisting for at least 3 months and Epworth Sleepiness Scale (ESS) score of more than 10
  - Therapy is prescribed by or in consultation with a neurologist, psychiatrist, or specialist in sleep medicine
  - The patient had a trial of or contraindication to one generic typical stimulant (e.g., amphetamine sulfate, methylphenidate, etc.) **AND** solriamfetol, armodafinil, or modafinil

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #2 per day.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PITOLISANT

INITIAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of cataplexy with narcolepsy and meet **ALL** of the following criteria?

- Therapy is prescribed by or in consultation with a neurologist, psychiatrist, or specialist in sleep medicine
- The patient has tried **TWO** of the following: venlafaxine, fluoxetine or a TCA (e.g., clomipramine, imipramine)

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #2 per day.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **PITOLISANT (Wakix)** requires the following rule(s) be met for approval:

A. You have one of the following:

1. Excessive daytime sleepiness (EDS) with narcolepsy (sleep disorder with extreme drowsiness)
2. Narcolepsy as demonstrated by cataplexy (sleep disorder with extreme drowsiness with sudden and uncontrollable muscle weakness)

B. **If you have excessive daytime sleepiness with narcolepsy, approval also requires:**

1. You have narcolepsy that is confirmed by **ONE** of the following:
  - a. A Multiple Sleep Latency Test showing a both an average sleep latency of 8 minutes or less **AND** 2 or more early-onset rapid eye movement (REM) sleep test periods
  - b. A Multiple Sleep Latency Test (MSLT) showing both an average sleep latency of 8 minutes or less **AND** one early-onset rapid eye movement (REM) sleep test period (SOREMP) **AND** additionally one SOREMP (within approximately 15 minutes) on a polysomnography (type of sleep test) the night preceding the MSLT, with the polysomnography ruling out non-narcolepsy causes of excessive daytime sleepiness
  - c. You have low orexin/hypocretin levels on a cerebrospinal fluid (CSF) assay (test showing you have low levels of a chemical that helps with staying awake)
2. You have excessive daytime sleepiness (EDS) lasting for at least 3 months and Epworth Sleepiness Scale (type of sleepiness test) score of more than 10
3. Therapy is prescribed by or in consultation with a neurologist (nerve doctor), psychiatrist (mental health doctor), or specialist in sleep medicine
4. You had a trial of one generic typical stimulant (such as amphetamine sulfate, methylphenidate, etc.) **AND** solriamfetol, armodafinil, or modafinil, unless there is a medical reason why you cannot (contraindication)

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PITOLISANT

INITIAL CRITERIA (CONTINUED)

**C. If you have cataplexy with narcolepsy, approval also requires:**

1. Wakix is prescribed by or in consultation with a neurologist (nerve doctor), psychiatrist (mental health doctor), or specialist in sleep medicine
2. You have tried TWO of the following: venlafaxine, fluoxetine, or a TCA (tricyclic antidepressant such as clomipramine, imipramine)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of excessive daytime sleepiness (EDS) with narcolepsy or cataplexy with narcolepsy and meet **ONE** of the following criteria?
  - The patient has demonstrated 25% or more improvement in Epworth Sleepiness Scale (ESS) scores compared to baseline
  - The patient has shown improvement in cataplexy symptoms compared to baseline
  - The patient has demonstrated improvement in sleep latency from baseline

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **PITOLISANT (Wakix)** requires the following rule(s) be met for renewal:

A. You have ONE of the following:

1. Excessive daytime sleepiness (EDS) with narcolepsy (sleep disorder with extreme drowsiness)
2. Narcolepsy as demonstrated by cataplexy (sleep disorder with extreme drowsiness with sudden and uncontrollable muscle weakness)

B. You meet ONE of the following:

1. You have demonstrated 25% or more improvement in Epworth Sleepiness Scale (type of sleepiness test) scores compared to baseline
2. You have shown improvement in cataplexy (sudden and uncontrollable muscle weakness) symptoms compared to baseline
3. You have demonstrated improvement in sleep latency (the amount of time it takes to fall asleep) from baseline

***(Renewal denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PITOLISANT

RENEWAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Wakix.

REFERENCES

- Wakix [Prescribing Information]. Plymouth Meeting, PA: Harmony Biosciences, LLC; October 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/23

Created: 10/19

Client Approval: 11/22

P&T Approval: 10/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PLASMINOGEN

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
PLASMINOGEN HUMAN-TVMH	RYPLAZIM	47437		GPI-10 (8540005070)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of plasminogen deficiency type 1 (hypoplasminogenemia)?

If yes, **approve for 12 months by HICL or GPI-10.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **PLASMINOGEN (Ryplazim)** requires the following rule(s) be met for approval:

A. You have a diagnosis of plasminogen deficiency type 1 (hypoplasminogenemia: a type of genetic condition)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Ryplazim.

**REFERENCES**

- Ryplazim [Prescribing Information]. Laval, Quebec, Canada: Prometic Bioproduction, Inc.; June 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/22

Created: 01/22

Client Approval: 02/22

P&T Approval: 01/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

POMALIDOMIDE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
POMALIDOMIDE	POMALYST	39996		GPI-10 (2145008000)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of multiple myeloma (MM) and meet ALL of the following criteria?
  - The patient is 18 years of age or older
  - The requested medication will be used in combination with dexamethasone
  - The patient has received at least two prior therapies including Revlimid (lenalidomide) and a proteasome inhibitor (e.g., Velcade [bortezomib], Kyprolis [carfilzomib], or Ninlaro [ixazomib])

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #21 per 28 days.**  
If no, continue to #2.

2. Does the patient have a diagnosis of Kaposi sarcoma (KS) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient meets ONE of the following criteria:
    - The patient has AIDS-related Kaposi sarcoma after failing highly active antiretroviral therapy (HAART)
    - The patient is HIV-negative

If yes, **approve for 12 months by HICL or GPI-10.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **POMALIDOMIDE (Pomalyst)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
  1. Multiple myeloma (MM: cancer that forms in your white blood cells)
  2. Kaposi sarcoma (KS: cancer that forms from the cells in your lymph or blood vessels)
- B. **If you have multiple myeloma, approval also requires:**
  1. You are 18 years of age or older
  2. The requested medication is used in combination with dexamethasone
  3. You have tried at least two drugs including Revlimid (lenalidomide) and a proteasome inhibitor (type of cancer drug such as Velcade [bortezomib], Kyprolis [carfilzomib], or Ninlaro [ixazomib])

***(Denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

POMALIDOMIDE

GUIDELINES FOR USE (CONTINUED)

C. If you have Kaposi sarcoma, approval also requires:

1. You are 18 years of age or older
2. You meet ONE of the following:
  - a. You have acquired immunodeficiency syndrome (AIDS)-related Kaposi sarcoma after failing highly active antiretroviral therapy (HAART: medications used to treat human immunodeficiency virus [HIV])
  - b. You are human immunodeficiency virus (HIV)-negative

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Pomalyst.

**REFERENCES**

- Pomalyst [Prescribing Information]. Summit, NJ: Celgene Corporation; May 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 02/13

Client Approval: 06/20

P&T Approval: 07/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PONATINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
PONATINIB HCL	ICLUSIG	39859		GPI-10 (2153187510)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of chronic myeloid leukemia (CML) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient had a mutational analysis prior to initiation AND Iclusig is appropriate per the NCCN guideline table for treatment recommendations based on BCR-ABL1 mutation profile (*Please see header CML-5 of the current NCCN guidelines*)

If yes, continue to #2.  
If no, continue to #5.

2. Does the patient have T315I-positive CML (chronic phase, accelerated phase, or blast phase)?

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**  
If no, continue to #3.

3. Does the patient have chronic phase (CP) chronic myeloid leukemia (CML) **AND** meet the following criterion?
  - The patient has a resistance or intolerance to at least TWO prior kinase inhibitors [e.g., Tassigna (nilotinib), Sprycel (dasatinib), Bosulif (bosutinib), Gleevec (imatinib)]

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**  
If no, continue to #4.

4. Does the patient have accelerated phase (AP) or blast phase (BP) chronic myeloid leukemia (CML) **AND** meet the following criterion?
  - There are no other kinase inhibitors [e.g., Tassigna (nilotinib), Sprycel (dasatinib), Bosulif (bosutinib), Gleevec (imatinib)] indicated for the patient

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**  
If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PONATINIB

GUIDELINES FOR USE (CONTINUED)

5. Does the patient have a diagnosis of Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient meets **ONE** of the following:
  - The patient's cancer is positive for the T315I mutation
  - There are no other kinase inhibitors [e.g., Tassigna (nilotinib), Sprycel (dasatinib), Bosulif (bosutinib), Gleevec (imatinib)] indicated for the patient

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **PONATINIB (Iclusig)** requires the following rule(s) be met for approval:

A. You have **ONE** of the following diagnoses:

1. Chronic myeloid leukemia (CML: type of blood-cell cancer that begins in the bone marrow)
2. Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) (type of white blood cell cancer)

B. You are 18 years of age or older

C. **If you have chronic myeloid leukemia, approval also requires:**

1. You had a mutational analysis prior to initiation of therapy **AND** Iclusig is appropriate per the National Comprehensive Cancer Network (NCCN) guideline table for treatment recommendations based on BCR-ABL1 mutation (breakpoint cluster region-Abelson murine leukemia 1; a type of abnormal gene) profile
2. You meet **ONE** of the following:
  - a. You have T315I-positive (a genetic mutation) CML (chronic phase, accelerated phase, or blast phase)
  - b. You have chronic phase CML **AND** have a resistance to or are not able to safely use at least **TWO** prior kinase inhibitor treatments such as Tassigna (nilotinib), Sprycel (dasatinib), Bosulif (bosutinib), Gleevec (imatinib)
  - c. You have accelerated phase or blast phase CML **AND** there are no other kinase inhibitors, such as Tassigna (nilotinib), Sprycel (dasatinib), Bosulif (bosutinib), Gleevec (imatinib), that can be used for your disease

D. **If you have Philadelphia chromosome positive acute lymphoblastic leukemia, approval also requires you meet ONE of the following:**

1. Your cancer is positive for the T315I mutation (a type of abnormal gene)
2. There are no other kinase inhibitors [e.g., Tassigna (nilotinib), Sprycel (dasatinib), Bosulif (bosutinib), Gleevec (imatinib)] indicated for the patient

***(Denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PONATINIB

**GUIDELINES FOR USE (CONTINUED)**

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Iclusig.

**REFERENCES**

- Iclusig [Prescribing Information]. Cambridge, MA: ARIAD Pharmaceuticals, Inc.; December 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/22

Created: 01/13

Client Approval: 02/22

P&T Approval: 04/21





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PONESIMOD

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
PONESIMOD	PONVORY	47221		GPI-10 (6240706000)	

GUIDELINES FOR USE

1. Does the patient have a diagnosis of a relapsing form of multiple sclerosis (MS), including clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease, **AND** meet the following criteria?
  - The patient is 18 years of age or older
  - The patient had a trial and failure of ONE sphingosine-1-phosphate receptor modulator (e.g., Gilenya, Mayzent) **AND** ONE other agent indicated for the treatment of MS

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **PONESIMOD (Ponvory)** requires the following rule(s) be met for approval:

- A. You have a relapsing form of multiple sclerosis (type of disease where body attacks its own nerves and symptoms return after treatment) to include clinically isolated syndrome (occurs once), relapsing-remitting disease (periods of symptoms and no symptoms), and active secondary progressive disease (advanced disease)
- B. You are 18 years of age or older
- C. You had a trial of one sphingosine-1-phosphate receptor modulator (such as Gilenya or Mayzent) **AND** one other agent indicated for the treatment of multiple sclerosis (**Please note:** Other multiple sclerosis agents may also require prior authorization)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Ponvory.

**REFERENCES**

- Ponvory [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; March 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/10/21

Created: 03/21

Client Approval: 03/21

P&T Approval: 01/21

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

POSACONAZOLE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
POSACONAZOLE	NOXAFIL, POSACONAZOLE	33461		GPI-10 (1140706000)	ROUTE = ORAL

**GUIDELINES FOR USE**

1. Is the request for continuation of therapy after the patient was started on posaconazole in the hospital?

If yes, **approve for 6 months by GPID or GPI-14.**

If no, continue to #2.

2. Is the request for the treatment of invasive aspergillosis and the patient meets **ALL** of the following criteria?

- The patient is 13 years of age or older
- The request is for posaconazole (Noxafil) tablets

If yes, **approve for 12 weeks by GPID or GPI-14.**

If no, continue to #3.

3. Is the request for prophylaxis of invasive aspergillus or candida infections **AND** the patient meets the following criterion?

- The patient is at high risk of developing these infections due to being severely immunocompromised, such as HSCT recipients with GVHD or has a hematologic malignancy with prolonged neutropenia from chemotherapy

If yes, continue to #4.

If no, continue to #7.

4. Is the request for posaconazole (Noxafil) tablets and the patient meets **ONE** of following criteria?

- The patient is 18 years of age or older
- The patient is 2 years of age or older AND weighs greater than 40 kg

If yes, **approve for 6 months by GPID or GPI-14.**

If no, continue to #5.

5. Is the request for posaconazole (Noxafil) oral suspension and the patient meets **ALL** of the following criteria?

- The patient is 13 years of age or older
- The patient is unable to swallow tablets

If yes, **approve for 6 months by GPID or GPI-14.**

If no, continue to #6.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

POSACONAZOLE

GUIDELINES FOR USE (CONTINUED)

6. Is the request for posaconazole (Noxafil) PowderMix and the patient meets **ALL** of the following criteria?

- The patient is 2 to less than 18 years of age AND weighs less than 40 kg
- The patient is unable to swallow tablets

If yes, **approve for 6 months by GPID or GPI-14.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

7. Does the patient have a diagnosis of oropharyngeal candidiasis (OPC) and meet **ALL** of the following criteria?

- The patient is 13 years of age or older
- The patient had a trial of or contraindication to fluconazole OR itraconazole
- The request is for posaconazole (Noxafil) oral suspension

If yes, **approve for 3 months by GPID or GPI-14.**

If no, continue to #8.

8. Does the patient have a diagnosis of esophageal candidiasis and meet **ALL** of the following criteria?

- The patient is 13 years of age or older
- The patient had a trial and failure of or contraindication to two of the following: fluconazole, itraconazole solution, or voriconazole

If yes, **approve for 3 months by GPID or GPI-14.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **POSACONAZOLE (Noxafil)** requires the following rule(s) be met for approval:

A. The request is for ONE of the following:

1. Continuation of therapy after hospital discharge
2. Treatment of invasive aspergillosis (type of fungal infection)
3. Prophylaxis (prevention) of invasive aspergillus or candida infections (types of fungal infection)
4. Oropharyngeal candidiasis (fungal infection of the throat)
5. Esophageal candidiasis (fungal infection in the tube connecting the throat and stomach)

***(Denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

POSACONAZOLE

GUIDELINES FOR USE (CONTINUED)

- B. If the request is for treatment of invasive aspergillosis, approval also requires:**
1. You are 13 years of age or older
  2. You are requesting Noxafil (posaconazole) tablets
- C. If the request is for prophylaxis of invasive aspergillus or candida infections, approval also requires:**
1. You are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplantation (HSCT: bone marrow transplant) recipient with graft versus host disease (GVHD: a type of immune disorder) or you have hematologic malignancies (cancer affecting the blood) with prolonged neutropenia (low levels of a type of white blood cell) from chemotherapy (cancer treatment)
  2. If the request is for posaconazole (Noxafil) tablets, you meet ONE of the following:  
You are 18 years of age or older  
You are 2 years of age or older AND weigh greater than 40 kg
  3. If the request is for posaconazole (Noxafil) suspension, you meet ALL of the following:  
You are 13 years of age or older  
You are unable to swallow tablets
  4. If the request is for posaconazole (Noxafil) PowderMix, you meet the following:  
You are 2 to 18 years of age AND weigh less than 40 kg  
You are unable to swallow tablets
- D. If the request is for oropharyngeal candidiasis, approval also requires:**
1. You are 13 years of age or older
  2. You had a trial of or contraindication (harmful for) to fluconazole OR itraconazole
  3. You are requesting Noxafil (posaconazole) oral suspension
- E. If the request is for esophageal candidiasis, approval also requires:**
1. You are 13 years of age or older
  2. You had a trial and failure of or contraindication (harmful for) to TWO of the following:  
fluconazole, itraconazole solution, or voriconazole

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**POSACONAZOLE**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Noxafil.

**REFERENCES**

- Noxafil [Prescribing Information]. Whitehouse Station, NJ: Merck & Co., Inc.; January 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/23

Created: 11/07

Client Approval: 11/22

P&T Approval: 10/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**PRALSETINIB**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
PRALSETINIB	GAVRETO	46818		GPI-10 (2153575000)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of metastatic non-small cell lung cancer (NSCLC) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient has a *RET* fusion-positive tumor as detected by an FDA-approved test

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**  
If no, continue to #2.

2. Does the patient have a diagnosis of advanced or metastatic medullary thyroid cancer (MTC) and meet **ALL** of the following criteria?
  - The patient is 12 years of age or older
  - The patient has a *RET*-mutant tumor
  - The patient requires systemic therapy

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**  
If no, continue to #3.

3. Does the patient have a diagnosis of advanced or metastatic thyroid cancer and meet **ALL** of the following criteria?
  - The patient is 12 years of age or older
  - The patient has a *RET* fusion-positive tumor
  - The patient requires systemic therapy
  - The patient is radioactive iodine-refractory (if radioactive iodine is appropriate)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**  
If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PRALSETINIB

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **PRALSETINIB (Gavreto)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
  1. Metastatic non-small cell lung cancer (NSCLC: type of lung cancer that has spread to other parts of the body)
  2. Advanced or metastatic medullary thyroid cancer (MTC: thyroid cancer that started in the center of the thyroid and has spread to other parts of the body)
  3. Advanced or metastatic thyroid cancer (thyroid cancer that has spread to other parts of the body)
- B. **If you have metastatic non-small cell lung cancer, approval also requires:**
  1. You are 18 years of age or older
  2. You have a rearranged during transfection (*RET*: type of gene) fusion-positive tumor that has been detected by an Food and Drug Administration (FDA)-approved test
- C. **If you have advanced or metastatic medullary thyroid cancer, approval also requires:**
  1. You are 12 years of age or older
  2. You have a rearranged during transfection (*RET*: type of gene) mutant tumor
  3. You need systemic therapy (medicine that goes into the entire body)
- D. **If you have advanced or metastatic thyroid cancer, approval also requires:**
  1. You are 12 years of age or older
  2. You have a rearranged during transfection (*RET*: type of gene) fusion-positive tumor
  3. You need systemic therapy (medicine that goes into the entire body)
  4. You have received treatment with radioactive iodine, and it did not work or is no longer working (if radioactive iodine is appropriate)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Gavreto.

**REFERENCES**

- Gavreto [Prescribing Information]. Cambridge, MA: Blueprint Medicines Corporation; December 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Created: 10/20

Commercial Effective: 04/10/21

Client Approval: 12/20

P&T Approval: 01/21

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PREDNISONE DELAYED-RELEASE TABS

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
PREDNISONE	RAYOS		33097 33098 33099	GPI-14 (22100045000610) GPI-14 (22100045000620) GPI-14 (22100045000630)	

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

- Is the request for an FDA approved indication and the patient meets **ALL** of the following criteria?
  - The patient had a previous trial of or contraindication to **ONE** of the following: generic prednisone, prednisolone, or methylprednisolone
  - The patient had a subclinical response or treatment failure of generic prednisone, prednisolone, or methylprednisolone

If yes, **approve for 6 months by GPID or GPI-14 for the requested strength.**

**APPROVAL TEXT:** Renewal requires the patient has a clinical benefit from using Rayos (e.g., improvement in inflammatory condition from baseline) and cannot be tapered off corticosteroid (i.e., Rayos).

If no, do not approve.

**INITIAL DENIAL TEXT:** *\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **PREDNISONE DELAYED-RELEASE TABS (Rayos)** requires the following rule(s) be met for approval:

- The request is for a Food and Drug Administration-approved indication
- You had a previous trial of **ONE** of the following, unless there is a medical reason why you cannot (contraindication): generic prednisone, prednisolone, or methylprednisolone
- You have had a subclinical response (not a full response) or treatment failure of generic prednisone, prednisolone, or methylprednisolone

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PREDNISONE DELAYED-RELEASE TABS

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

- Is the request for an FDA approved indication and the patient meets **ALL** of the following criteria?
  - The patient has clinical benefit from using Rayos (e.g., improvement in inflammatory condition from baseline)
  - The patient cannot be tapered off corticosteroid (i.e., Rayos)

If yes, **approve for 6 months by GPID or GPI-14 for the requested strength.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **PREDNISONE DELAYED-RELEASE TABS (Rayos)** requires the following rule(s) be met for renewal approval:

- The request is for a Food and Drug Administration-approved indication
- You have had a clinical benefit from using Rayos (such as improvement in inflammatory condition from baseline)
- You cannot be tapered off (slowly lowering the dose to stop use) corticosteroid (Rayos)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Rayos.

**REFERENCES**

- Rayos [Prescribing Information]. Lake Forest, IL: Horizon Pharma USA, Inc., January 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 08/19

Client Approval: 04/20

P&T Approval: 07/19



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PRE-EXPOSURE PROPHYLAXIS ZERO COST SHARE OVERRIDE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE	TRUVADA, EMTRICITABINE/ TENOFOVIR DISOPROXIL FUMARATE		23152	GPI-14 (12109902300320)	
EMTRICITABINE/TENOFOVIR ALAFENAMIDE FUMARATE	DESCOVY		40953	GPI-14 (12109902290320)	
TENOFOVIR DISOPROXIL FUMARATE	VIREAD, TENOFOVIR DISOPROXIL FUMARATE		14822	GPI-14 (12108570100320)	
EMTRICITABINE	EMTRIVA, EMTRICITABINE		20019	GPI-14 (12106030000120)	
CABOTEGRAVIR	APRETUDE	47270		GPI-10 (1210301000)	

**GUIDELINES FOR USE**

1. Is the patient requesting a cost share exception for the requested pre-exposure prophylaxis (PrEP) agent **AND** does the plan cover these agents at zero cost share (i.e., the plan follows Affordable Care Act [ACA] recommendations and is linked to MedImpact's Essential Health Benefit Tables)?

If yes, continue to #2.

If no, guideline does not apply.

2. Does the patient's plan have specific procedures, instructions, and/or policies for cost share exception processes or for multi-source brand agent overrides (DAW1 override)?

If yes, guideline does not apply.

If no, continue to #3.

3. Does the patient meet **ALL** of the following criteria?

- The requested agent is FDA-approved for PrEP or recommended by the CDC PrEP Guidelines
- The requested agent is being used for PrEP regardless of HIV medication use history (e.g., patient has a history of post-exposure prophylaxis (PEP) medication use)

If yes, continue to #4.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PRE-EXPOSURE PROPHYLAXIS ZERO COST SHARE OVERRIDE

GUIDELINES FOR USE (CONTINUED)

4. Is the request for a generic agent?

If yes, **approve for 12 months for the requested agent by GPID or GPI-14 at zero copay as follows:**

- **Emtricitabine/tenofovir disoproxil fumarate: #1 per day.**
- **Tenofovir disoproxil fumarate: #1 per day.**
- **Emtricitabine: #1 per day.**

If no, continue to #5.

5. Is the request for **ONE** of the following?

- A single-source brand (SSB) PrEP agent that has no preferred generic agents or therapeutically equivalent products available
- A multi-source brand (MSB) agent

If yes, continue to #6.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

6. Does the patient meet **ONE** of the following criteria?

- Two preferred medications are medically inappropriate for the patient (one if only one agent is available)
- The patient has tried or has a documented medical contraindication to two preferred medications (one if only one agent is available)
- The prescriber provided documentation confirming that the requested drug is considered medically necessary (considerations may include severity of side effects and ability to adhere to the appropriate use of the item or service)

If yes, **approve for 12 months for the requested agent by GPID or GPI-14 at zero copay as follows:**

- **Truvada: #1 per day.**
- **Descovy: #1 per day.**
- **Viread: #1 per day.**
- **Emtriva: #1 per day.**
- **Apretude: #24mL per 12 months.**

**APPROVAL TEXT (applicable to multi-source brand agents only):** Although your cost share has been reduced to zero-dollar, you may incur a dispense-as-written (DAW) penalty fee if you choose to fill a brand prescription instead of its generic equivalent.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PRE-EXPOSURE PROPHYLAXIS ZERO COST SHARE OVERRIDE

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **PRE-EXPOSURE PROPHYLAXIS ZERO COST SHARE OVERRIDE** requires the following rule(s) be met for approval:

- A. Your request is for ONE of the following:
  - 1. A generic agent
  - 2. A single-source brand (SSB) agent that has no preferred generic agents or therapeutically equivalent products available
  - 3. A multi-source brand (MSB) agent
- B. The requested medication is FDA (Food and Drug Administration)-approved for pre-exposure prophylaxis (PrEP) or recommended by the CDC (Centers for Disease Control and Prevention) PrEP Guidelines
- C. You are using the medication for PrEP regardless of your human immunodeficiency virus (HIV) medication use history (such as you have a history of post-exposure prophylaxis medication use)
- D. **If the request is for a single-source brand or multi-source brand medication, approval also requires you meet ONE of the following:**
  - 1. Two preferred medications are medically inappropriate for you (or one if only one agent is available)
  - 2. You have tried or have a documented medical contraindication (harmful for) to two preferred medications (or one if only one agent is available)
  - 3. Your doctor has provided documentation confirming that the requested drug is considered medically necessary for you (considerations may include severity of side effects and ability to adhere to appropriate use)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**PRE-EXPOSURE PROPHYLAXIS ZERO COST SHARE OVERRIDE**

**RATIONALE**

This guideline applies to plans where the pharmacy benefit allows for coverage of pre-exposure prophylaxis (PrEP) medications at zero copay. The override criteria allow patient access to all FDA-approved PrEP medications at zero copay by waiving the applicable cost-sharing for branded or non-preferred branded PrEP medications.

For further information, please refer to the Prescribing Information and/or Drug Monograph for Pre-Exposure Prophylaxis (PrEP) agents listed.

**REFERENCES**

- U.S. Department of Labor. Affordable Care Act Implementation Frequently Asked Questions. Available at: <https://www.dol.gov/agencies/ebsa/laws-and-regulations/laws/affordable-care-act/for-employers-and-advisers/aca-implementation-faqs>. Accessed May 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/22

Created: 05/20

Client Approval: 05/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PYRIMETHAMINE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
PYRIMETHAMINE	DARAPRIM		42930	GPI-10 (1300004000)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Is the patient being treated for acute toxoplasmosis **AND** meets the following criterion?
  - The medication is prescribed by or given in consultation with an infectious disease specialist

If yes, **approve for 6 weeks by GPID or GPI-10. Please enter two authorizations as follows:**

- **Approve one fill for #8 per day.**
- **Approve for 6 weeks with a quantity limit of #3 per day.**

**APPROVAL TEXT:** Renewal requires that the patient has persistent clinical disease (headache, neurological symptoms, or fever) and persistent radiographic disease (one or more mass lesions on brain imaging).

If no, continue to #2.

2. Is the patient being treated for chronic maintenance of toxoplasmosis and meets **ALL** of the following criteria?
  - The patient is infected with human immunodeficiency virus (HIV)
  - The patient has successfully completed treatment for acute toxoplasmosis for at least 6 weeks treatment duration
  - The medication is prescribed by or given in consultation with an infectious disease specialist

If yes, **approve for 6 months by GPID or GPI-10 with a quantity limit of #2 per day.**

**APPROVAL TEXT:** Renewal requires that the patient's CD4 count is less than 200 cells/mm(3) and the patient is currently taking ART (anti-retroviral therapy).

If no, continue to #3.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PYRIMETHAMINE

INITIAL CRITERIA (CONTINUED)

3. Is the patient being treated for primary prophylaxis of toxoplasmosis and meets **ALL** of the following criteria?

- The patient is infected with human immunodeficiency virus (HIV)
- The medication is prescribed by or given in consultation with an infectious disease specialist
- The patient had a previous trial of or contraindication to Bactrim (SMX/TMP)
- The patient is positive for *Toxoplasma gondii* IgG
- The patient has a CD4 count of less than 100 cells/mm(3)

If yes, **approve for 6 months by GPID or GPI-10 with a quantity limit of #3 per day.**

**APPROVAL TEXT:** Renewal requires that the patient's CD4 count is less than 200 cells/mm(3) and the patient is currently taking ART (anti-retroviral therapy).

If no, continue to #4.

4. Does the patient have a diagnosis of congenital toxoplasmosis **AND** meet the following criterion?

- The medication is prescribed by or given in consultation with a neonatologist or pediatric infectious disease specialist

If yes, **approve for 12 months by GPID or GPI-10.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline for **PYRIMETHAMINE (Daraprim)** requires the following rule(s) be met for approval:

A. The request is ONE of the following:

1. Acute treatment of toxoplasmosis (sudden and severe type of parasite infection)
2. Chronic maintenance therapy for toxoplasmosis
3. Primary prophylaxis of toxoplasmosis (prevention of a type of parasite infection)
4. Congenital toxoplasmosis (the infection was passed on to you as a baby from your mother)

B. **If you are being treated for acute toxoplasmosis, approval also requires:**

1. The medication is prescribed by or given in consultation with an infectious disease specialist (doctor that specializes in treating infections)

**(Initial denial text continued on next page)**

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PYRIMETHAMINE

INITIAL CRITERIA (CONTINUED)

- C. **If you are being treated for chronic maintenance for toxoplasmosis, approval also requires:**
1. You are also infected with human immunodeficiency virus (HIV: a virus that weakens your immune system with a parasite infection)
  2. You have successfully completed treatment for acute toxoplasmosis for at least 6 weeks treatment duration
  3. The medication is prescribed by or given in consultation with an infectious disease specialist (doctor that specializes in treating infections)
- D. **If you are being treated for primary prophylaxis of toxoplasmosis, approval also requires:**
1. You are also infected with human immunodeficiency virus (HIV)
  2. The medication is prescribed by or given in consultation with an infectious disease specialist (doctor that specializes in treating infections)
  3. You had a previous trial of Bactrim (sulfamethoxazole and trimethoprim), unless there is a medication reason why cannot (contraindication)
  4. You tested positive for *Toxoplasma gondii* (a type of parasite) Immunoglobulins (IgG) (i.e., you had a current or past infection with *Toxoplasma gondii*)
  5. Your CD4 count (an indicator of how weak your immune system is) is less than 100 cells/mm(3)
- E. **If you have congenital toxoplasmosis, approval also requires:**
1. The medication is prescribed by or given in consultation with a neonatologist (doctor that specializes in sick and premature newborn infants) or pediatric (children and adolescents) infectious disease specialist

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

**NOTE:** For the diagnosis of congenital toxoplasmosis, please refer to Initial Criteria section.

1. Is the patient being treated for acute toxoplasmosis **AND** meets the following criterion?
  - The patient has persistent clinical disease (headache, neurological symptoms, or fever) and persistent radiographic disease (one or more mass lesions on brain imaging)

If yes, **approve for 6 weeks by GPID or GPI-10 with a quantity limit of #3 per day.**  
If no, continue to #2.

CONTINUED ON NEXT PAGE





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

PYRIMETHAMINE

RENEWAL CRITERIA (CONTINUED)

2. Is the patient being treated for chronic maintenance of toxoplasmosis OR primary prophylaxis of toxoplasmosis and meets **ALL** of the following criteria?

- The patient is infected with human immunodeficiency virus (HIV)
- The patient has a CD4 count of less than 200 cells/mm(3)
- The patient is currently taking ART (anti-retroviral therapy)

If yes, **approve for 6 months by GPID or GPI-10 as follows:**

- **Chronic maintenance of toxoplasmosis: #2 per day.**
- **Primary prophylaxis of toxoplasmosis: #3 per day.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline for **PYRIMETHAMINE (Daraprim)** requires the following rule(s) be met for renewal:

A. The request is ONE of the following:

1. Acute treatment of toxoplasmosis (sudden and severe type of parasite infection)
2. Chronic maintenance therapy for toxoplasmosis
3. Primary prophylaxis of toxoplasmosis (prevention of a type of parasite infection)

B. **If you are being treated for acute toxoplasmosis, renewal also requires:**

1. You have persistent clinical disease (headache, neurological symptoms, or fever) and persistent radiographic disease (one or more mass lesions on brain imaging)

C. **If you are being treated for chronic maintenance of toxoplasmosis OR primary prophylaxis for toxoplasmosis, renewal also requires:**

1. You are also infected with human immunodeficiency virus (HIV: a virus that weakens your immune system with a parasite infection)
2. Your CD4 count (an indicator of how weak your immune system is) is less than 200 cells/mm(3)
3. You are currently taking ART (anti-retroviral therapy)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**PYRIMETHAMINE**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Daraprim.

**REFERENCES**

- Daraprim [Prescribing Information]. New York, NY: Vyera Pharmaceuticals LLC., August 2017.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/20

Created: 10/15

Client Approval: 02/20

P&T Approval: 01/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RANOLAZINE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
RANOLAZINE	ASPRUZYO SPRINKLE		52005 52006	GPI-14 (32200040003020, 32200040003040)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of chronic angina and meet **ALL** the following criteria?

- The patient had a trial of or contraindication to ranolazine ER tablets
- The patient is unable to swallow ranolazine ER tablets
- The patient had a trial of or contraindication to a nitrate (e.g., nitroglycerin, isosorbide mononitrate, isosorbide dinitrate)

If yes, **approve for 12 months by GPID or GPI-14 for the requested strength with the following quantity limits:**

- **500mg: #2 per day.**
- **1000mg: #2 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **RANOLAZINE (Aspruzyo Sprinkle)** requires the following rule(s) be met for approval:

- A. You have chronic angina (a type of heart condition)
- B. You had a trial of or contraindication (harmful for) to ranolazine ER (extended release) tablets
- C. You are unable to swallow ranolazine ER tablets
- D. You had a trial of or contraindication (harmful for) to a nitrate (such as nitroglycerin, isosorbide mononitrate, isosorbide dinitrate)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**RANOLAZINE**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Aspruzyo Sprinkle.

**REFERENCES**

- Aspruzyo Sprinkle [Prescribing Information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; March 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/01/22

Created: 08/22

Client Approval: 09/22

P&T Approval: 07/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

REGORAFENIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
REGORAFENIB	STIVARGA	39665		GPI-10 (2153305000)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of metastatic colorectal cancer (CRC) and meet **ALL** of the following criteria?
  - The patient has received previous treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy (e.g., FOLFOX, FOLFIRI, FOLFOXIRI, CapeOx, infusional 5-FU/LV, capecitabine)
  - The patient has received previous treatment with an anti-VEGF therapy (e.g., Avastin [bevacizumab], Zaltrap [ziv-aflibercept])

If yes, continue to #2.  
If no, continue to #4.
2. Is the colorectal cancer RAS wild-type (mutation negative)?

If yes, continue to #3.  
If no, **approve for 12 months by HICL or GPI-10 with a quantity limit of #84 per 28 days.**
3. Has the patient received previous treatment with an anti-EGFR therapy (e.g., Erbitux [cetuximab], Vectibix [panitumumab])?

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #84 per 28 days.**  
If no, do not approve.  
**DENIAL TEXT:** See the denial text at the end of the guideline.
4. Does the patient have a diagnosis of locally advanced, unresectable, or metastatic gastrointestinal stromal tumor (GIST) **AND** meet the following criterion?
  - The patient has received previous treatment with Gleevec (imatinib) and Sutent (sunitinib)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #84 per 28 days.**  
If no, continue to #5.
5. Does the patient have a diagnosis of hepatocellular carcinoma (HCC) **AND** meet the following criterion?
  - The patient has received previous treatment with Nexavar (sorafenib)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #84 per 28 days.**  
If no, do not approve.  
**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

REGORAFENIB

GUIDELINE FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **REGORAFENIB (Stivarga)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
1. Metastatic colorectal cancer (CRC: a type of digestive cancer that has spread to other parts of the body)
  2. Locally advanced, unresectable, or metastatic gastrointestinal stromal tumor (GIST: a type of digestive tumor that has spread from where it started to nearby tissue or lymph nodes, unable to remove by surgery, or has spread to other parts of the body)
  3. Hepatocellular carcinoma (HCC: a type of liver cancer)
- B. **If you have metastatic colorectal cancer, approval also requires:**
1. You had previous treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy such as FOLFOX, FOLFIRI, FOLFOXIRI, CapeOx, infusional 5-FU/LV, capecitabine
  2. You had previous treatment with an anti-VEGF therapy such as Avastin (bevacizumab), Zaltrap (ziv-aflibercept)
  3. If you have RAS wild-type (a type of unmutated gene) metastatic colorectal cancer, approval also requires you had previous treatment with an anti-EGFR therapy such as Erbitux (cetuximab), Vectibix (panitumumab)
- C. **If you have locally advanced, unresectable, or metastatic gastrointestinal stromal tumor, approval also requires:**
1. You had previous treatment with Gleevec (imatinib) and Sutent (sunitinib)
- D. **If you have hepatocellular carcinoma, approval also requires:**
1. You had previous treatment with Nexavar (sorafenib)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**REGORAFENIB**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Stivarga.

**REFERENCES**

- Stivarga [Prescribing Information]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc, December 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/22

Created: 10/12

Client Approval: 03/22

P&T Approval: 07/17



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RELUGOLIX

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
RELUGOLIX	ORGOVYX	47035		GPI-10 (2140557000)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of advanced prostate cancer **AND** meet the following criterion?
  - The patient is 18 years of age or older

If yes, **approve for a total of 12 months as follows:**

**FOR INITIAL REQUESTS:**

- **FIRST APPROVAL:** Approve for 1 month by HICL or GPI-10 with a quantity limit of #30 per 28 days.
- **SECOND APPROVAL:** Approve for 11 months by HICL or GPI-10 with a quantity limit of #1 per day (Please enter a start date of 3 WEEKS AFTER the START date of the first approval).

**FOR SUBSEQUENT/MAINTENANCE REQUESTS:**

- Approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.

If no, do not approve.

**DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **RELUGOLIX (Orgovyx)** requires the following rule(s) be met for approval:

- A. You have advanced prostate cancer
- B. You are 18 years of age or older

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Orgovyx.

**REFERENCES**

- Orgovyx [Prescribing Information]. Brisbane, CA: Myovant Sciences, Inc.; December 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/21

Created: 02/21

Client Approval: 02/21

P&T Approval: 01/21





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RELUGOLIX-ESTRADIOL-NORETHINDRONE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
RELUGOLIX/ ESTRADIOL/ NORETHINDRONE ACETATE	MYFEMBREE	47392		GPI-10 (2499350380)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Has the patient received a total of 24 months cumulative treatment with Myfembree?

If yes, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

If no, continue to #2.

2. Is the request for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) and the patient meets **ALL** the following criteria?

- The patient is 18 years of age or older
- The patient is a premenopausal woman
- Therapy is prescribed by or in consultation with an obstetrician or gynecologist (OB/GYN)

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #1 per day.**

If no, continue to #3.

3. Is the request for the management of moderate to severe pain associated with endometriosis and the patient meets **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient is a premenopausal woman
- Therapy is prescribed by or in consultation with an obstetrician or gynecologist (OB/GYN)
- The patient's diagnosis is confirmed via surgical or direct visualization (e.g., pelvic ultrasound) or histopathological confirmation (e.g., laparoscopy or laparotomy) in the last 10 years
- Myfembree will NOT be used concurrently with another GnRH-modulating agent (e.g., Orilissa, Lupron Depot, Synarel)

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #1 per day.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RELUGOLIX-ESTRADIOL-NORETHINDRONE

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **RELUGOLIX-ESTRADIOL-NORETHINDRONE (Myfembree)** requires the following rule(s) be met for approval:

- A. The request is for ONE of the following:
1. Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids: non-cancerous growths in the uterus)
  2. Management of moderate to severe pain associated with endometriosis (condition affecting the uterus)
- B. **If the request is for management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids), approval also requires:**
1. You are 18 years of age or older
  2. You are a premenopausal (before menopause) woman
  3. Therapy is prescribed by or in consultation with an obstetrician or gynecologist (OB/GYN: a type of women's health doctor)
  4. You have not received a total of 24 months cumulative (total) treatment with Myfembree
- C. **If the request is for management of moderate to severe pain associated with endometriosis, approval also requires:**
1. You are 18 years of age or older
  2. You are a premenopausal (before menopause) woman
  3. Therapy is prescribed by or in consultation with an obstetrician or gynecologist (OB/GYN: a type of women's health doctor)
  4. Your diagnosis of endometriosis is confirmed via surgical or direct visualization (such as pelvic ultrasound [type of imaging]) or histopathological (tissue) confirmation (such as laparoscopy [type of surgery] or laparotomy [type of surgery]) in the last 10 years
  5. Myfembree will NOT be used concurrently (at the same time) with another GnRH-modulating agent (such as Orilissa, Lupron Depot, Synarel)
  6. You have not received a total of 24 months cumulative (total) treatment with Myfembree

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RELUGOLIX-ESTRADIOL-NORETHINDRONE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Has the patient received a total of 24 months cumulative treatment with Myfembree?

If yes, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

If no, continue to #2.

2. Is the request for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) **AND** the patient meets the following criterion?

- The patient has had improvement of heavy menstrual bleeding

If yes, **approve for 18 months (or up to 24 months cumulative lifetime treatment duration) by HICL or GPI-10 with a quantity limit of #1 per day.**

If no, continue to #3.

3. Is the request for the management of moderate to severe pain associated with endometriosis and the patient meets **ALL** of the following criteria?

- The patient has had improvement in pain related to endometriosis
- Myfembree will NOT be used concurrently with another GnRH-modulating agent (e.g., Orilissa, Lupron Depot, Synarel)

If yes, **approve for 18 months (or up to 24 months cumulative lifetime treatment duration) by HICL or GPI-10 with a quantity limit of #1 per day.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **RELUGOLIX-ESTRADIOL-NORETHINDRONE (Myfembree)** requires the following rule(s) be met for renewal:

A. The request is for ONE of the following:

1. Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids: non-cancerous growths in the uterus)
2. Management of moderate to severe pain associated with endometriosis (condition affecting the uterus)

***(Renewal denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RELUGOLIX-ESTRADIOL-NORETHINDRONE

RENEWAL CRITERIA (CONTINUED)

- B. **If the request is for management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids), renewal also requires:**
  - 1. You had improvement of heavy menstrual bleeding on therapy
  - 2. You have not received a total of 24 months cumulative (total) treatment with Myfembree
- C. **If the request is for management of moderate to severe pain associated with endometriosis, renewal also requires:**
  - 1. You have had improvement in pain related to endometriosis while on therapy
  - 2. Myfembree will NOT be used concurrently (at the same time) with another GnRH-modulating agent (such as Orilissa, Lupron Depot, Synarel)
  - 3. You have not received a total of 24 months cumulative (total) treatment with Myfembree

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Myfembree.

**REFERENCES**

- Myfembree [Prescribing Information]. Brisbane, CA: Myovant Sciences, Inc., August 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 09/12/22

Created: 06/21

Client Approval: 08/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RIBOCICLIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
RIBOCICLIB SUCCINATE	KISQALI	44151		GPI-10 (2153107050)	
RIBOCICLIB SUCCINATE/ LETROZOLE	KISQALI FEMARA CO-PACK	44246		GPI-10 (2199000260)	

**GUIDELINES FOR USE**

1. Is the request for Kisqali-Femara Co-Pack?

If yes, continue to #2.

If no, continue to #5.

2. Does the patient have a diagnosis of advanced or metastatic breast cancer and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient's cancer is hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative

If yes, continue to #3.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

3. Is the patient a postmenopausal female or is a male and meets **ALL** of the following criteria?

- The patient had a trial of Ibrance (palbociclib) OR Verzenio (abemaciclib)
- The patient has NOT received prior endocrine-based therapy for advanced or metastatic breast cancer (e.g., letrozole, anastrozole, tamoxifen)

If yes, **approve for 12 months by GPID or GPI-14 for all daily dosage strengths with the following quantity limits:**

- **200mg (Co-Pack): #49 per 28 days.**
- **400mg (Co-Pack): #70 per 28 days.**
- **600mg (Co-Pack): #91 per 28 days.**

If no, continue to #4.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RIBOCICLIB

GUIDELINES FOR USE (CONTINUED)

4. Does the patient meet the following criterion?

- The patient has NOT received prior endocrine-based therapy for advanced or metastatic breast cancer (e.g., letrozole, anastrozole, tamoxifen)

If yes, **approve for 12 months by GPID or GPI-14 for all daily dosage strengths with the following quantity limits:**

- **200mg (Co-Pack): #49 per 28 days.**
- **400mg (Co-Pack): #70 per 28 days.**
- **600mg (Co-Pack): #91 per 28 days.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

5. Is the request for Kisqali?

If yes, continue to #6.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline

6. Does the patient have a diagnosis of advanced or metastatic breast cancer and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient's cancer is hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative

If yes, continue to #7.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline

7. Will Kisqali be used in combination with an aromatase inhibitor (e.g., letrozole, anastrozole, exemestane) **AND** the patient meets the following criterion?

- The patient has NOT received prior endocrine-based therapy for advanced or metastatic breast cancer (e.g., letrozole, anastrozole, tamoxifen)

If yes, continue to #8.

If no, continue to #10.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RIBOCICLIB

GUIDELINES FOR USE (CONTINUED)

8. Is the patient a postmenopausal female or is a male?

If yes, continue to #9.

If no, **approve for 12 months by GPID or GPI-14 for all daily dosage strengths with the following quantity limits:**

- **200mg: #21 per 28 days.**
- **400mg: #42 per 28 days.**
- **600mg: #63 per 28 days.**

9. Has the patient had a trial of Ibrance (palbociclib) OR Verzenio (abemaciclib)?

If yes, **approve for 12 months by GPID or GPI-14 for all daily dosage strengths with the following quantity limits:**

- **200mg: #21 per 28 days.**
- **400mg: #42 per 28 days.**
- **600mg: #63 per 28 days.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

10. Will Kisqali be used in combination with Faslodex (fulvestrant) in a postmenopausal female or a male and the patient meets **ONE** of the following criteria?

- The patient has experienced disease progression on endocrine therapy AND has had a trial of Ibrance (palbociclib) OR Verzenio (abemaciclib)
- The patient has NOT received prior endocrine-based therapy for advanced or metastatic breast cancer (e.g., letrozole, anastrozole, tamoxifen)

If yes, **approve for 12 months by GPID or GPI-14 for all daily dosage strengths with the following quantity limits:**

- **200mg: #21 per 28 days.**
- **400mg: #42 per 28 days.**
- **600mg: #63 per 28 days.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RIBOCICLIB

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **RIBOCICLIB (Kisqali, Kisqali/Femara co-pack)** requires the following rule(s) be met for approval:

- A. You have advanced or metastatic breast cancer (breast cancer that has progressed or has spread to other parts of the body)
- B. You are 18 years of age or older
- C. Your cancer is hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (a type of protein)
- D. **If you are requesting Kisqali-Femara Co-Pack, approval also requires:**
  - a. You have NOT received prior endocrine (hormone)-based therapy for advanced or metastatic breast cancer (such as letrozole, anastrozole, tamoxifen)
  - b. If you are a postmenopausal (after menopause) female or a male, you meet the following:
    1. You had a trial of Ibrance (palbociclib) or Verzenio (abemaciclib)
- E. **For Kisqali in combination with an aromatase inhibitor (such as anastrozole, exemestane, letrozole), approval also requires:**
  1. You have NOT received prior endocrine (hormone)-based therapy for advanced or metastatic breast cancer (such as letrozole, anastrozole, tamoxifen)
  2. If you are a postmenopausal (after menopause) female or a male, you meet the following:
    - a. You had a trial of Ibrance (palbociclib) or Verzenio (abemaciclib)
- F. **For Kisqali in combination with Faslodex (fulvestrant), approval also requires:**
  1. You are a postmenopausal (after menopause) female or a male
  2. You meet ONE of the following:
    - a. You have experienced disease progression (worsened) on endocrine (hormone) therapy AND you had a trial of Ibrance (palbociclib) or Verzenio (abemaciclib)
    - b. You have NOT received prior endocrine (hormone)-based therapy for advanced or metastatic breast cancer (such as letrozole, anastrozole, tamoxifen)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RIBOCICLIB

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Kisqali or Kisqali/Femara Co-Pack.

**REFERENCES**

- Kisqali [Prescribing Information]. East Hanover, NJ. Novartis; October 2022.
- Kisqali/Femara Co-Pack [Prescribing Information]. East Hanover, NJ. Novartis; December 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/01/22

Created: 05/17

Client Approval: 10/22

P&T Approval: 01/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RIFAXIMIN

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
RIFAXIMIN	XIFAXAN		28530 93749	GPI-14 (16000049000340) (16000049000320)	

**\*\* Please use the criteria for the specific drug requested \*\***

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

**XIFAXAN 550MG TABLETS**

1. Is the patient being treated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a hepatologist
  - The patient had a trial of lactulose or is currently on lactulose monotherapy

If yes, **approve for 12 months for Xifaxan 550mg by GPID or GPI-14 with a quantity limit of #2 per day.**

If no, continue to #2.

2. Does the patient have a diagnosis of irritable bowel syndrome with diarrhea (IBS-D) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a gastroenterologist
  - The patient had a trial of or contraindication to tricyclic anti-depressants or dicyclomine

If yes, **approve for 8 weeks for Xifaxan 550mg by GPID or GPI-14 for 1 fill of #42.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RIFAXIMIN

INITIAL CRITERIA - XIFAXAN 550MG TABLETS (CONTINUED)

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **RIFAXIMIN (Xifaxan 550 mg tablets)** requires the following rules be met for approval:

- A. You have ONE of the following diagnoses:
1. Reduction of risk of overt hepatic encephalopathy (HE: a type of brain condition caused by liver damage) recurrence
  2. Irritable bowel syndrome with diarrhea (IBS-D: a type of bowel disease)
- B. **For reduction in risk of overt hepatic encephalopathy recurrence, approval also requires:**
1. You are 18 years of age or older
  2. Therapy is prescribed by or in consultation with a hepatologist (a type of liver doctor)
  3. You have previously tried lactulose or you are currently taking lactulose monotherapy (drug used alone for treatment)
- C. **If you have irritable bowel syndrome with diarrhea, approval also requires:**
1. You are 18 years of age or older
  2. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
  3. You had a trial of or contraindication (harmful for) to tricyclic anti-depressants (such as amitriptyline, nortriptyline, etc.) or dicyclomine

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**XIFAXAN 200MG TABLETS**

1. Does the patient have a diagnosis of travelers' diarrhea (TD) and meet **ALL** of the following criteria?
  - The patient is 12 years of age or older
  - The patient had a trial of or contraindication to oral azithromycin, ciprofloxacin, ofloxacin, or levofloxacin

If yes, **approve for 3 days for Xifaxan 200mg by GPID or GPI-14 for 1 fill of #9.**  
If no, continue to #2.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RIFAXIMIN

INITIAL CRITERIA - XIFAXAN 200MG TABLETS (CONTINUED)

2. Is the request for the treatment of overt hepatic encephalopathy (HE) **AND** the patient meets the following criterion?

- The requested medication will be used in combination with lactulose

If yes, **approve for 10 days for Xifaxan 200mg by GPID or GPI-14 with a quantity limit of #6 per day.**

If no, continue to #3.

3. Does the patient have a diagnosis of *Clostridium difficile* infection (CDI) and meet **ALL** of the following criteria?

- The patient has had at least one previous occurrence of *Clostridium difficile* infection
- The requested medication will be used in combination with vancomycin
- Therapy is prescribed by or in consultation with an infectious disease specialist

If yes, **approve for 20 days for Xifaxan 200mg by GPID or GPI-14 with a quantity limit of #6 per day.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **RIFAXIMIN (Xifaxan 200 mg tablets)** requires the following rule(s) be met for approval:

A. You have **ONE** of the following diagnoses:

1. Travelers' diarrhea
2. *Clostridium difficile* infection (a type of bacterial infection)
3. Treatment of overt hepatic encephalopathy (HE: a type of brain condition caused by liver damage)

B. **If you have traveler's diarrhea, approval also requires:**

1. You are 12 years of age or older
2. You had a trial of or contraindication (harmful for) to oral azithromycin, ciprofloxacin, ofloxacin, or levofloxacin

C. **For the treatment of overt hepatic encephalopathy, approval also requires:**

1. The requested medication will be used in combination with lactulose

D. **If you have *Clostridium difficile* infection, approval also requires:**

1. You had at least one previous occurrence of *Clostridium difficile* infection
2. The requested medication will be used in combination with vancomycin
3. Therapy is prescribed by or in consultation with an infectious disease specialist (a doctor who specializes in the treatment of infections)

***(Initial Xifaxan 200mg tablets denial text continued on next page)***

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RIFAXIMIN

**INITIAL CRITERIA - XIFAXAN 200MG TABLETS (CONTINUED)**

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RENEWAL CRITERIA**

1. Is the request for renewal of Xifaxan 550mg tablet?

If yes, continue to #2.

If no, please refer to initial criteria above for Xifaxan 200mg request.

2. Is the patient being treated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence?

If yes, **approve for 12 months for Xifaxan 550mg by GPID or GPI-14 with a quantity limit of #2 per day.**

If no, continue to 3.

3. Does the patient have a diagnosis of irritable bowel syndrome with diarrhea (IBS-D) and meet **ALL** of the following criteria?

- At least 6 weeks have passed since the last treatment course of rifaximin
- Patient has experienced at least 30% decrease in abdominal pain (on a 0-10 point pain scale)
- Patient has experienced at least 50% reduction in the number of days per week with a stool consistency of mushy stool (Bristol Stool scale type 6) or entirely liquid stool (Bristol Stool scale type 7)

If yes, **approve for 12 months for Xifaxan 550mg by GPID or GPI-14 for up to 2 fills of #42 each fill, separated by at least 8 weeks (total of 2 fills in 12 months).**

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RIFAXIMIN

RENEWAL CRITERIA (CONTINUED)

**RENEWAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **RIFAXIMIN (Xifaxan 550 mg tablets)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following diagnoses:
  1. Reduction of risk of overt hepatic encephalopathy (HE: a type of brain condition caused by liver damage) recurrence
  2. Irritable bowel syndrome with diarrhea (IBS-D: a type of bowel disease)
- B. **If you have irritable bowel syndrome with diarrhea, renewal also requires:**
  1. At least 6 weeks have passed since your last treatment course of rifaximin
  2. You have experienced at least 30% decrease in abdominal pain (on a 0-10 point pain scale)
  3. You have experienced at least 50% reduction in the number of days per week with a stool consistency of mushy stool (Bristol Stool scale type 6) or entirely liquid stool (Bristol Stool scale type 7)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information for Xifaxan.

**REFERENCES**

- Xifaxan [Prescribing Information]. Bridgewater, NJ: Salix Pharmaceuticals. October 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/22

Created: 02/05

Client Approval: 02/22

P&T Approval: 01/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RILUZOLE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
RILUZOLE	EXSERVAN, TIGLUTIK		47362 44091	GPI-14 (74503070008220, 74503070001820)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of amyotrophic lateral sclerosis (ALS) and meets **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient has had a trial of riluzole tablets
  - The patient is unable to take riluzole tablet formulation

If yes, **approve for 12 months by GPID or GPI-14 with the following quantity limits:**

- **Exservan: #2 per day.**
- **Tiglutik: #20mL per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **RILUZOLE (Exservan, Tiglutik)** requires the following rule(s) be met for approval:

- A. You have amyotrophic lateral sclerosis (ALS: nervous system disease that weakens muscles and affects physical function)
- B. You are 18 years of age or older
- C. You have tried riluzole tablets
- D. You are unable to take riluzole tablet formulation

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Exservan or Tiglutik.

**REFERENCES**

- Exservan. [Prescribing Information]. Warren, NJ: Aquestive Therapeutics; April 2020.
- Tiglutik. [Prescribing Information]. Berwyn, PA: ITF Pharma, Inc.; September 2018.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**RILUZOLE**

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 06/01/21

Created: 11/18

Client Approval: 05/21

P&T Approval: 01/20





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RIMEGEPANT

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
RIMEGEPANT SULFATE	NURTEC ODT	46383		GPI-10 (6770106070)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Is the request for the acute treatment of migraine and the patient meets **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient had a trial of or contraindication to ONE triptan (e.g., sumatriptan, rizatriptan)

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #18 per 30 days.**  
If no, continue to #2.

2. Is the request for the preventive treatment of episodic migraines and the patient meets **ALL** of the following criteria?

- The patient is 18 years of age or older
- Nurtec ODT will NOT be used concurrently with other CGRP inhibitors (e.g., Ajovy, Aimovig, Emgality, Vyepti, Qulipta) for migraine prevention
- The patient had a trial of or contraindication to ONE of the following preventative migraine treatments: divalproex sodium/sodium valproate, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #16 per 30 days.**  
If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **RIMEGEPANT (Nurtec ODT)** requires the following rule(s) be met for approval:

- A. The request is for ONE of the following:
  - 1. Treatment of acute (quick onset) migraine
  - 2. Preventive treatment of episodic migraines
- B. You are 18 years of age or older
- C. **If the request is for the treatment of acute migraine, approval also requires:**
  - 1. You had a trial of or contraindication (harmful for) to ONE triptan (such as sumatriptan, rizatriptan)

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RIMEGEPANT

INITIAL CRITERIA (CONTINUED)

**D. If the request is for the preventive treatment of episodic migraines, approval also requires:**

1. You will NOT use Nurtec ODT concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Ajovy, Aimovig, Emgality, Vyepti, Qulipta) for migraine prevention
2. You had a trial of or contraindication (harmful for) to ONE of the following preventive migraine treatments: divalproex sodium/sodium valproate, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Is the request for the acute treatment of migraine and the patient meets **ONE** of the following criteria?
  - The patient has experienced an improvement from baseline in a validated acute treatment patient-reported outcome questionnaire (e.g., Migraine Assessment of Current Therapy [Migraine-ACT])
  - The patient has experienced clinical improvement as defined by ONE of the following:
    - Ability to function normally within 2 hours of dose
    - Headache pain disappears within 2 hours of dose
    - Therapy works consistently in majority of migraine attacks

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #18 per 30 days.**  
If no, continue to #2.

2. Is the request for the preventive treatment of episodic migraines **AND** does the patient meet the following criterion?
  - Nurtec ODT will NOT be used concurrently with other CGRP inhibitors (e.g., Ajovy, Aimovig, Emgality, Vyepti, Qulipta) for migraine prevention

If yes, continue to #3.  
If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RIMEGEPANT

RENEWAL CRITERIA (CONTINUED)

3. Does the patient meet **ONE** of the following criteria?

- The patient has experienced a reduction in migraine or headache frequency of at least 2 days per month
- The patient has experienced a reduction in migraine severity
- The patient has experienced a reduction in migraine duration

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #16 per 30 days.**  
If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **RIMEGEPANT (Nurtec ODT)** requires the following rule(s) be met for renewal:

A. The request is for **ONE** of the following:

1. Treatment of acute (quick onset) migraine
2. Preventive treatment of episodic migraines

B. **If the request is for treatment of acute migraine, renewal also requires ONE of the following:**

1. You have experienced an improvement from baseline in a validated acute treatment patient-reported outcome questionnaire (assessment tool used to help guide treatment such as migraine assessment of current therapy [MIGRAINE-ACT])
2. You have experienced clinical improvement as defined by **ONE** of the following:
  - a. Ability to function normally within 2 hours of dose
  - b. Headache pain disappears within 2 hours of dose
  - c. Treatment works consistently in majority of migraine attacks

C. **If the request is for the preventive treatment of episodic migraines, renewal also requires:**

1. You will **NOT** use Nurtec ODT concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Ajovy, Aimovig, Emgality, Vyepti, Qulipta) for migraine prevention
2. You meet **ONE** of the following:
  - a. You have experienced a reduction in migraine or headache frequency of at least 2 days per month
  - b. You experienced a reduction in migraine severity
  - c. You experienced a reduction in migraine duration

***(Renewal denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RIMEGEPANT

RENEWAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Nurtec ODT.

REFERENCES

- Nurtec ODT [Prescribing Information]. New Haven, CT: Biohaven Pharmaceuticals Inc; December 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/22

Created: 03/20

Client Approval: 02/22

P&T Approval: 01/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**RIOCIGUAT**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
RIOCIGUAT	ADEMPAS	40644		GPI-10 (4013405000)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group 1) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a cardiologist or pulmonologist
  - Documented confirmatory PAH diagnosis based on right heart catheterization with the following parameters:
    - Mean pulmonary artery pressure (PAP) > 20 mmHg
    - Pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg
    - Pulmonary vascular resistance (PVR) ≥ 3 Wood units
  - NYHA-WHO Functional Class II-IV symptoms
  - The patient is not concurrently taking nitrate or nitric oxide donors (e.g., amyl nitrate), phosphodiesterase inhibitors (e.g., sildenafil, tadalafil, or vardenafil), or non-specific phosphodiesterase inhibitors (e.g., dipyridamole, theophylline)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #3 per day.**  
If no, continue to #2.

2. Does the patient have a diagnosis of persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (WHO Group 4) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a cardiologist or pulmonologist
  - The patient has persistent or recurrent disease after surgical treatment OR the patient is not a candidate for surgery or has inoperable CTEPH
  - The patient has NYHA-WHO Functional Class II to IV symptoms
  - The patient is not concurrently taking nitrates or nitric oxide donors (e.g., amyl nitrate), phosphodiesterase inhibitors (e.g., sildenafil, tadalafil, or vardenafil), or non-specific phosphodiesterase inhibitors (e.g., dipyridamole, theophylline).

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #3 per day.**  
If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RIOCIQUAT

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **RIOCIQUAT (Adempas)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:

1. Persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH: form of high blood pressure affecting the lungs caused by blood clots) (World Health Organization [WHO] Group 4)
2. Pulmonary arterial hypertension (PAH: type of heart and lung condition) (World Health Organization [WHO] Group 1)

B. **If you have pulmonary arterial hypertension, approval also requires:**

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung/ breathing doctor)
3. You have a documented confirmatory pulmonary arterial hypertension diagnosis based on right heart catheterization (placing a small tube into the right side of heart) with the following lab values:
  - a. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
  - b. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
  - c. Pulmonary vascular resistance (PVR) greater than or equal to 3 Wood units
4. You have NYHA-WHO Functional Class II to IV symptoms (a way to classify how limited you are during physical activity)
5. You are not concurrently taking nitrates or nitric oxide donors (such as amyl nitrate), phosphodiesterase inhibitors (such as sildenafil, tadalafil, or vardenafil), or non-specific phosphodiesterase inhibitors (such as dipyridamole, theophylline)

C. **If you have chronic thromboembolic pulmonary hypertension, approval also requires:**

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung/ breathing doctor)
3. You have persistent or recurrent disease after surgical treatment (it continues to exist or returns after surgery) OR you are not a candidate for surgery or have inoperable chronic thromboembolic pulmonary hypertension
4. You have NYHA-WHO Functional Class II to IV symptoms (a way to classify how limited you are during physical activity)
5. You are not concurrently taking nitrates or nitric oxide donors (such as amyl nitrate), phosphodiesterase inhibitors (such as sildenafil, tadalafil, or vardenafil), or non-specific phosphodiesterase inhibitors (such as dipyridamole, theophylline)

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RIOCIGUAT

**GUIDELINES FOR USE (CONTINUED)**

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RENEWAL CRITERIA**

1. Does the patient have one of the following diagnoses?

- Persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (WHO (World Health Organization) Group 4)
- Pulmonary arterial hypertension (PAH) (WHO Group 1)

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

2. Is the patient concurrently taking nitrate or nitric oxide donors (e.g., amyl nitrate), phosphodiesterase inhibitors (e.g., sildenafil, tadalafil, or vardenafil), or non-specific phosphodiesterase inhibitors (e.g., dipyridamole, theophylline)?

If yes, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

If no, continue to #3.

3. Does the patient meet **ONE** of the following criteria?

- The patient has shown improvement from baseline in the 6-minute walk distance
- The patient has remained stable from baseline in the 6-minute walk distance with a stable or improved World Health Organization (WHO) functional class

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #3 per day.**

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RIOCIGUAT

RENEWAL CRITERIA (CONTINUED)

**RENEWAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **RIOCIGUAT (Adempas)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following diagnoses:
  - 1. Persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH: form of high blood pressure affecting the lungs caused by blood clots) (WHO (World Health Organization) Group 4)
  - 2. Pulmonary arterial hypertension (PAH: type of heart and lung condition) (WHO Group 1)
- B. You are not concurrently (at the same time) taking nitrate or nitric oxide donors (such as amyl nitrate), phosphodiesterase inhibitors (such as sildenafil, tadalafil, or vardenafil), or non-specific phosphodiesterase inhibitors (such as dipyridamole, theophylline)
- C. You show improvement from baseline in the 6-minute walk distance OR have a stable 6-minute walk distance with a stable or improved World Health Organization (WHO) functional class

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Adempas.

**REFERENCES**

- Adempas [Prescribing Information]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc.; September 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/22

Created: 11/13

Client Approval: 05/22

P&T Approval: 04/22





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RIPRETINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
RIPRETINIB	QINLOCK	46544		GPI-10 (2153305300)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of advanced gastrointestinal stromal tumor (GIST) and meet **ALL** of the following criteria?
- The patient is 18 years of age or older
  - The patient has received prior treatment with 3 or more kinase inhibitors (e.g. sunitinib, avapritinib, regorafenib), including imatinib

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #3 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **RIPRETINIB (Qinlock)** requires ALL of the following rule(s) be met for approval:

- A. You have advanced gastrointestinal stromal tumor (GIST: a type of cancer in your digestive tract)
- B. You are 18 years of age or older
- C. You have received prior treatment with 3 or more kinase inhibitors (class of drugs), including imatinib

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Qinlock.

**REFERENCES**

- Qinlock [Prescribing Information]. Waltham, MA: Deciphera Pharmaceuticals, May 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/10/21

Created: 07/20

Client Approval: 03/21

P&T Approval: 07/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**RISANKIZUMAB-RZAA**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
RISANKIZUMAB-RZAA	SKYRIZI	45699		GPI-10 (9025057070, 5250406070)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a dermatologist
  - The patient has psoriasis covering 3% or more of body surface area (BSA) OR psoriatic lesions affecting the hands, feet, face, or genital area
  - The patient had a trial of or contraindication to one or more forms of conventional therapies such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids, calcipotriene, acitretin, methotrexate, or cyclosporine

If yes, **approve the requested strength and dosage form for a total of 6 months by GPID or GPI-14. Please enter two authorizations as follows:**

**FIRST APPROVAL:**

- **150mg/1.66mL Kit: Approve for 1 month with a quantity limit of #1 kit (2 syringes) per 28 days.**
- **150mg/mL pen/syringe: Approve for 1 month with a quantity limit of #1mL per 28 days.**

**SECOND APPROVAL:**

- **150mg/1.66mL Kit: Approve for 5 months with a quantity limit of #1 kit (2 syringes) per 84 days (Please enter a start date of 3 WEEKS AFTER the START date of the first approval).**
- **150mg/mL pen/syringe: Approve for 5 months with a quantity limit of #1mL per 84 days. (Please enter a start date of 3 WEEKS AFTER the START date of the first approval).**

If no, continue to #2.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RISANKIZUMAB-RZAA

INITIAL CRITERIA (CONTINUED)

2. Does the patient have a diagnosis of psoriatic arthritis (PsA) and meet **ALL** of the following criteria?
- The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a rheumatologist or dermatologist
  - The patient had a trial of or contraindication to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

If yes, **approve the requested strength and dosage form for a total of 6 months by GPID or GPI-14. Please enter two authorizations as follows:**

**FIRST APPROVAL:**

- **150mg/1.66mL Kit: Approve for 1 month with a quantity limit of #1 kit (2 syringes) per 28 days.**
- **150mg/mL pen/syringe: Approve for 1 month with a quantity limit of #1mL per 28 days.**

**SECOND APPROVAL:**

- **150mg/1.66mL Kit: Approve for 5 months with a quantity limit of #1 kit (2 syringes) per 84 days (Please enter a start date of 3 WEEKS AFTER the START date of the first approval).**
- **150mg/mL pen/syringe: Approve for 5 months with a quantity limit of #1mL per 84 days. (Please enter a start date of 3 WEEKS AFTER the START date of the first approval).**

If no, continue to #3.

3. Does the patient have a diagnosis of moderate to severe Crohn's disease (CD) and meet **ALL** of the following criteria?
- The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a gastroenterologist
  - The patient had a trial of or contraindication to ONE conventional agent, such as corticosteroids (e.g., budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine

If yes, continue to #4.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RISANKIZUMAB-RZAA

INITIAL CRITERIA (CONTINUED)

4. Does the patient have non-self-administered (NSA) drug benefit coverage?

If yes, continue to #5.

If no, **approve a maintenance dose for 6 months by GPID or GPI-14 for the requested strength as follows:**

- **180mg/1.2mL: #1.2mL per 56 days.**
- **360mg/2.4mL: #2.4mL per 56 days.**

5. Is the prescriber requesting an intravenous infusion induction dose of **Skyrizi 600mg/10mL?**

**If yes, approve for a total of 6 months by GPID or GPI-14. Please enter two authorizations as follows:**

**FIRST APPROVAL:**

- **600mg/10mL: Approve for 3 months with a quantity limit of #10mL per 28 days.**

**SECOND APPROVAL:**

- **180mg/1.2mL: Approve for 3 months with a quantity limit of #1.2 mL per 56 days (Please enter start date of 11 WEEKS AFTER the START date of the first approval).**
- **360mg/2.4mL: Approve for 3 months with a quantity limit of #2.4 mL per 56 days (Please enter start date of 11 WEEKS AFTER the START date of the first approval).**

If no, **approve a maintenance dose for 6 months by GPID or GPI-14 for the requested strength as follows:**

- **180mg/1.2mL: #1.2mL per 56 days.**
- **360mg/2.4mL: #2.4mL per 56 days.**

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **RISANKIZUMAB-RZAA (Skyrizi)** requires the following rules be met for approval:

A. You have ONE of the following diagnoses:

1. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
2. Psoriatic arthritis (PsA: a type of skin and joint condition)
3. Moderate to severe Crohn's disease (CD: a type of bowel disorder)

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RISANKIZUMAB-RZAA

INITIAL CRITERIA (CONTINUED)

**B. If you have moderate to severe plaque psoriasis, approval also requires:**

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
3. You have psoriasis covering 3% or more of body surface area (BSA) OR psoriatic lesions (rashes) affecting the hands, feet, genital area, or face
4. You have tried or have a contraindication (harmful for) to one or more forms of standard therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids, calcipotriene, acitretin, methotrexate, or cyclosporine

**C. If you have psoriatic arthritis, approval also requires:**

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
3. You have tried or have a contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

**D. If you have moderate to severe Crohn's disease, approval also requires:**

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
3. You had a trial of or contraindication (harmful for) to ONE standard therapy, such as corticosteroids (such as budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) **AND** meet the following criterion?
  - The patient has achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more

If yes, **approve the requested strength and dosage form for 12 months by GPID or GPI-14 with the following quantity limits:**

- **150mg/1.66mL Kit: #1 kit (2 syringes) per 84 days.**
- **150mg/mL pen/syringe: #1mL per 84 days.**

If no, continue to #2.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RISANKIZUMAB-RZAA

RENEWAL CRITERIA (CONTINUED)

2. Does the patient have a diagnosis of psoriatic arthritis (PsA) **AND** meet the following criterion?
- The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

If yes, **approve the requested strength and dosage form for 12 months by GPID or GPI-14 with the following quantity limits:**

- **150mg/1.66mL Kit: #1 kit (2 syringes) per 84 days.**
- **150mg/mL pen/syringe: #1mL per 84 days.**

If no, continue to #3.

3. Does the patient have a diagnosis of moderate to severe Crohn's disease (CD)?

If yes, **approve for 12 months by GPID or GPI-14 for the requested strength as follows:**

- **180mg/1.2mL: #1.2mL per 56 days.**
- **360mg/2.4mL: #2.4mL per 56 days.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **RISANKIZUMAB-RZAA (Skyrizi)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following diagnoses:
1. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
  2. Psoriatic arthritis (PsA: a type of skin and joint condition)
  3. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
- B. **If you have moderate to severe plaque psoriasis, renewal also requires:**
1. You have achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more
- C. **If you have psoriatic arthritis, renewal also requires:**
1. You experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**RISANKIZUMAB-RZAA**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Skyrizi.

**REFERENCES**

- Skyrizi [Prescribing Information]. North Chicago, IL: AbbVie, Inc.; December 2022.

Library	Commercial	NSA
Yes	Yes	Yes

Part D Effective: N/A

Commercial Effective: 01/16/23

Created: 05/19

Client Approval: 12/22

P&T Approval: 01/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RISDIPLAM

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
RISDIPLAM	EVRYSDI	46765		GPI-10 (7470656000)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of spinal muscular atrophy (SMA) and meet **ALL** of the following criteria?
  - Diagnosis of spinal muscular atrophy (SMA) is confirmed by documentation of gene mutation analysis indicating mutations or deletions of both alleles of the survival motor neuron 1 (SMN1) gene (e.g., homozygous deletions of SMN1, homozygous mutations of SMN1, compound heterozygous mutations in SMN1 [i.e., deletion of SMN1 on one allele and point mutation of SMN1 on the other allele])
  - Therapy is prescribed by or given in consultation with a neuromuscular specialist or spinal muscular atrophy (SMA) specialist at a SMA Specialty Center

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Is the patient presymptomatic **AND** meets the following criterion?
  - There is documentation of up to (i.e., no more than) three copies of survival motor neuron 2 (SMN2) based on newborn screening

If yes, **approve for 12 months by HICL or GPI-10 for #240mL per 30 days.**

**APPROVAL TEXT:** Renewal requires that the patient has improved, maintained, or demonstrated less than expected decline in motor function assessments compared to baseline, OR in other muscle function.

If no, continue to #3.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RISDIPLAM

INITIAL CRITERIA (CONTINUED)

3. Is the patient symptomatic and meets **ALL** of the following criteria?

- The onset of spinal muscular atrophy (SMA) symptoms occurred before 20 years of age
- There is documentation of a baseline motor function assessment by a neuromuscular specialist or SMA specialist
- For patients who have received prior gene therapy: the patient had less than expected clinical benefit with gene therapy

If yes, **approve for 12 months by HICL or GPI-10 for #240mL per 30 days.**

**APPROVAL TEXT:** Renewal requires that the patient has improved, maintained, or demonstrated less than expected decline in motor function assessments compared to baseline, OR in other muscle function.

If no, do not approve.

**INITIAL DENIAL TEXT:** *\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **RISDIPLAM (Evrysdi)** requires the following rule(s) be met for approval:

- A. You have spinal muscular atrophy (SMA: genetic disorder where your muscles become weak and break down)
- B. Your diagnosis of spinal muscular atrophy (SMA) is confirmed by documentation of a gene mutation analysis indicating mutations or deletions of both alleles of the survival motor neuron 1 (SMN1: type of protein in spinal cord) gene (such as homozygous deletions of SMN1, homozygous mutations of SMN1, compound heterozygous mutations in SMN1 [deletion of SMN1 on one allele and point mutation of SMN1 on the other allele])
- C. The requested medication is prescribed by or given in consultation with a neuromuscular (nerve and muscle) specialist or spinal muscular atrophy (SMA) specialist at a SMA Specialty Center
- D. **If you are presymptomatic (symptoms have not yet appeared), approval also requires:**
  1. There is documentation showing you have up to three copies of survival motor neuron 2 (SMN2: type of protein in spinal cord) based on screening done when you were a newborn
- E. **If you are symptomatic (symptoms have appeared), approval also requires:**
  1. The onset of spinal muscular atrophy (SMA) symptoms occurred before 20 years of age
  2. There is documentation showing you had a baseline motor function assessment by a neuromuscular (nerve and muscle) specialist or SMA specialist
  3. If you previously had gene therapy, you had less than expected clinical benefit

*(Initial denial text continued on the next page)*

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RISDIPLAM

INITIAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

2. Does the patient have a diagnosis of spinal muscular atrophy (SMA) and meet **ONE** of the following criteria?
  - The patient has improved, maintained, or demonstrated less than expected decline in motor function assessments compared to baseline (e.g., HINE, HFMSE, CHOP-INTEND)
  - The patient has improved, maintained, or demonstrated less than expected decline in other muscle function (e.g., pulmonary)

If yes, **approve for 12 months by HICL or GPI-10 for #240mL per 30 days.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **RISDIPLAM (Evrysdi)** requires the following rule(s) be met for renewal:

- A. You have spinal muscular atrophy (SMA: genetic disorder where your muscles become weak and break down)
- B. You meet ONE of the following:
  1. You have improved, maintained, or demonstrated less than expected decline in motor function assessments compared to baseline. Some types of motor assessment tests include Hammersmith Infant Neurological Examination (HINE), Hammersmith Functional Motor Scale - Expanded (HFMSE) and Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND)
  2. You have improved, maintained, or demonstrated less than expected decline in other muscle function such as pulmonary (lung/breathing) function

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**RISDIPLAM**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Evrysdi.

**REFERENCES**

- Evrysdi [Prescribing Information]. South San Francisco, CA: Genentech, Inc.; August 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 09/07/20

Created: 08/20

Client Approval: 08/20

P&T Approval: 04/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ROFLUMILAST

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ROFLUMILAST	ZORYVE	37123		GPI-10 (9025004500)	ROUTE = TOPICAL

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of plaque psoriasis and meet **ALL** of the following criteria?
  - The patient is 12 years of age or older
  - Therapy is prescribed by or in consultation with a dermatologist
  - The patient has psoriasis covering 2% to 20% of body surface area (BSA) (excluding scalp, palms, and soles)
  - The patient is **NOT** concurrently using other systemic immunomodulating agents (e.g., Stelara, Otezla), topical corticosteroids (e.g., betamethasone dipropionate, clobetasol propionate), or topical non-steroidals (e.g., calcitriol, tazarotene)

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Has the patient had a trial of or contraindication to **TWO** of the following (from different categories)?
  - High or super-high potency topical corticosteroid (e.g., triamcinolone acetonide, fluocinonide, clobetasol propionate, halobetasol propionate)
  - Topical vitamin D analog (e.g., calcipotriene cream, calcitriol ointment)
  - Topical calcineurin inhibitor (e.g., tacrolimus, pimecrolimus)
  - Topical retinoid (e.g., tazarotene cream/gel)
  - Anthralin

If yes, **approve for 2 months by GPID or GPI-10.**

If no, do not approve.

**INITIAL DENIAL TEXT:** **\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ROFLUMILAST (Zoryve)** requires the following rule(s) be met for approval:

- A. You have plaque psoriasis (a type of skin condition)
  - B. You are 12 years of age or older
  - C. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
- (Initial denial text continued on next page)**

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ROFLUMILAST

INITIAL CRITERIA (CONTINUED)

- D. You have psoriasis covering 2% to 20% of body surface area (BSA) (excluding scalp, palms, and soles)
- E. You are NOT concurrently (at the same time) using other systemic immunomodulating agents (such as Stelara, Otezla), topical corticosteroids (such as betamethasone dipropionate, clobetasol propionate), or topical non-steroidals (such as calcitriol, tazarotene)
- F. You had a trial of or contraindication (harmful for) to TWO of the following (from different categories):
  - 1. High or super-high potency topical corticosteroid (such as triamcinolone acetonide, fluocinonide, clobetasol propionate, halobetasol propionate)
  - 2. Topical vitamin D analog (such as calcipotriene cream, calcitriol ointment)
  - 3. Topical calcineurin inhibitor (such as tacrolimus, pimecrolimus)
  - 4. Topical retinoid (such as tazarotene cream/gel)
  - 5. Anthralin

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

- 1. Does the patient have a diagnosis of plaque psoriasis and meet **ALL** of the following criteria?
  - The patient has achieved or maintained clear or minimal disease
  - The patient is NOT concurrently using other systemic immunomodulating agents (e.g., Stelara, Otezla), topical corticosteroids (e.g., betamethasone dipropionate, clobetasol propionate), or topical non-steroidals (e.g., calcitriol, tazarotene)

If yes, **approve for 12 months by GPID or GPI-10.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ROFLUMILAST (Zoryve)** requires the following rule(s) be met for renewal:

- A. You have plaque psoriasis (a type of skin condition)
- B. You have achieved or maintained clear or minimal disease
- C. You are NOT concurrently (at the same time) using other systemic immunomodulating agents (such as Stelara, Otezla), topical corticosteroids (such as betamethasone dipropionate, clobetasol propionate), or topical non-steroidals (such as calcitriol, tazarotene)  
**(Renewal denial text continued on next page)**

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ROFLUMILAST

RENEWAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Zoryve.

REFERENCES

- Zoryve [Prescribing Information]. Westlake Village, CA: Arcutis Biotherapeutics, Inc.; July 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 08/29/22

Created: 08/22

Client Approval: 08/22

P&T Approval: 07/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ROPEGINTERFERON ALFA-2B-NJFT

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ROPEGINTERFERON ALFA-2B-NJFT	BESREMI	47669		GPI-10 (2170007750)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of polycythemia vera **AND** meet the following criterion?
  - The patient is 18 years of age or older

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2mL per 28 days.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ROPEGINTERFERON ALFA-2B-NJFT (Besremi)** requires the following rule(s) be met for approval:

- A. You have polycythemia vera (a type of blood cancer)
- B. You are 18 years of age or older

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Besremi.

**REFERENCES**

- Besremi [Prescribing Information]. Burlington, MA: PharmaEssentia, Corp., November 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/22

Created: 01/22

Client Approval: 02/22

P&T Approval: 01/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RUCAPARIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
RUCAPARIB CAMSYLATE	RUBRACA	44002		GPI-10 (2153557020)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient's cancer has a deleterious BRCA mutation (germline and/or somatic)
- The patient is in complete or partial response to platinum-based chemotherapy
- The requested medication will be used for maintenance treatment

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**

If no, continue to #2.

2. Does the patient have a diagnosis of metastatic castration-resistant prostate cancer (mCRPC) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient's cancer has a deleterious BRCA mutation (germline and/or somatic) based on an FDA-approved companion diagnostic for Rubraca
- The patient has been treated with an androgen receptor-directed therapy and a taxane-based chemotherapy

If yes, continue to #3.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

3. Does the patient meet **ONE** of the following criteria?

- The patient previously had a bilateral orchiectomy
- The patient has a castrate level of testosterone (i.e., < 50 ng/dL)
- The requested medication will be used concurrently with a gonadotropin-releasing hormone (GnRH) analog (e.g., leuprolide, goserelin, histrelin)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RUCAPARIB

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **RUCAPARIB (Rubraca)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
1. Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (types of reproductive system cancers that has returned)
  2. Metastatic castration-resistant prostate cancer (mCRPC: prostate cancer that has spread to other parts of the body and no longer responds to testosterone lowering treatment)
- B. **If you have recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, approval also requires:**
1. You are 18 years of age or older
  2. Your cancer has a deleterious BRCA mutation (germline and/or somatic) (a type of gene mutation that is passed on from parent to child and/or acquired during life)
  3. You are in complete or partial response to platinum-based chemotherapy (a type of therapy to treat cancer)
  4. The requested medication will be used for maintenance treatment
- C. **If you have metastatic castration-resistant prostate cancer, approval also requires:**
1. You are 18 years of age or older
  2. Your cancer has a deleterious BRCA mutation (germline and/or somatic) (a type of gene mutation that is passed on from parent to child and/or acquired during life) based on a Food and Drug Administration (FDA)-approved companion diagnostic for Rubraca
  3. You have been treated with an androgen receptor-directed therapy and a taxane-based chemotherapy (types of therapy to treat cancer)
  4. You meet ONE of the following:
    - a. You previously received a bilateral orchiectomy (removal of testicles)
    - b. You have a castrate level of testosterone (blood testosterone levels are less than 50 ng/dL)
    - c. The requested medication will be used together with a gonadotropin-releasing hormone (GnRH) analog (such as leuprolide, goserelin, histrelin)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**RUCAPARIB**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Rubraca.

**REFERENCES**

- Rubraca [Prescribing Information]. Boulder, CO: Clovis Oncology, Inc.; December 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/23/23

Created: 12/16

Client Approval: 01/23

P&T Approval: 01/23



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RUXOLITINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
RUXOLITINIB PHOSPHATE	JAKAFI	38202		GPI-10 (2153756020)	ROUTE ≠ TOPICAL

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis **AND** meet the following criterion?

- The patient is 18 years of age or older

If yes, **approve for 6 months by GPID or GPI-10 with a quantity limit of #2 per day.**  
If no, continue to #2.

2. Does the patient have a diagnosis of polycythemia vera and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient has had a trial of or contraindication to hydroxyurea

If yes, **approve for 12 months by GPID or GPI-10 with a quantity limit of #2 per day.**  
If no, continue to #3.

3. Does the patient have a diagnosis of steroid-refractory acute graft-versus-host disease **AND** meet the following criterion?

- The patient is 12 years of age or older

If yes, **approve for 12 months by GPID or GPI-10 with a quantity limit of #2 per day.**  
If no, continue to #4.

4. Does the patient have a diagnosis of chronic graft-versus-host disease and meet **ALL** of the following criteria?

- The patient is 12 years of age or older
- The patient has had a failure of one or two lines of systemic therapy

If yes, **approve for 12 months by GPID or GPI-10 with a quantity limit of #2 per day.**  
If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RUXOLITINIB

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **RUXOLITINIB (Jakafi)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
  - 1. Intermediate or high-risk myelofibrosis, (type of bone marrow cancer such as primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis)
  - 2. Polycythemia vera (a type of blood cancer)
  - 3. Steroid -refractory acute graft-versus-host disease (a type of short-term immune disorder that did not respond to a type of treatment)
  - 4. Chronic graft-versus-host disease (a type of long-term immune disorder)
- B. **If you have intermediate or high-risk myelofibrosis, such as primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis, approval also requires:**
  - 1. You are 18 years of age or older
- C. **If you have polycythemia vera, approval also requires:**
  - 1. You are 18 years of age or older
  - 2. You had a trial of hydroxyurea, unless you have a contraindication (harmful for)
- D. **If you have steroid-refractory acute graft-versus-host disease, approval also requires:**
  - 1. You are 12 years of age or older
- E. **If you have chronic graft-versus-host disease, approval also requires:**
  - 1. You are 12 years of age or older
  - 2. You had a failure of one or two lines of systemic therapy (treatment that targets the entire body)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RUXOLITINIB

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

**NOTE:** For the diagnoses of polycythemia vera, acute graft-versus-host disease, or chronic graft-versus-host disease, please refer to the Initial Criteria section.

1. Does the patient have a diagnosis of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis?

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

2. Has the patient shown symptom improvement by meeting **ONE** of the following criteria?
  - The patient has a 50% or greater reduction in total symptom score (e.g., Myeloproliferative Neoplasm Symptom Assessment Form [MPN-SAF TSS], modified Myelofibrosis Symptom Assessment Form [MFSAF] v2.0)
  - The patient has a 50% or greater reduction in palpable spleen length
  - The patient has a spleen volume reduction of 35% or greater from baseline

If yes, **approve for 12 months by GPID or GPI-10 with a quantity limit of #2 per day.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **RUXOLITINIB (Jakafi)** requires the following rule(s) be met for renewal:

- A. You have intermediate or high-risk myelofibrosis, (type of bone marrow cancer such as primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis)
- B. You have shown symptom improvement by meeting ONE of the following:
  1. You have a 50 percent or greater reduction in total symptom score (such as Myeloproliferative Neoplasm Symptom Assessment Form [MPN-SAF TSS], modified Myelofibrosis Symptom Assessment Form [MFSAF] v2.0)
  2. You have a 50 percent or greater reduction in palpable (can be felt by external examination) spleen length
  3. You have a spleen volume reduction of 35 percent or greater from baseline

***(Renewal denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RUXOLITINIB

RENEWAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Jakafi.

**REFERENCES**

- Jakafi [Prescribing Information]. Wilmington, DE. Incyte Corporation; September 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/22

Created: 12/11

Client Approval: 11/21

P&T Approval: 10/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RUXOLITINIB TOPICAL

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
RUXOLITINIB PHOSPHATE	OPZELURA	38202		GPI-10 (9027206050)	ROUTE ≠ ORAL

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of mild to moderate atopic dermatitis and meet **ALL** of the following criteria?

- The patient is 12 years of age or older
- The patient is NOT immunocompromised
- The patient had a trial of or contraindication to a topical corticosteroid (e.g., halobetasol, triamcinolone, fluocinonide) OR a topical non-steroidal immunomodulating agent (e.g., pimecrolimus, tacrolimus)

If yes, continue to #2.

If no, continue to #3.

2. Will Opzelura be used concurrently with **ANY** of the following?

- Other non-steroid topicals (e.g., pimecrolimus, tacrolimus, Eucrisa)
- Systemic therapeutic biologics (e.g., Dupixent, Adbry)
- Other JAK inhibitors (e.g., Rinvoq, Cibinqo)
- Potent immunosuppressants (e.g., azathioprine, cyclosporine)

If yes, do not approve.

**DENIAL TEXT:** See the initial denial at the end of the guideline.

If no, **approve for 3 months by GPID or GPI-10 with a quantity limit of #60 grams per 30 days.**

3. Does the patient have a diagnosis of nonsegmental vitiligo and meet **ALL** of the following criteria?

- The patient is 12 years of age or older
- The patient has depigmented areas covering 10% or less of total body surface area
- The patient had a trial of or contraindication to a topical corticosteroid (e.g., halobetasol, triamcinolone, fluocinonide) OR a topical calcineurin inhibitor (e.g., pimecrolimus, tacrolimus)

If yes, continue to #4.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text on the next page.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RUXOLITINIB TOPICAL

INITIAL CRITERIA (CONTINUED)

4. Will Opzelura be used concurrently with **ANY** of the following?
- Other non-steroid topicals (e.g., pimecrolimus, tacrolimus, Eucrisa)
  - Systemic therapeutic biologics (e.g., Dupixent, Adbry)
  - Other JAK inhibitors (e.g., Rinvoq, Cibinqo)
  - Potent immunosuppressants (e.g., azathioprine, cyclosporine)

If yes, do not approve.

If no, **approve for 6 months by GPID or GPI-10 with a quantity limit of ##60 grams per 30 days.**

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **RUXOLITINIB TOPICAL (Opzelura)** requires the following rule(s) be met for approval:

- A. You have **ONE** of the following diagnoses:
1. Mild to moderate atopic dermatitis (a type of skin condition)
  2. Nonsegmental vitiligo (a type of skin condition)
- B. **If you have mild to moderate atopic dermatitis, approval also requires:**
1. You are 12 years of age or older
  2. You are **NOT** immunocompromised (low immune system)
  3. You had a trial of or contraindication (harmful for) to a topical corticosteroid (such as halobetasol, triamcinolone, fluocinonide) **OR** a topical non-steroidal immunomodulating agent (such as pimecrolimus, tacrolimus)
  4. You are **NOT** using Opzelura together with **ANY** of the following:
    - a. Other non-steroidal topicals (such as tacrolimus, pimecrolimus, Eucrisa)
    - b. Systemic therapeutic biologics (such as Dupixent, Adbry)
    - c. Other JAK inhibitors (such as Rinvoq, Cibinqo)
    - d. Potent immunosuppressants (such as azathioprine, cyclosporine)

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RUXOLITINIB TOPICAL

INITIAL CRITERIA (CONTINUED)

C. If you have nonsegmental vitiligo, approval also requires:

1. You are 12 years of age or older
2. You have depigmented (lightening of the skin) areas covering 10 percent or less of total body surface area
3. You had a trial of or contraindication (harmful for) to a topical corticosteroid (such as halobetasol, triamcinolone, fluocinonide) OR a topical calcineurin inhibitor (such as pimecrolimus, tacrolimus)
4. You are NOT using Opzelura together with ANY of the following:
  - a. Other non-steroidal topicals (such as tacrolimus, pimecrolimus, Eucrisa)
  - b. Systemic therapeutic biologics (such as Dupixent, Adbry)
  - c. Other JAK inhibitors (such as Rinvoq, Cibinqo)
  - d. Potent immunosuppressants (such as azathioprine, cyclosporine)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of mild to moderate atopic dermatitis **AND** meet the following criterion?
  - The patient has experienced or maintained improvement in pruritus, relapsing-remitting dermatitis, or facial/interdigital involvement

If yes, continue to #3.

If no, continue to #2.

2. Does the patient have a diagnosis of nonsegmental vitiligo **AND** meet the following criterion?
  - The patient has experienced or maintained clinically meaningful repigmentation

If yes, continue to #3.

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RUXOLITINIB TOPICAL

RENEWAL CRITERIA (CONTINUED)

3. Will Opzelura be used concurrently with **ANY** of the following?
- Other non-steroid topicals (e.g., pimecrolimus, tacrolimus, Eucrisa)
  - Systemic therapeutic biologics (e.g., Dupixent, Adbry)
  - Other JAK inhibitors (e.g., Rinvoq, Cibinqo)
  - Potent immunosuppressants (e.g., azathioprine, cyclosporine)

If yes, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

If no, **approve for 12 months by GPID or GPI-10 with a quantity limit of #60 grams per 30 days.**

**RENEWAL DENIAL TEXT:** *\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **RUXOLITINIB TOPICAL (Opzelura)** requires the following rule(s) be met for renewal:

- A. You have **ONE** of the following diagnoses:
1. Mild to moderate atopic dermatitis (a type of skin condition)
  2. Nonsegmental vitiligo (a type of skin condition)
- B. **If you have mild to moderate atopic dermatitis, renewal also requires:**
1. You have experienced or maintained improvement in pruritus (itchiness), relapsing-remitting (disease returns and goes away) dermatitis, or facial/interdigital (between the fingers or toes) involvement
  2. You are **NOT** using Opzelura together with **ANY** of the following:
    - a. Other non-steroidal topicals (such as tacrolimus, pimecrolimus, Eucrisa)
    - b. Systemic therapeutic biologics (such as Dupixent, Adbry)
    - c. Other JAK inhibitors (such as Rinvoq, Cibinqo)
    - d. Potent immunosuppressants (such as azathioprine, cyclosporine)
- C. **If you have nonsegmental vitiligo, renewal also requires:**
1. You have experienced or maintained clinically meaningful repigmentation (recoloration of the skin after loss in color)
  2. You are **NOT** using Opzelura together with **ANY** of the following:
    - a. Other non-steroidal topicals (such as tacrolimus, pimecrolimus, Eucrisa)
    - b. Systemic therapeutic biologics (such as Dupixent, Adbry)
    - c. Other JAK inhibitors (such as Rinvoq, Cibinqo)
    - d. Potent immunosuppressants (such as azathioprine, cyclosporine)

***(Renewal denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

RUXOLITINIB TOPICAL

RENEWAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Opzelura.

**REFERENCES**

- Opzelura [Prescribing Information]. Wilmington, DE: Incyte, Corp., September 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/23

Created: 09/21

Client Approval: 11/22

P&T Approval: 10/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SACROSIDASE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SACROSIDASE	SUCRAID	18554		GPI-10 (5120006000)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of genetically determined sucrose deficiency, which is part of congenital sucrose-isomaltase deficiency (CSID), and meet **ALL** of the following criteria?
  - Therapy is prescribed by or in consultation with a gastroenterologist or medical geneticist
  - The patient's diagnosis is confirmed by ONE of the following:
    - Small bowel biopsy
    - Sucrose breath test
    - Genetic test

If yes, **approve for 12 months by HICL or GPI-10.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SACROSIDASE (Sucraid)** requires the following rule be met for approval:

- A. You have a genetically determined sucrose deficiency, which is part of congenital sucrose-isomaltase deficiency (a type of genetic digestive condition)
- B. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions) or medical geneticist (doctor who treats gene disorders)
- C. Your diagnosis is confirmed by ONE of the following:
  1. Small bowel biopsy (removal of cells or tissue from the body for examination)
  2. Sucrose breath test
  3. Genetic test

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SACROSIDASE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

- Does the patient have a diagnosis of genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID) **AND** meet the following criterion?
  - The patient has experienced or maintained improvement on treatment

If yes, **approve for 12 months by HICL or GPI-10.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SACROSIDASE (Sucraid)** requires the following rule(s) be met for renewal:

- You have a genetically determined sucrase deficiency which is part of congenital sucrase-isomaltase deficiency (a type of genetic digestive condition)
- You have experienced or maintained improvement on treatment

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Sucraid.

**REFERENCES**

- Sucraid [Prescriber Information]. Vero Beach, FL: QOL Medical, LLC.; August 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/22

Created: 05/12

Client Approval: 05/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SARGRAMOSTIM

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SARGRAMOSTIM	LEUKINE	06074		GPI-10 (8240205000)	

**GUIDELINES FOR USE**

1. Therapy is prescribed by or given in consultation with a hematologist or oncologist?

If yes, **approve by HICL or GPI-10 for 3 months or requested duration of treatment up to 1 year.**

If no, continue to #2.

2. Is the request for **ONE** of the following indications?

- To shorten time to neutrophil recovery and to reduce the incidence of severe, life-threatening, or fatal infections following induction chemotherapy in a patient with acute myeloid leukemia (AML) AND the patient is 55 years of age or older
- For the mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis, the patient is undergoing autologous transplantation AND the patient is 18 years of age or older
- For the acceleration of myeloid reconstitution following autologous bone marrow or peripheral blood progenitor cell transplantation, in patients with non-Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (ALL) or Hodgkin's lymphoma AND the patient is 2 years of age or older
- For the acceleration of myeloid reconstitution following allogeneic bone marrow transplantation from HLA-matched related donors AND the patient is 2 years of age or older
- For the treatment of delayed neutrophil recovery or graft failure after autologous or allogeneic bone marrow transplantation AND the patient is 2 years of age or older
- To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS])

If yes, **approve by HICL or GPI-10 for 3 months or requested duration of treatment up to 1 year.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SARGRAMOSTIM (Leukine)** requires the following rule(s) be met for approval:

- A. The requested medication is prescribed by or given in consultation with a hematologist (blood specialist) or oncologist (cancer/tumor doctor), **OR** you meet **ONE** of the following:
1. You have acute myeloid leukemia (AML: type of blood and bone marrow cancer) and are using the requested medication to shorten time to neutrophil (a type of white blood cell) recovery and to reduce the incidence of severe, life-threatening, or fatal infections following induction chemotherapy AND you are 55 years of age or older

***(Denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SARGRAMOSTIM

GUIDELINES FOR USE (CONTINUED)

2. You are undergoing autologous transplantation (your own blood-forming stem cells are collected) and using the requested medication for the mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis (to collect blood sample and separate white blood cells in a lab test) AND you are 18 years of age or older
3. You have non-Hodgkin's lymphoma (NHL: type of cancer), acute lymphoblastic leukemia (ALL: type of white blood cell cancer) or Hodgkin's lymphoma (type of cancer) and are using the requested medication for the acceleration of myeloid reconstitution following autologous bone marrow or peripheral blood progenitor cell transplantation (to help your blood and bone marrow recover) AND you are 2 years of age or older
4. The requested medication is being used for the acceleration of myeloid reconstitution following allogeneic bone marrow transplantation from HLA-matched related donors (to help your blood and bone marrow recover after using a lab test to match you to the correct donors) AND you are 2 years of age or older
5. The requested medication is being used for the treatment of delayed neutrophil recovery or graft failure after autologous or allogeneic bone marrow transplantation AND you are 2 years of age or older
6. You are acutely exposed to myelosuppressive doses (doses that suppress bone marrow activity) of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]) and using the requested medication to increase your survival

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Leukine.

**REFERENCES**

- Leukine [Prescribing Information]. Lexington, MA: Partner Therapeutics, Inc.; April 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 02/03

Client Approval: 04/20

P&T Approval: 04/18



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SARILUMAB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SARILUMAB	KEVZARA	44183		GPI-10 (6650006000)	

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a rheumatologist
  - The patient had a trial of or contraindication to at least 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
  - The patient meets ONE of the following:
    - The patient had a trial of or contraindication to any TWO of the following preferred immunomodulators: Enbrel, Humira, Rinvoq, Xeljanz (IR/XR)
    - The patient has tried any TNF inhibitor (e.g., Humira, Enbrel) AND the physician has indicated the patient cannot use a JAK inhibitor (e.g., Rinvoq, Xeljanz) due to the black box warning for increased risk of mortality, malignancies, and serious cardiovascular events

[NOTE: pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #2.28 mL per 28 days.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SARILUMAB (Kevzara)** requires the following rule(s) be met for approval:

- A. You have moderate to severe rheumatoid arthritis (RA: a type of joint condition)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a rheumatologist a type of immune system doctor)
- D. You have tried or have a contraindication (harmful for) to at least 3 months of treatment with ONE DMARD (disease modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine

**(Initial denial text continued on next page)**

CONTINUED ON NEXT PAGE





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SARILUMAB

INITIAL CRITERIA (CONTINUED)

- E. You meet ONE of the following:
1. You have tried or have a contraindication (harmful for) to any TWO of the following preferred immunomodulators: Enbrel, Humira, Rinvoq, Xeljanz (immediate-release/extended-release)
  2. You have tried any tumor necrosis factor (TNF) inhibitor (such as Humira, Enbrel) AND your physician has indicated you cannot use a JAK inhibitor (such as Rinvoq, Xeljanz) due to the black box warning for increased risk of mortality (death), malignancies (cancerous), and serious cardiovascular (heart-related) events

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) AND meet the following criterion?
  - The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2.28 mL per 28 days.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SARILUMAB (Kevzara)** requires the following rule(s) be met for renewal:

- A. You have moderate to severe rheumatoid arthritis (RA: a type of joint condition)
- B. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SARILUMAB

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Kevzara.

**REFERENCE**

- Kevzara [Prescribing Information]. Bridgewater, NJ: Sanofi-Aventis US LLC; April 2018.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 03/14/22

Created: 11/16

Client Approval: 02/22

P&T Approval: 01/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SATRALIZUMAB-MWGE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SATRALIZUMAB-MWGE	ENSPRYNG	46781		GPI-10 (9940507040)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of neuromyelitis optica spectrum disorder (NMOSD) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or given in consultation with a neurologist
  - Diagnosis is confirmed by a positive serologic test for anti-aquaporin-4 (AQP4) antibodies
  - The patient is NOT concurrently using rituximab, inebilizumab or eculizumab

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Does the patient have **ONE** of the following core clinical characteristics?
  - Optic neuritis
  - Acute myelitis
  - Area postrema syndrome
  - Acute brainstem syndrome
  - Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions
  - Symptomatic cerebral syndrome with NMOSD-typical brain lesions

If yes, **approve for a total of 12 months by HICL or GPI-10 as follows:**

- **FIRST APPROVAL:** Approve for 30 days with a quantity limit of #2mL per 28 days.
- **SECOND APPROVAL:** Approve for 11 months with a quantity limit of #1mL per 28 days (Enter a start date 2 days before the end date of the first approval).

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SATRALIZUMAB-MWGE

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SATRALIZUMAB-MWGE (ENSPRYNG)** requires the following rule(s) be met for approval:

- A. You have neuromyelitis optica spectrum disorder (NMOSD: a rare immune system disease that affects the central nervous system and causes inflammation in the optic nerve and spinal cord)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or given in consultation with a neurologist (doctor who specializes in the brain, spinal cord, and nerves)
- D. Your diagnosis is confirmed by a positive serologic (blood) test for anti-aquaporin-4 (AQP4: type of protein) antibodies
- E. You are not concurrently (at the same time) using rituximab, inebilizumab, or eculizumab
- F. You have at least ONE of the following core clinical characteristics:
  - 1. Optic neuritis (inflammation that damages an eye nerve)
  - 2. Acute myelitis (sudden and severe inflammation of the spinal cord)
  - 3. Area postrema syndrome (attacks of uncontrollable nausea, vomiting, or hiccups)
  - 4. Acute brainstem syndrome (problems with vision, hearing, swallowing and muscle weakness in the head)
  - 5. Symptomatic narcolepsy (sudden attacks of sleep) or acute diencephalic clinical syndrome (rare disorder caused by a tumor above the brainstem) with NMOSD-typical diencephalic MRI lesions
  - 6. Symptomatic cerebral syndrome with NMOSD-typical brain lesions

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SATRALIZUMAB-MWGE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of neuromyelitis optica spectrum disorder (NMOSD) and meet **ALL** of the following criteria?

- The patient had a reduction in relapse frequency from baseline
- The patient is NOT concurrently using rituximab, inebilizumab or eculizumab

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1mL per 28 days.**  
If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SATRALIZUMAB-MWGE (ENSPRYNG)** requires the following rule(s) be met for renewal:

- A. You have neuromyelitis optica spectrum disorder (NMOSD: a rare disorder that affects the central nervous system and causes inflammation in the optic nerve and spinal cord)
- B. You had a reduction in relapse frequency from baseline
- C. You are not concurrently (at the same time) using rituximab, inebilizumab, or eculizumab

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Enspryng.

**REFERENCES**

- Enspryng [Prescribing Information]. South San Francisco, CA: Genentech, Inc.; March 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/22

Created: 08/20

Client Approval: 05/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SECUKINUMAB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SECUKINUMAB	COSENTYX	41715		GPI-10 (9025057500)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

- 1 Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) without psoriatic arthritis involvement and meet **ALL** of the following criteria?
  - The patient is 6 years of age or older
  - Therapy is prescribed by or in consultation with a dermatologist
  - The patient has psoriasis covering 3% or more of body surface area (BSA) OR psoriatic lesions affecting the hands, feet, genital area, or face
  - The patient had a trial of or contraindication to ONE or more forms of conventional therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids, calcipotriene, acitretin, methotrexate, or cyclosporine

If yes, **approve the requested strength and dosage form by NDC [FDB or Medi-Span] for a total of 6 months as follows:**

**FIRST APPROVAL**

- **75mg every week dosing: Approve for 1 month with a quantity limit of #2mL per 28 days. (PAC NOTE: Enter NDC 00078-1056-97 only)**
- **150mg every week dosing: Approve for 1 month with a quantity limit of #4mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only)**
- **300mg every week dosing: Approve for 1 month with a quantity limit of #8mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-41 or 00078-0639-98 only)**

**SECOND APPROVAL**

- **75mg every 4 weeks dosing: Approve for 5 months with a quantity limit of #0.5mL per 28 days. (PAC NOTE: Enter NDC 00078-1056-97 only. Start date is 3 DAYS BEFORE the END date of the first approval.)**
- **150mg every 4 weeks dosing: Approve for 5 months with a quantity limit of #1mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only. Start date is 3 DAYS BEFORE the END date of the first approval.)**
- **300mg every 4 weeks dosing: Approve for 5 months with a quantity limit of #2mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-41 or 00078-0639-98 only. Start date is 3 DAYS BEFORE the END date of the first approval.)**

If no, continue to #2.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SECUKINUMAB

INITIAL CRITERIA (CONTINUED)

2. Does the patient have a diagnosis of psoriatic arthritis (PsA) and meet **ALL** of the following criteria?
- Therapy is prescribed by or in consultation with a rheumatologist or dermatologist
  - The patient had a trial of or a contraindication to ONE DMARD (disease-modifying anti-rheumatic drugs), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

If yes, continue to #3.

If no, continue to #6.

3. Is the patient 2 to 17 years of age?

If yes, **approve the requested strength and dosage form by NDC [FDB or Medi-Span] for a total of 6 months as follows:**

**FIRST APPROVAL**

- **75mg every week dosing: Approve for 1 month with a quantity limit of #2mL per 28 days. (PAC NOTE: Enter NDC 00078-1056-97 only)**
- **150mg every week dosing: Approve for 1 month with a quantity limit of #4mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only)**

**SECOND APPROVAL**

- **75mg every 4 weeks dosing: Approve for 5 months with a quantity limit of #0.5mL per 28 days. (PAC NOTE: Enter NDC 00078-1056-97 only. Start date is 3 DAYS BEFORE the END date of the first approval.)**
- **150mg every 4 weeks dosing: Approve for 5 months with a quantity limit of #1mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only. Start date is 3 DAYS BEFORE the END date of the first approval.)**

If no, continue to #4.

4. Is the patient 18 years of age or older?

If yes, continue to #5.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SECUKINUMAB

INITIAL CRITERIA (CONTINUED)

5. Does the patient have coexistent moderate to severe plaque psoriasis (PsO)? (**Note:** For psoriatic arthritis patients with coexistent moderate to severe plaque psoriasis, use the dosing and administration recommendations for plaque psoriasis.)

If yes, **approve the requested strength and dosage form by NDC [FDB or Medi-Span] for a total of 6 months as follows:**

**FIRST APPROVAL**

- **150mg every week dosing: Approve for 1 month with a quantity limit of #4mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only)**
- **300mg every week dosing: Approve for 1 month with a quantity limit of #8mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-41 or 00078-0639-98 only)**

**SECOND APPROVAL**

- **150mg every 4 weeks dosing: Approve for 5 months with a quantity limit of #1mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only. Start date is 3 DAYS BEFORE the END date of the first approval.)**
- **300mg every 4 weeks dosing: Approve for 5 months with a quantity limit of #2mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-41 or 00078-0639-98 only. Start date is 3 DAYS BEFORE the END date of the first approval.)**

If no, continue to #7.

6. Does the patient have a diagnosis of ankylosing spondylitis (AS) and meet **ALL** of the following criteria?
- The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a rheumatologist
  - The patient had a trial of or contraindication to an NSAID (e.g., ibuprofen, naproxen, meloxicam, diclofenac, etc.)

If yes, continue to #7.

If no, continue to #12.

7. Does the patient require a loading dose?

If yes, continue to #8.

If no, continue to #10.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SECUKINUMAB

INITIAL CRITERIA (CONTINUED)

8. Is the request also for a maintenance dosage of 300mg?

If yes, continue to #9.

If no, **approve the 150mg dosage by NDC [FDB or Medi-Span] for a total of 6 months as follows:**

**FIRST APPROVAL**

- **150mg every week dosing: Approve for 1 month with a quantity limit of #4mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only)**

**SECOND APPROVAL**

- **150mg every 4 weeks dosing: Approve for 5 months with a quantity limit of #1mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only. Start date is 3 DAYS BEFORE the END date of the first approval.)**

9. Has the patient tried the 150mg maintenance dosing schedule **AND** continues to have active ankylosing spondylitis or active psoriatic arthritis?

If yes, **approve by NDC [FDB or Medi-Span] for a total of 6 months as follows:**

**FIRST APPROVAL**

- **150mg every week dosing: Approve for 1 month with a quantity limit of #4mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only)**

**SECOND APPROVAL**

- **300mg every 4 weeks dosing: Approve for 5 months with a quantity limit of #2mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-41 or 00078-0639-98 only. Start date is 3 DAYS BEFORE the END date of the first approval.)**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**[PAC NOTE: Enter proactive PAs for the 150mg dosage by NDC [FDB or Medi-Span] for a total of 6 months as follows:**

**FIRST APPROVAL**

- **150mg every week dosing: Approve for 1 month with a quantity limit of #4mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only)**

**SECOND APPROVAL**

- **150mg every 4 weeks dosing: Approve for 5 months with a quantity limit of #1mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only. Start date is 3 DAYS BEFORE the END date of the first approval.)**

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SECUKINUMAB

INITIAL CRITERIA (CONTINUED)

10. Is the request also for a maintenance dosage of 300mg?

If yes, continue to #11.

If no, **approve the 150mg dosage by NDC [FDB or Medi-Span] for 6 months with a quantity limit of #1mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only).**

11. Has the patient tried the 150mg maintenance dosing schedule **AND** continues to have active ankylosing spondylitis or active psoriatic arthritis?

If yes, **approve the 300mg dosage by NDC [FDB or Medi-Span] for 6 months with a quantity limit of #2mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-41 or 00078-0639-98 only).**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**[PAC NOTE: Enter a proactive PA for the 150mg maintenance dosage by NDC [FDB or Medi-Span] for 6 months with a quantity limit of #1mL per 28 days. Enter NDC 00078-0639-68 or 00078-0639-97 only].**

12. Does the patient have a diagnosis of non-radiographic axial spondyloarthritis (nr-axSpA) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- Therapy is prescribed by or in consultation with a rheumatologist
- The patient had a trial of or contraindication to an NSAID (e.g., ibuprofen, naproxen, meloxicam, diclofenac, etc.)
- The patient meets ONE of the following objective signs of inflammation:
  - C-reactive protein (CRP) levels above the upper limit of normal
  - Sacroiliitis on magnetic resonance imaging (MRI)

If yes, continue to #13.

If no, continue to #15.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SECUKINUMAB

INITIAL CRITERIA (CONTINUED)

13. Is the request for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA) with a loading dose?

If yes, approve the requested strength and dosage form by NDC [FDB or Medi-Span] for a total of 6 months as follows:

**FIRST APPROVAL**

- 150mg every week dosing: Approve for 1 month with a quantity of #4mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only)

**SECOND APPROVAL**

- 150mg every 4 weeks dosing: Approve for 5 months with a quantity limit of #1mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only. Start date is 3 DAYS BEFORE the END date of the first approval.)

If no, continue to #14.

14. Is the request for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA) without a loading dose?

If yes, approve the requested strength and dosage form by NDC [FDB or Medi-Span] for a total of 6 months as follows:

- 150mg every 4 weeks dosing: #1mL per 28 days (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only)

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SECUKINUMAB

INITIAL CRITERIA (CONTINUED)

15. Does the patient have a diagnosis of enthesitis-related arthritis (ERA) and meet **ALL** of the following criteria?

- The patient is 4 years of age or older
- Therapy is prescribed by or in consultation with a rheumatologist
- The patient had a trial of or contraindication to an NSAID (e.g., ibuprofen, naproxen, meloxicam, diclofenac, etc.), sulfasalazine, OR methotrexate

If yes, **approve the requested strength and dosage form by NDC [FDB or Medi-Span] for a total of 6 months as follow:**

**FIRST APPROVAL**

- **75mg every week dosing: Approve for 1 month with a quantity limit of #2mL per 28 days. (PAC NOTE: Enter NDC 00078-1056-97 only.)**
- **150mg every week dosing: Approve for 1 month with a quantity limit of #4mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only.)**

**SECOND APPROVAL**

- **75mg every 4 weeks dosing: Approve for 5 months with a quantity limit of #0.5mL per 28 days. (PAC NOTE: Enter NDC 00078-1056-97 only. Start date is 3 DAYS BEFORE the END date of the first approval.)**
- **150mg every 4 weeks dosing: Approve for 5 months with a quantity limit of #1mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only. Start date is 3 DAYS BEFORE the END date of the first approval.)**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SECUKINUMAB (Cosentyx)** requires the following rule(s) be met for approval:

A. You have **ONE** of the following diagnoses:

1. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
2. Psoriatic arthritis (PsA: a type of skin and joint condition)
3. Ankylosing spondylitis (AS: a type of joint condition)
4. Non-radiographic axial spondyloarthritis (nr-axSpA: a type of joint condition)
5. Enthesitis-related arthritis (ERA: a type of joint condition)

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SECUKINUMAB

INITIAL CRITERIA (CONTINUED)

- B. If you have moderate to severe plaque psoriasis, approval also requires:**
1. You are 6 years of age or older
  2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
  3. You have psoriasis covering 3% or more of body surface area (BSA) OR psoriatic lesions (rashes) affecting the hands, feet, genital area, or face
  4. You had a trial of or contraindication (harmful) to ONE or more forms of standard therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids, calcipotriene, acitretin, methotrexate, or cyclosporine
- C. If you have psoriatic arthritis, approval also requires:**
1. You are 2 years of age or older
  2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
  3. You had a trial of or contraindication (harmful) to ONE DMARD (disease-modifying anti-rheumatic drugs) such as methotrexate, leflunomide, hydroxychloroquine, sulfasalazine
  4. Request for 300mg dosage in psoriatic arthritis without coexisting plaque psoriasis requires you have tried the 150mg maintenance dosing schedule AND continue to have active psoriatic arthritis
- D. If you have ankylosing spondylitis, approval also requires:**
1. You are 18 years of age or older
  2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
  3. You had a trial of or contraindication (harmful for) to an NSAID (such as ibuprofen, naproxen, meloxicam, diclofenac)
  4. Request for 300mg dosage requires you have tried the 150mg maintenance dosage schedule AND continue to have active ankylosing spondylitis
- E. If you have non-radiographic axial spondyloarthritis, approval also requires:**
1. You are 18 years of age or older
  2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
  3. You had a trial of or contraindication (harmful for ) to an NSAID (such as ibuprofen, naproxen, meloxicam, diclofenac)
  4. You have ONE of the following signs of inflammation:
    - a. C-reactive protein (CRP: a measure of how much inflammation you have) levels above the upper limit of normal
    - b. Sacroiliitis (type of inflammation where lower spine and pelvis connect) on magnetic resonance imaging (MRI)

*(Initial denial text continued on next page)*

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SECUKINUMAB

INITIAL CRITERIA (CONTINUED)

F. If you have enthesitis-related arthritis, approval also requires:

1. You are 4 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
3. You had a trial of or contraindication (harmful for) to an NSAID (such as ibuprofen, naproxen, meloxicam, diclofenac), sulfasalazine, OR methotrexate

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) **AND** meet the following criterion?

- The patient has achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more while on therapy

If yes, **approve the requested strength and dosage form by NDC [FDB or Medi-Span] for 12 months with the following quantity limits:**

- **75mg every 4 weeks dosing: #0.5mL per 28 days. (PAC NOTE: Enter NDC 00078-1056-97 only)**
- **150mg every 4 weeks dosing: #1mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only)**
- **300mg every 4 weeks dosing: #2mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-41 or 00078-0639-98 only)**

If no, continue to #2.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SECUKINUMAB

RENEWAL CRITERIA (CONTINUED)

2. Does the patient have a diagnosis of psoriatic arthritis (PsA) **AND** meet the following criterion?
- The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

If yes, **approve the requested strength and dosage form by NDC [FDB or Medi-Span] for 12 months with the following quantity limits:**

- **150mg every 4 weeks dosing: #1mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only)**
- **300mg every 4 weeks dosing: #2mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-41 or 00078-0639-98 only)**

If no, continue to #3.

3. Does the patient have a diagnosis of ankylosing spondylitis (AS) **AND** meet the following criterion?
- The patient has experienced or maintained an improvement of at least 50% or 2 units (scale of 1 - 10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) while on therapy

If yes, **approve the requested strength and dosage form by NDC [FDB or Medi-Span] for 12 months with the following quantity limits:**

- **150mg every 4 weeks dosing: #1mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only)**
- **300mg every 4 weeks dosing: #2mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-41 or 00078-0639-98 only)**

If no, continue to #4.

4. Does the patient have a diagnosis of non-radiographic axial spondyloarthritis (nr-axSpA) **AND** meet the following criterion?

- The patient has experienced or maintained an improvement of at least 50% or 2 units (scale of 1 - 10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) while on therapy

If yes, **approve the requested dosage form by NDC [FDB or Medi-Span] for 12 months with the following quantity limit:**

- **150mg every 4 weeks dosing: #1mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only)**

If no, continue to #5.

CONTINUED ON NEXT PAGE





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SECUKINUMAB

RENEWAL CRITERIA (CONTINUED)

5. Does the patient have a diagnosis of enthesitis-related arthritis (ERA) **AND** meet the following criterion?

- The patient has experienced or maintained an improvement in global assessment of disease activity, functional ability, number of joints with active arthritis, OR number of joints with limited range of motion

If yes, approve the requested strength and dosage form by NDC [FDB or Medi-Span] for 12 months with the following quantity limits:

- 75mg every 4 weeks dosing: #0.5mL per 28 days. (PAC NOTE: Enter NDC 00078-1056-97 only).
- 150mg every 4 weeks dosing: #1mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only).

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SECUKINUMAB (Cosentyx)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following diagnoses:
1. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
  2. Psoriatic arthritis (PsA: a type of skin and joint condition)
  3. Ankylosing spondylitis (AS: a type of joint condition)
  4. Non-radiographic axial spondyloarthritis (nr-axSpA: a type of joint condition)
  5. Enthesitis-related arthritis (ERA: a type of joint condition)
- B. **If you have moderate to severe plaque psoriasis, renewal also requires:**
1. You have achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index: used to measure the severity and extent of psoriasis) of at least 50% or more while on therapy.
- C. **If you have psoriatic arthritis, renewal also requires:**
1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy.
- D. **If you have ankylosing spondylitis or non-radiographic axial spondyloarthritis, renewal also requires:**
1. You have experienced or maintained an improvement of at least 50% or 2 units (scale of 1 - 10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI: diagnostic test which allows a physician to determine the effectiveness of a current medication) while on therapy.

*(Renewal denial text continued on next page)*

CONTINUED ON NEXT PAGE





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SECUKINUMAB

RENEWAL CRITERIA (CONTINUED)

E. If you have enthesitis-related arthritis, renewal also requires:

1. You have experienced or maintained an improvement in global assessment of disease activity, functional ability, number of joints with active arthritis, OR number of joints with limited range of motion

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Cosentyx.

**REFERENCES**

- Cosentyx [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation. December 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/29/22

Created: 02/15

Client Approval: 07/22

P&T Approval: 01/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SELEXIPAG

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SELEXIPAG	UPTRAVI	42922		GPI-10 (4012007000)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group 1) and meets **ALL** of the following criteria?
  - Therapy is prescribed by or in consultation with a cardiologist or pulmonologist
  - Documented confirmatory PAH diagnosis based on right heart catheterization with the following parameters:
    - Mean pulmonary artery pressure (PAP) of > 20 mmHg
    - Pulmonary capillary wedge pressure (PCWP) of ≤ 15 mmHg
    - Pulmonary vascular resistance (PVR) of ≥ 3 Wood units
  - Patient has NYHA-WHO Functional Class II-IV symptoms

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SELEXIPAG

INITIAL CRITERIA (CONTINUED)

2. Does the patient have WHO Functional Class II or III symptoms **AND** meet the following criterion?
- The patient had a trial of or contraindication to TWO of the following agents from different drug classes:
    - Oral endothelin receptor antagonist (e.g., ambrisentan, bosentan, or macitentan)
    - Oral phosphodiesterase-5 inhibitor (e.g., sildenafil or tadalafil)
    - Oral cGMP stimulator (e.g., riociguat)

If yes, approve for 12 months by GPID or GPI-14 for the requested strength and formulation with the following quantity limits:

- Uptravi 200mcg tablet: #8 per day.
- Uptravi 400mcg tablet: #2 per day.
- Uptravi 600mcg tablet: #2 per day.
- Uptravi 800mcg tablet: #2 per day.
- Uptravi 1,000mcg tablet: #2 per day.
- Uptravi 1,200mcg tablet: #2 per day.
- Uptravi 1,400mcg tablet: #2 per day.
- Uptravi 1,600mcg tablet: #2 per day.
- Uptravi 200-800 Titration pack: #1 per 12 months.
- Uptravi 1800mcg vial: #2 per day.  
(NOTE: Uptravi vial is a non-self-administered [NSA] agent and may not be covered by some plans.)

If no, continue to #3.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SELEXIPAG

INITIAL CRITERIA (CONTINUED)

3. Does the patient have WHO Functional Class III symptoms with evidence of rapid progression/poor prognosis, or WHO Functional Class IV symptoms **AND** meet the following criterion?
- The patient had a trial of or contraindication to ONE IV/SQ prostacyclin (e.g., epoprostenol, treprostinil)

If yes, **approve for 12 months by GPID or GPI-14 for the requested strength and formulation with the following quantity limits:**

- Uptravi 200mcg tablet: #8 per day.
- Uptravi 400mcg tablet: #2 per day.
- Uptravi 600mcg tablet: #2 per day.
- Uptravi 800mcg tablet: #2 per day.
- Uptravi 1,000mcg tablet: #2 per day.
- Uptravi 1,200mcg tablet: #2 per day.
- Uptravi 1,400mcg tablet: #2 per day.
- Uptravi 1,600mcg tablet: #2 per day.
- Uptravi 200-800 Titration pack: #1 per 12 months.
- Uptravi 1800mcg vial: #2 per day.  
(NOTE: Uptravi vial is a non-self-administered [NSA] agent and may not be covered by some plans.)

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SELEXIPAG

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SELEXIPAG (Upravi)** requires the following rule(s) be met for approval:

- A. You have pulmonary arterial hypertension (PAH: a type of heart and lung condition)
- B. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung doctor)
- C. You have documented confirmatory pulmonary arterial hypertension diagnosis based on right heart catheterization (a test used to measure how well your heart is pumping) with the following lab values:
  - 1. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
  - 2. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
  - 3. Pulmonary vascular resistance (PVR) greater than or equal to 3 Wood units
- D. You have New York Heart Association-World Health Organization (NYHA-WHO) Functional Class II-IV symptoms (classification system for heart failure)
- E. **If you have WHO Functional Class II or III symptoms, approval also requires:**
  - 1. You had a trial of or contraindication (harmful for) to TWO of the following agents from different drug classes:
    - a. Oral endothelin receptor antagonist (such as Tracleer, Letairis, Opsumit)
    - b. Oral phosphodiesterase-5 inhibitor (such as Adcirca or Revatio)
    - c. Oral cGMP stimulator (such as Adempas)
- F. **If you have WHO Functional Class III symptoms with evidence of rapid progression/poor prognosis, or WHO Functional Class IV symptoms, approval also requires:**
  - 1. You had a trial of or contraindication (harmful for) to ONE intravenous or subcutaneous prostacyclin (such as Flolan/Veletri or Remodulin)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SELEXIPAG

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group 1) and meet **ONE** of the following criteria?
  - The patient shown improvement from baseline in the 6-minute walk distance test
  - The patient remained stable from baseline in the 6-minute walk distance test **AND** the patients WHO functional class remained stable or has improved

If yes, **approve for 12 months by GPID or GPI-14 for the requested strength and formulation with the following quantity limits:**

- Uptravi 200mcg tablet: #8 per day.
  - Uptravi 400mcg tablet: #2 per day.
  - Uptravi 600mcg tablet: #2 per day.
  - Uptravi 800mcg tablet: #2 per day.
  - Uptravi 1,000mcg tablet: #2 per day.
  - Uptravi 1,200mcg tablet: #2 per day.
  - Uptravi 1,400mcg tablet: #2 per day.
  - Uptravi 1,600mcg tablet: #2 per day.
  - Uptravi 1800mcg vial: #2 per day.
- (NOTE: Uptravi vial is a non-self-administered [NSA] agent and may not be covered by some plans.)

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SELEXIPAG (Uptravi)** requires the following rule(s) be met for renewal:

- A. You have pulmonary arterial hypertension (PAH: a type of heart and lung condition)
- B. You meet ONE of the following:
  1. You have shown improvement from baseline in the 6-minute walk distance
  2. You have a stable 6-minute walk distance from baseline AND your World Health Organization (WHO) functional class (classification system for heart failure) has remained stable or improved

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**SELEXIPAG**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Upravi.

**REFERENCES**

- Upravi [Prescribing Information]; San Francisco, CA: Actelion Pharmaceuticals US, Inc.; July 2021.

Library	Commercial	NSA
Yes	Yes	Yes

Part D Effective: N/A

Commercial Effective: 04/01/22

Created: 01/16

Client Approval: 02/22

P&T Approval: 01/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**SELINEXOR**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SELINEXOR	XPOVIO	45854		GPI-10 (2156006000)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of multiple myeloma (MM) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The requested medication will be used in combination with bortezomib **AND** dexamethasone
  - The patient has received at least one prior therapy

If yes, approve for 12 months by GPID or GPI-14 for all strengths as follows:

- **Xpovio 20mg tablet for**
  - 40mg once weekly dose: #8 per 28 days.
  - 60mg once weekly dose: #12 per 28 days.
  - 80mg once weekly dose: #16 per 28 days.
  - 100mg once weekly dose: #20 per 28 days.
- **Xpovio 40mg tablet for**
  - 40mg once weekly dose: #4 per 28 days.
  - 80mg once weekly dose: #8 per 28 days.
- **Xpovio 50mg tablet for**
  - 100mg once weekly dose: #8 per 28 days.
- **Xpovio 60mg tablet for**
  - 60mg once weekly dose: #4 per 28 days.

If no, continue to #2.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SELINEXOR

**GUIDELINES FOR USE (CONTINUED)**

2. Does the patient have a diagnosis of relapsed or refractory multiple myeloma (RRMM) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The requested medication will be used in combination with dexamethasone
- The patient has received at least four prior therapies for the treatment of RRMM
- The patient's RRMM is refractory to **ALL** of the following:
  - Two proteasome inhibitors (e.g., bortezomib, carfilzomib)
  - Two immunomodulatory agents (e.g., lenalidomide, pomalidomide)
  - One anti-CD38 monoclonal antibody (e.g., daratumumab)

If yes, approve for 12 months by GPID or GPI-14 for all strengths as follows:

- **Xpovio 20mg tablet for**
  - 60mg once weekly dose: #12 per 28 days.
  - 80mg once weekly dose: #16 per 28 days.
  - 100mg once weekly dose: #20 per 28 days.
  - 80mg twice weekly (160mg total per week) dose: #32 per 28 days.
- **Xpovio 40mg tablet for**
  - 80mg once weekly: #8 per 28 days.
- **Xpovio 50mg tablet for**
  - 100mg once weekly dose: #8 per 28 days.
- **Xpovio 60mg tablet for**
  - 60mg once weekly dose: #4 per 28 days.

If no, continue to #3.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SELINEXOR

GUIDELINES FOR USE (CONTINUED)

3. Does the patient have a diagnosis of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma and meet **ALL** of the following criteria?
- The patient is 18 years of age or older
  - The patient has received at least two lines of systemic therapy

If yes, approve for 12 months by GPID or GPI-14 for all strengths as follows:

- **Xpovio 20mg tablet for**
  - 40mg once weekly dose: #8 per 28 days.
  - 60mg once weekly dose: #12 per 28 days.
  - 40mg twice weekly (80mg total per week) dose: #16 per 28 days.
  - 60mg twice weekly (120mg total per week) dose: #24 per 28 days.
- **Xpovio 40mg tablet for**
  - 40mg once weekly dose: #4 per 28 days.
  - 40mg twice weekly (80 mg total per week) dose: #8 per 28 days.
- **Xpovio 60mg tablet for**
  - 60mg once weekly dose: #4 per 28 days.

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SELINEXOR (Xpovio)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:

1. Multiple myeloma (MM: cancer of a type of white blood cells called plasma cells)
2. Relapsed or refractory multiple myeloma (RRMM: cancer of a type of white blood cells called plasma cells, that has return or did not respond to treatment)
3. Relapsed or refractory diffuse large B-cell lymphoma (DLBCL: type of cancer that starts in the immune system), including DLBCL arising from follicular lymphoma

B. You are 18 years of age or older

C. **If you have multiple myeloma, approval also requires:**

1. The requested medication will be used in combination with Velcade (bortezomib) and dexamethasone
2. You have received at least one therapy before Xpovio

**(Denial text continued on next page)**

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SELINEXOR

GUIDELINES FOR USE (CONTINUED)

- D. **If you have relapsed or refractory multiple myeloma, approval also requires:**
  1. The requested medication will be used in combination with dexamethasone
  2. You have received at least four prior therapies for the treatment of RRMM)
  3. Your RRMM is refractory (non-responsive) to **ALL** of the following:
    - a. Two proteasome inhibitors (such as bortezomib, carfilzomib)
    - b. Two immunomodulatory agents (such as lenalidomide, pomalidomide)
    - c. One anti-CD38 monoclonal antibody (such as daratumumab)
- E. **If you have relapsed or refractory diffuse large B-cell lymphoma (DLBCL), approval also requires:**
  1. You have received at least two lines of systemic therapy (treatment that spreads throughout the body)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Xpovio.

**REFERENCES**

- Xpovio [Prescribing Information]. Newton, MA: Karyopharm Therapeutics Inc.; April 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 05/10/21

Created: 07/19

Client Approval: 04/21

P&T Approval: 01/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**SELPERCATINIB**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SELPERCATINIB	RETEVMO	46525		GPI-10 (2153577900)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of locally advanced or metastatic non-small cell lung cancer (NSCLC) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient's cancer has a *RET* gene fusion, as detected by an FDA-approved test

If yes, **approve for 12 months by GPID or GPI-14 for all strengths as follows:**

- **40mg: #6 per day.**
- **80mg: #4 per day.**

If no, continue to #2.

2. Does the patient have a diagnosis of advanced or metastatic medullary thyroid cancer (MTC) and meet **ALL** of the following criteria?

- The patient is 12 years of age or older
- The patient's cancer has a *RET*-mutation, as detected by an FDA-approved test
- The patient requires systemic therapy

If yes, **approve for 12 months by GPID or GPI-14 for all strengths as follows:**

- **40mg: #6 per day.**
- **80mg: #4 per day.**

If no, continue to #3.

3. Does the patient have a diagnosis of advanced or metastatic thyroid cancer and meet **ALL** of the following criteria?

- The patient is 12 years of age or older
- The patient's cancer has a *RET* gene fusion, as detected by an FDA-approved test
- The patient requires systemic therapy
- The thyroid cancer is refractory to radioactive iodine therapy (if radioactive iodine is appropriate)

If yes, **approve for 12 months by GPID or GPI-14 for all strengths as follows:**

- **40mg: #6 per day.**
- **80mg: #4 per day.**

If no, continue to #4.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SELPERCATINIB

GUIDELINES FOR USE (CONTINUED)

4. Does the patient have a diagnosis of locally advanced or metastatic solid tumors and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient's tumor has a *RET* gene fusion
- The tumor has progressed on or following prior systemic treatment OR the patient has no satisfactory alternative treatment options

If yes, **approve for 12 months by GPID or GPI-14 for all strengths as follows:**

- **40mg: #6 per day.**
- **80mg: #4 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SELPERCATINIB (Retevmo)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:

1. Locally advanced or metastatic non-small cell lung cancer (a type of lung cancer that has spread to nearby tissue or lymph nodes, or has spread to other parts of the body)
2. Advanced or metastatic medullary thyroid cancer (a type of thyroid cancer that has progressed or has spread to other parts of the body)
3. Advanced or metastatic thyroid cancer (thyroid cancer that has progressed or has spread to other parts of the body)
4. Locally advanced or metastatic solid tumors (abnormal mass that has spread to nearby tissue or lymph nodes, or has spread to other parts of the body)

B. **If you have locally advanced or metastatic non-small cell lung cancer, approval also requires:**

1. You are 18 years of age or older
2. Your cancer has a rearranged during transfection (*RET*: type of gene) gene fusion, as detected by a Food and Drug Administration (FDA) approved test

C. **If you have advanced or metastatic medullary thyroid cancer, approval also requires:**

1. You are 12 years of age or older
2. Your cancer has a rearranged during transfection (*RET*: type of gene) mutation, as detected by a Food and Drug Administration (FDA) approved test
3. You require systemic therapy (treatment that travels through the entire body)

**(Denial text continued on next page)**

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SELPERCATINIB

GUIDELINES FOR USE (CONTINUED)

- D. **If you have advanced or metastatic thyroid cancer, approval also requires:**
  1. You are 12 years of age or older
  2. You require systemic therapy (treatment that travels through the entire body)
  3. Your cancer has a rearranged during transfection (*RET*: type of gene) gene fusion, as detected by a Food and Drug Administration (FDA) approved test
  4. Your thyroid cancer is refractory (has not responded) to radioactive iodine therapy, if radioactive iodine is appropriate
- E. **If you have locally advanced or metastatic solid tumors, approval also requires:**
  1. You are 18 years of age or older
  2. Your tumor has a rearranged during transfection (*RET*: type of gene) gene fusion
  3. Your tumor has progressed on or following prior systemic treatment OR you have no satisfactory alternative treatment options

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Retevmo.

**REFERENCES**

- Retevmo [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC; September 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/17/22

Created: 07/20

Client Approval: 09/22

P&T Approval: 10/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**SELUMETINIB**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SELUMETINIB	KOSELUGO	46451		GPI-10 (2153356550)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of neurofibromatosis type 1 (NF1) and meet **ALL** of the following criteria?

- The patient is 2 to 17 years of age
- The patient has symptomatic, inoperable plexiform neurofibromas (PN)

If yes, **approve for 12 months by GPID or GPI-14 for the requested strength with the following quantity limits:**

- **Koselugo 10mg: #10 per day.**

**Koselugo 25mg: #4 per day.**

- 

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SELUMETINIB (Koselugo)** requires the following rule(s) be met for approval:

- A. You have neurofibromatosis type 1 (NF1: a genetic disorder that causes light brown skin spots and non-cancerous tumors to form on nerve tissue)
- B. You are 2 to 17 years of age
- C. You have symptomatic, inoperable (not treatable by surgery) plexiform neurofibromas (PN: tumors that grow from nerves anywhere in the body)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Koselugo.

**REFERENCES**

- Koselugo [Prescribing Information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; April 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/01/20

Created: 07/20

Client Approval: 08/20

P&T Approval: 07/20

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SETMELANOTIDE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SETMELANOTIDE ACETATE	IMCIVREE	47002		GPI-10 (6125386010)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Is the request for chronic weight management in obesity, and does the patient meet **ALL** of the following criteria?
  - The patient is 6 years of age or older
  - The patient's obesity is due to **ONE** of the following deficiencies:
    - Proopiomelanocortin (POMC)
    - Proprotein convertase subtilisin/kexin type 1 (PCSK1)
    - Leptin receptor (LEPR)
  - Confirmed genetic testing demonstrates variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS)

If yes, **approve for 16 weeks by HICL or GPI-10 with a quantity limit of #9mL (9 vials) per 30 days.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SETMELANOTIDE (Imcivree)** requires the following rule(s) be met for approval:

- A. The request is for chronic weight loss management
- B. You are 6 years of age or older
- C. Your obesity is confirmed by ONE of the following deficiencies:
  - a. Proopiomelanocortin (POMC: type of gene)
  - b. Proprotein convertase subtilisin/kexin type 1 (PCSK1: type of gene)
  - c. Leptin receptor (LEPR: type of gene)
- D. Confirmed genetic testing shows variants (changes) in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic (causing disease), likely pathogenic, or of uncertain significance (VUS)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SETMELANOTIDE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

- 1. Has the patient lost at least 5% of baseline body weight or 5% of baseline BMI for those with continued growth potential?

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #9mL (9 vials) per 30 days.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SETMELANOTIDE (Imcivree)** requires the following rule(s) be met for approval:

- A. You have lost at least 5% of your baseline body weight or 5% of your baseline body mass index (BMI: a measure of body fat based on your height and weight)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Imcivree.

**REFERENCES**

- Imcivree [Prescribing Information]. Boston, MA: Rhythm Pharmaceuticals, Inc.; November 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/21

Created: 02/21

Client Approval: 02/21

P&T Approval: 01/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SILDENAFIL IV

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SILDENAFIL CITRATE	REVATIO, SILDENAFIL CITRATE		28273	GPI-14 (40143060102020)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group 1) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- Therapy is prescribed by or in consultation with a cardiologist or pulmonologist
- The patient has NYHA-WHO Functional Class II to IV symptoms
- The patient is NOT concurrently or intermittently taking oral erectile dysfunction agents (e.g., Cialis, Viagra) or any organic nitrates in any form
- The patient is NOT concurrently taking guanylate cyclase stimulators (e.g., Adempas)

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Does the patient have documentation (e.g., chart note, lab result, diagnostic test result, etc.) confirming PAH diagnosis based on right heart catheterization with **ALL** of the following parameters?

- Mean pulmonary artery pressure (PAP) > 20 mmHg
- Pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg
- Pulmonary vascular resistance (PVR) ≥ 3 Wood units

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #37.5mL per day.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SILDENAFIL IV

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SILDENAFIL IV (Revatio)** requires the following rule(s) be met for approval:

- A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO Group 1: a way to classify the severity of disease)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung/breathing doctor)
- D. There is documentation (such as chart note, lab result, diagnostic test result) showing you have pulmonary arterial hypertension based on all of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
  - 1. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
  - 2. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
  - 3. Pulmonary vascular resistance (PVR) greater than or equal to 3 Wood units
- E. You have New York Heart Association-World Health Organization (NYHA-WHO) Functional Class II to IV symptoms (a way to classify how limited you are during physical activity)
- F. You are NOT concurrently (at the same time) or intermittently (off and on) taking oral erectile dysfunction agents (such as Cialis, Viagra) or any organic nitrates in any form
- G. You are NOT concurrently (at the same time) taking guanylate cyclase stimulators (drugs that also treat pulmonary hypertension such as Adempas)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SILDENAFIL IV

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group 1) and meet **ALL** the following criteria?

- The patient is NOT concurrently or intermittently taking oral erectile dysfunction agents (e.g., Cialis, Viagra) or any organic nitrates in any form
- The patient is NOT concurrently taking guanylate cyclase stimulators (e.g., Adempas)
- The patient has shown improvement from baseline in the 6-minute walk distance test OR has remained stable from baseline in the 6-minute walk distance test with a stable or improved WHO functional class

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #37.5mL per day.**  
If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SILDENAFIL IV (Revatio)** requires the following rule(s) be met for renewal:

- A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO) Group 1 (a way to classify the severity of disease)
- B. You are NOT concurrently (at the same time) or intermittently (off and on) taking oral erectile dysfunction agents (such as Cialis, Viagra) or any organic nitrates in any form
- C. You are NOT concurrently (at the same time) taking guanylate cyclase stimulators (drugs that also treat pulmonary hypertension such as Adempas)
- D. You have shown improvement from baseline in the 6-minute walk distance test, OR have remained stable from baseline in the 6-minute walk distance test with a stable or improved World Health Organization functional class (a way to classify how limited you are during physical activity)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**SILDENAFIL IV**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Revatio.

**REFERENCES**

- Revatio [Prescribing Information]. New York, NY: Pfizer Inc.; January 2023.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 03/06/23

Created: 01/08

Client Approval: 02/23

P&T Approval: 10/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SILDENAFIL SUSPENSION

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SILDENAFIL CITRATE	REVATIO, SILDENAFIL CITRATE		33186	GPI-14 (40143060102020)	

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group I) **AND** meet the following criterion?

- The patient is 1 to 17 years of age

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #14.93mL per day (4 bottles per 30 days).**

If no, continue to #2.

2. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group 1) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- Therapy is prescribed by or in consultation with a cardiologist or pulmonologist
- The patient has NYHA-WHO Functional Class II to IV symptoms
- The patient is NOT concurrently or intermittently taking oral erectile dysfunction agents (e.g., Cialis, Viagra) or any organic nitrates in any form
- The patient is NOT concurrently taking guanylate cyclase stimulators (e.g., Adempas)
- The patient is unable to swallow pills and has tried crushed sildenafil tablets

If yes, continue to #3.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

3. Does the patient have documentation (e.g., chart note, lab result, diagnostic test result, etc.) confirming PAH diagnosis based on right heart catheterization with **ALL** of the following parameters?

- Mean pulmonary artery pressure (PAP) > 20 mmHg
- Pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg
- Pulmonary vascular resistance (PVR) ≥ 3 Wood units

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #26.13mL per day (7 bottles per 30 days).**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SILDENAFIL SUSPENSION

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SILDENAFIL SUSPENSION (Revatio)** requires the following rule(s) be met for approval:

- A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO Group 1: a way to classify the severity of disease)
- B. You are 1 year of age or older
- C. **If you are 18 years of age or older, approval also requires:**
  1. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung/breathing doctor)
  2. There is documentation (such as chart note, lab result, diagnostic test result) showing you have pulmonary arterial hypertension based on all of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
    - i. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
    - ii. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
    - iii. Pulmonary vascular resistance (PVR) greater than or equal to 3 Wood units
  3. You have New York Heart Association-World Health Organization (NYHA-WHO) Functional Class II to IV symptoms (a way to classify how limited you are during physical activity)
  4. You are NOT concurrently (at the same time) or intermittently (off and on) taking oral erectile dysfunction agents (such as Cialis, Viagra) or any organic nitrates in any form
  5. You are NOT concurrently (at the same time) taking guanylate cyclase stimulators (drugs that also treat pulmonary hypertension such as Adempas)
  6. You are unable to swallow pills AND you have tried crushed sildenafil tablets

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SILDENAFIL SUSPENSION

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group I) **AND** meet the following criterion?

- The patient is 1 to 17 years old

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #14.93mL per day (4 bottles per 30 days).**

If no, continue to #2.

2. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group 1) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient is NOT concurrently or intermittently taking oral erectile dysfunction agents (e.g., Cialis, Viagra) or any organic nitrates in any form
- The patient is NOT concurrently taking guanylate cyclase stimulators (e.g., Adempas)
- The patient has shown improvement from baseline in the 6-minute walk distance test OR has remained stable from baseline in the 6-minute walk distance test with a stable or improved WHO functional class

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #26.13mL per day (7 bottles per 30 days).**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SILDENAFIL SUSPENSION (Revatio)** requires the following rule(s) be met for renewal:

- A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO) Group 1 (a way to classify the severity of disease)
- B. You are 1 year of age or older

***(Renewal denial text continued on next page)***

CONTINUED ON NEXT PAGE





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SILDENAFIL SUSPENSION

RENEWAL CRITERIA (CONTINUED)

C. If you are 18 years of age or older, approval also requires:

1. You are NOT concurrently (at the same time) or intermittently (off and on) taking oral erectile dysfunction agents (such as Cialis, Viagra) or any organic nitrates in any form
2. You are NOT concurrently (at the same time) taking guanylate cyclase stimulators (drugs that also treat pulmonary hypertension such as Adempas)
3. You have shown improvement from baseline in the 6-minute walk distance test OR have remained stable from baseline in the 6-minute walk distance test with a stable or improved World Health Organization functional class (a way to classify how limited you are during physical activity)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Revatio.

REFERENCES

- Revatio [Prescribing Information]. New York, NY: Pfizer Inc.; January 2023.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 03/06/23

Created: 01/08

Client Approval: 02/23

P&T Approval: 04/23



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SILDENAFIL TABLET

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SILDENAFIL CITRATE	REVATIO, SILDENAFIL CITRATE		24758	GPI-14 (40143060100320)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group I) **AND** meet the following criterion?

- The patient is 1 to 17 years of age

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #6 per day.**  
If no, continue to #2.

2. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group 1) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- Therapy is prescribed by or in consultation with a cardiologist or pulmonologist
- The patient has NYHA-WHO Functional Class II to IV symptoms
- The patient is NOT concurrently or intermittently taking oral erectile dysfunction agents (e.g., Cialis, Viagra) or any organic nitrates in any form
- The patient is NOT concurrently taking guanylate cyclase stimulators (e.g., Adempas)

If yes, continue to #3.  
If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

3. Does the patient have documentation (e.g., chart note, lab result, diagnostic test result, etc.) confirming PAH diagnosis based on right heart catheterization with **ALL** of the following parameters?

- Mean pulmonary artery pressure (PAP) > 20 mmHg
- Pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg
- Pulmonary vascular resistance (PVR) ≥ 3 Wood units

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #12 per day.**  
If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SILDENAFIL TABLET

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SILDENAFIL TABLET (Revatio)** requires the following rule(s) be met for approval:

- A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO Group 1: a way to classify the severity of disease)
- B. You are 1 year of age or older
- C. **If you are 18 years of age or older, approval also requires:**
  1. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung/breathing doctor)
  2. There is documentation (such as chart note, lab result, diagnostic test result) showing you have pulmonary arterial hypertension based on all of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
    - i. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
    - ii. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
    - iii. Pulmonary vascular resistance (PVR) greater than or equal to 3 Wood units
  3. You have New York Heart Association-World Health Organization (NYHA-WHO) Functional Class II to IV symptoms (a way to classify how limited you are during physical activity)
  4. You are NOT concurrently (at the same time) or intermittently (off and on) taking oral erectile dysfunction agents (such as Cialis, Viagra) or any organic nitrates in any form
  5. You are NOT concurrently (at the same time) taking guanylate cyclase stimulators (drugs that also treat pulmonary hypertension such as Adempas)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group I) **AND** meet the following criterion?
  - The patient is 1 to 17 years old

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #6 per day.**  
If no, continue to #2.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SILDENAFIL TABLET

RENEWAL CRITERIA (CONTINUED)

2. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group 1) and meet **ALL** the following criteria?

- The patient is 18 years of age or older
- The patient is NOT concurrently or intermittently taking oral erectile dysfunction agents (e.g., Cialis, Viagra) or any organic nitrates in any form
- The patient is NOT concurrently taking guanylate cyclase stimulators (e.g., Adempas)
- The patient has shown improvement from baseline in the 6-minute walk distance test OR has remained stable from baseline in the 6-minute walk distance test with a stable or improved WHO functional class

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #12 per day.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SILDENAFIL TABLET (Revatio)** requires the following rule(s) be met for renewal:

- A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO) Group 1 (a way to classify the severity of disease)
- B. You are 1 year of age or older
- C. **If you are 18 years of age or older, approval also requires:**
  1. You are NOT concurrently (at the same time) or intermittently (off and on) taking oral erectile dysfunction agents (such as Cialis, Viagra) or any organic nitrates in any form
  2. You are NOT concurrently (at the same time) taking guanylate cyclase stimulators (drugs that also treat pulmonary hypertension such as Adempas)
  3. You have shown improvement from baseline in the 6-minute walk distance test OR have remained stable from baseline in the 6-minute walk distance test with a stable or improved World Health Organization functional class (a way to classify how limited you are during physical activity)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**SILDENAFIL TABLET**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Revatio.

**REFERENCES**

- Revatio [Prescribing Information]. New York, NY: Pfizer Inc.; January 2023.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 03/06/23

Created: 01/08

Client Approval: 02/23

P&T Approval: 04/23



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SIMEPREVIR

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SIMEPREVIR	OLYSIO	40771		GPI-10 (1235307710)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of chronic hepatitis C, genotype 1 and meet **ALL** of the following?
  - The patient is 18 years of age or older
  - The patient has a recent HCV infection documented by one detectable HCV RNA level within the past 6 months

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Has the patient completed a prior full course of therapy with 1) any HCV protease inhibitor [for example, telaprevir (Incivek), simeprevir (Olysio), or boceprevir (Victrelis)] OR 2) regimen containing an NS5A inhibitor (e.g., Harvoni, Epclusa, Technivie, Viekira Pak or Viekira XR, Zepatier, or Daklinza-containing regimen) and has not achieved a sustained virologic response (SVR)?

If yes, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

If no, continue to #3.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SIMEPREVIR

GUIDELINES FOR USE (CONTINUED)

3. Does the patient meet **ONE** of the following criteria?

- The patient has decompensated or compensated cirrhosis
- The patient has limited life expectancy (less than 12 months) due to non-liver related comorbid conditions
- The requested medication is being used with ribavirin AND peginterferon alfa
- The patient is taking any of the following medications that are not recommended for concurrent use with Olysio:
  - Amiodarone, carbamazepine, phenytoin, phenobarbital, oxcarbazepine, rifampin, rifabutin, rifapentine, erythromycin (does not include topical formulations), clarithromycin, telithromycin, itraconazole, ketoconazole, posaconazole, fluconazole (does not include topical formulations), voriconazole, dexamethasone, cisapride, cyclosporine, rosuvastatin (dose above 10mg), or atorvastatin (dose above 40mg)
  - Any of the following HIV medications:
    - A cobicistat-containing medication (e.g., Stribild or Genvoya [elvitegravir/cobicistat/emtricitabine/tenofovir], Evotaz, PrezcoBix, Tybost)
    - An HIV protease inhibitor (e.g., atazanavir, fosamprenavir, lopinavir, indinavir, nelfinavir, saquinavir, tipranavir, ritonavir, darunavir/ritonavir)
    - Delavirdine, etravirine, nevirapine, or efavirenz

If yes, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

If no, continue to #4.

4. Is the request for a combination regimen with Sovaldi plus Olysio for 12 weeks?

If yes, continue to #5.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

5. Does the patient meet **ONE** of the following?

- The patient has contraindications to Epclusa, Harvoni and Mavyret
- The patient has previously failed a short trial with Epclusa, Harvoni or Mavyret (e.g., inability to tolerate, adverse effect early in therapy); [**NOTE:** An individual who has completed a full course of therapy with Epclusa, Harvoni or Mavyret that did not achieve SVR will not be approved]

If yes, continue to #6.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SIMEPREVIR

GUIDELINES FOR USE (CONTINUED)

6. Does the patient meet **ONE** of the following?

- The patient is treatment naïve
- The patient is treatment experienced with prior treatment with peginterferon/ribavirin

If yes, **approve for the requested strengths for 12 weeks by HICL or GPI-10 for #1 per day.**

**CLINICAL PHARMACISTS:** Please review Sovaldi prior authorization guideline, member history, and hepatitis C MRF if available to ensure appropriate length of approval.

If no, do not approve.

**DENIAL TEXT:** *\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **SIMEPREVIR (Olysio)** requires the following rule(s) be met for approval:

- A. You have chronic hepatitis C, genotype 1 (type of liver inflammation)
- B. You are 18 years of age or older
- C. You must have documentation of a recent hepatitis c virus infection by at least one detectable HCV RNA level (amount of virus in your blood) within the past 6 months
- D. You will be using Olysio with Sovaldi taken at the same time
- E. You have previously failed a short trial of Harvoni, Mavyret or Epclusa and stopped due to reasons such as adverse effect or intolerance early in therapy, unless there is a medical reason why you cannot (contraindication) take all 3 agents. The medication will not be approved for an individual who has completed a full course of therapy that did not achieve SVR (sustained virologic response)
- F. You are treatment naïve (never previously treated) or treatment-experienced with prior treatment with peginterferon/ribavirin

**Olysio will not be approved for the following patients:**

- A. You have failed a full course of treatment with 1) any HCV protease inhibitor (for example, simeprevir [Olysio], telaprevir [Incivek] or boceprevir [Victrelis]) OR 2) a regimen containing an NS5A inhibitor (e.g., Harvoni, Epclusa, Technivie, Viekira Pak or Viekira XR, Zepatier, or Daklinza-containing regimen)
- B. You have compensated cirrhosis (no symptoms related to liver damage) or decompensated cirrhosis (you have symptoms related to liver damage)
- C. You have a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions
- D. You are using Olysio with ribavirin and peginterferon alfa  
**(Denial text continued on next page)**

CONTINUED ON NEXT PAGE





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SIMEPREVIR

GUIDELINES FOR USE (CONTINUED)

- E. You are taking any of the following medications that are not recommended for concurrent use with Olysio:
1. Amiodarone, carbamazepine, phenytoin, phenobarbital, oxcarbazepine, rifampin, rifabutin, rifapentine, erythromycin, clarithromycin, telithromycin, itraconazole, ketoconazole, posaconazole, fluconazole, voriconazole, dexamethasone, cisapride, cyclosporine, rosuvastatin (dose above 10mg), or atorvastatin (dose above 40mg)
  2. Any cobicistat-containing medication (such as Stribild or Genvoya [elvitegravir/cobicistat/emtricitabine/tenofovir], Evotaz, Prezcofix, Tybost)
  3. Delavirdine, etravirine, nevirapine, or efavirenz
  4. Any HIV protease inhibitor (such as atazanavir, fosamprenavir, lopinavir, indinavir, nelfinavir, saquinavir, tipranavir, ritonavir, darunavir/ritonavir)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Olysio.

REFERENCES

- Guidance from the American Association for the Study of Liver Diseases (AASLD) and the Infectious Disease Society of America (IDSA) Recommendations for Testing, Managing, and Treating hepatitis C. Available online at <http://www.hcvguidelines.org/full-report-view> Accessed November 3, 2022.
- Olysio [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals; November 2017.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/23

Created: 02/14

Client Approval: 11/22

P&T Approval: 10/17



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**SIMVASTATIN 80**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
EZETIMIBE/ SIMVASTATIN	VYTORIN		23126	GPI-14 (39994002300350)	
SIMVASTATIN	ZOCOR, SIMVASTATIN		26535	GPI-14 (39400075000360)	

**GUIDELINES FOR USE**

1. Has the patient been taking the requested medication for at least 12 months?

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #1 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SIMVASTATIN 80 (VYTORIN, ZOCOR)** requires the following rule(s) be met for approval:

A. You have been taking the medication for at least 12 months

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Vytorin and Zocor.

**REFERENCES**

- Vytorin [Prescribing Information]. Whitehouse Station, NJ: Merck & Co., Inc.; September 2020.
- Zocor [Prescribing Information]. Whitehouse Station, NJ: Merck & Co., Inc.; September 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 05/14/21

Created: 08/11

Client Approval: 05/21

P&T Approval: 08/11



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**SIMVASTATIN ORAL SUSPENSION**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SIMVASTATIN	FLOLIPID		41189 41192	GPI-14 (39400075001810) (39400075001820)	

**GUIDELINES FOR USE**

1. Does the patient meet **ALL** of the following criteria?

- Previous trial of or contraindication to simvastatin tablets
- Prescriber documentation that the patient has dysphagia, difficulty swallowing tablets, or has a feeding tube (e.g., G-tube or J-tube)

If yes, continue to #2.

If no, do not approve

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Is the patient also requesting a zero dollar cost share exception (i.e., the plan follows Affordable Care Act [ACA] recommendations and is linked to MedImpact's Essential Health Benefit Tables)?

If yes, continue to #3.

If no, **approve for 12 months by GPID or GPI-14 with the following quantity limits (NOTE: Override the PA edit only, no change in copay):**

- **Flolipid 20mg/5mL: 150mL (#1 bottle) per 30 days.**
- **Flolipid 40mg/5mL: 150mL (#1 bottle) per 30 days.**

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SIMVASTATIN ORAL SUSPENSION

GUIDELINES FOR USE (CONTINUED)

3. Is the patient between 40-75 years of age without a history of cardiovascular disease and has **NOT** used any of the following secondary prevention medications for cardiovascular disease within the past 120 days based on the patient's prescription claims profile or medical records?
- Aspirin/dipyridamole (Aggrenox)
  - Clopidogrel (Plavix)
  - Dipyridamole
  - Nitroglycerin (i.e., oral, sublingual, transdermal patch or ointment, translingual dosage forms)
  - Prasugrel (Effient)
  - Praluent Pen
  - Repatha
  - Ticagrelor (Brilinta)
  - Ticlopidine
  - Vorapaxar sulfate (Zontivity)

If yes, approve for 12 months by GPID or GPI-14 at zero cost share with the following quantity limits (NOTE: Override the PA edit and update the copay amount field with ZERO copay):

- Flolipid 20mg/5mL: 150mL (#1 bottle) per 30 days.
- Flolipid 40mg/5mL: 150mL (#1 bottle) per 30 days.

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SIMVASTATIN ORAL SUSPENSION (Flolipid)** requires the following rule(s) be met for approval:

- A. You had a previous trial of simvastatin tablets, unless there is a medical reason why you cannot (contraindication)
- B. Your prescriber provides documentation showing that you have dysphagia (general swallowing difficulties), difficulty swallowing tablets, or a feeding tube such as a G-tube or J-tube

***(Denial text continued on next page)***

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SIMVASTATIN ORAL SUSPENSION

GUIDELINES FOR USE (CONTINUED)

C. Requests for zero dollar cost share also requires that you are between 40-75 years of age without a history of cardiovascular disease (relating to heart and blood vessels) and you have not used any of the following secondary prevention medications for cardiovascular disease within the past 120 days based on your prescription claims profile or medical records:

1. Aspirin/dipyridamole (Aggrenox)
2. Clopidogrel (Plavix)
3. Dipyridamole
4. Nitroglycerin (i.e., oral, sublingual, transdermal patch or ointment, translingual dosage forms)
5. Prasugrel (Effient)
6. Praluent Pen
7. Repatha
8. Ticagrelor (Brilinta)
9. Ticlopidine
10. Vorapaxar sulfate (Zontivity)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Flolipid.

**REFERENCES**

- Flolipid [Prescribing Information]. Brooksville, FL: Salerno Pharmaceuticals LP; October 2017.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 03/18

Client Approval: 04/20

P&T Approval: 01/18



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SIPONIMOD

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SIPONIMOD	MAYZENT	45670		GPI-10 (6240707020)	

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, or active secondary progressive disease **AND** meet the following criterion?

- The patient is 18 years of age or older

If yes, continue to #2.

If no, do not approve

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Does the patient have a CYP2C9 \*1/\*1, \*1/\*2, or \*2/\*2 genotype?

If yes, **approve for 12 months by GPID or GPI-14 for all strengths as follows:**

- **Mayzent 0.25mg starter pack for 2 mg maintenance dose: #12 tablets (1 pack) per fill.**
- **Mayzent 2mg: #1 per day.**

If no, continue to #3.

3. Does the patient have a CYP2C9 \*1/\*3 or \*2/\*3 genotype?

If yes, **approve for 12 months by GPID or GPI-14 for all strengths as follows:**

- **Mayzent 0.25mg starter pack for 1 mg maintenance dose: #7 tablets (1 pack) per fill.**
- **Mayzent 0.25mg: #4 per day.**
- **Mayzent 1mg: #1 per day.**

If no, do not approve.

**INITIAL DENIAL TEXT:** **\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SIPONIMOD (Mayzent)** requires the following rule(s) be met for approval:

- A. You have relapsing forms of multiple sclerosis (MS: a type of nerve disorder), to include clinically isolated syndrome (symptoms occur once), relapsing-remitting disease (symptoms return and go away), or active secondary progressive disease (advanced disease)
- B. You are 18 years of age or older
- C. You have CYP2C9 (type of enzyme) \*1/\*1, \*1/\*2, \*2/\*2, \*1/\*3, or \*2/\*3 genotype  
**(Initial denial text continued on next page)**

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SIPONIMOD

INITIAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of relapsing forms of multiple sclerosis (MS) to include clinically isolated syndrome, relapsing-remitting disease, or active secondary progressive disease and meet **ALL** of the following criteria?
  - The patient has demonstrated a clinical benefit compared to pre-treatment baseline
  - The patient does not have lymphopenia

If yes, continue to #2.

If no, do not approve

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

2. Does the patient have a CYP2C9 \*1/\*1, \*1/\*2, or \*2/\*2 genotype?

If yes, **approve for 12 months by GPID or GPI-14 for all strengths as follows:**

- **Mayzent 0.25mg starter pack for 2 mg maintenance dose: #12 tablets (1 pack) per fill.**
- **Mayzent 2mg: #1 per day.**

If no, continue to #3.

3. Does the patient have a CYP2C9 \*1/\*3 or \*2/\*3 genotype?

If yes, **approve for 12 months by GPID or GPI-14 for all strengths as follows:**

- **Mayzent 0.25mg starter pack for 1 mg maintenance dose: #7 tablets (1 pack) per fill.**
- **Mayzent 0.25mg: #4 per day.**
- **Mayzent 1mg: #1 per day.**

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SIPONIMOD

RENEWAL CRITERIA (CONTINUED)

**RENEWAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **SIPONIMOD (Mayzent)** requires the following rule(s) be met for renewal:

- A. You have a relapsing form of multiple sclerosis (MS: a type of nerve disorder), to include clinically isolated syndrome (symptoms occur once), relapsing-remitting disease (symptoms return and go away), or active secondary progressive disease (advanced disease)
- B. You have demonstrated a clinical benefit compared to pre-treatment baseline
- C. You do not have lymphopenia (low levels of a type of white blood cell)
- D. You have CYP2C9 (type of enzyme) \*1/\*1, \*1/\*2, \*2/\*2, \*1/\*3, or \*2/\*3 genotype

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Mayzent.

**REFERENCES**

- Mayzent [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/11/22

Created: 04/19

Client Approval: 03/22

P&T Approval: 10/19





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SIROLIMUS TOPICAL

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SIROLIMUS	HYFTOR		52138	GPI-10 (9078407000)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of facial angiofibroma associated with tuberous sclerosis **AND** meet the following criterion?
  - The patient is 6 years of age or older

If yes, **approve for 12 weeks by GPID or GPI-10.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SIROLIMUS TOPICAL (Hyftor)** requires the following rule(s) be met for approval:

- A. You have facial angiofibroma (a skin condition) associated with tuberous sclerosis (a rare type of tumor disorder)
- B. You are 6 years of age or older

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RENEWAL CRITERIA**

1. Does the patient have a diagnosis of facial angiofibroma associated with tuberous sclerosis?

If yes, **approve for 12 months by GPID or GPI-10.**

If no, do not approve.

**DENIAL TEXT:** See the renewal denial at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SIROLIMUS TOPICAL

RENEWAL CRITERIA (CONTINUED)

**RENEWAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **SIROLIMUS TOPICAL (Hyftor)** requires the following rule(s) be met for renewal:

- A. You have facial angiofibroma (a skin condition) associated with tuberous sclerosis (a rare type of tumor disorder)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Hyftor.

**REFERENCES**

- Hyftor [Prescribing Information]. Bethesda, MD: Nobelpharma America, LLC.; March 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 08/29/22

Created: 08/22

Client Approval: 08/22

P&T Approval: 07/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SMOKING CESSATION ZERO COST SHARE OVERRIDE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
BUPROPION HCL	ZYBAN, BUROPION HCL SR		27901	GPI-10 (6210000210)	
VARENICLINE TARTRATE	CHANTIX, VARENICLINE TARTRATE		27046 27047 27048	GPI-10 (6210008020)	
NICOTINE	NICOTROL, NICOTROL NS, NICOTINE PATCH, NICODERM CQ, NTS, NICOTINE	06249		GPI-10 (6210000500)	
NICOTINE POLACRILEX	NICOTINE GUM, NICOTINE LOZENGE, NICORETTE, VARIOUS	0249		GPI-14 (6210001000)	

**GUIDELINES FOR USE**

1. Is the patient requesting a cost share exception for the requested smoking cessation agent **AND** does the plan cover these agents at zero cost share (i.e., the plan follows Affordable Care Act [ACA] recommendations and is linked to MedImpact's Essential Health Benefit Tables)?

If yes, continue to #2.  
If no, guideline does not apply.

2. Does the patient's plan have specific procedures, instructions, and/or policies for cost share exception processes or for multi-source brand agent overrides (DAW1 override)?

If yes, guideline does not apply.  
If no, continue to #3.

3. Is the patient 18 years of age or older?

If yes, continue to #4.  
If no, do not approve.  
**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SMOKING CESSATION ZERO COST SHARE OVERRIDE

GUIDELINES FOR USE (CONTINUED)

4. Is the request for a generic agent?

If yes, continue to #7.

If no, continue to #5.

5. Is the request for **ONE** of the following?

- A single-source brand (SSB) agent that has no preferred generic agents or therapeutically equivalent products available
- A multi-source brand (MSB) agent

If yes, continue to #6.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

6. Does the patient meet **ONE** of the following criteria?

- Two preferred medications are medically inappropriate for the patient (one if only one agent is available)
- The patient has tried or has a documented medical contraindication to TWO preferred medications (one if only one agent is available)
- The prescriber provided documentation confirming that the requested drug is considered medically necessary (considerations may include severity of side effects and ability to adhere to the appropriate use of the item or service)

If yes, continue to #7.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

7. Does the requested medication also require step therapy? (**NOTE:** Analyze the claim to determine if it also rejects for step therapy)

If yes, continue to #8.

If no, **approve the requested agent for 12 months by GPID or GPI-14 at zero copay. (Note: If the claim also rejects for exceeds quantity limit, please review for a quantity limit exception)**

**APPROVAL TEXT (applies to multi-source brand agents only):** Although your cost share has been reduced to zero-dollar, you may incur a dispense-as-written (DAW) penalty fee if you choose to fill a brand prescription instead of its generic equivalent.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SMOKING CESSATION ZERO COST SHARE OVERRIDE

GUIDELINES FOR USE (CONTINUATION)

8. Has the patient met the step therapy requirement? (**NOTE:** Analyze the claim to determine step therapy agents)

If yes, **approve the requested agent for 12 months by GPID or GPI-14 at zero copay and also override the step restriction. (Note: If the claim also rejects for exceeds quantity limit, please review for a quantity limit exception)**

**APPROVAL TEXT (applicable to multi-source brand agents only):** Although your cost share has been reduced to zero-dollar, you may incur a dispense-as-written (DAW) penalty fee if you choose to fill a brand prescription instead of its generic equivalent.

If no, do not approve.

**DENIAL TEXT:** *\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **SMOKING CESSATION ZERO COST SHARE OVERRIDE** requires the following rule(s) be met for approval:

- A. Your request is for ONE of the following:
1. A generic agent
  2. A single-source brand (SSB) agent that has no preferred generic agents or therapeutically equivalent products available
  3. A multi-source brand (MSB) agent
- B. You are 18 years of age or older
- C. Approval may also require that you have tried preferred agent(s), unless you have a contraindication (harmful for). (**NOTE TO REVIEWER:** Provide the list of the preferred medication(s))
- D. **If the request is for a single-source brand or multi-source brand agent, approval also requires ONE of the following:**
1. Two preferred medications are medically inappropriate for you (one if only one agent is available)
  2. You have tried or have a documented medical contraindication (harmful for) to TWO preferred medications (one if only one agent is available)
  3. Your doctor has provided documentation confirming that your requested drug is considered medically necessary for you (considerations may include severity of side effects and ability to adhere to the appropriate use of the item or service)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**SMOKING CESSATION ZERO COST SHARE OVERRIDE**

---

**RATIONALE**

This guideline applies to plans where the pharmacy benefit allows for coverage of smoking cessation medication at zero copay. The override criteria allow patient access to all FDA-approved smoking cessation medications at zero copay by waiving the applicable cost-sharing for branded or non-preferred branded medications.

**REFERENCES**

- U.S. Department of Labor. Affordable Care Act Implementation Frequently Asked Questions. Available at: <https://www.dol.gov/agencies/ebsa/laws-and-regulations/laws/affordable-care-act/for-employers-and-advisers/aca-implementation-faqs>. Accessed May 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/22

Created: 05/22

Client Approval: 05/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SODIUM/CALCIUM/MAG/POT OXYBATE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SODIUM, CALCIUM, MAG, POT OXYBATE	XYWAV	46743		GPI-10 (6245990420)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Is the patient concurrently on a sedative hypnotic agent (e.g., Lunesta [eszopiclone], Ambien [zolpidem], Sonata [zaleplon], estazolam, Restoril [temazepam], Halcion [triazolam], flurazepam, quazepam, Belsomra [suvorexant])?

If yes, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

If no, continue to #2.

2. Does the patient have a diagnosis of idiopathic hypersomnia (IH) and the diagnosis is confirmed by **ALL** of the following criteria?

- The patient does not have cataplexy
- The patient has a Multiple Sleep Latency Test (MSLT) showing less than 2 sleep-onset REM sleep periods (SOREMP) OR no SOREMPs if REM sleep latency on polysomnogram is 15 minutes or less
- The patient has 1 or more MSLT mean sleep latency of 8 minutes or less, OR total 24-hour sleep is 660 minutes or more on 24-hour polysomnography or by wrist actigraphy in association with a sleep log
- The patient has had insufficient sleep syndrome ruled out, AND there is no better explanation by another sleep/medical/psychiatric disorder or use of drugs/medications, AND the patient has experienced daily periods of irrepressible need to sleep or daytime lapses into sleep for at least 3 months

If yes, continue to #3.

If no, continue to #4.

3. Does the patient meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- Therapy is prescribed by or in consultation with a neurologist, psychiatrist, or specialist in sleep medicine
- The patient had a trial and failure of or contraindication to armodafinil OR modafinil

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #18mL per day.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SODIUM/CALCIUM/MAG/POT OXYBATE

INITIAL CRITERIA (CONTINUED)

4. Does the patient have a diagnosis of cataplexy in narcolepsy and meet **ALL** of the following criteria?
- The patient is 7 years of age or older
  - Therapy is prescribed by or in consultation with a neurologist, psychiatrist, or specialist in sleep medicine
  - The patient has tried TWO of the following: venlafaxine, fluoxetine, or a TCA (e.g., amitriptyline, clomipramine, imipramine)

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #18mL per day.**  
If no, continue to #5.

5. Does the patient have a diagnosis of excessive daytime sleepiness (EDS) in narcolepsy and the narcolepsy diagnosis is confirmed by **ONE** of the following criteria?
- The patient has a Multiple Sleep Latency Test (MSLT) showing both a mean sleep latency of 8 minutes or less AND two or more early-onset REM sleep periods (SOREMPs)
  - The patient has a Multiple Sleep Latency Test (MSLT) showing both a mean sleep latency of 8 minutes or less AND one or more early-onset REM sleep periods (SOREMPs) AND additionally one early-onset SOREMP (within approx. 15 minutes or less) on a polysomnography the night preceding the MSLT, with the polysomnography has ruled out non-narcolepsy causes of EDS  
[**Note to pharmacist:** Multiple Sleep Latency Test (MSLT) is a guideline-supported instrument for assessing the severity and likelihood of narcolepsy, which consists of five 20-minute nap periods spread throughout a single test day at 2-hour intervals]
  - The patient has low Orexin/Hypocretin levels on CSF assay

If yes, continue to #6.  
If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SODIUM/CALCIUM/MAG/POT OXYBATE

INITIAL CRITERIA (CONTINUED)

6. Does the patient meet **ALL** of the following criteria?

- The patient is 7 years of age or older
- Therapy is prescribed by or in consultation with a neurologist, psychiatrist, or specialist in sleep medicine
- The patient has EDS persisting for 3 months or more and an Epworth Sleepiness Scale (ESS) score greater than 10
- The patient meets ONE of the following:
  - The patient is 7 to 17 years of age AND had a trial and failure of or contraindication to one generic stimulant indicated for EDS in narcolepsy (e.g., amphetamine, dextroamphetamine, or methylphenidate)
  - The patient is 18 years of age or older AND had a trial and failure of or contraindication to one agent from EACH of the following categories:
    - Generic typical stimulant (e.g., amphetamine sulfate, dextroamphetamine, methylphenidate)
    - Armodafinil OR modafinil

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #18mL per day.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SODIUM/CALCIUM/MAG/POT OXYBATE (Xywav)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:

1. Idiopathic hypersomnia (IH: a type of sleep disorder)
2. Cataplexy in narcolepsy (sudden and uncontrollable muscle weakness or paralysis associated with a sleep disorder)
3. Excessive daytime sleepiness (EDS) in narcolepsy (a type of sleep disorder)

B. You are not concurrently on a sedative hypnotic agent (drugs that make you sleepy), such as Lunesta [eszopiclone], Ambien [zolpidem], Sonata [zaleplon], estazolam, Restoril [temazepam], Halcion [triazolam], flurazepam, quazepam, Belsomra [suvorexant]

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**SODIUM/CALCIUM/MAG/POT OXYBATE**

**INITIAL CRITERIA (CONTINUED)**

**C. If you have idiopathic hypersomnia, approval also requires:**

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a neurologist (nerve doctor), psychiatrist (mental health doctor), or specialist in sleep medicine
3. Your diagnosis is confirmed by ALL of the following:
  - a. You do not have cataplexy (sudden and uncontrollable muscle weakness or paralysis associated with a sleep disorder)
  - b. You have a Multiple Sleep Latency Test (MSLT) showing less than 2 sleep-onset REM sleep periods (SOREMP) OR no SOREMPs if REM sleep latency on polysomnogram (type of sleep test) is 15 minutes or less
  - c. You have 1 or more MSLT mean sleep latency of 8 minutes or less, OR total 24-hour sleep is 660 minutes or more on 24-hour polysomnography or by wrist actigraphy (device that monitors movement) in association with a sleep log
  - d. You have had insufficient sleep syndrome ruled out, AND there is no better explanation by another sleep/medical/psychiatric disorder or use of drugs/medications, AND you have experienced daily periods of irrepressible need to sleep or daytime lapses into sleep for at least 3 months
4. You tried and failed or have a contraindication (harmful for) to armodafinil OR modafinil

**D. If you have cataplexy in narcolepsy, approval also requires:**

1. You are 7 years of age or older
2. Therapy is prescribed by or in consultation with a neurologist (nerve doctor), psychiatrist (mental health doctor), or specialist in sleep medicine
3. You have tried TWO of the following: venlafaxine, fluoxetine, or tricyclic anti-depressants (such as amitriptyline, clomipramine, imipramine)

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SODIUM/CALCIUM/MAG/POT OXYBATE

INITIAL CRITERIA (CONTINUED)

**E. If you have excessive daytime sleepiness in narcolepsy, approval also requires:**

1. You are 7 years of age or older
2. Therapy is prescribed by or in consultation with a neurologist (nerve doctor), psychiatrist (mental health doctor), or specialist in sleep medicine
3. You have EDS persisting for 3 or more months and an Epworth Sleepiness Scale (tool to measure your sleepiness) score of more than 10
4. Your diagnosis of narcolepsy is confirmed by ONE of the following:
  - a. A Multiple Sleep Latency Test showing a both an average sleep latency of 8 minutes or less AND 2 or more early-onset rapid eye movement (REM) sleep test periods
  - b. A Multiple Sleep Latency Test (MSLT) showing both an average sleep latency of 8 minutes or less AND one early-onset rapid eye movement (REM) sleep test period (SOREMP) AND additionally one SOREMP (within approximately 15 minutes) on a polysomnography (type of sleep test) the night preceding the MSLT, with the polysomnography ruling out non-narcolepsy causes of excessive daytime sleepiness
  - c. You have low orexin/hypocretin levels on a cerebrospinal fluid (CSF) assay (test showing you have low levels of a chemical that helps with staying awake)
5. If you are 7 to 17 years old, you tried and failed or have a contraindication (harmful for) to one generic stimulant indicated for EDS in narcolepsy (such as amphetamine, dextroamphetamine, or methylphenidate)
6. If you are 18 years or older, you tried and failed or have a contraindication (harmful for) to one agent from EACH of the following categories:
  - a. Generic typical stimulant (such as amphetamine sulfate, methylphenidate, etc.)
  - b. Armodafinil OR modafinil

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RENEWAL CRITERIA**

1. Is the patient concurrently on a sedative hypnotic agent (e.g., Lunesta [eszopiclone], Ambien [zolpidem], Sonata [zaleplon], estazolam, Restoril [temazepam], Halcion [triazolam], flurazepam, quazepam, Belsomra [suvorexant])?

If yes, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

If no, continue to #2.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SODIUM/CALCIUM/MAG/POT OXYBATE

RENEWAL CRITERIA (CONTINUED)

2. Does the patient have a diagnosis of narcolepsy and meet **ONE** of the following criteria?
- The patient has demonstrated improvement of cataplexy symptoms compared to baseline
  - The patient has maintained an improvement in Epworth Sleepiness Scale (ESS) scores by at least 25% compared to baseline
  - The patient has demonstrated improvement in sleep latency from baseline

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #18mL per day.**  
If no, continue to #3.

3. Does the patient have a diagnosis of idiopathic hypersomnia (IH) and meet **ONE** of the following criteria?
- The patient has demonstrated improvement of idiopathic hypersomnia symptoms compared to baseline
  - The patient has maintained an improvement in Epworth Sleepiness Scale (ESS) scores by at least 25% compared to baseline

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #18mL per day.**  
If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SODIUM/CALCIUM/MAG/POT OXYBATE (Xywav)** requires the following rule(s) be met for renewal:

- A. You have **ONE** of the following diagnoses:
1. Narcolepsy (uncontrollable daytime sleepiness)
  2. Idiopathic hypersomnia (IH: a type of sleep disorder)
- B. You are not concurrently (at the same time) on a sedative hypnotic agent (drugs that make you sleepy), such as Lunesta [eszopiclone], Ambien [zolpidem], Sonata [zaleplon], estazolam, Restoril [temazepam], Halcion [triazolam], flurazepam, quazepam, Belsomra [suvorexant]
- C. **If you have narcolepsy, renewal also requires you meet ONE of the following:**
1. You have demonstrated improvement in cataplexy symptoms (sudden and uncontrollable muscle weakness) compared to baseline
  2. You have maintained an improvement in Epworth Sleepiness Scale (tool to measure sleepiness) scores by at least 25% compared to baseline
  3. You have demonstrated improvement in sleep latency (the amount of time it takes you to fall asleep)

***(Renewal denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SODIUM/CALCIUM/MAG/POT OXYBATE

RENEWAL CRITERIA (CONTINUED)

D. If you have idiopathic hypersomnia, renewal also requires you meet ONE of the following:

1. You have demonstrated improvement of idiopathic hypersomnia symptoms compared to baseline
2. You have maintained an improvement in Epworth Sleepiness Scale (tool to measure sleepiness) scores by at least 25% compared to baseline

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Xywav.

REFERENCES

- Xywav [Prescribing Information]. Palo Alto, CA: Jazz Pharmaceuticals, Inc.; October 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/23

Created: 11/20

Client Approval: 11/22

P&T Approval: 10/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SODIUM OXYBATE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SODIUM OXYBATE	XYREM, SODIUM OXYBATE	12346		GPI-10 (6245006020)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Is the patient concurrently on a sedative hypnotic agent (e.g., Lunesta [eszopiclone], Ambien [zolpidem], Sonata [zaleplon], estazolam, Restoril [temazepam], Halcion [triazolam], flurazepam, quazepam, Belsomra [suvorexant])?

If yes, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

If no, continue to #2.

2. Does the patient have a diagnosis of idiopathic hypersomnia (IH) and the diagnosis is confirmed by **ALL** of the following criteria?

- The patient does not have cataplexy
- The patient has a Multiple Sleep Latency Test (MSLT) showing less than 2 sleep-onset REM sleep periods (SOREMP) OR no SOREMPs if REM sleep latency on polysomnogram is 15 minutes or less
- The patient has 1 or more MSLT mean sleep latency of 8 minutes or less, OR total 24-hour sleep is 660 minutes or more on 24-hour polysomnography or by wrist actigraphy in association with a sleep log
- The patient has had insufficient sleep syndrome ruled out, AND there is no better explanation by another sleep/medical/psychiatric disorder or use of drugs/medications, AND the patient has experienced daily periods of irrepressible need to sleep or daytime lapses into sleep for at least 3 months

If yes, continue to #3.

If no, continue to #4.

3. Does the patient meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- Therapy is prescribed by or in consultation with a neurologist, psychiatrist, or specialist in sleep medicine
- The patient had a trial and failure of or contraindication to armodafinil OR modafinil

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #18mL per day.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SODIUM OXYBATE

INITIAL CRITERIA (CONTINUED)

4. Does the patient have a diagnosis of cataplexy in narcolepsy and meet **ALL** of the following criteria?
- The patient is 7 years of age or older
  - Therapy is prescribed by or in consultation with a neurologist, psychiatrist, or specialist in sleep medicine
  - The patient has tried TWO of the following: venlafaxine, fluoxetine, or a TCA (e.g., amitriptyline, clomipramine, imipramine)

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #18mL per day.**  
If no, continue to #5.

5. Does the patient have a diagnosis of excessive daytime sleepiness (EDS) in narcolepsy **AND** narcolepsy diagnosis is confirmed by **ONE** of the following criteria?
- The patient has a Multiple Sleep Latency Test (MSLT) showing both a mean sleep latency of 8 minutes or less AND two or more early-onset REM sleep periods (SOREMPs)
  - The patient has a Multiple Sleep Latency Test (MSLT) showing both a mean sleep latency of 8 minutes or less AND one or more early-onset REM sleep periods (SOREMPs) AND additionally one early-onset SOREMP (within approx. 15 minutes or less) on a polysomnography the night preceding the MSLT, with the polysomnography has ruled out non-narcolepsy causes of EDS  
**[Note to pharmacist:** Multiple Sleep Latency Test (MSLT) is a guideline-supported instrument for assessing the severity and likelihood of narcolepsy, which consists of five 20-minute nap periods spread throughout a *single test* day at 2-hour intervals]
  - The patient has low Orexin/Hypocretin levels on CSF assay

If yes, continue to #6.  
If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SODIUM OXYBATE

INITIAL CRITERIA (CONTINUED)

6. Does the patient meet **ALL** of the following criteria?

- The patient is 7 years of age or older
- Therapy is prescribed by or in consultation with a neurologist, psychiatrist, or specialist in sleep medicine
- The patient has EDS persisting for 3 or more months and an Epworth Sleepiness Scale (ESS) score of more than 10
- The patient meets ONE of the following:
  - The patient is 7 to 17 years of age AND had a trial and failure of or contraindication to one generic stimulant indicated for excessive daytime sleepiness (EDS) in narcolepsy (e.g., amphetamine, dextroamphetamine, or methylphenidate)
  - The patient is 18 years of age or older AND had a trial and failure of or contraindication to one agent from EACH of the following categories:
    - Generic typical stimulant (e.g., amphetamine sulfate, dextroamphetamine, methylphenidate)
    - Armodafinil OR modafinil

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #18mL per day.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SODIUM OXYBATE (Xyrem)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:

1. Idiopathic hypersomnia (IH: a type of sleep disorder)
2. Cataplexy in narcolepsy (sudden and uncontrollable muscle weakness or paralysis associated with a sleep disorder)
3. Excessive daytime sleepiness (EDS) in narcolepsy (sleep disorder)

B. You are not concurrently (at the same time) on a sedative hypnotic agent (drugs that make you sleepy), such as Lunesta [eszopiclone], Ambien [zolpidem], Sonata [zaleplon], estazolam, Restoril [temazepam], Halcion [triazolam], flurazepam, quazepam, Belsomra [suvorexant]

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**





**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**SODIUM OXYBATE**

**INITIAL CRITERIA (CONTINUED)**

**C. If you have idiopathic hypersomnia, approval also requires:**

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a neurologist (nerve doctor), psychiatrist (mental health doctor), or specialist in sleep medicine
3. Your diagnosis is confirmed by ALL of the following:
  - a. You do not have cataplexy (sudden and uncontrollable muscle weakness or paralysis associated with a sleep disorder)
  - b. You have a Multiple Sleep Latency Test (MSLT) showing less than 2 sleep-onset REM sleep periods (SOREMP) OR no SOREMPs if REM sleep latency on polysomnogram (type of sleep test) is 15 minutes or less
  - c. You have 1 or more MSLT mean sleep latency of 8 minutes or less, OR total 24-hour sleep is 660 minutes or more on 24-hour polysomnography or by wrist actigraphy (device that monitors movement) in association with a sleep log
  - d. You have had insufficient sleep syndrome ruled out, AND there is no better explanation by another sleep/medical/psychiatric disorder or use of drugs/medications, AND you have experienced daily periods of irrepressible need to sleep or daytime lapses into sleep for at least 3 months
4. You have tried and failed or have a contraindication (harmful for) to armodafinil OR modafinil

**D. If you have cataplexy in narcolepsy, approval also requires:**

1. You are 7 years of age or older
2. Therapy is prescribed by or in consultation with a neurologist (nerve doctor), psychiatrist (mental health doctor), or specialist in sleep medicine
3. You have tried TWO of the following: venlafaxine, fluoxetine, or a tricyclic anti-depressant (such as amitriptyline, clomipramine, imipramine)

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SODIUM OXYBATE

INITIAL CRITERIA (CONTINUED)

E. If you have excessive daytime sleepiness in narcolepsy, approval also requires:

1. You are 7 years of age or older
2. Therapy is prescribed by or in consultation with a neurologist (nerve doctor), psychiatrist (mental health doctor), or specialist in sleep medicine
3. You have EDS persisting for 3 or more months and an Epworth Sleepiness Scale (tool to measure your sleepiness) score of more than 10
4. Your diagnosis of narcolepsy is confirmed by ONE of the following:
  - a. A Multiple Sleep Latency Test showing a both an average sleep latency of 8 minutes or less AND 2 or more early-onset rapid eye movement (REM) sleep test periods
  - b. A Multiple Sleep Latency Test (MSLT) showing both an average sleep latency of 8 minutes or less AND one early-onset rapid eye movement (REM) sleep test period (SOREMP) AND additionally one SOREMP (within approximately 15 minutes) on a polysomnography (type of sleep test) the night preceding the MSLT, with the polysomnography ruling out non-narcolepsy causes of excessive daytime sleepiness
  - c. You have low orexin/hypocretin levels on a cerebrospinal fluid (CSF) assay (test showing you have low levels of a chemical that helps with staying awake)
5. If you are 7 to 17 years old, you tried and failed or have a contraindication (harmful for) to one other generic stimulant indicated for EDS in narcolepsy (such as amphetamine, dextroamphetamine, or methylphenidate)
6. If you are 18 years or older, you tried and failed or have a contraindication (harmful for) to one agent from EACH of the following categories:
  - a. Generic typical stimulant (such as amphetamine sulfate, dextroamphetamine, methylphenidate)
  - b. Armodafinil OR modafinil

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Is the patient concurrently on a sedative hypnotic agent (e.g., Lunesta [eszopiclone], Ambien [zolpidem], Sonata [zaleplon], estazolam, Restoril [temazepam], Halcion [triazolam], flurazepam, quazepam, Belsomra [suvorexant])?

If yes, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

If no, continue to #2.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SODIUM OXYBATE

RENEWAL CRITERIA (CONTINUED)

2. Does the patient have a diagnosis of narcolepsy and meet **ONE** of the following criteria?
- The patient has demonstrated improvement of cataplexy symptoms compared to baseline
  - The patient has maintained an improvement in Epworth Sleepiness Scale (ESS) scores by at least 25% compared to baseline
  - The patient has demonstrated improvement in sleep latency from baseline

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #18mL per day.**  
If no, continue to #3.

2. Does the patient have a diagnosis of idiopathic hypersomnia (IH) and meet **ONE** of the following criteria?
- The patient has demonstrated improvement of idiopathic hypersomnia symptoms compared to baseline
  - The patient has maintained an improvement in Epworth Sleepiness Scale (ESS) scores by at least 25% compared to baseline

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #18mL per day.**  
If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SODIUM OXYBATE (Xyrem)** requires the following rule(s) be met for renewal:

- A. You have **ONE** of the following diagnoses:
1. Narcolepsy (uncontrollable daytime sleepiness)
  2. Idiopathic hypersomnia (IH: a type of sleep disorder)
- B. You are **NOT** concurrently (at the same time) on a sedative hypnotic agent (drugs that make you sleepy), such as Lunesta [eszopiclone], Ambien [zolpidem], Sonata [zaleplon], estazolam, Restoril [temazepam], Halcion [triazolam], flurazepam, quazepam, Belsomra [suvorexant]
- C. **If you have narcolepsy, renewal also requires you meet ONE of the following:**
1. You have demonstrated improvement in cataplexy symptoms (sudden and uncontrollable muscle weakness) compared to baseline
  2. You have maintained improvement in Epworth Sleepiness Scale (tool to measure sleepiness) scores by at least 25% compared to baseline
  3. You have demonstrated improvement in sleep latency (the amount of time it takes you to fall asleep)

***(Renewal denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SODIUM OXYBATE

RENEWAL CRITERIA (CONTINUED)

D. If you have idiopathic hypersomnia, renewal also requires you meet ONE of the following:

1. You have demonstrated improvement of idiopathic hypersomnia symptoms compared to baseline
2. You have maintained an improvement in Epworth Sleepiness Scale (tool to measure sleepiness) scores by at least 25% compared to baseline

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Xyrem.

REFERENCES

- Xyrem [Prescribing Information]. Palo Alto, CA: Jazz Pharmaceuticals, Inc.; November 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/16/23

Created: 11/13

Client Approval: 12/22

P&T Approval: 10/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SODIUM PHENYLBUTYRATE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SODIUM PHENYLBUTYRATE	BUPHENYL, PHEBURANE, SODIUM PHENYLBUTYRATE	11317		GPI-14 (3090806000)	ROUTE = ORAL

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of a urea cycle disorder (UCD) and meet **ALL** of the following criteria?
  - There is documentation of confirmation of UCD via enzymatic, biochemical or genetic testing
  - The requested medication will be used as adjunctive therapy along with dietary protein restriction
  - The patient cannot be managed by dietary protein restriction or amino acid supplementation alone

If yes, continue to #2.

If no, do not approve.

**INITIAL DENIAL TEXT:** See the initial denial text at the end of guideline.

2. Is the request for Pheburane and the patient meets **ALL** of the following criteria?
  - The patient had a trial of or contradiction to generic sodium phenylbutyrate powder
  - The patient is unable to swallow Buphenyl (sodium phenylbutyrate) tablets

If yes, **approve Pheburan for 12 months by GPID or GPI-14 with a quantity limit of #20 grams per day.**

If no, **approve Buphenyl (sodium phenylbutyrate) for 12 months by GPID or GPI-14 with the following quantity limits:**

- **Oral tablet: #40 tablets per day.**
- **Oral powder: #750 grams per 30 days.**

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SODIUM PHENYLBUTYRATE

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **SODIUM PHENYLBUTYRATE (Buphenyl, Pheburane)** requires the following rule(s) be met for approval:

- A. You have urea cycle disorder (a genetic disorder that causes high ammonia levels in the blood)
- B. There is documentation confirming you have urea cycle disorder via enzymatic, biochemical or genetic testing (types of lab tests)
- C. The requested medication will be used as adjunctive (add-on) therapy along with dietary protein restriction
- D. Your condition cannot be managed by dietary protein restriction or amino acid supplementation alone
- E. **If your request is for Pheburane, approval also requires ALL of the following:**
  1. You have tried or have a contraindication to (harmful for) generic sodium phenylbutyrate powder
  2. You are unable to swallow Buphenyl (sodium phenylbutyrate) tablets

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of a urea cycle disorder (UCD) **AND** meet the following criterion?
  - The patient has experienced clinical benefit from baseline (e.g., normal fasting glutamine, low-normal fasting ammonia levels, mental status clarity)

If yes, **approve the requested medication for 12 months by GPID or GPI-14 as follows:**

- **Buphenyl (sodium phenylbutyrate) oral tablet: #40 tablets per day.**
- **Buphenyl (sodium phenylbutyrate) oral powder: #750 grams per 30 days.**
- **Pheburane oral pellets: #20 grams per day.**

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SODIUM PHENYLBUTYRATE

RENEWAL CRITERIA (CONTINUED)

**RENEWAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **SODIUM PHENYLBUTYRATE (Buphenyl, Pheburane)** requires the following rule(s) be met for renewal:

- A. You have a urea cycle disorder (a genetic disorder that causes high ammonia levels in the blood)
- B. You have experienced clinical benefit from baseline (such as you are having normal fasting glutamine, low-normal fasting ammonia levels, mental status clarity).

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Buphenyl or Pheburane.

**REFERENCES**

- Buphenyl [Prescribing Information]. Lake Forest, IL: Horizon Pharma USA, Inc.; July 2022.
- Pheburane [Prescribing Information]. Bryn Mawr, PA: Medunik USA, Inc.; June 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/23

Created: 08/19

Client Approval: 11/22

P&T Approval: 10/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOD PHENYLBUTYRATE-TAURURSODIOL

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SOD PHENYLBUTYRAT /TAURURSODIOL	RELYVRIO	48081		GPI-10 (7450990270)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of amyotrophic lateral sclerosis (ALS) and meet **ALL** the following?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a neurologist or ALS specialist or being seen at an ALS Specialty Center or Care Clinic

If yes, **approve for a total of 6 months by HICL or GPI-10. Please enter two authorizations as follows:**

- **FIRST APPROVAL: Approve for 21 days with a quantity limit of #1 per day.**
- **SECOND APPROVAL: Approve for the remaining days with a quantity limit of #2 per day.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SOD PHENYLBUTYRATE-TAURURSODIOL (Relyvrio)** requires the following rule(s) be met for approval:

- A. You have amyotrophic lateral sclerosis (ALS: a type of brain and nerve condition)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor) or ALS specialist or being seen at an ALS Specialty Center or Care Clinic

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOD PHENYLBUTYRATE-TAURURSODIOL

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of amyotrophic lateral sclerosis (ALS) and meet **ALL** of the following criteria?

- The patient does not require invasive ventilation
- The patient has improved or maintained baseline functional ability measured by functional assessments (e.g., Amyotrophic Lateral Sclerosis Functional Rating Scale [ALSFRS])

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SOD PHENYLBUTYRATE-TAURURSODIOL (Relyvrio)** requires the following rule(s) be met for renewal:

- A. You have amyotrophic lateral sclerosis (ALS: a type of brain and nerve condition)
- B. You do not require invasive ventilation (inserting a breathing tube into your throat)
- C. You have improved or maintained baseline functional ability measured by functional assessments (e.g., Amyotrophic Lateral Sclerosis Functional Rating Scale [ALSFRS: a tool for evaluating functional status])

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Relyvrio.

**REFERENCES**

- Relyvrio [Prescribing Information]. Cambridge, MA: Amylyx Pharmaceuticals, Inc., September 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/24/22

Created: 10/22

Client Approval: 10/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOFOSBUVIR

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SOFOSBUVIR	SOVALDI	40795		GPI-10 (1235308000)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of chronic hepatitis C and meet **ONE** of the following criteria?

- The patient is 18 years of age or older with genotype 1 or 3
- The patient is 3 to 17 years old with genotype 2 or 3

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient meet at least **ONE** of the following?

- The patient has severe renal impairment (estimated glomerular filtration rate (GFR) less than 30 mL/min/1.73m<sup>2</sup>), end stage renal disease, or requires dialysis
- The patient has a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions
- The patient is currently taking any of the following medications: carbamazepine, phenytoin, phenobarbital, oxcarbazepine, rifampin, rifabutin, rifapentine, tipranavir/ritonavir, velpatasvir/sofosbuvir (Epclusa), ledipasvir/sofosbuvir (Harvoni), velpatasvir/sofosbuvir/voxilaprevir (Vosevi), or elbasvir/grazoprevir (Zepatier)
- The patient is using Sovaldi with a direct acting antiviral (e.g., Olysio or Daklinza) AND is concurrently taking amiodarone

If yes, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

If no, continue to #3.

3. Does the patient have an HCV RNA level within the past 6 months?

If yes, continue to #4.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

4. Is the patient under 18 years of age?

If yes, continue to #17.

If no, continue to #5.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOFOSBUVIR

**GUIDELINES FOR USE (CONTINUED)**

5. Does the patient meet **ALL** of the following?

- The patient is treatment naïve OR treatment experienced (prior treatment with peginterferon/ribavirin)
- The patient is without cirrhosis OR has decompensated cirrhosis OR is post-liver transplant (with or without cirrhosis)

If yes, continue to #6.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

6. Has the patient failed a short trial of the preferred formulary agent or has a contraindication to therapy with the preferred formulary agent(s)? (see criteria below)

- For genotype 1 HCV infection: a short trial of Epclusa or Harvoni (e.g., adverse effect early in therapy to Harvoni or Epclusa) or contraindication to BOTH agents
- For genotype 3 HCV infection: a short trial of Epclusa (e.g., adverse effect early in therapy to Epclusa) or contraindication to this agent

**(NOTE:** An individual who has completed a full course of therapy with the preferred agent that did not achieve SVR will not be approved)

If yes, continue to #7.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

7. Does the patient have decompensated cirrhosis?

If yes, continue to #12.

If no, continue to #8.

8. Is the requested medication being used with 1) ribavirin **OR** 2) peginterferon alfa and ribavirin?

If yes, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

If no, continue to #9.

9. Is this request for Sovaldi use in combination with Daklinza?

**CLINICAL PHARMACISTS:** Patient must also meet all criteria in Daklinza guideline to be approvable for both agents. Review hepatitis C MRF and Daklinza request to ensure patient meets criteria for both agents.

If yes, continue to #13.

If no, continue to #10.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOFOSBUVIR

GUIDELINES FOR USE (CONTINUED)

10. Is the request for a combination regimen with Sovaldi plus Olysio in a patient with genotype 1 hepatitis C infection?

If yes, continue to #11.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

11. Does the patient meet **ONE** or more of the following?

- The patient has cirrhosis
- The patient completed a prior full course of therapy with 1) any HCV protease inhibitor [for example, Incivek (telaprevir), Olysio (simeprevir), or Victrelis (boceprevir)] and has not achieved a sustained virologic response (SVR) OR 2) a regimen containing NS5A inhibitor (e.g., Harvoni, Epclusa, Technivie, Viekira Pak or Viekira XR, Zepatier, or Daklinza-containing regimen)
- The patient is concurrently using any of the following medications with Sovaldi/Olysio which are not recommended by the manufacturer of Olysio:
  - Carbamazepine, phenytoin, phenobarbital, oxcarbazepine, rifampin, rifabutin, rifapentine, erythromycin (does not include topical formulations), clarithromycin, telithromycin, itraconazole, ketoconazole, posaconazole, fluconazole (does not include topical formulations), voriconazole, dexamethasone, cisapride, cyclosporine, rosuvastatin (dose above 10mg), or atorvastatin (dose above 40mg)
  - Any of the following HIV medications: delavirdine, efavirenz, nevirapine, or efavirenz
  - A cobicistat-containing medication (e.g., Stribild or Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir), Evotaz, PrezcoBix, or Tybost)
  - An HIV protease inhibitor (e.g., atazanavir, fosamprenavir, lopinavir, indinavir, nelfinavir, saquinavir, tipranavir, ritonavir, or darunavir/ritonavir)

If yes, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

If no, **approve for 12 weeks for the requested strength by GPID or GPI-14 as follows:**

- **Sovaldi 400mg tablets: #1 per day.**
- **Sovaldi 200mg pellets: #2 packets per day.**

**(NOTE: Regimen approved for genotype 1 patient without cirrhosis: Olysio and Sovaldi for 12 weeks)**

**CLINICAL SPECIALISTS:** Patient is on combination therapy with Olysio; please also view Olysio prior authorization guideline, member history, and hepatitis C MRF, if available to ensure appropriate length of approval and that the patient also meets approval for Olysio.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOFOSBUVIR

GUIDELINES FOR USE (CONTINUED)

12. Is this request for Sovaldi use in combination with Daklinza?

**CLINICAL PHARMACISTS:** Patient must also meet all criteria in Daklinza guideline to be approvable for both agents. Review hepatitis C MRF and Daklinza request to ensure patient meets criteria for both agents.

If yes, continue to #13.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

13. Is the patient concurrently using Sovaldi/Daklinza with any of the following (contraindicated or not recommended by the manufacturer, except specified HIV medications) medications: amiodarone, carbamazepine, phenytoin, rifampin, or rifapentine?

If yes, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

If no, continue to #14.

14. Does the patient have compensated cirrhosis?

If yes, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

If no, continue to #15.

15. Does the patient have decompensated cirrhosis or is post-liver transplant?

If yes, continue to #16.

If no, **approve for 12 weeks for the requested strength by GPID or GPI-14 as follows:  
(Sovaldi in combination with Daklinza)**

- **Sovaldi 400mg tablets: #1 per day.**
- **Sovaldi 200mg pellets: #2 packets per day.**

**CLINICAL PHARMACISTS:** Patient is on combination therapy with Daklinza; please also view Daklinza prior authorization guideline, member history, and hepatitis C MRF, if available to ensure appropriate length of approval and that the patient also meets approval for Daklinza.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOFOSBUVIR

GUIDELINES FOR USE (CONTINUED)

16. Is the patient using a regimen of Daklinza and Sovaldi (sofosbuvir) **WITH** ribavirin?

If yes, **approve for 12 weeks for the requested strength by GPID or GPI-14 as follows: (Sovaldi in combination with Daklinza and ribavirin)**

- **Sovaldi 400mg tablets: #1 per day.**
- **Sovaldi 200mg pellets: #2 packets per day.**

**CLINICAL PHARMACISTS:** Patient is on combination therapy with Daklinza; please also view Daklinza prior authorization guideline, member history, and hepatitis C MRF, if available to ensure appropriate length of approval and that the patient also meets approval for Daklinza.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

17. Does the patient have genotype 2 infection **AND** has compensated cirrhosis (Child-Pugh A) or is without cirrhosis?

If yes, continue to #18.

If no, continue to #19.

18. Is the requested medication being used with ribavirin?

If yes, **approve for 12 weeks for the requested strength by GPID or GPI-14 as follows:**

- **Sovaldi 400mg tablets: #1 per day.**
- **Sovaldi 200mg tablets: #1 per day.**
- **Sovaldi 200mg pellets: #2 packets per day.**
- **Sovaldi 150mg pellets: #1 packet per day.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

19. Does the patient have genotype 3 infection **AND** has compensated cirrhosis (Child-Pugh A) or is without cirrhosis?

If yes, continue to #20.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOFOSBUVIR

GUIDELINES FOR USE (CONTINUED)

20. Is the requested medication being used with ribavirin?

If yes, approve for 24 weeks for the requested strength by GPID or GPI-14 as follows:

- Sovaldi 400mg tablets: #1 per day.
- Sovaldi 200mg tablets: #1 per day.
- Sovaldi 200mg pellets: #2 packets per day.
- Sovaldi 150mg pellets: #1 packet per day.

If no, do not approve.

**DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **SOFOSBUVIR (Sovaldi)** requires the following rule(s) be met for approval:

- A. You have chronic hepatitis C (type of liver inflammation)
- B. You are 18 years of age or older with genotype 1 or 3, OR you are 3 to 17 years old with genotype 2 or 3
- C. You have an HCV RNA level (amount of virus in your blood) within the past 6 months
- D. **If you are an adult patient (18 years of age or older), approval also requires:**
  1. You are treatment naive (never previously treated) or treatment experienced (prior treatment with peginterferon/ribavirin)
  2. You will be using Sovaldi with Olysio (genotype 1 only) or Daklinza (genotype 1 or 3 only)
  3. You had a short trial of a preferred formulary agent (you stopped because of intolerance or adverse effect early in therapy) or have a contraindication (medical reason why you cannot use) to therapy with the preferred formulary agent(s) as specified below. An individual who has completed a full course of therapy that did not achieve a sustained virologic response (SVR) will not be approved
    - a. If you have genotype 1 infection, you had a short trial of Epclusa or Harvoni or you have a contraindication to BOTH agents
    - b. If you have genotype 3 infection, you had a short trial of Epclusa or you have a contraindication to this agent

***(Denial text continued on next page)***

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOFOSBUVIR

GUIDELINES FOR USE (CONTINUED)

**E. If you are a pediatric patient (under 18 years of age), approval also requires:**

1. The request must meet the Food and Drug Administration (FDA)-approved indication [treatment naive (never previously treated) or treatment experienced patient with compensated cirrhosis (no symptoms related to liver damage) (Child-Pugh A) or without cirrhosis (liver scarring)]
2. You will be using Sovaldi together with ribavirin (genotypes 2 and 3)

**Sovaldi will not be approved if you meet any of the following:**

- A. You have severe renal (kidney) impairment (glomerular filtration rate less than 30 mL/min/1.73m<sup>2</sup>), end stage renal disease and/or those requiring dialysis
- B. You have a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions (additional diseases)
- C. You are an adult with compensated cirrhosis (no symptoms related to liver damage)
- D. You are using any of the following medications at the same time while on Sovaldi: carbamazepine, phenytoin, phenobarbital, oxcarbazepine, rifampin, rifabutin, rifapentine, tipranavir/ritonavir, velpatasvir/sofosbuvir (Epclusa), ledipasvir/sofosbuvir (Harvoni), velpatasvir/sofosbuvir/voxilaprevir (Vosevi), or elbasvir/grazoprevir (Zepatier)
- E. You are using Sovaldi with another direct acting antiviral (e.g., Olysio or Daklinza) AND are on concurrent amiodarone
- F. You are an adult who is taking Sovaldi with ribavirin OR peginterferon alfa and ribavirin

**For requests for Sovaldi/Olysio regimen for genotype 1, the following must also be met:**

- A. You are 18 years of age or older
- B. You do not have cirrhosis (liver scarring)
- C. You have not previously failed a full course of therapy with 1) any hepatitis c virus protease inhibitor (type of Hep C drug such as Incivek [telaprevir], Olysio [simeprevir], or Victrelis [boceprevir] OR 2) a regimen containing NS5A inhibitor (type of hepatitis medication such as Harvoni, Epclusa, Technivie, Viekira Pak or Viekira XR, Zepatier, or Daklinza-containing regimen)

***(Denial text continued on next page)***

CONTINUED ON NEXT PAGE





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOFOSBUVIR

GUIDELINES FOR USE (CONTINUED)

- D. You will not be using the requested medication together with any of the following medications as they are contraindicated (there is a medical reason why you cannot use the drug) or not recommended by the manufacturer:
1. Carbamazepine, phenytoin, phenobarbital, oxcarbazepine, rifampin, rifabutin, rifapentine, erythromycin (does not include topical formulations), clarithromycin, telithromycin, itraconazole, ketoconazole, posaconazole, fluconazole (does not include topical formulations), voriconazole, dexamethasone, cisapride, cyclosporine, rosuvastatin (dose above 10mg), or atorvastatin (dose above 40mg)
  2. Any of the following human immunodeficiency virus (HIV) medications: delavirdine, etravirine, nevirapine, or efavirenz
  3. A cobicistat-containing medication such as Stribild or Genvoya [elvitegravir/cobicistat/emtricitabine/tenofovir], Evotaz, Prezcoibix, or Tybost
  4. A human immunodeficiency virus (HIV) protease inhibitor such as atazanavir, fosamprenavir, lopinavir, indinavir, nelfinavir, saquinavir, tipranavir, ritonavir, or darunavir/ritonavir)

**For patients using Sovaldi with Daklinza, the following must also be met:**

- A. You are 18 years of age or older
- B. You have genotype 1 or 3 hepatitis C (type of liver inflammation)
- C. You will not be using the requested medication together with any of the following medications because they are contraindicated (medical reason why you cannot use a drug) or not recommended by the manufacturer): amiodarone, carbamazepine, phenytoin, rifampin, or rifapentine
- D. You will be taking ribavirin together with Sovaldi and Daklinza if you have decompensated cirrhosis (you have symptoms related to liver damage) or you are post-liver transplant

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Sovaldi.

**REFERENCES**

- Sovaldi [Prescribing Information]. Foster City, CA: Gilead Sciences; March 2020.
- Guidance from the American Association for the Study of Liver Diseases (AASLD) and the Infectious Disease Society of America (IDSA) Recommendations for Testing, and Managing. Available online at <http://www.hcvguidelines.org/full-report-view> Accessed November 3, 2022.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**SOFOSBUVIR**

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/23

Created: 01/14

Client Approval: 11/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOFOSBUVIR/VELPATASVIR

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SOFOSBUVIR/ VELPATASVIR	EPCLUSA, SOFOSBUVIR- VELPATASVIR	43561		GPI-10 (1235990265)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of chronic hepatitis C, genotype 1, 2, 3, 4, 5, or 6 and meet **ALL** of the following criteria?
  - The patient is 3 years of age or older
  - The patient has an HCV RNA level within the past 6 months

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient meet at least **ONE** of the following criteria?
  - The patient is currently taking any of the following medications: amiodarone, carbamazepine, phenytoin, phenobarbital, oxcarbazepine, rifampin, rifabutin, rifapentine, efavirenz-containing HIV regimens, rosuvastatin at doses above 10mg, tipranavir/ritonavir, topotecan, sofosbuvir (Sovaldi) (as a single agent), ledipasvir/sofosbuvir (Harvoni), elbasvir/grazoprevir (Zepatier), pibrentasvir/glecaprevir (Mavyret), or velpatasvir/sofosbuvir/voxilaprevir (Vosevi)
  - The patient has a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions (e.g., physician attestation)

If yes, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

If no, continue to #3.

3. Does the patient have decompensated cirrhosis **AND** the requested medication will be used with ribavirin?

If yes, **approve for 12 weeks by GPID or GPI-14 for the requested strength as follows:**

- **400mg-100mg tablets: #1 per day.**
- **200mg-50mg tablets: #1 per day.**
- **200mg-50mg pellets: #2 per day.**
- **150mg-37.5mg pellets: #1 per day.**

If no, continue to #4.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOFOSBUVIR/VELPATASVIR

GUIDELINES FOR USE (CONTINUED)

4. Does the patient meet **ONE** of the following?

- Treatment naïve and genotype 1-6 infection
- Treatment experienced, genotype 1-6 infection, with prior treatment with one of the following: 1) peginterferon/ribavirin or 2) NS3 protease inhibitor triple therapy (Olysio, Incivek or Victrelis with peginterferon/ribavirin)
- Treatment experienced, genotype 1b or genotype 2 infection, with previous treatment with Sovaldi (sofosbuvir)-containing regimen (e.g., Sovaldi/ribavirin with or without peginterferon or Sovaldi/Olysio) that does not include an NS5A inhibitor

If yes, **approve for 12 weeks by GPID or GPI-14 for the requested strength as follows:**

- **400mg-100mg tablets: #1 per day.**
- **200mg-50mg tablets: #1 per day.**
- **200mg-50mg pellets: #2 per day.**
- **150mg-37.5mg pellets: #1 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SOFOSBUVIR/VELPATASVIR (Epclusa)** requires the following rule(s) be met for approval:

- A. You have chronic hepatitis C (type of liver inflammation) with genotype 1, 2, 3, 4, 5, or 6
- B. You are 3 years of age or older
- C. You have an HCV RNA level (amount of virus in your blood) within the past 6 months
- D. **If you have decompensated cirrhosis (symptoms related to liver damage), approval also requires:**
  1. The requested medication will be used with ribavirin
- E. **If you do not have cirrhosis (liver damage) OR you have compensated cirrhosis (a condition where liver is extensively scarred, but you do not have symptoms of liver damage), approval also requires ONE of the following:**
  1. You are treatment naïve (never previously treated)
  2. You are treatment experienced (have previously been treated) with peginterferon/ribavirin or NS3 protease inhibitor triple therapy (type of hepatitis drug such as Olysio, Incivek or Victrelis with peginterferon/ribavirin)
  3. You have genotype 1b or genotype 2 infection AND you are treatment experienced with a Sovaldi (sofosbuvir)-containing regimen that does not include an NS5A inhibitor (type of hepatitis drug) such as Sovaldi/ribavirin with or without peginterferon or Sovaldi/Olysio

***(Denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOFOSBUVIR/VELPATASVIR

GUIDELINES FOR USE (CONTINUED)

**Epclusa will not be approved if you meet any of the following:**

- A. You are using any of the following medications with the requested agent: amiodarone, carbamazepine, phenytoin, phenobarbital, oxcarbazepine, rifampin, rifabutin, rifapentine, efavirenz-containing HIV (human immunodeficiency virus) regimens, rosuvastatin at doses above 10mg, tipranavir/ritonavir, topotecan, sofosbuvir (Sovaldi) (as a single agent), ledipasvir/sofosbuvir (Harvoni), elbasvir/grazoprevir (Zepatier), pibrentasvir/glecaprevir (Mavyret), or velpatasvir/sofosbuvir/voxilaprevir (Vosevi)
- B. You have a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Epclusa.

**REFERENCES**

- Guidance from the American Association for the Study of Liver Diseases (AASLD) and the Infectious Disease Society of America (IDSA) Recommendations for Testing, Managing, and Treating hepatitis C. Available online at <http://www.hcvguidelines.org/full-report-view> Accessed July 28, 2016.
- Epclusa [Prescribing Information]. Foster City, CA: Gilead Sciences; April 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/23

Created: 07/16

Client Approval: 11/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SOFOSBUVIR/ VELPATASVIR/ VOXILAPREVIR	VOSEVI	44428		GPI-10 (1235990380)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of chronic hepatitis C, genotype 1, 2, 3, 4, 5, or 6 and meet **ALL** the following criteria?

- The patient is 18 years of age or older
- The patient has an HCV RNA level within the past 6 months

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient meet at least **ONE** of the following criteria?

- The patient is concurrently taking any of the following medications: amiodarone, rifampin, carbamazepine, phenytoin, phenobarbital, oxcarbazepine, rifabutin, rifapentine, HIV regimen containing atazanavir, lopinavir, tipranavir/ritonavir, or efavirenz, rosuvastatin, pitavastatin, pravastatin (at doses above 40mg), cyclosporine, methotrexate, mitoxantrone, imatinib, irinotecan, lapatinib, sulfasalazine, topotecan, sofosbuvir (Sovaldi) (as a single agent), velpatasvir/sofosbuvir (Epclusa), ledipasvir/sofosbuvir (Harvoni), elbasvir/grazoprevir (Zepatier), or pibrentasvir/glecaprevir (Mavyret)
- The patient has moderate or severe hepatic impairment (Child-Pugh B or C)
- The patient has a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions (e.g., physician attestation)

If yes, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

If no, continue to #3.

3. Does the patient meet **ONE** of the following criteria?

- Genotype 1-6, treatment experienced and previously failed a full course of therapy with DAA regimen that includes NS5A inhibitor (e.g., Harvoni, Epclusa, Technivie, Viekira Pak or Viekira XR, Zepatier, Daklinza/Sovaldi combination)
- Genotype 1a or 3, treatment experienced and previously failed a full course of therapy with DAA regimen that includes sofosbuvir without NS5A inhibitor (e.g., Sovaldi/ribavirin, Sovaldi/peginterferon/ribavirin, Olysio/Sovaldi (or other HCV protease inhibitor in combination with Sovaldi))

If yes, **approve for 12 weeks by HICL or GPI-10 for #1 per day.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR (Vosevi)** requires the following rule(s) be met for approval:

- A. You have chronic hepatitis C (type of liver inflammation)
- B. You are 18 years of age or older
- C. You have an HCV RNA level (amount of virus in your blood) within the past 6 months
- D. You meet ONE of the following:
  - 1. You have genotype 1, 2, 3, 4, 5, or 6 and previously failed a full course of therapy with a direct-acting antiviral (DAA) regimen that includes NS5A inhibitor (class of hepatitis C drug such as Harvoni, Epclusa, Technivie, Viekira Pak or Viekira XR, Zepatier, Daklinza/Sovaldi combination)
  - 2. You have genotype 1a or genotype 3 and previously failed a full course of therapy with DAA regimen that includes sofosbuvir without NS5A inhibitor (class of hepatitis C drug such as Sovaldi/ribavirin, Sovaldi/peginterferon/ribavirin, Olysio/Sovaldi (or other hepatitis c virus protease inhibitor in combination with Sovaldi))

**Vosevi will not be approved if you meet any of the following:**

- A. You are using the requested agent concurrently (at the same time) with any of the following medications: amiodarone, rifampin, carbamazepine, phenytoin, phenobarbital, oxcarbazepine, rifabutin, rifapentine, HIV (human immunodeficiency virus) regimen containing atazanavir, lopinavir, tipranavir/ritonavir, or efavirenz, rosuvastatin, pitavastatin, pravastatin (at doses above 40mg), cyclosporine, methotrexate, mitoxantrone, imatinib, irinotecan, lapatinib, sulfasalazine, topotecan, sofosbuvir (Sovaldi) (as a single agent), velpatasvir/sofosbuvir (Epclusa), ledipasvir/sofosbuvir (Harvoni), elbasvir/grazoprevir (Zepatier), or pibrentasvir/glecaprevir (Mavyret)
- B. You have moderate or severe hepatic (liver) impairment (Child-Pugh B or C)
- C. You have a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions (other diseases)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Vosevi.

**REFERENCES**

- Guidance from the American Association for the Study of Liver Diseases (AASLD) and the Infectious Disease Society of America (IDSA) Recommendations for Testing, Managing, and Treating hepatitis C. Available online at <http://www.hcvguidelines.org/full-report-view> Accessed July 7, 2017.
- Vosevi [Prescribing Information]. Foster City, CA: Gilead Sciences; November 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/23

Created: 08/17

Client Approval: 11/22

P&T Approval: 04/22





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOLIFENACIN SUSPENSION

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SOLIFENACIN SUCCINATE	VESICARE LS		47476	GPI-14 (54100055201820)	

GUIDELINES FOR USE

1. Does the patient have a diagnosis of neurogenic detrusor overactivity and meet **ALL** of the following criteria?
  - The patient is 2 years of age or older
  - The patient had a trial of or contraindication to TWO of the following:
    - Anticholinergics (e.g., oxybutynin)
    - Beta-3 agonists (e.g., mirabegron)
  - The patient is unable to swallow oral solifenacin tablets

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #10mL per day.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SOLIFENACIN SUSPENSION (Vesicare LS)** requires the following rule(s) be met for approval:

- A. You have neurogenic detrusor overactivity (type of bladder dysfunction)
- B. You are 2 years of age or older
- C. You had a trial of or contraindication (harmful for) to TWO of the following:
  1. Anticholinergics (such as oxybutynin)
  2. Beta-3 agonists (such as mirabegron)
- D. You are unable to swallow oral solifenacin tablets

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Vesicare LS.

REFERENCES

- Vesicare LS [Prescribing Information]. Northbrook, IL: Astellas Pharma US, Inc., June 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/22

Created: 05/21

Client Approval: 11/21

P&T Approval: 10/21

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOLRIAMFETOL

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SOLRIAMFETOL	SUNOSI	45666		GPI-10 (6137007020)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of excessive daytime sleepiness (EDS) with narcolepsy **AND** the narcolepsy is confirmed by **ONE** of the following criteria?
  - The patient has a Multiple Sleep Latency Test (MSLT) showing both a mean sleep latency of 8 minutes or less **AND** 2 or more early-onset rapid eye movement (REM) sleep test periods (SOREMPs)
  - The patient has a Multiple Sleep Latency Test (MSLT) showing both a mean sleep latency of 8 minutes or less **AND** one early-onset rapid eye movement (REM) sleep test period (SOREMP) **AND** additionally one SOREMP (within approximately 15 minutes) on a polysomnography the night preceding the MSLT, with the polysomnography ruling out non-narcolepsy causes of excessive daytime sleepiness (EDS)
  - The patient has low orexin (aka hypocretin) levels on a cerebrospinal fluid (CSF) assay

If yes, continue to #2.

If no, continue to #3.

2. Does the patient meet **ALL** of the following criteria?
  - Excessive Daytime Sleepiness (EDS) persisting for at least 3 months and Epworth Sleepiness Scale (ESS) score of more than 10
  - Therapy is prescribed by or given in consultation with a neurologist, psychiatrist, or specialist in sleep medicine
  - The patient had a trial of or contraindication to one amphetamine derivative (e.g., amphetamine sulfate, methylphenidate, etc.) **AND** modafinil or armodafinil

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #1 per day.**

**APPROVAL TEXT:** Renewal requires the patient has demonstrated 25% or more improvement in Epworth Sleepiness Scale (ESS) scores compared to baseline.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOLRIAMFETOL

INITIAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of excessive daytime sleepiness (EDS) with obstructive sleep apnea (OSA) **AND** that OSA is confirmed by **ONE** of the following criteria?

- Polysomnography
- Home sleep apnea testing devices
- Hospital-based bedside monitoring

If yes, continue to #4.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

4. Does the patient meet **ALL** of the following criteria?

- Excessive Daytime Sleepiness (EDS) persisting for at least 3 months and Epworth Sleepiness Scale (ESS) score of more than 10
- The patient had a trial of or contraindication to modafinil or armodafinil
- The patient is on ongoing treatment to address the obstructive causes of OSA, for at least one month since initiation, and has been counseled on weight-loss intervention (if BMI > 30)

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #1 per day.**

**APPROVAL TEXT:** Renewal requires the patient has demonstrated 25% or more improvement in Epworth Sleepiness Scale (ESS) scores compared to baseline.

If no, do not approve.

**INITIAL DENIAL TEXT:** *\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **SOLRIAMFETOL (Sunosi)** requires the following rule(s) be met for approval:

A. You have excessive daytime sleepiness (EDS) with narcolepsy (a sleep disorder); or obstructive sleep apnea (OSA: a disorder where airflow is blocked during sleep).

***(Initial denial text continued on the next page)***

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOLRIAMFETOL

INITIAL CRITERIA (CONTINUED)

**B. If you have excessive daytime sleepiness (EDS) with narcolepsy, approval also requires:**

1. Your diagnosis of narcolepsy is confirmed by **ONE** of the following:
  - i. You have a Multiple Sleep Latency Test (MSLT) showing an average sleep latency of 8 minutes or less **AND** two (2) or more early-onset rapid eye movement (REM) sleep test periods (SOREMPs)
  - ii. You have a Multiple Sleep Latency Test (MSLT) showing an average sleep latency of 8 minutes or less **AND** one (1) early-onset rapid eye movement (REM) sleep test period (SOREMP) **AND** one (1) SOREMP (within about 15 minutes) on a sleep study (polysomnography) the night before the MSLT, with the sleep study ruling out non-narcolepsy causes of excessive daytime sleepiness (EDS)
  - iii. You have low orexin levels on a cerebrospinal fluid (CSF) assay (a test to determine the amount of a type of chemical for wakefulness in your brain)
2. You have had Excessive Daytime Sleepiness (EDS) persisting for at least 3 months and Epworth Sleepiness Scale (ESS) score of more than 10
3. Therapy is prescribed by or given in consultation with a neurologist (brain doctor), psychiatrist (mental health doctor), or specialist in sleep medicine
4. You have tried one amphetamine derivative (e.g., amphetamine sulfate, methylphenidate, etc.) **AND** modafinil or armodafinil, unless there is a medical reason why you cannot (contraindication)

**C. If you have excessive daytime sleepiness (EDS) with obstructive sleep apnea (OSA), approval also require:**

1. Your diagnosis of OSA is confirmed by a sleep study (polysomnography), home sleep apnea testing devices, or hospital-based bedside monitoring
2. You have had Excessive Daytime Sleepiness (EDS) for at least 3 months and your Epworth Sleepiness Scale (ESS) score is more than 10
3. You have tried modafinil or armodafinil, unless there is a medical reason why you cannot (contraindication)
4. You have been on a treatment for the obstructive causes of OSA, for at least one month since initiation, and you have been counseled on weight-loss intervention [if your BMI (Body Mass Index: a measure of body fat based on height and weight) is greater than 30]

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOLRIAMFETOL

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

- Does the patient have a diagnosis of excessive daytime sleepiness (EDS) with narcolepsy or obstructive sleep apnea (OSA) **AND** meet the following criterion?
  - The patient has demonstrated 25% or more improvement in Epworth Sleepiness Scale (ESS) scores compared to baseline

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #30 per 30 days.**  
If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SOLRIAMFETOL (Sunosi)** requires the following rule(s) be met for renewal:

- You have excessive daytime sleepiness (EDS) with narcolepsy (a sleep disorder); or obstructive sleep apnea (OSA: a disorder where airflow is blocked during sleep).
- You have sustained improvement in Epworth Sleepiness Scale (ESS) scores by at least 25% compared to baseline

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Sunosi.

**REFERENCES**

- Sunosi [Prescribing Information]. Palo Alto, CA: Jazz Pharmaceuticals, Inc.; June 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 07/19

Client Approval: 04/20

P&T Approval: 10/19



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - GENOTROPIN

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SOMATROPIN	GENOTROPIN	02824		GPI-10 (3010002000)	MEDI-SPAN & FDB: BRAND = GENOTROPIN. MEDI-SPAN: BRAND = GENOTROPIN MINIQUICK.

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Is the request for treatment of **ANY** of the following?

- Athletic enhancement
- Anti-aging purposes
- Idiopathic short stature

If yes, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

If no, continue to #2.

2. Does the patient have **ONE** of the following diagnoses and meet the associated criteria?

**For pediatric growth hormone deficiency (GHD), approval requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient had a trial of or contraindication to the preferred agent: Norditropin
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- The patient meets at least ONE of the following criteria for short stature:
  - Patient's height greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender
  - Height velocity less than the 25th percentile for age
  - Documented low peak growth hormone (less than 10ng/mL) on two GH stimulation tests or insulin-like growth factor 1 (IGF-1) greater than or equal to 2 SD below the mean for age and gender

**For growth failure associated with Turner syndrome, approval requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient had a trial of or contraindication to the preferred agent: Norditropin
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- The patient's height is greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender

***(Initial criteria continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - GENOTROPIN

INITIAL CRITERIA (CONTINUED)

**For growth failure due to Prader-Willi syndrome (PWS), approval requires ALL of the following:**

- Confirmed genetic diagnosis of PWS
- Therapy is prescribed by or in consultation with an endocrinologist
- The patient had a trial of or contraindication to the preferred agent: Norditropin

**For growth failure in children born small for gestational age (SGA), approval requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient had a trial of or contraindication to the preferred agent: Norditropin
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- Patient with no catch-up growth by age 2 years
- The patient's height is greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender

**For adult growth hormone deficiency, approval requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient had a trial of or contraindication to the preferred agent: Norditropin
- The patient has growth hormone deficiency alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary diseases, hypothalamic disease, surgery, radiation therapy, trauma, or continuation of therapy from childhood onset growth hormone deficiency

If yes, **approve for 12 months by GPID or GPI-14 for all strengths.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SOMATROPIN (Genotropin)** requires the following rule(s) be met for approval:

A. You have one of the following diagnoses:

1. Pediatric growth hormone deficiency (GHD: a type of hormone disorder with low growth hormone)
2. Growth failure associated with Turner syndrome (TS: a type of gene condition)
3. Growth failure due to Prader-Willi syndrome (PWS: a type of gene condition)
4. Growth failure in children born small for gestational age (SGA)
5. Adult growth hormone deficiency

This medication will not be approved for treatment of **ANY** of the following conditions:

1. Athletic enhancement
2. Anti-aging purposes
3. Idiopathic short stature (unknown cause of short height)

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - GENOTROPIN

INITIAL CRITERIA (CONTINUED)

- B. If you have pediatric growth hormone deficiency, approval also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
  2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
  3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
  4. You meet at least ONE of the following criteria for short stature:
    - a. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender
    - b. Your height velocity is less than the 25th percentile for your age
    - c. You have documented low peak growth hormone (less than 10ng/mL) on two GH (growth hormone) stimulation tests or insulin-like growth factor 1 (IGF-1) greater than or equal to 2 standard deviations below the mean for your age and gender
- C. If you have growth failure associated with Turner syndrome, approval also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
  2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
  3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph of the wrist and hand
  4. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender
- D. If you have growth failure due to Prader-Willi syndrome (PWS), approval also requires:**
1. You have a confirmed genetic diagnosis of Prader-Willi syndrome
  2. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
  3. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
- E. If you have growth failure and are a child born small for gestational age (SGA), approval also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
  2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
  3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph of the wrist and hand
  4. You had no catch-up growth by age 2 years
  5. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender

*(Initial denial text continued on next page)*

CONTINUED ON NEXT PAGE





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - GENOTROPIN

INITIAL CRITERIA (CONTINUED)

F. If you have adult growth hormone deficiency, approval also requires:

1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
3. You have growth hormone deficiency alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary diseases (disease of a major hormone producing gland), hypothalamic disease (disease of a small area of the brain important for hormone production and body processes), surgery, radiation therapy, trauma, or continuation of therapy from childhood onset growth hormone deficiency

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Is the request for treatment of **ANY** of the following?

- Athletic enhancement
- Anti-aging purposes
- Idiopathic short stature

If yes, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

If no, continue to #2.

2. Does the patient have **ONE** of the following diagnoses and meet the associated criteria?

**For pediatric growth hormone deficiency (GHD), renewal requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand or the patient has not completed prepubertal growth)
- The patient meets ONE of the following:
  - Annual growth velocity of 2 cm or more compared with what was observed from the previous year
  - Annual growth velocity of 1 cm or more compared with what was observed from the previous year for patients who are near the terminal phase of puberty

***(Renewal criteria continued on next page)***

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - GENOTROPIN

RENEWAL CRITERIA (CONTINUED)

**For short stature associated with Turner syndrome, renewal requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- Growth velocity of 2 cm or more compared with what was observed from the previous year or patient has not reached 50th percentile for patient's predicted adult height

**For growth failure due to Prader-Willi syndrome (PWS), renewal requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- Improvement in body composition

**For growth failure in children born small for gestational age (SGA), renewal requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- Growth velocity of 2 cm or more compared with what was observed from the previous year or patient has not reached 50th percentile for patient's predicted adult height

**For adult growth hormone deficiency, renewal requires:**

- Therapy is prescribed by or in consultation with an endocrinologist

If yes, **approve for 12 months by GPID or GPI-14 for all strengths.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SOMATROPIN (Genotropin)** requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:

1. Pediatric growth hormone deficiency (GHD)
2. Growth failure associated with Turner syndrome (type of genetic disorder where you are missing a X chromosome)
3. Growth failure due to Prader-Willi syndrome (PWS: genetic disorder that causes obesity, intellectual disability, and short height)
4. Growth failure in children born small for gestational age (SGA)
5. Adult growth hormone deficiency

This medication will not be approved for treatment of ANY of the following conditions:

1. Athletic enhancement
2. Anti-aging purposes
3. Idiopathic short stature (unknown cause of short height)

***(Renewal denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - GENOTROPIN

RENEWAL CRITERIA (CONTINUED)

- B. If you have pediatric growth hormone deficiency, renewal also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
  2. Your epiphyses (end part of long bone) are NOT closed (confirmed by radiograph [type of imaging test] of the wrist and hand or you have not completed prepubertal growth)
  3. You meet ONE of the following:
    - a. Your annual growth velocity is 2 cm or more compared with what was observed from the previous year
    - b. Your annual growth velocity is 1 cm or more compared with what was observed from the previous year if you are near the terminal (end) phase of puberty
- C. If you have short stature associated with Turner syndrome, renewal also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
  2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
  3. Your growth velocity is 2 cm or more compared with what was observed from the previous year and/or you have not reached 50th percentile for your predicted adult height
- D. If you have growth failure due to Prader-Willi syndrome, renewal also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
  2. You have experienced improvement in body composition
- E. If you have growth failure and are a child born small for gestational age, renewal also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
  2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
  3. Your growth velocity is 2 cm or more compared with what was observed from the previous year and/or you have not reached 50th percentile for your predicted adult height
- F. If you have adult growth hormone deficiency, renewal also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**SOMATROPIN - GENOTROPIN**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Genotropin.

**REFERENCES**

- Genotropin [Prescribing Information]. New York, NY: Pharmacia & Upjohn Co.; April 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/01/22

Created: 10/22

Client Approval: 10/22

P&T Approval: 04/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - HUMATROPE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SOMATROPIN	HUMATROPE	02824		GPI-10 (3010002000)	BRAND = HUMATROPE

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Is the request for treatment of **ANY** of the following?

- Athletic enhancement
- Anti-aging purposes
- Idiopathic short stature

If yes, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

If no, continue to #2.

2. Does the patient have **ONE** of the following diagnoses and meet the associated criteria?

**For pediatric growth hormone deficiency (GHD), approval requires ALL of the following:**

Therapy is prescribed by or in consultation with an endocrinologist

- The patient had a trial of or contraindication to the preferred agent: Norditropin
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- Patient meets at least ONE of the following criteria for short stature:
  - Patient's height greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender
  - Height velocity less than the 25th percentile for age
  - Documented low peak growth hormone (less than 10ng/mL) on two GH stimulation tests or insulin-like growth factor 1 (IGF-1) greater than or equal to 2 SD below the mean for age and gender

**For short stature associated with Turner syndrome, approval requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient had a trial of or contraindication to the preferred agent: Norditropin
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- The patient's height is greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender

**For short stature or growth failure in children with SHOX deficiency, approval requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- The patient's height is greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender

*(Initial criteria continued on next page)*

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - HUMATROPE

INITIAL CRITERIA (CONTINUED)

**For growth failure in children born small for gestational age (SGA), approval requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient had a trial of or contraindication to the preferred agent: Norditropin
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- Patient with no catch-up growth by age 2 to 4 years
- The patient's height is greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender

**For adult growth hormone deficiency, approval requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient had a trial of or contraindication to the preferred agent: Norditropin
- The patient has growth hormone deficiency alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary diseases, hypothalamic disease, surgery, radiation therapy, trauma, or continuation of therapy from childhood onset growth hormone deficiency

If yes, **approve for 12 months by GPID or GPI-14 for all strengths.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SOMATROPIN (Humatrope)** requires the following rule(s) be met for approval:

A. You have one of the following diagnoses:

1. Pediatric growth hormone deficiency (GHD: a type of hormone disorder with low growth hormone)
2. Short stature associated with Turner syndrome (TS: a type of gene condition)
3. Short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency (you're missing a certain gene, causing short height)
4. Growth failure in children born small for gestational age (SGA)
5. Adult growth hormone deficiency

This medication will not be approved for treatment of ANY of the following conditions:

1. Athletic enhancement
2. Anti-aging purposes
3. Idiopathic short stature (unknown cause for short height)

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - HUMATROPE

INITIAL CRITERIA (CONTINUED)

- B. If you have pediatric growth hormone deficiency, approval also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
  2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
  3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
  4. You meet at least ONE of the following criteria for short stature:
    - a. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender
    - b. Your height velocity is less than the 25th percentile for age
    - c. You have documented low peak growth hormone (less than 10ng/mL) on two GH (growth hormone) stimulation tests or insulin-like growth factor 1 (IGF-1) greater than or equal to 2 standard deviations below the mean for your age and gender
- C. If you have short stature associated with Turner syndrome, approval also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
  2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
  3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
  4. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender
- D. If you have short stature or growth failure in short stature homeobox-containing gene deficiency, approval also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
  2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
  3. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender
- E. If you have growth failure and are a child born small for gestational age, approval also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
  2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
  3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
  4. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender
  5. You had no catch-up growth by age 2 to 4 years
- (Initial denial text continued on next page)*

CONTINUED ON NEXT PAGE





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - HUMATROPE

INITIAL CRITERIA (CONTINUED)

**F. If you have adult growth hormone deficiency, approval also requires:**

1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
3. You have growth hormone deficiency alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary diseases (disease of a major hormone producing gland), hypothalamic disease (disease of a small area of the brain important for hormone production and body processes), surgery, radiation therapy, trauma, or continuation of therapy from childhood onset growth hormone deficiency

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Is the request for treatment of **ANY** of the following?

- Athletic enhancement
- Anti-aging purposes
- Idiopathic short stature

If yes, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

If no, continue to #2.

2. Does the patient have **ONE** of the following diagnoses and meet the associated criteria?

**For pediatric growth hormone deficiency (GHD), renewal requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand or the patient has not completed prepubertal growth)
- The patient meets ONE of the following:
  - Annual growth velocity of 2 cm or more compared with what was observed from the previous year
  - Annual growth velocity of 1 cm or more compared with what was observed from the previous year for patients who are near the terminal phase of puberty

***(Renewal criteria continued on next page)***

CONTINUED ON NEXT PAGE





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - HUMATROPE

RENEWAL CRITERIA (CONTINUED)

**For short stature associated with Turner syndrome, renewal requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- Growth velocity of 2 cm or more compared with what was observed from the previous year or patient has not reached 50th percentile for patient's predicted adult height

**For short stature or growth failure in children with SHOX deficiency, renewal requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- Growth velocity of 2 cm or more compared with what was observed from the previous year or patient has not reached 50th percentile for patient's predicted adult height

**For growth failure in children born small for gestational age (SGA), renewal requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- Growth velocity of 2 cm or more compared with what was observed from the previous year or patient has not reached 50th percentile for patient's predicted adult height

**For adult growth hormone deficiency, renewal requires:**

- Therapy is prescribed by or in consultation with an endocrinologist

If yes, **approve for 12 months by GPID or GPI-14 for all strengths.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SOMATROPIN (Humatrope)** requires the following rule(s) be met for renewal:

A. You have one of the following diagnoses:

1. Pediatric growth hormone deficiency (GHD: a type of hormone disorder with low growth hormone)
2. Short stature associated with Turner syndrome (TS: a type of gene condition)
3. Short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency (you're missing a certain gene, causing short height)
4. Growth failure in children born small for gestational age (SGA)
5. Adult growth hormone deficiency

This medication will not be approved for treatment of ANY of the following conditions:

1. Athletic enhancement
2. Anti-aging purposes
3. Idiopathic short stature (unknown cause for short height)

***(Renewal denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - HUMATROPE

RENEWAL CRITERIA (CONTINUED)

- B. If you have pediatric growth hormone deficiency, renewal also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
  2. Your epiphyses (end part of long bone) are NOT closed (confirmed by radiograph [type of imaging test] of the wrist and hand or you have not completed prepubertal growth)
  3. You meet ONE of the following:
    - a. Your annual growth velocity is 2 cm or more compared with what was observed from the previous year
    - b. Your annual growth velocity is 1 cm or more compared with what was observed from the previous year if you are near the terminal (end) phase of puberty
- C. If you have short stature associated with Turner syndrome, renewal also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
  2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
  3. Your growth velocity is 2 cm or more compared with what was observed from the previous year and/or you have not reached 50th percentile for your predicted adult height
- D. If you have short stature or growth failure in children with SHOX deficiency, renewal also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
  2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
  3. Your growth velocity is 2 cm or more compared with what was observed from the previous year and/or you have not reached 50th percentile for your predicted adult height
- E. If you have growth failure and are a child born small for gestational age, renewal also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
  2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
  3. Your growth velocity is 2 cm or more compared with what was observed from the previous year and/or you have not reached 50th percentile for your predicted adult height
- F. If you have adult growth hormone deficiency, renewal also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**SOMATROPIN - HUMATROPE**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Humatrope.

**REFERENCES**

- Humatrope [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC; October 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/01/22

Created: 10/22

Client Approval: 10/22

P&T Approval: 04/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - NORDITROPIN

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SOMATROPIN	NORDITROPIN FLEXPRO	02824		GPI-10 (3010002000)	BRAND = NORDITROPIN FLEXPRO

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Is the request for treatment of **ANY** of the following?

- Athletic enhancement
- Anti-aging purposes
- Idiopathic short stature

If yes, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

If no, continue to #2.

2. Does the patient have **ONE** of the following diagnoses and meet the associated criteria?

**For pediatric growth hormone deficiency (GHD), approval requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- The patient meets at least ONE of the following criteria for short stature:
  - Patient's height greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender
  - Height velocity less than the 25th percentile for age
  - Documented low peak growth hormone (less than 10ng/mL) on two GH stimulation tests or insulin-like growth factor 1 (IGF-1) greater than or equal to 2 SD below the mean for age and gender

**For short stature associated with Turner syndrome, approval requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- The patient's height is greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender

**For short stature associated with Noonan syndrome, approval requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- The patient's height is greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender

***(Initial criteria continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - NORDITROPIN

INITIAL CRITERIA (CONTINUED)

**For short stature in pediatric patients born small for gestational age (SGA), approval requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- Patient with no catch-up growth by age 2 to 4 years
- The patient's height is greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender

**For adult growth hormone deficiency, approval requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient has growth hormone deficiency alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary diseases, hypothalamic disease, Surgery, radiation therapy, trauma, or continuation of therapy from childhood onset growth hormone deficiency

**For growth failure due to Prader-Willi syndrome (PWS), approval requires ALL of the following:**

- Confirmed genetic diagnosis of PWS
- Therapy is prescribed by or in consultation with an endocrinologist

If yes, **approve for 12 months by GPID or GPI-14 for all strengths.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SOMATROPIN (Norditropin Flexpro)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:

1. Pediatric growth hormone deficiency (GHD: a type of hormone disorder with low growth hormone)
2. Short stature associated with Turner syndrome (TS: a type of gene condition)
3. Short stature associated with Noonan syndrome (a type of gene condition)
4. Short stature born small for gestational age (SGA) in a pediatric patient
5. Adult growth hormone deficiency
6. Growth failure due to Prader-Willi syndrome (PWS: a type of gene condition)

This medication will not be approved for treatment of ANY of the following conditions:

1. Athletic enhancement
2. Anti-aging purposes
3. Idiopathic short stature (short height due to unknown cause)

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - NORDITROPIN

INITIAL CRITERIA (CONTINUED)

- B. If you have pediatric growth hormone deficiency, approval also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
  2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
  3. You meet at least ONE of the following criteria for short stature:
    - a. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender
    - b. Your height velocity is less than the 25th percentile for your age
    - c. You have documented low peak growth hormone (less than 10ng/mL) on two GH (growth hormone) stimulation tests or insulin-like growth factor 1 (IGF-1) greater than or equal to 2 standard deviations below the mean for your age and gender
- C. If you have short stature associated with Turner syndrome, approval also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
  2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
  3. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender
- D. If you have short stature associated with Noonan syndrome, approval also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
  2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
  3. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender
- E. If you are a child with short stature born small for gestational age, approval also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
  2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
  3. You had no catch-up growth by age 2 to 4 years
  4. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender
- F. If you have adult growth hormone deficiency, approval also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
  2. You have growth hormone deficiency alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary diseases (disease of a major hormone producing gland), hypothalamic disease (disease of a small area of the brain important for hormone production and body processes), surgery, radiation therapy, trauma, or continuation of therapy from childhood onset growth hormone deficiency
- (Initial denial text continued on next page)***

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - NORDITROPIN

INITIAL CRITERIA (CONTINUED)

**G. If you have growth failure due to Prader-Willi syndrome, approval also requires:**

1. You have confirmed genetic diagnosis of Prader-Willi syndrome
2. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Is the request for treatment of **ANY** of the following?

- Athletic enhancement
- Anti-aging purposes
- Idiopathic short stature

If yes, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

If no, continue to #2.

2. Does the patient have **ONE** of the following diagnoses and meet the associated criteria?

**For pediatric growth hormone deficiency (GHD), renewal requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand or the patient has not completed prepubertal growth)
- The patient meets ONE of the following:
  - Annual growth velocity of 2 cm or more compared with what was observed from the previous year
  - Annual growth velocity of 1 cm or more compared with what was observed from the previous year for patients who are near the terminal phase of puberty

**For short stature associated with Noonan syndrome, renewal requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- Growth velocity of 2 cm or more compared with what was observed from the previous year or patient has not reached 50th percentile for patient's predicted adult height

***(Renewal criteria continued on next page)***

CONTINUED ON NEXT PAGE





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - NORDITROPIN

RENEWAL CRITERIA (CONTINUED)

**For short stature associated with Turner syndrome, renewal requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- Growth velocity of 2 cm or more compared with what was observed from the previous year or patient has not reached 50th percentile for patient's predicted adult height

**For short stature in pediatric patients born small for gestational age (SGA), renewal requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- Growth velocity of 2 cm or more compared with what was observed from the previous year or patient has not reached 50th percentile for patient's predicted adult height

**For adult growth hormone deficiency, renewal requires:**

- Therapy is prescribed by or in consultation with an endocrinologist

**For growth failure due to Prader-Willi syndrome (PWS), renewal requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- Improvement in body composition

If yes, **approve for 12 months by GPID or GPI-14 for all strengths.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SOMATROPIN (Norditropin Flexpro)** requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:

1. Pediatric growth hormone deficiency (GHD)
2. Short stature associated with Turner syndrome (type of genetic disorder where you are missing a X chromosome)
3. Short stature associated with Noonan syndrome (a type of genetic disorder causing abnormal body development)
4. Short stature born small for gestational age (SGA) in a pediatric patient
5. Adult growth hormone deficiency
6. Growth failure due to Prader-Willi syndrome (PWS: genetic disorder that causes obesity, intellectual disability, and short height)

This medication will not be approved for treatment of **ANY** of the following conditions:

1. Athletic enhancement
2. Anti-aging purposes
3. Idiopathic short stature (unknown cause for short height)

***(Renewal denial text continued on next page)***

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - NORDITROPIN

RENEWAL CRITERIA (CONTINUED)

- B. If you have pediatric growth hormone deficiency, renewal also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
  2. Your epiphyses (end part of long bone) are NOT closed (confirmed by radiograph [type of imaging test] of the wrist and hand or you have not completed prepubertal growth
  3. You meet ONE of the following:
    - a. Your annual growth velocity is 2 cm or more compared with what was observed from the previous year
    - b. Your annual growth velocity is 1 cm or more compared with what was observed from the previous year if you are near the terminal (end) phase of puberty
- C. If you have short stature associated with Noonan syndrome, renewal also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
  2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
  3. Your growth velocity is 2 cm or more compared with what was observed from the previous year and/or you have not reached 50th percentile for your predicted adult height
- D. If you have short stature associated with Turner syndrome, renewal also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
  2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
  3. Your growth velocity is 2 cm or more compared with what was observed from the previous year and/or you have not reached 50th percentile for your predicted adult height
- E. If you are a child with short stature born small for gestational age, renewal also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
  2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
  3. Your growth velocity is 2 cm or more compared with what was observed from the previous year and/or you have not reached 50th percentile for your predicted adult height
- F. If you have adult growth hormone deficiency, renewal also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
- G. If you have growth failure due to Prader-Willi syndrome, renewal also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
  2. You had improvement in body composition

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**SOMATROPIN - NORDITROPIN**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Norditropin.

**REFERENCES**

- Norditropin [Prescribing Information]. Plainsboro, NJ: Novo Nordisk; March 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/01/22

Created: 10/22

Client Approval: 10/22

P&T Approval: 04/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - NUTROPIN

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SOMATROPIN	NUTROPIN AQ NUSPIN	02824		GPI-10 (3010002000)	FDB: BRAND = NUTROPIN AQ NUSPIN. MEDI-SPAN: BRAND = NUTROPIN AQ NUSPIN 5, NUTROPIN AQ NUSPIN 10, NUTROPIN AQ NUSPIN 20

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Is the request for treatment of **ANY** of the following?

- Athletic enhancement
- Anti-aging purposes
- Idiopathic short stature

If yes, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

If no, continue to #2.

2. Does the patient have **ONE** of the following diagnoses and meet the associated criteria?

**For pediatric growth hormone deficiency (GHD), approval requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient had a trial of or contraindication to the preferred agent: Norditropin
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- The patient meets at least ONE of the following criteria for short stature:
  - The patient's height is greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender
  - Height velocity less than the 25th percentile for age
  - Documented low peak growth hormone (less than 10ng/mL) on two GH stimulation tests or insulin-like growth factor 1 (IGF-1) greater than or equal to 2 SD below the mean for age and gender

**For growth failure secondary to chronic kidney disease (CKD), approval requires ALL of the following:**

- Therapy is prescribed by or in consultation with a nephrologist
- The patient has NOT undergone a renal transplantation
- The patient's height or growth velocity is greater than or equal to 2 standard deviations (SD) below the mean for normal children of the same age and gender

***(Initial criteria continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - NUTROPIN

INITIAL CRITERIA CONTINUED)

**For short stature associated with Turner syndrome, approval requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient had a trial of or contraindication to the preferred agent: Norditropin
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- The patient's height is greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender

**For adult growth hormone deficiency, approval requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient had a trial of or contraindication to the preferred agent: Norditropin
- The patient has growth hormone deficiency alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary diseases, hypothalamic disease, surgery, radiation therapy, trauma, or continuation of therapy from childhood onset growth hormone deficiency

If yes, **approve for 12 months by GPID or GPI-14 for all strengths.**

If no, do not approve.

**INITIAL DENIAL TEXT: Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SOMATROPIN (Nutropin AQ Nuspin)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:

1. Pediatric growth hormone deficiency (GHD: a type of hormone disorder with low growth hormone)
2. Growth failure secondary to chronic kidney disease (CKD)
3. Short stature associated with Turner syndrome (TS: a type of gene condition)
4. Adult growth hormone deficiency

This medication will not be approved for treatment of ANY of the following conditions:

1. Athletic enhancement
2. Anti-aging purposes
3. Idiopathic short stature (short height due to unknown cause)

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - NUTROPIN

INITIAL CRITERIA (CONTINUED)

**B. If you have pediatric growth hormone deficiency, approval also requires:**

1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
4. You meet at least ONE of the following criteria for short stature:
  - a. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender
  - b. Your height velocity is less than the 25th percentile for your age
  - c. You have documented low peak growth hormone (less than 10ng/mL) on two growth hormone stimulation tests or insulin-like growth factor 1 (IGF-1) greater than or equal to 2 standard deviations below the mean for your age and gender

**If you have growth failure secondary to chronic kidney disease, approval also requires:**

1. You have NOT undergone a renal (kidney) transplantation
2. Therapy is prescribed by or in consultation with a nephrologist (kidney doctor)
3. Your height or growth velocity is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender

**D. If you have short stature associated with Turner syndrome, approval also requires:**

1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
4. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender

**E. If you have adult growth hormone deficiency, approval also requires:**

1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
3. You have growth hormone deficiency alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary diseases (disease of a major hormone producing gland), hypothalamic disease (disease of a small area of the brain important for hormone production and body processes), surgery, radiation therapy, trauma, or continuation of therapy from childhood onset growth hormone deficiency

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - NUTROPIN

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Is the request for treatment of **ANY** of the following?

- Athletic enhancement
- Anti-aging purposes
- Idiopathic short stature

If yes, do not approve.

**DENIALTEXT:** See the renewal denial text at the end of the guideline.

If no, continue to #2.

2. Does the patient have **ONE** of the following diagnoses and meet the associated criteria?

**For pediatric growth hormone deficiency (GHD), renewal requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand or the patient has not completed prepubertal growth)
- The patient meets ONE of the following:
  - Annual growth velocity of 2 cm or more compared with what was observed from the previous year
  - Annual growth velocity of 1 cm or more compared with what was observed from the previous year for patients who are near the terminal phase of puberty

**For growth failure secondary to chronic kidney disease (CKD), renewal requires ALL of the following:**

- The patient has not undergone a renal transplantation
- Growth velocity of 2 cm or more compared with what was observed from the previous year or patient has not reached 50th percentile for patient's predicted adult height

**For short stature associated with Turner syndrome, renewal requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- Growth velocity of 2 cm or more compared with what was observed from the previous year or patient has not reached 50th percentile for patient's predicted adult height

**For adult growth hormone deficiency, renewal requires:**

- Therapy is prescribed by or in consultation with an endocrinologist

If yes, **approve for 12 months by GPID or GPI-14 for all strengths.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - NUTROPIN

RENEWAL CRITERIA (CONTINUED)

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SOMATROPIN (Nutropin AQ Nuspin)** requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:

1. Pediatric growth hormone deficiency (GHD: a type of hormone disorder with low growth hormone)
2. Growth failure secondary to chronic kidney disease (CKD)
3. Short stature associated with Turner syndrome (TS: a type of gene condition)
4. Adult growth hormone deficiency

This medication will not be approved for treatment of **ANY** of the following conditions:

1. Athletic enhancement
2. Anti-aging purposes
3. Idiopathic short stature (short height due to unknown cause)

B. **If you have pediatric growth hormone deficiency, renewal also requires:**

1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
2. Your epiphyses (end part of long bone) are NOT closed (confirmed by radiograph [type of imaging test] of the wrist and hand or you have not completed prepubertal growth)
3. You meet ONE of the following:
  - a. Your annual growth velocity is 2 cm or more compared with what was observed from the previous year
  - b. Your annual growth velocity is 1 cm or more compared with what was observed from the previous year if you are near the terminal (end) phase of puberty

C. **If you have growth failure secondary to chronic kidney disease, renewal also requires:**

1. You have not had a renal (kidney) transplantation
2. Your growth velocity is 2 cm or more compared with what was observed from the previous year or you have not reached 50th percentile for your predicted adult height

D. **If you have short stature associated with Turner syndrome, renewal also requires:**

1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
3. Your growth velocity is 2 cm or more compared with what was observed from the previous year and/or you have not reached 50th percentile for your predicted adult height

E. **If you have adult growth hormone deficiency, renewal also requires:**

1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)

***(Renewal denial text continued on next page)***

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - NUTROPIN

RENEWAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Nutropin AQ.

REFERENCES

- Nutropin [Prescribing Information]. South San Francisco, CA: Genentech, Inc.; December 2016.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/01/22

Created: 10/22

Client Approval: 10/22

P&T Approval: 04/21





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - OMNITROPE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SOMATROPIN	OMNITROPE	02824		GPI-10 (3010002000)	BRAND = OMNITROPE

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Is the request for treatment of **ANY** of the following?

- Athletic enhancement
- Anti-aging purposes
- Idiopathic short stature

If yes, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline

If no, continue to #2.

2. Does the patient have **ONE** of the following diagnoses and meet the associated criteria?

**For pediatric growth hormone deficiency (GHD), approval requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient had a trial of or contraindication to the preferred agent: Norditropin
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- The patient meets at least ONE of the following criteria for short stature:
  - Patient's height is greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender
  - Height velocity less than the 25th percentile for age
  - Documented low peak growth hormone (less than 10ng/mL) on two GH stimulation tests or insulin-like growth factor 1 (IGF-1) greater than or equal to 2 SD below the mean for age and gender

**For growth failure due to Prader-Willi syndrome (PWS), approval requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- Confirmed genetic diagnosis of PWS
- The patient had a trial of or contraindication to the preferred agent: Norditropin  
*(Initial criteria continued on next page)*

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - OMNITROPE

INITIAL CRITERIA (CONTINUED)

**For growth failure in children born small for gestational age (SGA), approval requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- Patient with no catch-up growth by age 2 years
- The patient had a trial of or contraindication to the preferred agent: Norditropin
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- The patient's height is greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender

**For growth failure associated with Turner syndrome, approval requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient had a trial of or contraindication to the preferred agent: Norditropin
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- The patient's height is greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender

**For adult growth hormone deficiency, approval requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient had a trial of or contraindication to the preferred agent: Norditropin
- The patient has growth hormone deficiency alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary diseases, hypothalamic disease, surgery, radiation therapy, trauma, or continuation of therapy from childhood onset growth hormone deficiency

If yes, **approve for 12 months by GPID or GPI-14 for all strengths.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SOMATROPIN (Omnitrope)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:

1. Pediatric growth hormone deficiency (GHD: a type of hormone disorder with low growth hormone)
2. Growth failure due to Prader-Willi syndrome (PWS: a type of gene condition)
3. Growth failure in children born small for gestational age (SGA)
4. Growth failure associated with Turner syndrome (TS: a type of gene condition)
5. Adult growth hormone deficiency

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - OMNITROPE

INITIAL CRITERIA (CONTINUED)

This medication will not be approved for treatment of ANY of the following conditions:

1. Athletic enhancement
2. Anti-aging purposes
3. Idiopathic short stature (unknown cause of short height)
- B. **If you have pediatric growth hormone deficiency, approval also requires:**
  1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
  2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
  3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
  4. You meet at least ONE of the following criteria for short stature:
    - a. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender
    - b. Your height velocity is less than the 25th percentile for your age
    - c. You have documented low peak growth hormone (less than 10ng/mL) on two growth hormone stimulation tests or insulin-like growth factor 1 (IGF-1) greater than or equal to 2 standard deviations below the mean for your age and gender
- C. **If you have growth failure due to Prader-Willi syndrome, approval also requires:**
  1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
  2. You have confirmed genetic diagnosis of Prader-Willi Syndrome
  3. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
- D. **If you have growth failure and are a child born small for gestational age, approval also requires:**
  1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
  2. You had no catch-up growth by age 2 years
  3. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
  4. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
  5. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender
- E. **If you have growth failure associated with Turner syndrome, approval also requires:**
  1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
  2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
  3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
  4. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender

*(Initial denial text continued on next page)*

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - OMNITROPE

INITIAL CRITERIA (CONTINUED)

**F. If you have adult growth hormone deficiency, approval also requires:**

1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
3. You have growth hormone deficiency alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary diseases (disease of a major hormone producing gland), hypothalamic disease (disease of a small area of the brain important for hormone production and body processes), surgery, radiation therapy, trauma, or continuation of therapy from childhood onset growth hormone deficiency

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Is the request for treatment of **ANY** of the following?

- Athletic enhancement
- Anti-aging purposes
- Idiopathic short stature

If yes, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

If no, continue to #2.

2. Does the patient have **ONE** of the following diagnoses and meet the associated criteria?

**For pediatric growth hormone deficiency (GHD), renewal requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand or the patient has not completed prepubertal growth)
- The patient meets ONE of the following:
  - Annual growth velocity of 2 cm or more compared with what was observed from the previous year
  - Annual growth velocity of 1 cm or more compared with what was observed from the previous year in patients who are near the terminal phase of puberty

*(Renewal criteria continued on next page)*

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - OMNITROPE

RENEWAL CRITERIA (CONTINUED)

**For growth failure due to Prader-Willi syndrome (PWS), renewal requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- Improvement in body composition

**For growth failure in children born small for gestational age (SGA), renewal requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- Growth velocity of 2 cm or more compared with what was observed from the previous year or patient has not reached 50th percentile for patients predicted adult height

**For growth failure associated with Turner syndrome, renewal requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- Growth velocity of 2 cm or more compared with what was observed from the previous year or patient has not reached 50th percentile for patient's predicted adult height

**For adult growth hormone deficiency, renewal requires:**

- Therapy is prescribed by or in consultation with an endocrinologist

If yes, **approve for 12 months by GPID or GPI-14 for all strengths.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SOMATROPIN (Omnitrope)** requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:

1. Pediatric growth hormone deficiency (GHD: a type of hormone disorder with low growth hormone)
2. Growth failure due to Prader-Willi syndrome (PWS: a type of gene condition)
3. Growth failure in children born small for gestational age (SGA)
4. Growth failure associated with Turner syndrome (TS: a type of gene condition)
5. Adult growth hormone deficiency

This medication will not be approved for treatment of **ANY** of the following conditions:

1. Athletic enhancement
2. Anti-aging purposes
3. Idiopathic short stature (short height due to unknown cause)

***(Renewal denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN – OMNITROPE

RENEWAL CRITERIA (CONTINUED)

- B. If you have pediatric growth hormone deficiency, renewal also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
  2. Your epiphyses (end part of long bone) are NOT closed (confirmed by radiograph [type of imaging test] of the wrist and hand or you have not completed prepubertal growth)
  3. You meet ONE of the following:
    - a. Your annual growth velocity is 2 cm or more compared with what was observed from the previous year
    - b. Your annual growth velocity is 1 cm or more compared with what was observed from the previous year if you are near the terminal (end) phase of puberty
- C. If you have growth failure due to Prader-Willi syndrome, renewal also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
  2. You have experienced improvement in body composition
- D. If you have growth failure and are a child born small for gestational age, renewal also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
  2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
  3. Your growth velocity is 2 cm or more compared with what was observed from the previous year and/or you have not reached 50th percentile for your predicted adult height
- E. If you have growth failure associated with Turner syndrome, renewal also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
  2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
  3. Your growth velocity is 2 cm or more compared with what was observed from the previous year and/or you have not reached 50th percentile for your predicted adult height
- F. If you have adult growth hormone deficiency, renewal also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**SOMATROPIN – OMNITROPE**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Omnitrope.

**REFERENCES**

- Omnitrope [Prescribing Information]. Princeton, NJ: Sandoz, Inc.; June 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/01/22

Created: 10/22

Client Approval: 10/22

P&T Approval: 04/21





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - SAIZEN

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SOMATROPIN	SAIZEN, SAIZEN- SAIZENPREP	02824		GPI-10 (3010002010)	FDB: BRAND = SAIZEN, SAIZEN-SAIZENPREP  MEDI-SPAN: BRAND = SAIZEN, SAIZENPREP RECONSTITUTIONKIT

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Is the request for treatment of **ANY** of the following?

- Athletic enhancement
- Anti-aging purposes
- Idiopathic short stature

If yes, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

If no, continue to #2.

2. Does the patient have **ONE** of the following diagnoses and meet the associated criteria?

**For pediatric growth hormone deficiency (GHD), approval requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient had a trial of or contraindication to the preferred agent: Norditropin
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- The patient meets at least ONE of the following criteria for short stature:
  - Patient's height is greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender
  - Height velocity is less than the 25th percentile for age
  - Documented low peak growth hormone (less than 10ng/mL) on two GH stimulation tests or insulin-like growth factor 1 (IGF-1) greater than or equal to 2 SD below the mean for age and gender

**For adult growth hormone deficiency, approval requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient had a trial of or contraindication to the preferred agent: Norditropin
- The patient has growth hormone deficiency alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary diseases, hypothalamic disease, surgery, radiation therapy, trauma, or continuation of therapy from childhood onset growth hormone deficiency

If yes, **approve for 12 months by GPID or GPI-14 for all strengths.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial at the end of the guideline.

**CONTINUED ON NEXT PAGE**

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - SAIZEN

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT:** Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **SOMATROPIN (Saizen)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:

1. Pediatric growth hormone deficiency (GHD: a type of hormone disorder with low growth hormone)
2. Adult growth hormone deficiency

This medication will not be approved for treatment of **ANY** of the following conditions:

1. Athletic enhancement
2. Anti-aging purposes
3. Idiopathic short stature (short height due to unknown cause)

B. **If you have pediatric growth hormone deficiency, approval also requires:**

1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
2. You had a trial of or contraindication to the preferred medication: Norditropin
3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
4. You meet at least ONE of the following criteria for short stature:
  - Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender
  - Your height velocity is less than the 25th percentile for your age
  - You have documented low peak growth hormone (less than 10ng/mL) on two growth hormone stimulation tests or insulin-like growth factor 1 (IGF-1) greater than or equal to 2 standard deviations below the mean for your age and gender

C. **If you have adult growth hormone deficiency, approval also requires:**

1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
2. You had a trial of or contraindication to the preferred medication: Norditropin
3. You have growth hormone deficiency alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary diseases (disease of a major hormone producing gland), hypothalamic disease (disease of a small area of the brain important for hormone production and body processes), surgery, radiation therapy, trauma, or continuation of therapy from childhood onset growth hormone deficiency

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - SAIZEN

RENEWAL CRITERIA (CONTINUED)

1. Is the request for treatment of **ANY** of the following?

- Athletic enhancement
- Anti-aging purposes
- Idiopathic short stature

If yes, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

If no, continue to #2.

2. Does the patient have **ONE** of the following diagnoses and meet the associated criteria?

**For pediatric growth hormone deficiency (GHD), renewal requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand or the patient has not completed prepubertal growth)
- The patient meets ONE of the following:
  - Annual growth velocity of 2 cm or more compared with what was observed from the previous year
  - Annual growth velocity of 1 cm or more compared with what was observed from the previous year in patients who are near the terminal phase of puberty

**For adult growth hormone deficiency, renewal requires:**

- Therapy is prescribed by or in consultation with an endocrinologist

If yes, **approve for 12 months by GPID or GPI-14 for all strengths.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SOMATROPIN (Saizen)** requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:

1. Pediatric growth hormone deficiency (GHD: a type of hormone disorder with low growth hormone)
2. Adult growth hormone deficiency

This medication will not be approved for treatment of ANY of the following conditions:

1. Athletic enhancement
2. Anti-aging purposes
3. Idiopathic short stature (short height due to unknown cause)

***(Renewal denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - SAIZEN

RENEWAL CRITERIA (CONTINUED)

**B. If you have pediatric growth hormone deficiency, renewal also requires:**

1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
2. Your epiphyses (end part of long bone) are NOT closed (confirmed by radiograph [type of imaging test] of the wrist and hand or you have not completed prepubertal growth)
3. You meet ONE of the following:
  - a. Your annual growth velocity is 2 cm or more compared with what was observed from the previous year
  - b. Your annual growth velocity is 1 cm or more compared with what was observed from the previous year if you are near the terminal (end) phase of puberty

**C. If you have adult growth hormone deficiency, renewal also requires:**

1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Saizen

**REFERENCES**

- Saizen [Prescribing Information]. Rockland, MA: EMD Serono, Inc.; February 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/01/22

Created: 10/22

Client Approval: 10/22

P&T Approval: 04/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - SEROSTIM

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SOMATROPIN	SEROSTIM	02824		GPI-10 (3010002010)	BRAND = SEROSTIM

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Is the request for a patient with a diagnosis of HIV wasting/cachexia who meets **ALL** of the following criteria?
  - The requested medication is NOT prescribed for athletic enhancement or anti-aging purposes
  - Therapy is prescribed by or in consultation with ONE of the following specialists: gastroenterologist, nutritional support specialist, or infectious disease specialist
  - The patient is on HIV anti-retroviral therapy
  - The patient has inadequate response to previous therapy (i.e., exercise training, nutritional supplements, appetite stimulants, or anabolic steroids)
  - The patient has an inadequate response to previous pharmacological therapy including one of the following: cyproheptadine, Marinol (dronabinol), or Megace (megestrol acetate)
  - Alternative causes of wasting have been ruled out; alternative causes include:
    - Altered metabolism (from metabolic and hormonal abnormalities) including testosterone deficiency or peripheral growth hormone resistance
    - Diarrhea
    - Inadequate energy (caloric) intake
    - Malignancies
    - Opportunistic infections
  - The patient meets **ONE** of the following criteria for weight loss:
    - 10% unintentional weight loss over 12 months
    - 7.5% unintentional weight loss over 6 months
    - 5% body cell mass (BCM) loss within 6 months
    - BCM less than 35% (men) AND a body mass index (BMI) less than 27 kg per meter squared
    - BCM less than 23% (women) of total body weight AND a body mass index (BMI) less than 27 kg per meter squared
    - BMI less than 18.5 kg per meter squared

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - SEROSTIM

INITIAL CRITERIA (CONTINUED)

2. Is the patient hypogonadal as defined by **ONE** of the following?

- Total serum testosterone level of less than 300ng/dL (10.4 nmol/L)
- A low total serum testosterone level as indicated by a lab result, with a reference range, obtained within 90 days
- A free serum testosterone level of less than 5 ng/dL (0.17 nmol/L)

If yes, continue to #3.

If no, **approve for 12 weeks by GPID or GPI-14 for all strengths.**

3. For patients who are hypogonadal, does the patient meet the following criterion?

- The patient has tried testosterone therapy (e.g., testosterone cypionate, AndroGel, Androderm, Axiron, Delatestryl, Fortesta, Striant, Testim, Testopel, Vogelxo, Natesto)

If yes, **approve for 12 weeks by GPID or GPI-14 for all strengths.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SOMATROPIN (Serostim)** requires the following rule(s) be met for approval:

- A. You have HIV (human immunodeficiency virus) wasting/cachexia (extreme weight loss and muscle loss)
  - B. The requested medication is NOT prescribed for athletic enhancement or anti-aging purposes
  - C. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions), nutritional support specialist OR infectious disease specialist (doctor who specializes in the treatment of infections)
  - D. You are on HIV (human immunodeficiency virus) anti-retroviral therapy
  - E. You have had an inadequate response to previous therapy such as exercise training, nutritional supplements, appetite stimulants or anabolic steroids
  - F. You have had an inadequate response to previous pharmacological (drug) therapy including one of the following: cyproheptadine, Marinol (dronabinol), or Megace (megestrol acetate)
- (Initial denial text continued on next page)**

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - SEROSTIM

INITIAL CRITERIA (CONTINUED)

- G. Alternative causes of wasting have been ruled out. Alternative causes may include:
1. Altered metabolism (from metabolic and hormonal abnormalities) including testosterone deficiency or peripheral growth hormone resistance
  2. Diarrhea
  3. Inadequate energy (caloric) intake
  4. Malignancies (tumors)
  5. Opportunistic infections (an infection that can occur because of a weakened immune system)
- H. You meet ONE of the following criteria for weight loss:
1. 10% unintentional weight loss over 12 months
  2. 7.5% unintentional weight loss over 6 months
  3. 5% body cell mass (BCM) loss within 6 months
  4. BCM less than 35% (men) and a body mass index (BMI) less than 27 kg per meter squared
  5. BCM less than 23% (women) of total body weight and a body mass index (BMI) less than 27 kg per meter squared
  6. BMI less than 18.5 kg per meter squared
- I. **If you are hypogonadal (you have low testosterone levels), approval also requires:**
1. You meet one of the following criteria for low testosterone:
    - a. Total serum testosterone level of less than 300ng/dL (10.4nmol/L)
    - b. A low total serum testosterone level as indicated by a lab result, with a reference range, obtained within 90 days
    - c. A free serum testosterone level of less than 5 ng/dL (0.17 nmol/L)
  2. You have tried testosterone therapy (examples include testosterone cypionate, AndroGel, Androderm, Axiron, Delatestryl, Fortesta, Striant, Testim, Testopel, Vogelxo, Natesto)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - SEROSTIM

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Has the patient received more than 24 weeks of therapy within the plan year?

If yes, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

If no, continue to #2.

2. Is the request for a patient with HIV wasting/cachexia who meets **ALL** of the following criteria?
  - The requested agent is NOT prescribed for athletic enhancement or anti-aging purposes
  - The patient has shown clinical benefit in muscle mass and weight as indicated by a 10% or greater increase in weight or BCM from baseline (**Note:** Current and baseline weight must be documented including dates of measurement)
  - The patient is on HIV anti-retroviral therapy

If yes, **approve for 12 weeks by GPID or GPI-14 for all strengths.**

If no, do not approve.

**RENEWAL DENIAL TEXT:** **\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SOMATROPIN (Serostim)** requires the following rule(s) be met for renewal:

- A. You have HIV (human immunodeficiency virus) wasting/cachexia (severe muscle and weight loss)
- B. You have NOT received more than 24 weeks of therapy within the plan year
- C. The requested agent is NOT prescribed for athletic enhancement or anti-aging purposes
- D. You have shown clinical benefit in muscle mass and weight as indicated by at least a 10 percent increase in weight or BCM (body cell mass) from baseline (Note: current and baseline weight must be documented including dates of measurement)
- E. You are on HIV anti-retroviral therapy

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**SOMATROPIN - SEROSTIM**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Serostim.

**REFERENCES**

- Serostim [Prescribing Information]. Rockland, MA: EMD Serono, Inc.; June 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/23

Created: 10/22

Client Approval: 11/22

P&T Approval: 04/21





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - ZOMACTON

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SOMATROPIN	ZOMACTON	02824		GPI-10 (3010002000)	BRAND = ZOMACTON

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Is the request for treatment of **ANY** of the following?

- Athletic enhancement
- Anti-aging purposes
- Idiopathic short stature

If yes, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

If no, continue to #2.

2. Does the patient have **ONE** of the following diagnoses and meet the associated criteria?

**For pediatric growth hormone deficiency (GHD) approval requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient had a trial of or contraindication to the preferred agent: Norditropin
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- The patient meets at least ONE of the following criteria for short stature:
  - The patient's height is greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender
  - Height velocity is less than the 25th percentile for age
  - Documented low peak growth hormone (less than 10ng/mL) on two GH stimulation tests or insulin-like growth factor 1 (IGF-1) greater than or equal to 2 SD below the mean for age and gender

**For short stature associated with Turner syndrome, approval requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient had a trial of or contraindication to the preferred agent: Norditropin
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- The patient's height is greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender

**For short stature in children born small for gestational age (SGA), approval requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient had a trial of or contraindication to the preferred agent: Norditropin
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- Patient with no catch-up growth by age 2 to 4 years
- The patient's height is greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender

*(Initial criteria continued on next page)*

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - ZOMACTON

INITIAL CRITERIA (CONTINUED)

**For short stature or growth failure in children with SHOX deficiency, approval requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- The patient's height is greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender

**For adult growth hormone deficiency, approval requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient had a trial of or contraindication to the preferred agent: Norditropin
- The patient has growth hormone deficiency alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary diseases, hypothalamic disease, surgery, radiation therapy, trauma, or continuation of therapy from childhood onset growth hormone deficiency

If yes, **approve for 12 months by GPID or GPI-14 for all strengths.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SOMATROPIN (Zomacton)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:

1. Pediatric growth hormone deficiency (GHD: a type of hormone disorder with low growth hormone)
2. Short stature associated with Turner syndrome (TS: a type of gene condition)
3. Short stature in children born small for gestational age (SGA)
4. Short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency (you're missing a certain gene, causing short height)
5. Adult growth hormone deficiency

This medication will not be approved for treatment of **ANY** of the following conditions:

1. Athletic enhancement
2. Anti-aging purposes
3. Idiopathic short stature (short height due to unknown cause)

**(Initial denial text continued on next page)**

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - ZOMACTON

INITIAL CRITERIA (CONTINUED)

- B. If you have pediatric growth hormone deficiency, approval also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
  2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
  3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
  4. You meet at least ONE of the following criteria for short stature:
    - a. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender
    - b. Your height velocity is less than the 25th percentile for your age
    - c. You have documented low peak growth hormone (less than 10ng/mL) on two growth hormone stimulation tests or insulin-like growth factor 1 (IGF-1) greater than or equal to 2 standard deviations below mean for your age and gender
- C. If you have short stature associated with Turner syndrome, approval also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
  2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
  3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
  4. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender
- D. If you are a child with short stature born small for gestational age, approval also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
  2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
  3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
  4. You had no catch-up growth by age 2 to 4 years
  5. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender
- E. If you have short stature or growth failure in children with SHOX deficiency, approval also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
  2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
  3. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender

*(Initial denial text continued on next page)*

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - ZOMACTON

INITIAL CRITERIA (CONTINUED)

F. If you have adult growth hormone deficiency, approval also requires:

1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
3. You have growth hormone deficiency alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary diseases (disease of a major hormone producing gland), hypothalamic disease, surgery (disease of a small area of the brain important for hormone production and body processes), radiation therapy, trauma, or continuation of therapy from childhood onset growth hormone deficiency

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Is the request for treatment of **ANY** of the following?

- Athletic enhancement
- Anti-aging purposes
- Idiopathic short stature

If yes, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

If no, continue to #2.

2. Does the patient have **ONE** of the following diagnoses and meet the associated criteria?

**For pediatric growth hormone deficiency (GHD), renewal requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand or the patient has not completed prepubertal growth)
- The patient meets ONE of the following:
  - Annual growth velocity of 2 cm or more compared with what was observed from the previous year
  - Annual growth velocity of 1 cm or more compared with what was observed from the previous year in patients who are near the terminal phase of puberty

***(Renewal criteria continued on next page)***

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - ZOMACTON

RENEWAL CRITERIA (CONTINUED)

**For short stature associated with Turner syndrome, renewal requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- Growth velocity of 2 cm or more compared with what was observed from the previous year or patient has not reached 50th percentile for patient's predicted adult height

**For short stature in children born small for gestational age (SGA), renewal requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- Growth velocity of 2 cm or more compared with what was observed from the previous year or patient has not reached 50th percentile for patient's predicted adult height

**For short stature or growth failure in children with SHOX deficiency, renewal requires ALL of the following:**

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- Growth velocity of 2 cm or more compared with what was observed from the previous year or patient has not reached 50th percentile for patient's predicted adult height

**For adult growth hormone deficiency, renewal requires:**

- Therapy is prescribed by or in consultation with an endocrinologist

If yes, **approve for 12 months by GPID or GPI-14 for all strengths.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SOMATROPIN (Zomacton)** requires the following rule(s) be met for renewal:

A. You have one of the following diagnoses:

1. Pediatric growth hormone deficiency (GHD: a type of hormone disorder with low growth hormone)
2. Short stature associated with Turner syndrome (TS: a type of gene condition)
3. Short stature in children born small for gestational age (SGA)
4. Short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency (you're missing a certain gene, causing short height)
5. Adult growth hormone deficiency

***(Renewal denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - ZOMACTON

RENEWAL CRITERIA (CONTINUED)

This medication will not be approved for treatment of ANY of the following conditions:

1. Athletic enhancement
  2. Anti-aging purposes
  3. Idiopathic short stature (short height due to unknown cause)
- B. If you have pediatric growth hormone deficiency, renewal also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
  2. Your epiphyses (end part of long bone) are NOT closed (confirmed by radiograph [type of imaging test] of the wrist and hand or you have not completed prepubertal growth)
  3. You meet ONE of the following:
    - a. Your annual growth velocity is 2 cm or more compared with what was observed from the previous year
    - b. Your annual growth velocity is 1 cm or more compared with what was observed from the previous year if you are near the terminal (end) phase of puberty
- C. If you have short stature associated with Turner syndrome, renewal also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
  2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
  3. Your growth velocity is 2 cm or more compared with what was observed from the previous year and/or you have not reached 50th percentile for your predicted adult height
- D. If you have growth failure and are a child born small for gestational age, renewal also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
  2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
  3. Your growth velocity is 2 cm or more compared with what was observed from the previous year and/or you have not reached 50th percentile for your predicted adult height
- E. If you have short stature or growth failure in children with SHOX deficiency, renewal also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
  2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
  3. Your growth velocity is 2 cm or more compared with what was observed from the previous year and/or you have not reached 50th percentile for your predicted adult height
- F. If you have adult growth hormone deficiency, renewal also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**SOMATROPIN - ZOMACTON**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Zomacton

**REFERENCES**

- Zomacton [Prescribing Information]. Parsippany, NJ: Ferring Pharmaceuticals Inc.; July 2018.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/01/22

Created: 10/22

Client Approval: 10/22

P&T Approval: 04/21





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - ZORBTIVE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SOMATROPIN	ZORBTIVE		12767	GPI-14 (30100020102132)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Is the request for a patient with a diagnosis of short bowel syndrome who meets **ALL** of the following criteria?
  - Therapy is prescribed by or in consultation with a gastroenterologist
  - The requested medication is NOT prescribed for athletic enhancement or anti-aging purposes
  - The patient is currently on specialized nutritional support (such as high carbohydrate, low-fat diet, adjusted for individual requirements and preferences)

If yes, **approve for 4 weeks by GPID or GPI-14 for #1 vial per day (max dose not to exceed 8mg per day).**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SOMATROPIN (Zorbtive)** requires the following rule(s) be met for approval:

- A. You have short bowel syndrome (the body cannot absorb fluids and nutrients due to a lack of a functional small intestine)
- B. Therapy is prescribed by or in consultation with a gastroenterologist (digestive system doctor)
- C. The requested medication is NOT prescribed for athletic enhancement or anti-aging purposes
- D. You are currently on specialized nutritional support such as high carbohydrate, low-fat diet, adjusted for individual requirements and preferences

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOMATROPIN - ZORBTIVE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of short bowel syndrome?

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

2. Has the patient been on the medication for 4 weeks?

If yes, do not approve. [**Note:** The patient should only be approved for one 4 weeks fill in a lifetime.]

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

If no, **approve by GPID or GPI-14 for the remainder of therapy with a maximum of 4 weeks of therapy. (Please subtract any previous fills; maximum cumulative approval is for 4 weeks.)**

**RENEWAL DENIAL TEXT:** **\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SOMATROPIN (Zorbtive)** requires the following rule(s) be met for renewal:

- A. You have short bowel syndrome (the body cannot absorb fluids and nutrients due to a lack of a functional small intestine)
- B. You have not been on the requested medication for 4 weeks

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**SOMATROPIN - ZORBTIVE**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Zorbtive.

**REFERENCES**

- Zorbtive [Prescribing Information]. Rockland, MA: EMD Serono, Inc.; September 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/01/22

Created: 10/22

Client Approval: 10/22

P&T Approval: 04/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SONIDEGIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SONIDEGIB PHOSPHATE	ODOMZO	42369		GPI-10 (2137006020)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of locally advanced basal cell carcinoma (BCC) and meet the following criteria?
  - The patient is 18 years of age or older
  - This is a recurrence of BCC after the patient has already had surgery or radiation therapy or the patient is not a candidate for surgery or radiation therapy

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at end of the guideline.

2. Has the patient obtained the following tests prior to initiating therapy?
  - Baseline serum creatinine kinase (CK) level
  - Baseline serum creatinine
  - Pregnancy status of females of reproductive potential

If yes, **approve for 12 months by HICL or GPI 10 with a quantity limit of #1 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SONIDEGIB (Odomzo)** requires the following rule(s) be met for approval:

- A. You have locally advanced basal cell carcinoma (BCC: type of skin cancer).
- B. You are 18 years of age or older
- C. This is a recurrence (disease returns) of basal cell carcinoma after surgery or radiation therapy OR you are not a candidate for surgery or radiation therapy
- D. Baseline serum creatine kinase (CK: type of lab test) and serum creatinine levels have been obtained before starting therapy
- E. If you are a female of reproductive potential, you must verify your pregnancy status before starting therapy

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**SONIDEGIB**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Odomzo.

**REFERENCES**

- Odomzo [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals, Corp. May 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/22

Created: 10/15

Client Approval: 12/21

P&T Approval: 01/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**SORAFENIB**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SORAFENIB TOSYLATE	NEXAVAR, SORAFENIB TOSYLATE	33400		GPI-10 (2153306040)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of advanced renal cell carcinoma (RCC)?

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**  
If no, continue to #2.

2. Does the patient have a diagnosis of unresectable hepatocellular carcinoma?

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**  
If no, continue to #3.

3. Does the patient have a diagnosis of locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment?

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SORAFENIB (Nexavar)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:

1. Advanced renal cell carcinoma (RCC: type of kidney cancer)
2. Unresectable hepatocellular carcinoma (liver cancer that cannot be removed with surgery)
3. Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment (thyroid cancer that has returned or spread, is getting worse and is not responding to a type of treatment)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**SORAFENIB**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Review for Nexavar.

**REFERENCES**

- Nexavar [Prescribing Information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc. July 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/18/22

Created: 05/11

Client Approval: 06/22

P&T Approval: 02/14



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SOTORASIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SOTORASIB	LUMAKRAS	47400		GPI-10 (2153248000)	

GUIDELINES FOR USE

1. Does the patient have a diagnosis of locally advanced or metastatic non-small cell lung cancer (NSCLC) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient has a KRAS G12C-mutation, as determined by an FDA-approved test
  - The patient has received at least one prior systemic therapy

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #8 per day.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SOTORASIB (Lumakras)** requires the following rule(s) be met for approval:

- A. You have locally advanced or metastatic non-small cell lung cancer (NSCLC) (type of lung cancer that has grown outside the organ it started in but has not spread to other parts of the body or lung cancer that has spread to other parts of the body)
- B. You are 18 years of age or older
- C. You have a KRAS G12C-mutation (type of gene mutation), as determined by a Food and Drug Administration (FDA)-approved test
- D. You have received at least one prior systemic therapy (treatment that spreads throughout the body through the bloodstream)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Lumakras.

REFERENCES

- Lumakras [Prescribing Information]. Thousand Oaks, CA: Amgen, Inc.; May 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/01/21

Created: 07/21

Client Approval: 08/21

P&T Approval: 07/21

Copyright © 2023 MediImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MediImpact. MediImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SPARSENTAN

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SPARSENTAN	FILSPARI	48721		GPI-10 (5648306500)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of primary immunoglobulin A nephropathy (IgAN) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a nephrologist
  - The patient's diagnosis is confirmed by a biopsy
  - The patient is at risk of rapid disease progression (e.g., urine protein-to-creatinine ratio [UPCR] 1.5 g/g or greater)
  - The patient has proteinuria of at least 1 g/day
  - The patient has an eGFR of at least 30 mL/min/1.73 m<sup>2</sup>

If yes, **approve for 9 months by HICL or GPI-10 with a quantity limit of #1 per day.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SPARSENTAN (Filspari)** requires the following rule(s) be met for approval:

- A. You have primary immunoglobulin A nephropathy (IgAN: a type of kidney disease)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a nephrologist (a type of kidney doctor)
- D. Your diagnosis is confirmed by a biopsy (removal of cells or tissue for examination)
- E. You are at risk of rapid disease progression (such as urine protein-to-creatinine-ratio [UPCR: test that measures the amount of protein in urine] of 1.5 g/g or greater)
- F. You have proteinuria (increased levels of protein in the urine) of at least 1 g/day
- G. You have an eGFR (a tool for evaluating kidney function) of at least 30 mL/min/1.73 m<sup>2</sup>

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SPARSENTAN

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of primary immunoglobulin A nephropathy (IgAN) and meet **ONE** of the following criteria?

- The patient has had a reduction in proteinuria
- The patient has improved, or stable kidney function compared to baseline

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**  
If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SPARSENTAN (Filspari)** requires the following rule(s) be met for renewal:

- A. You have primary immunoglobulin A nephropathy (IgAN: a type of kidney disease)
- B. You meet ONE of the following:
  - 1. You had a reduction in proteinuria (increased levels of protein in the urine)
  - 2. You have improvement or stable kidney function compared to baseline

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Filspari.

**REFERENCES**

- Filspari [Prescribing Information]. San Diego, CA: Traverre Therapeutics, Inc.; February 2023.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 03/13/23

Created: 03/23

Client Approval: 03/23

P&T Approval: 01/23



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**STATIN ZERO COST SHARE OVERRIDE**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ROSUVASTATIN CALCIUM	CRESTOR, EZALLOR SPRINKLE, ROSUVASTATIN CALCIUM		19153 20229 39996 38314	GPI-14 (39400060100305) (39400060100310) (39400060106805) (39400060106810)	
PRAVASTATIN SODIUM	PRAVACHOL, PRAVASTATIN SODIUM	06227		GPI-10 (3940006510)	
SIMVASTATIN	ZOCOR, SIMVASTATIN		26531 26532 26533 26534	GPI-14 (39400075000310) (39400075000320) (39400075000330) (39400075000340)	
ATORVASTATIN CALCIUM	LIPITOR, ATORVASTATIN CALCIUM		43720 43721	GPI-14 (39400010100310) (39400010100320)	
LOVASTATIN, LOVASTATIN EXTENDED- RELEASE	ALTOPREV, LOVASTATIN	02793		GPI-10 (3940005000)	
FLUVASTATIN SODIUM , FLUVASTATIN EXTENDED- RELEASE	LESCOL, FLUVASTATIN SODIUM, LESCOL XL, FLUVASTATIN EXTENDED- RELEASE	08946		GPI-10 (3940003010)	
PITAVASTATIN CALCIUM	LIVALO, PITAVASTATIN CALCIUM	36983		GPI-10 (3940005810)	
PITAVASTATIN MAGNESIUM	ZYPITAMAG, PITAVASTATIN MAGNESIUM	44422		GPI-10 (3940005830)	

**GUIDELINES FOR USE**

1. Is the patient requesting a cost share exception for the requested low to moderate-intensity statin **AND** does the plan cover these agents at zero cost share (i.e., the plan follows Affordable Care Act [ACA] recommendations and is linked to MedImpact's Essential Health Benefit Tables)?

If yes, continue to #2.  
If no, guideline does not apply.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

STATIN ZERO COST SHARE OVERRIDE

GUIDELINES FOR USE (CONTINUED)

2. Does the patient's plan have specific procedures, instructions, and/or policies for cost share exception processes or for multi-source brand agent overrides (DAW1 override)?

If yes, guideline does not apply.  
If no, continue to #3.

3. Is the patient between 40-75 years of age without a history of cardiovascular disease and has **NOT** used any of the following secondary prevention medications for cardiovascular disease within the past 120 days based on the patient's prescription claims profile or medical records?

- Aspirin/dipyridamole (Aggrenox)
- Clopidogrel (Plavix)
- Dipyridamole
- Nitroglycerin (i.e., oral, sublingual, transdermal patch or ointment, translingual dosage forms)
- Prasugrel (Effient)
- Praluent Pen
- Repatha
- Ticagrelor (Brilinta)
- Ticlopidine
- Vorapaxar sulfate (Zontivity)

If yes, continue to #4.  
If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

4. Is the request for a generic agent?

If yes, continue to #7.  
If no, continue to #5.

5. Is the request for **ONE** of the following?

- A single-source brand (SSB) agent that has no preferred generic agents or therapeutically equivalent products available
- A multi-source brand (MSB) agent

If yes, continue to #6.  
If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

STATIN ZERO COST SHARE OVERRIDE

GUIDELINES FOR USE (CONTINUED)

6. Does the patient meet **ONE** of the following criteria?

- Two preferred medications are medically inappropriate for the patient (alternatively, one if only one agent is available)
- The patient has tried or has a documented medical contraindication to TWO preferred medications (alternatively, one if only one agent is available)
- The prescriber provided documentation confirming that the requested drug is considered medically necessary (considerations may include severity of side effects and ability to adhere to the appropriate use of the item or service)

If yes, continue to #7.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

7. Approve the requested agent for 12 months by GPID or GPI-14 at zero copay with the following quantity limits:

- Atorvastatin (Lipitor): #1 per day.
- Fluvastatin (Lescol): #2 per day.
- Fluvastatin ER (Lescol XL): #1 per day.
- Lovastatin: #2 per day.
- Lovastatin ER (Altoprev): no quantity limit.
- Pitavastatin calcium (Livalo): #1 per day.
- Pitavastatin magnesium (Zypitamag): #1 per day.
- Pravastatin (Pravachol): #1 per day.
- Rosuvastatin (Crestor, Ezallor Sprinkle): #1 per day.
- Simvastatin (Zocor): #1 per day.

**APPROVAL TEXT (applicable to multi-source brand agents only):** Although your cost share has been reduced to zero-dollar, you may incur a dispense-as-written (DAW) penalty fee if you choose to fill a brand prescription instead of its generic equivalent.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

STATIN ZERO COST SHARE OVERRIDE

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **STATIN ZERO COST SHARE OVERRIDE** requires that the following rules be met for approval:

- A. The request is for ONE of the following:
  - 1. A generic agent
  - 2. A single-source brand (SSB) agent that has no preferred generic agents or therapeutically equivalent products available
  - 3. A multi-source brand (MSB) agent
- B. You are between 40 to 75 years of age without a history of cardiovascular disease (heart disease)
- C. You have not used any of the following secondary prevention medications for cardiovascular disease within the past 120 days based on your prescription claims profile or medical records:
  - 1. Aspirin/dipyridamole (Aggrenox)
  - 2. Clopidogrel (Plavix)
  - 3. Dipyridamole
  - 4. Nitroglycerin (i.e., oral, sublingual, transdermal patch or ointment, translingual dosage forms)
  - 5. Prasugrel (Effient)
  - 6. Praluent Pen
  - 7. Repatha
  - 8. Ticagrelor (Brilinta)
  - 9. Ticlopidine
  - 10. Vorapaxar sulfate (Zontivity)
- D. **If the request is for a single-source brand or multi-source brand agent, approval also requires ONE of the following:**
  - 1. Two preferred medications are medically inappropriate for you (or one if only one agent is available)
  - 2. You have tried or have a documented medical contraindication (harmful for) to TWO preferred medications (or a trial of one if only one agent is available)
  - 3. Your doctor has provided documentation confirming that the requested drug is considered medically necessary for you, (considerations may include severity of side effects and ability to adhere to the appropriate use of the item or service)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**STATIN ZERO COST SHARE OVERRIDE**

**RATIONALE**

This guideline applies to plans where the pharmacy benefit allows for coverage of low-to-moderate intensity statins at zero copay. The override criteria allow patient access to all FDA-approved statins at zero copay by waiving the applicable cost-sharing for branded or non-preferred branded statins.

In November 2016, the US Preventive Services Task Force (USPSTF) issued its final recommendations on statin use for the primary prevention of cardiovascular disease (CVD) in adults. CVD is a broad term that includes a number of conditions such as coronary heart disease and cerebrovascular disease, which ultimately manifest as heart attack and stroke, respectively. CVD is the leading cause of morbidity and mortality in the US, accounting for one out of every three deaths among adults.

Based on the well-established benefit of statin therapy in reducing the risk of CVD events and mortality, the USPSTF now recommends that adults without a history of CVD use a low- to moderate-dose statin for the primary prevention of CVD events and mortality when all of the following criteria are met (Grade B recommendation):

- (1) Age 40 to 75 years
- (2) One or more CVD risk factors (i.e., dyslipidemia, diabetes, hypertension, or smoking)
- (3) Calculated 10-year risk of a cardiovascular event of 10% or greater

Under the Affordable Care Act (ACA), plans are required to cover USPSTF preventive recommendations that have an A or B rating.

In light of USPSTF recommendations, MedImpact has created an edit to allow for a zero copay to be approved for all low- to moderate-intensity statins for qualifying members. This edit is not applicable to Medicare Part D formularies.

**REFERENCES**

- U.S. Preventive Services Task Force [Final Summary]. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication. Updated November 2016. Available at: <https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/statin-use-in-adults-preventive-medication1>. Accessed December 2017.
- U.S. Department of Labor. Affordable Care Act Implementation Frequently Asked Questions. Available at: <https://www.dol.gov/agencies/ebsa/laws-and-regulations/laws/affordable-care-act/for-employers-and-advisers/aca-implementation-faqs>. Accessed December 2017.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/22

Created: 12/17

Client Approval: 05/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

STIRIPENTOL

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
STIRIPENTOL	DIACOMIT	35461		GPI-10 (7260007000)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of seizures associated with Dravet syndrome and meet **ALL** of the following criteria?
  - The patient is 6 months of age or older AND weighs 7kg or more
  - Therapy is prescribed by or in consultation with a neurologist
  - The patient is currently being treated with clobazam
  - The patient had a trial of or contraindication to TWO of the following: valproic acid derivatives, clobazam, topiramate

If yes, **approve for 12 months by GPID or GPI-14 for the requested drug with the following quantity limits:**

- **250mg capsule: #12 per day.**
- **500mg capsule: #6 per day.**
- **250mg powder packet: #12 per day.**
- **500mg powder packet: #6 per day.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **STIRIPENTOL (Diacomit)** requires the following rule(s) be met for approval:

- A. You have seizures associated with Dravet syndrome (a rare type of seizure)
- B. You are 6 months of age or older AND weighs 7kg or more
- C. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor)
- D. You are currently being treated with clobazam (a type of seizure drug)
- E. You had a trial of or contraindication (harmful for) to TWO of the following: valproic acid derivatives, clobazam, topiramate

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

STIRIPENTOL

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

- Does the patient have a diagnosis of seizures associated with Dravet syndrome **AND** meet the following criterion?
  - The patient is currently being treated with clobazam

If yes, approve for 12 months by GPID or GPI-14 for the requested drug with the following quantity limits:

- 250mg capsule: #12 per day.
- 500mg capsule: #6 per day.
- 250mg powder packet: #12 per day.
- 500mg powder packet: #6 per day.

If no, do not approve.

**RENEWAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **STIRIPENTOL (Diacomit)** requires the following rule(s) be met for renewal:

- You have seizures associated with Dravet syndrome (a rare type of seizure)
- You are currently being treated with clobazam (type of seizure drug)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Diacomit.

**REFERENCES**

- Diacomit [Prescribing Information]. Beauvais, France: Biocodex, July 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 08/29/22

Created: 05/19

Client Approval: 08/22

P&T Approval: 10/22





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SUNITINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SUNITINIB MALATE	SUTENT, SUNITINIB MALATE	33445		GPI-10 (2153307030)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of advanced renal cell carcinoma (RCC) **AND** meet the following criterion?

- The patient is 18 years of age or older

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**  
If no, continue to #2.

2. Does the patient have a diagnosis of gastrointestinal stromal tumor (GIST) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient had a trial of or contraindication to imatinib mesylate (Gleevec)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**  
If no, continue to #3.

3. Does the patient have a diagnosis of unresectable locally advanced or metastatic pancreatic neuroendocrine carcinoma (pNET) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient's tumor is progressive and well-differentiated

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**  
If no, continue to #4.

4. Is the request for adjuvant treatment of renal cell carcinoma and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient is at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy

If yes, **approve for 12 months by HICL or GPI-10, with a quantity limit of #1 per day.**  
If no, do not approve.

**DENIAL TEXT:** See denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SUNITINIB

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SUNITINIB (Sutent)** requires the following rule(s) be met for approval:

- A. The requested medication is being used for ONE of the following:
  - 1. Advanced renal cell carcinoma (RCC: type of kidney cancer)
  - 2. Gastrointestinal stromal tumor (GIST: type of growth in the digestive system)
  - 3. Unresectable locally advanced or metastatic pancreatic neuroendocrine carcinoma (pNET: type of pancreas cancer)
  - 4. Adjuvant (add-on) treatment of renal cell carcinoma.
- B. **If you have advanced renal cell carcinoma (RCC), approval also requires:**
  - 1. You are 18 years of age or older
- C. **If you have gastrointestinal stromal tumor (GIST), approval also requires:**
  - 1. You are 18 years of age or older
  - 2. You had a trial of imatinib mesylate (Gleevec), unless there is a medical reason why you cannot (contraindication)
- D. **If you have unresectable locally advanced or metastatic pancreatic neuroendocrine carcinoma (pNET), approval also requires:**
  - 1. You are 18 years of age or older
  - 2. Your tumor is progressive (getting worse) and well-differentiated
- E. **If the request is for adjuvant treatment of renal cell carcinoma, approval also requires:**
  - 1. You are 18 years of age or older
  - 2. You are at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy (surgical removal of kidney)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Sutent.

**REFERENCES**

- Sutent [Prescriber Information]. New York, NY. Pfizer, Inc. August 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 09/06/21

Created: 05/11

Client Approval: 08/21

P&T Approval: 01/18



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TADALAFIL

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TADALAFIL	CIALIS		20736 99409	GPI-14 (40304080000305) (40304080000302)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of Benign Prostatic Hyperplasia (BPH)?

If yes, continue to #2.

If no, continue to #3.

2. Has the patient tried or had a contraindication to at least **TWO** preferred formulary agents, including **ONE** agent from **EACH** of the following classes?

- 5-alpha-reductase inhibitors: (e.g., finasteride or dutasteride)
- Alpha blockers: (e.g., doxazosin, terazosin, tamsulosin, or alfuzosin)

If yes, **approve for 12 months by GPID or GPI-14 for the requested strength as follows:**

- **Cialis 2.5mg OR 5mg: #30 per 30 days.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

3. Does the patient have a diagnosis of erectile dysfunction?

If yes, continue to #4.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

4. Is erectile dysfunction a covered benefit?

If yes, continue to #5.

If no, guideline does not apply.

5. Has the patient tried generic sildenafil (Viagra)?

If yes, **approve for 12 months by GPID or GPI-14 for the requested strength as follows:**

- **Cialis 2.5mg OR 5mg: #30 per 30 days.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TADALAFIL

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TADALAFIL (Cialis)** requires the following rule(s) be met for approval:

- A. You have benign prostatic hyperplasia (BPH: your prostate is too big causing difficulty urinating) OR erectile dysfunction (difficulty getting/keeping an erection)
- B. **If you have benign prostatic hyperplasia (BPH), approval also requires:**
  - 1. You previously tried at least two preferred formulary alternatives, including one medication from each of the following classes:
    - a. 5-alpha-reductase inhibitors: (such as finasteride or dutasteride)
    - b. Alpha blockers: (such as doxazosin, terazosin, tamsulosin, or alfuzosin)
- C. **If you have erectile dysfunction, approval also requires:**
  - 1. You have previously tried generic sildenafil (Viagra)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Cialis.

**REFERENCES**

- Cialis [Prescribing Information]. Indianapolis, IN: Eli Lilly and Company. February 2018.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 09/07/20

Created: 11/14

Client Approval: 08/20

P&T Approval: 01/18



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TADALAFIL-ADCIRCA, ALYQ

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TADALAFIL	ADCIRCA, ALYQ, TADALAFIL		26587	GPI-14 (40143080000320)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group 1) and meet **ALL** of the following criteria?

- Therapy is prescribed by or in consultation with a cardiologist or pulmonologist
- The patient has NYHA-WHO Functional Class II to IV symptoms
- The patient is NOT concurrently or intermittently taking oral erectile dysfunction agents (e.g., Cialis, Viagra) or any organic nitrates in any form
- The patient is NOT concurrently taking guanylate cyclase stimulators (e.g., Adempas)

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Does the patient have documentation (e.g., chart note, lab result, diagnostic test result, etc.) confirming PAH diagnosis based on right heart catheterization with **ALL** of the following parameters?

- Mean pulmonary artery pressure (PAP) > 20 mmHg
- Pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg
- Pulmonary vascular resistance (PVR) ≥ 3 Wood units

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #2 per day.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TADALAFIL-ADCIRCA, ALYQ (Adcirca/Alyq)** requires the following rule(s) be met for approval:

- A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO Group 1: a way to classify the severity of disease)
- B. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung/breathing doctor)

***(Initial denial text continued on the next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TADALAFIL-ADCIRCA, ALYQ

INITIAL CRITERIA (CONTINUED)

- C. There is documentation (such as chart note, lab result, diagnostic test result) showing you have pulmonary arterial hypertension based on all of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
1. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
  2. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
  3. Pulmonary vascular resistance (PVR) greater than or equal to 3 Wood units
- D. You have New York Heart Association-World Health Organization (NYHA-WHO) Functional Class II to IV symptoms (a way to classify how limited you are during physical activity)
- E. You are NOT concurrently (at the same time) or intermittently (off and on) taking oral erectile dysfunction agents (such as Cialis, Viagra) or any organic nitrates in any form
- F. You are NOT concurrently (at the same time) taking guanylate cyclase stimulators (drugs that also treat pulmonary hypertension such as Adempas)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group 1) and meet **ALL** the following criteria?
  - The patient is NOT concurrently or intermittently taking oral erectile dysfunction agents (e.g., Cialis, Viagra) or any organic nitrates in any form
  - The patient is NOT concurrently taking guanylate cyclase stimulators (e.g., Adempas)
  - The patient has shown improvement from baseline in the 6-minute walk distance test OR has remained stable from baseline in the 6-minute walk distance test with a stable or improved WHO functional class

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #2 per day.**

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TADALAFIL-ADCIRCA, ALYQ

RENEWAL CRITERIA (CONTINUED)

**RENEWAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **TADALAFIL-ADCIRCA, ALYQ (Adcirca/Alyq)** requires the following rule(s) be met for renewal:

- A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO) Group 1 (a way to classify the severity of disease)
- B. You are NOT concurrently (at the same time) or intermittently (off and on) taking oral erectile dysfunction agents (such as Cialis, Viagra) or any organic nitrates in any form
- C. You are NOT concurrently (at the same time) taking guanylate cyclase stimulators (drugs that also treat pulmonary hypertension such as Adempas)
- D. You have shown improvement from baseline in the 6-minute walk distance test OR have remained stable from baseline in the 6-minute walk distance test with a stable or improved World Health Organization functional class (a way to classify how limited you are during physical activity)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Adcirca/Alyq.

**REFERENCES**

- Adcirca [Prescribing Information]. Indianapolis, IN: Eli Lilly and Company; September 2020.
- Alyq [Prescribing Information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; September 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 03/06/23

Created: 01/08

Client Approval: 02/23

P&T Approval: 10/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TADALAFIL-TADLIQ

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TADALAFIL	TADLIQ		52585	GPI-14 (40143080001820)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group 1) and meet **ALL** of the following criteria?
  - Therapy is prescribed by or in consultation with a cardiologist or pulmonologist
  - The patient has NYHA-WHO Functional Class II to IV symptoms
  - The patient is NOT concurrently or intermittently taking oral erectile dysfunction agents (e.g., Cialis, Viagra) or any organic nitrates in any form
  - The patient is NOT concurrently taking guanylate cyclase stimulators (e.g., Adempas)
  - The patient is unable to swallow tadalafil tablets

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Does the patient have documentation (e.g., chart note, lab result, diagnostic test result, etc.) confirming PAH diagnosis based on right heart catheterization with **ALL** of the following parameters?
  - Mean pulmonary artery pressure (PAP) > 20 mmHg
  - Pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg
  - Pulmonary vascular resistance (PVR) ≥ 3 Wood units

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #10mL per day.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TADALAFIL-TADLIQ (Tadliq)** requires the following rule(s) be met for approval:

- A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO Group 1: a way to classify the severity of disease)
- B. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung/breathing doctor)

***(Initial denial text continued on the next page)***

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TADALAFIL-TADLIQ

INITIAL CRITERIA (CONTINUED)

- C. There is documentation (such as chart note, lab result, diagnostic test result) showing you have pulmonary arterial hypertension based on all of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
  - i. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
  - ii. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
  - iii. Pulmonary vascular resistance (PVR) greater than or equal to 3 Wood units
- D. You have New York Heart Association-World Health Organization (NYHA-WHO) Functional Class II to IV symptoms (a way to classify how limited you are during physical activity)
- E. You are NOT concurrently (at the same time) or intermittently (off and on) taking oral erectile dysfunction agents (such as Cialis, Viagra) or any organic nitrates in any form
- F. You are NOT concurrently (at the same time) taking guanylate cyclase stimulators (drugs that also treat pulmonary hypertension such as Adempas)
- G. You are unable to swallow tadalafil tablets

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

- 1 Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group 1) and meet **ALL** the following criteria?
  - The patient is NOT concurrently or intermittently taking oral erectile dysfunction agents (e.g., Cialis, Viagra) or any organic nitrates in any form
  - The patient is NOT concurrently taking guanylate cyclase stimulators (e.g., Adempas)
  - The patient has shown improvement from baseline in the 6-minute walk distance test OR has remained stable from baseline in the 6-minute walk distance test with a stable or improved WHO functional class

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #10mL per day.**  
If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TADALAFIL-TADLIQ

RENEWAL CRITERIA (CONTINUED)

**RENEWAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **TADALAFIL-TADLIQ (Tadliq)** requires the following rule(s) be met for renewal:

- A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO) Group 1 (a way to classify the severity of disease)
- B. You are NOT concurrently (at the same time) or intermittently (off and on) taking oral erectile dysfunction agents (such as Cialis, Viagra) or any organic nitrates in any form
- C. You are NOT concurrently (at the same time) taking guanylate cyclase stimulators (drugs that also treat pulmonary hypertension such as Adempas)
- D. You have shown improvement from baseline in the 6-minute walk distance test OR have remained stable from baseline in the 6-minute walk distance test with a stable or improved World Health Organization functional class (a way to classify how limited you are during physical activity)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Tadliq.

**REFERENCES**

- Tadliq [Prescribing Information]. Farmville, NC: CMP Pharma, Inc., June 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 03/06/23

Created: 01/08

Client Approval: 02/23

P&T Approval: 10/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TAFAMIDIS

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TAFAMIDIS MEGLUMINE	VYNDAQEL	41631		GPI-10 (4055008020)	
TAFAMIDIS	VYNDAMAX	45729		GPI-10 (4055008000)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a documented diagnosis of cardiomyopathy associated with wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) as confirmed by **ONE** of the following?
  - Bone scan (scintigraphy) strongly positive for myocardial uptake of 99mTcPYP/DPD  
(**Note:** *Strongly positive defined as heart to contralateral lung [H/CL] ratio of at least 1.5 or Grade 2 or greater localization to the heart using the Perugini Grade 1-3 scoring system*)
  - Biopsy of tissue of affected organ(s) (cardiac and possibly non-cardiac sites) to confirm amyloid presence **AND** chemical typing to confirm presence of transthyretin (TTR) protein

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Does the patient meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or given in consultation with a cardiologist, transthyretin amyloidosis (ATTR) specialist, or medical geneticist
  - The patient has New York Heart Association (NYHA) class I, II, or III heart failure

If yes, **approve for 12 months for both of the following drugs:**

- **Vyndaqel (tafamidis meglumine): Approve by HICL or GPI-10 with a quantity limit of #4 per day.**
- **Vyndamax (tafamidis): Approve by HICL or GPI-10 with a quantity limit of #1 per day.**

**APPROVAL TEXT:** Renewal requires that the patient has not progressed to New York Heart Association (NYHA) Class IV heart failure.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TAFAMIDIS

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **TAFAMIDIS (Vyndaqel, Vyndamax)** requires the following rule(s) be met for approval:

- A. You have cardiomyopathy associated with wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM: heart disease caused by a build-up of a type of protein) which is confirmed by ONE of the following:
  1. Bone scan (scintigraphy) strongly positive for myocardial uptake of 99mTcPYP/DPD (a type of test that shows your heart absorbs a chemical for imaging) (Note: Strongly positive defined as heart to contralateral lung [H/Cl] ratio of at least 1.5 or grade 2 or greater localization to the heart using the Perugini grade 1-3 scoring system)
  2. Biopsy of tissue of affected organ(s) (can be heart or non-heart related organs) to confirm amyloid (type of protein) presence **AND** chemical typing to confirm presence of transthyretin (TTR) protein
- B. You are 18 years of age or older
- C. Therapy is prescribed by or given in consultation with a cardiologist (heart doctor), transthyretin amyloidosis (ATTR) specialist, or medical geneticist
- D. You have New York Heart Association (NYHA) class I, II or III heart failure (classification of heart failure symptoms)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of cardiomyopathy associated with wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) **AND** meet the following criterion?
  - The patient has not progressed to New York Heart Association (NYHA) Class IV heart failure

If yes, **approve for 12 months for both of the following drugs:**

  - **Vyndaqel (tafamidis meglumine): Approve by HICL or GPI-10 with a quantity limit of #4 per day.**
  - **Vyndamax (tafamidis): Approve by HICL or GPI-10 with a quantity limit of #1 per day.**

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TAFAMIDIS

RENEWAL CRITERIA (CONTINUED)

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TAFAMIDIS (Vyndaqel, Vyndamax)** requires the following rule(s) be met for renewal:

- A. You have cardiomyopathy associated with wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM: heart disease caused by a build-up of a type of protein)
- B. You have not progressed to (gotten worse to) New York Heart Association (NYHA) Class IV heart failure (classification of heart failure symptoms)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Vyndaqel and Vyndamax.

**REFERENCES**

- Vyndaqel [Prescribing Information]. New York, NY: Pfizer Inc.; August 2019.
- Vyndamax [Prescribing Information]. New York, NY: Pfizer Inc.; August 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 05/19

Client Approval: 04/20

P&T Approval: 04/19



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TALAZOPARIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TALAZOPARIB TOSYLATE	TALZENNA	45368		GPI-10 (2153558040)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient has a deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutation (gBRCAm) as confirmed by an FDA-approved test
- The patient has been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient meet **ONE** of the following criteria?

- The patient does NOT have hormone receptor (HR)-positive breast cancer
- The patient has hormone receptor (HR)-positive breast cancer AND has received prior treatment with endocrine therapy or be considered inappropriate for endocrine therapy

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TALAZOPARIB (Talzenna)** requires the following rule(s) be met for approval:

- A. You have human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer (cancer that does not have a type of protein and has spread from where it started to nearby tissue or lymph nodes or has spread to other parts of the body)
- B. You are 18 years of age or older
- C. You have a deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutation (gBRCAm: a type of gene mutation) as confirmed by a Food and Drug Administration-approved test

**(Denial text continued on next page)**

**CONTINUE ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TALAZOPARIB

GUIDELINES FOR USE (CONTINUED)

- D. You have been treated with chemotherapy in the neoadjuvant (drugs used to treat cancer given before main treatment), adjuvant (add-on to main treatment), or metastatic setting (treating disease that has spread)
- E. **If you have hormone receptor (HR)-positive breast cancer, approval also requires:**
  - 1. You have had additional treatment with endocrine (hormone) therapy or are considered inappropriate for endocrine therapy

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Talzenna.

REFERENCES

- Talzenna [Prescribing Information]. New York, NY: Pfizer Labs; September 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/22

Created: 02/19

Client Approval: 05/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TAPINAROF

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TAPINAROF	VTAMA	48031		GPI-10 (9025007500)	

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

- Does the patient have a diagnosis of plaque psoriasis and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a dermatologist
  - The patient has psoriasis covering 3% to 20% of body surface area (BSA) (excluding scalp, palms, fingernails, toenails, and soles)
  - The patient is NOT concurrently using other systemic immunomodulating agents (e.g., Stelara, Otezla), topical corticosteroids (e.g., betamethasone dipropionate, clobetasol propionate), or topical non-steroidals (e.g., calcitriol, tazarotene)

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See initial denial text at the end of the guideline.

- Has the patient had a trial of or contraindication to **TWO** of the following (from different categories)?
  - High or super-high potency topical corticosteroid (e.g., triamcinolone acetonide, fluocinonide, clobetasol propionate, halobetasol propionate)
  - Topical vitamin D analog (e.g., calcipotriene cream, calcitriol ointment)
  - Topical calcineurin inhibitor (e.g., tacrolimus, pimecrolimus)
  - Topical retinoid (e.g., tazarotene cream/gel)
  - Anthralin

If yes, **approve for 3 months by HICL or GPI-10.**

If no, do not approve.

**INITIAL DENIAL TEXT:** **\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TAPINAROF (Vtama)** requires the following rule(s) be met for approval:

- You have plaque psoriasis (a type of skin condition)
- You are 18 years of age or older
- Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
- You have psoriasis covering 3% to 20% of body surface area (BSA) (excluding scalp, palms, fingernails, toenails, and soles)

**(Initial denial text continued on next page)**

CONTINUED ON NEXT PAGE





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TAPINAROF

INITIAL CRITERIA (CONTINUED)

- E. You are NOT concurrently (at the same time) using other systemic immunomodulating agents (such as Stelara, Otezla), topical corticosteroids (such as betamethasone dipropionate, clobetasol propionate), or topical non-steroidals (such as calcitriol, tazarotene)
- F. You had a trial of or contraindication (harmful for) to TWO of the following (from different categories):
  - 1. High or super-high potency topical corticosteroid (such as triamcinolone acetonide, fluocinonide, clobetasol propionate, halobetasol propionate)
  - 2. Topical vitamin D analog (such as calcipotriene cream, calcitriol ointment)
  - 3. Topical calcineurin inhibitor (such as tacrolimus, pimecrolimus)
  - 4. Topical retinoid (such as tazarotene cream/gel)
  - 5. Anthralin

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

- 1. Does the patient have a diagnosis of plaque psoriasis and meet **ALL** of the following criteria?
  - The patient has achieved or maintained clear or minimal disease
  - The patient is NOT concurrently using other systemic immunomodulating agents (e.g., Stelara, Otezla), topical corticosteroids (e.g., betamethasone dipropionate, clobetasol propionate), or topical non-steroidals (e.g., calcitriol, tazarotene)

If yes, **approve for 12 months by HICL or GPI-10.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TAPINAROF (Vtama)** requires the following rule(s) be met for renewal:

- A. You have plaque psoriasis (a type of skin condition)
  - B. You have achieved or maintained clear or minimal disease
  - C. You are NOT concurrently (at the same time) using other systemic immunomodulating agents (such as Stelara, Otezla), topical corticosteroids (such as betamethasone dipropionate, clobetasol propionate), or topical non-steroidals (such as calcitriol, tazarotene)
- (Renewal denial text continued on next page)**

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TAPINAROF

RENEWAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Vtama.

REFERENCES

- Vtama [Prescribing Information]. Long Beach, CA: Dermavant Sciences, Inc.; May 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 06/15/22

Created: 05/22

Client Approval: 05/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TASIMELTEON

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TASIMELTEON	HETLIOZ, HETLIOZ LQ, TASIMELTEON	40927		GPI-10 (6025007000)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of non-24 hour sleep-wake disorder (N24HSWD) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient is light-insensitive or has total blindness
  - The patient had a trial and failure of maximally-tolerated melatonin therapy
  - The requested medication is for the Hetlioz (tasimelteon) capsules

If yes, **approve the capsule for a lifetime by GPID or GPI-14 with a quantity limit of #1 per day.**

If no, continue to #2.

2. Does the patient have a diagnosis of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and meet the following criterion?
  - The patient had a trial and failure of maximally-tolerated melatonin therapy

If yes, continue to #3.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

3. Does the patient meet **ONE** of the following criteria?
  - The requested medication is for the brand Hetlioz capsules AND the patient is 16 years of age or older
  - The requested medication is for the Hetlioz LQ oral suspension AND the patient is 3 years to 15 years of age

If yes, **approve the requested medication for a lifetime by GPID or GPI-14 with the following quantity limits:**

- **Brand Hetlioz capsules: #1 per day.**
- **Hetlioz LQ oral suspension: #5mL per day.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TASIMELTEON

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TASIMELTEON (Hetlioz, Hetlioz LQ)** requires the following rule(s) be met for approval:

- A. You have one of the following:
  1. Non-24 hour sleep-wake disorder (N24HSWD) (type of sleep disorder where your sleep time increasingly gets delayed)
  2. Nighttime sleep disturbances in Smith-Magenis syndrome (SMS) (type of genetic disorder that causes sleeping problems)
- B. **If you have non-24 hour sleep-wake disorder, approval also requires:**
  1. You are 18 years of age or older
  2. You are light-insensitive or have total blindness
  3. You have previously tried and failed maximally-tolerated melatonin therapy
  4. You are requesting the capsule
- C. **If you have nighttime sleep disturbances in Smith-Magenis syndrome, approval also requires:**
  1. You are requesting brand Hetlioz capsules if you are 16 years of age or older
  2. You are requesting Hetlioz LQ oral suspension if you are 3 to 15 years old
  3. You have previously tried and failed maximally-tolerated melatonin therapy

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, refer to the Prescribing Information and/or Drug Monograph for Hetlioz.

**REFERENCES**

- Hetlioz [Prescribing Information]. Washington, D.C.: Vanda Pharmaceuticals, Inc.; December 2020.
- Tasimelteon [Prescribing Information]. Parsippany, NJ: Teva Pharmaceuticals; May 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 02/01/23

Created: 03/14

Client Approval: 01/23

P&T Approval: 01/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TAVABOROLE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TAVABOROLE	KERYDIN, TAVABOROLE	41353		GPI-10 (9015608000)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of onychomycosis (fungal infection) of the toenails?  
  
If yes, continue to #2.  
If no, do not approve.  
**DENIAL TEXT:** See the denial text at the end of the guideline.
2. Does the patient have a diagnosis of diabetes, peripheral vascular disease (PVD), or immunosuppression?  
  
If yes, continue to #4.  
If no, continue to #3.
3. Does the patient have pain surrounding the nail or soft tissue involvement?  
  
If yes, continue to #4.  
If no, do not approve.  
**DENIAL TEXT:** See the denial text at the end of the guideline.
4. Has the patient previously tried or have a contraindication to oral terbinafine **OR** oral itraconazole **AND** ciclopirox topical solution?  
  
If yes, continue to #5.  
If no, do not approve.  
**DENIAL TEXT:** See the denial text at the end of the guideline.
5. Are five or less toenails affected?  
  
If yes, **approve for 48 weeks by HICL or GPI-10 with a quantity limit of #10mL (1 bottle) per 60 days.**  
  
If no, **approve for 48 weeks by HICL or GPI-10 with a quantity limit of #10mL (1 bottle) per 30 days.**

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TAVABOROLE

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TAVABOROLE (Kerydin)** requires the following rule(s) be met for approval:

- A. You have onychomycosis of the toenails (toenail fungus infection)
- B. You have complicating factors such as diabetes, peripheral vascular disease (narrowed blood vessels cause low blood flow), a suppressed immune system, or pain surrounding the nail or soft tissue
- C. You have previously tried the following agents, unless there is a medical reason why you cannot (contraindication):
  - 1. Oral terbinafine OR oral itraconazole
  - 2. Ciclopirox topical solution

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Kerydin.

**REFERENCES**

- Kerydin [Prescribing Information]. Palo Alto, CA: Anacor Pharmaceuticals; October 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/09/20

Created: 11/14

Client Approval: 10/20

P&T Approval: 07/18



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TAZEMETOSTAT

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TAZEMETOSTAT	TAZVERIK	46312		GPI-10 (2153367520)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of metastatic or locally advanced epithelioid sarcoma and meet **ALL** of the following criteria?

- The patient is 16 years of age or older
- The patient is not eligible for complete resection

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #8 per day.**  
If no, continue to #2.

2. Does the patient have a diagnosis of relapsed or refractory follicular lymphoma **AND** meet the following criterion?

- The patient is 18 years of age or older

If yes, continue to #3.  
If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

3. Does the patient meet **ALL** of the following criteria?

- The tumors are positive for an EZH2 mutation as detected by an FDA-approved test
- The patient has received at least 2 prior systemic therapies

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #8 per day.**  
If no, continue to #4.

4. Does the patient have no satisfactory alternative treatment options?

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #8 per day.**  
If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TAZEMETOSTAT

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TAZEMETOSTAT (Tazverik)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
  - 1. Metastatic or locally advanced (cancer that has spread to other parts of the body or has grown outside the organ it started in, but has not yet spread to distant parts of the body) epithelioid sarcoma (rare type of soft tissue cancer)
  - 2. Relapsed or refractory follicular lymphoma (cancer of the white blood cells that has returned or is resistant to previous treatment)
- B. **If you have metastatic or locally advanced epithelioid sarcoma, approval also requires:**
  - 1. You are 16 years of age or older
  - 2. You are not eligible for complete resection (surgically removing all of a tissue/organ)
- C. **If you have relapsed or refractory follicular lymphoma, approval also requires:**
  - 1. You are 18 years or older
  - 2. You meet ONE of the following:
    - a. Your tumors are positive for an EZH2 (type of gene) mutation as detected by a Food and Drug Administration (FDA)-approved test AND you have received at least 2 prior systemic therapies (medication/treatment that spreads throughout your body)
    - b. You have no satisfactory alternative treatment options

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Tazverik.

**REFERENCES**

- Tazverik [Prescribing Information]. Cambridge, MA: Epizyme, Inc.; June 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/13/20

Created: 05/20

Client Approval: 06/20

P&T Approval: 07/20





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**TBO-FILGRASTIM**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TBO-FILGRASTIM	GRANIX	40426		GPI-10 (8240152070)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of a non-myeloid malignancy and meet **ALL** of the following criteria?

- The patient is 1 month of age or older
- Therapy is prescribed by or in consultation with a hematologist or oncologist
- The patient is receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever
- The patient had a trial of or contraindication to the preferred agent: Nivestym

If yes, **approve for 12 months by HICL or GPI-10.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TBO-FILGRASTIM (Granix)** requires the following rule(s) be met for approval:

- A. You have a non-myeloid malignancy (cancer not affecting bone marrow)
- B. You are 1 month of age or older
- C. Therapy is prescribed by or in consultation with a hematologist (blood specialist) or oncologist (cancer/tumor doctor)
- D. You are receiving myelosuppressive anti-cancer drugs (drugs that decrease bone marrow activity) associated with a significant incidence of severe neutropenia (a type of blood condition) with fever
- E. You had a trial of or contraindication (harmful for) to the preferred medication: Nivestym

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**TBO-FILGRASTIM**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Granix.

**REFERENCES**

- Granix [Prescribing Information]. North Wales, PA: Teva Pharmaceuticals; April 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/01/22

Created: 10/22

Client Approval: 10/22

P&T Approval: 07/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TEDUGLUTIDE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TEDUGLUTIDE	GATTEX	39890		GPI-10 (5253307000)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of short bowel syndrome (SBS) and meet **ALL** of the following criteria?
  - The patient is 1 year of age or older
  - Therapy is prescribed by or in consultation with a gastroenterologist
  - The patient is dependent on intravenous parenteral nutrition, defined as requiring parenteral nutrition at least three times per week

If yes, **approve for 6 months by HICL or GPI-10.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TEDUGLUTIDE (Gattex)** requires the following rule(s) be met for approval:

- A. You have short bowel syndrome (SBS: the body cannot absorb fluids and nutrients due to a lack of a functional small intestine)
- B. You are 1 year of age or older
- C. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
- D. You are dependent on parenteral nutrition (administration of nutrition through a vein), defined as requiring parenteral nutrition at least three times per week

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TEDUGLUTIDE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of short bowel syndrome (SBS) and meet **ALL** of the following criteria?
  - Therapy is prescribed by or in consultation with a gastroenterologist
  - The patient has achieved or maintained a decreased need for parenteral support compared to baseline

If yes, **approve for 12 months by HICL or GPI-10.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TEDUGLUTIDE (Gattex)** requires the following rule(s) be met for renewal:

- A. You have short bowel syndrome (SBS: the body cannot absorb fluids and nutrients due to a lack of a functional small intestine)
- B. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
- C. You have achieved or maintained a decreased need for parenteral support (administration of nutrition through a vein) compared to baseline

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Gattex.

**REFERENCES**

- Gattex [Prescribing Information]. Lexington, MA: Shire-NPS Pharmaceutical; January 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/22

Created: 02/13

Client Approval: 02/22

P&T Approval: 01/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TELOTRISTAT

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TELOTRISTAT	XERMELO	44132		GPI-10 (5257007510)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of carcinoid syndrome diarrhea and meet **ALL** of the following criteria?
  - The medication will be used in combination with a somatostatin analog (e.g., octreotide)
  - The patient is 18 years of age or older
  - Therapy is prescribed by or given in consultation with an oncologist or gastroenterologist
  - Documentation that the patient has been receiving or has a contraindication to a stable dose of long-acting somatostatin analog therapy [e.g., Sandostatin LAR (octreotide), Somatuline Depot (lanreotide)] for a minimum of 3 months
  - The patient's diarrhea is inadequately controlled as defined by the presence of at least four bowel movements per day

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #3 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TELOTRISTAT (Xermelo)** requires the following rule(s) be met for approval:

- A. You have carcinoid syndrome diarrhea (diarrhea caused by a type of tumor affecting nerves/hormones)
- B. The medication will be used in combination with a somatostatin analog such as octreotide
- C. You are 18 years of age or older
- D. The medication is being prescribed by or given in consultation with an oncologist (cancer/tumor doctor) or gastroenterologist (digestive system doctor)
- E. There is documentation showing that you have been receiving a stable dose of long-acting somatostatin analog therapy such as Sandostatin LAR (octreotide) or Somatuline Depot (lanreotide) for a minimum of 3 months – unless there is a medical reason why you cannot (contraindication)
- F. You have diarrhea that is inadequately controlled as defined by the presence of at least four bowel movements per day

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**TELOTRISTAT**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Xermelo.

**REFERENCES**

- Xermelo [Prescribing Information]. The Woodlands, Texas. Lexicon Pharmaceuticals, Inc; March 2017.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 03/17

Client Approval: 04/20

P&T Approval: 04/17



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TEMOZOLOMIDE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TEMOZOLOMIDE	TEMODAR , TEMOZOLOMIDE	20355		GPI-10 (2110407000)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have **ONE** of the following diagnoses?

- Anaplastic astrocytoma
- Glioblastoma multiforme
- Small cell lung cancer (SCLC)

If yes, **approve for 12 months as follows:**

- **If the plan covers non-self-administered (NSA) agents, approve by HICL or GPI-10.**
- **If the plan does NOT cover NSA agents, approve only Temozolomide PO for all strengths by GPID or GPI-14.**

If no, continue to #2.

2. Does the patient have a diagnosis of metastatic melanoma **AND** meet the following criterion?

- Temodar will NOT be used concurrently with an immunosuppressive therapy or a medical therapy for the treatment of melanoma

If yes, **approve for 12 months as follows:**

- **If the plan covers non-self-administered (NSA) agents, approve by HICL or GPI-10.**
- **If the plan does NOT cover NSA agents, approve only Temozolomide PO for all strengths by GPID or GPI-14.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TEMOZOLOMIDE (Temodar)** requires the following rule(s) be met for approval:

A. You have **ONE** of the following diagnoses:

1. Anaplastic astrocytoma (type of brain tumor)
2. Glioblastoma multiforme (type of tumor affecting brain or spine)
3. Small cell lung cancer (SCLC: a type of lung cancer)
4. Metastatic melanoma (type of skin cancer)

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TEMOZOLOMIDE

INITIAL CRITERIA (CONTINUED)

**B. If you have metastatic melanoma, approval also requires:**

1. You are not concurrently (at the same time) using an immunosuppressive therapy (treatment that lowers the activity of the body's immune system) or a medical therapy for the treatment of melanoma

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

**NOTE:** For the diagnoses of Anaplastic astrocytoma, Glioblastoma multiforme, or Small cell lung cancer (SCLC), please refer to the Initial Criteria section.

1. Does the patient have a diagnosis of metastatic melanoma **AND** meet the following criterion?
  - Temodar will NOT be used concurrently with an immunosuppressive therapy or a medical therapy for the treatment of melanoma

If yes, **approve for 12 months as follows:**

- **If the plan covers non-self-administered (NSA) agents, approve by HICL or GPI-10.**
- **If the plan does NOT cover NSA agents, approve only Temozolomide PO for all strengths by GPID or GPI-14.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TEMOZOLOMIDE (Temodar)** requires the following rule(s) be met for renewal:

- A. You have metastatic melanoma (type of skin cancer)
- B. You are not concurrently (at the same time) using an immunosuppressive therapy (treatment that lowers the activity of the body's immune system) or a medical therapy for the treatment of melanoma

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**





**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**TEMOZOLOMIDE**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Temodar.

**REFERENCES**

- Temodar [Prescribing Information]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp.; November 2019.

Library	Commercial	NSA
Yes	Yes	Yes

Part D Effective: N/A

Commercial Effective: 07/01/22

Created: 02/12

Client Approval: 05/22

P&T Approval: 04/22



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**TENAPANOR**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TENAPANOR HCL	IBSRELA	46009		GPI-10 (5255858010)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of irritable bowel syndrome with constipation (IBS-C) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient had a trial of the preferred agents: lubiprostone AND Linzess

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TENAPANOR (Ibsrela)** requires the following rule(s) be met for approval:  
A. You have irritable bowel syndrome with constipation (IBS-C: a type of bowel disease)  
B. You are 18 years of age or older  
C. You had a trial of the preferred agents: lubiprostone AND Linzess

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Ibsrela.

**REFERENCES**

- Ibsrela [Prescribing Information]. Waltham, MA: Ardelyx, Inc.; April 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/22

Created: 05/22

Client Approval: 05/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TEPOTINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TEPOTINIB HCL	TEPMETKO	47095		GPI-10 (2153377310)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of metastatic non-small cell lung cancer (NSCLC) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Mesenchymal-epithelial transition (MET) exon 14 skipping alterations are present

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TEPOTINIB (Tepmetko)** requires the following rule(s) be met for approval:

- A. You have metastatic non-small cell lung cancer (NSCLC) (type of lung cancer that has spread to other parts of the body)
- B. You are 18 years of age or older
- C. Mesenchymal-epithelial transition (MET) exon 14 skipping alterations (abnormal change in a gene that makes MET protein) are present

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Tepmetko.

**REFERENCES**

- Tepmetko [Prescribing Information]. Rockland, MA: EMD Serono, Inc.; February 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/09/21

Created: 05/21

Client Approval: 08/21

P&T Approval: 04/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TERIFLUNOMIDE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TERIFLUNOMIDE	AUBAGIO	39624		GPI-10 (6240407000)	

**GUIDELINES FOR USE**

- Does the patient have a diagnosis of a relapsing form of multiple sclerosis to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TERIFLUNOMIDE (Aubagio)** requires the following rule(s) be met for approval:

- You have a diagnosis of a relapsing form of multiple sclerosis (immune system eats away at protective covering of nerves and you have new or increasing symptoms), to include clinically isolated syndrome, relapsing-remitting disease (symptoms return and go away) and active secondary progressive disease (advanced disease)
- You are 18 years of age or older

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Review for Aubagio.

**REFERENCES**

- Aubagio [Prescribing Information]. Cambridge, MA: Genzyme Corporation; September 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/20

Created: 10/12

Client Approval: 02/20

P&T Approval: 01/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TERIPARATIDE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TERIPARATIDE	FORTEO, TERIPARATIDE	24700		GPI-10 (3004407000)	

**GUIDELINES FOR USE**

1. Is the medication being used for **ONE** of the following diagnoses?

- Postmenopausal osteoporosis
- Primary or hypogonadal osteoporosis in a male patient
- Glucocorticoid-induced osteoporosis

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient meet **ONE** of the following criteria?

- The patient is at high risk for fractures defined as **ONE** of the following:
  - History of osteoporotic (i.e., fragility, low trauma) fracture(s)
  - 2 or more risk factors for fracture (e.g., history of multiple recent low trauma fractures, BMD T-score less than or equal to -2.5, corticosteroid use, or use of GnRH analogs such as nafarelin, etc.)
  - No prior treatment for osteoporosis **AND** FRAX score  $\geq 20\%$  for any major fracture OR  $\geq 3\%$  for hip fracture
- The patient is unable to use oral therapy (i.e., upper gastrointestinal [GI] problems - unable to tolerate oral medication, lower GI problems - unable to absorb oral medications, trouble remembering to take oral medications or coordinating an oral bisphosphonate with other oral medications or their daily routine)
- The patient has a trial of, intolerance to, or a contraindication to bisphosphonates (e.g., alendronate, risedronate, ibandronate)

If yes, continue to #3.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

3. Has the patient received a total of 24 months cumulative treatment with Forteo (teriparatide)?

If yes, continue to #4.

If no, **approve the requested drug up to 24 months lifetime cumulative treatment duration by GPID or GPI-14 with the following quantity limits:**

- Forteo 600mcg/2.4mL: #2.4mL per 28 days.
- Teriparatide 620mcg/2.48mL: #2.48mL per 28 days.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TERIPARATIDE

GUIDELINES FOR USE (CONTINUED)

4. Does the patient remain at or has returned to having a high risk for fracture?

If yes, approve the requested drug up to 12 months by GPID or GPI-14 with the following quantity limits:

- Forteo 600mcg/2.4mL: #2.4mL per 28 days.
- Teriparatide 620mcg/2.48mL: #2.48mL per 28 days.

If no, do not approve.

**DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **TERIPARATIDE (Forteo, Teriparatide)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
1. Postmenopausal osteoporosis (a type of joint condition)
  2. Primary or hypogonadal (sex organs don't function properly) osteoporosis in a male patient
  3. Glucocorticoid (steroid)-induced osteoporosis
- B. You meet ONE of the following:
1. You are at high risk for fractures defined as ONE of the following:
    - a. History of osteoporotic (i.e., fragility, low trauma) fracture(s)
    - b. 2 or more risk factors for fracture (such as history of multiple recent low trauma fractures, bone marrow density (BMD) T-score less than or equal to -2.5, corticosteroid use, or use of GnRH analogs such as nafarelin, etc.)
    - c. No prior treatment for osteoporosis AND FRAX (test for your risk of fractures) score at least 20% for any major fracture OR at least 3% for hip fracture
  2. You are unable to use oral therapy due to reasons such as upper gastrointestinal [GI] problems - unable to tolerate oral medication, lower GI problems - unable to absorb oral medications, trouble remembering to take oral medications or coordinating an oral bisphosphonate with other oral medications or their daily routine
  3. You had a trial of or intolerance (side effect) or contraindication (harmful for) to bisphosphonates (such as alendronate, risedronate, ibandronate)
- C. You meet ONE of the following:
1. You have received a total of 24 months of cumulative treatment with Forteo (teriparatide) AND remain at or have returned to having a high risk for fracture
  2. You have received less than 24 months of cumulative treatment

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**TERIPARATIDE**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Forteo and Teriparatide.

**REFERENCE**

- Forteo [Prescribing Information]. Indianapolis, IN.: Eli Lilly and Company; April 2021.
- Teriparatide [Prescribing Information]. Morristown, NJ.: Alvogen, Inc; October 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 05/23/22

Created: 05/03

Client Approval: 04/22

P&T Approval: 01/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TESAMORELIN

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TESAMORELIN ACETATE	EGRIFTA , EGRIFTA SV	37268		GPI-10 (3015008510)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of HIV with lipodystrophy and meets **ALL** the following criteria?

- The patient is 18 years of age or older
- The requested medication is being used for the reduction of excess abdominal fat
- The patient is currently receiving treatment with a protease inhibitor (PI), PI combination (i.e., saquinavir, ritonavir, indinavir, nelfinavir, lopinavir/ritonavir, atazanavir, fosamprenavir, or tipranavir), a nucleoside reverse transcriptase inhibitor (NRTI), OR an NRTI combination (i.e., zidovudine, didanosine, stavudine, lamivudine, abacavir, tenofovir, emtricitabine, lamivudine/zidovudine, or abacavir/lamivudine/zidovudine, efavirenz/emtricitabine/tenofovir, emtricitabine/tenofovir)

If yes, **approve for 3 months by HICL or GPI-10 with a quantity limit of #60 vials per month.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TESAMORELIN (Egrifta, Egrifta SV)** requires the following rule(s) be met for approval:

- A. You have human immunodeficiency virus (HIV: a type of immune disorder) with lipodystrophy (abnormal distribution of fat in the body)
- B. You are 18 years of age or older
- C. The requested medication is being used for the reduction of excess abdominal fat
- D. You are currently receiving treatment with a protease inhibitor (PI: a type of drug), PI combination (saquinavir, ritonavir, indinavir, nelfinavir, lopinavir/ritonavir, atazanavir, fosamprenavir, or tipranavir), a nucleoside reverse transcriptase inhibitor (NRTI: a type of drug), OR an NRTI combination (zidovudine, didanosine, stavudine, lamivudine, abacavir, tenofovir, emtricitabine, lamivudine/zidovudine, or abacavir/lamivudine/zidovudine, efavirenz/emtricitabine/tenofovir, emtricitabine/tenofovir)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**





**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**TESAMORELIN**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Egrifta.

**REFERENCES**

- Egrifta SV [Prescribing Information]. Montreal, Québec, Canada: Theratechnologies Inc.; July 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/22

Created: 02/11

Client Approval: 03/22

P&T Approval: 02/11



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TESTOSTERONE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TESTOSTERONE	ANDRODERM, ANDROGEL, AXIRON, FORTESTA, NATESTO, STRIANT, TESTIM, VOGELXO, TESTOSTERONE	01403		GPI-10 (2310003000)	ROUTE ≠ MISCELL., IMPLANT

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Is the request for a male patient with a diagnosis of primary or secondary hypogonadism (hypotestosteronism or low testosterone) who meets **ONE** of the following criteria?
  - The patient has a previously approved prior authorization for testosterone or has been receiving any form of testosterone replacement therapy as indicated per physician attestation or claims history
  - The patient has AT LEAST ONE of the following laboratory values confirming low testosterone levels:
    - At least two total serum testosterone levels of less than 300 ng/dL (10.4 nmol/L) taken on separate occasions
    - Free serum testosterone level of less than 5 ng/dL (0.17 nmol/L)

If yes, continue to #2.

If no, continue to #6.

2. Is the patient 40 years of age or older?

If yes, continue to #3.

If no, continue to #4.

3. Has the patient's prostate specific antigen (PSA) been evaluated for prostate cancer screening?

If yes, continue to #4.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TESTOSTERONE

INITIAL CRITERIA (CONTINUED)

4. Is the request for AndroGel 1%, AndroGel 1.62%, Axiron, Testim, or Vogelxo?

If yes, approve the requested agent for 12 months by GPID or GPI-14 with the following quantity limits:

- AndroGel 1% (testosterone) (2.5 gram packet): #5 grams per day; (5 gram packet): #10 grams per day
- AndroGel 1.62% (testosterone) (1.25 gram packet): #1.25 grams per day; (2.5 gram packet): #5 grams per day; (75 gram pump): #150 grams per 30 days.
- Axiron (testosterone) (90 mL pump): #180 mL per 30 days.
- Testim (testosterone) (5 gram gel tube): #10 grams per day.
- Vogelxo (testosterone) (5 gram gel tube): #10 grams per day; (5 gram gel packet): #10 grams per day; (75 gram pump): #300 grams per 30 days.

If no, continue to #5.

5. Is the request for Androderm, Fortesta, Natesto, or Striant, **AND** the patient meets the following criterion?

- The patient had a trial of or contraindication to TWO lower cost testosterone agents (e.g., testosterone cypionate, intramuscular testosterone enanthate)

If yes, approve the requested agent for 12 months by GPID or GPI-14 with the following quantity limits:

- Androderm: #30 per 30 days
- Fortesta (testosterone): #120 grams per 30 days
- Natesto: #21.96 grams per 30 days
- Striant: #60 per 30 days

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

6. Is the requested agent for gender dysphoria as supported by the compendia (e.g., DrugDex strength of recommendation Class I, IIa, or IIb) **AND** the patient meets the following criterion?

- The patient is 16 years of age or older

If yes, approve the requested agent for 12 months by GPID or GPI-14 and override quantity limits.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TESTOSTERONE

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TESTOSTERONE** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
  - 1. Primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
  - 2. Gender dysphoria (you identify yourself as a member of the opposite sex)
- B. **If you are a male with primary or secondary hypogonadism, approval also requires:**
  - 1. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening
  - 2. You meet ONE of the following:
    - a. You have a previously approved prior authorization for testosterone, or you have been receiving any form of testosterone replacement therapy as indicated per physician attestation or claims history
    - b. You have ONE of the following lab values showing you have low testosterone levels:
      - i. At least two total serum (blood) testosterone levels of less than 300 ng/dL (10.4 nmol/L) taken on separate occasions
      - ii. Free serum testosterone level of less than 5 ng/dL (0.17 nmol/L)
- C. If the request is for Androderm, Fortesta, Natesto or Striant, you had a trial of or contraindication (harmful for) to TWO lower cost testosterone agents (such as testosterone cypionate, intramuscular [injected into the muscle] testosterone enanthate)
- D. **If you have gender dysphoria, approval also requires:**
  - 1. Only agents supported by the compendia (accepted medical references such as DrugDex strength of recommendation Class I, IIa, or IIb) for treatment of gender dysphoria may be approved
  - 2. You are 16 years of age or older

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TESTOSTERONE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Is the request for a male patient with a diagnosis of primary or secondary hypogonadism (hypotestosteronism or low testosterone) who meets **ALL** of the following criteria?
  - The patient has improved symptoms compared to baseline and tolerance to treatment
  - There is documentation (e.g., chart notes, lab results) of normalized serum testosterone levels and hematocrit concentrations compared to baseline
  - If the patient is 40 years of age or older, the patient's prostate specific antigen (PSA) has been evaluated for prostate cancer screening

If yes, **approve requested agent for 12 months by GPID or GPI-14 with the following quantity limits:**

- **Androderm: #30 per 30 days.**
- **AndroGel 1.62% (testosterone) (1.25 gram packet): #1.25 grams per day; (2.5 gram packet): #5 grams per day; (75 gram pump): #150 grams per 30 days.**
- **AndroGel 1% (testosterone) (2.5 gram packet): #5 grams per day; (5 gram packet): #10 grams per day.**
- **Axiron (testosterone) (90 mL pump): #180 mL per 30 days.**
- **Testim (testosterone) (5 gram gel tube): #10 grams per day.**
- **Vogelxo (testosterone) (5 gram gel tube): #10 grams per day; (5 gram gel packet): #10 grams per day; (75 gram pump): #300 grams per 30 days.**
- **Fortesta (testosterone): #120 grams per 30 days.**
- **Natesto: #21.96 grams per 30 days.**
- **Striant: #60 per 30 days.**

If no, continue to #2.

2. Is the requested agent for gender dysphoria as supported by the compendia (e.g., DrugDex strength of recommendation Class I, IIa, or IIb)?

If yes, **approve the requested agent for 12 months by GPID or GPI-14 and override quantity limits.**

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TESTOSTERONE

RENEWAL CRITERIA (CONTINUED)

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TESTOSTERONE** requires the following rule(s) be met for renewal:

- A. You have ONE of the following diagnoses:
  1. Primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
  2. Gender dysphoria (you identify yourself as a member of the opposite sex)
- B. If you are a male with primary or secondary hypogonadism, renewal also requires:
  1. You have shown improvement in your symptoms compared to baseline and tolerance to treatment
  2. There is documentation (such as chart notes, lab results) of normalized serum testosterone levels and hematocrit concentrations (type of blood test) compared to baseline
  3. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening
- C. **If you have gender dysphoria, renewal also requires:**
  1. Only agents supported by the compendia (accepted medical references such as DrugDex strength of recommendation Class I, IIa, or IIb) for treatment of gender dysphoria may be approved

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for the related testosterone formulation.

**REFERENCES**

- Androderm [Prescribing Information]. Parsippany, NJ: Allergan; May 2020.
- Androgel 1% [Prescribing Information]. North Chicago, IL: AbbVie Inc.; April 2020.
- Androgel 1.62% [Prescribing Information]. North Chicago, IL: Abbvie Inc.; April 2020.
- Axiron [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC.; July 2017.
- Fortesta [Prescribing Information]. Malvern, PA: Endo Pharmaceuticals.; January 2022.
- Natesto [Prescribing Information]. Englewood, CO: Aytu BioScience Inc.; December 2019.
- Striant [Prescribing Information]. Malvern, PA: Actient Pharmaceuticals LLC.; October 2016.
- Testim [Prescribing Information]. San Antonio, TX: DPT Laboratories, Ltd.; May 2019.
- Vogelxo [Prescribing Information]. Maple Grove, MN: Upsher-Smith Lab., Inc.; July 2020.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**TESTOSTERONE**

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/23

Created: 02/01

Client Approval: 02/23

P&T Approval: 07/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TESTOSTERONE CYPIONATE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TESTOSTERONE CYPIONATE	DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE	01400		GPI-10 (2310003010)	NDC ≠ 76420065001 FDB: ROUTE ≠ MISCELL. MEDISPAN: ROUTE ≠ DOES NOT APPLY.

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Is the request for a male patient with a diagnosis of primary or secondary hypogonadism (hypotestosteronism or low testosterone) who meets **ONE** of the following criteria?
  - The patient has a previously approved prior authorization for testosterone or has been receiving any form of testosterone replacement therapy as indicated per physician attestation or claims history
  - The patient has AT LEAST ONE of the following laboratory values confirming low testosterone levels:
    - At least two total serum testosterone levels of less than 300 ng/dL (10.4 nmol/L) taken on separate occasions
    - Free serum testosterone level of less than 5 ng/dL (0.17 nmol/L)

If yes, continue to #2.

If no, continue to #4.

2. Is the patient 40 years of age or older?

If yes, continue to #3.

If no, **approve for 12 months by GPID or GPI-14 with the following quantity limits:**

- **100 mg/mL, 200 mg/mL (10 mL vial): up to #10 mL per 28 days.**
- **200 mg/mL (1 mL vial): up to #10 mL per 30 days.**

3. Has the patient's prostate specific antigen (PSA) been evaluated for prostate cancer screening?

If yes, **approve for 12 months by GPID or GPI-14 with the following quantity limits:**

- **100 mg/mL, 200 mg/mL (10 mL vial): up to #10 mL per 28 days.**
- **200 mg/mL (1 mL vial): up to #10 mL per 30 days.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TESTOSTERONE CYPIONATE

INITIAL CRITERIA (CONTINUED)

4. Is the requested agent for gender dysphoria as supported by the compendia (e.g., DrugDex strength of recommendation Class I, IIa, or IIb) **AND** the patient meets the following criterion?
- The patient is 16 years of age or older

If yes, **approve for 12 months by GPID or GPI-14 and override quantity limits.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TESTOSTERONE CYPIONATE (Depo-Testosterone)** requires the following rule(s) be met for approval:

- A. You have **ONE** of the following diagnoses:
1. Primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
  2. Gender dysphoria (you identify yourself as a member of the opposite sex)
- B. **If you have gender dysphoria, approval also requires:**
1. You are 16 years of age or older
  2. Only agents supported by the compendia (accepted medical references such as DrugDex strength of recommendation Class I, IIa, or IIb) for treatment of gender dysphoria may be approved
- C. **If you are a male with primary or secondary hypogonadism, approval also requires:**
1. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening
  2. You meet **ONE** of the following:
    - a. You have a previously approved prior authorization for testosterone, or you have been receiving any form of testosterone replacement therapy as indicated per physician attestation or claims history
    - b. You have **ONE** of the following lab values showing you have low testosterone levels:
      - i. At least two total serum (blood) testosterone levels of less than 300 ng/dL (10.4 nmol/L) taken on separate occasions
      - ii. Free serum testosterone level of less than 5 ng/dL (0.17 nmol/L)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TESTOSTERONE CYPIONATE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Is the request for a male patient with a diagnosis of primary or secondary hypogonadism (hypotestosteronism or low testosterone) who meets **ALL** of the following criteria?
  - The patient has improved symptoms compared to baseline and tolerance to treatment
  - There is documentation (e.g., chart notes, lab results) of normalized serum testosterone levels and hematocrit concentrations compared to baseline
  - If the patient is 40 years of age or older, the patient's prostate specific antigen (PSA) has been evaluated for prostate cancer screening

If yes, **approve for 12 months by GPID or GPI-14 with the following quantity limits:**

- **100 mg/mL, 200 mg/mL (10 mL vial): up to #10 mL per 28 days.**
- **200 mg/mL (1 mL vial): up to #10 mL per 30 days.**

If no, continue to #2.

2. Is the requested agent for gender dysphoria as supported by the compendia (e.g., DrugDex strength of recommendation Class I, IIa, or IIb)?

If yes, **approve for 12 months by GPID or GPI-14 and override quantity limits.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TESTOSTERONE CYPIONATE (Depo-Testosterone)** requires the following rule(s) be met for renewal:

- A. You have **ONE** of the following diagnoses:
  1. Primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
  2. Gender dysphoria (you identify yourself as a member of the opposite sex)
- B. **If you have gender dysphoria, renewal also requires:**
  1. Only agents supported by the compendia (accepted medical references such as DrugDex strength of recommendation Class I, IIa, or IIb) for treatment of gender dysphoria may be approved

***(Renewal denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TESTOSTERONE CYPIONATE

RENEWAL CRITERIA (CONTINUED)

C. If you are a male patient with primary or secondary hypogonadism, renewal also requires:

1. You have shown improvement in your symptoms compared to baseline and tolerance to treatment
2. There is documentation (such as chart notes, lab results) of normalized serum testosterone levels and hematocrit concentrations (type of blood test) compared to baseline
3. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Depo-Testosterone.

**REFERENCES**

- Depo-Testosterone [Prescribing Information]. New York, NY: Pharmacia & Upjohn Company; August 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/23

Created: 02/23

Client Approval: 02/23

P&T Approval: 07/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TESTOSTERONE ENANTHATE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TESTOSTERONE ENANTHATE	TESTOSTERONE ENANTHATE, XYOSTED	01401		GPI-10 (2310003020)	FDB: ROUTE ≠ MISCELL.

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Is the request for a male patient with a diagnosis of primary or secondary hypogonadism (hypotestosteronism or low testosterone) who meets **ONE** of the following criteria?
  - The patient has a previously approved prior authorization for testosterone or has been receiving any form of testosterone replacement therapy as indicated per physician attestation or claims history
  - The patient has AT LEAST ONE of the following laboratory values confirming low testosterone levels:
    - At least two total serum testosterone levels of less than 300 ng/dL (10.4 nmol/L) taken on separate occasions
    - Free serum testosterone level of less than 5 ng/dL (0.17 nmol/L)

If yes, continue to #2.

If no, continue to #6.

2. Is the patient 40 years of age or older?

If yes, continue to #3.

If no, continue to #4.

3. Has the patient's prostate specific antigen (PSA) been evaluated for prostate cancer screening?

If yes, continue to #4.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

4. Is the request for generic intramuscular testosterone enanthate 200 mg/mL?

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #5 mL per 28 days.**

If no, continue to #5.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TESTOSTERONE ENANTHATE

INITIAL CRITERIA (CONTINUED)

5. Is the request for Xyosted and the patient meets **ALL** of the following criteria?

- The patient is 18 years of age or older
- The requested medication is being used for testosterone replacement therapy

If yes, **approve all strengths for 12 months by GPID or GPI-10 with a quantity limit of #2 mL per 28 days.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

6. Is the request for generic intramuscular testosterone enanthate 200 mg/mL and the patient meets **ONE** of the following criteria?

- The patient is female with a diagnosis of metastatic breast cancer
- The patient is male with a diagnosis of delayed puberty not secondary to a pathological disorder

If yes, **approve for lifetime by GPID or GPI-14 with a quantity limit of #5 mL per 28 days.**

If no, continue to #7.

7. Is the requested agent for gender dysphoria as supported by the compendia (e.g., DrugDex strength of recommendation Class I, IIa, or IIb) **AND** the patient meets the following criterion?

- The patient is 16 years of age or older

If yes, **approve the requested agent for 12 months by GPID or GPI-14 and override quantity limits.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TESTOSTERONE ENANTHATE

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TESTOSTERONE ENANTHATE (Xyosted)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
  - 1. Primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
  - 2. Delayed puberty not due to a pathological disorder (not due to disease) in a male
  - 3. Gender dysphoria (you identify yourself as a member of the opposite sex)
  - 4. Metastatic breast cancer (cancer spreading to other areas of body) in a female
- B. **If you are a male with primary or secondary hypogonadism, approval also requires:**
  - 1. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening
  - 2. You meet ONE of the following:
    - a. You have a previously approved prior authorization for testosterone, or you have been receiving any form of testosterone replacement therapy as indicated per physician attestation or claims history
    - b. You have ONE of the following lab values showing you have low testosterone levels:
      - i. At least two total serum (blood) testosterone levels of less than 300 ng/dL (10.4 nmol/L) taken on separate occasions
      - ii. Free serum testosterone level of less than 5 ng/ dL (0.17 nmol/L)
  - 3. If the request is for Xyosted, approval also requires:
    - a. You are 18 years of age or older
    - b. The requested medication is being used for testosterone replacement therapy
- C. **If you are a female with metastatic breast cancer OR you are a male with delayed puberty not secondary to a pathological disorder**, only intramuscular (injected into muscle) testosterone enanthate may be approved
- D. **If you have gender dysphoria, approval also requires:**
  - 1. Only agents supported by the compendia (accepted medical references such as DrugDex strength of recommendation Class I, IIa, or IIb) for treatment of gender dysphoria may be approved
  - 2. You are 16 years of age or older

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TESTOSTERONE ENANTHATE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Is the request for a male patient with a diagnosis of primary or secondary hypogonadism (hypotestosteronism or low testosterone) who meets **ALL** of the following criteria?
  - The patient has improved symptoms compared to baseline and tolerance to treatment
  - There is documentation (e.g., chart notes, lab results) of normalized serum testosterone levels and hematocrit concentrations compared to baseline
  - If the patient is 40 years of age or older, the patient's prostate specific antigen (PSA) has been evaluated for prostate cancer screening

If yes, **approve all strengths of the requested agent for 12 months by GPID or GPI-14 with the following quantity limits:**

- **Intramuscular testosterone enanthate: #5 mL per 28 days.**
- **Xyosted: #2 mL per 28 days.**

If no, continue to #2.

2. Is the request for generic intramuscular testosterone enanthate 200 mg/mL and the patient meets **ONE** of the following criteria?
  - The patient is male with a diagnosis of delayed puberty not secondary to a pathological disorder
  - The patient is female with a diagnosis of metastatic breast cancer

If yes, **approve by GPID or GPI-14 for lifetime with a quantity limit of #5 mL per 28 days.**

If no, continue to #3.

3. Is the requested agent for gender dysphoria as supported by the compendia (e.g., DrugDex strength of recommendation Class I, IIa, or IIb)?

If yes, **approve the requested agent for 12 months by GPID or GPI-14 and override quantity limits.**

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TESTOSTERONE ENANTHATE

RENEWAL CRITERIA (CONTINUED)

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TESTOSTERONE ENANTHATE (Xyosted)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following diagnoses:
  - 1. Primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
  - 2. Delayed puberty not due to a pathological disorder (not due to disease) in a male
  - 3. Metastatic breast cancer (cancer spreading to other areas of body) in a female
  - 4. Gender dysphoria (you identify yourself as a member of the opposite sex)
- B. **If you are a male with primary or secondary hypogonadism, renewal also requires:**
  - 1. You have shown improvement in your symptoms compared to baseline and tolerance to treatment
  - 2. There is documentation (such as chart notes, lab results) of normalized serum testosterone levels and hematocrit concentrations (type of blood test) compared to baseline
  - 3. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening
- C. **If you are a female with metastatic breast cancer OR you are a male with delayed puberty not secondary to a pathological disorder**, only intramuscular (injected into muscle) testosterone enanthate may be approved.
- D. **If you have gender dysphoria, renewal also requires:**
  - 1. Only agents supported by the compendia (accepted medical references such as DrugDex strength of recommendation Class I, IIa, or IIb) for treatment of gender dysphoria may be approved.

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE





**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**TESTOSTERONE ENANTHATE**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for the related testosterone enanthate/Xyosted.

**REFERENCES**

- Testosterone Enanthate [Prescribing Information]. Parsippany, NJ: Actavis Pharma, Inc.; December 2017.
- Xyosted [Prescribing Information]. Ewing, NJ: Antares Pharma, Inc.; November 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/23

Created: 02/23

Client Approval: 02/23

P&T Approval: 07/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TESTOSTERONE-KYZATREX

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TESTOSTERONE UNDECANOATE	KYZATREX		52646 52647 52648	GPI-14 (23100030800124) (23100030800128) (23100030800136)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Is the request for a male patient with a diagnosis of primary or secondary hypogonadism (hypotestosteronism or low testosterone) AND the patient meets the following criterion?

- The patient is 18 years of age or older

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Does the patient meet **ONE** of the following criteria?

- The patient has a previously approved prior authorization for testosterone or has been receiving any form of testosterone replacement therapy as indicated per physician attestation or claims history
- The patient has AT LEAST ONE of the following laboratory values confirming low testosterone levels:
  - At least two total serum testosterone levels of less than 300 ng/dL (10.4 nmol/L) taken on separate occasions
  - Free serum testosterone level of less than 5 ng/dL (0.17 nmol/L)

If yes, continue to #3.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

3. Is the patient 40 years of age or older?

If yes, continue to #4.

If no, **approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:**

- **100mg: #2 per day.**
- **150mg: #4 per day.**
- **200mg: #4 per day.**

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TESTOSTERONE-KYZATREX

INITIAL CRITERIA (CONTINUED)

4. Has the patient's prostate specific antigen (PSA) been evaluated for prostate cancer screening?

If yes, approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:

- 100mg: #2 per day.
- 150mg: #4 per day.
- 200mg: #4 per day.

If no, do not approve.

**INITIAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **TESTOSTERONE-KYZATREX** requires the following rule(s) be met for approval:

- A. You have primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
- B. You are 18 years of age or older
- C. You meet ONE of the following:
  1. You have a previously approved prior authorization for testosterone, or you have been receiving any form of testosterone replacement therapy as indicated per physician attestation or claims history
  2. You have ONE of the following lab values showing you have low testosterone levels:
    1. At least two total serum (blood) testosterone levels of less than 300 ng/dL (10.4 nmol/L) taken on separate occasions
    2. Free serum testosterone level of less than 5 ng/dL (0.17 nmol/L)
- D. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TESTOSTERONE-KYZATREX

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Is the request for a male patient with a diagnosis of primary or secondary hypogonadism (hypotestosteronism or low testosterone) who meets **ALL** of the following criteria?
  - The patient has improved symptoms compared to baseline and tolerance to treatment
  - There is documentation of normalized serum testosterone levels and hematocrit concentrations compared to baseline

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

2. Is the patient 40 years of age or older?

If yes, continue to #3.

If no, **approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:**

- **100mg: #2 per day.**
- **150mg: #4 per day.**
- **200mg: #4 per day.**

3. Has the patient's prostate specific antigen (PSA) been evaluated for prostate cancer screening?

If yes, **approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:**

- **100mg: #2 per day.**
- **150mg: #4 per day.**
- **200mg: #4 per day.**

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TESTOSTERONE-KYZATREX

RENEWAL CRITERIA (CONTINUED)

**RENEWAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **TESTOSTERONE-KYZATREX** requires the following rule(s) be met for renewal:

- A. You have primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
- B. You have shown improvement in your symptoms compared to baseline and tolerance to treatment
- C. There is documentation of normalized serum (blood) testosterone and hematocrit concentrations (type of blood test) compared to baseline
- D. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Kyzatrex.

**REFERENCES**

- Kyzatrex [Prescribing Information]. Raleigh, NC: Marius Pharmaceuticals; July 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 12/01/22

Created: 09/22

Client Approval: 11/22

P&T Approval: 10/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TESTOSTERONE-TLANDO

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TESTOSTERONE UNDECANOATE	TLANDO		52120	GPI-14 (23100030800125)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Is the request for a male patient with a diagnosis of primary or secondary hypogonadism (hypotestosteronism or low testosterone) AND the patient meets **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient had a trial of or contraindication to TWO lower cost testosterone agents (e.g., AndroGel 1%, Axiron, Testim, Vogelxo, Depo-Testosterone, intramuscular testosterone enanthate, Androderm, AndroGel 1.62%, Fortesta, Natesto, Striant, Jatenzo)

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Does the patient meet **ONE** of the following criteria?
  - The patient has a previously approved prior authorization for testosterone or has been receiving any form of testosterone replacement therapy as indicated per physician attestation or claims history
  - The patient has AT LEAST ONE of the following laboratory values confirming low testosterone levels:
    - At least two total serum testosterone levels of less than 300 ng/dL (10.4 nmol/L) taken on separate occasions
    - Free serum testosterone level of less than 5 ng/dL (0.17 nmol/L)

If yes, continue to #3.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

3. Is the patient 40 years of age or older?

If yes, continue to #4.

If no, **approve for 12 months by GPID or GPI-14 with a quantity limit of #4 per day.**

4. Has the patient's prostate specific antigen (PSA) been evaluated for prostate cancer screening?

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #4 per day.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TESTOSTERONE-TLANDO

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **TESTOSTERONE-TLANDO** requires the following rule(s) be met for approval:

- A. You have primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
- B. You are 18 years of age or older
- C. You have tried or have a contraindication (harmful for) to TWO lower cost testosterone agents (such as AndroGel 1% or 1.62%, Axiron, Testim, Vogelxo, Depo-Testosterone, intramuscular testosterone enanthate, Androderm, Fortesta, Natesto, Striant, Jatenzo)
- D. You meet ONE of the following:
  1. You have a previously approved prior authorization for testosterone, or you have been receiving any form of testosterone replacement therapy as indicated per physician attestation or claims history
  2. You have ONE of the following lab values showing you have low testosterone levels:
    - a. At least two total serum (blood) testosterone levels of less than 300 ng/dL (10.4 nmol/L) taken on separate occasions
    - b. Free serum testosterone level of less than 5 ng/dL (0.17 nmol/L)
- E. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Is the request for a male patient with a diagnosis of primary or secondary hypogonadism (hypotestosteronism or low testosterone) who meets **ALL** of the following criteria?
  - The patient has improved symptoms compared to baseline and tolerance to treatment
  - There is documentation of normalized serum testosterone levels and hematocrit concentrations compared to baseline

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TESTOSTERONE-TLANDO

RENEWAL CRITERIA (CONTINUED)

2. Is the patient 40 years of age or older?

If yes, continue to #3.

If no, **approve for 12 months by GPID or GPI-14 with a quantity limit of #4 per day.**

3. Has the patient's prostate specific antigen (PSA) been evaluated for prostate cancer screening?

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #4 per day.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TESTOSTERONE-TLANDO** requires the following rule(s) be met for renewal:

- A. You have primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
- B. You have shown improvement in your symptoms compared to baseline and tolerance to treatment
- C. There is documentation of normalized serum testosterone and hematocrit concentrations (type of blood test) compared to baseline
- D. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Tlando.

**REFERENCES**

- Tlando [Prescribing Information]. Ewing, NJ: Antares Pharma, Inc.; March 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 12/01/22

Created: 08/22

Client Approval: 11/22

P&T Approval: 07/22

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TESTOSTERONE UNDECANOATE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TESTOSTERONE UNDECANOATE	JATENZO, KYZATREX, TLANDO	07304		GPI-10 (2310003080)	BRAND ≠ AVEED

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Is the request for a male patient with a diagnosis of primary or secondary hypogonadism (hypotestosteronism or low testosterone) **AND** the patient meets the following criterion?

- The patient is 18 years of age or older

If yes, continue to #2.  
If no, continue to #7.

2. Does the patient meet **ONE** of the following criteria?

- The patient has a previously approved prior authorization for testosterone or has been receiving any form of testosterone replacement therapy as indicated per physician attestation or claims history
- The patient has AT LEAST ONE of the following laboratory values confirming low testosterone levels:
  - At least two total serum testosterone levels of less than 300 ng/dL (10.4 nmol/L) taken on separate occasions
  - Free serum testosterone level of less than 5 ng/dL (0.17 nmol/L)

If yes, continue to #3.  
If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

3. Is the patient 40 years of age or older?

If yes, continue to #4.  
If no, continue to #5.

4. Has the patient's prostate specific antigen (PSA) been evaluated for prostate cancer screening?

If yes, continue to #5.  
If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TESTOSTERONE UNDECANOATE

INITIAL CRITERIA (CONTINUED)

5. Is the request for Kyzatrex?

If yes, **approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:**

- **100 mg: #2 per day.**
- **150 mg and 200 mg: #4 per day.**

If no, continue to #6.

6. Is the request for Jatenzo or Tlando **AND** the patient meets the following criterion?

- The patient had a trial of or contraindication to **TWO** lower cost testosterone agents (e.g., intramuscular testosterone cypionate, intramuscular testosterone enanthate)

If yes, **approve all strengths of the requested agent for 12 months by GPID or GPI-14 with the following quantity limits:**

- **Jatenzo 158 mg and 198 mg: #4 per day.**
- **Jatenzo 237 mg: #2 per day.**
- **Tlando 112.5 mg: #4 per day.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

7. Is the requested agent for gender dysphoria as supported by the compendia (e.g., DrugDex strength of recommendation Class I, IIa, or IIb) **AND** the patient meets the following criterion?

- The patient is 16 years of age or older

If yes, **approve the requested agent for 12 months by GPID or GPI-14 and override quantity limits.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TESTOSTERONE UNDECANOATE

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TESTOSTERONE UNDECANOATE (Jatenzo, Kyzatrex, Tlando)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
  - 1. Primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
  - 2. Gender dysphoria (you identify yourself as a member of the opposite sex)
- B. **If you have gender dysphoria, approval also requires:**
  - 1. You are 16 years of age or older
  - 2. Only agents supported by the compendia (accepted medical references such as DrugDex strength of recommendation Class I, Iia, or Iib) for treatment of gender dysphoria may be approved
- C. **If you are a male with primary or secondary hypogonadism, approval also requires:**
  - 1. You are 18 years of age or older
  - 2. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening
  - 3. You meet ONE of the following:
    - a. You have a previously approved prior authorization for testosterone, or you have been receiving any form of testosterone replacement therapy as indicated per physician attestation or claims history
    - b. You have ONE of the following lab values showing you have low testosterone levels:
      - i. At least two total serum (blood) testosterone levels of less than 300 ng/dL (10.4 nmol/L) taken on separate occasions
      - ii. Free serum testosterone level of less than 5 ng/dL (0.17 nmol/L)
  - 4. If the request is for Jatenzo or Tlando, you had a trial of or contraindication to (harmful for) TWO lower cost testosterone agents (such as intramuscular testosterone cypionate, intramuscular testosterone enanthate)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TESTOSTERONE UNDECANOATE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Is the request for a male patient with a diagnosis of primary or secondary hypogonadism (hypotestosteronism or low testosterone) who meets **ALL** of the following criteria?
  - The patient has improved symptoms compared to baseline and tolerance to treatment
  - There is documentation (e.g., chart notes, lab results) of normalized serum testosterone levels and hematocrit concentrations compared to baseline
  - If the patient is 40 years of age or older, the patient's prostate specific antigen (PSA) has been evaluated for prostate cancer screening

If yes, **approve all strengths of the requested agent for 12 months by GPID or GPI-14 with the following quantity limits:**

- Kyzatrex 100 mg: #2 per day.
- Kyzatrex 150 mg and 200mg: #4 per day.
- Jatenzo 158 mg and 198 mg: #4 per day.
- Jatenzo 237 mg: #2 per day.
- Tlando 112.5 mg: #4 per day.

If no, continue to #2.

2. Is the requested agent for gender dysphoria as supported by the compendia (e.g., DrugDex strength of recommendation Class I, IIa, or IIb)?

If yes, **approve the requested agent for 12 months by GPID or GPI-14 and override quantity limits.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TESTOSTERONE UNDECANOATE (Jatenzo, Kyzatrex, Tlando)** requires the following rule(s) be met for renewal:

- A. You have **ONE** of the following diagnoses:
  1. Primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
  2. Gender dysphoria (you identify yourself as a member of the opposite sex)
- B. **If you have gender dysphoria, renewal also requires:**
  1. Only agents supported by the compendia (accepted medical references such as DrugDex strength of recommendation Class I, IIa, or lib) for treatment of gender dysphoria may be approved

***(Renewal denial text continued on next page)***

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TESTOSTERONE UNDECANOATE

RENEWAL CRITERIA (CONTINUED)

C. If you are a male with primary or secondary hypogonadism, renewal also requires:

1. You have shown improvement in your symptoms compared to baseline and tolerance to treatment
2. There is documentation (such as chart notes, lab results) of normalized serum testosterone levels and hematocrit concentrations (type of blood test) compared to baseline
3. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Jatenzo, Kyzatrex, and Tlando.

REFERENCES

- Jatenzo [Prescribing Information]. Northbrook, IL: Clarus Therapeutics, Inc.; September 2019.
- Kyzatrex [Prescribing Information]. Raleigh, NC: Marius Pharmaceuticals; July 2022.
- Tlando [Prescribing Information]. Ewing, NJ: Antares Pharma, Inc.; March 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/23

Created: 02/23

Client Approval: 02/23

P&T Approval: 01/23



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TETRABENAZINE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TETRABENAZINE	XENAZINE	07350		GPI-10 (6238007000)	

GUIDELINES FOR USE

1. Is the request for a tetrabenazine dosage that exceeds 50mg?

If yes, continue to #2.

If no, continue to #3.

2. Does the patient have a diagnosis of chorea (involuntary movements) associated with Huntington's disease and meets **ALL** of the following criteria?

- Therapy is prescribed by or given in consultation with a neurologist
- The patient has been genotyped for CYP2D6 and is identified as an extensive metabolizer (EM) or intermediate metabolizer (IM) of CYP2D6

If yes, **approve for 12 months by GPID or GPI-14 with the following quantity limits:**

- **Xenazine 12.5mg: #3 per day**
- **Xenazine 25mg: #4 per day**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

3. Does the patient have a diagnosis of chorea (involuntary movements) associated with Huntington's disease and meets **ALL** of the following criteria?

- Therapy is prescribed by or given in consultation with a neurologist

If yes, **approve for 12 months by GPID or GPI-14 with the following quantity limits:**

- **Xenazine 12.5mg: #3 per day**
- **Xenazine 25mg: #2 per day**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TETRABENAZINE (Xenazine)** requires the following rule(s) be met for approval:

- A. You have chorea (involuntary movements) associated with Huntington's disease (type of inherited disease that causes nerve cells in brain to break down over time)
- B. The medication has been prescribed or given in consultation with a neurologist (nerve doctor)
- C. If your request is for a tetrabenazine dosage that exceeds 50mg, approval also requires:
  1. You have been genotyped for CYP2D6 (type of enzyme) and you are identified as an extensive (EM) or intermediate metabolizer (IM) of CYP2D6.

**(Denial text continued on next page)**

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TETRABENAZINE

GUIDELINES FOR USE (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Xenazine.

**REFERENCES**

- Xenazine [Prescribing Information]. Deerfield, IL: Lundbeck Pharmaceuticals, Inc.; November 2019.

Library	Commercial	NSA
Yes	Yes	No

Created: 02/09

Effective: 07/01/20

Client Approval: 04/20

P&T Approval: 11/15



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**TEZACAFTOR/IVACAFTOR**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TEZACAFTOR/IVACAFTOR	SYMDEKO	44771		GPI-10 (4530990280)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

- Does the patient have a diagnosis of cystic fibrosis (CF) and meet **ALL** of the following criteria?
  - The patient is 6 years of age or older
  - Therapy is prescribed by or given in consultation with a pulmonologist or cystic fibrosis (CF) expert

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See initial denial text at the end of the guideline.

- Does the patient meet **ONE** of the following criteria?
  - Documentation that the patient is homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
  - Documentation that the patient has at least **ONE** of the following mutations in the CFTR gene:

546insCTA	E92K	G576A	L346P	R117G	S589N
711+3A→G	E116K	G576A; R668C	L967S	R117H	S737F
2789+5G→A	E193K	G622D	L997F	R117L	S912L
3272-26A→G	E403D	G970D	L1324P	R117P	S945L
3849+10kbC→T	E588V	G1069R	L1335P	R170H	S977F
A120T	E822K	G1244E	L1480P	R258G	S1159F
A234D	E831X	G1249R	M152V	R334L	S1159P
A349V	F191V	G1349D	M265R	R334Q	S1251N
A455E	F311del	H939R	M952I	R347H	S1255P
A554E	F311L	H1054D	M952T	R347L	T338I
A1006E	F508C	H1375P	P5L	R347P	T1036N
A1067T	F508C; S1251N	I148T	P67L	R352Q	T1053I
D110E	F508del	I175V	P205S	R352W	V201M
D110H	F575Y	I336K	Q98R	R553Q	V232D
D192G	F1016S	I601F	Q237E	R668C	V562I
D443Y	F1052V	I618T	Q237H	R751L	V754M

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.





**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

D443Y; G576A; R668C	F1074L	I807M	Q359R	R792G	V1153E
D579G	F1099L	I980K	Q1291R	R933G	V1240G
D614G	G126D	I1027T	R31L	R1066H	V1293G
D836Y	G178E	I1139V	R74Q	R1070Q	W1282R
D924N	G178R	I1269N	R74W	R1070W	Y109N
D979V	G194R	I1366N	R74W; D1270N	R1162L	Y161S
D1152H	G194V	K1060T	R74W; V201M	R1283M	Y1014C
D1270N	G314E	L15P	R74W; V201M; D1270N	R1283S	Y1032C
E56K	G551D	L206W	R75Q	S549N	
E60K	G551S	L320V	R117C	S549R	

If yes, **approve for 24 weeks by HICL or GPI-10 with a quantity limit of #2 per day.**

**APPROVAL TEXT:** Renewal requires the patient have shown improvement in clinical status compared to baseline as shown by ONE of the following: i) patient has improved, maintained, or demonstrated less than expected decline in FEV1, ii) patient has improved, maintained, or demonstrated less than expected decline in BMI, or iii) patient has experienced a reduction in rate of pulmonary exacerbations.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TEZACAFTOR/IVACAFTOR

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **TEZACAFTOR/IVACAFTOR (Symdeko)** requires the following rule(s) be met for approval:

- A. You have cystic fibrosis (inherited life-threatening disorder that damages the lungs and digestive system)
- B. You are 6 years of age or older
- C. Therapy is prescribed by or given in consultation with a pulmonologist (lung/breathing doctor) or cystic fibrosis expert
- D. You have documentation that you are either homozygous (you have 2 copies of the same gene) for the F508del-CFTR (Cystic fibrosis transmembrane conductance regulator) gene mutation; **OR** you have documentation that you have at least one of the following mutations in the CFTR gene:

546insCTA	E92K	G576A	L346P	R117G	S589N
711+3A→G	E116K	G576A; R668C	L967S	R117H	S737F
2789+5G→A	E193K	G622D	L997F	R117L	S912L
3272-26A→G	E403D	G970D	L1324P	R117P	S945L
3849+10kbC→T	E588V	G1069R	L1335P	R170H	S977F
A120T	E822K	G1244E	L1480P	R258G	S1159F
A234D	E831X	G1249R	M152V	R334L	S1159P
A349V	F191V	G1349D	M265R	R334Q	S1251N
A455E	F311del	H939R	M952I	R347H	S1255P
A554E	F311L	H1054D	M952T	R347L	T338I
A1006E	F508C	H1375P	P5L	R347P	T1036N
A1067T	F508C; S1251N	I148T	P67L	R352Q	T1053I
D110E	F508del	I175V	P205S	R352W	V201M
D110H	F575Y	I336K	Q98R	R553Q	V232D
D192G	F1016S	I601F	Q237E	R668C	V562I
D443Y	F1052V	I618T	Q237H	R751L	V754M
D443Y; G576A; R668C	F1074L	I807M	Q359R	R792G	V1153E
D579G	F1099L	I980K	Q1291R	R933G	V1240G

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

D614G	G126D	I1027T	R31L	R1066H	V1293G
D836Y	G178E	I1139V	R74Q	R1070Q	W1282R
D924N	G178R	I1269N	R74W	R1070W	Y109N
D979V	G194R	I1366N	R74W; D1270N	R1162L	Y161S
D1152H	G194V	K1060T	R74W; V201M	R1283M	Y1014C
D1270N	G314E	L15P	R74W; V201M; D1270N	R1283S	Y1032C
E56K	G551D	L206W	R75Q	S549N	
E60K	G551S	L320V	R117C	S549R	

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RENEWAL CRITERIA**

1. Does the patient have a diagnosis of cystic fibrosis (CF) and improvement in clinical status compared to baseline as shown by **ONE** of the following?
  - The patient has improved, maintained, or demonstrated less than expected decline in FEV1 (forced expiratory volume)
  - The patient has improved, maintained, or demonstrated less than expected decline in BMI (body mass index)
  - The patient has experienced a reduction in rate of pulmonary exacerbations

If yes, **approve for lifetime by HICL or GPI-10 with a quantity limit of #2 per day.**

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TEZACAFTOR/IVACAFTOR

RENEWAL CRITERIA (CONTINUED)

**RENEWAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **TEZACAFTOR/IVACAFTOR (Symdeko)** requires the following rule(s) be met for renewal:

- A. You have cystic fibrosis (CF: inherited life-threatening disorder that damages the lungs and digestive system)
- B. You have shown improvement in clinical (medical) status compared to baseline as shown by ONE of the following:
  1. You have improved, maintained, or demonstrated less than expected decline in FEV1 (forced expiratory volume: amount of air you can exhale in 1 second)
  2. You have improved, maintained, or demonstrated less than expected decline in BMI (body mass index)
  3. You have experienced a reduction in rate of pulmonary exacerbations (you have less attacks of breathing problems)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Symdeko.

**REFERENCES**

- Symdeko [Prescribing Information]. Boston, MA: Vertex Pharmaceuticals Inc.; December 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 02/01/21

Created: 02/18

Client Approval: 01/21

P&T Approval: 01/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TEZEPELUMAB-EKKO

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TEZEPELUMAB-EKKO	TEZSPIRE	47740		GPI-10 (4460807525)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of severe asthma and meet **ALL** of the following criteria?
  - The patient is 12 years of age or older
  - Therapy is prescribed by or in consultation with a physician specializing in allergy or pulmonary medicine
  - The patient is concurrently treated with a medium, high-dose, or maximally tolerated inhaled corticosteroid (ICS) [such as triamcinolone acetonide, beclomethasone, mometasone, budesonide, etc.] AND at least one other maintenance medication (e.g., long-acting inhaled beta2-agonist [such as salmeterol, formoterol, etc.], long-acting muscarinic antagonist [such as acclidinium bromide, ipratropium, tiotropium, umeclidinium, etc.], a leukotriene receptor antagonist [such as montelukast, zafirlukast, zileuton, etc.], theophylline)
  - Tezspire will NOT be used concurrently with Xolair, Dupixent, or another anti-IL5 biologic (e.g., Nucala, Cinqair, Fasentra) when used for the treatment of asthma

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Does the patient meet **ONE** of the following criteria?
  - The patient has experienced at least **ONE** asthma exacerbation requiring systemic corticosteroid burst lasting at least 3 days within the past 12 months
  - The patient has at least **ONE** serious exacerbation requiring hospitalization or emergency room visit within the past 12 months

If yes, continue to #4.

If no, continue to #3.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TEZEPELUMAB-EKKO

INITIAL CRITERIA (CONTINUED)

3. Does the patient have poor symptom control despite current therapy as evidenced by at least THREE of the following within the past 4 weeks?
- Daytime asthma symptoms more than twice per week
  - Any night waking due to asthma
  - Use of a short-acting inhaled beta2-agonist (SABA; such as albuterol) reliever for symptoms more than twice per week
  - Any activity limitation due to asthma

If yes, continue to #4.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

4. Does the patient have a diagnosis of severe asthma with an eosinophilic phenotype and meet **ALL** of the following criteria?
- The patient has a documented blood eosinophil level of at least 150 cells/mcL within the last 12 months
  - The patient had a trial of or contraindication to TWO of the following preferred agents: Fasenra, Nucala, Dupixent

If yes, continue to #7.

If no, continue to #5.

5. Does the patient have a diagnosis of severe oral corticosteroid-dependent asthma **AND** meet the following criterion?
- The patient had a trial of or contraindication to the following preferred agent: Dupixent

If yes, continue to #7.

If no, continue to #6.

6. Does the patient have a diagnosis of severe allergic asthma **AND** meet the following criterion?
- The patient had a trial of or contraindication to the following preferred agent: Xolair

If yes, continue to #7.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TEZEPELUMAB-EKKO

INITIAL CRITERIA (CONTINUED)

7. Does the patient have non-self-administered (NSA) drug benefit coverage?

If yes, **approve for 4 months by HICL or GPI-10 with a quantity limit of #1.91mL per 28 days.**

If no, **approve Tezspire 210 mg/1.91 prefilled pen for 4 months by GPID or GPI-14 with a quantity limit of #1.91mL per 28 days.**

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TEZEPELUMAB-EKKO (Tezspire)** requires the following rule(s) be met for approval:

- A. You have severe asthma (a type of lung condition)
- B. You are 12 years of age or older
- C. Therapy is prescribed by or in consultation with a doctor specializing in allergy or pulmonary (lung/breathing) medicine
- D. You are being treated with a medium, high-dose, or maximally tolerated inhaled corticosteroid [such as triamcinolone acetonide, beclomethasone, mometasone, budesonide] AND at least one other maintenance medication such as a long-acting inhaled beta2-agonist (such as salmeterol, formoterol), long-acting muscarinic antagonist (such as aclidinium bromide, ipratropium, umeclidinium, tiotropium), leukotriene receptor antagonist (such as montelukast, zafirlukast, zileuton), or theophylline
- E. You meet ONE of the following:
  - 1. You experienced at least ONE asthma exacerbation (worsening of symptoms) requiring systemic corticosteroid burst lasting at least 3 days within the past 12 months OR at least ONE serious exacerbation requiring hospitalization or emergency room visit within the past 12 months
  - 2. You have poor symptom control despite current therapy as evidenced by at least THREE of the following within the past 4 weeks:
    - a. Daytime asthma symptoms more than twice per week
    - b. Any night waking due to asthma
    - c. Use of a short-acting inhaled beta2-agonist reliever (such as albuterol) for symptoms more than twice per week
    - d. Any activity limitation due to asthma

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TEZPELUMAB-EKKO

INITIAL CRITERIA (CONTINUED)

- F. You will NOT use Tezspire concurrently (at the same time) with Xolair, Dupixent, or another anti-IL5 biologic (such as Nucala, Cinqair, Fasenra) when used for the treatment of asthma
- G. **If you have severe asthma with an eosinophilic phenotype (type of inflammatory asthma), approval also requires:**
1. You have a documented blood eosinophil level of at least 150 cells/mcL within the last 12 months
  2. You had a trial of or contraindication (harmful for) to TWO of the following: Fasenra, Nucala, Dupixent
- H. **If you have severe oral corticosteroid-dependent asthma, approval also requires:**
1. You had a trial of or contraindication (harmful for) to Dupixent
- I. **If you have severe allergic asthma, approval also requires:**
1. You had a trial of or contraindication (harmful for) to Xolair

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Has the patient shown a clinical response as evidenced by **ONE** of the following?
  - Reduction in asthma exacerbation from baseline
  - Decreased utilization of rescue medications
  - Increase in percent predicted FEV1 from pretreatment baseline
  - Reduction in severity or frequency of asthma-related symptoms (e.g., wheezing, shortness of breath, coughing, etc.)

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TEZPELUMAB-EKKO

RENEWAL CRITERIA (CONTINUED)

2. Does the patient meet **ALL** of the following criteria?

- The patient will continue to use an inhaled corticosteroid (ICS) AND at least one other maintenance medication (e.g., long-acting inhaled beta2-agonist [such as salmeterol, formoterol, etc.], long-acting muscarinic antagonist [such as acclidinium bromide, ipratropium, tiotropium, umeclidinium, etc.], a leukotriene receptor antagonist [such as montelukast, zafirlukast, zileuton, etc.], theophylline)
- Tezspire will NOT be used concurrently with Xolair, Dupixent, or another anti-IL5 biologic (e.g., Nucala, Cinqair, Fasentra) when used for the treatment of asthma

If yes, continue to #3.

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

3. Does the patient have non-self-administered (NSA) drug benefit coverage?

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1.91mL per 28 days.**

If no, **approve Tezspire 210 mg/1.91 prefilled pen for 12 months by GPID or GPI-14 with a quantity limit of #1.91mL per 28 days.**

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TEZPELUMAB-EKKO (Tezspire)** requires the following rule(s) be met for renewal:

- A. You have shown a clinical response as evidenced by ONE of the following:
1. Reduction in asthma exacerbation (worsening of symptoms) from baseline
  2. Decreased use of rescue medications
  3. Increase in percent predicted FEV1 (amount of air exhaled in one second) from pretreatment baseline
  4. Reduction in severity or frequency of asthma-related symptoms such as wheezing, shortness of breath, coughing, etc.
- B. You will continue to use an inhaled corticosteroid (ICS, such as triamcinolone acetonide, beclomethasone) AND at least one other maintenance medication such as a long-acting inhaled beta2-agonist (such as formoterol, salmeterol), long-acting muscarinic antagonist (such as tiotropium), leukotriene receptor antagonist (such as montelukast), or theophylline
- C. You will NOT use Tezspire concurrently (at the same time) with Xolair, Dupixent, or another anti-IL5 biologic (such as Nucala, Cinqair, Fasentra) when used for the treatment of asthma  
**(Renewal denial text continued on next page)**

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TEZPELUMAB-EKKO

RENEWAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Tezspire.

REFERENCES

- Tezspire [Prescribing Information]. Thousand Oaks, CA: Amgen, Inc.; December 2021.

Library	Commercial	NSA
Yes	Yes	Yes

Part D Effective: N/A

Commercial Effective: 03/01/23

Created: 01/22

Client Approval: 02/23

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

THALIDOMIDE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
THALIDOMIDE	THALOMID	11465		GPI-10 (9939207000)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of multiple myeloma **AND** meet the following criterion?

- Thalomid will be used in combination with dexamethasone

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**

If no, continue to #2.

2. Does the patient have a diagnosis of erythema nodosum leprosum (ENL)?

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.**

If no, continue to #3.

3. Does the patient have a diagnosis of anemia due to myelodysplastic syndrome **AND** meet the following criterion?

- The patient has been previously treated for anemia due to myelodysplastic syndrome

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.**

If no, continue to #4.

4. Does the patient have a diagnosis of Waldenström's macroglobulinemia?

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

THALIDOMIDE

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **THALIDOMIDE (Thalomid)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
  1. Multiple myeloma (a type of blood cancer)
  2. Erythema nodosum leprosum (ENL: a type of immune condition)
  3. Anemia due to myelodysplastic syndrome (a type of blood condition due to blood cancer)
  4. Waldenström's macroglobulinemia (a type of blood cancer)
- B. **If you have multiple myeloma, approval also requires:**
  1. Thalomid will be used in combination with dexamethasone
- C. **If you have anemia due to myelodysplastic syndrome, approval also requires:**
  1. You have been previously treated for anemia due to myelodysplastic syndrome

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Thalomid.

**REFERENCES**

- Thalomid [Prescribing Information]. Summit, NJ: Celgene Corporation; February 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/22

Created: 08/12

Client Approval: 03/22

P&T Approval: 08/12



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TIVOZANIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TIVOZANIB HCL	FOTIVDA	45740		GPI-10 (2153307625)	

**GUIDELINES FOR USE**

- Does the patient have a diagnosis of relapsed or refractory advanced renal cell carcinoma (RCC) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient received two or more prior systemic therapies (e.g., Cabometyx, Keytruda, Opdivo)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #21 per 28 days.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TIVOZANIB (Fotivda)** requires the following rule(s) be met for approval:

- You have relapsed or refractory advanced renal cell carcinoma (type of kidney cancer that returned or no longer responds to treatment)
- You are 18 years of age or older
- You previously received two or more systemic therapies (such as Cabometyx, Keytruda, Opdivo)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Fotivda.

**REFERENCES**

- Fotivda [Prescribing Information]. Boston, MA: AVEO Pharmaceuticals, Inc.; March 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/21

Created: 05/21

Client Approval: 05/21

P&T Approval: 04/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TOBRAMYCIN INHALED

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TOBRAMYCIN	BETHKIS, TOBRAMYCIN		16122	GPI-14 (07000070002530)	
TOBRAMYCIN IN 0.225% SOD CHLOR	TOBI, TOBRAMYCIN		61551	GPI-14 (07000070002520)	
TOBRAMYCIN	TOBI PODHALER		30025 34461	GPI-14 (07000070000120)	
TOBRAMYCIN/NEBULIZER	KITABIS PAK, TOBRAMYCIN		37569	GPI-14 (07000070002520)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of cystic fibrosis and meet **ALL** of the following criteria?

- The patient is 6 years of age or older
- The patient has a lung infection with a gram-negative species (such as *Pseudomonas aeruginosa*; *Staphylococcus aureus* is not a gram-negative species)

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Is the request for Bethkis (tobramycin), Tobi (tobramycin) inhalation solution, or Kitabis Pak (tobramycin)?

If yes, **approve the requested agent for 12 months by GPID or GPI-14 as follows:**

**Tobi inhalation solution: #280mL (#56 of 5mL ampules) per 28 days (fill count = 6).**

**Bethkis: #224mL (#56 of 4mL ampules) per 28 days (fill count = 6).**

**Kitabis Pak: #280mL per 28 days (fill count = 6).**

If no, continue to #3.

3. Is the request for Tobi Podhaler and the patient meets **ONE** of the following criteria?

- The patient had a trial and failure of or contraindication to ONE generic inhaled tobramycin product
- The patient is not able to tolerate the prolonged administration of nebulizers

If yes, **Tobi Podhaler for 12 months by GPID or GPI-14 with a quantity limit of #224 capsules per 28 days (fill count = 6).**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TOBRAMYCIN INHALED

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TOBRAMYCIN INHALED (Bethkis, Tobi, Tobi Podhaler, Kitabis Pak)** requires the following rule(s) be met for approval:

- A. You have cystic fibrosis (inherited life-threatening disorder that damages the lungs and digestive system)
- B. You are 6 years of age or older
- C. You have a lung infection with a gram-negative species (type of bacteria that does not stain a purple color)
- D. **If the request is for Tobi Podhaler, approval also requires ONE of the following:**
  - 1. You had a trial and failure of or contraindication (harmful for) to ONE generic inhaled tobramycin product
  - 2. You are not able to tolerate the prolonged administration of nebulizers

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Tobi, Tobi Podhaler, Bethkis or Kitabis.

**REFERENCES**

- Tobi [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; October 2018.
- Tobi Podhaler [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; July 2020.
- Bethkis [Prescribing Information]. Woodstock, IL: Chiesi USA, Inc.; December 2019.
- Kitabis Pak [Prescribing Information]. Midothian, VA: PARI Respiratory Equipment, Inc.; September 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/22

Created: 05/12

Client Approval: 11/21

P&T Approval: 10/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TOCILIZUMAB - SQ

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TOCILIZUMAB - SQ	ACTEMRA - SQ		35486 45082	GPI-14 (6650007000E520) (6650007000D520)	

**PAC NOTE:** For requests for the IV dosage form of Actemra, please see the Actemra IV PA Guideline.

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a rheumatologist
  - The patient had a trial of or contraindication to 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
  - The patient had a trial of or contraindication to the preferred agent: Humira [**NOTE:** pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

If yes, **approve for 6 months by GPID or GPI-14 for all subcutaneous formulations (syringe and pen injector) with a quantity limit of #3.6mL per 28 days.**

If no, continue to #2.

2. Does the patient have a diagnosis of giant cell arteritis (GCA) **AND** meet the following criterion?
  - The patient is 18 years of age or older

If yes, **approve for 6 months by GPID or GPI-14 for all subcutaneous formulations (syringe and pen injector) with a quantity limit of #3.6mL per 28 days.**

If no, continue to #3.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TOCILIZUMAB - SQ

INITIAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of systemic sclerosis-associated interstitial lung disease (SSc-ILD) and meet **ALL** of the following criteria?
- The patient is 18 years of age or older
  - The patient has a diagnosis of Systemic Sclerosis (SSc) according to American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR)
  - Therapy is prescribed by or in consultation with a pulmonologist or rheumatologist
  - The patient does NOT have other etiologies of interstitial lung disease (ILD) [e.g., heart failure/fluid overload, drug-induced lung toxicity (cyclophosphamide, methotrexate, ACE-inhibitors), recurrent aspiration (such as from GERD), pulmonary vascular disease, pulmonary edema, pneumonia, chronic pulmonary thromboembolism, alveolar hemorrhage or ILD caused by another rheumatic disease, such as mixed connective tissue disease (MCTD)]

If yes, **approve for 6 months by GPID or GPI-14 for all subcutaneous formulations (syringe and pen injector) with a quantity limit of #3.6mL per 28 days.**

If no, continue to #4.

4. Does the patient have a diagnosis of polyarticular juvenile idiopathic arthritis (PJIA) and meet **ALL** of the following criteria?
- The patient is 2 years of age or older
  - Therapy is prescribed by or in consultation with a rheumatologist
  - The patient had a trial of or contraindication to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
  - The patient had a trial of or contraindication to the preferred agent: Humira [**NOTE:** pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

If yes, **approve for 6 months by GPID or GPI-14 for all subcutaneous formulations (syringe and pen injector) with a quantity limit of #1.8mL per 28 days.**

If no, continue to #5.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TOCILIZUMAB - SQ

INITIAL CRITERIA (CONTINUED)

5. Does the patient have a diagnosis of systemic juvenile idiopathic arthritis (SJIA) and meet **ALL** of the following criteria?
- The patient is 2 years of age or older
  - Therapy is prescribed by or in consultation with a rheumatologist, dermatologist, or immunologist
  - The patient had a trial of or contraindication to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

If yes, **approve for 6 months by GPID or GPI-14 for all subcutaneous formulations (syringe and pen injector) with a quantity limit of #3.6mL per 28 days.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TOCILIZUMAB - SQ (Actemra - SQ)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
1. Moderate to severe rheumatoid arthritis (a type of joint condition)
  2. Giant cell arteritis (inflammation of blood vessels typically in and around the head)
  3. Systemic sclerosis-associated interstitial lung disease (disorder that causes hardening of lung tissue)
  4. Polyarticular juvenile idiopathic arthritis (a type of joint condition)
  5. Systemic juvenile idiopathic arthritis (a type of joint condition)

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TOCILIZUMAB - SQ

INITIAL CRITERIA (CONTINUED)

- B. If you have moderate to severe rheumatoid arthritis, approval also requires:**
1. You are 18 years of age or older
  2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
  3. You had a trial of or contraindication (harmful for) to 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
  4. You had a trial of or contraindication (harmful for) to the preferred medication: Humira
- C. If you have giant cell arteritis, approval also requires:**
1. You are 18 years of age or older
- D. If you have systemic sclerosis-associated interstitial lung disease, approval also requires:**
1. You are 18 years of age or older
  2. Your diagnosis of Systemic Sclerosis (SSc) is according to the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR)
  3. Therapy is prescribed by or in consultation with a pulmonologist (lung/breathing doctor) or rheumatologist (a type of immune system doctor)
  4. Other causes of interstitial lung disease have been ruled out. Other causes may include heart failure/fluid overload, drug-induced lung toxicity [cyclophosphamide, methotrexate, ACE-inhibitors (class of blood pressure medications)], recurrent aspiration (inhaling) such as from GERD (acid reflux), pulmonary vascular disease (affecting blood vessels in lungs), pulmonary edema (excess fluid in the lungs), pneumonia (type of lung infection), chronic pulmonary thromboembolism (blood clot in lungs), alveolar hemorrhage (bleeding of a part of the lungs) or interstitial lung disease caused by another rheumatic (inflammatory) disease, such as mixed connective tissue disease
- E. If you have polyarticular juvenile idiopathic arthritis, approval also requires:**
1. You are 2 years of age or older
  2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
  3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
  4. You had a trial of or contraindication (harmful for) to the preferred medication: Humira
- (Initial denial text continued on next page)*

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TOCILIZUMAB - SQ

INITIAL CRITERIA (CONTINUED)

F. If you have systemic juvenile idiopathic arthritis, approval also requires:

1. You are 2 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor), dermatologist (skin doctor), or immunologist (immune system doctor)
3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) **AND** meet the following criterion?
  - The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

If yes, **approve for 12 months by GPID or GPI-14 for all subcutaneous formulations (syringe and pen injector) with a quantity limit of #3.6mL per 28 days.**

If no, continue to #2.

2. Does the patient have a diagnosis of giant cell arteritis (GCA)?

If yes, **approve for 12 months by GPID or GPI-14 for all subcutaneous formulations (syringe and pen injector) with a quantity limit of #3.6mL per 28 days.**

If no, continue to #3.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TOCILIZUMAB - SQ

**RENEWAL CRITERIA (CONTINUED)**

3. Does the patient have a diagnosis of systemic sclerosis-associated interstitial lung disease (SSc-ILD) **AND** meet the following criterion?

- The patient has experienced a clinical meaningful improvement or maintenance in annual rate of decline

If yes, **approve for 12 months by GPID or GPI-14 for all subcutaneous formulations (syringe and pen injector) with a quantity limit of #3.6mL per 28 days.**

If no, continue to #4.

4. Does the patient have a diagnosis of polyarticular juvenile idiopathic arthritis (PJIA) **AND** meet the following criterion?

- The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

If yes, **approve for 12 months by GPID or GPI-14 for all subcutaneous formulations (syringe and pen injector) with a quantity limit of #1.8mL per 28 days.**

If no, continue to #5.

5. Does the patient have a diagnosis of systemic juvenile idiopathic arthritis (SJIA) and meet **ONE** of the following criteria?

- The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
- The patient has shown maintained or improved systemic inflammatory disease (e.g., fevers, pain, rash, arthritis)

If yes, **approve for 12 months by GPID or GPI-14 for all subcutaneous formulations (syringe and pen injector) with a quantity limit of #3.6mL per 28 days.**

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TOCILIZUMAB - SQ

RENEWAL CRITERIA (CONTINUED)

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TOCILIZUMAB - SQ (Actemra - SQ)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following diagnoses:
  - 1. Moderate to severe rheumatoid arthritis (a type of joint condition)
  - 2. Giant cell arteritis (inflammation of blood vessels typically in and around the head)
  - 3. Systemic sclerosis-associated interstitial lung disease (disorder that causes hardening of lung tissue)
  - 4. Polyarticular juvenile idiopathic arthritis (a type of joint condition)
  - 5. Systemic juvenile idiopathic arthritis (a type of joint condition)
- B. **If you have moderate to severe rheumatoid arthritis or polyarticular juvenile idiopathic arthritis, renewal also requires:**
  - 1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
- C. **If you have systemic sclerosis-associated interstitial lung disease, renewal also requires:**
  - 1. You have experienced a clinically meaningful improvement or maintenance in annual rate of decline
- D. **If you have Systemic Juvenile Idiopathic Arthritis, renewal also requires ONE of the following:**
  - 1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
  - 2. You have shown maintained or improved systemic inflammatory disease (such as fevers, pain, rash, arthritis)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**TOCILIZUMAB - SQ**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Actemra.

**REFERENCE**

- Actemra [Prescribing Information]. South San Francisco, CA: Genentech, Inc.; March 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/01/22

Created: 11/13

Client Approval: 09/22

P&T Approval: 04/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TOFACITINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TOFACITINIB CITRATE	XELJANZ, XELJANZ XR	39768		GPI-10 (6660306510)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a rheumatologist
  - The patient had a trial of or contraindication to at least 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
  - The patient had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers (e.g., Humira, Enbrel) [**NOTE:** Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

If yes, **approve for 6 months for the requested strength by GPID or GPI-14 as follows:**

- **Xeljanz 5mg: #2 per day.**
- **Xeljanz XR 11mg: #1 per day.**

If no, continue to #2.

2. Does the patient have a diagnosis of psoriatic arthritis (PsA) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a rheumatologist or dermatologist
  - The patient had a trial of or contraindication to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
  - The patient had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers (e.g., Humira, Enbrel) [**NOTE:** Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

If yes, **approve for 6 months for the requested strength by GPID or GPI-14 as follows:**

- **Xeljanz 5mg: #2 per day.**
- **Xeljanz XR 11mg: #1 per day.**

If no, continue to #3.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TOFACITINIB

INITIAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of ankylosing spondylitis (AS) and meet **ALL** of the following criteria?
- The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a rheumatologist
  - The patient had a trial of or contraindication to an NSAID (e.g., ibuprofen, naproxen, meloxicam, diclofenac, etc.)
  - The patient had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers (e.g., Humira, Enbrel) [**NOTE:** Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

If yes, **approve for 6 months for the requested strength by GPID or GPI-14 as follows:**

- **Xeljanz 5mg: #2 per day.**
- **Xeljanz XR 11mg: #1 per day.**

If no, continue to #4.

4. Does the patient have a diagnosis of moderate to severe ulcerative colitis (UC) and meet **ALL** of the following criteria?
- The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a gastroenterologist
  - The patient had a trial of or contraindication to ONE conventional therapy (e.g., corticosteroids [e.g., budesonide, methylprednisolone], azathioprine, mercaptopurine, methotrexate, mesalamine)
  - The patient had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers (e.g., Humira) [**NOTE:** Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

If yes, **approve for 6 months for ALL strengths by GPID or GPI-14 as follows:**

- **Xeljanz 5mg and 10mg: #2 per day.**
- **Xeljanz XR 11mg and 22mg: #1 per day.**

If no, continue to #5.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TOFACITINIB

INITIAL CRITERIA (CONTINUED)

5. Does the patient have a diagnosis of polyarticular course juvenile idiopathic arthritis (pcJIA) and meet **ALL** of the following criteria?
- The patient is 2 years of age or older
  - Therapy is prescribed by or in consultation with a rheumatologist
  - The patient had a trial of or contraindication to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
  - The patient had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers (e.g., Humira, Enbrel) [**NOTE:** Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

If yes, **approve for 6 months by GPID or GPI-14 for the requested agent as follows:**

- **Xeljanz 5mg: #2 per day.**
- **Xeljanz oral solution: #10mL per day.**

If no, do not approve.

**INITIAL DENIAL TEXT:** **\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TOFACITINIB (Xeljanz, Xeljanz XR)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
  2. Psoriatic arthritis (PsA: a type of skin and joint condition)
  3. Ankylosing spondylitis (AS: a type of joint condition)
  4. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
  5. Polyarticular course juvenile idiopathic arthritis (pcJIA: a type of joint condition)
- B. **If you have moderate to severe rheumatoid arthritis, approval also requires:**
1. You are 18 years of age or older
  2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
  3. You had a trial of or contraindication (harmful for) to at least 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
  4. You had an inadequate response (drug did not work) or intolerance (side effect) to one or more tumor necrosis factor (TNF) blockers (such as Humira, Enbrel)

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TOFACITINIB

INITIAL CRITERIA (CONTINUED)

**C. If you have psoriatic arthritis, approval also requires:**

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
4. You had an inadequate response (drug did not work) or intolerance (side effect) to one or more tumor necrosis factor (TNF) blockers (such as Humira, Enbrel)

**D. If you have ankylosing spondylitis, approval also requires:**

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
3. You had a trial of or contraindication (harmful for) to an NSAID (nonsteroidal anti-inflammatory drug, such as ibuprofen, naproxen, meloxicam, diclofenac)
4. You had an inadequate response (drug did not work) or intolerance (side effect) to one or more tumor necrosis factor (TNF) blockers (such as Humira, Enbrel)

**E. If you have moderate to severe ulcerative colitis, approval also requires:**

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
3. You had a trial of or contraindication (harmful for) to ONE standard therapy, such as corticosteroids (such as budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine
4. You had an inadequate response (drug did not work) or intolerance (side effect) to one or more tumor necrosis factor (TNF) blockers (such as Humira)

**F. If you have polyarticular course juvenile idiopathic arthritis, approval also requires:**

1. You are 2 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
4. You had an inadequate response (drug did not work) or intolerance (side effect) to one or more tumor necrosis factor (TNF) blockers (such as Humira, Enbrel)

**NOTE:** The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

***(Initial denial text continued on next page)***

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TOFACITINIB

INITIAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) or psoriatic arthritis (PsA) **AND** meet the following criterion?
  - The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

If yes, **approve for 12 months for the requested strength by GPID or GPI-14 as follows:**

- **Xeljanz 5mg: #2 per day.**
- **Xeljanz XR 11mg: #1 per day.**

If no, continue to #2.

2. Does the patient have a diagnosis of ankylosing spondylitis (AS) **AND** meet the following criterion?
  - The patient has experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score while on therapy

If yes, **approve for 12 months for the requested strength by GPID or GPI-14 as follows:**

- **Xeljanz 5mg: #2 per day.**
- **Xeljanz XR 11mg: #1 per day.**

If no, continue to #3.

3. Does the patient have a diagnosis of moderate to severe ulcerative colitis (UC)?

If yes, **approve for 12 months for ALL strengths by GPID or GPI-14 as follows:**

- **Xeljanz 5mg and 10mg: #2 per day.**
- **Xeljanz 11mg and 22mg: #1 per day.**

If no, continue to #4.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TOFACITINIB

RENEWAL CRITERIA (CONTINUED)

4. Does the patient have a diagnosis of polyarticular course juvenile idiopathic arthritis (pcJIA) and meet the following criterion?
- The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

If yes, **approve for 12 months by GPID or GPI-14 for the requested agent as follows:**

- **Xeljanz 5mg: #2 per day.**
- **Xeljanz oral solution: #10mL per day.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TOFACITINIB (Xeljanz, Xeljanz XR)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following diagnoses:
1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
  2. Psoriatic arthritis (PsA: a type of skin and joint condition)
  3. Ankylosing spondylitis (AS: a type of joint condition)
  4. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
  5. Polyarticular course juvenile idiopathic arthritis (pcJIA: a type of joint condition)
- B. **If you have moderate to severe rheumatoid arthritis, psoriatic arthritis, or polyarticular course juvenile idiopathic arthritis, renewal also requires:**
1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
- C. **If you have ankylosing spondylitis, renewal also requires:**
1. You have experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI: diagnostic test which allows a physician to determine the effectiveness of a current medication) score while on therapy

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**TOFACITINIB**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Xeljanz/Xeljanz XR.

**REFERENCES**

- Xeljanz, Xeljanz XR [Prescribing Information]. New York, NY: Pfizer Laboratories Div Pfizer Inc.; December 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 06/15/22

Created: 11/12

Client Approval: 05/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TOLVAPTAN

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TOLVAPTAN	JYNARQUE	36348		GPI-10 (3045406000)	BRAND = JYNARQUE

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of autosomal dominant polycystic kidney disease (ADPKD) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a nephrologist
  - The patient does not have end-stage renal disease (ESRD; including no renal transplantation or dialysis)

If yes, approve for 6 months for all strengths as follows:

- 90mg-30mg (GPID or GPI-14): #56 per 28 days.
- 45mg-15mg (GPID or GPI-14): #56 per 28 days.
- 60mg-30mg (GPID or GPI-14): #56 per 28 days.
- 30-15mg (GPID or GPI-14): #56 per 28 days.
- 15-15mg (GPID or GPI-14): #56 per 28 days.
- 15mg (NDC 59148-0082-13) [FDB & Medi-Span]: #60 per 30 days.
- 30 mg (NDC 59148-0083-13) [FDB & Medi-Span]: #30 per 30 days.

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TOLVAPTAN (Jynarque)** requires the following rule(s) be met for approval:

- A. You have autosomal dominant polycystic kidney disease (ADPKD: inherited disorder in which clusters of cysts develop in the kidneys)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a nephrologist (kidney specialist)
- D. You do not have end-stage renal disease (ESRD: advanced kidney disease) including no renal transplantation (kidney transplant) or dialysis

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TOLVAPTAN

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of autosomal dominant polycystic kidney disease (ADPKD) **AND** meet the following criterion?
  - The patient has not progressed to end-stage renal disease (ESRD)

If yes, approve for 12 months for all strengths as follows:

- 90mg-30mg (GPID or GPI-14): #56 per 28 days.
- 45mg-15mg (GPID or GPI-14): #56 per 28 days.
- 60mg-30mg (GPID or GPI-14): #56 per 28 days.
- 30-15mg (GPID or GPI-14): #56 per 28 days.
- 15-15mg (GPID or GPI-14): #56 per 28 days.
- 15mg (NDC 59148-0082-13) [FDB & Medi-Span]: #60 per 30 days.
- 30 mg (NDC 59148-0083-13) [FDB & Medi-Span]: #30 per 30 days.

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TOLVAPTAN (Jynarque)** requires the following rule(s) be met for renewal:

- A. You have autosomal dominant polycystic kidney disease (ADPKD: inherited disorder in which clusters of cysts develop in the kidneys)
- B. You have NOT progressed to end stage renal (kidney) disease (ESRD)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TOLVAPTAN

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Jynarque.

**REFERENCES**

- Jynarque [Prescribing Information]. Rockville, MD: Otsuka America Pharmaceutical, Inc.; October 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/23

Created: 08/18

Client Approval: 02/23

P&T Approval: 01/23



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TOPIRAMATE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TOPIRAMATE	EPRONTIA		51457	GPI-14 (72600075002020)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of partial-onset or primary generalized tonic-clonic seizures and meet **ALL** of the following criteria?
  - Eprontia will be used as initial monotherapy OR adjunctive therapy
  - Therapy is prescribed by or in consultation with a neurologist
  - The patient is unable to take oral tablets or capsules
  - The patient meets ONE of the following:
    - The patient is 2 to 5 years of age AND had a trial of or contraindication to ONE preferred agent: generic topiramate tablet/sprinkle, topiramate ER sprinkle
    - The patient is 6 years of age or older AND had a trial of or contraindication to ONE preferred agent: Trokendi XR, generic topiramate tablet/sprinkle, topiramate ER sprinkle

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #16mL per day.**  
If no, continue to #2.

2. Does the patient have a diagnosis of seizures associated with Lennox-Gastaut syndrome and meet **ALL** of the following criteria?
  - Eprontia will be used as adjunctive therapy
  - Therapy is prescribed by or in consultation with a neurologist
  - The patient is unable to take oral tablets or capsules
  - The patient meets ONE of the following:
    - The patient is 2 to 5 years of age AND had a trial of or contraindication to ONE preferred agent: generic topiramate tablet/sprinkle, topiramate ER sprinkle
    - The patient is 6 years of age or older AND had a trial of or contraindication to ONE preferred agent: Trokendi XR, generic topiramate tablet/sprinkle, topiramate ER sprinkle

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #16mL per day.**  
If no, continue to #3.

3. Does the patient have a diagnosis of migraine and meet **ALL** of the following criteria?
  - The patient is 12 years of age or older
  - Eprontia will be used as preventative treatment of migraines
  - The patient is unable to take oral tablets or capsules
  - The patient had a trial of or contraindication to ONE preferred agent: Trokendi XR, generic topiramate tablet/sprinkle, topiramate ER sprinkle

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #4mL per day.**  
If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TOPIRAMATE

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TOPIRAMATE (Eprontia)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
  - 1. Partial-onset seizures (a type of seizure)
  - 2. Primary generalized tonic-clonic seizures (a type of seizure)
  - 3. Seizures associated with Lennox-Gastaut syndrome (a type of seizure disorder in young children)
  - 4. Migraine
- B. You are unable to take oral tablets or capsules
- C. **If you have partial-onset seizures or primary generalized tonic-clonic seizures, approval also requires:**
  - 1. Eprontia will be used as initial monotherapy OR adjunctive therapy (drugs taken together with)
  - 2. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor)
  - 3. You meet ONE of the following:
    - a. You are 2 to 5 years of age AND had a trial of or contraindication (harmful for) to ONE preferred agent: generic topiramate tablet/sprinkle, topiramate ER sprinkle
    - b. You are 6 years of age or older AND had a trial of or contraindication (harmful for) to ONE preferred agent: Trokendi XR, generic topiramate tablet/sprinkle, topiramate ER sprinkle
- D. **If you have seizures associated with Lennox-Gastaut syndrome, approval also requires:**
  - 1. Eprontia will be used as adjunctive therapy (drugs taken together with)
  - 2. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor)
  - 3. You meet ONE of the following:
    - a. You are 2 to 5 years of age AND had a trial of or contraindication (harmful for) to ONE preferred agent: generic topiramate tablet/sprinkle, topiramate ER sprinkle
    - b. You are 6 years of age or older AND had a trial of or contraindication (harmful for) to ONE preferred agent: Trokendi XR, generic topiramate tablet/sprinkle, or topiramate ER sprinkle
- E. **If you have migraines, approval also requires:**
  - 1. You are 12 years of age or older
  - 2. Eprontia will be used as preventative treatment of migraines
  - 3. You had a trial of or contraindication (harmful for) to ONE preferred agent: Trokendi XR, generic topiramate tablet/sprinkle, topiramate ER sprinkle

***(Denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TOPIRAMATE

**GUIDELINES FOR USE (CONTINUED)**

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Eprontia.

**REFERENCES**

- Eprontia [Prescribing Information]. Wilmington, MA: Azurity Pharmaceuticals, Inc.; November 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/22

Created: 02/22

Client Approval: 05/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TOREMIFENE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TOREMIFENE CITRATE	FARESTON	11632		GPI-10 (2140268510)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of metastatic breast cancer and meet **ALL** of the following criteria?

- The patient is a postmenopausal female
- The patient has an estrogen-receptor positive or unknown tumor

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #30 per 30 days.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TOREMIFENE (Fareston)** requires the following rule(s) be met for approval:

- A. You have metastatic breast cancer (cancer has spread to other parts of body)
- B. You are a postmenopausal female (already gone through menopause)
- C. You have an estrogen-receptor positive or unknown tumor

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Fareston.

**REFERENCES**

- Fareston [Prescribing Information] Bedminster, NJ: Kyowa Kirin Inc. May 2017.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 08/13

Client Approval: 04/20

P&T Approval: 08/13



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**TORSEMIDE**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TORSEMIDE	SOANZ		52032 52033	GPI-14 (37200080000335 37200080000345)	

**GUIDELINES FOR USE**

- 1 Does the patient have a diagnosis of edema associated with heart failure or renal disease and meet **ALL** of the following criteria?
- The patient is 18 years of age or older
  - The patient had a trial of or contraindication to TWO generic loop diuretics (e.g., furosemide, bumetanide)

If yes, **approve for 12 months by GPID or GPI-14 for the requested strength with the following quantity limits:**

- **40mg: #5 per day.**
- **60mg: #3 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TORSEMIDE (Soanz)** requires the following rule(s) be met for approval:

- A. You have edema (swelling caused by fluid build-up in the body) associated with heart failure (a type of heart condition) or renal (kidney) disease
- B. You are 18 years of age or older
- C. You had a trial of or contraindication (harmful for) to TWO generic loop diuretics (such as furosemide, bumetanide)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Soanz.

**REFERENCES**

- Soanz [Prescribing Information]. Vienna, VA: Sarfez Pharmaceuticals, Inc.; December 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/22

Created: 05/22

Client Approval: 05/22

P&T Approval: 05/22

Copyright © 2023 MediImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MediImpact. MediImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TRALOKINUMAB-LDRM

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TRALOKINUMAB-LDRM	ADBRY	47741		GPI-10 (9027308045)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of moderate to severe atopic dermatitis and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a dermatologist, allergist, or immunologist
  - The patient has atopic dermatitis involving at least 10% of body surface area (BSA) OR atopic dermatitis affecting the face, head, neck, hands, feet, groin, or intertriginous areas
  - The patient has TWO of the following: intractable pruritus, cracking and oozing/bleeding of affected skin, impaired activities of daily living
  - The patient had a trial of or contraindication to ONE preferred immunomodulator: Dupixent (dupilumab) or Rinvoq (upadacitinib)
  - Adbry will NOT be used concurrently with other systemic biologics (e.g., Dupixent) or any JAK inhibitors (e.g., Cibinco, topical Opzelura, Rinvoq) for the treatment of atopic dermatitis

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Does the patient have a trial of or contraindication to **TWO** of the following?
  - High or super-high potency topical corticosteroid (e.g., triamcinolone acetonide, fluocinonide, clobetasol propionate)
  - Topical calcineurin inhibitor (e.g., tacrolimus, pimecrolimus)
  - Topical PDE-4 inhibitor (e.g., crisaborole)
  - Topical JAK inhibitor (e.g., ruxolitinib)
  - Phototherapy

If yes, enter two approvals by HICL or GPI-10 for a total of 6 months as follows:

- **FIRST APPROVAL:** Approve with an end date of 30 days with a quantity limit of #6mL per 28 days.
- **SECOND APPROVAL:** Approve for 5 months (enter a start date of 2 days before the end of the first approval) with a quantity limit of #4mL per 28 days.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TRALOKINUMAB-LDRM

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TRALOKINUMAB-LDRM (Adbry)** requires the following rule(s) be met for approval:

- A. You have moderate to severe atopic dermatitis (a type of skin condition)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor), allergist (a type of allergy doctor), or immunologist (a type of immune system doctor)
- D. You have atopic dermatitis involving at least 10% of body surface area (BSA) OR atopic dermatitis affecting the face, head, neck, hands, feet, groin, or intertriginous areas (between skin folds, the hands, feet, etc.)
- E. You have TWO of the following: intractable pruritus (severe itching), cracking and oozing/bleeding of affected skin, impaired activities of daily living
- F. You had a trial of or contraindication (harmful for) to TWO of the following:
  - 1. High or super-high potency topical corticosteroid (such as triamcinolone acetonide, fluocinonide, clobetasol propionate)
  - 2. Topical calcineurin inhibitor (e.g., tacrolimus, pimecrolimus)
  - 3. Topical PDE-4 inhibitor (e.g., crisaborole)
  - 4. Topical JAK inhibitor (e.g., ruxolitinib)
  - 5. Phototherapy (light therapy)
- G. You had a trial of or contraindication (harmful for) to ONE preferred immunomodulator: Dupixent (dupilumab) or Rinvoq (upadacitinib)
- H. You will NOT use Adbry concurrently (at the same time) with other systemic biologics (such as Dupixent) or any JAK inhibitors (such as Cibinco, topical Opzelura, Rinvoq) for the treatment of atopic dermatitis

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TRALOKINUMAB-LDRM

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of moderate to severe atopic dermatitis and meet **ALL** of the following criteria?

- The patient has shown improvement while on therapy
- Adbry will NOT be used concurrently with other systemic biologics (e.g., Dupixent) or any JAK inhibitors (e.g., Cibinqo, topical Opzelura, Rinvoq) for the treatment of atopic dermatitis

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4mL per 28 days.**  
If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TRALOKINUMAB-LDRM (Adbry)** requires the following rule(s) be met for renewal:

- A. You have moderate to severe atopic dermatitis (a type of skin condition)
- B. You have shown improvement while on therapy
- C. You will NOT use Adbry concurrently (at the same time) with other systemic biologics (such as Dupixent) or any JAK inhibitors (such as Cibinqo, topical Opzelura, Rinvoq) for the treatment of atopic dermatitis

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Adbry.

**REFERENCES**

- Adbry [Prescribing Information]. Ballerup, Denmark: LEO Pharma A/X; January 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 12/01/22

Created: 01/22

Client Approval: 11/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TRAMADOL

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TRAMADOL HCL	QDOLO, TRAMADOL HCL		48598	GPI-14 (65100095102005)	

**GUIDELINES FOR USE**

- Is the request for the management of pain and the patient meets **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient's pain is severe enough to require an opioid analgesic and alternative treatments are inadequate
  - The patient had a trial of or contraindication to generic tramadol IR tablet or a generic tramadol with acetaminophen product
  - The patient is unable to take oral solid formulations of tramadol or tramadol with acetaminophen (e.g., difficulty swallowing)

If yes, **approve for 6 months by GPID or GPI-14 with a quantity limit of #80mL per day.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TRAMADOL (Qdolo)** requires the following rule(s) be met for approval:

- The request is for the management of pain
- You are 18 years of age or older
- Your pain is severe enough to require an opioid analgesic (type of pain medication) and alternative treatments are inadequate
- You had a trial of or contraindication (harmful for) to generic tramadol immediate-release (IR) tablet or a generic tramadol with acetaminophen product
- You are unable to take oral solid formulations of tramadol or tramadol with acetaminophen (such as with difficulty swallowing)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**TRAMADOL**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Qdolo.

**REFERENCES**

- Qdolo [Prescribing Information]. Athens, GA: Athena Bioscience, LLC; September 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 03/14/22

Created: 02/21

Client Approval: 02/22

P&T Approval: 01/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TRAMETINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TRAMETINIB DIMETHYL SULFOXIDE	MEKINIST	40361		GPI-10 (2153357010)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of unresectable or metastatic melanoma and meet **ALL** of the following criteria?
  - The patient has BRAF V600E or V600K mutations as detected by an FDA-approved test
  - The requested medication will be used in combination with Tafinlar (dabrafenib) OR as a single agent in a BRAF-inhibitor treatment-naive patient

If yes, **approve for 12 months by GPID or GPI-14 with the following quantity limits:**

  - **2mg: #1 per day.**
  - **0.5mg: #3 per day.**

If no, continue to #2.
2. Does the patient have a diagnosis of metastatic non-small cell lung cancer (NSCLC) and meet **ALL** of the following criteria?
  - The patient has BRAF V600E mutation as detected by an FDA-approved test
  - The requested medication will be used in combination with Tafinlar (dabrafenib)

If yes, **approve for 12 months by GPID or GPI-14 with the following quantity limits:**

  - **2mg: #1 per day.**
  - **0.5mg: #3 per day.**

If no, continue to #3.
3. Does the patient have a diagnosis of melanoma and meet **ALL** of the following criteria?
  - The patient has BRAF V600E or V600K mutations as detected by an FDA-approved test
  - The requested medication will be used as an adjuvant therapy in combination with Tafinlar (dabrafenib)
  - There is involvement of lymph node(s), following complete resection

If yes, **approve for 12 months by GPID or GPI-14 with the following quantity limits:**

  - **2mg: #1 per day.**
  - **0.5mg: #3 per day.**

If no, continue to #4.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TRAMETINIB

GUIDELINES FOR USE (CONTINUED)

4. Does the patient have a diagnosis of locally advanced or metastatic anaplastic thyroid cancer (ATC) and meet **ALL** of the following criteria?

- The patient has BRAF V600E mutation
- The requested medication will be used in combination with Tafinlar (dabrafenib)
- The patient has no satisfactory locoregional treatment options available

If yes, **approve for 12 months by GPID or GPI-14 with the following quantity limits:**

- **2mg: #1 per day.**
- **0.5mg: #3 per day.**

If no, continue to #5.

5. Does the patient have a diagnosis of unresectable or metastatic solid tumors and meet **ALL** of the following criteria?

- The patient is 6 years of age or older
- The patient has BRAF V600E mutation
- The requested medication will be used in combination with Tafinlar (dabrafenib)
- The patient has progressed following prior treatment and has no satisfactory alternative treatment options

If yes, **approve for 12 months by GPID or GPI-14 with the following quantity limits:**

- **2mg: #1 per day.**
- **0.5mg: #3 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TRAMETINIB (Mekinist)** requires the following rule(s) be met for approval:

A. You have **ONE** of the following diagnoses:

1. Unresectable or metastatic melanoma (a type of skin cancer that cannot be removed by surgery or it has spread to other parts of the body)
2. Metastatic non-small cell lung cancer (NSCLC: a type of lung cancer that has spread to other part of the body)
3. Melanoma (a type of skin cancer)
4. Locally advanced or metastatic anaplastic thyroid cancer (ATC: a type of thyroid cancer that has spread from where it started to nearby tissue or lymph nodes or it has spread to other parts of the body)

***(Denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TRAMETINIB

GUIDELINES FOR USE (CONTINUED)

5. Unresectable or metastatic solid tumors (tumors that cannot be removed by surgery or it has spread to other parts of the body)
- B. If you have unresectable or metastatic melanoma, approval also requires:**
  1. You have BRAF V600E or V600K mutations (types of genes) as detected by a Food and Drug Administration (FDA)-approved test
  2. The requested medication will be used in combination with Tafinlar (dabrafenib) OR as a single agent in a BRAF-inhibitor treatment-naïve patient (you have not been previously treated for this cancer)
- C. If you have metastatic non-small cell lung cancer (NSCLC), approval also requires:**
  1. You have BRAF V600E mutation (type of gene) as detected by a Food and Drug Administration -approved test
  2. The requested medication will be used in combination with Tafinlar (dabrafenib)
- D. If you have melanoma, approval also requires:**
  1. You have BRAF V600E or V600K mutations (types of genes) as detected by a Food and Drug Administration (FDA)-approved test
  2. The requested medication will be used in combination with Tafinlar (dabrafenib)
  3. There is involvement of lymph node(s), following complete resection (surgical removal)
- E. If you have locally advanced or metastatic anaplastic thyroid cancer (ATC), approval also requires:**
  1. You have BRAF V600E mutation (type of gene mutation)
  2. The requested medication will be used in combination with Tafinlar (dabrafenib)
  3. You do not have any satisfactory locoregional treatment options available (treatments that are focused on the affected area)
- F. If you have unresectable or metastatic solid tumors, approval also requires:**
  1. You are 6 years of age or older
  2. You have BRAF V600E mutation (type of gene mutation)
  3. The requested medication will be used in combination with Tafinlar (dabrafenib)
  4. You have progressed following prior treatment and have no satisfactory alternative treatment options

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**TRAMETINIB**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Mekinist.

**REFERENCES**

- Mekinist [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; June 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/25/22

Created: 07/13

Client Approval: 07/22

P&T Approval: 07/18





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TREPROSTINIL

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TREPROSTINIL SODIUM	REMODYLIN, TREPROSTINIL	23650		GPI-10 (4017008000)	
TREPROSTINIL, TREPROSTINIL DPI	TYVASO, TYVASO DPI	36537 36539 36541		GPI-10 (4017008000)	
TREPROSTINIL DIOLAMINE	ORENITRAM	40827		GPI-10 (4017008005)	

**\*\*Please use the criteria for the specific drug requested\*\***

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

**REMODYLIN**

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group 1) and meet **ALL** of the following criteria?
  - Therapy is prescribed by or in consultation with a cardiologist or pulmonologist
  - The patient has a documented confirmatory PAH diagnosis based on right heart catheterization with the following parameters:
    - Mean pulmonary artery pressure (PAP) > 20 mmHg
    - Pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg
    - Pulmonary vascular resistance (PVR) ≥ 3 Wood units (WU)

If yes, continue to #2.

If no, do not approve

**DENIAL TEXT:** See the initial denial text at the end of the **REMODYLIN** guideline

2. Is the request for continuation of Remodylin (treprostinil) therapy from hospital discharge **AND** the patient meets the following criterion?

- The patient has NYHA/WHO Functional Class II, III, or IV symptoms

If yes, **approve for 12 months by HICL or GPI-14.**

If no, continue to #3.

3. Is this a new request for Remodylin **AND** the patient meets the following criterion?

- The patient has NYHA/WHO Functional Class III or IV symptoms

If yes, **approve for 12 months by HICL or GPI-10.**

If no, continue to #4.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TREPROSTINIL

INITIAL CRITERIA - REMODULIN (CONTINUED)

4. Is this a new request for Remodulin and the patient meets **ALL** of the following criteria?
- The patient has NYHA-WHO Functional Class II symptoms
  - The patient had a previous trial of or contraindication to TWO of the following agents from different drug classes:
    - Oral endothelin receptor antagonist (e.g., ambrisentan, bosentan, or macitentan)
    - Oral phosphodiesterase-5 inhibitor (e.g., sildenafil or tadalafil)
    - Oral cGMP stimulator (e.g., riociguat)

If yes, **approve for 12 months by HICL or GPI-14.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TREPROSTINIL (Remodulin)** requires the following rule(s) be met for approval:

- A. You have pulmonary arterial hypertension (PAH: a type of heart and lung condition) World Health Organization (WHO) Group 1 (type of classification of the disease)
- B. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung/breathing doctor)
- C. You have a documented confirmed diagnosis of pulmonary arterial hypertension based on right heart catheterization (a test used to measure how well your heart is pumping) with the following lab values:
  - 1. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
  - 2. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
  - 3. Pulmonary vascular resistance (PVR) greater than or equal to 3 Wood units
- D. **For continuation of current therapy from hospital discharge, approval also requires:**
  - 1. You have NYHA-WHO Functional Class II, III, or IV symptoms (classification system for heart failure)
- E. **For new start requests, approval also requires ONE of the following:**
  - 1. You have NYHA-WHO Functional Class III or IV symptoms (classification system for heart failure)
  - 2. You have NYHA-WHO Functional Class II symptoms AND had a previous trial of or contraindication (harmful for) to TWO of the following agents from different drug classes:
    - a. Oral endothelin receptor antagonist (such as Tracleer, Letairis, Opsumit)
    - b. Oral phosphodiesterase-5 inhibitor (such as Adcirca or Revatio)
    - c. Oral cGMP stimulator (such as Adempas)

***(Initial Remodulin denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TREPROSTINIL

INITIAL CRITERIA - REMODULIN (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**TYVASO, TYVASO DPI**

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group 1) and meet **ALL** of the following criteria?
  - Therapy is prescribed by or in consultation with a cardiologist or pulmonologist
  - The patient has a documented confirmatory PAH diagnosis based on right heart catheterization with the following parameters:
    - Mean pulmonary artery pressure (PAP) > 20 mmHg
    - Pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg
    - Pulmonary vascular resistance (PVR) ≥ 3 Wood units (WU)
  - The patient has New York Heart Association-World Health Organization (NYHA-WHO) Functional Class III or IV symptoms

If yes, continue to #2.

If no, continue to #4.

2. Does the patient have WHO Functional Class III symptoms **AND** meet the following criterion?
  - The patient had a previous trial of or contraindication to TWO of the following agents from different drug classes:
    - Oral endothelin receptor antagonist (e.g., ambrisentan, bosentan, or macitentan)
    - Oral phosphodiesterase-5 inhibitor (e.g., sildenafil or tadalafil)
    - Oral cGMP stimulator (e.g., riociguat)

If yes, **approve for 12 months by HICL or GPI-10. (NOTE: Enter approval for all of the available HICLs.)**

If no, continue to #3.

3. Does the patient have WHO Functional Class III symptoms with evidence of rapid progression/poor prognosis, or WHO Functional Class IV symptoms **AND** meet the following criterion?
  - The patient had a trial of or contraindication to ONE IV/SQ prostacyclin (e.g., epoprostenol or treprostinil)

If yes, **approve for 12 months by HICL or GPI-10. (NOTE: Enter approval for all of the available HICLs.)**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the **TYVASO** guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TREPROSTINIL

INITIAL CRITERIA - TYVASO, TYVASO DPI (CONTINUED)

4. Does the patient have a diagnosis of pulmonary hypertension associated with interstitial lung disease (PH-ILD: WHO Group 3) and meet **ALL** of the following criteria?
- Therapy is prescribed by or in consultation with a cardiologist or pulmonologist
  - Diagnosis is confirmed based on right heart catheterization with the following parameters:
    - Pulmonary vascular resistance (PVR)  $\geq$  3 Wood units (WU)
    - Mean pulmonary artery pressure (PAP)  $>$  20 mmHg
    - Pulmonary capillary wedge pressure (PCWP)  $\leq$  15 mmHg

If yes, **approve for 6 months by HICL or GPI-10.** (NOTE: Enter approval for all of the available HICLs.)

If not, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TREPROSTINIL (Tyvaso, Tyvaso DPI)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:

1. Pulmonary arterial hypertension (PAH: a type of heart and lung condition) World Health Organization (WHO) Group 1 (type of classification of the disease)
2. Pulmonary hypertension associated with interstitial lung disease (PH-ILD: a type of heart and lung condition) World Health Organization (WHO) Group 3 (type of classification of the disease)

B. **If you have PAH (WHO Group 1), approval also requires:**

1. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung/breathing doctor)
2. You have a documented confirmed diagnosis of pulmonary arterial hypertension based on right heart catheterization (a test used to measure how well your heart is pumping) with the following lab values:
  - a. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
  - b. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
  - c. Pulmonary vascular resistance (PVR) greater than or equal to 3 Wood units
3. You have NYHA-WHO Functional Class III or IV symptoms (classification system for heart failure)

***(Initial Tyvaso, Tyvaso DPI denial text continued on next page)***

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TREPROSTINIL

INITIAL CRITERIA - TYVASO, TYVASO DPI (CONTINUED)

4. **If you have WHO Functional Class III symptoms, approval also requires:**
    2. You had a trial of or contraindication (harmful for) to TWO of the following medications from different drug classes:
      - i. Oral endothelin receptor antagonist (such as Tracleer, Letairis, Opsumit)
      - ii. Oral phosphodiesterase-5 inhibitor (such as Adcirca or Revatio)
      - iii. Oral cGMP stimulator (such as Adempas)
  5. **If you have WHO Functional Class III symptoms with evidence of rapid progression/poor prognosis, or WHO Functional Class IV symptoms, approval also requires:**
    - a. You had a trial of or contraindication (harmful for) to ONE intravenous or subcutaneous prostacyclin (such as Flolan/Veletri or Remodulin)
- C. **If you have pulmonary hypertension (PH) (WHO Group 3), approval also requires:**
1. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung/breathing doctor)
  2. Your diagnosis is confirmed by right heart catheterization (a test used to measure how well your heart is pumping) with the following lab values:
    - a. Pulmonary vascular resistance (PVR) greater than or equal to 3 Wood units (WU)
    - b. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
    - c. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**ORENITRAM**

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group 1) and meet **ALL** of the following criteria?
  - Therapy is prescribed by or in consultation with a cardiologist or pulmonologist
  - The patient has a documented confirmatory PAH diagnosis based on right heart catheterization with the following parameters:
    - Mean pulmonary artery pressure (PAP) > 20 mmHg
    - Pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg
    - Pulmonary vascular resistance (PVR) ≥ 3 Wood units (WU)
  - The patient does NOT have severe hepatic impairment

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the **ORENITRAM** guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TREPROSTINIL

INITIAL CRITERIA - ORENITRAM (CONTINUED)

2. Is the request for continuation of Orenitram (treprostinil) therapy from hospital discharge **AND** the patient meets the following criterion?

- The patient has New York Heart Association-World Health Organization (NYHA-WHO) Functional Class II, III or IV symptoms

If yes, **approve for 12 months by HICL or GPI-10.**

If no, continue to #3.

3. Is the request for a new start of Orenitram (treprostinil) therapy for a patient with WHO Functional Class II or III symptoms and the patient meets **ALL** of the following?

- The patient had a trial of or contraindication to TWO of the following agents from different drug classes:
  - Oral endothelin receptor antagonist (e.g., ambrisentan, bosentan, or macitentan)
  - Oral phosphodiesterase-5 inhibitor (e.g., sildenafil or tadalafil)
  - Oral cGMP stimulator (e.g., riociguat)
- The patient had a trial of or contraindication to the preferred oral prostanoid: Uptravi

If yes, **approve for 12 months by HICL or GPI-10.**

If no, continue to #4.

4. Is the request for a new start of Orenitram (treprostinil) therapy for a patient with WHO Functional Class III symptoms with evidence of rapid progression/poor prognosis, or WHO Functional Class IV symptoms and the patient meets **ALL** of the following criteria?

- The patient had a trial of or contraindication to ONE IV/SQ prostacyclin (e.g., epoprostenol, treprostinil)
- The patient had a trial of or contraindication to the preferred prostanoid: Uptravi

If yes, **approve for 12 months by HICL or GPI-10.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TREPROSTINIL (Orenitram)** requires the following rule(s) be met for approval:

- A. You have pulmonary arterial hypertension (PAH: a type of heart and lung condition) World Health Organization Group 1 (type of classification of the disease)
- B. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung/breathing doctor)

***(Initial Orenitram denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TREPROSTINIL

INITIAL CRITERIA - ORENITRAM (CONTINUED)

- C. You have a documented confirmed diagnosis of pulmonary arterial hypertension based on right heart catheterization (a test used to measure how well your heart is pumping) with the following lab values:
  - A. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
  - B. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
  - C. Pulmonary vascular resistance (PVR) greater than or equal to 3 Wood units (WU)
- D. You do not have severe hepatic (liver) impairment
- E. **For continuation of current therapy from hospital discharge, approval also requires:**
  - 1. You have NYHA-WHO Functional Class II, III, or IV symptoms (classification system for heart failure)
- F. **For new start requests, approval also requires ONE of the following:**
  - 1. You have WHO Functional class II or III symptoms (classification system for heart failure) and meet ALL of the following:
    - a. You had a trial of or contraindication (harmful for) to TWO of the following agents from different drug classes:
      - i. Oral endothelin receptor antagonist (such as Tracleer, Letairis, Opsumit)
      - ii. Oral phosphodiesterase-5 inhibitor (such as Revatio or Adcirca)
      - iii. Oral cGMP stimulator (such as Adempas)
    - b. The patient had a trial of or contraindication (harmful for) to the preferred oral prostanoid: Uptravi
  - 2. You have WHO Functional Class III symptoms with evidence of rapid progression/poor prognosis, or WHO Functional Class IV symptoms and meet ALL of the following:
    - a. You had a trial of or contraindication (harmful for) to ONE intravenous or subcutaneous prostacyclin (such as Flolan/Veletri or Remodulin)
    - b. You had a trial of or contraindication (harmful for) to the preferred prostanoid: Uptravi

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TREPROSTINIL

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

REMODULIN, ORENITRAM

5. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group 1) and meet **ONE** of the following criteria?

- The patient has shown improvement from baseline in the 6-minute walk distance test
- The patient has remained stable from baseline in the 6-minute walk distance test AND the patient's World Health Organization (WHO) functional class has improved or remained stable

If yes, **approve the requested drug for 12 months by HICL or GPI-10.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TREPROSTINIL (Remodulin, Orenitram)** requires the following rule(s) be met for renewal:

- A. You have pulmonary arterial hypertension (PAH: a type of heart and lung condition) World Health Organization Group 1 (type of classification of the disease)
- B. You meet **ONE** of the following:
  1. You have shown improvement from baseline in the 6-minute walk distance test
  2. You have remained stable from baseline in the 6-minute walk distance test AND your World Health Organization (WHO) functional class (classification system for heart failure) has improved or remained stable

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

TYVASO, TYVASO DPI

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group 1) and meet **ONE** of the following criteria?

- The patient has shown improvement from baseline in the 6-minute walk distance test
- The patient has remained stable from baseline in the 6-minute walk distance test AND the patient's World Health Organization (WHO) functional class has improved or remained stable

If yes, **approve for 12 months by HICL or GPI-10. (NOTE: Enter approval for all of the available HICLs.)**

If no, continue to #2.

CONTINUED ON NEXT PAGE





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TREPROSTINIL

RENEWAL CRITERIA – TYVASO, TYVASO DPI (CONTINUED)

2. Does the patient have a diagnosis of pulmonary hypertension associated with interstitial lung disease (PH-ILD) (WHO Group 3) and meet **ONE** of the following criteria?
- The patient has shown improvement from baseline in the 6-minute walk distance test
  - The patient has a stable 6-minute walk distance test

If yes, **approve for 12 months by HICL or GPI-10. (NOTE: Enter approval for all of the available HICLs.)**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TREPROSTINIL (Tyvaso, Tyvaso DPI)** requires the following rule(s) be met for renewal:

- A. You have **ONE** of the following diagnoses:
1. Pulmonary arterial hypertension (PAH: a type of heart and lung condition) World Health Organization (WHO) Group 1 (type of classification of the disease)
  2. Pulmonary hypertension (PH-ILD: a type of heart and lung condition) World Health Organization (WHO) Group 3 (type of classification of the disease)
- B. **If you have PAH (WHO Group 1), renewal also requires ONE of the following:**
1. You have shown improvement from baseline in the 6-minute walk distance test
  2. You have remained stable from baseline in the 6-minute walk distance test AND your World Health Organization (WHO) functional class (classification system for heart failure) has improved or remained stable
- C. **If you have PH-ILD (WHO Group 3), renewal also requires ONE of the following:**
1. You have shown improvement from baseline in the 6-minute walk distance test
  2. You had a stable 6-minute walk distance test

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**TREPROSTINIL**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Remodulin, Tyvaso and Orenitram.

**REFERENCES**

- Remodulin [Prescribing Information]. Research Triangle Park, NC; United Therapeutics Corp., July 2021.
- Tyvaso [Prescribing Information]. Research Triangle Park, NC United Therapeutics Corp., March 2021.
- Tyvaso DPI [Prescribing Information]. Research Triangle Park, NC: United Therapeutics Corp., May 2022.
- Orenitram [Prescribing Information]. Research Triangle Park, NC United Therapeutics Corp., November 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/18/22

Created: 09/05

Client Approval: 06/22

P&T Approval: 01/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TRIENTINE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TRIENTINE HCL	SYPRINE, CLOVIQUE	01109		GPI-10 (9920002010)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of Wilson's disease and meet **ALL** of the following criteria?
  - Therapy is prescribed by or in consultation with a hepatologist
  - The patient has a Leipzig score  $\geq 4$
  - The patient is willing to follow a diet avoiding high copper foods (e.g., shellfish, nuts, chocolate, mushrooms, organ meat)
  - The patient has had a trial of or contraindication to Depen (penicillamine)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #8 per day.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TRIENTINE (Syprine, Clovique)** requires the following rule(s) be met for approval:

- A. You have Wilson's disease (a genetic disorder that leads to copper accumulation in the organs)
- B. Therapy is prescribed by or in consultation with a hepatologist (a type of liver doctor)
- C. You have a Leipzig score of 4 or greater (a type of diagnostic score)
- D. You are willing to follow a diet avoiding high copper foods (such as shellfish, nuts, chocolate, mushrooms, organ meat)
- E. You have had a trial of or contraindication (harmful for) to Depen (penicillamine)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RENEWAL CRITERIA**

1. Does the patient have a diagnosis of Wilson's disease **AND** meet the following criterion?
  - The patient has achieved a free serum copper of less than 10 mcg/dL

If yes, **approve for lifetime by HICL or GPI-10 with a quantity limit of #8 per day.**

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TRIENTINE

RENEWAL CRITERIA (CONTINUED)

**RENEWAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **TRIENTINE (Syprine, Clovique)** requires the following rules be met for renewal:

- A. You have Wilson's disease (a genetic disorder that leads to copper accumulation in the organs)
- B. You have achieved a free serum copper (amount of copper in your blood) of less than 10 mcg/dL

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Syprine.

**REFERENCES**

- Syprine [Prescribing Information]. Bridgewater, NJ: Valeant Pharmaceuticals; September 2020.
- Clovique [Prescribing Information]. Warrendale, PA: Kadmon Pharmaceuticals, LLC; September 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/23

Created: 08/16

Client Approval: 11/22

P&T Approval: 10/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TRIFLURIDINE/TIPIRACIL

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TRIFLURIDINE/ TIPIRACIL HCL	LONSURF	42544		GPI-10 (2199000275)	

**GUIDELINES FOR USE**

- 1 Does the patient have a diagnosis of metastatic colorectal cancer and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient has received previous treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy in combination with an anti-VEGF biological therapy [e.g., Avastin (bevacizumab), Zaltrap (ziv-aflibercept), or Cyramza (ramucirumab)]

If yes, continue to #2.  
If no, continue to #4.
- 2 Is the patient's metastatic colorectal cancer RAS wild-type?
  - If yes, continue to #3.
  - If no, **approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:**
    - Trifluridine/tipiracil 15/6.14mg: #100 per 28 days.
    - Trifluridine/tipiracil 20/8.19mg: #80 per 28 days.
- 3 Has the patient had previous treatment with an anti-EGFR agent [e.g., Erbitux (cetuximab), Vectibix (panitumumab)]?
  - If yes, **approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:**
    - Trifluridine/tipiracil 15/6.14mg: #100 per 28 days.
    - Trifluridine/tipiracil 20/8.19mg: #80 per 28 days.
  - If no, do not approve.
  - DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TRIFLURIDINE/TIPIRACIL

GUIDELINES FOR USE (CONTINUED)

- 4 Does the patient have a diagnosis of metastatic gastric or gastroesophageal junction adenocarcinoma and meet **ALL** of the following criteria?
- The patient is 18 years of age or older
  - The patient has received previous treatment with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy

If yes, **approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:**

- Trifluridine/tipiracil 15/6.14mg: #100 per 28 days.
- Trifluridine/tipiracil 20/8.19mg: #80 per 28 days.

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TRIFLURIDINE/TIPIRACIL (Lonsurf)** requires the following rule(s) be met for approval:

- A. You have **ONE** of the following diagnoses:
1. Metastatic colorectal cancer (a type of digestive system cancer that has spread to other parts of the body)
  2. Metastatic gastric or gastroesophageal junction adenocarcinoma (a type of digestive system cancer that has spread to other parts of the body)
- B. **If you have metastatic colorectal cancer, approval also requires:**
1. You are 18 years of age or older
  2. You had previous treatment with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy (drugs used to treat cancer) in combination with an anti-VEGF biological therapy such as Avastin (bevacizumab), Zaltrap (ziv-aflibercept), or Cyramza (ramucirumab)
  3. If your metastatic colorectal cancer is RAS wild-type (a type of gene), you also had a previous treatment with an anti-EGFR agent such as Erbitux (cetuximab), Vectibix (panitumumab)
- C. **If you have metastatic gastric or gastroesophageal junction adenocarcinoma, approval also requires:**
- B. You are 18 years of age or older
  - C. You had previous treatment with at least two prior lines of chemotherapy (drugs used to treat cancer) that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2 (type of gene)/neu-targeted therapy

***(Denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TRIFLURIDINE/TIPIRACIL

GUIDELINES FOR USE (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Lonsurf.

REFERENCES

- Lonsurf [Prescribing Information]; Princeton, NJ: Taiho Oncology, Inc; December 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/22

Created: 10/15

Client Approval: 02/22

P&T Approval: 01/16



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**TRiheptanoIn**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TRiheptanoIn	DOJOLVI	46676		GPI-10 (8020008000)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of a long-chain fatty acid oxidation disorder (LC-FAOD) and meet **ALL** of the following criteria?
  - The patient's diagnosis is confirmed by documentation of at least **TWO** of the following:
    - Disease-specific elevations of acylcarnitines on a newborn blood spot or in plasma
    - Low enzyme activity in cultured fibroblasts
    - One or more known pathogenic mutations in *CPT2*, *ACADVL*, *HADHA*, or *HADHB*
  - The patient is symptomatic (e.g. rhabdomyolysis, cardiomyopathy) for LC-FAOD
  - Therapy is prescribed by or given in consultation with a gastroenterologist or physician specialist in medical genetics/inherited metabolic disorders
  - The patient had a trial of or contraindication to commercial MCT oil (medical food product)

If yes, **approve for 4 months by HICL or GPI-10.**

**APPROVAL TEXT:** Renewal requires the patient had a positive clinical response (e.g., improved exercise tolerance) or stabilization of clinical status compared to baseline.

If no, do not approve.

**INITIAL DENIAL TEXT:** *\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **TRiheptanoIn (Dojolvi)** requires the following rule(s) be met for approval:

- A. You have a long-chain fatty acid oxidation disorder (LC-FAOD: rare, genetic disorder that affects how the body breaks down fat)
- B. Your diagnosis is confirmed by documentation of at least TWO of the following:
  1. Disease-specific elevations of acylcarnitines on a newborn blood spot or in plasma
  2. Low enzyme activity in cultured fibroblasts
  3. One or more known pathogenic mutations in *CPT2*, *ACADVL*, *HADHA*, or *HADHB*
- C. You are symptomatic for LC-FAOD (for example you have rhabdomyolysis [break down of muscle tissue] or cardiomyopathy [disease of the heart muscle])
- D. Therapy is prescribed by or given in consultation with a gastroenterologist (digestive tract doctor) or physician specialist in medical genetics/inherited metabolic disorders
- E. You have previously tried commercial MCT oil (a medical food product) unless there is a medical reason you are unable to (contraindication)

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TRiheptanoIn

INITIAL CRITERIA (CONTINUED ON NEXT)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

- Does the patient have a diagnosis of a long-chain fatty acid oxidation disorder (LC-FAOD) AND meet the following criterion?
  - The patient had a positive clinical response (e.g. improved exercise tolerance) or stabilization of clinical status compared to baseline

If yes, **approve for 12 months by HICL or GPI-10.**  
If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TRiheptanoIn (Dojolvi)** requires the following rule(s) be met for renewal:

- You have a long-chain fatty acid oxidation disorder (LC-FAOD: rare, genetic disorder that affects how the body breaks down fat)
- You had a positive clinical response (such as improved exercise tolerance) or stabilization of clinical status compared to baseline

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Dojolvi.

REFERENCES

- Dojolvi [Prescribing Information]. Novato, CA: Ultragenyx Pharmaceutical Inc.; June 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/21

Created: 10/20

Client Approval: 11/20

P&T Approval: 10/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

T: SLIM/MINIMED INSULIN PUMPS

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SUBCUTANEOUS INSULIN PUMP	T:SLIM X2, T:SLIM X2 CONTROL-IQ, T:SLIM X2 WITH BASAL-IQ, MINIMED 670G, MINIMED 770G	35487		GPI-10 (9720103000)	FDB & Medi-Span: BRAND = MINIMED 670G, MINIMED 770G, T:SLIM X2%, T:SLIM X2 CONTROL-IQ%, T:SLIM X2 WITH BASAL-IQ%

GUIDELINES FOR USE

1. Is the claim rejecting for the following POS message: “**Coverage of this product should be provided through medical benefit, available manufacturer programs, or patient assistance programs**”?

If yes, guideline does not apply.  
If no, continue to #2.

2. Does the patient meet **ALL** of the following criteria?
  - The insulin pump is prescribed by or given in consultation with an endocrinologist
  - The patient has completed a comprehensive diabetes education program within the preceding 24 months
  - The patient follows a maintenance program of at least 3 injections of insulin per day and requires frequent self-adjustments of insulin dose for the past 6 months
  - The patient requires glucose self-testing of at least 4 times per day on average in the preceding 2 months
  - The patient has not received an insulin pump within the last 4 years (Exception: pump is malfunctioning, not repairable, and not under warranty)

If yes, continue to #3.  
If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

T: SLIM/MINIMED INSULIN PUMPS

GUIDELINES FOR USE (CONTINUED)

3. Does the patient meet **ONE** of the following criteria while on a multiple daily insulin injection regimen?

- The patient's glycosylated hemoglobin level (HbA1c) >7%
- The patient has a history of recurring hypoglycemia
- The patient has wide fluctuations in blood glucose before mealtime
- The patient experiences the dawn phenomenon with fasting blood glucose levels frequently exceeding 200 mg/dL
- The patient has a history of severe glycemic excursions (i.e. sudden spikes in blood sugar levels)

If yes, continue to #4.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

4. Is the request for T: Slim X2 OR T: Slim X2 with Basal-IQ **AND** the patient meets the following criterion?

- The patient is 6 years of age or older

If yes, **approve for 1 month by NDC [FDB or Medi-Span] with a quantity limit of #1 fill.**

If no, continue to #5.

5. Is the request for the T: Slim X2 with Control-IQ **AND** the patient meets the following criterion?

- The patient is 6 years of age or older

If yes, **approve for 1 month by NDC [FDB or Medi-Span] with a quantity limit of #1 fill.**

If no, continue to #6.

6. Is the request for MiniMed 670G and the patient meets **ALL** of the following criteria?

- The patient has a diagnosis of type 1 diabetes mellitus
- The patient is 7 years of age or older

If yes, **approve for 1 month by NDC [FDB or Medi-Span] with a quantity limit of #1 fill.**

If no, continue to #7.

7. Is the request for MiniMed 770G and the patient meets **ALL** of the following criteria?

- The patient has a diagnosis of type 1 diabetes mellitus
- The patient is 2 years of age or older

If yes, **approve for 1 month by NDC [FDB or Medi-Span] with a quantity limit of #1 fill.**

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

T: SLIM/MINIMED INSULIN PUMPS

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **T: SLIM/MINIMED INSULIN PUMPS** requires the following rule(s) be met for approval:

- A. The requested insulin pump is prescribed by or given in consultation with an endocrinologist (hormone doctor)
- B. You have completed a comprehensive diabetes education program within the previous 24 months
- C. You follow a maintenance program of at least 3 injections of insulin per day and require frequent self-adjustments of your insulin dose for the past 6 months
- D. You require glucose self-testing of at least 4 times per day on average in the previous 2 months
- E. You have not received an insulin pump within the last 4 years (Exception: your pump is malfunctioning, not repairable, and not under warranty)
- F. You are on a multiple daily insulin injection regimen and meet ONE of the following:
  - 1. You have a glycosylated hemoglobin level (HbA1c: measure of how well controlled your blood sugar has been over a period of about 3 months) greater than 7 percent
  - 2. You have a history of recurring hypoglycemia (low blood sugar)
  - 3. You have wide fluctuations in blood sugar before mealtime
  - 4. You experience the dawn phenomenon (abnormal early morning increase in blood sugar, usually between 2 a.m. and 8 a.m.) with fasting blood glucose levels frequently exceeding 200 mg/dL
  - 5. You have a history of severe glycemic excursions (sudden spikes in blood sugar levels)
- G. **If you are requesting the T: Slim X2 OR T: Slim X2 with Basal-IQ, approval also requires:**
  - 1. You are 6 years of age or older
- H. **If you are requesting the T: Slim X2 with Control-IQ, approval also requires:**
  - 1. You are 6 years of age or older
- I. **If you are requesting the MiniMed 670G, approval also requires:**
  - 1. You have type 1 diabetes mellitus (a disorder with high blood sugar)
  - 2. You are 7 years of age or older
- J. **If you are requesting the MiniMed 770G, approval also requires:**
  - 1. You have type 1 diabetes mellitus (a disorder with high blood sugar)
  - 2. You are 2 years of age or older

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different product or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**T: SLIM/MINIMED INSULIN PUMPS**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for the related insulin pumps.

**REFERENCES**

- T: Slim FreeStyle Libre Flash Glucose Monitoring System. Abbott Laboratories. Indications and Safety Information. Available at: <https://www.freestylelibre.us/safety-information>
- MiniMed 670G System. Medtronic. Important Safety Information. Available at: <https://www.medtronicdiabetes.com/important-safety-information#minimed-670g>
- MiniMed 770G System. Medtronic. Important Safety Information. Available at: <https://www.medtronicdiabetes.com/important-safety-information#minimed-770g>

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/01/22

Created: 08/20

Client Approval: 09/22

P&T Approval: 07/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TUCATINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TUCATINIB	TUKYSA	46459		GPI-10 (2117008000)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of advanced unresectable or metastatic HER2-positive breast cancer and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient has received one or more prior anti-HER2-based regimens (i.e., trastuzumab or trastuzumab with pertuzumab) in the metastatic setting
- The requested medication will be used in combination with trastuzumab and capecitabine

If yes, **approve for 12 months by GPID or GPI-14 for the requested strength with the following quantity limits:**

- **50mg: #10 per day.**
- **150mg: #4 per day.**

If no, continue to #2.

2. Does the patient have a diagnosis of RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient's cancer has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy
- The requested medication will be used in combination with trastuzumab

If yes, **approve for 12 months by GPID or GPI-14 for the requested strength with the following quantity limits:**

- **50mg: #10 per day.**
- **150mg: #4 per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **TUCATINIB (Tukysa)** requires the following rule(s) be met for approval:

A. You have **ONE** of the following diagnoses:

1. Advanced unresectable (cannot be removed with surgery) or metastatic (disease that has spread to other parts of the body) human epidermal growth factor receptor 2 (HER2: type of protein)-positive breast cancer
2. RAS wild-type (a type of gene), HER2-positive unresectable or metastatic colorectal cancer (a type of digestive cancer)

***(Denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TUCATINIB

GUIDELINES FOR USE (CONTINUED)

- B. **If you have advanced unresectable or metastatic HER2-positive breast cancer, approval also requires:**
  1. You are 18 years of age or older
  2. You have received one or more prior anti-HER2-based treatment (specifically either trastuzumab or trastuzumab with pertuzumab) for metastatic disease
  3. The requested medication will be used in combination with trastuzumab and capecitabine
- C. **If you have RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer, approval also requires:**
  1. You are 18 years of age or older
  2. Your cancer has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy (drugs used to treat cancer)
  3. The requested medication will be used in combination with trastuzumab

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Tukysa.

**REFERENCES**

- Tukysa [Prescribing Information]. Bothell, WA: Seattle Genetics, Inc.; January 2023.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 02/06/23

Created: 08/20

Client Approval: 01/23

P&T Approval: 04/23



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

UBROGEPANT

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
UBROGEPANT	UBRELVY	46273		GPI-10 (6770108000)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Is the request for the acute treatment of migraine and the patient meets **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient has a trial of or contraindication to ONE triptan (e.g., sumatriptan, rizatriptan)

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #16 per 30 days.**

**APPROVAL TEXT:** Renewal requires that the request is for acute treatment of migraines and the patient has experienced an improvement from baseline in a validated acute treatment patient-reported outcome questionnaire (e.g., Migraine Assessment of Current Therapy [Migraine-ACT]) OR the patient has experienced clinical improvement as defined by ONE of the following: 1) ability to function normally within 2 hours of dose, 2) headache pain disappears within 2 hours of dose, or 3) therapy works consistently in majority of migraine attacks.

If no, do not approve.

**INITIAL DENIAL TEXT:** **\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **UBROGEPANT (Ubrelyvy)** requires the following rule(s) be met for approval:

- A. You are being treated for acute (quick onset) migraine
- B. You are 18 years of age or older
- C. You have previously tried ONE triptan (such as sumatriptan, rizatriptan), unless there is a medical reason why you cannot (contraindication)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

UBROGEPANT

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Is the request for the acute treatment of migraine and the patient meets **ONE** of the following criteria?
  - The patient has experienced an improvement from baseline in a validated acute treatment patient-reported outcome questionnaire (e.g., Migraine Assessment of Current Therapy [Migraine-ACT])
  - The patient has experienced clinical improvement as defined by **ONE** of the following:
    - Ability to function normally within 2 hours of dose
    - Headache pain disappears within 2 hours of dose
    - Therapy works consistently in majority of migraine attacks

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #16 per 30 days.**  
If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **UBROGEPANT (Ubrovelvy)** requires the following rule(s) be met for approval:

- A. You are being treated for acute (quick onset) migraine
- B. You meet ONE of the following:
  1. You have experienced an improvement from baseline in a validated acute treatment patient-reported outcome questionnaire (assessment tool used to help guide treatment such as migraine assessment of current therapy [MIGRAINE-ACT])
  2. You have experienced clinical improvement as defined by ONE of the following:
    - a. Ability to function normally within 2 hours of dose
    - b. Headache pain disappears within 2 hours of dose
    - c. Treatment works consistently in majority of migraine attacks

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**UBROGEPANT**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Ubrelvy.

**REFERENCES**

- Ubrelvy [Prescribing Information]. Madison, NJ: Allergan; June 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/21

Created: 01/20

Client Approval: 11/20

P&T Approval: 10/19



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

UPADACITINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
UPADACITINIB	RINVOQ	45955		GPI-10 (6660307200)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a rheumatologist
  - The patient had a trial of or contraindication to 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drugs), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
  - The patient had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers (e.g., Humira, Enbrel)

If yes, **approve Rinvoq 15mg for 6 months by GPID or GPI-14 with a quantity limit of #1 per day.**

If no, continue to #2.

2. Does the patient have a diagnosis of psoriatic arthritis (PsA) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a rheumatologist or dermatologist
  - The patient had a trial of or contraindication to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
  - The patient had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers (e.g., Humira, Enbrel)

If yes, **approve Rinvoq 15mg for 6 months by GPID or GPI-14 with a quantity limit of #1 per day.**

If no, continue to #3.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

UPADACITINIB

INITIAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of moderate to severe atopic dermatitis and meet **ALL** of the following criteria?
- The patient is 12 years of age or older
  - Therapy is prescribed by or in consultation with a dermatologist, allergist, or immunologist
  - The patient has atopic dermatitis involving at least 10% of body surface area (BSA) OR atopic dermatitis affecting the face, head, neck, hands, feet, groin, or intertriginous areas
  - The patient has at least TWO of the following: intractable pruritus, cracking and oozing/bleeding of affected skin, impaired activities of daily living
  - Rinvoq will NOT be used concurrently with other systemic biologics (e.g., Adbry, Dupixent) or any JAK inhibitors (e.g., topical Opzelura, Cibinqo) for the treatment of atopic dermatitis

If yes, continue to #4.

If no, continue to #5.

4. Does the patient have a trial of or contraindication to **ONE** of the following?
- Topical corticosteroid (e.g., hydrocortisone, clobetasol, halobetasol propionate)
  - Topical calcineurin inhibitor [e.g., Elidel (pimecrolimus), Protopic (tacrolimus)]
  - Topical PDE-4 inhibitor [e.g., Eucrisa (crisaborole)]
  - Topical JAK inhibitor [e.g., Opzelura (ruxolitinib)]
  - Phototherapy

If yes, **approve for 6 months by GPID or GPI-14 for all strengths as follows:**

- **Rinvoq 15mg: #1 per day.**
- **Rinvoq 30mg: #1 per day.**

If no, do not approve.

**DENIAL TEXT:** See initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

UPADACITINIB

INITIAL CRITERIA (CONTINUED)

5. Does the patient have a diagnosis of moderate to severe ulcerative colitis (UC) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- Therapy is prescribed or in consultation with a gastroenterologist
- The patient had a trial of or contraindication to ONE conventional therapy (e.g., corticosteroids [e.g., budesonide, methylprednisolone], azathioprine, mercaptopurine, methotrexate, mesalamine)
- The patient had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers (e.g., Humira)

If yes, **approve for a total of 6 months by GPID or GPI-14 as follows:**

- **FIRST APPROVAL: Approve Rinvoq 45mg for 8 weeks with a quantity limit of #1 per day.**
- **SECOND APPROVAL: Approve Rinvoq 15mg and Rinvoq 30mg for 4 months with a quantity limit of #1 per day. (Please enter start date of 2 days before the end date of the first approval).**

If no, continue to #6.

6. Does the patient have a diagnosis of ankylosing spondylitis (AS) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- Therapy is prescribed by or in consultation with a rheumatologist
- The patient had a trial of or contraindication to an NSAID (e.g., ibuprofen, naproxen, meloxicam)
- The patient had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers (e.g., Humira, Enbrel)

If yes, **approve Rinvoq 15mg for 6 months by GPID or GPI-14 with a quantity limit of #1 per day.**

If no, continue to #7.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

UPADACITINIB

INITIAL CRITERIA (CONTINUED)

7. Does the patient have a diagnosis of non-radiographic axial spondyloarthritis (nr-axSpA) and meet **ALL** of the following criteria?
- The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a rheumatologist
  - The patient had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers (e.g., Cimzia)
  - The patient had a trial of or contraindication to an NSAID (e.g., ibuprofen, naproxen, meloxicam)
  - The patient meets **ONE** of the following objective signs of inflammation:
    - C-reactive protein (CRP) levels above the upper limit of normal
    - Sacroiliitis on magnetic resonance imaging (MRI)

If yes, **approve Rinvoq 15mg for 6 months by GPID or GPI-14 with a quantity limit of #1 per day.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **UPADACITINIB (Rinvoq)** requires the following rule(s) be met for approval:

- A. You have **ONE** of the following diagnoses:
1. Moderate to severe rheumatoid arthritis (RA: type of joint condition)
  2. Psoriatic arthritis (PsA: type of skin and joint condition)
  3. Moderate to severe atopic dermatitis (a type of skin condition)
  4. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
  5. Ankylosing spondylitis (AS: a type of joint condition)
  6. Non-radiographic axial spondyloarthritis (NR-axSpA: a type of joint condition)
- B. **If you have moderate to severe rheumatoid arthritis, approval also requires:**
1. You are 18 years of age or older
  2. Therapy is prescribed by or in consultation with a rheumatologist (type of immune system doctor)
  3. You have tried or have a contraindication (harmful for) to 3 months of treatment with **ONE** DMARD (disease-modifying antirheumatic drugs), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
  4. You had an inadequate response (drug did not work) or intolerance (side effect) to one or more tumor necrosis factor (TNF) blockers (such as Humira, Enbrel)

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

UPADACITINIB

INITIAL CRITERIA (CONTINUED)

**C. If you have psoriatic arthritis, approval also requires:**

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (skin doctor)
3. You have tried or have a contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
4. You had an inadequate response (drug did not work) or intolerance (side effect) to one or more tumor necrosis factor (TNF) blockers (such as Humira, Enbrel)

**D. If you have moderate to severe atopic dermatitis, approval also requires:**

1. You are 12 years of age or older
2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor), allergist (a type of allergy doctor), or immunologist (a type of immune system doctor)
3. You have atopic dermatitis involving at least 10% of body surface area (BSA) OR atopic dermatitis affecting the face, head, neck, hands, feet, groin, or intertriginous areas (between skin folds, the hands, feet, etc.)
4. You have at least TWO of the following: intractable pruritus (severe itching), cracking and oozing/bleeding of affected skin, impaired activities of daily living
5. You had a trial of or contraindication (harmful for) to ONE of the following: topical corticosteroid (such as hydrocortisone, clobetasol, halobetasol propionate), topical calcineurin inhibitor (such as Elidel [pimecrolimus], Protopic [tacrolimus]), topical PDE-4 inhibitor (such as Eucrisa [crisaborole]), topical JAK inhibitor (such as Opzelura [ruxolitinib]), phototherapy (light therapy)
6. You will NOT use Rinvoq concurrently (at the same time) with other systemic biologics (such as Adbry, Dupixent) or any JAK inhibitors (such as topical Opzelura, Cibinqo) for the treatment of atopic dermatitis

**E. If you have moderate to severe ulcerative colitis, approval also requires:**

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
3. You had a trial of or contraindication (harmful for) to ONE standard therapy, such as corticosteroids (such as budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine
4. You had an inadequate response (drug did not work) or intolerance (side effect) to one or more tumor necrosis factor (TNF) blockers (such as Humira)

*(Initial denial text continued on next page)*

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

UPADACITINIB

INITIAL CRITERIA (CONTINUED)

F. **If you have ankylosing spondylitis, approval also requires:**

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (type of immune system doctor)
3. You had a trial of or contraindication (harmful for) to an NSAID (nonsteroidal anti-inflammatory drug, such as ibuprofen, naproxen, meloxicam)
4. You had an inadequate response (drug did not work) or intolerance (side effect) to one or more tumor necrosis factor (TNF) blockers (such as Humira, Enbrel)

G. **If you have non-radiographic axial spondyloarthritis, approval also requires:**

6. You are 18 years of age or older
7. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
8. You had an inadequate response (drug did not work) or intolerance (side effect) to at least ONE tumor necrosis factor (TNF) blockers (such as Cimzia)
9. You had a trial of or contraindication (harmful for) to an NSAID (non-steroidal anti-inflammatory drug: such as ibuprofen, naproxen, meloxicam)
10. You have ONE of the following signs of inflammation:
  - a. C-reactive protein (CRP: a measure of how much inflammation you have) levels above the upper limit of normal
  - b. Sacroiliitis (type of inflammation where lower spine and pelvis connect) on magnetic resonance imaging (MRI: type of imaging lab)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) OR psoriatic arthritis (PsA) **AND** meet the following criterion?
  - The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

If yes, **approve Rinvoq 15mg for 12 months by GPID or GPI-14 with a quantity limit of #1 per day.**

If no, continue to #2.

CONTINUED ON NEXT PAGE





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

UPADACITINIB

RENEWAL CRITERIA (CONTINUED)

2. Does the patient have a diagnosis of moderate to severe atopic dermatitis and meet **ALL** of the following criteria?

- The patient has shown improvement while on therapy
- Rinvoq will NOT be used concurrently with other systemic biologics (e.g., Adbry, Dupixent) or any JAK inhibitors (e.g., topical Opzelura, Cibinqo) for the treatment of atopic dermatitis

If yes, **approve for 12 months by GPID or GPI-14 for all strengths as follows:**

- **Rinvoq 15mg: #1 per day.**
- **Rinvoq 30mg: #1 per day.**

If no, continue to #3.

3. Does the patient have a diagnosis of moderate to severe ulcerative colitis (UC)?

If yes, **approve for 12 months by GPID or GPI-14 for all strengths as follows:**

- **Rinvoq 15mg: #1 per day.**
- **Rinvoq 30mg: #1 per day.**

If no, continue to #4.

4. Does the patient have a diagnosis of ankylosing spondylitis (AS) or non-radiographic axial spondyloarthritis (nr-axSpA) **AND** meet the following criterion?

- The patient has experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score while on therapy

If yes, **approve Rinvoq 15mg for 12 months by GPID or GPI-14 with a quantity limit of #1 per day.**

If no, do not approve.

**DENIAL TEXT:** See renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

UPADACITINIB

RENEWAL CRITERIA (CONTINUED)

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **UPADACITINIB (Rinvoq)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following diagnoses:
1. Moderate to severe rheumatoid arthritis (RA: type of joint condition)
  2. Psoriatic arthritis (PsA: a type of skin and joint condition)
  3. Moderate to severe atopic dermatitis (a type of skin condition)
  4. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
  5. Ankylosing spondylitis (AS: a type of joint condition)
  6. Non-radiographic axial spondyloarthritis (NR-axSpA: a type of joint condition)
- B. **If you have moderate to severe rheumatoid arthritis or psoriatic arthritis, renewal also requires:**
1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
- C. **If you have moderate to severe atopic dermatitis, renewal also requires:**
1. You have shown improvement while on therapy
  2. You will NOT use Rinvoq concurrently (at the same time) with other systemic biologics (such as Adbry, Dupixent) or any JAK inhibitors (such as topical Opzelura, Cibinqo) for the treatment of atopic dermatitis
- D. **If you have ankylosing spondylitis or non-radiographic axial spondyloarthritis, renewal also requires:**
1. You have experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI: diagnostic test which allows a physician to determine the effectiveness of a current medication) score while on therapy

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Rinvoq.

**REFERENCES**

- Rinvoq [Prescribing Information]. North Chicago, IL: AbbVie Inc., October 2022.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**UPADACITINIB**

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/21/22

Created: 08/19

Client Approval: 11/22

P&T Approval: 07/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

URIDINE TRIACETATE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
URIDINE TRIACETATE	XURIDEN		39481	GPI-10 (3090387520)	

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a documented diagnosis of hereditary orotic aciduria as confirmed by **ALL** of the following criteria?
  - Presence of a mutation in the uridine monophosphate synthase (UMPS) gene
  - Patient has an elevated urinary orotic acid level according to an age-specific reference range

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at end of the guideline.

2. Is the medication prescribed by or given in consultation with a prescriber specializing in inherited metabolic diseases?

If yes, **approve for 6 months by GPID or GPI-10 up to #4 packets per day.**

**APPROVAL TEXT:** Renewal requires that the patient's age dependent hematologic parameters (e.g., neutrophil count, neutrophil percent, white blood cell count, mean corpuscular volume) have stabilized or improved from baseline while on treatment with uridine triacetate.

If no, do not approve.

**INITIAL DENIAL TEXT:** **\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **URIDINE TRIACETATE (Xuriden)** requires the following rule(s) be met for approval:

- A. You have hereditary orotic aciduria (HOA: genetic disease where you do not have a type of protein to make a chemical)
- B. Your diagnosis is confirmed by ALL of the following:
  1. Presence of a mutation in the uridine monophosphate synthase (UMPS) gene
  2. Elevated urinary orotic acid levels according to your age-specific reference range
- C. Therapy is prescribed by or given in consultation with a doctor specializing in inherited metabolic diseases (genetic diseases that result in metabolism problems)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

URIDINE TRIACETATE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

- 1. Has the patient's age dependent hematologic parameters (e.g., neutrophil count, neutrophil percent, white blood cell count, mean corpuscular volume) stabilized or improved from baseline while on treatment with uridine triacetate?

If yes, **approve for 12 months by GPID or GPI-10 up to #4 packets per day.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **URIDINE TRIACETATE (Xuriden)** requires the following rule(s) to be met for renewal:

- A. Your age dependent hematologic parameters (blood lab tests) have stabilized or improved from baseline while on treatment with Xuriden (uridine triacetate).

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Xuriden.

**REFERENCES**

- Xuriden [Prescribing Information]. Gaithersburg, MD: Wellstat Therapeutics Corporation. December 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 09/07/20

Created: 02/16

Client Approval: 08/20

P&T Approval: 05/16



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

URSODIOL

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
URSODIOL	RELTONE, URSODIOL		1073 49115	GPI-14 (52100040000112, 52100040000130)	

**GUIDELINES FOR USE**

- 2 Does the patient have a diagnosis of radiolucent, noncalcified gallbladder stones and meet **ALL** of the following criteria?
- The patient's gallbladder stones are less than 20 mm in greatest diameter
  - Elective cholecystectomy is planned unless the patient is at increased surgical risk due to systemic disease, advanced age, or idiosyncratic reaction to general anesthesia, OR the patient refuses surgery
  - The patient had a trial of generic ursodiol (300mg capsule, 250mg tablet, or 500mg tablet)
  - The patient is unable to take generic ursodiol formulations (300mg capsule, 250mg tablet, or 500mg tablet)

If yes, **approve for 12 months by GPID or GPI-14 for the requested strength.**

If no, do not approve.

**CLINICAL SPECIALIST NOTE:** Use for prevention of gallstone formation in obese patients with rapid weight loss is not covered for this medication.

**DENIAL TEXT:** **\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **URSODIOL (Reltone)** requires the following rule(s) be met for approval:

- A. You have radiolucent, noncalcified gallbladder stones (hardened deposits of bile, that is barely visible on x-ray, in your gallbladder that do not contain calcium)
- B. Your gallbladder stones are less than 20 mm in diameter
- C. You plan to have elective cholecystectomy (surgery to remove gallbladder) unless you are at increased surgical risk due to systemic (entire body) disease, advanced age, or idiosyncratic reaction (an unexpected adverse reaction) to general anesthesia, OR you refuse surgery
- D. You have tried generic ursodiol (300mg capsule, 250mg tablet, or 500mg tablet)
- E. You are unable to take generic ursodiol (300mg capsule, 250mg tablet, or 500mg tablet) formulations

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**URSODIOL**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Reltone.

**REFERENCES**

- Ursodiol 200 mg & 400 mg Capsules [Prescribing Information]. Las Vegas, NV: Intra-Sana Laboratories LLC; February 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/22

Created: 02/21

Client Approval: 03/22

P&T Approval: 01/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

USTEKINUMAB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
USTEKINUMAB	STELARA	36187		GPI-10 (9025058500) (5250407000)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) and meet **ALL** of the following criteria?
  - The patient is 6 years of age or older
  - Therapy is prescribed by or in consultation with a dermatologist
  - The patient has psoriasis covering 3% or more of body surface area (BSA) OR psoriatic lesions affecting the hands, feet, face, or genital area
  - The patient had a trial of or contraindication to ONE or more forms of conventional therapies such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids, calcipotriene, acitretin, methotrexate, or cyclosporine

If yes, enter two approvals for a total of 6 months by GPID or GPI-14 as follows:

- **FIRST APPROVAL:** Approve for 1 month with a quantity limit of 1mL (two 45mg/0.5mL prefilled syringes, two 45mg/0.5mL vials, or one 90mg/mL prefilled syringe) per 28 days for 1 fill.
- **SECOND APPROVAL:** Approve for 5 months with a quantity limit of 1mL (two 45mg/0.5mL prefilled syringes, two 45mg/0.5mL vials, or one 90mg/mL prefilled syringe) per 84 days for 2 fills (Start date is 3 weeks AFTER the start date of the first approval).

If no, continue to #2.

2. Does the patient have a diagnosis of psoriatic arthritis (PsA) and meet **ALL** of the following criteria?
  - The patient is 6 years of age or older
  - Therapy is prescribed by or in consultation with a rheumatologist or dermatologist
  - The patient had a trial of or contraindication to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

If yes, continue to #3.

If no, continue to #4.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

USTEKINUMAB

INITIAL CRITERIA (CONTINUED)

3. Does the patient have coexistent moderate to severe plaque psoriasis (PsO)?

If yes, enter two approvals for a total of 6 months by GPID or GPI-14 as follows:

- **FIRST APPROVAL:** Approve for 1 month with a quantity limit of 1mL (two 45mg/0.5mL prefilled syringes, two 45mg/0.5mL vials, or one 90mg/mL prefilled syringe) per 28 days for 1 fill.
- **SECOND APPROVAL:** Approve for 5 months with a quantity limit of 1mL (two 45mg/0.5mL prefilled syringes, two 45mg/0.5mL vials, or one 90mg/mL prefilled syringe) per 84 days for 2 fills (Start date is 3 weeks AFTER the start date of the first approval).

If no, enter two approvals for a total of 6 months by GPID or GPI-14 as follows:

- **FIRST APPROVAL:** Approve for 1 month with a quantity limit of 0.5mL (one 45mg/0.5mL prefilled syringe or one 45mg/0.5mL vial) per 28 days for 1 fill.
- **SECOND APPROVAL:** Approve for 5 months with a quantity limit of 0.5mL (one 45mg/0.5mL prefilled syringe or one 45mg/0.5mL vial) per 84 days for 2 fills (Start date is 3 weeks AFTER the start date of the first approval).

4. Does the patient have a diagnosis of moderate to severe Crohn's disease (CD) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- Therapy is prescribed by or in consultation with a gastroenterologist
- The patient had a trial of or contraindication to ONE conventional agent, such as corticosteroids (i.e., budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine

If yes, continue to #6.

If no, continue to #5.

5. Does the patient have a diagnosis of moderate to severe active ulcerative colitis (UC) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- Therapy is prescribed by or in consultation with a gastroenterologist
- The patient had a trial of or contraindication to ONE conventional agent, such as corticosteroids (i.e., budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine

If yes, continue to #6.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

USTEKINUMAB

INITIAL CRITERIA (CONTINUED)

6. Does the patient have non-self-administered (NSA) drug benefit coverage?

If yes, continue to #7.

If no, **approve maintenance dose for 6 months by GPID or GPI-14 with a quantity limit of 1mL (two 45mg/0.5mL prefilled syringes, two 45mg/0.5mL vials, or one 90mg/mL prefilled syringe) per 56 days for 3 fills.**

7. Is the prescriber requesting an intravenous infusion induction dose of **Stelara 130mg/26mL**?

If yes, **enter two approvals for a total of 6 months by GPID or GPI-14 as follows:**

- **FIRST APPROVAL (NOTE: Do not enter a loading dose if the member does not have coverage for non-self-administered drug benefit. Please deny for benefit exclusion.): Approve for 2 months by GPID or GPI-14 with a quantity limit of 104mL (four 130mg/26mL vials) per 56 days for 1 fill.**
- **SECOND APPROVAL: Approve for 4 months by GPID or GPI-14 with a quantity limit of 1mL (two 45mg/0.5mL prefilled syringes, two 45mg/0.5mL vials, or one 90mg/mL prefilled syringe) per 56 days for 2 fills (Start date is 7 weeks AFTER the start date of the first approval).**

If no, **approve for 6 months by GPID or GPI-14 with a quantity limit of 1mL (two 45mg/0.5mL prefilled syringes, two 45mg/0.5mL vials, or one 90mg/mL prefilled syringe) per 56 days for 3 fills.**

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **USTEKINUMAB (Stelara)** requires the following rules be met for approval:

A. You have ONE of the following diagnoses:

1. Psoriatic arthritis (PsA: a type of skin and joint condition)
2. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
3. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
4. Moderate to severe active ulcerative colitis (UC: a type of digestive disorder)

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

USTEKINUMAB

INITIAL CRITERIA (CONTINUED)

**B. If you have moderate to severe plaque psoriasis, approval also requires:**

1. You are 6 years of age or older
2. Therapy is prescribed by or in consultation with a dermatologist (type of skin doctor)
3. You have psoriasis covering 3% or more of body surface area (BSA) OR psoriatic lesions (rashes) affecting the hands, feet, genital area, or face
4. You have tried or have a contraindication (harmful for) to ONE or more forms of standard therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids, calcipotriene, acitretin, methotrexate, or cyclosporine

**C. If you have psoriatic arthritis, approval also requires:**

1. You are 6 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (type of immune system doctor) OR dermatologist (type of skin doctor)
3. You have tried or have a contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

**D. If you have moderate to severe Crohn's disease, approval also requires:**

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
3. You have tried or have a contraindication (harmful for) to ONE standard therapy, such as corticosteroids (budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine

**E. If you have moderate to severe active ulcerative colitis, approval also requires:**

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
3. You have tried or have a contraindication (harmful for) to ONE standard therapy, such as corticosteroids (budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

USTEKINUMAB

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of psoriatic arthritis (PsA) **AND** meet the following criterion?
  - The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

If yes, continue to #2.

If no, continue to #3.

2. Does the patient have coexistent moderate to severe plaque psoriasis (PsO)?

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of 1mL (two 45mg/0.5mL prefilled syringes, two 45mg/0.5mL vials, or one 90mg/mL prefilled syringe) per 84 days.**

If no, **approve for 12 months by GPID or GPI-14 with a quantity limit of 0.5mL (one 45mg/0.5mL prefilled syringe or one 45mg/0.5mL vial) per 84 days.**

3. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) **AND** meet the following criterion?
  - The patient has achieved or maintained clear or minimal disease OR a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of 1mL (two 45mg/0.5mL prefilled syringes, two 45mg/0.5mL vials, or one 90mg/mL prefilled syringe) per 84 days.**

If no, continue to #4.

4. Does the patient have a diagnosis of moderate to severe Crohn's disease (CD)?

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of 1mL (two 45mg/0.5mL prefilled syringes, two 45mg/0.5mL vials, or one 90mg/mL prefilled syringe) per 56 days.**

If no, continue to #5.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

USTEKINUMAB

RENEWAL CRITERIA (CONTINUED)

5. Does the patient have a diagnosis of moderate to severe ulcerative colitis (UC)?

If yes, approve for 12 months by GPID or GPI-14 with a quantity limit of 1mL (two 45mg/0.5mL prefilled syringes, two 45mg/0.5mL vials, or one 90mg/mL prefilled syringe) per 56 days.

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **USTEKINUMAB (Stelara)** requires the following rules be met for renewal:

A. You have ONE of the following diagnoses:

1. Psoriatic arthritis (PsA: a type of skin and joint condition)
2. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
3. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
4. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)

B. **If you have psoriatic arthritis, renewal also requires:**

1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

C. **If you have moderate to severe plaque psoriasis, renewal also requires:**

1. You have achieved or maintained clear or minimal disease OR a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Stelara.

**REFERENCES**

- Stelara [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. July 2022.

Library	Commercial	NSA
Yes	Yes	Yes

Part D Effective: N/A

Commercial Effective: 04/01/23

Created: 10/09

Client Approval: 02/23

P&T Approval: 10/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

VALBENAZINE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
VALBENAZINE TOSYLATE	INGREZZA	44202		GPI-10 (6238008020)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of moderate to severe tardive dyskinesia and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with a neurologist, movement disorder specialist, or psychiatrist
  - Moderate to severe tardive dyskinesia has been present for at least 3 months
  - The patient has a prior history of using antipsychotic medications or metoclopramide for at least 3 months (or at least 1 month if patient is 60 years of age or older) as documented in the prescription claims history
  - The patient had a trial of or contraindication to Austedo

If yes, **approve for 12 months by GPID or GPI-14 for all strengths as follows:**

- **Ingrezza 40mg, 60mg, 80mg: #1 per day.**
- **Ingrezza Initiation pack: 1 pack (#28) per fill.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **VALBENAZINE (Ingrezza)** requires the following rule(s) be met for approval:

- A. You have moderate to severe tardive dyskinesia (uncontrolled body movements) AND it has been present for at least 3 months
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor), movement disorder specialist, or psychiatrist (a type of mental health doctor)
- D. You have a history of using antipsychotic medications or metoclopramide for at least 3 months (or at least 1 month if you are 60 years of age or older) as documented in your prescription claims history
- E. You had a trial of or contraindication (harmful for) to Austedo

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

VALBENZINE

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Ingrezza.

**REFERENCES**

- Ingrezza [Prescribing Information]. San Diego, CA. Neurocrine Biosciences, Inc; April 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/22

Created: 04/17

Client Approval: 02/22

P&T Approval: 10/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

**VANDETANIB**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
VANDETANIB	CAPRELSA	37531		GPI-10 (2153308500)	

**GUIDELINES FOR USE**

1. Is the patient currently stable on the requested medication?

If yes, approve for 12 months by GPID or GPI-14 as follows:

- Caprelsa 100mg: #2 per day.
- Caprelsa 300mg: #1 per day.

If no, continue to #2.

2. Does the patient have diagnosis of symptomatic or progressive medullary thyroid cancer with unresectable locally advanced or metastatic disease?

If yes, approve for 12 months by GPID or GPI-14 as follows:

- Caprelsa 100mg: #2 per day.
- Caprelsa 300mg: #1 per day.

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline for **VANDETANIB (Caprelsa)** requires **ONE** of the following rule(s) be met for approval:

- A. You are currently stable on the requested medication
- B. You have symptomatic or progressive medullary thyroid cancer with unresectable locally advanced or metastatic disease (advanced thyroid cancer that cannot be removed with surgery or has spread in body)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**





**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**VANDETANIB**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Caprelsa.

**REFERENCES**

- Caprelsa [Prescribing Information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP. October 2018.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/10/21

Created: 05/11

Client Approval: 03/21

P&T Approval: 11/13



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

VARENICLINE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
VARENICLINE TARTRATE	TYRVAYA		51384	GPI-10 (8628008020)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of dry eye disease and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with an ophthalmologist or optometrist
  - The patient has at least one positive diagnostic test (e.g., tear breakup time, tear film osmolarity, ocular surfacing staining, Schirmer test, etc.)
  - The patient had a trial of or contraindication to ONE ocular lubricant (e.g., carboxymethylcellulose [Refresh, Celluvisc, Thera Tears, Genteal, etc.], polyvinyl alcohol [Liquitears, Refresh Classic, etc.], or wetting agents [Systane, Lacrilube, etc.])
  - The patient had a trial of or contraindication to BOTH of the following preferred agents: Restasis AND Xiidra

If yes, **approve for 6 months by GPID or GPI-10 with a quantity limit of #8.4 mL per 30 days.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **VARENICLINE (Tyrvaya)** requires the following rule(s) be met for approval:

- A. You have dry eye disease
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with an ophthalmologist or optometrist (types of eye doctor)
- D. You have at least one positive diagnostic test (such as tear breakup time, tear film osmolarity, ocular surfacing staining, Schirmer test)
- E. You had a trial of or contraindication to (harmful for) to ONE ocular lubricant (such as carboxymethylcellulose [Refresh, Celluvisc, Thera Tears, Genteal, etc.], polyvinyl alcohol [Liquitears, Refresh Classic], or wetting agents [Systane, Lacrilube])
- F. You had a trial of or contraindication to (harmful for) BOTH of the following preferred agents: Restasis AND Xiidra

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

VARENICLINE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

- Does the patient have a diagnosis of dry eye disease **AND** meet the following criterion?
  - The patient has demonstrated improvement of dry eye disease

If yes, **approve for 12 months by GPID or GPI-10 with a quantity limit of #8.4 mL per 30 days.**

If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **VARENICLINE (Tyrvaya)** requires the following rule(s) be met for renewal:

- You have dry eye disease
- You have demonstrated improvement of dry eye disease

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Tyrvaya.

**REFERENCES**

- Tryvaya [Prescribing Information]. Princeton, NJ: Oyster Point Pharma, Inc., October 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 11/08/21

Created: 10/21

Client Approval: 10/21

P&T Approval: 10/21



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

VEMURAFENIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
VEMURAFENIB	ZELBORAF	37837		GPI-10 (2153208000)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of unresectable or metastatic melanoma and meet **ALL** of the following criteria?
  - The patient has a genetic mutation called BRAF V600E as detected by an FDA-approved test
  - Zelboraf will be used alone or in combination with Cotellic (cobimetinib)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #8 per day.**  
If no, continue to #2.

2. Does the patient have a diagnosis of Erdheim-Chester Disease **AND** meet the following criterion?
  - The patient has a genetic mutation called BRAF V600

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #8 per day.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **VEMURAFENIB (Zelboraf)** requires the following rules be met for approval:

- A. You have ONE of the following diagnoses:
  1. Unresectable or metastatic melanoma (a type of skin cancer that cannot be removed with surgery or has spread to other parts of the body)
  2. Erdheim-Chester Disease (a type of multisystem mutation)
- B. **If you have unresectable or metastatic melanoma, approval also requires:**
  1. You have a BRAF V600E mutation (a type of gene mutation) as detected by a Food and Drug Administration (FDA)-approved test
  2. Zelboraf will be used alone or in combination with Cotellic (cobimetinib)
- C. **If you have Erdheim-Chester Disease, approval also requires:**
  1. You have a BRAF V600 mutation (a type of gene mutation)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**VEMURAFENIB**

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Zelboraf.

**REFERENCES**

- Zelboraf [Prescribing Information]. South San Francisco, CA: Genentech, Inc.; May 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/22

Created: 08/11

Client Approval: 05/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

VENETOCLAX

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
VENETOCLAX	VENCLEXTA	43284		GPI-10 (2147008000)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of chronic lymphocytic leukemia (CLL) **OR** small lymphocytic lymphoma (SLL) and meet the following criterion?

- The patient is 18 years of age or older

If yes, **approve for 12 months for the requested strength by GPID or GPI-14 with the following quantity limits:**

- **Venclexta Starting pack: #42 (1 pack) per 28 days.**
- **Venclexta 10mg: #2 per day.**
- **Venclexta 50mg: #1 per day.**
- **Venclexta 100mg: #4 per day.**

If no, continue to #2.

2. Does the patient have newly-diagnosed acute myeloid leukemia (AML) and meet **ALL** of the following criteria?

- The patient is 75 years of age or older, **OR** the patient is 18 years of age or older with comorbidities that preclude the use of intensive induction chemotherapy
- The requested medication will be used in combination with azacitidine or decitabine

If yes, **approve for 12 months for the requested strength by GPID or GPI-14 with the following quantity limits:**

- **Venclexta 10mg: #2 per day.**
- **Venclexta 50mg: #1 per day.**
- **Venclexta 100mg: #4 per day.**

If no, continue to #3.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

VENETOCLAX

GUIDELINES FOR USE (CONTINUED)

3. Does the patient have newly-diagnosed acute myeloid leukemia (AML) and meet **ALL** of the following criteria?

- The patient is 75 years of age or older, **OR** the patient is 18 years of age or older with comorbidities that preclude the use of intensive induction chemotherapy
- The requested medication will be used in combination with low-dose cytarabine

If yes, **approve for 12 months for the requested strength by GPID or GPI-14 with the following quantity limits:**

- Venclexta 10mg: #2 per day.
- Venclexta 50mg: #1 per day.
- Venclexta 100mg: #6 per day.

If no, do not approve.

**DENIAL TEXT:** **\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **VENETOCLAX (Venclexta)** requires that the following rules are met for approval:

- A. You have **ONE** of the following diagnoses:
1. Chronic lymphocytic leukemia (CLL: type of blood and bone marrow cancer), small lymphocytic lymphoma (SLL: type of immune system cancer)
  2. Newly-diagnosed acute myeloid leukemia (AML: type of blood and bone marrow cancer with too many undeveloped white blood cells)
- B. **If you have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), approval also requires:**
1. You are 18 years of age or older
- C. **If you have newly-diagnosed acute myeloid leukemia (AML), approval also requires:**
1. You are 75 years of age or older, **OR** you are 18 years of age or older with comorbidities (additional diseases) that preclude (prevent) the use of intensive induction chemotherapy
  2. The requested medication will be used in combination with azacitidine or decitabine or low-dose cytarabine

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**VENETOCLAX**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Venclexta.

**REFERENCES**

10. Venclexta [Prescribing Information]. North Chicago, IL: AbbVie Inc.; July 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/20

Created: 11/16

Client Approval: 04/20

P&T Approval: 07/19





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

VERICIGUAT

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
VERICIGUAT	VERQUVO	47075		GPI-10 (4090008500)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of chronic heart failure and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient has an ejection fraction of less than 45%
  - The patient is **NOT** concurrently taking long-acting nitrates or nitric oxide donors (e.g. isosorbide dinitrate, isosorbide mononitrate, transdermal nitroglycerin), riociguat, or PDE-5 inhibitors (e.g. vardenafil, tadalafil)

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Does the patient meet **ALL** of the following criteria?
  - The patient had a trial of or contraindication to **ONE** of the following preferred SGLT-2 inhibitors: Farxiga, Xigduo XR, Jardiance, Synjardy
  - The patient had a trial of or contraindication to **ONE** agent from **EACH** of the following classes:
    - ACE inhibitor (e.g., enalapril, lisinopril), ARB (e.g., valsartan, candesartan), or angiotensin receptor-neprilysin inhibitor [ARNI] (e.g., sacubitril/valsartan)
    - Beta-blocker (bisoprolol, carvedilol, metoprolol succinate)
    - Aldosterone antagonists (spironolactone or eplerenone)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **VERICIGUAT (Verquvo)** requires the following rule(s) be met for approval:

- A. You have chronic heart failure
  - B. You have an ejection fraction (measurement of how well your heart pumps out blood with each heartbeat) of less than 45%
  - C. You are 18 years of age or older
- (Initial denial text continued on next page)**

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

VERICIGUAT

INITIAL CRITERIA (CONTINUED)

- D. You will not be taking Verquvo together with long-acting nitrates or nitric oxide donors (such as isosorbide dinitrate, isosorbide mononitrate, transdermal nitroglycerin), riociguat, or PDE-5 inhibitors (such as vardenafil, tadalafil)
- E. You have previously tried ONE of the following sodium-glucose transporter-2 inhibitors (SGLT-2 inhibitors: class of drugs) unless there is a medical reason why you cannot (contraindication): Farxiga, Xigduo XR, Jardiance, Synjardy
- F. You have previously tried ONE agent from EACH of the following classes unless there is a medical reason why you cannot (contraindication):
  - 1. Angiotensin converting enzyme (ACE) inhibitors (such as enalapril, lisinopril), angiotensin II receptor blockers (ARB: such as valsartan, candesartan), or angiotensin receptor-neprilysin inhibitor (ARNI: such as sacubitril/valsartan)
  - 2. Beta-blocker (bisoprolol, carvedilol, metoprolol succinate)
  - 3. Aldosterone antagonists (spironolactone or eplerenone)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

- 1. Does the patient have a diagnosis of chronic heart failure and meet **ALL** of the following criteria?
  - The patient has an ejection fraction of less than 45%
  - The patient is **NOT** concurrently taking long-acting nitrates or nitric oxide donors (e.g. isosorbide dinitrate, isosorbide mononitrate, transdermal nitroglycerin), riociguat, or PDE-5 inhibitors (e.g. vardenafil, tadalafil)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**  
If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **VERICIGUAT (Verquvo)** requires the following rule(s) be met for renewal:

- A. You have chronic heart failure
- B. You have an ejection fraction (measurement of how well your heart pumps out blood with each heartbeat) of less than 45%

**(Renewal denial text continued on next page)**

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

VERICIGUAT

RENEWAL CRITERIA (CONTINUED)

- C. You will not be taking Verquvo together with long-acting nitrates or nitric oxide donors (such as isosorbide dinitrate, isosorbide mononitrate, transdermal nitroglycerin), riociguat, or PDE-5 inhibitors (such as vardenafil, tadalafil)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Verquvo.

REFERENCES

- Verquvo [Prescribing Information]. Whitehouse Station, NJ: Merck & Co., Inc.; January 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 02/15/21

Created: 02/21

Client Approval: 02/21

P&T Approval: 10/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

VIGABATRIN

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
VIGABATRIN	SABRIL, VIGABATRIN, VIGADRONE	07377		GPI-10 (7217008500)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of refractory complex partial seizures (CPS) and meet **ALL** of the following criteria?
  - The patient is 2 years of age or older
  - Therapy is prescribed by or in consultation with a neurologist
  - The requested medication will be used as adjunctive therapy
  - The benefits outweigh the potential for vision loss
  - The patient had a trial of or contraindication to THREE antiepileptic medications, at least two of which must be generic (e.g., carbamazepine, divalproex/valproic acid, oxcarbazepine, levetiracetam IR/ER, gabapentin, zonisamide, topiramate, lamotrigine)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #6 per day.**  
If no, continue to #2.

2. Does the patient have a diagnosis of infantile spasms and meet **ALL** of the following criteria?
  - The patient is 1 month to 2 years of age
  - Therapy is prescribed by or in consultation with a neurologist
  - The requested medication will be used as monotherapy
  - The benefits outweigh the potential for vision loss

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #6 per day.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **VIGABATRIN (Sabril)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
    1. Refractory complex partial seizures (a type of seizure)
    2. Infantile spasms (a type of seizure disorder in infancy and childhood)
- (Denial text continued on the next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

VIGABATRIN

GUIDELINES FOR USE (CONTINUED)

**B. If you have refractory complex partial seizures, approval also requires:**

1. You are 2 years of age or older
2. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor)
3. The requested medication will be used as adjunctive (add-on) therapy
4. Your benefits outweigh the potential for vision loss
5. You had a trial of or contraindication (harmful for) to THREE antiepileptic medications, at least two of which must be generic (seizure drugs such as carbamazepine, divalproex/valproic acid, oxcarbazepine, levetiracetam immediate-release/extended-release, gabapentin, zonisamide, topiramate, lamotrigine)

**C. If you have infantile spasms, approval also requires:**

1. You are 1 month to 2 years of age
2. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor)
3. The requested medication will be used as monotherapy (one drug for treatment)
4. Your benefits outweigh the potential for vision loss

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Sabril.

**REFERENCES**

- Sabril [Prescribing Information]. Deerfield, IL: Lundbeck, October 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/22

Created: 05/22

Client Approval: 05/22

P&T Approval: 04/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

VISMODEGIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
VISMODEGIB	ERIVEDGE	38455		GPI-10 (2137007000)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of metastatic basal cell carcinoma **AND** meet the following criterion?

- The patient is 18 years of age or older

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**  
If no, continue to #2.

2. Does the patient have a diagnosis of locally advanced basal cell carcinoma and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient's cancer has recurred following surgery or the patient is not a candidate for surgery or radiation

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **VISMODEGIB (Erivedge)** requires the following rule(s) be met for approval:

- A. You have metastatic basal cell carcinoma or locally advanced basal cell carcinoma (type of skin cancer that has spread in the body or is advanced but has not spread)
- B. You are 18 years of age or older
- C. **If you have locally advanced basal cell carcinoma, approval also requires:**
  - 1. Your cancer has returned after surgery OR you are not a candidate for surgery or radiation

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**VISMODEGIB**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Erivedge.

**REFERENCES**

- Erivedge [Prescribing Information]. South San Francisco, CA: Genentech, Inc., July 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/22

Created: 02/12

Client Approval: 12/21

P&T Approval: 01/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

VOCLOSPORIN

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
VOCLOSPORIN	LUPKYNIS	47077		GPI-10 (9940208000)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of active lupus nephritis (LN) and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or given in consultation with a rheumatologist or nephrologist
  - The requested medication will be used in combination with a background immunosuppressive therapy regimen (e.g., mycophenolate mofetil, corticosteroids)

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #6 per day.**

**APPROVAL TEXT:** Renewal requires improvement in renal response from baseline laboratory values (eGFR or proteinuria) and/or clinical parameters (e.g., fluid retention, use of rescue drugs, glucocorticoid use).

If no, do not approve.

**INITIAL DENIAL TEXT:** **\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **VOCLOSPORIN (Lupkynis)** requires the following rule(s) be met for approval:

- A. You have active lupus nephritis (LN: inflammation of the kidneys caused by lupus when the immune system attacks its own tissues)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or given in consultation with a rheumatologist (doctor who specializes in conditions that affect the muscles and skeletal system, especially the joints) or nephrologist (doctor who specializes in the kidney)
- D. The requested medication will be used in combination with a background immunosuppressive therapy regimen (such as mycophenolate mofetil, corticosteroids)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

VOCLOSPORIN

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

- Does the patient have a diagnosis of active lupus nephritis (LN) **AND** meet the following criterion?
  - The patient has improvement in renal response from baseline laboratory values (i.e., eGFR or proteinuria) and/or clinical parameters (e.g., fluid retention, use of rescue drugs, glucocorticoid use)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #6 per day.**  
If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **VOCLOSPORIN (Lupkynis)** requires the following rule(s) be met for renewal:

- You have active lupus nephritis (LN: inflammation of the kidneys caused by lupus when the immune system attacks its own tissues)
- You have improvement in renal response from baseline laboratory values (eGFR [measurement of kidney function] or proteinuria [level of protein in urine]) and/or clinical parameters (such as fluid retention, use of rescue drugs, glucocorticoid use)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Lupkynis.

**REFERENCES**

- Lupkynis [Prescribing Information]. Victoria, BC: Aurinia Pharmaceuticals Inc.; January 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 02/15/21

Created: 02/21

Client Approval: 02/21

P&T Approval: 10/20



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

VONOPRAZAN

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
VONOPRAZAN/AMOXICILLIN	VOQUEZNA DUAL PAK	47981		GPI-10 (4999320220)	
VONOPRAZAN/AMOXICILLIN /CLARITH	VOQUEZNA TRIPLE PAK	47983		GPI-10 (4999320320)	

**GUIDELINES FOR USE**

1. Is the patient being treated for *Helicobacter pylori* (*H. pylori*) infection and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient had a trial of or contraindication to a bismuth-based quadruple regimen (i.e., bismuth/tetracycline/metronidazole plus PPI [e.g., omeprazole, lansoprazole])

If yes, **approve for 30 days by HICL or GPI-10 with a quantity limit of #112 per 14 days for 1 fill.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **VONOPRAZAN (Voquezna)** requires the following rule(s) be met for approval:

- A. You are being treated for *Helicobacter pylori* (*H. pylori*: a type of bacteria) infection
- B. You are 18 years of age or older
- C. You had a trial of or contraindication (harmful for) to a bismuth-based quadruple regimen (bismuth/tetracycline/metronidazole plus proton pump inhibitor [PPI, such as omeprazole, lansoprazole])

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Voquezna.

**REFERENCES**

- Voquezna [Prescribing Information]. Buffalo Grove, IL: Phathom Pharmaceuticals, Inc.; May 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 06/15/22

Created: 06/22

Client Approval: 06/22

P&T Approval: 04/22

Copyright © 2023 MediImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MediImpact. MediImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

VOSORITIDE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
VOSORITIDE	VOXZOGO	47677		GPI-10 (3095008000)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of achondroplasia and meet **ALL** of the following criteria?

- The patient is 5 years of age or older
- The patient has open epiphyses

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 vial per day.**

If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **VOSORITIDE (Voxzogo)** requires the following rule(s) be met for approval:

- A. You have achondroplasia (a type of bone condition)
- B. You are 5 years of age or older
- C. You have open epiphyses (the end part of a long bone)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Voxzogo.

**REFERENCES**

- Voxzogo [Prescribing Information]. Novato, CA: BioMarin Pharmaceutical, Inc.; November 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/22

Created: 01/22

Client Approval: 02/22

P&T Approval: 01/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

VOXELOTOR

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
VOXELOTOR	OXBRYTA	46225		GPI-10 (8280508000)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of sickle cell disease and meet **ALL** of the following criteria?
  - The patient is 4 years of age or older
  - The patient has a hemoglobin of less than 10.5 g/dL
  - Therapy is prescribed by or in consultation with a hematologist
  - The patient is having symptoms of anemia which are interfering with activities of daily living
  - The patient had a trial of or contraindication to hydroxyurea

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Is the request for the 300 mg tablet for oral suspension **AND** the patient weighs less than 40 kg?

If yes, **approve 300mg tablets for oral suspension for 6 months by GPID or GPI-14 with a quantity limit of #5 per day.**

If no, continue to #3.

3. Is the request for the 300 mg tablet for oral suspension and the patient meets **ALL** of the following criteria?
  - The patient weighs 40 kg or more
  - The patient has tried or has a contraindication to Oxbryta 500mg tablets
  - The patient is unable to swallow Oxbryta 500mg tablets

If yes, **approve 300mg tablets for oral suspension for 6 months by GPID or GPI-14 with a quantity limit of #5 per day.**

If no, **approve for 6 months by GPID or GPI-14 as follow:**

- **500mg tablets: #3 per day.**
- **300mg tablets: #3 per day.**

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

VOXELOTOR

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **VOXELOTOR (Oxbryta)** requires the following rule(s) be met for approval:

- A. You have sickle cell disease (a type of blood disorder)
- B. You are 4 years of age or older
- C. Your hemoglobin (a type of blood cell) is less than 10.5 g/dL
- D. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor)
- E. You are having symptoms of anemia (a type of blood condition) which are interfering with activities of daily living
- F. You had a trial of or contraindication (harmful for) to hydroxyurea
- G. **If the request is for the 300 mg tablets for oral suspension, approval also requires ONE of the following:**
  1. You weigh less than 40 kilograms
  2. You weigh 40 kilograms or more and meet ALL of the following:
    - a. You have tried or have a contraindication (harmful for) to Oxbryta 500mg tablets
    - b. You are unable to swallow Oxbryta 500mg tablets

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of sickle cell disease **AND** meet the following criterion?
  - The patient has maintained an improvement in symptoms associated with anemia

If yes, **approve for 12 months by GPID or GPI-14 for the requested strength with the following quantity limits:**

- **500mg tablets: #3 per day.**
- **300mg tablets: #3 per day.**
- **300mg tablets for oral suspension: #5 per day.**

If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

VOXELOTOR

RENEWAL CRITERIA (CONTINUED)

**RENEWAL DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **VOXELOTOR (Oxbryta)** requires the following rule(s) be met for renewal:

- A. You have sickle cell disease (a type of blood disorder)
- B. You have maintained an improvement in symptoms associated with anemia (a type of blood condition)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Oxbryta.

**REFERENCES**

- Oxbryta [Prescribing Information]. South San Francisco, CA: Global Blood Therapeutics, Inc., October 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/16/23

Created: 02/20

Client Approval: 01/23

P&T Approval: 01/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ZANUBRUTINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ZANUBRUTINIB	BRUKINSA	46212		GPI-10 (2153219500)	

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of mantle cell lymphoma (MCL) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient has received at least ONE prior therapy for mantle cell lymphoma

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**  
If no, continue to #2.

2. Does the patient have a diagnosis of Waldenstrom's macroglobulinemia (WM) **AND** meet the following criterion?

- The patient is 18 years of age or older

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**  
If no, continue to #3.

3. Does the patient have a diagnosis of relapsed or refractory marginal zone lymphoma (MZL) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient has received at least ONE anti-CD20-based regimen

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**  
If no, continue to #4.

4. Does the patient have a diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) **AND** meet the following criterion?

- The patient is 18 years of age or older

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**  
If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ZANUBRUTINIB

GUIDELINES FOR USE (CONTINUED)

**DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **ZANUBRUTINIB (Brukinsa)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
  1. Mantle cell lymphoma (MCL: type of white blood cell cancer)
  2. Waldenstrom's macroglobulinemia (WM: type of blood cancer)
  3. Relapsed or refractory marginal zone lymphoma (MZL: a type of blood cancer)
  4. Chronic lymphocytic leukemia (CLL: a type of blood cancer)
  5. Small lymphocytic lymphoma (SLL: a type of blood cancer)
- B. You are 18 years of age or older
- C. **If you have Mantel cell lymphoma (MCL), approval also requires:**
  1. You have previously received at least ONE prior therapy for mantle cell lymphoma
- D. **If you have relapsed or refractory marginal zone lymphoma (MZL), approval also requires:**
  1. You have received at least ONE anti-CD20-based regimen (a type of blood cancer treatment plan)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Brukinsa.

**REFERENCES**

- Brukinsa [Prescribing Information]. San Mateo, CA: BeiGene USA, Inc.; January 2023.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 02/06/23

Created: 02/20

Client Approval: 01/23

P&T Approval: 01/23





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

ZONISAMIDE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ZONISAMIDE	ZONISADE	21140		GPI-10 (7260009000)	BRAND = ZONISADE

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of partial-onset seizures and meet **ALL** of the following criteria?
- The patient is 16 years of age or older
  - Zonisade will be used as adjunctive treatment
  - The patient is unable to swallow zonisamide capsules

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #30 mL per day.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **ZONISAMIDE (Zonisade)** requires the following rule(s) be met for approval:

- A. You have partial-onset seizures (a type of seizure)
- B. You are 16 years of age or older
- C. Zonisade will be used as adjunctive (add-on) treatment
- D. You are unable to swallow to zonisamide capsules

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Zonisade.

**REFERENCES**

- Zonisade [Prescribing Information]. Wilmington, MA: Azurity Pharmaceuticals, Inc., July 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/23

Created: 11/22

Client Approval: 11/22

P&T Approval: 10/22



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

INDEX

A

ABALOPARATIDE .....	3	AMLODIPINE BENZOATE.....	72
ABATACEPT - SQ.....	6	AMLODIPINE BESYLATE/CELECOXIB .....	73
ABEMACICLIB .....	11	AMPHETAMINE SULFATE.....	75
ABILIFY MYCITE .....	117	AMPHETAMINE SULFATE ODT .....	78
ABIRATERONE ACET,SUBMICRONIZED .....	14	AMPYRA.....	288
ABIRATERONE ACETATE .....	14	ANABOLIC STEROIDS.....	80
ABROCITINIB .....	18	ANADROL-50.....	80
ABSTRAL.....	481	ANAKINRA.....	88
ACALABRUTINIB.....	21	ANASTROZOLE .....	184
ACCRUFER .....	483	ANDRODERM.....	1262
ACETAMINOPHEN DAILY LIMIT OVERRIDE.....	23	ANDROGEL .....	1262
ACNE AGE RESTRICTION OVERRIDE.....	25	ANDROID .....	752
ACTEMRA - SQ .....	1308	ANTI-OBESITY AGENTS .....	91
ACTHAR .....	270	APALUTAMIDE.....	102
ACTIMMUNE .....	619	APOKYN .....	106
ACTIQ .....	481	APOMORPHINE - SL.....	108
ADAGRASIB .....	28	APOMORPHINE HCL .....	106
ADALIMUMAB .....	29	APREMILAST .....	111
ADAPALENE.....	25	APRETUDE.....	982
ADAPALENE/BENZOYL PEROXIDE.....	25	ARANESP .....	290
ADBRY .....	1332	ARAZLO.....	25
ADCIRCA.....	1225	ARESTIN (NSA).....	770
ADDYI .....	503	ARIKAYCE .....	69
ADEMPAS.....	1017	ARIMIDEX.....	184
ADLARITY.....	349	ARIPIRAZOLE TABLETS WITH SENSOR.....	117
ADLYXIN.....	544	AROMASIN.....	184
AFATINIB DIMALEATE.....	41	ASCENIV .....	586
AFINITOR .....	455	ASCIMINIB HYDROCHLORIDE .....	120
AFINITOR DISPERZ.....	455	ASFOTASE ALFA.....	123
AFREZZA.....	599	ASPARAGINASE ERWINIA-RYWN.....	122
AIMOVIG.....	438	ASPIRIN.....	133
AJOVY .....	521	ASPIRIN EC.....	133
AKLIEF.....	25	ASPIRIN ER.....	129
ALECENSA.....	43	ASPIRIN ZERO COST SHARE OVERRIDE.....	133
ALECTINIB HCL .....	43	ASPIRIN-OMEPRAZOLE.....	131
ALKINDI SPRINKLE.....	562	ASPRUZYO SPRINKLE.....	991
ALLERGEN EXTRACT - MIXED GRASS POLLEN .....	47	ATOGEPAANT .....	136
ALLERGEN EXTRACT - SHORT RAGWEED POLLEN .....	50	ATORVASTATIN CALCIUM .....	1214
ALLERGEN EXTRACT-HOUSE DUST MITE .....	44	ATRALIN .....	25
ALLERGEN EXTRACT-TIMOTHY GRASS POLLEN.....	53	AUBAGIO.....	1256
ALPELISIB .....	56	AUSTEDO.....	333
ALPELISIB (VIJOICE).....	58	AUVELITY.....	335
ALTOPREV.....	1214	AVACOPAN .....	139
ALTRENO .....	25	AVAPRITINIB.....	141
ALUNBRIG.....	191	AVATROMBOPAG MALEATE .....	143
ALYQ.....	1225	AVITA.....	25
AMANTADINE EXTENDED RELEASE.....	59	AVONEX .....	611
AMANTADINE HCL.....	59	AVONEX PEN.....	611
AMBRISENTAN .....	63	AXIRON .....	1262
AMIFAMPRIDINE.....	66	AXITINIB .....	146
AMIKACIN LIPOSOMAL/NEB. ACCESSR.....	69	AYVAKIT .....	141
		AZACITIDINE.....	148
		AZTREONAM INHALED .....	149
		AZTREONAM LYSINE.....	149

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

B	C		
BACLOFEN (FLEQSUVY).....	150	C1 ESTERASE INHIBITOR (BERINERT).....	200
BACLOFEN (LYVISPAH).....	150	C1 ESTERASE INHIBITOR (CINRYZE).....	202
BACLOFEN (OZOBAX).....	150	C1 ESTERASE INHIBITOR (HAEGARDA).....	204
BAFIERTAM.....	785	C1 ESTERASE INHIBITOR, RECOMBINANT.....	206
BALVERSA.....	436	CABLIVI.....	216
BARICITINIB.....	152	CABOMETYX.....	208
BAXDELA.....	325	CABOTEGRAVIR.....	982
BEDAQUILINE FUMARATE.....	156	CABOZANTINIB S-MALATE.....	208
BELIMUMAB - SQ.....	158	CALQUENCE.....	21
BELUMOSUDIL MESYLATE.....	161	CAMZYOS.....	729
BELVIQ.....	715	CAPECITABINE.....	212
BELVIQ XR.....	715	CAPLACIZUMAB-YHDP.....	216
BELZUTIFAN.....	162	CAPMATINIB HYDROCHLORIDE.....	218
BENLYSTA - SQ.....	158	CAPRELSA.....	1388
BENRALIZUMAB (NSA).....	163	CAPSAICIN 8% PATCH.....	219
BERINERT.....	200	CARAC.....	510
BEROTRALSTAT HYDROCHLORIDE.....	168	CARBAGLU.....	222
BESREMI.....	1035	CARBIDOPA/LEVODOPA.....	220
BETAINE.....	170	CARBOXYMETHYLCELLULOSE-CELLULOSE-CITRIC ACID.....	221
BETASERON.....	612	CARGLUMIC ACID.....	222
BETHKIS.....	1306	CARIMUNE NF NANOFILTERED (COMMERCIAL, NSA) .....	586
BEXAROTENE SOFTGEL.....	171	CAYSTON.....	149
BEXAROTENE TOPICAL GEL.....	171	CELECOXIB (ELYXYB).....	225
BINIMETINIB.....	173	CENEGERMIN-BKBJ.....	226
BISACODYL/PEG/ELECTROLYTES.....	180	CEQUR SIMPLICITY.....	228
BIVIGAM (COMMERCIAL, NSA).....	586	CEQUR SIMPLICITY INSERTER.....	228
BLOOD SUGAR DIAGNOSTIC.....	338	CERITINIB.....	233
BLOOD SUGAR DIAGNOSTIC, DISC.....	338	CERTOLIZUMAB PEGOL.....	234
BLOOD SUGAR DIAGNOSTIC, DRUM.....	338	CHANTIX.....	1111
BLOOD-GLUCOSE SENSOR.....	260	CHENODAL.....	245
BLOOD-GLUCOSE TRANSMITTER.....	260	CHENODIOL.....	245
BOLUS INSULIN PUMP, 200 UNIT.....	228	CHOLBAM.....	248
BOSENTAN.....	174	CHOLIC ACID.....	248
BOSULIF.....	178	CIALIS.....	1223
BOSUTINIB.....	178	CIBINQO.....	18
BOWEL PREP FOR CRC SCREENING ZERO COST SHARE OVERRIDE.....	180	CIMZIA.....	234
BRAFTOVI.....	409	CINRYZE.....	202
BREAST CANCER PREVENTION ZERO COST SHARE OVERRIDE.....	184	CLADRIBINE.....	250
BREMELANOTIDE.....	187	CLASCOTERONE.....	252
BREXAFEMME.....	565	CLENPIQ.....	180
BRIGATINIB.....	191	CLOBAZAM-SYMPAZAN.....	254
BRODALUMAB.....	192	CLOVIQUE.....	1351
BRUKINSA.....	1411	COBIMETINIB FUMARATE.....	256
BUDESONIDE (ORTIKOS).....	195	COLLAGENASE CLOSTRIDIUM HIST.....	258
BUDESONIDE (TARPEYO).....	197	COMETRIQ.....	208
BUPHENYL.....	1129	CONJUPRI.....	686
BUPROPION HCL.....	1111	CONSENSI.....	73
BYDUREON.....	545	CONTINUOUS BLOOD GLUCOSE SENSOR.....	260
BYDUREON BCISE.....	545	CONTINUOUS BLOOD-GLUCOSE METER/RECEIVER .....	260
BYDUREON PEN.....	545	CONTINUOUS GLUCOSE MONITORS - STAND-ALONE .....	260
BYETTA.....	545	CONTRACEPTIVE ZERO COPAY OVERRIDE.....	266
BYLVAY.....	821	CONTRACEPTIVE, INTRAVAGINAL.....	266
BYNFEZIA.....	817		

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

CONTRACEPTIVES, IMPLANTABLE.....	266
CONTRACEPTIVES, INJECTABLE.....	266
CONTRACEPTIVES, INTRAVAGINAL, SYSTEMIC.....	266
CONTRACEPTIVES, ORAL.....	266
CONTRACEPTIVES, TRANSDERMAL.....	266
CONTRACEVE ER.....	91
COPAXONE.....	537
COPIKTRA.....	369
CORTICOTROPIN.....	270
COSENTYX.....	1058
COTELLIC.....	256
CRESEMBA.....	622
CRESTOR.....	1214
CRIZOTINIB.....	272
CUPRIMINE.....	944
CUTAQUIG.....	586
CUVITRU.....	586
CYCLOSPORINE (VERKAZIA).....	274
CYSTADANE.....	170
CYSTADROPS.....	276
CYSTARAN.....	276
CYSTEAMINE BITARTRATE.....	275
CYSTEAMINE HCL.....	276

**D**

DABRAFENIB MESYLATE.....	278
DACLATASVIR DIHYDROCHLORIDE.....	281
DACOMITINIB.....	286
DAKLINZA.....	281
DALFAMPRIDINE.....	288
DARAPRIM.....	986
DARBEPOETIN ALFA IN POLYSORBAT.....	290
DARIDOREXANT HCL.....	298
DAROLUTAMIDE.....	301
DASATINIB.....	305
DAURISMO.....	535
DECITABINE/.....	308
DEFERASIROX.....	310
DEFERIPRONE.....	314
DEFEROXAMINE.....	318
DEFLAZACORT.....	320
DELAFLOXACIN.....	325
DEPEN.....	944
DEPO-TESTOSTERONE.....	1268
DESCOVY.....	982
DESFERAL.....	318
DESIRUDIN.....	330
DEUCRAVACITINIB.....	331
DEUTETRABENAZINE.....	333
DEXCOM G4.....	260
DEXCOM G5.....	260
DEXCOM G5-G4 SENSOR.....	260
DEXCOM G6.....	260
DEXTROMETHORPHAN HBR/BUPROPION.....	335
DEXTROMETHORPHAN/.....	337
DIABETIC SUPPLIES,MISCELL.....	228
DIABETIC TEST STRIPS.....	338

DIACOMIT.....	1219
DIAPHRAGMS/CERVICAL CAP.....	266
DIBENZYLINE.....	953
DICHLORPHENAMIDE.....	340
DICLOFENAC SODIUM (PENNSAID).....	344
DICLOFENAC SODIUM (SOLARAZE).....	343
DIFFERIN.....	25
DIGOXIN.....	345
DIMETHYL FUMARATE.....	346
DIROXIMEL FUMARATE.....	348
DOJOLVI.....	1356
DONEPEZIL HCL.....	349
DOPTELET.....	143
DORNASE ALFA.....	350
D-PENAMINE.....	944
DRIZALMA SPRINKLE.....	355
DROXIDOPA.....	352
DULAGLUTIDE.....	545
DULOXETINE HCL (DRIZALMA SPRINKLE).....	355
DUOPA.....	220
DUPILUMAB.....	357
DUPIXENT.....	357
DURAGESIC.....	478
DURLAZA.....	129
DUVELISIB.....	369

**E**

EDARAVONE (ORAL).....	370
EDECIN.....	453
EFINACONAZOLE.....	373
EGRIFTA.....	1260
EGRIFTA SV.....	1260
ELAGOLIX AND ESTRADIOL AND NORETHINDRONE.....	386
ELAGOLIX SODIUM.....	378
ELAPEGDEMASE-LVLR.....	375
ELBASVIR/GRAZOPREXAVIR.....	382
ELEXACAFOR/TEZACAFOR/IVACAFOR.....	389
ELIGARD.....	684
ELMIRON.....	950
ELTROMBOPAG OLAMINE.....	394
ELUXADOLINE.....	402
ELYXYB.....	225
EMFLAZA.....	320
EMGALITY.....	527
EMICIZUMAB-KXWH.....	405
EMPAVELI.....	922
EMTRICITABINE.....	982
EMTRICITABINE/TENOFOVIR ALAFENAMIDE.....	
FUMARATE.....	982
EMTRICITABINE/TENOFOVIR DISOPROXIL.....	
FUMARATE.....	982
EMTRIVA.....	982
EMVERM.....	731
ENASIDENIB.....	408
ENBREL.....	445
ENCORAFENIB.....	409

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

GAVILYTE-C.....	180	IGG/HYALURONIDASE, RECOMBINANT (COMMERCIAL, NSA).....	586
GAVILYTE-G.....	180	ILOPROST TROMETHAMINE.....	575
GAVILYTE-N, PEG 3350-ELECTROLYTE.....	180	IMATINIB MESYLATE.....	578
GAVRETO.....	978	IMBRUVICA.....	568
GEFITINIB.....	533	IMCIVREE.....	1084
GENOTROPIN.....	1154	IMMUN GLOB G(IGG)/GLY/IGA OV50.....	586
GILENYA.....	498	IMMUN GLOB G(IGG)-HIP/MALTOSE.....	586
GILOTRIF.....	41	IMMUN GLOB G(IGG)-IFAS/GLYCINE.....	586
GILTERITINIB FUMARATE.....	534	IMMUNE GLOB, GAM CAPRYLATE (COMMERCIAL, NSA).....	586
GIMOTI.....	757	IMMUNE GLOBULIN (HUMAN)-KLHW.....	586
GLASDEGIB MALEATE.....	535	IMMUNE GLOBULIN (HUMAN)-SLRA.....	586
GLATIRAMER ACETATE.....	537	IMMUNE GLOBULIN / MALTOSE (COMMERCIAL, NSA) .....	586
GLATOPA.....	537	IMMUNE GLOBULIN INTRAVENOUS (COMMERCIAL, NSA).....	586
GLECAPREVIR/PIBRENTASVIR.....	539	IMPAVIDO.....	768
GLEEVEC.....	578	INBRIJA.....	690
GLEOSTINE.....	707	INCRELEX.....	735
GLP-1 AGONIST (ADLYXIN.....	544	INDOCIN.....	594
GLP-1 STEP OVERRIDE.....	545	INDOCIN RECTAL.....	593
GLUTAMINE (L-GLUTAMINE).....	658	INDOMETHACIN (SUSPENSION).....	594
GLYCEROL PHENYL BUTYRATE.....	547	INDOMETHACIN RECTAL.....	593
GLYCOPYRRONIUM TOSYLATE.....	549	INFIGRATINIB PHOSPHATE.....	596
GOCOVRI.....	59	INGENOL MEBUTATE.....	598
GOLIMUMAB - SQ.....	550	INGREZZA.....	1386
GOLYTELY.....	180	INHALED INSULIN.....	599
GR POL-ORC/SW VER/RYE/KENT/TIM.....	47	INLYTA.....	146
GRANIX.....	1245	INOTERSEN SODIUM.....	605
GRASS POLLEN-TIMOTHY, STD.....	53	INQOVI.....	308
GRASTEK.....	53	INREBIC.....	468
GUARDIAN CONNECT TRANSMITTER.....	260	INSULIN REGULAR, HUMAN (AFREZZA).....	599
GUARDIAN SENSOR 3.....	260	INTERFERON ALFA-2B,RECOMB.....	607
GUSELKUMAB.....	557	INTERFERON BETA-1A.....	611
<b>H</b>			
HAEGARDA.....	204	INTERFERON BETA-1A/ALBUMIN.....	617
HARVONI.....	661	INTERFERON BETA-1B.....	612, 613
HEMLIBRA.....	405	INTERFERON GAMMA-1B,RECOMB.....	619
HETLIOZ.....	1239	INTERFERONS FOR MS - AVONEX.....	611
HETLIOZ LQ.....	1239	INTERFERONS FOR MS - BETASERON.....	612
HIZENTRA (COMMERCIAL, NSA).....	586	INTERFERONS FOR MS - EXTAVIA.....	613
HOUSE DUST MITE.....	44	INTERFERONS FOR MS - PLEGRIDY.....	615
HUMATROPE.....	1161	INTERFERONS FOR MS - REBIF.....	617
HUMIRA.....	29	INTRA-UTERINE DEVICES (IUD'S).....	266
HYDROCORTISONE.....	562	INTRON A.....	607
HYDROMORPHONE HCL.....	563	IPRIVASK.....	330
HYFTOR.....	1109	IRESSA.....	533
HYQVIA (COMMERCIAL, NSA).....	586	ISAVUCONAZONIUM.....	622
<b>I</b>			
IBRANCE.....	905	ISTRADEFYLLINE.....	624
IBREXAFUNGERP CITRATE.....	565	ISTURISA.....	890
IBRUTINIB.....	568	ITRACONAZOLE-TOLSURA.....	626
IBSRELA.....	1254	IVACAFTOR.....	628
ICATIBANT ACETATE.....	572	IVOSIDENIB.....	633
ICLUSIG.....	970	IXAZOMIB CITRATE.....	636
IDELALISIB.....	574	IXEKIZUMAB.....	637
IDHIFA.....	408		

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

J

JADENU	310
JADENU SPRINKLE	310
JAKAFI	1039
JATENZO	1285
JUBLIA	373
JUXTAPID	703
JYNARQUE	1323

K

KALYDECO	628
KATERZIA	72
KERENDIA	496
KERYDIN	1241
KESIMPTA	822
KEVEYIS	340
KEVZARA	1052
KINERET	88
KISQALI	1001
KISQALI FEMARA CO-PACK	1001
KITABIS PAK	1306
KORLYM	760
KOSELUGO	1083
KRAZATI	28
KYNAMRO	773
KYNMOBI	108
KYZATREX	1278, 1285

L

LACTIC ACID/CITRIC/ POTASSIUM	644
LANADELUMAB-FLYO	648
LAPATINIB DITOSYLATE	651
LAROTRECTINIB	653
LASMIDITAN SUCCINATE	655
LAZANDA	474
LEDIPASVIR/SOFOSBUVIR	661
LEFAMULIN	667
LENACAPAVIR SODIUM	669
LENALIDOMIDE	671
LENVATINIB MESYLATE	674
LENVIMA	674
LESCOL	1214
LESCOL XL	1214
LETAIRIS	63
LETERMOVIR PO	678
LEUKINE	1050
LEUPROLIDE ACETATE (ELIGARD)	684
LEUPROLIDE ACETATE (GENERIC)	680
LEVAMLODIPINE MALEATE	686
LEVETIRACETAM (SPRITAM)	687
LEVODOPA	690
LEVOKETOCONAZOLE	693
LEVOTHYROXINE SODIUM (ERMEZA)	695
LEVOTHYROXINE SODIUM (TIROSINT-SOL)	697, 699

LIPITOR	1214
LIRAGLUTIDE	91, 545
LIVALO	1214
LIVMARLI	727
LIVTENCITY	728
LIXISENATIDE	544
LOFEXIDINE	701
LOMITAPIDE	703
LOMUSTINE	707
LONAFARNIB	709
LONAPEG SOMATROPIN-TCGD	711
LONSURF	1353
LORBRENA	716
LORCASERIN HCL	715
LORLATINIB	716
LOTEPREDNOL ETABONATE	718
LOVASTATIN	1214
LOVASTATIN EXTENDED-RELEASE	1214
LUCEMYRA	701
LUDENT FLUORIDE (FLUORIDE ZERO COST SHARE OVERRIDE)	507
LUMACFTOR/IVACFTOR	719
LUMAKRAS	1211
LUPKYNIS	1404
LUSUTROMBOPAG	722
LYBALVI	824
LYNPARZA	826
LYTGOBI	525
LYVISPAH	150

M

MACITENTAN	724
MARALIXIBAT CHLORIDE	727
MARIBAVIR	728
MAVACAMTEN	729
MAVENCLAD	250
MAVYRET	539
MAYZENT	1106
MEBENDAZOLE	731
MECAMYLAMINE HCL	733
MECASERMIN	735
MECHLORETHAMINE HCL	738
MEKINIST	1337
MEKTOVI	173
MEPOLIZUMAB	739
METHITEST	752
METHOXY PEG-EPOETIN BETA	746
METHYLNALTREXONE BROMIDE	750
METHYLTESTOSTERONE	752
METOCLOPRAMIDE	757
MIDOSTAURIN	758
MIFEPRISTONE	760
MIGALASTAT HCL	763
MIGERGOT	442
MIGLUSTAT	767
MILTEFOSINE	768
MINIMED 670G	1358

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

MINIMED 770G	1358
MINOCYCLINE HCL MICROSPHERES (NSA)	770
MIPOMERSEN SODIUM	773
MIRABEGRON	777
MIRCERA	746
MITAPIVAT SULFATE	778
MOBOCERTINIB SUCCINATE	780
MOMETASONE FUROATE (NSA)	782
MONOMETHYL FUMARATE	785
MORPHINE SULFATE	560
MOUNJARO	545
MOVIPREP	180
MULPLETA	722
MYCAPSSA	815
MYFEMBREE	997
MYRBETRIQ	777

**N**

NAFARELIN ACETATE	787
NALTREXONE HCL/BUPROPION HCL	91
NATESTO	1262
NATPARA	909
NERATINIB MALEATE	791
NERLYNX	791
NEULASTA	925
NEULASTA ONPRO	925
NEUPOGEN	484
NEXAVAR	1209
NICODERM CQ	1111
NICORETTE	1111
NICOTINE	1111
NICOTINE GUM	1111
NICOTINE LOZENGE	1111
NICOTINE PATCH	1111
NICOTINE POLACRILEX	1111
NICOTROL	1111
NICOTROL NS	1111
NILOTINIB HCL	793
NIMODIPINE	795
NINLARO	636
NINTEDANIB	797
NIRAPARIB TOSYLATE	802
NITISINONE	805
NITYR	805
NIVESTYM	487
NORDITROPIN FLEXPOR	1168
NORTHERA	352
NOURIANZ	624
NOXAFIL	974
NTS	1111
NUBEQA	301
NUCALA	739
NUEDEXTA	337
NULIBRY	515
NULYTELY	180
NUPLAZID	957
NURTEC ODT	1013

NUTROPIN AQ NUSPIN	1175
NUZYRA	834
NYMALIZE	795
NYVEPRIA	927

**O**

OBETICHOLIC ACID	808
OCALIVA	808
OCTAGAM (COMMERCIAL, NSA)	586
OCTREOTIDE ACETATE - ORAL	815
OCTREOTIDE ACETATE - SQ	817
OCTREOTIDE ACETATE, MI-SPHERES	811
ODACTRA	44
ODEVIXIBAT	821
ODOMZO	1207
OFATUMUMAB-SQ	822
OFEV	797
OLANZAPINE/SAMIDORPHAN MALATE	824
OLAPARIB	826
OLUMIANT	152
OLUTASIDENIB	832
OLYSIO	1098
OMACETAXINE MEPESUCCINATE	833
OMADACYCLINE	834
OMALIZUMAB	838
OMBITASVIR/PARITAPREVIR/RITONAVIR	845
OMBITASVIR/PARITAPREVIR/RITONAVIR/DASABUVIR	849
OMNITROPE	1181
ONGENTYS	855
ONUREG	148
OPICAPONE	855
OPIOID -BUPRENORPHINE CONCURRENT USE	863
OPIOID CUMULATIVE DOSING OVERRIDE	866
OPIOID LONG-ACTING DUPLICATIVE THERAPY	871
OPIOID NAIVE FILL LIMIT	880
OPIOID SINGLE CLAIM DOSING AT POS (OSCDP)	883
OPIOID-ANTIPSYCHOTIC CONCURRENT USE	857
OPIOID-BENZODIAZEPINE CONCURRENT USE	860
OPIOID-NAIVE CUMULATIVE DOSING	874
OPIOID-NAIVE DAY SUPPLY LIMITATION	877
OPIOID-SOMA-BENZODIAZEPINE CONCURRENT USE	887
OPSUMIT	724
OPZELURA	1043
ORALAIR	47
ORENCIA - SQ	6
ORENCIA CLICKJECT - SQ	6
ORENITRAM	1341
ORFADIN	805
ORGOVYX	996
ORIAHNN	386
ORLISSA	378
ORKAMBI	719
ORLADEYO	168
ORLISTAT	91
ORTIKOS	195

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.





STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

OSILODROSTAT .....	890
OSIMERTINIB MESYLATE .....	893
OSMOLEX ER .....	59
OSMOPREP .....	180
OTESECONAZOLE .....	896
OTEZLA .....	111
OXANDRIN .....	80
OXANDROLONE .....	80
OXBRYTA .....	1408
OXERVATE .....	226
OXYCODONE HCL .....	560
OXYMETAZOLINE HCL/PF .....	898
OXYMETHOLONE .....	80
OZANIMOD HYDROCHLORIDE .....	900
OZEMPIC .....	545
OZOBAX .....	150

**P**

PACRITINIB CITRATE .....	903
PALBOCICLIB .....	905
PALFORZIA .....	918
PALYNZIQ .....	940
PANOBINOSTAT .....	907
PANZYGA .....	586
PARATHYROID HORMONE .....	909
PASIREOTIDE .....	911
PATIROMER CALCIUM SORBITE .....	913
PAZOPANIB HCL .....	916
PEANUT (ARACHIS HYPOGAEA) ALLERGEN POWDER-DNFP .....	918
PEG 3350-ELECTROLYTES .....	180
PEG3350/SOD SULF,BICARB,CL/KCL .....	180
PEG3350-SOD SUL-NACL-KCL-ASB-C .....	180
PEGASYS .....	935
PEGASYS PROCLICK .....	935
PEGCETACOPLAN .....	922
PEGFILGRASTIM .....	925
PEGFILGRASTIM-APGF .....	927
PEGFILGRASTIM-BMEZ .....	928
PEGFILGRASTIM-CBQV .....	929
PEGFILGRASTIM-FPGK .....	930
PEGFILGRASTIM-JMDB .....	931
PEGFILGRASTIM-PBBK .....	932
PEGINTERFERON ALFA-2A .....	935
PEGINTERFERON ALFA-2B .....	935
PEG-INTERFERON ALFA-2B-SYLATRON .....	933
PEGINTERFERON BETA-1A .....	615
PEGINTRON .....	935
PEG-PREP .....	180
PEGVALIASE-PQPZ .....	940
PEMAZYRE .....	942
PEMIGATINIB .....	942
PENICILLAMINE .....	944
PENNSAID .....	344
PENTOSAN POLYSULFATE SODIUM .....	950
PEXIDARTINIB HYDROCHLORIDE .....	952
PHEBURANE .....	1129

PHENOXYBENZAMINE HCL .....	953
PHENTERMINE/TOPIRAMATE .....	91
PHEXXI .....	644
PICATO .....	598
PILOCARPINE HCL .....	955
PIMAVANSERIN .....	957
PIQRAY .....	56
PIRFENIDONE .....	959
PITAVASTATIN CALCIUM .....	1214
PITAVASTATIN MAGNESIUM .....	1214
PITOLISANT HCL .....	963
PLASMINOGEN HUMAN-TVMH .....	967
PLEGRIDY .....	615
PLEGRIDY PEN .....	615
PLENITY .....	221
PLENVU .....	180
PLIXDA .....	25
POMALIDOMIDE .....	968
POMALYST .....	968
PONATINIB HCL .....	970
PONESIMOD .....	973
PONVORY .....	973
POSACONAZOLE .....	974
PRALSETINIB .....	978
PRAVACHOL .....	1214
PRAVASTATIN SODIUM .....	1214
PREDNISONE (RAYOS) .....	980
PRE-EXPOSURE PROPHYLAXIS ZERO COST SHARE OVERRIDE .....	982
PREPOPIK .....	180
PREVYMIS PO .....	678
PRIVIGEN (COMMERCIAL, NSA) .....	586
PROCRIT .....	417
PROCYSBI .....	275
PROMACTA .....	394
PULMOZYME .....	350
PYRIMETHAMINE .....	986
PYRUKYND .....	778

**Q**

QBREXZA .....	549
QDOLO .....	1335
QINLOCK .....	1021
QSYMIA .....	91
QULIPTA .....	136
QUTENZA .....	219
QUVIVIQ .....	298

**R**

RADICAVA ORS .....	370
RAGWITEK .....	50
RALOXIFENE HCL .....	184
RANOLAZINE .....	991
RAVICTI .....	547
RAYOS .....	980
REBIF .....	617

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

REBIF REBIDOSE .....	617	SANTYL .....	258
REBYOTA .....	466	SARGRAMOSTIM .....	1050
RECORLEV .....	693	SARILUMAB .....	1052
REGORAFENIB .....	993	SATRALIZUMAB-MWGE .....	1055
RELEUKO .....	489	SAXENDA .....	91
RELISTOR .....	750	SCEMBLIX .....	120
RELTONE .....	1378	SECUKINUMAB .....	1058
RELUGOLIX .....	996	SELEXIPAG .....	1070
RELUGOLIX/ESTRADIOL/NORETHINDRONE ACETATE .....	997	SELINEXOR .....	1076
RELYVRIO .....	1132	SELPERCATINIB .....	1080
REMODULIN .....	1341	SELUMETINIB .....	1083
RETACRIT .....	429	SEMAGLUTIDE .....	91, 545
RETEVMO .....	1080	SEROSTIM .....	1192
RETIN-A .....	25	SETMELANOTIDE ACETATE .....	1084
RETIN-A MICRO .....	25	SIGNIFOR .....	911
RETIN-A MICRO PUMP .....	25	SILDENAFIL CITRATE (IV)-REVATIO .....	1086
REVATIO (IV) .....	1086	SILDENAFIL CITRATE (SUSPENSION)-REVATIO .....	1090
REVATIO (SUSPENSION) .....	1090	SILDENAFIL CITRATE (TABLET)-REVATIO .....	1094
REVATIO (TABLET) .....	1094	SILIQ .....	192
REVCIVI .....	375	SIMEPREVIR .....	1098
REVLIMID .....	671	SIMPONI - SQ .....	550
REYVOW .....	655	SIMVASTATIN .....	1214
REZLIDHIA .....	832	SIMVASTATIN 80 .....	1102
REZUROCK .....	161	SIMVASTATIN ORAL SUSPENSION .....	1103
RIBOCICLIB SUCCINATE .....	1001	SINUVA (NSA) .....	782
RIBOCICLIB SUCCINATE/ LETROZOLE .....	1001	SIPONIMOD .....	1106
RIFAXIMIN .....	1006	SIROLIMUS TOPICAL (HYFTOR) .....	1109
RILUZOLE .....	1011	SIRTURO .....	156
RIMEGEPANT SULFATE .....	1013	SKYRIZI .....	1022
RINVOQ .....	1367	SKYTROFA .....	711
RIOCIGUAT .....	1017	SMOKING CESSATION ZERO COST SHARE OVERRIDE .....	1111
RIPRETINIB .....	1021	SOANZ .....	1331
RISANKIZUMAB-RZAA .....	1022	SOD PHENYL BUTYRAT /TAURURSODIOL .....	1132
RISDIPLAM .....	1028	SOD PHOSPHATE MBAS/SOD PHOS,DI .....	180
ROFLUMILAST .....	1032	SOD PICOSULF/MAG OX/CITRIC AC .....	180
ROPEGINTERFERON ALFA-2B-NJFT .....	1035	SOD SULF/POT CHLORIDE/MAG SULF .....	180
ROSUVASTATIN CALCIUM .....	1214	SODIUM CHLORIDE/NAHCO3/ KCL/PE .....	180
ROZLYTREK .....	411	SODIUM OXYBATE .....	1122
RUBRACA .....	1036	SODIUM PHENYL BUTYRATE .....	1129
RUCAPARIB CAMSYLATE .....	1036	SODIUM, CALCIUM, MAG, POT OXYBATE .....	1115
RUCONEST .....	206	SODIUM, POTASSIUM,MAG SULFATES .....	180
RUKOBIA .....	519	SOFOSBUVIR .....	1134
RUXOLITINIB PHOSPHATE .....	1039	SOFOSBUVIR/VELPATASVIR .....	1143
RUXOLITINIB PHOSPHATE TOPICAL .....	1043	SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR .....	1146
RUZURGI .....	66	SOLARAZE .....	343
RYDAPT .....	758	SOLIFENACIN SUCCINATE .....	1149
RYLAZE .....	122	SOLRIAMFETOL .....	1150
RYPLAZIM .....	967	SOMATROPIN .....	1161
<b>S</b>			
SABRIL .....	1400	SOMATROPIN (GENOTROPIN) .....	1154
SACROSIDASE .....	1048	SOMATROPIN (NORDITROPIN) .....	1168
SAIZEN .....	1188	SOMATROPIN (NUTROPIN AQ NUSPIN) .....	1175
SAIZEN-SAIZENPREP .....	1188	SOMATROPIN (OMNITROPE) .....	1181
SAJAZIR .....	572	SOMATROPIN (SAIZEN) .....	1188
SANDOSTATIN LAR DEPOT .....	811	SOMATROPIN (SEROSTIM) .....	1192
		SOMATROPIN (ZOMACTON) .....	1197
		SOMATROPIN (ZORBTIVE) .....	1204
		SONIDEGIB PHOSPHATE .....	1207

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SORAFENIB TOSYLATE.....	1209	TAVABOROLE.....	1241
SOTORASIB.....	1211	TAVALISSE.....	516
SOTYKTU.....	331	TAVNEOS.....	139
SOVALDI.....	1134	TAZAROTENE.....	25
SPARSENTAN.....	1212	TAZEMETOSTAT.....	1243
SPRITAM.....	687	TAZVERIK.....	1243
SPRYCEL.....	305	TBO-FILGRASTIM.....	1245
STATIN ZERO COST SHARE OVERRIDE.....	1214	TECFIDERA.....	346
STELARA.....	1380	TECHNIVIE.....	845
STIMUFEND.....	930	TEDUGLUTIDE.....	1247
STIRIPENTOL.....	1219	TEGSEDI.....	605
STIVARGA.....	993	TELOTTRISTAT.....	1249
STRENSIQ.....	123	TEMODAR.....	1251
STRIANT.....	1262	TEMOZOLOMIDE.....	1251
SUBCUTANEOUS INSULIN PUMP.....	1358	TENAPANOR HCL.....	1254
SUBSYS.....	476	TENOFOVIR DISOPROXIL FUMARATE.....	982
SUCRAID.....	1048	TEPMETKO.....	1255
SUNITINIB MALATE.....	1221	TEPOTINIB HCL.....	1255
SUNLENCA.....	669	TERIFLUNOMIDE.....	1256
SUNOSI.....	1150	TERIPARATIDE.....	1257
SUPREP.....	180	TESAMORELIN.....	1260
SUTAB.....	180	TESTIM.....	1262
SUTENT.....	1221	TESTOSTERONE.....	1262
SYLATRON.....	933	TESTOSTERONE CYPIONATE.....	1268
SYLATRON 4-PACK.....	933	TESTOSTERONE ENANTHATE.....	1272
SYMDEKO.....	1292	TESTOSTERONE UNDECANOATE.....	1278, 1285
SYMPAZAN.....	254	TESTOSTERONE UNDECANOATE (TLANDO).....	1282
SYNAREL.....	787	TESTRED.....	752
SYNRIBO.....	833	TETRABENAZINE.....	1290
SYPRINE.....	1351	TEZACAFTOR/IVACAFTOR.....	1292
<b>T</b>			
T: SLIM/MINIMED INSULIN PUMPS.....	1358	TEZEPELUMAB-EKKO (NSA).....	1297
T:SLIM X2.....	1358	TEZSPIRE (NSA).....	1297
T:SLIM X2 CONTROL-IQ.....	1358	THALIDOMIDE.....	1303
T:SLIM X2 WITH BASAL-IQ.....	1358	THALOMID.....	1303
TABRECTA.....	218	TIBSOVO.....	633
TADALAFIL (CIALIS).....	1223	TIGLUTIK.....	1011
TADALAFIL-ADCIRCA, ALYQ.....	1225	TIROSINT.....	697
TADALAFIL-TADLIQ.....	1228	TIROSINT-SOL.....	699
TADLIQ.....	1228	TIRZEPATIDE.....	545
TAFAMIDIS.....	1231	TIVOZANIB HCL.....	1305
TAFAMIDIS MEGLUMINE.....	1231	TLANDO.....	1282, 1285
TAFINLAR.....	278	TOBI.....	1306
TAGRISSE.....	893	TOBI PODHALER.....	1306
TAKHZYRO.....	648	TOBRAMYCIN.....	1306
TALAZOPARIB TOSYLATE.....	1234	TOBRAMYCIN IN 0.225% SOD CHLOR.....	1306
TALTZ.....	637	TOBRAMYCIN INHALED.....	1306
TALZENNA.....	1234	TOBRAMYCIN/NEBULIZER.....	1306
TAMOXIFEN CITRATE.....	184	TOCILIZUMAB - SQ.....	1308
TAPINAROF.....	1236	TOFACITINIB CITRATE.....	1316
TARCEVA.....	443	TOLSURA.....	626
TARGRETIN.....	171	TOLVAPTAN.....	1323
TARPEYO.....	197	TOPIRAMATE (EPRONTIA).....	1326
TASCENSO ODT.....	500	TOREMIFENE CITRATE.....	1330
TASIGNA.....	793	TORSEMIDE.....	1331
TASIMELTEON.....	1239	TRACLEER.....	174
		TRALOKINUMAB-LDRM.....	1332
		TRAMADOL HCL.....	1335
		TRAMETINIB DIMETHYL SULFOXIDE.....	1337

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TREMFYA .....	557
TREPROSTINIL .....	1341
TREPROSTINIL DIOLAMINE .....	1341
TREPROSTINIL SODIUM .....	1341
TRETINOIN .....	25
TRETINOIN MICROSPHERES .....	25
TRETIN-X .....	25
TRIENTINE HCL .....	1351
TRIFAROTENE .....	25
TRIFLURIDINE/TIPIRACIL HCL .....	1353
TRihePTANOIN .....	1356
TRIKAFTA .....	389
TRULICITY .....	545
TRUSELTIQ .....	596
TRUVADA .....	982
TUCATINIB .....	1362
TUKYSA .....	1362
TURALIO .....	952
TYKERB .....	651
TYMLOS .....	3
TYRVAYA .....	1390
TYVASO .....	1341

**U**

UBRELVY .....	1364
UBROGEPANT .....	1364
UDENYCA .....	929
UPADACITINIB .....	1367
UPNEEQ .....	898
UPTRAVI .....	1070
URIDINE TRIACETATE .....	1376
URSODIOL .....	1378
USTEKINUMAB .....	1380

**V**

VALBENZAZINE TOSYLATE .....	1386
VALCHLOR .....	738
VANDETANIB .....	1388
VARENICLINE TARTRATE (CHANTIX) .....	1111
VARENICLINE TARTRATE (TYRVAYA) .....	1390
VECAMYL .....	733
VELTASSA .....	913
VEMURAFENIB .....	1392
VENCLEXTA .....	1394
VENETOCLAX .....	1394
VENTAVIS .....	575
VERICIGUAT .....	1397
VERKAZIA .....	274
VERQUVO .....	1397
VERZENIO .....	11
VESICARE LS .....	1149
VIBERZI .....	402
VICTOZA .....	545
VIEKIRA PAK .....	849
VIEKIRA XR .....	849
VIGABATRIN .....	1400

VIGADRONE .....	1400
VIJOICE .....	58
VIREAD .....	982
VISMODEGIB .....	1402
VITRAKVI .....	653
VIVJOA .....	896
VIZIMPRO .....	286
VOCLOSPORIN .....	1404
VOGELXO .....	1262
VONJO .....	903
VONOPRAZAN/ .....	1406
VOQUEZNA DUAL PAK .....	1406
VOQUEZNA TRIPLE PAK .....	1406
VOSEVI .....	1146
VOSORITIDE .....	1407
VOTRIENT .....	916
VOXELOTOR .....	1408
VOXZOGO .....	1407
VTAMA .....	1236
VUITY .....	955
VUMERITY .....	348
VYLEESI .....	187
VYNDAMAX .....	1231
VYNDAQEL .....	1231
VYTORIN .....	1102

**W**

WAKIX .....	963
WEED POLLEN-SHORT RAGWEED .....	50
WEGOVY .....	91
WELIREG .....	162
WINLEVI .....	252

**X**

XALKORI .....	272
XELJANZ .....	1316
XELJANZ XR .....	1316
XELODA .....	212
XEMBIFY .....	586
XENAZINE .....	1290
XENICAL .....	91
XENLETA .....	667
XERMELO .....	1249
XIFAXAN .....	1006
XOLAIR .....	838
XOSPATA .....	534
XPOVIO .....	1076
XTANDI .....	413
XURIDEN .....	1376
XYOSTED .....	1272
XYREM .....	1122
XYWAV .....	1115

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

<b>Y</b>		ZOCOR .....	1214
YONSA.....	14	ZOCOR-SIMVASTATIN 80 .....	1102
YOSPRALA.....	131	ZOKINVY .....	709
<b>Z</b>		ZOMACTON.....	1197
ZANUBRUTINIB.....	1411	ZONISADE.....	1413
ZARXIO.....	491	ZONISAMIDE.....	1413
ZAVESCA .....	767	ZORBTIVE .....	1204
ZEJULA.....	802	ZORYVE .....	1032
ZELBORAF .....	1392	ZTALMY .....	532
ZEPATIER.....	382	ZYBAN .....	1111
ZEPOSIA.....	900	ZYCLARA .....	584
ZIEXTENZO .....	928	ZYDELIG.....	574
		ZYKADIA.....	233
		ZYPITAMAG .....	1214
		ZYTIGA .....	14